Identification	O	NOUN	B
of	O	ADP	O
APC2	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
tumour	I-Disease	NOUN	O
suppressor	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	I-Disease	PUNCT	O
APC	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
tumour	I-Disease	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
protein	O	NOUN	I
controls	O	VERB	O
the	O	DET	O
Wnt	O	NOUN	B
signalling	O	NOUN	I
pathway	O	NOUN	I
by	O	ADP	O
forming	O	VERB	O
a	O	DET	O
complex	O	NOUN	B
with	O	ADP	O
glycogen	O	NOUN	B
synthase	O	NOUN	I
kinase	O	NOUN	I
3beta	O	NOUN	I
(	O	PUNCT	O
GSK	O	PROPN	B
-	O	PUNCT	O
3beta	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
axin	O	NOUN	B
/	O	SYM	O
conductin	O	NOUN	B
and	O	CCONJ	O
betacatenin	O	NOUN	B
.	O	PUNCT	O


Complex	O	NOUN	B
formation	O	NOUN	B
induces	O	VERB	B
the	O	DET	O
rapid	O	ADJ	O
degradation	O	NOUN	B
of	O	ADP	O
betacatenin	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
colon	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
cells	O	NOUN	O
,	O	PUNCT	O
loss	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
betacatenin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
,	O	PUNCT	O
where	O	SCONJ	O
it	O	PRON	O
binds	O	VERB	B
to	O	PART	O
and	O	CCONJ	O
activates	O	VERB	B
the	O	DET	O
Tcf	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	B
transcription	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
reviewed	O	VERB	B
in	O	ADP	O
[	O	PUNCT	O
1	O	NUM	O
]	O	PUNCT	O
[	O	PUNCT	O
2	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
identification	O	NOUN	B
and	O	CCONJ	O
genomic	O	ADJ	B
structure	O	NOUN	I
of	O	ADP	O
APC	O	NOUN	B
homologues	O	NOUN	B
.	O	PUNCT	O


Mammalian	O	ADJ	B
APC2	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
closely	O	ADV	O
resembles	O	VERB	O
APC	O	NOUN	B
in	O	ADP	O
overall	O	ADJ	O
domain	O	NOUN	B
structure	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
functionally	O	ADV	O
analyzed	O	VERB	B
and	O	CCONJ	O
shown	O	VERB	O
to	O	PART	O
contain	O	VERB	O
two	O	NUM	O
SAMP	O	NOUN	B
domains	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
required	O	VERB	O
for	O	ADP	O
binding	O	VERB	B
to	O	PART	O
conductin	O	NOUN	B
.	O	PUNCT	O


Like	O	ADP	O
APC	O	NOUN	B
,	O	PUNCT	O
APC2	O	NOUN	B
regulates	O	VERB	B
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
active	O	ADJ	O
betacatenin	O	NOUN	B
-	O	PUNCT	O
Tcf	O	NOUN	B
complexes	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
demonstrated	O	VERB	O
using	O	VERB	O
transient	O	ADJ	B
transcriptional	O	ADJ	O
activation	O	NOUN	O
assays	O	NOUN	O
in	O	ADP	O
APC	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
colon	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
cells	O	NOUN	O
.	O	PUNCT	O


Human	O	ADJ	B
APC2	O	NOUN	B
maps	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	B
19p13	O	NOUN	I
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


APC	O	NOUN	B
and	O	CCONJ	O
APC2	O	NOUN	B
may	O	AUX	O
therefore	O	ADV	O
have	O	AUX	O
comparable	O	ADJ	O
functions	O	NOUN	B
in	O	ADP	O
development	O	NOUN	B
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
MSH2	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
English	O	PROPN	B
and	O	CCONJ	O
North	O	ADJ	B
American	O	ADJ	I
HNPCC	B-Disease	NOUN	B
families	O	NOUN	B
:	O	PUNCT	O
origin	O	NOUN	B
,	O	PUNCT	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sex	O	NOUN	B
specific	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
,	O	PUNCT	O
origin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
MSH2	O	NOUN	I
gene	O	NOUN	B
mutation	O	NOUN	I
previously	O	ADV	O
identified	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
kindreds	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
non	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
polyposis	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HNPCC	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
(	O	PUNCT	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
at	O	ADP	O
nt943	O	NOUN	B
+	O	CCONJ	O
3	O	NUM	O
)	O	PUNCT	O
disrupts	O	VERB	B
the	O	DET	O
3	O	NUM	O
splice	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
this	O	DET	O
exon	O	NOUN	B
from	O	ADP	O
MSH2	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
represents	O	VERB	O
the	O	DET	O
only	O	ADV	O
frequent	O	ADJ	B
MSH2	O	NOUN	B
mutation	O	NOUN	B
so	O	ADV	O
far	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
initially	O	ADV	O
detected	O	VERB	B
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
33	O	NUM	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
analysed	O	VERB	B
from	O	ADP	O
eastern	O	ADJ	B
England	O	PROPN	I
,	O	PUNCT	O
more	O	ADV	O
extensive	O	ADJ	O
analysis	O	NOUN	B
has	O	AUX	O
reduced	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
to	O	PART	O
four	O	NUM	O
of	O	ADP	O
52	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
English	O	ADJ	B
HNPCC	B-Disease	NOUN	B
kindreds	O	NOUN	B
analysed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
MSH2	O	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
10	O	NUM	O
of	O	ADP	O
20	O	NUM	O
(	O	PUNCT	O
50	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
separately	O	ADV	O
identified	O	VERB	B
colorectal	B-Disease	ADJ	B
families	O	NOUN	I
from	O	ADP	O
Newfoundland	O	PROPN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
from	O	ADP	O
England	O	PROPN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Newfoundland	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
using	O	VERB	O
microsatellite	O	NOUN	B
markers	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
MSH2	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
English	O	PROPN	B
and	O	CCONJ	O
US	O	PROPN	B
families	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
little	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
recent	O	ADJ	O
common	O	ADJ	O
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MSH2	O	NOUN	B
splice	O	NOUN	B
site	O	NOUN	I
mutation	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
haplotype	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
at	O	ADP	O
the	O	DET	O
two	O	NUM	O
flanking	O	NOUN	B
markers	O	NOUN	B
(	O	PUNCT	O
CA5	O	NOUN	B
and	O	CCONJ	O
D2S288	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
eight	O	NUM	O
of	O	ADP	O
the	O	DET	O
Newfoundland	O	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggested	O	VERB	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
within	O	ADP	O
Newfoundland	O	NOUN	B
similar	O	ADJ	O
to	O	ADP	O
that	O	DET	O
reported	O	VERB	O
by	O	ADP	O
others	O	NOUN	O
for	O	ADP	O
two	O	NUM	O
MLH1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
Finnish	O	ADJ	B
HNPCC	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
calculated	O	VERB	B
age	O	NOUN	B
related	O	ADJ	O
risks	O	NOUN	B
of	O	ADP	O
all	O	DET	O
,	O	PUNCT	O
colorectal	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
endometrial	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
in	O	ADP	O
nt943	O	NOUN	B
+	O	CCONJ	O
3	O	NUM	O
A	O	NOUN	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
MSH2	O	NOUN	O
mutation	O	NOUN	B
carriers	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
76	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
separately	O	ADV	B
.	O	PUNCT	O


For	O	ADP	O
both	O	DET	O
sexes	O	NOUN	B
combined	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
penetrances	O	NOUN	B
at	O	ADP	O
age	O	NOUN	B
60	O	NUM	O
years	O	NOUN	B
for	O	ADP	O
all	O	DET	O
cancers	B-Disease	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
were	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


86	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
significantly	O	ADV	B
higher	O	ADJ	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
males	O	NOUN	B
than	O	ADP	O
females	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
63	O	NUM	O
v	O	PART	O
0	O	NUM	O
.	O	PUNCT	O
30	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O
84	O	NUM	O
v	O	PART	O
0	O	NUM	O
.	O	PUNCT	O
44	O	NUM	O
at	O	ADP	O
ages	O	NOUN	B
50	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
females	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
high	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
at	O	ADP	O
age	O	NOUN	B
60	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
premenopausal	B-Disease	ADJ	B
ovarian	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
at	O	ADP	O
50	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
intersex	O	NOUN	B
differences	O	NOUN	O
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risks	O	NOUN	B
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
screening	O	NOUN	B
programmes	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
attempts	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
modifiers	O	NOUN	B
.	O	PUNCT	O


Age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
in	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
sex	O	NOUN	B
specific	O	ADJ	B
influence	O	NOUN	B
of	O	ADP	O
apolipoprotein	O	NOUN	B
E	O	NOUN	I
genotype	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
CAG	O	NOUN	B
repeat	O	NOUN	I
length	O	NOUN	I
.	O	PUNCT	O


Age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
(	O	PUNCT	O
AO	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
length	O	NOUN	B
of	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Apolipoprotein	O	NOUN	B
E	O	NOUN	I
(	O	PUNCT	O
APOE	O	NOUN	B
)	O	PUNCT	O
genotype	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
turn	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
influence	O	VERB	B
AO	O	PROPN	B
in	O	ADP	O
Alzheimer	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
rendering	O	VERB	O
the	O	DET	O
APOE	O	NOUN	B
gene	O	NOUN	I
a	O	DET	O
likely	O	ADJ	O
candidate	O	NOUN	O
to	O	PART	O
affect	O	VERB	O
AO	O	PROPN	B
in	O	ADP	O
other	O	ADJ	O
neurological	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
too	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
determined	O	VERB	O
APOE	O	ADJ	B
genotype	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
CAG	O	NOUN	B
repeat	O	NOUN	I
length	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
for	O	ADP	O
138	O	NUM	O
HD	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
previously	O	ADV	O
analysed	O	VERB	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
CAG	O	NOUN	B
repeat	O	NOUN	I
length	O	NOUN	I
.	O	PUNCT	O


Genotyping	O	NOUN	B
for	O	ADP	O
APOE	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
blind	O	ADJ	B
to	O	PART	O
clinical	O	ADJ	B
information	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
highlighting	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
repeat	O	NOUN	I
length	O	NOUN	B
upon	O	SCONJ	O
AO	O	NOUN	B
in	O	ADP	O
maternally	O	ADV	B
inherited	O	VERB	I
HD	B-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
male	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
APOE	O	NOUN	B
epsilon2epsilon3	O	NOUN	O
genotype	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
significantly	O	ADV	O
earlier	O	ADJ	O
AO	O	PROPN	B
in	O	ADP	O
males	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Such	O	DET	O
a	O	DET	O
sex	O	NOUN	B
difference	O	NOUN	O
in	O	ADP	O
AO	O	NOUN	B
was	O	AUX	O
not	O	PART	O
apparent	O	ADJ	B
for	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
APOE	O	ADJ	B
genotypes	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
subtle	O	ADJ	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neurodegeneration	B-Disease	NOUN	B
in	O	ADP	O
HD	B-Disease	NOUN	B
may	O	AUX	O
allow	O	VERB	O
interacting	O	VERB	B
genes	O	NOUN	I
to	O	PART	O
exert	O	VERB	O
gender	O	NOUN	B
specific	O	ADJ	O
effects	O	NOUN	B
upon	O	SCONJ	O
AO	O	PROPN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
associated	O	VERB	B
with	O	ADP	I
recurrent	O	ADJ	B
bacteremic	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
due	I-Disease	ADJ	O
to	I-Disease	PART	O
Neisseria	I-Disease	PROPN	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
of	O	ADP	O
a	O	DET	O
29	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
old	O	ADJ	O
woman	O	NOUN	B
with	O	ADP	O
a	O	DET	O
recent	O	ADJ	O
episode	O	NOUN	B
of	O	ADP	O
disseminated	B-Disease	ADJ	B
gonococcal	I-Disease	ADJ	B
infection	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
and	O	CCONJ	O
arthritis	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
child	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
lack	O	VERB	O
serum	O	NOUN	B
hemolytic	O	ADJ	O
complement	O	NOUN	O
activity	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
seventh	O	ADJ	O
component	O	NOUN	O
of	O	ADP	O
complement	O	NOUN	O
(	O	PUNCT	O
C7	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
by	O	ADP	O
functional	O	ADJ	B
or	O	CCONJ	O
immunochemical	O	ADJ	B
assays	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
other	O	ADJ	O
components	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
by	O	ADP	O
hemolytic	O	ADJ	B
and	O	CCONJ	O
immunochemical	O	ADJ	B
assessment	O	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
fresh	O	ADJ	B
serum	O	NOUN	B
lacked	O	VERB	O
complement	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
bactericidal	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
Neisseria	O	X	B
gonorrhoeae	O	X	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
fresh	O	ADJ	B
normal	O	ADJ	O
serum	O	NOUN	B
or	O	CCONJ	O
purified	O	VERB	B
C7	O	NOUN	B
restored	O	VERB	O
bactericidal	O	ADJ	B
activity	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
hemolytic	O	ADJ	B
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
functional	I-Disease	ADJ	B
C7	I-Disease	NOUN	B
activity	O	NOUN	I
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
an	O	DET	O
inhibitor	O	NOUN	B
.	O	PUNCT	O


Opsonization	O	NOUN	B
and	O	CCONJ	O
generation	O	NOUN	B
of	O	ADP	O
chemotactic	O	ADJ	B
activity	O	NOUN	I
functioned	O	VERB	O
normally	O	ADV	O
.	O	PUNCT	O


Complete	B-Disease	ADJ	B
absence	I-Disease	NOUN	B
of	I-Disease	ADP	O
C7	I-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
found	O	VERB	O
in	O	ADP	O
one	O	NUM	O
sibling	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
the	O	DET	O
clinical	O	ADJ	B
syndrome	O	NOUN	I
of	O	ADP	O
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
and	O	CCONJ	O
arthritis	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
child	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
this	O	DET	O
siblings	O	NOUN	B
clinically	O	ADV	B
well	O	ADV	O
eight	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
son	O	NOUN	I
.	O	PUNCT	O


HLA	O	NOUN	B
histocompatibility	O	NOUN	I
typing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
family	O	NOUN	B
members	O	NOUN	I
did	O	AUX	O
not	O	PART	O
demonstrate	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
genetic	O	ADJ	B
linkage	O	NOUN	I
of	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
with	O	ADP	O
the	O	DET	O
major	O	ADJ	O
histocompatibility	O	NOUN	B
loci	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
infectious	O	ADJ	B
complications	O	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
bactericidal	O	ADJ	B
activity	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
host	O	NOUN	B
defense	O	NOUN	B
against	O	ADP	O
bacteremic	B-Disease	ADJ	B
neisseria	I-Disease	NOUN	O
infections	I-Disease	NOUN	O
.	O	PUNCT	O


Increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cartilage	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
hair	I-Disease	NOUN	B
hypoplasia	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
Previous	O	ADJ	O
reports	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cartilage	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
hair	I-Disease	NOUN	B
hypoplasia	I-Disease	NOUN	I
(	O	PUNCT	O
CHH	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
further	O	ADV	O
evaluate	O	VERB	B
this	O	DET	O
risk	O	NOUN	B
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CHH	B-Disease	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	O
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
One	O	NUM	O
hundred	O	NUM	O
twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
CHH	B-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
through	O	ADP	O
2	O	NUM	O
countrywide	O	NOUN	B
epidemiologic	O	ADJ	B
surveys	O	NOUN	O
in	O	ADP	O
1974	O	NUM	O
and	O	CCONJ	O
in	O	ADP	O
1986	O	NUM	O
.	O	PUNCT	O


Their	O	PRON	O
parents	O	NOUN	B
and	O	CCONJ	O
nonaffected	O	ADJ	B
siblings	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
through	O	ADP	O
the	O	DET	O
Population	O	PROPN	B
Register	O	PROPN	I
Center	O	PROPN	I
.	O	PUNCT	O


This	O	DET	O
cohort	O	NOUN	B
underwent	O	VERB	O
follow	O	VERB	B
-	O	PUNCT	O
up	O	NOUN	O
for	O	ADP	O
cancer	B-Disease	NOUN	B
incidence	O	NOUN	B
through	O	ADP	O
the	O	DET	O
Finnish	O	PROPN	B
Cancer	O	PROPN	I
Registry	O	PROPN	I
to	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
1995	O	NUM	O
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
excess	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
among	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
CHH	B-Disease	NOUN	B
(	O	PUNCT	O
standardized	O	ADJ	B
incidence	O	NOUN	I
ratio	O	NOUN	I
6	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O
3	O	NUM	O
to	O	PART	O
16	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
mainly	O	ADV	O
attributable	O	ADJ	O
to	O	PART	O
non	B-Disease	ADV	B
-	I-Disease	PUNCT	O
Hodgkins	I-Disease	NOUN	B
lymphoma	I-Disease	NOUN	I
(	O	PUNCT	O
standardized	O	ADJ	B
incidence	O	NOUN	I
ratio	O	NOUN	I
90	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
18	O	NUM	O
to	O	PART	O
264	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
excess	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
basal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
was	O	AUX	O
seen	O	VERB	O
(	O	PUNCT	O
standardized	O	ADJ	B
incidence	O	NOUN	I
ratio	O	NOUN	I
35	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
7	O	NUM	I
.	O	PUNCT	O
2	O	NUM	O
to	O	PART	O
102	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
cancer	B-Disease	NOUN	B
incidence	O	NOUN	B
among	O	ADP	O
the	O	DET	O
siblings	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
parents	O	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
from	O	ADP	O
the	O	DET	O
average	O	ADJ	B
cancer	B-Disease	NOUN	B
incidence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Finnish	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
confirms	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
Hodgkins	I-Disease	NOUN	B
lymphoma	I-Disease	NOUN	I
,	O	PUNCT	O
probably	O	ADV	O
attributable	O	ADJ	O
to	O	PART	O
defective	O	ADJ	B
immunity	O	NOUN	B
,	O	PUNCT	O
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
CHH	B-Disease	NOUN	B
.	O	PUNCT	O


Genotype	O	NOUN	B
and	O	CCONJ	O
phenotype	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
dihydropyrimidine	B-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Dihydropyrimidine	B-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
DPD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
characterised	O	VERB	O
by	O	ADP	O
thymine	O	NOUN	B
-	O	PUNCT	O
uraciluria	O	NOUN	B
in	O	ADP	O
homozygous	O	ADJ	B
deficient	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
variable	O	ADJ	B
clinical	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
and	O	CCONJ	O
phenotypic	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
DPD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
reviewed	O	VERB	B
17	O	NUM	O
families	O	NOUN	B
presenting	O	VERB	O
22	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
complete	O	ADJ	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
DPD	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
including	O	VERB	O
2	O	NUM	O
deletions	O	NOUN	B
[	O	PUNCT	O
295	O	NUM	O
-	O	PUNCT	O
298delTCAT	O	NOUN	B
,	O	PUNCT	O
1897delC	O	NOUN	O
]	O	PUNCT	O
,	O	PUNCT	O
1	O	NUM	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
[	O	PUNCT	O
IVS14	O	NOUN	B
+	O	CCONJ	I
1G	O	NOUN	O
>	O	X	O
A	O	NOUN	O
)	O	PUNCT	O
]	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
85T	O	NOUN	O
>	O	X	O
C	O	NOUN	B
,	O	PUNCT	O
703C	O	X	O
>	O	X	O
T	O	NOUN	B
,	O	PUNCT	O
2658G	O	PROPN	O
>	O	X	O
A	O	NOUN	O
,	O	PUNCT	O
2983G	O	ADJ	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
various	O	ADJ	O
mutations	O	NOUN	B
among	O	ADP	O
DPD	B-Disease	NOUN	B
patients	O	NOUN	B
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
point	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
invariant	O	ADJ	B
splice	O	NOUN	I
donor	O	NOUN	I
site	O	NOUN	I
is	O	AUX	O
by	O	ADP	O
far	O	ADV	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
(	O	PUNCT	O
52	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
six	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
less	O	ADV	O
frequently	O	ADV	O
observed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
large	O	ADJ	O
phenotypic	O	ADJ	B
variability	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
convulsive	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
motor	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
being	O	AUX	O
the	O	DET	O
most	O	ADV	O
abundant	O	ADJ	B
manifestations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
clear	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
and	O	CCONJ	O
phenotype	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
established	O	VERB	O
.	O	PUNCT	O


An	O	DET	O
altered	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
alanine	O	NOUN	B
,	O	PUNCT	O
uracil	O	NOUN	B
and	O	CCONJ	O
thymine	O	NOUN	B
homeostasis	O	NOUN	B
might	O	AUX	O
underlie	O	VERB	O
the	O	DET	O
various	O	ADJ	O
clinical	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
encountered	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
DPD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Fibroblast	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
homologous	O	ADJ	I
factor	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
FHF2	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
gene	O	NOUN	B
structure	O	NOUN	I
,	O	PUNCT	O
expression	O	NOUN	B
and	O	CCONJ	O
mapping	O	NOUN	B
to	O	ADP	O
the	O	DET	O
Borjeson	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Forssman	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lehmann	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
region	O	NOUN	I
in	O	ADP	O
Xq26	O	NOUN	B
delineated	O	VERB	O
by	O	ADP	O
a	O	DET	O
duplication	O	NOUN	B
breakpoint	O	NOUN	O
in	O	ADP	O
a	O	DET	O
BFLS	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
patient	O	NOUN	B
.	O	PUNCT	O


Borjeson	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Forssman	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lehmann	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
BFLS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
syndromal	O	ADJ	B
X	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
mental	I-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
by	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
q26	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	O
a	O	DET	O
male	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
BFLS	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
features	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
duplication	O	NOUN	B
,	O	PUNCT	O
46	O	NUM	O
,	O	PUNCT	O
Y	O	NOUN	B
,	O	PUNCT	O
dup	O	NOUN	O
(	O	PUNCT	O
X	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
q26q28	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
inherited	O	VERB	B
from	O	ADP	O
his	O	PRON	O
phenotypically	O	ADV	B
normal	O	ADJ	I
mother	O	NOUN	B
.	O	PUNCT	O


Fluorescence	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridisation	O	NOUN	I
using	O	VERB	O
yeast	O	NOUN	B
artificial	O	ADJ	O
chromosome	O	NOUN	O
clones	O	NOUN	O
from	O	ADP	O
Xq26	O	NOUN	B
localised	O	VERB	I
the	O	DET	O
duplication	O	NOUN	B
breakpoint	O	NOUN	O
to	O	PART	O
an	O	DET	O
approximately	O	ADV	B
400	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
interval	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Xq26	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
region	O	NOUN	O
between	O	ADP	O
DXS155	O	NOUN	B
and	O	CCONJ	O
DXS294	O	PROPN	B
/	O	SYM	O
DXS730	O	NOUN	B
.	O	PUNCT	O


Database	O	NOUN	B
searches	O	NOUN	B
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
available	O	ADJ	O
genomic	O	ADJ	B
DNA	O	NOUN	I
sequence	O	NOUN	I
from	O	ADP	O
the	O	DET	O
region	O	NOUN	B
revealed	O	VERB	B
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
fibroblast	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
homologous	O	ADJ	I
factor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
FHF2	O	NOUN	B
,	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
duplication	O	NOUN	B
breakpoint	O	NOUN	O
interval	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
structure	O	NOUN	I
of	O	ADP	O
FHF2	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
and	O	CCONJ	O
two	O	NUM	O
new	O	ADJ	O
exons	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
new	O	ADJ	O
5	O	NUM	O
end	O	NOUN	O
exon	O	NOUN	B
,	O	PUNCT	O
1B	O	NOUN	B
.	O	PUNCT	O


FHF2	O	NOUN	B
is	O	AUX	O
a	O	DET	O
large	O	ADJ	O
gene	O	NOUN	B
extending	O	VERB	O
over	O	ADV	O
approximately	O	ADV	O
200	O	NUM	O
kb	O	NOUN	O
in	O	ADP	O
Xq26	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
and	O	CCONJ	O
is	O	AUX	O
composed	O	VERB	O
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
seven	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
shows	O	VERB	O
tissue	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
alternative	O	ADJ	B
splicing	O	NOUN	B
and	O	CCONJ	O
alternative	O	ADJ	B
transcription	O	NOUN	B
starts	O	NOUN	O
.	O	PUNCT	O


Northern	O	NOUN	B
blot	O	NOUN	I
hybridisation	O	NOUN	I
showed	O	VERB	O
highest	O	ADJ	O
expression	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
FHF2	O	NOUN	B
gene	O	NOUN	B
localisation	O	NOUN	I
and	O	CCONJ	O
tissue	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
expression	O	NOUN	B
pattern	O	NOUN	O
suggest	O	VERB	O
it	O	PRON	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
familial	O	ADJ	B
cases	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BFLS	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
syndromal	O	ADJ	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
mental	I-Disease	ADJ	B
retardation	I-Disease	NOUN	I
mapping	O	NOUN	O
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
E	O	PROPN	I
-	O	PUNCT	O
cadherin	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CDH1	O	NOUN	B
)	O	PUNCT	O
mutations	O	NOUN	B
predispose	O	VERB	O
to	O	PART	O
familial	B-Disease	ADJ	B
gastric	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Inherited	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
E	O	PROPN	B
-	O	PUNCT	O
cadherin	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CDH1	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
described	O	VERB	O
recently	O	ADV	O
in	O	ADP	O
three	O	NUM	O
Maori	O	ADJ	B
kindreds	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
gastric	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
gastric	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
is	O	AUX	O
genetically	O	ADV	B
heterogeneous	O	ADJ	I
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
what	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Maori	O	PROPN	B
populations	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
germline	O	NOUN	B
CDH1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
screened	O	VERB	B
eight	O	NUM	O
familial	B-Disease	ADJ	B
gastric	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
kindreds	O	NOUN	B
of	O	ADP	O
British	O	ADJ	B
and	O	CCONJ	O
Irish	O	ADJ	B
origin	O	NOUN	B
for	O	ADP	O
germline	O	NOUN	B
CDH1	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
all	O	DET	O
16	O	NUM	O
exons	O	NOUN	B
and	O	CCONJ	O
flanking	O	ADJ	O
sequences	O	NOUN	O
.	O	PUNCT	O


Each	O	DET	O
family	O	NOUN	B
contained	O	VERB	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
first	O	ADJ	O
degree	O	NOUN	O
relatives	O	NOUN	O
with	O	ADP	O
one	O	NUM	O
affected	O	VERB	B
before	O	ADP	O
age	O	NOUN	B
50	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
or	O	CCONJ	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
three	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Novel	O	ADJ	B
germline	O	NOUN	B
CDH1	O	NOUN	B
mutations	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
nonsense	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
splice	O	NOUN	B
site	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
truncate	O	VERB	B
the	O	DET	O
E	O	PROPN	B
-	O	PUNCT	O
cadherin	O	NOUN	B
protein	O	NOUN	I
in	O	ADP	O
the	O	DET	O
signal	O	NOUN	B
peptide	O	NOUN	I
domain	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
penetrance	O	NOUN	B
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
both	O	CCONJ	O
gastric	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
colorectal	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
;	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
six	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
CDH1	O	NOUN	B
mutation	O	NOUN	B
carrier	O	NOUN	I
developed	O	VERB	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
at	O	ADP	O
age	O	NOUN	B
30	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
confirmed	O	VERB	O
that	O	SCONJ	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
CDH1	O	NOUN	B
gene	O	NOUN	B
cause	O	VERB	O
familial	B-Disease	ADJ	B
gastric	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Maori	O	PROPN	B
populations	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
minority	O	NOUN	B
of	O	ADP	O
familial	O	ADJ	B
gastric	B-Disease	ADJ	I
cancers	I-Disease	NOUN	I
can	O	AUX	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
CDH1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
E	O	PROPN	B
-	O	PUNCT	O
cadherin	O	NOUN	B
function	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
sporadic	O	ADJ	B
colorectal	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
other	I-Disease	ADJ	O
cancers	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
our	O	PRON	O
findings	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
germline	O	NOUN	B
CDH1	O	NOUN	B
mutations	O	NOUN	B
predispose	O	VERB	O
to	O	PART	O
early	O	ADJ	B
onset	O	NOUN	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
CDH1	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
investigated	O	VERB	B
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
inherited	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
both	O	CCONJ	O
gastric	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
colorectal	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
truncation	O	NOUN	B
of	O	ADP	O
murine	O	ADJ	B
WT1	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
characteristic	O	ADJ	B
urogenital	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
of	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
WT1	O	NOUN	B
,	O	PUNCT	O
plays	O	VERB	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
urogenital	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
WT1	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	O
is	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
neoplastic	B-Disease	ADJ	B
(	O	PUNCT	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
,	O	PUNCT	O
mesothelioma	B-Disease	NOUN	B
,	O	PUNCT	O
leukemias	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
nonneoplastic	B-Disease	ADJ	B
(	O	PUNCT	O
glomerulosclerosis	B-Disease	NOUN	O
)	O	PUNCT	O
disease	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
diseases	O	NOUN	B
linked	O	VERB	O
specifically	O	ADV	O
with	O	ADP	O
WT1	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
DDS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
can	O	AUX	O
provide	O	VERB	O
valuable	O	ADJ	O
insight	O	NOUN	O
concerning	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
WT1	O	NOUN	B
in	O	ADP	O
development	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
.	O	PUNCT	O


DDS	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
childhood	O	NOUN	B
disease	O	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
nephropathy	B-Disease	NOUN	B
involving	O	VERB	O
mesangial	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
,	O	PUNCT	O
XY	O	NOUN	B
pseudohermaphroditism	B-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
(	O	PUNCT	O
WT	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DDS	B-Disease	NOUN	B
patients	O	NOUN	B
are	O	AUX	O
constitutionally	O	ADV	O
heterozygous	O	ADJ	B
for	O	ADP	O
exonic	O	ADJ	B
point	O	NOUN	I
mutations	O	NOUN	I
in	O	ADP	O
WT1	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
include	O	VERB	O
mutations	O	NOUN	B
predicted	O	VERB	O
to	O	PART	O
truncate	O	VERB	O
the	O	DET	O
protein	O	NOUN	B
within	O	ADP	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
zinc	O	NOUN	B
finger	O	NOUN	I
(	O	PUNCT	O
ZF	O	NOUN	O
)	O	PUNCT	O
region	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
heterozygosity	O	NOUN	B
for	O	ADP	O
a	O	DET	O
targeted	O	VERB	O
murine	O	ADJ	B
Wt1	O	NOUN	B
allele	O	NOUN	B
,	O	PUNCT	O
Wt1	O	NOUN	B
(	O	PUNCT	O
tmT396	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
truncates	O	VERB	B
ZF3	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
396	O	NUM	I
,	O	PUNCT	O
induces	O	VERB	O
mesangial	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
characteristic	O	NOUN	O
of	O	ADP	O
DDS	B-Disease	NOUN	B
in	O	ADP	O
adult	O	ADJ	B
heterozygous	O	ADJ	B
and	O	CCONJ	O
chimeric	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Male	B-Disease	ADJ	B
genital	I-Disease	ADJ	B
defects	I-Disease	NOUN	I
also	O	ADV	O
were	O	AUX	O
evident	O	ADJ	B
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
single	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
in	O	ADP	O
which	O	DET	O
the	O	DET	O
transcript	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nontargeted	O	ADJ	B
allele	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
exon	O	NOUN	B
9	O	NUM	I
skipping	O	NOUN	B
event	O	NOUN	I
,	O	PUNCT	O
implying	O	VERB	O
a	O	DET	O
causal	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
Wt1	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
Wilms	B-Disease	NOUN	B
tumorigenesis	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mutant	O	ADJ	B
WT1	O	NOUN	B
(	O	PUNCT	O
tmT396	O	NOUN	B
)	O	PUNCT	O
protein	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
only	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
WT1	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
heterozygous	O	ADJ	B
embryonic	O	ADJ	I
stem	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
WT	B-Disease	PROPN	B
.	O	PUNCT	O


This	O	DET	O
has	O	AUX	O
implications	O	NOUN	O
regarding	O	VERB	O
the	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
exerts	O	VERB	O
its	O	PRON	O
effect	O	NOUN	B
.	O	PUNCT	O


Mechanism	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
iron	O	NOUN	B
absorption	O	NOUN	I
in	O	ADP	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
:	O	PUNCT	O
increased	O	VERB	B
duodenal	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
iron	O	NOUN	B
transporter	O	NOUN	I
DMT1	O	NOUN	B
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
(	O	PUNCT	O
HH	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
tissue	O	NOUN	B
iron	O	NOUN	B
deposition	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
excessive	O	ADJ	B
dietary	O	ADJ	B
iron	O	NOUN	O
absorption	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
reported	O	VERB	O
that	O	SCONJ	O
HFE	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
defective	O	ADJ	B
in	O	ADP	O
HH	B-Disease	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
physically	O	ADV	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
transferrin	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
TfR	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
duodenal	O	ADJ	B
crypt	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
proposed	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
HFE	O	NOUN	B
attenuate	O	VERB	B
the	O	DET	O
uptake	O	NOUN	B
of	O	ADP	O
transferrin	O	NOUN	B
-	O	PUNCT	O
bound	O	VERB	B
iron	O	NOUN	B
from	O	ADP	O
plasma	O	NOUN	B
by	O	ADP	O
duodenal	O	ADJ	B
crypt	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	ADP	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
transporters	O	NOUN	B
for	O	ADP	O
dietary	O	ADJ	B
iron	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
HFE	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
have	O	AUX	O
increased	O	VERB	B
duodenal	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
divalent	O	ADJ	B
metal	O	NOUN	O
transporter	O	NOUN	O
(	O	PUNCT	O
DMT1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
HFE	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
demonstrated	O	VERB	O
iron	O	NOUN	B
loading	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
HFE	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
+	O	CCONJ	O
littermates	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
elevated	O	ADJ	B
transferrin	O	NOUN	B
saturations	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
.	O	PUNCT	O
49	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
elevated	O	ADJ	B
liver	O	NOUN	B
iron	O	NOUN	I
concentrations	O	NOUN	I
(	O	PUNCT	O
985	O	NUM	O
micrograms	O	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O
381	O	NUM	O
micrograms	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
Northern	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
quantitated	O	VERB	B
duodenal	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
both	O	DET	O
classes	O	NOUN	B
of	O	ADP	O
DMT1	O	NOUN	B
transcripts	O	NOUN	B
one	O	NUM	O
containing	O	VERB	O
an	O	DET	O
iron	O	NOUN	B
responsive	O	ADJ	I
element	O	NOUN	I
(	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
called	O	VERB	O
DMT1	O	NOUN	B
(	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
containing	O	VERB	O
no	O	DET	O
IRE	O	NOUN	B
,	O	PUNCT	O
called	O	VERB	O
DMT1	O	NOUN	B
(	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
IRE	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
positive	O	ADJ	B
control	O	NOUN	O
for	O	ADP	O
DMT1	O	NOUN	B
up	O	ADP	O
-	O	PUNCT	O
regulation	O	NOUN	B
was	O	AUX	O
a	O	DET	O
murine	O	ADJ	B
model	O	NOUN	B
of	O	ADP	O
dietary	B-Disease	ADJ	B
iron	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
that	O	PRON	O
demonstrated	O	VERB	O
greatly	O	ADV	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
duodenal	O	ADJ	B
DMT1	O	NOUN	B
(	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
mRNA	O	NOUN	B
.	O	PUNCT	O


HFE	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
also	O	ADV	O
demonstrated	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
duodenal	O	ADJ	B
DMT1	O	NOUN	B
(	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
mRNA	O	NOUN	B
(	O	PUNCT	O
average	O	NOUN	O
7	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
despite	O	SCONJ	O
their	O	PRON	O
elevated	O	ADJ	B
transferrin	O	NOUN	B
saturation	O	NOUN	B
and	O	CCONJ	O
hepatic	O	ADJ	B
iron	O	NOUN	I
content	O	NOUN	I
.	O	PUNCT	O


Duodenal	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
DMT1	O	NOUN	B
(	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
increased	O	VERB	B
,	O	PUNCT	O
nor	O	CCONJ	O
was	O	AUX	O
hepatic	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
DMT1	O	NOUN	B
increased	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
model	O	NOUN	B
for	O	ADP	O
HH	O	NOUN	B
in	O	ADP	O
which	O	DET	O
HFE	O	NOUN	B
mutations	O	NOUN	B
lead	O	VERB	O
to	O	PART	O
inappropriately	O	ADV	O
low	O	ADJ	B
crypt	O	NOUN	O
cell	O	NOUN	B
iron	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
resultant	O	ADJ	O
stabilization	O	NOUN	B
of	O	ADP	O
DMT1	O	NOUN	B
(	O	PUNCT	O
IRE	O	NOUN	B
)	O	PUNCT	O
mRNA	O	NOUN	B
,	O	PUNCT	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
DMT1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
absorption	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
iron	O	NOUN	I
.	O	PUNCT	O


Neurophysiologic	O	ADJ	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
dietary	O	ADJ	B
treatment	O	NOUN	I
in	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
adrenoleukodystrophy	B-Disease	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
monitor	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
dietary	O	ADJ	B
treatment	O	NOUN	I
in	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
adrenoleukodystrophy	B-Disease	NOUN	I
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
somatosensory	O	ADJ	B
evoked	O	VERB	I
potentials	O	NOUN	I
(	O	PUNCT	O
SEPs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
motor	O	NOUN	B
evoked	O	VERB	I
potentials	O	NOUN	I
(	O	PUNCT	O
MEPs	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
SEPs	O	NOUN	B
and	O	CCONJ	O
MEPs	O	NOUN	B
have	O	AUX	O
proved	O	VERB	O
useful	O	ADJ	O
in	O	ADP	O
revealing	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
progressively	O	ADV	O
severe	O	ADJ	B
,	O	PUNCT	O
central	O	ADJ	B
dying	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
back	I-Disease	NOUN	B
axonopathy	I-Disease	NOUN	I
in	O	ADP	O
early	O	ADJ	B
stages	O	NOUN	I
of	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Eight	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
ALD	B-Disease	NOUN	B
underwent	O	VERB	O
clinical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
brain	O	NOUN	B
and	O	CCONJ	O
spine	O	NOUN	B
MRI	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
SEP	O	PROPN	B
and	O	CCONJ	O
MEP	O	PROPN	B
studies	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
Lorenzos	O	PROPN	B
oil	O	NOUN	I
dietary	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	O
Before	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
MRI	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
pure	O	ADJ	O
spinal	B-Disease	ADJ	B
SEP	I-Disease	NOUN	O
abnormalities	I-Disease	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
two	O	NUM	O
patients	O	NOUN	B
SEPs	O	NOUN	B
showed	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
involvement	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
spinal	O	ADJ	B
and	O	CCONJ	O
cerebral	O	ADJ	B
somatosensory	O	ADJ	I
tracts	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
pure	O	ADJ	O
spinal	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
showed	O	VERB	O
clinical	O	ADJ	B
and	O	CCONJ	O
neurophysiologic	O	ADJ	B
worsening	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
more	O	ADV	O
advanced	O	ADJ	B
stage	O	NOUN	I
of	O	ADP	O
disease	O	NOUN	O
(	O	PUNCT	O
exhibited	O	VERB	O
by	O	ADP	O
SEPs	O	NOUN	B
)	O	PUNCT	O
showed	O	VERB	O
substantially	O	ADV	O
unchanged	O	ADJ	B
clinical	O	ADJ	B
and	O	CCONJ	O
neurophysiologic	O	ADJ	B
features	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
abnormal	O	ADJ	B
brain	O	NOUN	B
MRI	O	NOUN	I
at	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
treatment	O	NOUN	B
showed	O	VERB	O
clinical	O	ADJ	B
and	O	CCONJ	O
neurophysiologic	O	ADJ	B
worsening	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Lorenzos	O	PROPN	B
oil	O	NOUN	I
therapy	O	NOUN	I
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
inflammatory	B-Disease	ADJ	B
brain	I-Disease	NOUN	B
lesions	I-Disease	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
without	O	ADP	O
clear	O	ADJ	O
signs	O	NOUN	O
of	O	ADP	O
inflammatory	O	ADJ	B
damage	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
treatment	O	NOUN	B
does	O	AUX	O
not	O	PART	O
modify	O	VERB	O
significantly	O	ADV	O
the	O	DET	O
natural	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
because	O	SCONJ	O
effective	O	ADJ	B
treatments	O	NOUN	B
should	O	AUX	O
begin	O	VERB	O
before	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
severe	O	ADJ	B
neurologic	O	ADJ	B
symptoms	O	NOUN	I
,	O	PUNCT	O
SEPs	O	NOUN	B
and	O	CCONJ	O
MEPs	O	PROPN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effectiveness	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
experimental	O	ADJ	B
treatments	O	NOUN	I
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
negative	O	ADJ	B
brain	O	NOUN	B
MRI	O	NOUN	I
.	O	PUNCT	O


GCH1	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
oromandibular	B-Disease	ADJ	B
dystonia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
report	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
of	O	ADP	O
GCH1	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
oromandibular	B-Disease	ADJ	B
dystonia	I-Disease	NOUN	I
and	O	CCONJ	O
no	O	DET	O
obvious	O	ADJ	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
dystonia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
responded	O	VERB	B
positively	O	ADV	B
to	O	PART	O
treatment	O	NOUN	B
with	O	ADP	O
L	O	NOUN	B
-	O	PUNCT	O
dopa	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
GCH1	O	NOUN	B
mutations	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
even	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
dystonic	B-Disease	ADJ	B
symptoms	O	NOUN	I
not	O	PART	O
typical	O	ADJ	O
of	O	ADP	O
dopa	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
responsive	I-Disease	ADJ	B
dystonia	I-Disease	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Korean	O	ADJ	B
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
extensively	O	ADV	O
analyzed	O	VERB	O
genomic	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
messenger	O	NOUN	B
RNA	O	NOUN	I
(	O	PUNCT	O
mRNA	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
62	O	NUM	O
unrelated	O	ADJ	O
Korean	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
identification	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
adenomatous	B-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
adopted	O	VERB	O
both	O	CCONJ	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
method	O	NOUN	B
of	O	ADP	O
analysis	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
reverse	O	ADJ	B
transcription	O	NOUN	I
-	O	PUNCT	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
truncation	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
PTT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DNA	O	NOUN	B
sequencing	O	NOUN	I
confirmed	O	VERB	O
all	O	DET	O
alterations	O	NOUN	B
represented	O	VERB	O
by	O	ADP	O
aberrant	O	ADJ	B
bands	O	NOUN	O
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
38	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Nineteen	O	NUM	O
of	O	ADP	O
the	O	DET	O
detected	O	VERB	B
mutations	O	NOUN	B
were	O	AUX	O
presumed	O	VERB	O
to	O	PART	O
be	O	AUX	O
novel	O	ADJ	B
,	O	PUNCT	O
thus	O	ADV	O
emphasizing	O	VERB	O
the	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutational	O	ADJ	B
spectrum	O	NOUN	I
in	O	ADP	O
Korean	O	ADJ	B
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
48	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
PTT	O	PROPN	B
for	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
for	O	ADP	O
whom	O	PRON	O
no	O	DET	O
detectable	O	ADJ	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
by	O	ADP	O
SSCP	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
combined	O	ADJ	O
approach	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	O
germline	O	NOUN	B
APC	B-Disease	NOUN	I
gene	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
29	O	NUM	O
of	O	ADP	O
the	O	DET	O
48	O	NUM	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
including	O	VERB	O
6	O	NUM	O
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
SSCP	O	NOUN	B
analysis	O	NOUN	I
failed	O	VERB	B
to	O	PART	O
distinguish	O	VERB	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
14	O	NUM	O
later	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	O
truncating	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
9	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
64	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
using	O	VERB	O
PTT	O	PROPN	B
only	O	ADV	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
confirm	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
detection	O	NOUN	O
rate	O	NOUN	B
with	O	ADP	O
PTT	O	PROPN	B
was	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
that	O	DET	O
with	O	ADP	O
SSCP	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
PTT	O	PROPN	B
would	O	AUX	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
practical	O	ADJ	O
screening	O	NOUN	B
method	O	NOUN	I
to	O	PART	O
detect	O	VERB	B
germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
epidemiology	O	NOUN	I
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
heterozygotes	O	NOUN	B
with	O	ADP	O
an	O	DET	O
Arg95Stop	O	ADJ	B
mutation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
C9	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
ninth	I-Disease	ADJ	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
human	I-Disease	ADJ	B
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C9	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
complement	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Japan	O	PROPN	B
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
one	O	NUM	O
homozygote	O	NOUN	B
in	O	ADP	O
1000	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
very	O	ADV	O
rare	O	ADJ	O
in	O	ADP	O
other	O	ADJ	O
countries	O	NOUN	B
.	O	PUNCT	O


Genetic	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
Japanese	O	ADJ	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
TGA	O	NOUN	B
stop	O	VERB	I
codon	O	NOUN	B
for	O	ADP	O
Arg95	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
of	O	ADP	O
the	O	DET	O
C9	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
Arg95Stop	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
Japanese	O	ADJ	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
heterozygous	O	ADJ	B
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Arg95Stop	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
collected	O	VERB	O
DNA	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
300	O	NUM	O
individuals	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
the	O	DET	O
four	O	NUM	O
main	O	ADJ	O
islands	O	NOUN	O
of	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


Heterozygote	O	NOUN	B
detection	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
with	O	ADP	O
an	O	DET	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
system	O	NOUN	O
designed	O	VERB	O
to	O	PART	O
detect	O	VERB	B
exclusively	O	ADV	O
only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
mutant	O	ADJ	B
alleles	O	NOUN	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
confirmation	O	NOUN	B
with	O	ADP	O
PCR	O	NOUN	B
/	O	SYM	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	O
individuals	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
Arg95Stop	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


None	O	NOUN	O
was	O	AUX	O
homozygous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Arg95Stop	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
/	O	SYM	O
300	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
estimated	O	ADJ	B
frequency	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
complete	O	ADJ	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
homozygous	O	ADJ	B
Arg95Stop	O	ADJ	B
mutation	O	NOUN	I
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
frequencies	O	NOUN	B
determined	O	VERB	O
by	O	ADP	O
serological	O	ADJ	B
studies	O	NOUN	I


The	O	DET	O
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
HFE	O	NOUN	B
,	O	PUNCT	O
specifically	O	ADV	O
regulates	O	VERB	B
transferrin	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
iron	O	NOUN	B
uptake	O	NOUN	I
in	O	ADP	O
HeLa	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


HFE	O	NOUN	B
is	O	AUX	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
the	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
(	O	PUNCT	O
Feder	O	PROPN	B
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O


N	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Gnirke	O	PROPN	B
,	O	PUNCT	O
A	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Thomas	O	PROPN	B
,	O	PUNCT	O
W	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Tsuchihashi	O	PROPN	B
,	O	PUNCT	O
Z	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Ruddy	O	PROPN	B
,	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
.	O	PUNCT	O
,	O	PUNCT	O
Basava	O	PROPN	B
,	O	PUNCT	O
A	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Dormishian	O	ADJ	B
,	O	PUNCT	O
F	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Domingo	O	PROPN	B
,	O	PUNCT	O
R	O	PROPN	B
.	O	PUNCT	O


J	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Ellis	O	PROPN	B
,	O	PUNCT	O
M	O	PROPN	B
.	O	PUNCT	O


C	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Fullan	O	PROPN	B
,	O	PUNCT	O
A	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Hinton	O	PROPN	B
,	O	PUNCT	O
L	O	PROPN	B
.	O	PUNCT	O


M	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Jones	O	PROPN	B
,	O	PUNCT	O
N	O	PROPN	B
.	O	PUNCT	O


L	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Kimmel	O	PROPN	B
,	O	PUNCT	O
B	O	NOUN	B
.	O	PUNCT	O


E	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Kronmal	O	PROPN	B
,	O	PUNCT	O
G	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Lauer	O	PROPN	B
,	O	PUNCT	O
P	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Lee	O	PROPN	O
,	O	PUNCT	O
V	O	PROPN	B
.	O	PUNCT	O


K	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Loeb	O	PROPN	B
,	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O


B	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Mapa	O	NOUN	B
,	O	PUNCT	O
F	O	PROPN	B
.	O	PUNCT	O


A	O	DET	O
.	O	PUNCT	O
,	O	PUNCT	O
McClelland	O	PROPN	B
,	O	PUNCT	O
E	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Meyer	O	PROPN	B
,	O	PUNCT	O
N	O	PROPN	B
.	O	PUNCT	O


C	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Mintier	O	PROPN	B
,	O	PUNCT	O
G	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
.	O	PUNCT	O
,	O	PUNCT	O
Moeller	O	PROPN	B
,	O	PUNCT	O
N	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Moore	O	PROPN	B
,	O	PUNCT	O
T	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Morikang	O	PROPN	B
,	O	PUNCT	O
E	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Prasss	O	PROPN	B
,	O	PUNCT	O
C	O	PROPN	B
.	O	PUNCT	O


E	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Quintana	O	PROPN	B
,	O	PUNCT	O
L	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Starnes	O	PROPN	B
,	O	PUNCT	O
S	O	PROPN	B
.	O	PUNCT	O


M	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Schatzman	O	PROPN	B
,	O	PUNCT	O
R	O	PROPN	B
.	O	PUNCT	O


C	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Brunke	O	PROPN	B
,	O	PUNCT	O
K	O	PROPN	B
.	O	PUNCT	O


J	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Drayna	O	PROPN	B
,	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O


T	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Risch	O	PROPN	B
,	O	PUNCT	O
N	O	NOUN	B
.	O	PUNCT	O


J	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Bacon	O	PROPN	B
,	O	PUNCT	O
B	O	NOUN	B
.	O	PUNCT	O


R	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Wolff	O	PROPN	B
,	O	PUNCT	O
R	O	PROPN	B
.	O	PUNCT	O


R	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
1996	O	NUM	O
)	O	PUNCT	O
Nat	O	PROPN	O
.	O	PUNCT	O


Genet	O	NOUN	B
.	O	PUNCT	O


13	O	NUM	O
,	O	PUNCT	O
399	O	NUM	O
-	O	PUNCT	O
408	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
surface	O	NOUN	I
,	O	PUNCT	O
HFE	O	NOUN	B
complexes	O	NOUN	B
with	O	ADP	O
transferrin	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
TfR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
increasing	O	VERB	B
the	O	DET	O
dissociation	O	NOUN	B
constant	O	NOUN	B
of	O	ADP	O
transferrin	O	NOUN	B
(	O	PUNCT	O
Tf	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
its	O	PRON	O
receptor	O	NOUN	B
10	O	NUM	I
-	O	PUNCT	O
fold	O	ADJ	B
(	O	PUNCT	O
Gross	O	PROPN	B
,	O	PUNCT	O
C	O	PROPN	B
.	O	PUNCT	O


N	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Irrinki	O	PROPN	B
,	O	PUNCT	O
A	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Feder	O	PROPN	B
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
N	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Enns	O	PROPN	B
,	O	PUNCT	O
C	O	NOUN	B
.	O	PUNCT	O
A	O	DET	O
.	O	PUNCT	O
(	O	PUNCT	O
1998	O	NUM	O
)	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
Biol	O	NOUN	O
.	O	PUNCT	O
Chem	O	PROPN	O
.	O	PUNCT	O
273	O	NUM	O
,	O	PUNCT	O
22068	O	NUM	O
-	O	SYM	O
22074	O	NUM	O
;	O	PUNCT	O
Feder	O	PROPN	B
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
N	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
Penny	O	PROPN	B
,	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Irrinki	O	PROPN	B
,	O	PUNCT	O
A	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Lee	O	PROPN	O
,	O	PUNCT	O
V	O	PROPN	O
.	O	PUNCT	O
K	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
Lebron	O	PROPN	B
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
A	O	DET	O
.	O	PUNCT	O
,	O	PUNCT	O
Watson	O	PROPN	B
,	O	PUNCT	O
N	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Tsuchihashi	O	PROPN	B
,	O	PUNCT	O
Z	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Sigal	O	PROPN	B
,	O	PUNCT	O
E	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Bjorkman	O	PROPN	B
,	O	PUNCT	O
P	O	NOUN	O
.	O	PUNCT	O
J	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Schatzman	O	PROPN	B
,	O	PUNCT	O
R	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
(	O	PUNCT	O
1998	O	NUM	O
)	O	PUNCT	O
Proc	O	PROPN	O
.	O	PUNCT	O
Natl	O	NOUN	O
.	O	PUNCT	O


Acad	O	PROPN	B
.	O	PUNCT	O


Sci	O	PROPN	O
.	O	PUNCT	O


U	O	NOUN	B
S	O	NOUN	I
A	O	PROPN	I
95	O	NUM	I
,	O	PUNCT	O
1472	O	NUM	O
-	O	SYM	O
1477	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


HFE	O	NOUN	B
does	O	AUX	O
not	O	PART	O
remain	O	VERB	O
at	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
surface	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
traffics	O	VERB	B
with	O	ADP	O
TfR	O	NOUN	B
to	O	PART	O
Tf	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
internal	O	ADJ	B
compartments	O	NOUN	I
(	O	PUNCT	O
Gross	O	X	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1998	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
HeLa	O	NOUN	B
cell	O	NOUN	I
line	O	NOUN	I
in	O	ADP	O
which	O	DET	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
HFE	O	NOUN	B
is	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
tetracycline	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
HFE	O	NOUN	B
reduces	O	VERB	B
55Fe	O	NOUN	O
uptake	O	NOUN	B
from	O	ADP	O
Tf	O	NOUN	B
by	O	ADP	O
33	O	NUM	O
%	O	NOUN	O
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
endocytic	O	ADJ	B
or	O	CCONJ	O
exocytic	O	ADJ	B
rates	O	NOUN	I
of	O	ADP	O
TfR	O	NOUN	B
cycling	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
HFE	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
reduce	O	VERB	O
cellular	O	ADJ	B
acquisition	O	NOUN	I
of	O	ADP	O
iron	O	NOUN	B
from	O	ADP	O
Tf	O	NOUN	B
within	O	ADP	O
endocytic	O	ADJ	B
compartments	O	NOUN	I
.	O	PUNCT	O


HFE	O	NOUN	B
specifically	O	ADV	O
reduces	O	VERB	B
iron	O	NOUN	B
uptake	O	NOUN	I
from	O	ADP	O
Tf	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Tf	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
iron	O	NOUN	B
uptake	O	NOUN	I
from	O	ADP	O
Fe	O	PROPN	B
-	O	PUNCT	O
nitrilotriacetic	O	ADJ	B
acid	O	NOUN	I
is	O	AUX	O
not	O	PART	O
altered	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
explain	O	VERB	O
the	O	DET	O
decreased	O	VERB	B
ferritin	O	NOUN	B
levels	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
our	O	PRON	O
HeLa	O	NOUN	B
cell	O	NOUN	B
system	O	NOUN	I
and	O	CCONJ	O
demonstrate	O	VERB	O
the	O	DET	O
specific	O	ADJ	O
control	O	NOUN	B
of	O	ADP	O
HFE	O	NOUN	B
over	O	ADP	O
the	O	DET	O
Tf	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
pathway	O	NOUN	B
of	O	ADP	O
iron	O	NOUN	B
uptake	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
also	O	ADV	O
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
the	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
cellular	O	ADJ	B
iron	O	NOUN	I
homeostasis	O	NOUN	I
in	O	ADP	O
organs	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
,	O	PUNCT	O
pancreas	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
spleen	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
iron	O	NOUN	B
loaded	O	VERB	O
in	O	ADP	O
hereditary	B-Disease	ADJ	B
hemochromatotic	I-Disease	ADJ	B
individuals	O	NOUN	B
lacking	O	VERB	O
functional	O	ADJ	B
HFE	O	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
and	O	CCONJ	O
haplotype	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	B
fever	I-Disease	NOUN	I
reveal	O	VERB	O
new	O	ADJ	O
ancestral	O	ADJ	B
relationships	O	NOUN	B
and	O	CCONJ	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
high	O	ADJ	B
carrier	O	NOUN	I
frequency	O	NOUN	O
with	O	ADP	O
reduced	O	VERB	B
penetrance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
episodes	O	NOUN	B
of	O	ADP	O
fever	O	NOUN	B
with	O	ADP	O
serositis	B-Disease	NOUN	B
or	O	CCONJ	O
synovitis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
FMF	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
MEFV	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
cloned	O	VERB	B
recently	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
four	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
present	O	VERB	O
data	O	NOUN	B
from	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
and	O	CCONJ	O
Arab	O	ADJ	B
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
we	O	PRON	O
had	O	AUX	O
not	O	PART	O
originally	O	ADV	O
found	O	VERB	O
mutations	O	NOUN	B
and	O	CCONJ	O
from	O	ADP	O
a	O	DET	O
new	O	ADJ	O
,	O	PUNCT	O
more	O	ADV	O
ethnically	O	ADV	B
diverse	O	ADJ	O
panel	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
90	O	NUM	O
symptomatic	O	ADJ	B
mutation	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
individuals	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
mutations	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
79	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
carrier	O	NOUN	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
novel	O	ADJ	B
,	O	PUNCT	O
one	O	NUM	O
alters	O	VERB	O
the	O	DET	O
same	O	ADJ	O
residue	O	NOUN	B
(	O	PUNCT	O
680	O	NUM	O
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
previously	O	ADV	O
known	O	VERB	O
mutation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
(	O	PUNCT	O
P369S	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
another	O	DET	O
recent	O	ADJ	O
report	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
E148Q	O	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
ethnicities	O	NOUN	B
and	O	CCONJ	O
on	O	ADP	O
multiple	O	ADJ	B
microsatellite	O	NOUN	B
haplotypes	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
haplotype	O	NOUN	B
data	O	NOUN	B
indicate	O	VERB	O
an	O	DET	O
ancestral	O	ADJ	B
relationships	O	NOUN	B
between	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
Italian	O	ADJ	B
and	O	CCONJ	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
FMF	B-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
affected	O	VERB	B
populations	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
approximately	O	ADV	O
200	O	NUM	O
anonymous	O	ADJ	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
DNA	O	NOUN	B
samples	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
MEFV	O	NOUN	B
carrier	O	NOUN	O
frequency	O	NOUN	B
was	O	AUX	O
21	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
E148Q	O	NOUN	B
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
lines	O	NOUN	O
of	O	ADP	O
evidence	O	NOUN	B
indicate	O	VERB	O
reduced	O	VERB	B
penetrance	O	NOUN	B
among	O	ADP	O
Ashkenazi	O	PROPN	B
Jews	O	PROPN	B
,	O	PUNCT	O
especially	O	ADV	O
for	O	ADP	O
E148Q	O	NOUN	B
,	O	PUNCT	O
P369S	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
K695R	O	NOUN	B
.	O	PUNCT	O


Nevertheless	O	ADV	O
,	O	PUNCT	O
E148Q	O	NOUN	B
helps	O	VERB	O
account	O	NOUN	O
for	O	ADP	O
recessive	O	ADJ	B
inheritance	O	NOUN	I
in	O	ADP	O
an	O	DET	O
Ashkenazi	O	ADJ	B
family	O	NOUN	B
previously	O	ADV	O
reported	O	VERB	O
as	O	ADP	O
an	O	DET	O
unusual	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
dominantly	O	ADV	O
inherited	O	VERB	B
FMF	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
frequent	O	ADJ	B
MEFV	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
multiple	O	ADJ	O
Mediterranean	O	ADJ	B
populations	O	NOUN	B
strongly	O	ADV	O
suggests	O	VERB	O
a	O	DET	O
heterozygote	O	NOUN	B
advantage	O	NOUN	O
in	O	ADP	O
this	O	DET	O
geographic	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


Autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
with	O	ADP	O
defective	O	ADJ	B
Fas	O	NOUN	B
:	O	PUNCT	O
genotype	O	NOUN	B
influences	O	VERB	B
penetrance	O	NOUN	B
.	O	PUNCT	O


Autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALPS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
lymphocyte	I-Disease	NOUN	B
homeostasis	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
immunological	I-Disease	ADJ	B
tolerance	I-Disease	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
patients	O	NOUN	B
have	O	AUX	O
a	O	DET	O
heterozygous	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APT1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	O
Fas	O	NOUN	B
(	O	PUNCT	O
CD95	O	NOUN	B
,	O	PUNCT	O
APO	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
mediator	O	NOUN	O
of	O	ADP	O
an	O	DET	O
apoptotic	O	ADJ	B
pathway	O	NOUN	I
crucial	O	ADJ	O
to	O	PART	O
lymphocyte	O	NOUN	B
homeostasis	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
17	O	NUM	O
unique	O	ADJ	O
APT1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
unrelated	O	ADJ	O
ALPS	B-Disease	NOUN	B
probands	O	NOUN	B
,	O	PUNCT	O
12	O	NUM	O
(	O	PUNCT	O
71	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
exons	O	NOUN	B
7	O	NUM	O
-	O	SYM	O
9	O	NUM	B
,	O	PUNCT	O
which	O	DET	O
encode	O	VERB	B
the	O	DET	O
intracellular	O	ADJ	B
portion	O	NOUN	B
of	O	ADP	O
Fas	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
,	O	PUNCT	O
activated	O	VERB	B
lymphocytes	O	NOUN	I
from	O	ADP	O
all	O	DET	O
17	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
apoptotic	O	ADJ	B
defects	O	NOUN	I
when	O	SCONJ	O
exposed	O	VERB	B
to	O	PART	O
an	O	DET	O
anti	O	X	B
-	O	PUNCT	O
Fas	O	NOUN	B
agonist	O	NOUN	B
monoclonal	O	ADJ	B
antibody	O	NOUN	I
.	O	PUNCT	O


Similar	O	ADJ	O
defects	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
a	O	DET	O
Fas	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
cell	O	NOUN	B
line	O	NOUN	I
transfected	O	VERB	B
with	O	ADP	O
cDNAs	O	NOUN	B
bearing	O	VERB	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
cotransfection	O	NOUN	B
experiments	O	NOUN	I
,	O	PUNCT	O
Fas	O	NOUN	B
constructs	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
intra	O	ADJ	B
-	O	PUNCT	O
or	O	CCONJ	O
extracellular	O	ADJ	B
mutations	O	NOUN	I
caused	O	VERB	O
dominant	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
apoptosis	O	NOUN	B
mediated	O	VERB	O
by	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
Fas	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
missense	O	NOUN	B
Fas	O	NOUN	B
variants	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
restricted	O	ADJ	O
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
ALPS	B-Disease	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Variant	O	ADJ	B
A	O	NOUN	I
(	O	PUNCT	O
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
T	O	NOUN	B
at	O	ADP	O
the	O	DET	O
Fas	O	NOUN	B
signal	O	NOUN	B
-	O	PUNCT	O
sequence	O	NOUN	B
cleavage	O	NOUN	B
site	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
mediates	O	VERB	O
apoptosis	O	NOUN	B
less	O	ADV	O
well	O	ADV	O
than	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
Fas	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
partially	O	ADV	O
inhibitory	O	ADJ	B
,	O	PUNCT	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
African	O	ADJ	B
American	O	ADJ	I
alleles	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
ALPS	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
Fas	O	NOUN	B
mutants	O	NOUN	B
,	O	PUNCT	O
dominant	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
apoptosis	O	NOUN	B
was	O	AUX	O
much	O	ADV	O
more	O	ADV	O
pronounced	O	ADJ	O
in	O	ADP	O
mutants	O	NOUN	B
affecting	O	VERB	B
the	O	DET	O
intracellular	O	ADJ	B
,	O	PUNCT	O
versus	O	CCONJ	O
extracellular	O	ADJ	B
,	O	PUNCT	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Fas	O	NOUN	B
receptor	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
causing	O	VERB	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intracellular	O	ADJ	B
Fas	O	NOUN	B
death	O	NOUN	I
domain	O	NOUN	O
also	O	ADV	O
showed	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
penetrance	O	NOUN	B
of	O	ADP	O
ALPS	B-Disease	NOUN	B
phenotype	O	NOUN	B
features	O	NOUN	B
in	O	ADP	O
mutation	O	NOUN	B
-	O	PUNCT	O
bearing	O	VERB	B
relatives	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
ALPS	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
morbidity	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
44	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
relatives	O	NOUN	B
with	O	ADP	O
intracellular	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
versus	O	CCONJ	O
0	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
relatives	O	NOUN	B
with	O	ADP	O
extracellular	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
within	O	ADP	O
APT1	O	NOUN	B
strongly	O	ADV	O
influences	O	VERB	B
the	O	DET	O
development	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
ALPS	B-Disease	NOUN	B
.	O	PUNCT	O


Multicentric	O	ADJ	B
origin	O	NOUN	I
of	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
HFE	O	NOUN	B
)	O	PUNCT	O
mutations	O	NOUN	B
.	O	PUNCT	O


Genetic	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
(	O	PUNCT	O
GH	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
disease	O	NOUN	B
restricted	O	ADJ	B
to	O	PART	O
those	O	DET	O
of	O	ADP	O
European	O	ADJ	B
ancestry	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
northwestern	O	ADJ	B
Europe	O	PROPN	I
,	O	PUNCT	O
>	O	PROPN	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
GH	B-Disease	NOUN	B
patients	O	NOUN	B
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
one	O	NUM	O
mutation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
tyrosine	O	NOUN	B
for	O	ADP	O
cysteine	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
282	O	NUM	O
(	O	PUNCT	O
C282Y	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
unprocessed	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
GH	B-Disease	NOUN	B
patients	O	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
present	O	ADJ	O
,	O	PUNCT	O
C282Y	O	NOUN	B
and	O	CCONJ	O
H63D	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
this	O	DET	O
second	O	ADJ	O
mutation	O	NOUN	B
is	O	AUX	O
such	O	ADJ	O
that	O	SCONJ	O
it	O	PRON	O
appears	O	VERB	O
to	O	PART	O
predispose	O	VERB	O
1	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
to	O	PART	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
differ	O	VERB	O
,	O	PUNCT	O
C282Y	O	NOUN	B
being	O	AUX	O
limited	O	VERB	O
to	O	ADP	O
those	O	DET	O
of	O	ADP	O
northwestern	O	ADJ	B
European	O	ADJ	B
ancestry	O	NOUN	B
and	O	CCONJ	O
H63D	O	NOUN	B
being	O	AUX	O
found	O	VERB	O
at	O	ADP	O
allele	O	NOUN	B
frequencies	O	NOUN	B
>	O	VERB	O
5	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
Europe	O	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
countries	O	NOUN	B
bordering	O	VERB	O
the	O	DET	O
Mediterranean	O	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Middle	O	PROPN	B
East	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
Indian	O	ADJ	B
subcontinent	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
occurs	O	VERB	O
on	O	ADP	O
a	O	DET	O
haplotype	O	NOUN	B
that	O	PRON	O
extends	O	VERB	O
<	O	X	O
/	O	PUNCT	O
=	O	ADJ	O
6	O	NUM	O
Mb	O	NOUN	O
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
arisen	O	VERB	O
during	O	ADP	O
the	O	DET	O
past	O	NOUN	O
2	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
H63D	O	NOUN	B
mutation	O	NOUN	I
is	O	AUX	O
older	O	ADJ	B
and	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
occur	O	VERB	O
on	O	ADP	O
such	O	DET	O
a	O	DET	O
large	O	ADJ	O
extended	O	VERB	O
haplotype	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
haplotype	O	NOUN	B
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
extending	O	VERB	O
<	O	X	O
/	O	PUNCT	O
=	O	ADJ	O
700	O	NUM	O
kb	O	NOUN	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
the	O	DET	O
H63D	O	NOUN	B
and	O	CCONJ	O
C282Y	O	NOUN	B
mutations	O	NOUN	B
on	O	ADP	O
new	O	ADJ	O
haplotypes	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Sri	O	PROPN	B
Lanka	O	PROPN	I
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
H63D	O	NOUN	B
on	O	ADP	O
three	O	NUM	O
new	O	ADJ	O
haplotypes	O	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
found	O	VERB	O
C282Y	O	NOUN	B
on	O	ADP	O
one	O	NUM	O
new	O	ADJ	O
haplotype	O	NOUN	B
,	O	PUNCT	O
demonstrating	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
mutations	O	NOUN	B
have	O	AUX	O
arisen	O	VERB	O
independently	O	ADV	O
on	O	ADP	O
this	O	DET	O
island	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
HFE	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
the	O	DET	O
subject	O	NOUN	B
of	O	ADP	O
selection	O	NOUN	B
pressure	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
selection	O	NOUN	B
pressures	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
infectious	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
environmental	O	ADJ	B
conditions	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
other	O	ADJ	O
genetic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
anemia	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
retrospective	O	ADJ	B
anonymous	O	ADJ	O
pilot	O	NOUN	O
study	O	NOUN	O
in	O	ADP	O
screening	O	VERB	B
newborns	O	NOUN	I
for	O	ADP	O
HFE	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
Scandinavian	O	ADJ	B
populations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
retrospectively	O	ADV	B
analyzed	O	VERB	I
837	O	NUM	O
random	O	ADJ	B
anonymized	O	VERB	B
dried	O	VERB	O
blood	O	NOUN	O
spot	O	NOUN	O
(	O	PUNCT	O
DBS	O	NOUN	B
)	O	PUNCT	O
samples	O	NOUN	B
from	O	ADP	O
neonatal	O	ADJ	B
screening	O	NOUN	B
programs	O	NOUN	I
in	O	ADP	O
Scandinavia	O	PROPN	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
HFE	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
C282Y	O	NOUN	B
allele	O	NOUN	B
frequencies	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
+	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
Greenland	O	PROPN	B
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
Iceland	O	PROPN	B
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Faeroe	O	PROPN	B
Islands	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
Denmark	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
HFE	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
Denmark	O	PROPN	B
suggests	O	VERB	O
that	O	SCONJ	O
population	O	NOUN	B
screening	O	NOUN	B
for	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
highly	O	ADV	O
advantageous	O	ADJ	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
preventive	O	ADJ	B
health	O	NOUN	B
care	O	NOUN	I
.	O	PUNCT	O


Long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
follow	O	VERB	B
-	O	PUNCT	O
up	O	ADP	O
evaluation	O	NOUN	B
of	O	ADP	O
C282Y	O	NOUN	B
homozygotes	O	NOUN	B
and	O	CCONJ	O
H63D	O	NOUN	B
/	O	PUNCT	O
C282Y	O	NOUN	B
compound	O	NOUN	O
heterozygotes	O	NOUN	B
will	O	AUX	O
give	O	VERB	O
an	O	DET	O
indication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
penetrance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alkaptonuria	B-Disease	NOUN	B
mouse	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


Alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
aku	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
inborn	B-Disease	ADJ	B
error	I-Disease	NOUN	I
of	I-Disease	ADP	O
metabolism	I-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
homogentisate	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
dioxygenase	O	NOUN	B
(	O	PUNCT	O
HGD	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
created	O	VERB	O
by	O	ADP	O
ethylnitrosourea	O	NOUN	B
mutagenesis	O	NOUN	I
but	O	CCONJ	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
these	O	DET	O
mice	O	NOUN	B
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	NOUN	B
to	O	PART	O
amplify	O	VERB	O
the	O	DET	O
Hgd	O	NOUN	B
cDNA	O	NOUN	I
from	O	ADP	O
Hgd	O	NOUN	B
(	O	PUNCT	O
aku	O	NOUN	B
)	O	PUNCT	O
/	O	SYM	O
Hgd	O	PROPN	B
(	O	PUNCT	O
aku	O	NOUN	B
)	O	PUNCT	O
mice	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
products	O	NOUN	B
shorter	O	ADJ	B
than	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
product	O	NOUN	B
were	O	AUX	O
amplified	O	VERB	B
.	O	PUNCT	O


Restriction	O	NOUN	B
mapping	O	NOUN	I
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
were	O	AUX	O
then	O	ADV	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
Hgd	O	PROPN	B
(	O	PUNCT	I
aku	O	NOUN	I
)	O	PUNCT	O
mouse	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
single	O	ADJ	O
base	O	NOUN	O
change	O	NOUN	O
in	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
consensus	O	NOUN	B
sequence	O	NOUN	I
,	O	PUNCT	O
causing	O	VERB	O
exon	O	NOUN	B
skipping	O	NOUN	I
and	O	CCONJ	O
frame	O	NOUN	B
-	O	PUNCT	O
shifted	O	VERB	B
products	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
base	O	NOUN	B
change	O	NOUN	I
allowed	O	VERB	O
us	O	PRON	O
to	O	PART	O
create	O	VERB	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
radioactive	O	ADJ	B
genotyping	O	NOUN	O
assay	O	NOUN	O
for	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
.	O	PUNCT	O


Non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	O
associated	O	VERB	B
with	O	ADP	I
enlarged	B-Disease	ADJ	B
vestibular	I-Disease	ADJ	B
aqueduct	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
PDS	B-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Enlarged	B-Disease	ADJ	B
vestibular	I-Disease	ADJ	I
aqueduct	I-Disease	NOUN	I
(	O	PUNCT	O
EVA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
known	O	VERB	O
as	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
inner	B-Disease	ADJ	B
ear	I-Disease	NOUN	I
abnormality	I-Disease	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
of	O	ADP	O
particular	O	ADJ	O
genetic	O	ADJ	B
interest	O	NOUN	O
because	O	SCONJ	O
this	O	DET	O
anomaly	O	NOUN	B
is	O	AUX	O
inherited	O	VERB	B
in	O	ADP	O
a	O	DET	O
recessive	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
locus	O	NOUN	B
for	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
sensorineural	I-Disease	ADJ	O
hearing	I-Disease	NOUN	O
loss	I-Disease	NOUN	O
with	O	ADP	O
EVA	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
chromosomal	O	ADJ	B
region	O	NOUN	I
,	O	PUNCT	O
7q31	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
seven	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
PDS	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
families	O	NOUN	B
of	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
sensorineural	I-Disease	ADJ	O
hearing	I-Disease	NOUN	O
loss	I-Disease	NOUN	O
with	O	ADP	O
EVA	B-Disease	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
family	O	NOUN	B
is	O	AUX	O
homozygous	O	ADJ	B
,	O	PUNCT	O
three	O	NUM	O
families	O	NOUN	B
are	O	AUX	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
families	O	NOUN	B
are	O	AUX	O
heterozygous	O	ADJ	B
but	O	CCONJ	O
with	O	ADP	O
no	O	DET	O
other	O	ADJ	O
mutation	O	NOUN	B
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
PDS	O	PROPN	B
cause	O	VERB	O
both	O	CCONJ	O
syndromic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
non	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Mutational	O	ADJ	B
analysis	O	NOUN	I
and	O	CCONJ	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
of	O	ADP	O
29	O	NUM	O
unrelated	O	ADJ	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
disease	I-Disease	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
progressive	O	ADJ	B
neurologic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
occasionally	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
adrenal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
classic	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
ALD	B-Disease	NOUN	B
usually	O	ADV	O
has	O	AUX	O
onset	O	NOUN	O
in	O	ADP	O
childhood	O	NOUN	O
(	O	PUNCT	O
childhood	B-Disease	NOUN	B
cerebral	I-Disease	ADJ	I
ALD	I-Disease	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
rapid	O	ADJ	O
neurologic	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
vegetative	O	ADJ	B
state	O	NOUN	I
.	O	PUNCT	O


Adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
also	O	ADV	O
presents	O	VERB	O
with	O	ADP	O
rapidly	O	ADV	O
progressive	O	ADJ	B
neurologic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Milder	O	ADJ	B
phenotypes	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
adrenomyeloneuropathy	B-Disease	ADJ	B
and	O	CCONJ	O
Addison	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
only	O	ADV	O
also	O	ADV	O
have	O	AUX	O
been	O	AUX	O
recognized	O	VERB	O
.	O	PUNCT	O


Despite	O	SCONJ	O
discovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
causative	O	ADJ	B
gene	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
the	O	DET	O
diverse	O	ADJ	B
clinical	O	ADJ	B
presentations	O	NOUN	O
remains	O	VERB	O
to	O	PART	O
be	O	AUX	O
elucidated	O	VERB	O
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
conduct	O	VERB	O
mutational	O	ADJ	B
analyses	O	NOUN	I
in	O	ADP	O
29	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
from	O	ADP	O
29	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
obtain	O	VERB	O
knowledge	O	NOUN	B
of	O	ADP	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
study	O	VERB	B
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
29	O	NUM	O
patients	O	NOUN	B
comprised	O	VERB	O
13	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
childhood	B-Disease	NOUN	B
cerebral	I-Disease	ADJ	I
ALD	I-Disease	NOUN	I
,	O	PUNCT	O
11	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adrenomyeloneuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
detailed	O	ADJ	O
mutational	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
29	O	NUM	O
unrelated	O	ADJ	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
by	O	ADP	O
genomic	O	ADJ	B
Southern	O	NOUN	I
blot	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
direct	O	ADJ	B
nucleotide	O	NOUN	I
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
-	O	PUNCT	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
products	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
total	O	ADJ	O
RNA	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
extracted	O	VERB	O
from	O	ADP	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	O
,	O	PUNCT	O
lymphoblastoid	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
were	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
having	O	VERB	O
large	O	ADJ	O
genomic	O	ADJ	B
rearrangements	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
26	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
having	O	VERB	O
21	O	NUM	O
independent	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
12	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
small	O	ADJ	B
nucleotide	O	NOUN	B
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
.	O	PUNCT	O


Eighteen	O	NUM	O
(	O	PUNCT	O
69	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
26	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
missense	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
involved	O	VERB	O
amino	O	NOUN	B
acids	O	NOUN	I
conserved	O	VERB	O
in	O	ADP	O
homologous	O	ADJ	B
gene	O	NOUN	I
products	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
PMP70	O	NOUN	B
,	O	PUNCT	O
mALDRP	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Pxa1p	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
AG	O	NOUN	B
dinucleotide	O	NOUN	O
deletion	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
1081	O	NUM	O
-	O	SYM	O
1082	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
white	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
identified	O	VERB	O
as	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
phenotypes	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
mutations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
protein	O	NOUN	B
truncation	O	NOUN	I
or	O	CCONJ	O
subtle	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
changes	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
phenotypic	O	ADJ	B
expressions	O	NOUN	B
between	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
involving	O	VERB	O
conserved	O	VERB	O
amino	O	NOUN	B
acids	O	NOUN	I
and	O	CCONJ	O
those	O	DET	O
involving	O	VERB	O
nonconserved	O	ADJ	B
amino	O	NOUN	I
acids	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
There	O	PRON	O
are	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
correlations	O	NOUN	B
between	O	ADP	O
the	O	DET	O
phenotypes	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
genotypes	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
genetic	O	ADJ	B
or	O	CCONJ	O
environmental	O	ADJ	B
factors	O	NOUN	I
modify	O	VERB	B
the	O	DET	O
phenotypic	O	ADJ	B
expressions	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
human	O	ADJ	B
skin	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
activating	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
.	O	PUNCT	O


WNT	O	NOUN	B
signalling	O	NOUN	B
orchestrates	O	VERB	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
developmental	O	ADJ	B
programs	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
response	O	NOUN	B
to	O	ADP	O
this	O	DET	O
stimulus	O	NOUN	B
,	O	PUNCT	O
cytoplasmic	O	ADJ	B
beta	O	NOUN	O
-	O	PUNCT	O
catenin	O	NOUN	B
(	O	PUNCT	O
encoded	O	VERB	B
by	O	ADP	O
CTNNB1	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
stabilized	O	VERB	B
,	O	PUNCT	O
enabling	O	VERB	O
downstream	O	ADJ	B
transcriptional	O	ADJ	B
activation	O	NOUN	I
by	O	ADP	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LEF	O	NOUN	B
/	O	SYM	O
TCF	O	NOUN	B
family	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
target	O	NOUN	B
genes	O	NOUN	O
for	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	PROPN	B
/	O	SYM	O
TCF	O	PROPN	B
encodes	O	VERB	O
c	O	X	O
-	O	PUNCT	O
MYC	O	NOUN	B
,	O	PUNCT	O
explaining	O	VERB	O
why	O	SCONJ	O
constitutive	O	ADJ	B
activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WNT	O	NOUN	B
pathway	O	NOUN	I
can	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
the	O	DET	O
colon	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
colon	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
arise	O	VERB	O
from	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
protein	O	NOUN	B
required	O	VERB	O
for	O	ADP	O
ubiquitin	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
degradation	O	NOUN	B
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
small	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
colon	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
some	I-Disease	DET	O
other	I-Disease	ADJ	O
cancers	I-Disease	NOUN	B
harbour	O	VERB	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
-	O	PUNCT	O
stabilizing	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
discovered	O	VERB	O
that	O	SCONJ	O
transgenic	O	ADJ	B
mice	O	NOUN	I
expressing	O	VERB	B
an	O	DET	O
activated	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
are	O	AUX	O
predisposed	O	VERB	O
to	O	ADP	O
developing	O	VERB	O
skin	B-Disease	NOUN	B
tumours	I-Disease	NOUN	I
resembling	O	VERB	O
pilomatricomas	B-Disease	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
skin	O	NOUN	B
of	O	ADP	O
these	O	DET	O
adult	O	ADJ	B
mice	O	NOUN	B
also	O	ADV	O
exhibits	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
de	O	X	O
novo	O	X	O
hair	O	NOUN	B
-	O	PUNCT	O
follicle	O	NOUN	B
morphogenesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
wondered	O	VERB	O
whether	O	SCONJ	O
human	O	ADJ	B
pilomatricomas	B-Disease	NOUN	B
might	O	AUX	O
originate	O	VERB	O
from	O	ADP	O
hair	O	NOUN	B
matrix	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
whether	O	SCONJ	O
they	O	PRON	O
might	O	AUX	O
possess	O	VERB	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
-	O	PUNCT	O
stabilizing	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
explore	O	VERB	O
the	O	DET	O
cell	O	NOUN	B
origin	O	NOUN	I
and	O	CCONJ	O
aetiology	O	NOUN	B
of	O	ADP	O
this	O	DET	O
common	O	ADJ	O
human	O	ADJ	B
skin	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
nuclear	O	ADJ	B
LEF	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
the	O	DET	O
dividing	O	VERB	B
tumour	B-Disease	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
providing	O	VERB	O
biochemical	O	ADJ	B
evidence	O	NOUN	B
that	O	SCONJ	O
pilomatricomas	B-Disease	NOUN	B
are	O	AUX	O
derived	O	VERB	O
from	O	ADP	O
hair	O	NOUN	B
matrix	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


At	O	ADV	O
least	O	ADV	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
these	O	DET	O
tumours	B-Disease	NOUN	B
possess	O	VERB	O
mutations	O	NOUN	B
affecting	O	VERB	B
the	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
segment	O	NOUN	B
,	O	PUNCT	O
normally	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
phosphorylation	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
,	O	PUNCT	O
ubiquitin	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
degradation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
CTNNB1	O	NOUN	B
mutations	O	NOUN	B
is	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
all	O	DET	O
other	O	ADJ	O
human	O	ADJ	B
tumours	B-Disease	NOUN	I
examined	O	VERB	B
thus	O	ADV	O
far	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
directly	O	ADV	O
implicates	O	VERB	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
/	O	SYM	O
LEF	O	NOUN	B
misregulation	O	NOUN	B
as	O	ADP	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
hair	O	NOUN	B
matrix	O	NOUN	I
cell	O	NOUN	I
tumorigenesis	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
gene	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
chloride	O	NOUN	B
-	O	PUNCT	O
iodide	O	NOUN	B
transport	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
syndromic	B-Disease	ADJ	B
deafness	I-Disease	NOUN	I
and	O	CCONJ	O
characterized	O	VERB	B
by	O	ADP	O
congenital	O	ADJ	B
sensorineural	B-Disease	ADJ	I
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
and	O	CCONJ	O
goitre	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
disorder	O	NOUN	B
was	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
7	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
gene	O	NOUN	B
causing	O	VERB	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PDS	B-Disease	PROPN	B
)	O	PUNCT	O
was	O	AUX	O
subsequently	O	ADV	O
identified	O	VERB	B
by	O	ADP	O
positional	O	ADJ	B
cloning	O	NOUN	I
.	O	PUNCT	O


PDS	O	PROPN	B
encodes	O	VERB	B
a	O	DET	O
putative	O	ADJ	B
transmembrane	O	ADJ	I
protein	O	NOUN	I
designated	O	VERB	O
pendrin	O	NOUN	B
.	O	PUNCT	O


Pendrin	O	NOUN	B
is	O	AUX	O
closely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
family	O	NOUN	B
of	O	ADP	O
sulfate	O	NOUN	B
transport	O	NOUN	I
proteins	O	NOUN	I
that	O	PRON	O
includes	O	VERB	O
the	O	DET	O
rat	O	NOUN	B
sulfate	O	NOUN	B
-	O	PUNCT	O
anion	O	NOUN	B
transporter	O	NOUN	I
(	O	PUNCT	O
encoded	O	VERB	B
by	O	ADP	O
Sat	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
identity	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
human	O	ADJ	B
diastrophic	B-Disease	ADJ	O
dysplasia	I-Disease	NOUN	O
sulfate	O	NOUN	B
transporter	O	NOUN	I
(	O	PUNCT	O
encoded	O	VERB	B
by	O	ADP	O
DTD	O	NOUN	B
;	O	PUNCT	O
32	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
human	O	ADJ	B
sulfate	O	NOUN	I
transporter	O	NOUN	I
downregulated	O	VERB	B
in	O	ADP	O
adenoma	B-Disease	NOUN	B
(	O	PUNCT	O
encoded	O	VERB	B
by	O	ADP	O
DRA	O	NOUN	B
;	O	PUNCT	O
45	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
this	O	DET	O
homology	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
slightly	O	ADV	O
modified	O	VERB	B
sulfate	O	NOUN	B
-	O	PUNCT	O
transporter	O	NOUN	B
signature	O	NOUN	O
sequence	O	NOUN	O
comprising	O	VERB	O
its	O	PRON	O
putative	O	ADJ	O
second	O	ADJ	O
transmembrane	O	ADJ	O
domain	O	NOUN	O
,	O	PUNCT	O
pendrin	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
to	O	PART	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
sulfate	O	NOUN	B
transporter	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
evidence	O	NOUN	B
of	O	ADP	O
sulfate	O	NOUN	B
transport	O	NOUN	I
following	O	VERB	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
pendrin	O	NOUN	B
in	O	ADP	O
Xenopus	O	NOUN	B
laevis	O	NOUN	I
oocytes	O	NOUN	B
by	O	ADP	O
microinjection	O	NOUN	B
of	O	ADP	O
PDS	O	X	B
cRNA	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
Sf9	O	NOUN	B
cells	O	NOUN	I
following	O	VERB	O
infection	O	NOUN	B
with	O	ADP	O
PDS	O	PROPN	B
-	O	PUNCT	O
recombinant	O	ADJ	B
baculovirus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rates	O	NOUN	B
of	O	ADP	O
transport	O	NOUN	B
for	O	ADP	O
iodide	O	NOUN	B
and	O	CCONJ	O
chloride	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
following	O	VERB	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
pendrin	O	NOUN	B
in	O	ADP	O
both	O	DET	O
cell	O	NOUN	B
systems	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
pendrin	O	NOUN	B
functions	O	VERB	B
as	O	ADP	O
a	O	DET	O
transporter	O	NOUN	B
of	O	ADP	O
chloride	O	NOUN	B
and	O	CCONJ	O
iodide	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
sulfate	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
provide	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
thyroid	O	NOUN	B
physiology	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


HFE	O	NOUN	B
mutations	O	NOUN	B
analysis	O	NOUN	O
in	O	ADP	O
711	O	NUM	O
hemochromatosis	B-Disease	NOUN	B
probands	O	NOUN	B
:	O	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
S65C	O	NOUN	B
implication	O	NOUN	B
in	O	ADP	O
mild	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
(	O	PUNCT	O
HH	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
of	O	ADP	O
iron	O	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
HFE	O	NOUN	B
candidate	O	NOUN	O
gene	O	NOUN	O
encoding	O	VERB	B
an	O	DET	O
HLA	O	NOUN	B
class	O	NOUN	I
I	O	NUM	I
-	O	PUNCT	O
like	O	ADJ	B
protein	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
HH	B-Disease	PROPN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
1996	O	NUM	O
.	O	PUNCT	O


Two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
C282Y	O	NOUN	B
,	O	PUNCT	O
accounting	O	VERB	O
for	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
to	O	PART	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
HH	B-Disease	NOUN	B
chromosomes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
H63D	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
milder	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
representing	O	VERB	O
40	O	NUM	O
%	O	NOUN	O
to	O	PART	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
C282Y	O	NOUN	B
HH	B-Disease	NOUN	B
chromosomes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
on	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
C282Y	O	NOUN	B
,	O	PUNCT	O
H63D	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
193A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
substitution	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
S65C	O	NOUN	B
missense	O	NOUN	B
substitution	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
probands	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
confirm	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
C282Y	O	NOUN	B
substitution	O	NOUN	B
was	O	AUX	O
the	O	DET	O
main	O	ADJ	O
mutation	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
,	O	PUNCT	O
accounting	O	VERB	O
for	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
carrier	O	NOUN	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
H63D	O	NOUN	B
substitution	O	NOUN	B
represented	O	VERB	O
39	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
HH	B-Disease	NOUN	B
chromosomes	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
carry	O	VERB	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
our	O	PRON	O
screening	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
S65C	O	NOUN	B
substitution	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
enriched	O	VERB	O
in	O	ADP	O
probands	O	NOUN	B
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
chromosome	O	NOUN	B
without	O	ADP	O
an	O	DET	O
assigned	O	VERB	B
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
substitution	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
HH	B-Disease	NOUN	B
chromosomes	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
neither	O	CCONJ	O
C282Y	O	NOUN	B
nor	O	CCONJ	O
H63D	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
enrichment	O	NOUN	O
of	O	ADP	O
S65C	O	NOUN	B
among	O	ADP	O
HH	B-Disease	NOUN	B
chromosomes	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
S65C	O	NOUN	B
substitution	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
mild	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
BRCA1	O	NOUN	B
alterations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
series	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
provide	O	VERB	O
more	O	ADV	O
accurate	O	ADJ	B
frequency	O	NOUN	B
estimates	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	O
gene	O	NOUN	O
1	O	NUM	O
(	O	PUNCT	O
BRCA1	O	NOUN	B
)	O	PUNCT	O
germline	O	NOUN	B
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
population	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
achieve	O	VERB	O
this	O	DET	O
,	O	PUNCT	O
we	O	PRON	O
determined	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
alterations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
series	O	NOUN	B
of	O	ADP	O
consecutive	O	ADJ	B
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
study	O	NOUN	B
reporting	O	VERB	O
BRCA1	O	NOUN	B
alterations	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
a	O	DET	O
comprehensive	O	ADJ	B
screen	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
seven	O	NUM	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
BRCA1	O	NOUN	B
alterations	O	NOUN	B
using	O	VERB	O
the	O	DET	O
RNase	O	NOUN	B
mismatch	O	NOUN	B
cleavage	O	NOUN	I
assay	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
truncating	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
962del4	O	NUM	B
and	O	CCONJ	O
3600del11	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Both	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
novel	O	ADJ	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
previously	O	ADV	O
reported	O	VERB	O
uncharacterized	O	ADJ	B
variants	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
identified	O	VERB	B
,	O	PUNCT	O
some	O	DET	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
cancer	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
distribution	O	NOUN	B
of	O	ADP	O
common	O	ADJ	O
polymorphisms	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
the	O	DET	O
91	O	NUM	O
Caucasian	O	ADJ	B
cancer	B-Disease	NOUN	B
cases	O	NOUN	B
in	O	ADP	O
this	O	DET	O
series	O	NOUN	B
and	O	CCONJ	O
24	O	NUM	O
sister	O	NOUN	B
controls	O	NOUN	I
using	O	VERB	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
amplification	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rare	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Q356R	O	NOUN	B
polymorphism	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
polymorphism	O	NOUN	B
may	O	AUX	O
influence	O	VERB	B
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risk	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
some	O	DET	O
uncharacterized	O	ADJ	B
variants	O	NOUN	B
and	O	CCONJ	O
rare	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
polymorphisms	O	NOUN	B
in	O	ADP	O
determining	O	VERB	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risk	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
highlight	O	VERB	O
the	O	DET	O
necessity	O	NOUN	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
missense	O	NOUN	B
alterations	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
truncating	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Adrenoleukodystrophy	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
protein	O	NOUN	B
can	O	AUX	O
compensate	O	VERB	O
functionally	O	ADV	O
for	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
protein	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
)	O	PUNCT	O
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Inherited	B-Disease	ADJ	B
defects	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
peroxisomal	O	ADJ	B
ATP	O	NOUN	I
-	O	PUNCT	O
binding	O	VERB	B
cassette	O	NOUN	I
(	O	PUNCT	O
ABC	O	NOUN	B
)	O	PUNCT	O
transporter	O	NOUN	O
adrenoleukodystrophy	B-Disease	NOUN	O
protein	O	NOUN	O
(	O	PUNCT	O
ALDP	O	NOUN	B
)	O	PUNCT	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
lethal	O	ADJ	B
peroxisomal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
for	O	ADP	O
which	O	DET	O
no	O	DET	O
efficient	O	ADJ	B
treatment	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
established	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


Three	O	NUM	O
other	O	ADJ	O
peroxisomal	O	ADJ	B
ABC	O	NOUN	I
transporters	O	NOUN	I
currently	O	ADV	O
are	O	AUX	O
known	O	VERB	O
adrenoleukodystrophy	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
protein	O	NOUN	B
(	O	PUNCT	O
ALDRP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
70	O	NUM	O
kDa	O	NOUN	O
peroxisomal	O	ADJ	B
membrane	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
PMP70	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
PMP70	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
protein	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
transient	O	ADJ	B
and	O	CCONJ	O
stable	O	ADJ	B
overexpression	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
cDNAs	O	NOUN	B
encoding	O	VERB	B
ALDP	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
closest	O	ADJ	O
relative	O	ADJ	O
ALDRP	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
could	O	AUX	O
restore	O	VERB	B
the	O	DET	O
impaired	O	ADJ	B
peroxisomal	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
in	O	ADP	O
fibroblasts	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pathognomonic	O	ADJ	B
accumulation	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
could	O	AUX	O
also	O	ADV	O
be	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
overexpression	O	NOUN	B
of	O	ADP	O
ALDRP	O	NOUN	B
in	O	ADP	O
immortalized	O	VERB	B
X	O	NOUN	I
-	O	PUNCT	O
ALD	O	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


Immunofluorescence	O	NOUN	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
functional	O	ADJ	B
replacement	O	NOUN	I
of	O	ADP	O
ALDP	O	NOUN	B
by	O	ADP	O
ALDRP	O	NOUN	B
was	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
stabilization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutated	O	VERB	B
ALDP	O	PROPN	B
itself	O	PRON	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
restore	O	VERB	B
the	O	DET	O
peroxisomal	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
defect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
of	O	ADP	O
ALDP	O	PROPN	B
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
by	O	ADP	O
stimulation	O	NOUN	B
of	O	ADP	O
ALDRP	O	NOUN	B
and	O	CCONJ	O
PMP70	O	NOUN	B
gene	O	NOUN	I
expression	O	NOUN	B
through	O	ADP	O
a	O	DET	O
dietary	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
the	O	DET	O
peroxisome	O	NOUN	B
proliferator	O	NOUN	I
fenofibrate	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
correction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
biochemical	O	ADJ	B
defect	O	NOUN	O
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
could	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
by	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
overexpression	O	NOUN	B
or	O	CCONJ	O
ectopic	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
ALDRP	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Centrosome	O	NOUN	B
amplification	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
defective	O	ADJ	B
G2	O	NOUN	B
-	O	PUNCT	O
M	O	NOUN	B
cell	O	NOUN	I
cycle	O	NOUN	I
checkpoint	O	NOUN	I
induce	O	VERB	O
genetic	O	ADJ	B
instability	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
exon	O	NOUN	B
11	O	NUM	O
isoform	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
cells	O	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Brca1	O	NOUN	B
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
predispose	O	VERB	O
women	O	NOUN	B
to	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
mechanisms	O	NOUN	B
underlying	O	VERB	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
tumorigenesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
derived	O	VERB	O
mouse	O	NOUN	B
embryonic	O	ADJ	O
fibroblast	O	NOUN	B
cells	O	NOUN	I
carrying	O	VERB	O
a	O	DET	O
targeted	O	VERB	B
deletion	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
of	O	ADP	O
the	O	DET	O
Brca1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutant	O	ADJ	B
cells	O	NOUN	I
maintain	O	VERB	O
an	O	DET	O
intact	O	ADJ	B
G1	O	NOUN	B
-	O	PUNCT	O
S	O	NOUN	B
cell	O	NOUN	I
cycle	O	NOUN	I
checkpoint	O	NOUN	O
and	O	CCONJ	O
proliferate	O	VERB	B
poorly	O	ADV	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
defective	O	ADJ	B
G2	O	NOUN	B
-	O	PUNCT	O
M	O	NOUN	B
checkpoint	O	NOUN	B
in	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
is	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
extensive	O	ADJ	O
chromosomal	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Mutant	O	ADJ	B
fibroblasts	O	NOUN	B
contain	O	VERB	O
multiple	O	ADJ	B
,	O	PUNCT	O
functional	O	ADJ	B
centrosomes	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
lead	O	VERB	O
to	O	PART	O
unequal	O	ADJ	O
chromosome	O	NOUN	B
segregation	O	NOUN	I
,	O	PUNCT	O
abnormal	O	ADJ	B
nuclear	O	ADJ	O
division	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
aneuploidy	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
uncover	O	VERB	O
an	O	DET	O
essential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
maintaining	O	VERB	O
genetic	O	ADJ	B
stability	O	NOUN	I
through	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
centrosome	O	NOUN	B
duplication	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
G2	O	NOUN	B
-	O	PUNCT	O
M	O	NOUN	B
checkpoint	O	NOUN	B
and	O	CCONJ	O
provide	O	VERB	O
a	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
tumorigenesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Defective	O	ADJ	B
CD95	O	NOUN	B
/	O	SYM	O
APO	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
/	O	SYM	O
Fas	O	NOUN	B
signal	O	NOUN	O
complex	O	NOUN	O
formation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
autoimmune	B-Disease	ADJ	I
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
,	I-Disease	PUNCT	O
type	I-Disease	NOUN	B
Ia	I-Disease	NOUN	I
.	O	PUNCT	O


Heterozygous	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
CD95	O	NOUN	B
(	O	PUNCT	O
APO	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
/	O	SYM	O
Fas	O	NOUN	B
)	O	PUNCT	O
receptor	O	NOUN	O
occur	O	VERB	O
in	O	ADP	O
most	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALPS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
dominantly	O	ADV	O
interfere	O	VERB	B
with	O	ADP	I
apoptosis	O	NOUN	B
by	O	ADP	O
an	O	DET	O
unknown	O	ADJ	O
mechanism	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
local	O	ADJ	B
or	O	CCONJ	O
global	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cytoplasmic	O	ADJ	B
death	O	NOUN	I
domain	O	NOUN	O
from	O	ADP	O
nine	O	NUM	O
independent	O	ADJ	B
ALPS	B-Disease	NOUN	B
CD95	O	NOUN	B
death	O	NOUN	I
-	O	PUNCT	O
domain	O	NOUN	B
mutations	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
failure	O	NOUN	B
to	O	PART	O
bind	O	VERB	B
the	O	DET	O
FADD	O	NOUN	B
/	O	SYM	O
MORT1	O	NOUN	B
signaling	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
heterozygosity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
abnormal	O	ADJ	B
allele	O	NOUN	B
,	O	PUNCT	O
lymphocytes	O	NOUN	B
from	O	ADP	O
ALPS	B-Disease	NOUN	B
patients	O	NOUN	B
showed	O	VERB	O
markedly	O	ADV	O
decreased	O	VERB	B
FADD	O	NOUN	B
association	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
caspase	O	NOUN	B
recruitment	O	NOUN	B
and	O	CCONJ	O
activation	O	NOUN	B
after	O	ADP	O
CD95	O	NOUN	B
crosslinking	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
intracytoplasmic	O	ADJ	B
CD95	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
ALPS	B-Disease	NOUN	B
impair	O	VERB	B
apoptosis	O	NOUN	B
chiefly	O	ADV	O
by	O	ADP	O
disrupting	O	VERB	B
death	O	NOUN	B
-	O	PUNCT	O
domain	O	NOUN	B
interactions	O	NOUN	B
with	O	ADP	O
the	O	DET	O
signaling	O	NOUN	B
protein	O	NOUN	I
FADD	O	NOUN	B
/	O	SYM	O
MORT1	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
AKU	B-Disease	NOUN	B
)	O	PUNCT	O
mutations	O	NOUN	B
and	O	CCONJ	O
polymorphisms	O	NOUN	B
reveals	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
CCC	O	NOUN	B
sequence	O	NOUN	I
motif	O	NOUN	B
is	O	AUX	O
a	O	DET	O
mutational	O	ADJ	B
hot	O	ADJ	O
spot	O	NOUN	O
in	O	ADP	O
the	O	DET	O
homogentisate	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	O
dioxygenase	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
HGO	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
showed	O	VERB	O
that	O	SCONJ	O
alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
AKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
loss	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
function	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
homogentisate	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	O
dioxygenase	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
HGO	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Herein	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
haplotype	O	NOUN	B
and	O	CCONJ	O
mutational	O	ADJ	B
analyses	O	NOUN	I
of	O	ADP	O
HGO	O	NOUN	B
in	O	ADP	O
seven	O	NUM	O
new	O	ADJ	O
AKU	B-Disease	NOUN	B
pedigrees	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
analyses	O	NOUN	B
identified	O	VERB	B
two	O	NUM	O
novel	O	ADJ	O
single	O	ADJ	B
-	O	PUNCT	O
nucleotide	O	NOUN	B
polymorphisms	O	NOUN	B
(	O	PUNCT	O
INV4	O	ADJ	B
+	O	CCONJ	O
31A	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
and	O	CCONJ	O
INV11	O	NOUN	B
+	O	CCONJ	O
18A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
novel	O	ADJ	O
AKU	B-Disease	NOUN	B
mutations	O	NOUN	B
(	O	PUNCT	O
INV1	O	NOUN	B
-	O	PUNCT	O
1G	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
,	O	PUNCT	O
W60G	O	ADJ	B
,	O	PUNCT	O
Y62C	O	NOUN	O
,	O	PUNCT	O
A122D	O	NOUN	B
,	O	PUNCT	O
P230T	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D291E	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
further	O	ADV	O
illustrates	O	VERB	O
the	O	DET	O
remarkable	O	ADJ	O
allelic	O	ADJ	B
heterogeneity	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
AKU	B-Disease	PROPN	B
.	O	PUNCT	O


Reexamination	O	NOUN	B
of	O	ADP	O
all	O	DET	O
29	O	NUM	O
mutations	O	NOUN	B
and	O	CCONJ	O
polymorphisms	O	NOUN	B
thus	O	ADV	O
far	O	ADV	O
described	O	VERB	O
in	O	ADP	O
HGO	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
nucleotide	O	NOUN	B
changes	O	NOUN	B
are	O	AUX	O
not	O	PART	O
randomly	O	ADV	O
distributed	O	VERB	B
;	O	PUNCT	O
the	O	DET	O
CCC	O	NOUN	B
sequence	O	NOUN	I
motif	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
inverted	O	ADJ	B
complement	O	NOUN	I
,	O	PUNCT	O
GGG	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
preferentially	O	ADV	O
mutated	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
analyses	O	NOUN	B
also	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
nucleotide	O	NOUN	B
substitutions	O	NOUN	I
in	O	ADP	O
HGO	O	NOUN	B
do	O	AUX	O
not	O	PART	O
involve	O	VERB	O
CpG	O	NOUN	B
dinucleotides	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
illustrates	O	VERB	O
important	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
HGO	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
genes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
at	O	ADP	O
specific	O	ADJ	O
short	O	ADJ	B
-	O	PUNCT	O
sequence	O	NOUN	B
motifs	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
CCC	O	NOUN	B
sequence	O	NOUN	I
motifs	O	NOUN	B
comprise	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
(	O	PUNCT	O
34	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
all	O	DET	O
mutated	O	VERB	B
bases	O	NOUN	O
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
HGO	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
CCC	O	PROPN	B
triplet	O	NOUN	B
is	O	AUX	O
a	O	DET	O
mutational	O	ADJ	B
hot	O	ADJ	O
spot	O	NOUN	O
in	O	ADP	O
HGO	O	NOUN	B
.	O	PUNCT	O


Fabry	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
alpha	O	NOUN	B
-	O	PUNCT	O
galactosidase	O	NOUN	B
A	O	NOUN	O
mutations	O	NOUN	B
and	O	CCONJ	O
molecular	O	ADJ	B
carrier	O	NOUN	I
detection	O	NOUN	I
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
fluorescent	O	ADJ	B
chemical	O	ADJ	I
cleavage	O	NOUN	I
of	O	ADP	O
mismatches	O	NOUN	B
.	O	PUNCT	O


Fabry	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
FD	B-Disease	PROPN	B
)	O	PUNCT	O
(	O	PUNCT	O
angiokeratoma	B-Disease	NOUN	B
corporis	I-Disease	NOUN	I
diffusum	I-Disease	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
inborn	I-Disease	ADJ	B
error	I-Disease	NOUN	I
of	I-Disease	ADP	O
glycosphingolipid	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lysosomal	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
galactosidase	O	NOUN	B
A	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
GLA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
enzymatic	O	ADJ	B
defect	O	NOUN	O
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
systemic	O	ADJ	B
accumulation	O	NOUN	B
of	O	ADP	O
neutral	O	ADJ	B
glycosphingolipids	O	NOUN	I
with	O	ADP	O
terminal	O	ADJ	O
alpha	O	NOUN	B
-	O	PUNCT	O
galactosyl	O	NOUN	B
moieties	O	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	B
,	O	PUNCT	O
affected	O	VERB	B
hemizygous	O	ADJ	B
males	O	NOUN	O
have	O	AUX	O
angiokeratoma	B-Disease	NOUN	B
,	O	PUNCT	O
severe	B-Disease	ADJ	B
acroparesthesia	I-Disease	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
vasculopathy	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
heart	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
brain	I-Disease	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
demonstration	O	NOUN	O
of	O	ADP	O
alpha	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
galactosidase	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
leukocytes	O	NOUN	B
is	O	AUX	O
diagnostic	O	ADJ	B
in	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
,	O	PUNCT	O
enzymatic	O	ADJ	B
detection	O	NOUN	I
of	O	ADP	O
female	O	ADJ	B
carriers	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
inconclusive	O	ADJ	B
,	O	PUNCT	O
due	O	ADP	O
to	O	ADP	O
random	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
chromosomal	O	ADJ	B
inactivation	O	NOUN	B
,	O	PUNCT	O
underlining	O	VERB	O
the	O	DET	O
need	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
investigations	O	NOUN	I
for	O	ADP	O
accurate	O	ADJ	B
genetic	O	ADJ	B
counseling	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
chemical	O	ADJ	B
cleavage	O	NOUN	I
of	O	ADP	O
mismatches	O	NOUN	B
adapted	O	VERB	O
to	O	ADP	O
fluorescence	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
detection	O	NOUN	B
systems	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
characterized	O	VERB	B
the	O	DET	O
mutations	O	NOUN	B
underlying	O	VERB	O
alpha	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Gal	I-Disease	NOUN	B
A	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	B
in	O	ADP	O
16	O	NUM	O
individuals	O	NOUN	B
from	O	ADP	O
six	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
with	O	ADP	O
FD	B-Disease	PROPN	B
.	O	PUNCT	O


The	O	DET	O
mutational	O	ADJ	B
spectrum	O	NOUN	I
included	O	VERB	O
five	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
C202W	O	NOUN	B
,	O	PUNCT	O
C223G	O	X	B
,	O	PUNCT	O
N224D	O	NOUN	B
,	O	PUNCT	O
R301Q	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Q327K	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
[	O	PUNCT	O
IVS3	O	NOUN	O
G	O	NOUN	O
(	O	PUNCT	O
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
C	O	NOUN	B
]	O	PUNCT	O
.	O	PUNCT	O


Studies	O	NOUN	B
at	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
level	O	NOUN	O
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
latter	O	ADJ	O
led	O	VERB	O
to	O	PART	O
altered	O	ADJ	O
pre	O	ADJ	B
-	O	PUNCT	O
mRNA	O	NOUN	B
splicing	O	NOUN	B
with	O	ADP	O
consequent	O	ADJ	O
alteration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
translational	O	ADJ	O
reading	O	NOUN	O
frame	O	NOUN	O
and	O	CCONJ	O
generation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	I
of	O	ADP	I
translation	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
this	O	DET	O
strategy	O	NOUN	O
,	O	PUNCT	O
carrier	O	NOUN	B
status	O	NOUN	I
was	O	AUX	O
accurately	O	ADV	O
assessed	O	VERB	B
in	O	ADP	O
all	O	DET	O
seven	O	NUM	O
at	O	ADP	O
-	O	PUNCT	O
risk	O	NOUN	B
females	O	NOUN	B
tested	O	VERB	B
,	O	PUNCT	O
whereas	O	SCONJ	O
enzymatic	O	ADJ	B
dosages	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
diagnose	O	VERB	B
or	O	CCONJ	O
exclude	O	VERB	O
heterozygosity	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Prenatal	O	ADJ	B
diagnosis	O	NOUN	I
by	O	ADP	O
FISH	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
duplication	O	NOUN	B
of	O	ADP	O
PLP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MIM	O	NOUN	B
312080	O	NUM	I
)	O	PUNCT	O
was	O	AUX	O
made	O	VERB	O
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
boy	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
boys	O	NOUN	B
maternal	O	ADJ	B
aunt	O	NOUN	O
came	O	VERB	O
for	O	ADP	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
when	O	SCONJ	O
16	O	NUM	O
+	O	CCONJ	O
weeks	O	NOUN	B
pregnant	O	ADJ	B
and	O	CCONJ	O
carrying	O	VERB	O
a	O	DET	O
male	O	NOUN	B
fetus	O	NOUN	B
.	O	PUNCT	O


Samples	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
duplication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
interphase	O	NOUN	B
FISH	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
lymphocyte	O	NOUN	B
preparations	O	NOUN	I
from	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
,	O	PUNCT	O
his	O	PRON	O
aunt	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
amniotic	O	ADJ	B
fluid	O	ADJ	I
cell	O	NOUN	O
preparation	O	NOUN	O
from	O	ADP	O
the	O	DET	O
fetus	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
the	O	DET	O
duplication	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
confirming	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
Merzbacher	I-Disease	PROPN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
neither	O	CCONJ	O
the	O	DET	O
aunt	O	NOUN	B
nor	O	CCONJ	O
the	O	DET	O
fetus	O	NOUN	B
carried	O	VERB	O
a	O	DET	O
duplication	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Dominant	O	ADJ	B
negative	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC1309	O	NOUN	B
mutation	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
possible	O	ADJ	O
explanation	O	NOUN	O
for	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
.	O	PUNCT	O


Inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
product	O	NOUN	I
initiates	O	VERB	B
colorectal	O	ADJ	B
tumorigenesis	O	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
APC	I-Disease	NOUN	O
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
carry	O	VERB	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
develop	O	VERB	O
multiple	O	ADJ	B
colorectal	B-Disease	ADJ	B
adenomas	I-Disease	NOUN	I
and	O	CCONJ	O
subsequent	O	ADJ	O
carcinomas	B-Disease	NOUN	B
early	O	ADV	B
in	O	ADP	O
life	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
correlates	O	VERB	B
with	O	ADP	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
the	O	DET	O
inherited	O	VERB	B
APC	B-Disease	NOUN	B
mutation	O	NOUN	O
(	O	PUNCT	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Together	O	ADV	O
with	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
both	O	CCONJ	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
and	O	CCONJ	O
sporadic	O	ADJ	B
APC	B-Disease	NOUN	B
mutations	O	NOUN	O
cluster	O	VERB	O
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
points	O	VERB	O
to	O	PART	O
a	O	DET	O
dominant	O	ADJ	B
negative	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
certain	O	ADJ	O
APC	B-Disease	NOUN	B
mutants	O	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
APC	B-Disease	NOUN	B
function	O	NOUN	B
was	O	AUX	O
recently	O	ADV	O
shown	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
enhanced	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	O
Tcf	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
transcription	O	NOUN	B
in	O	ADP	O
colon	O	NOUN	B
epithelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
provide	O	VERB	O
experimental	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
dominant	O	ADJ	B
negative	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
products	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
severe	O	ADJ	B
polyposis	B-Disease	NOUN	B
.	O	PUNCT	O


Wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	B-Disease	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	O
Tcf	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
transcription	O	NOUN	B
was	O	AUX	O
strongly	O	ADV	O
inhibited	O	VERB	B
by	O	ADP	O
a	O	DET	O
mutant	O	ADJ	B
APC	B-Disease	NOUN	B
that	O	PRON	O
is	O	AUX	O
truncated	O	VERB	B
at	O	ADP	O
codon	O	NOUN	B
1309	O	NUM	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
mutant	O	ADJ	B
APC	B-Disease	NOUN	O
gene	O	NOUN	O
products	O	NOUN	O
that	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
attenuated	B-Disease	VERB	B
polyposis	I-Disease	NOUN	B
(	O	PUNCT	O
codon	O	NOUN	B
386	O	NUM	O
or	O	CCONJ	O
1465	O	NUM	O
)	O	PUNCT	O
interfered	O	VERB	B
only	O	ADV	O
weakly	O	ADV	O
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	B-Disease	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
molecular	O	ADJ	B
explanation	O	NOUN	O
for	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
idea	O	NOUN	O
that	O	SCONJ	O
colorectal	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
growth	O	NOUN	I
might	O	AUX	O
be	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
driven	O	VERB	O
by	O	ADP	O
selection	O	NOUN	B
for	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
cluster	O	NOUN	I
region	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
interacts	O	VERB	O
with	O	ADP	O
components	O	NOUN	B
of	O	ADP	O
the	O	DET	O
histone	O	NOUN	B
deacetylase	O	NOUN	I
complex	O	NOUN	I
.	O	PUNCT	O


Germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
tumor	O	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
contains	O	VERB	O
a	O	DET	O
carboxyl	O	ADJ	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	O
(	O	PUNCT	O
BRCT	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
is	O	AUX	O
shared	O	VERB	O
with	O	ADP	O
several	O	ADJ	O
other	O	ADJ	O
proteins	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
maintaining	O	VERB	O
genome	O	NOUN	B
integrity	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
effort	O	NOUN	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
sought	O	VERB	O
to	O	PART	O
isolate	O	VERB	B
proteins	O	NOUN	B
that	O	PRON	O
interact	O	VERB	B
with	O	ADP	O
the	O	DET	O
BRCT	O	NOUN	B
domain	O	NOUN	I
.	O	PUNCT	O


Purified	O	VERB	B
BRCT	O	NOUN	I
polypeptide	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
to	O	PART	O
screen	O	VERB	O
a	O	DET	O
human	O	ADJ	B
placenta	O	NOUN	B
cDNA	O	NOUN	B
expression	O	NOUN	B
library	O	NOUN	I
by	O	ADP	O
Far	O	PROPN	B
Western	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
interacts	O	VERB	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
with	O	ADP	O
the	O	DET	O
Rb	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
proteins	O	NOUN	I
,	O	PUNCT	O
RbAp46	O	NOUN	B
and	O	CCONJ	O
RbAp48	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
with	O	ADP	O
Rb	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
BRCT	O	NOUN	B
domain	O	NOUN	I
associates	O	VERB	B
with	O	ADP	I
the	O	DET	O
histone	O	NOUN	B
deacetylases	O	NOUN	I
HDAC1	O	NOUN	B
and	O	CCONJ	O
HDAC2	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
interacts	O	VERB	O
with	O	ADP	O
components	O	NOUN	B
of	O	ADP	O
the	O	DET	O
histone	O	NOUN	B
deacetylase	O	NOUN	I
complex	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
therefore	O	ADV	O
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
multiple	O	ADJ	B
processes	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
transcription	O	NOUN	B
,	O	PUNCT	O
DNA	O	NOUN	B
repair	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
recombination	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Combined	B-Disease	ADJ	B
genetic	I-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
C6	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
routine	O	ADJ	O
screening	O	NOUN	B
of	O	ADP	O
sera	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
subject	O	NOUN	B
was	O	AUX	O
discovered	O	VERB	O
who	O	PRON	O
showed	O	VERB	O
a	O	DET	O
sub	B-Disease	ADV	B
-	I-Disease	PUNCT	O
total	I-Disease	ADJ	B
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
C6	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
clinical	O	ADJ	O
disease	O	NOUN	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
deficiency	O	NOUN	B
which	O	DET	O
was	O	AUX	O
transmitted	O	VERB	B
through	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
family	O	NOUN	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
genetic	O	ADJ	B
characteristic	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
C6	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
being	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
silent	O	ADJ	B
allele	O	NOUN	B
at	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
locus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
propositus	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
low	O	ADJ	B
quantities	O	NOUN	B
of	O	ADP	O
an	O	DET	O
abnormal	O	ADJ	B
C6	O	NOUN	B
which	O	DET	O
was	O	AUX	O
both	O	DET	O
antigenically	O	ADV	B
deficient	O	ADJ	B
and	O	CCONJ	O
smaller	O	ADJ	B
in	O	ADP	O
size	O	NOUN	B
than	O	ADP	O
normal	O	ADJ	B
C6	O	NOUN	B
(	O	PUNCT	O
110	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
daltons	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
140	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
daltons	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
small	O	ADJ	B
quantities	O	NOUN	B
of	O	ADP	O
apparently	O	ADV	O
normal	O	ADJ	O
C7	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
most	O	ADV	O
likely	O	ADJ	O
explanation	O	NOUN	B
for	O	ADP	O
this	O	DET	O
defect	O	NOUN	B
is	O	AUX	O
that	O	SCONJ	O
the	O	DET	O
subject	O	NOUN	B
has	O	AUX	O
a	O	DET	O
structural	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
his	O	PRON	O
C6	O	NOUN	B
gene	O	NOUN	I
which	O	DET	O
produces	O	VERB	O
hyopsynthesis	O	NOUN	B
not	O	PART	O
only	O	ADV	O
of	O	ADP	O
C6	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
of	O	ADP	O
the	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
gene	O	NOUN	B
for	O	ADP	O
C7	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
C6	O	NOUN	B
and	O	CCONJ	O
C7	O	NOUN	B
may	O	AUX	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
genetic	O	ADJ	B
unit	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
primary	O	ADJ	B
transcript	O	NOUN	I
copied	O	VERB	O
from	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
includes	O	VERB	O
information	O	NOUN	B
for	O	ADP	O
both	O	DET	O
proteins	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Changes	O	NOUN	B
at	O	ADP	O
P183	O	NOUN	B
of	O	ADP	O
emerin	O	NOUN	B
weaken	O	VERB	O
its	O	PRON	O
protein	O	NOUN	B
-	O	PUNCT	O
protein	O	NOUN	B
interactions	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EDMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
early	O	ADJ	B
contractures	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
elbows	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
Achilles	I-Disease	NOUN	B
tendons	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
spine	I-Disease	NOUN	B
,	O	PUNCT	O
slowly	O	ADV	O
progressive	O	ADJ	B
muscle	B-Disease	NOUN	B
wasting	I-Disease	NOUN	I
and	O	CCONJ	O
weakness	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cardiomyopathy	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cardiac	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
defects	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
emerin	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
Xq28	O	NOUN	B
and	O	CCONJ	O
encodes	O	VERB	B
a	O	DET	O
34	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
serine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
emerin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
the	O	DET	O
nuclear	O	ADJ	B
envelope	O	NOUN	I
in	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
variety	O	NOUN	O
of	O	ADP	O
tissues	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
skeletal	O	ADJ	B
and	O	CCONJ	O
cardiac	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
spanning	O	VERB	O
the	O	DET	O
emerin	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
EDMD	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
here	O	ADV	O
the	O	DET	O
effect	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
emerin	O	NOUN	B
protein	O	NOUN	I
expression	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
identified	O	VERB	B
in	O	ADP	O
unrelated	O	ADJ	O
EDMD	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
alterations	O	NOUN	B
predict	O	VERB	O
the	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
a	O	DET	O
proline	O	NOUN	B
residue	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
183	O	NUM	O
with	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
histidine	O	NOUN	B
or	O	CCONJ	O
a	O	DET	O
threonine	O	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
analysis	O	NOUN	I
has	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mobility	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
emerin	O	NOUN	B
are	O	AUX	O
indistinguishable	O	ADJ	B
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
emerin	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
that	O	SCONJ	O
they	O	PRON	O
have	O	AUX	O
weakened	O	VERB	O
interactions	O	NOUN	B
with	O	ADP	O
nuclear	O	ADJ	B
lamina	O	NOUN	I
components	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
usual	O	ADJ	O
EDMD	B-Disease	NOUN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
P183	O	NOUN	B
missense	O	NOUN	I
mutations	O	NOUN	I
have	O	AUX	O
a	O	DET	O
later	O	ADJ	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
first	O	ADJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
elbow	B-Disease	NOUN	B
contractures	I-Disease	NOUN	I
,	O	PUNCT	O
ankle	B-Disease	NOUN	B
contractures	I-Disease	NOUN	I
,	O	PUNCT	O
upper	B-Disease	ADJ	B
limb	I-Disease	NOUN	I
weakness	I-Disease	NOUN	I
and	O	CCONJ	O
lower	B-Disease	ADJ	B
limb	I-Disease	NOUN	I
weakness	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
for	O	ADP	O
the	O	DET	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
cardiac	B-Disease	ADJ	B
involvement	I-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
studies	O	NOUN	I
on	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
EDMD	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
proline	O	NOUN	B
183	O	NUM	O
for	O	ADP	O
the	O	DET	O
proper	O	ADJ	O
structure	O	NOUN	B
/	O	PUNCT	O
function	O	NOUN	B
of	O	ADP	O
emerin	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Microdeletions	O	NOUN	B
at	O	ADP	O
chromosome	O	NOUN	B
bands	O	NOUN	I
1q32	O	NOUN	I
-	O	PUNCT	O
q41	O	NOUN	B
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
Van	B-Disease	PROPN	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Van	B-Disease	NOUN	O
der	I-Disease	NOUN	O
Woude	I-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
(	O	PUNCT	O
VWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
comprising	O	VERB	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
and	O	CCONJ	I
lip	B-Disease	NOUN	B
pits	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
reported	O	VERB	O
previously	O	ADV	O
a	O	DET	O
family	O	NOUN	B
whose	O	DET	O
underlying	O	VERB	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
500	O	NUM	O
-	O	PUNCT	O
800	O	NUM	O
kb	O	NOUN	O
deletion	O	NOUN	B
localized	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
bands	O	NOUN	I
1q32	O	NOUN	I
-	O	PUNCT	O
q41	O	NOUN	B
[	O	PUNCT	O
Sander	O	PROPN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
1994	O	NUM	O
Hum	O	PROPN	O
Mol	O	PROPN	O
Genet	O	PROPN	O
3	O	NUM	O
576	O	NUM	O
-	O	SYM	O
578	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


Along	O	ADP	O
with	O	ADP	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
/	I-Disease	SYM	O
palate	I-Disease	ADJ	B
and	O	CCONJ	O
lip	B-Disease	NOUN	B
pits	I-Disease	NOUN	I
,	O	PUNCT	O
affected	O	VERB	B
relatives	O	NOUN	B
exhibit	O	VERB	O
developmental	B-Disease	ADJ	B
delays	I-Disease	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
nearby	O	ADV	I
may	O	AUX	O
also	O	ADV	O
be	O	AUX	O
disrupted	O	VERB	B
.	O	PUNCT	O


To	O	PART	O
further	O	ADV	O
localize	O	VERB	O
the	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	I
we	O	PRON	O
searched	O	VERB	O
for	O	ADP	O
other	O	ADJ	O
deletions	O	NOUN	B
that	O	PRON	O
cause	O	VERB	O
VWS	B-Disease	NOUN	B
.	O	PUNCT	O


An	O	DET	O
allele	O	NOUN	B
loss	O	NOUN	I
assay	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
highly	O	ADV	O
polymorphic	O	ADJ	B
marker	O	NOUN	I
,	O	PUNCT	O
D1S3753	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
37	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
an	O	DET	O
allele	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
phenotype	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
generations	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
was	O	AUX	O
confined	O	VERB	O
to	O	PART	O
the	O	DET	O
cardinal	O	ADJ	O
signs	O	NOUN	B
of	O	ADP	O
VWS	B-Disease	NOUN	B
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
mapping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
new	O	ADJ	O
deletion	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
extended	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
1	O	NUM	O
Mb	O	NOUN	O
beyond	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
breakpoint	O	NOUN	I
for	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
described	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


No	O	DET	O
deletions	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
popliteal	B-Disease	ADJ	B
pterygia	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
76	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
mixed	O	ADJ	O
syndromic	B-Disease	ADJ	B
forms	I-Disease	NOUN	I
of	I-Disease	ADP	O
cleft	I-Disease	NOUN	B
lip	I-Disease	NOUN	I
and	I-Disease	CCONJ	I
palate	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
178	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
nonsyndromic	B-Disease	ADJ	B
cleft	I-Disease	NOUN	I
lip	I-Disease	NOUN	I
and	I-Disease	CCONJ	I
palate	I-Disease	NOUN	B
.	O	PUNCT	O


Splicing	O	NOUN	B
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
ATM	O	NOUN	B
:	O	PUNCT	O
underlying	O	VERB	O
mutations	O	NOUN	B
and	O	CCONJ	O
consequences	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
defective	O	ADJ	B
splicing	O	NOUN	B
constitute	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
/	O	SYM	O
62	O	NUM	O
[	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
AT	B-Disease	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
were	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
truncation	O	NOUN	B
assay	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
.	O	PUNCT	O


Fewer	O	ADJ	O
than	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
splicing	O	NOUN	B
mutations	O	NOUN	I
involved	O	VERB	O
the	O	DET	O
canonical	O	ADJ	B
AG	O	NOUN	I
splice	O	NOUN	I
-	O	PUNCT	O
acceptor	O	NOUN	B
site	O	NOUN	I
or	O	CCONJ	O
GT	O	NOUN	B
splice	O	NOUN	I
-	O	PUNCT	O
donor	O	NOUN	B
site	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
higher	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
occurred	O	VERB	O
at	O	ADP	O
less	O	ADV	O
stringently	O	ADV	O
conserved	O	VERB	B
sites	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
silent	O	ADJ	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
last	O	ADJ	O
nucleotide	O	NOUN	B
of	O	ADP	I
exons	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
nucleotides	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
the	O	DET	O
conserved	O	VERB	B
AG	O	PROPN	I
and	O	CCONJ	O
GT	O	NOUN	B
in	O	ADP	O
the	O	DET	O
consensus	O	NOUN	B
splice	O	NOUN	I
sites	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
creation	O	NOUN	B
of	O	ADP	O
splice	O	NOUN	B
-	O	PUNCT	O
acceptor	O	NOUN	B
or	O	CCONJ	O
splice	O	NOUN	B
-	O	PUNCT	O
donor	O	NOUN	B
sites	O	NOUN	O
in	O	ADP	O
either	O	CCONJ	O
introns	O	NOUN	B
or	O	CCONJ	O
exons	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
splicing	O	NOUN	B
mutations	O	NOUN	I
led	O	VERB	O
to	O	PART	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
consequences	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
exon	O	NOUN	B
skipping	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
lesser	O	ADJ	B
degree	O	NOUN	B
,	O	PUNCT	O
intron	O	NOUN	B
retention	O	NOUN	B
,	O	PUNCT	O
activation	O	NOUN	B
of	O	ADP	O
cryptic	O	ADJ	B
splice	O	NOUN	I
sites	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
creation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
splice	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
5	O	NUM	O
of	O	ADP	O
12	O	NUM	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
and	O	CCONJ	O
1	O	NUM	O
missense	O	NOUN	B
mutation	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exons	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
mutations	O	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


No	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
western	O	NOUN	B
blotting	O	NOUN	I
in	O	ADP	O
any	O	DET	O
AT	B-Disease	ADP	B
cell	O	NOUN	I
line	O	NOUN	I
in	O	ADP	O
which	O	DET	O
splicing	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Several	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
skipping	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
normal	O	ADJ	B
controls	O	NOUN	I
and	O	CCONJ	O
patients	O	NOUN	B
for	O	ADP	O
whom	O	PRON	O
no	O	DET	O
underlying	O	VERB	O
defect	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
in	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	B
,	O	PUNCT	O
suggesting	O	VERB	O
caution	O	NOUN	O
in	O	ADP	O
the	O	DET	O
interpretation	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
deletions	O	NOUN	B
observed	O	VERB	O
in	O	ADP	O
ATM	O	NOUN	B
cDNA	O	NOUN	B
when	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
accompanying	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Alpha	O	NOUN	B
-	O	PUNCT	O
cardiac	O	ADJ	B
actin	O	NOUN	I
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
disease	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
hypertrophic	I-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
cardiac	O	ADJ	B
actin	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ACTC	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
disease	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
a	O	DET	O
pedigree	O	NOUN	B
suffering	O	NOUN	I
from	O	ADP	O
familial	B-Disease	ADJ	B
hypertrophic	I-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
(	O	PUNCT	O
FHC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
analyses	O	NOUN	I
excluded	O	VERB	O
all	O	DET	O
the	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
FHC	B-Disease	NOUN	B
loci	O	NOUN	B
as	O	ADP	O
possible	O	ADJ	O
disease	O	NOUN	B
loci	O	NOUN	I
in	O	ADP	O
the	O	DET	O
family	O	NOUN	B
studied	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
lod	O	NOUN	B
scores	O	NOUN	I
varying	O	VERB	O
between	O	ADP	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
and	O	CCONJ	O
-	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
0	O	NUM	O
.	O	PUNCT	O


Further	O	ADJ	O
linkage	O	NOUN	B
analyses	O	NOUN	I
of	O	ADP	O
plausible	O	ADJ	O
candidate	O	NOUN	O
genes	O	NOUN	B
highly	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
the	O	DET	O
adult	O	ADJ	B
human	O	ADJ	B
heart	O	NOUN	O
identified	O	VERB	O
ACTC	O	NOUN	B
as	O	ADP	O
the	O	DET	O
most	O	ADV	O
likely	O	ADJ	O
disease	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
showing	O	VERB	O
a	O	DET	O
maximal	O	ADJ	B
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
6	O	NUM	O
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
ACTC	O	NOUN	B
revealed	O	VERB	O
an	O	DET	O
Ala295Ser	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
close	O	ADV	O
to	O	PART	O
2	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
recently	O	ADV	O
described	O	VERB	O
to	O	PART	O
cause	O	VERB	O
the	O	DET	O
inherited	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
idiopathic	B-Disease	ADJ	B
dilated	I-Disease	ADJ	I
cardiomyopathy	I-Disease	NOUN	I
(	O	PUNCT	O
IDC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Overgrowth	B-Disease	NOUN	B
of	I-Disease	ADP	O
oral	I-Disease	ADJ	B
mucosa	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
facial	I-Disease	ADJ	B
skin	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
aspartylglucosaminuria	B-Disease	NOUN	B
.	O	PUNCT	O


Aspartylglucosaminuria	B-Disease	NOUN	B
(	O	PUNCT	O
AGU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
lysosomal	B-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
aspartylglucosaminidase	I-Disease	NOUN	B
(	O	PUNCT	O
AGA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
main	O	ADJ	O
symptom	O	NOUN	B
is	O	AUX	O
progressive	O	ADJ	B
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
mutations	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
Cys163Ser	O	NOUN	B
)	O	PUNCT	O
being	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
Finnish	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
examine	O	VERB	O
66	O	NUM	O
Finnish	O	ADJ	B
AGU	B-Disease	NOUN	B
patients	O	NOUN	B
for	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
oral	O	ADJ	B
mucosa	O	NOUN	I
and	O	CCONJ	O
44	O	NUM	O
of	O	ADP	O
these	O	DET	O
for	O	ADP	O
changes	O	NOUN	B
in	O	ADP	O
facial	O	ADJ	B
skin	O	NOUN	I
.	O	PUNCT	O


Biopsy	O	NOUN	B
specimens	O	NOUN	I
of	O	ADP	O
16	O	NUM	O
oral	O	ADJ	B
lesions	O	NOUN	I
,	O	PUNCT	O
12	O	NUM	O
of	O	ADP	O
them	O	PRON	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
teeth	O	NOUN	B
,	O	PUNCT	O
plus	O	CCONJ	O
two	O	NUM	O
facial	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
were	O	AUX	O
studied	O	VERB	O
histologically	O	ADV	B
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
staining	O	NOUN	I
for	O	ADP	O
AGA	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
15	O	NUM	O
oral	O	ADJ	B
specimens	O	NOUN	I
.	O	PUNCT	O


Skin	O	NOUN	B
was	O	AUX	O
seborrhoeic	O	ADJ	B
in	O	ADP	O
adolescent	O	ADJ	B
and	O	CCONJ	O
adult	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
erythema	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
facial	I-Disease	ADJ	B
skin	I-Disease	NOUN	I
already	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
44	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
nine	O	NUM	O
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
facial	B-Disease	ADJ	B
angiofibromas	I-Disease	NOUN	I
,	O	PUNCT	O
tumours	B-Disease	NOUN	B
primarily	O	ADV	O
occurring	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
tuberous	B-Disease	ADJ	B
sclerosis	I-Disease	NOUN	I
.	O	PUNCT	O


Oedemic	B-Disease	ADJ	B
buccal	I-Disease	ADJ	I
mucosa	I-Disease	NOUN	I
(	O	PUNCT	O
leucoedema	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
gingival	B-Disease	ADJ	B
overgrowths	I-Disease	NOUN	B
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
AGU	B-Disease	NOUN	B
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
16	O	NUM	O
oral	B-Disease	ADJ	B
mucosal	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
studied	O	VERB	O
histologically	O	ADV	B
,	O	PUNCT	O
15	O	NUM	O
represented	O	VERB	O
fibroepithelial	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
epithelial	I-Disease	ADJ	B
hyperplasias	I-Disease	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
reactive	O	ADJ	B
in	O	ADP	O
nature	O	NOUN	B
.	O	PUNCT	O


Cytoplasmic	O	ADJ	B
vacuolisation	O	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
four	O	NUM	O
.	O	PUNCT	O


Immunohistochemically	O	ADV	B
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
AGA	O	NOUN	B
in	O	ADP	O
AGU	B-Disease	NOUN	B
patients	O	NOUN	B
mucosal	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
from	O	ADP	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
corresponding	O	ADJ	O
lesions	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
mucosal	B-Disease	ADJ	B
overgrowth	I-Disease	NOUN	I
in	O	ADP	O
AGU	B-Disease	NOUN	B
patients	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
directly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
lysosomal	O	ADJ	B
storage	O	NOUN	I
or	O	CCONJ	O
with	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
AGA	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
mosaicism	O	NOUN	O
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
Lowe	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
identification	O	NOUN	B
of	O	ADP	O
seven	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
OCRL1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
oculocerebrorenal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
of	I-Disease	ADP	O
Lowe	I-Disease	PROPN	O
(	O	PUNCT	O
OCRL	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disorder	I-Disease	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
major	O	ADJ	O
abnormalities	B-Disease	NOUN	B
of	I-Disease	ADP	O
eyes	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
nervous	I-Disease	ADJ	B
system	I-Disease	NOUN	I
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
kidneys	I-Disease	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
OCRL1	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


OCRL1	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
phosphatidylinositol	O	NOUN	B
4	O	NUM	I
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
biphosphate	O	NOUN	B
(	O	PUNCT	O
PtdIns	O	NOUN	B
[	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
]	O	PUNCT	O
P2	O	NOUN	O
)	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
OCRL1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
eight	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
OCRL	B-Disease	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
found	O	VERB	O
seven	O	NUM	O
new	O	ADJ	O
mutations	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
recurrent	O	ADJ	B
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletion	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
new	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
(	O	PUNCT	O
R317X	O	NOUN	B
and	O	CCONJ	O
E558X	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
other	O	ADJ	O
frameshift	O	NOUN	B
mutations	O	NOUN	I
caused	O	VERB	O
premature	O	ADJ	B
termination	O	NOUN	I
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
R483G	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
PtdIns	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
P2	O	NOUN	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
domain	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
one	O	NUM	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
2799delC	O	NOUN	O
,	O	PUNCT	O
modifies	O	VERB	B
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
part	O	NOUN	O
of	O	ADP	O
OCRL1	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
extension	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
.	O	PUNCT	O


Altogether	O	ADV	O
,	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
are	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
exon	O	NOUN	B
15	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
52	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
mutations	O	NOUN	B
cluster	O	NOUN	O
in	O	ADP	O
exons	O	NOUN	B
11	O	NUM	O
-	O	SYM	O
15	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
identified	O	VERB	O
two	O	NUM	O
new	O	ADJ	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
for	O	ADP	O
the	O	DET	O
OCRL1	O	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
detected	O	VERB	B
a	O	DET	O
germline	O	NOUN	B
mosaicism	O	NOUN	O
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
has	O	AUX	O
direct	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
of	O	ADP	O
Lowe	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


MEFV	O	NOUN	B
-	O	PUNCT	O
Gene	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
armenian	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
:	O	PUNCT	O
diagnostic	O	ADJ	B
value	O	NOUN	I
and	O	CCONJ	O
unfavorable	O	ADJ	B
renal	O	ADJ	B
prognosis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
M694V	O	NOUN	B
homozygous	O	ADJ	B
genotype	O	NOUN	B
-	O	PUNCT	O
genetic	O	ADJ	B
and	O	CCONJ	O
therapeutic	O	ADJ	B
implications	O	NOUN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessively	B-Disease	ADV	O
inherited	I-Disease	VERB	B
disorder	I-Disease	NOUN	O
that	O	PRON	O
is	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
Armenian	O	ADJ	B
ancestry	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
,	O	PUNCT	O
its	O	PRON	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
be	O	AUX	O
made	O	VERB	O
only	O	ADV	O
retrospectively	O	ADV	B
,	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
exclusion	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
entirely	O	ADV	O
on	O	ADP	O
nonspecific	O	ADJ	B
clinical	O	ADJ	B
signs	O	NOUN	O
that	O	PRON	O
result	O	VERB	O
from	O	ADP	O
serosal	B-Disease	ADJ	B
inflammation	I-Disease	NOUN	I
and	O	CCONJ	O
that	O	DET	O
may	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
unnecessary	O	ADJ	O
surgery	O	NOUN	B
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
amyloidosis	I-Disease	NOUN	I
,	O	PUNCT	O
prevented	O	VERB	B
by	O	ADP	O
colchicine	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
severe	O	ADJ	B
complication	O	NOUN	B
of	O	ADP	O
FMF	B-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
disorder	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MEFV	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
diagnostic	O	ADJ	B
and	O	CCONJ	O
prognostic	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
MEFV	O	NOUN	B
-	O	PUNCT	O
gene	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
90	O	NUM	O
Armenian	O	ADJ	B
FMF	B-Disease	NOUN	B
patients	O	NOUN	B
from	O	ADP	O
77	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
not	O	PART	O
selected	O	VERB	O
through	O	ADP	O
genetic	O	ADJ	B
-	O	PUNCT	O
linkage	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
(	O	PUNCT	O
R408Q	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
new	O	ADJ	O
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
account	O	VERB	O
for	O	ADP	O
93	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
163	O	NUM	O
independent	O	ADJ	O
FMF	B-Disease	NOUN	B
alleles	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
both	O	DET	O
FMF	B-Disease	NOUN	B
alleles	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
89	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
several	O	ADJ	O
instances	O	NOUN	O
,	O	PUNCT	O
family	O	NOUN	B
studies	O	NOUN	I
provided	O	VERB	O
molecular	O	ADJ	B
evidence	O	NOUN	I
for	O	ADP	O
pseudodominant	O	ADJ	B
transmission	O	NOUN	B
and	O	CCONJ	O
incomplete	O	ADJ	B
penetrance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
M694V	O	NOUN	B
homozygous	O	ADJ	B
genotype	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
higher	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
amyloidosis	I-Disease	NOUN	I
and	O	CCONJ	O
arthritis	B-Disease	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
genotypes	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
0002	O	NUM	O
and	O	CCONJ	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
006	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
demonstration	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
diagnostic	O	ADJ	B
and	O	CCONJ	O
prognostic	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
MEFV	O	NOUN	B
analysis	O	NOUN	B
and	O	CCONJ	O
particular	O	ADJ	O
modes	O	NOUN	B
of	O	ADP	O
inheritance	O	NOUN	B
should	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
new	O	ADJ	O
ways	O	NOUN	O
for	O	ADP	O
management	O	NOUN	B
of	O	ADP	O
FMF	O	PROPN	B
-	O	PUNCT	O
including	O	VERB	B
genetic	O	ADJ	B
counseling	O	NOUN	I
and	O	CCONJ	O
therapeutic	O	ADJ	B
decisions	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
families	O	NOUN	B
.	O	PUNCT	O


Noninvasive	O	ADJ	B
test	O	NOUN	I
for	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
hair	O	NOUN	B
root	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
repeat	O	NOUN	B
-	O	PUNCT	O
amplification	O	NOUN	B
mechanism	O	NOUN	B
causing	O	VERB	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
led	O	VERB	O
to	O	PART	O
development	O	NOUN	B
of	O	ADP	O
reliable	O	ADJ	O
DNA	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
diagnostic	O	ADJ	B
methods	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
and	O	CCONJ	O
PCR	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
methods	O	NOUN	B
are	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
DNA	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
measure	O	VERB	B
the	O	DET	O
repeat	O	NOUN	O
size	O	NOUN	B
in	O	ADP	O
FMR1	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
an	O	DET	O
immunocytochemical	O	ADJ	B
technique	O	NOUN	I
on	O	ADP	O
blood	O	NOUN	B
smears	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
recently	O	ADV	O
developed	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
test	O	NOUN	O
for	O	ADP	O
identification	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
method	O	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
called	O	VERB	O
"	O	PUNCT	O
antibody	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
"	O	PUNCT	O
uses	O	VERB	O
monoclonal	O	ADJ	B
antibodies	O	NOUN	I
against	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
(	O	PUNCT	O
FMRP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
a	O	DET	O
new	O	ADJ	O
diagnostic	O	ADJ	B
test	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
male	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
lack	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
hair	O	NOUN	B
roots	O	NOUN	I
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
in	O	ADP	O
hair	O	NOUN	B
roots	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
FMRP	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
antibody	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
-	O	PUNCT	O
expressing	O	VERB	B
hair	O	NOUN	B
roots	O	NOUN	I
in	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
male	O	NOUN	B
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
patients	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


Control	O	ADJ	B
individuals	O	NOUN	B
showed	O	VERB	O
clear	O	ADJ	O
expression	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
in	O	ADP	O
nearly	O	ADV	O
every	O	DET	O
hair	O	NOUN	B
root	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
male	O	NOUN	B
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
patients	O	NOUN	B
lacked	O	VERB	O
expression	O	NOUN	B
of	O	ADP	O
FMRP	O	NOUN	B
in	O	ADP	O
almost	O	ADV	O
all	O	DET	O
their	O	PRON	O
hair	O	NOUN	B
roots	O	NOUN	I
.	O	PUNCT	O


Mentally	B-Disease	ADV	B
retarded	I-Disease	VERB	B
female	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
full	O	ADJ	O
mutation	O	NOUN	B
showed	O	VERB	O
FMRP	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
only	O	ADV	O
some	O	DET	O
of	O	ADP	O
their	O	PRON	O
hair	O	NOUN	B
roots	O	NOUN	I
(	O	PUNCT	O
<	O	X	O
55	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
overlap	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
female	O	ADJ	O
controls	O	NOUN	O
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
advantages	O	NOUN	O
of	O	ADP	O
this	O	DET	O
test	O	NOUN	B
are	O	AUX	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
plucking	O	NOUN	B
of	O	ADP	O
hair	O	NOUN	B
follicles	O	NOUN	I
does	O	AUX	O
no	O	DET	O
appreciable	O	ADJ	O
harm	O	NOUN	O
to	O	ADP	O
the	O	DET	O
mentally	B-Disease	ADV	B
retarded	I-Disease	VERB	B
patient	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
hairs	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
sent	O	VERB	O
in	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
envelope	O	NOUN	O
to	O	PART	O
a	O	DET	O
diagnostic	O	ADJ	B
center	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
test	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
within	O	ADP	O
5	O	NUM	O
h	O	NOUN	O
of	O	ADP	O
plucking	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
test	O	NOUN	B
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
identify	O	VERB	O
two	O	NUM	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
the	O	DET	O
full	O	ADJ	O
mutation	O	NOUN	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
blood	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
Swedish	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
HPC1	O	NOUN	B
locus	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
1q24	O	NOUN	I
-	O	PUNCT	O
25	O	NUM	O
is	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
families	O	NOUN	B
with	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
clusters	O	NOUN	B
in	O	ADP	O
some	O	DET	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
estimated	O	VERB	B
5	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
are	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
result	O	VERB	O
from	O	ADP	O
inheritance	O	NOUN	B
of	O	ADP	O
prostate	O	NOUN	B
cancer	O	NOUN	I
-	O	PUNCT	O
susceptibility	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
reported	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
region	O	NOUN	B
(	O	PUNCT	O
HPC1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
91	O	NUM	O
North	O	ADJ	B
American	O	ADJ	I
and	O	CCONJ	O
Swedish	O	ADJ	B
families	O	NOUN	B
each	O	DET	O
with	O	ADP	O
multiple	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
Smith	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
1996	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
report	O	NOUN	B
we	O	PRON	O
analyze	O	VERB	B
40	O	NUM	O
(	O	PUNCT	O
12	O	NUM	O
original	O	ADJ	B
and	O	CCONJ	O
28	O	NUM	O
newly	O	ADV	O
identified	O	VERB	B
)	O	PUNCT	O
Swedish	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
HPC	B-Disease	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
40	O	NUM	O
markers	O	NOUN	B
spanning	O	VERB	O
a	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
interval	O	NOUN	B
within	O	ADP	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
,	O	PUNCT	O
have	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
complete	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
maximum	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
LOD	O	NOUN	B
score	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


10	O	NUM	O
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
D1S413	O	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
fraction	O	NOUN	I
[	O	PUNCT	O
theta	O	NOUN	B
]	O	PUNCT	O
of	O	ADP	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
maximum	O	ADJ	B
NPL	O	NOUN	B
(	O	PUNCT	O
nonparametric	O	ADJ	B
linkage	O	NOUN	I
)	O	PUNCT	O
Z	O	NOUN	B
score	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


64	O	NUM	O
at	O	ADP	O
D1S202	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
this	O	DET	O
region	O	NOUN	B
originated	O	VERB	O
almost	O	ADV	O
exclusively	O	ADV	O
from	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
12	O	NUM	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
<	O	X	O
65	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
families	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
yielded	O	VERB	O
a	O	DET	O
maximum	O	ADJ	O
LOD	O	NOUN	B
score	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


38	O	NUM	O
at	O	ADP	O
D1S413	O	NOUN	B
(	O	PUNCT	O
straight	O	ADJ	O
theta	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
NPL	O	NOUN	B
Z	O	NOUN	I
score	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


95	O	NUM	O
at	O	ADP	O
D1S422	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Estimates	O	NOUN	B
from	O	ADP	O
heterogeneity	O	NOUN	B
tests	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
within	O	ADP	O
Sweden	O	PROPN	B
,	O	PUNCT	O
as	O	ADV	O
many	O	ADJ	O
as	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
families	O	NOUN	B
had	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
HPC1	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
HPC1	O	NOUN	B
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
those	O	DET	O
with	O	ADP	O
an	O	DET	O
early	O	ADJ	B
age	O	NOUN	I
at	O	ADP	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
feline	O	ADJ	B
beta	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
glucuronidase	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
:	O	PUNCT	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
mucopolysaccharidosis	B-Disease	NOUN	B
VII	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
of	O	ADP	O
domestic	O	ADJ	B
cats	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
that	O	PRON	O
exhibited	O	VERB	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
abnormalities	O	NOUN	I
consistent	O	ADJ	B
with	O	ADP	I
mucopolysaccharidosis	B-Disease	NOUN	B
VII	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
lysosomal	I-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
beta	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
glucuronidase	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
.	O	PUNCT	O


beta	O	NOUN	B
-	O	PUNCT	O
Glucuronidase	O	NOUN	B
activity	O	NOUN	B
was	O	AUX	O
undetectable	O	ADJ	B
in	O	ADP	O
affected	O	VERB	B
cat	O	NOUN	B
fibroblasts	O	NOUN	B
and	O	CCONJ	O
restored	O	VERB	B
by	O	ADP	O
retroviral	O	ADJ	B
gene	O	NOUN	I
transfer	O	NOUN	I
of	O	ADP	O
rat	O	NOUN	B
beta	O	NOUN	B
-	O	PUNCT	O
glucuronidase	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


beta	O	NOUN	B
-	O	PUNCT	O
Glucuronidase	O	PROPN	B
mRNA	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
affected	O	VERB	B
cat	O	NOUN	B
testis	O	NOUN	I
by	O	ADP	O
Northern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Normal	O	ADJ	B
feline	O	NOUN	O
beta	O	NOUN	B
-	O	PUNCT	O
glucuronidase	O	NOUN	B
cDNA	O	NOUN	B
was	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
amplified	O	VERB	B
from	O	ADP	O
affected	O	VERB	B
cat	O	NOUN	B
fibroblasts	O	NOUN	B
by	O	ADP	O
reverse	O	ADJ	B
transcription	O	NOUN	I
coupled	O	ADJ	I
polymerase	O	NOUN	I
chain	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	DET	O
transition	O	NOUN	B
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
cat	O	NOUN	B
cDNA	O	NOUN	B
that	O	PRON	O
predicted	O	VERB	B
an	O	DET	O
E351K	O	NOUN	B
substitution	O	NOUN	B
,	O	PUNCT	O
destroyed	O	VERB	O
a	O	DET	O
BssSI	O	NOUN	B
site	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
eliminated	O	VERB	O
GUSB	O	NOUN	B
enzymatic	O	ADJ	B
activity	O	NOUN	I
in	O	ADP	O
expression	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


Multiple	O	ADJ	B
species	O	NOUN	B
comparison	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
crystal	O	NOUN	B
structure	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
glucuronidase	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
E351	O	NOUN	B
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
residue	O	NOUN	B
most	O	ADV	O
likely	O	ADV	O
essential	O	ADJ	O
in	O	ADP	O
maintenance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzymes	O	NOUN	B
conformation	O	NOUN	B
.	O	PUNCT	O


BssSI	O	NOUN	B
digestion	O	NOUN	B
of	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
products	O	NOUN	I
amplified	O	VERB	B
from	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
affected	O	VERB	B
cats	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
and	O	CCONJ	O
cats	O	NOUN	B
with	O	ADP	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
glucuronidase	O	NOUN	B
activity	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


Carriers	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
this	O	DET	O
manner	O	NOUN	O
produced	O	VERB	O
affected	O	VERB	B
kittens	O	NOUN	B
in	O	ADP	O
prospective	O	ADJ	B
breedings	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
feline	O	NOUN	B
MPS	B-Disease	NOUN	B
VII	I-Disease	NOUN	O
breeding	O	NOUN	B
colony	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
established	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
molecular	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
rearrangement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
22q11	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
chromosome	O	NOUN	B
22q11	O	NOUN	I
region	O	NOUN	I
is	O	AUX	O
susceptible	O	ADJ	B
to	O	PART	O
rearrangements	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
congenital	B-Disease	ADJ	B
anomaly	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
malignant	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
congenital	B-Disease	ADJ	B
anomaly	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
cat	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
der	B-Disease	NOUN	B
(	I-Disease	PUNCT	O
)	I-Disease	PUNCT	O
syndrome	I-Disease	NOUN	O
and	O	CCONJ	O
velo	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cardio	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
facial	I-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
/	O	SYM	O
DiGeorge	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
VCFS	B-Disease	NOUN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
)	O	PUNCT	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
tetrasomy	O	NOUN	B
,	O	PUNCT	O
trisomy	O	NOUN	B
or	O	CCONJ	O
monosomy	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
22q11	O	NOUN	O
.	O	PUNCT	O


VCFS	B-Disease	NOUN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
syndrome	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
22q11	O	NOUN	B
rearrangements	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
are	O	AUX	O
particular	O	ADJ	O
regions	O	NOUN	B
on	O	ADP	O
22q11	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
prone	O	ADJ	O
to	O	ADP	O
rearrangements	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
deletion	O	NOUN	B
end	O	NOUN	O
-	O	PUNCT	O
points	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
VCFS	B-Disease	PROPN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
patients	O	NOUN	B
were	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
VCFS	B-Disease	PROPN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
patients	O	NOUN	B
have	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
3	O	NUM	B
Mb	O	NOUN	I
deletion	O	NOUN	B
,	O	PUNCT	O
some	O	DET	O
have	O	AUX	O
a	O	DET	O
nested	O	ADJ	B
distal	O	ADJ	I
deletion	O	NOUN	O
breakpoint	O	NOUN	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
Mb	O	NOUN	O
deletion	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
few	O	ADJ	O
rare	O	ADJ	B
patients	O	NOUN	B
have	O	AUX	O
unique	O	ADJ	O
deletions	O	NOUN	B
or	O	CCONJ	O
translocations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disorder	O	NOUN	B
in	O	ADP	O
the	O	DET	O
population	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
most	O	ADJ	O
cases	O	NOUN	B
occur	O	VERB	O
sporadically	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
sequences	O	NOUN	B
at	O	ADP	O
or	O	CCONJ	O
near	O	ADP	B
the	O	DET	O
breakpoints	O	NOUN	B
confer	O	VERB	O
susceptibility	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
rearrangements	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
developed	O	VERB	O
hamster	O	NOUN	B
-	O	PUNCT	O
human	O	ADJ	B
somatic	O	ADJ	B
hybrid	O	NOUN	O
cell	O	NOUN	O
lines	O	NOUN	O
from	O	ADP	O
VCFS	B-Disease	PROPN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
patients	O	NOUN	B
with	O	ADP	O
all	O	DET	O
three	O	NUM	O
classes	O	NOUN	B
of	O	ADP	O
deletions	O	NOUN	B
and	O	CCONJ	O
we	O	PRON	O
now	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
breakpoints	O	NOUN	B
occur	O	VERB	O
within	O	ADP	O
similar	O	ADJ	O
low	O	ADJ	B
copy	O	NOUN	B
repeats	O	NOUN	I
,	O	PUNCT	O
termed	O	VERB	O
LCR22s	O	ADJ	B
.	O	PUNCT	O


To	O	PART	O
support	O	VERB	O
this	O	DET	O
idea	O	NOUN	O
further	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
a	O	DET	O
family	O	NOUN	B
that	O	PRON	O
carries	O	VERB	O
an	O	DET	O
interstitial	O	ADJ	B
duplication	O	NOUN	I
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
3	O	NUM	B
Mb	O	NOUN	I
region	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
VCFS	B-Disease	NOUN	B
/	O	SYM	O
DGS	B-Disease	PROPN	B
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
models	O	NOUN	B
to	O	PART	O
explain	O	VERB	O
how	O	SCONJ	O
the	O	DET	O
LCR22s	O	NOUN	B
can	O	AUX	O
mediate	O	VERB	O
different	O	ADJ	O
homologous	O	ADJ	B
recombination	O	NOUN	I
events	O	NOUN	O
,	O	PUNCT	O
thereby	O	ADV	O
generating	O	VERB	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
rearrangements	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
congenital	B-Disease	ADJ	B
anomaly	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
five	O	NUM	O
additional	O	ADJ	O
copies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LCR22	O	NOUN	B
on	O	ADP	O
22q11	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
mediate	O	VERB	O
other	O	ADJ	O
rearrangements	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
disease	O	NOUN	B
.	O	PUNCT	O


Functional	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	I
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
growth	O	NOUN	B
response	O	NOUN	I
2	O	NUM	I
gene	O	NOUN	I
(	O	PUNCT	O
EGR2	O	NOUN	B
)	O	PUNCT	O
correlate	O	VERB	B
with	O	ADP	O
severity	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
myelinopathies	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
early	O	ADJ	B
growth	O	NOUN	B
response	O	NOUN	I
2	O	NUM	I
gene	O	NOUN	I
(	O	PUNCT	O
EGR2	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
Cys2His2zinc	O	NOUN	B
finger	O	NOUN	I
transcription	O	NOUN	I
factor	O	NOUN	I
which	O	DET	O
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
myelination	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
idea	O	NOUN	O
is	O	AUX	O
based	O	VERB	O
partly	O	ADV	O
on	O	ADP	O
the	O	DET	O
phenotype	O	NOUN	B
of	O	ADP	O
homozygous	O	ADJ	B
Krox20	O	NOUN	B
(	O	PUNCT	O
Egr2	O	NOUN	B
)	O	PUNCT	O
knockout	O	NOUN	B
mice	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
display	O	VERB	O
hypomyelination	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
PNS	I-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
block	O	NOUN	B
of	O	ADP	O
Schwann	O	NOUN	B
cells	O	NOUN	I
at	O	ADP	O
an	O	DET	O
early	O	ADJ	B
stage	O	NOUN	I
of	O	ADP	O
differentiation	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
EGR2	O	NOUN	O
gene	O	NOUN	O
have	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
inherited	B-Disease	VERB	B
peripheral	I-Disease	ADJ	B
neuropathies	I-Disease	NOUN	I
Charcot	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Marie	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Tooth	I-Disease	PROPN	B
type	I-Disease	NOUN	I
1	I-Disease	NUM	I
,	O	PUNCT	O
Dejerine	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sottas	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
congenital	B-Disease	ADJ	B
hypomyelinating	I-Disease	ADJ	I
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
the	O	DET	O
four	O	NUM	O
EGR2	O	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
dominant	O	ADJ	B
and	O	CCONJ	O
occur	O	VERB	O
within	O	ADP	O
the	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
mutation	O	NOUN	B
is	O	AUX	O
recessive	O	ADJ	B
and	O	CCONJ	O
affects	O	VERB	O
the	O	DET	O
inhibitory	O	ADJ	B
domain	O	NOUN	I
(	O	PUNCT	O
R1	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
binds	O	VERB	B
the	O	DET	O
NAB	O	NOUN	B
transcriptional	O	ADJ	B
co	O	X	B
-	O	PUNCT	O
repressors	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	NOUN	B
assays	O	NOUN	I
and	O	CCONJ	O
transcriptional	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
mutations	O	NOUN	B
affect	O	VERB	O
DNA	O	NOUN	B
binding	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
residual	O	ADJ	B
binding	O	NOUN	B
directly	O	ADV	O
correlates	O	VERB	O
with	O	ADP	O
disease	O	NOUN	B
severity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
R1	O	NOUN	B
domain	O	NOUN	I
mutation	O	NOUN	I
prevents	O	VERB	O
interaction	O	NOUN	B
of	O	ADP	O
EGR2	O	NOUN	B
with	O	ADP	O
the	O	DET	O
NAB	O	PROPN	B
co	O	X	B
-	O	PUNCT	O
repressors	O	NOUN	B
and	O	CCONJ	O
thereby	O	ADV	O
increases	O	VERB	B
transcriptional	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
provide	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
disease	O	NOUN	B
mechanisms	O	NOUN	B
underlying	O	VERB	O
EGR2	O	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
reason	O	NOUN	O
for	O	ADP	O
varying	O	VERB	O
severity	O	NOUN	B
and	O	CCONJ	O
differences	O	NOUN	B
in	O	ADP	O
inheritance	O	NOUN	B
patterns	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
familial	I-Disease	ADJ	B
neurohypophyseal	I-Disease	ADJ	O
diabetes	I-Disease	NOUN	O
insipidus	I-Disease	NOUN	B
with	O	ADP	O
continued	O	ADJ	O
secretion	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
weakly	O	ADV	O
active	O	ADJ	O
vasopressin	O	NOUN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
neurohypophyseal	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
post	O	NOUN	B
-	O	PUNCT	O
natal	O	NOUN	B
development	O	NOUN	B
of	O	ADP	O
arginine	B-Disease	NOUN	B
vasopressin	I-Disease	NOUN	I
(	I-Disease	PUNCT	I
AVP	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
AVP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
published	O	VERB	B
mutations	O	NOUN	I
affect	O	VERB	O
the	O	DET	O
signal	O	NOUN	B
peptide	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
neurophysin	O	NOUN	B
-	O	PUNCT	O
II	O	NUM	B
carrier	O	NOUN	I
protein	O	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
presumed	O	VERB	O
to	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
processing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
preprohormone	O	NOUN	B
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
neuronal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
an	O	DET	O
unusual	O	ADJ	O
Palestinian	O	ADJ	B
family	O	NOUN	O
consisting	O	VERB	O
of	O	ADP	O
asymptomatic	O	ADJ	B
first	O	ADJ	B
cousin	O	NOUN	I
parents	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
children	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
neurohypophyseal	B-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
autosomal	O	ADJ	B
recessive	O	ADJ	I
inheritance	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
affected	O	VERB	B
children	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
parents	O	NOUN	B
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
single	O	ADJ	O
novel	O	ADJ	O
mutation	O	NOUN	B
(	O	PUNCT	O
C301	O	NOUN	B
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
replacing	O	VERB	O
Pro7	O	NOUN	B
of	O	ADP	O
mature	O	ADJ	B
AVP	O	NOUN	B
with	O	ADP	O
Leu	O	NOUN	B
(	O	PUNCT	O
Leu	O	NOUN	B
-	O	PUNCT	O
AVP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Leu	O	NOUN	B
-	O	PUNCT	O
AVP	O	NOUN	B
was	O	AUX	O
a	O	DET	O
weak	O	ADJ	B
agonist	O	NOUN	B
with	O	ADP	O
approximately	O	ADV	O
30	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
reduced	O	VERB	B
binding	O	NOUN	B
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
V2	O	NOUN	I
receptor	O	NOUN	I
.	O	PUNCT	O


Measured	O	VERB	B
by	O	ADP	O
radioimmunoassay	O	NOUN	B
with	O	ADP	O
a	O	DET	O
synthetic	O	ADJ	B
Leu	O	NOUN	B
-	O	PUNCT	O
AVP	O	NOUN	B
standard	O	NOUN	B
,	O	PUNCT	O
serum	O	NOUN	B
Leu	O	NOUN	I
-	O	PUNCT	O
AVP	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
elevated	O	ADJ	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
children	O	NOUN	B
and	O	CCONJ	O
further	O	ADV	O
increased	O	VERB	B
during	O	ADP	O
water	O	NOUN	B
deprivation	O	NOUN	I
to	O	ADP	O
as	O	ADV	O
high	O	ADJ	O
as	O	ADP	O
30	O	NUM	O
times	O	NOUN	O
normal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
youngest	O	ADJ	O
child	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
years	O	NOUN	O
old	O	ADJ	O
)	O	PUNCT	O
was	O	AUX	O
only	O	ADV	O
mildly	O	ADV	B
affected	O	VERB	B
but	O	CCONJ	O
had	O	AUX	O
Leu	O	NOUN	B
-	O	PUNCT	O
AVP	O	NOUN	B
levels	O	NOUN	B
similar	O	ADJ	O
to	O	ADP	O
her	O	PRON	O
severely	O	ADV	B
affected	O	VERB	B
8	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
brother	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
unknown	O	ADJ	O
mechanisms	O	NOUN	B
may	O	AUX	O
partially	O	ADV	O
compensate	O	VERB	B
for	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
active	I-Disease	ADJ	B
AVP	I-Disease	NOUN	B
in	O	ADP	O
very	O	ADV	O
young	O	ADJ	B
children	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


X	O	NOUN	B
inactivation	O	NOUN	B
and	O	CCONJ	O
somatic	O	ADJ	B
cell	O	NOUN	I
selection	O	NOUN	O
rescue	O	NOUN	O
female	O	NOUN	B
mice	O	NOUN	O
carrying	O	VERB	O
a	O	DET	O
Piga	O	PROPN	B
-	O	PUNCT	O
null	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
the	O	DET	O
X	O	NOUN	B
linked	O	VERB	O
PIGA	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
glycosyl	I-Disease	NOUN	B
phosphatidylinositol	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
GPI	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
-	I-Disease	PUNCT	O
anchored	I-Disease	VERB	B
proteins	I-Disease	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
cells	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
paroxysmal	B-Disease	ADJ	B
nocturnal	I-Disease	ADJ	I
hemoglobinuria	I-Disease	NOUN	I
.	O	PUNCT	O


No	O	DET	O
inherited	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
GPI	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
anchor	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Because	O	SCONJ	O
conventional	O	ADJ	O
Piga	O	NOUN	B
gene	O	NOUN	I
knockout	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
high	O	ADJ	O
embryonic	B-Disease	ADJ	O
lethality	I-Disease	NOUN	O
in	O	ADP	O
chimeric	O	ADJ	B
mice	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
the	O	DET	O
Cre	O	PROPN	B
/	O	SYM	O
loxP	O	NOUN	B
system	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
generated	O	VERB	O
mice	O	NOUN	B
in	O	ADP	O
which	O	DET	O
two	O	NUM	O
loxP	O	NOUN	B
sites	O	NOUN	I
flank	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
Piga	O	NOUN	B
exon	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


After	O	ADP	O
crossbreeding	O	VERB	B
with	O	ADP	O
female	O	ADJ	B
mice	O	NOUN	I
of	O	ADP	O
the	O	DET	O
EIIa	O	NOUN	B
-	O	PUNCT	O
cre	O	NOUN	B
strain	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
floxed	O	ADJ	B
allele	O	NOUN	I
undergoes	O	VERB	O
Cre	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
recombination	O	NOUN	B
with	O	ADP	O
high	O	ADJ	O
efficiency	O	NOUN	B
during	O	ADP	O
early	O	ADJ	B
embryonic	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
X	O	NOUN	B
chromosome	O	NOUN	I
inactivation	O	NOUN	I
,	O	PUNCT	O
female	O	ADJ	B
offspring	O	NOUN	B
are	O	AUX	O
mosaic	O	ADJ	B
for	O	ADP	O
cells	O	NOUN	B
that	O	PRON	O
express	O	VERB	B
or	O	CCONJ	O
lack	O	VERB	O
GPI	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
proteins	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
mosaic	O	ADJ	B
mice	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
heart	O	NOUN	B
,	O	PUNCT	O
lung	O	NOUN	B
,	O	PUNCT	O
kidney	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
liver	O	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
Piga	O	PROPN	B
is	O	AUX	O
active	O	ADJ	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
tissues	O	NOUN	B
require	O	VERB	O
GPI	O	PROPN	B
-	O	PUNCT	O
linked	O	VERB	B
proteins	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
salient	O	ADJ	O
exceptions	O	NOUN	O
were	O	AUX	O
spleen	O	NOUN	B
,	O	PUNCT	O
thymus	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
had	O	AUX	O
almost	O	ADV	O
equal	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
cells	O	NOUN	B
expressing	O	VERB	B
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
recombined	O	VERB	B
allele	O	NOUN	B
,	O	PUNCT	O
implying	O	VERB	O
that	O	SCONJ	O
GPI	O	PROPN	B
-	O	PUNCT	O
linked	O	VERB	B
proteins	O	NOUN	B
are	O	AUX	O
not	O	PART	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
derivation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
tissues	O	NOUN	B
.	O	PUNCT	O


PIGA	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
cells	O	NOUN	B
had	O	AUX	O
no	O	DET	O
growth	O	NOUN	B
advantage	O	NOUN	O
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
factors	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
for	O	ADP	O
their	O	PRON	O
clonal	O	ADJ	B
dominance	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
paroxysmal	B-Disease	ADJ	B
nocturnal	I-Disease	ADJ	I
hemoglobinuria	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
causing	O	VERB	O
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
does	O	AUX	O
not	O	PART	O
produce	O	VERB	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
.	O	PUNCT	O


Targeted	O	VERB	B
mutagenesis	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
produce	O	VERB	O
two	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
murine	O	ADJ	B
hemochromatosis	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
Hfe	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
mutation	O	NOUN	B
deletes	O	VERB	O
a	O	DET	O
large	O	ADJ	O
portion	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
,	O	PUNCT	O
generating	O	VERB	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
mutation	O	NOUN	B
introduces	O	VERB	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
C282Y	O	NOUN	B
)	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
Hfe	O	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
otherwise	O	ADV	O
leaves	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
intact	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
mutation	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
.	O	PUNCT	O


Mice	O	NOUN	B
carrying	O	VERB	B
each	O	DET	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
bred	O	VERB	B
and	O	CCONJ	O
analyzed	O	VERB	B
.	O	PUNCT	O


Homozygosity	O	NOUN	B
for	O	ADP	O
either	O	CCONJ	O
mutation	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
postnatal	O	ADJ	B
iron	O	NOUN	B
loading	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
null	O	ADJ	B
mutation	O	NOUN	I
are	O	AUX	O
more	O	ADV	O
severe	O	ADJ	B
than	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


Mice	O	NOUN	B
heterozygous	O	ADJ	B
for	O	ADP	O
either	O	CCONJ	O
mutation	O	NOUN	B
accumulate	O	VERB	B
more	O	ADJ	O
iron	O	NOUN	B
than	O	ADP	O
normal	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
although	O	SCONJ	O
liver	O	NOUN	B
iron	O	NOUN	B
stores	O	NOUN	I
are	O	AUX	O
greatly	O	ADV	O
increased	O	VERB	B
,	O	PUNCT	O
splenic	O	ADJ	B
iron	O	NOUN	I
is	O	AUX	O
decreased	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
does	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genotype	O	ADJ	B
-	O	PUNCT	O
phenotype	O	NOUN	B
analysis	O	NOUN	B
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
milder	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
emerin	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
22	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EMD	B-Disease	PROPN	B
)	O	PUNCT	O
revealed	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
21	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
confirming	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
mutations	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
EMD	I-Disease	PROPN	B
.	O	PUNCT	O


Most	O	ADJ	O
emerin	O	NOUN	B
mutations	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
three	O	NUM	O
mutations	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
Pro183Thr	O	X	B
and	O	CCONJ	O
two	O	NUM	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletions	O	NOUN	B
removing	O	VERB	O
residues	O	NOUN	O
95	O	NUM	O
-	O	SYM	O
99	O	NUM	O
and	O	CCONJ	O
236	O	NUM	O
-	O	SYM	O
241	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
were	O	AUX	O
unusual	O	ADJ	B
in	O	ADP	O
being	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
expression	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
phenotype	O	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
was	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
detail	O	NOUN	O
with	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
in	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
typical	O	ADJ	O
null	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
in	O	X	O
-	O	PUNCT	O
frame	O	NOUN	B
deletions	O	NOUN	B
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
family	O	NOUN	B
with	O	ADP	O
the	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
the	O	DET	O
phenotype	O	NOUN	B
was	O	AUX	O
milder	O	ADJ	B
.	O	PUNCT	O


Age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
was	O	AUX	O
later	O	ADV	O
for	O	ADP	O
first	O	ADJ	O
symptoms	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
ankle	B-Disease	NOUN	B
contractures	I-Disease	NOUN	I
and	O	CCONJ	O
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
have	O	AUX	O
diagnostic	O	ADJ	B
implications	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
pointing	O	VERB	O
to	O	ADP	O
functionally	O	ADV	O
important	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
emerin	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Severe	O	ADJ	B
clinical	O	ADJ	B
expression	O	NOUN	I
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EDMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
relatively	O	ADV	O
rare	O	ADJ	O
benign	B-Disease	ADJ	B
neuromuscular	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
which	O	DET	O
can	O	AUX	O
vary	O	VERB	O
remarkably	O	ADV	O
in	O	ADP	O
onset	O	NOUN	O
,	O	PUNCT	O
course	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
TCTAC	O	NOUN	B
deletion	O	NOUN	B
spanning	O	VERB	O
the	O	DET	O
nucleotides	O	NOUN	B
631	O	NUM	O
-	O	SYM	O
635	O	NUM	O
of	O	ADP	O
the	O	DET	O
emerin	O	NOUN	B
gene	O	NOUN	I
caused	O	VERB	O
an	O	DET	O
unusually	O	ADV	O
severe	O	ADJ	O
disease	O	NOUN	B
phenotype	O	NOUN	B
including	O	VERB	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
ambulation	I-Disease	NOUN	B
and	O	CCONJ	O
severe	O	ADJ	B
muscle	B-Disease	NOUN	B
wasting	I-Disease	NOUN	I
in	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
brothers	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
in	O	ADP	O
an	O	DET	O
unrelated	O	ADJ	B
family	O	NOUN	B
showing	O	VERB	O
a	O	DET	O
significantly	O	ADV	O
milder	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
interfamilial	O	ADJ	B
heterogeneity	O	NOUN	B
in	O	ADP	O
distribution	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
features	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
families	O	NOUN	B
point	O	VERB	O
to	O	ADP	O
environmental	O	ADJ	B
or	O	CCONJ	O
genetic	O	ADJ	B
modification	O	NOUN	I
as	O	ADP	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
variability	O	NOUN	B
in	O	ADP	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Common	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
do	O	AUX	O
not	O	PART	O
contribute	O	VERB	O
to	O	PART	O
early	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
Jewish	O	ADJ	B
men	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
subsequently	O	ADV	O
shown	O	VERB	O
to	O	PART	O
have	O	AUX	O
terminating	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
,	O	PUNCT	O
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
higher	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
among	O	ADP	O
male	O	NOUN	B
relatives	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
common	O	ADJ	O
germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
in	O	ADP	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
men	O	NOUN	B
predisposed	O	VERB	B
them	O	PRON	O
to	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
examined	O	VERB	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
83	O	NUM	O
(	O	PUNCT	O
for	O	ADP	O
BRCA1	O	NOUN	B
185delAG	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
82	O	NUM	O
(	O	PUNCT	O
for	O	ADP	O
BRCA2	O	NOUN	B
6174delT	O	NOUN	I
)	O	PUNCT	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
most	O	ADJ	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
at	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
young	O	ADJ	B
age	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
each	O	DET	O
gene	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
Ashkenazi	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	B
Our	O	PRON	O
study	O	NOUN	B
should	O	AUX	O
have	O	AUX	O
been	O	AUX	O
able	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
mutation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
3	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
mutant	O	ADJ	B
allele	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
two	O	NUM	O
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
BRCA2	O	NOUN	B
mutation	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
6	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
these	O	DET	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
closely	O	ADV	O
matched	O	VERB	O
their	O	PRON	O
incidence	O	NOUN	B
(	O	PUNCT	O
about	O	ADV	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
general	O	ADJ	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
unlike	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
do	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
predispose	O	VERB	O
men	O	NOUN	B
to	O	PART	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I


Beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
accumulation	O	NOUN	B
and	O	CCONJ	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTNNB1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
hepatoblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


Hepatoblastoma	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
malignant	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
that	O	PRON	O
occurs	O	VERB	O
in	O	ADP	O
children	O	NOUN	B
at	O	ADP	O
an	O	DET	O
average	O	ADJ	B
age	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
to	O	PART	O
3	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Epidemiologic	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
an	O	DET	O
increased	O	VERB	B
frequency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
tumor	B-Disease	NOUN	B
type	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
epidemiologic	O	ADJ	B
data	O	NOUN	B
,	O	PUNCT	O
molecular	O	ADJ	B
genetic	O	ADJ	I
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
tumor	I-Disease	NOUN	O
suppressor	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
hepatoblastoma	B-Disease	NOUN	B
tumorigenesis	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
major	O	ADJ	O
function	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
is	O	AUX	O
the	O	DET	O
downregulation	O	NOUN	B
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
transcription	O	NOUN	B
-	O	PUNCT	O
activating	O	VERB	B
protein	O	NOUN	B
with	O	ADP	O
oncogenic	O	ADJ	B
potential	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
ongoing	O	ADJ	O
immunohistochemical	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
sporadic	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
types	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
increased	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cytoplasm	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
nuclei	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
investigated	O	VERB	B
hepatoblastomas	B-Disease	NOUN	B
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
of	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CTNNB1	O	NOUN	B
)	O	PUNCT	O
revealed	O	VERB	O
an	O	DET	O
activating	O	VERB	B
mutation	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
samples	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
indicate	O	VERB	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
that	O	SCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
accumulation	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hepatoblastoma	B-Disease	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
activating	O	VERB	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
gene	O	NOUN	B
may	O	AUX	O
substitute	O	VERB	O
biallelic	O	ADJ	B
APC	O	NOUN	B
inactivation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
tumor	B-Disease	NOUN	B
type	O	NOUN	I
.	O	PUNCT	O


Genes	O	NOUN	B
Chromosomes	O	NOUN	B
Cancer	O	PROPN	I
25	O	NUM	O
399	O	NUM	O
-	O	SYM	O
402	O	NUM	O
,	O	PUNCT	O
1999	O	NUM	O
.	O	PUNCT	O
.	O	PUNCT	O


Decrease	O	NOUN	B
in	O	ADP	O
GTP	O	NOUN	B
cyclohydrolase	O	NOUN	I
I	O	NUM	I
gene	O	NOUN	B
expression	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
inactivation	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
in	O	ADP	O
hereditary	B-Disease	ADJ	B
progressive	I-Disease	ADJ	O
dystonia	I-Disease	NOUN	B
with	O	ADP	O
marked	O	ADJ	O
diurnal	O	ADJ	B
fluctuation	O	NOUN	O
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
progressive	I-Disease	ADJ	I
dystonia	I-Disease	NOUN	I
with	O	ADP	O
marked	O	ADJ	O
diurnal	O	ADJ	B
fluctuation	O	NOUN	O
(	O	PUNCT	O
HPD	B-Disease	NOUN	B
;	O	PUNCT	O
dopa	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
responsive	I-Disease	ADJ	B
dystonia	I-Disease	NOUN	B
,	O	PUNCT	O
DRD	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
GTP	O	NOUN	B
cyclohydrolase	O	NOUN	I
I	O	NUM	I
(	O	PUNCT	O
GCH1	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
quantified	O	VERB	B
the	O	DET	O
mRNA	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
GCH1	O	NOUN	B
in	O	ADP	O
phytohemagglutinin	O	NOUN	B
(	O	PUNCT	O
PHA	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
stimulated	O	VERB	B
mononuclear	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
one	O	NUM	O
Japanese	O	ADJ	B
family	O	NOUN	B
that	O	PRON	O
do	O	AUX	O
not	O	PART	O
have	O	AUX	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
or	O	CCONJ	O
splice	O	NOUN	B
junctions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
amounts	O	NOUN	O
of	O	ADP	O
the	O	DET	O
GCH1	O	NOUN	B
mRNA	O	NOUN	B
were	O	AUX	O
decreased	O	VERB	B
to	O	PART	O
about	O	ADV	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
level	O	NOUN	B
in	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
carriers	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
GCH1	O	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
transcribed	O	VERB	B
from	O	ADP	O
only	O	ADV	O
one	O	NUM	O
allele	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
allele	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
an	O	DET	O
inactive	O	ADJ	B
state	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
novel	O	ADJ	B
mutations	O	NOUN	B
should	O	AUX	O
exist	O	VERB	O
on	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
alleles	O	NOUN	B
in	O	ADP	O
some	O	DET	O
unknown	O	ADJ	O
region	O	NOUN	O
of	O	ADP	O
the	O	DET	O
GCH1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
decrease	O	VERB	B
the	O	DET	O
GCH1	O	NOUN	B
mRNA	O	NOUN	B
causing	O	VERB	O
the	O	DET	O
HPD	B-Disease	PROPN	B
/	O	SYM	O
DRD	B-Disease	PROPN	B
symptoms	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Sulfate	O	NOUN	B
transport	O	NOUN	I
is	O	AUX	O
not	O	PART	O
impaired	O	ADJ	B
in	O	ADP	O
pendred	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
thyrocytes	O	NOUN	B
.	O	PUNCT	O


Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
syndromic	B-Disease	ADJ	B
deafness	I-Disease	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
dyshormonogenic	B-Disease	ADJ	B
goiter	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
sensory	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
neural	I-Disease	ADJ	B
deafness	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
(	O	PUNCT	O
PDS	B-Disease	PROPN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
its	O	PRON	O
function	O	NOUN	B
is	O	AUX	O
as	O	ADP	O
yet	O	ADV	O
unknown	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
connection	O	NOUN	B
between	O	ADP	O
thyroid	B-Disease	NOUN	B
goiter	I-Disease	NOUN	I
and	O	CCONJ	O
sensory	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
neural	I-Disease	ADJ	B
deafness	I-Disease	NOUN	I
remains	O	VERB	O
an	O	DET	O
enigma	O	NOUN	O
.	O	PUNCT	O


PDS	O	PROPN	B
codes	O	VERB	O
for	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
protein	O	NOUN	B
,	O	PUNCT	O
pendrin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
closely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
sufate	O	NOUN	B
transporters	O	NOUN	I
.	O	PUNCT	O


Mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
abnormal	O	ADJ	B
sulfate	O	NOUN	B
transport	O	NOUN	I
could	O	AUX	O
deleteriously	O	ADV	O
affect	O	VERB	O
iodide	O	NOUN	B
organification	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
tested	O	VERB	B
sulfate	O	NOUN	B
transport	O	NOUN	I
in	O	ADP	O
thyrocytes	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
patients	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
not	O	PART	O
defective	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
pendrin	O	NOUN	B
in	O	ADP	O
fact	O	NOUN	O
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
a	O	DET	O
sulfate	O	NOUN	B
transporter	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
emphasizes	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
functional	O	ADJ	B
studies	O	NOUN	I
on	O	ADP	O
this	O	DET	O
novel	O	ADJ	O
protein	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Small	O	ADJ	B
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
triple	O	ADJ	I
helix	O	NOUN	I
produce	O	VERB	O
kniest	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	B
.	O	PUNCT	O


Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
moderately	O	ADV	O
severe	O	ADJ	B
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
collagenopathy	I-Disease	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
short	O	ADJ	B
trunk	O	NOUN	I
and	O	CCONJ	O
limbs	O	NOUN	B
,	O	PUNCT	O
kyphoscoliosis	B-Disease	NOUN	B
,	O	PUNCT	O
midface	B-Disease	NOUN	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
myopia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
encodes	O	VERB	B
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
(	O	PUNCT	O
COL2A1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
predominant	O	ADJ	O
protein	O	NOUN	B
of	O	ADP	O
cartilage	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
previously	O	ADV	O
described	O	VERB	O
mutations	O	NOUN	B
cause	O	VERB	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletions	O	NOUN	B
in	O	ADP	O
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
,	O	PUNCT	O
either	O	CCONJ	O
by	O	ADP	O
small	O	ADJ	O
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
or	O	CCONJ	O
splice	O	NOUN	B
site	O	NOUN	I
alterations	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
is	O	AUX	O
located	O	ADJ	O
between	O	ADP	O
exons	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
24	O	NUM	O
in	O	ADP	O
the	O	DET	O
COL2A1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
heteroduplex	O	NOUN	B
analysis	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
sequence	O	NOUN	B
anomalies	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
index	O	NOUN	O
patients	O	NOUN	B
genomic	O	ADJ	B
DNA	O	NOUN	I
identified	O	VERB	O
four	O	NUM	O
new	O	ADJ	O
dominant	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
COL2A1	O	NOUN	B
that	O	PRON	O
result	O	VERB	O
in	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
a	O	DET	O
21	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
16	O	NUM	O
,	O	PUNCT	O
an	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
19	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
sites	O	NOUN	I
of	O	ADP	O
introns	O	NOUN	B
14	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
described	O	VERB	O
28	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
COL2A1	O	NOUN	B
exon	O	NOUN	I
12	O	NUM	I
-	O	PUNCT	O
intron	O	NOUN	B
12	O	NUM	O
junction	O	NOUN	B
,	O	PUNCT	O
deleting	O	VERB	B
the	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
case	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
three	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
skipping	O	NOUN	I
in	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
encoded	O	VERB	B
from	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
results	O	VERB	B
from	O	ADP	O
shorter	O	ADJ	B
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
monomers	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
alteration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
COL2A1	O	NOUN	B
domain	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
span	O	VERB	O
from	O	ADP	O
exons	O	NOUN	B
12	O	NUM	O
to	O	PART	O
24	O	NUM	O
,	O	PUNCT	O
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
phenotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Classical	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
and	O	CCONJ	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyl	O	ADJ	I
transferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Classical	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	O	NOUN	B
in	O	ADP	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
galactose	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyl	O	ADJ	I
transferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
,	O	PUNCT	O
in	O	ADP	O
turn	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
GALT	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
disorder	O	NOUN	B
exhibits	O	VERB	O
considerable	O	ADJ	O
allelic	O	ADJ	B
heterogeneity	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
1998	O	NUM	O
,	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
150	O	NUM	O
different	O	ADJ	O
base	O	NOUN	B
changes	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
24	O	NUM	O
different	O	ADJ	O
populations	O	NOUN	B
and	O	CCONJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
in	O	ADP	O
15	O	NUM	O
countries	O	NOUN	B
worldwide	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
most	O	ADV	O
frequently	O	ADV	O
cited	O	VERB	O
are	O	AUX	O
Q188R	O	NOUN	B
,	O	PUNCT	O
K285N	O	NOUN	B
,	O	PUNCT	O
S135L	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
N314D	O	NOUN	B
.	O	PUNCT	O


Q188R	O	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
European	O	ADJ	B
populations	O	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
those	O	DET	O
predominantly	O	ADV	O
of	O	ADP	O
European	O	ADJ	B
descent	O	NOUN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
accounts	O	VERB	O
for	O	ADP	O
60	O	NUM	O
-	O	SYM	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
there	O	PRON	O
are	O	AUX	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
its	O	PRON	O
relative	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
individual	O	ADJ	O
populations	O	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
homoallelic	O	ADJ	B
for	O	ADP	O
Q188R	O	NOUN	B
tend	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
and	O	CCONJ	O
this	O	DET	O
is	O	AUX	O
in	O	ADP	O
keeping	O	VERB	O
with	O	ADP	O
the	O	DET	O
virtually	O	ADV	O
complete	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
enzyme	O	NOUN	B
activity	O	NOUN	I
observed	O	VERB	O
in	O	ADP	O
in	O	X	B
vitro	O	X	I
expression	O	NOUN	B
systems	O	NOUN	I
.	O	PUNCT	O


Globally	O	ADV	B
,	O	PUNCT	O
K285N	O	NOUN	B
is	O	AUX	O
rarer	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
many	O	ADJ	O
European	O	ADJ	B
populations	O	NOUN	B
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
found	O	VERB	O
on	O	ADP	O
25	O	NUM	O
-	O	SYM	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
invariably	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


S135L	O	NOUN	B
is	O	AUX	O
found	O	VERB	O
almost	O	ADV	O
exclusively	O	ADV	O
in	O	ADP	O
African	O	ADJ	B
Americans	O	PROPN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
expression	O	NOUN	B
results	O	NOUN	B
are	O	AUX	O
discrepant	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
some	O	DET	O
individuals	O	NOUN	B
carrying	O	VERB	O
S135L	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
exhibit	O	VERB	O
GALT	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
some	O	DET	O
tissues	O	NOUN	B
.	O	PUNCT	O


Duarte	O	PROPN	B
1	O	NUM	I
(	O	PUNCT	O
or	O	CCONJ	O
Los	O	PROPN	B
Angeles	O	PROPN	I
)	O	PUNCT	O
and	O	CCONJ	O
Duarte	O	PROPN	B
2	O	NUM	I
(	O	PUNCT	O
or	O	CCONJ	O
Duarte	O	PROPN	B
)	O	PUNCT	O
variants	O	NOUN	B
carry	O	VERB	O
the	O	DET	O
same	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
,	O	PUNCT	O
N314D	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
D1	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
erythrocyte	O	NOUN	B
GALT	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
D2	O	NOUN	B
with	O	ADP	O
reduced	O	VERB	B
activity	O	NOUN	B
.	O	PUNCT	O


N314D	O	NOUN	B
is	O	AUX	O
in	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	O
with	O	ADP	O
other	O	ADJ	O
base	O	NOUN	B
changes	O	NOUN	I
that	O	PRON	O
differ	O	VERB	O
on	O	ADP	O
the	O	DET	O
D1	O	NOUN	B
and	O	CCONJ	O
D2	O	NOUN	B
alleles	O	NOUN	I
.	O	PUNCT	O


N314D	O	NOUN	B
does	O	AUX	O
not	O	PART	O
impair	O	VERB	O
GALT	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
in	O	X	B
vitro	O	X	I
expression	O	NOUN	B
systems	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
abundance	O	NOUN	B
of	O	ADP	O
GALT	O	NOUN	B
protein	O	NOUN	I
in	O	ADP	O
lymphoblastoid	O	ADJ	B
cells	O	NOUN	I
lines	O	NOUN	I
from	O	ADP	O
D2	O	NOUN	B
and	O	CCONJ	O
D1	O	NOUN	B
individuals	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
unclear	O	ADJ	O
whether	O	SCONJ	O
the	O	DET	O
specific	O	ADJ	O
molecular	O	ADJ	B
changes	O	NOUN	I
that	O	PRON	O
distinguish	O	VERB	O
the	O	DET	O
D1	O	NOUN	B
and	O	CCONJ	O
D2	O	NOUN	B
alleles	O	NOUN	I
account	O	VERB	O
for	O	ADP	O
the	O	DET	O
different	O	ADJ	O
activities	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
considerable	O	ADJ	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
documented	O	VERB	B
to	O	PART	O
date	O	NOUN	O
undoubtedly	O	ADV	O
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
phenotypic	O	ADJ	B
heterogeneity	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
galactosemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
additional	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
nonallelic	O	ADJ	B
variation	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
constitutional	O	ADJ	B
factors	O	NOUN	I
on	O	ADP	O
phenotypic	O	ADJ	B
variability	O	NOUN	B
remain	O	VERB	O
to	O	PART	O
be	O	AUX	O
elucidated	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
:	O	PUNCT	O
definition	O	NOUN	B
of	O	ADP	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
VHL	B-Disease	NOUN	B
patients	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
an	O	DET	O
RCC	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
somatic	O	ADJ	B
von	B-Disease	NOUN	I
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	O	PUNCT	O
VHL	B-Disease	NOUN	B
)	O	PUNCT	O
mutations	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
173	O	NUM	O
primary	O	ADJ	B
sporadic	O	ADJ	B
human	O	ADJ	B
renal	B-Disease	ADJ	O
cell	I-Disease	NOUN	O
carcinomas	I-Disease	NOUN	O
for	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
tumor	I-Disease	NOUN	O
suppressor	O	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
using	O	VERB	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformational	O	ADJ	B
polymorphism	O	NOUN	O
analysis	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
DNA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
detected	O	VERB	B
abnormal	O	ADJ	B
SSCP	O	NOUN	B
pattern	O	NOUN	B
in	O	ADP	O
73	O	NUM	O
samples	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
sequencing	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	O
microdeletions	O	NOUN	B
in	O	ADP	O
58	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
,	O	PUNCT	O
microinsertions	O	NOUN	B
in	O	ADP	O
17	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
8	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
17	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
%	O	NOUN	O
correspond	O	VERB	O
to	O	ADP	O
new	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


VHL	B-Disease	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
nonpapillary	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
RCC	B-Disease	NOUN	B
)	O	PUNCT	O
subtype	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
previously	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
compare	O	VERB	B
somatic	O	ADJ	B
and	O	CCONJ	O
germline	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
the	O	DET	O
VHL	B-Disease	NOUN	B
database	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
includes	O	VERB	O
507	O	NUM	O
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
of	O	ADP	O
mutational	O	ADJ	B
events	O	NOUN	I
revealed	O	VERB	B
a	O	DET	O
significant	O	ADJ	O
difference	O	NOUN	O
between	O	ADP	O
somatic	O	ADJ	B
and	O	CCONJ	O
germline	O	NOUN	B
mutations	O	NOUN	I
with	O	ADP	O
mutations	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
truncated	O	VERB	B
proteins	O	NOUN	I
observed	O	VERB	O
in	O	ADP	O
78	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
somatic	O	ADJ	B
mutations	O	NOUN	I
vs	O	CCONJ	O
only	O	ADV	O
37	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
postulated	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
specific	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
VHL	B-Disease	NOUN	B
mutations	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
sporadic	B-Disease	ADJ	B
RCC	I-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
pattern	O	NOUN	B
corresponds	O	VERB	O
to	O	PART	O
mutations	O	NOUN	B
leading	O	VERB	O
mainly	O	ADV	O
to	O	PART	O
truncated	O	VERB	B
proteins	O	NOUN	I
with	O	ADP	O
few	O	ADJ	O
specific	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
analyzed	O	VERB	B
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
RCC	B-Disease	NOUN	B
in	O	ADP	O
VHL	B-Disease	NOUN	B
families	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
RCC	B-Disease	NOUN	B
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
member	O	NOUN	O
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
families	O	NOUN	B
in	O	ADP	O
77	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
mutations	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
truncated	O	VERB	B
proteins	O	NOUN	I
versus	O	CCONJ	O
55	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
cases	O	NOUN	B
with	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
mutations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
truncated	O	VERB	B
proteins	O	NOUN	I
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
higher	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
RCC	B-Disease	NOUN	B
in	O	ADP	O
VHL	B-Disease	NOUN	B
patients	O	NOUN	B


Defective	O	ADJ	B
CTLA	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
cycling	O	NOUN	B
pathway	O	NOUN	I
in	O	ADP	O
Chediak	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Higashi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
possible	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
deregulation	O	NOUN	B
of	O	ADP	O
T	O	NOUN	B
lymphocyte	O	NOUN	I
activation	O	NOUN	I
.	O	PUNCT	O


Cytotoxic	O	ADJ	B
T	O	NOUN	I
lymphocyte	O	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
antigen	O	NOUN	I
4	O	NUM	I
(	O	PUNCT	O
CTLA	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
CD152	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
major	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
T	O	NOUN	B
cell	O	NOUN	I
activation	O	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
membrane	O	NOUN	B
expression	O	NOUN	B
is	O	AUX	O
highly	O	ADV	O
regulated	O	VERB	O
by	O	ADP	O
endocytosis	O	NOUN	B
and	O	CCONJ	O
trafficking	O	VERB	B
through	O	ADP	O
the	O	DET	O
secretory	O	ADJ	B
lysosome	O	NOUN	O
pathway	O	NOUN	O
.	O	PUNCT	O


Chediak	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Higashi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
CHS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lysosomal	O	ADJ	B
trafficking	O	NOUN	I
regulator	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
LYST	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
results	O	VERB	B
in	O	ADP	O
defective	O	ADJ	B
membrane	O	NOUN	O
targeting	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proteins	O	NOUN	B
present	O	ADJ	O
in	O	ADP	O
secretory	O	ADJ	B
lysosomes	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
features	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
lymphoproliferative	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
hemophagocytosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
murine	O	ADJ	B
equivalent	O	NOUN	B
of	O	ADP	O
CHS	B-Disease	NOUN	B
,	O	PUNCT	O
beige	O	NOUN	B
mice	O	NOUN	I
,	O	PUNCT	O
present	O	VERB	O
similar	O	ADJ	O
characteristics	O	NOUN	B
but	O	CCONJ	O
do	O	AUX	O
not	O	PART	O
develop	O	VERB	O
the	O	DET	O
lymphoproliferative	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
herein	O	ADV	O
that	O	SCONJ	O
CTLA	O	PROPN	B
-	O	PUNCT	O
4	O	NUM	O
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
enlarged	O	ADJ	B
,	O	PUNCT	O
abnormal	O	ADJ	B
vesicles	O	NOUN	B
in	O	ADP	O
CHS	B-Disease	NOUN	B
T	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
properly	O	ADV	O
expressed	O	VERB	B
at	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
surface	O	NOUN	I
after	O	ADP	O
T	O	NOUN	B
cell	O	NOUN	I
activation	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
its	O	PRON	O
surface	O	NOUN	B
expression	O	NOUN	B
is	O	AUX	O
not	O	PART	O
impaired	O	ADJ	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
proposed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
defective	O	ADJ	B
surface	O	NOUN	B
expression	O	NOUN	B
of	O	ADP	O
CTLA	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
by	O	ADP	O
CHS	B-Disease	NOUN	B
T	O	NOUN	B
cells	O	NOUN	I
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
lymphoproliferative	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
CTLA	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Proteolipoprotein	O	ADJ	B
gene	O	NOUN	I
analysis	O	NOUN	I
in	O	ADP	O
82	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
sporadic	O	ADJ	B
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
Disease	I-Disease	PROPN	I
:	O	PUNCT	O
duplications	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
originate	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
male	O	ADJ	B
germ	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
point	O	NOUN	O
mutations	O	NOUN	B
do	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


The	O	DET	O
Clinical	O	ADJ	B
European	O	PROPN	I
Network	O	PROPN	I
on	O	ADP	O
Brain	B-Disease	PROPN	B
Dysmyelinating	I-Disease	PROPN	I
Disease	I-Disease	PROPN	I
.	O	PUNCT	O


Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
Disease	I-Disease	PROPN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
developmental	I-Disease	ADJ	B
defect	I-Disease	NOUN	O
of	I-Disease	ADP	O
myelination	I-Disease	NOUN	B
affecting	O	VERB	B
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
and	O	CCONJ	O
segregating	O	VERB	B
with	O	ADP	O
the	O	DET	O
proteolipoprotein	O	NOUN	B
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
.	O	PUNCT	O


Investigating	O	VERB	B
82	O	NUM	O
strictly	O	ADV	O
selected	O	VERB	O
sporadic	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
PMD	B-Disease	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
PLP	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
77	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
complete	O	ADJ	O
PLP	O	NOUN	B
-	O	PUNCT	O
gene	O	NOUN	B
duplications	O	NOUN	I
were	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
abnormality	O	NOUN	B
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
point	O	NOUN	O
mutations	O	NOUN	B
in	O	ADP	O
coding	O	VERB	B
or	O	CCONJ	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
were	O	AUX	O
involved	O	VERB	O
less	O	ADV	O
frequently	O	ADV	O
(	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
maternal	O	ADJ	B
status	O	NOUN	I
of	O	ADP	O
56	O	NUM	O
cases	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
PLP	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
since	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
relevant	O	ADJ	O
to	O	PART	O
genetic	O	ADJ	B
counseling	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
22	O	NUM	O
point	O	NOUN	O
mutations	O	NOUN	O
,	O	PUNCT	O
68	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mothers	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
value	O	NOUN	O
identical	O	ADJ	B
to	O	PART	O
the	O	DET	O
two	O	NUM	O
-	O	PUNCT	O
thirds	O	NOUN	B
of	O	ADP	O
carrier	O	NOUN	B
mothers	O	NOUN	B
that	O	PRON	O
would	O	AUX	O
be	O	AUX	O
expected	O	VERB	O
if	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
an	O	DET	O
equal	O	ADJ	O
mutation	O	NOUN	B
rate	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
germ	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
sharp	O	ADJ	O
contrast	O	NOUN	O
,	O	PUNCT	O
among	O	ADP	O
the	O	DET	O
34	O	NUM	O
duplicated	O	ADJ	B
cases	O	NOUN	B
,	O	PUNCT	O
91	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mothers	O	NOUN	B
were	O	AUX	O
carriers	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
value	O	NOUN	O
significantly	O	ADV	O
(	O	PUNCT	O
chi2	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
.	O	PUNCT	O
20	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
a	O	DET	O
male	O	NOUN	B
bias	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
estimation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
male	O	NOUN	B
/	O	SYM	O
female	O	ADJ	B
mutation	O	NOUN	B
frequency	O	NOUN	I
(	O	PUNCT	O
k	O	X	O
)	O	PUNCT	O
of	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
3	O	NUM	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
de	O	X	B
novo	O	X	I
mutations	O	NOUN	B
between	O	ADP	O
parental	O	ADJ	B
and	O	CCONJ	O
grandparental	O	ADJ	B
generations	O	NOUN	I
in	O	ADP	O
17	O	NUM	O
three	O	NUM	O
-	O	PUNCT	O
generation	O	NOUN	B
families	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
allowed	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
estimation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
k	O	NOUN	O
value	O	NOUN	O
(	O	PUNCT	O
k	O	NOUN	O
=	O	ADJ	O
11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Again	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
male	O	NOUN	B
mutation	O	NOUN	B
imbalance	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
for	O	ADP	O
the	O	DET	O
duplications	O	NOUN	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
breakage	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
and	I-Disease	CCONJ	O
Angelman	I-Disease	ADJ	B
syndromes	I-Disease	NOUN	I
involves	O	VERB	O
recombination	O	NOUN	B
between	O	ADP	O
large	O	ADJ	O
,	O	PUNCT	O
transcribed	O	VERB	B
repeats	O	NOUN	I
at	O	ADP	O
proximal	O	ADJ	B
and	O	CCONJ	O
distal	O	ADJ	B
breakpoints	O	NOUN	I
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
distinct	O	ADJ	O
neurobehavioral	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
that	O	PRON	O
most	O	ADV	O
often	O	ADV	O
arise	O	VERB	O
from	O	ADP	O
a	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
Mb	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
during	O	ADP	O
paternal	O	ADJ	B
or	O	CCONJ	O
maternal	O	ADJ	B
gametogenesis	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


At	O	ADP	O
a	O	DET	O
de	O	X	B
novo	O	X	I
frequency	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
.	O	PUNCT	O


67	O	NUM	O
-	O	SYM	O
1	O	NUM	O
/	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
births	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
deletions	O	NOUN	B
represent	O	VERB	O
a	O	DET	O
common	O	ADJ	O
structural	O	ADJ	B
chromosome	O	NOUN	I
change	O	NOUN	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
genome	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
mechanism	O	NOUN	B
underlying	O	VERB	O
these	O	DET	O
events	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
characterized	O	VERB	B
the	O	DET	O
regions	O	NOUN	B
that	O	PRON	O
contain	O	VERB	O
two	O	NUM	O
proximal	O	ADJ	B
breakpoint	O	NOUN	O
clusters	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
distal	O	ADJ	B
cluster	O	NOUN	I
.	O	PUNCT	O


Novel	O	ADJ	B
DNA	O	NOUN	B
sequences	O	NOUN	I
potentially	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
breakpoints	O	NOUN	B
were	O	AUX	O
positionally	O	ADV	O
cloned	O	VERB	B
from	O	ADP	O
YACs	O	NOUN	B
within	O	ADP	O
or	O	CCONJ	O
near	O	ADP	B
these	O	DET	O
regions	O	NOUN	B
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
rodent	O	ADJ	B
-	O	PUNCT	O
human	O	ADJ	B
somatic	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
hybrids	O	NOUN	I
,	O	PUNCT	O
YAC	O	NOUN	B
contigs	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
FISH	O	NOUN	B
of	O	ADP	I
normal	O	ADJ	I
or	O	CCONJ	O
rearranged	O	ADJ	B
chromosomes	O	NOUN	I
15	O	NUM	O
identified	O	VERB	B
duplicated	O	ADJ	O
sequences	O	NOUN	O
(	O	PUNCT	O
the	O	DET	O
END	O	NOUN	B
repeats	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
or	O	CCONJ	O
near	O	ADP	B
the	O	DET	O
breakpoints	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
END	O	PROPN	B
-	O	PUNCT	O
repeat	O	NOUN	B
units	O	NOUN	B
are	O	AUX	O
derived	O	VERB	O
from	O	ADP	O
large	O	ADJ	O
genomic	O	ADJ	B
duplications	O	NOUN	I
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	O
(	O	PUNCT	O
HERC2	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
many	O	ADJ	O
copies	O	NOUN	B
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
transcriptionally	O	ADV	B
active	O	ADJ	B
in	O	ADP	O
germline	O	NOUN	B
tissues	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
five	O	NUM	O
PWS	B-Disease	PROPN	B
/	O	PUNCT	O
AS	B-Disease	ADJ	B
patients	O	NOUN	B
analyzed	O	VERB	B
to	O	PART	O
date	O	NOUN	B
has	O	AUX	O
an	O	DET	O
identifiable	O	ADJ	B
,	O	PUNCT	O
rearranged	O	ADJ	O
HERC2	O	NOUN	B
transcript	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
event	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
END	O	NOUN	B
repeats	O	NOUN	B
flanking	O	VERB	I
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
mediate	O	VERB	O
homologous	O	ADJ	B
recombination	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
deletion	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
active	O	ADJ	B
transcription	O	NOUN	B
of	O	ADP	O
these	O	DET	O
repeats	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
germ	O	NOUN	O
cells	O	NOUN	O
may	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
homologous	O	ADJ	B
recombination	O	NOUN	I
process	O	NOUN	I
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Brazilian	O	ADJ	B
family	O	NOUN	O
with	O	ADP	O
van	B-Disease	X	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
suggests	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
susceptibility	O	NOUN	B
locus	O	NOUN	I
for	O	ADP	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
at	O	ADP	I
17p11	O	NOUN	I
.	O	PUNCT	O
2	O	NUM	O
-	O	SYM	O
11	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


van	B-Disease	X	O
der	I-Disease	NOUN	O
Woude	I-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
(	O	PUNCT	O
VWS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
1q32	O	NOUN	B
-	O	PUNCT	O
41	O	NUM	O
,	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
pits	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
sinuses	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
lower	I-Disease	ADJ	B
lip	I-Disease	NOUN	I
,	O	PUNCT	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
/	I-Disease	PUNCT	O
palate	I-Disease	NOUN	B
(	O	PUNCT	O
CL	B-Disease	NOUN	B
/	I-Disease	SYM	O
P	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
(	O	PUNCT	I
CP	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
bifid	B-Disease	NOUN	B
uvula	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hypodontia	B-Disease	NOUN	B
(	O	PUNCT	O
H	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
VWS	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
incomplete	O	ADJ	B
penetrance	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
highly	O	ADV	O
variable	O	ADJ	B
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
CL	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
P	I-Disease	NOUN	B
and	O	CCONJ	O
CP	B-Disease	NOUN	B
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
genealogy	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
recurrence	O	NOUN	B
risk	O	NOUN	I
<	O	X	O
40	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
CP	B-Disease	NOUN	B
among	O	ADP	O
descendants	O	NOUN	B
with	O	ADP	O
VWS	B-Disease	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
clefts	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
is	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
modifying	O	VERB	O
genes	O	NOUN	B
at	O	ADP	O
other	O	ADJ	O
loci	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
conducted	O	VERB	O
linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Brazilian	O	ADJ	B
kindred	O	NOUN	B
with	O	ADP	O
VWS	B-Disease	NOUN	B
,	O	PUNCT	O
considering	O	VERB	O
as	O	ADP	O
affected	O	VERB	B
the	O	DET	O
individuals	O	NOUN	B
with	O	ADP	O
CP	B-Disease	NOUN	B
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
whether	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
other	O	ADJ	O
clinical	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
VWS	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
gene	O	NOUN	B
at	O	ADP	O
17p11	O	NOUN	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
11	O	NUM	O
2	O	NUM	O
-	O	SYM	O
11	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
the	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	I
at	O	ADP	O
1p32	O	NOUN	B
-	O	PUNCT	O
41	O	NUM	O
,	O	PUNCT	O
enhances	O	VERB	B
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
CP	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
two	O	NUM	O
at	O	ADP	O
-	O	PUNCT	O
risk	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
this	O	DET	O
hypothesis	O	NOUN	B
is	O	AUX	O
confirmed	O	VERB	O
in	O	ADP	O
other	O	ADJ	O
VWS	B-Disease	NOUN	B
pedigrees	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
will	O	AUX	O
represent	O	VERB	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
first	O	ADJ	O
examples	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
mapped	O	VERB	B
through	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
modifies	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
a	O	DET	O
major	O	ADJ	O
gene	O	NOUN	B
.	O	PUNCT	O


New	O	ADJ	B
mutations	O	NOUN	O
,	O	PUNCT	O
polymorphisms	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
rare	O	ADJ	B
variants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
detected	O	VERB	B
by	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
SSCP	O	NOUN	B
strategy	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
,	O	PUNCT	O
ATM	O	NOUN	B
,	O	PUNCT	O
spans	O	VERB	O
about	O	ADV	O
150	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
.	O	PUNCT	O


ATM	O	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
found	O	VERB	O
along	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
gene	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
mutational	O	ADJ	B
hot	O	ADJ	I
spot	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
DNA	O	NOUN	B
as	O	ADP	O
the	O	DET	O
starting	O	NOUN	O
material	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
screened	O	VERB	B
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
92	O	NUM	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
an	O	DET	O
optimized	O	ADJ	B
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
technique	O	NOUN	O
that	O	PRON	O
detected	O	VERB	B
all	O	DET	O
previously	O	ADV	O
known	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
segments	O	NOUN	B
being	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


To	O	PART	O
expedite	O	VERB	O
screening	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
sequentially	O	ADV	O
loaded	O	VERB	O
the	O	DET	O
SSCP	O	NOUN	B
gels	O	NOUN	O
with	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
sets	O	NOUN	B
of	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
that	O	PRON	O
were	O	AUX	O
pretested	O	VERB	B
to	O	PART	O
avoid	O	VERB	O
overlapping	O	VERB	O
patterns	O	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
changes	O	NOUN	I
we	O	PRON	O
detected	O	VERB	B
were	O	AUX	O
intragenic	O	ADJ	B
polymorphisms	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
an	O	DET	O
expected	O	VERB	O
177	O	NUM	O
unknown	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
approximately	O	ADV	O
70	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
mostly	O	ADV	O
protein	O	NOUN	B
truncating	O	NOUN	I
mutations	O	NOUN	I
(	O	PUNCT	O
that	O	PRON	O
would	O	AUX	O
have	O	AUX	O
been	O	AUX	O
detectable	O	ADJ	B
by	O	ADP	O
protein	O	NOUN	B
truncation	O	NOUN	I
testing	O	NOUN	I
if	O	SCONJ	O
RNA	O	NOUN	B
starting	O	NOUN	O
material	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
available	O	ADJ	O
)	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
defined	O	VERB	O
for	O	ADP	O
every	O	DET	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Herein	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
present	O	VERB	O
35	O	NUM	O
new	O	ADJ	O
mutations	O	NOUN	B
and	O	CCONJ	O
34	O	NUM	O
new	O	ADJ	O
intragenic	O	ADJ	B
polymorphisms	O	NOUN	B
or	O	CCONJ	O
rare	O	ADJ	B
variants	O	NOUN	B
within	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
comprehensive	O	ADJ	B
compilation	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
polymorphisms	O	NOUN	B
assembled	O	VERB	O
to	O	PART	O
date	O	NOUN	O
.	O	PUNCT	O


Defining	O	VERB	O
polymorphic	O	ADJ	B
sites	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
of	O	ADP	O
great	O	ADJ	O
importance	O	NOUN	O
in	O	ADP	O
designing	O	VERB	O
automated	O	VERB	B
methods	O	NOUN	O
for	O	ADP	O
detecting	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
McLeod	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
XK	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
XK	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
McLeod	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
50	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
showed	O	VERB	O
progressive	O	ADJ	B
muscular	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
,	O	PUNCT	O
choreic	B-Disease	ADJ	B
movement	I-Disease	NOUN	B
,	O	PUNCT	O
elevated	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
creatinine	O	NOUN	I
kinase	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acanthocytosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
all	O	DET	O
the	O	DET	O
Kell	O	NOUN	B
antigens	O	NOUN	I
in	O	ADP	O
erythrocyte	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
and	O	CCONJ	O
molecular	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
(	O	PUNCT	O
T	O	NOUN	O
)	O	PUNCT	O
deletion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
nucleotide	O	NOUN	B
position	O	NOUN	I
1095	O	NUM	O
in	O	ADP	O
XK	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
deletion	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
in	O	ADP	O
translation	O	NOUN	B
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
at	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
position	O	NOUN	I
408	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
this	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
deletion	O	NOUN	B
causes	O	VERB	O
defective	O	ADJ	B
Kx	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
McLeod	B-Disease	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Association	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
with	O	ADP	O
the	O	DET	O
hRad50	O	ADJ	B
-	O	PUNCT	O
hMre11	O	PROPN	B
-	O	PUNCT	O
p95	O	NOUN	B
complex	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
interacts	O	VERB	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
with	O	ADP	O
hRad50	O	ADJ	B
,	O	PUNCT	O
which	O	DET	O
forms	O	VERB	O
a	O	DET	O
complex	O	NOUN	B
with	O	ADP	O
hMre11	O	NOUN	B
and	O	CCONJ	O
p95	O	NOUN	B
/	O	PUNCT	O
nibrin	O	NOUN	B
.	O	PUNCT	O


Upon	O	SCONJ	O
irradiation	O	NOUN	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
discrete	O	ADJ	O
foci	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
colocalize	O	VERB	B
with	O	ADP	O
hRad50	O	ADJ	B
.	O	PUNCT	O


Formation	O	NOUN	B
of	O	ADP	O
irradiation	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
foci	O	NOUN	B
positive	O	ADJ	B
for	O	ADP	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
hRad50	O	ADJ	B
,	O	PUNCT	O
hMre11	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
p95	O	NOUN	B
was	O	AUX	O
dramatically	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
HCC	O	NOUN	B
/	O	SYM	O
1937	O	NUM	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
cells	O	NOUN	O
carrying	O	VERB	O
a	O	DET	O
homozygous	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
but	O	CCONJ	O
was	O	AUX	O
restored	O	VERB	B
by	O	ADP	O
transfection	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
BRCA1	O	NOUN	B
.	O	PUNCT	O


Ectopic	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
mutated	O	VERB	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
in	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
rendered	O	VERB	O
them	O	PRON	O
less	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
the	O	DET	O
DNA	O	NOUN	B
damage	O	NOUN	I
agent	O	NOUN	I
,	O	PUNCT	O
methyl	O	NOUN	B
methanesulfonate	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
is	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
DNA	O	NOUN	B
damage	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
hRad50	O	ADJ	B
-	O	PUNCT	O
hMre11	O	PROPN	B
-	O	PUNCT	O
p95	O	NOUN	B
complex	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Relationship	O	NOUN	B
among	O	ADP	O
genotype	O	NOUN	B
,	O	PUNCT	O
biochemical	O	ADJ	B
phenotype	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cognitive	O	ADJ	B
performance	O	NOUN	I
in	O	ADP	O
females	O	NOUN	B
with	O	ADP	O
phenylalanine	B-Disease	NOUN	B
hydroxylase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
report	O	VERB	B
from	O	ADP	O
the	O	DET	O
Maternal	B-Disease	ADJ	B
Phenylketonuria	I-Disease	PROPN	I
Collaborative	O	PROPN	I
Study	O	PROPN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
examine	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
genotypes	O	NOUN	B
to	O	PART	O
biochemical	O	ADJ	B
phenotype	O	NOUN	B
and	O	CCONJ	O
cognitive	O	ADJ	B
development	O	NOUN	I
in	O	ADP	O
maternal	B-Disease	ADJ	B
phenylketonuria	I-Disease	NOUN	I
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODOLOGY	O	ADJ	O
PAH	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
222	O	NUM	O
hyperphenylalaninemic	B-Disease	ADJ	B
females	O	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
Maternal	B-Disease	ADJ	B
PKU	I-Disease	PROPN	O
Collaborative	O	PROPN	O
Study	O	PROPN	O
(	O	PUNCT	O
MPKUCS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
84	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
complete	O	ADJ	O
genotype	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
199	O	NUM	O
individuals	O	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
previous	O	ADJ	O
knowledge	O	NOUN	B
about	O	ADP	O
mutation	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
associations	O	NOUN	B
,	O	PUNCT	O
78	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
classes	O	NOUN	B
of	O	ADP	O
severity	O	NOUN	B
(	O	PUNCT	O
severe	O	ADJ	B
PKU	B-Disease	NOUN	B
,	O	PUNCT	O
moderate	O	ADJ	B
PKU	B-Disease	NOUN	B
,	O	PUNCT	O
mild	O	ADJ	B
PKU	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mild	B-Disease	ADJ	B
hyperphenylalaninemia	I-Disease	NOUN	B
[	O	PUNCT	O
MHP	B-Disease	PROPN	B
]	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Then	O	ADV	O
,	O	PUNCT	O
189	O	NUM	O
MPKUCS	O	NOUN	B
subjects	O	NOUN	B
were	O	AUX	O
grouped	O	VERB	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
various	O	ADJ	O
combinations	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
classifications	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
sample	O	NOUN	B
sizes	O	NOUN	I
were	O	AUX	O
large	O	ADJ	O
enough	O	ADV	O
for	O	ADP	O
statistical	O	ADJ	B
testing	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
mutation	O	NOUN	B
that	O	PRON	O
completely	O	ADV	O
abolishes	O	VERB	O
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
considered	O	VERB	O
functionally	O	ADV	O
hemizygous	O	ADJ	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
biochemical	O	ADJ	B
phenotype	O	NOUN	B
predicted	O	VERB	B
from	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
in	O	ADP	O
functionally	O	ADV	O
hemizygous	O	ADJ	B
patients	O	NOUN	B
was	O	AUX	O
related	O	VERB	O
significantly	O	ADV	O
to	O	PART	O
the	O	DET	O
assigned	O	VERB	O
phenylalanine	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


Cognitive	O	ADJ	B
performance	O	NOUN	I
(	O	PUNCT	O
IQ	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
genotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
IQ	O	NOUN	B
of	O	ADP	O
PAH	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mothers	O	NOUN	B
with	O	ADP	O
a	O	DET	O
severe	O	ADJ	B
PKU	B-Disease	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
a	O	DET	O
MHP	B-Disease	NOUN	B
mutation	O	NOUN	B
or	O	CCONJ	O
a	O	DET	O
mild	O	ADJ	B
PKU	B-Disease	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
99	O	NUM	O
and	O	CCONJ	O
96	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
IQ	O	NOUN	B
of	O	ADP	O
PKU	B-Disease	NOUN	B
mothers	O	NOUN	B
with	O	ADP	O
two	O	NUM	O
severe	O	ADJ	B
PKU	B-Disease	NOUN	B
mutations	O	NOUN	B
or	O	CCONJ	O
with	O	ADP	O
one	O	NUM	O
severe	O	ADJ	B
and	O	CCONJ	O
one	O	NUM	O
moderate	O	ADJ	B
PKU	B-Disease	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
83	O	NUM	O
and	O	CCONJ	O
84	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
PKU	B-Disease	NOUN	B
,	O	PUNCT	O
92	O	NUM	O
%	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
during	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


Those	O	DET	O
who	O	PRON	O
were	O	AUX	O
untreated	O	ADJ	B
or	O	CCONJ	O
treated	O	VERB	B
late	O	ADV	O
had	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
average	O	ADJ	B
IQ	O	NOUN	B
scores	O	NOUN	I
for	O	ADP	O
their	O	PRON	O
group	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
combinations	O	NOUN	I
.	O	PUNCT	O


Females	O	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
or	O	CCONJ	O
mild	O	ADJ	B
PKU	B-Disease	NOUN	B
who	O	PRON	O
were	O	AUX	O
treated	O	VERB	B
early	O	ADV	B
and	O	CCONJ	O
treated	O	VERB	B
for	O	ADP	O
>	O	NOUN	O
6	O	NUM	O
years	O	NOUN	B
showed	O	VERB	O
IQ	O	NOUN	B
scores	O	NOUN	I
10	O	NUM	O
points	O	NOUN	O
above	O	ADP	O
average	O	NOUN	B
for	O	ADP	O
their	O	PRON	O
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
reproductive	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
maternal	B-Disease	ADJ	B
phenylketonuria	I-Disease	NOUN	I
is	O	AUX	O
dependent	O	ADJ	O
on	O	ADP	O
prenatal	O	ADJ	B
metabolic	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
postnatal	O	ADJ	B
environmental	O	ADJ	B
circumstances	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
factors	O	NOUN	B
depend	O	VERB	O
on	O	ADP	O
the	O	DET	O
intellectual	O	ADJ	B
resources	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mother	O	NOUN	B
with	O	ADP	O
PKU	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
significant	O	ADJ	B
relationship	O	NOUN	B
among	O	ADP	O
genotype	O	NOUN	B
,	O	PUNCT	O
biochemical	O	ADJ	B
phenotype	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cognitive	O	ADJ	B
performance	O	NOUN	I
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
importance	O	NOUN	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
an	O	DET	O
optimal	O	ADJ	B
strategy	O	NOUN	O
for	O	ADP	O
future	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
females	O	NOUN	B
with	O	ADP	O
PKU	B-Disease	NOUN	B
who	O	PRON	O
plan	O	VERB	B
pregnancy	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Spinal	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
variant	O	NOUN	B
of	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
seven	O	NUM	O
Dutch	O	ADJ	B
patients	O	NOUN	B
from	O	ADP	O
six	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
slowly	O	ADV	O
progressive	O	ADJ	B
,	O	PUNCT	O
mainly	O	ADV	O
spinal	B-Disease	ADJ	B
cord	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
that	O	PRON	O
remained	O	VERB	O
for	O	ADP	O
many	O	ADJ	O
years	O	NOUN	B
the	O	DET	O
sole	O	NOUN	O
expression	O	NOUN	B
of	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


MRI	O	NOUN	B
demonstrated	O	VERB	O
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
lateral	O	ADJ	B
and	O	CCONJ	O
dorsal	O	ADJ	B
columns	O	NOUN	I
of	O	ADP	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
.	O	PUNCT	O


Post	O	NOUN	B
-	O	PUNCT	O
mortem	O	X	B
examination	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
showed	O	VERB	O
extensive	O	ADJ	O
myelin	O	NOUN	B
loss	O	NOUN	O
in	O	ADP	O
these	O	DET	O
columns	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
array	O	NOUN	B
of	O	ADP	O
genotypes	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
spinal	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
radiological	O	ADJ	B
separate	O	ADJ	O
entity	O	NOUN	B
of	O	ADP	O
CTX	B-Disease	NOUN	B
that	O	PRON	O
should	O	AUX	O
be	O	AUX	O
included	O	VERB	O
in	O	ADP	O
the	O	DET	O
differential	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
chronic	B-Disease	ADJ	B
myelopathy	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
transgene	O	NOUN	B
insertion	O	NOUN	B
creating	O	VERB	O
a	O	DET	O
heritable	O	ADJ	B
chromosome	O	NOUN	B
deletion	O	NOUN	I
mouse	O	NOUN	I
model	O	NOUN	I
of	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
and	I-Disease	CCONJ	O
angelman	I-Disease	ADJ	B
syndromes	I-Disease	NOUN	I
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	ADJ	B
)	O	PUNCT	O
result	O	VERB	O
from	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	I
function	O	NOUN	I
of	O	ADP	O
imprinted	O	ADJ	B
genes	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
central	O	ADJ	B
part	O	NOUN	I
of	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
7	O	NUM	I
is	O	AUX	O
homologous	O	ADJ	O
to	O	PART	O
human	O	ADJ	B
15q11	O	NOUN	O
-	O	PUNCT	O
q13	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
conservation	O	NOUN	B
of	O	ADP	O
both	O	DET	O
gene	O	NOUN	B
order	O	NOUN	I
and	O	CCONJ	O
imprinted	O	ADJ	B
features	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
transgene	O	NOUN	B
insertion	O	NOUN	I
(	O	PUNCT	O
Epstein	O	PROPN	B
-	O	PUNCT	O
Barr	O	PROPN	B
virus	O	NOUN	I
Latent	O	ADJ	B
Membrane	O	NOUN	I
Protein	O	NOUN	I
2A	O	NOUN	I
,	O	PUNCT	O
LMP2A	O	NOUN	B
)	O	PUNCT	O
into	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
7C	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
resulted	O	VERB	O
in	O	ADP	O
mouse	O	NOUN	B
models	O	NOUN	I
for	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
AS	B-Disease	NOUN	B
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
sex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transmitting	O	VERB	B
parent	O	NOUN	B
.	O	PUNCT	O


Epigenotype	O	NOUN	B
(	O	PUNCT	O
allelic	O	ADJ	B
expression	O	NOUN	I
and	O	CCONJ	O
DNA	O	NOUN	B
methylation	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
analyses	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
transgene	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
mutation	O	NOUN	B
has	O	AUX	O
generated	O	VERB	O
a	O	DET	O
complete	O	ADJ	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PWS	B-Disease	PROPN	B
/	O	PUNCT	O
AS	B-Disease	ADJ	B
-	O	PUNCT	O
homologous	O	ADJ	B
region	O	NOUN	I
but	O	CCONJ	O
has	O	AUX	O
not	O	PART	O
deleted	O	VERB	O
flanking	O	ADJ	O
loci	O	NOUN	O
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
intact	O	ADJ	B
chromosome	O	NOUN	O
7	O	NUM	O
,	O	PUNCT	O
opposite	O	ADJ	O
the	O	DET	O
deleted	O	VERB	B
homolog	O	NOUN	B
,	O	PUNCT	O
maintains	O	VERB	O
the	O	DET	O
correct	O	ADJ	O
imprint	O	NOUN	B
in	O	ADP	O
somatic	O	ADJ	B
cells	O	NOUN	I
of	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
AS	B-Disease	ADJ	B
mice	O	NOUN	B
and	O	CCONJ	O
establishes	O	VERB	O
the	O	DET	O
correct	O	ADJ	O
imprint	O	NOUN	B
in	O	ADP	O
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
germ	O	NOUN	B
cells	O	NOUN	I
of	O	ADP	O
AS	B-Disease	ADJ	B
mice	O	NOUN	B
,	O	PUNCT	O
homologous	O	ADJ	B
association	O	NOUN	B
and	O	CCONJ	O
replication	O	NOUN	B
asynchrony	O	NOUN	B
are	O	AUX	O
not	O	PART	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
imprinting	O	NOUN	B
mechanism	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
heritable	O	ADJ	B
-	O	PUNCT	O
deletion	O	NOUN	B
mouse	O	NOUN	O
model	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
particularly	O	ADV	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
etiological	O	ADJ	B
genes	O	NOUN	I
and	O	CCONJ	O
mechanisms	O	NOUN	B
,	O	PUNCT	O
phenotypic	O	ADJ	B
basis	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
investigation	O	NOUN	B
of	O	ADP	O
therapeutic	O	ADJ	B
approaches	O	NOUN	I
for	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
5	O	NUM	O
novel	O	ADJ	B
van	B-Disease	X	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
kindreds	O	NOUN	B
to	O	PART	O
1q32	O	NOUN	B
-	O	PUNCT	O
q41	O	NOUN	B
markers	O	NOUN	B
further	O	ADV	O
supports	O	VERB	O
locus	O	NOUN	B
homogeneity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
trait	O	NOUN	I
.	O	PUNCT	O


van	B-Disease	X	O
der	I-Disease	NOUN	O
Woude	I-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
(	O	PUNCT	O
vWS	B-Disease	NOUN	B
,	O	PUNCT	O
MIM	O	NOUN	B
119300	O	NUM	I
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
clefting	I-Disease	NOUN	B
condition	I-Disease	NOUN	O
with	O	ADP	O
cardinal	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
mucous	B-Disease	ADJ	B
cysts	I-Disease	NOUN	I
(	O	PUNCT	O
lower	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
lip	I-Disease	NOUN	B
pits	I-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
clefts	B-Disease	NOUN	B
to	I-Disease	ADP	O
the	I-Disease	DET	O
lip	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
palate	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
vWS	B-Disease	NOUN	B
gene	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
locus	O	NOUN	B
in	O	ADP	O
1q32	O	NOUN	B
-	O	PUNCT	O
q41	O	NOUN	B
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
and	O	CCONJ	O
physical	O	ADJ	B
mapping	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
5	O	NUM	O
novel	O	ADJ	O
vWS	B-Disease	NOUN	B
families	O	NOUN	B
through	O	ADP	O
probands	O	NOUN	B
attended	O	VERB	O
for	O	ADP	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
palate	I-Disease	ADJ	B
repair	O	NOUN	I
at	O	ADP	O
the	O	DET	O
Department	O	PROPN	B
of	O	ADP	I
Maxillofacial	O	PROPN	I
Surgery	O	PROPN	I
of	O	ADP	O
Hopital	O	PROPN	B
Trousseau	O	PROPN	I
,	O	PUNCT	O
Paris	O	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
tentatively	O	ADV	O
refine	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
map	O	NOUN	I
of	O	ADP	O
the	O	DET	O
vWS	B-Disease	NOUN	B
region	O	NOUN	B
in	O	ADP	O
1q32	O	NOUN	B
-	O	PUNCT	O
q41	O	NOUN	B
and	O	CCONJ	O
possibly	O	ADV	O
identify	O	VERB	O
unlinked	O	ADJ	O
pedigrees	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
to	O	PART	O
6	O	NUM	O
microsatellite	O	NOUN	B
markers	O	NOUN	I
(	O	PUNCT	O
D1S249	O	NOUN	B
,	O	PUNCT	O
D1S425	O	NOUN	B
,	O	PUNCT	O
D1S491	O	NOUN	B
,	O	PUNCT	O
D1S205	O	NOUN	B
,	O	PUNCT	O
D1S414	O	NOUN	B
,	O	PUNCT	O
D1S425	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
yielding	O	VERB	O
a	O	DET	O
maximum	O	ADJ	O
cumulative	O	ADJ	B
LOD	O	NOUN	B
score	O	NOUN	B
of	O	ADP	O
Z	O	NOUN	B
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
for	O	ADP	O
D1S245	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
innermost	O	ADJ	B
four	O	NUM	O
markers	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	ADP	O
one	O	NUM	O
another	O	DET	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
recombination	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
support	O	VERB	O
linkage	O	NOUN	B
of	O	ADP	O
vWS	B-Disease	NOUN	B
within	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
tightly	O	ADV	O
linked	O	VERB	O
markers	O	NOUN	B
and	O	CCONJ	O
do	O	AUX	O
not	O	PART	O
favour	O	VERB	O
locus	O	NOUN	B
heterogeneity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
trait	O	NOUN	I
.	O	PUNCT	O


Null	O	NOUN	B
mutation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
murine	O	NOUN	B
ATP7B	O	NOUN	B
(	O	PUNCT	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
gene	O	NOUN	B
results	O	VERB	I
in	O	ADP	O
intracellular	B-Disease	ADJ	B
copper	I-Disease	NOUN	B
accumulation	I-Disease	NOUN	B
and	O	CCONJ	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
onset	I-Disease	NOUN	B
hepatic	I-Disease	ADJ	B
nodular	I-Disease	ADJ	I
transformation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Atp7b	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
a	O	DET	O
copper	O	NOUN	B
-	O	PUNCT	O
transporting	O	VERB	B
ATPase	O	NOUN	B
expressed	O	VERB	B
predominantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
a	O	DET	O
lesser	O	ADJ	B
extent	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
other	O	ADJ	O
tissues	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATP7B	O	NOUN	B
gene	O	NOUN	I
lead	O	VERB	O
to	O	PART	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
copper	B-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
dramatic	O	ADJ	O
build	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
intracellular	O	ADJ	B
hepatic	O	ADJ	B
copper	O	NOUN	I
with	O	ADP	O
subsequent	O	ADJ	O
hepatic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
neuro	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
logical	I-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
homologous	O	ADJ	B
recombination	O	NOUN	I
to	O	PART	O
disrupt	O	VERB	B
the	O	DET	O
normal	O	ADJ	B
translation	O	NOUN	B
of	O	ADP	O
ATP7B	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
a	O	DET	O
strain	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
homozygous	O	ADJ	B
mutants	O	NOUN	B
(	O	PUNCT	O
null	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ATP7B	O	NOUN	B
null	O	ADJ	B
mice	O	NOUN	I
display	O	VERB	O
a	O	DET	O
gradual	O	ADJ	O
accumulation	O	NOUN	B
of	O	ADP	O
hepatic	O	ADJ	B
copper	O	NOUN	I
that	O	PRON	O
increases	O	VERB	B
to	O	PART	O
a	O	DET	O
level	O	NOUN	B
60	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
greater	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	B
by	O	ADP	O
5	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
copper	O	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
placenta	O	NOUN	B
and	O	CCONJ	O
lactating	O	VERB	B
mammary	O	ADJ	B
glands	O	NOUN	I
of	O	ADP	O
homo	O	ADJ	B
-	O	PUNCT	O
zygous	O	NOUN	B
mutants	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
milk	O	NOUN	B
from	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
glands	O	NOUN	I
was	O	AUX	O
copper	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
.	O	PUNCT	O


Morphological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	O
resembling	O	VERB	O
cirrhosis	B-Disease	NOUN	B
developed	O	VERB	O
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
livers	O	NOUN	B
from	O	ADP	O
homozygous	O	ADJ	B
mutants	O	NOUN	B
older	O	ADJ	B
than	O	ADP	O
7	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Progeny	O	NOUN	B
of	O	ADP	O
the	O	DET	O
homozygous	O	ADJ	B
mutant	O	ADJ	B
females	O	NOUN	B
demonstrated	O	VERB	O
neurological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
and	O	CCONJ	O
growth	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
characteristic	O	NOUN	O
of	O	ADP	O
copper	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Copper	O	NOUN	B
concentration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
livers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
newborn	O	ADJ	B
homozygous	O	ADJ	B
null	O	ADJ	B
mutants	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
dramatically	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
murine	O	NOUN	B
ATP7B	O	NOUN	B
gene	O	NOUN	I
produces	O	VERB	O
a	O	DET	O
form	O	NOUN	O
of	O	ADP	O
cirrhotic	B-Disease	ADJ	B
liver	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
that	O	PRON	O
resembles	O	VERB	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
toxic	O	ADJ	B
milk	O	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


French	O	PROPN	B
Machado	B-Disease	PROPN	O
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
do	O	AUX	O
not	O	PART	O
exhibit	O	VERB	O
gametic	O	ADJ	B
segregation	O	NOUN	I
distortion	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
sperm	O	NOUN	B
typing	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Segregation	O	NOUN	B
distortion	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
the	O	DET	O
trinucleotide	B-Disease	NOUN	B
repeat	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
a	O	DET	O
sperm	O	NOUN	B
typing	O	NOUN	I
study	O	NOUN	B
performed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
Japanese	O	ADJ	B
descent	O	NOUN	B
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
reported	O	VERB	O
that	O	SCONJ	O
disease	O	NOUN	B
alleles	O	NOUN	I
are	O	AUX	O
preferentially	O	ADV	O
transmitted	O	VERB	B
during	O	ADP	O
meiosis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
sperm	O	NOUN	B
typing	O	NOUN	I
study	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
MJD	B-Disease	NOUN	B
patients	O	NOUN	B
of	O	ADP	O
French	O	ADJ	B
descent	O	NOUN	I
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
pooled	O	VERB	B
data	O	NOUN	B
shows	O	VERB	O
a	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
mutant	O	NOUN	B
to	O	PART	O
normal	O	ADJ	O
alleles	O	NOUN	B
of	O	ADP	O
379	O	NUM	O
436	O	NUM	O
(	O	PUNCT	O
46	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
53	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
does	O	AUX	O
not	O	PART	O
support	O	VERB	O
meiotic	O	ADJ	B
segregation	O	NOUN	I
distortion	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
confirm	O	VERB	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
sperm	O	NOUN	B
typing	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
polymorphic	O	ADJ	B
marker	O	NOUN	I
,	O	PUNCT	O
D14S1050	O	NOUN	B
,	O	PUNCT	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
910	O	NUM	O
sperm	O	NOUN	B
analyzed	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
allele	O	NOUN	B
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
chromosome	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
50	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
samples	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
allele	O	NOUN	B
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
normal	O	ADJ	B
chromosome	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
49	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
sperm	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
frequency	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
alleles	O	NOUN	B
is	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
8423	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Likelihood	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
analysis	O	NOUN	B
of	O	ADP	O
segregation	O	NOUN	B
distortion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
single	O	ADJ	B
sperm	O	NOUN	B
data	O	NOUN	B
using	O	VERB	O
the	O	DET	O
SPERMSEG	O	ADJ	B
program	O	NOUN	I
also	O	ADV	O
showed	O	VERB	O
no	O	DET	O
support	O	NOUN	O
for	O	ADP	O
segregation	O	NOUN	B
distortion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
gamete	O	NOUN	B
level	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
previous	O	ADJ	O
report	O	NOUN	O
on	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
patients	O	NOUN	B
also	O	ADV	O
suggested	O	VERB	O
that	O	SCONJ	O
disease	O	NOUN	B
allele	O	NOUN	I
stability	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
a	O	DET	O
trans	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
an	O	DET	O
intragenic	O	ADJ	B
polymorphism	O	NOUN	B
(	O	PUNCT	O
987	O	NUM	O
G	O	NOUN	B
/	O	SYM	O
C	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
the	O	DET	O
French	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
this	O	DET	O
polymorphism	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
variance	O	NOUN	B
in	O	ADP	O
repeat	O	NOUN	O
number	O	NOUN	O
in	O	ADP	O
sperm	O	NOUN	B
from	O	ADP	O
the	O	DET	O
French	O	ADJ	B
MJD	B-Disease	NOUN	B
patients	O	NOUN	B
overlapped	O	VERB	B
significantly	O	ADV	B
with	O	ADP	I
the	O	DET	O
variance	O	NOUN	B
in	O	ADP	O
repeat	O	NOUN	O
number	O	NOUN	O
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
C	O	PROPN	B
/	O	PUNCT	O
C	O	NOUN	B
homozygous	O	ADJ	B
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
alternative	O	ADJ	B
splice	O	NOUN	O
region	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
eye	B-Disease	NOUN	B
anomalies	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
ocular	O	ADJ	B
morphogenesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
PAX6	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
various	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
ocular	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
,	O	PUNCT	O
corneal	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
congenital	B-Disease	ADJ	B
cataract	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
foveal	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
transcriptional	O	ADJ	B
regulator	O	NOUN	I
that	O	PRON	O
recognizes	O	VERB	O
target	O	NOUN	B
genes	O	NOUN	O
through	O	ADP	O
its	O	PRON	O
paired	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
paired	O	ADJ	B
domain	O	NOUN	I
is	O	AUX	O
composed	O	VERB	O
of	O	ADP	O
two	O	NUM	O
distinct	O	ADJ	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
subdomains	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
subdomain	O	NOUN	O
(	O	PUNCT	O
NTS	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
subdomain	O	NOUN	O
(	O	PUNCT	O
CTS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
bind	O	VERB	B
respective	O	ADJ	O
consensus	O	NOUN	B
DNA	O	NOUN	I
sequences	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
PAX6	O	NOUN	B
gene	O	NOUN	I
produces	O	VERB	O
two	O	NUM	O
alternative	O	ADJ	B
splice	O	NOUN	B
isoforms	O	NOUN	I
that	O	PRON	O
have	O	AUX	O
the	O	DET	O
distinct	O	ADJ	O
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paired	O	ADJ	B
domain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
insertion	O	NOUN	B
,	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
NTS	O	PROPN	B
,	O	PUNCT	O
of	O	ADP	O
14	O	NUM	O
additional	O	ADJ	O
amino	O	NOUN	B
acids	O	NOUN	I
encoded	O	VERB	B
by	O	ADP	O
exon	O	NOUN	B
5a	O	NOUN	I
abolishes	O	VERB	B
the	O	DET	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	NOUN	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NTS	O	PROPN	B
and	O	CCONJ	O
unmasks	O	VERB	O
the	O	DET	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	NOUN	B
ability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTS	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
exon	O	NOUN	B
5a	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
switch	O	NOUN	I
that	O	PRON	O
specifies	O	VERB	O
target	O	NOUN	B
genes	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
ascertained	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
pedigrees	O	NOUN	B
with	O	ADP	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
,	O	PUNCT	O
congenital	B-Disease	ADJ	B
cataract	I-Disease	NOUN	I
,	O	PUNCT	O
Axenfeldt	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
foveal	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
,	O	PUNCT	O
to	O	PART	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
mutation	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
variant	O	ADJ	B
region	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
20th	O	ADJ	O
nucleotide	O	NOUN	B
position	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
5a	O	NOUN	I
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asp	O	NOUN	B
(	O	PUNCT	O
GTC	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
GAC	O	NOUN	B
)	O	PUNCT	O
substitution	O	NOUN	B
at	O	ADP	O
the	O	DET	O
7th	O	ADJ	O
codon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alternative	O	ADJ	B
splice	O	NOUN	O
region	O	NOUN	O
.	O	PUNCT	O


Functional	O	ADJ	B
analyses	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
V54D	O	NOUN	O
mutation	O	NOUN	B
slightly	O	ADV	O
increased	O	VERB	B
NTS	O	NOUN	B
binding	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
CTS	O	NOUN	B
transactivation	O	NOUN	B
activity	O	NOUN	B
to	O	ADP	O
almost	O	ADV	O
half	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


Penetrances	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
1675delA	O	NOUN	B
and	O	CCONJ	O
1135insA	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
and	O	CCONJ	O
predictive	O	ADJ	B
testing	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
penetrances	O	NOUN	B
and	O	CCONJ	O
expressions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
underlying	O	VERB	O
mutations	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
known	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
reported	O	VERB	O
two	O	NUM	O
BRCA1	O	NOUN	B
founder	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Norwegian	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Index	O	NOUN	O
cases	O	NOUN	B
for	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
two	O	NUM	O
different	O	ADJ	O
ways	O	NOUN	O
through	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
consecutive	O	ADJ	B
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
16	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
through	O	ADP	O
our	O	PRON	O
family	O	NOUN	B
cancer	B-Disease	NOUN	I
clinic	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
14	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Altogether	O	ADV	O
,	O	PUNCT	O
20	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
BRCA1	O	NOUN	B
1675delA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
10	O	NUM	O
had	O	AUX	O
1135insA	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
relatives	O	NOUN	B
were	O	AUX	O
described	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
absence	O	NOUN	B
/	O	SYM	O
presence	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
133	O	NUM	O
living	O	VERB	B
female	O	ADJ	O
relatives	O	NOUN	O
,	O	PUNCT	O
83	O	NUM	O
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
tested	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
difference	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
penetrance	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
,	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
whereas	O	SCONJ	O
differences	O	NOUN	O
according	O	VERB	O
to	O	ADP	O
method	O	NOUN	B
of	O	ADP	O
ascertainment	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
findings	O	NOUN	B
were	O	AUX	O
that	O	SCONJ	O
disease	O	NOUN	B
started	O	VERB	O
to	O	PART	O
occur	O	VERB	O
at	O	ADP	O
age	O	NOUN	B
30	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
by	O	ADP	O
age	O	NOUN	B
50	O	NUM	O
years	O	NOUN	B
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
-	O	PUNCT	O
carrying	O	VERB	B
women	O	NOUN	B
had	O	AUX	O
experienced	O	VERB	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


More	O	ADV	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
than	O	ADP	O
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
.	O	PUNCT	O


Both	O	CCONJ	O
penetrance	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
(	O	PUNCT	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
vs	O	CCONJ	O
.	O	PUNCT	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
in	O	ADP	O
reports	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
founder	O	NOUN	I
mutations	O	NOUN	B
.	O	PUNCT	O


Whether	O	SCONJ	O
the	O	DET	O
reported	O	VERB	O
differences	O	NOUN	B
reflect	O	VERB	O
true	O	ADJ	O
differences	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
methodological	O	ADJ	B
problems	O	NOUN	I
is	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


An	O	DET	O
observed	O	VERB	O
excess	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
carriers	O	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
methodological	O	ADJ	B
problems	O	NOUN	I
;	O	PUNCT	O
possible	O	ADJ	O
explanations	O	NOUN	B
were	O	AUX	O
a	O	DET	O
"	O	PUNCT	O
true	O	ADJ	O
"	O	PUNCT	O
low	O	ADJ	B
penetrance	O	NOUN	B
or	O	CCONJ	O
preferential	O	ADJ	O
segregation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
dermatofibrosarcoma	B-Disease	ADJ	B
protuberans	I-Disease	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
collagen	O	NOUN	B
type	O	NOUN	O
Ialpha1	O	NOUN	B
/	O	PUNCT	O
platelet	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
growth	O	NOUN	B
factor	O	NOUN	I
(	O	PUNCT	O
PDGF	O	NOUN	B
)	O	PUNCT	O
B	O	NOUN	B
-	O	PUNCT	O
chain	O	NOUN	B
fusion	O	NOUN	I
gene	O	NOUN	I
generates	O	VERB	O
a	O	DET	O
transforming	O	VERB	B
protein	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
processed	O	VERB	O
to	O	PART	O
functional	O	ADJ	B
PDGF	O	NOUN	B
-	O	PUNCT	O
BB	O	NOUN	B
.	O	PUNCT	O


Dermatofibrosarcoma	B-Disease	ADJ	B
protuberans	I-Disease	NOUN	I
(	O	PUNCT	O
DFSP	B-Disease	NOUN	B
)	O	PUNCT	O
displays	O	VERB	O
chromosomal	O	ADJ	B
rearrangements	O	NOUN	I
involving	O	VERB	O
chromosome	O	NOUN	B
17	O	NUM	I
and	O	CCONJ	O
22	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
fuse	O	VERB	B
the	O	DET	O
collagen	O	NOUN	B
type	O	NOUN	I
Ialpha1	O	NOUN	I
(	O	PUNCT	O
COLIA1	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
to	O	PART	O
the	O	DET	O
platelet	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
growth	O	NOUN	B
factor	O	NOUN	I
(	O	PUNCT	O
PDGF	O	NOUN	B
)	O	PUNCT	O
B	O	NOUN	B
-	O	PUNCT	O
chain	O	NOUN	B
(	O	PUNCT	O
PDGFB	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
characterize	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
and	O	CCONJ	O
structural	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
the	O	DET	O
COLIA1	O	NOUN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
fusion	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
generated	O	VERB	O
a	O	DET	O
stable	O	ADJ	O
NIH3T3	O	NOUN	B
cell	O	NOUN	I
line	O	NOUN	I
that	O	PRON	O
contained	O	VERB	O
a	O	DET	O
tumor	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
chimeric	O	ADJ	B
gene	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
COIA1	O	NOUN	B
intron	O	NOUN	B
7	O	NUM	O
-	O	PUNCT	O
PDGFB	O	NOUN	B
intron	O	NOUN	B
1	O	NUM	O
fusion	O	NOUN	B
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
fusion	O	NOUN	B
protein	O	NOUN	I
led	O	VERB	O
to	O	PART	O
morphological	O	ADJ	B
transformation	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
growth	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PDGF	O	NOUN	B
receptor	O	NOUN	I
kinase	O	NOUN	I
inhibitor	O	NOUN	I
CGP57148B	O	NOUN	B
reversed	O	VERB	O
the	O	DET	O
transformed	O	VERB	B
phenotype	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
the	O	DET	O
growth	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
COLIA1	O	NOUN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
-	O	PUNCT	O
expressing	O	VERB	B
cells	O	NOUN	B
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effects	O	NOUN	I
on	O	ADP	O
control	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
dimeric	O	ADJ	B
COLIA1	O	NOUN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
precursors	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
through	O	ADP	O
PDGFB	O	NOUN	B
immunoprecipitations	O	NOUN	B
of	O	ADP	O
metabolically	O	ADV	B
labeled	O	VERB	I
cells	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
by	O	ADP	O
PDGFB	O	NOUN	B
immunoprecipitations	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
immunoblotting	O	NOUN	B
with	O	ADP	O
COLIA1	O	NOUN	B
antibodies	O	NOUN	I
.	O	PUNCT	O


Pulse	O	NOUN	B
-	O	PUNCT	O
chase	O	NOUN	B
studies	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
COLIA1	O	NOUN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
precursor	O	NOUN	B
was	O	AUX	O
processed	O	VERB	O
to	O	PART	O
an	O	DET	O
end	O	NOUN	O
product	O	NOUN	O
that	O	PRON	O
was	O	AUX	O
indistinguishable	O	ADJ	B
from	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
PDGF	O	NOUN	B
-	O	PUNCT	O
BB	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
COLIA1	O	PROPN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
-	O	PUNCT	O
expressing	O	VERB	B
cells	O	NOUN	B
generated	O	VERB	O
tumors	B-Disease	NOUN	B
after	O	ADP	O
s	O	NOUN	O
.	O	PUNCT	O


c	O	NOUN	O
c	O	NOUN	O
.	O	PUNCT	O
injection	O	NOUN	B
into	O	ADP	O
nude	O	ADJ	B
mice	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
tumor	B-Disease	NOUN	B
growth	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
CGP57148B	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
COLIA1	O	NOUN	B
/	O	PUNCT	O
PDGFB	O	NOUN	B
fusion	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
DFSP	B-Disease	NOUN	B
contributes	O	VERB	O
to	O	PART	O
tumor	B-Disease	NOUN	B
development	O	NOUN	I
through	O	ADP	O
ectopic	O	ADJ	B
production	O	NOUN	I
of	O	ADP	O
PDGF	O	NOUN	B
-	O	PUNCT	O
BB	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
an	O	DET	O
autocrine	O	NOUN	B
loop	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
PDGF	O	NOUN	B
receptors	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
target	O	NOUN	B
for	O	ADP	O
pharmacological	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
DFSP	B-Disease	NOUN	B
and	O	CCONJ	O
giant	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
fibroblastoma	I-Disease	NOUN	I
,	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O
g	O	NOUN	O
.	O	PUNCT	O
,	O	PUNCT	O
through	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
PDGF	O	NOUN	B
receptor	O	NOUN	I
kinase	O	NOUN	I
inhibitors	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
CGP57148B	O	NOUN	B
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
common	O	ADJ	O
PEX1	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Zellweger	B-Disease	NOUN	B
spectrum	I-Disease	NOUN	O
of	I-Disease	ADP	O
disease	I-Disease	NOUN	B
,	O	PUNCT	O
encompassing	O	VERB	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
progressively	O	ADV	O
milder	O	ADJ	O
phenotypes	O	NOUN	B
of	O	ADP	O
neonatal	B-Disease	ADJ	B
adrenoleukodystrophy	I-Disease	NOUN	B
and	O	CCONJ	O
infantile	B-Disease	ADJ	B
Refsum	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
failure	O	NOUN	B
to	O	PART	O
form	O	VERB	O
functional	O	ADJ	B
peroxisomes	O	NOUN	B
.	O	PUNCT	O


Cell	O	NOUN	B
fusion	O	NOUN	I
complementation	O	NOUN	I
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
diseases	O	NOUN	B
are	O	AUX	O
genetically	O	ADV	B
heterogeneous	O	ADJ	I
,	O	PUNCT	O
with	O	ADP	O
two	O	NUM	O
-	O	PUNCT	O
thirds	O	NOUN	B
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
lying	O	VERB	O
within	O	ADP	O
a	O	DET	O
single	O	ADJ	O
complementation	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
CG1	O	PROPN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
genetic	O	ADJ	I
and	O	CCONJ	O
cell	O	NOUN	B
biology	O	NOUN	I
studies	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
PEX1	O	NOUN	B
is	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
many	O	ADJ	O
CG1	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
focused	O	VERB	O
on	O	ADP	O
mildly	O	ADV	B
affected	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
there	O	PRON	O
is	O	AUX	O
still	O	ADV	O
no	O	DET	O
report	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
mutant	O	ADJ	B
PEX1	O	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
any	O	DET	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
patient	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PMP70	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
two	O	NUM	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
patients	O	NOUN	B
from	O	ADP	O
CG1	O	PROPN	B
,	O	PUNCT	O
raising	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
CG1	O	NOUN	B
patients	O	NOUN	B
may	O	AUX	O
represent	O	VERB	O
a	O	DET	O
mixture	O	NOUN	O
of	O	ADP	O
PEX1	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
and	O	CCONJ	O
PMP70	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
address	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
disease	O	NOUN	B
in	O	ADP	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
patients	O	NOUN	B
from	O	ADP	O
CG1	O	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
all	O	DET	O
24	O	NUM	O
PEX1	O	NOUN	B
exons	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
both	O	DET	O
patients	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
mutations	O	NOUN	B
in	O	ADP	O
PMP70	O	NOUN	B
.	O	PUNCT	O


PEX1	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
all	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
insertion	O	NOUN	B
(	O	PUNCT	O
c	O	NOUN	O
.	O	PUNCT	O
2097insT	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
13	O	NUM	I
that	O	PRON	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
studies	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
half	O	NOUN	B
of	O	ADP	O
all	O	DET	O
CG1	O	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
correlates	O	VERB	B
with	O	ADP	O
the	O	DET	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
phenotype	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
function	O	VERB	I
its	O	PRON	O
frequency	O	NOUN	B
makes	O	VERB	O
it	O	PRON	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
helping	O	VERB	O
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
high	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
that	O	PRON	O
belong	O	VERB	O
to	O	ADP	O
CG1	O	NOUN	B
.	O	PUNCT	O


Novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
transcriptional	O	ADJ	B
,	O	PUNCT	O
translational	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
clinical	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	AUX	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
eczema	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
recurrent	O	ADJ	B
infections	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


WASP	O	NOUN	B
contains	O	VERB	O
several	O	ADJ	O
functional	O	ADJ	B
domains	O	NOUN	I
through	O	ADP	O
which	O	DET	O
it	O	PRON	O
interacts	O	VERB	O
with	O	ADP	O
proteins	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
intracellular	O	ADJ	B
signaling	O	NOUN	B
and	O	CCONJ	O
regulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
actin	O	NOUN	B
cytoskeleton	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
WASP	O	NOUN	B
gene	O	NOUN	I
mutations	O	NOUN	O
were	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
12	O	NUM	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
novel	O	ADJ	O
.	O	PUNCT	O


DNA	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
obligate	O	ADJ	B
carriers	O	NOUN	B
was	O	AUX	O
PCR	O	NOUN	B
amplified	O	VERB	B
and	O	CCONJ	O
analyzed	O	VERB	B
by	O	ADP	O
SSCA	O	NOUN	B
,	O	PUNCT	O
heteroduplex	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
level	O	NOUN	O
were	O	AUX	O
ascertained	O	VERB	O
by	O	ADP	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
and	O	CCONJ	O
Western	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
exons	O	NOUN	B
1	O	NUM	I
-	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O


Most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
nonsense	O	NOUN	B
,	O	PUNCT	O
frameshift	O	NOUN	B
and	O	CCONJ	O
splice	O	NOUN	B
site	O	NOUN	I
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
exons	O	NOUN	B
6	O	NUM	O
-	O	SYM	O
11	O	NUM	O
.	O	PUNCT	O


Mutations	O	NOUN	B
that	O	PRON	O
alter	O	VERB	O
splice	O	NOUN	B
sites	O	NOUN	I
led	O	VERB	O
to	O	PART	O
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
mRNAs	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
fraction	O	NOUN	B
of	O	ADP	O
which	O	DET	O
represented	O	VERB	O
the	O	DET	O
normally	O	ADV	O
spliced	O	VERB	B
product	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
normally	O	ADV	O
spliced	O	VERB	B
transcripts	O	NOUN	B
was	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
a	O	DET	O
milder	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
one	O	NUM	O
such	O	ADJ	O
case	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
Western	O	NOUN	B
blotting	O	NOUN	I
,	O	PUNCT	O
reduced	O	VERB	B
amounts	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
-	O	PUNCT	O
size	O	NOUN	B
WASP	O	PROPN	B
were	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
other	O	ADJ	O
cases	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
or	O	CCONJ	O
mutant	O	ADJ	B
WASP	O	NOUN	B
present	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
phenotypes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
individuals	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
protein	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
two	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
WAS	B-Disease	AUX	B
.	O	PUNCT	O


Reduced	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
a	O	DET	O
normal	O	ADJ	B
-	O	PUNCT	O
size	O	NOUN	B
WASP	O	PROPN	B
with	O	ADP	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
two	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
XLT	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
mutation	O	NOUN	B
analysis	O	NOUN	I
at	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
level	O	NOUN	I
is	O	AUX	O
not	O	PART	O
sufficient	O	ADJ	O
for	O	ADP	O
predicting	O	VERB	B
clinical	O	ADJ	B
course	O	NOUN	I
.	O	PUNCT	O


Studies	O	NOUN	B
at	O	ADP	O
the	O	DET	O
transcript	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
level	O	NOUN	O
are	O	AUX	O
needed	O	VERB	O
for	O	ADP	O
a	O	DET	O
better	O	ADJ	O
assessment	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Aminoglycoside	O	NOUN	B
antibiotics	O	NOUN	I
restore	O	VERB	O
dystrophin	O	ADJ	B
function	O	NOUN	I
to	O	PART	O
skeletal	O	ADJ	B
muscles	O	NOUN	I
of	O	ADP	O
mdx	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
protein	O	NOUN	I
in	O	ADP	O
striated	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
premature	O	ADJ	B
stop	O	NOUN	I
codons	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
that	O	SCONJ	O
aminoglycoside	O	ADJ	B
treatment	O	NOUN	B
can	O	AUX	O
suppress	O	VERB	B
stop	O	VERB	B
codons	O	NOUN	I
in	O	ADP	O
cultured	O	VERB	B
cells	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
gentamicin	O	NOUN	B
on	O	ADP	O
cultured	O	VERB	B
muscle	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
the	O	DET	O
mdx	O	NOUN	B
mouse	O	NOUN	B
-	O	PUNCT	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
DMD	B-Disease	PROPN	B
that	O	PRON	O
possesses	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
in	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Exposure	O	NOUN	B
of	O	ADP	O
mdx	O	NOUN	B
myotubes	O	NOUN	O
to	O	PART	O
gentamicin	O	NOUN	B
led	O	VERB	O
to	O	PART	O
the	O	DET	O
expression	O	NOUN	B
and	O	CCONJ	O
localization	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
to	O	PART	O
the	O	DET	O
cell	O	NOUN	B
membrane	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
differing	O	VERB	O
dosages	O	NOUN	B
of	O	ADP	O
gentamicin	O	NOUN	B
on	O	ADP	O
expression	O	NOUN	B
and	O	CCONJ	O
functional	O	ADJ	B
protection	O	NOUN	B
of	O	ADP	O
the	O	DET	O
muscles	O	NOUN	B
of	O	ADP	O
mdx	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
treatment	O	NOUN	B
regimen	O	NOUN	I
that	O	PRON	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
membrane	O	NOUN	I
in	O	ADP	O
all	O	DET	O
striated	O	ADJ	B
muscles	O	NOUN	I
examined	O	VERB	B
and	O	CCONJ	O
that	O	DET	O
provided	O	VERB	O
functional	O	ADJ	B
protection	O	NOUN	B
against	O	ADP	O
muscular	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
results	O	NOUN	B
are	O	AUX	O
the	O	DET	O
first	O	ADJ	O
to	O	PART	O
demonstrate	O	VERB	O
that	O	SCONJ	O
aminoglycosides	O	NOUN	B
can	O	AUX	O
suppress	O	VERB	B
stop	O	VERB	B
codons	O	NOUN	I
not	O	PART	O
only	O	ADV	O
in	O	X	B
vitro	O	X	I
but	O	CCONJ	O
also	O	ADV	O
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
raise	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	B
treatment	O	NOUN	B
regimen	O	NOUN	O
for	O	ADP	O
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
diseases	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	O
mutations	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
treatment	O	NOUN	B
could	O	AUX	O
prove	O	VERB	O
effective	O	ADJ	B
in	O	ADP	O
up	O	ADV	O
to	O	PART	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
causes	O	VERB	O
oxidative	O	ADJ	B
damage	O	NOUN	I
in	O	ADP	O
target	O	NOUN	B
organs	O	NOUN	O
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
markedly	O	ADV	O
increased	O	VERB	B
sensitivity	O	NOUN	B
to	O	PART	O
ionizing	O	VERB	B
radiation	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neurodegeneration	B-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
of	O	ADP	O
the	O	DET	O
cerebellar	O	ADJ	B
Purkinje	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


Ionizing	O	VERB	B
radiation	O	NOUN	I
oxidizes	O	VERB	O
macromolecules	O	NOUN	B
and	O	CCONJ	O
causes	O	VERB	O
tissue	O	NOUN	B
damage	O	NOUN	O
through	O	ADP	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
reactive	O	ADJ	B
oxygen	O	NOUN	I
species	O	NOUN	I
(	O	PUNCT	O
ROS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
hypothesized	O	VERB	B
that	O	SCONJ	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
oxidative	O	ADJ	B
damage	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
loss	O	NOUN	B
of	O	ADP	I
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
employed	O	VERB	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
with	O	ADP	O
a	O	DET	O
disrupted	O	VERB	B
Atm	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
organs	O	NOUN	B
which	O	DET	O
develop	O	VERB	O
pathologic	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Atm	O	PROPN	B
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
are	O	AUX	O
targets	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
damage	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
cerebellar	O	ADJ	B
Purkinje	O	NOUN	B
cells	O	NOUN	I
are	O	AUX	O
particularly	O	ADV	O
affected	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
mechanistic	O	ADJ	O
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
lay	O	VERB	O
a	O	DET	O
rational	O	ADJ	O
foundation	O	NOUN	O
for	O	ADP	O
therapeutic	O	ADJ	B
intervention	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Recessively	O	ADV	B
inherited	O	VERB	B
multiple	B-Disease	ADJ	O
epiphyseal	I-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
with	O	ADP	O
normal	O	ADJ	B
stature	O	NOUN	I
,	O	PUNCT	O
club	B-Disease	NOUN	B
foot	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
double	B-Disease	ADJ	B
layered	I-Disease	VERB	I
patella	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
DTDST	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
observed	O	VERB	O
over	O	ADP	O
25	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
sulphate	O	NOUN	B
transporter	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
DTDST	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
the	O	DET	O
recessive	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
achondrogenesis	B-Disease	NOUN	I
1B	I-Disease	NOUN	I
,	O	PUNCT	O
atelosteogenesis	B-Disease	NOUN	B
2	I-Disease	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
c862t	O	ADJ	B
(	O	PUNCT	O
R279W	O	NOUN	B
)	O	PUNCT	O
transition	O	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Finnish	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
these	O	DET	O
disorders	O	NOUN	B
it	O	PRON	O
is	O	AUX	O
usually	O	ADV	O
combined	O	VERB	O
with	O	ADP	O
other	O	ADJ	O
DTDST	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
had	O	AUX	O
not	O	PART	O
seen	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
homozygosity	O	NOUN	B
for	O	ADP	O
c862t	O	ADJ	B
(	O	PUNCT	O
R279W	O	NOUN	B
)	O	PUNCT	O
until	O	ADP	O
we	O	PRON	O
analysed	O	VERB	B
DNA	O	NOUN	B
from	O	ADP	O
a	O	DET	O
36	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
male	O	NOUN	B
with	O	ADP	O
tall	O	ADJ	B
-	O	PUNCT	O
normal	O	ADJ	B
stature	O	NOUN	I
(	O	PUNCT	O
180	O	NUM	O
cm	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
asked	O	VERB	O
for	O	ADP	O
genetic	O	ADJ	B
counselling	O	NOUN	I
for	O	ADP	O
suspected	O	VERB	B
multiple	B-Disease	ADJ	B
epiphyseal	I-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
for	O	ADP	O
club	B-Disease	NOUN	B
foot	I-Disease	NOUN	I
and	O	CCONJ	O
hip	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
at	O	ADP	O
birth	O	NOUN	B
.	O	PUNCT	O


Skeletal	O	ADJ	B
changes	O	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
multiple	B-Disease	ADJ	B
epiphyseal	I-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
peculiar	O	ADJ	O
finding	O	NOUN	B
of	O	ADP	O
a	O	DET	O
double	B-Disease	ADJ	B
layered	I-Disease	VERB	I
patella	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
recognised	O	VERB	O
during	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


Cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
,	O	PUNCT	O
swelling	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
ear	I-Disease	NOUN	B
pinna	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hitch	B-Disease	ADJ	B
hiker	I-Disease	NOUN	I
thumb	I-Disease	NOUN	I
were	O	AUX	O
absent	O	ADJ	B
.	O	PUNCT	O


He	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
homozygous	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
both	O	CCONJ	O
healthy	O	ADJ	B
parents	O	NOUN	B
heterozygous	O	ADJ	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
R279W	O	NOUN	B
mutation	O	NOUN	O
in	O	ADP	O
DTDST	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
his	O	PRON	O
fibroblasts	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
sulphate	O	NOUN	B
incorporation	O	NOUN	I
defect	O	NOUN	I
typical	O	ADJ	O
of	O	ADP	O
DTDST	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Counselling	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
for	O	ADP	O
a	O	DET	O
recessive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
thereby	O	ADV	O
considerably	O	ADV	O
reducing	O	VERB	B
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
offspring	O	NOUN	B
.	O	PUNCT	O


Multiple	B-Disease	ADJ	B
epiphyseal	I-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
is	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
dominant	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
COMP	O	NOUN	B
(	O	PUNCT	O
EDM1	B-Disease	NOUN	B
,	O	PUNCT	O
McKusick	O	NOUN	B
132400	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
COL9A2	O	NOUN	B
genes	O	NOUN	I
(	O	PUNCT	O
EDM2	B-Disease	NOUN	B
,	O	PUNCT	O
McKusick	O	NOUN	B
600204	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
few	O	ADJ	O
other	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
families	O	NOUN	B
with	O	ADP	O
features	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
our	O	PRON	O
proband	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
previously	O	ADV	O
and	O	CCONJ	O
considered	O	VERB	O
to	O	PART	O
have	O	AUX	O
autosomal	O	ADJ	B
recessive	O	ADJ	I
MED	B-Disease	NOUN	I
(	O	PUNCT	O
EDM4	B-Disease	NOUN	B
,	O	PUNCT	O
McKusick	O	NOUN	O
226900	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
confirms	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
this	O	DET	O
entity	O	NOUN	B
and	O	CCONJ	O
assigns	O	VERB	O
it	O	PRON	O
to	O	ADP	O
the	O	DET	O
phenotypic	O	ADJ	B
spectrum	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
DTDST	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Homozygosity	O	NOUN	B
for	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
DTDST	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
a	O	DET	O
'	O	PUNCT	O
broad	O	ADJ	O
bone	O	NOUN	B
-	O	PUNCT	O
platyspondylic	O	NOUN	B
'	O	PART	O
variant	O	NOUN	B
of	O	ADP	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Atypical	O	ADJ	B
or	O	CCONJ	O
variant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
well	O	ADV	O
-	O	PUNCT	O
known	O	VERB	B
chondrodysplasias	B-Disease	NOUN	B
may	O	AUX	O
pose	O	VERB	O
diagnostic	O	ADJ	B
problems	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
features	O	NOUN	I
suggesting	O	VERB	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
but	O	CCONJ	O
with	O	ADP	O
unusual	O	ADJ	O
radiographic	O	ADJ	B
features	O	NOUN	B
including	O	VERB	O
severe	O	ADJ	B
platyspondyly	B-Disease	NOUN	B
,	O	PUNCT	O
wide	O	ADJ	B
metaphyses	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
fibular	O	NOUN	B
overgrowth	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
partially	O	ADV	O
reminiscent	O	ADJ	O
of	O	ADP	O
metatropic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
diagnosis	O	NOUN	B
was	O	AUX	O
clarified	O	VERB	O
by	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DTDST	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
revealed	O	VERB	O
homozygosity	O	NOUN	B
for	O	ADP	O
a	O	DET	O
previously	O	ADV	O
undescribed	O	ADJ	O
mutation	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
Q454P	O	NOUN	B
substitution	O	NOUN	B
in	O	ADP	O
the	O	DET	O
10th	O	ADJ	O
transmembrane	O	ADJ	B
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DTDST	O	NOUN	B
sulfate	O	NOUN	I
transporter	O	NOUN	I
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
particular	O	ADJ	O
value	O	NOUN	O
in	O	ADP	O
such	O	ADJ	O
atypical	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
type	O	NOUN	O
of	O	ADP	O
somatic	O	ADJ	B
mutation	O	NOUN	O
at	O	ADP	O
APC	O	NOUN	B
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
is	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
germline	O	NOUN	B
mutation	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
facet	O	NOUN	B
to	O	ADP	O
Knudson	O	PROPN	B
'	O	PART	I
s	O	NOUN	I
'	O	PUNCT	O
two	O	NUM	O
-	O	PUNCT	O
hit	O	NOUN	B
'	O	PUNCT	O
hypothesis	O	NOUN	B
.	O	PUNCT	O


APC	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
cited	O	VERB	O
as	O	ADP	O
a	O	DET	O
prime	O	ADJ	B
example	O	NOUN	O
of	O	ADP	O
a	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Truncating	O	NOUN	B
germline	O	NOUN	B
and	O	CCONJ	O
somatic	O	ADJ	B
mutations	O	NOUN	I
(	O	PUNCT	O
or	O	CCONJ	O
,	O	PUNCT	O
infrequently	O	ADV	O
,	O	PUNCT	O
allelic	O	ADJ	B
loss	O	NOUN	I
)	O	PUNCT	O
occur	O	VERB	O
in	O	ADP	O
tumors	B-Disease	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
(	O	PUNCT	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Most	O	ADV	O
sporadic	B-Disease	ADJ	B
colorectal	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
also	O	ADV	O
have	O	AUX	O
two	O	NUM	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Clues	O	NOUN	B
from	O	ADP	O
attenuated	B-Disease	VERB	B
polyposis	I-Disease	NOUN	B
,	O	PUNCT	O
missense	O	NOUN	B
germline	O	NOUN	I
variants	O	NOUN	I
with	O	ADP	O
mild	O	ADJ	B
disease	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
somatic	O	ADJ	B
mutation	O	NOUN	O
cluster	O	NOUN	O
region	O	NOUN	O
(	O	PUNCT	O
codons	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
250	O	NUM	O
-	O	SYM	O
1	O	NUM	O
,	O	PUNCT	O
450	O	NUM	O
)	O	PUNCT	O
indicate	O	VERB	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
might	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
simple	O	ADJ	O
loss	O	NOUN	O
of	O	ADP	O
protein	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
germline	O	NOUN	B
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
within	O	ADP	O
a	O	DET	O
small	O	ADJ	B
region	O	NOUN	I
(	O	PUNCT	O
codons	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
194	O	NUM	O
-	O	SYM	O
1	O	NUM	O
,	O	PUNCT	O
392	O	NUM	O
at	O	ADP	O
most	O	ADJ	O
)	O	PUNCT	O
mainly	O	ADV	O
show	O	VERB	O
allelic	O	ADJ	B
loss	O	NOUN	O
in	O	ADP	O
their	O	PRON	O
colorectal	B-Disease	ADJ	B
adenomas	I-Disease	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
other	O	ADJ	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
whose	O	DET	O
second	O	ADJ	O
hits	O	NOUN	B
tend	O	VERB	O
to	O	PART	O
occur	O	VERB	O
by	O	ADP	O
truncating	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
cluster	O	NOUN	I
region	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
provide	O	VERB	O
cells	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
selective	O	ADJ	O
advantages	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
mutations	O	NOUN	B
close	O	ADV	O
to	O	PART	O
codon	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
300	O	NUM	O
providing	O	VERB	O
the	O	DET	O
greatest	O	ADJ	O
advantage	O	NOUN	O
.	O	PUNCT	O


Allelic	O	ADJ	B
loss	O	NOUN	I
is	O	AUX	O
selected	O	VERB	O
strongly	O	ADV	O
in	O	ADP	O
cells	O	NOUN	B
with	O	ADP	O
one	O	NUM	O
mutation	O	NOUN	B
near	O	ADP	O
codon	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
300	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
different	O	ADJ	O
germline	O	NOUN	B
-	O	PUNCT	O
somatic	O	ADJ	B
APC	B-Disease	NOUN	B
mutation	O	NOUN	B
association	O	NOUN	B
exists	O	VERB	O
in	O	ADP	O
FAP	B-Disease	NOUN	B
desmoids	I-Disease	NOUN	B
.	O	PUNCT	O


APC	O	NOUN	B
is	O	AUX	O
not	O	PART	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
classical	O	ADJ	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
also	O	ADV	O
indicate	O	VERB	O
a	O	DET	O
new	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
disease	O	NOUN	B
severity	O	NOUN	B
if	O	SCONJ	O
a	O	DET	O
broader	O	ADJ	O
spectrum	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
is	O	AUX	O
selected	O	VERB	O
in	O	ADP	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
somatic	O	ADJ	B
mutation	O	NOUN	B
rate	O	NOUN	B
is	O	AUX	O
effectively	O	ADV	O
higher	O	ADJ	B
and	O	CCONJ	O
more	O	ADJ	O
tumors	B-Disease	NOUN	B
grow	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Mxi1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
neurofibrosarcomas	B-Disease	NOUN	B
.	O	PUNCT	O


Mxi1	O	NOUN	B
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
negatively	O	ADV	O
regulate	O	VERB	B
Myc	O	NOUN	B
function	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
a	O	DET	O
potential	O	ADJ	B
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Little	O	ADJ	O
effort	O	NOUN	O
has	O	AUX	O
yet	O	ADV	O
been	O	AUX	O
made	O	VERB	O
to	O	PART	O
find	O	VERB	O
alterations	O	NOUN	B
involving	O	VERB	O
this	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
solid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
screened	O	VERB	B
31	O	NUM	O
human	O	ADJ	B
gastric	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
7	O	NUM	O
esophageal	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
85	O	NUM	O
bone	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
soft	I-Disease	ADJ	B
tissue	I-Disease	NOUN	I
tumors	I-Disease	NOUN	I
of	O	ADP	O
various	O	ADJ	O
types	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
4	O	NUM	O
neurofibrosarcomas	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
examined	O	VERB	O
29	O	NUM	O
human	O	ADJ	B
tumor	B-Disease	NOUN	O
cell	O	NOUN	O
lines	O	NOUN	O
consisting	O	VERB	O
of	O	ADP	O
12	O	NUM	O
esophageal	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
7	O	NUM	O
glioma	B-Disease	NOUN	B
/	O	PUNCT	O
glioblastomas	B-Disease	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
others	O	NOUN	O
for	O	ADP	O
Mxi1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
exons	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
(	O	PUNCT	O
HLH	O	ADJ	B
domain	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
5	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


Polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	B
(	O	PUNCT	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
subsequent	O	ADJ	O
sequencing	O	NOUN	B
revealed	O	VERB	O
three	O	NUM	O
distinct	O	ADJ	O
polymorphisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
-	O	PUNCT	O
exon	O	NOUN	B
boundary	O	NOUN	O
upstream	O	ADJ	O
from	O	ADP	O
exon	O	NOUN	B
6	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
discovered	O	VERB	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
GCA	O	NOUN	B
to	O	PART	O
GTA	O	NOUN	B
(	O	PUNCT	O
Ala	O	NOUN	B
54	O	NUM	I
Val	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
in	O	ADP	O
a	O	DET	O
neurofibrosarcoma	B-Disease	NOUN	B
patient	O	NOUN	B
(	O	PUNCT	O
case	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
AAA	O	PROPN	B
to	O	ADP	O
CAA	O	PROPN	B
(	O	PUNCT	O
Lys	O	NOUN	B
118	O	NUM	O
Gln	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
GAA	O	NOUN	B
to	O	PART	O
GGA	O	NOUN	B
(	O	PUNCT	O
Glu	O	NOUN	B
154	O	NUM	O
Gly	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
of	O	ADP	O
another	O	DET	O
neurofibrosarcoma	B-Disease	ADJ	B
patient	O	NOUN	B
(	O	PUNCT	O
case	O	NOUN	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
,	O	PUNCT	O
GTG	O	NOUN	B
to	O	PART	O
GCG	O	NOUN	B
(	O	PUNCT	O
Val	O	NOUN	B
179	O	NUM	I
Ala	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
GTT	O	NOUN	B
to	O	PART	O
GCT	O	NOUN	B
(	O	PUNCT	O
Val	O	NOUN	B
181	O	NUM	I
Ala	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
TTC	O	NOUN	B
to	O	PART	O
CTC	O	NOUN	B
(	O	PUNCT	O
Phe	O	NOUN	B
186	O	NUM	I
Leu	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
third	O	ADJ	O
neurofibrosarcoma	B-Disease	NOUN	B
patient	O	NOUN	B
(	O	PUNCT	O
case	O	NOUN	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
case	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
demonstrated	O	VERB	O
by	O	ADP	O
informative	O	ADJ	B
(	O	PUNCT	O
TTC	O	NOUN	B
)	O	PUNCT	O
3	O	NUM	O
/	O	SYM	O
(	O	PUNCT	B
TTC	O	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
polymorphism	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
occur	O	VERB	O
in	O	ADP	O
the	O	DET	O
Mxi1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
neurofibrosarcoma	B-Disease	NOUN	B
.	O	PUNCT	O


Missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
domain	O	NOUN	I
of	O	ADP	O
Mxi1	O	NOUN	B
in	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
neurofibrosarcoma	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
expression	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hemochromatosis	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
homozygosity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hemochromatosis	B-Disease	NOUN	B
(	O	PUNCT	O
HFE	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
6	O	NUM	I
,	O	PUNCT	O
elevated	O	ADJ	B
serum	O	NOUN	O
transferrin	O	NOUN	O
saturation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
excess	B-Disease	ADJ	B
iron	I-Disease	NOUN	B
deposits	I-Disease	NOUN	I
throughout	O	ADP	O
the	O	DET	O
body	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
the	O	DET	O
HFE	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
conducted	O	VERB	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
in	O	ADP	O
Busselton	O	PROPN	B
,	O	PUNCT	O
Australia	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
1994	O	NUM	O
,	O	PUNCT	O
we	O	PRON	O
obtained	O	VERB	O
blood	O	NOUN	B
samples	O	NOUN	I
for	O	ADP	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
transferrin	O	NOUN	O
saturation	O	NOUN	O
and	O	CCONJ	O
ferritin	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
H63D	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
increased	O	VERB	B
hepatic	O	ADJ	B
iron	O	NOUN	I
levels	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
3011	O	NUM	O
unrelated	O	ADJ	O
white	O	ADJ	B
adults	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
all	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
persistently	O	ADV	B
elevated	O	ADJ	B
transferrin	O	NOUN	B
-	O	PUNCT	O
saturation	O	NOUN	B
values	O	NOUN	O
(	O	PUNCT	O
45	O	NUM	O
percent	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
)	O	PUNCT	O
or	O	CCONJ	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recommended	O	VERB	B
liver	O	NOUN	B
biopsy	O	NOUN	I
for	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
serum	O	NOUN	B
ferritin	O	NOUN	I
levels	O	NOUN	I
of	O	ADP	O
300	O	NUM	O
ng	O	NOUN	O
per	O	ADP	O
milliliter	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
were	O	AUX	O
followed	O	VERB	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
four	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
Sixteen	O	NUM	O
of	O	ADP	O
the	O	DET	O
subjects	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
424	O	NUM	O
(	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
heterozygous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
transferrin	O	NOUN	O
saturation	O	NOUN	B
was	O	AUX	O
45	O	NUM	O
percent	O	NOUN	O
or	O	CCONJ	O
higher	O	ADJ	B
in	O	ADP	O
15	O	NUM	O
of	O	ADP	O
the	O	DET	O
16	O	NUM	O
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
;	O	PUNCT	O
in	O	ADP	O
1	O	NUM	O
subject	O	NOUN	B
it	O	PRON	O
was	O	AUX	O
43	O	NUM	O
percent	O	NOUN	O
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
the	O	DET	O
homozygous	O	ADJ	B
subjects	O	NOUN	B
had	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
given	O	VERB	O
a	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
had	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


Seven	O	NUM	O
of	O	ADP	O
these	O	DET	O
12	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
elevated	O	ADJ	B
serum	O	NOUN	B
ferritin	O	NOUN	I
levels	O	NOUN	I
in	O	ADP	O
1994	O	NUM	O
;	O	PUNCT	O
6	O	NUM	O
of	O	ADP	O
the	O	DET	O
7	O	NUM	O
had	O	AUX	O
further	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
1998	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
had	O	AUX	O
a	O	DET	O
decrease	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
value	O	NOUN	B
remained	O	VERB	O
elevated	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
ferritin	O	NOUN	I
levels	O	NOUN	I
in	O	ADP	O
the	O	DET	O
four	O	NUM	O
other	O	ADJ	O
homozygous	O	ADJ	B
patients	O	NOUN	B
remained	O	VERB	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NOUN	O
of	O	ADP	O
the	O	DET	O
16	O	NUM	O
homozygous	O	ADJ	B
subjects	O	NOUN	B
underwent	O	VERB	O
liver	O	NOUN	B
biopsy	O	NOUN	I
;	O	PUNCT	O
3	O	NUM	O
had	O	AUX	O
hepatic	B-Disease	ADJ	B
fibrosis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
excessive	B-Disease	ADJ	B
alcohol	I-Disease	NOUN	B
consumption	I-Disease	NOUN	I
,	O	PUNCT	O
had	O	AUX	O
cirrhosis	B-Disease	NOUN	B
and	O	CCONJ	O
mild	O	ADJ	B
microvesicular	B-Disease	ADJ	B
steatosis	I-Disease	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
of	O	ADP	O
the	O	DET	O
16	O	NUM	O
homozygous	O	ADJ	B
subjects	O	NOUN	B
had	O	AUX	O
clinical	O	ADJ	B
findings	O	NOUN	I
that	O	PRON	O
were	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
hemochromatosis	I-Disease	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
hepatomegaly	B-Disease	NOUN	B
,	O	PUNCT	O
skin	B-Disease	NOUN	B
pigmentation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
arthritis	B-Disease	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
white	O	ADJ	B
adults	O	NOUN	I
of	O	ADP	O
northern	O	ADJ	B
European	O	ADJ	B
ancestry	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
percent	O	NOUN	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
C282Y	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HFE	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
only	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
those	O	DET	O
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
had	O	AUX	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
quarter	O	NOUN	B
had	O	AUX	O
serum	O	NOUN	B
ferritin	O	NOUN	I
levels	O	NOUN	I
that	O	PRON	O
remained	O	VERB	O
normal	O	ADJ	B
over	O	ADP	O
a	O	DET	O
four	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Large	O	ADJ	O
heterozygous	O	ADJ	B
deletion	O	NOUN	O
masquerading	O	VERB	O
as	O	ADP	O
homozygous	O	ADJ	B
missense	O	NOUN	B
mutation	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
pitfall	O	NOUN	O
in	O	ADP	O
diagnostic	O	ADJ	B
mutation	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
analyses	O	NOUN	I
in	O	ADP	O
recessive	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
relies	O	VERB	O
on	O	ADP	O
the	O	DET	O
exact	O	ADJ	O
characterization	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
mutant	O	ADJ	B
alleles	O	NOUN	O
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
patient	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
can	O	AUX	O
be	O	AUX	O
problematic	O	ADJ	O
when	O	SCONJ	O
only	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
is	O	AUX	O
examined	O	VERB	B
or	O	CCONJ	O
when	O	SCONJ	O
relevant	O	ADJ	B
DNA	O	NOUN	B
alterations	O	NOUN	I
are	O	AUX	O
not	O	PART	O
recognized	O	VERB	O
by	O	ADP	O
standard	O	ADJ	B
methods	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
child	O	NOUN	B
in	O	ADP	O
whom	O	DET	O
phenylketonuria	B-Disease	NOUN	B
was	O	AUX	O
apparently	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
homozygosity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
E390G	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
of	O	ADP	I
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
severity	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
was	O	AUX	O
not	O	PART	O
quite	O	ADV	O
as	O	ADV	O
mild	O	ADJ	B
as	O	ADP	O
expected	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
identified	O	VERB	O
in	O	ADP	O
the	O	DET	O
father	O	NOUN	B
despite	O	SCONJ	O
confirmed	O	VERB	O
paternity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
paternal	O	ADJ	B
allele	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
highly	O	ADV	O
unusual	O	ADJ	B
pattern	O	NOUN	B
of	O	ADP	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
large	O	ADJ	O
deletion	O	NOUN	B
involving	O	VERB	O
exons	O	NOUN	B
9	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
11	O	NUM	O
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	I
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
range	O	NOUN	B
PCR	O	NOUN	B
.	O	PUNCT	O


Diagnostic	O	ADJ	B
DNA	O	NOUN	I
analyses	O	NOUN	I
should	O	AUX	O
include	O	VERB	O
a	O	DET	O
comprehensive	O	ADJ	B
examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
relevant	O	ADJ	O
gene	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
confirmation	O	NOUN	B
of	O	ADP	O
carrier	O	NOUN	B
status	O	NOUN	I
in	O	ADP	O
both	O	DET	O
parents	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Early	O	ADJ	B
onset	O	NOUN	I
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
with	O	ADP	O
emerin	O	NOUN	B
gene	O	NOUN	I
deletion	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
boy	O	NOUN	B
developed	O	VERB	O
contractures	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
Achilles	I-Disease	NOUN	B
tendons	I-Disease	NOUN	I
at	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
postcervical	O	ADJ	B
muscles	O	NOUN	I
at	O	ADP	O
7	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
neither	O	DET	O
contractures	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
elbows	I-Disease	NOUN	B
nor	O	CCONJ	O
cardiac	B-Disease	ADJ	B
abnormality	I-Disease	NOUN	I
were	O	AUX	O
recognized	O	VERB	O
by	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
9	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Muscle	O	PROPN	B
computed	O	VERB	I
tomography	O	NOUN	I
scanning	O	NOUN	I
revealed	O	VERB	O
changes	O	NOUN	O
characteristic	O	ADJ	O
of	O	ADP	O
muscle	O	NOUN	B
involvement	O	NOUN	B
.	O	PUNCT	O


Emerin	O	NOUN	B
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
biopsied	O	ADJ	B
muscle	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	NOUN	B
and	O	CCONJ	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
analyses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
emerin	O	NOUN	B
gene	O	NOUN	I
demonstrated	O	VERB	O
no	O	DET	O
amplification	O	NOUN	O
product	O	NOUN	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	O
confirmed	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EDMD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
reinforce	O	VERB	O
the	O	DET	O
necessity	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
genetic	O	ADJ	I
diagnosis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
membrane	O	NOUN	B
protein	O	NOUN	I
emerin	O	NOUN	B
in	O	ADP	O
younger	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
possible	O	ADJ	O
EDMD	B-Disease	NOUN	B
before	O	ADP	O
appearance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
typical	O	ADJ	O
symptoms	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
avoid	O	VERB	O
sudden	B-Disease	ADJ	B
cardiac	I-Disease	ADJ	I
death	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Duchenne	B-Disease	PROPN	B
/	I-Disease	SYM	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
:	O	PUNCT	O
correlation	O	NOUN	B
of	O	ADP	O
phenotype	O	NOUN	B
by	O	ADP	O
electroretinography	O	NOUN	B
with	O	ADP	O
sites	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dark	O	ADV	B
-	O	PUNCT	O
adapted	O	VERB	B
electroretinogram	O	NOUN	B
(	O	PUNCT	O
ERG	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	PROPN	B
/	O	PUNCT	O
BMD	B-Disease	PROPN	B
)	O	PUNCT	O
shows	O	VERB	O
a	O	DET	O
marked	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
b	O	X	B
-	O	PUNCT	O
wave	O	NOUN	B
amplitude	O	NOUN	B
.	O	PUNCT	O


Genotype	O	ADJ	B
-	O	PUNCT	O
phenotype	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
models	O	NOUN	I
for	O	ADP	O
DMD	B-Disease	NOUN	B
show	O	VERB	O
position	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
upon	O	SCONJ	O
the	O	DET	O
phenotype	O	NOUN	B
mice	O	NOUN	B
with	O	ADP	O
5	O	NUM	O
defects	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
have	O	AUX	O
normal	O	ADJ	O
ERGs	O	NOUN	B
,	O	PUNCT	O
those	O	DET	O
with	O	ADP	O
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
region	O	NOUN	I
have	O	AUX	O
a	O	DET	O
normal	O	ADJ	O
b	O	NOUN	O
-	O	PUNCT	O
wave	O	NOUN	B
amplitude	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
prolonged	O	ADJ	B
implicit	O	NOUN	B
times	O	NOUN	I
for	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
b	O	NOUN	B
-	O	PUNCT	O
wave	O	NOUN	B
and	O	CCONJ	O
oscillatory	O	ADJ	B
potentials	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mice	O	NOUN	B
with	O	ADP	O
3	O	NUM	O
defects	O	NOUN	B
have	O	AUX	O
a	O	DET	O
phenotype	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
DMD	B-Disease	PROPN	B
/	O	SYM	O
BMD	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mouse	O	NOUN	B
studies	O	NOUN	I
suggest	O	VERB	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
the	O	DET	O
carboxyl	O	NOUN	B
terminal	O	ADJ	O
dystrophin	O	NOUN	O
isoform	O	NOUN	O
,	O	PUNCT	O
Dp260	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
retinal	O	ADJ	B
electrophysiology	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
undertaken	O	VERB	O
a	O	DET	O
systematic	O	ADJ	B
evaluation	O	NOUN	I
of	O	ADP	O
DMD	B-Disease	PROPN	B
/	O	SYM	O
BMD	B-Disease	NOUN	B
patients	O	NOUN	B
through	O	ADP	O
clinical	O	ADJ	B
examination	O	NOUN	I
and	O	CCONJ	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
position	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
man	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
wider	O	ADJ	O
variation	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
defects	I-Disease	NOUN	B
correlate	O	VERB	O
with	O	ADP	O
reductions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
b	O	NOUN	B
-	O	PUNCT	O
wave	O	NOUN	B
amplitude	O	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
ERGs	O	NOUN	B
have	O	AUX	O
mutations	O	NOUN	B
predominantly	O	ADV	O
located	O	ADJ	O
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
transcript	O	NOUN	B
initiation	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
Dp260	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
most	O	ADV	O
important	O	ADJ	O
determinant	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ERG	O	NOUN	B
b	O	NOUN	O
-	O	PUNCT	O
wave	O	NOUN	B
phenotype	O	NOUN	B
is	O	AUX	O
the	O	DET	O
mutation	O	NOUN	B
position	O	NOUN	O
,	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
muscle	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
severity	O	NOUN	B
.	O	PUNCT	O


Forty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mutations	O	NOUN	B
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
Dp260	O	NOUN	B
transcript	O	NOUN	B
start	O	NOUN	O
site	O	NOUN	O
have	O	AUX	O
abnormal	O	ADJ	B
ERGs	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
opposed	O	VERB	O
to	O	ADP	O
94	O	NUM	O
%	O	NOUN	O
with	O	ADP	O
more	O	ADV	O
distal	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
Dp260	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
retinal	O	ADJ	B
electrophysiology	O	NOUN	O
and	O	CCONJ	O
may	O	AUX	O
also	O	ADV	O
reflect	O	VERB	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
dystrophin	O	NOUN	B
isoforms	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
contributions	O	NOUN	B
to	O	PART	O
retinal	O	ADJ	B
signal	O	NOUN	O
transmission	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Cis	O	NOUN	B
and	O	CCONJ	O
trans	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
cell	O	NOUN	B
culture	O	NOUN	I
model	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
untranslated	O	ADJ	B
region	O	NOUN	I
(	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
mechanism	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
pathogenesis	O	NOUN	B
remain	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


Studies	O	NOUN	B
using	O	VERB	O
DM	B-Disease	NOUN	B
patient	O	NOUN	O
materials	O	NOUN	O
have	O	AUX	O
often	O	ADV	O
produced	O	VERB	O
confusing	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
controlled	O	VERB	B
environment	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
established	O	VERB	O
a	O	DET	O
cell	O	NOUN	B
culture	O	NOUN	I
model	O	NOUN	I
system	O	NOUN	I
using	O	VERB	O
C2C12	O	NOUN	B
mouse	O	NOUN	B
myoblasts	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
expressing	O	VERB	B
chimeric	O	ADJ	B
reporter	O	NOUN	I
constructs	O	NOUN	O
containing	O	VERB	O
a	O	DET	O
reporter	O	NOUN	B
gene	O	NOUN	I
fused	O	VERB	I
to	O	PART	O
a	O	DET	O
human	O	ADJ	B
DMPK	O	NOUN	B
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
both	O	CCONJ	O
cis	O	NOUN	B
and	O	CCONJ	O
trans	O	ADJ	B
effects	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
mutant	O	ADJ	B
DMPK	O	NOUN	B
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
as	O	ADV	O
few	O	ADJ	O
as	O	ADP	O
57	O	NUM	O
CTGs	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
negative	O	ADJ	B
cis	O	NOUN	O
effect	O	NOUN	O
on	O	ADP	O
protein	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
aggregation	O	NOUN	B
of	O	ADP	O
reporter	O	NOUN	B
transcripts	O	NOUN	I
into	O	ADP	O
discrete	O	ADJ	B
nuclear	O	ADJ	B
foci	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
determined	O	VERB	O
by	O	ADP	O
deletion	O	NOUN	B
analysis	O	NOUN	I
that	O	SCONJ	O
an	O	DET	O
expanded	O	ADJ	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
)	O	PUNCT	O
tract	O	NOUN	O
alone	O	ADV	O
was	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
mediate	O	VERB	O
these	O	DET	O
cis	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
normal	O	ADJ	O
DMPK	O	NOUN	B
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
mutant	O	ADJ	B
DMPK	O	NOUN	B
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
mRNA	O	NOUN	B
with	O	ADP	O
(	O	PUNCT	O
CUG	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
200	O	NUM	O
)	O	PUNCT	O
selectively	O	ADV	O
inhibited	O	VERB	B
myogenic	O	ADJ	B
differentiation	O	NOUN	I
of	O	ADP	O
C2C12	O	NOUN	B
myoblasts	O	NOUN	B
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
Cre	O	NOUN	B
-	O	PUNCT	O
loxP	O	NOUN	B
system	O	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
clearly	O	ADV	O
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
myoblast	O	NOUN	B
fusion	O	NOUN	I
defect	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
rescued	O	VERB	O
by	O	ADP	O
eliminating	O	VERB	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
DMPK	O	NOUN	O
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
transcript	O	NOUN	B
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
spontaneous	O	ADJ	B
deletion	O	NOUN	O
events	O	NOUN	O
mapped	O	VERB	B
the	O	DET	O
inhibitory	O	ADJ	B
effect	O	NOUN	O
to	O	PART	O
the	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
)	O	PUNCT	O
expansion	O	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
3	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DMPK	O	NOUN	B
3	O	NUM	O
-	O	PUNCT	O
UTR	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	O
acts	O	VERB	O
in	O	ADP	O
cis	O	NOUN	O
to	O	PART	O
reduce	O	VERB	O
protein	O	NOUN	B
production	O	NOUN	I
(	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
DMPK	B-Disease	NOUN	B
haploinsufficiency	I-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
trans	O	ADJ	O
as	O	ADP	O
a	O	DET	O
riboregulator	O	NOUN	B
to	O	PART	O
inhibit	O	VERB	B
myogenesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Coats	B-Disease	PROPN	B
'	I-Disease	PART	I
disease	I-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
(	O	PUNCT	O
unilateral	B-Disease	ADJ	B
retinal	I-Disease	ADJ	O
telangiectasis	I-Disease	NOUN	O
)	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
norrin	O	NOUN	B
in	O	ADP	O
retinal	O	ADJ	B
angiogenesis	O	NOUN	B
.	O	PUNCT	O


Coats	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
abnormal	B-Disease	ADJ	B
retinal	I-Disease	ADJ	B
vascular	I-Disease	ADJ	O
development	I-Disease	NOUN	O
(	O	PUNCT	O
so	O	ADV	O
-	O	PUNCT	O
called	O	VERB	B
retinal	B-Disease	ADJ	B
telangiectasis	I-Disease	NOUN	O
)	O	PUNCT	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
massive	O	ADJ	B
intraretinal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
subretinal	I-Disease	ADJ	B
lipid	I-Disease	NOUN	O
accumulation	I-Disease	NOUN	O
(	O	PUNCT	O
exudative	B-Disease	ADJ	B
retinal	I-Disease	ADJ	I
detachment	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
classical	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
Coats	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
almost	O	ADV	O
invariably	O	ADV	O
isolated	O	VERB	B
,	O	PUNCT	O
unilateral	O	ADJ	B
and	O	CCONJ	O
seen	O	VERB	O
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
female	O	NOUN	B
with	O	ADP	O
a	O	DET	O
unilateral	O	ADJ	B
variant	O	NOUN	B
of	O	ADP	O
Coats	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
gave	O	VERB	O
birth	O	NOUN	B
to	O	ADP	O
a	O	DET	O
son	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
carried	O	VERB	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
within	O	ADP	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
Xp11	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
2	O	NUM	O
.	O	PUNCT	O


Subsequently	O	ADV	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retinas	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
enucleated	O	ADJ	B
eyes	O	NOUN	I
from	O	ADP	O
males	O	NOUN	B
with	O	ADP	O
Coats	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
demonstrated	O	VERB	O
in	O	ADP	O
one	O	NUM	O
a	O	DET	O
somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	I
which	O	DET	O
was	O	AUX	O
not	O	PART	O
present	O	ADJ	O
within	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
retinal	O	ADJ	B
tissue	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
Coats	B-Disease	ADJ	B
telangiectasis	I-Disease	NOUN	B
is	O	AUX	O
secondary	O	ADJ	O
to	O	PART	O
somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	I
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
norrin	I-Disease	NOUN	B
(	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	I
)	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
developing	O	VERB	O
retina	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
supports	O	VERB	O
recent	O	ADJ	O
observations	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	O
retinal	O	ADJ	B
vasculogenesis	O	NOUN	B
.	O	PUNCT	O


Hereditary	O	ADJ	B
TP53	O	NOUN	I
codon	O	NOUN	B
292	O	NUM	I
and	O	CCONJ	O
somatic	O	ADJ	B
P16INK4A	O	NOUN	B
codon	O	NOUN	O
94	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
family	O	NOUN	B
.	O	PUNCT	O


Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
that	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
various	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
cancer	B-Disease	NOUN	B
in	O	ADP	O
childhood	O	NOUN	B
and	O	CCONJ	O
adult	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
hereditary	O	ADJ	B
TP53	O	NOUN	B
mutation	O	NOUN	B
is	O	AUX	O
very	O	ADV	O
rare	O	ADJ	O
in	O	ADP	O
different	O	ADJ	O
human	O	ADJ	B
cancers	B-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
frequently	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
hereditary	O	ADJ	B
mutations	O	NOUN	I
of	O	ADP	O
TP57KIP2	O	NOUN	B
,	O	PUNCT	O
P15INK4B	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
P16INK4A	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
affect	O	VERB	O
the	O	DET	O
cell	O	NOUN	B
cycle	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
TP53	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
some	O	DET	O
types	O	NOUN	O
of	O	ADP	O
cancer	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
Turkish	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
mutation	O	NOUN	B
pattern	O	NOUN	O
of	O	ADP	O
TP53	O	NOUN	B
,	O	PUNCT	O
P57KIP2	O	NOUN	B
,	O	PUNCT	O
P15INK4B	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
P16INK4A	O	NOUN	B
in	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
blood	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	I
heterozygosity	O	NOUN	I
(	O	PUNCT	O
homo	O	ADJ	B
/	O	SYM	O
hemizygous	O	ADJ	B
deletion	O	NOUN	I
)	O	PUNCT	O
pattern	O	NOUN	B
of	O	ADP	O
TP53	O	NOUN	B
and	O	CCONJ	O
P15INK4B	O	NOUN	B
/	O	SYM	O
P16INK4A	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
tumor	B-Disease	NOUN	B
tissues	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
propositus	O	NOUN	B
had	O	AUX	O
a	O	DET	O
seminoma	B-Disease	NOUN	B
,	O	PUNCT	O
his	O	PRON	O
daughter	O	NOUN	B
a	O	DET	O
medulloblastoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
his	O	PRON	O
healthy	O	ADJ	B
cousins	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
TP53	O	NOUN	B
codon	O	NOUN	B
292	O	NUM	I
missense	O	NOUN	B
point	O	NOUN	I
mutation	O	NOUN	I
(	O	PUNCT	O
AAA	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
ATA	O	NOUN	B
;	O	PUNCT	O
Lys	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Ile	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


Tumor	O	NOUN	B
tissue	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
propositus	O	NOUN	B
with	O	ADP	O
the	O	DET	O
seminoma	B-Disease	NOUN	B
revealed	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TP53	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
analyses	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
tissues	O	NOUN	I
from	O	ADP	O
the	O	DET	O
propositus	O	NOUN	B
and	O	CCONJ	O
his	O	PRON	O
daughter	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
P16INK4A	O	NOUN	B
codon	O	NOUN	O
94	O	NUM	O
missense	O	NOUN	B
point	O	NOUN	I
mutation	O	NOUN	I
(	O	PUNCT	O
GCG	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
GAG	O	NOUN	B
;	O	PUNCT	O
Ala	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Glu	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
the	O	DET	O
hereditary	O	ADJ	B
TP53	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


P16INK4A	O	NOUN	B
codon	O	NOUN	B
94	O	NUM	I
mutation	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
our	O	PRON	O
family	O	NOUN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
gene	O	NOUN	B
alteration	O	NOUN	I
in	O	ADP	O
TP53	O	NOUN	B
,	O	PUNCT	O
P57KIP2	O	NOUN	B
,	O	PUNCT	O
P15INK4B	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
P16INK4A	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Existence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
P16INK4A	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
hereditary	O	ADJ	B
TP53	O	NOUN	B
mutation	O	NOUN	B
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TP53	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
seminoma	B-Disease	NOUN	B
/	O	SYM	O
medulloblastoma	B-Disease	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
common	O	ADJ	O
mechanism	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
tumorogenesis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
alterations	O	NOUN	I
in	O	ADP	O
TP53	O	NOUN	B
and	O	CCONJ	O
P16INK4A	O	NOUN	B
genes	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
tumor	B-Disease	NOUN	B
markers	O	NOUN	B
in	O	ADP	O
our	O	PRON	O
family	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sodium	O	NOUN	B
/	O	PUNCT	O
iodide	O	NOUN	B
symporter	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
largest	O	ADJ	O
family	O	NOUN	B
with	O	ADP	O
iodide	B-Disease	NOUN	B
transport	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
reported	O	VERB	O
nine	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
an	O	DET	O
autosomally	O	ADV	B
recessive	O	ADJ	I
form	O	NOUN	O
of	O	ADP	O
congenital	B-Disease	ADJ	B
hypothyroidism	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
iodide	B-Disease	NOUN	B
transport	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Hutterite	O	ADJ	B
family	O	NOUN	O
with	O	ADP	O
extensive	O	ADJ	O
consanguinity	O	NOUN	B
living	O	VERB	B
in	O	ADP	O
central	O	ADJ	B
Canada	O	PROPN	I
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
original	O	ADJ	B
report	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
diagnosed	O	VERB	B
congenital	B-Disease	ADJ	B
hypothyroidism	I-Disease	NOUN	I
by	O	ADP	O
newborn	O	ADJ	B
TSH	O	NOUN	B
screening	O	NOUN	B
in	O	ADP	O
9	O	NUM	O
additional	O	ADJ	O
children	O	NOUN	B
from	O	ADP	O
the	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
direct	O	ADJ	O
sequencing	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PCR	O	NOUN	B
products	O	NOUN	I
of	O	ADP	O
each	O	DET	O
NIS	O	PROPN	B
(	O	PUNCT	O
sodium	O	NOUN	B
/	O	SYM	O
iodide	O	NOUN	B
symporter	O	NOUN	I
)	O	PUNCT	O
gene	O	NOUN	B
exon	O	NOUN	I
with	O	ADP	O
flanking	O	ADJ	B
introns	O	NOUN	I
amplified	O	VERB	B
from	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
extracted	O	VERB	O
from	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
novel	O	ADJ	O
NIS	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
G395R	O	NOUN	B
(	O	PUNCT	O
Gly395	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Arg	O	NOUN	B
;	O	PUNCT	O
GGA	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
AGA	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
examined	O	VERB	B
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
the	O	DET	O
parents	O	NOUN	B
tested	O	VERB	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
10th	O	ADJ	O
transmembrane	O	ADJ	B
helix	O	NOUN	I
.	O	PUNCT	O


Expression	O	NOUN	B
experiments	O	NOUN	O
by	O	ADP	O
transfection	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
NIS	O	NOUN	B
complimentary	O	ADJ	O
DNA	O	NOUN	O
into	O	ADP	O
COS	O	NOUN	B
-	O	PUNCT	O
7	O	NUM	B
cells	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
perchlorate	O	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
iodide	O	NOUN	B
uptake	O	NOUN	B
,	O	PUNCT	O
confirming	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
the	O	DET	O
direct	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
iodide	B-Disease	NOUN	B
transport	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
showed	O	VERB	O
an	O	DET	O
intermediate	O	ADJ	B
saliva	O	NOUN	B
/	O	SYM	O
serum	O	NOUN	B
technetium	O	NOUN	I
ratio	O	NOUN	I
(	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
;	O	PUNCT	O
normal	O	ADJ	B
,	O	PUNCT	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
considered	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
partial	O	ADJ	B
or	O	CCONJ	O
less	O	ADV	O
severe	O	ADJ	B
defect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
previous	O	ADJ	O
report	O	NOUN	O
(	O	PUNCT	O
IX	O	NUM	B
-	O	PUNCT	O
24	O	NUM	O
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
a	O	DET	O
NIS	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
now	O	ADV	O
possible	O	ADJ	O
to	O	PART	O
use	O	VERB	O
gene	O	NOUN	B
diagnostics	O	NOUN	I
of	O	ADP	O
this	O	DET	O
unique	O	ADJ	O
NIS	O	NOUN	B
mutation	O	NOUN	B
to	O	PART	O
identify	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
congenital	B-Disease	ADJ	B
hypothyroidism	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
iodide	B-Disease	NOUN	B
transport	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
carrier	O	NOUN	B
state	O	NOUN	I
of	O	ADP	O
potential	O	ADJ	B
parents	O	NOUN	B
for	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
and	O	CCONJ	O
arranging	O	VERB	O
rapid	O	ADJ	B
and	O	CCONJ	O
early	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
their	O	PRON	O
infants	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
neurohypophyseal	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	B
:	O	PUNCT	O
early	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
an	O	DET	O
asymptomatic	O	ADJ	B
carrier	O	NOUN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
neurohypophyseal	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I
(	O	PUNCT	O
FNDI	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	O	VERB	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
hormone	I-Disease	NOUN	B
arginine	I-Disease	NOUN	I
vasopressin	I-Disease	NOUN	I
(	O	PUNCT	I
AVP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
transmitted	O	VERB	B
as	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
trait	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
the	O	DET	O
AVP	O	NOUN	B
-	O	PUNCT	O
neurophysin	O	NOUN	B
II	O	NUM	I
(	O	PUNCT	O
AVP	O	NOUN	B
-	O	PUNCT	O
NPII	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Spanish	O	ADJ	B
kindred	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
seven	O	NUM	O
members	O	NOUN	B
(	O	PUNCT	O
four	O	NUM	O
clinically	O	ADV	B
affected	O	VERB	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
at	O	ADP	O
the	O	DET	O
Hospital	O	PROPN	B
Universitario	O	PROPN	I
Gregorio	O	PROPN	I
Maranon	O	PROPN	I
(	O	PUNCT	O
Madrid	O	PROPN	B
,	O	PUNCT	O
Spain	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
AVP	O	NOUN	B
-	O	PUNCT	O
NPII	O	NOUN	B
gene	O	NOUN	B
of	O	ADP	O
all	O	DET	O
family	O	NOUN	B
members	O	NOUN	I
was	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
PCR	O	NOUN	B
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
affected	O	VERB	B
individuals	O	NOUN	B
presented	O	VERB	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
G1757	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
)	O	PUNCT	O
that	O	PRON	O
replaces	O	VERB	O
glycine	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
23	O	NUM	O
with	O	ADP	O
arginine	O	NOUN	B
within	O	ADP	O
the	O	DET	O
NPII	O	NOUN	B
domain	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
substitution	O	NOUN	B
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
restriction	O	NOUN	B
endonuclease	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
heterozygosis	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
asymptomatic	O	ADJ	B
relatives	O	NOUN	O
(	O	PUNCT	O
a	O	DET	O
girl	O	NOUN	B
8	O	NUM	O
months	O	NOUN	B
old	O	ADJ	O
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	I
study	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
carrier	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
and	O	CCONJ	O
developed	O	VERB	O
the	O	DET	O
disease	O	NOUN	B
3	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
alteration	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
all	O	DET	O
individuals	O	NOUN	B
harboring	O	VERB	O
the	O	DET	O
mutation	O	NOUN	B
had	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
diagnosed	O	VERB	B
or	O	CCONJ	O
have	O	AUX	O
eventually	O	ADV	O
developed	O	VERB	O
FNDI	B-Disease	PROPN	B
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
defect	O	NOUN	I
underlying	O	VERB	O
FNDI	B-Disease	NOUN	B
in	O	ADP	O
affected	O	VERB	B
families	O	NOUN	B
is	O	AUX	O
a	O	DET	O
powerful	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
early	O	ADJ	B
asymptomatic	O	ADJ	B
diagnosis	O	NOUN	B
in	O	ADP	O
infants	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Deficit	O	NOUN	B
of	O	ADP	O
in	O	X	B
vivo	O	X	I
mitochondrial	O	ADJ	B
ATP	O	NOUN	B
production	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
of	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
ataxias	I-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
degenerative	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
clinically	O	ADV	B
by	O	ADP	O
onset	O	NOUN	O
before	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
of	O	ADP	O
progressive	B-Disease	ADJ	B
gait	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
limb	I-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
,	O	PUNCT	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
deep	I-Disease	ADJ	B
tendon	I-Disease	NOUN	I
reflexes	I-Disease	NOUN	I
,	O	PUNCT	O
extensor	B-Disease	ADJ	B
plantar	I-Disease	NOUN	I
responses	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
position	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
vibration	I-Disease	NOUN	B
sense	I-Disease	NOUN	O
in	O	ADP	O
the	O	DET	O
lower	O	ADJ	B
limbs	O	NOUN	I
.	O	PUNCT	O


FRDA	B-Disease	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
GAA	O	NOUN	B
triplet	O	NOUN	B
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
intron	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FRDA	B-Disease	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
9q13	O	NOUN	I
in	O	ADP	O
97	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
FRDA	B-Disease	NOUN	B
gene	O	NOUN	O
encodes	O	VERB	B
a	O	DET	O
widely	O	ADV	O
expressed	O	VERB	B
210	O	NUM	O
-	O	PUNCT	O
aa	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
frataxin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
mitochondria	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
severely	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
FRDA	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Frataxin	O	NOUN	B
function	O	NOUN	O
is	O	AUX	O
still	O	ADV	O
unknown	O	ADJ	O
but	O	CCONJ	O
the	O	DET	O
knockout	O	NOUN	B
of	O	ADP	O
the	O	DET	O
yeast	O	NOUN	B
frataxin	O	NOUN	B
homologue	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
YFH1	O	NOUN	B
)	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
severe	O	ADJ	B
defect	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
respiration	O	NOUN	B
and	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
mtDNA	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
elevated	O	ADJ	B
intramitochondrial	O	ADJ	B
iron	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
in	O	X	B
vivo	O	X	I
evidence	O	NOUN	B
of	O	ADP	O
impaired	O	ADJ	B
mitochondrial	O	ADJ	B
respiration	O	NOUN	O
in	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
of	O	ADP	O
FRDA	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
phosphorus	O	NOUN	B
magnetic	O	ADJ	I
resonance	O	NOUN	I
spectroscopy	O	NOUN	I
we	O	PRON	O
demonstrated	O	VERB	O
a	O	DET	O
maximum	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
muscle	O	NOUN	B
mitochondrial	O	ADJ	B
ATP	O	NOUN	O
production	O	NOUN	B
(	O	PUNCT	O
V	O	NOUN	O
(	O	PUNCT	O
max	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
below	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
in	O	ADP	O
all	O	DET	O
12	O	NUM	O
FRDA	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
strong	O	ADJ	O
negative	O	ADJ	B
correlation	O	NOUN	B
between	O	ADP	O
mitochondrial	O	ADJ	B
V	O	NOUN	I
(	O	PUNCT	O
max	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
GAA	O	NOUN	B
repeats	O	NOUN	O
in	O	ADP	O
the	O	DET	O
smaller	O	ADJ	O
allele	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
FRDA	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
nuclear	O	ADJ	B
-	O	PUNCT	O
encoded	O	VERB	B
mitochondrial	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
affecting	O	VERB	O
oxidative	O	ADJ	B
phosphorylation	O	NOUN	O
and	O	CCONJ	O
give	O	VERB	O
a	O	DET	O
rationale	O	NOUN	O
for	O	ADP	O
treatments	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
improve	O	VERB	B
mitochondrial	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	B
R21X	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
arginase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ARG1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
four	O	NUM	O
Portuguese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
argininemia	B-Disease	NOUN	B
.	O	PUNCT	O


Argininemia	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
autossomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
deficiency	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
cytosolic	I-Disease	ADJ	B
liver	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
type	I-Disease	NOUN	B
arginase	I-Disease	NOUN	O
enzyme	I-Disease	NOUN	O
(	O	PUNCT	O
L	O	NOUN	B
-	O	PUNCT	O
arginine	O	NOUN	B
urea	O	NOUN	B
-	O	PUNCT	O
hydrolase	O	NOUN	B
;	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
argininemia	B-Disease	NOUN	B
in	O	ADP	O
four	O	NUM	O
unrelated	O	ADJ	O
Portuguese	O	ADJ	B
patients	O	NOUN	B
(	O	PUNCT	O
two	O	NUM	O
from	O	ADP	O
northern	O	ADJ	B
Portugal	O	PROPN	I
and	O	CCONJ	O
two	O	NUM	O
from	O	ADP	O
Madeira	O	PROPN	B
Island	O	PROPN	I
)	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
DNA	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
all	O	DET	O
the	O	DET	O
exons	O	NOUN	B
and	O	CCONJ	O
exon	O	NOUN	B
/	O	SYM	O
intron	O	NOUN	B
boundaries	O	NOUN	B
of	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
arginase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ARG1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
newly	O	ADV	O
identified	O	VERB	B
C	O	NOUN	B
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
in	O	ADP	O
codon	O	NOUN	B
21	O	NUM	I
(	O	PUNCT	O
exon	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
substituting	O	VERB	O
arginine	O	NOUN	B
for	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
(	O	PUNCT	O
R21X	O	NOUN	O
CGA	O	NOUN	B
to	O	PART	O
TGA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
generating	O	VERB	O
a	O	DET	O
NlaIII	O	NOUN	B
restriction	O	NOUN	I
site	O	NOUN	I
.	O	PUNCT	O


Restriction	O	NOUN	B
digestion	O	NOUN	B
following	O	VERB	O
PCR	O	NOUN	B
amplification	O	NOUN	I
of	O	ADP	O
ARG1	O	NOUN	B
exon	O	NOUN	B
2	O	NUM	I
confirmed	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sterol	O	NOUN	B
27	O	NUM	I
-	O	PUNCT	O
hydroxylase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CYP27	O	NOUN	B
)	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
truncation	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
expressed	O	VERB	B
in	O	ADP	O
leucocytes	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	VERB	O
A	O	DET	O
Japanese	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
for	O	ADP	O
a	O	DET	O
sequence	O	NOUN	B
alteration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sterol	O	NOUN	B
27	O	NUM	I
-	O	PUNCT	O
hydroxylase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CYP27	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
CYP27	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
mostly	O	ADV	O
explored	O	VERB	O
using	O	VERB	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
,	O	PUNCT	O
prompting	O	VERB	O
the	O	DET	O
examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transcripts	O	NOUN	B
from	O	ADP	O
blood	O	NOUN	B
leucocytes	O	NOUN	I
as	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
and	O	CCONJ	O
rapid	O	ADJ	O
technique	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
An	O	DET	O
alteration	O	NOUN	B
in	O	ADP	O
CYP27	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
was	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
single	O	ADJ	B
strand	O	NOUN	O
conformation	O	NOUN	O
polymorphism	O	NOUN	B
(	O	PUNCT	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
sequencing	O	NOUN	B
.	O	PUNCT	O


Samples	O	NOUN	B
of	O	ADP	O
RNA	O	NOUN	B
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
reverse	O	VERB	B
transcription	O	NOUN	I
PCR	O	NOUN	I
(	O	PUNCT	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
product	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
was	O	AUX	O
amplified	O	VERB	B
with	O	ADP	O
nested	O	ADJ	B
primers	O	NOUN	I
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
homozygous	O	ADJ	B
G	O	NOUN	I
to	O	PART	O
A	O	DET	O
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
intron	O	NOUN	B
7	O	NUM	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	NOUN	B
analysis	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
truncated	O	VERB	B
transcript	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
both	O	CCONJ	O
normal	O	ADJ	B
and	O	CCONJ	O
truncated	O	VERB	B
transcripts	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
siblings	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
cDNA	O	NOUN	B
fragment	O	NOUN	I
disclosed	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
conjuction	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
6	O	NUM	I
and	O	CCONJ	O
exon	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
truncation	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
were	O	AUX	O
identical	O	ADJ	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
a	O	DET	O
recently	O	ADV	O
reported	O	VERB	O
Italian	O	ADJ	B
patient	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
different	O	ADJ	O
in	O	ADP	O
symptomatology	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
application	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
leucocytes	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
a	O	DET	O
simple	O	ADJ	O
technique	O	NOUN	B
on	O	ADP	O
analysing	O	VERB	O
a	O	DET	O
constructive	O	ADJ	B
abnormality	B-Disease	NOUN	I
of	I-Disease	ADP	O
CYP27	I-Disease	NOUN	B
mRNA	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
genetic	O	ADJ	I
analysis	O	NOUN	I
of	O	ADP	O
19	O	NUM	O
Wolfram	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
kindreds	O	NOUN	B
demonstrating	O	VERB	O
a	O	DET	O
wide	O	ADJ	O
spectrum	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
WFS1	O	NOUN	B
.	O	PUNCT	O


Wolfram	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
neurodegenerative	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
juvenile	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
onset	I-Disease	NOUN	B
diabetes	I-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
and	O	CCONJ	O
progressive	O	ADJ	B
optic	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
.	O	PUNCT	O


mtDNA	O	NOUN	B
deletions	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
WFS1	O	NOUN	B
)	O	PUNCT	O
recently	O	ADV	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
on	O	ADP	O
chromosome	O	NOUN	B
4p16	O	NOUN	I
,	O	PUNCT	O
encoding	O	VERB	B
a	O	DET	O
predicted	O	VERB	B
890	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
transmembrane	O	ADJ	I
protein	O	NOUN	I
.	O	PUNCT	O


Direct	O	ADJ	B
DNA	O	NOUN	I
sequencing	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
to	O	PART	O
screen	O	VERB	B
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
WFS1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
19	O	NUM	O
British	O	ADJ	B
kindreds	O	NOUN	B
with	O	ADP	O
Wolfram	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


DNA	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
screened	O	VERB	B
for	O	ADP	O
structural	O	ADJ	B
rearrangements	O	NOUN	I
(	O	PUNCT	O
deletions	O	NOUN	B
and	O	CCONJ	O
duplications	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
mtDNA	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
pathogenic	O	ADJ	B
mtDNA	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
our	O	PRON	O
cohort	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	O
24	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
WFS1	O	NOUN	B
gene	O	NOUN	I
8	O	NUM	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
8	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletions	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
insertion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
frameshift	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
23	O	NUM	O
were	O	AUX	O
novel	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
most	O	ADV	O
occurred	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
were	O	AUX	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
for	O	ADP	O
two	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
common	O	ADJ	O
founder	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
analyzed	O	VERB	B
for	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
relationships	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
some	O	DET	O
interesting	O	ADJ	O
cases	O	NOUN	B
were	O	AUX	O
noted	O	VERB	O
,	O	PUNCT	O
consideration	O	NOUN	O
of	O	ADP	O
the	O	DET	O
small	O	ADJ	O
sample	O	NOUN	B
size	O	NOUN	I
and	O	CCONJ	O
frequency	O	NOUN	B
of	O	ADP	O
each	O	DET	O
mutation	O	NOUN	B
indicated	O	VERB	O
no	O	DET	O
clear	O	ADV	O
-	O	PUNCT	O
cut	O	NOUN	B
correlations	O	NOUN	B
between	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
observed	O	VERB	B
mutations	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
severity	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
mutation	O	NOUN	B
hot	O	ADJ	B
spots	O	NOUN	I
or	O	CCONJ	O
clusters	O	NOUN	B
.	O	PUNCT	O


Hence	O	ADV	O
,	O	PUNCT	O
molecular	O	ADJ	B
screening	O	NOUN	I
for	O	ADP	O
Wolfram	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
affected	O	VERB	B
families	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
Wolfram	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
-	O	PUNCT	O
carrier	O	NOUN	B
status	O	NOUN	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
psychiatric	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
or	O	CCONJ	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
will	O	AUX	O
require	O	VERB	O
complete	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
and	O	CCONJ	O
upstream	O	ADJ	B
exons	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	O
fever	I-Disease	NOUN	O
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
a	O	DET	O
subset	O	NOUN	O
with	O	ADP	O
distinct	O	ADJ	O
clinical	O	ADJ	B
,	O	PUNCT	O
demographic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
molecular	O	ADJ	B
genetic	O	ADJ	I
characteristics	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
and	O	CCONJ	O
characterize	O	VERB	B
demographic	O	ADJ	B
,	O	PUNCT	O
clinical	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
genetic	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
late	O	ADJ	B
onset	O	NOUN	I
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
experiencing	O	VERB	O
their	O	PRON	O
first	O	ADJ	O
FMF	B-Disease	NOUN	B
attack	O	NOUN	B
at	O	ADP	O
age	O	NOUN	B
40	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
more	O	ADJ	O
were	O	AUX	O
identified	O	VERB	B
using	O	VERB	O
the	O	DET	O
computerized	O	VERB	B
registry	O	NOUN	I
of	O	ADP	O
our	O	PRON	O
FMF	B-Disease	NOUN	B
clinic	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
thoroughly	O	ADV	O
interviewed	O	VERB	B
and	O	CCONJ	O
examined	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
40	O	NUM	O
consecutive	O	ADJ	B
FMF	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
arrived	O	VERB	O
at	O	ADP	O
the	O	DET	O
FMF	B-Disease	NOUN	B
clinic	O	NOUN	B
for	O	ADP	O
their	O	PRON	O
regular	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	B
visit	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
40	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
or	O	CCONJ	O
older	O	ADJ	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	B
of	O	ADP	O
the	O	DET	O
examination	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
controls	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
using	O	VERB	O
a	O	DET	O
modified	O	ADJ	B
score	O	NOUN	I
,	O	PUNCT	O
developed	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


Mutational	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
FMF	B-Disease	NOUN	B
gene	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
commercial	O	ADJ	B
kit	O	NOUN	B
.	O	PUNCT	O


Only	O	ADV	O
20	O	NUM	O
of	O	ADP	O
4000	O	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
patients	O	NOUN	B
had	O	AUX	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
FMF	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
mostly	O	ADV	O
men	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
North	O	ADJ	B
African	O	ADJ	B
origin	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
compared	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
had	O	AUX	O
abdominal	O	ADJ	B
attacks	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
most	O	ADJ	O
these	O	DET	O
were	O	AUX	O
the	O	DET	O
only	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
disease	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
001	O	NUM	O
.	O	PUNCT	O


None	O	NOUN	O
had	O	AUX	O
chronic	O	ADJ	B
or	O	CCONJ	O
prolonged	O	ADJ	B
manifestations	O	NOUN	B
of	O	ADP	O
FMF	B-Disease	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
example	O	NOUN	O
,	O	PUNCT	O
amyloidosis	B-Disease	NOUN	B
,	O	PUNCT	O
chronic	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
protracted	O	ADJ	B
myalgia	B-Disease	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
response	O	NOUN	B
to	O	PART	O
treatment	O	NOUN	B
was	O	AUX	O
good	O	ADJ	O
despite	O	SCONJ	O
using	O	VERB	O
low	O	ADJ	B
colchicine	O	NOUN	B
dose	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
severity	O	NOUN	B
score	O	NOUN	I
indicated	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
disease	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
.	O	PUNCT	O


Mutational	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
absence	O	NOUN	B
of	O	ADP	O
M694V	O	NOUN	B
homozygosity	O	NOUN	B
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
our	O	PRON	O
regular	O	ADJ	O
FMF	B-Disease	NOUN	B
population	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
FMF	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
late	O	ADJ	O
age	O	NOUN	B
defines	O	VERB	O
a	O	DET	O
milder	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
disease	O	NOUN	B
with	O	ADP	O
typical	O	ADJ	O
clinical	O	ADJ	B
,	O	PUNCT	O
demographic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
molecular	O	ADJ	B
genetic	O	ADJ	I
characteristics	O	NOUN	I


A	O	DET	O
highly	O	ADV	O
accurate	O	ADJ	B
,	O	PUNCT	O
low	O	ADJ	B
cost	O	NOUN	I
test	O	NOUN	I
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
widespread	O	ADJ	O
use	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
testing	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
limited	O	ADJ	O
to	O	ADP	O
date	O	NOUN	O
by	O	ADP	O
three	O	NUM	O
principal	O	ADJ	B
concerns	O	NOUN	B
the	O	DET	O
fear	O	NOUN	B
of	O	ADP	I
loss	O	NOUN	I
of	O	ADP	I
health	O	NOUN	I
and	O	CCONJ	I
life	O	NOUN	I
insurance	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
uncertain	O	ADJ	O
clinical	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
a	O	DET	O
positive	O	ADJ	B
test	O	NOUN	I
result	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
current	O	ADJ	O
lack	O	NOUN	B
of	O	ADP	O
an	O	DET	O
inexpensive	O	ADJ	B
and	O	CCONJ	O
sensitive	O	ADJ	B
screening	O	NOUN	O
test	O	NOUN	O
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
an	O	DET	O
inexpensive	O	ADJ	B
system	O	NOUN	I
for	O	ADP	O
gene	O	NOUN	B
mutational	O	ADJ	I
scanning	O	NOUN	I
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
extensive	O	ADJ	B
multiplex	O	ADJ	O
PCR	O	NOUN	O
amplification	O	NOUN	O
and	O	CCONJ	O
two	O	NUM	O
dimensional	O	ADJ	O
electrophoresis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
efficiency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
system	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
screening	O	VERB	B
test	O	NOUN	I
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
60	O	NUM	O
samples	O	NOUN	B
from	O	ADP	O
high	O	ADJ	B
risk	O	NOUN	I
women	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
of	O	ADP	O
which	O	DET	O
contained	O	VERB	O
a	O	DET	O
previously	O	ADV	O
identified	O	VERB	B
mutation	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
14	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
five	O	NUM	O
that	O	PRON	O
had	O	AUX	O
previously	O	ADV	O
escaped	O	VERB	O
detection	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	ADP	O
the	O	DET	O
19	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
15	O	NUM	O
different	O	ADJ	O
polymorphic	O	ADJ	B
variants	O	NOUN	B
were	O	AUX	O
scored	O	VERB	B
,	O	PUNCT	O
most	O	ADJ	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
recurring	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
were	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
nucleotide	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cost	O	NOUN	B
of	O	ADP	O
screening	O	NOUN	B
per	O	ADP	O
sample	O	NOUN	B
was	O	AUX	O
calculated	O	VERB	B
to	O	PART	O
be	O	AUX	O
approximately	O	ADV	O
US	O	PROPN	B
$	O	SYM	O
70	O	NUM	O
for	O	ADP	O
the	O	DET	O
manual	O	ADJ	B
technique	O	NOUN	I
used	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
approximately	O	ADV	O
US	O	PROPN	B
$	O	SYM	O
10	O	NUM	O
with	O	ADP	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
commercially	O	ADV	O
available	O	ADJ	O
PCR	O	NOUN	B
robotics	O	NOUN	I
and	O	CCONJ	O
fluorescent	O	ADJ	B
imaging	O	NOUN	I
.	O	PUNCT	O


Implementation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
method	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
screening	O	NOUN	B
in	O	ADP	O
the	O	DET	O
research	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
setting	O	NOUN	I
should	O	AUX	O
permit	O	VERB	O
rapid	O	ADJ	O
accrual	O	NOUN	B
of	O	ADP	O
quantitative	O	ADJ	B
data	O	NOUN	B
on	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
associations	O	NOUN	B
for	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
diagnostic	O	ADJ	B
testing	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Maternal	B-Disease	ADJ	B
uniparental	I-Disease	ADJ	B
disomy	I-Disease	NOUN	I
for	I-Disease	ADP	O
chromosome	I-Disease	NOUN	O
14	I-Disease	NUM	O
in	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
with	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
karyotype	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
with	O	ADP	O
a	O	DET	O
maternal	B-Disease	ADJ	B
uniparental	I-Disease	ADJ	B
disomy	I-Disease	NOUN	I
for	I-Disease	ADP	O
chromosome	I-Disease	NOUN	O
14	I-Disease	NUM	O
(	O	PUNCT	O
UPD	B-Disease	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
7	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
he	O	PRON	O
was	O	AUX	O
referred	O	VERB	O
to	O	ADP	O
us	O	PRON	O
by	O	ADP	O
the	O	DET	O
paediatrician	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
symptoms	O	NOUN	B
of	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


He	O	PRON	O
showed	O	VERB	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
,	O	PUNCT	O
obesity	B-Disease	NOUN	B
,	O	PUNCT	O
mild	O	ADJ	B
developmental	B-Disease	ADJ	I
delay	I-Disease	NOUN	I
,	O	PUNCT	O
cryptorchidism	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
some	O	DET	O
mild	O	ADJ	B
dysmorphic	B-Disease	ADJ	B
features	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
history	O	NOUN	B
further	O	ADV	O
indicated	O	VERB	O
intrauterine	B-Disease	NOUN	B
growth	I-Disease	NOUN	I
retardation	I-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
pregnancy	O	NOUN	B
.	O	PUNCT	O


His	O	PRON	O
mother	O	NOUN	B
was	O	AUX	O
44	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
at	O	ADP	O
the	O	DET	O
time	O	NOUN	O
of	O	ADP	O
his	O	PRON	O
birth	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
birth	O	NOUN	B
he	O	PRON	O
showed	O	VERB	O
hypotonia	B-Disease	NOUN	B
with	O	ADP	O
poor	O	ADJ	B
sucking	O	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
which	O	DET	O
gavage	O	NOUN	B
feeding	O	NOUN	B
was	O	AUX	O
needed	O	VERB	O
.	O	PUNCT	O


Motor	O	NOUN	B
development	O	NOUN	I
was	O	AUX	O
delayed	O	VERB	B
.	O	PUNCT	O


After	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
he	O	PRON	O
became	O	VERB	O
obese	B-Disease	ADJ	B
despite	O	SCONJ	O
a	O	DET	O
normal	O	ADJ	B
appetite	O	NOUN	I
.	O	PUNCT	O


Recurrent	O	ADJ	B
middle	B-Disease	ADJ	B
ear	I-Disease	NOUN	I
infections	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
high	O	ADJ	B
pain	O	NOUN	I
threshold	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
great	O	ADJ	O
skill	O	NOUN	B
with	O	ADP	O
jigsaw	O	NOUN	O
puzzles	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
behavioural	O	ADJ	B
problems	O	NOUN	I
or	O	CCONJ	O
sleep	O	ADJ	B
disturbance	O	NOUN	I
.	O	PUNCT	O


Chromosomal	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	O
(	O	PUNCT	O
46	O	NUM	O
,	O	PUNCT	O
XY	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DNA	O	NOUN	B
analysis	O	NOUN	I
for	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
showed	O	VERB	O
no	O	DET	O
abnormalities	O	NOUN	O
.	O	PUNCT	O


Two	O	NUM	O
years	O	NOUN	B
later	O	ADV	O
he	O	PRON	O
was	O	AUX	O
re	O	ADP	B
-	O	PUNCT	O
examined	O	VERB	B
because	O	SCONJ	O
we	O	PRON	O
thought	O	VERB	O
his	O	PRON	O
features	O	NOUN	B
fitted	O	VERB	O
the	O	DET	O
PWS	B-Disease	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
phenotype	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
maternal	O	ADJ	B
UPD	B-Disease	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
that	O	DET	O
time	O	NOUN	O
precocious	O	ADJ	B
puberty	O	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
.	O	PUNCT	O


DNA	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
maternal	B-Disease	ADJ	B
heterodisomy	I-Disease	NOUN	B
for	O	ADP	O
chromosome	O	NOUN	B
14	O	NUM	I
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
the	O	DET	O
previously	O	ADV	O
described	O	VERB	O
11	O	NUM	O
cases	O	NOUN	B
with	O	ADP	O
maternal	O	ADJ	B
UPD	B-Disease	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
Robertsonian	O	ADJ	B
translocation	O	NOUN	B
involving	O	VERB	O
chromosome	O	NOUN	B
14	O	NUM	I
was	O	AUX	O
detected	O	VERB	B
cytogenetically	O	ADV	B
before	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	B
of	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
maternal	O	ADJ	B
UPD	B-Disease	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
features	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
underlines	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
for	O	ADP	O
maternal	O	ADJ	B
UPD	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
PWS	B-Disease	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
phenotype	O	NOUN	B
even	O	ADV	O
without	O	ADP	O
previous	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
Robertsonian	O	ADJ	B
translocation	O	NOUN	B
involving	O	VERB	O
chromosome	O	NOUN	B
14	O	NUM	I
.	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
genetic	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
in	O	ADP	O
an	O	DET	O
Australian	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FRDA	B-Disease	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
encodes	O	VERB	B
a	O	DET	O
210	O	NUM	O
-	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
protein	O	NOUN	I
called	O	VERB	O
frataxin	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
GAA	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	I
intron	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
alleles	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
83	O	NUM	O
people	O	NOUN	B
we	O	PRON	O
studied	O	VERB	O
who	O	PRON	O
have	O	AUX	O
mutations	O	NOUN	B
in	O	ADP	O
FRDA	O	NOUN	B
,	O	PUNCT	O
78	O	NUM	O
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
GAA	O	NOUN	B
repeat	O	NOUN	O
;	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
five	O	NUM	O
patients	O	NOUN	B
have	O	AUX	O
an	O	DET	O
expansion	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
present	O	VERB	O
a	O	DET	O
detailed	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
genetic	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
51	O	NUM	O
patients	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
an	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GAA	O	NOUN	B
repeat	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
smaller	O	ADJ	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
expanded	O	VERB	O
alleles	O	NOUN	B
and	O	CCONJ	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
,	O	PUNCT	O
age	O	NOUN	B
into	O	ADP	O
wheelchair	O	NOUN	B
,	O	PUNCT	O
scoliosis	B-Disease	NOUN	B
,	O	PUNCT	O
impaired	O	VERB	B
vibration	O	NOUN	B
sense	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
foot	B-Disease	NOUN	B
deformity	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
smaller	O	ADJ	O
allele	O	NOUN	B
and	O	CCONJ	O
cardiomyopathy	B-Disease	NOUN	B
,	O	PUNCT	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
,	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	I
proprioception	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
bladder	B-Disease	NOUN	B
symptoms	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
larger	O	ADJ	O
allele	O	NOUN	B
size	O	NOUN	I
correlated	O	VERB	B
with	O	ADP	O
bladder	B-Disease	NOUN	B
symptoms	I-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
foot	B-Disease	NOUN	B
deformity	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
duration	O	NOUN	B
of	O	ADP	I
disease	O	NOUN	O
is	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
wheelchair	O	NOUN	B
use	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
diabetes	B-Disease	NOUN	B
,	O	PUNCT	O
scoliosis	B-Disease	NOUN	B
,	O	PUNCT	O
bladder	B-Disease	NOUN	B
symptoms	I-Disease	NOUN	B
and	O	CCONJ	O
impaired	B-Disease	ADJ	B
proprioception	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
vibration	O	NOUN	B
sense	O	NOUN	O
but	O	CCONJ	O
no	O	DET	O
other	O	ADJ	O
complications	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
XLRS1	O	NOUN	B
causing	O	VERB	O
retinoschisis	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
first	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
putative	O	ADJ	B
leader	O	NOUN	I
sequence	O	NOUN	I
change	O	NOUN	I
.	O	PUNCT	O


Juvenile	B-Disease	ADJ	B
retinoschisis	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
screened	O	VERB	B
31	O	NUM	O
new	O	ADJ	O
unrelated	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
families	O	NOUN	B
for	O	ADP	O
XLRS1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
previously	O	ADV	O
reported	O	VERB	O
mutations	O	NOUN	B
for	O	ADP	O
60	O	NUM	O
of	O	ADP	O
our	O	PRON	O
families	O	NOUN	B
(	O	PUNCT	O
Retinoschisis	B-Disease	PROPN	B
Consortium	O	PROPN	I
,	O	PUNCT	O
Hum	O	PROPN	O
Mol	O	PROPN	O
Genet	O	PROPN	O
1998	O	NUM	O
;	O	PUNCT	O
7	O	NUM	O
1185	O	NUM	O
-	O	SYM	O
1192	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
including	O	VERB	O
12	O	NUM	O
novel	O	ADJ	O
ones	O	NOUN	O
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
28	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
include	O	VERB	O
19	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
intragenic	O	ADJ	B
deletion	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
microdeletions	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
insertion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
intronic	O	ADJ	B
sequence	O	NOUN	I
substitution	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
site	O	NOUN	I
defect	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
c	O	NOUN	O
.	O	PUNCT	O


38T	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	B
(	O	PUNCT	O
L13P	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
c	O	NOUN	O
.	O	PUNCT	O


667T	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	B
(	O	PUNCT	O
C223R	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
present	O	VERB	O
the	O	DET	O
first	O	ADJ	O
genetic	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
significance	O	NOUN	O
of	O	ADP	O
the	O	DET	O
putative	O	ADJ	B
leader	O	NOUN	I
peptide	O	NOUN	I
sequence	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
significance	O	NOUN	I
at	O	ADP	O
the	O	DET	O
carboxyl	O	NOUN	B
terminal	O	NOUN	B
of	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
protein	O	NOUN	I
beyond	O	ADP	O
the	O	DET	O
discoidin	O	NOUN	B
domain	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
25	O	NUM	O
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
were	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
exons	O	NOUN	B
4	O	NUM	O
-	O	SYM	O
6	O	NUM	O
,	O	PUNCT	O
emphasizing	O	VERB	O
the	O	DET	O
critical	O	ADJ	B
functional	O	ADJ	I
significance	O	NOUN	O
of	O	ADP	O
the	O	DET	O
discoidin	O	NOUN	B
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
protein	O	NOUN	I


Growth	O	NOUN	B
hormone	O	NOUN	I
treatment	O	NOUN	B
increases	O	VERB	B
CO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
response	O	NOUN	B
,	O	PUNCT	O
ventilation	O	NOUN	B
and	O	CCONJ	O
central	O	ADJ	B
inspiratory	O	ADJ	I
drive	O	NOUN	O
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
beneficial	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
growth	O	NOUN	B
hormone	O	NOUN	I
(	O	PUNCT	O
GH	O	NOUN	B
)	O	PUNCT	O
treatment	O	NOUN	B
on	O	ADP	O
growth	O	NOUN	B
and	O	CCONJ	O
body	O	NOUN	B
composition	O	NOUN	I
in	O	ADP	O
PWS	B-Disease	NOUN	B
are	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
respiratory	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
measured	O	VERB	B
resting	O	VERB	B
ventilation	O	NOUN	I
,	O	PUNCT	O
airway	O	NOUN	B
occlusion	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
ventilatory	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
CO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
nine	O	NUM	O
children	O	NOUN	B
,	O	PUNCT	O
aged	O	ADJ	B
7	O	NUM	O
-	O	PUNCT	O
14	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
before	O	ADP	O
and	O	CCONJ	O
6	O	NUM	O
-	O	SYM	O
9	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
GH	O	NOUN	B
treatment	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
GH	O	NOUN	B
treatment	O	NOUN	I
,	O	PUNCT	O
resting	O	VERB	B
ventilation	O	NOUN	I
increased	O	VERB	B
by	O	ADP	O
26	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
by	O	ADP	O
72	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	PART	O
CO	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
by	O	ADP	O
65	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
002	O	NUM	O
,	O	PUNCT	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
04	O	NUM	O
and	O	CCONJ	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
02	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
observed	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
ventilatory	O	ADJ	B
output	O	NOUN	I
was	O	AUX	O
not	O	PART	O
correlated	O	VERB	B
to	O	PART	O
changes	O	NOUN	B
in	O	ADP	O
body	O	NOUN	B
mass	O	NOUN	I
index	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Treatment	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
seems	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
stimulatory	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
central	O	ADJ	B
respiratory	O	ADJ	I
structures	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
observed	O	VERB	O
increase	O	NOUN	B
in	O	ADP	O
ventilation	O	NOUN	B
and	O	CCONJ	O
inspiratory	O	ADJ	B
drive	O	NOUN	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
improved	O	VERB	O
activity	O	NOUN	B
level	O	NOUN	B
reported	O	VERB	O
by	O	ADP	O
parents	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
children	O	NOUN	B
during	O	ADP	O
growth	O	NOUN	B
hormone	O	NOUN	I
therapy	O	NOUN	I


G130V	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
FRDA	B-Disease	NOUN	B
point	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
appears	O	VERB	O
to	O	PART	O
have	O	AUX	O
arisen	O	VERB	O
from	O	ADP	O
a	O	DET	O
common	O	ADJ	O
founder	O	NOUN	B
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
inherited	B-Disease	VERB	B
ataxia	I-Disease	NOUN	B
.	O	PUNCT	O


About	O	ADV	O
98	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
alleles	O	NOUN	O
have	O	AUX	O
an	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
GAA	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	I
intron	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
gene	O	NOUN	B
,	O	PUNCT	O
FRDA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
2	O	NUM	O
%	O	NOUN	O
are	O	AUX	O
point	O	NOUN	O
mutations	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
17	O	NUM	O
point	O	NOUN	O
mutations	O	NOUN	B
so	O	ADV	O
far	O	ADV	O
described	O	VERB	O
,	O	PUNCT	O
three	O	NUM	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
these	O	DET	O
is	O	AUX	O
the	O	DET	O
G130V	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
of	O	ADP	O
FRDA	O	NOUN	B
.	O	PUNCT	O


G130V	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
present	O	ADJ	O
with	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
GAA	O	NOUN	B
repeat	O	NOUN	O
on	O	ADP	O
the	O	DET	O
other	O	ADJ	O
allele	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
atypical	O	ADJ	B
FRDA	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Haplotype	O	NOUN	B
analysis	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
on	O	ADP	O
the	O	DET	O
four	O	NUM	O
families	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
with	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
common	O	ADJ	O
founder	O	NOUN	B
for	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
marked	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
extragenic	O	ADJ	B
marker	O	NOUN	I
haplotypes	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
,	O	PUNCT	O
similar	O	ADJ	O
intragenic	O	ADJ	B
haplotyping	O	NOUN	O
suggests	O	VERB	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
founder	O	NOUN	I
for	O	ADP	O
this	O	DET	O
family	O	NOUN	B
with	O	ADP	O
the	O	DET	O
differences	O	NOUN	O
explicable	O	ADJ	O
by	O	ADP	O
two	O	NUM	O
recombination	O	NOUN	B
events	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Synergistic	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
histone	O	NOUN	B
hyperacetylation	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
demethylation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
reactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Most	O	ADV	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
patients	O	NOUN	B
have	O	AUX	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
(	O	PUNCT	O
CGG	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
)	O	PUNCT	O
sequence	O	NOUN	B
with	O	ADP	O
>	O	NOUN	O
200	O	NUM	O
repeats	O	NOUN	B
(	O	PUNCT	O
full	O	ADJ	O
mutation	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O


Hypermethylation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
repeat	O	NOUN	O
and	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
promoter	O	NOUN	B
is	O	AUX	O
almost	O	ADV	O
always	O	ADV	O
present	O	ADJ	O
and	O	CCONJ	O
apparently	O	ADV	O
suppresses	O	VERB	B
transcription	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
showed	O	VERB	O
that	O	SCONJ	O
transcriptional	O	ADJ	B
reactivation	O	NOUN	I
of	O	ADP	O
FMR1	O	NOUN	B
full	O	ADJ	O
mutations	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
achieved	O	VERB	O
by	O	ADP	O
inducing	O	VERB	B
DNA	O	NOUN	B
demethylation	O	NOUN	I
with	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
azadeoxycytidine	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
azadC	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
level	O	NOUN	B
of	O	ADP	O
histone	O	NOUN	B
acetylation	O	NOUN	I
is	O	AUX	O
another	O	DET	O
important	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
regulating	O	VERB	B
gene	O	NOUN	B
expression	O	NOUN	I
;	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
treated	O	VERB	B
lymphoblastoid	O	ADJ	B
cell	O	NOUN	I
lines	O	NOUN	I
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
mosaic	O	ADJ	B
full	O	ADJ	O
mutation	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
three	O	NUM	O
drugs	O	NOUN	B
capable	O	ADJ	O
of	O	ADP	O
inducing	O	VERB	B
histone	O	NOUN	B
hyperacetylation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
a	O	DET	O
consistent	O	ADJ	O
,	O	PUNCT	O
although	O	SCONJ	O
modest	O	ADJ	O
,	O	PUNCT	O
reactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
with	O	ADP	O
4	O	NUM	B
-	O	PUNCT	O
phenylbutyrate	O	NOUN	B
,	O	PUNCT	O
sodium	O	NOUN	B
butyrate	O	NOUN	I
and	O	CCONJ	O
trichostatin	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
shown	O	VERB	O
by	O	ADP	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
combining	O	VERB	O
these	O	DET	O
drugs	O	NOUN	B
with	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
azadC	O	NOUN	B
results	O	NOUN	B
in	O	ADP	O
a	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
5	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
FMR1	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
obtained	O	VERB	O
with	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
azadC	O	NOUN	B
alone	O	ADV	O
,	O	PUNCT	O
thus	O	ADV	O
showing	O	VERB	O
a	O	DET	O
marked	O	ADJ	O
synergistic	O	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
histone	O	NOUN	B
hyperacetylation	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
demethylation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
reactivation	O	NOUN	B
of	O	ADP	O
FMR1	O	NOUN	B
full	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Constitutional	O	ADJ	B
von	B-Disease	NOUN	I
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	O	PUNCT	O
VHL	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
deletions	O	NOUN	I
detected	O	VERB	B
in	O	ADP	O
VHL	B-Disease	NOUN	B
families	O	NOUN	B
by	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	I-Disease	PUNCT	O
VHL	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
disease	I-Disease	NOUN	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominantly	I-Disease	ADV	O
inherited	I-Disease	VERB	B
cancer	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
predisposing	O	VERB	B
to	O	PART	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
types	O	NOUN	I
that	O	PRON	O
include	O	VERB	O
retinal	O	ADJ	B
hemangioblastomas	B-Disease	NOUN	B
,	O	PUNCT	O
hemangioblastomas	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
,	O	PUNCT	O
pancreatic	B-Disease	ADJ	B
cysts	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
tumors	I-Disease	NOUN	B
,	O	PUNCT	O
pheochromocytomas	B-Disease	NOUN	B
,	O	PUNCT	O
endolymphatic	B-Disease	ADJ	B
sac	I-Disease	NOUN	I
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
epididymal	B-Disease	ADJ	B
cystadenomas	I-Disease	NOUN	I
[	O	PUNCT	O
W	O	PROPN	O
.	O	PUNCT	O


M	O	NOUN	B
.	O	PUNCT	O


Linehan	O	X	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
J	O	NOUN	O
.	O	PUNCT	O


Am	O	NOUN	O
.	O	PUNCT	O
Med	O	PROPN	O
.	O	PUNCT	O
Assoc	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
273	O	NUM	O
564	O	NUM	O
-	O	PUNCT	O
570	O	NUM	O
,	O	PUNCT	O
1995	O	NUM	O
;	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
A	O	DET	O
.	O	PUNCT	O
Maher	O	PROPN	O
and	O	CCONJ	O
W	O	PROPN	O
.	O	PUNCT	O
G	O	NOUN	B
.	O	PUNCT	O
Kaelin	O	NOUN	B
,	O	PUNCT	O
Jr	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
Medicine	O	PROPN	B
(	O	PUNCT	I
Baltimore	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
76	O	NUM	O
381	O	NUM	O
-	O	SYM	O
391	O	NUM	O
,	O	PUNCT	O
1997	O	NUM	O
;	O	PUNCT	O
W	O	NOUN	O
.	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O
Linehan	O	NOUN	B
and	O	CCONJ	O
R	O	NOUN	B
.	O	PUNCT	O
D	O	NOUN	O
.	O	PUNCT	O
Klausner	O	PROPN	O
,	O	PUNCT	O
In	O	ADP	O
B	O	NOUN	B
.	O	PUNCT	O
Vogelstein	O	NOUN	B
and	O	CCONJ	O
K	O	PROPN	B
.	O	PUNCT	O
Kinzler	O	PROPN	O
(	O	PUNCT	O
eds	O	PROPN	O
.	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
The	O	DET	O
Genetic	O	ADJ	B
Basis	O	NOUN	I
of	O	ADP	O
Human	O	PROPN	B
Cancer	O	PROPN	I
,	O	PUNCT	O
pp	O	NOUN	O
.	O	PUNCT	O


455	O	NUM	O
-	O	PUNCT	O
473	O	NUM	O
,	O	PUNCT	O
McGraw	O	PROPN	B
-	O	PUNCT	O
Hill	O	PROPN	B
,	O	PUNCT	O
1998	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
chromosome	O	NOUN	B
3p25	O	NOUN	I
-	O	PUNCT	O
26	O	NUM	O
and	O	CCONJ	O
cloned	O	VERB	B
[	O	PUNCT	O
F	O	PROPN	B
.	O	PUNCT	O
Latif	O	NOUN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
Science	O	PROPN	B
(	O	PUNCT	O
Washington	O	PROPN	O
DC	O	PROPN	O
)	O	PUNCT	O
,	O	PUNCT	O
260	O	NUM	O
1317	O	NUM	O
-	O	SYM	O
1320	O	NUM	O
,	O	PUNCT	O
1993	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
VHL	B-Disease	NOUN	B
kindreds	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reported	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
VHL	B-Disease	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
has	O	AUX	O
varied	O	VERB	O
from	O	ADP	O
39	O	NUM	O
to	O	PART	O
80	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
J	O	NOUN	O
.	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O
Whaley	O	NOUN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Am	O	NOUN	O
.	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
Hum	O	NOUN	O
.	O	PUNCT	O
Genet	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
55	O	NUM	O
1092	O	NUM	O
-	O	SYM	O
1102	O	NUM	O
,	O	PUNCT	O
1994	O	NUM	O
;	O	PUNCT	O
Clinical	O	PROPN	B
Research	O	PROPN	I
Group	O	PROPN	I
for	O	ADP	O
Japan	O	PROPN	B
,	O	PUNCT	O
Hum	O	PROPN	B
.	O	PUNCT	O
Mol	O	PROPN	O
.	O	PUNCT	O
Genet	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
4	O	NUM	O
2233	O	NUM	O
-	O	SYM	O
2237	O	NUM	O
,	O	PUNCT	O
1995	O	NUM	O
;	O	PUNCT	O
F	O	PROPN	B
.	O	PUNCT	O
Chen	O	PROPN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
Hum	O	PROPN	O
.	O	PUNCT	O
Mutat	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
5	O	NUM	O
66	O	NUM	O
-	O	SYM	O
75	O	NUM	O
,	O	PUNCT	O
1995	O	NUM	O
;	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
R	O	NOUN	B
.	O	PUNCT	O
Maher	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
Med	O	PROPN	O
.	O	PUNCT	O
Genet	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
33	O	NUM	O
328	O	NUM	O
-	O	SYM	O
332	O	NUM	O
,	O	PUNCT	O
1996	O	NUM	O
;	O	PUNCT	O
B	O	NOUN	B
.	O	PUNCT	O
Zbar	O	PROPN	B
,	O	PUNCT	O
Cancer	O	PROPN	O
Surv	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
25	O	NUM	O
219	O	NUM	O
-	O	SYM	O
232	O	NUM	O
,	O	PUNCT	O
1995	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Recently	O	ADV	O
a	O	DET	O
quantitative	O	ADJ	B
Southern	O	NOUN	B
blotting	O	NOUN	I
procedure	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
improve	O	VERB	B
this	O	DET	O
frequency	O	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
.	O	PUNCT	O
Stolle	O	NOUN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
Hum	O	PROPN	O
.	O	PUNCT	O
Mutat	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
12	O	NUM	O
417	O	NUM	O
-	O	SYM	O
423	O	NUM	O
,	O	PUNCT	O
1998	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
method	O	NOUN	B
to	O	PART	O
detect	O	VERB	B
and	O	CCONJ	O
characterize	O	VERB	O
VHL	B-Disease	NOUN	B
germline	O	NOUN	B
deletions	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
reexamined	O	VERB	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
VHL	B-Disease	NOUN	B
patients	O	NOUN	B
shown	O	VERB	O
previously	O	ADV	O
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
and	O	CCONJ	O
sequencing	O	NOUN	B
analysis	O	NOUN	I
not	O	PART	O
to	O	PART	O
harbor	O	VERB	O
point	O	NOUN	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
locus	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
constitutional	O	ADJ	B
deletions	O	NOUN	B
in	O	ADP	O
29	O	NUM	O
of	O	ADP	O
30	O	NUM	O
VHL	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
using	O	VERB	O
cosmid	O	NOUN	B
and	O	CCONJ	O
P1	O	NOUN	B
probes	O	NOUN	B
that	O	PRON	O
cover	O	VERB	O
the	O	DET	O
VHL	B-Disease	NOUN	B
locus	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
then	O	ADV	O
tested	O	VERB	B
six	O	NUM	O
phenotypically	O	ADV	B
normal	O	ADJ	O
offspring	O	NOUN	B
from	O	ADP	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
VHL	B-Disease	NOUN	B
families	O	NOUN	B
two	O	NUM	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
the	O	DET	O
deletion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
four	O	NUM	O
were	O	AUX	O
deletion	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
germline	O	NOUN	B
mosaicism	O	NOUN	I
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
sum	O	NOUN	O
,	O	PUNCT	O
FISH	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
simple	O	ADJ	O
and	O	CCONJ	O
reliable	O	ADJ	O
method	O	NOUN	B
to	O	PART	O
detect	O	VERB	B
VHL	B-Disease	NOUN	B
germline	O	NOUN	B
deletions	O	NOUN	I
and	O	CCONJ	O
practically	O	ADV	O
useful	O	ADJ	O
in	O	ADP	O
cases	O	NOUN	B
where	O	SCONJ	O
other	O	ADJ	O
methods	O	NOUN	B
of	O	ADP	O
screening	O	NOUN	B
have	O	AUX	O
failed	O	VERB	B
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
VHL	B-Disease	NOUN	B
gene	I-Disease	NOUN	I
abnormality	I-Disease	NOUN	O


Spectrum	O	NOUN	B
of	O	ADP	O
hSNF5	O	NOUN	B
/	O	SYM	O
INI1	O	NOUN	B
somatic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
cancer	B-Disease	NOUN	I
and	O	CCONJ	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hSNF5	O	NOUN	B
/	O	SYM	O
INI1	O	NOUN	B
gene	O	NOUN	I
which	O	DET	O
encodes	O	VERB	B
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SWI	O	PROPN	B
/	O	SYM	O
SNF	O	NOUN	B
chromatin	O	NOUN	B
ATP	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
remodeling	O	NOUN	B
complex	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
localized	O	VERB	B
on	O	ADP	O
chromosome	O	NOUN	B
22q11	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
recently	O	ADV	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
malignant	B-Disease	ADJ	B
rhabdoid	I-Disease	ADJ	I
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
hSNF5	O	NOUN	B
/	O	PUNCT	O
INI1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
229	O	NUM	O
tumors	B-Disease	NOUN	B
of	O	ADP	O
various	O	ADJ	O
origins	O	NOUN	B
using	O	VERB	O
a	O	DET	O
screening	O	NOUN	B
method	O	NOUN	I
based	O	VERB	O
on	O	ADP	O
denaturing	O	VERB	B
high	O	ADJ	B
-	O	PUNCT	O
performance	O	NOUN	B
liquid	O	ADJ	B
chromatography	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
31	O	NUM	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
and	O	CCONJ	O
36	O	NUM	O
point	O	NOUN	O
alterations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Point	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
scattered	O	VERB	B
along	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
and	O	CCONJ	O
included	O	VERB	O
15	O	NUM	O
nonsense	O	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
frameshift	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
splice	O	NOUN	B
site	O	NOUN	I
,	O	PUNCT	O
two	O	NUM	O
missense	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
editing	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
retrieved	O	VERB	O
in	O	ADP	O
most	O	ADJ	O
rhabdoid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
whatever	O	DET	O
their	O	PRON	O
sites	O	NOUN	B
of	O	ADP	O
occurrence	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
the	O	DET	O
common	O	ADJ	O
pathogenetic	O	ADJ	B
origin	O	NOUN	I
of	O	ADP	O
these	O	DET	O
tumors	B-Disease	NOUN	B
.	O	PUNCT	O


Recurrent	O	ADJ	B
hSNF5	O	NOUN	B
/	O	SYM	O
INI1	O	NOUN	B
alterations	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
choroid	B-Disease	ADJ	B
plexus	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
central	O	ADJ	B
primitive	O	ADJ	I
neuroectodermal	B-Disease	ADJ	I
tumors	I-Disease	NOUN	I
(	O	PUNCT	O
cPNETs	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
medulloblastomas	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
hSNF5	O	NOUN	B
/	O	SYM	O
INI1	O	NOUN	B
point	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
Wilms	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
gliomas	B-Disease	NOUN	B
,	O	PUNCT	O
ependymomas	B-Disease	NOUN	B
,	O	PUNCT	O
sarcomas	B-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
tumor	B-Disease	NOUN	B
types	O	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
most	O	ADV	O
analyzed	O	VERB	B
cases	O	NOUN	B
harbored	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
at	O	ADP	O
22q11	O	NOUN	B
.	O	PUNCT	O


2	O	NUM	O
loci	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
rhabdoid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
choroid	B-Disease	ADJ	B
plexus	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
medulloblastomas	B-Disease	NOUN	B
and	O	CCONJ	O
cPNETs	O	NOUN	B
share	O	VERB	O
common	O	ADJ	O
pathways	O	NOUN	B
of	O	ADP	O
oncogenesis	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
hSNF5	O	NOUN	B
/	O	SYM	O
INI1	O	NOUN	B
alteration	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
hSNF5	O	NOUN	B
/	O	PUNCT	O
INI1	O	NOUN	B
mutations	O	NOUN	B
define	O	VERB	O
a	O	DET	O
genetically	O	ADV	B
homogeneous	O	ADJ	O
family	O	NOUN	O
of	O	ADP	O
highly	O	ADV	O
aggressive	O	ADJ	B
cancers	B-Disease	NOUN	I
mainly	O	ADV	O
occurring	O	VERB	O
in	O	ADP	O
young	O	ADJ	B
children	O	NOUN	B
and	O	CCONJ	O
frequently	O	ADV	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
always	O	ADV	O
,	O	PUNCT	O
exhibiting	O	VERB	O
a	O	DET	O
rhabdoid	B-Disease	ADJ	B
phenotype	O	NOUN	B


Ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
with	O	ADP	O
an	O	DET	O
altered	O	ADJ	O
conformation	O	NOUN	B
that	O	PRON	O
exposes	O	VERB	O
the	O	DET	O
polyglutamine	O	NOUN	B
domain	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
nuclear	O	ADJ	B
matrix	O	NOUN	I
.	O	PUNCT	O


Spinocerebellar	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
type	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
3	I-Disease	NUM	O
or	O	CCONJ	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
SCA3	B-Disease	NOUN	B
/	O	SYM	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CAG	B-Disease	PROPN	B
/	I-Disease	PUNCT	O
polyglutamine	I-Disease	NOUN	B
repeat	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
family	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
family	O	NOUN	B
of	O	ADP	O
disorders	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
normally	O	ADV	O
polymorphic	O	ADJ	B
CAG	O	NOUN	B
repeat	O	NOUN	I
becomes	O	VERB	O
expanded	O	VERB	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
polyglutamine	O	NOUN	B
domain	O	NOUN	I
in	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
.	O	PUNCT	O


Experimental	O	ADJ	B
models	O	NOUN	I
of	O	ADP	O
polyglutamine	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
implicate	O	VERB	O
the	O	DET	O
nucleus	O	NOUN	B
in	O	ADP	O
pathogenesis	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
link	O	NOUN	O
between	O	ADP	O
intranuclear	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
expanded	O	VERB	O
polyglutamine	O	NOUN	B
and	O	CCONJ	O
neuronal	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
protein	O	NOUN	I
in	O	ADP	O
SCA3	B-Disease	NOUN	B
/	O	SYM	O
MJD	B-Disease	NOUN	B
,	O	PUNCT	O
adopts	O	VERB	O
a	O	DET	O
unique	O	ADJ	B
conformation	O	NOUN	B
when	O	SCONJ	O
expressed	O	VERB	B
within	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
of	O	ADP	O
transfected	O	VERB	B
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
1C2	O	NOUN	B
is	O	AUX	O
known	O	VERB	O
preferentially	O	ADV	O
to	O	PART	O
bind	O	VERB	B
expanded	O	VERB	O
polyglutamine	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
we	O	PRON	O
find	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
also	O	ADV	O
binds	O	VERB	B
a	O	DET	O
fragment	O	NOUN	B
of	O	ADP	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
containing	O	VERB	O
a	O	DET	O
normal	O	ADJ	O
glutamine	O	NOUN	B
repeat	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
within	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
exposes	O	VERB	O
the	O	DET	O
glutamine	O	NOUN	B
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
non	O	NOUN	B
-	O	PUNCT	O
pathological	O	ADJ	B
protein	O	NOUN	O
,	O	PUNCT	O
allowing	O	VERB	O
it	O	PRON	O
to	O	PART	O
bind	O	VERB	B
the	O	DET	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
1C2	O	NOUN	B
.	O	PUNCT	O


Fractionation	O	NOUN	B
and	O	CCONJ	O
immunochemical	O	ADJ	B
experiments	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
novel	O	ADJ	B
conformation	O	NOUN	B
of	O	ADP	O
intranuclear	O	ADJ	B
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
is	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
proteolysis	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
instead	O	ADV	O
that	O	DET	O
association	O	NOUN	B
with	O	ADP	I
nuclear	O	ADJ	B
protein	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
alters	O	VERB	O
the	O	DET	O
structure	O	NOUN	B
of	O	ADP	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
which	O	DET	O
exposes	O	VERB	O
the	O	DET	O
polyglutamine	O	NOUN	B
domain	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
conformationally	O	ADV	B
altered	O	ADJ	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
is	O	AUX	O
bound	O	VERB	O
to	O	PART	O
the	O	DET	O
nuclear	O	ADJ	B
matrix	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
pathological	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
with	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
polyglutamine	O	NOUN	B
domain	O	NOUN	I
also	O	ADV	O
associates	O	VERB	B
with	O	ADP	I
the	O	DET	O
nuclear	O	ADJ	B
matrix	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
early	O	ADJ	B
event	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
SCA3	B-Disease	NOUN	B
/	O	SYM	O
MJD	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
altered	O	ADJ	O
conformation	O	NOUN	B
of	O	ADP	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
within	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
that	O	PRON	O
exposes	O	VERB	O
the	O	DET	O
polyglutamine	O	NOUN	B
domain	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
MAGEL2	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
mouse	O	NOUN	B
homologue	O	NOUN	B
are	O	AUX	O
paternally	O	ADV	B
expressed	O	VERB	I
and	O	CCONJ	O
mapped	O	VERB	B
to	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
region	O	NOUN	I
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
complex	O	ADJ	O
neurogenetic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
phenotype	O	NOUN	B
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
contiguous	B-Disease	ADJ	B
gene	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
involving	O	VERB	O
genes	O	NOUN	B
which	O	DET	O
are	O	AUX	O
paternally	O	ADV	B
expressed	O	VERB	B
only	O	ADV	O
,	O	PUNCT	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
mouse	O	NOUN	B
models	O	NOUN	I
of	O	ADP	O
PWS	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
but	O	CCONJ	O
these	O	DET	O
do	O	AUX	O
not	O	PART	O
definitively	O	ADV	O
allow	O	VERB	O
the	O	DET	O
delineation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
critical	O	ADJ	B
region	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
associated	O	VERB	B
genes	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
targeted	O	VERB	B
mutagenesis	O	NOUN	I
of	O	ADP	O
mouse	O	NOUN	B
homologues	O	NOUN	I
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
candidate	O	NOUN	O
PWS	B-Disease	NOUN	B
genes	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
features	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
genes	O	NOUN	B
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B
remains	O	VERB	O
crucial	O	ADJ	O
for	O	ADP	O
a	O	DET	O
better	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
manuscript	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
characterization	O	NOUN	B
of	O	ADP	O
MAGEL2	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
mouse	O	NOUN	B
homologue	O	NOUN	B
Magel2	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
are	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
and	O	CCONJ	O
mouse	O	NOUN	B
7C	O	NOUN	I
regions	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
close	O	ADJ	O
proximity	O	NOUN	B
to	O	ADP	O
NDN	O	NOUN	B
/	O	SYM	O
Ndn	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
northern	O	ADJ	B
blot	O	NOUN	I
analysis	O	NOUN	I
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
detect	O	VERB	B
any	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
MAGEL2	O	NOUN	B
/	O	PUNCT	O
Magel2	O	ADJ	B
but	O	CCONJ	O
by	O	ADP	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
analysis	O	NOUN	B
,	O	PUNCT	O
specific	O	ADJ	O
expression	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
fetal	O	ADJ	B
and	O	CCONJ	O
adult	O	ADJ	B
brain	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
placenta	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
genes	O	NOUN	B
are	O	AUX	O
intronless	O	ADJ	B
with	O	ADP	O
tandem	O	ADJ	B
direct	O	ADJ	I
repeat	O	NOUN	I
sequences	O	NOUN	I
contained	O	VERB	O
within	O	ADP	O
a	O	DET	O
CpG	O	NOUN	B
island	O	NOUN	I
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
untranscribed	O	VERB	B
region	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
transcripts	O	NOUN	B
encode	O	VERB	B
putative	O	ADJ	B
proteins	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
homologous	O	ADJ	B
to	O	PART	O
the	O	DET	O
MAGE	O	NOUN	B
proteins	O	NOUN	I
and	O	CCONJ	O
NDN	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
MAGEL2	O	NOUN	B
/	O	PUNCT	O
Magel2	O	NOUN	B
are	O	AUX	O
expressed	O	VERB	B
only	O	ADV	O
from	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
allele	O	NOUN	I
in	O	ADP	O
brain	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
mouse	O	NOUN	B
model	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


cDNA	O	NOUN	B
microarrays	O	NOUN	O
detect	O	VERB	B
activation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
myogenic	O	ADJ	B
transcription	O	NOUN	I
program	O	NOUN	I
by	O	ADP	O
the	O	DET	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
oncogene	O	NOUN	I
.	O	PUNCT	O


Alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
aggressive	O	ADJ	B
pediatric	B-Disease	ADJ	O
cancer	I-Disease	NOUN	O
of	I-Disease	ADP	O
striated	I-Disease	ADJ	B
muscle	I-Disease	NOUN	I
characterized	O	VERB	B
in	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
by	O	ADP	O
a	O	DET	O
t	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
13	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q35	O	NOUN	B
;	O	PUNCT	O
q14	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
results	O	NOUN	B
in	O	ADP	O
the	O	DET	O
fusion	O	NOUN	B
of	O	ADP	O
PAX3	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
developmental	O	ADJ	B
transcription	O	NOUN	B
factor	O	NOUN	I
required	O	VERB	O
for	O	ADP	O
limb	O	NOUN	B
myogenesis	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
FKHR	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
forkhead	O	NOUN	B
family	O	NOUN	I
of	O	ADP	O
transcription	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
resultant	O	ADJ	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
gene	O	NOUN	B
possesses	O	VERB	O
transforming	O	VERB	B
properties	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
this	O	DET	O
chimeric	O	ADJ	B
oncogene	O	NOUN	I
on	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
are	O	AUX	O
largely	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
these	O	DET	O
transcription	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
both	O	CCONJ	O
Pax3	O	NOUN	B
and	O	CCONJ	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
were	O	AUX	O
introduced	O	VERB	O
into	O	ADP	O
NIH	O	NOUN	B
3T3	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
resultant	O	ADJ	O
gene	O	NOUN	B
expression	O	NOUN	I
changes	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
with	O	ADP	O
a	O	DET	O
murine	O	ADJ	B
cDNA	O	NOUN	B
microarray	O	NOUN	I
containing	O	VERB	O
2	O	NUM	O
,	O	PUNCT	O
225	O	NUM	O
elements	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
PAX3	O	NOUN	B
activated	O	VERB	B
a	O	DET	O
myogenic	O	ADJ	B
transcription	O	NOUN	I
program	O	NOUN	I
including	O	VERB	O
the	O	DET	O
induction	O	NOUN	B
of	O	ADP	O
transcription	O	NOUN	B
factors	O	NOUN	I
MyoD	O	NOUN	B
,	O	PUNCT	O
Myogenin	O	NOUN	B
,	O	PUNCT	O
Six1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Slug	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
battery	O	NOUN	B
of	O	ADP	I
genes	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
muscle	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


Notable	O	ADJ	O
among	O	ADP	O
this	O	DET	O
group	O	NOUN	B
were	O	AUX	O
the	O	DET	O
growth	O	NOUN	B
factor	O	NOUN	I
gene	O	NOUN	I
Igf2	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
binding	O	NOUN	B
protein	O	NOUN	I
Igfbp5	O	NOUN	B
.	O	PUNCT	O


Relevance	O	NOUN	B
of	O	ADP	O
this	O	DET	O
model	O	NOUN	B
was	O	AUX	O
suggested	O	VERB	O
by	O	ADP	O
verification	O	NOUN	B
that	O	SCONJ	O
three	O	NUM	O
of	O	ADP	O
these	O	DET	O
genes	O	NOUN	B
(	O	PUNCT	O
IGFBP5	O	NOUN	B
,	O	PUNCT	O
HSIX1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Slug	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
cell	O	NOUN	I
lines	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
utilizes	O	VERB	O
cDNA	O	NOUN	B
microarrays	O	NOUN	I
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
an	O	DET	O
oncogenic	O	ADJ	B
transcription	O	NOUN	O
factor	O	NOUN	O
and	O	CCONJ	O
demonstrates	O	VERB	O
the	O	DET	O
profound	O	ADJ	O
myogenic	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
in	O	ADP	O
NIH	O	NOUN	B
3T3	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Experimental	O	ADJ	B
hemochromatosis	B-Disease	NOUN	B
due	O	ADP	O
to	O	PART	O
MHC	O	NOUN	B
class	O	NOUN	B
I	O	NUM	I
HFE	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
:	O	PUNCT	O
immune	O	ADJ	B
status	O	NOUN	I
and	O	CCONJ	O
iron	O	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
puzzling	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
genetic	O	ADJ	B
hemochromatosis	B-Disease	NOUN	I
and	O	CCONJ	O
histocompatibility	O	NOUN	B
loci	O	NOUN	I
became	O	VERB	O
even	O	ADV	O
more	O	ADV	O
so	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
involved	O	VERB	O
,	O	PUNCT	O
HFE	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Indeed	O	ADV	O
,	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
well	O	ADV	O
defined	O	VERB	O
,	O	PUNCT	O
mainly	O	ADV	O
peptide	O	NOUN	B
-	O	PUNCT	O
binding	O	NOUN	B
,	O	PUNCT	O
MHC	O	NOUN	B
class	O	NOUN	I
I	O	NUM	I
family	O	NOUN	O
of	O	ADP	O
molecules	O	NOUN	B
,	O	PUNCT	O
HFE	O	PROPN	B
seems	O	VERB	O
to	O	PART	O
perform	O	VERB	O
an	O	DET	O
unusual	O	ADJ	B
yet	O	ADV	O
essential	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
yet	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
HFE	O	NOUN	B
function	O	NOUN	B
in	O	ADP	O
iron	O	NOUN	B
homeostasis	O	NOUN	I
is	O	AUX	O
only	O	ADV	O
partial	O	ADJ	B
;	O	PUNCT	O
an	O	DET	O
even	O	ADV	O
more	O	ADV	O
open	O	ADJ	O
question	O	NOUN	O
is	O	AUX	O
its	O	PRON	O
possible	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
immune	O	ADJ	B
system	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
advance	O	VERB	O
on	O	ADP	O
both	O	DET	O
of	O	ADP	O
these	O	DET	O
avenues	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
HFE	O	NOUN	B
alpha1	O	NOUN	I
and	O	CCONJ	O
alpha2	O	NOUN	B
putative	O	ADJ	O
ligand	O	NOUN	O
binding	O	NOUN	O
domains	O	NOUN	O
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


HFE	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
animals	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
a	O	DET	O
comprehensive	O	ADJ	B
set	O	NOUN	O
of	O	ADP	O
metabolic	O	ADJ	B
and	O	CCONJ	O
immune	O	ADJ	B
parameters	O	NOUN	I
.	O	PUNCT	O


Faithfully	O	ADV	B
mimicking	O	VERB	I
human	O	ADJ	B
hemochromatosis	B-Disease	NOUN	B
,	O	PUNCT	O
mice	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
develop	O	VERB	O
iron	O	NOUN	B
overload	O	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
plasma	O	NOUN	B
iron	O	NOUN	B
content	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
raised	O	VERB	O
transferrin	O	NOUN	B
saturation	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
an	O	DET	O
elevated	O	ADJ	B
hepatic	O	ADJ	B
iron	O	NOUN	O
load	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
defect	O	NOUN	O
could	O	AUX	O
,	O	PUNCT	O
indeed	O	ADV	O
,	O	PUNCT	O
be	O	AUX	O
traced	O	VERB	O
to	O	PART	O
an	O	DET	O
augmented	O	ADJ	B
duodenal	O	ADJ	B
iron	O	NOUN	O
absorption	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
parallel	O	NOUN	O
,	O	PUNCT	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gut	O	NOUN	B
mucosal	O	ADJ	B
iron	O	NOUN	B
content	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
iron	O	NOUN	B
regulatory	O	ADJ	I
proteins	O	NOUN	I
allows	O	VERB	O
a	O	DET	O
more	O	ADV	O
informed	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
various	O	ADJ	O
hypotheses	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
precise	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
HFE	O	NOUN	B
in	O	ADP	O
iron	O	NOUN	B
homeostasis	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
extensive	O	ADJ	O
phenotyping	O	NOUN	B
of	O	ADP	O
primary	O	ADJ	B
and	O	CCONJ	O
secondary	O	ADJ	B
lymphoid	O	ADJ	B
organs	O	NOUN	I
including	O	VERB	O
the	O	DET	O
gut	O	NOUN	B
provides	O	VERB	O
no	O	DET	O
compelling	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
an	O	DET	O
obvious	O	ADJ	O
immune	O	ADJ	B
-	O	PUNCT	O
linked	O	VERB	B
function	O	NOUN	B
for	O	ADP	O
HFE	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Somatic	O	ADJ	B
rearrangement	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
14	O	NUM	O
in	O	ADP	O
human	O	ADJ	B
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
genetic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
immune	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
chromosome	B-Disease	NOUN	B
instability	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
predisposition	O	NOUN	B
to	O	PART	O
lymphoid	B-Disease	ADJ	B
malignancy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
detected	O	VERB	B
chromosomally	O	ADV	B
anomalous	O	ADJ	I
clones	O	NOUN	B
of	O	ADP	O
lymphocytes	O	NOUN	B
in	O	ADP	O
eight	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
banding	O	NOUN	B
disclosed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
clones	O	NOUN	B
are	O	AUX	O
consistently	O	ADV	O
marked	O	VERB	O
by	O	ADP	O
structural	O	ADJ	B
rearrangement	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
(	O	PUNCT	O
q	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
chromosome	O	NOUN	B
14	O	NUM	I
.	O	PUNCT	O


A	O	DET	O
translocation	O	NOUN	B
involving	O	VERB	O
14q	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
clones	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
seven	O	NUM	O
of	O	ADP	O
the	O	DET	O
eight	O	NUM	O
patients	O	NOUN	B
whereas	O	SCONJ	O
a	O	DET	O
ring	O	NOUN	B
14	O	NUM	I
chromosome	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
a	O	DET	O
clone	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
data	O	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
others	O	NOUN	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
structural	O	ADJ	B
rearrangement	O	NOUN	I
of	O	ADP	O
14q	O	NOUN	O
is	O	AUX	O
the	O	DET	O
initial	O	ADJ	O
chromosomal	O	ADJ	B
change	O	NOUN	I
in	O	ADP	O
lymphocyte	O	NOUN	B
clones	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O


Chromosomes	O	NOUN	B
of	O	ADP	O
lymphocytes	O	NOUN	B
from	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
chronic	B-Disease	ADJ	B
lymphocytic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
.	O	PUNCT	O


Before	O	ADP	O
leukemia	B-Disease	NOUN	B
was	O	AUX	O
diagnosed	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
lymphocyte	O	NOUN	B
clone	O	NOUN	B
with	O	ADP	O
a	O	DET	O
14q	O	NOUN	B
translocation	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
clone	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
have	O	AUX	O
given	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
the	O	DET	O
leukemic	B-Disease	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
structural	O	ADJ	B
rearrangement	O	NOUN	I
of	O	ADP	O
14q	O	NOUN	O
is	O	AUX	O
directly	O	ADV	O
related	O	VERB	O
to	O	PART	O
abnormal	O	ADJ	B
growth	O	NOUN	B
of	O	ADP	O
lymphocytes	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
step	O	NOUN	O
toward	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
lymphoid	B-Disease	ADJ	B
malignancies	I-Disease	NOUN	I
.	O	PUNCT	O


Increasing	O	VERB	B
evidence	O	NOUN	B
,	O	PUNCT	O
provided	O	VERB	O
by	O	ADP	O
others	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
nonrandom	O	ADJ	B
involvement	O	NOUN	B
of	O	ADP	O
14q	O	NOUN	B
in	O	ADP	O
African	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
Burkitts	B-Disease	PROPN	B
lymphoma	I-Disease	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
lymphoid	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	B
further	O	ADV	O
strengthens	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Exon	O	NOUN	B
9	O	NUM	I
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
without	O	ADP	O
influencing	O	VERB	O
KTS	O	NOUN	B
splice	O	NOUN	B
isoforms	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
also	O	ADV	O
responsible	O	ADJ	O
for	O	ADP	O
Frasier	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
new	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
of	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
+	O	CCONJ	O
/	O	SYM	B
-	O	PUNCT	O
KTS	O	NOUN	B
splice	O	NOUN	B
isoforms	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
Frasier	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
FS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
intron	O	NOUN	B
9	O	NUM	O
inducing	O	VERB	B
defective	O	ADJ	B
alternative	O	ADJ	O
splicing	O	NOUN	O
was	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
our	O	PRON	O
cases	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
as	O	ADP	O
detected	O	VERB	B
in	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
DDS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
previously	O	ADV	O
proposed	O	VERB	O
mechanism	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
syndromes	O	NOUN	B
originate	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
WT1	B-Disease	NOUN	B
gene	I-Disease	NOUN	B
abnormality	I-Disease	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
biological	O	ADJ	O
point	O	NOUN	O
of	O	ADP	O
view	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
diseases	O	NOUN	B
were	O	AUX	O
not	O	PART	O
separable	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
FS	B-Disease	PROPN	B
should	O	AUX	O
be	O	AUX	O
included	O	VERB	O
as	O	ADP	O
an	O	DET	O
atypical	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
DDS	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
intrafamilial	O	ADJ	B
variability	O	NOUN	B
for	O	ADP	O
deafness	B-Disease	NOUN	B
in	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
recessive	B-Disease	ADJ	B
inherited	I-Disease	VERB	I
disorder	I-Disease	NOUN	I
that	O	PRON	O
consists	O	VERB	O
of	O	ADP	O
developmental	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
cochlea	I-Disease	NOUN	B
,	O	PUNCT	O
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
diffuse	B-Disease	ADJ	B
thyroid	I-Disease	NOUN	I
enlargement	I-Disease	NOUN	I
(	O	PUNCT	O
goiter	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
disorder	O	NOUN	B
may	O	AUX	O
account	O	VERB	O
for	O	ADP	O
up	O	ADV	O
to	O	PART	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
deafness	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
PDS	B-Disease	PROPN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
7q22	O	NOUN	I
-	O	PUNCT	O
q31	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
encodes	O	VERB	B
a	O	DET	O
chloride	O	NOUN	B
-	O	PUNCT	O
iodide	O	NOUN	B
transport	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
mutation	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
individual	O	ADJ	B
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	PROPN	B
gene	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
Spanish	O	ADJ	B
family	O	NOUN	B
that	O	PRON	O
shows	O	VERB	O
intrafamilial	O	ADJ	B
variability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deafness	B-Disease	NOUN	B
phenotype	O	NOUN	B
(	O	PUNCT	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
profound	O	ADJ	O
and	O	CCONJ	O
one	O	NUM	O
with	O	ADP	O
moderate	O	ADJ	B
-	O	PUNCT	O
severe	O	ADJ	B
deafness	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
new	O	ADJ	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
affecting	O	VERB	O
intron	O	NOUN	B
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	PROPN	B
gene	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
639	O	NUM	O
+	O	CCONJ	O
7	O	NUM	O
.	O	PUNCT	O


RNA	O	NOUN	B
analysis	O	NOUN	I
from	O	ADP	O
lymphocytes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
patients	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
mutation	O	NOUN	B
639	O	NUM	O
+	O	CCONJ	O
7A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
generates	O	VERB	O
a	O	DET	O
new	O	ADJ	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
an	O	DET	O
mRNA	O	NOUN	B
with	O	ADP	O
an	O	DET	O
insertion	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
nucleotides	O	NOUN	B
from	O	ADP	O
intron	O	NOUN	B
4	O	NUM	O
of	O	ADP	O
PDS	O	PROPN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
newly	O	ADV	O
created	O	VERB	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
compete	O	VERB	B
with	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
one	O	NOUN	O
,	O	PUNCT	O
variations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
aberrant	O	ADJ	B
transcripts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
cochlea	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
variability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
deafness	B-Disease	NOUN	B
presentation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
Sjogren	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Larsson	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
mutation	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fatty	O	ADJ	B
aldehyde	O	NOUN	I
dehydrogenase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Sjogren	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Larsson	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
SLS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
ichthyosis	B-Disease	NOUN	B
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
spasticity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
deficient	B-Disease	ADJ	B
activity	I-Disease	NOUN	B
of	I-Disease	ADP	O
fatty	I-Disease	ADJ	B
aldehyde	I-Disease	NOUN	I
dehydrogenase	I-Disease	NOUN	I
(	O	PUNCT	O
FALDH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
define	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
defects	O	NOUN	I
causing	O	VERB	O
SLS	B-Disease	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
mutation	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
FALDH	O	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
probands	O	NOUN	B
from	O	ADP	O
63	O	NUM	O
kindreds	O	NOUN	B
with	O	ADP	O
SLS	B-Disease	PROPN	B
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
49	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
-	O	PUNCT	O
including	O	VERB	B
10	O	NUM	O
deletions	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
insertions	O	NOUN	B
,	O	PUNCT	O
22	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
,	O	PUNCT	O
3	O	NUM	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
9	O	NUM	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
defects	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
complex	O	NOUN	B
mutations	O	NOUN	B
-	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
SLS	B-Disease	PROPN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
mutations	O	NOUN	B
.	O	PUNCT	O


Nineteen	O	NUM	O
of	O	ADP	O
the	O	DET	O
missense	O	NOUN	B
mutations	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
severe	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
FALDH	O	NOUN	B
enzyme	O	NOUN	B
catalytic	O	ADJ	O
activity	O	NOUN	O
when	O	SCONJ	O
expressed	O	VERB	B
in	O	ADP	O
mammalian	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
one	O	NUM	O
mutation	O	NOUN	B
(	O	PUNCT	O
798G	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
C	O	PROPN	O
[	O	PUNCT	O
K266N	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
seemed	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
greater	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
mRNA	O	NOUN	B
stability	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutations	O	NOUN	B
led	O	VERB	O
to	O	PART	O
exon	O	NOUN	B
skipping	O	NOUN	I
or	O	CCONJ	O
utilization	O	NOUN	B
of	O	ADP	O
cryptic	O	ADJ	B
acceptor	O	NOUN	I
-	O	PUNCT	O
splice	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
mutations	O	NOUN	B
were	O	AUX	O
private	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
probands	O	NOUN	B
of	O	ADP	O
European	O	ADJ	B
or	O	CCONJ	O
Middle	O	PROPN	B
Eastern	O	ADJ	I
descent	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
single	O	ADJ	B
-	O	PUNCT	O
nucleotide	O	NOUN	B
polymorphisms	O	NOUN	B
(	O	PUNCT	O
SNPs	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
FALDH	O	NOUN	B
gene	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
least	O	ADJ	O
four	O	NUM	O
of	O	ADP	O
the	O	DET	O
common	O	ADJ	O
mutations	O	NOUN	B
(	O	PUNCT	O
551C	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
,	O	PUNCT	O
682C	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
,	O	PUNCT	O
733G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
798	O	NUM	O
+	O	CCONJ	O
1delG	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
multiple	O	ADJ	B
SNP	O	NOUN	B
haplotypes	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
mutations	O	NOUN	B
originated	O	VERB	O
independently	O	ADV	O
on	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
one	O	NUM	O
occasion	O	NOUN	B
or	O	CCONJ	O
were	O	AUX	O
ancient	O	ADJ	O
SLS	B-Disease	NOUN	B
genes	O	NOUN	B
that	O	PRON	O
had	O	AUX	O
undergone	O	VERB	O
intragenic	O	ADJ	B
recombination	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
SLS	B-Disease	PROPN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
strikingly	O	ADV	O
heterogeneous	O	ADJ	B
group	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FALDH	O	NOUN	B
gene	O	NOUN	O
and	O	CCONJ	O
provide	O	VERB	O
a	O	DET	O
framework	O	NOUN	B
for	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
basis	O	NOUN	O
of	O	ADP	O
SLS	B-Disease	PROPN	B
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
diagnostic	O	ADJ	B
tests	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Loss	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
function	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
gene	O	NOUN	I
result	O	VERB	O
in	O	ADP	O
periodontal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
palmoplantar	B-Disease	NOUN	B
keratosis	I-Disease	NOUN	I
.	O	PUNCT	O


Papillon	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lefevre	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
keratosis	B-Disease	NOUN	B
palmoplantaris	I-Disease	NOUN	I
with	O	ADP	I
periodontopathia	B-Disease	NOUN	B
(	O	PUNCT	O
PLS	B-Disease	PROPN	B
,	O	PUNCT	O
MIM	O	NOUN	B
245000	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
that	O	PRON	O
is	O	AUX	O
mainly	O	ADV	O
ascertained	O	VERB	O
by	O	ADP	O
dentists	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
periodontitis	B-Disease	NOUN	I
that	O	PRON	O
afflicts	O	VERB	O
patients	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
deciduous	O	ADJ	B
and	O	CCONJ	O
permanent	O	ADJ	B
dentitions	O	NOUN	O
are	O	AUX	O
affected	O	VERB	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
premature	O	ADJ	B
tooth	B-Disease	NOUN	I
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Palmoplantar	B-Disease	NOUN	B
keratosis	I-Disease	NOUN	I
,	O	PUNCT	O
varying	O	VERB	O
from	O	ADP	O
mild	O	ADJ	B
psoriasiform	O	NOUN	B
scaly	O	NOUN	I
skin	O	NOUN	I
to	O	ADP	O
overt	O	ADJ	B
hyperkeratosis	B-Disease	NOUN	B
,	O	PUNCT	O
typically	O	ADV	O
develops	O	VERB	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
three	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
life	O	NOUN	O
.	O	PUNCT	O


Keratosis	B-Disease	NOUN	B
also	O	ADV	O
affects	O	VERB	O
other	O	ADJ	O
sites	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
elbows	O	NOUN	B
and	O	CCONJ	O
knees	O	NOUN	B
.	O	PUNCT	O


Most	O	ADJ	O
PLS	B-Disease	NOUN	B
patients	O	NOUN	B
display	O	VERB	B
both	O	CCONJ	O
periodontitis	B-Disease	NOUN	B
and	O	CCONJ	O
hyperkeratosis	B-Disease	NOUN	B
.	O	PUNCT	O


Some	O	DET	O
patients	O	NOUN	B
have	O	AUX	O
only	O	ADV	O
palmoplantar	B-Disease	NOUN	B
keratosis	I-Disease	NOUN	I
or	O	CCONJ	O
periodontitis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
rare	O	ADJ	B
individuals	O	NOUN	B
the	O	DET	O
periodontitis	B-Disease	NOUN	B
is	O	AUX	O
mild	O	ADJ	B
and	O	CCONJ	O
of	O	ADP	O
late	O	ADJ	O
onset	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
PLS	O	PROPN	B
locus	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
11q14	O	NOUN	I
-	O	PUNCT	O
q21	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
7	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
homozygosity	O	NOUN	B
mapping	O	NOUN	I
in	O	ADP	O
eight	O	NUM	O
small	O	ADJ	O
consanguineous	O	ADJ	B
families	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
narrowed	O	VERB	O
the	O	DET	O
candidate	O	NOUN	B
region	O	NOUN	I
to	O	PART	O
a	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
interval	O	NOUN	B
between	O	ADP	O
D11S4082	O	NOUN	B
and	O	CCONJ	O
D11S931	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
CTSC	O	NOUN	B
)	O	PUNCT	O
encoding	O	VERB	B
the	O	DET	O
lysosomal	O	ADJ	B
protease	O	NOUN	I
cathepsin	O	NOUN	O
C	O	NOUN	O
(	O	PUNCT	O
or	O	CCONJ	O
dipeptidyl	O	ADJ	B
aminopeptidase	O	NOUN	I
I	O	NUM	I
)	O	PUNCT	O
lies	O	VERB	O
within	O	ADP	O
this	O	DET	O
interval	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
defined	O	VERB	O
the	O	DET	O
genomic	O	ADJ	B
structure	O	NOUN	I
of	O	ADP	O
CTSC	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
all	O	DET	O
eight	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
we	O	PRON	O
used	O	VERB	O
a	O	DET	O
functional	O	ADJ	B
assay	O	NOUN	I
to	O	PART	O
demonstrate	O	VERB	O
an	O	DET	O
almost	O	ADV	O
total	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
activity	O	NOUN	B
in	O	ADP	O
PLS	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
reduced	O	VERB	B
activity	O	NOUN	B
in	O	ADP	O
obligate	O	ADJ	B
carriers	O	NOUN	B
.	O	PUNCT	O


Confirmation	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
of	O	ADP	O
Van	B-Disease	PROPN	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
to	O	PART	O
chromosome	O	NOUN	O
1q32	O	NOUN	O
:	O	PUNCT	O
evidence	O	NOUN	B
of	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
STR	O	NOUN	B
alleles	O	NOUN	B
suggests	O	VERB	O
possible	O	ADJ	O
unique	O	ADJ	B
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


Van	B-Disease	NOUN	O
der	I-Disease	NOUN	O
Woude	I-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
(	O	PUNCT	O
VWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	B
craniofacial	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
with	O	ADP	O
high	O	ADJ	O
penetrance	O	NOUN	B
and	O	CCONJ	O
variable	O	ADJ	B
expression	O	NOUN	B
.	O	PUNCT	O


Its	O	PRON	O
clinical	O	ADJ	B
features	O	NOUN	I
are	O	AUX	O
variably	O	ADV	O
expressed	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
include	O	VERB	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
,	O	PUNCT	O
lip	B-Disease	NOUN	B
pits	I-Disease	NOUN	I
and	O	CCONJ	O
hypodontia	B-Disease	NOUN	B
.	O	PUNCT	O


All	O	DET	O
VWS	B-Disease	NOUN	B
families	O	NOUN	B
studied	O	VERB	O
to	O	PART	O
date	O	NOUN	B
map	O	NOUN	I
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
a	O	DET	O
<	O	NOUN	O
2	O	NUM	O
cM	O	NOUN	O
region	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	B
1q32	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
locus	O	NOUN	B
heterogeneity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
refine	O	VERB	O
the	O	DET	O
localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
further	O	ADV	O
assess	O	VERB	O
possible	O	ADJ	O
heterogeneity	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
four	O	NUM	O
multiplex	O	ADJ	B
VWS	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
available	O	ADJ	O
members	O	NOUN	B
were	O	AUX	O
clinically	O	ADV	B
assessed	O	VERB	B
and	O	CCONJ	O
genotyped	O	VERB	B
for	O	ADP	O
19	O	NUM	O
short	O	ADJ	B
tandem	O	ADJ	I
repeat	O	NOUN	I
markers	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
1	O	NUM	I
in	O	ADP	O
the	O	DET	O
VWS	B-Disease	NOUN	B
candidate	O	NOUN	O
gene	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
and	O	CCONJ	O
multipoint	O	ADJ	B
limit	O	NOUN	I
of	O	ADP	I
detection	O	NOUN	I
(	O	PUNCT	O
LOD	O	NOUN	B
)	O	PUNCT	O
score	O	NOUN	O
analyses	O	NOUN	B
using	O	VERB	O
a	O	DET	O
high	O	ADJ	O
penetrance	O	NOUN	B
autosomal	O	ADJ	B
dominant	O	ADJ	I
model	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
families	O	NOUN	B
showed	O	VERB	O
positive	O	ADJ	B
LOD	O	NOUN	B
scores	O	NOUN	O
without	O	ADP	O
any	O	DET	O
recombination	O	NOUN	B
in	O	ADP	O
the	O	DET	O
candidate	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
largest	O	ADJ	O
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
LOD	O	NOUN	B
score	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
.	O	PUNCT	O


87	O	NUM	O
87	O	NUM	O
.	O	PUNCT	O


Our	O	PRON	O
assay	O	NOUN	B
method	O	NOUN	O
for	O	ADP	O
short	O	ADJ	B
tandem	O	ADJ	I
repeat	O	NOUN	I
(	O	PUNCT	I
STR	O	NOUN	B
)	O	PUNCT	O
markers	O	NOUN	B
provided	O	VERB	O
highly	O	ADV	O
accurate	O	ADJ	B
size	O	NOUN	B
estimation	O	NOUN	B
of	O	ADP	O
marker	O	NOUN	B
allele	O	NOUN	O
fragment	O	NOUN	O
sizes	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
therefore	O	ADV	O
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
specific	O	ADJ	O
alleles	O	NOUN	B
segregating	O	VERB	B
with	O	ADP	O
the	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
our	O	PRON	O
four	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
a	O	DET	O
striking	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
STR	O	NOUN	B
allele	O	NOUN	B
sharing	O	NOUN	B
at	O	ADP	O
several	O	ADJ	O
closely	O	ADV	O
linked	O	VERB	O
loci	O	NOUN	B
among	O	ADP	O
our	O	PRON	O
four	O	NUM	O
Caucasian	O	ADJ	B
VWS	B-Disease	NOUN	B
families	O	NOUN	B
recruited	O	VERB	O
at	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
locations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
US	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
unique	O	ADJ	B
origin	O	NOUN	B
for	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
many	O	ADJ	O
or	O	CCONJ	O
most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
VWS	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
point	O	NOUN	B
mutation	O	NOUN	I
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
Met	O	NOUN	B
on	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
integrin	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
human	O	ADJ	B
platelet	O	NOUN	O
alloantigen	O	NOUN	O
Sit	O	PROPN	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
and	O	CCONJ	O
affects	O	VERB	O
collagen	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
aggregation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
platelet	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
alloantigen	O	NOUN	B
,	O	PUNCT	O
termed	O	VERB	O
Sit	O	PROPN	B
(	O	PUNCT	I
a	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
a	O	DET	O
severe	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
neonatal	B-Disease	ADJ	B
alloimmune	I-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Sit	O	PROPN	B
(	O	PUNCT	O
a	O	DET	O
)	O	PUNCT	O
alloantigen	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
low	O	ADJ	B
frequency	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
400	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
German	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Immunochemical	O	ADJ	B
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Sit	O	PROPN	B
(	O	PUNCT	I
a	O	DET	O
)	O	PUNCT	O
epitopes	O	NOUN	B
reside	O	VERB	O
on	O	ADP	O
platelet	O	NOUN	B
glycoprotein	O	NOUN	I
(	O	PUNCT	O
GP	O	NOUN	B
)	O	PUNCT	O
Ia	O	NOUN	O
.	O	PUNCT	O


Nucleotide	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
GPIa	O	NOUN	B
cDNA	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
Sit	O	PROPN	B
(	O	PUNCT	I
a	O	X	O
)	O	PUNCT	O
-	O	PUNCT	O
positive	O	ADJ	B
platelets	O	NOUN	B
showed	O	VERB	O
C	O	NOUN	B
(	O	PUNCT	O
2531	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
(	O	PUNCT	O
2531	O	NUM	O
)	O	PUNCT	O
point	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
Met	O	NOUN	B
dimorphism	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
22	O	NUM	O
Sit	O	PROPN	B
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
-	O	PUNCT	O
negative	O	ADJ	B
normal	O	ADJ	B
individuals	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
encoded	O	VERB	B
by	O	ADP	O
ACG	O	NOUN	B
(	O	PUNCT	O
2532	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
90	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
ACA	O	NOUN	B
(	O	PUNCT	O
2532	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
establish	O	VERB	O
a	O	DET	O
DNA	O	NOUN	B
typing	O	NOUN	I
technique	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
elucidated	O	VERB	O
the	O	DET	O
organization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GPIa	O	NOUN	B
gene	O	NOUN	B
adjacent	O	ADJ	B
to	O	PART	O
the	O	DET	O
polymorphic	O	ADJ	B
bases	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
introns	O	NOUN	B
(	O	PUNCT	O
421	O	NUM	O
bp	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
kb	O	NOUN	O
)	O	PUNCT	O
encompass	O	VERB	O
a	O	DET	O
142	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
exon	O	NOUN	B
with	O	ADP	O
the	O	DET	O
2	O	NUM	O
polymorphic	O	ADJ	B
bases	O	NOUN	B
2531	O	NUM	O
and	O	CCONJ	O
2532	O	NUM	O
.	O	PUNCT	O


Polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
restriction	O	NOUN	B
fragment	O	NOUN	O
length	O	NOUN	O
polymorphism	O	NOUN	O
analysis	O	NOUN	O
on	O	ADP	O
DNA	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
100	O	NUM	O
donors	O	NOUN	B
using	O	VERB	O
the	O	DET	O
restriction	O	NOUN	B
enzyme	O	NOUN	I
Mae	O	PROPN	I
III	O	NUM	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Met	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
form	O	NOUN	O
of	O	ADP	O
GPIa	O	NOUN	B
is	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
Sit	O	VERB	B
(	O	PUNCT	I
a	O	X	O
)	O	PUNCT	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
phenotype	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
stable	O	ADJ	B
Chinese	O	ADJ	I
hamster	O	NOUN	I
ovary	O	NOUN	I
transfectants	O	NOUN	B
expressing	O	VERB	B
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
recombinant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
GPIa	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
anti	O	ADJ	B
-	O	PUNCT	O
Sit	O	PROPN	B
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
exclusively	O	ADV	O
reacted	O	VERB	O
with	O	ADP	O
the	O	DET	O
Glu	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Met	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
the	O	DET	O
Glu	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Lys	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
isoforms	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
Br	O	PROPN	B
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
(	O	PUNCT	O
HPA	O	ADJ	B
-	O	PUNCT	O
5b	O	NOUN	B
)	O	PUNCT	O
only	O	ADV	O
recognized	O	VERB	O
the	O	DET	O
Lys	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
form	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
anti	O	X	B
-	O	PUNCT	O
Br	O	PROPN	B
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
(	O	PUNCT	O
HPA	O	ADJ	B
-	O	PUNCT	O
5a	O	NOUN	B
)	O	PUNCT	O
reacted	O	VERB	O
with	O	ADP	O
both	O	CCONJ	O
Glu	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
Glu	O	NOUN	B
(	O	PUNCT	O
505	O	NUM	O
)	O	PUNCT	O
Met	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
isoforms	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Met	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
formation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Sit	O	PROPN	B
(	O	PUNCT	I
a	O	DET	O
)	O	PUNCT	O
alloantigenic	O	ADJ	B
determinants	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
amino	O	NOUN	B
acid	O	NOUN	I
505	O	NUM	I
(	O	PUNCT	O
Lys	O	NOUN	B
or	O	CCONJ	O
Glu	O	NOUN	B
)	O	PUNCT	O
specifically	O	ADV	O
controls	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
Br	O	PROPN	B
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
and	O	CCONJ	O
Br	O	PROPN	B
(	O	PUNCT	I
b	O	X	I
)	O	PUNCT	I
epitopes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Platelet	O	NOUN	B
aggregation	O	NOUN	I
responses	O	NOUN	B
of	O	ADP	O
Sit	O	PROPN	B
(	O	PUNCT	I
a	O	X	O
)	O	PUNCT	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
individuals	O	NOUN	B
were	O	AUX	O
diminished	O	VERB	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
collagen	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Thr	O	NOUN	B
(	O	PUNCT	O
799	O	NUM	O
)	O	PUNCT	O
Met	O	NOUN	B
mutation	O	NOUN	B
affects	O	VERB	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GPIa	O	NOUN	B
/	O	SYM	O
IIa	O	NOUN	B
complex	O	NOUN	B


Mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
gene	O	NOUN	I
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
Papillon	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lefevre	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Papillon	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lefevre	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PLS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
characterised	O	VERB	O
by	O	ADP	O
palmoplantar	B-Disease	NOUN	B
hyperkeratosis	I-Disease	NOUN	I
and	O	CCONJ	O
severe	O	ADJ	B
early	O	ADJ	O
onset	O	NOUN	O
periodontitis	B-Disease	NOUN	O
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
premature	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
and	O	CCONJ	O
secondary	O	ADJ	B
dentitions	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
major	O	ADJ	O
gene	O	NOUN	B
locus	O	NOUN	I
for	O	ADP	O
PLS	B-Disease	PROPN	B
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
a	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
cM	O	NOUN	B
interval	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
11q14	O	NOUN	I
.	O	PUNCT	O


Correlation	O	NOUN	B
of	O	ADP	O
physical	O	ADJ	B
and	O	CCONJ	O
genetic	O	ADJ	B
maps	O	NOUN	I
of	O	ADP	O
this	O	DET	O
interval	O	NOUN	B
indicate	O	VERB	O
it	O	PRON	O
includes	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
40	O	NUM	O
ESTs	O	NOUN	B
and	O	CCONJ	O
six	O	NUM	O
known	O	ADJ	O
genes	O	NOUN	B
including	O	VERB	O
the	O	DET	O
lysosomal	O	ADJ	B
protease	O	NOUN	I
cathepsin	O	NOUN	O
C	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
CTSC	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
CTSC	O	NOUN	B
message	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
at	O	ADP	O
high	O	ADJ	O
levels	O	NOUN	B
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
immune	O	ADJ	B
cells	O	NOUN	I
including	O	VERB	O
polymorphonuclear	O	ADJ	B
leucocytes	O	NOUN	B
,	O	PUNCT	O
macrophages	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
precursors	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
CTSC	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
epithelial	O	ADJ	B
regions	O	NOUN	I
commonly	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
PLS	B-Disease	PROPN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
palms	O	NOUN	B
,	O	PUNCT	O
soles	O	NOUN	B
,	O	PUNCT	O
knees	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
oral	O	ADJ	B
keratinised	O	ADJ	I
gingiva	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
4	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
kb	O	NOUN	O
CTSC	O	NOUN	B
gene	O	NOUN	O
consists	O	VERB	O
of	O	ADP	O
two	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
CTSC	O	NOUN	B
from	O	ADP	O
subjects	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
PLS	B-Disease	PROPN	B
from	O	ADP	O
five	O	NUM	O
consanguineous	O	ADJ	B
Turkish	O	ADJ	B
families	O	NOUN	B
identified	O	VERB	B
four	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
exon	O	NOUN	B
1	O	NUM	I
nonsense	O	NOUN	O
mutation	O	NOUN	O
(	O	PUNCT	O
856C	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
introduces	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
286	O	NUM	O
.	O	PUNCT	O


Three	O	NUM	O
exon	O	NOUN	B
2	O	NUM	I
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
single	O	ADJ	B
nucleotide	O	NOUN	I
deletion	O	NOUN	I
(	O	PUNCT	O
2692delA	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
codon	O	NOUN	B
349	O	NUM	I
introducing	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
and	O	CCONJ	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
2	O	NUM	O
bp	O	NOUN	O
deletion	O	NOUN	B
(	O	PUNCT	O
2673	O	NUM	O
-	O	PUNCT	O
2674delCT	O	NUM	O
)	O	PUNCT	O
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
introduction	O	NOUN	B
of	O	ADP	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
343	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
substitution	O	NOUN	B
in	O	ADP	O
codon	O	NOUN	B
429	O	NUM	I
(	O	PUNCT	O
2931G	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
)	O	PUNCT	O
introducing	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
PLS	B-Disease	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
mutations	O	NOUN	O
inherited	O	VERB	B
from	O	ADP	O
a	O	DET	O
common	O	ADJ	O
ancestor	O	NOUN	B
.	O	PUNCT	O


Parents	O	NOUN	B
and	O	CCONJ	O
sibs	O	NOUN	B
heterozygous	O	ADJ	B
for	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
mutations	O	NOUN	B
do	O	AUX	O
not	O	PART	O
show	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
palmoplantar	B-Disease	NOUN	B
hyperkeratosis	I-Disease	NOUN	I
or	O	CCONJ	O
severe	O	ADJ	B
early	O	ADJ	O
onset	O	NOUN	O
periodontitis	B-Disease	NOUN	B
characteristic	O	NOUN	O
of	O	ADP	O
PLS	B-Disease	PROPN	B
.	O	PUNCT	O


A	O	DET	O
more	O	ADV	O
complete	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
physiology	O	NOUN	B
of	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
carries	O	VERB	O
significant	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
understanding	O	VERB	O
normal	O	ADJ	B
and	O	CCONJ	O
abnormal	O	ADJ	B
skin	O	NOUN	O
development	O	NOUN	O
and	O	CCONJ	O
periodontal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
susceptibility	O	NOUN	B


Mutational	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
HGO	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Finnish	O	ADJ	B
alkaptonuria	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
AKU	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
prototypic	O	ADJ	B
inborn	B-Disease	ADJ	O
error	I-Disease	NOUN	O
of	I-Disease	ADP	O
metabolism	I-Disease	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
function	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
homogentisate	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
dioxygenase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
HGO	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


So	O	ADV	O
far	O	ADV	O
17	O	NUM	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
characterised	O	VERB	B
in	O	ADP	O
AKU	B-Disease	NOUN	B
patients	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
ethnic	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
three	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
(	O	PUNCT	O
R58fs	O	NOUN	B
,	O	PUNCT	O
R330S	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
H371R	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
common	O	ADJ	O
AKU	B-Disease	NOUN	B
mutation	O	NOUN	B
(	O	PUNCT	O
M368V	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
detected	O	VERB	B
by	O	ADP	O
mutational	O	ADJ	B
and	O	CCONJ	O
polymorphism	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HGO	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
Finnish	O	ADJ	B
AKU	B-Disease	NOUN	B
pedigrees	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
novel	O	ADJ	O
AKU	B-Disease	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
most	O	ADV	O
likely	O	ADV	O
specific	O	ADJ	O
for	O	ADP	O
the	O	DET	O
Finnish	O	ADJ	B
population	O	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
originated	O	VERB	O
recently	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
identical	O	ADJ	B
5	O	NUM	O
'	O	PART	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
acceptor	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
attenuated	B-Disease	VERB	B
APC	I-Disease	NOUN	B
families	O	NOUN	B
from	O	ADP	O
Newfoundland	O	PROPN	B
demonstrates	O	VERB	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Inherited	O	VERB	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
predispose	O	VERB	O
carriers	O	NOUN	B
to	O	PART	O
multiple	O	ADJ	O
adenomatous	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
colon	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
rectum	I-Disease	NOUN	B
and	O	CCONJ	O
to	O	PART	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
located	O	ADJ	O
at	O	ADP	O
the	O	DET	O
extreme	O	ADJ	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
less	O	ADV	O
severe	O	ADJ	B
disease	O	NOUN	B
known	O	VERB	O
as	O	ADP	O
attenuated	B-Disease	VERB	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
AAPC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Many	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
AAPC	B-Disease	NOUN	B
develop	O	VERB	O
relatively	O	ADV	O
few	O	ADJ	O
colorectal	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
but	O	CCONJ	O
are	O	AUX	O
still	O	ADV	O
at	O	ADP	O
high	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
5	O	NUM	O
APC	B-Disease	NOUN	B
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
separately	O	ADV	O
ascertained	O	VERB	O
AAPC	B-Disease	NOUN	B
families	O	NOUN	B
from	O	ADP	O
Newfoundland	O	PROPN	B
,	O	PUNCT	O
Canada	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
single	O	ADJ	O
basepair	O	NOUN	O
change	O	NOUN	O
(	O	PUNCT	O
G	O	NOUN	B
to	O	PART	O
A	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
acceptor	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
APC	B-Disease	NOUN	B
intron	O	NOUN	O
3	O	NUM	O
that	O	PRON	O
creates	O	VERB	O
a	O	DET	O
mutant	O	ADJ	B
RNA	O	NOUN	I
without	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
of	O	ADP	O
APC	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
observation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
APC	B-Disease	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
five	O	NUM	O
families	O	NOUN	B
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
geographic	O	ADJ	B
area	O	NOUN	I
demonstrates	O	VERB	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
this	O	DET	O
germline	O	NOUN	B
mutation	O	NOUN	I
strengthens	O	VERB	O
the	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
5	O	NUM	O
location	O	NOUN	B
of	O	ADP	O
an	O	DET	O
APC	B-Disease	NOUN	B
disease	O	NOUN	I
-	O	PUNCT	O
causing	O	VERB	B
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
attenuated	B-Disease	VERB	B
polyposis	I-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Alstrom	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
2p13	O	NOUN	I
.	O	PUNCT	O


Alstrom	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
,	O	PUNCT	O
sensorineural	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
,	O	PUNCT	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
obesity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
insulin	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
dependent	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
Alstrom	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALMS1	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
localized	O	VERB	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
2p13	O	NOUN	I
by	O	ADP	O
homozygosity	O	NOUN	B
mapping	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
distinct	O	ADJ	O
isolated	O	VERB	B
populations	O	NOUN	B
-	O	PUNCT	O
French	O	PROPN	B
Acadian	O	PROPN	B
and	O	CCONJ	O
North	O	ADJ	B
African	O	ADJ	I
.	O	PUNCT	O


Pair	O	NOUN	B
-	O	PUNCT	O
wise	O	ADJ	O
analyses	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
maximum	O	ADJ	O
lod	O	NOUN	O
(	O	PUNCT	O
logarithm	O	NOUN	B
of	O	ADP	O
the	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
)	O	PUNCT	O
scores	O	NOUN	O
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


84	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


To	O	PART	O
confirm	O	VERB	O
these	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
large	O	ADJ	O
linkage	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
twelve	O	NUM	O
additional	O	ADJ	O
families	O	NOUN	B
segregating	O	VERB	B
for	O	ADP	O
Alstrom	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
maximum	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
lod	O	NOUN	I
score	O	NOUN	I
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
(	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
marker	O	NOUN	B
D2S2110	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
maximum	O	ADJ	O
cumulative	O	ADJ	O
multipoint	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


16	O	NUM	O
for	O	ADP	O
marker	O	NOUN	B
D2S2110	O	NOUN	O
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
further	O	ADV	O
supporting	O	VERB	O
linkage	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
2p13	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


Meiotic	O	ADJ	B
recombination	O	NOUN	I
events	O	NOUN	I
have	O	AUX	O
localized	O	VERB	B
the	O	DET	O
critical	O	ADJ	B
region	O	NOUN	I
containing	O	VERB	O
ALMS1	O	NOUN	B
to	O	ADP	O
a	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
interval	O	NOUN	B
flanked	O	VERB	I
by	O	ADP	O
markers	O	NOUN	B
D2S327	O	NOUN	B
and	O	CCONJ	O
D2S286	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
fine	O	ADJ	O
resolution	O	NOUN	O
radiation	O	NOUN	O
hybrid	O	NOUN	O
map	O	NOUN	O
of	O	ADP	O
31	O	NUM	O
genes	O	NOUN	B
and	O	CCONJ	O
markers	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
constructed	O	VERB	O
.	O	PUNCT	O


Pendred	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
phenotypic	O	ADJ	B
variability	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
same	O	ADJ	O
PDS	B-Disease	PROPN	B
missense	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
comprises	O	VERB	O
congenital	B-Disease	ADJ	B
sensorineural	I-Disease	ADJ	I
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
,	O	PUNCT	O
thyroid	B-Disease	NOUN	B
goiter	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
positive	O	ADJ	B
perchlorate	O	NOUN	B
discharge	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
an	O	DET	O
anion	O	NOUN	B
transporter	O	NOUN	I
called	O	VERB	O
pendrin	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	PROPN	B
gene	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
two	O	NUM	O
consanguineous	O	ADJ	B
large	O	ADJ	O
families	O	NOUN	B
from	O	ADP	O
Southern	O	PROPN	B
Tunisia	O	PROPN	I
comprising	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
23	O	NUM	O
individuals	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
profound	O	ADJ	O
congenital	B-Disease	ADJ	B
deafness	I-Disease	NOUN	I
;	O	PUNCT	O
the	O	DET	O
same	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
L445W	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
all	O	DET	O
affected	O	VERB	B
individuals	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
widened	B-Disease	ADJ	B
vestibular	I-Disease	ADJ	I
aqueduct	I-Disease	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
computed	O	ADJ	B
tomography	O	NOUN	I
(	O	PUNCT	O
CT	O	NOUN	B
)	O	PUNCT	O
scan	O	ADJ	B
exploration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
ear	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
goiter	B-Disease	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
only	O	ADV	O
11	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
interestingly	O	ADV	O
had	O	AUX	O
a	O	DET	O
normal	O	ADJ	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
perchlorate	O	NOUN	B
discharge	O	NOUN	I
test	O	NOUN	I
whenever	O	SCONJ	O
performed	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
question	O	VERB	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
perchlorate	O	NOUN	B
test	O	NOUN	I
for	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
assessment	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
to	O	ADP	O
profound	O	ADJ	O
congenital	B-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
inner	B-Disease	ADJ	B
ear	I-Disease	NOUN	I
morphological	I-Disease	ADJ	B
anomaly	I-Disease	NOUN	O
even	O	ADV	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
thyroid	B-Disease	NOUN	B
goiter	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Knobloch	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
involving	O	VERB	O
midline	B-Disease	NOUN	B
scalp	I-Disease	NOUN	O
defect	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
frontal	I-Disease	ADJ	B
region	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
4	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
Knobloch	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
has	O	AUX	O
vitreoretinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
,	O	PUNCT	O
high	B-Disease	ADJ	B
myopia	I-Disease	NOUN	I
,	O	PUNCT	O
cataract	B-Disease	NOUN	B
,	O	PUNCT	O
telecanthus	B-Disease	ADJ	B
,	O	PUNCT	O
hypertelorism	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
high	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
arched	I-Disease	ADJ	B
palate	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
also	O	ADV	O
has	O	AUX	O
a	O	DET	O
defect	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
anterior	I-Disease	ADJ	B
midline	I-Disease	NOUN	B
scalp	I-Disease	NOUN	O
with	O	ADP	O
involvement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
frontal	O	ADJ	B
bone	O	NOUN	I
as	O	ADP	O
documented	O	VERB	B
by	O	ADP	O
a	O	DET	O
computed	O	VERB	B
tomography	O	NOUN	I
(	O	PUNCT	O
CT	O	NOUN	O
)	O	PUNCT	O
scan	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
brain	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
on	O	ADP	O
CT	O	NOUN	B
scan	O	NOUN	I
and	O	CCONJ	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
the	O	DET	O
23	O	NUM	O
published	O	VERB	B
cases	O	NOUN	B
with	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
patient	O	NOUN	B
illustrates	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
investigating	O	VERB	B
for	O	ADP	O
underlying	O	VERB	O
ocular	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
pathology	O	NOUN	B
whenever	O	SCONJ	O
midline	B-Disease	NOUN	B
scalp	I-Disease	NOUN	I
defects	I-Disease	NOUN	B
are	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
DNA	O	NOUN	B
double	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
break	O	NOUN	O
repair	O	NOUN	O
gene	O	NOUN	O
hMRE11	O	NOUN	B
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
an	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
like	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
hypomorphic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
hMRE11	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
ATM	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
certain	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
an	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
like	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
ATLD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
cellular	O	ADJ	B
features	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
these	O	DET	O
hMRE11	O	NOUN	B
mutations	O	NOUN	I
are	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
seen	O	VERB	O
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
NBS	B-Disease	NOUN	B
and	O	CCONJ	O
include	O	VERB	O
hypersensitivity	B-Disease	NOUN	B
to	I-Disease	PART	O
ionizing	I-Disease	VERB	B
radiation	I-Disease	NOUN	I
,	O	PUNCT	O
radioresistant	O	ADJ	B
DNA	O	NOUN	I
synthesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
abrogation	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
events	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
Jun	O	NOUN	B
kinase	O	NOUN	I
following	O	VERB	O
exposure	O	NOUN	B
to	O	PART	I
gamma	O	NOUN	B
irradiation	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
mutant	O	ADJ	B
hMre11	O	NOUN	B
proteins	O	NOUN	I
retain	O	VERB	O
some	O	DET	O
ability	O	NOUN	O
to	O	PART	O
interact	O	VERB	B
with	O	ADP	O
hRad50	O	ADJ	B
and	O	CCONJ	O
Nbs1	O	NOUN	B
,	O	PUNCT	O
formation	O	NOUN	B
of	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
hMre11	O	NOUN	B
and	O	CCONJ	O
Nbs1	O	NOUN	B
foci	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	O
in	O	ADP	O
hMRE11	O	NOUN	B
mutant	O	ADJ	I
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
ATM	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
hMre11	O	NOUN	B
/	O	PUNCT	O
hRad50	O	ADJ	B
/	O	PUNCT	O
Nbs1	O	NOUN	B
protein	O	NOUN	I
complex	O	NOUN	I
act	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
pathway	O	NOUN	I
and	O	CCONJ	O
link	O	VERB	O
hMre11	O	VERB	B
to	O	PART	O
the	O	DET	O
complex	O	ADJ	B
pathology	O	NOUN	B
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
TNFRSF11A	O	NOUN	B
,	O	PUNCT	O
affecting	O	VERB	B
the	O	DET	O
signal	O	NOUN	B
peptide	O	NOUN	I
of	O	ADP	O
RANK	O	NOUN	B
,	O	PUNCT	O
cause	O	VERB	O
familial	B-Disease	ADJ	B
expansile	I-Disease	ADJ	O
osteolysis	I-Disease	NOUN	O
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
expansile	I-Disease	ADJ	I
osteolysis	I-Disease	NOUN	I
(	O	PUNCT	O
FEO	B-Disease	PROPN	B
,	O	PUNCT	O
MIM	O	NOUN	B
174810	O	NUM	I
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
,	O	PUNCT	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
bone	I-Disease	NOUN	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
focal	O	ADJ	B
areas	O	NOUN	I
of	O	ADP	O
increased	B-Disease	VERB	B
bone	I-Disease	NOUN	B
remodelling	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
osteolytic	B-Disease	ADJ	B
lesions	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
develop	O	VERB	O
usually	O	ADV	O
in	O	ADP	O
the	O	DET	O
long	O	ADJ	B
bones	O	NOUN	I
during	O	ADP	O
early	O	ADJ	B
adulthood	O	NOUN	I
,	O	PUNCT	O
show	O	VERB	O
increased	O	VERB	B
osteoblast	O	NOUN	B
and	O	CCONJ	O
osteoclast	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
previous	O	ADJ	O
linkage	O	NOUN	B
studies	O	NOUN	I
mapped	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
FEO	B-Disease	PROPN	B
to	O	ADP	O
an	O	DET	O
interval	O	NOUN	B
of	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
cM	O	NOUN	O
between	O	ADP	O
D18S64	O	NOUN	B
and	O	CCONJ	O
D18S51	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	O
18q21	O	NOUN	O
.	O	PUNCT	O


2	O	NUM	O
-	O	SYM	O
21	O	NUM	O
2	O	NUM	O
-	O	SYM	O
21	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Northern	O	PROPN	B
Irish	O	ADJ	O
family	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
encoding	O	NOUN	O
receptor	O	NOUN	B
activator	O	NOUN	I
of	O	ADP	O
nuclear	O	ADJ	O
factor	O	NOUN	O
-	O	PUNCT	O
kappa	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
RANK	O	NOUN	B
;	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
5	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
TNFRSF11A	O	NOUN	B
,	O	PUNCT	O
maps	O	VERB	B
to	O	PART	O
this	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O


RANK	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	O
in	O	ADP	O
osteoclast	O	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
two	O	NUM	O
heterozygous	O	ADJ	B
insertion	O	NOUN	B
mutations	O	NOUN	O
in	O	ADP	O
exon	O	NOUN	B
1	O	NUM	I
of	O	ADP	O
TNFRSF11A	O	NOUN	B
in	O	ADP	O
affected	O	VERB	O
members	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
FEO	B-Disease	NOUN	B
or	O	CCONJ	O
familial	B-Disease	ADJ	B
Paget	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
of	I-Disease	ADP	O
bone	I-Disease	NOUN	B
(	O	PUNCT	O
PDB	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


One	O	NUM	O
was	O	AUX	O
a	O	DET	O
duplication	O	NOUN	B
of	O	ADP	O
18	O	NUM	O
bases	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
a	O	DET	O
duplication	O	NOUN	B
of	O	ADP	O
27	O	NUM	O
bases	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
affected	O	VERB	B
the	O	DET	O
signal	O	NOUN	B
peptide	O	NOUN	I
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
RANK	O	NOUN	B
molecule	O	NOUN	O
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
forms	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
RANK	O	NOUN	B
proteins	O	NOUN	I
revealed	O	VERB	B
perturbations	O	NOUN	B
in	O	ADP	O
expression	O	NOUN	B
levels	O	NOUN	I
and	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	O
cleavage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
signal	O	NOUN	B
peptide	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
caused	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
RANK	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
nuclear	O	ADJ	B
factor	O	NOUN	I
-	O	PUNCT	O
kappaB	O	NOUN	B
(	O	PUNCT	O
NF	O	NOUN	B
-	O	PUNCT	O
kappaB	O	NOUN	B
)	O	PUNCT	O
signalling	O	NOUN	B
in	O	X	B
vitro	O	X	I
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
activating	O	VERB	B
mutation	O	NOUN	B
.	O	PUNCT	O


Cardiac	O	PROPN	B
Na	O	PROPN	I
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
channel	O	NOUN	O
dysfunction	O	NOUN	O
in	O	ADP	O
Brugada	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
aggravated	O	VERB	B
by	O	ADP	O
beta	O	NOUN	B
(	O	PUNCT	I
1	O	NUM	I
)	O	PUNCT	I
-	O	PUNCT	O
subunit	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
human	O	ADJ	B
cardiac	O	ADJ	O
Na	O	PROPN	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
channel	O	NOUN	O
alpha	O	NOUN	O
-	O	PUNCT	O
subunit	O	NOUN	B
(	O	PUNCT	O
hH1	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
chromosome	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
linked	O	VERB	B
congenital	B-Disease	ADJ	B
long	I-Disease	ADV	B
-	I-Disease	PUNCT	O
QT	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
LQT3	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
idiopathic	B-Disease	ADJ	B
ventricular	I-Disease	ADJ	I
fibrillation	I-Disease	NOUN	I
(	O	PUNCT	O
IVF	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
auxiliary	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
subunit	O	NOUN	B
,	O	PUNCT	O
widely	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
excitable	O	ADJ	B
tissues	O	NOUN	I
,	O	PUNCT	O
shifts	O	VERB	B
the	O	DET	O
voltage	O	NOUN	B
dependence	O	NOUN	O
of	O	ADP	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
inactivation	O	NOUN	B
toward	O	ADP	O
more	O	ADV	O
negative	O	ADJ	B
potentials	O	NOUN	B
and	O	CCONJ	O
restores	O	VERB	B
normal	O	ADJ	O
gating	O	NOUN	O
kinetics	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
channels	O	NOUN	O
expressed	O	VERB	B
in	O	ADP	O
Xenopus	O	NOUN	B
oocytes	O	NOUN	B
but	O	CCONJ	O
has	O	AUX	O
little	O	ADJ	O
if	O	SCONJ	O
any	O	DET	O
functional	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
cardiac	O	ADJ	B
isoform	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
characterize	O	VERB	O
the	O	DET	O
altered	O	ADJ	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
human	O	ADJ	B
beta	O	NOUN	I
(	O	PUNCT	I
1	O	NUM	I
)	O	PUNCT	O
-	O	PUNCT	O
subunit	O	NOUN	B
(	O	PUNCT	O
hbeta	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
heterologously	O	ADV	B
expressed	O	VERB	B
hH1	O	NOUN	B
mutation	O	NOUN	B
(	O	PUNCT	O
T1620M	O	NOUN	B
)	O	PUNCT	O
previously	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
IVF	B-Disease	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	NOUN	O
When	O	SCONJ	O
expressed	O	VERB	B
alone	O	ADV	O
in	O	ADP	O
Xenopus	O	NOUN	B
oocytes	O	NOUN	B
,	O	PUNCT	O
T1620M	O	NOUN	B
exhibited	O	VERB	O
no	O	DET	O
persistent	O	ADJ	B
currents	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
the	O	DET	O
LQT3	B-Disease	NOUN	B
mutant	O	ADJ	O
channels	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
midpoint	O	NOUN	O
of	O	ADP	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
inactivation	O	NOUN	B
(	O	PUNCT	O
V	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
)	O	PUNCT	O
)	O	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
shifted	O	VERB	O
toward	O	ADP	O
more	O	ADV	O
positive	O	ADJ	B
potentials	O	NOUN	B
than	O	ADP	O
for	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
hH1	O	NUM	B
.	O	PUNCT	O


Coexpression	O	NOUN	B
of	O	ADP	O
hbeta	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
alter	O	VERB	O
current	O	ADJ	O
decay	O	NOUN	B
or	O	CCONJ	O
recovery	O	NOUN	B
from	O	ADP	O
inactivation	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
hH1	O	NUM	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
further	O	ADV	O
shifted	O	VERB	O
the	O	DET	O
V	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
)	O	PUNCT	O
and	O	CCONJ	O
accelerated	O	VERB	B
the	O	DET	O
recovery	O	NOUN	B
from	O	ADP	O
inactivation	O	NOUN	B
of	O	ADP	O
T1620M	O	NOUN	B
.	O	PUNCT	O


Oocyte	O	NOUN	B
macropatch	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
activation	O	NOUN	B
kinetics	O	NOUN	B
of	O	ADP	O
T1620M	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
coexpression	O	NOUN	B
of	O	ADP	O
hbeta	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
exposes	O	VERB	O
a	O	DET	O
more	O	ADV	O
severe	O	ADJ	B
functional	O	ADJ	B
defect	O	NOUN	I
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
greater	O	ADJ	O
overlap	O	NOUN	B
in	O	ADP	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
channel	O	NOUN	B
inactivation	O	NOUN	B
and	O	CCONJ	O
activation	O	NOUN	B
(	O	PUNCT	O
window	O	NOUN	B
current	O	ADJ	I
)	O	PUNCT	O
in	O	ADP	O
T1620M	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
proposed	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
potential	O	ADJ	B
pathophysiological	O	ADJ	B
mechanism	O	NOUN	B
of	O	ADP	O
IVF	B-Disease	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


One	O	NUM	O
possible	O	ADJ	O
explanation	O	NOUN	O
for	O	ADP	O
our	O	PRON	O
finding	O	NOUN	B
is	O	AUX	O
an	O	DET	O
altered	O	ADJ	O
alpha	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	O
beta	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
subunit	O	NOUN	B
association	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutant	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Meiotic	O	ADJ	B
segregation	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
RB1	O	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
pedigrees	O	NOUN	B
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
sperm	O	NOUN	B
typing	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
hereditary	B-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
,	O	PUNCT	O
different	O	ADJ	O
epidemiological	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
indicated	O	VERB	O
a	O	DET	O
preferential	O	ADJ	O
paternal	O	ADJ	B
transmission	O	NOUN	I
of	O	ADP	O
mutant	O	ADJ	B
retinoblastoma	B-Disease	NOUN	I
alleles	O	NOUN	I
to	O	ADP	O
offspring	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
meiotic	O	ADJ	B
drive	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
this	O	DET	O
mechanism	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
sperm	O	NOUN	B
samples	O	NOUN	B
from	O	ADP	O
six	O	NUM	O
individuals	O	NOUN	B
from	O	ADP	O
five	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


Single	O	ADJ	B
-	O	PUNCT	O
sperm	O	NOUN	B
typing	O	NOUN	O
techniques	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
each	O	DET	O
sample	O	NOUN	B
by	O	ADP	O
study	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
informative	O	ADJ	O
short	O	ADJ	B
tandem	O	ADJ	I
repeats	O	NOUN	I
located	O	ADJ	O
either	O	CCONJ	O
in	O	ADP	O
or	O	CCONJ	O
close	O	ADV	O
to	O	PART	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
segregation	O	NOUN	B
probability	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
RB1	O	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
sperm	O	NOUN	B
samples	O	NOUN	B
was	O	AUX	O
assessed	O	VERB	B
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
SPERMSEG	O	NOUN	B
program	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
includes	O	VERB	O
experimental	O	ADJ	B
parameters	O	NOUN	B
,	O	PUNCT	O
recombination	O	NOUN	B
fractions	O	NOUN	I
between	O	ADP	O
the	O	DET	O
markers	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
segregation	O	NOUN	B
parameters	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
952	O	NUM	O
single	O	ADJ	O
sperm	O	NOUN	B
from	O	ADP	O
the	O	DET	O
six	O	NUM	O
donors	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
detected	O	VERB	B
a	O	DET	O
significant	O	ADJ	B
segregation	O	NOUN	B
distortion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
data	O	NOUN	B
as	O	ADP	O
a	O	DET	O
whole	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
0099	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
heterogeneity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
segregation	O	NOUN	B
rate	O	NOUN	B
across	O	ADP	O
donors	O	NOUN	B
(	O	PUNCT	O
.	O	PUNCT	O
0092	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Further	O	ADJ	O
analysis	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
result	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
segregation	O	NOUN	B
distortion	O	NOUN	B
in	O	ADP	O
favor	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
allele	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
donor	O	NOUN	B
only	O	ADV	O
and	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
does	O	AUX	O
not	O	PART	O
provide	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
significant	O	ADJ	B
segregation	O	NOUN	B
distortion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
donors	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
segregation	O	NOUN	B
distortion	O	NOUN	B
favoring	O	VERB	O
the	O	DET	O
mutant	O	ADJ	B
RB1	O	NOUN	B
allele	O	NOUN	B
does	O	AUX	O
not	O	PART	O
seem	O	VERB	O
to	O	PART	O
occur	O	VERB	O
during	O	ADP	O
spermatogenesis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
meiotic	O	ADJ	B
drive	O	NOUN	O
may	O	AUX	O
result	O	VERB	O
either	O	CCONJ	O
from	O	ADP	O
various	O	ADJ	O
mechanisms	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
fertilization	O	NOUN	B
advantage	O	NOUN	O
or	O	CCONJ	O
a	O	DET	O
better	O	ADJ	O
mobility	O	NOUN	B
in	O	ADP	O
sperm	O	NOUN	B
bearing	O	VERB	O
a	O	DET	O
mutant	O	ADJ	B
RB1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
from	O	ADP	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
defectively	O	ADV	B
imprinted	O	ADJ	O
gene	O	NOUN	O
located	O	ADJ	O
on	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
:	O	PUNCT	O
an	O	DET	O
overview	O	NOUN	B
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
neurodegenerative	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
of	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
ataxias	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
discovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
FRDA	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
rapid	O	ADJ	O
advances	O	NOUN	B
in	O	ADP	O
the	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


About	O	ADV	O
98	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
alleles	O	NOUN	O
have	O	AUX	O
an	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
GAA	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	I
intron	O	NOUN	B
1	O	NUM	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
leads	O	VERB	O
to	O	PART	O
reduced	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
,	O	PUNCT	O
frataxin	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
mounting	O	VERB	B
evidence	O	NOUN	B
to	O	PART	O
suggest	O	VERB	O
that	O	SCONJ	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
accumulation	O	NOUN	B
of	O	ADP	O
iron	O	NOUN	B
in	O	ADP	O
mitochondria	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
excess	O	ADJ	B
production	O	NOUN	B
of	O	ADP	O
free	O	ADJ	B
radicals	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
then	O	ADV	O
results	O	VERB	B
in	O	ADP	O
cellular	O	ADJ	B
damage	O	NOUN	I
and	O	CCONJ	O
death	O	NOUN	B
.	O	PUNCT	O


Currently	O	ADV	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
known	O	ADJ	O
treatment	O	NOUN	B
that	O	PRON	O
alters	O	VERB	O
the	O	DET	O
natural	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
discovery	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FRDA	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
possible	O	ADJ	O
function	O	NOUN	B
has	O	AUX	O
raised	O	VERB	O
hope	O	NOUN	O
that	O	SCONJ	O
rational	O	ADJ	O
therapeutic	O	ADJ	B
strategies	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
developed	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
retinoschisis	I-Disease	NOUN	B
with	O	ADP	O
point	O	NOUN	O
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
retinoschisis	I-Disease	NOUN	B
(	O	PUNCT	O
XLRS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
relatively	O	ADV	O
rare	O	ADJ	B
vitreoretinal	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
that	O	PRON	O
causes	O	VERB	O
visual	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
in	O	ADP	O
young	O	ADJ	B
men	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
designated	O	VERB	O
XLRS1	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
several	O	ADJ	O
deleterious	O	ADJ	O
gene	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
analyze	O	VERB	O
Japanese	O	ADJ	B
patients	O	NOUN	B
clinically	O	ADV	B
diagnosed	O	VERB	I
as	O	ADP	O
having	O	VERB	O
XLRS	B-Disease	NOUN	B
formutational	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Ten	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
XLRS	B-Disease	NOUN	B
underwent	O	VERB	O
full	O	ADJ	O
ophthalmologic	O	ADJ	B
examination	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
slitlamp	O	NOUN	B
biomicroscopy	O	NOUN	I
and	O	CCONJ	O
dilated	O	ADJ	B
funduscopy	O	NOUN	I
.	O	PUNCT	O


Genomic	O	ADJ	B
DNA	O	NOUN	I
was	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
leukocytes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
and	O	CCONJ	O
analyzed	O	VERB	B
using	O	VERB	O
a	O	DET	O
direct	O	ADJ	B
sequencing	O	NOUN	I
method	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
all	O	DET	O
10	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
identical	O	ADJ	B
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
2	O	NUM	O
pairs	O	NOUN	B
of	O	ADP	O
brothers	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
of	O	ADP	O
the	O	DET	O
point	O	NOUN	B
mutations	O	NOUN	I
represented	O	VERB	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
was	O	AUX	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
was	O	AUX	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
newly	O	ADV	O
reported	O	VERB	O
herein	O	ADV	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
discovery	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
point	O	NOUN	O
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
increases	O	VERB	B
the	O	DET	O
available	O	ADJ	O
information	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
genetic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
and	O	CCONJ	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
of	O	ADP	O
XLRS	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
limited	O	ADJ	B
data	O	NOUN	B
failed	O	VERB	O
to	O	PART	O
reveal	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
mutation	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


CLINICAL	O	X	O
RELEVANCE	O	NOUN	O
Identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
XLRS1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
expanded	O	ADJ	O
information	O	NOUN	B
on	O	ADP	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
will	O	AUX	O
facilitate	O	VERB	O
early	O	ADJ	B
diagnosis	O	NOUN	I
,	O	PUNCT	O
appropriate	O	ADJ	O
early	O	ADJ	B
therapy	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
genetic	O	ADJ	B
counseling	O	NOUN	I
regarding	O	VERB	O
the	O	DET	O
prognosis	O	NOUN	B
of	O	ADP	O
XLRS	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Atm	O	NOUN	B
and	O	CCONJ	O
Bax	O	NOUN	B
cooperate	O	VERB	B
in	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
hereditary	B-Disease	ADJ	B
multisystemic	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
ataxia	B-Disease	NOUN	B
telangiectasia	I-Disease	NOUN	I
,	O	PUNCT	O
mutated	O	VERB	B
(	O	PUNCT	O
ATM	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
neurodegeneration	B-Disease	NOUN	B
,	O	PUNCT	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
immune	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hypersensitivity	B-Disease	NOUN	B
to	I-Disease	PART	O
ionizing	I-Disease	VERB	B
radiation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
details	O	NOUN	I
of	O	ADP	O
ATM	O	NOUN	B
function	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nervous	O	ADJ	B
system	O	NOUN	I
are	O	AUX	O
unclear	O	ADJ	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
neurological	B-Disease	ADJ	B
lesion	I-Disease	NOUN	I
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
becomes	O	VERB	O
apparent	O	ADJ	B
early	O	ADV	B
in	O	ADP	O
life	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
developmental	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
(	O	PUNCT	O
CNS	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
Atm	O	PROPN	B
-	O	PUNCT	O
null	O	ADJ	B
mice	O	NOUN	O
shows	O	VERB	O
a	O	DET	O
pronounced	O	ADJ	O
defect	O	NOUN	B
in	O	ADP	O
apoptosis	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
genotoxic	O	ADJ	B
stress	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
ATM	O	NOUN	B
functions	O	NOUN	B
to	O	PART	O
eliminate	O	VERB	O
neurons	O	NOUN	B
with	O	ADP	O
excessive	O	ADJ	B
genomic	O	ADJ	B
damage	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
death	O	NOUN	B
effector	O	NOUN	O
Bax	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
a	O	DET	O
large	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
Atm	O	PROPN	B
-	O	PUNCT	O
dependent	O	ADJ	B
apoptosis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
developing	O	VERB	O
CNS	O	NOUN	B
after	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
(	O	PUNCT	O
IR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
Bax	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
and	O	CCONJ	O
Atm	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
were	O	AUX	O
radioresistant	O	ADJ	B
,	O	PUNCT	O
mice	O	NOUN	B
nullizygous	O	ADJ	B
for	O	ADP	O
both	O	CCONJ	O
Bax	O	NOUN	B
and	O	CCONJ	O
Atm	O	NOUN	B
showed	O	VERB	O
additional	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
IR	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
major	O	ADJ	O
IR	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptotic	O	ADJ	B
pathway	O	NOUN	I
in	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
requires	O	VERB	O
Atm	O	NOUN	B
and	O	CCONJ	O
Bax	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
p53	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
collateral	O	ADJ	B
pathway	O	NOUN	I
exists	O	VERB	O
that	O	PRON	O
has	O	AUX	O
both	O	CCONJ	O
Atm	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
Bax	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
branches	O	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
,	O	PUNCT	O
Atm	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
Bax	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
apoptosis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CNS	O	NOUN	B
also	O	ADV	O
required	O	VERB	O
caspase	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
activation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
implicate	O	VERB	O
Bax	O	NOUN	B
and	O	CCONJ	O
caspase	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
as	O	ADP	O
death	O	NOUN	B
effectors	O	NOUN	O
in	O	ADP	O
neurodegenerative	O	ADJ	B
pathways	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Haim	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Munk	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
Papillon	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lefevre	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
are	O	AUX	O
allelic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
many	O	ADJ	O
palmoplantar	B-Disease	NOUN	B
keratoderma	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
PPK	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
conditions	I-Disease	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
Papillon	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Lefevre	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PLS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Haim	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Munk	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HMS	B-Disease	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
premature	O	ADJ	B
periodontal	O	ADJ	I
destruction	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
both	O	DET	O
PLS	B-Disease	PROPN	B
and	O	CCONJ	O
HMS	B-Disease	PROPN	B
share	O	VERB	O
the	O	DET	O
cardinal	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
PPK	B-Disease	NOUN	B
and	O	CCONJ	O
severe	O	ADJ	B
periodontitis	B-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
additional	O	ADJ	O
findings	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
HMS	B-Disease	NOUN	B
including	O	VERB	O
arachnodactyly	B-Disease	ADJ	B
,	O	PUNCT	O
acro	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
osteolysis	I-Disease	NOUN	B
,	O	PUNCT	O
atrophic	B-Disease	ADJ	B
changes	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
nails	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
radiographic	B-Disease	ADJ	B
deformity	I-Disease	NOUN	O
of	I-Disease	ADP	O
the	I-Disease	DET	O
fingers	I-Disease	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
PLS	B-Disease	PROPN	B
cases	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
world	O	NOUN	B
,	O	PUNCT	O
HMS	B-Disease	PROPN	B
has	O	AUX	O
only	O	ADV	O
been	O	AUX	O
described	O	VERB	O
among	O	ADP	O
descendants	O	NOUN	B
of	O	ADP	O
a	O	DET	O
religious	O	ADJ	B
isolate	O	NOUN	B
originally	O	ADV	O
from	O	ADP	O
Cochin	O	PROPN	B
,	O	PUNCT	O
India	O	PROPN	B
.	O	PUNCT	O


Parental	O	ADJ	B
consanguinity	O	NOUN	O
is	O	AUX	O
a	O	DET	O
characteristic	O	NOUN	O
of	O	ADP	O
many	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
both	O	DET	O
conditions	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
autosomal	O	ADJ	B
recessive	O	ADJ	B
transmission	O	NOUN	I
of	O	ADP	O
PLS	B-Disease	PROPN	B
is	O	AUX	O
evident	O	ADJ	O
,	O	PUNCT	O
a	O	DET	O
more	O	ADJ	O
"	O	PUNCT	O
complex	O	ADJ	B
"	O	PUNCT	O
autosomal	O	ADJ	B
recessive	O	ADJ	O
pattern	O	NOUN	O
of	O	ADP	O
inheritance	O	NOUN	B
with	O	ADP	O
phenotypic	O	ADJ	B
influences	O	NOUN	B
from	O	ADP	O
a	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
modifying	O	VERB	O
locus	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
hypothesised	O	VERB	O
for	O	ADP	O
HMS	B-Disease	PROPN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
the	O	DET	O
underlying	O	ADJ	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
in	O	ADP	O
PLS	B-Disease	PROPN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
a	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
mutation	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
responsible	O	ADJ	O
for	O	ADP	O
HMS	B-Disease	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
sequenced	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
and	O	CCONJ	O
unaffected	O	ADJ	O
subjects	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Cochin	O	PROPN	B
isolate	O	NOUN	B
in	O	ADP	O
which	O	DET	O
both	O	CCONJ	O
the	O	DET	O
PLS	B-Disease	PROPN	B
and	O	CCONJ	O
HMS	B-Disease	PROPN	B
phenotypes	O	NOUN	B
appear	O	VERB	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
(	O	PUNCT	O
exon	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
2127A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
changes	O	VERB	B
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
amino	O	NOUN	B
acid	O	NOUN	I
in	O	ADP	O
the	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
peptide	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
segregates	O	VERB	B
with	O	ADP	O
HMS	B-Disease	NOUN	B
in	O	ADP	O
four	O	NUM	O
nuclear	O	ADJ	B
families	O	NOUN	I
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
shared	O	ADJ	O
common	O	ADJ	O
haplotype	O	NOUN	B
for	O	ADP	O
genetic	O	ADJ	B
loci	O	NOUN	I
flanking	O	VERB	O
the	O	DET	O
cathepsin	O	NOUN	B
C	O	NOUN	I
gene	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
affected	O	VERB	B
subjects	O	NOUN	B
descended	O	VERB	O
from	O	ADP	O
the	O	DET	O
Cochin	O	PROPN	B
isolate	O	NOUN	B
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
inherited	O	VERB	B
"	O	PUNCT	O
identical	O	ADJ	B
by	O	ADP	O
descent	O	NOUN	B
"	O	PUNCT	O
from	O	ADP	O
a	O	DET	O
common	O	ADJ	O
ancestor	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
supports	O	VERB	O
simple	O	ADJ	O
autosomal	O	ADJ	B
recessive	O	ADJ	O
inheritance	O	NOUN	B
for	O	ADP	O
HMS	B-Disease	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
report	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
exon	O	NOUN	B
6	O	NUM	O
CTSC	O	NOUN	B
codon	O	NOUN	B
(	O	PUNCT	O
2126C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
Turkish	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
classical	O	ADJ	O
PLS	B-Disease	PROPN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
PLS	B-Disease	PROPN	B
and	O	CCONJ	O
HMS	B-Disease	PROPN	B
are	O	AUX	O
allelic	O	ADJ	B
variants	O	NOUN	B
of	O	ADP	O
cathepsin	O	NOUN	B
C	O	NOUN	I
gene	O	NOUN	I
mutations	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


ATM	O	NOUN	B
-	O	PUNCT	O
heterozygous	O	ADJ	B
germline	O	NOUN	B
mutations	O	NOUN	I
contribute	O	VERB	O
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
-	O	PUNCT	O
susceptibility	O	NOUN	B
.	O	PUNCT	O


Approximately	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
ataxia	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
MIM	O	NOUN	B
208900	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
that	O	SCONJ	O
ATM	O	NOUN	B
-	O	PUNCT	O
heterozygotes	O	NOUN	B
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
relative	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
supported	O	VERB	O
by	O	ADP	O
some	O	DET	O
studies	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
confirmed	O	VERB	O
by	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
this	O	DET	O
discrepancy	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
a	O	DET	O
selected	O	VERB	O
group	O	NOUN	B
of	O	ADP	O
Dutch	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
ATM	O	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
blood	O	NOUN	I
lymphocytes	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
truncation	O	NOUN	B
test	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
genomic	O	ADJ	B
-	O	PUNCT	O
sequence	O	NOUN	B
analysis	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
was	O	AUX	O
demonstrated	O	VERB	O
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
sporadic	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
82	O	NUM	O
patients	O	NOUN	B
included	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
had	O	AUX	O
developed	O	VERB	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
at	O	ADP	O
age	O	NOUN	B
<	O	X	O
45	O	NUM	O
and	O	CCONJ	O
had	O	AUX	O
survived	O	VERB	O
>	O	X	O
/	O	PUNCT	O
=	O	ADJ	O
5	O	NUM	O
years	O	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
15	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
33	O	NUM	O
(	O	PUNCT	O
40	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
a	O	DET	O
contralateral	O	ADJ	B
breast	O	NOUN	B
tumor	O	NOUN	I
had	O	AUX	O
been	O	AUX	O
diagnosed	O	VERB	B
.	O	PUNCT	O


Among	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
we	O	PRON	O
identified	O	VERB	O
seven	O	NUM	O
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
ATM	O	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
five	O	NUM	O
are	O	AUX	O
distinct	O	ADJ	O
.	O	PUNCT	O


One	O	NUM	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
(	O	PUNCT	O
IVS10	O	NOUN	B
-	O	PUNCT	O
6T	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
three	O	NUM	O
times	O	NOUN	O
in	O	ADP	O
our	O	PRON	O
series	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
heterozygous	O	ADJ	B
carriers	O	NOUN	B
were	O	AUX	O
patients	O	NOUN	B
with	O	ADP	O
bilateral	O	ADJ	B
breast	O	NOUN	I
cancer	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutations	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
are	O	AUX	O
"	O	PUNCT	O
A	O	PROPN	B
-	O	PUNCT	O
T	O	NOUN	B
disease	O	NOUN	I
-	O	PUNCT	O
causing	O	VERB	B
"	O	PUNCT	O
mutations	O	NOUN	B
that	O	PRON	O
might	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
in	O	ADP	O
heterozygotes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
ATM	O	NOUN	B
heterozygotes	O	NOUN	B
have	O	AUX	O
an	O	DET	O
approximately	O	ADV	O
ninefold	O	ADV	B
-	O	PUNCT	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
a	O	DET	O
type	O	NOUN	O
of	O	ADP	O
breast	O	NOUN	B
cancer	O	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
frequent	O	ADJ	B
bilateral	O	ADJ	B
occurrence	O	NOUN	B
,	O	PUNCT	O
early	O	ADJ	B
age	O	NOUN	I
at	O	ADP	O
onset	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
survival	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
specific	O	ADJ	O
characteristics	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
population	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
why	O	SCONJ	O
such	O	DET	O
a	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
other	O	ADJ	O
series	O	NOUN	B
.	O	PUNCT	O


Human	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
glucose	O	NOUN	B
6	O	NUM	I
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
reflect	O	VERB	O
evolutionary	O	ADJ	B
history	O	NOUN	I
.	O	PUNCT	O


Glucose	O	NOUN	B
6	O	NUM	I
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
cytosolic	O	ADJ	B
enzyme	O	NOUN	O
encoded	O	VERB	B
by	O	ADP	O
a	O	DET	O
housekeeping	O	ADJ	B
X	O	NOUN	I
-	O	PUNCT	O
linked	O	VERB	B
gene	O	NOUN	B
whose	O	DET	O
main	O	ADJ	O
function	O	NOUN	B
is	O	AUX	O
to	O	PART	O
produce	O	VERB	O
NADPH	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
key	O	ADJ	O
electron	O	NOUN	O
donor	O	NOUN	O
in	O	ADP	O
the	O	DET	O
defense	O	NOUN	B
against	O	ADP	O
oxidizing	O	NOUN	B
agents	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
reductive	O	ADJ	B
biosynthetic	O	ADJ	I
reactions	O	NOUN	I
.	O	PUNCT	O


Inherited	O	VERB	B
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
episodic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	B
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
triggered	O	VERB	B
by	O	ADP	I
fava	O	NOUN	B
beans	O	NOUN	I
or	O	CCONJ	O
other	O	ADJ	O
agents	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
life	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
long	I-Disease	ADJ	B
hemolytic	I-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
here	O	ADV	O
that	O	SCONJ	O
an	O	DET	O
evolutionary	O	ADJ	B
analysis	O	NOUN	I
is	O	AUX	O
a	O	DET	O
key	O	NOUN	O
to	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
biology	O	NOUN	B
of	O	ADP	O
a	O	DET	O
housekeeping	O	ADJ	B
gene	O	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
alignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
(	O	PUNCT	O
aa	O	NOUN	O
)	O	PUNCT	O
sequence	O	NOUN	O
of	O	ADP	O
52	O	NUM	O
glucose	O	NOUN	B
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
species	O	NOUN	B
from	O	ADP	O
42	O	NUM	O
different	O	ADJ	O
organisms	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
a	O	DET	O
striking	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
aa	O	NOUN	B
replacements	O	NOUN	I
that	O	PRON	O
cause	O	VERB	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
in	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
sequence	O	NOUN	B
conservation	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
two	O	NUM	O
-	O	PUNCT	O
thirds	O	NOUN	B
of	O	ADP	O
such	O	ADJ	O
replacements	O	NOUN	B
are	O	AUX	O
in	O	ADP	O
highly	O	ADV	B
and	O	CCONJ	O
moderately	O	ADV	O
conserved	O	VERB	O
(	O	PUNCT	O
50	O	NUM	O
-	O	SYM	O
99	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
aa	O	NOUN	B
;	O	PUNCT	O
relatively	O	ADV	O
few	O	ADJ	O
are	O	AUX	O
in	O	ADP	O
fully	O	ADV	O
conserved	O	VERB	B
aa	O	NOUN	I
(	O	PUNCT	O
where	O	SCONJ	O
they	O	PRON	O
might	O	AUX	O
be	O	AUX	O
lethal	O	ADJ	B
)	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
poorly	O	ADV	O
conserved	O	VERB	B
aa	O	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
presumably	O	ADV	O
they	O	PRON	O
simply	O	ADV	O
would	O	AUX	O
not	O	PART	O
cause	O	VERB	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
all	O	DET	O
human	O	ADJ	B
mutants	O	NOUN	B
have	O	AUX	O
residual	O	ADJ	B
enzyme	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
null	O	ADJ	B
mutations	O	NOUN	I
are	O	AUX	O
lethal	O	ADJ	B
at	O	ADP	O
some	O	DET	O
stage	O	NOUN	B
of	O	ADP	O
development	O	NOUN	B
.	O	PUNCT	O


Comparing	O	VERB	B
the	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
human	O	ADJ	B
housekeeping	O	ADJ	O
gene	O	NOUN	O
with	O	ADP	O
evolutionary	O	ADJ	B
conservation	O	NOUN	I
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
pinpointing	O	VERB	O
amino	O	NOUN	B
acid	O	NOUN	I
residues	O	NOUN	I
important	O	ADJ	O
for	O	ADP	O
the	O	DET	O
stability	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
protein	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
explosive	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
full	O	ADJ	O
genome	O	NOUN	B
sequencing	O	NOUN	I
projects	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
tool	O	NOUN	B
will	O	AUX	O
become	O	VERB	O
rapidly	O	ADV	O
available	O	ADJ	O
for	O	ADP	O
numerous	O	ADJ	O
other	O	ADJ	O
genes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Constitutive	O	ADJ	B
and	O	CCONJ	O
regulated	O	VERB	O
modes	O	NOUN	B
of	O	ADP	O
splicing	O	NOUN	B
produce	O	VERB	O
six	O	NUM	O
major	O	ADJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
isoforms	O	NOUN	B
with	O	ADP	O
distinct	O	ADJ	O
properties	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
prevalent	O	ADJ	O
inherited	B-Disease	VERB	B
neuromuscular	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
adults	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
CTG	O	NOUN	B
triplet	O	NOUN	I
repeat	O	NOUN	I
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
,	O	PUNCT	O
consisting	O	VERB	O
of	O	ADP	O
15	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
transgenic	O	ADJ	B
DMPK	O	NOUN	B
-	O	PUNCT	O
overexpressor	O	NOUN	B
mouse	O	NOUN	B
model	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
here	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
endogenous	O	ADJ	B
mouse	O	NOUN	B
DMPK	O	NOUN	B
gene	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
human	O	ADJ	B
DMPK	O	NOUN	B
transgene	O	NOUN	B
produce	O	VERB	O
six	O	NUM	O
major	O	ADJ	O
alternatively	O	ADV	O
spliced	O	VERB	B
mRNAs	O	NOUN	B
which	O	DET	O
have	O	AUX	O
almost	O	ADV	O
identical	O	ADJ	B
cell	O	NOUN	B
type	O	NOUN	I
-	O	PUNCT	O
dependent	O	ADJ	B
distribution	O	NOUN	B
frequencies	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
patterns	O	NOUN	I
.	O	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
a	O	DET	O
cryptic	O	ADJ	B
5	O	NUM	O
splice	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
absence	O	NOUN	B
or	O	CCONJ	O
presence	O	NOUN	B
of	O	ADP	O
15	O	NUM	O
nucleotides	O	NOUN	B
specifying	O	VERB	O
a	O	DET	O
VSGGG	O	NOUN	B
peptide	O	NOUN	I
motif	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
cryptic	O	ADJ	B
3	O	NUM	O
splice	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
14	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
frameshift	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
reading	O	NOUN	I
frame	O	NOUN	I
,	O	PUNCT	O
occur	O	VERB	O
as	O	ADP	O
independent	O	ADJ	B
stochastic	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
all	O	DET	O
tissues	O	NOUN	B
examined	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
excision	O	NOUN	B
of	O	ADP	O
exons	O	NOUN	O
13	O	NUM	O
/	O	SYM	O
14	O	NUM	O
that	O	PRON	O
causes	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
and	O	CCONJ	O
creates	O	VERB	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
terminally	O	ADV	B
truncated	O	VERB	O
protein	O	NOUN	O
is	O	AUX	O
clearly	O	ADV	O
cell	O	NOUN	B
type	O	NOUN	I
dependent	O	ADJ	B
and	O	CCONJ	O
occurs	O	VERB	O
predominantly	O	ADV	O
in	O	ADP	O
smooth	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
generated	O	VERB	O
all	O	DET	O
six	O	NUM	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
mouse	O	NOUN	B
cDNAs	O	NOUN	O
that	O	PRON	O
result	O	VERB	O
from	O	ADP	O
combinations	O	NOUN	B
of	O	ADP	O
these	O	DET	O
three	O	NUM	O
major	O	ADJ	O
splicing	O	NOUN	B
events	O	NOUN	I
and	O	CCONJ	O
show	O	VERB	O
that	O	SCONJ	O
their	O	PRON	O
transfection	O	NOUN	B
into	O	ADP	O
cells	O	NOUN	B
in	O	ADP	O
culture	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
production	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
different	O	ADJ	O
approximately	O	ADV	B
74	O	NUM	O
kDa	O	NOUN	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
(	O	PUNCT	O
heart	O	NOUN	B
-	O	PUNCT	O
,	O	PUNCT	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
-	O	PUNCT	O
or	O	CCONJ	O
brain	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
C	O	PROPN	B
-	O	PUNCT	O
terminally	O	ADV	B
truncated	O	VERB	B
approximately	O	ADV	O
68	O	NUM	O
kDa	O	NOUN	O
(	O	PUNCT	O
smooth	O	ADJ	B
muscle	O	NOUN	I
-	O	PUNCT	O
specific	O	ADJ	B
)	O	PUNCT	O
isoforms	O	NOUN	B
.	O	PUNCT	O


Information	O	NOUN	B
on	O	ADP	O
DMPK	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
isoform	O	NOUN	I
expression	O	NOUN	B
patterns	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
recognizing	O	VERB	O
differential	O	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
n	O	NOUN	O
)	O	PUNCT	O
expansion	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
manifestation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
phenotypic	O	ADJ	B
diagnosis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
risk	O	NOUN	B
of	O	ADP	O
venous	B-Disease	ADJ	B
thrombosis	I-Disease	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
inherited	O	VERB	B
deficiencies	B-Disease	NOUN	B
of	I-Disease	ADP	O
protein	I-Disease	NOUN	B
S	I-Disease	NOUN	I
.	O	PUNCT	O


Protein	B-Disease	NOUN	B
S	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
recognized	O	VERB	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
venous	B-Disease	ADJ	B
thrombosis	I-Disease	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
all	O	DET	O
the	O	DET	O
inherited	O	VERB	B
thrombophilic	B-Disease	ADJ	B
conditions	I-Disease	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
remains	O	VERB	O
the	O	DET	O
most	O	ADV	O
difficult	O	ADJ	O
to	O	PART	O
diagnose	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
phenotypic	O	ADJ	B
variability	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
inconclusive	O	ADJ	O
results	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
overcome	O	VERB	O
this	O	DET	O
problem	O	NOUN	B
by	O	ADP	O
studying	O	VERB	O
a	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
from	O	ADP	O
a	O	DET	O
single	O	ADJ	O
center	O	NOUN	O
where	O	SCONJ	O
the	O	DET	O
diagnosis	O	NOUN	B
was	O	AUX	O
confirmed	O	VERB	O
at	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
level	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
index	O	NOUN	O
patients	O	NOUN	B
with	O	ADP	O
protein	B-Disease	NOUN	B
S	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
PROS1	B-Disease	NOUN	B
gene	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
were	O	AUX	O
studied	O	VERB	O
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
109	O	NUM	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
avoid	O	VERB	O
selection	O	NOUN	B
bias	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
confined	O	VERB	O
analysis	O	NOUN	B
of	O	ADP	O
total	O	NOUN	O
and	O	CCONJ	O
free	O	ADJ	O
protein	O	NOUN	O
S	O	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
thrombotic	O	ADJ	B
risk	O	NOUN	I
to	O	PART	O
the	O	DET	O
patients	O	NOUN	B
relatives	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
relatives	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
low	O	ADJ	B
free	O	ADJ	I
protein	O	NOUN	I
S	O	NOUN	I
level	O	NOUN	O
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
reliable	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
a	O	DET	O
PROS1	B-Disease	NOUN	B
gene	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
(	O	PUNCT	O
sensitivity	O	NOUN	B
97	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
specificity	O	NOUN	B
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


First	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	B
with	O	ADP	O
a	O	DET	O
PROS1	B-Disease	NOUN	B
gene	I-Disease	NOUN	I
defect	I-Disease	NOUN	I
had	O	AUX	O
a	O	DET	O
5	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	PUNCT	O
fold	O	VERB	B
higher	O	ADJ	B
risk	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
-	O	SYM	O
16	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
with	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
PROS1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
no	O	DET	O
other	O	ADJ	O
recognized	O	VERB	O
thrombophilic	B-Disease	ADJ	B
defect	I-Disease	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
pregnancy	O	NOUN	B
/	O	SYM	O
puerperium	O	NOUN	B
and	O	CCONJ	O
immobility	O	NOUN	B
/	O	PUNCT	O
trauma	B-Disease	NOUN	B
were	O	AUX	O
important	O	ADJ	O
precipitating	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
thrombosis	B-Disease	NOUN	B
,	O	PUNCT	O
almost	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
events	O	NOUN	B
were	O	AUX	O
spontaneous	O	ADJ	B
.	O	PUNCT	O


Relatives	O	NOUN	B
with	O	ADP	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
or	O	CCONJ	O
major	O	ADJ	O
structural	O	ADJ	B
defects	B-Disease	NOUN	O
in	I-Disease	ADP	O
the	I-Disease	DET	O
PROS1	I-Disease	NOUN	B
gene	I-Disease	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
have	O	AUX	O
had	O	AUX	O
a	O	DET	O
thrombotic	O	ADJ	B
event	O	NOUN	I
and	O	CCONJ	O
had	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
total	O	NOUN	O
and	O	CCONJ	O
free	O	ADJ	O
protein	O	NOUN	O
S	O	NOUN	O
levels	O	NOUN	O
than	O	ADP	O
those	O	DET	O
relatives	O	NOUN	B
having	O	VERB	O
missense	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
persons	O	NOUN	B
with	O	ADP	O
PROS1	B-Disease	NOUN	B
gene	I-Disease	NOUN	I
defects	I-Disease	NOUN	B
and	O	CCONJ	O
protein	B-Disease	NOUN	B
S	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
are	O	AUX	O
at	O	ADP	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
free	O	ADJ	B
protein	O	NOUN	I
S	O	NOUN	I
estimation	O	NOUN	B
offers	O	VERB	O
the	O	DET	O
most	O	ADV	O
reliable	O	ADJ	O
way	O	NOUN	O
of	O	ADP	O
diagnosing	O	VERB	B
the	O	DET	O
deficiency	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
Blood	O	PROPN	B
.	O	PUNCT	O
2000	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
1935	O	NUM	O
-	O	PUNCT	O
1941	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALPS	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
from	O	ADP	O
consanguineous	O	ADJ	B
parents	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
dominant	O	ADJ	B
or	O	CCONJ	O
recessive	O	ADJ	B
disease	O	NOUN	I
?	O	PUNCT	O


Autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALPS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
autoimmune	O	ADJ	B
features	O	NOUN	I
and	O	CCONJ	O
lymphoproliferations	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
generally	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
defective	O	ADJ	B
Fas	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
apoptosis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
ALPS	B-Disease	NOUN	B
without	O	ADP	O
detectable	O	ADJ	B
Fas	O	NOUN	B
expression	O	NOUN	B
on	O	ADP	O
freshly	O	ADV	O
isolated	O	VERB	B
blood	O	NOUN	O
leukocytes	O	NOUN	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
FAS	O	NOUN	B
transcripts	O	NOUN	B
via	O	ADP	O
real	O	ADJ	B
-	O	PUNCT	O
time	O	NOUN	B
quantitative	O	ADJ	O
PCR	O	NOUN	O
made	O	VERB	O
a	O	DET	O
severe	O	ADJ	O
transcriptional	O	ADJ	B
defect	O	NOUN	I
unlikely	O	ADJ	O
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FAS	O	PROPN	B
gene	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
20	O	NUM	O
-	O	PUNCT	O
nucleotide	O	NOUN	B
duplication	O	NOUN	I
in	O	ADP	O
the	O	DET	O
last	O	ADJ	O
exon	O	NOUN	B
affecting	O	VERB	B
the	O	DET	O
cytoplasmic	O	ADJ	B
signaling	O	NOUN	O
domain	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
consanguineous	O	ADJ	B
parents	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
siblings	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
is	O	AUX	O
a	O	DET	O
human	O	ADJ	B
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Fas	O	NOUN	B
-	O	PUNCT	O
null	O	ADJ	B
mouse	O	NOUN	B
,	O	PUNCT	O
inasmuch	O	ADV	O
as	O	ADP	O
she	O	PRON	O
carries	O	VERB	O
an	O	DET	O
autosomal	O	ADJ	B
homozygous	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FAS	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
she	O	PRON	O
shows	O	VERB	O
the	O	DET	O
severe	O	ADJ	B
and	O	CCONJ	O
accelerated	O	VERB	B
ALPS	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
heterozygous	O	ADJ	B
family	O	NOUN	B
members	O	NOUN	I
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
the	O	DET	O
ALPS	B-Disease	NOUN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
FAS	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
is	O	AUX	O
autosomal	O	ADJ	B
recessive	O	ADJ	I
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
imprinted	O	ADJ	B
transcripts	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
deletion	O	NOUN	B
region	O	NOUN	I
:	O	PUNCT	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
regional	O	ADJ	B
imprinting	O	NOUN	I
control	O	NOUN	I
.	O	PUNCT	O


Deletions	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
abnormalities	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
two	O	NUM	O
developmental	O	ADJ	B
disorders	O	NOUN	I
,	O	PUNCT	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
imprinted	O	ADJ	B
,	O	PUNCT	O
paternally	O	ADV	B
expressed	O	VERB	I
genes	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
imprinted	O	ADJ	B
genes	O	NOUN	I
that	O	PRON	O
contribute	O	VERB	O
to	O	ADP	O
PWS	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
range	O	NOUN	B
over	O	ADP	O
which	O	DET	O
the	O	DET	O
imprinting	O	VERB	B
signal	O	NOUN	I
acts	O	VERB	O
to	O	PART	O
silence	O	VERB	B
one	O	NUM	O
copy	O	NOUN	B
of	O	ADP	I
the	O	DET	I
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
parent	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
origin	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
manner	O	NOUN	O
,	O	PUNCT	O
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
identify	O	VERB	O
additional	O	ADJ	O
imprinted	O	ADJ	B
genes	O	NOUN	I
that	O	PRON	O
could	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
PWS	B-Disease	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
regional	O	ADJ	B
control	O	NOUN	I
of	O	ADP	O
imprinting	O	NOUN	B
in	O	ADP	O
15q11	O	NOUN	B
-	O	PUNCT	O
q13	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
constructed	O	VERB	O
an	O	DET	O
imprinted	O	ADJ	B
transcript	O	NOUN	I
map	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PWS	O	PROPN	B
-	O	PUNCT	O
AS	O	ADJ	B
deletion	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
imprinting	O	VERB	B
status	O	NOUN	I
of	O	ADP	O
22	O	NUM	O
expressed	O	VERB	B
sequence	O	NOUN	B
tags	O	NOUN	O
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
radiation	O	NOUN	B
-	O	PUNCT	O
hybrid	O	NOUN	B
human	O	ADJ	B
transcript	O	NOUN	B
maps	O	NOUN	B
or	O	CCONJ	O
physical	O	ADJ	B
maps	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
a	O	DET	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
-	O	PUNCT	O
PCR	O	NOUN	B
assay	O	NOUN	B
and	O	CCONJ	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transcripts	O	NOUN	B
on	O	ADP	O
the	O	DET	O
physical	O	ADJ	B
map	O	NOUN	I
.	O	PUNCT	O


Seven	O	NUM	O
new	O	ADJ	O
paternally	O	ADV	B
expressed	O	VERB	B
transcripts	O	NOUN	B
localize	O	VERB	B
to	O	PART	O
an	O	DET	O
approximately	O	ADV	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
Mb	O	NOUN	O
domain	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
SNRPN	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
imprinting	O	NOUN	B
center	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
already	O	ADV	O
includes	O	VERB	O
four	O	NUM	O
imprinted	O	ADJ	B
,	O	PUNCT	O
paternally	O	ADV	B
expressed	O	VERB	I
genes	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
other	O	ADJ	O
tested	O	VERB	B
new	O	ADJ	O
transcripts	O	NOUN	B
in	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
region	O	NOUN	I
were	O	AUX	O
expressed	O	VERB	B
from	O	ADP	O
both	O	DET	O
alleles	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
domain	O	NOUN	B
of	O	ADP	O
exclusive	O	ADJ	O
paternal	O	ADJ	B
expression	O	NOUN	I
surrounding	O	VERB	O
the	O	DET	O
imprinting	O	NOUN	B
center	O	NOUN	I
suggests	O	VERB	O
strong	O	ADJ	O
regional	O	ADJ	B
control	O	NOUN	I
of	O	ADP	O
the	O	DET	O
imprinting	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
the	O	DET	O
means	O	NOUN	O
for	O	ADP	O
further	O	ADJ	O
investigation	O	NOUN	B
of	O	ADP	O
additional	O	ADJ	O
genes	O	NOUN	B
that	O	PRON	O
cause	O	VERB	B
or	O	CCONJ	O
modify	O	VERB	B
the	O	DET	O
phenotypes	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
rearrangements	O	NOUN	B
of	O	ADP	O
15q11	O	NOUN	B
-	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O


Combined	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
linkage	O	NOUN	B
to	O	ADP	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
:	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
772	O	NUM	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
families	O	NOUN	B
from	O	ADP	O
the	O	DET	O
International	O	PROPN	B
Consortium	O	PROPN	I
for	O	ADP	I
Prostate	B-Disease	PROPN	I
Cancer	I-Disease	PROPN	I
Genetics	O	PROPN	I
.	O	PUNCT	O


A	O	DET	O
previous	O	ADJ	O
linkage	O	NOUN	B
study	O	NOUN	I
provided	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
-	O	PUNCT	O
susceptibility	O	NOUN	B
locus	O	NOUN	O
at	O	ADP	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
.	O	PUNCT	O


Subsequent	O	ADJ	O
reports	O	NOUN	B
in	O	ADP	O
additional	O	ADJ	O
collections	O	NOUN	B
of	O	ADP	O
families	O	NOUN	B
have	O	AUX	O
yielded	O	VERB	O
conflicting	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
locus	O	NOUN	B
heterogeneity	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
provided	O	VERB	O
by	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
putative	O	ADJ	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
loci	O	NOUN	O
on	O	ADP	O
Xq27	O	NOUN	B
-	O	PUNCT	O
28	O	NUM	O
,	O	PUNCT	O
1q42	O	NOUN	B
-	O	PUNCT	O
43	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1p36	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
describes	O	VERB	O
a	O	DET	O
combined	O	ADJ	B
analysis	O	NOUN	I
for	O	ADP	O
six	O	NUM	O
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
region	O	NOUN	B
in	O	ADP	O
772	O	NUM	O
families	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
ascertained	O	VERB	O
by	O	ADP	O
the	O	DET	O
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
International	O	PROPN	B
Consortium	O	PROPN	I
for	O	ADP	I
Prostate	B-Disease	PROPN	I
Cancer	I-Disease	PROPN	I
Genetics	O	PROPN	I
(	O	PUNCT	O
ICPCG	O	PROPN	B
)	O	PUNCT	O
from	O	ADP	O
North	O	PROPN	B
America	O	PROPN	I
,	O	PUNCT	O
Australia	O	PROPN	B
,	O	PUNCT	O
Finland	O	PROPN	B
,	O	PUNCT	O
Norway	O	PROPN	B
,	O	PUNCT	O
Sweden	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
some	O	DET	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
peak	O	ADJ	B
parametric	O	ADJ	I
multipoint	O	ADJ	I
LOD	O	NOUN	I
score	O	NOUN	I
assuming	O	VERB	O
heterogeneity	O	NOUN	B
(	O	PUNCT	O
HLOD	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


40	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
at	O	ADP	O
D1S212	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
estimated	O	VERB	B
proportion	O	NOUN	B
of	O	ADP	O
families	O	NOUN	B
(	O	PUNCT	O
alpha	O	NOUN	B
)	O	PUNCT	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
locus	O	NOUN	B
was	O	AUX	O
.	O	PUNCT	O


06	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
LOD	O	NOUN	B
support	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O
01	O	NUM	O
-	O	PUNCT	O
.	O	PUNCT	O
12	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
evidence	O	NOUN	B
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
by	O	ADP	O
a	O	DET	O
nonparametric	O	ADJ	B
approach	O	NOUN	I
,	O	PUNCT	O
presumably	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
extensive	O	ADJ	B
heterogeneity	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
parametric	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
male	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
male	O	NOUN	B
disease	O	NOUN	B
transmission	O	NOUN	I
within	O	ADP	O
the	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
491	O	NUM	O
such	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
peak	O	NOUN	B
HLOD	O	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
491	O	NUM	O
such	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
peak	O	NOUN	B
HLOD	O	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


56	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
0006	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
alpha	O	NOUN	B
=	O	ADJ	O
.	O	PUNCT	O


11	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
LOD	O	NOUN	B
support	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O
04	O	NUM	O
-	O	PUNCT	O
.	O	PUNCT	O
19	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
HLODs	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
281	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
families	O	NOUN	B
with	O	ADP	O
male	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
male	O	NOUN	B
disease	O	NOUN	B
transmission	O	NOUN	I
,	O	PUNCT	O
alpha	O	NOUN	B
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
early	O	ADJ	B
mean	O	ADJ	I
age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
(	O	PUNCT	O
<	O	X	O
65	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
alpha	O	NOUN	B
=	O	ADJ	O
.	O	PUNCT	O
19	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
LOD	O	NOUN	B
support	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O
06	O	NUM	O
-	O	PUNCT	O
.	O	PUNCT	O
34	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
affected	O	VERB	B
family	O	NOUN	B
members	O	NOUN	I
(	O	PUNCT	O
five	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
alpha	O	NOUN	B
=	O	ADJ	O
.	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
LOD	O	NOUN	B
support	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O
04	O	NUM	O
-	O	PUNCT	O
.	O	PUNCT	O
28	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
highest	O	ADJ	O
value	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
the	O	DET	O
48	O	NUM	O
families	O	NOUN	B
that	O	PRON	O
met	O	VERB	O
all	O	DET	O
three	O	NUM	O
criteria	O	NOUN	B
(	O	PUNCT	O
peak	O	NOUN	B
HLOD	O	NOUN	I
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O
25	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
001	O	NUM	O
,	O	PUNCT	O
alpha	O	NOUN	B
=	O	ADJ	O
.	O	PUNCT	O
29	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
LOD	O	NOUN	B
support	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O
08	O	NUM	O
-	O	PUNCT	O
.	O	PUNCT	O
53	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
-	O	PUNCT	O
susceptibility	O	NOUN	B
gene	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
1q24	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
,	O	PUNCT	O
albeit	O	SCONJ	O
in	O	ADP	O
a	O	DET	O
defined	O	VERB	O
subset	O	NOUN	O
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
HPC1	O	NOUN	B
accounts	O	VERB	O
for	O	ADP	O
only	O	ADV	O
a	O	DET	O
small	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
all	O	DET	O
families	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
hereditary	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
to	O	PART	O
play	O	VERB	O
a	O	DET	O
more	O	ADV	O
prominent	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
several	O	ADJ	O
members	O	NOUN	B
affected	O	VERB	B
at	O	ADP	O
an	O	DET	O
early	O	ADJ	B
age	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
male	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
male	O	NOUN	B
disease	O	NOUN	B
transmission	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
recurrent	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
maternal	O	ADJ	B
allele	O	NOUN	O
with	O	ADP	O
36	O	NUM	O
CAG	O	NOUN	B
repeats	O	NOUN	I
causes	O	VERB	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
two	O	NUM	O
sisters	O	NOUN	B
.	O	PUNCT	O


Large	O	ADJ	O
intergenerational	O	ADJ	B
repeat	O	NOUN	I
expansions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
for	O	ADP	O
the	O	DET	O
male	O	NOUN	B
germline	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
recurrent	O	ADJ	B
large	O	ADJ	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
maternal	O	ADJ	B
allele	O	NOUN	O
with	O	ADP	O
36	O	NUM	O
CAG	O	NOUN	B
repeats	O	NOUN	I
(	O	PUNCT	O
to	O	PART	O
66	O	NUM	O
and	O	CCONJ	O
57	O	NUM	O
repeats	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
two	O	NUM	O
daughters	O	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
onset	O	NOUN	O
of	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
and	O	CCONJ	O
third	O	ADJ	O
decade	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
without	O	ADP	O
history	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
give	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gonadal	O	NOUN	B
mosaicism	O	NOUN	B
in	O	ADP	O
the	O	DET	O
unaffected	O	ADJ	B
mother	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
large	O	ADJ	O
expansions	O	NOUN	B
also	O	ADV	O
occur	O	VERB	O
in	O	ADP	O
the	O	DET	O
female	O	ADJ	B
germline	O	NOUN	O
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
negative	O	ADJ	B
selection	O	NOUN	B
of	O	ADP	O
oocytes	O	NOUN	B
with	O	ADP	O
long	O	ADJ	B
repeats	O	NOUN	I
might	O	AUX	O
explain	O	VERB	O
the	O	DET	O
different	O	ADJ	O
instability	O	NOUN	B
behavior	O	NOUN	B
of	O	ADP	O
the	O	DET	O
male	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
female	O	NOUN	B
germlines	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Abnormal	O	ADJ	B
development	O	NOUN	I
of	O	ADP	O
Purkinje	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
lymphocytes	O	NOUN	B
in	O	ADP	O
Atm	O	NOUN	B
mutant	O	ADJ	I
mice	O	NOUN	O
.	O	PUNCT	O


Motor	B-Disease	NOUN	B
incoordination	I-Disease	NOUN	I
,	O	PUNCT	O
immune	B-Disease	ADJ	B
deficiencies	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
are	O	AUX	O
the	O	DET	O
characteristic	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
ataxia	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Through	O	ADP	O
gene	O	NOUN	B
targeting	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
a	O	DET	O
line	O	NOUN	O
of	O	ADP	O
Atm	O	NOUN	B
mutant	O	ADJ	I
mice	O	NOUN	O
,	O	PUNCT	O
Atm	O	NOUN	B
(	O	PUNCT	O
y	O	NOUN	O
/	O	SYM	O
y	O	NOUN	O
)	O	PUNCT	O
mice	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
other	O	ADJ	O
Atm	O	NOUN	B
mutant	O	ADJ	I
mice	O	NOUN	O
,	O	PUNCT	O
Atm	O	NOUN	B
(	O	PUNCT	O
y	O	NOUN	O
/	O	SYM	O
y	O	NOUN	O
)	O	PUNCT	O
mice	O	NOUN	B
show	O	VERB	O
a	O	DET	O
lower	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
thymic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
and	O	CCONJ	O
survive	O	VERB	B
beyond	O	ADP	O
a	O	DET	O
few	O	ADJ	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Atm	O	NOUN	B
(	O	PUNCT	O
y	O	NOUN	O
/	O	SYM	O
y	O	NOUN	O
)	O	PUNCT	O
mice	O	NOUN	B
exhibit	O	VERB	O
deficits	O	NOUN	B
in	O	ADP	O
motor	O	NOUN	B
learning	O	NOUN	I
indicative	O	ADJ	B
of	O	ADP	O
cerebellar	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
.	O	PUNCT	O


Even	O	ADV	O
though	O	SCONJ	O
we	O	PRON	O
found	O	VERB	O
no	O	DET	O
gross	O	ADJ	B
cerebellar	B-Disease	ADJ	I
degeneration	I-Disease	NOUN	I
in	O	ADP	O
older	O	ADJ	B
Atm	O	NOUN	B
(	O	PUNCT	O
y	O	NOUN	O
/	O	SYM	O
y	O	NOUN	B
)	O	PUNCT	O
animals	O	NOUN	B
,	O	PUNCT	O
ectopic	O	ADJ	B
and	O	CCONJ	O
abnormally	O	ADV	B
differentiated	O	VERB	O
Purkinje	O	NOUN	B
cells	O	NOUN	I
were	O	AUX	O
apparent	O	ADJ	B
in	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	I
of	O	ADP	O
all	O	DET	O
ages	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
establish	O	VERB	O
that	O	SCONJ	O
some	O	DET	O
neuropathological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
seen	O	VERB	O
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
also	O	ADV	O
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
Atm	O	NOUN	B
mutant	O	ADJ	I
mice	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
a	O	DET	O
previously	O	ADV	O
unrecognized	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
Atm	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
on	O	ADP	O
development	O	NOUN	B
or	O	CCONJ	O
maintenance	O	NOUN	B
of	O	ADP	O
CD4	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
8	O	NUM	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
thymocytes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
discuss	O	VERB	O
these	O	DET	O
findings	O	NOUN	B
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
abnormal	O	ADJ	B
development	O	NOUN	I
of	O	ADP	O
Purkinje	O	NOUN	B
cells	O	NOUN	I
and	O	CCONJ	O
lymphocytes	O	NOUN	B
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Novel	O	ADJ	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATP7B	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
WD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
copper	O	NOUN	B
accumulation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
kidneys	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
corneas	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
culminating	O	VERB	O
in	O	ADP	O
copper	O	NOUN	B
toxication	O	NOUN	B
in	O	ADP	O
these	O	DET	O
organs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
responsible	O	ADJ	O
gene	O	NOUN	B
,	O	PUNCT	O
ATP7B	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
four	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
WD	B-Disease	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
direct	O	ADJ	B
sequencing	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
five	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
two	O	NUM	O
were	O	AUX	O
novel	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
polymorphisms	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
6	O	NUM	O
were	O	AUX	O
novel	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
2871delC	O	NUM	O
and	O	CCONJ	O
2513delA	O	NOUN	O
shift	O	NOUN	B
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
so	O	SCONJ	O
that	O	SCONJ	O
truncated	O	VERB	B
abnormal	O	ADJ	O
protein	O	NOUN	O
is	O	AUX	O
expected	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
these	O	DET	O
mutations	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hepatic	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
onset	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mutations	O	NOUN	B
A874V	O	NOUN	O
,	O	PUNCT	O
R778L	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
3892delGTC	O	NUM	O
were	O	AUX	O
either	O	CCONJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
frame	O	NOUN	O
1	O	NUM	O
-	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
deletion	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
hepato	O	NOUN	B
-	O	PUNCT	O
neurologic	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
late	O	ADJ	O
onset	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
2871delC	O	NUM	O
and	O	CCONJ	O
R778L	O	PROPN	B
have	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
large	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
R778L	O	NOUN	B
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
prevalent	O	ADJ	B
in	O	ADP	O
Asian	O	ADJ	B
countries	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
other	O	ADJ	O
countries	O	NOUN	B
of	O	ADP	O
the	O	DET	O
world	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
mutations	O	NOUN	B
tend	O	VERB	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
types	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
WD	B-Disease	NOUN	B
will	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
fast	O	ADJ	B
and	O	CCONJ	O
effective	O	ADJ	B
genetic	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
WD	B-Disease	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Autoinhibition	O	NOUN	B
and	O	CCONJ	O
activation	O	NOUN	B
mechanisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Rho	O	NOUN	B
-	O	PUNCT	O
family	O	NOUN	B
GTPase	O	NOUN	B
,	O	PUNCT	O
Cdc42	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
regulate	O	VERB	B
the	O	DET	O
actin	O	NOUN	B
cytoskeleton	O	NOUN	I
through	O	ADP	O
activation	O	NOUN	B
of	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	B
)	O	PUNCT	O
family	O	NOUN	B
members	O	NOUN	I
.	O	PUNCT	O


Activation	O	NOUN	B
relieves	O	VERB	O
an	O	DET	O
autoinhibitory	O	ADJ	B
contact	O	NOUN	B
between	O	ADP	O
the	O	DET	O
GTPase	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
autoinhibited	O	ADJ	B
structure	O	NOUN	O
of	O	ADP	O
the	O	DET	O
GTPase	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
of	O	ADP	O
WASP	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
be	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	O
or	O	CCONJ	O
by	O	ADP	O
organic	O	ADJ	B
co	O	X	B
-	O	PUNCT	O
solvents	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
autoinhibited	O	ADJ	B
complex	O	NOUN	I
,	O	PUNCT	O
intramolecular	O	ADJ	B
interactions	O	NOUN	I
with	O	ADP	O
the	O	DET	O
GTPase	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
occlude	O	VERB	O
residues	O	NOUN	O
of	O	ADP	O
the	O	DET	O
C	O	NOUN	O
terminus	O	NOUN	B
that	O	PRON	O
regulate	O	VERB	B
the	O	DET	O
Arp2	O	PROPN	B
/	O	SYM	O
3	O	NUM	B
actin	O	NOUN	B
-	O	PUNCT	O
nucleating	O	VERB	B
complex	O	NOUN	I
.	O	PUNCT	O


Binding	O	NOUN	B
of	O	ADP	O
Cdc42	O	NOUN	B
to	O	PART	O
the	O	DET	O
GTPase	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
causes	O	VERB	O
a	O	DET	O
dramatic	O	ADJ	O
conformational	O	ADJ	B
change	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hydrophobic	O	ADJ	B
core	O	NOUN	B
and	O	CCONJ	O
release	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C	O	NOUN	B
terminus	O	NOUN	B
,	O	PUNCT	O
enabling	O	VERB	O
its	O	PRON	O
interaction	O	NOUN	B
with	O	ADP	O
the	O	DET	O
actin	O	NOUN	B
regulatory	O	ADJ	I
machinery	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
intrinsically	O	ADV	O
unstructured	O	ADJ	O
peptides	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
GTPase	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
of	O	ADP	O
WASP	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
induced	O	VERB	B
into	O	ADP	O
distinct	O	ADJ	O
structural	O	ADJ	B
and	O	CCONJ	O
functional	O	ADJ	B
states	O	NOUN	B
depending	O	VERB	O
on	O	ADP	O
context	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


hCds1	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
phosphorylation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
regulates	O	VERB	B
the	O	DET	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
are	O	AUX	O
found	O	VERB	O
in	O	ADP	O
almost	O	ADV	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
with	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
and	O	CCONJ	O
about	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
with	O	ADP	O
only	O	ADV	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
biochemical	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
is	O	AUX	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
repair	O	NOUN	I
and	O	CCONJ	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
checkpoint	O	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
exists	O	VERB	O
in	O	ADP	O
nuclear	O	ADJ	B
foci	O	NOUN	I
but	O	CCONJ	O
is	O	AUX	O
hyperphosphorylated	O	VERB	B
and	O	CCONJ	O
disperses	O	VERB	B
after	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
whether	O	SCONJ	O
BRCA1	O	NOUN	B
phosphorylation	O	NOUN	B
and	O	CCONJ	O
dispersion	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
function	O	NOUN	B
in	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
are	O	AUX	O
related	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
yeast	O	NOUN	B
the	O	DET	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
replication	O	NOUN	B
-	O	PUNCT	O
block	O	NOUN	B
checkpoint	O	NOUN	B
are	O	AUX	O
mediated	O	VERB	O
partly	O	ADV	O
through	O	ADP	O
the	O	DET	O
Cds1	O	NOUN	B
kinase	O	NOUN	I
family	O	NOUN	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
human	O	ADJ	B
Cds1	O	NOUN	O
kinase	O	NOUN	O
(	O	PUNCT	O
hCds1	O	NOUN	B
/	O	SYM	O
Chk2	O	NOUN	B
)	O	PUNCT	O
regulates	O	VERB	B
BRCA1	O	NOUN	B
function	O	NOUN	B
after	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
by	O	ADP	O
phosphorylating	O	VERB	B
serine	O	NOUN	I
988	O	NUM	I
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
hCds1	O	NOUN	B
and	O	CCONJ	O
BRCA1	O	NOUN	B
interact	O	VERB	B
and	O	CCONJ	O
co	O	X	B
-	O	PUNCT	O
localize	O	NOUN	B
within	O	ADP	O
discrete	O	ADJ	O
nuclear	O	ADJ	B
foci	O	NOUN	I
but	O	CCONJ	O
separate	O	ADJ	O
after	O	ADP	O
gamma	O	NOUN	B
irradiation	O	NOUN	I
.	O	PUNCT	O


Phosphorylation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
at	O	ADP	O
serine	O	NOUN	B
988	O	NUM	I
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
from	O	ADP	O
hCds1	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
phosphorylation	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
important	O	ADJ	O
for	O	ADP	O
the	O	DET	O
ability	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
to	O	PART	O
restore	O	VERB	B
survival	O	NOUN	B
after	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
mutated	O	VERB	B
cell	O	NOUN	I
line	O	NOUN	I
HCC1937	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
spinocerebellar	O	NOUN	O
ataxia	O	NOUN	O
type	O	NOUN	O
3	O	NUM	O
gene	O	NOUN	O
.	O	PUNCT	O


Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
belongs	O	VERB	O
to	O	PART	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
clinically	O	ADV	B
and	O	CCONJ	O
genetically	O	ADV	B
heterogeneous	O	ADJ	O
neurodegenerative	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
progressive	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
mutation	O	NOUN	B
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
an	O	DET	O
unstable	O	ADJ	B
and	O	CCONJ	O
expanded	O	VERB	O
(	O	PUNCT	O
CAG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
trinucleotide	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	B
of	O	ADP	O
unknown	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Caucasians	O	PROPN	B
,	O	PUNCT	O
repeat	O	NOUN	O
expansions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
clinically	O	ADV	B
distinct	O	ADJ	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
spinocerebellar	B-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
type	I-Disease	NOUN	I
3	I-Disease	NUM	I
(	O	PUNCT	O
SCA3	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
gain	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
biology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
/	O	SYM	O
SCA3	O	NOUN	B
gene	O	NOUN	O
we	O	PRON	O
cloned	O	VERB	B
the	O	DET	O
rat	O	NOUN	B
homologue	O	NOUN	B
and	O	CCONJ	O
studied	O	VERB	O
its	O	PRON	O
expression	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rat	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	O
genes	O	NOUN	B
are	O	AUX	O
highly	O	ADV	O
homologous	O	ADJ	B
with	O	ADP	O
an	O	DET	O
overall	O	ADJ	O
sequence	O	NOUN	B
identity	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
88	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
terminal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
putative	O	ADJ	B
protein	O	NOUN	I
differs	O	VERB	O
strongly	O	ADV	O
from	O	ADP	O
the	O	DET	O
published	O	VERB	B
human	O	ADJ	B
sequence	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
(	O	PUNCT	O
CAG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
block	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
cDNA	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
just	O	ADV	O
three	O	NUM	O
interrupted	O	ADJ	B
units	O	NOUN	O
suggesting	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
long	O	ADJ	O
polyglutamine	O	NOUN	B
stretch	O	NOUN	I
is	O	AUX	O
not	O	PART	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ataxin	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
protein	O	NOUN	I
in	O	ADP	O
rodents	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
pattern	O	NOUN	I
of	O	ADP	O
the	O	DET	O
SCA3	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
various	O	ADJ	O
rat	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
tissues	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
Northern	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mature	O	ADJ	B
transcript	O	NOUN	B
is	O	AUX	O
approximately	O	ADV	O
6	O	NUM	O
kb	O	NOUN	O
in	O	ADP	O
length	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
rat	O	NOUN	B
testis	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
smaller	O	ADJ	O
transcript	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
kb	O	NOUN	O
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Transcription	O	NOUN	B
of	O	ADP	O
rsca3	O	PROPN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
most	O	ADJ	O
rat	O	NOUN	B
tissues	O	NOUN	B
including	O	VERB	O
brain	O	NOUN	B
.	O	PUNCT	O


Analyzing	O	VERB	O
the	O	DET	O
expression	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SCA3	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
several	O	ADJ	O
human	O	ADJ	B
brain	O	NOUN	B
sections	O	NOUN	I
revealed	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
higher	O	ADJ	O
mRNA	O	NOUN	B
level	O	NOUN	O
in	O	ADP	O
regions	O	NOUN	B
predominantly	O	ADV	O
affected	O	VERB	B
in	O	ADP	O
MJD	B-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
additional	O	ADJ	O
molecules	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
regulatory	O	ADJ	B
events	O	NOUN	I
are	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
exclusive	O	ADJ	O
degeneration	B-Disease	NOUN	B
of	I-Disease	ADP	O
certain	I-Disease	ADJ	O
brain	I-Disease	NOUN	B
areas	I-Disease	NOUN	I
.	O	PUNCT	O


Emerin	B-Disease	NOUN	B
,	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
of	O	ADP	O
which	O	DET	O
causes	O	VERB	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
localized	O	ADJ	B
at	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
nuclear	O	ADJ	I
membrane	O	NOUN	I
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
Emery	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EDMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
muscle	I-Disease	NOUN	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
triad	O	NOUN	I
of	O	ADP	O
progressive	O	ADJ	B
wasting	B-Disease	NOUN	B
of	I-Disease	ADP	O
humero	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
peroneal	I-Disease	NOUN	B
muscles	I-Disease	NOUN	I
,	O	PUNCT	O
early	O	ADJ	B
contractures	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
elbows	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
Achilles	I-Disease	NOUN	B
tendons	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
postcervical	I-Disease	ADJ	B
muscles	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
block	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
high	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
EDMD	B-Disease	NOUN	B
on	O	ADP	O
Xq28	O	NOUN	B
encodes	O	VERB	I
a	O	DET	O
novel	O	ADJ	O
protein	O	NOUN	B
named	O	VERB	O
emerin	O	NOUN	B
that	O	PRON	O
localizes	O	VERB	B
at	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
membrane	O	NOUN	I
of	O	ADP	O
skeletal	O	ADJ	B
,	O	PUNCT	O
cardiac	O	ADJ	B
and	O	CCONJ	O
smooth	O	ADJ	B
muscles	O	NOUN	I
and	O	CCONJ	O
some	O	DET	O
other	O	ADJ	O
non	O	ADJ	B
-	O	PUNCT	O
muscle	O	NOUN	B
tissues	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
a	O	DET	O
possible	O	ADJ	O
physiological	O	ADJ	B
role	O	NOUN	O
for	O	ADP	O
emerin	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
ultrastructural	O	ADJ	B
localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
skeletal	O	ADJ	B
muscle	O	NOUN	I
and	O	CCONJ	O
HeLa	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
ultrathin	O	ADJ	B
cryosections	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
immune	O	ADJ	B
-	O	PUNCT	O
labeled	O	VERB	B
colloidal	O	ADJ	B
gold	O	NOUN	B
particles	O	NOUN	O
were	O	AUX	O
localized	O	VERB	B
on	O	ADP	O
the	O	DET	O
nucleoplasmic	O	ADJ	B
surface	O	NOUN	I
of	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
nuclear	O	ADJ	I
membrane	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
on	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
pore	O	NOUN	I
.	O	PUNCT	O


Emerin	O	NOUN	B
stayed	O	VERB	O
on	O	ADP	O
the	O	DET	O
cytoplasmic	O	ADJ	B
surface	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
lamina	O	NOUN	I
,	O	PUNCT	O
even	O	ADV	O
after	O	ADP	O
detergent	O	NOUN	B
treatment	O	NOUN	B
that	O	PRON	O
solubilizes	O	VERB	B
membrane	O	NOUN	I
lipids	O	NOUN	I
and	O	CCONJ	O
washes	O	VERB	B
out	O	ADP	O
membrane	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
anchors	O	NOUN	I
at	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
nuclear	O	ADJ	I
membrane	O	NOUN	I
through	O	ADP	O
the	O	DET	O
hydrophobic	O	ADJ	B
stretch	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
protrudes	O	VERB	B
from	O	ADP	O
the	O	DET	O
hydrophilic	O	ADJ	B
region	O	NOUN	B
to	O	PART	O
the	O	DET	O
nucleoplasm	O	NOUN	B
where	O	SCONJ	O
it	O	PRON	O
interacts	O	VERB	O
with	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
lamina	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
speculate	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
contributes	O	VERB	O
to	O	PART	O
maintain	O	VERB	O
the	O	DET	O
nuclear	O	ADJ	B
structure	O	NOUN	I
and	O	CCONJ	O
stability	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
nuclear	O	ADJ	B
functions	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
muscle	O	NOUN	B
tissues	O	NOUN	I
that	O	PRON	O
have	O	AUX	O
severe	O	ADJ	B
stress	O	NOUN	B
with	O	ADP	O
rigorous	O	ADJ	O
contraction	O	NOUN	B
-	O	PUNCT	O
relaxation	O	NOUN	B
movements	O	NOUN	B
and	O	CCONJ	O
calcium	O	NOUN	B
flux	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Locus	O	NOUN	B
heterogeneity	O	NOUN	B
in	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
ataxia	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
was	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
9	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
STM7	O	NOUN	B
/	O	SYM	O
X25	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
isolated	O	VERB	B
.	O	PUNCT	O


To	O	PART	O
date	O	VERB	O
most	O	ADJ	O
data	O	NOUN	B
suggest	O	VERB	O
locus	O	NOUN	B
homogeneity	O	NOUN	B
in	O	ADP	O
FRDA	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
provide	O	VERB	O
strong	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
second	O	ADJ	O
FRDA	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


Studying	O	VERB	O
two	O	NUM	O
siblings	O	NOUN	B
with	O	ADP	O
FRDA	B-Disease	NOUN	B
from	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
detect	O	VERB	B
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
STM7	O	NOUN	B
/	O	SYM	O
X25	O	NOUN	B
.	O	PUNCT	O


Haplotype	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
STM7	O	NOUN	B
/	O	SYM	O
X25	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	B
9	O	NUM	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
relevant	O	ADJ	B
portion	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
9	O	NUM	I
differs	O	VERB	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
studied	O	VERB	O
had	O	AUX	O
typical	O	ADJ	O
FRDA	B-Disease	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
sibpair	O	NOUN	B
had	O	AUX	O
the	O	DET	O
uncommon	O	ADJ	O
symptom	O	NOUN	B
of	O	ADP	O
retained	O	VERB	B
tendon	O	NOUN	B
reflexes	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
retained	O	VERB	B
tendon	O	NOUN	B
reflexes	O	NOUN	I
are	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
FRDA	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
second	O	ADJ	O
locus	O	NOUN	B
,	O	PUNCT	O
FRDA2	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
an	O	DET	O
unrelated	O	ADJ	O
FRDA	B-Disease	NOUN	B
patient	O	NOUN	B
with	O	ADP	O
retained	O	VERB	O
tendon	O	NOUN	B
reflexes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
observation	O	NOUN	B
of	O	ADP	O
typical	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
STM7	O	NOUN	B
/	O	SYM	O
X25	O	NOUN	B
(	O	PUNCT	O
GAA	O	NOUN	B
expansions	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
genetically	O	ADV	B
different	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
FRDA	B-Disease	NOUN	B
cannot	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
clinically	O	ADV	B
.	O	PUNCT	O
.	O	PUNCT	O


Glycerol	O	NOUN	B
as	O	ADP	O
a	O	DET	O
correlate	O	NOUN	B
of	O	ADP	O
impaired	B-Disease	ADJ	B
glucose	I-Disease	NOUN	B
tolerance	I-Disease	NOUN	I
:	O	PUNCT	O
dissection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
system	O	NOUN	I
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
simple	O	ADJ	O
genetic	O	ADJ	B
trait	O	NOUN	I
.	O	PUNCT	O


Glycerol	O	NOUN	B
kinase	O	NOUN	I
(	O	PUNCT	O
GK	O	NOUN	B
)	O	PUNCT	O
represents	O	VERB	O
the	O	DET	O
primary	O	ADJ	B
entry	O	NOUN	O
of	O	ADP	O
glycerol	O	NOUN	B
into	O	ADP	O
glucose	O	NOUN	B
and	O	CCONJ	O
triglyceride	O	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


Impaired	B-Disease	ADJ	B
glucose	I-Disease	NOUN	I
tolerance	I-Disease	NOUN	I
(	O	PUNCT	O
IGT	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
hypertriglyceridemia	B-Disease	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
and	O	CCONJ	O
cardiovascular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
glycerol	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
IGT	B-Disease	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
is	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
undertook	O	VERB	O
the	O	DET	O
study	O	NOUN	B
of	O	ADP	O
fasting	O	VERB	B
plasma	O	NOUN	B
glycerol	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
a	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
056	O	NUM	O
unrelated	O	ADJ	O
men	O	NOUN	B
and	O	CCONJ	O
women	O	NOUN	B
of	O	ADP	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
descent	O	NOUN	B
.	O	PUNCT	O


Family	O	NOUN	B
screening	O	NOUN	I
in	O	ADP	O
the	O	DET	O
initial	O	ADJ	O
cohort	O	NOUN	B
identified	O	VERB	B
18	O	NUM	O
men	O	NOUN	B
from	O	ADP	O
five	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
hyperglycerolemia	B-Disease	NOUN	B
(	O	PUNCT	O
values	O	NOUN	B
above	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
liter	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
demonstrated	O	VERB	O
an	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
pattern	O	NOUN	B
of	O	ADP	O
inheritance	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
from	O	ADP	O
12	O	NUM	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
Xp21	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
GK	O	NOUN	B
gene	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
peak	O	NOUN	O
LOD	O	NOUN	O
score	O	NOUN	B
of	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


46	O	NUM	O
,	O	PUNCT	O
centered	O	VERB	O
around	O	ADP	O
marker	O	NOUN	B
DXS8039	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
since	O	SCONJ	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
originated	O	VERB	O
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
with	O	ADP	O
a	O	DET	O
proven	O	VERB	O
founder	O	NOUN	B
effect	O	NOUN	B
-	O	PUNCT	O
the	O	DET	O
Saguenay	O	PROPN	B
Lac	O	PROPN	I
-	O	PUNCT	O
St	O	PROPN	B
.	O	PUNCT	O


-	O	PUNCT	O
Jean	O	PROPN	B
region	O	NOUN	I
of	O	ADP	O
Quebec	O	PROPN	B
-	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
disease	O	NOUN	B
haplotype	O	NOUN	B
was	O	AUX	O
sought	O	VERB	O
.	O	PUNCT	O


Indeed	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
six	O	NUM	B
-	O	PUNCT	O
marker	O	NOUN	B
haplotype	O	NOUN	B
extending	O	VERB	O
over	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
cM	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


Resequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GK	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
family	O	NOUN	B
members	O	NOUN	I
led	O	VERB	O
to	O	PART	O
the	O	DET	O
discovery	O	NOUN	B
of	O	ADP	O
a	O	DET	O
N288D	O	NOUN	B
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
10	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
asparagine	O	NOUN	B
residue	O	NOUN	B
by	O	ADP	O
a	O	DET	O
negatively	O	ADV	B
charged	O	VERB	I
aspartic	O	ADJ	I
acid	O	NOUN	I
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
genetics	O	NOUN	O
of	O	ADP	O
primary	B-Disease	ADJ	B
dystonias	I-Disease	NOUN	I
.	O	PUNCT	O


Primary	B-Disease	ADJ	B
dystonias	I-Disease	NOUN	I
are	O	AUX	O
movement	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
with	O	ADP	O
dystonia	B-Disease	NOUN	B
as	O	ADP	O
a	O	DET	O
major	O	ADJ	O
symptom	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
are	O	AUX	O
frequently	O	ADV	O
inherited	O	VERB	B
as	O	ADP	O
Mendelian	O	ADJ	B
traits	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
eight	O	NUM	O
clinically	O	ADV	B
distinct	O	ADJ	O
autosomal	O	ADJ	B
dominant	O	ADJ	B
and	O	CCONJ	O
two	O	NUM	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
recessive	O	ADJ	B
forms	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
pedigree	O	NOUN	B
analyses	O	NOUN	I
suggest	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	O
variant	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
classification	O	NOUN	I
is	O	AUX	O
increasingly	O	ADV	O
being	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
one	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
date	O	NOUN	O
gene	O	NOUN	B
loci	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
six	O	NUM	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
forms	O	NOUN	O
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
idiopathic	B-Disease	ADJ	B
torsion	I-Disease	NOUN	I
dystonia	I-Disease	NOUN	I
(	O	PUNCT	O
9q34	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
focal	B-Disease	ADJ	B
dystonia	I-Disease	NOUN	I
(	O	PUNCT	O
18p	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
idiopathic	B-Disease	ADJ	B
torsion	I-Disease	NOUN	I
dystonia	I-Disease	NOUN	I
of	O	ADP	O
mixed	O	ADJ	B
type	O	NOUN	I
(	O	PUNCT	O
8p21	O	NOUN	B
-	O	PUNCT	O
q22	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
dopa	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
responsive	I-Disease	ADJ	B
dystonia	I-Disease	NOUN	B
(	O	PUNCT	O
14q22	O	NOUN	O
.	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
q22	O	NOUN	B
.	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
paroxysmal	B-Disease	ADJ	B
dystonic	I-Disease	ADJ	I
choreoathetosis	I-Disease	NOUN	I
(	O	PUNCT	O
2q25	O	NOUN	B
-	O	PUNCT	O
q33	O	NOUN	B
;	O	PUNCT	O
1p21	O	NOUN	B
-	O	PUNCT	O
p13	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Gene	O	NOUN	B
loci	O	NOUN	I
in	O	ADP	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
recessive	O	ADJ	B
forms	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
Xq13	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
in	O	ADP	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
dystonia	I-Disease	NOUN	B
parkinsonism	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
Xq22	O	NOUN	B
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
sensorineural	I-Disease	ADJ	B
deafness	I-Disease	NOUN	I
,	O	PUNCT	O
dystonia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
genes	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
two	O	NUM	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
forms	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
recessive	O	ADJ	B
form	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
an	O	DET	O
ATP	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
protein	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
idiopathic	B-Disease	ADJ	B
torsion	I-Disease	NOUN	I
dystonia	I-Disease	NOUN	I
(	O	PUNCT	O
DYT1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
GTP	O	NOUN	B
cyclohydrolase	O	NOUN	I
1	O	NUM	I
gene	O	NOUN	I
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
dopa	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
responsive	I-Disease	ADJ	B
dystonia	I-Disease	NOUN	B
(	O	PUNCT	O
DYT5	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
sensorineural	B-Disease	ADJ	B
deafness	I-Disease	NOUN	I
,	O	PUNCT	O
dystonia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
DDP	O	NOUN	B
coding	O	VERB	B
for	O	ADP	O
a	O	DET	O
polypeptide	O	NOUN	B
of	O	ADP	O
unknown	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	O
reviews	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
genetics	O	NOUN	O
of	O	ADP	O
primary	B-Disease	ADJ	B
dystonias	I-Disease	NOUN	I
,	O	PUNCT	O
critically	O	ADV	O
discusses	O	VERB	O
present	O	ADJ	O
findings	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
proposes	O	VERB	O
referring	O	VERB	O
to	O	ADP	O
the	O	DET	O
known	O	ADJ	O
forms	O	NOUN	O
,	O	PUNCT	O
most	O	ADJ	O
of	O	ADP	O
which	O	DET	O
can	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
by	O	ADP	O
genetic	O	ADJ	B
criteria	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
dystonias	B-Disease	NOUN	B
1	I-Disease	NUM	O
-	I-Disease	SYM	O
12	I-Disease	NUM	O
.	O	PUNCT	O


Determination	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
15	O	NUM	O
not	O	PART	O
previously	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
peroxisomal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
mainly	O	ADV	O
involves	O	VERB	O
the	O	DET	O
nervous	O	ADJ	B
system	O	NOUN	I
white	O	ADJ	B
matter	O	NOUN	I
,	O	PUNCT	O
adrenal	O	ADJ	B
cortex	O	NOUN	I
and	O	CCONJ	O
testes	O	NOUN	B
.	O	PUNCT	O


Several	O	ADJ	O
distinct	O	ADJ	O
clinical	O	ADJ	B
phenotypes	O	NOUN	B
are	O	AUX	O
known	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
principal	O	ADJ	B
biochemical	O	ADJ	B
abnormality	O	NOUN	O
is	O	AUX	O
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
saturated	O	VERB	B
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
(	O	PUNCT	O
VLCFAs	O	NOUN	B
>	O	X	O
C22	O	NOUN	O
0	O	NUM	O
,	O	PUNCT	O
mainly	O	ADV	O
C26	O	NOUN	O
0	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
impaired	O	ADJ	B
capacity	O	NOUN	B
for	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
in	O	ADP	O
peroxisomes	O	NOUN	B
.	O	PUNCT	O


Diagnosis	O	NOUN	B
is	O	AUX	O
usually	O	ADV	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
VLCFA	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
or	O	CCONJ	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	B
in	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
carriers	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
plasma	O	NOUN	B
C26	O	NOUN	O
0	O	NUM	O
level	O	NOUN	B
is	O	AUX	O
borderline	O	NOUN	B
normal	O	ADJ	I
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
obligate	O	ADJ	B
female	O	ADJ	B
carriers	O	NOUN	B
have	O	AUX	O
normal	O	ADJ	O
results	O	NOUN	O
.	O	PUNCT	O


Effective	O	ADJ	B
mutation	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
is	O	AUX	O
therefore	O	ADV	O
fundamental	O	ADJ	O
to	O	PART	O
unambiguously	O	ADV	O
determine	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
status	O	NOUN	I
of	O	ADP	O
each	O	DET	O
individual	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
particular	O	ADJ	O
concern	O	NOUN	O
are	O	AUX	O
female	O	ADJ	B
members	O	NOUN	I
of	O	ADP	O
kindreds	O	NOUN	B
segregating	O	VERB	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
normal	O	ADJ	O
VLCFA	O	NOUN	B
levels	O	NOUN	B
do	O	AUX	O
not	O	PART	O
guarantee	O	VERB	O
lack	O	NOUN	O
of	O	ADP	O
carrier	O	NOUN	B
status	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
fast	O	ADJ	B
method	O	NOUN	I
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
method	O	NOUN	B
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
nested	O	ADJ	B
PCR	O	NOUN	B
fragments	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
sequence	O	NOUN	B
-	O	PUNCT	O
determination	O	NOUN	B
reactions	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
methodology	O	NOUN	B
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
30	O	NUM	O
kindreds	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
15	O	NUM	O
not	O	PART	O
previously	O	ADV	O
reported	O	VERB	O
.	O	PUNCT	O


beta	O	NOUN	B
-	O	PUNCT	O
galactosidase	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
affecting	O	VERB	O
the	O	DET	O
lysosomal	O	ADJ	B
enzyme	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
elastin	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
protein	O	NOUN	I
in	O	ADP	O
GM1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
gangliosidosis	I-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
cardiac	B-Disease	ADJ	B
involvement	I-Disease	NOUN	B
.	O	PUNCT	O


GM1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
gangliosidosis	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
lysosomal	B-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
acid	I-Disease	NOUN	B
beta	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
galactosidase	I-Disease	NOUN	B
(	O	PUNCT	O
GLB1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
five	O	NUM	O
new	O	ADJ	O
beta	O	NOUN	B
-	O	PUNCT	O
galactosidase	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
nine	O	NUM	O
Italian	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
fetus	O	NOUN	B
,	O	PUNCT	O
segregating	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
of	O	ADP	O
the	O	DET	O
eight	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
infantile	O	ADJ	B
,	O	PUNCT	O
severe	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
presented	O	VERB	O
cardiac	B-Disease	ADJ	B
involvement	I-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
feature	O	NOUN	O
rarely	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
GM1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
gangliosidosis	I-Disease	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
RNA	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
identified	O	VERB	B
two	O	NUM	O
new	O	ADJ	O
RNA	O	NOUN	B
splicing	O	NOUN	I
defects	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
new	O	ADJ	O
and	O	CCONJ	O
three	O	NUM	O
previously	O	ADV	O
described	O	VERB	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
cardiac	B-Disease	ADJ	B
involvement	I-Disease	NOUN	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
R59H	O	NOUN	O
,	O	PUNCT	O
Y591C	O	NOUN	B
,	O	PUNCT	O
Y591N	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
IVS14	O	NOUN	B
-	O	PUNCT	O
2A	O	NOUN	B
>	O	X	O
G	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
all	O	DET	O
other	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
compound	O	NOUN	B
heterozygous	O	ADJ	I
for	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
following	O	VERB	O
mutations	O	NOUN	B
R201H	O	NOUN	B
,	O	PUNCT	O
R482H	O	NOUN	O
,	O	PUNCT	O
G579D	O	NOUN	O
,	O	PUNCT	O
IVS8	O	NOUN	B
+	O	CCONJ	O
2T	O	NOUN	O
>	O	NOUN	O
C	O	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
we	O	PRON	O
could	O	AUX	O
not	O	PART	O
directly	O	ADV	O
correlate	O	VERB	B
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
cardiac	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
with	O	ADP	O
specific	O	ADJ	O
genetic	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mutations	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cardiomyopathy	B-Disease	NOUN	B
fell	O	VERB	O
in	O	ADP	O
the	O	DET	O
GLB1	O	NOUN	B
cDNA	O	NOUN	B
region	O	NOUN	I
common	O	ADJ	O
to	O	PART	O
the	O	DET	O
lysosomal	O	ADJ	B
enzyme	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
Hbeta	O	PROPN	B
-	O	PUNCT	O
Gal	O	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
protein	O	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
the	O	DET	O
elastin	O	NOUN	B
binding	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
EBP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
both	O	DET	O
molecules	O	NOUN	B
are	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
they	O	PRON	O
may	O	AUX	O
contribute	O	VERB	O
differently	O	ADV	O
to	O	PART	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
clinical	O	ADJ	B
manifestations	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


In	O	X	B
vivo	O	X	I
modulation	O	NOUN	B
of	O	ADP	O
Hmgic	O	NOUN	B
reduces	O	VERB	B
obesity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
HMGI	O	NOUN	B
family	O	NOUN	O
of	O	ADP	O
proteins	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
three	O	NUM	O
members	O	NOUN	B
,	O	PUNCT	O
HMGIC	O	NOUN	B
,	O	PUNCT	O
HMGI	O	NOUN	B
and	O	CCONJ	O
HMGI	O	NOUN	B
(	O	PUNCT	O
Y	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
that	O	PRON	O
function	O	VERB	B
as	O	ADP	O
architectural	O	ADJ	B
factors	O	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
essential	O	ADJ	O
components	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enhancesome	O	NOUN	B
.	O	PUNCT	O


HMGIC	O	NOUN	B
is	O	AUX	O
predominantly	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
proliferating	O	NOUN	B
,	O	PUNCT	O
undifferentiated	O	ADJ	B
mesenchymal	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
adult	O	ADJ	B
tissues	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
disrupted	O	VERB	B
and	O	CCONJ	O
misexpressed	O	VERB	B
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
mesenchymal	B-Disease	ADJ	B
tumour	I-Disease	NOUN	I
cell	O	NOUN	I
types	O	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
fat	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
tumours	I-Disease	NOUN	I
(	O	PUNCT	O
lipomas	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
Hmgic	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
have	O	AUX	O
a	O	DET	O
deficiency	O	NOUN	B
in	O	ADP	O
fat	O	NOUN	B
tissue	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
its	O	PRON	O
role	O	NOUN	O
in	O	ADP	O
adipogenesis	O	NOUN	B
and	O	CCONJ	O
obesity	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
Hmgic	O	ADJ	B
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
adipose	O	NOUN	B
tissue	O	NOUN	I
of	O	ADP	O
adult	O	ADJ	B
,	O	PUNCT	O
obese	B-Disease	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


Mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
partial	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
complete	I-Disease	ADJ	O
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
Hmgic	I-Disease	ADJ	B
resisted	O	ADJ	O
diet	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
obesity	B-Disease	NOUN	B
.	O	PUNCT	O


Disruption	O	NOUN	B
of	O	ADP	O
Hmgic	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
obesity	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
leptin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
Lepob	O	PROPN	B
/	O	SYM	O
Lepob	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
-	O	PUNCT	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
studies	O	NOUN	B
implicate	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
HMGIC	O	NOUN	B
in	O	ADP	O
fat	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
proliferation	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
adipose	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
target	O	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obesity	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
relationship	O	NOUN	B
in	O	ADP	O
factor	B-Disease	NOUN	B
X	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Factor	B-Disease	NOUN	B
X	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
haemorrhagic	B-Disease	ADJ	B
condition	I-Disease	NOUN	O
,	O	PUNCT	O
normally	O	ADV	O
inherited	O	VERB	B
as	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	B
trait	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
a	O	DET	O
variable	O	ADJ	B
clinical	O	ADJ	B
presentation	O	NOUN	O
correlates	O	VERB	O
poorly	O	ADV	B
with	O	ADP	O
laboratory	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
factor	O	NOUN	B
X	O	NOUN	I
(	O	PUNCT	O
F10	O	NOUN	O
)	O	PUNCT	O
genes	O	NOUN	O
of	O	ADP	O
14	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
factor	B-Disease	NOUN	B
X	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
12	O	NUM	O
familial	O	ADJ	B
and	O	CCONJ	O
two	O	NUM	O
sporadic	O	ADJ	B
cases	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
sequenced	O	VERB	B
yielding	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
13	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


Family	O	NOUN	B
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
distinguish	O	VERB	O
the	O	DET	O
contributions	O	NOUN	B
of	O	ADP	O
individual	O	ADJ	O
mutant	O	ADJ	B
F10	O	NOUN	O
alleles	O	NOUN	B
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


Missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
modelling	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
single	O	ADJ	O
basepair	O	NOUN	B
substitutions	O	NOUN	I
in	O	ADP	O
splice	O	NOUN	B
sites	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
5	O	NUM	O
flanking	O	NOUN	B
region	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
in	O	X	B
vitro	O	X	I
splicing	O	NOUN	B
assay	O	NOUN	I
and	O	CCONJ	O
luciferase	O	NOUN	B
reporter	O	NOUN	I
gene	O	NOUN	I
assay	O	NOUN	I
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
allele	O	NOUN	I
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
hexanucleotide	O	NOUN	B
insertion	O	NOUN	I
/	O	SYM	O
deletion	O	NOUN	B
polymorphism	O	NOUN	B
in	O	ADP	O
the	O	DET	O
F10	O	NOUN	B
gene	O	NOUN	I
promoter	O	NOUN	B
region	O	NOUN	I
was	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
reporter	O	NOUN	B
gene	O	NOUN	I
assay	O	NOUN	I
,	O	PUNCT	O
to	O	PART	O
reduce	O	VERB	O
promoter	O	NOUN	B
activity	O	NOUN	I
by	O	ADP	O
approximately	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
family	O	NOUN	B
manifesting	O	VERB	O
an	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
pattern	O	NOUN	O
of	O	ADP	O
inheritance	O	NOUN	B
possessed	O	VERB	O
three	O	NUM	O
clinically	O	ADV	B
affected	O	VERB	O
members	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
a	O	DET	O
truncated	O	VERB	B
protein	O	NOUN	I
product	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
model	O	NOUN	B
which	O	DET	O
accounts	O	VERB	O
for	O	ADP	O
the	O	DET	O
dominant	O	ADJ	B
negative	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
this	O	DET	O
lesion	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


Variation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
antigen	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
heterozygous	O	ADJ	B
relatives	O	NOUN	O
of	O	ADP	O
probands	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
between	O	ADP	O
families	O	NOUN	B
than	O	ADP	O
within	O	ADP	O
families	O	NOUN	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
nature	O	NOUN	B
of	O	ADP	O
the	O	DET	O
F10	O	NOUN	B
lesion	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
segregating	O	VERB	B
in	O	ADP	O
a	O	DET	O
given	O	VERB	O
family	O	NOUN	B
is	O	AUX	O
a	O	DET	O
prime	O	ADJ	O
determinant	O	NOUN	B
of	O	ADP	O
the	O	DET	O
laboratory	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
such	O	ADJ	O
relationship	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
discerned	O	VERB	O
between	O	ADP	O
laboratory	O	ADJ	B
phenotype	O	NOUN	B
and	O	CCONJ	O
polymorphism	O	NOUN	B
genotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Transgenic	O	ADJ	B
mice	O	NOUN	I
expressing	O	VERB	B
a	O	DET	O
truncated	O	VERB	B
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
high	O	ADJ	B
mobility	O	NOUN	B
group	O	NOUN	I
I	O	NUM	I
-	O	PUNCT	O
C	O	NOUN	B
protein	O	NOUN	I
develop	O	VERB	O
adiposity	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
abnormally	O	ADV	B
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
lipomas	B-Disease	NOUN	B
.	O	PUNCT	O


Chromosomal	O	ADJ	B
translocations	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
lipomas	B-Disease	NOUN	I
frequently	O	ADV	O
create	O	VERB	O
fusion	O	NOUN	B
transcripts	O	NOUN	B
encoding	O	VERB	B
high	O	ADJ	O
mobility	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
HMG	O	NOUN	B
)	O	PUNCT	O
I	O	NUM	O
-	O	PUNCT	O
C	O	NOUN	B
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domains	O	NOUN	I
and	O	CCONJ	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
sequences	O	NOUN	B
from	O	ADP	O
different	O	ADJ	O
presumed	O	VERB	O
transcription	O	NOUN	B
factors	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
HMG	O	NOUN	B
I	O	NUM	I
-	O	PUNCT	O
C	O	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
lipomas	B-Disease	NOUN	B
.	O	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
HMG	O	NOUN	B
I	O	NUM	I
-	O	PUNCT	O
C	O	NOUN	B
component	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
three	O	NUM	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domains	O	NOUN	O
of	O	ADP	O
HMG	O	NOUN	B
I	O	NUM	I
-	O	PUNCT	O
C	O	PROPN	B
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
ubiquitous	O	ADJ	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
truncated	O	VERB	B
HMG	O	NOUN	O
I	O	NUM	O
-	O	PUNCT	O
C	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
transgenic	O	ADJ	B
mice	O	NOUN	I
develop	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
abundance	O	NOUN	B
of	O	ADP	O
fat	O	ADJ	B
tissue	O	NOUN	I
early	O	ADV	O
in	O	ADP	O
life	O	NOUN	B
,	O	PUNCT	O
show	O	VERB	O
marked	O	ADJ	O
adipose	B-Disease	NOUN	B
tissue	I-Disease	NOUN	I
inflammation	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
have	O	AUX	O
an	O	DET	O
abnormally	O	ADV	B
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
lipomas	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
DNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domains	O	NOUN	O
of	O	ADP	O
HMG	O	NOUN	B
I	O	NUM	I
-	O	PUNCT	O
C	O	PROPN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
fusion	O	NOUN	B
partner	O	NOUN	O
,	O	PUNCT	O
are	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
perturb	O	VERB	B
adipogenesis	O	NOUN	B
and	O	CCONJ	O
predispose	O	VERB	O
to	O	PART	O
lipomas	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
provide	O	VERB	O
data	O	NOUN	B
supporting	O	VERB	O
the	O	DET	O
central	O	ADJ	O
utility	O	NOUN	O
of	O	ADP	O
this	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
as	O	ADP	O
a	O	DET	O
tool	O	NOUN	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
underlying	O	VERB	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
kind	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
benign	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


ATM	O	NOUN	B
phosphorylates	O	VERB	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	NOUN	B
in	O	ADP	O
an	O	DET	O
S	O	NOUN	B
-	O	PUNCT	O
phase	O	NOUN	B
checkpoint	O	NOUN	I
pathway	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rare	B-Disease	ADJ	B
diseases	I-Disease	NOUN	B
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
AT	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
Nijmegen	B-Disease	NOUN	B
breakage	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NBS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
share	O	VERB	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
phenotypic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
chromosomal	B-Disease	ADJ	B
instability	I-Disease	NOUN	I
,	O	PUNCT	O
radiation	O	NOUN	B
sensitivity	O	NOUN	I
and	O	CCONJ	O
defects	O	NOUN	B
in	O	ADP	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
checkpoints	O	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
ionizing	O	VERB	B
radiation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
encodes	O	VERB	B
a	O	DET	O
protein	O	NOUN	B
kinase	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
activated	O	VERB	B
by	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
or	O	CCONJ	O
radiomimetic	O	ADJ	B
drugs	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	NOUN	B
is	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
complex	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
responses	O	NOUN	B
to	O	PART	O
DNA	O	NOUN	B
double	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
breaks	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
similarities	O	NOUN	B
between	O	ADP	O
AT	B-Disease	ADP	B
and	O	CCONJ	O
NBS	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
functional	O	ADJ	B
interactions	O	NOUN	B
between	O	ADP	O
ATM	O	NOUN	B
and	O	CCONJ	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	PROPN	B
.	O	PUNCT	O


Activation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
kinase	O	NOUN	I
by	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
and	O	CCONJ	O
induction	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
responses	O	NOUN	B
in	O	ADP	O
NBS	B-Disease	NOUN	B
cells	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	PROPN	B
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
required	O	VERB	O
for	O	ADP	O
signalling	O	NOUN	B
to	O	PART	O
ATM	O	NOUN	B
after	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	PROPN	B
was	O	AUX	O
phosphorylated	O	VERB	B
on	O	ADP	O
serine	O	NOUN	B
343	O	NUM	I
in	O	ADP	O
an	O	DET	O
ATM	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
after	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	NOUN	B
construct	O	NOUN	O
mutated	O	VERB	B
at	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
phosphorylation	O	NOUN	B
site	O	NOUN	O
abrogated	O	VERB	B
an	O	DET	O
S	O	NOUN	B
-	O	PUNCT	O
phase	O	NOUN	B
checkpoint	O	NOUN	O
induced	O	VERB	B
by	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
failed	O	VERB	B
to	O	PART	O
compensate	O	VERB	B
for	O	ADP	O
this	O	DET	O
functional	O	ADJ	B
deficiency	O	NOUN	I
in	O	ADP	O
NBS	B-Disease	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
link	O	VERB	O
ATM	O	NOUN	B
and	O	CCONJ	O
p95	O	NOUN	B
/	O	SYM	O
nbs1	O	NOUN	B
in	O	ADP	O
a	O	DET	O
common	O	ADJ	O
signalling	O	NOUN	B
pathway	O	NOUN	I
and	O	CCONJ	O
provide	O	VERB	O
an	O	DET	O
explanation	O	NOUN	B
for	O	ADP	O
phenotypic	O	ADJ	B
similarities	O	NOUN	B
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
diseases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Understanding	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Fragile	B-Disease	NOUN	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
inherited	B-Disease	VERB	B
mental	I-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
mainly	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
massive	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
CGG	O	NOUN	B
triplet	O	NOUN	I
repeats	O	NOUN	I
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
mental	I-Disease	ADJ	B
retardation	I-Disease	NOUN	I
-	O	PUNCT	O
1	O	NUM	B
(	O	PUNCT	O
FMR1	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
expanded	O	VERB	O
CGG	O	NOUN	B
triplet	O	NOUN	I
repeats	O	NOUN	I
are	O	AUX	O
hypermethylated	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
repressed	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
FMR1	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
FMRP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
subsequent	O	ADJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


FMRP	O	NOUN	B
is	O	AUX	O
an	O	DET	O
RNA	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
protein	O	NOUN	I
that	O	PRON	O
shuttles	O	VERB	B
between	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
and	O	CCONJ	O
cytoplasm	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
protein	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
protein	O	NOUN	B
translation	O	NOUN	I
as	O	ADP	O
it	O	PRON	O
is	O	AUX	O
found	O	VERB	O
associated	O	VERB	B
with	O	ADP	I
polyribosomes	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
rough	O	ADJ	B
endoplasmic	O	ADJ	I
reticulum	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
discuss	O	VERB	O
here	O	ADV	O
the	O	DET	O
recent	O	ADJ	O
progress	O	NOUN	B
made	O	VERB	O
towards	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
mechanism	O	NOUN	O
of	O	ADP	O
CGG	O	NOUN	B
repeat	O	NOUN	O
expansion	O	NOUN	B
and	O	CCONJ	O
physiological	O	ADJ	B
function	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
FMRP	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
will	O	AUX	O
not	O	PART	O
only	O	ADV	O
help	O	VERB	O
to	O	PART	O
illuminate	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
general	O	ADJ	B
class	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
diseases	O	NOUN	I
with	O	ADP	O
trinucleotide	O	NOUN	B
repeat	O	NOUN	I
expansion	O	NOUN	I
but	O	CCONJ	O
also	O	ADV	O
provide	O	VERB	O
an	O	DET	O
avenue	O	NOUN	O
to	O	PART	O
understand	O	VERB	O
aspects	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
cognition	O	NOUN	B
and	O	CCONJ	O
intelligence	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Haploinsufficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
transcription	I-Disease	NOUN	B
factors	I-Disease	NOUN	I
FOXC1	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
FOXC2	I-Disease	NOUN	B
results	O	NOUN	B
in	O	ADP	O
aberrant	O	ADJ	B
ocular	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


Anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	I
developmental	I-Disease	ADJ	I
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
Axenfeld	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Rieger	I-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
(	O	PUNCT	O
ARA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
variably	O	ADV	O
associate	O	VERB	B
with	O	ADP	I
harmfully	O	ADV	B
elevated	O	ADJ	I
intraocular	O	ADJ	I
pressure	O	NOUN	I
(	O	PUNCT	O
IOP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
causes	O	VERB	O
glaucoma	B-Disease	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	B
observed	O	VERB	O
dysgenesis	O	NOUN	B
does	O	AUX	O
not	O	PART	O
correlate	O	VERB	O
with	O	ADP	O
IOP	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
etiology	O	NOUN	B
of	O	ADP	O
glaucoma	B-Disease	NOUN	B
development	O	NOUN	B
is	O	AUX	O
not	O	PART	O
understood	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
forkhead	O	NOUN	B
transcription	O	NOUN	I
factor	O	NOUN	I
genes	O	NOUN	I
Foxc1	O	NOUN	B
(	O	PUNCT	O
formerly	O	ADV	O
Mf1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Foxc2	O	NOUN	B
(	O	PUNCT	O
formerly	O	ADV	O
Mfh1	O	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
the	O	DET	O
mesenchyme	O	NOUN	B
from	O	ADP	O
which	O	DET	O
the	O	DET	O
ocular	O	ADJ	B
drainage	O	NOUN	O
structures	O	NOUN	O
derive	O	VERB	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
homolog	O	NOUN	B
of	O	ADP	O
Foxc1	O	NOUN	B
,	O	PUNCT	O
FKHL7	O	NOUN	B
,	O	PUNCT	O
cause	O	VERB	O
dominant	O	ADJ	B
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
defects	I-Disease	NOUN	B
and	O	CCONJ	O
glaucoma	B-Disease	NOUN	B
in	O	ADP	O
various	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
Foxc1	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
have	O	AUX	O
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
abnormalities	I-Disease	NOUN	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
reported	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
abnormalities	O	NOUN	B
include	O	VERB	O
small	O	ADJ	B
or	O	CCONJ	O
absent	O	ADJ	B
Schlemms	O	ADJ	B
canal	O	NOUN	I
,	O	PUNCT	O
aberrantly	O	ADV	B
developed	O	VERB	O
trabecular	O	NOUN	B
meshwork	O	NOUN	I
,	O	PUNCT	O
iris	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
severely	O	ADV	B
eccentric	O	ADJ	B
pupils	O	NOUN	I
and	O	CCONJ	O
displaced	O	VERB	B
Schwalbes	O	PROPN	I
line	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
penetrance	O	NOUN	B
of	O	ADP	O
clinically	O	ADV	B
obvious	O	ADJ	O
abnormalities	O	NOUN	B
varies	O	VERB	O
with	O	ADP	O
genetic	O	ADJ	B
background	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
some	O	DET	O
affected	O	VERB	B
eyes	O	NOUN	B
,	O	PUNCT	O
collagen	O	NOUN	B
bundles	O	NOUN	B
were	O	AUX	O
half	O	ADV	O
normal	O	ADJ	O
diameter	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
collagen	O	NOUN	B
and	O	CCONJ	O
elastic	O	ADJ	B
tissue	O	NOUN	I
were	O	AUX	O
very	O	ADV	O
sparse	O	ADJ	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
abnormalities	O	NOUN	B
in	O	ADP	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
synthesis	O	NOUN	B
or	O	CCONJ	O
organization	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ocular	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
abnormalities	O	NOUN	B
in	O	ADP	O
ocular	O	ADJ	B
drainage	O	NOUN	O
structures	O	NOUN	O
in	O	ADP	O
Foxc1	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
,	O	PUNCT	O
IOP	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
almost	O	ADV	O
all	O	DET	O
mice	O	NOUN	B
analyzed	O	VERB	B
,	O	PUNCT	O
on	O	ADP	O
all	O	DET	O
genetic	O	ADJ	B
backgrounds	O	NOUN	I
and	O	CCONJ	O
at	O	ADP	O
all	O	DET	O
ages	O	NOUN	B
.	O	PUNCT	O


Similar	O	ADJ	O
abnormalities	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
Foxc2	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
homolog	O	NOUN	O
FKHL14	O	NOUN	B
in	O	ADP	O
32	O	NUM	O
ARA	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Foxc1	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
Foxc2	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
are	O	AUX	O
useful	O	ADJ	O
models	O	NOUN	B
for	O	ADP	O
studying	O	VERB	O
anterior	O	ADJ	B
segment	O	NOUN	O
development	O	NOUN	O
and	O	CCONJ	O
its	O	PRON	O
anomalies	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
may	O	AUX	O
allow	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
genes	O	NOUN	B
that	O	PRON	O
interact	O	VERB	B
with	O	ADP	O
Foxc1	O	NOUN	B
and	O	CCONJ	O
Foxc2	O	NOUN	B
(	O	PUNCT	O
or	O	CCONJ	O
FKHL7	O	NOUN	B
and	O	CCONJ	O
FKHL14	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
produce	O	VERB	O
a	O	DET	O
phenotype	O	NOUN	B
with	O	ADP	O
elevated	O	ADJ	B
IOP	O	NOUN	B
and	O	CCONJ	O
glaucoma	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


(	O	PUNCT	O
Over	O	ADV	O
)	O	PUNCT	O
correction	O	NOUN	B
of	O	ADP	O
FMR1	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
with	O	ADP	O
YAC	O	NOUN	B
transgenics	O	NOUN	B
:	O	PUNCT	O
behavioral	O	ADJ	B
and	O	CCONJ	O
physical	O	ADJ	B
features	O	NOUN	I
.	O	PUNCT	O


Fragile	B-Disease	NOUN	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
involving	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMR1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
role	O	NOUN	O
of	O	ADP	O
FMR1	O	NOUN	B
remains	O	VERB	O
undetermined	O	ADJ	B
but	O	CCONJ	O
the	O	DET	O
protein	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
RNA	O	NOUN	B
metabolism	O	NOUN	I
.	O	PUNCT	O


Fmr1	O	NOUN	B
knockout	O	ADJ	B
mice	O	NOUN	I
exhibit	O	VERB	O
a	O	DET	O
phenotype	O	NOUN	B
with	O	ADP	O
some	O	DET	O
similarities	O	NOUN	B
to	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
macroorchidism	B-Disease	NOUN	B
and	O	CCONJ	O
behavioral	O	ADJ	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
step	O	NOUN	O
toward	O	ADP	O
understanding	O	VERB	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
FMR1	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
therapeutic	O	ADJ	B
approaches	O	NOUN	I
to	O	PART	O
fragile	B-Disease	VERB	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
yeast	O	NOUN	B
artificial	O	ADJ	O
chromosome	O	NOUN	O
(	O	PUNCT	O
YAC	O	NOUN	B
)	O	PUNCT	O
transgenic	O	ADJ	B
mice	O	NOUN	I
were	O	AUX	O
generated	O	VERB	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
the	O	DET	O
Fmr1	O	NOUN	B
knockout	O	ADJ	B
mouse	O	NOUN	I
phenotype	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
rescued	O	VERB	B
.	O	PUNCT	O


Several	O	ADJ	O
transgenic	O	ADJ	B
lines	O	NOUN	I
were	O	AUX	O
generated	O	VERB	O
that	O	PRON	O
carried	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
FMR1	O	NOUN	B
locus	O	NOUN	O
with	O	ADP	O
extensive	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
flanking	O	ADJ	B
sequence	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
YAC	O	NOUN	B
transgene	O	NOUN	I
supported	O	VERB	O
production	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
protein	O	NOUN	I
(	O	PUNCT	O
FMRP	O	NOUN	B
)	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
levels	O	NOUN	B
10	O	NUM	O
to	O	PART	O
15	O	NUM	O
times	O	NOUN	O
that	O	DET	O
of	O	ADP	O
endogenous	O	ADJ	B
protein	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
a	O	DET	O
cell	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
tissue	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


Macro	O	ADJ	B
-	O	PUNCT	O
orchidism	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
knockout	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
the	O	DET	O
YAC	O	NOUN	B
transgene	O	NOUN	I
indicating	O	VERB	O
functional	O	ADJ	B
rescue	O	NOUN	I
by	O	ADP	O
the	O	DET	O
human	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
complex	O	ADJ	B
behavioral	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mild	O	ADJ	B
phenotype	O	NOUN	B
previously	O	ADV	O
reported	O	VERB	O
for	O	ADP	O
the	O	DET	O
Fmr1	O	NOUN	B
knockout	O	ADJ	B
mouse	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
more	O	ADV	O
thorough	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Fmr1	O	NOUN	B
knockout	O	ADJ	B
phenotype	O	NOUN	I
using	O	VERB	O
additional	O	ADJ	O
behavioral	O	ADJ	B
assays	O	NOUN	O
that	O	PRON	O
had	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
for	O	ADP	O
this	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mouse	O	NOUN	B
displayed	O	VERB	O
reduced	O	VERB	B
anxiety	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
responses	O	NOUN	B
with	O	ADP	O
increased	O	VERB	B
exploratory	O	ADJ	B
behavior	O	NOUN	I
.	O	PUNCT	O


FMR1	O	NOUN	B
YAC	O	NOUN	I
transgenic	O	ADJ	B
mice	O	NOUN	I
overexpressing	O	VERB	B
the	O	DET	O
human	O	ADJ	B
protein	O	NOUN	I
did	O	AUX	O
produce	O	VERB	O
opposing	O	VERB	O
behavioral	O	ADJ	B
responses	O	NOUN	O
and	O	CCONJ	O
additional	O	ADJ	O
abnormal	O	ADJ	B
behaviors	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
have	O	AUX	O
significant	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
gene	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
since	O	SCONJ	O
overexpression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
may	O	AUX	O
harbor	O	VERB	O
its	O	PRON	O
own	O	ADJ	O
phenotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Transgenic	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
large	O	ADJ	O
human	O	ADJ	B
genomic	O	ADJ	B
sequences	O	NOUN	I
with	O	ADP	O
expanded	O	VERB	O
CTG	O	NOUN	B
repeat	O	NOUN	I
mimic	O	VERB	O
closely	O	ADV	O
the	O	DET	O
DM	B-Disease	NOUN	B
CTG	O	NOUN	O
repeat	O	NOUN	O
intergenerational	O	ADJ	B
and	O	CCONJ	O
somatic	O	ADJ	B
instability	O	NOUN	I
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3UTR	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
very	O	ADV	O
high	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
instability	O	NOUN	B
is	O	AUX	O
observed	O	VERB	O
through	O	ADP	O
successive	O	ADJ	O
generations	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
is	O	AUX	O
generally	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
tissues	O	NOUN	B
from	O	ADP	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
exhibit	O	VERB	O
somatic	O	ADJ	B
mosaicism	O	NOUN	B
that	O	PRON	O
increases	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
generated	O	VERB	O
transgenic	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
large	O	ADJ	O
human	O	ADJ	B
genomic	O	ADJ	B
sequences	O	NOUN	I
with	O	ADP	O
20	O	NUM	O
,	O	PUNCT	O
55	O	NUM	O
or	O	CCONJ	O
>	O	X	O
300	O	NUM	O
CTG	O	NOUN	B
,	O	PUNCT	O
cloned	O	VERB	B
from	O	ADP	O
patients	O	NOUN	B
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
affected	O	ADJ	B
DM	B-Disease	NOUN	B
family	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
large	O	ADJ	O
human	O	ADJ	B
flanking	O	NOUN	O
sequences	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
large	O	ADJ	O
amplification	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
intergenerational	O	ADJ	B
CTG	O	NOUN	O
repeat	O	NOUN	O
instability	O	NOUN	B
is	O	AUX	O
reproduced	O	VERB	O
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
strong	O	ADJ	O
bias	O	NOUN	B
towards	O	ADP	O
expansions	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
sex	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
size	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
characteristics	O	NOUN	B
as	O	ADP	O
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
high	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
instability	O	NOUN	B
,	O	PUNCT	O
increasing	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
tissues	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
sperm	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
observe	O	VERB	O
dramatic	O	ADJ	O
expansions	O	NOUN	O
(	O	PUNCT	O
or	O	CCONJ	O
big	O	ADJ	B
jumps	O	NOUN	I
over	O	ADP	O
several	O	ADJ	O
hundred	O	NUM	O
CTG	O	NOUN	B
repeats	O	NOUN	I
)	O	PUNCT	O
as	O	ADP	O
in	O	ADP	O
congenital	O	ADJ	B
forms	O	NOUN	I
of	O	ADP	O
DM	B-Disease	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
model	O	NOUN	B
carrying	O	VERB	O
>	O	X	O
300	O	NUM	O
CTG	O	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
to	O	PART	O
show	O	VERB	O
instability	O	NOUN	B
so	O	ADV	O
close	O	ADV	O
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
DM	B-Disease	NOUN	B
situation	O	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
three	O	NUM	O
models	O	NOUN	B
carrying	O	VERB	O
different	O	ADJ	O
sizes	O	NOUN	B
of	O	ADP	O
CTG	O	NOUN	B
repeat	O	NOUN	O
provide	O	VERB	O
insight	O	NOUN	O
on	O	ADP	O
the	O	DET	O
different	O	ADJ	O
factors	O	NOUN	B
modulating	O	VERB	B
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
instability	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
mouse	O	NOUN	B
gene	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
early	O	ADJ	O
embryonic	B-Disease	ADJ	B
lethality	I-Disease	NOUN	O
without	O	ADP	O
iron	O	NOUN	B
accumulation	O	NOUN	I
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
ataxia	I-Disease	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
in	O	ADP	O
almost	O	ADV	O
all	O	DET	O
cases	O	NOUN	B
by	O	ADP	O
homozygous	O	ADJ	B
intronic	O	ADJ	B
expansions	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
frataxin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
mitochondrial	O	ADJ	B
protein	O	NOUN	I
conserved	O	VERB	O
through	O	ADP	O
evolution	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
involved	O	VERB	O
in	O	ADP	O
mitochondrial	O	ADJ	B
iron	O	NOUN	B
homeostasis	O	NOUN	I
.	O	PUNCT	O


Yeast	O	NOUN	B
knockout	O	NOUN	B
models	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
histological	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
data	O	NOUN	B
from	O	ADP	O
patient	O	NOUN	B
heart	O	NOUN	O
biopsies	O	NOUN	O
or	O	CCONJ	O
autopsies	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
frataxin	O	NOUN	B
defect	O	NOUN	B
causes	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
iron	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
sulfur	I-Disease	NOUN	B
protein	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
mitochondrial	O	ADJ	B
iron	O	NOUN	O
accumulation	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
pathological	O	ADJ	B
changes	O	NOUN	B
.	O	PUNCT	O


Affected	O	ADJ	B
human	O	ADJ	B
tissues	O	NOUN	B
are	O	AUX	O
rarely	O	ADV	O
available	O	ADJ	O
to	O	PART	O
further	O	ADV	O
examine	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
generated	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
by	O	ADP	O
deletion	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
leading	O	VERB	O
to	O	PART	O
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Frda	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
cause	O	VERB	O
embryonic	B-Disease	ADJ	B
lethality	I-Disease	NOUN	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
after	O	ADP	O
implantation	O	NOUN	B
,	O	PUNCT	O
demonstrating	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
frataxin	O	NOUN	B
during	O	ADP	O
early	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
milder	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
residual	O	ADJ	B
frataxin	O	NOUN	B
expression	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
expansion	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
frataxin	O	NOUN	B
knockout	O	NOUN	B
mouse	O	NOUN	I
,	O	PUNCT	O
no	O	DET	O
iron	O	NOUN	B
accumulation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
during	O	ADP	O
embryonic	O	ADJ	B
resorption	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
cell	O	NOUN	B
death	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
mechanism	O	NOUN	B
independent	O	ADJ	B
of	O	ADP	O
iron	O	NOUN	B
accumulation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Gaucher	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
the	O	DET	O
origins	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	I
N370S	O	NOUN	I
and	O	CCONJ	O
84GG	O	ADJ	O
acid	O	NOUN	B
beta	O	NOUN	I
-	O	PUNCT	O
glucosidase	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Type	O	NOUN	B
1	O	NUM	I
Gaucher	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
GD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
neuronopathic	O	ADJ	B
lysosomal	B-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
results	O	VERB	B
from	O	ADP	O
the	O	DET	O
deficient	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
beta	O	NOUN	I
-	O	PUNCT	O
glucosidase	O	NOUN	B
(	O	PUNCT	O
GBA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Type	O	NOUN	B
1	O	NUM	I
disease	O	NOUN	I
is	O	AUX	O
panethnic	O	ADJ	B
but	O	CCONJ	O
is	O	AUX	O
more	O	ADV	O
prevalent	O	ADJ	O
in	O	ADP	O
individuals	O	NOUN	B
of	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	PROPN	B
(	O	PUNCT	O
AJ	O	PROPN	B
)	O	PUNCT	O
descent	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
causative	O	ADJ	B
GBA	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
N370S	O	NOUN	B
is	O	AUX	O
particularly	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
AJ	O	PROPN	B
population	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
q	O	NOUN	O
approximately	O	ADV	B
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
84GG	O	ADJ	O
insertion	O	NOUN	B
(	O	PUNCT	O
q	O	NOUN	O
approximately	O	ADV	B
.	O	PUNCT	O
003	O	NUM	O
)	O	PUNCT	O
occurs	O	VERB	O
exclusively	O	ADV	O
in	O	ADP	O
the	O	DET	O
Ashkenazim	O	PROPN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
genetic	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
AJ	O	PROPN	B
population	O	NOUN	B
,	O	PUNCT	O
short	O	ADJ	B
tandem	O	ADJ	I
repeat	O	NOUN	I
(	O	PUNCT	I
STR	O	NOUN	B
)	O	PUNCT	O
markers	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
map	O	VERB	B
a	O	DET	O
9	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
region	O	NOUN	B
containing	O	VERB	O
the	O	DET	O
GBA	O	NOUN	B
locus	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
genotype	O	NOUN	B
261	O	NUM	O
AJ	O	NOUN	B
N370S	O	NOUN	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
60	O	NUM	O
European	O	ADJ	B
non	O	NOUN	B
-	O	PUNCT	O
Jewish	O	ADJ	B
N370S	O	NOUN	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
62	O	NUM	O
AJ	O	PROPN	B
84GG	O	ADJ	I
chromosomes	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
haplotype	O	NOUN	B
at	O	ADP	O
four	O	NUM	O
markers	O	NOUN	B
flanking	O	ADJ	O
GBA	O	NOUN	B
(	O	PUNCT	O
PKLR	O	NOUN	B
,	O	PUNCT	O
D1S1595	O	NOUN	O
,	O	PUNCT	O
D1S2721	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
D1S2777	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
AJ	O	PROPN	B
chromosomes	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
N370S	O	NOUN	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
founder	O	NOUN	B
common	O	ADJ	O
to	O	PART	O
both	O	DET	O
populations	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
note	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
divergent	O	ADJ	O
haplotypes	O	NOUN	B
suggested	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
de	O	X	O
novo	O	X	O
,	O	PUNCT	O
recurrent	O	ADJ	O
N370S	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
different	O	ADJ	O
conserved	O	VERB	O
haplotype	O	NOUN	B
at	O	ADP	O
these	O	DET	O
markers	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
on	O	ADP	O
the	O	DET	O
84GG	O	ADJ	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
unique	O	ADJ	O
to	O	PART	O
the	O	DET	O
AJ	O	PROPN	B
population	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
(	O	PUNCT	O
LD	O	NOUN	B
)	O	PUNCT	O
delta	O	NOUN	O
values	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
European	O	ADJ	B
N370S	O	NOUN	B
chromosomes	O	NOUN	I
had	O	AUX	O
greater	O	ADJ	O
haplotype	O	NOUN	B
diversity	O	NOUN	B
and	O	CCONJ	O
less	O	ADJ	O
LD	O	NOUN	B
at	O	ADP	O
the	O	DET	O
markers	O	NOUN	B
flanking	O	VERB	B
the	O	DET	O
conserved	O	VERB	O
haplotype	O	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
AJ	O	PROPN	B
N370S	O	NOUN	O
chromosomes	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
N370S	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
European	O	ADJ	B
population	O	NOUN	I
prior	O	ADV	O
to	O	ADP	O
the	O	DET	O
founding	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AJ	O	PROPN	B
population	O	NOUN	B
.	O	PUNCT	O


Coalescence	O	NOUN	B
analyses	O	NOUN	I
for	O	ADP	O
the	O	DET	O
N370S	O	NOUN	B
and	O	CCONJ	O
84GG	O	ADJ	O
mutations	O	NOUN	B
estimated	O	VERB	B
similar	O	ADJ	O
coalescence	O	NOUN	B
times	O	NOUN	O
,	O	PUNCT	O
of	O	ADP	O
48	O	NUM	O
and	O	CCONJ	O
55	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
generations	O	NOUN	B
ago	O	ADV	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	O
bottleneck	O	NOUN	B
occurring	O	VERB	O
in	O	ADP	O
the	O	DET	O
AJ	O	PROPN	B
population	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
millennium	O	NOUN	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
population	O	NOUN	B
became	O	VERB	O
established	O	VERB	O
in	O	ADP	O
Europe	O	PROPN	B
.	O	PUNCT	O


HLA	O	NOUN	B
B27	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
genetics	O	NOUN	B
of	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
of	O	ADP	O
145	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
HLA	O	NOUN	B
B27	O	NOUN	I
positive	O	ADJ	B
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
sero	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
peripheral	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
resembling	O	VERB	O
peripheral	B-Disease	ADJ	B
psoriatic	I-Disease	ADJ	I
arthritis	I-Disease	NOUN	I
and	O	CCONJ	O
3	O	NUM	O
of	O	ADP	O
these	O	DET	O
were	O	AUX	O
B27	O	NOUN	O
negative	O	ADJ	B
.	O	PUNCT	O


One	O	NUM	O
further	O	ADJ	O
B27	O	NOUN	O
negative	O	ADJ	B
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
sister	O	NOUN	B
with	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
and	O	CCONJ	O
ulcerative	B-Disease	ADJ	B
colitis	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
mother	O	NOUN	B
with	O	ADP	O
ulcerative	B-Disease	ADJ	B
colitis	I-Disease	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
somewhat	O	ADV	O
later	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	B
of	O	ADP	I
symptoms	O	NOUN	B
in	O	ADP	O
B27	O	NOUN	B
negative	O	ADJ	I
patients	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
interpreted	O	VERB	O
as	O	ADP	O
suggesting	O	VERB	O
some	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
in	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
with	O	ADP	O
genes	O	NOUN	B
for	O	ADP	O
psoriasis	B-Disease	NOUN	B
and	O	CCONJ	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
being	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
some	O	DET	O
individuals	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
those	O	DET	O
who	O	PRON	O
are	O	AUX	O
B27	O	NOUN	O
negative	O	ADJ	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
five	O	NUM	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	B
with	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
were	O	AUX	O
all	O	DET	O
B27	O	NOUN	O
positive	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
only	O	ADJ	O
instance	O	NOUN	O
of	O	ADP	O
disassociation	O	NOUN	B
of	O	ADP	O
B27	O	NOUN	B
and	O	CCONJ	O
spondylitis	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
was	O	AUX	O
where	O	SCONJ	O
the	O	DET	O
proband	O	NOUN	B
had	O	AUX	O
ulcerative	B-Disease	ADJ	B
colitis	I-Disease	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
spondylitis	B-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
13	O	NUM	O
B27	O	NOUN	O
positive	O	ADJ	B
fathers	O	NOUN	B
3	O	NUM	O
could	O	AUX	O
be	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
definite	O	ADJ	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
(	O	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
thought	O	VERB	O
to	O	PART	O
provide	O	VERB	O
evidence	O	NOUN	B
against	O	ADP	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
B27	O	NOUN	B
but	O	CCONJ	O
a	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
gene	O	NOUN	B
and	O	CCONJ	O
favour	O	VERB	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
environmental	O	ADJ	B
event	O	NOUN	I
affecting	O	VERB	B
approximately	O	ADV	O
one	O	NUM	O
-	O	PUNCT	O
fifth	O	NOUN	B
of	O	ADP	O
B27	O	NOUN	O
positive	O	ADJ	B
males	O	NOUN	B
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
disease	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Founder	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Polish	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
undertaken	O	VERB	O
a	O	DET	O
hospital	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
identify	O	VERB	O
possible	O	ADJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
founder	O	NOUN	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Polish	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
66	O	NUM	O
Polish	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
cancer	B-Disease	NOUN	B
who	O	PRON	O
have	O	AUX	O
at	O	ADV	O
least	O	ADJ	O
three	O	NUM	O
related	O	ADJ	O
females	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
who	O	PRON	O
had	O	AUX	O
cancer	B-Disease	NOUN	B
diagnosed	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
affected	O	VERB	B
females	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
age	O	NOUN	B
<	O	X	O
50	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
26	O	NUM	O
families	O	NOUN	B
had	O	AUX	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
4	O	NUM	O
families	O	NOUN	B
had	O	AUX	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
36	O	NUM	O
families	O	NOUN	B
had	O	AUX	O
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
only	O	ADV	O
.	O	PUNCT	O


Genomic	O	ADJ	B
DNA	O	NOUN	I
was	O	AUX	O
prepared	O	VERB	O
from	O	ADP	O
the	O	DET	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
affected	O	VERB	B
woman	O	NOUN	B
from	O	ADP	O
each	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
was	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
SSCP	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
observed	O	VERB	B
variants	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
35	O	NUM	O
(	O	PUNCT	O
53	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
66	O	NUM	O
families	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
within	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


BRCA1	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
all	O	DET	O
four	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
27	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
34	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
35	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
only	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
single	O	ADJ	O
family	O	NOUN	B
with	O	ADP	O
a	O	DET	O
BRCA2	O	NOUN	B
mutation	O	NOUN	B
had	O	AUX	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	O
.	O	PUNCT	O


Seven	O	NUM	O
distinct	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
;	O	PUNCT	O
five	O	NUM	O
of	O	ADP	O
these	O	DET	O
occurred	O	VERB	O
in	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
total	O	NOUN	O
,	O	PUNCT	O
recurrent	O	ADJ	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
33	O	NUM	O
(	O	PUNCT	O
94	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
35	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
detected	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
BRCA1	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	B
-	O	PUNCT	O
5382insC	O	PROPN	B
,	O	PUNCT	O
C61G	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
4153delA	O	NOUN	B
-	O	PUNCT	O
accounted	O	VERB	B
for	O	ADP	O
51	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
11	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
identified	O	VERB	B
mutations	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
very	B-Disease	ADV	O
long	I-Disease	ADJ	O
chain	I-Disease	NOUN	B
acyl	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
CoA	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
three	O	NUM	O
Israeli	O	ADJ	B
patients	O	NOUN	B
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
mutant	O	ADJ	B
allele	O	NOUN	O
with	O	ADP	O
P65L	O	NOUN	B
and	O	CCONJ	I
K247Q	O	NOUN	I
mutations	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
former	O	ADJ	O
being	O	AUX	O
an	O	DET	O
exonic	O	ADJ	B
mutation	O	NOUN	I
causing	O	VERB	O
exon	O	NOUN	B
3	O	NUM	I
skipping	O	NOUN	B
.	O	PUNCT	O


Very	B-Disease	ADV	O
long	I-Disease	ADJ	O
chain	I-Disease	NOUN	B
acyl	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
CoA	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
VLCAD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
disorder	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
fatty	O	ADJ	I
acid	O	NOUN	I
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
four	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
the	O	DET	O
severe	O	ADJ	B
childhood	O	NOUN	O
form	O	NOUN	O
of	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
with	O	ADP	O
early	O	ADJ	B
onset	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
mortality	O	NOUN	B
.	O	PUNCT	O


Immunoblot	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
VLCAD	O	NOUN	B
protein	O	NOUN	I
was	O	AUX	O
undetectable	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
whereas	O	SCONJ	O
normal	O	ADJ	B
-	O	PUNCT	O
size	O	NOUN	B
VLCAD	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
aberrant	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
VLCAD	O	NOUN	B
(	O	PUNCT	O
4kDa	O	NUM	O
smaller	O	ADJ	O
)	O	PUNCT	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
patient	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O


As	O	ADP	O
expected	O	VERB	O
,	O	PUNCT	O
null	O	ADJ	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
patient	O	NOUN	B
2	O	NUM	I
is	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
del	O	X	O
4	O	NUM	O
bp	O	NOUN	O
at	O	ADP	O
798	O	NUM	O
-	O	SYM	O
801	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
patient	O	NOUN	B
3	O	NUM	I
is	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
65C	O	NOUN	I
>	O	X	O
A	O	NOUN	O
(	O	PUNCT	O
S22X	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Patient	O	NOUN	B
1	O	NUM	I
was	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
mutant	O	ADJ	B
allele	O	NOUN	B
containing	O	VERB	O
two	O	NUM	O
alterations	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
194C	O	NOUN	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
(	O	PUNCT	O
P65L	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
739A	O	NOUN	O
>	O	X	O
C	O	NOUN	O
transversion	O	NOUN	O
(	O	PUNCT	O
K247Q	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
P65L	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
change	O	NOUN	I
does	O	AUX	O
not	O	PART	O
reduce	O	VERB	O
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
nucleotide	O	NOUN	B
change	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
skipping	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
latter	O	ADJ	O
K247Q	O	NOUN	B
mutation	O	NOUN	B
had	O	AUX	O
a	O	DET	O
drastic	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
verified	O	VERB	O
these	O	DET	O
events	O	NOUN	B
by	O	ADP	O
in	O	X	B
vivo	O	X	I
splicing	O	NOUN	B
experiments	O	NOUN	O
and	O	CCONJ	O
transient	O	ADJ	B
expression	O	NOUN	O
analysis	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
cDNAs	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
P65L	O	NOUN	B
mutation	O	NOUN	I
locates	O	VERB	O
11	O	NUM	O
bases	O	NOUN	B
upstream	O	ADJ	B
of	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
3	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
an	O	DET	O
example	O	NOUN	O
of	O	ADP	O
an	O	DET	O
exonic	O	ADJ	B
mutation	O	NOUN	I
which	O	DET	O
affects	O	VERB	O
exon	O	NOUN	B
-	O	PUNCT	O
splicing	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Submicroscopic	O	ADJ	B
deletion	O	NOUN	I
in	O	ADP	O
cousins	O	NOUN	B
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
causes	O	VERB	O
a	O	DET	O
grandmatrilineal	O	NOUN	B
inheritance	O	NOUN	I
pattern	O	NOUN	B
:	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
imprinting	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
critical	O	ADJ	B
region	O	NOUN	I
on	O	ADP	O
15q11	O	NOUN	B
-	O	PUNCT	O
q13	O	NOUN	B
is	O	AUX	O
subject	O	ADJ	O
to	O	ADP	O
imprinting	O	NOUN	B
.	O	PUNCT	O


PWS	B-Disease	PROPN	B
becomes	O	VERB	O
apparent	O	ADJ	B
when	O	SCONJ	O
genes	O	NOUN	B
on	O	ADP	O
the	O	DET	O
paternally	O	ADV	B
inherited	O	VERB	I
chromosome	O	NOUN	I
are	O	AUX	O
not	O	PART	O
expressed	O	VERB	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
PWS	I-Disease	PROPN	B
is	O	AUX	O
rare	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
a	O	DET	O
male	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
female	O	ADJ	B
paternal	O	NOUN	O
first	O	ADJ	O
cousin	O	NOUN	O
both	O	DET	O
have	O	AUX	O
PWS	B-Disease	NOUN	B
with	O	ADP	O
cytogenetically	O	ADV	B
normal	O	ADJ	I
karyotypes	O	NOUN	I
.	O	PUNCT	O


Fluorescence	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	O
shows	O	VERB	O
a	O	DET	O
submicroscopic	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
SNRPN	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
closely	O	ADV	O
associated	O	VERB	O
loci	O	NOUN	O
D15S10	O	NOUN	B
,	O	PUNCT	O
D15S11	O	NOUN	B
,	O	PUNCT	O
D15S63	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
GABRB3	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cousins	O	NOUN	B
fathers	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
paternal	O	ADJ	B
aunts	O	NOUN	I
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
deletion	O	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
clinically	O	ADV	B
normal	O	ADJ	I
.	O	PUNCT	O


The	O	DET	O
grandmother	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cousins	O	NOUN	B
is	O	AUX	O
deceased	O	VERB	B
and	O	CCONJ	O
not	O	PART	O
available	O	ADJ	O
for	O	ADP	O
study	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
grandfather	O	NOUN	B
is	O	AUX	O
not	O	PART	O
deleted	O	VERB	O
for	O	ADP	O
SNRPN	O	NOUN	B
.	O	PUNCT	O


DNA	O	NOUN	B
methylation	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
D15S63	O	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
abnormality	O	NOUN	B
of	O	ADP	O
the	O	DET	O
imprinting	O	NOUN	B
center	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


"	O	PUNCT	O
Grandmatrilineal	O	PROPN	B
"	O	PUNCT	O
inheritance	O	NOUN	B
occurs	O	VERB	O
when	O	SCONJ	O
a	O	DET	O
woman	O	NOUN	B
with	O	ADP	O
deletion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
imprinted	O	ADJ	B
,	O	PUNCT	O
paternally	O	ADV	B
expressed	O	VERB	I
gene	O	NOUN	I
is	O	AUX	O
at	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
having	O	VERB	O
affected	O	VERB	B
grandchildren	O	NOUN	B
through	O	ADP	O
her	O	PRON	O
sons	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
case	O	NOUN	B
,	O	PUNCT	O
PWS	B-Disease	NOUN	B
does	O	AUX	O
not	O	PART	O
become	O	VERB	O
evident	O	ADJ	O
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
is	O	AUX	O
passed	O	VERB	O
through	O	ADP	O
the	O	DET	O
matrilineal	O	ADJ	B
line	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
represents	O	VERB	O
a	O	DET	O
unique	O	ADJ	B
inheritance	O	NOUN	B
pattern	O	NOUN	B
due	O	ADJ	O
to	O	ADP	O
imprinting	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Human	O	ADJ	B
glycine	O	NOUN	O
decarboxylase	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
GLDC	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
highly	O	ADV	O
conserved	O	VERB	O
processed	O	VERB	O
pseudogene	O	NOUN	O
(	O	PUNCT	O
psiGLDC	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
their	O	PRON	O
structure	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
large	O	ADJ	O
deletion	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
glycine	O	NOUN	B
decarboxylase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
GLDC	O	NOUN	B
)	O	PUNCT	O
cause	O	VERB	O
nonketotic	B-Disease	ADJ	B
hyperglycinemia	I-Disease	NOUN	I
(	O	PUNCT	O
NKH	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
in	B-Disease	ADV	O
-	I-Disease	PUNCT	O
born	I-Disease	VERB	B
error	I-Disease	NOUN	O
of	I-Disease	ADP	O
metabolism	I-Disease	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
severe	O	ADJ	B
neurological	B-Disease	ADJ	B
disturbance	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
structure	O	NOUN	B
of	O	ADP	O
GLDC	O	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
its	O	PRON	O
pseudogene	O	NOUN	B
(	O	PUNCT	O
psiGLDC	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
studied	O	VERB	O
their	O	PRON	O
expression	O	NOUN	B
for	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
NKH	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
GLDC	O	NOUN	B
gene	O	NOUN	O
spans	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
135	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
consists	O	VERB	O
of	O	ADP	O
25	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
donor	O	NOUN	B
and	O	CCONJ	O
acceptor	O	NOUN	B
sites	O	NOUN	I
adhere	O	VERB	O
to	O	PART	O
the	O	DET	O
canonical	O	ADJ	B
GT	O	NOUN	I
-	O	PUNCT	O
AG	O	PROPN	B
rule	O	NOUN	O
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
21	O	NUM	O
,	O	PUNCT	O
where	O	SCONJ	O
a	O	DET	O
variant	O	ADJ	B
form	O	NOUN	O
GC	O	NOUN	B
is	O	AUX	O
used	O	VERB	O
instead	O	ADV	O
of	O	ADP	O
GT	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
transcription	O	NOUN	B
initiation	O	NOUN	I
site	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
a	O	DET	O
residue	O	NOUN	O
163	O	NUM	O
bp	O	NOUN	O
upstream	O	ADJ	B
from	O	ADP	O
the	O	DET	O
translation	O	NOUN	B
initiation	O	NOUN	O
triplet	O	NOUN	O
by	O	ADP	O
primer	O	NOUN	B
extension	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
psiGLDC	O	ADJ	B
gene	O	NOUN	I
has	O	AUX	O
no	O	DET	O
intron	O	NOUN	B
and	O	CCONJ	O
shares	O	VERB	O
97	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
homology	O	NOUN	B
with	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
functional	O	ADJ	B
GLDC	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
psiGLDC	O	NOUN	B
is	O	AUX	O
a	O	DET	O
processed	O	VERB	O
pseudogene	O	NOUN	B
that	O	PRON	O
arose	O	VERB	O
from	O	ADP	O
the	O	DET	O
GLDC	O	NOUN	B
transcript	O	NOUN	B
about	O	ADP	O
4	O	NUM	O
-	O	SYM	O
8	O	NUM	O
million	O	NUM	O
years	O	NOUN	B
ago	O	ADV	O
.	O	PUNCT	O


RNA	O	NOUN	B
blotting	O	NOUN	I
analysis	O	NOUN	I
has	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
GLDC	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
human	O	ADJ	B
liver	O	NOUN	B
,	O	PUNCT	O
kidney	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
placenta	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
also	O	ADV	O
examined	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
NKH	B-Disease	NOUN	B
with	O	ADP	O
no	O	DET	O
detectable	O	ADJ	B
GLDC	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
his	O	PRON	O
lymphoblasts	O	NOUN	B
.	O	PUNCT	O


Exons	O	NOUN	B
1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
GLDC	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
are	O	AUX	O
not	O	PART	O
amplified	O	VERB	B
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
those	O	DET	O
from	O	ADP	O
control	O	ADJ	B
subjects	O	NOUN	I
are	O	AUX	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
large	O	ADJ	O
homozygous	O	ADJ	B
deletion	O	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
least	O	ADV	O
30	O	NUM	O
kb	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
devised	O	VERB	O
a	O	DET	O
semi	O	ADJ	B
-	O	PUNCT	O
quantitative	O	ADJ	B
PCR	O	NOUN	B
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
GLDC	O	NOUN	B
alleles	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
psiGLDC	O	NOUN	B
as	O	ADP	O
an	O	DET	O
internal	O	ADJ	B
control	O	NOUN	I
and	O	CCONJ	O
have	O	AUX	O
confirmed	O	VERB	O
the	O	DET	O
homozygosity	O	NOUN	B
and	O	CCONJ	O
heterozygosity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
his	O	PRON	O
parents	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Structural	O	ADJ	B
information	O	NOUN	B
of	O	ADP	O
GLDC	O	NOUN	B
and	O	CCONJ	O
psiGLDC	O	NOUN	B
should	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
NKH	B-Disease	NOUN	B
.	O	PUNCT	O


De	O	X	B
novo	O	X	I
deletions	O	NOUN	B
of	O	ADP	O
SNRPN	O	NOUN	B
exon	O	NOUN	I
1	O	NUM	I
in	O	ADP	O
early	O	ADJ	O
human	O	ADJ	B
and	O	CCONJ	O
mouse	O	NOUN	B
embryos	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
paternal	O	NOUN	B
to	O	PART	O
maternal	O	ADJ	B
imprint	O	ADJ	O
switch	O	NOUN	O
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
neurogenetic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
infantile	B-Disease	ADJ	B
hypotonia	I-Disease	NOUN	I
,	O	PUNCT	O
gonadal	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
obsessive	O	ADJ	B
behaviour	O	NOUN	I
and	O	CCONJ	O
neonatal	O	ADJ	B
feeding	O	NOUN	B
difficulties	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
hyperphagia	B-Disease	NOUN	B
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
profound	O	ADJ	O
obesity	B-Disease	NOUN	B
.	O	PUNCT	O


PWS	B-Disease	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
paternal	O	ADJ	B
genetic	O	ADJ	O
information	O	NOUN	O
at	O	ADP	O
15q11	O	NOUN	B
-	O	PUNCT	O
q13	O	NOUN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Five	O	NUM	O
imprinted	O	ADJ	B
,	O	PUNCT	O
paternally	O	ADV	B
expressed	O	VERB	I
genes	O	NOUN	I
map	O	VERB	O
to	O	PART	O
the	O	DET	O
PWS	B-Disease	NOUN	B
region	O	NOUN	O
,	O	PUNCT	O
MKRN3	O	NOUN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
NDN	O	NOUN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
NDNL1	O	NOUN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
5	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
SNRPN	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
6	O	NUM	O
-	O	SYM	O
8	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
IPW	O	PROPN	B
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
two	O	NUM	O
poorly	O	ADV	O
characterized	O	VERB	B
framents	O	NOUN	B
designated	O	VERB	O
PAR	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
PAR	O	PROPN	B
-	O	PUNCT	O
5	O	NUM	O
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Imprinting	O	NOUN	B
of	O	ADP	O
this	O	DET	O
region	O	NOUN	B
involves	O	VERB	O
a	O	DET	O
bipartite	O	ADJ	B
imprinting	O	NOUN	I
centre	O	NOUN	I
(	O	PUNCT	O
IC	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
overlaps	O	VERB	O
SNRPN	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
10	O	NUM	O
,	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SNRPN	O	NOUN	B
promoter	O	NOUN	B
/	O	PUNCT	O
exon	O	NOUN	B
1	O	NUM	I
region	O	NOUN	I
(	O	PUNCT	O
the	O	DET	O
PWS	B-Disease	NOUN	B
IC	O	NOUN	O
element	O	NOUN	B
)	O	PUNCT	O
appears	O	VERB	O
to	O	PART	O
impair	O	VERB	B
the	O	DET	O
establishment	O	NOUN	O
of	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
imprint	O	NOUN	I
in	O	ADP	O
the	O	DET	O
male	O	NOUN	B
germ	O	NOUN	B
line	O	NOUN	I
and	O	CCONJ	O
leads	O	VERB	O
to	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
a	O	DET	O
PWS	B-Disease	NOUN	B
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
father	O	NOUN	B
is	O	AUX	O
mosaic	O	ADJ	B
for	O	ADP	O
an	O	DET	O
IC	O	NOUN	B
deletion	O	NOUN	B
on	O	ADP	O
his	O	PRON	O
paternal	O	ADJ	B
chromosome	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
chromosome	O	NOUN	I
has	O	AUX	O
acquired	O	VERB	O
a	O	DET	O
maternal	O	ADJ	B
methylation	O	NOUN	B
imprint	O	NOUN	B
in	O	ADP	O
his	O	PRON	O
somatic	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
made	O	VERB	O
identical	O	ADJ	O
findings	O	NOUN	B
in	O	ADP	O
chimaeric	O	ADJ	B
mice	O	NOUN	I
generated	O	VERB	O
from	O	ADP	O
two	O	NUM	O
independent	O	ADJ	O
embryonic	O	ADJ	B
stem	O	NOUN	I
(	O	PUNCT	O
ES	O	NOUN	B
)	O	PUNCT	O
cell	O	NOUN	B
lines	O	NOUN	I
harbouring	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
deletion	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
studies	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
PWS	B-Disease	NOUN	B
IC	O	NOUN	B
element	O	NOUN	B
is	O	AUX	O
not	O	PART	O
only	O	ADV	O
required	O	VERB	O
for	O	ADP	O
the	O	DET	O
establishment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
imprint	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
for	O	ADP	O
its	O	PRON	O
postzygotic	O	ADJ	B
maintenance	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mice	O	NOUN	B
deficient	B-Disease	ADJ	B
in	I-Disease	ADP	O
Six5	I-Disease	NOUN	B
develop	O	VERB	O
cataracts	B-Disease	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
UTR	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
DMPK	O	NOUN	I
at	O	ADP	O
the	O	DET	O
DM1	O	NOUN	B
locus	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	O
19	O	NUM	O
causes	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
dominantly	B-Disease	ADV	O
inherited	I-Disease	VERB	B
disease	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
skeletal	O	ADJ	B
muscle	B-Disease	NOUN	I
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
myotonia	B-Disease	NOUN	B
,	O	PUNCT	O
cataracts	B-Disease	NOUN	B
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
defects	I-Disease	NOUN	I
.	O	PUNCT	O


Targeted	O	VERB	B
deletion	O	NOUN	I
of	O	ADP	O
Dm15	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
orthologue	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
DMPK	O	NOUN	B
,	O	PUNCT	O
produced	O	VERB	O
mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
mild	O	ADJ	B
myopathy	B-Disease	ADJ	I
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
abnormalities	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
without	O	ADP	O
other	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
myotonia	B-Disease	NOUN	B
and	O	CCONJ	O
cataracts	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
,	O	PUNCT	O
and	O	CCONJ	O
others	O	NOUN	O
,	O	PUNCT	O
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
repeat	O	NOUN	O
expansion	O	NOUN	B
decreases	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adjacent	O	ADJ	B
gene	O	NOUN	B
SIX5	O	NOUN	I
(	O	PUNCT	O
refs	O	NOUN	O
7	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
a	O	DET	O
homeodomain	O	NOUN	B
transcription	O	NOUN	I
factor	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
SIX5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
phenotype	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
disrupted	O	VERB	B
mouse	O	NOUN	B
Six5	O	NOUN	B
by	O	ADP	O
replacing	O	VERB	O
the	O	DET	O
first	O	ADJ	O
exon	O	NOUN	B
with	O	ADP	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
galactosidase	O	NOUN	B
reporter	O	NOUN	I
.	O	PUNCT	O


Six5	O	NOUN	B
-	O	PUNCT	O
mutant	O	ADJ	B
mice	O	NOUN	B
showed	O	VERB	O
reporter	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
multiple	O	ADJ	B
tissues	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
developing	O	VERB	O
lens	O	NOUN	B
.	O	PUNCT	O


Homozygous	O	ADJ	B
mutant	O	ADJ	O
mice	O	NOUN	O
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	O
abnormalities	B-Disease	NOUN	B
of	I-Disease	ADP	O
skeletal	I-Disease	ADJ	B
muscle	I-Disease	NOUN	I
function	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
developed	O	VERB	O
lenticular	B-Disease	ADJ	B
opacities	I-Disease	NOUN	I
at	O	ADP	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
SIX5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
contributes	O	VERB	O
to	O	PART	O
the	O	DET	O
cataract	B-Disease	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
represents	O	VERB	O
a	O	DET	O
multigenic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Heterozygous	O	ADJ	B
loss	O	NOUN	O
of	O	ADP	O
Six5	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
is	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
cause	O	VERB	O
ocular	O	ADJ	B
cataracts	B-Disease	NOUN	I
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
skeletal	O	ADJ	B
muscle	B-Disease	NOUN	I
wasting	I-Disease	NOUN	B
,	O	PUNCT	O
myotonia	B-Disease	NOUN	B
,	O	PUNCT	O
cardiac	B-Disease	ADJ	B
arrhythmia	I-Disease	NOUN	I
,	O	PUNCT	O
hyperinsulinaemia	B-Disease	NOUN	B
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
and	O	CCONJ	O
ocular	O	ADJ	B
cataracts	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
in	O	ADP	O
DM	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
expansion	O	NOUN	B
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
DMPK	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
of	O	ADP	O
a	O	DET	O
homeodomain	O	NOUN	B
-	O	PUNCT	O
encoding	O	VERB	B
gene	O	NOUN	B
,	O	PUNCT	O
SIX5	O	NOUN	B
(	O	PUNCT	O
formerly	O	ADV	O
DMAHP	O	NOUN	B
;	O	PUNCT	O
refs	O	NOUN	O
2	O	NUM	O
-	O	SYM	O
5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
three	O	NUM	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
CTG	O	NOUN	B
expansion	O	NOUN	B
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
repeat	O	NOUN	O
expansion	O	NOUN	B
may	O	AUX	O
alter	O	VERB	O
the	O	DET	O
processing	O	NOUN	B
or	O	CCONJ	O
transport	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
DMPK	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
consequently	O	ADV	O
reduce	O	VERB	O
DMPK	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
CTG	O	NOUN	B
expansion	O	NOUN	B
may	O	AUX	O
establish	O	VERB	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
heterochromatin	O	NOUN	B
3	O	NUM	I
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
sequence	O	NOUN	B
and	O	CCONJ	O
decrease	O	VERB	B
SIX5	O	NOUN	B
transcription	O	NOUN	B
.	O	PUNCT	O


Third	O	ADV	B
,	O	PUNCT	O
toxic	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
expansion	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
intrinsic	O	ADJ	B
to	O	PART	O
the	O	DET	O
repeated	O	VERB	O
elements	O	NOUN	B
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
or	O	CCONJ	O
RNA	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
10	O	NUM	O
,	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
Dm15	O	NOUN	B
(	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
DMPK	O	NOUN	B
homologue	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
mice	O	NOUN	B
produces	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
DM	B-Disease	NOUN	B
phenotype	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
decreased	O	VERB	B
development	O	NOUN	B
of	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
force	O	NOUN	O
and	O	CCONJ	O
cardiac	B-Disease	ADJ	B
conduction	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
Six5	O	NOUN	B
loss	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
analysed	O	VERB	B
a	O	DET	O
strain	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
in	O	ADP	O
which	O	DET	O
Six5	O	NOUN	B
was	O	AUX	O
deleted	O	VERB	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
rate	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
cataract	B-Disease	NOUN	B
formation	O	NOUN	I
is	O	AUX	O
inversely	O	ADV	O
related	O	ADJ	O
to	O	PART	O
Six5	O	NOUN	B
dosage	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
temporally	O	ADV	O
progressive	O	ADJ	B
.	O	PUNCT	O


Six5	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	B
-	O	PUNCT	B
and	O	CCONJ	O
Six5	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
show	O	VERB	O
increased	O	VERB	B
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Na	O	PROPN	B
+	O	CCONJ	O
/	O	SYM	O
K	O	PROPN	B
+	O	CCONJ	O
-	O	PUNCT	O
ATPase	O	NOUN	B
alpha	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
subunit	O	NOUN	B
and	O	CCONJ	O
decreased	O	VERB	B
Dm15	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
altered	O	ADJ	O
ion	O	NOUN	B
homeostasis	O	NOUN	B
within	O	ADP	O
the	O	DET	O
lens	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
cataract	B-Disease	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
ocular	O	ADJ	B
cataracts	B-Disease	NOUN	I
are	O	AUX	O
a	O	DET	O
characteristic	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
DM	B-Disease	NOUN	B
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
decreased	O	VERB	B
SIX5	O	NOUN	B
transcription	O	NOUN	B
is	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
DM	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
contiguous	O	ADJ	B
gene	O	NOUN	I
syndrome	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
partial	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
DMPK	O	NOUN	B
and	O	CCONJ	O
SIX5	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


ATM	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
phosphorylation	O	NOUN	B
of	O	ADP	O
nibrin	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
radiation	O	NOUN	B
exposure	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
ATM	O	NOUN	I
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
genetic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
cerebellar	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
radiosensitivity	O	NOUN	B
,	O	PUNCT	O
chromosomal	O	ADJ	B
instability	O	NOUN	I
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
predisposition	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
similarity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
to	O	PART	O
other	O	ADJ	O
DNA	O	NOUN	B
-	O	PUNCT	O
damage	O	NOUN	B
sensors	O	NOUN	I
suggests	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
ATM	O	NOUN	B
in	O	ADP	O
biochemical	O	ADJ	B
pathways	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
recognition	O	NOUN	B
,	O	PUNCT	O
signalling	O	NOUN	B
and	O	CCONJ	O
repair	O	NOUN	B
of	O	ADP	I
DNA	O	NOUN	I
double	O	ADJ	I
-	O	PUNCT	O
strand	O	NOUN	B
breaks	O	NOUN	I
(	O	PUNCT	O
DSBs	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
strong	O	ADJ	O
parallels	O	NOUN	O
between	O	ADP	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
radiosensitivity	O	NOUN	B
,	O	PUNCT	O
chromosomal	O	ADJ	B
instability	O	NOUN	I
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
predisposition	O	NOUN	I
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Nijmegen	B-Disease	NOUN	B
breakage	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NBS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
defective	O	ADJ	B
in	O	ADP	O
NBS	B-Disease	NOUN	B
,	O	PUNCT	O
nibrin	O	NOUN	B
(	O	PUNCT	O
encoded	O	VERB	B
by	O	ADP	O
NBS1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
forms	O	VERB	O
a	O	DET	O
complex	O	NOUN	B
with	O	ADP	O
MRE11	O	NOUN	B
and	O	CCONJ	O
RAD50	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
complex	O	NOUN	B
localizes	O	VERB	B
to	O	PART	O
DSBs	O	NOUN	B
within	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
cellular	O	ADJ	B
exposure	O	NOUN	I
to	O	PART	O
ionizing	O	VERB	B
radiation	O	NOUN	I
(	O	PUNCT	O
IR	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
brightly	O	ADV	B
staining	O	VERB	I
nuclear	O	ADJ	B
foci	O	NOUN	I
after	O	ADP	O
a	O	DET	O
longer	O	ADJ	O
period	O	NOUN	O
of	O	ADP	O
time	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
overlap	O	NOUN	B
between	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
cellular	O	ADJ	B
phenotypes	O	NOUN	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
and	O	CCONJ	O
NBS	B-Disease	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
ATM	O	NOUN	B
and	O	CCONJ	O
nibrin	O	NOUN	B
may	O	AUX	O
function	O	VERB	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
biochemical	O	ADJ	B
pathway	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
nibrin	O	NOUN	B
is	O	AUX	O
phosphorylated	O	VERB	B
within	O	ADP	O
one	O	NUM	O
hour	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
cells	O	NOUN	B
with	O	ADP	O
IR	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
response	O	NOUN	B
is	O	AUX	O
abrogated	O	VERB	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
cells	O	NOUN	I
that	O	SCONJ	O
either	O	DET	O
do	O	AUX	O
not	O	PART	O
express	O	VERB	O
ATM	O	NOUN	B
protein	O	NOUN	I
or	O	CCONJ	O
express	O	VERB	B
near	O	ADP	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
mutant	O	ADJ	O
protein	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
ATM	O	NOUN	B
physically	O	ADV	B
interacts	O	VERB	I
with	O	ADP	O
and	O	CCONJ	O
phosphorylates	O	VERB	B
nibrin	O	NOUN	B
on	O	ADP	O
serine	O	NOUN	B
343	O	NUM	I
both	O	CCONJ	O
in	O	X	B
vivo	O	X	I
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Phosphorylation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
site	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
functionally	O	ADV	O
important	O	ADJ	O
because	O	SCONJ	O
mutated	O	VERB	B
nibrin	O	NOUN	O
(	O	PUNCT	O
S343A	O	NOUN	B
)	O	PUNCT	O
does	O	AUX	O
not	O	PART	O
completely	O	ADV	O
complement	O	NOUN	B
radiosensitivity	O	NOUN	B
in	O	ADP	O
NBS	B-Disease	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


ATM	O	NOUN	B
phosphorylation	O	NOUN	B
of	O	ADP	O
nibrin	O	NOUN	B
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
nibrin	O	NOUN	B
-	O	PUNCT	O
MRE11	O	NOUN	B
-	O	PUNCT	O
RAD50	O	NOUN	B
association	O	NOUN	B
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
radiation	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
foci	O	NOUN	B
formation	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
biochemical	O	ADJ	B
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
similarity	O	NOUN	B
in	O	ADP	O
phenotype	O	NOUN	B
between	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
and	O	CCONJ	O
NBS	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Clinicopathologic	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
BRCA	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
and	I-Disease	CCONJ	O
sporadic	I-Disease	ADJ	B
ovarian	I-Disease	ADJ	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


CONTEXT	O	NOUN	B
Most	O	ADV	O
hereditary	B-Disease	ADJ	B
ovarian	I-Disease	ADJ	I
cancers	I-Disease	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


Attempts	O	VERB	O
to	O	PART	O
define	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
BRCA	O	NOUN	B
mutation	O	NOUN	B
status	O	NOUN	I
in	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
have	O	AUX	O
produced	O	VERB	O
conflicting	O	ADJ	O
results	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
regarding	O	VERB	O
survival	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
hereditary	B-Disease	ADJ	B
ovarian	I-Disease	ADJ	I
cancers	I-Disease	NOUN	I
have	O	AUX	O
distinct	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
pathological	O	ADJ	B
features	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
sporadic	B-Disease	ADJ	B
(	I-Disease	PUNCT	O
nonhereditary	I-Disease	ADJ	B
)	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


DESIGN	O	NOUN	O
AND	O	CCONJ	O
SETTING	O	VERB	O
Retrospective	O	ADJ	B
cohort	O	NOUN	O
study	O	NOUN	O
of	O	ADP	O
a	O	DET	O
consecutive	O	ADJ	B
series	O	NOUN	B
of	O	ADP	O
933	O	NUM	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
diagnosed	O	VERB	B
and	O	CCONJ	O
treated	O	VERB	B
at	O	ADP	O
our	O	PRON	O
institution	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
comprehensive	O	ADJ	B
cancer	B-Disease	NOUN	B
center	O	NOUN	I
as	O	ADP	O
designated	O	VERB	O
by	O	ADP	O
the	O	DET	O
National	O	PROPN	B
Cancer	B-Disease	PROPN	I
Institute	O	PROPN	I
,	O	PUNCT	O
over	O	ADP	O
a	O	DET	O
12	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
(	O	PUNCT	O
December	O	PROPN	O
1986	O	NUM	O
to	O	ADP	O
August	O	PROPN	O
1998	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


PATIENTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
patients	O	NOUN	B
of	O	ADP	O
Jewish	O	ADJ	B
origin	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
ease	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
genotyping	O	NOUN	B
in	O	ADP	O
this	O	DET	O
ethnic	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
189	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
identified	O	VERB	O
themselves	O	PRON	O
as	O	ADP	O
Jewish	O	ADJ	B
,	O	PUNCT	O
88	O	NUM	O
hereditary	O	ADJ	B
cases	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
with	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
founder	O	NOUN	I
mutation	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
101	O	NUM	O
cases	O	NOUN	B
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
series	O	NOUN	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
BRCA	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
additional	O	ADJ	O
groups	O	NOUN	B
(	O	PUNCT	O
Gynecologic	O	PROPN	B
Oncology	O	PROPN	I
Group	O	PROPN	I
protocols	O	NOUN	I
52	O	NUM	O
and	O	CCONJ	O
111	O	NUM	O
)	O	PUNCT	O
with	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
from	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
(	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
survival	O	NOUN	B
analysis	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
included	O	VERB	O
for	O	ADP	O
comparison	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	B
MEASURES	O	ADJ	O
Age	O	PROPN	B
at	O	ADP	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
surgical	O	ADJ	B
stage	O	NOUN	I
,	O	PUNCT	O
histologic	O	ADJ	B
cell	O	NOUN	I
type	O	NOUN	I
and	O	CCONJ	O
grade	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
surgical	O	ADJ	B
outcome	O	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
response	O	NOUN	B
to	O	PART	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
survival	O	NOUN	B
for	O	ADP	O
advanced	O	ADJ	B
-	O	PUNCT	O
stage	O	NOUN	B
(	O	PUNCT	O
II	O	NUM	B
and	O	CCONJ	O
IV	O	NUM	B
)	O	PUNCT	O
cases	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Hereditary	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
were	O	AUX	O
rarely	O	ADV	O
diagnosed	O	VERB	B
before	O	ADP	O
age	O	NOUN	B
40	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
common	O	ADJ	O
after	O	ADP	O
age	O	NOUN	B
60	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
mean	O	ADJ	O
age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
being	O	AUX	O
significantly	O	ADV	O
younger	O	ADJ	O
for	O	ADP	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
vs	O	CCONJ	O
BRCA2	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
patients	O	NOUN	B
(	O	PUNCT	O
54	O	NUM	O
vs	O	CCONJ	O
62	O	NUM	O
years	O	NOUN	B
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Histology	O	NOUN	B
,	O	PUNCT	O
grade	O	NOUN	B
,	O	PUNCT	O
stage	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
success	O	NOUN	B
of	O	ADP	O
cytoreductive	O	ADJ	B
surgery	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
for	O	ADP	O
hereditary	O	ADJ	B
and	O	CCONJ	O
sporadic	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hereditary	O	ADJ	B
group	O	NOUN	I
had	O	AUX	O
a	O	DET	O
longer	O	ADV	O
disease	O	NOUN	B
-	O	PUNCT	O
free	O	ADJ	B
interval	O	NOUN	O
following	O	VERB	O
primary	O	ADJ	B
chemotherapy	O	NOUN	I
in	O	ADP	O
comparison	O	NOUN	B
with	O	ADP	O
the	O	DET	O
nonhereditary	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
median	O	ADJ	B
time	O	NOUN	O
to	O	PART	O
recurrence	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
7	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Those	O	DET	O
with	O	ADP	O
hereditary	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
had	O	AUX	O
improved	O	VERB	B
survival	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
nonhereditary	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
stage	B-Disease	NOUN	B
III	I-Disease	NUM	I
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
BRCA	O	NOUN	B
mutation	O	NOUN	B
status	O	NOUN	I
was	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
prognostic	O	ADJ	B
variable	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Although	O	SCONJ	O
BRCA	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
associated	I-Disease	VERB	B
hereditary	I-Disease	ADJ	B
ovarian	I-Disease	ADJ	I
cancers	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
have	O	AUX	O
surgical	O	ADJ	B
and	O	CCONJ	O
pathological	O	ADJ	B
characteristics	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
sporadic	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
advanced	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
stage	I-Disease	NOUN	B
hereditary	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
survive	O	VERB	B
longer	O	ADV	O
than	O	ADP	O
nonhereditary	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Age	O	NOUN	B
penetrance	O	NOUN	B
is	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
BRCA1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
than	I-Disease	ADP	O
for	I-Disease	ADP	O
BRCA2	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
cancers	I-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
,	O	PUNCT	O
MEFV	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
early	O	ADJ	B
leukocyte	O	NOUN	B
development	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
regulated	O	VERB	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
inflammatory	O	ADJ	B
mediators	O	NOUN	I
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
episodes	O	NOUN	B
of	O	ADP	O
fever	B-Disease	NOUN	B
and	O	CCONJ	O
neutrophil	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
mediated	I-Disease	VERB	B
serosal	I-Disease	ADJ	B
inflammation	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
identified	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
causing	O	VERB	O
FMF	B-Disease	NOUN	B
,	O	PUNCT	O
designated	O	VERB	O
MEFV	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
found	O	VERB	O
it	O	PRON	O
to	O	PART	O
be	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
mature	O	ADJ	B
neutrophils	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
functions	O	VERB	B
as	O	ADP	O
an	O	DET	O
inflammatory	O	ADJ	B
regulator	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
facilitate	O	VERB	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
MEFV	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
extended	O	VERB	O
our	O	PRON	O
previous	O	ADJ	O
studies	O	NOUN	B
.	O	PUNCT	O


MEFV	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
-	O	PUNCT	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
in	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
leukocytes	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
differential	O	ADJ	O
expression	O	NOUN	B
observed	O	VERB	O
among	O	ADP	O
cells	O	NOUN	B
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


CD34	O	NOUN	B
hematopoietic	O	ADJ	B
stem	O	NOUN	I
-	O	PUNCT	O
cell	O	NOUN	B
cultures	O	NOUN	I
induced	O	VERB	B
toward	O	ADP	O
the	O	DET	O
granulocytic	O	ADJ	B
lineage	O	NOUN	B
expressed	O	VERB	B
MEFV	O	NOUN	B
at	O	ADP	O
the	O	DET	O
myelocyte	O	NOUN	B
stage	O	NOUN	O
,	O	PUNCT	O
concurrently	O	ADV	O
with	O	ADP	O
lineage	O	NOUN	B
commitment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
prepromyelocytic	O	ADJ	B
cell	O	NOUN	I
line	O	NOUN	I
HL60	O	NOUN	B
expressed	O	VERB	B
MEFV	O	NOUN	B
only	O	ADV	O
at	O	ADP	O
granulocytic	O	ADJ	B
and	O	CCONJ	O
monocytic	O	ADJ	B
differentiation	O	NOUN	I
.	O	PUNCT	O


MEFV	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
the	O	DET	O
monocytic	O	ADJ	B
cell	O	NOUN	I
lines	O	NOUN	I
U937	O	NOUN	B
and	O	CCONJ	O
THP	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


Among	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	B
,	O	PUNCT	O
MEFV	O	NOUN	B
expression	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
neutrophils	O	NOUN	B
,	O	PUNCT	O
eosinophils	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	ADP	O
varying	O	VERB	O
degrees	O	NOUN	B
,	O	PUNCT	O
monocytes	O	NOUN	B
.	O	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
tissue	O	NOUN	B
specificity	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
,	O	PUNCT	O
complete	O	ADJ	O
sequencing	O	NOUN	B
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
upstream	O	ADJ	B
regulatory	O	ADJ	O
regions	O	NOUN	O
of	O	ADP	O
MEFV	O	NOUN	B
revealed	O	VERB	O
homology	O	NOUN	B
to	O	PART	O
myeloid	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
promoters	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
more	O	ADV	O
broadly	O	ADV	O
expressed	O	VERB	B
inflammatory	O	ADJ	B
promoter	O	NOUN	B
elements	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
stimulation	O	NOUN	B
of	O	ADP	O
monocytes	O	NOUN	B
with	O	ADP	O
the	O	DET	O
proinflammatory	O	ADJ	B
agents	O	NOUN	I
interferon	O	NOUN	B
(	O	PUNCT	O
IFN	O	NOUN	B
)	O	PUNCT	O
gamma	O	NOUN	B
,	O	PUNCT	O
tumor	B-Disease	NOUN	B
necrosis	O	NOUN	I
factor	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
lipopolysaccharide	O	NOUN	B
induced	O	VERB	B
MEFV	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
antiinflammatory	O	ADJ	B
cytokines	O	NOUN	I
interleukin	O	NOUN	I
(	O	PUNCT	O
IL	O	NOUN	B
)	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
IL	O	NOUN	B
-	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
transforming	O	VERB	B
growth	O	NOUN	I
factor	O	NOUN	I
beta	O	NOUN	I
inhibited	O	VERB	B
such	O	ADJ	O
expression	O	NOUN	B
.	O	PUNCT	O


Induction	O	NOUN	B
by	O	ADP	O
IFN	O	NOUN	B
-	O	PUNCT	O
gamma	O	NOUN	B
occurred	O	VERB	B
rapidly	O	ADV	O
and	O	CCONJ	O
was	O	AUX	O
resistant	O	ADJ	B
to	O	PART	O
cycloheximide	O	NOUN	B
.	O	PUNCT	O


IFN	O	NOUN	B
-	O	PUNCT	O
alpha	O	NOUN	B
also	O	ADV	O
induced	O	VERB	B
MEFV	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
granulocytes	O	NOUN	B
,	O	PUNCT	O
MEFV	O	NOUN	B
was	O	AUX	O
up	O	ADV	O
-	O	PUNCT	O
regulated	O	VERB	B
by	O	ADP	O
IFN	O	NOUN	B
-	O	PUNCT	O
gamma	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
IFN	O	NOUN	B
-	O	PUNCT	O
alpha	O	NOUN	B
and	O	CCONJ	O
colchicine	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
refine	O	VERB	O
understanding	O	NOUN	O
of	O	ADP	O
MEFV	O	NOUN	B
by	O	ADP	O
placing	O	VERB	O
the	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myelomonocytic	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
proinflammatory	O	ADJ	B
pathway	O	NOUN	I
and	O	CCONJ	O
identifying	O	VERB	B
it	O	PRON	O
as	O	ADP	O
an	O	DET	O
IFN	O	NOUN	B
-	O	PUNCT	O
gamma	O	NOUN	B
immediate	O	ADJ	B
early	O	ADJ	O
gene	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Biochemical	O	ADJ	B
and	O	CCONJ	O
structural	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
N	O	NOUN	B
-	O	PUNCT	O
acetylgalactosamine	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
sulfate	O	NOUN	B
sulfatase	O	NOUN	I
causing	O	VERB	O
mucopolysaccharidosis	B-Disease	NOUN	B
IVA	I-Disease	NOUN	I
phenotypes	O	NOUN	B
.	O	PUNCT	O


Mucopolysaccharidosis	B-Disease	NOUN	B
IVA	I-Disease	NOUN	I
(	O	PUNCT	O
MPS	B-Disease	PROPN	B
IVA	I-Disease	PROPN	B
;	O	PUNCT	O
OMIM	O	NOUN	B
#	O	NOUN	O
253000	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
lysosomal	B-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
N	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
acetylgalactosamine	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
sulfate	I-Disease	NOUN	B
sulfatase	I-Disease	NOUN	I
(	O	PUNCT	O
GALNS	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
variable	O	ADJ	B
clinical	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


To	O	ADP	O
date	O	NOUN	O
we	O	PRON	O
have	O	AUX	O
identified	O	VERB	O
65	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
GALNS	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
MPS	B-Disease	NOUN	B
IVA	I-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
genotype	O	NOUN	B
and	O	CCONJ	O
phenotype	O	NOUN	B
has	O	AUX	O
remained	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
17	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
using	O	VERB	O
biochemical	O	ADJ	B
approaches	O	NOUN	I
and	O	CCONJ	O
32	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
structural	O	ADJ	B
analyses	O	NOUN	I
.	O	PUNCT	O


Fifteen	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
newly	O	ADV	O
engineered	O	VERB	B
active	O	ADJ	B
site	O	NOUN	I
mutations	O	NOUN	O
(	O	PUNCT	O
C79S	O	NOUN	B
,	O	PUNCT	O
C79T	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
transient	O	ADJ	B
expression	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


Mutant	O	ADJ	B
proteins	O	NOUN	I
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
C79S	O	NOUN	B
and	O	CCONJ	O
C79T	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
destabilized	O	VERB	B
and	O	CCONJ	O
detected	O	VERB	B
as	O	ADP	O
insoluble	O	ADJ	B
precursor	O	NOUN	O
forms	O	NOUN	O
while	O	SCONJ	O
the	O	DET	O
C79S	O	NOUN	B
and	O	CCONJ	O
C79T	O	NOUN	B
mutants	O	NOUN	I
were	O	AUX	O
of	O	ADP	O
a	O	DET	O
soluble	O	ADJ	B
mature	O	ADJ	B
size	O	NOUN	B
.	O	PUNCT	O


Mutants	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
had	O	AUX	O
no	O	DET	O
activity	O	NOUN	O
.	O	PUNCT	O


Mutants	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
mild	O	ADJ	B
phenotype	O	NOUN	B
had	O	AUX	O
a	O	DET	O
considerable	O	ADJ	O
residual	O	ADJ	O
activity	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
-	O	SYM	O
13	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
GALNS	O	NOUN	B
activity	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Sulfatases	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
GALNS	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
gene	O	NOUN	B
family	O	NOUN	I
sharing	O	VERB	O
an	O	DET	O
extensive	O	ADJ	O
sequence	O	NOUN	O
homology	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
tertiary	O	ADJ	B
structural	O	ADJ	I
model	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
GALNS	O	NOUN	B
was	O	AUX	O
constructed	O	VERB	O
from	O	ADP	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
ray	O	NOUN	B
crystal	O	NOUN	B
structure	O	NOUN	I
of	O	ADP	O
N	O	NOUN	B
-	O	PUNCT	O
acetylgalacto	O	VERB	B
-	O	PUNCT	O
samine	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	B
-	O	PUNCT	O
sulfatase	O	NOUN	B
and	O	CCONJ	O
arylsulfatase	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
homology	O	NOUN	B
modeling	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
32	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
are	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
different	O	ADJ	O
reasons	O	NOUN	B
for	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
destruction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hydrophobic	O	ADJ	B
core	O	NOUN	O
or	O	CCONJ	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
packing	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
removal	O	NOUN	B
of	O	ADP	O
a	O	DET	O
salt	O	NOUN	B
bridge	O	NOUN	I
to	O	PART	O
destabilize	O	VERB	B
the	O	DET	O
entire	O	ADJ	O
conformation	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
iii	O	X	O
)	O	PUNCT	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
active	O	ADJ	B
site	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
mild	O	ADJ	B
mutations	O	NOUN	B
were	O	AUX	O
mostly	O	ADV	O
located	O	ADJ	O
on	O	ADP	O
the	O	DET	O
surface	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GALNS	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
shed	O	VERB	O
further	O	ADJ	O
light	O	NOUN	O
on	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
of	O	ADP	O
MPS	B-Disease	NOUN	B
IVA	I-Disease	PROPN	B
and	O	CCONJ	O
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
relationship	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sulfatase	O	NOUN	B
family	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
locus	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
phenotypes	O	NOUN	B
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
band	O	NOUN	I
11q22	O	NOUN	I
cause	O	VERB	O
a	O	DET	O
distinctive	O	ADJ	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
in	O	ADP	O
homozygotes	O	NOUN	B
and	O	CCONJ	O
predispose	O	VERB	O
heterozygotes	O	NOUN	B
to	O	PART	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
ischemic	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
early	O	ADJ	B
mortality	O	NOUN	B
.	O	PUNCT	O


PCR	O	NOUN	B
amplification	O	NOUN	I
from	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
automated	O	VERB	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	O
region	O	NOUN	O
(	O	PUNCT	O
66	O	NUM	O
exons	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
splice	O	NOUN	B
junctions	O	NOUN	I
detected	O	VERB	B
77	O	NUM	O
mutations	O	NOUN	B
(	O	PUNCT	O
85	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
90	O	NUM	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


Heteroduplex	O	NOUN	B
analysis	O	NOUN	I
detected	O	VERB	B
another	O	DET	O
42	O	NUM	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


Out	O	ADP	O
of	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
71	O	NUM	O
unique	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
were	O	AUX	O
found	O	VERB	O
only	O	ADV	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
51	O	NUM	O
had	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


Most	O	ADV	O
(	O	PUNCT	O
58	O	NUM	O
/	O	SYM	O
71	O	NUM	O
,	O	PUNCT	O
82	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
mutations	O	NOUN	B
were	O	AUX	O
frameshift	O	NOUN	B
and	O	CCONJ	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
predicted	O	VERB	B
to	O	PART	O
cause	O	VERB	O
truncation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
protein	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
less	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
types	O	NOUN	I
were	O	AUX	O
missense	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
/	O	SYM	O
71	O	NUM	O
,	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
splicing	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
/	O	SYM	O
71	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletion	O	NOUN	B
,	O	PUNCT	O
2546	O	NUM	O
3	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
71	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	B
survival	O	NOUN	I
and	O	CCONJ	O
height	O	NOUN	B
distribution	O	NOUN	B
of	O	ADP	O
134	O	NUM	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
correlated	O	VERB	B
significantly	O	ADV	O
with	O	ADP	O
the	O	DET	O
specific	O	ADJ	O
mutations	O	NOUN	B
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
single	O	ADJ	O
truncating	O	ADJ	B
mutation	O	NOUN	B
,	O	PUNCT	O
typically	O	ADV	O
near	O	ADP	B
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
in	O	X	B
-	O	PUNCT	I
frame	O	NOUN	I
deletion	O	NOUN	B
2546	O	NUM	O
3	O	NUM	O
,	O	PUNCT	O
were	O	AUX	O
shorter	O	ADJ	B
and	O	CCONJ	O
had	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
survival	O	NOUN	I
than	O	ADP	O
those	O	DET	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
site	O	NOUN	I
or	O	CCONJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
heterozygous	O	ADJ	B
for	O	ADP	O
two	O	NUM	O
truncating	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


Alterations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
length	O	NOUN	B
or	O	CCONJ	O
amino	O	NOUN	B
acid	O	NOUN	I
composition	O	NOUN	I
of	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
affect	O	VERB	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
clinical	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
ways	O	NOUN	O
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
at	O	ADP	O
the	O	DET	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
locus	O	NOUN	O
may	O	AUX	O
help	O	VERB	O
estimate	O	VERB	B
the	O	DET	O
prognosis	O	NOUN	B
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Isolation	O	NOUN	B
,	O	PUNCT	O
genomic	O	ADJ	B
organization	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
expression	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
homologs	O	NOUN	B
of	O	ADP	O
MEFV	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
familial	B-Disease	ADJ	B
mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
episodes	O	NOUN	B
of	O	ADP	O
fever	B-Disease	NOUN	B
with	O	ADP	O
serositis	B-Disease	NOUN	B
or	O	CCONJ	O
synovitis	B-Disease	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
the	O	DET	O
FMF	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
MEFV	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
cloned	O	VERB	B
;	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
,	O	PUNCT	O
pyrin	O	NOUN	B
/	O	SYM	O
marenostrin	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
regulate	O	VERB	B
inflammation	O	NOUN	B
in	O	ADP	O
myeloid	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
manuscript	O	NOUN	B
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
homologs	O	NOUN	B
of	O	ADP	O
MEFV	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
murine	O	ADJ	B
gene	O	NOUN	B
contains	O	VERB	O
ten	O	NUM	O
exons	O	NOUN	B
with	O	ADP	O
a	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
2304	O	NUM	O
bp	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
rat	O	NOUN	B
homolog	O	NOUN	B
has	O	AUX	O
nine	O	NUM	O
exons	O	NOUN	B
with	O	ADP	O
a	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
2253	O	NUM	O
bp	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
considerable	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
homology	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
(	O	PUNCT	O
47	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
identity	O	NOUN	B
and	O	CCONJ	O
65	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
similarity	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
between	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
genes	O	NOUN	B
(	O	PUNCT	O
73	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
identity	O	NOUN	B
and	O	CCONJ	O
82	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
similarity	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
predicted	O	VERB	O
rodent	O	ADJ	B
proteins	O	NOUN	I
have	O	AUX	O
several	O	ADJ	O
important	O	ADJ	O
domains	O	NOUN	B
and	O	CCONJ	O
signals	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
pyrin	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
B	O	NOUN	B
-	O	PUNCT	O
box	O	NOUN	B
zinc	O	NOUN	B
finger	O	NOUN	I
domain	O	NOUN	I
,	O	PUNCT	O
Robbins	O	PROPN	B
-	O	PUNCT	O
Dingwall	O	PROPN	B
nuclear	O	ADJ	I
localization	O	NOUN	I
signal	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
coiled	O	VERB	B
-	O	PUNCT	O
coil	O	NOUN	B
domain	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
perhaps	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
an	O	DET	O
ancient	O	ADJ	O
frame	O	NOUN	B
-	O	PUNCT	O
shift	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
neither	O	CCONJ	O
the	O	DET	O
mouse	O	NOUN	B
nor	O	CCONJ	O
the	O	DET	O
rat	O	NOUN	B
protein	O	NOUN	O
has	O	AUX	O
an	O	DET	O
intact	O	ADJ	B
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
B30	O	NOUN	B
.	O	PUNCT	O


2	O	NUM	O
domain	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
most	O	ADJ	O
FMF	B-Disease	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
MEFV	O	NOUN	B
.	O	PUNCT	O


Nevertheless	O	ADV	O
,	O	PUNCT	O
like	O	ADP	O
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
,	O	PUNCT	O
mouse	O	NOUN	B
Mefv	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
granulocytes	O	NOUN	I
but	O	CCONJ	O
not	O	PART	O
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
its	O	PRON	O
expression	O	NOUN	B
in	O	ADP	O
granulocytes	O	NOUN	B
,	O	PUNCT	O
Mefv	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
at	O	ADP	O
high	O	ADJ	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
follicles	O	NOUN	I
and	O	CCONJ	O
marginal	O	ADJ	B
zones	O	NOUN	B
of	O	ADP	O
the	O	DET	O
splenic	O	ADJ	B
white	O	ADJ	I
pulp	O	NOUN	I
.	O	PUNCT	O


Mefv	O	NOUN	B
is	O	AUX	O
localized	O	ADJ	B
on	O	ADP	O
mouse	O	NOUN	B
Chromosome	O	NOUN	I
(	O	PUNCT	O
Chr	O	NOUN	B
)	O	PUNCT	O
16	O	NUM	O
,	O	PUNCT	O
region	O	NOUN	B
A3	O	NOUN	I
-	O	PUNCT	O
B1	O	NOUN	B
,	O	PUNCT	O
extending	O	VERB	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
synteny	O	NOUN	B
with	O	ADP	O
human	O	ADJ	B
Chr	O	NOUN	O
16p13	O	NOUN	O
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


Development	O	NOUN	B
of	O	ADP	O
knockout	O	NOUN	B
and	O	CCONJ	O
knockin	O	ADJ	B
mouse	O	NOUN	B
models	O	NOUN	I
may	O	AUX	O
provide	O	VERB	O
further	O	ADJ	O
insights	O	NOUN	O
into	O	ADP	O
the	O	DET	O
functional	O	ADJ	B
evolution	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Additional	O	ADJ	O
copies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
causing	O	VERB	O
Pelizaeus	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
arise	O	VERB	O
by	O	ADP	O
separate	O	ADJ	O
integration	O	NOUN	B
into	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
normally	O	ADV	O
present	O	ADJ	O
at	O	ADP	O
chromosome	O	NOUN	B
Xq22	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
and	O	CCONJ	O
duplications	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
two	O	NUM	O
new	O	ADJ	O
families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
males	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
PMD	B-Disease	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
copy	O	NOUN	B
of	O	ADP	I
PLP	O	NOUN	B
on	O	ADP	O
the	O	DET	O
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
a	O	DET	O
normal	O	ADJ	O
copy	O	NOUN	O
on	O	ADP	O
Xq22	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
extra	O	ADJ	O
copy	O	NOUN	O
was	O	AUX	O
first	O	ADV	O
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AhaII	O	NOUN	B
dimorphism	O	NOUN	B
within	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
FISH	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
additional	O	ADJ	O
copy	O	NOUN	B
of	O	ADP	I
PLP	O	NOUN	B
in	O	ADP	O
Xp22	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
although	O	SCONJ	O
no	O	DET	O
chromosomal	O	ADJ	B
rearrangements	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
standard	O	ADJ	B
karyotype	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


Another	O	DET	O
three	O	NUM	O
affected	O	VERB	B
males	O	NOUN	B
from	O	ADP	O
the	O	DET	O
family	O	NOUN	B
had	O	AUX	O
similar	O	ADJ	O
findings	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
second	O	ADJ	O
unrelated	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
PMD	B-Disease	NOUN	B
,	O	PUNCT	O
cytogenetic	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
pericentric	O	ADJ	B
inversion	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
inv	O	NOUN	B
(	O	PUNCT	I
X	O	NOUN	I
)	O	PUNCT	O
carried	O	VERB	O
by	O	ADP	O
several	O	ADJ	O
affected	O	VERB	B
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
FISH	O	NOUN	B
showed	O	VERB	O
PLP	O	NOUN	B
signals	O	NOUN	B
at	O	ADP	O
Xp11	O	NOUN	B
.	O	PUNCT	O


4	O	NUM	O
and	O	CCONJ	O
Xq22	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
third	O	ADJ	O
family	O	NOUN	B
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
affected	O	VERB	B
members	O	NOUN	B
had	O	AUX	O
an	O	DET	O
extra	O	ADJ	O
copy	O	NOUN	B
of	O	ADP	I
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
detected	O	VERB	B
at	O	ADP	O
Xq26	O	NOUN	B
in	O	ADP	O
a	O	DET	O
chromosome	O	NOUN	B
with	O	ADP	O
an	O	DET	O
otherwise	O	ADV	O
normal	O	ADJ	O
banding	O	NOUN	B
pattern	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
separate	O	ADJ	O
families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
PLP	O	NOUN	B
is	O	AUX	O
duplicated	O	VERB	B
at	O	ADP	O
a	O	DET	O
noncontiguous	O	ADJ	B
site	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
such	O	ADJ	O
duplications	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
relatively	O	ADV	O
common	O	ADJ	O
but	O	CCONJ	O
previously	O	ADV	O
undetected	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
genetic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
exon	O	NOUN	B
13	O	NUM	O
duplication	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
a	O	DET	O
founder	O	NOUN	B
mutation	O	NOUN	B
present	O	ADJ	O
in	O	ADP	O
geographically	O	ADV	B
diverse	O	ADJ	O
populations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
Exon	O	NOUN	B
13	O	NUM	I
Duplication	O	PROPN	I
Screening	O	PROPN	B
Group	O	PROPN	I
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
duplication	O	NOUN	I
of	O	ADP	I
exon	O	NOUN	I
13	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
creates	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
three	O	NUM	O
unrelated	O	ADJ	B
U	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
S	O	NOUN	I
.	O	PUNCT	O
families	O	NOUN	B
of	O	ADP	O
European	O	ADJ	B
ancestry	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
Portuguese	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
goal	O	NOUN	B
was	O	AUX	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
geographic	O	ADJ	B
diversity	O	NOUN	I
of	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
this	O	DET	O
duplication	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
do	O	AUX	O
this	O	DET	O
,	O	PUNCT	O
a	O	DET	O
collaborative	O	ADJ	B
screening	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
set	O	VERB	O
up	O	ADP	O
that	O	DET	O
involved	O	VERB	O
39	O	NUM	O
institutions	O	NOUN	B
from	O	ADP	O
19	O	NUM	O
countries	O	NOUN	B
and	O	CCONJ	O
included	O	VERB	O
3	O	NUM	O
,	O	PUNCT	O
580	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
the	O	DET	I
disease	O	NOUN	I
and	O	CCONJ	O
934	O	NUM	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
11	O	NUM	O
additional	O	ADJ	O
families	O	NOUN	B
carrying	O	VERB	O
this	O	DET	O
mutation	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
Australia	O	PROPN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Belgium	O	PROPN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Canada	O	PROPN	B
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Great	O	PROPN	B
Britain	O	PROPN	I
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Haplotyping	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
derive	O	VERB	O
from	O	ADP	O
a	O	DET	O
common	O	ADJ	O
ancestor	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
of	O	ADP	O
northern	O	ADJ	B
British	O	ADJ	I
origin	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
strongly	O	ADV	O
advisable	O	ADJ	O
,	O	PUNCT	O
for	O	ADP	O
laboratories	O	NOUN	B
carrying	O	VERB	O
out	O	ADP	O
screening	O	VERB	B
either	O	CCONJ	O
in	O	ADP	O
English	O	PROPN	B
-	O	PUNCT	O
speaking	O	VERB	B
countries	O	NOUN	B
or	O	CCONJ	O
in	O	ADP	O
countries	O	NOUN	B
with	O	ADP	O
historical	O	ADJ	B
links	O	NOUN	O
with	O	ADP	O
Britain	O	PROPN	B
,	O	PUNCT	O
to	O	PART	O
include	O	VERB	O
within	O	ADP	O
their	O	PRON	O
BRCA1	O	NOUN	B
screening	O	NOUN	B
protocols	O	NOUN	I
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
based	O	VERB	B
assay	O	NOUN	B
described	O	VERB	O
in	O	ADP	O
this	O	DET	O
report	O	NOUN	B
.	O	PUNCT	O


Genotype	O	ADJ	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	O	PUNCT	O
VHL	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	I-Disease	PUNCT	O
VHL	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
disease	I-Disease	NOUN	O
is	O	AUX	O
a	O	DET	O
hereditary	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
predisposition	O	NOUN	B
for	O	ADP	O
bilateral	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
multi	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
centric	I-Disease	ADJ	B
hemangioblastoma	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
and	O	CCONJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
pheochromocytoma	B-Disease	NOUN	B
,	O	PUNCT	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cysts	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
kidney	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
pancreas	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
epididymis	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
five	O	NUM	O
families	O	NOUN	B
for	O	ADP	O
which	O	DET	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
had	O	AUX	O
failed	O	VERB	B
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
family	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mutation	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
molecular	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
deletions	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
partial	O	ADJ	B
deletions	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
exons	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
fifth	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
FISH	O	NOUN	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
quantitative	O	ADJ	B
)	O	PUNCT	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
is	O	AUX	O
a	O	DET	O
sensitive	O	ADJ	B
method	O	NOUN	O
for	O	ADP	O
detecting	O	VERB	O
germline	O	NOUN	B
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
implemented	O	VERB	O
in	O	ADP	O
routine	O	ADJ	B
DNA	O	NOUN	B
diagnosis	O	NOUN	I
for	O	ADP	O
VHL	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
previously	O	ADV	O
established	O	VERB	O
observation	O	NOUN	B
that	O	SCONJ	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
deletion	O	NOUN	I
have	O	AUX	O
a	O	DET	O
low	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
pheochromocytoma	B-Disease	NOUN	B
.	O	PUNCT	O


Further	O	ADV	O
unraveling	O	NOUN	O
of	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
in	O	ADP	O
VHL	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
has	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
full	O	ADJ	O
or	O	CCONJ	O
partial	O	ADJ	B
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
exhibit	O	VERB	O
a	O	DET	O
phenotype	O	NOUN	B
with	O	ADP	O
a	O	DET	O
preponderance	O	NOUN	B
of	O	ADP	O
central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
hemangioblastoma	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Age	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intronic	O	ADJ	B
GAA	O	NOUN	O
triplet	O	NOUN	O
repeat	O	NOUN	O
expansion	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
frequently	O	ADV	O
inherited	B-Disease	VERB	B
ataxia	I-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
due	O	ADJ	O
in	O	ADP	O
the	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
to	O	ADP	O
a	O	DET	O
large	O	ADJ	O
expansion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intronic	O	ADJ	B
GAA	O	NOUN	I
repeat	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
analysis	O	NOUN	I
based	O	VERB	O
on	O	ADP	O
haplotype	O	NOUN	B
data	O	NOUN	B
of	O	ADP	O
seven	O	NUM	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
close	O	ADV	O
to	O	PART	O
the	O	DET	O
frataxin	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
FRDA	B-Disease	NOUN	B
founding	O	NOUN	B
mutational	O	ADJ	B
event	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
682	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
203	O	NUM	O
generations	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
564	O	NUM	O
-	O	SYM	O
801	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
dating	O	NOUN	B
which	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
negative	O	ADJ	B
selection	O	NOUN	B
and	O	CCONJ	O
provides	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
an	O	DET	O
ancient	O	ADJ	O
spread	O	NOUN	B
of	O	ADP	O
a	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
mutation	O	NOUN	B
(	O	PUNCT	O
at	O	ADP	O
-	O	PUNCT	O
risk	O	NOUN	B
alleles	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
western	O	ADJ	B
Europe	O	PROPN	I
.	O	PUNCT	O
.	O	PUNCT	O


Functional	O	ADJ	B
link	O	NOUN	O
between	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
and	O	CCONJ	O
Nijmegen	B-Disease	NOUN	B
breakage	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
gene	O	NOUN	B
products	O	NOUN	I
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Nijmegen	B-Disease	NOUN	B
breakage	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
NBS	B-Disease	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
recessive	B-Disease	ADJ	B
genetic	I-Disease	ADJ	I
disorders	I-Disease	NOUN	I
with	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
cancer	B-Disease	NOUN	B
and	O	CCONJ	O
similar	O	ADJ	O
cellular	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
,	O	PUNCT	O
designated	O	VERB	O
ATM	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
member	O	NOUN	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
of	O	ADP	O
kinases	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
phosphatidylinositol	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
kinase	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
domain	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
NBS1	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
specifically	O	ADV	O
mutated	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Nijmegen	B-Disease	NOUN	B
breakage	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
forms	O	VERB	O
a	O	DET	O
complex	O	NOUN	B
with	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
repair	O	NOUN	I
proteins	O	NOUN	I
Rad50	O	NOUN	B
and	O	CCONJ	O
Mrel1	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
phosphorylation	O	NOUN	B
of	O	ADP	O
NBS1	O	NOUN	B
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
ionizing	O	VERB	B
radiation	O	NOUN	I
,	O	PUNCT	O
requires	O	VERB	O
catalytically	O	ADV	B
active	O	ADJ	O
ATM	O	NOUN	B
.	O	PUNCT	O


Complexes	O	NOUN	B
containing	O	VERB	O
ATM	O	NOUN	B
and	O	CCONJ	O
NBS1	O	NOUN	B
exist	O	VERB	O
in	O	X	B
vivo	O	X	I
in	O	ADP	O
both	O	CCONJ	O
untreated	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
cells	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
ionizing	O	VERB	B
radiation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	O
two	O	NUM	O
residues	O	NOUN	B
of	O	ADP	O
NBS1	O	NOUN	B
,	O	PUNCT	O
Ser	O	NOUN	B
278	O	NUM	I
and	O	CCONJ	O
Ser	O	NOUN	B
343	O	NUM	O
that	O	PRON	O
are	O	AUX	O
phosphorylated	O	VERB	B
in	O	X	B
vitro	O	X	I
by	O	ADP	O
ATM	O	NOUN	B
and	O	CCONJ	O
whose	O	DET	O
modification	O	NOUN	B
in	O	X	B
vivo	O	X	I
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
DNA	O	NOUN	B
damage	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
response	O	NOUN	B
includes	O	VERB	O
S	O	NOUN	B
-	O	PUNCT	O
phase	O	NOUN	B
checkpoint	O	NOUN	I
activation	O	NOUN	I
,	O	PUNCT	O
formation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NBS1	O	NOUN	B
/	O	SYM	O
Mrel1	O	PROPN	B
/	O	PUNCT	O
Rad50	O	NOUN	B
nuclear	O	ADJ	O
foci	O	NOUN	O
and	O	CCONJ	O
rescue	O	NOUN	B
of	O	ADP	O
hypersensitivity	B-Disease	NOUN	B
to	I-Disease	PART	O
ionizing	I-Disease	VERB	B
radiation	I-Disease	NOUN	I
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
a	O	DET	O
biochemical	O	ADJ	B
link	O	NOUN	O
between	O	ADP	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
checkpoints	O	NOUN	I
activated	O	VERB	B
by	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
and	O	CCONJ	O
DNA	O	NOUN	B
repair	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
genetic	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
with	O	ADP	O
overlapping	O	VERB	O
phenotypes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Homozygosity	O	NOUN	B
mapping	O	NOUN	I
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
microcephaly	B-Disease	NOUN	B
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
to	O	ADP	O
a	O	DET	O
Cohen	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
region	O	NOUN	I
on	O	ADP	O
8q21	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
8q22	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
:	O	PUNCT	O
redefining	O	VERB	O
a	O	DET	O
clinical	O	ADJ	B
entity	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
syndrome	O	NOUN	O
of	O	ADP	O
microcephaly	B-Disease	NOUN	B
,	O	PUNCT	O
progressive	O	ADJ	B
postnatal	B-Disease	ADJ	B
growth	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
two	O	NUM	O
brothers	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
cousin	O	NOUN	B
from	O	ADP	O
a	O	DET	O
multiply	O	ADV	O
consanguineous	O	ADJ	B
kindred	O	NOUN	B
of	O	ADP	O
Lebanese	O	ADJ	B
descent	O	NOUN	I
.	O	PUNCT	O


Hypotonia	B-Disease	NOUN	B
,	O	PUNCT	O
chorioretinal	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
myopia	B-Disease	NOUN	B
were	O	AUX	O
also	O	ADV	O
identified	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
condition	O	NOUN	B
varied	O	VERB	O
among	O	ADP	O
the	O	DET	O
closely	O	ADV	O
related	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
distinctive	O	ADJ	O
facial	O	ADJ	B
appearance	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
initially	O	ADV	O
considered	O	VERB	O
clinical	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
Cohen	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
was	O	AUX	O
withdrawn	O	VERB	B
and	O	CCONJ	O
a	O	DET	O
novel	O	ADJ	O
genetic	O	ADJ	B
entity	O	NOUN	I
was	O	AUX	O
assumed	O	VERB	O
.	O	PUNCT	O


Homozygosity	O	NOUN	B
mapping	O	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
assigned	O	VERB	I
the	O	DET	O
gene	O	NOUN	B
to	O	PART	O
a	O	DET	O
26	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
region	O	NOUN	B
on	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
band	O	NOUN	I
8q21	O	NOUN	I
.	O	PUNCT	O


3	O	NUM	O
-	O	SYM	O
22	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
microsatellites	O	NOUN	B
at	O	ADP	O
D8S270	O	NOUN	B
and	O	CCONJ	O
D8S514	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
maximum	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
LOD	O	NOUN	B
score	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
marker	O	NOUN	B
at	O	ADP	O
D8S267	O	NOUN	B
(	O	PUNCT	O
Zmax	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O
.	O	PUNCT	O
237	O	NUM	O
at	O	ADP	O
Omax	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Intriguingly	O	ADV	O
enough	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
identified	O	VERB	B
gene	O	NOUN	B
region	O	NOUN	I
overlaps	O	VERB	O
the	O	DET	O
refined	O	ADJ	O
gene	O	NOUN	B
region	O	NOUN	I
for	O	ADP	O
Cohen	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
COH1	O	NOUN	B
)	O	PUNCT	O
[	O	PUNCT	O
Kolehmainen	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1997	O	NUM	O
Euro	O	PROPN	B
J	O	PROPN	I
Hum	O	PROPN	I
Genet	O	PROPN	I
5	O	NUM	I
206	O	NUM	O
-	O	SYM	O
213	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
fact	O	NOUN	O
encourages	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
described	O	VERB	O
kindred	O	NOUN	B
segregates	O	VERB	B
for	O	ADP	O
a	O	DET	O
variant	O	NOUN	B
of	O	ADP	O
Cohen	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
a	O	DET	O
redefinition	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
phenotype	O	NOUN	B


Polymorphisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CYP2D6	O	NOUN	B
gene	O	NOUN	I
increase	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
.	O	PUNCT	O


Ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
and	O	CCONJ	O
highly	O	ADV	O
familial	O	ADJ	B
rheumatic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sibling	O	NOUN	B
recurrence	O	NOUN	B
risk	O	NOUN	O
ratio	O	NOUN	O
for	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
63	O	NUM	O
and	O	CCONJ	O
heritability	O	NOUN	B
assessed	O	VERB	B
in	O	ADP	O
twins	O	NOUN	B
>	O	VERB	O
90	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
MHC	O	NOUN	B
genes	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
HLA	O	NOUN	B
-	O	PUNCT	O
B27	O	NOUN	B
,	O	PUNCT	O
contribute	O	VERB	O
only	O	ADV	O
20	O	NUM	O
-	O	SYM	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
risk	O	NOUN	I
for	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
MHC	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
yet	O	ADV	O
been	O	AUX	O
convincingly	O	ADV	B
demonstrated	O	VERB	O
to	O	PART	O
influence	O	VERB	B
either	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
or	O	CCONJ	O
its	O	PRON	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
linkage	O	NOUN	B
and	O	CCONJ	O
association	O	NOUN	B
studies	O	NOUN	I
have	O	AUX	O
suggested	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
susceptibility	O	NOUN	B
gene	O	NOUN	I
for	O	ADP	O
AS	B-Disease	ADJ	B
close	O	ADV	O
to	O	PART	O
,	O	PUNCT	O
or	O	CCONJ	O
within	O	ADP	O
,	O	PUNCT	O
the	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
2D6	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
CYP2D6	O	NOUN	B
,	O	PUNCT	O
debrisoquine	O	NOUN	B
hydroxylase	O	NOUN	I
)	O	PUNCT	O
located	O	ADJ	O
at	O	ADP	O
chromosome	O	NOUN	B
22q13	O	NOUN	I
.	O	PUNCT	O
1	O	X	O
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
a	O	DET	O
linkage	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	B
22	O	NUM	I
in	O	ADP	O
200	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
AS	B-Disease	ADJ	B
affected	O	VERB	O
sibling	O	NOUN	B
-	O	PUNCT	O
pairs	O	NOUN	B
.	O	PUNCT	O


Association	O	NOUN	B
of	O	ADP	O
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CYP2D6	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
both	O	DET	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
and	O	CCONJ	O
within	O	ADP	B
-	O	PUNCT	O
family	O	NOUN	B
means	O	NOUN	O
.	O	PUNCT	O


For	O	ADP	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
studies	O	NOUN	I
,	O	PUNCT	O
617	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
AS	B-Disease	ADJ	B
(	O	PUNCT	O
361	O	NUM	O
probands	O	NOUN	B
from	O	ADP	O
sibling	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
and	O	CCONJ	O
parent	O	NOUN	B
-	O	PUNCT	O
case	O	NOUN	B
trio	O	NOUN	B
families	O	NOUN	B
and	O	CCONJ	O
256	O	NUM	O
unrelated	O	ADJ	O
non	O	ADJ	B
-	O	PUNCT	O
familial	O	ADJ	B
sporadic	O	ADJ	B
cases	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
402	O	NUM	O
healthy	O	ADJ	B
ethnically	O	ADV	B
matched	O	VERB	O
controls	O	NOUN	O
were	O	AUX	O
employed	O	VERB	O
.	O	PUNCT	O


For	O	ADP	O
within	O	ADP	O
-	O	PUNCT	O
family	O	NOUN	B
association	O	NOUN	O
studies	O	NOUN	O
,	O	PUNCT	O
361	O	NUM	O
families	O	NOUN	B
including	O	VERB	O
161	O	NUM	O
parent	O	NOUN	B
-	O	PUNCT	O
case	O	NOUN	B
trios	O	NOUN	B
and	O	CCONJ	O
200	O	NUM	O
affected	O	VERB	O
sibling	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
families	O	NOUN	B
were	O	AUX	O
employed	O	VERB	O
.	O	PUNCT	O


Homozygosity	O	NOUN	B
for	O	ADP	O
poor	O	ADJ	B
metabolizer	O	NOUN	B
alleles	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
AS	B-Disease	NOUN	B
.	O	PUNCT	O


Heterozygosity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
poor	O	ADJ	B
metabolizer	O	NOUN	B
allele	O	NOUN	I
(	O	PUNCT	O
CYP2D6	O	NOUN	B
*	O	PUNCT	I
4	O	NUM	I
)	O	PUNCT	O
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
AS	B-Disease	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
within	O	ADP	O
-	O	PUNCT	O
family	O	NOUN	B
association	O	NOUN	B
of	O	ADP	O
CYP2D6	O	NOUN	B
*	O	PUNCT	O
4	O	NUM	O
alleles	O	NOUN	B
and	O	CCONJ	O
AS	B-Disease	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


Weak	O	ADJ	B
linkage	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
demonstrated	O	VERB	O
between	O	ADP	O
CYP2D6	O	NOUN	B
and	O	CCONJ	O
AS	B-Disease	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
altered	O	ADJ	O
metabolism	O	NOUN	B
of	O	ADP	O
a	O	DET	O
natural	O	ADJ	B
toxin	O	NOUN	I
or	O	CCONJ	O
antigen	O	NOUN	B
by	O	ADP	O
the	O	DET	O
CYP2D6	O	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
increase	O	VERB	B
susceptibility	O	NOUN	B
to	O	ADP	O
AS	B-Disease	NOUN	B
.	O	PUNCT	O


Functional	O	ADJ	B
differences	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PDS	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
phenotypic	O	ADJ	B
variation	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
(	O	PUNCT	O
DFNB4	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
PDS	B-Disease	PROPN	B
gene	O	NOUN	O
encodes	O	VERB	B
a	O	DET	O
transmembrane	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
known	O	VERB	O
as	O	ADP	O
pendrin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
functions	O	VERB	B
as	O	ADP	O
a	O	DET	O
transporter	O	NOUN	B
of	O	ADP	O
iodide	O	NOUN	B
and	O	CCONJ	O
chloride	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
non	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	O
at	O	ADP	O
the	O	DET	O
DFNB4	B-Disease	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
7q31	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
screen	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
individuals	O	NOUN	B
from	O	ADP	O
the	O	DET	O
midwestern	O	ADJ	B
USA	O	NOUN	I
with	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	O
and	O	CCONJ	O
dilated	O	ADJ	B
vestibular	O	ADJ	B
aqueducts	O	NOUN	I
identified	O	VERB	O
three	O	NUM	O
people	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
with	O	ADP	O
PDS	B-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
PDS	B-Disease	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
differ	O	VERB	O
functionally	O	ADV	O
from	O	ADP	O
PDS	B-Disease	PROPN	B
mutations	O	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	B
three	O	NUM	O
common	O	ADJ	O
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
allele	O	NOUN	B
variants	O	NOUN	I
(	O	PUNCT	O
L236P	O	NOUN	B
,	O	PUNCT	O
T416P	O	NOUN	B
and	O	CCONJ	O
E384G	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
three	O	NUM	O
PDS	B-Disease	PROPN	B
mutations	O	NOUN	B
reported	O	VERB	O
only	O	ADV	O
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
syndromic	I-Disease	ADJ	B
hearing	I-Disease	NOUN	I
loss	I-Disease	NOUN	I
(	O	PUNCT	O
V480D	O	NOUN	O
,	O	PUNCT	O
V653A	O	NOUN	B
and	O	CCONJ	O
I490L	O	NOUN	B
/	O	SYM	O
G497S	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
Pendred	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
have	O	AUX	O
complete	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
pendrin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chloride	O	NOUN	B
and	O	CCONJ	O
iodide	O	NOUN	B
transport	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
alleles	O	NOUN	B
unique	O	ADJ	B
to	O	ADP	O
people	O	NOUN	B
with	O	ADP	O
DFNB4	B-Disease	NOUN	B
are	O	AUX	O
able	O	ADJ	O
to	O	PART	O
transport	O	VERB	B
both	O	CCONJ	O
iodide	O	NOUN	B
and	O	CCONJ	O
chloride	O	NOUN	B
,	O	PUNCT	O
albeit	O	SCONJ	O
at	O	ADP	O
a	O	DET	O
much	O	ADV	O
lower	O	ADJ	O
level	O	NOUN	B
than	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
pendrin	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
residual	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
anion	O	NOUN	B
transport	O	NOUN	I
is	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
eliminate	O	VERB	O
or	O	CCONJ	O
postpone	O	VERB	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
goiter	B-Disease	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
DFNB4	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
pendrin	O	NOUN	B
function	O	NOUN	O
in	O	ADP	O
the	O	DET	O
thyroid	O	NOUN	B
in	O	ADP	O
which	O	DET	O
pendrin	O	NOUN	B
transports	O	VERB	O
iodide	O	NOUN	O
across	O	ADP	O
the	O	DET	O
apical	O	ADJ	B
membrane	O	NOUN	I
of	O	ADP	O
the	O	DET	O
thyrocyte	O	NOUN	B
into	O	ADP	O
the	O	DET	O
colloid	O	NOUN	B
space	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
factor	O	NOUN	I
IX	O	NUM	I
gene	O	NOUN	I
as	O	ADP	O
germline	O	NOUN	B
mutagen	O	NOUN	I
test	O	NOUN	I
:	O	PUNCT	O
samples	O	NOUN	B
from	O	ADP	O
Mainland	O	PROPN	B
China	O	PROPN	I
have	O	AUX	O
the	O	DET	O
putatively	O	ADV	O
endogenous	O	ADJ	B
pattern	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
are	O	AUX	O
the	O	DET	O
major	O	ADJ	O
source	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
variation	O	NOUN	I
that	O	PRON	O
allows	O	VERB	O
a	O	DET	O
species	O	NOUN	B
to	O	PART	O
evolve	O	VERB	O
over	O	ADP	O
time	O	NOUN	B
but	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
cost	O	NOUN	B
of	O	ADP	O
Mendelian	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
genetic	O	ADJ	B
predisposition	O	NOUN	I
to	O	PART	O
multifactorial	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
analyses	O	NOUN	B
have	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
factor	O	NOUN	B
IX	O	NUM	I
gene	O	NOUN	I
(	O	PUNCT	O
F9	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
similar	O	ADJ	O
among	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
ethnically	O	ADV	B
and	O	CCONJ	O
geographically	O	ADV	B
diverse	O	ADJ	O
populations	O	NOUN	B
and	O	CCONJ	O
compatible	O	ADJ	B
with	O	ADP	O
the	O	DET	O
ancient	O	ADJ	O
pattern	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
shaped	O	VERB	O
the	O	DET	O
mammalian	O	ADJ	B
genome	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
compare	O	VERB	B
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
hemophilia	B-Disease	NOUN	B
B	I-Disease	NOUN	I
patients	O	NOUN	B
from	O	ADP	O
Mainland	O	PROPN	B
China	O	PROPN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
66	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
that	O	DET	O
in	O	ADP	O
U	O	NOUN	B
.	O	PUNCT	O


S	O	NOUN	B
.	O	PUNCT	O


Caucasians	O	PROPN	B
,	O	PUNCT	O
Blacks	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Mexican	O	PROPN	B
Hispanics	O	PROPN	B
and	O	CCONJ	O
stratify	O	VERB	B
by	O	ADP	O
disease	O	NOUN	B
severity	O	NOUN	I
and	O	CCONJ	O
ethnicity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
similar	O	ADJ	O
pattern	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
all	O	DET	O
ethnic	O	ADJ	B
groups	O	NOUN	I
studied	O	VERB	O
to	O	ADP	O
date	O	NOUN	O
provides	O	VERB	O
additional	O	ADJ	O
data	O	NOUN	B
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
inference	O	NOUN	B
that	O	SCONJ	O
endogenous	O	ADJ	B
processes	O	NOUN	B
predominate	O	VERB	O
in	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Fas	O	NOUN	B
preassociation	O	NOUN	B
required	O	VERB	O
for	O	ADP	O
apoptosis	O	NOUN	B
signaling	O	NOUN	B
and	O	CCONJ	O
dominant	O	ADJ	B
inhibition	O	NOUN	B
by	O	ADP	O
pathogenic	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


Heterozygous	O	ADJ	B
mutations	O	NOUN	I
encoding	O	VERB	O
abnormal	O	ADJ	B
forms	O	NOUN	I
of	O	ADP	O
the	O	DET	O
death	O	NOUN	B
receptor	O	NOUN	I
Fas	O	NOUN	B
dominantly	O	ADV	O
interfere	O	VERB	B
with	O	ADP	I
Fas	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lymphocyte	O	NOUN	B
apoptosis	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
autoimmune	B-Disease	ADJ	O
lymphoproliferative	I-Disease	ADJ	O
syndrome	I-Disease	NOUN	O
.	O	PUNCT	O


This	O	DET	O
effect	O	NOUN	B
,	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
depending	O	VERB	O
on	O	ADP	O
ligand	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
receptor	O	NOUN	B
oligomerization	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
stem	O	VERB	B
from	O	ADP	O
ligand	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
interaction	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
and	O	CCONJ	O
mutant	O	ADJ	B
Fas	O	NOUN	B
receptors	O	NOUN	I
through	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
region	O	NOUN	O
in	O	ADP	O
the	O	DET	O
extracellular	O	ADJ	B
domain	O	NOUN	I
.	O	PUNCT	O


Preassociated	O	VERB	B
Fas	O	NOUN	B
complexes	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
living	O	NOUN	B
cells	O	NOUN	I
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
fluorescence	O	NOUN	B
resonance	O	NOUN	I
energy	O	NOUN	I
transfer	O	NOUN	I
between	O	ADP	O
variants	O	NOUN	B
of	O	ADP	O
green	O	ADJ	B
fluorescent	O	ADJ	I
protein	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
formation	O	NOUN	B
of	O	ADP	O
preassociated	O	ADJ	B
receptor	O	NOUN	I
complexes	O	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
Fas	O	NOUN	B
signaling	O	NOUN	I
and	O	CCONJ	O
dominant	O	ADJ	B
interference	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Determination	O	NOUN	B
of	O	ADP	O
carrier	O	NOUN	B
status	O	NOUN	I
for	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
by	O	ADP	O
flow	O	NOUN	B
cytometric	O	ADJ	I
analysis	O	NOUN	I
of	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
mononuclear	O	ADJ	I
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
on	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
study	O	NOUN	B
disclosed	O	VERB	O
that	O	SCONJ	O
flow	O	NOUN	B
cytometric	O	ADJ	I
analysis	O	NOUN	I
of	O	ADP	O
intracellular	O	ADJ	B
WASP	O	NOUN	B
expression	O	NOUN	B
(	O	PUNCT	O
FCM	O	NOUN	B
-	O	PUNCT	O
WASP	O	PROPN	B
analysis	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
lymphocytes	O	NOUN	B
was	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	AUX	B
patients	O	NOUN	B
.	O	PUNCT	O


Lymphocytes	O	NOUN	B
from	O	ADP	O
all	O	DET	O
WAS	B-Disease	AUX	B
patients	O	NOUN	B
showed	O	VERB	O
WASPdim	O	NOUN	B
instead	O	ADV	O
of	O	ADP	O
WASPbright	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
FCM	O	NOUN	B
-	O	PUNCT	O
WASP	O	PROPN	B
analysis	O	NOUN	B
in	O	ADP	O
monocytes	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
carrier	O	NOUN	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


Monocytes	O	NOUN	B
from	O	ADP	O
all	O	DET	O
nine	O	NUM	O
WAS	B-Disease	PROPN	B
carriers	O	NOUN	B
showed	O	VERB	O
varied	O	ADJ	O
population	O	NOUN	B
of	O	ADP	O
WASPdim	O	NOUN	B
together	O	ADV	O
with	O	ADP	O
WASPbright	O	NOUN	B
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
control	O	ADJ	B
individuals	O	NOUN	B
possessed	O	VERB	O
the	O	DET	O
WASPdim	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
lymphocytes	O	NOUN	B
from	O	ADP	O
all	O	DET	O
the	O	DET	O
carriers	O	NOUN	B
except	O	SCONJ	O
two	O	NUM	O
lacked	O	VERB	O
the	O	DET	O
WASPdim	O	NOUN	B
population	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
difference	O	NOUN	O
of	O	ADP	O
the	O	DET	O
WASPdim	O	NOUN	B
population	O	NOUN	I
in	O	ADP	O
monocytes	O	NOUN	B
and	O	CCONJ	O
lymphocytes	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
WAS	B-Disease	AUX	B
carriers	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
WASP	O	PROPN	B
plays	O	VERB	O
a	O	DET	O
more	O	ADV	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
lymphocytes	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
that	O	DET	O
of	O	ADP	O
monocytes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
skewed	O	ADJ	O
X	O	NOUN	B
-	O	PUNCT	O
chromosomal	O	ADJ	B
inactivation	O	NOUN	B
pattern	O	NOUN	B
observed	O	VERB	O
in	O	ADP	O
WAS	B-Disease	AUX	B
carrier	O	NOUN	B
peripheral	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
is	O	AUX	O
not	O	PART	O
fixed	O	VERB	O
at	O	ADP	O
the	O	DET	O
hemopoietic	O	ADJ	B
stem	O	NOUN	I
cell	O	NOUN	I
level	O	NOUN	B
but	O	CCONJ	O
progresses	O	VERB	O
after	O	ADP	O
the	O	DET	O
lineage	O	NOUN	B
commitment	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Restoration	O	NOUN	B
of	O	ADP	O
photoreceptor	O	NOUN	B
ultrastructure	O	NOUN	B
and	O	CCONJ	O
function	O	NOUN	B
in	O	ADP	O
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	O
slow	O	ADJ	B
mice	O	NOUN	I
by	O	ADP	O
gene	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
Prph2	O	NOUN	B
encodes	O	VERB	B
a	O	DET	O
photoreceptor	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
membrane	O	NOUN	B
glycoprotein	O	NOUN	I
,	O	PUNCT	O
peripherin	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
(	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
peripherin	O	NOUN	B
/	O	SYM	O
rds	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
inserted	O	VERB	O
into	O	ADP	O
the	O	DET	O
rims	O	NOUN	B
of	O	ADP	O
photoreceptor	O	NOUN	B
outer	O	ADJ	O
segment	O	NOUN	O
discs	O	NOUN	O
in	O	ADP	O
a	O	DET	O
complex	O	NOUN	B
with	O	ADP	O
rom	O	PROPN	O
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
complex	O	NOUN	B
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
the	O	DET	O
stabilization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
discs	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
renewed	O	VERB	O
constantly	O	ADV	O
throughout	O	ADP	O
life	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
which	O	DET	O
contain	O	VERB	O
the	O	DET	O
visual	O	ADJ	B
pigments	O	NOUN	I
necessary	O	ADJ	O
for	O	ADP	O
photon	O	ADJ	B
capture	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
Prph2	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
photoreceptor	B-Disease	NOUN	B
dystrophies	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
retinitis	I-Disease	NOUN	B
pigmentosa	I-Disease	NOUN	I
and	O	CCONJ	O
macular	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
these	O	DET	O
diseases	O	NOUN	B
is	O	AUX	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
photoreceptor	O	NOUN	B
function	O	NOUN	O
,	O	PUNCT	O
also	O	ADV	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	O
slow	O	NOUN	O
(	O	PUNCT	O
rds	O	NOUN	B
or	O	CCONJ	O
Prph2	O	NOUN	B
Rd2	O	NOUN	B
/	O	PUNCT	O
Rd2	O	NOUN	B
)	O	PUNCT	O
mouse	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
null	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
Prph2	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
failure	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
photoreceptor	O	NOUN	B
discs	O	NOUN	I
and	O	CCONJ	O
outer	O	ADJ	B
segments	O	NOUN	I
,	O	PUNCT	O
downregulation	O	NOUN	B
of	O	ADP	O
rhodopsin	O	NOUN	B
and	O	CCONJ	O
apoptotic	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
photoreceptor	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
electroretinograms	O	NOUN	B
(	O	PUNCT	O
ERGs	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
Prph2Rd2	O	PROPN	B
/	O	SYM	O
Rd2	O	NOUN	B
mice	O	NOUN	B
have	O	AUX	O
greatly	O	ADV	O
diminished	O	VERB	B
a	O	DET	O
-	O	PUNCT	O
wave	O	NOUN	B
and	O	CCONJ	O
b	O	X	B
-	O	PUNCT	O
wave	O	NOUN	B
amplitudes	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
decline	O	VERB	B
to	O	PART	O
virtually	O	ADV	O
undetectable	O	ADJ	B
concentrations	O	NOUN	B
by	O	ADP	O
two	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Subretinal	O	ADJ	B
injection	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
adeno	O	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
virus	O	NOUN	B
(	O	PUNCT	O
AAV	O	NOUN	B
)	O	PUNCT	O
encoding	O	VERB	B
a	O	DET	O
Prph2	O	NOUN	B
transgene	O	NOUN	I
results	O	VERB	B
in	O	ADP	O
stable	O	ADJ	B
generation	O	NOUN	I
of	O	ADP	O
outer	O	ADJ	B
segment	O	NOUN	I
structures	O	NOUN	I
and	O	CCONJ	O
formation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
stacks	O	NOUN	B
of	O	ADP	O
discs	O	NOUN	B
containing	O	VERB	O
both	O	DET	O
perpherin	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
and	O	CCONJ	O
rhodopsin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
in	O	ADP	O
many	O	ADJ	O
cases	O	NOUN	B
are	O	AUX	O
morphologically	O	ADV	B
similar	O	ADJ	O
to	O	PART	O
normal	O	ADJ	O
outer	O	ADJ	O
segments	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
re	O	ADP	B
-	O	PUNCT	O
establishment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
integrity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
photoreceptor	O	NOUN	B
layer	O	NOUN	I
also	O	ADV	O
results	O	VERB	O
in	O	ADP	O
electrophysiological	O	ADJ	B
correction	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
demonstrate	O	VERB	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
that	O	PRON	O
a	O	DET	O
complex	O	ADJ	B
ultrastructural	O	ADJ	B
cell	O	NOUN	O
defect	O	NOUN	O
can	O	AUX	O
be	O	AUX	O
corrected	O	VERB	O
both	O	CCONJ	O
morphologically	O	ADV	B
and	O	CCONJ	O
functionally	O	ADV	O
by	O	ADP	O
in	O	X	B
vivo	O	X	I
gene	O	NOUN	B
transfer	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
fibrinogen	O	NOUN	B
aalpha	O	NOUN	I
gene	O	NOUN	I
account	O	NOUN	O
for	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
congenital	B-Disease	ADJ	B
afibrinogenemia	I-Disease	NOUN	I
.	O	PUNCT	O


Congenital	B-Disease	ADJ	B
afibrinogenemia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
,	O	PUNCT	O
autosomal	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
recessive	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
complete	O	ADJ	B
absence	O	NOUN	B
of	O	ADP	O
detectable	O	ADJ	B
fibrinogen	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
identified	O	VERB	B
the	O	DET	O
first	O	ADJ	O
causative	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
a	O	DET	O
nonconsanguineous	O	ADJ	B
Swiss	O	ADJ	B
family	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
4	O	NUM	O
affected	O	VERB	B
persons	O	NOUN	B
have	O	AUX	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
11	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
fibrinogen	O	NOUN	B
alpha	O	NOUN	I
(	O	PUNCT	O
FGA	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Haplotype	O	ADJ	B
data	O	NOUN	B
implied	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
deletions	O	NOUN	B
occurred	O	VERB	O
on	O	ADP	O
distinct	O	ADJ	O
ancestral	O	ADJ	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
region	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
susceptible	O	ADJ	B
to	O	PART	O
deletion	O	NOUN	B
by	O	ADP	O
a	O	DET	O
common	O	ADJ	O
mechanism	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
subsequently	O	ADV	O
showed	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
the	O	DET	O
deletions	O	NOUN	B
were	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
the	O	DET	O
base	O	NOUN	B
pair	O	NOUN	I
and	O	CCONJ	O
probably	O	ADV	O
resulted	O	VERB	O
from	O	ADP	O
a	O	DET	O
nonhomologous	O	ADJ	B
recombination	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
7	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
direct	O	ADJ	O
repeats	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
collected	O	VERB	O
data	O	NOUN	B
on	O	ADP	O
13	O	NUM	O
additional	O	ADJ	O
unrelated	O	ADJ	O
patients	O	NOUN	B
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
causative	O	ADJ	B
mutations	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
11	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
deletion	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
common	O	ADJ	O
recurrent	O	ADJ	B
mutation	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
FGA	O	NOUN	B
intron	O	NOUN	O
4	O	NUM	O
(	O	PUNCT	O
IVS4	O	NOUN	B
+	O	CCONJ	O
1	O	NUM	O
G	O	NOUN	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
accounted	O	VERB	O
for	O	ADP	O
14	O	NUM	O
of	O	ADP	O
the	O	DET	O
26	O	NUM	O
(	O	PUNCT	O
54	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
alleles	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
was	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
previously	O	ADV	O
identified	O	VERB	B
deletion	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
more	O	ADJ	O
frameshift	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
2	O	NUM	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
second	O	ADJ	O
splice	O	NOUN	B
site	O	NOUN	I
mutation	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
identified	O	VERB	B
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
86	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
afibrinogenemia	B-Disease	NOUN	B
alleles	O	NOUN	B
analyzed	O	VERB	B
to	O	PART	O
date	O	NOUN	O
have	O	AUX	O
truncating	O	VERB	B
mutations	O	NOUN	B
of	O	ADP	O
FGA	O	NOUN	B
,	O	PUNCT	O
though	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
all	O	DET	O
3	O	NUM	O
fibrinogen	O	NOUN	B
genes	O	NOUN	I
,	O	PUNCT	O
FGG	O	NOUN	B
,	O	PUNCT	O
FGA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
FGB	O	NOUN	B
,	O	PUNCT	O
might	O	AUX	O
be	O	AUX	O
predicted	O	VERB	B
to	O	PART	O
cause	O	VERB	O
congenital	B-Disease	ADJ	B
afibrinogenemia	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
:	O	PUNCT	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
CUG	O	NOUN	B
triplet	O	NOUN	B
repeats	O	NOUN	I
in	O	ADP	O
splicing	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
DMPK	O	NOUN	B
exon	O	NOUN	B
and	O	CCONJ	O
altered	O	VERB	O
cytoplasmic	O	ADJ	B
DMPK	O	NOUN	B
mRNA	O	NOUN	B
isoform	O	NOUN	O
ratios	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
by	O	ADP	O
which	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
UTR	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMPK	O	NOUN	B
gene	O	NOUN	B
causes	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	O
four	O	NUM	O
RNA	O	NOUN	B
splicing	O	NOUN	I
factors	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
hnRNP	O	NOUN	B
C	O	NOUN	B
,	O	PUNCT	O
U2AF	O	NOUN	B
(	O	PUNCT	O
U2	O	NOUN	O
auxiliary	O	ADJ	O
factor	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
PTB	O	NOUN	B
(	O	PUNCT	O
polypyrimidine	O	ADJ	B
tract	O	NOUN	I
binding	O	NOUN	I
protein	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
PSF	O	PROPN	B
(	O	PUNCT	O
PTB	O	NOUN	B
associated	O	VERB	O
splicing	O	NOUN	O
factor	O	NOUN	O
)	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
that	O	PRON	O
bind	O	VERB	B
to	O	PART	O
two	O	NUM	O
short	O	ADJ	B
regions	O	NOUN	I
3	O	NUM	I
of	O	ADP	I
the	O	DET	I
(	O	PUNCT	O
CUG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
found	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
3	O	NUM	O
DMPK	O	NOUN	B
exon	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
an	O	DET	O
mRNA	O	NOUN	B
lacking	O	VERB	O
the	O	DET	O
repeats	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
(	O	PUNCT	O
CUG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
is	O	AUX	O
an	O	DET	O
essential	O	ADJ	O
cis	O	NOUN	O
acting	O	NOUN	O
element	O	NOUN	O
for	O	ADP	O
this	O	DET	O
splicing	O	NOUN	B
event	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
(	O	PUNCT	O
CUG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
containing	O	VERB	O
mRNAs	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
novel	O	ADJ	O
isoform	O	NOUN	B
is	O	AUX	O
not	O	PART	O
retained	O	VERB	O
in	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
imbalances	O	NOUN	B
in	O	ADP	O
relative	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
cytoplasmic	O	ADJ	B
DMPK	O	NOUN	B
mRNA	O	NOUN	B
isoforms	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
new	O	ADJ	O
dominant	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
on	O	ADP	O
DMPK	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Expression	O	NOUN	B
and	O	CCONJ	O
imprinting	O	NOUN	B
of	O	ADP	O
MAGEL2	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
willi	I-Disease	X	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
homologous	O	ADJ	B
murine	O	ADJ	B
imprinting	O	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
imprinted	O	ADJ	B
genes	O	NOUN	I
in	O	ADP	O
chromosome	O	NOUN	B
15q11	O	NOUN	I
-	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O


Affected	O	ADJ	B
individuals	O	NOUN	B
exhibit	O	VERB	O
neonatal	B-Disease	ADJ	B
hypotonia	I-Disease	NOUN	B
,	O	PUNCT	O
developmental	B-Disease	ADJ	B
delay	I-Disease	NOUN	I
and	O	CCONJ	O
childhood	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
onset	I-Disease	NOUN	B
obesity	I-Disease	NOUN	B
.	O	PUNCT	O


Necdin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
protein	O	NOUN	B
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
terminal	O	ADJ	B
differentiation	O	NOUN	B
of	O	ADP	O
neurons	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
only	O	ADJ	O
PWS	B-Disease	NOUN	B
candidate	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
reduce	O	VERB	B
viability	O	NOUN	B
when	O	SCONJ	O
disrupted	O	VERB	B
in	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
characterized	O	VERB	B
MAGEL2	O	NOUN	B
(	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
NDNL1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
gene	O	NOUN	B
with	O	ADP	O
51	O	NUM	O
%	O	NOUN	O
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
similarity	O	NOUN	B
to	O	PART	O
necdin	O	NOUN	B
and	O	CCONJ	O
located	O	ADJ	O
41	O	NUM	O
kb	O	NOUN	O
distal	O	ADJ	B
to	O	PART	O
NDN	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
deletion	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


MAGEL2	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
predominantly	O	ADV	O
in	O	ADP	O
brain	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
primary	O	ADJ	B
tissue	O	NOUN	I
affected	O	VERB	B
in	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
several	O	ADJ	O
fetal	O	ADJ	B
tissues	O	NOUN	I
as	O	ADP	O
shown	O	VERB	O
by	O	ADP	O
northern	O	ADJ	B
blot	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


MAGEL2	O	NOUN	B
is	O	AUX	O
imprinted	O	VERB	B
with	O	ADP	O
monoallelic	O	ADJ	B
expression	O	NOUN	B
in	O	ADP	O
control	O	ADJ	B
brain	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
paternal	O	ADJ	B
-	O	PUNCT	O
only	O	ADJ	O
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
its	O	PRON	O
lack	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
from	O	ADP	O
a	O	DET	O
PWS	B-Disease	PROPN	B
-	O	PUNCT	O
affected	O	VERB	B
individual	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
orthologous	O	ADJ	B
mouse	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
Magel2	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
within	O	ADP	O
150	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
NDN	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
imprinted	O	VERB	B
with	O	ADP	O
paternal	O	ADJ	B
-	O	PUNCT	O
only	O	ADJ	O
expression	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
expressed	O	VERB	B
predominantly	O	ADV	O
in	O	ADP	O
late	O	ADJ	O
developmental	O	ADJ	B
stages	O	NOUN	I
and	O	CCONJ	O
adult	O	ADJ	B
brain	O	NOUN	B
as	O	ADP	O
shown	O	VERB	O
by	O	ADP	O
northern	O	ADJ	B
blotting	O	NOUN	I
,	O	PUNCT	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
and	O	CCONJ	O
whole	O	ADJ	B
-	O	PUNCT	O
mount	O	NOUN	B
RNA	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


Magel2	O	ADJ	B
distribution	O	NOUN	B
partially	O	ADV	O
overlaps	O	VERB	O
that	O	DET	O
of	O	ADP	O
NDN	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
strong	O	ADJ	O
expression	O	NOUN	B
being	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
in	O	ADP	O
mid	O	ADJ	B
-	O	PUNCT	O
gestation	O	NOUN	B
mouse	O	NOUN	B
embryos	O	NOUN	B
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
although	O	SCONJ	O
loss	O	NOUN	B
of	O	ADP	O
necdin	O	NOUN	B
expression	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
presentation	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
,	O	PUNCT	O
loss	O	NOUN	B
of	O	ADP	O
MAGEL2	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
critical	O	ADJ	O
to	O	PART	O
abnormalities	B-Disease	NOUN	B
in	I-Disease	ADP	O
brain	I-Disease	NOUN	B
development	I-Disease	NOUN	I
and	O	CCONJ	O
dysmorphic	B-Disease	ADJ	B
features	I-Disease	NOUN	I
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Retinoschisin	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
retinoschisis	I-Disease	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
secreted	O	VERB	B
photoreceptor	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
expressed	O	VERB	B
and	O	CCONJ	O
released	O	VERB	B
by	O	ADP	O
Weri	O	PROPN	B
-	O	PUNCT	O
Rb1	O	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
retinoschisis	I-Disease	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
microcystic	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	O
changes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
macular	O	NOUN	B
region	O	NOUN	I
and	O	CCONJ	O
schisis	O	NOUN	B
within	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
retinal	O	ADJ	I
layers	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	ADP	O
visual	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	I
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
missense	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
-	O	PUNCT	O
truncating	O	VERB	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
causative	O	ADJ	B
gene	O	NOUN	I
RS1	O	NOUN	B
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
are	O	AUX	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
inactivating	O	VERB	B
.	O	PUNCT	O


RS1	O	NOUN	B
encodes	O	VERB	B
a	O	DET	O
224	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
retinoschisin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
contains	O	VERB	O
a	O	DET	O
discoidin	O	NOUN	B
domain	O	NOUN	I
but	O	CCONJ	O
is	O	AUX	O
of	O	ADP	O
unknown	O	ADJ	O
function	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
a	O	DET	O
polyclonal	O	ADJ	B
antibody	O	NOUN	I
against	O	ADP	O
a	O	DET	O
peptide	O	NOUN	B
from	O	ADP	O
a	O	DET	O
unique	O	ADJ	B
region	O	NOUN	O
within	O	ADP	O
retinoschisin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
detects	O	VERB	O
a	O	DET	O
protein	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
28	O	NUM	O
kDa	O	NOUN	O
in	O	ADP	O
retinal	O	ADJ	B
samples	O	NOUN	B
reduced	O	VERB	B
with	O	ADP	O
dithiothreitol	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
multimers	O	NOUN	B
sized	O	ADJ	B
>	O	VERB	O
40	O	NUM	O
kDa	O	NOUN	O
under	O	ADP	O
non	O	ADV	B
-	O	PUNCT	O
reducing	O	VERB	B
conditions	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
screen	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
tissues	O	NOUN	B
with	O	ADP	O
this	O	DET	O
antibody	O	NOUN	B
reveals	O	VERB	O
retinoschisin	O	NOUN	B
to	O	PART	O
be	O	AUX	O
retina	O	ADV	B
specific	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
antibody	O	NOUN	B
detects	O	VERB	O
a	O	DET	O
protein	O	NOUN	B
of	O	ADP	O
similar	O	ADJ	O
size	O	NOUN	B
in	O	ADP	O
bovine	O	ADJ	B
and	O	CCONJ	O
murine	O	ADJ	B
retinae	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
pattern	O	NOUN	O
in	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
RS1	O	NOUN	B
mRNA	O	NOUN	B
(	O	PUNCT	O
using	O	VERB	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
with	O	ADP	O
riboprobes	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
retinoschisin	O	NOUN	B
(	O	PUNCT	O
using	O	VERB	O
immunohistochemistry	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
antisense	O	ADJ	B
riboprobe	O	NOUN	I
detected	O	VERB	B
RS1	O	NOUN	B
mRNA	O	NOUN	B
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
photoreceptor	O	NOUN	B
layer	O	NOUN	I
but	O	CCONJ	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
both	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
photoreceptors	O	NOUN	B
and	O	CCONJ	O
within	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
portions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
retina	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
differentiated	O	VERB	O
retinoblastoma	B-Disease	NOUN	O
cells	O	NOUN	O
(	O	PUNCT	O
Weri	O	PROPN	B
-	O	PUNCT	O
Rb1	O	NOUN	B
cells	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
express	O	VERB	O
RS1	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
release	O	VERB	O
retinoschisin	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
retinoschisin	O	NOUN	B
is	O	AUX	O
released	O	VERB	O
by	O	ADP	O
photo	O	NOUN	B
-	O	PUNCT	O
receptors	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
functions	O	NOUN	B
within	O	ADP	O
the	O	DET	O
inner	O	ADJ	B
retinal	O	ADJ	I
layers	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
retinoschisis	I-Disease	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
abnormalities	O	NOUN	B
in	O	ADP	O
a	O	DET	O
putative	O	ADJ	O
secreted	O	VERB	O
photoreceptor	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
example	O	NOUN	O
of	O	ADP	O
a	O	DET	O
secreted	O	VERB	B
photo	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
protein	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
retinal	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
voltage	O	NOUN	B
-	O	PUNCT	O
gated	O	VERB	B
sodium	O	NOUN	B
channel	O	NOUN	I
beta	O	NOUN	I
1	O	NUM	I
subunit	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
SCN1B	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
benign	B-Disease	ADJ	B
familial	I-Disease	ADJ	O
infantile	I-Disease	ADJ	O
convulsions	I-Disease	NOUN	O
syndrome	I-Disease	NOUN	O
(	O	PUNCT	O
BFIC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Benign	B-Disease	ADJ	B
familial	I-Disease	ADJ	O
infantile	I-Disease	ADJ	O
convulsions	I-Disease	NOUN	O
(	O	PUNCT	O
BFIC	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
epilepsy	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
syndrome	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
described	O	VERB	O
in	O	ADP	O
Italian	O	ADJ	B
and	O	CCONJ	O
French	O	ADJ	B
pedigrees	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
present	O	ADJ	O
with	O	ADP	O
partial	O	ADJ	B
,	O	PUNCT	O
then	O	ADV	O
generalized	O	VERB	B
seizures	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
onset	O	NOUN	O
at	O	ADP	O
age	O	NOUN	B
three	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
seizures	O	NOUN	B
usually	O	ADV	O
spontaneously	O	ADV	B
cease	O	VERB	O
after	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
without	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
leaving	O	VERB	O
no	O	DET	O
neurological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
mapped	O	VERB	O
BFIC	B-Disease	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
19q	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
Italian	O	ADJ	B
pedigrees	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
sodium	O	NOUN	B
channel	O	NOUN	I
beta1	O	NOUN	I
subunit	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
SCN1B	O	NOUN	B
)	O	PUNCT	O
maps	O	VERB	B
to	O	PART	O
this	O	DET	O
candidate	O	NOUN	O
region	O	NOUN	O
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
one	O	NUM	O
Australian	O	ADJ	B
pedigree	O	NOUN	B
with	O	ADP	O
generalized	B-Disease	VERB	B
epilepsy	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
febrile	I-Disease	ADJ	B
seizures	I-Disease	NOUN	I
"	I-Disease	PUNCT	O
plus	I-Disease	CCONJ	B
"	I-Disease	PUNCT	O
(	O	PUNCT	O
GEFS	O	NOUN	B
+	O	CCONJ	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
SCN1B	O	NOUN	B
cosegregates	O	VERB	B
with	O	ADP	I
the	O	DET	O
GEFS	O	NOUN	B
+	O	CCONJ	O
phenotype	O	NOUN	B
.	O	PUNCT	O


BFIC	B-Disease	NOUN	B
and	O	CCONJ	O
GEFS	O	NOUN	B
+	O	CCONJ	O
have	O	AUX	O
clinical	O	ADJ	B
features	O	NOUN	I
in	O	ADP	O
common	O	ADJ	O
,	O	PUNCT	O
therefore	O	ADV	O
SCN1B	O	NOUN	B
is	O	AUX	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
BFIC	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
SCN1B	O	NOUN	B
exons	O	NOUN	I
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
,	O	PUNCT	O
using	O	VERB	O
four	O	NUM	O
SSCP	O	NOUN	B
methods	O	NOUN	I
in	O	ADP	O
10	O	NUM	O
Caucasian	O	ADJ	B
BFIC	B-Disease	NOUN	B
probands	O	NOUN	B
of	O	ADP	O
Western	O	PROPN	B
Europe	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
no	O	DET	O
exon	O	NOUN	B
variants	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
variant	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
intron	O	NOUN	B
5	O	NUM	I
(	O	PUNCT	O
IVS5	O	NOUN	B
-	O	PUNCT	O
10C	O	NOUN	B
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
did	O	AUX	O
not	O	PART	O
segregate	O	VERB	O
with	O	ADP	O
BFIC	B-Disease	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
controls	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
variant	O	NOUN	B
in	O	ADP	O
intron	O	NOUN	B
5	O	NUM	O
was	O	AUX	O
identified	O	VERB	B
(	O	PUNCT	O
IVS5	O	NOUN	B
+	O	CCONJ	O
30G	O	NOUN	O
>	O	X	O
A	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
segregating	O	VERB	B
with	O	ADP	O
the	O	DET	O
BFIC	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Inactivation	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutant	O	ADJ	I
APC	B-Disease	NOUN	B
alleles	O	NOUN	O
by	O	ADP	O
attenuated	O	VERB	B
somatic	O	ADJ	B
mutations	O	NOUN	O
:	O	PUNCT	O
a	O	DET	O
molecular	O	ADJ	B
genetic	O	ADJ	I
mechanism	O	NOUN	I
for	O	ADP	O
attenuated	B-Disease	VERB	B
familial	I-Disease	ADJ	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	I-Disease	PUNCT	O
APC	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
tumor	I-Disease	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
result	O	VERB	O
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
FAP	B-Disease	NOUN	B
typically	O	ADV	O
develop	O	VERB	O
hundreds	O	NOUN	O
to	O	ADP	O
thousands	O	NOUN	O
of	O	ADP	O
benign	B-Disease	ADJ	B
colorectal	I-Disease	NOUN	B
tumors	I-Disease	NOUN	I
and	O	CCONJ	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
germline	O	NOUN	B
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
an	O	DET	O
attenuated	B-Disease	VERB	B
FAP	I-Disease	NOUN	B
(	O	PUNCT	O
AFAP	B-Disease	NOUN	B
)	O	PUNCT	O
phenotype	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
patients	O	NOUN	B
develop	O	VERB	O
fewer	O	ADJ	O
tumors	B-Disease	NOUN	B
and	O	CCONJ	O
develop	O	VERB	O
them	O	PRON	O
at	O	ADP	O
an	O	DET	O
older	O	ADJ	B
age	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
a	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
locations	O	NOUN	B
of	O	ADP	O
APC	B-Disease	NOUN	B
germline	O	NOUN	B
mutations	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
AFAP	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
well	O	ADV	O
documented	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
AFAP	B-Disease	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
well	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
AFAP	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
carrying	O	VERB	O
a	O	DET	O
mutant	O	ADJ	B
APC	B-Disease	NOUN	B
allele	O	NOUN	I
(	O	PUNCT	O
APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
that	O	PRON	O
has	O	AUX	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
alternatively	O	ADV	O
spliced	O	VERB	O
region	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
.	O	PUNCT	O


APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	ADP	O
down	O	ADV	B
-	O	PUNCT	O
regulate	O	VERB	B
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
-	O	PUNCT	O
regulated	O	VERB	B
transcription	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
major	O	ADJ	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
function	O	NOUN	O
of	O	ADP	O
APC	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
did	O	AUX	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	O	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	B-Disease	NOUN	B
alleles	O	NOUN	O
were	O	AUX	O
somatically	O	ADV	O
mutated	O	VERB	B
in	O	ADP	O
most	O	ADJ	O
colorectal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
from	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Functional	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
4666insA	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
these	O	DET	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
inactivate	O	VERB	B
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
carriers	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
develop	O	VERB	O
fewer	O	ADJ	O
colorectal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
than	O	ADP	O
do	O	AUX	O
typical	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
FAP	B-Disease	NOUN	B
because	O	SCONJ	O
somatic	O	ADJ	B
inactivation	O	NOUN	B
of	O	ADP	O
both	O	DET	O
APC	B-Disease	NOUN	B
alleles	O	NOUN	B
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
colorectal	O	ADJ	B
tumorigenesis	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
patients	O	NOUN	B
develop	O	VERB	O
colorectal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
more	O	ADV	O
frequently	O	ADV	O
than	O	ADP	O
does	O	AUX	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
because	O	SCONJ	O
APC	O	NOUN	B
(	O	PUNCT	O
AS9	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
inactivated	O	VERB	B
by	O	ADP	O
mutations	O	NOUN	B
that	O	PRON	O
do	O	AUX	O
not	O	PART	O
inactivate	O	VERB	B
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Iron	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
self	O	NOUN	B
-	O	PUNCT	O
assembly	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
yeast	O	NOUN	O
frataxin	O	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


Frataxin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
primary	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
cardiodegenerative	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
neurodegenerative	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Frataxin	O	NOUN	B
is	O	AUX	O
a	O	DET	O
nuclear	O	ADJ	B
-	O	PUNCT	O
encoded	O	VERB	B
mitochondrial	O	ADJ	B
protein	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
widely	O	ADV	O
conserved	O	VERB	O
among	O	ADP	O
eukaryotes	O	NOUN	B
.	O	PUNCT	O


Genetic	O	ADJ	B
inactivation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
yeast	O	NOUN	B
frataxin	O	NOUN	O
homologue	O	NOUN	O
(	O	PUNCT	O
Yfh1p	O	NOUN	B
)	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
mitochondrial	B-Disease	ADJ	B
iron	I-Disease	NOUN	B
accumulation	I-Disease	NOUN	I
and	O	CCONJ	O
hypersensitivity	B-Disease	NOUN	B
to	I-Disease	PART	O
oxidative	I-Disease	ADJ	B
stress	I-Disease	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
iron	O	NOUN	B
deposition	O	NOUN	I
and	O	CCONJ	O
evidence	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
damage	O	NOUN	I
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
cardiac	O	ADJ	B
tissue	O	NOUN	I
and	O	CCONJ	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
FRDA	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
frataxin	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
mitochondrial	O	ADJ	B
iron	O	NOUN	B
homeostasis	O	NOUN	I
and	O	CCONJ	O
protection	O	NOUN	B
from	O	ADP	O
iron	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
formation	O	NOUN	B
of	O	ADP	O
free	O	ADJ	B
radicals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
functional	O	ADJ	B
mechanism	O	NOUN	B
of	O	ADP	O
frataxin	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
is	O	AUX	O
still	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
expressed	O	VERB	B
the	O	DET	O
mature	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
Yfh1p	O	NOUN	B
(	O	PUNCT	O
mYfh1p	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Escherichia	O	X	B
coli	O	X	I
and	O	CCONJ	O
have	O	AUX	O
analyzed	O	VERB	B
its	O	PRON	O
function	O	NOUN	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Isolated	O	VERB	B
mYfh1p	O	NOUN	B
is	O	AUX	O
a	O	DET	O
soluble	O	ADJ	B
monomer	O	NOUN	I
(	O	PUNCT	O
13	O	NUM	O
,	O	PUNCT	O
783	O	NUM	O
Da	O	NOUN	O
)	O	PUNCT	O
that	O	PRON	O
contains	O	VERB	O
no	O	DET	O
iron	O	NOUN	B
and	O	CCONJ	O
shows	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
tendency	O	NOUN	O
to	O	PART	O
self	O	NOUN	B
-	O	PUNCT	O
associate	O	NOUN	B
.	O	PUNCT	O


Aerobic	O	ADJ	B
addition	O	NOUN	O
of	O	ADP	O
ferrous	O	ADJ	B
iron	O	NOUN	I
to	O	PART	O
mYfh1p	O	NOUN	B
results	O	NOUN	B
in	O	ADP	O
assembly	O	NOUN	B
of	O	ADP	O
regular	O	ADJ	O
spherical	O	ADJ	O
multimers	O	NOUN	O
with	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
mass	O	NOUN	I
of	O	ADP	O
approximately	O	ADV	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
MDa	O	NOUN	B
(	O	PUNCT	O
megadaltons	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
diameter	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
2	O	NUM	O
nm	O	NOUN	O
.	O	PUNCT	O


Each	O	DET	O
multimer	O	NOUN	B
consists	O	VERB	O
of	O	ADP	O
approximately	O	ADV	O
60	O	NUM	O
subunits	O	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
sequester	O	VERB	B
>	O	NOUN	O
3	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
atoms	O	NOUN	O
of	O	ADP	O
iron	O	NOUN	B
.	O	PUNCT	O


Titration	O	NOUN	B
of	O	ADP	O
mYfh1p	O	NOUN	B
with	O	ADP	O
increasing	O	VERB	B
iron	O	NOUN	B
concentrations	O	NOUN	I
supports	O	VERB	O
a	O	DET	O
stepwise	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
multimer	O	NOUN	B
assembly	O	NOUN	B
.	O	PUNCT	O


Sequential	O	ADJ	B
addition	O	NOUN	O
of	O	ADP	O
an	O	DET	O
iron	O	NOUN	B
chelator	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
reducing	O	VERB	B
agent	O	NOUN	I
results	O	NOUN	B
in	O	ADP	O
quantitative	O	ADJ	B
iron	O	NOUN	B
release	O	NOUN	I
with	O	ADP	O
concomitant	O	ADJ	B
disassembly	O	NOUN	B
of	O	ADP	O
the	O	DET	O
multimer	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
mYfh1p	O	NOUN	B
sequesters	O	VERB	B
iron	O	NOUN	O
in	O	ADP	O
an	O	DET	O
available	O	ADJ	O
form	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
yeast	O	NOUN	B
mitochondria	O	NOUN	B
,	O	PUNCT	O
native	O	ADJ	B
mYfh1p	O	NOUN	B
exists	O	VERB	O
as	O	ADP	O
monomer	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
higher	O	ADJ	B
-	O	PUNCT	O
order	O	NOUN	B
species	O	NOUN	B
with	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
weight	O	NOUN	I
>	O	NOUN	O
600	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
.	O	PUNCT	O


After	O	ADP	O
addition	O	NOUN	O
of	O	ADP	O
(	O	PUNCT	O
55	O	NUM	O
)	O	PUNCT	O
Fe	O	PROPN	B
to	O	ADP	O
the	O	DET	O
medium	O	NOUN	B
,	O	PUNCT	O
immunoprecipitates	O	NOUN	B
of	O	ADP	O
this	O	DET	O
species	O	NOUN	B
contain	O	VERB	O
>	O	NOUN	O
16	O	NUM	O
atoms	O	NOUN	B
of	O	ADP	O
(	O	PUNCT	O
55	O	NUM	O
)	O	PUNCT	O
Fe	O	PROPN	B
per	O	ADP	O
molecule	O	NOUN	O
of	O	ADP	O
mYfh1p	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
iron	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
self	O	NOUN	B
-	O	PUNCT	O
assembly	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
mYfh1p	O	NOUN	B
reflects	O	VERB	O
a	O	DET	O
physiological	O	ADJ	B
role	O	NOUN	O
for	O	ADP	O
frataxin	O	NOUN	B
in	O	ADP	O
mitochondrial	O	ADJ	B
iron	O	NOUN	B
sequestration	O	NOUN	I
and	O	CCONJ	O
bioavailability	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pleckstrin	O	NOUN	B
homology	O	NOUN	I
(	O	PUNCT	O
PH	O	NOUN	B
)	O	PUNCT	O
domain	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FGD1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
an	O	DET	O
Italian	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
faciogenital	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
(	O	PUNCT	O
Aarskog	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Scott	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Aarskog	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Scott	I-Disease	PROPN	B
Syndrome	I-Disease	PROPN	I
(	O	PUNCT	O
AAS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disorder	I-Disease	NOUN	B
characterised	O	VERB	O
by	O	ADP	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
and	O	CCONJ	O
multiple	O	ADJ	B
facial	B-Disease	ADJ	I
,	I-Disease	PUNCT	O
limb	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
genital	I-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
FGD1	O	NOUN	B
,	O	PUNCT	O
altered	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
AAS	B-Disease	NOUN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
found	O	VERB	O
to	O	PART	O
encode	O	VERB	B
a	O	DET	O
protein	O	NOUN	B
with	O	ADP	O
homology	O	NOUN	B
to	O	PART	O
Rho	O	NOUN	B
/	O	PUNCT	O
Rac	O	NOUN	B
guanine	O	NOUN	B
nucleotide	O	NOUN	I
exchange	O	NOUN	I
factors	O	NOUN	I
(	O	PUNCT	O
Rho	O	NOUN	B
/	O	PUNCT	O
Rac	O	NOUN	B
GEF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
since	O	SCONJ	O
this	O	DET	O
original	O	ADJ	O
report	O	NOUN	B
on	O	ADP	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutated	O	VERB	B
FGD1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
an	O	DET	O
AAS	B-Disease	NOUN	B
patient	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
additional	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FGD1	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
analysed	O	VERB	B
13	O	NUM	O
independent	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
AAS	B-Disease	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
presented	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
nucleotide	O	NOUN	B
change	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
10	O	NUM	I
of	O	ADP	I
the	O	DET	O
FGD1	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
G2559	O	NOUN	B
>	O	X	O
A	O	NOUN	O
)	O	PUNCT	O
substituting	O	VERB	O
a	O	DET	O
Gln	O	NOUN	B
for	O	ADP	O
Arg	O	NOUN	B
in	O	ADP	O
position	O	NOUN	O
610	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
segregate	O	VERB	B
with	O	ADP	O
the	O	DET	O
AAS	B-Disease	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
carrier	O	NOUN	B
females	O	NOUN	B
in	O	ADP	O
the	O	DET	O
family	O	NOUN	B
of	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
Arg	O	PROPN	B
-	O	PUNCT	O
610	O	NUM	O
is	O	AUX	O
located	O	ADJ	O
within	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
pleckstrin	O	NOUN	B
homology	O	NOUN	I
(	O	PUNCT	O
PH	O	NOUN	B
)	O	PUNCT	O
domains	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FGD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
it	O	PRON	O
corresponds	O	VERB	O
to	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
residue	O	NOUN	B
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
InsP	O	NOUN	B
binding	O	NOUN	B
in	O	ADP	O
PH	O	NOUN	B
domains	O	NOUN	I
of	O	ADP	O
other	O	ADJ	O
proteins	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
residue	O	NOUN	B
is	O	AUX	O
often	O	ADV	O
mutated	O	VERB	B
in	O	ADP	O
the	O	DET	O
Brutons	O	NOUN	B
tyrosine	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
Btk	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
agammaglobulinemia	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Arg610Gln	O	NOUN	B
mutation	O	NOUN	B
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PH	O	NOUN	B
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
FGD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
additional	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
PH	O	NOUN	B
domains	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	O
to	O	ADP	O
human	O	ADJ	B
diseases	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
fragments	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
huntingtin	O	NOUN	B
show	O	VERB	O
selective	O	ADJ	O
accumulation	O	NOUN	B
in	O	ADP	O
striatal	O	ADJ	B
neurons	O	NOUN	B
and	O	CCONJ	O
synaptic	O	ADJ	B
toxicity	O	NOUN	B
.	O	PUNCT	O


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
glutamine	O	NOUN	B
repeat	O	NOUN	O
in	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
of	O	ADP	O
huntingtin	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
its	O	PRON	O
widespread	O	ADJ	O
expression	O	NOUN	B
,	O	PUNCT	O
mutant	O	ADJ	B
huntingtin	O	NOUN	B
induces	O	VERB	O
selective	O	ADJ	O
neuronal	O	ADJ	B
loss	O	NOUN	I
in	O	ADP	O
striatal	O	ADJ	B
neurons	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	O
expressing	O	VERB	B
HD	B-Disease	NOUN	B
repeats	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
production	O	NOUN	B
and	O	CCONJ	O
aggregation	O	NOUN	B
of	O	ADP	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
huntingtin	O	NOUN	B
fragments	O	NOUN	B
preferentially	O	ADV	O
occur	O	VERB	O
in	O	ADP	O
HD	B-Disease	NOUN	B
-	O	PUNCT	O
affected	O	VERB	B
neurons	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
processes	O	NOUN	B
and	O	CCONJ	O
axonal	O	ADJ	B
terminals	O	NOUN	B
.	O	PUNCT	O


N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
fragments	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
huntingtin	O	NOUN	B
form	O	NOUN	O
aggregates	O	NOUN	B
and	O	CCONJ	O
induce	O	VERB	B
neuritic	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
in	O	ADP	O
cultured	O	VERB	B
striatal	O	ADJ	I
neurons	O	NOUN	I
.	O	PUNCT	O


N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
mutant	O	ADJ	B
huntingtin	O	NOUN	B
also	O	ADV	O
binds	O	VERB	B
to	O	PART	O
synaptic	O	ADJ	B
vesicles	O	NOUN	I
and	O	CCONJ	O
inhibits	O	VERB	B
their	O	PRON	O
glutamate	O	NOUN	B
uptake	O	NOUN	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


The	O	DET	O
specific	O	ADJ	O
processing	O	NOUN	B
and	O	CCONJ	O
accumulation	O	NOUN	B
of	O	ADP	O
toxic	O	ADJ	B
fragments	O	NOUN	O
of	O	ADP	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
huntingtin	O	NOUN	B
in	O	ADP	O
HD	B-Disease	NOUN	B
-	O	PUNCT	O
affected	O	VERB	B
striatal	O	ADJ	B
neurons	O	NOUN	O
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
their	O	PRON	O
neuronal	O	ADJ	B
processes	O	NOUN	I
and	O	CCONJ	O
axonal	O	ADJ	B
terminals	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
selective	O	ADJ	O
neuropathology	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
human	O	ADJ	B
SWI	O	PROPN	B
/	O	SYM	O
SNF	O	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
complex	O	NOUN	B
:	O	PUNCT	O
linking	O	VERB	O
chromatin	O	NOUN	B
remodeling	O	NOUN	I
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
predispose	O	VERB	O
individuals	O	NOUN	B
to	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
affinity	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
conventional	O	ADJ	B
chromatographic	O	ADJ	B
techniques	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
a	O	DET	O
predominant	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
a	O	DET	O
multiprotein	O	ADJ	B
BRCA1	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
complex	O	NOUN	B
from	O	ADP	O
human	O	ADJ	B
cells	O	NOUN	I
displaying	O	VERB	O
chromatin	O	NOUN	B
-	O	PUNCT	O
remodeling	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


Mass	O	ADJ	B
spectrometric	O	ADJ	I
sequencing	O	NOUN	I
of	O	ADP	O
components	O	NOUN	B
of	O	ADP	O
this	O	DET	O
complex	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
SWI	O	PROPN	B
/	O	SYM	O
SNF	O	PROPN	B
-	O	PUNCT	O
related	O	VERB	B
complex	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
can	O	AUX	O
directly	O	ADV	O
interact	O	VERB	B
with	O	ADP	O
the	O	DET	O
BRG1	O	NOUN	B
subunit	O	NOUN	B
of	O	ADP	O
the	O	DET	O
SWI	O	PROPN	B
/	O	SYM	O
SNF	O	NOUN	B
complex	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
p53	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
stimulation	O	NOUN	B
of	O	ADP	O
transcription	O	NOUN	B
by	O	ADP	O
BRCA1	O	NOUN	B
was	O	AUX	O
completely	O	ADV	O
abrogated	O	VERB	B
by	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
dominant	O	ADJ	B
-	O	PUNCT	O
negative	O	ADJ	B
mutant	O	NOUN	B
of	O	ADP	O
BRG1	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
cancer	B-Disease	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
deletion	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
reveal	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
function	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
transcriptional	O	ADJ	B
control	O	NOUN	I
through	O	ADP	O
modulation	O	NOUN	B
of	O	ADP	O
chromatin	O	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Asef	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
link	O	NOUN	O
between	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
APC	O	NOUN	I
and	O	CCONJ	O
G	O	NOUN	B
-	O	PUNCT	O
protein	O	NOUN	B
signaling	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
gene	O	NOUN	I
(	O	PUNCT	O
APC	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
sporadic	O	ADJ	B
colorectal	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
is	O	AUX	O
shown	O	VERB	O
to	O	PART	O
bind	O	VERB	B
through	O	ADP	O
its	O	PRON	O
armadillo	O	ADJ	B
repeat	O	NOUN	I
domain	O	NOUN	I
to	O	PART	O
a	O	DET	O
Rac	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
guanine	O	NOUN	B
nucleotide	O	NOUN	I
exchange	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
GEF	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
termed	O	VERB	O
Asef	O	PROPN	B
.	O	PUNCT	O


Endogenous	O	ADJ	B
APC	O	NOUN	B
colocalized	O	VERB	B
with	O	ADP	O
Asef	O	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
colon	O	NOUN	I
epithelial	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
neuronal	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
APC	O	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
GEF	O	NOUN	B
activity	O	NOUN	O
of	O	ADP	O
Asef	O	NOUN	B
and	O	CCONJ	O
stimulated	O	VERB	B
Asef	O	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
cell	O	NOUN	B
flattening	O	NOUN	I
,	O	PUNCT	O
membrane	O	NOUN	B
ruffling	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
lamellipodia	O	NOUN	B
formation	O	NOUN	B
in	O	ADP	O
MDCK	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
APC	O	NOUN	B
-	O	PUNCT	O
Asef	O	NOUN	B
complex	O	NOUN	O
may	O	AUX	O
regulate	O	VERB	B
the	O	DET	O
actin	O	NOUN	B
cytoskeletal	O	ADJ	O
network	O	NOUN	O
,	O	PUNCT	O
cell	O	NOUN	B
morphology	O	NOUN	I
and	O	CCONJ	O
migration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
neuronal	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Function	O	NOUN	B
of	O	ADP	O
an	O	DET	O
axonal	O	ADJ	B
chemoattractant	O	NOUN	O
modulated	O	VERB	B
by	O	ADP	O
metalloprotease	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
axonal	O	ADJ	B
chemoattractant	O	NOUN	O
netrin	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
guides	O	VERB	B
spinal	O	ADJ	B
commissural	O	ADJ	B
axons	O	NOUN	B
by	O	ADP	O
activating	O	VERB	B
its	O	PRON	O
receptor	O	NOUN	B
DCC	O	NOUN	I
(	O	PUNCT	O
Deleted	O	VERB	B
in	O	ADP	O
Colorectal	B-Disease	PROPN	B
Cancer	I-Disease	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
chemical	O	NOUN	B
inhibitors	O	NOUN	I
of	O	ADP	O
metalloproteases	O	NOUN	B
potentiate	O	VERB	O
netrin	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
axon	O	NOUN	B
outgrowth	O	NOUN	I
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
also	O	ADV	O
found	O	VERB	O
that	O	SCONJ	O
DCC	O	PROPN	B
is	O	AUX	O
a	O	DET	O
substrate	O	NOUN	B
for	O	ADP	O
metalloprotease	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
ectodomain	O	NOUN	B
shedding	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
inhibitors	O	NOUN	B
block	O	VERB	O
proteolytic	O	ADJ	B
processing	O	NOUN	I
of	O	ADP	O
DCC	O	PROPN	B
and	O	CCONJ	O
cause	O	VERB	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
DCC	O	NOUN	B
protein	O	NOUN	I
levels	O	NOUN	O
on	O	ADP	O
axons	O	NOUN	B
within	O	ADP	O
spinal	O	ADJ	B
cord	O	NOUN	I
explants	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
potentiation	O	NOUN	B
of	O	ADP	O
netrin	O	NOUN	B
activity	O	NOUN	I
by	O	ADP	O
inhibitors	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
from	O	ADP	O
stabilization	O	NOUN	B
of	O	ADP	O
DCC	O	PROPN	B
on	O	ADP	O
the	O	DET	O
axons	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
proteolytic	O	ADJ	B
activity	O	NOUN	I
may	O	AUX	O
regulate	O	VERB	O
axon	O	NOUN	B
migration	O	NOUN	I
by	O	ADP	O
controlling	O	VERB	B
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
functional	O	ADJ	B
extracellular	O	ADJ	O
axon	O	NOUN	O
guidance	O	NOUN	O
receptors	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
expressing	O	VERB	B
an	O	DET	O
expanded	O	VERB	O
CUG	O	NOUN	B
repeat	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
in	O	ADP	O
adult	O	ADJ	B
humans	O	NOUN	B
,	O	PUNCT	O
results	O	NOUN	B
from	O	ADP	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DMPK	O	NOUN	B
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutant	O	ADJ	B
DMPK	O	NOUN	O
messenger	O	NOUN	O
RNA	O	NOUN	O
(	O	PUNCT	O
mRNA	O	NOUN	B
)	O	PUNCT	O
contains	O	VERB	O
an	O	DET	O
expanded	O	VERB	O
CUG	O	NOUN	B
repeat	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
retained	O	VERB	O
in	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
expressed	O	VERB	B
an	O	DET	O
untranslated	O	ADJ	B
CUG	O	NOUN	I
repeat	O	NOUN	O
in	O	ADP	O
an	O	DET	O
unrelated	O	ADJ	O
mRNA	O	NOUN	B
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Mice	O	NOUN	B
that	O	PRON	O
expressed	O	VERB	B
expanded	O	VERB	O
CUG	O	NOUN	B
repeats	O	NOUN	O
developed	O	VERB	O
myotonia	B-Disease	NOUN	B
and	O	CCONJ	O
myopathy	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
mice	O	NOUN	B
expressing	O	VERB	B
a	O	DET	O
nonexpanded	O	ADJ	B
repeat	O	NOUN	O
did	O	AUX	O
not	O	PART	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
transcripts	O	NOUN	B
with	O	ADP	O
expanded	O	VERB	O
CUG	O	NOUN	B
repeats	O	NOUN	O
are	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
generate	O	VERB	O
a	O	DET	O
DM	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
supports	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
RNA	O	NOUN	B
gain	O	NOUN	O
of	O	ADP	O
function	O	NOUN	B
in	O	ADP	O
disease	O	NOUN	B
pathogenesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genomic	O	ADJ	B
rearrangements	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
tumor	I-Disease	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	I-Disease	PUNCT	O
APC	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
tumor	I-Disease	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
result	O	VERB	O
in	O	ADP	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
colorectal	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Almost	O	ADV	O
all	O	DET	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
are	O	AUX	O
single	O	ADJ	B
-	O	PUNCT	O
nucleotide	O	NOUN	B
alterations	O	NOUN	B
,	O	PUNCT	O
small	O	ADJ	B
insertions	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
small	O	ADJ	B
deletions	O	NOUN	B
that	O	PRON	O
would	O	AUX	O
truncate	O	VERB	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


No	O	INTJ	O
well	O	ADV	O
-	O	PUNCT	O
characterized	O	VERB	B
intragenic	O	ADJ	B
rearrangement	O	NOUN	O
of	O	ADP	O
APC	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
this	O	DET	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
screened	O	VERB	B
49	O	NUM	O
potential	O	ADJ	B
FAP	B-Disease	NOUN	B
families	O	NOUN	B
and	O	CCONJ	O
identified	O	VERB	B
26	O	NUM	O
different	O	ADJ	O
germline	O	NOUN	B
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
30	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
genomic	O	ADJ	B
rearrangements	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
homologous	O	ADJ	B
and	O	CCONJ	O
nonhomologous	O	ADJ	B
recombinations	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
Alu	O	NOUN	B
elements	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
these	O	DET	O
four	O	NUM	O
rearrangements	O	NOUN	B
were	O	AUX	O
complex	O	ADJ	B
,	O	PUNCT	O
involving	O	VERB	O
deletion	O	NOUN	B
and	O	CCONJ	O
insertion	O	NOUN	B
of	O	ADP	O
nucleotides	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
four	O	NUM	O
rearrangements	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
exons	O	NOUN	B
11	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
and	O	CCONJ	O
two	O	NUM	O
others	O	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
either	O	CCONJ	O
complete	O	ADJ	B
or	O	CCONJ	O
partial	O	ADJ	B
deletion	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
14	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
rearrangement	O	NOUN	B
grossly	O	ADV	B
altered	O	VERB	O
the	O	DET	O
sequence	O	NOUN	B
within	O	ADP	O
intron	O	NOUN	B
14	O	NUM	O
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
rearrangement	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
any	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
APC	O	NOUN	B
at	O	ADP	O
the	O	DET	O
genomic	O	ADJ	B
DNA	O	NOUN	I
level	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
caused	O	VERB	O
inappropriate	O	ADJ	O
splicing	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
14	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
rearrangements	O	NOUN	B
were	O	AUX	O
initially	O	ADV	O
revealed	O	VERB	B
by	O	ADP	O
analyzing	O	VERB	O
cDNAs	O	NOUN	B
and	O	CCONJ	O
could	O	AUX	O
not	O	PART	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
using	O	VERB	O
mutation	O	NOUN	B
detection	O	NOUN	I
methods	O	NOUN	I
that	O	PRON	O
screened	O	VERB	B
each	O	DET	O
exon	O	NOUN	B
individually	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
rearrangement	O	NOUN	B
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
alter	O	VERB	O
any	O	DET	O
coding	O	VERB	B
exons	O	NOUN	I
yet	O	ADV	O
affected	O	VERB	B
the	O	DET	O
splicing	O	NOUN	B
further	O	ADV	O
underscores	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
using	O	VERB	O
cDNA	O	NOUN	B
for	O	ADP	O
mutation	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
genomic	O	ADJ	B
rearrangements	O	NOUN	I
among	O	ADP	O
30	O	NUM	O
mutations	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
genomic	O	ADJ	B
rearrangements	O	NOUN	I
are	O	AUX	O
frequent	O	ADJ	B
germline	O	NOUN	B
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
and	O	CCONJ	O
second	O	ADJ	O
recurrent	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CACNA1A	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
EA	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
2	I-Disease	NUM	B
and	O	CCONJ	O
FHM	B-Disease	PROPN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
specific	O	ADJ	O
P	O	NOUN	B
/	O	SYM	O
Q	O	NOUN	B
type	O	NOUN	I
Ca2	O	NOUN	I
+	O	CCONJ	I
channel	O	NOUN	I
alpha1	O	NOUN	I
subunit	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
CACNA1A	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
three	O	NUM	O
clinically	O	ADV	B
distinct	O	ADJ	I
disorders	O	NOUN	B
,	O	PUNCT	O
viz	O	ADJ	O
.	O	PUNCT	O
episodic	B-Disease	ADJ	B
ataxia	I-Disease	NOUN	O
type	I-Disease	NOUN	O
2	I-Disease	NUM	O
(	O	PUNCT	O
EA	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
2	I-Disease	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
familial	B-Disease	ADJ	B
hemiplegic	I-Disease	ADJ	I
migraine	I-Disease	NOUN	I
(	O	PUNCT	O
FHM	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
spinocerebellar	B-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
6	I-Disease	NUM	I
(	O	PUNCT	O
SCA6	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
EA	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
2	I-Disease	NUM	B
,	O	PUNCT	O
the	O	DET	O
mutations	O	NOUN	B
described	O	VERB	O
thus	O	ADV	O
far	O	ADV	O
are	O	AUX	O
presumed	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
truncated	O	VERB	B
protein	O	NOUN	I
product	O	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
different	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
FHM	B-Disease	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
least	O	ADJ	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
on	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
chromosome	O	NOUN	B
19p13	O	NOUN	I
haplotypes	O	NOUN	B
and	O	CCONJ	O
thus	O	ADV	O
represent	O	VERB	O
recurrent	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
screened	O	VERB	B
several	O	ADJ	O
individuals	O	NOUN	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
all	O	DET	O
47	O	NUM	O
exons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CACNA1A	O	NOUN	B
gene	O	NOUN	I
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
characterised	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
G5260A	O	INTJ	B
,	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
32	O	NUM	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
segregating	O	VERB	I
for	O	ADP	O
EA	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
2	I-Disease	NUM	B
.	O	PUNCT	O


The	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
this	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
an	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
at	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
position	O	NOUN	O
within	O	ADP	O
the	O	DET	O
CACNA1A	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
point	O	NOUN	O
mutation	O	NOUN	B
not	O	PART	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
proposed	O	VERB	O
truncated	O	VERB	B
protein	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
member	O	NOUN	I
with	O	ADP	O
mild	O	ADJ	B
clinical	O	ADJ	B
signs	O	NOUN	I
including	O	VERB	O
only	O	ADJ	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
second	O	ADJ	O
previously	O	ADV	O
identified	O	VERB	O
recurrent	O	ADJ	O
muta	O	ADJ	B
tion	O	NOUN	I
,	O	PUNCT	O
C2272T	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
16	O	NUM	O
has	O	AUX	O
been	O	AUX	O
discovered	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
FHM	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Analbuminemia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
neonate	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
small	O	ADJ	B
-	O	PUNCT	O
for	O	ADP	O
-	O	PUNCT	O
gestational	O	NOUN	B
-	O	PUNCT	O
age	O	NOUN	B
infant	O	NOUN	B
,	O	PUNCT	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
analbuminemia	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
period	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
reported	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
twelve	O	NUM	O
cases	O	NOUN	B
recorded	O	VERB	O
in	O	ADP	O
the	O	DET	O
world	O	NOUN	B
literature	O	NOUN	I
are	O	AUX	O
reviewed	O	VERB	B
.	O	PUNCT	O


Patients	O	NOUN	B
lacking	O	VERB	O
this	O	DET	O
serum	O	NOUN	B
protein	O	NOUN	I
are	O	AUX	O
essentially	O	ADV	O
asymptomatic	O	ADJ	B
,	O	PUNCT	O
apart	O	ADV	O
from	O	ADP	O
minimal	O	ADJ	B
ankle	B-Disease	NOUN	B
edema	I-Disease	NOUN	I
and	O	CCONJ	O
ease	B-Disease	NOUN	O
of	I-Disease	ADP	O
fatigue	I-Disease	NOUN	B
.	O	PUNCT	O


Apparent	O	ADJ	B
compensatory	O	ADJ	O
mechanisms	O	NOUN	B
which	O	DET	O
come	O	VERB	O
into	O	ADP	O
play	O	NOUN	O
when	O	SCONJ	O
serum	O	NOUN	B
albumin	O	NOUN	I
is	O	AUX	O
low	O	ADV	B
include	O	VERB	O
prolonged	O	ADJ	B
half	O	NOUN	B
-	O	PUNCT	O
life	O	NOUN	B
of	O	ADP	O
albumin	O	NOUN	B
and	O	CCONJ	O
transferrin	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
globulins	O	NOUN	I
,	O	PUNCT	O
beta	O	NOUN	B
lipoprotein	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
glycoproteins	O	NOUN	B
,	O	PUNCT	O
arterial	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	I
with	O	ADP	O
reduced	O	VERB	B
capillary	O	ADJ	O
hydrostatic	O	ADJ	O
pressure	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
respond	O	VERB	O
with	O	ADP	O
rapid	O	ADJ	O
sodium	O	NOUN	B
and	O	CCONJ	O
chloride	O	NOUN	B
diuresis	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
small	O	ADJ	O
volume	O	NOUN	B
changes	O	NOUN	O
.	O	PUNCT	O


Examination	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
amino	O	NOUN	B
acids	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
investigation	O	NOUN	B
not	O	PART	O
previously	O	ADV	O
reported	O	VERB	O
,	O	PUNCT	O
revealed	O	VERB	O
an	O	DET	O
extremely	O	ADV	O
low	O	ADJ	B
plasma	O	NOUN	B
tryptophan	O	NOUN	O
level	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
finding	O	NOUN	B
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
tryptophan	O	NOUN	B
in	O	ADP	O
albumin	O	NOUN	B
synthesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Histidinemia	B-Disease	PROPN	B
.	O	PUNCT	O


Classical	O	ADJ	B
and	O	CCONJ	O
atypical	O	ADJ	B
form	O	NOUN	O
in	O	ADP	O
siblings	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
brothers	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
and	O	CCONJ	O
13	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
,	O	PUNCT	O
had	O	AUX	O
histidinemia	B-Disease	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
observations	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
younger	O	ADJ	B
boy	O	NOUN	I
was	O	AUX	O
considered	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
classical	O	ADJ	O
type	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
older	O	ADJ	B
boy	O	NOUN	I
had	O	AUX	O
an	O	DET	O
atypical	O	ADJ	B
form	O	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
partial	O	ADJ	B
impairment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
histidase	O	NOUN	O
activity	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
moderately	O	ADV	B
prolonged	O	ADJ	B
half	O	NOUN	B
-	O	PUNCT	O
life	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
histidine	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mother	O	NOUN	B
is	O	AUX	O
a	O	DET	O
heterozygous	O	ADJ	B
carrier	O	NOUN	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
father	O	NOUN	B
and	O	CCONJ	O
sister	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
normal	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


Carrier	O	NOUN	B
detection	O	NOUN	B
of	O	ADP	O
pyruvate	B-Disease	NOUN	B
carboxylase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
fibroblasts	O	NOUN	B
and	O	CCONJ	O
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Pyruvate	O	NOUN	B
carboxylase	O	NOUN	I
(	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
activity	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
the	O	DET	O
circulating	O	VERB	B
peripheral	O	ADJ	O
lymphocytes	O	NOUN	O
and	O	CCONJ	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	O
from	O	ADP	O
the	O	DET	O
family	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
hepatic	O	ADJ	B
,	O	PUNCT	O
cerebral	O	ADJ	B
,	O	PUNCT	O
renal	O	ADJ	B
cortical	O	ADJ	I
,	O	PUNCT	O
leukocyte	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
fibroblast	O	NOUN	B
pyruvate	B-Disease	NOUN	I
carboxylase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
PC	B-Disease	NOUN	B
Portland	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Lymphocyte	O	NOUN	B
activities	O	NOUN	I
were	O	AUX	O
mother	O	NOUN	B
,	O	PUNCT	O
33	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
39	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
father	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
29	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
brother	O	NOUN	B
,	O	PUNCT	O
82	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
103	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
sister	O	NOUN	B
,	O	PUNCT	O
38	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
lowest	O	ADV	B
normal	O	ADJ	B
.	O	PUNCT	O


Fibroblasts	O	NOUN	B
from	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
mother	O	NOUN	B
and	O	CCONJ	O
father	O	NOUN	B
had	O	AUX	O
42	O	NUM	O
and	O	CCONJ	O
34	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lowest	O	ADV	B
normal	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
inherited	O	VERB	B
in	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	I
manner	O	NOUN	O
and	O	CCONJ	O
that	O	SCONJ	O
lymphocytes	O	NOUN	B
and	O	CCONJ	O
fibroblasts	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
detect	O	VERB	B
carriers	O	NOUN	B
.	O	PUNCT	O


Neither	O	CCONJ	O
pyruvate	O	NOUN	B
carboxylase	O	NOUN	I
nor	O	CCONJ	O
mitochondrial	O	ADJ	B
PEPCK	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
lymphocytes	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
by	O	ADP	O
a	O	DET	O
21	O	NUM	O
-	O	PUNCT	O
hr	O	NOUN	B
fast	O	ADV	B
.	O	PUNCT	O


Glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variants	O	NOUN	B
from	O	ADP	O
Italian	O	ADJ	B
subjects	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
severe	B-Disease	ADJ	B
neonatal	I-Disease	ADJ	B
jaundice	I-Disease	NOUN	O
.	O	PUNCT	O


Screening	O	VERB	B
for	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
at	O	ADP	O
the	O	DET	O
Maternity	O	PROPN	B
Division	O	PROPN	I
of	O	ADP	O
the	O	DET	O
Galliera	O	PROPN	B
Hospital	O	PROPN	I
in	O	ADP	O
Genoa	O	PROPN	B
,	O	PUNCT	O
Italy	O	PROPN	B
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
hyperbilirubinaemia	B-Disease	NOUN	B
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
immunological	O	ADJ	B
origin	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
302	O	NUM	O
newborn	O	ADJ	B
babies	O	NOUN	I
of	O	ADP	O
Sardinian	O	ADJ	B
extraction	O	NOUN	B
(	O	PUNCT	O
on	O	ADP	O
cord	O	NOUN	B
blood	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
201	O	NUM	O
newborn	O	ADJ	B
babies	O	NOUN	I
of	O	ADP	O
south	O	ADJ	B
Italian	O	ADJ	I
ancestry	O	NOUN	B
(	O	PUNCT	O
on	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Among	O	ADP	O
503	O	NUM	O
subjects	O	NOUN	B
,	O	PUNCT	O
43	O	NUM	O
showed	O	VERB	O
an	O	DET	O
enzyme	O	NOUN	B
deficiency	O	NOUN	I
;	O	PUNCT	O
in	O	ADP	O
39	O	NUM	O
the	O	DET	O
defect	O	NOUN	B
was	O	AUX	O
of	O	ADP	O
the	O	DET	O
Mediterranean	O	ADJ	B
type	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
described	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
enzyme	O	NOUN	B
was	O	AUX	O
of	O	ADP	O
the	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
type	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
cases	O	NOUN	B
three	O	NUM	O
different	O	ADJ	O
variants	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
work	O	NOUN	O
these	O	DET	O
three	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
each	O	DET	O
with	O	ADP	O
severe	B-Disease	ADJ	B
neonatal	I-Disease	ADJ	B
jaundice	I-Disease	NOUN	O
,	O	PUNCT	O
are	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Their	O	PRON	O
parents	O	NOUN	B
originated	O	VERB	O
from	O	ADP	O
Calabria	O	PROPN	B
,	O	PUNCT	O
from	O	ADP	O
Sardinia	O	PROPN	B
and	O	CCONJ	O
from	O	ADP	O
Sicily	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
abnormal	O	ADJ	B
enzymes	O	NOUN	B
are	O	AUX	O
respectively	O	ADV	O
designated	O	VERB	O
as	O	ADP	O
GdDcbrousse	O	PROPN	B
-	O	PUNCT	O
like	O	PROPN	B
,	O	PUNCT	O
GdGallura	O	PROPN	B
and	O	CCONJ	O
GdAgrigento	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Cytogenetic	O	ADJ	B
investigations	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
.	O	PUNCT	O


Chromosomal	O	ADJ	B
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
lymphocytes	O	NOUN	I
and	O	CCONJ	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	O
from	O	ADP	O
five	O	NUM	O
Israeli	O	ADJ	B
-	O	PUNCT	O
Moroccan	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
24	O	NUM	O
individuals	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
seven	O	NUM	O
propositi	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Among	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
,	O	PUNCT	O
significantly	O	ADV	O
elevated	O	ADJ	B
rates	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	B
damage	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
blood	O	NOUN	B
and	O	CCONJ	O
skin	O	NOUN	B
.	O	PUNCT	O


Skin	O	NOUN	B
fibroblasts	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
showed	O	VERB	O
several	O	ADJ	O
orders	O	NOUN	O
of	O	ADP	O
magnitude	O	NOUN	B
more	O	ADJ	O
chromosome	O	NOUN	B
breakage	O	NOUN	I
than	O	ADP	O
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Increased	O	VERB	B
rates	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
damage	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
fibroblasts	O	NOUN	B
of	O	ADP	O
some	O	DET	O
phenotypically	O	ADV	B
normal	O	ADJ	I
family	O	NOUN	I
members	O	NOUN	I
(	O	PUNCT	O
obligate	O	ADJ	B
heterozygotes	O	NOUN	B
and	O	CCONJ	O
sibs	O	NOUN	B
)	O	PUNCT	O
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
normal	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
apparent	O	ADJ	B
abnormal	O	ADJ	B
clone	O	NOUN	O
of	O	ADP	O
cells	O	NOUN	B
,	O	PUNCT	O
possessing	O	VERB	O
a	O	DET	O
large	O	ADJ	O
acrocentric	O	ADJ	B
marker	O	NOUN	I
chromosome	O	NOUN	I
(	O	PUNCT	O
14q	O	NOUN	O
+	O	CCONJ	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
varying	O	VERB	O
proportions	O	NOUN	B
among	O	ADP	O
cells	O	NOUN	B
of	O	ADP	O
all	O	DET	O
the	O	DET	O
propositi	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
-	O	SYM	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
lymphocytes	O	NOUN	B
;	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
fibroblasts	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O
.	O	PUNCT	O


Prenatal	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
Wolman	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
pregnancies	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
for	O	ADP	O
Wolman	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
were	O	AUX	O
monitored	O	VERB	O
by	O	ADP	O
assay	O	NOUN	B
and	O	CCONJ	O
electrophoresis	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
in	O	ADP	O
cultured	O	VERB	B
amniotic	O	ADJ	I
-	O	PUNCT	O
fluid	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Cells	O	NOUN	B
from	O	ADP	O
patient	O	NOUN	B
1	O	NUM	O
had	O	AUX	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
control	O	ADJ	B
levels	O	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
14C	O	NOUN	B
-	O	PUNCT	O
triolein	O	NOUN	B
as	O	ADP	O
substrate	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
when	O	SCONJ	O
artificial	O	ADJ	B
substrates	O	NOUN	I
(	O	PUNCT	O
esters	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
-	O	PUNCT	O
methylumbelliferone	O	NOUN	B
and	O	CCONJ	O
p	O	NOUN	B
-	O	PUNCT	O
nitrophenol	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
measure	O	VERB	B
acid	O	NOUN	I
lipase	O	NOUN	I
,	O	PUNCT	O
these	O	DET	O
cells	O	NOUN	B
had	O	AUX	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
control	O	NOUN	B
levels	O	NOUN	I
.	O	PUNCT	O


Electrophoresis	O	NOUN	B
of	O	ADP	O
cell	O	NOUN	B
extracts	O	NOUN	I
revealed	O	VERB	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
A	O	NOUN	O
form	O	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
Wolman	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
tissues	O	NOUN	I
following	O	VERB	O
prostaglandin	O	NOUN	B
termination	O	NOUN	I
of	O	ADP	O
this	O	DET	O
pregnancy	O	NOUN	B
confirmed	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


Assay	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
-	O	PUNCT	O
skin	O	NOUN	B
fibroblasts	O	NOUN	B
with	O	ADP	O
14C	O	NOUN	B
-	O	PUNCT	O
triolein	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
with	O	ADP	O
artificial	O	ADJ	B
substrates	O	NOUN	I
,	O	PUNCT	O
showed	O	VERB	O
marked	O	ADJ	O
deficiency	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
activity	O	NOUN	B
.	O	PUNCT	O


Electrophoresis	O	NOUN	B
of	O	ADP	O
fetal	O	ADJ	B
-	O	PUNCT	O
tissue	O	NOUN	B
extracts	O	NOUN	B
also	O	ADV	O
demonstrated	O	VERB	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
A	O	NOUN	O
form	O	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
.	O	PUNCT	O


Amniotic	O	ADJ	B
-	O	PUNCT	O
fluid	O	ADJ	B
cells	O	NOUN	I
from	O	ADP	O
patient	O	NOUN	B
2	O	NUM	I
showed	O	VERB	O
normal	O	ADJ	O
levels	O	NOUN	O
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
with	O	ADP	O
all	O	DET	O
substrates	O	NOUN	B
tested	O	VERB	B
;	O	PUNCT	O
the	O	DET	O
electrophoretic	O	ADJ	B
pattern	O	NOUN	I
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
was	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
Wolman	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
be	O	AUX	O
made	O	VERB	O
using	O	VERB	O
the	O	DET	O
radioassay	O	NOUN	B
of	O	ADP	O
acid	O	NOUN	B
lipase	O	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
electrophoresis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Malignant	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
families	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greatly	O	ADV	O
increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
malignant	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
in	O	ADP	O
homozygous	O	ADJ	B
affected	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


Heterozygotes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
are	O	AUX	O
thought	O	VERB	O
to	O	PART	O
comprise	O	VERB	O
about	O	ADV	O
1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
important	O	ADJ	O
to	O	PART	O
know	O	VERB	O
whether	O	SCONJ	O
this	O	DET	O
gene	O	NOUN	B
also	O	ADV	O
predisposes	O	VERB	O
the	O	DET	O
heterozygous	O	ADJ	B
carrier	O	NOUN	O
to	O	PART	O
cancers	B-Disease	NOUN	B
.	O	PUNCT	O


Heterozygous	O	ADJ	B
carriers	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
are	O	AUX	O
common	O	ADJ	O
among	O	ADP	O
the	O	DET	O
close	O	ADJ	O
relatives	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
individual	O	ADJ	O
carriers	O	NOUN	B
cannot	O	VERB	O
be	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
any	O	DET	O
clinical	O	ADJ	B
criterion	O	NOUN	I
or	O	CCONJ	O
laboratory	O	ADJ	B
test	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
this	O	DET	O
reason	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
death	O	NOUN	B
from	O	ADP	O
malignant	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
in	O	ADP	O
2	O	NUM	O
families	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
to	O	ADP	O
that	O	DET	O
expected	O	VERB	O
in	O	ADP	O
a	O	DET	O
random	O	ADJ	B
sample	O	NOUN	B
of	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
59	O	NUM	O
deaths	O	NOUN	B
from	O	ADP	O
malignant	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
in	O	ADP	O
relatives	O	NOUN	B
dying	O	VERB	I
before	O	ADP	O
age	O	NOUN	B
75	O	NUM	O
,	O	PUNCT	O
compared	O	VERB	B
to	O	ADP	O
42	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
expected	O	VERB	O
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O
02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
heterozygotes	O	NOUN	B
younger	O	ADJ	B
than	O	ADP	O
age	O	NOUN	B
45	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
dying	O	VERB	B
from	O	ADP	O
a	O	DET	O
malignant	B-Disease	ADJ	B
neoplasm	I-Disease	NOUN	I
was	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
times	O	NOUN	O
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


A	B-Disease	DET	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
heterozygotes	O	NOUN	B
may	O	AUX	O
comprise	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
persons	O	NOUN	B
dying	O	VERB	B
from	O	ADP	O
a	O	DET	O
cancer	B-Disease	NOUN	B
before	O	ADP	O
age	O	NOUN	B
45	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
gastric	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
biliary	I-Disease	ADJ	B
system	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
leukemia	B-Disease	NOUN	B
and	O	CCONJ	O
lymphoma	B-Disease	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
these	O	DET	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
neoplasms	B-Disease	NOUN	B
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
heterozygotes	O	NOUN	B
include	O	VERB	O
pancreatic	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
basal	I-Disease	ADJ	B
cell	I-Disease	NOUN	I
,	I-Disease	PUNCT	O
colonic	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
breast	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
cervical	I-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


Striking	O	VERB	B
prevalence	O	NOUN	B
of	O	ADP	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
in	O	ADP	O
"	O	PUNCT	O
healthy	O	ADJ	B
"	O	PUNCT	O
w27	O	NOUN	O
positive	O	ADJ	B
males	O	NOUN	B
and	O	CCONJ	O
females	O	NOUN	B
.	O	PUNCT	O


Ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
is	O	AUX	O
diagnosed	O	VERB	B
once	O	ADV	O
or	O	CCONJ	O
twice	O	ADV	O
in	O	ADP	O
each	O	DET	O
1000	O	NUM	O
males	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
tenth	O	ADV	O
as	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
females	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
true	O	ADJ	O
prevalence	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Indentification	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
marker	O	NOUN	I
,	O	PUNCT	O
HL	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	B
W27	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
susceptible	O	ADJ	B
persons	O	NOUN	B
has	O	AUX	O
provided	O	VERB	O
a	O	DET	O
tool	O	NOUN	B
facilitating	O	VERB	O
epidemiologic	O	ADJ	B
studies	O	NOUN	I
and	O	CCONJ	O
allowing	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
control	O	NOUN	B
"	O	PUNCT	O
populations	O	NOUN	B
without	O	ADP	O
the	O	DET	O
marker	O	NOUN	B
.	O	PUNCT	O


Evaluation	O	NOUN	B
by	O	ADP	O
postal	O	ADJ	B
questionnaires	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
pelvic	O	ADJ	B
radiography	O	NOUN	I
of	O	ADP	O
78	O	NUM	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	PROPN	B
27W	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
blood	O	NOUN	B
donors	O	NOUN	I
selected	O	VERB	O
from	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
apparently	O	ADV	O
healthy	O	ADJ	B
subjects	O	NOUN	I
revealed	O	VERB	B
14	O	NUM	O
who	O	PRON	O
satisfied	O	VERB	O
the	O	DET	O
criteria	O	NOUN	B
for	O	ADP	O
definite	O	ADJ	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
sexes	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
and	O	CCONJ	O
twenty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
W27	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
controls	O	NOUN	B
matched	O	VERB	O
for	O	ADP	O
race	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
failed	O	VERB	O
to	O	PART	O
yield	O	VERB	O
a	O	DET	O
single	O	ADJ	O
case	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
a	O	DET	O
person	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
sex	O	NOUN	B
with	O	ADP	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	PROPN	B
W27	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
about	O	ADP	O
a	O	DET	O
20	O	NUM	O
per	O	X	O
cent	O	NOUN	O
chance	O	NOUN	B
that	O	SCONJ	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
will	O	AUX	O
develop	O	VERB	O
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
to	O	PART	O
15	O	NUM	O
per	O	ADP	O
thousand	O	NUM	O
.	O	PUNCT	O


Hitherto	O	PROPN	O
accepted	O	VERB	O
figures	O	NOUN	B
may	O	AUX	O
underestimate	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
by	O	ADP	O
a	O	DET	O
factor	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
to	O	PART	O
20	O	NUM	O
.	O	PUNCT	O
.	O	PUNCT	O


Analbuminemia	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
American	O	ADJ	B
Indian	O	ADJ	I
girl	O	NOUN	I
.	O	PUNCT	O


Analbuminemia	B-Disease	NOUN	B
was	O	AUX	O
fortuitously	O	ADV	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
nonedematous	O	ADJ	B
12	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
American	O	ADJ	I
Indian	O	ADJ	B
girl	O	NOUN	I
with	O	ADP	O
atopic	B-Disease	ADJ	B
dermatitis	I-Disease	NOUN	I
,	O	PUNCT	O
mild	O	ADJ	B
bronchial	B-Disease	ADJ	I
asthma	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
mild	O	ADJ	B
seizure	B-Disease	NOUN	I
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hyperlipoproteinemia	B-Disease	NOUN	B
with	O	ADP	O
a	O	DET	O
corneal	B-Disease	NOUN	B
arcus	I-Disease	NOUN	I
.	O	PUNCT	O


Immunologic	O	ADJ	B
methods	O	NOUN	I
revealed	O	VERB	O
trace	O	NOUN	B
amounts	O	NOUN	I
(	O	PUNCT	O
17	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
ml	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
apparently	O	ADV	O
normal	O	ADJ	O
serum	O	NOUN	B
albumin	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
parents	O	NOUN	B
were	O	AUX	O
remotely	O	ADV	O
related	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
pedigree	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
findings	O	NOUN	I
were	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
autosomal	O	ADJ	B
recessive	O	ADJ	O
transmission	O	NOUN	O
of	O	ADP	O
analbuminemia	B-Disease	NOUN	B
.	O	PUNCT	O


Heterozygotes	O	NOUN	B
had	O	AUX	O
subnormal	O	ADJ	B
levels	O	NOUN	O
of	O	ADP	O
serum	O	NOUN	B
albumin	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Gc	O	PROPN	B
-	O	PUNCT	O
locus	O	NOUN	B
is	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
structural	O	ADJ	B
albumin	O	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


Gc	O	NOUN	B
-	O	PUNCT	O
protein	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
together	O	ADV	O
with	O	ADP	O
normal	O	ADJ	O
chromosomal	O	ADJ	B
banding	O	NOUN	I
studies	O	NOUN	I
make	O	VERB	O
it	O	PRON	O
unlikely	O	ADJ	O
that	O	SCONJ	O
a	O	DET	O
chromosomal	O	ADJ	B
deletion	O	NOUN	I
caused	O	VERB	O
analbuminemia	B-Disease	NOUN	B
.	O	PUNCT	O


Gc	O	NOUN	B
-	O	PUNCT	O
types	O	NOUN	B
in	O	ADP	O
the	O	DET	O
family	O	NOUN	B
were	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
,	O	PUNCT	O
but	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
prove	O	VERB	O
,	O	PUNCT	O
linkage	O	NOUN	B
of	O	ADP	O
analbuminemia	B-Disease	NOUN	B
to	O	PART	O
the	O	DET	O
Gc	O	PROPN	B
-	O	PUNCT	O
locus	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
"	O	PUNCT	O
thalassemia	B-Disease	NOUN	B
"	O	PUNCT	O
-	O	PUNCT	O
like	O	ADJ	B
mutation	O	NOUN	B
for	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KIT	O	NOUN	B
and	O	CCONJ	O
PDGFRA	O	NOUN	B
genes	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
piebaldism	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
human	O	ADJ	B
piebaldism	B-Disease	NOUN	B
results	O	VERB	B
from	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KIT	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
the	O	DET	O
receptor	O	NOUN	B
for	O	ADP	O
the	O	DET	O
mast	O	NOUN	B
/	O	SYM	O
stem	O	NOUN	B
cell	O	NOUN	I
growth	O	NOUN	O
factor	O	NOUN	O
and	O	CCONJ	O
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
chromosome	O	NOUN	B
segment	O	NOUN	I
4q12	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
DNA	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
piebaldism	B-Disease	NOUN	B
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
multiple	B-Disease	ADJ	O
congenital	I-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
46	O	NUM	O
,	O	PUNCT	O
XY	O	NOUN	B
,	O	PUNCT	O
del	O	X	O
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q12q21	O	NOUN	O
.	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
karyotype	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
carried	O	VERB	O
out	O	ADP	O
quantitative	O	ADJ	B
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
analyses	O	NOUN	O
of	O	ADP	O
the	O	DET	O
KIT	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
adjacent	O	ADJ	B
PDGFRA	O	NOUN	B
(	O	PUNCT	O
platelet	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
growth	O	NOUN	B
factor	O	NOUN	I
receptor	O	NOUN	I
alpha	O	NOUN	I
subunit	O	NOUN	I
)	O	PUNCT	O
genes	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
hemizygous	O	ADJ	B
for	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
KIT	O	NOUN	B
and	O	CCONJ	O
PDGFRA	O	NOUN	B
genes	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
of	O	ADP	O
these	O	DET	O
genes	O	NOUN	B
are	O	AUX	O
included	O	VERB	O
within	O	ADP	O
the	O	DET	O
deleted	O	VERB	B
region	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KIT	O	NOUN	B
and	O	CCONJ	O
PDGFRA	O	NOUN	B
genes	O	NOUN	I
may	O	AUX	O
account	O	VERB	O
for	O	ADP	O
the	O	DET	O
piebald	B-Disease	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
germ	O	NOUN	B
line	O	NOUN	I
mutation	O	NOUN	B
within	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
for	O	ADP	O
the	O	DET	O
putative	O	ADJ	O
5	O	NUM	O
-	O	PUNCT	O
phosphoribosyl	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
pyrophosphate	O	NOUN	B
binding	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
hypoxanthine	O	NOUN	B
-	O	PUNCT	O
guanine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patient	O	NOUN	B
:	O	PUNCT	O
missense	O	NOUN	B
mutations	O	NOUN	I
within	O	ADP	O
a	O	DET	O
functionally	O	ADV	O
important	O	ADJ	O
region	O	NOUN	B
probably	O	ADV	O
cause	O	VERB	O
disease	O	NOUN	B
.	O	PUNCT	O


Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
complete	B-Disease	ADJ	O
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
hypoxanthine	I-Disease	NOUN	B
guanine	I-Disease	NOUN	I
phosphoribosyltransferase	I-Disease	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
heterogeneous	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
germ	O	NOUN	B
line	O	NOUN	I
mutations	O	NOUN	I
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
each	O	DET	O
mutant	O	ADJ	B
gene	O	NOUN	I
provides	O	VERB	O
valuable	O	ADJ	O
information	O	NOUN	B
as	O	ADP	O
to	O	PART	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
that	O	PRON	O
occurs	O	VERB	O
spontaneously	O	ADV	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
a	O	DET	O
newly	O	ADV	O
identified	O	VERB	O
HPRT	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
designated	O	VERB	O
HPRT	O	PROPN	B
Tokyo	O	PROPN	B
,	O	PUNCT	O
had	O	AUX	O
a	O	DET	O
single	O	ADJ	O
nucleotide	O	NOUN	O
change	O	NOUN	O
from	O	ADP	O
G	O	NOUN	B
to	O	PART	O
A	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
identified	O	VERB	B
by	O	ADP	O
sequencing	O	VERB	B
cDNA	O	NOUN	B
amplified	O	VERB	B
by	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


Allele	O	ADJ	B
specific	O	ADJ	O
oligonucleotide	O	NOUN	B
hybridization	O	NOUN	I
analysis	O	NOUN	O
using	O	VERB	O
amplified	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutant	O	ADJ	B
gene	O	NOUN	I
was	O	AUX	O
transmitted	O	VERB	B
from	O	ADP	O
the	O	DET	O
maternal	O	ADJ	B
germ	O	NOUN	O
line	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
would	O	AUX	O
lead	O	VERB	O
to	O	PART	O
an	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
of	O	ADP	O
Asp	O	NOUN	B
for	O	ADP	O
Gly	O	NOUN	B
at	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
position	O	NOUN	I
140	O	NUM	O
located	O	ADJ	O
within	O	ADP	O
the	O	DET	O
putative	O	ADJ	O
5	O	NUM	O
-	O	PUNCT	O
phosphoribosyl	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
pyrophosphate	O	NOUN	B
(	O	PUNCT	O
PRPP	O	NOUN	B
)	O	PUNCT	O
binding	O	NOUN	O
region	O	NOUN	O
.	O	PUNCT	O


Missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
HPRT	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
patients	O	NOUN	B
thus	O	ADV	O
far	O	ADV	O
reported	O	VERB	O
tend	O	VERB	O
to	O	PART	O
accumulate	O	VERB	B
in	O	ADP	O
this	O	DET	O
functionally	O	ADV	O
active	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
data	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
missense	O	NOUN	B
and	O	CCONJ	O
synonymous	O	ADJ	B
mutations	O	NOUN	I
can	O	AUX	O
occur	O	VERB	O
at	O	ADP	O
any	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
germ	O	NOUN	O
line	O	NOUN	O
HPRT	O	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
limited	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
all	O	DET	O
the	O	DET	O
missense	O	NOUN	B
mutations	O	NOUN	I
cause	O	VERB	O
disease	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
probability	O	NOUN	B
that	O	SCONJ	O
a	O	DET	O
mutation	O	NOUN	B
will	O	AUX	O
cause	O	VERB	O
disease	O	NOUN	B
tends	O	VERB	O
to	O	PART	O
be	O	AUX	O
higher	O	ADJ	B
when	O	SCONJ	O
the	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
is	O	AUX	O
within	O	ADP	O
a	O	DET	O
functionally	O	ADV	O
important	O	ADJ	O
sequence	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Characterisation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
rare	O	ADJ	B
fragile	O	ADJ	B
site	O	NOUN	I
easily	O	ADV	O
confused	O	VERB	O
with	O	ADP	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
fragile	O	ADJ	B
site	O	NOUN	I
(	O	PUNCT	O
FRAXE	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Xq28	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
typical	O	ADJ	O
folate	O	NOUN	B
sensitive	O	ADJ	B
fragile	O	ADJ	B
site	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
fragile	O	ADJ	B
site	O	NOUN	I
is	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
does	O	AUX	O
not	O	PART	O
give	O	VERB	O
abnormal	O	ADJ	B
results	O	NOUN	O
when	O	SCONJ	O
subjected	O	VERB	O
to	O	PART	O
Southern	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
probe	O	NOUN	B
pfxa3	O	NOUN	B
which	O	DET	O
detects	O	VERB	O
the	O	DET	O
unstable	O	ADJ	O
DNA	O	NOUN	B
sequence	O	NOUN	I
characteristic	O	ADJ	O
of	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
mapping	O	NOUN	O
locates	O	VERB	O
the	O	DET	O
fragile	O	ADJ	B
site	O	NOUN	I
between	O	ADP	O
150	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
600	O	NUM	O
kb	O	NOUN	O
distal	O	ADJ	O
to	O	PART	O
FRAXA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
distinction	O	NOUN	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
fragile	O	ADJ	B
sites	O	NOUN	I
is	O	AUX	O
important	O	ADJ	O
clinically	O	ADV	B
since	O	SCONJ	O
cytogenetic	O	ADJ	B
detection	O	NOUN	I
of	O	ADP	O
FRAXE	O	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
could	O	AUX	O
result	O	VERB	O
in	O	ADP	O
misdiagnosis	O	NOUN	B
of	O	ADP	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	B
maps	O	VERB	I
to	O	PART	O
a	O	DET	O
150	O	NUM	O
kb	O	NOUN	O
region	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
Xp11	O	NOUN	I
.	O	PUNCT	O
3	O	X	O
.	O	PUNCT	O


Norrie	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
human	O	ADJ	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
of	O	ADP	O
unknown	O	ADJ	O
etiology	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
congenital	B-Disease	ADJ	B
blindness	I-Disease	NOUN	I
,	O	PUNCT	O
sensory	B-Disease	ADJ	B
neural	I-Disease	ADJ	I
deafness	I-Disease	NOUN	I
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
previously	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
DXS7	O	NOUN	B
(	O	PUNCT	O
L1	O	NOUN	O
.	O	PUNCT	O
28	O	NUM	O
)	O	PUNCT	O
locus	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
MAO	O	NOUN	B
genes	O	NOUN	O
in	O	ADP	O
band	O	NOUN	B
Xp11	O	NOUN	I
.	O	PUNCT	O


3	O	NUM	O
3	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
fine	O	ADJ	O
physical	O	ADJ	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
obligate	O	ADJ	B
region	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
NDP	O	NOUN	B
)	O	PUNCT	O
defined	O	VERB	O
by	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
smallest	O	ADJ	O
submicroscopic	O	ADJ	B
chromosomal	O	ADJ	O
deletion	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
identified	O	VERB	B
to	O	PART	O
date	O	NOUN	O
.	O	PUNCT	O


Analysis	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
in	O	ADP	O
addition	O	NOUN	O
two	O	NUM	O
overlapping	O	VERB	O
YAC	O	NOUN	B
clones	O	NOUN	O
from	O	ADP	O
this	O	DET	O
region	O	NOUN	B
,	O	PUNCT	O
allowed	O	VERB	O
orientation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MAOA	O	NOUN	B
and	O	CCONJ	O
MAOB	O	NOUN	B
genes	O	NOUN	O
in	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
configuration	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
recombination	O	NOUN	B
event	O	NOUN	B
between	O	ADP	O
a	O	DET	O
(	O	PUNCT	O
GT	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
polymorphism	O	NOUN	B
in	O	ADP	O
intron	O	NOUN	B
2	O	NUM	O
of	O	ADP	O
the	O	DET	O
MAOB	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
NDP	O	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
previously	O	ADV	O
reported	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
recombination	O	NOUN	B
between	O	ADP	O
DXS7	O	NOUN	B
and	O	CCONJ	O
NDP	O	PROPN	B
,	O	PUNCT	O
delineates	O	VERB	O
a	O	DET	O
flanking	O	ADJ	B
marker	O	NOUN	B
telomeric	O	ADJ	B
to	O	PART	O
this	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
anonymous	O	ADJ	B
DNA	O	NOUN	B
probe	O	NOUN	I
,	O	PUNCT	O
dc12	O	NOUN	B
,	O	PUNCT	O
present	O	ADJ	O
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
YACs	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
submicroscopic	O	ADJ	B
deletion	O	NOUN	I
which	O	DET	O
includes	O	VERB	O
MAOA	O	NOUN	B
and	O	CCONJ	O
MAOB	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
L1	O	NOUN	O
.	O	PUNCT	O


28	O	NUM	O
,	O	PUNCT	O
serves	O	VERB	O
as	O	ADP	O
a	O	DET	O
flanking	O	ADJ	B
marker	O	NOUN	B
centromeric	O	ADJ	B
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
Alu	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
fragment	O	NOUN	B
from	O	ADP	O
the	O	DET	O
right	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	O
the	O	DET	O
MAO	O	NOUN	B
YAC	O	NOUN	B
(	O	PUNCT	O
YMAO	O	NOUN	B
.	O	PUNCT	O
AluR	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
not	O	PART	O
deleted	O	VERB	O
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
delineates	O	VERB	O
the	O	DET	O
centromeric	O	ADJ	B
extent	O	NOUN	B
of	O	ADP	O
the	O	DET	O
obligate	O	ADJ	B
disease	O	NOUN	O
region	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
apparent	O	ADJ	B
order	O	NOUN	O
of	O	ADP	O
these	O	DET	O
loci	O	NOUN	B
is	O	AUX	O
telomere	O	NOUN	B
.	O	PUNCT	O


DXS7	O	NOUN	B
-	O	PUNCT	O
MAOA	O	PROPN	B
-	O	PUNCT	O
MAOB	O	PROPN	B
-	O	PUNCT	O
NDP	O	PROPN	B
-	O	PUNCT	O
dc12	O	PROPN	B
-	O	PUNCT	O
YMAO	O	VERB	B
DXS7	O	NOUN	B
-	O	PUNCT	O
MAOA	O	PROPN	B
-	O	PUNCT	O
MAOB	O	PROPN	B
-	O	PUNCT	O
NDP	O	PROPN	B
-	O	PUNCT	O
dc12	O	PROPN	B
-	O	PUNCT	O
YMAO	O	PROPN	B
.	O	PUNCT	O


AluR	O	NOUN	B
.	O	PUNCT	O
centromere	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
these	O	DET	O
data	O	NOUN	B
define	O	VERB	O
the	O	DET	O
obligate	O	ADJ	B
region	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
NDP	O	NOUN	B
gene	O	NOUN	O
to	O	PART	O
a	O	DET	O
chromosomal	O	ADJ	B
segment	O	NOUN	I
less	O	ADJ	O
than	O	ADP	O
150	O	NUM	O
kb	O	NOUN	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
and	O	CCONJ	O
related	O	ADJ	O
hyperphenylalaninemias	B-Disease	NOUN	B
:	O	PUNCT	O
mutations	O	NOUN	B
and	O	CCONJ	O
polymorphisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
phenylalanine	O	NOUN	O
hydroxylase	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
phenylalanine	O	NOUN	O
hydroxylase	O	NOUN	O
gene	O	NOUN	O
producing	O	VERB	O
phenylketonuria	B-Disease	NOUN	B
or	O	CCONJ	O
hyperphenylalaninemia	B-Disease	NOUN	B
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
many	O	ADJ	O
patients	O	NOUN	B
from	O	ADP	O
various	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
mutations	O	NOUN	B
all	O	DET	O
exhibit	O	VERB	O
a	O	DET	O
high	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
specific	O	ADJ	O
restriction	O	NOUN	B
fragment	O	NOUN	B
-	O	PUNCT	O
length	O	NOUN	B
polymorphism	O	NOUN	B
haplotypes	O	NOUN	B
at	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


About	O	ADV	O
50	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
substitutions	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
six	O	NUM	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
and	O	CCONJ	O
eight	O	NUM	O
splicing	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
remainder	O	NOUN	O
being	O	AUX	O
missense	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
splicing	O	NOUN	B
mutation	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
3	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
insertion	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
large	O	ADJ	O
deletions	O	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
single	O	ADJ	O
codon	O	NOUN	B
deletions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
single	O	ADJ	O
base	O	NOUN	O
deletions	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Twelve	O	NUM	O
of	O	ADP	O
the	O	DET	O
missense	O	NOUN	B
mutations	O	NOUN	I
apparently	O	ADV	O
result	O	VERB	O
from	O	ADP	O
the	O	DET	O
methylation	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
deamination	O	NOUN	B
of	O	ADP	O
highly	O	ADV	O
mutagenic	O	ADJ	B
CpG	O	NOUN	B
dinucleotides	O	NOUN	I
.	O	PUNCT	O


Recurrent	O	ADJ	B
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
several	O	ADJ	O
of	O	ADP	O
these	O	DET	O
sites	O	NOUN	B
,	O	PUNCT	O
producing	O	VERB	O
associations	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
haplotypes	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
populations	O	NOUN	B
.	O	PUNCT	O


About	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
all	O	DET	O
missense	O	NOUN	B
mutations	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
in	O	X	B
vitro	O	X	I
expression	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
significant	O	ADJ	O
correlation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
residual	O	ADJ	B
PAH	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
continuing	O	VERB	O
advances	O	NOUN	O
in	O	ADP	O
molecular	O	ADJ	B
methodologies	O	NOUN	I
have	O	AUX	O
dramatically	O	ADV	O
accelerated	O	VERB	B
the	O	DET	O
rate	O	NOUN	B
in	O	ADP	O
which	O	DET	O
new	O	ADJ	O
mutations	O	NOUN	B
are	O	AUX	O
being	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
,	O	PUNCT	O
this	O	DET	O
register	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
updated	O	VERB	O
periodically	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
glycine250	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
aspartate	O	NOUN	B
substitution	O	NOUN	I
in	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
of	O	ADP	O
hexosaminidase	O	NOUN	B
A	O	NOUN	I
causes	O	VERB	O
juvenile	O	NOUN	B
-	O	PUNCT	O
onset	O	NOUN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
Lebanese	O	ADJ	B
-	O	PUNCT	O
Canadian	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
juvenile	O	NOUN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
two	O	NUM	O
sibs	O	NOUN	B
of	O	ADP	O
Lebanese	O	PROPN	B
-	O	PUNCT	O
Maronite	O	PROPN	B
origin	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


An	O	DET	O
mRNA	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
extract	O	NOUN	B
of	O	ADP	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
template	O	NOUN	B
to	O	PART	O
amplify	O	VERB	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
hexosaminidase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
Hex	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
amplified	O	VERB	B
cDNA	O	NOUN	B
fragments	O	NOUN	O
revealed	O	VERB	O
a	O	DET	O
single	O	ADJ	O
alteration	O	NOUN	B
,	O	PUNCT	O
guanine	O	NOUN	B
to	O	PART	O
adenine	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
749	O	NUM	O
creating	O	VERB	O
a	O	DET	O
G250D	O	NOUN	O
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
introduces	O	VERB	O
a	O	DET	O
new	O	ADJ	O
recognition	O	NOUN	B
site	O	NOUN	I
for	O	ADP	O
the	O	DET	O
restriction	O	NOUN	B
enzyme	O	NOUN	O
Eco	O	PROPN	O
RV	O	PROPN	O
,	O	PUNCT	O
permitting	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
heterozygotes	O	NOUN	B
for	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
following	O	VERB	O
PCR	O	NOUN	B
amplification	O	NOUN	I
and	O	CCONJ	O
Eco	O	NOUN	B
RV	O	ADJ	I
digestion	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
sequences	O	NOUN	I
from	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
templates	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
this	O	DET	O
substitution	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
in	O	X	B
vitro	O	X	I
mutagenized	O	VERB	B
cDNA	O	NOUN	B
construct	O	NOUN	I
was	O	AUX	O
introduced	O	VERB	O
into	O	ADP	O
a	O	DET	O
mammalian	O	ADJ	B
expression	O	NOUN	B
vector	O	NOUN	I
and	O	CCONJ	O
transfected	O	VERB	B
into	O	ADP	O
monkey	O	NOUN	B
Cos	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
cells	O	NOUN	B
separately	O	ADV	O
or	O	CCONJ	O
along	O	ADP	O
with	O	ADP	O
a	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
cDNA	O	NOUN	B
expression	O	NOUN	B
vector	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
mutant	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
cDNA	O	NOUN	B
was	O	AUX	O
the	O	DET	O
only	O	ADJ	O
gene	O	NOUN	B
introduced	O	VERB	O
into	O	ADP	O
COS	O	NOUN	B
cells	O	NOUN	B
no	O	DET	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
above	O	ADP	O
endogenous	O	ADJ	B
COS	O	NOUN	B
cell	O	NOUN	O
activity	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Cotransfection	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
cDNA	O	NOUN	B
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
cDNA	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
immunoprecipitation	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
Hex	O	NOUN	B
A	O	NOUN	I
resulted	O	VERB	O
in	O	ADP	O
20	O	NUM	O
-	O	PUNCT	O
fold	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ratio	O	NOUN	B
between	O	ADP	O
positive	O	ADJ	B
and	O	CCONJ	O
negative	O	ADJ	B
(	O	PUNCT	O
mock	O	ADJ	B
transfection	O	NOUN	I
)	O	PUNCT	O
control	O	NOUN	B
values	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
allowed	O	VERB	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
some	O	DET	O
residual	O	ADJ	B
activity	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
positive	O	ADJ	B
control	O	NOUN	O
)	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
mutant	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
cDNA	O	NOUN	B
replaced	O	VERB	O
its	O	PRON	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
counterpart	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
predicted	O	VERB	O
protein	O	NOUN	B
environment	O	NOUN	I
in	O	ADP	O
which	O	DET	O
the	O	DET	O
mutation	O	NOUN	B
occurs	O	VERB	O
is	O	AUX	O
compared	O	VERB	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
mutation	O	NOUN	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
Gly269	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Ser	O	NOUN	B
substitution	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Novel	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
mutations	O	NOUN	I
from	O	ADP	O
China	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
three	O	NUM	O
HEXA	O	NOUN	B
mutations	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
infantile	O	ADJ	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
three	O	NUM	O
unrelated	O	ADJ	O
nonconsanguineous	O	ADJ	B
Chinese	O	ADJ	I
families	O	NOUN	B
.	O	PUNCT	O


Novel	O	ADJ	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
third	O	NOUN	O
is	O	AUX	O
a	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
mutation	O	NOUN	B
(	O	PUNCT	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
1444	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
Nakano	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1988	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
identified	O	VERB	B
a	O	DET	O
novel	O	ADJ	O
insertion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
A	O	NOUN	O
after	O	ADP	O
nt	O	NOUN	O
547	O	NUM	O
in	O	ADP	O
family	O	NOUN	B
1	O	NUM	I
.	O	PUNCT	O


This	O	DET	O
change	O	NOUN	O
generates	O	VERB	O
an	O	DET	O
early	O	ADJ	O
termination	O	NOUN	B
codon	O	NOUN	B
6	O	NUM	I
bp	O	NOUN	I
downstream	O	ADJ	I
from	O	ADP	O
the	O	DET	O
insertion	O	NOUN	B
site	O	NOUN	I
.	O	PUNCT	O


Allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
oligonucleotide	O	NOUN	B
hybridization	O	NOUN	I
confirmed	O	VERB	O
homozygosity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
.	O	PUNCT	O


Single	O	ADJ	B
strand	O	NOUN	I
conformational	O	ADJ	I
polymorphism	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
direct	O	ADJ	O
sequencing	O	NOUN	O
of	O	ADP	O
amplified	O	VERB	B
exon	O	NOUN	O
13	O	NUM	O
revealed	O	VERB	B
a	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
1453	O	NUM	O
with	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	O
W485R	O	NOUN	O
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
creates	O	VERB	O
an	O	DET	O
Fnu4HI	O	ADJ	B
restriction	O	NOUN	I
site	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
is	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
site	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mutagenized	O	ADJ	B
alpha	O	NOUN	B
cDNA	O	NOUN	I
carrying	O	VERB	O
the	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
1453	O	NUM	O
was	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
COS	O	NOUN	B
1	O	NUM	O
cells	O	NOUN	B
hexosaminidase	O	NOUN	B
S	O	NOUN	I
activity	O	NOUN	I
was	O	AUX	O
not	O	PART	O
detectable	O	ADJ	B
above	O	ADP	O
background	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
1444	O	NUM	O
(	O	PUNCT	O
exon	O	NOUN	B
13	O	NUM	I
)	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
E482K	O	NOUN	B
substitution	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
occurs	O	VERB	O
at	O	ADP	O
a	O	DET	O
CpG	O	NOUN	B
dinucleotide	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
an	O	DET	O
Italian	O	ADJ	B
TSD	B-Disease	NOUN	B
proband	O	NOUN	B
and	O	CCONJ	O
causes	O	VERB	O
defective	O	ADJ	B
intracellular	O	ADJ	B
transport	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
from	O	ADP	O
the	O	DET	O
rough	O	ADJ	B
endoplasmic	O	ADJ	I
reticulum	O	NOUN	I
to	O	PART	O
the	O	DET	O
Golgi	O	PROPN	B
apparatus	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
causing	O	VERB	O
mild	O	ADJ	O
hyperphenylalaninemia	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
DNA	O	NOUN	B
haplotype	O	NOUN	I
12	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
genetic	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
most	O	ADJ	O
phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
hyperphenylalaninemia	B-Disease	NOUN	B
(	O	PUNCT	O
HPA	B-Disease	ADJ	B
)	O	PUNCT	O
cases	O	NOUN	B
are	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Approximately	O	ADV	O
50	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
Caucasians	O	PROPN	B
and	O	CCONJ	O
are	O	AUX	O
reflected	O	VERB	O
in	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
severities	O	NOUN	I
.	O	PUNCT	O


Most	O	ADJ	O
mutations	O	NOUN	B
are	O	AUX	O
linked	O	VERB	O
to	O	PART	O
specific	O	ADJ	O
haplotypes	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
defined	O	VERB	O
by	O	ADP	O
eight	O	NUM	O
polymorphic	O	ADJ	B
restriction	O	NOUN	O
sites	O	NOUN	O
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
hypothesized	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
mild	O	ADJ	B
mutation	O	NOUN	B
linked	O	VERB	O
to	O	PART	O
haplotype	O	NOUN	B
12	O	NUM	O
in	O	ADP	O
the	O	DET	O
Swedish	O	ADJ	B
PKU	B-Disease	PROPN	B
/	O	PUNCT	O
HPA	B-Disease	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
since	O	SCONJ	O
7	O	NUM	O
of	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
carrying	O	VERB	O
haplotype	O	NOUN	B
12	O	NUM	O
had	O	AUX	O
mild	O	ADJ	B
HPA	B-Disease	NOUN	B
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
G	O	NOUN	B
transversion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
second	O	ADJ	O
base	O	NOUN	O
of	O	ADP	O
codon	O	NOUN	B
322	O	NUM	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
glycine	O	NOUN	B
for	O	ADP	O
alanine	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
four	O	NUM	O
mutant	O	ADJ	B
haplotype	O	NOUN	B
12	O	NUM	O
genes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
second	O	ADJ	O
base	O	NOUN	O
of	O	ADP	O
codon	O	NOUN	B
408	O	NUM	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
glutamine	O	NOUN	B
for	O	ADP	O
arginine	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
another	O	DET	O
three	O	NUM	O
mutant	O	ADJ	B
haplotype	O	NOUN	O
12	O	NUM	O
genes	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
mutations	O	NOUN	B
segregated	O	VERB	O
with	O	ADP	O
mutant	O	ADJ	B
haplotype	O	NOUN	B
12	O	NUM	O
alleles	O	NOUN	B
in	O	ADP	O
nuclear	O	ADJ	B
families	O	NOUN	I
but	O	CCONJ	O
were	O	AUX	O
not	O	PART	O
present	O	ADJ	O
on	O	ADP	O
normal	O	ADJ	B
or	O	CCONJ	O
other	O	ADJ	O
mutant	O	ADJ	B
alleles	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
in	O	ADP	O
a	O	DET	O
eukaryotic	O	ADJ	B
expression	O	NOUN	I
system	O	NOUN	I
in	O	ADP	O
which	O	DET	O
enzyme	O	NOUN	B
activities	O	NOUN	I
of	O	ADP	O
different	O	ADJ	O
mutant	O	ADJ	B
PAH	O	NOUN	B
enzymes	O	NOUN	B
reflect	O	VERB	O
the	O	DET	O
relative	O	ADJ	O
severities	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
these	O	DET	O
in	O	X	B
vitro	O	X	I
activities	O	NOUN	B
cannot	O	AUX	O
be	O	AUX	O
translated	O	VERB	B
directly	O	ADV	O
into	O	ADP	O
in	O	X	B
vivo	O	X	I
hepatic	O	ADJ	B
activities	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
A322G	O	ADJ	O
mutant	O	ADJ	B
PAH	O	NOUN	B
had	O	AUX	O
about	O	ADV	O
75	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
R408Q	O	NOUN	B
mutant	O	ADJ	I
PAH	O	NOUN	B
about	O	ADP	O
55	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
PAH	O	NOUN	B
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
in	O	X	B
vitro	O	X	I
activities	O	NOUN	B
are	O	AUX	O
the	O	DET	O
highest	O	ADJ	O
reported	O	VERB	O
for	O	ADP	O
mutant	O	ADJ	B
PAH	O	NOUN	B
enzymes	O	NOUN	B
produced	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
expression	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
correlations	O	NOUN	B
for	O	ADP	O
I65T	O	NOUN	B
and	O	CCONJ	O
M1V	O	NOUN	B
mutations	O	NOUN	I
at	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
locus	O	NOUN	O
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
are	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
hyperphenylalaninemia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
described	O	VERB	O
four	O	NUM	O
mutations	O	NOUN	B
(	O	PUNCT	O
M1V	O	NOUN	B
,	O	PUNCT	O
IVS12nt1	O	NOUN	B
,	O	PUNCT	O
R408W	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
S349P	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
French	O	PROPN	B
Canadians	O	PROPN	B
with	O	ADP	O
ancestry	O	NOUN	B
in	O	ADP	O
eastern	O	ADJ	B
Quebec	O	PROPN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	B
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
another	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
a	O	DET	O
haplotype	O	NOUN	B
9	O	NUM	O
chromosome	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
converts	O	VERB	O
codon	O	NOUN	B
65	O	NUM	O
from	O	ADP	O
isoleucine	O	NOUN	B
(	O	PUNCT	O
ATT	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
threonine	O	NOUN	B
(	O	PUNCT	O
ACT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
I65T	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
COS	O	NOUN	B
cells	O	NOUN	I
demonstrating	O	VERB	O
75	O	NUM	O
%	O	NOUN	O
loss	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
immunoreactive	O	ADJ	B
protein	O	NOUN	I
and	O	CCONJ	O
enzyme	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
expression	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
prevalent	O	ADJ	O
PKU	B-Disease	NOUN	B
allele	O	NOUN	B
(	O	PUNCT	O
M1V	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
eastern	O	ADJ	B
Quebec	O	PROPN	I
,	O	PUNCT	O
showing	O	VERB	O
nondetectable	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
PAH	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
activity	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
finding	O	NOUN	O
compatible	O	ADJ	O
with	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
translation	O	NOUN	B
initiation	O	NOUN	O
codon	O	NOUN	B
.	O	PUNCT	O


Homozygosity	O	NOUN	B
for	O	ADP	O
M1V	O	NOUN	B
and	O	CCONJ	O
codominant	O	ADJ	B
inheritance	O	NOUN	B
of	O	ADP	O
I65T	O	NOUN	B
/	O	SYM	O
R408W	O	NOUN	B
were	O	AUX	O
both	O	DET	O
associated	O	VERB	B
with	O	ADP	I
classical	B-Disease	ADJ	O
phenylketonuria	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
hexosaminidase	B-Disease	NOUN	B
A	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
pseudodeficiency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Berks	O	PROPN	B
County	O	PROPN	I
Pennsylvania	O	PROPN	I
Dutch	O	PROPN	B
.	O	PUNCT	O


Following	O	VERB	O
the	O	DET	O
birth	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
infants	O	NOUN	B
with	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	PROPN	B
,	O	PUNCT	O
Pennsylvania	O	PROPN	B
Dutch	O	ADJ	I
kindred	O	NOUN	I
was	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
TSD	B-Disease	NOUN	B
carriers	O	NOUN	B
using	O	VERB	O
the	O	DET	O
biochemical	O	ADJ	B
assay	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
who	O	PRON	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
TSD	B-Disease	NOUN	B
heterozygotes	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
(	O	PUNCT	O
Kelly	O	PROPN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
1975	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
evidence	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
increased	O	VERB	B
carrier	O	NOUN	B
frequency	O	NOUN	O
was	O	AUX	O
due	O	ADJ	O
to	O	PART	O
at	O	ADP	O
least	O	ADJ	O
two	O	NUM	O
altered	O	ADJ	O
alleles	O	NOUN	B
for	O	ADP	O
the	O	DET	O
hexosaminidase	O	NOUN	B
A	O	NOUN	I
alpha	O	NOUN	I
-	O	PUNCT	O
subunit	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
two	O	NUM	O
mutant	O	ADJ	B
alleles	O	NOUN	O
in	O	ADP	O
this	O	DET	O
Pennsylvania	O	PROPN	B
Dutch	O	ADJ	I
kindred	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
polymorphism	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
allele	O	NOUN	B
,	O	PUNCT	O
reported	O	VERB	O
originally	O	ADV	O
in	O	ADP	O
a	O	DET	O
French	O	ADJ	B
TSD	B-Disease	NOUN	O
patient	O	NOUN	B
(	O	PUNCT	O
Akli	O	PROPN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
1991	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
GT	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
AT	O	ADP	B
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
of	O	ADP	O
intron	O	NOUN	B
9	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
second	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
at	O	ADP	O
nucleotide	O	NOUN	B
739	O	NUM	I
(	O	PUNCT	O
Arg247Trp	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
Triggs	O	PROPN	B
-	O	PUNCT	O
Raine	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O


(	O	PUNCT	O
1992	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
clinically	O	ADV	B
benign	O	ADJ	I
"	O	PUNCT	O
pseudodeficient	O	ADJ	B
"	O	PUNCT	O
allele	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
reduced	O	VERB	B
enzyme	O	NOUN	B
activity	O	NOUN	I
against	O	ADP	O
artificial	O	ADJ	B
substrate	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
polymorphism	O	NOUN	B
[	O	PUNCT	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
(	O	PUNCT	O
759	O	NUM	O
)	O	PUNCT	O
]	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
leaves	O	VERB	B
valine	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
253	O	NUM	O
unchanged	O	ADJ	B
,	O	PUNCT	O
is	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
mutation	O	NOUN	B
common	O	ADJ	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
frequency	O	NOUN	B
and	O	CCONJ	O
RNA	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
encoding	O	VERB	B
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lysosomal	O	ADJ	B
enzyme	O	NOUN	I
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
N	O	NOUN	B
-	O	PUNCT	O
acetylhexosaminidase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
Hex	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
discovered	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
mutation	O	NOUN	B
,	O	PUNCT	O
IVS	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
+	O	CCONJ	O
1	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	PROPN	O
,	O	PUNCT	O
first	O	ADV	O
detected	O	VERB	B
by	O	ADP	O
Akli	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O


(	O	PUNCT	O
Genomics	O	NOUN	B
11	O	NUM	O
124	O	NUM	O
-	O	SYM	O
134	O	NUM	O
,	O	PUNCT	O
1991	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
disease	O	NOUN	B
allele	O	NOUN	I
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
Caucasians	O	PROPN	B
(	O	PUNCT	O
10	O	NUM	O
/	O	SYM	O
58	O	NUM	O
alleles	O	NOUN	B
examined	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
diagnostic	O	ADJ	B
test	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
detects	O	VERB	O
an	O	DET	O
NlaIII	O	NOUN	B
site	O	NOUN	I
generated	O	VERB	O
by	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
revealed	O	VERB	O
a	O	DET	O
frequency	O	NOUN	B
among	O	ADP	O
enzyme	O	NOUN	B
-	O	PUNCT	O
defined	O	VERB	B
carriers	O	NOUN	B
of	O	ADP	O
9	O	NUM	B
/	O	SYM	O
64	O	NUM	O
(	O	PUNCT	O
14	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Most	O	ADJ	O
of	O	ADP	O
those	O	DET	O
carrying	O	VERB	O
the	O	DET	O
allele	O	NOUN	B
trace	O	VERB	I
their	O	PRON	O
origins	O	NOUN	B
to	O	ADP	O
the	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
,	O	PUNCT	O
Ireland	O	PROPN	B
,	O	PUNCT	O
or	O	CCONJ	O
Western	O	PROPN	B
Europe	O	PROPN	I
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
not	O	PART	O
identified	O	VERB	O
among	O	ADP	O
12	O	NUM	O
Black	O	ADJ	B
American	O	ADJ	I
TSD	B-Disease	NOUN	B
alleles	O	NOUN	O
or	O	CCONJ	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
18	O	NUM	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
,	O	PUNCT	O
enzyme	O	NOUN	B
-	O	PUNCT	O
defined	O	VERB	B
carriers	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
carry	O	VERB	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
common	O	ADJ	O
to	O	PART	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
normally	O	ADV	I
spliced	O	VERB	O
RNA	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
generated	O	VERB	O
from	O	ADP	O
reverse	O	ADJ	B
transcription	O	NOUN	I
of	O	ADP	O
RNA	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
IVS	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
mutation	O	NOUN	B
.	O	PUNCT	O


Instead	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
low	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
from	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
were	O	AUX	O
comprised	O	VERB	O
of	O	ADP	O
aberrant	O	ADJ	B
species	O	NOUN	B
resulting	O	VERB	O
from	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
either	O	DET	O
of	O	ADP	O
two	O	NUM	O
cryptic	O	ADJ	B
donor	O	NOUN	O
sites	O	NOUN	O
,	O	PUNCT	O
one	O	NUM	O
truncating	O	VERB	B
exon	O	NOUN	I
9	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
within	O	ADP	O
IVS	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
,	O	PUNCT	O
spliced	O	VERB	B
to	O	PART	O
exon	O	NOUN	O
10	O	NUM	O
.	O	PUNCT	O


Numerous	O	ADJ	O
additional	O	ADJ	O
splice	O	NOUN	B
products	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
,	O	PUNCT	O
most	O	ADV	O
involving	O	VERB	O
skipping	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
surrounding	O	VERB	B
exons	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
with	O	ADP	O
a	O	DET	O
recently	O	ADV	O
identified	O	VERB	B
allele	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
Hex	O	NOUN	B
A	O	NOUN	I
pseudodeficiency	O	NOUN	I
(	O	PUNCT	O
Triggs	O	PROPN	B
-	O	PUNCT	O
Raine	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
Am	O	NOUN	O
J	O	PROPN	O
Hum	O	PROPN	O
Genet	O	PROPN	O
,	O	PUNCT	O
1992	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
these	O	DET	O
two	O	NUM	O
alleles	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
almost	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
29	O	NUM	O
/	O	SYM	O
64	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
TSD	B-Disease	NOUN	B
or	O	CCONJ	O
carrier	O	NOUN	B
alleles	O	NOUN	O
ascertained	O	VERB	O
by	O	ADP	O
enzyme	O	NOUN	B
screening	O	NOUN	I
tests	O	NOUN	I
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
Caucasians	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Aberrant	O	ADJ	B
splicing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
choroideremia	B-Disease	NOUN	B
.	O	PUNCT	O


Choroideremia	B-Disease	NOUN	B
(	O	PUNCT	O
CHM	B-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	O
progressive	I-Disease	ADJ	B
degeneration	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
choroid	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
retina	I-Disease	NOUN	B
.	O	PUNCT	O


12	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
unrelated	O	ADJ	O
male	O	NOUN	B
patients	O	NOUN	B
carry	O	VERB	O
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
partially	O	ADV	O
cloned	O	VERB	B
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Finland	O	PROPN	B
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
more	O	ADJ	O
than	O	ADP	O
120	O	NUM	O
living	O	VERB	O
CHM	B-Disease	NOUN	B
patients	O	NOUN	B
belonging	O	VERB	O
to	O	PART	O
eight	O	NUM	O
apparently	O	ADV	O
unrelated	O	ADJ	O
pedigrees	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
deletions	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
three	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
screened	O	VERB	B
the	O	DET	O
remaining	O	VERB	O
five	O	NUM	O
families	O	NOUN	B
for	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
large	O	ADJ	O
family	O	NOUN	O
a	O	DET	O
single	O	ADJ	B
nucleotide	O	NOUN	I
(	O	PUNCT	I
T	O	NOUN	O
)	O	PUNCT	O
insertion	O	NOUN	B
into	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
C	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
two	O	NUM	O
aberrantly	O	ADV	O
spliced	O	VERB	B
mRNAs	O	NOUN	B
both	O	CCONJ	O
producing	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
assayed	O	VERB	B
easily	O	ADV	O
by	O	ADP	O
amplification	O	NOUN	B
and	O	CCONJ	O
digestion	O	NOUN	B
with	O	ADP	O
Msel	O	PROPN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
provide	O	VERB	O
additional	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
pathogenetic	O	ADJ	B
role	O	NOUN	O
of	O	ADP	O
CHM	B-Disease	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
provide	O	VERB	O
a	O	DET	O
diagnostic	O	ADJ	B
tool	O	NOUN	I
for	O	ADP	O
one	O	NUM	O
fifth	O	NOUN	O
of	O	ADP	O
the	O	DET	O
worlds	O	NOUN	B
known	O	VERB	O
CHM	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Germline	O	NOUN	B
intronic	O	ADJ	I
and	O	CCONJ	O
exonic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Wilms	B-Disease	NOUN	B
'	I-Disease	PART	I
tumour	I-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
WT1	O	NOUN	B
)	O	PUNCT	O
affecting	O	VERB	B
urogenital	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O


Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
human	O	ADJ	B
developmental	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
affecting	O	VERB	B
the	O	DET	O
urogenital	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
leading	O	VERB	O
to	O	PART	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
intersex	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
Wilms	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
are	O	AUX	O
described	O	VERB	O
carrying	O	VERB	O
germline	O	NOUN	B
point	O	NOUN	I
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Wilms	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
suppressor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
WT1	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
domains	O	NOUN	I
of	O	ADP	O
WT1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
occurred	O	VERB	O
within	O	ADP	O
intron	O	NOUN	B
9	O	NUM	O
,	O	PUNCT	O
preventing	O	VERB	B
splicing	O	NOUN	B
at	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
alternatively	O	ADV	B
chosen	O	VERB	O
splice	O	NOUN	B
donor	O	NOUN	I
sites	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
when	O	SCONJ	O
assayed	O	VERB	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
genetic	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
distinct	O	ADJ	O
functional	O	ADJ	B
roles	O	NOUN	O
of	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
isoforms	O	NOUN	B
in	O	ADP	O
urogenital	O	ADJ	B
development	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
region	O	NOUN	I
predicts	O	VERB	O
multiple	O	ADJ	B
protein	O	NOUN	I
isoform	O	NOUN	O
-	O	PUNCT	O
encoding	O	VERB	B
mRNAs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
underlying	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
an	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
polymorphic	O	ADJ	B
CTG	O	NOUN	B
-	O	PUNCT	O
repeat	O	NOUN	B
in	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
encoding	O	NOUN	O
protein	O	NOUN	B
kinase	O	NOUN	I
activity	O	NOUN	O
.	O	PUNCT	O


Brain	O	PROPN	B
and	O	CCONJ	O
heart	O	NOUN	B
transcripts	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DM	O	NOUN	B
-	O	PUNCT	O
kinase	O	NOUN	B
(	O	PUNCT	O
DMR	O	NOUN	B
-	O	PUNCT	O
B15	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
are	O	AUX	O
subject	O	ADJ	O
to	O	PART	O
alternative	O	ADJ	O
RNA	O	NOUN	B
splicing	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
human	O	ADJ	B
and	O	CCONJ	O
mouse	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
unstable	O	ADJ	B
[	O	PUNCT	O
CTG	O	NOUN	B
]	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
30	O	NUM	O
motif	O	NOUN	B
is	O	AUX	O
found	O	VERB	O
uniquely	O	ADV	O
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
flanking	O	ADJ	B
nucleotides	O	NOUN	B
are	O	AUX	O
also	O	ADV	O
present	O	ADJ	O
in	O	ADP	O
mouse	O	NOUN	B
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
region	O	NOUN	I
of	O	ADP	O
both	O	DET	O
species	O	NOUN	B
reveals	O	VERB	O
another	O	DET	O
active	O	ADJ	B
gene	O	NOUN	I
(	O	PUNCT	O
DMR	O	NOUN	B
-	O	PUNCT	O
N9	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
close	O	ADJ	O
proximity	O	NOUN	B
to	O	PART	O
the	O	DET	O
kinase	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


DMR	O	NOUN	B
-	O	PUNCT	O
N9	O	NOUN	B
transcripts	O	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
testis	O	NOUN	B
,	O	PUNCT	O
possess	O	VERB	O
a	O	DET	O
single	O	ADJ	O
,	O	PUNCT	O
large	O	ADJ	O
open	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
protein	O	NOUN	B
product	O	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Clinical	O	ADJ	B
manifestation	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
CTG	O	NOUN	B
-	O	PUNCT	O
repeat	O	NOUN	B
compromising	O	VERB	B
the	O	DET	O
(	O	PUNCT	O
alternative	O	ADJ	B
)	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
DM	O	NOUN	B
-	O	PUNCT	O
kinase	O	NOUN	B
or	O	CCONJ	O
DMR	O	NOUN	B
-	O	PUNCT	O
N9	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Fragile	B-Disease	NOUN	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
without	O	ADP	O
CCG	O	NOUN	B
amplification	O	NOUN	I
has	O	AUX	O
an	O	DET	O
FMR1	O	NOUN	B
deletion	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
typical	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
without	O	ADP	O
cytogenetic	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
or	O	CCONJ	O
an	O	DET	O
amplified	O	VERB	B
CCG	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
fragment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
has	O	AUX	O
a	O	DET	O
previously	O	ADV	O
uncharacterized	O	ADJ	B
submicroscopic	O	ADJ	B
deletion	O	NOUN	I
encompassing	O	VERB	O
the	O	DET	O
CCG	O	NOUN	B
repeat	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
entire	O	ADJ	O
FMR1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
about	O	ADV	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
megabases	O	NOUN	B
of	O	ADP	O
flanking	O	ADJ	B
sequences	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	O
confirms	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
phenotype	O	NOUN	B
can	O	AUX	O
exist	O	VERB	O
,	O	PUNCT	O
without	O	ADP	O
amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CCG	O	NOUN	B
repeat	O	NOUN	I
or	O	CCONJ	O
cytogenetic	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
the	O	DET	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
fragile	B-Disease	ADJ	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
genetically	O	ADV	B
homogeneous	O	ADJ	O
disorder	O	NOUN	O
involving	O	VERB	O
FMR1	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
found	O	VERB	O
random	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
inactivation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mother	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
carrier	O	NOUN	B
of	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


Cloning	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
region	O	NOUN	I
in	O	ADP	O
yeast	O	NOUN	B
artificial	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
a	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
million	O	NUM	O
base	O	NOUN	O
pair	O	NOUN	O
(	O	PUNCT	O
Mb	O	NOUN	O
)	O	PUNCT	O
region	O	NOUN	O
between	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
D4S10	O	NOUN	B
and	O	CCONJ	O
D4S168	O	NOUN	B
on	O	ADP	O
the	O	DET	O
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
4	O	NUM	I
.	O	PUNCT	O


As	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
strategy	O	NOUN	O
to	O	PART	O
clone	O	NOUN	B
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
chromosomal	O	ADJ	B
location	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
isolated	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
region	O	NOUN	B
as	O	ADP	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
overlapping	O	VERB	O
yeast	O	NOUN	B
artificial	O	ADJ	O
chromosome	O	NOUN	O
(	O	PUNCT	O
YAC	O	NOUN	O
)	O	PUNCT	O
clones	O	NOUN	O
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
YAC	O	NOUN	B
clones	O	NOUN	O
were	O	AUX	O
identified	O	VERB	O
by	O	ADP	O
screening	O	VERB	B
human	O	ADJ	B
YAC	O	NOUN	B
libraries	O	NOUN	O
with	O	ADP	O
twelve	O	NUM	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
sequence	O	NOUN	B
-	O	PUNCT	O
tagged	O	VERB	B
sites	O	NOUN	I
(	O	PUNCT	O
STSs	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
assembled	O	VERB	O
the	O	DET	O
YAC	O	NOUN	B
clones	O	NOUN	B
into	O	ADP	O
overlapping	O	VERB	O
sets	O	NOUN	O
by	O	ADP	O
hybridizing	O	VERB	B
them	O	PRON	O
to	O	ADP	O
a	O	DET	O
large	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
DNA	O	NOUN	B
probes	O	NOUN	I
from	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
region	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
STSs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
isolated	O	VERB	B
the	O	DET	O
ends	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
DNA	O	NOUN	B
inserts	O	NOUN	I
of	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
YAC	O	NOUN	B
clones	O	NOUN	B
to	O	PART	O
assist	O	VERB	O
in	O	ADP	O
the	O	DET	O
construction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
contig	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
almost	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
YACs	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
contain	O	VERB	O
chimeric	O	ADJ	B
inserts	O	NOUN	I
and	O	CCONJ	O
several	O	ADJ	O
contain	O	VERB	O
internal	O	ADJ	B
deletions	O	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
rearrangements	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
obtain	O	VERB	O
over	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
Mb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
region	O	NOUN	O
in	O	ADP	O
YACs	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
one	O	NUM	O
continuous	O	ADJ	B
segment	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
Mb	O	NOUN	O
covering	O	VERB	O
the	O	DET	O
region	O	NOUN	B
that	O	PRON	O
most	O	ADV	O
likely	O	ADV	O
contains	O	VERB	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Ten	O	NUM	O
of	O	ADP	O
the	O	DET	O
twenty	O	NUM	O
eight	O	NUM	O
YAC	O	NOUN	B
clones	O	NOUN	B
comprise	O	VERB	O
a	O	DET	O
minimal	O	ADJ	B
set	O	NOUN	O
spanning	O	VERB	O
the	O	DET	O
2	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
Mb	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
clones	O	NOUN	B
provide	O	VERB	O
reagents	O	NOUN	B
for	O	ADP	O
the	O	DET	O
complete	O	ADJ	O
characterization	O	NOUN	B
of	O	ADP	O
this	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
the	O	DET	O
eventual	O	ADJ	B
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
YAC	O	NOUN	B
containing	O	VERB	O
part	O	NOUN	O
or	O	CCONJ	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
from	O	ADP	O
pulsed	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
(	O	PUNCT	O
PFGE	O	NOUN	B
)	O	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
monoamine	O	NOUN	B
oxidase	O	NOUN	I
genes	O	NOUN	I
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	O
(	O	PUNCT	O
MAOA	O	NOUN	B
&	O	CCONJ	O
MAOB	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
DXS7	O	NOUN	B
loci	O	NOUN	I
are	O	AUX	O
physically	O	ADV	B
very	O	ADV	I
close	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
therefore	O	ADV	O
extended	O	VERB	O
studies	O	NOUN	B
on	O	ADP	O
their	O	PRON	O
relationship	O	NOUN	B
through	O	ADP	O
the	O	DET	O
characterisation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
650	O	NUM	O
kb	O	NOUN	O
YAC	O	NOUN	B
isolated	O	VERB	B
using	O	VERB	O
L1	O	NOUN	B
.	O	PUNCT	O


28	O	NUM	O
(	O	PUNCT	O
recognising	O	VERB	O
the	O	DET	O
DXS7	O	NOUN	B
locus	O	NOUN	I
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
.	O	PUNCT	O


Restriction	O	NOUN	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
YAC	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
contains	O	VERB	O
both	O	CCONJ	O
MAOA	O	NOUN	B
and	O	CCONJ	O
MAOB	O	NOUN	B
genes	O	NOUN	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
DXS7	O	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
map	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
YL1	O	NOUN	B
.	O	PUNCT	O


28	O	NUM	O
-	O	PUNCT	O
YAC	O	NOUN	B
is	O	AUX	O
compatible	O	ADJ	O
both	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
map	O	NOUN	B
from	O	ADP	O
an	O	DET	O
independently	O	ADV	O
derived	O	VERB	O
YAC	O	NOUN	B
carrying	O	VERB	O
MAOA	O	NOUN	B
and	O	CCONJ	O
B	O	NOUN	B
genes	O	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
the	O	DET	O
long	O	ADJ	B
range	O	NOUN	I
genomic	O	ADJ	B
map	O	NOUN	I
for	O	ADP	O
the	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
series	O	NOUN	B
of	O	ADP	O
subclones	O	NOUN	B
prepared	O	VERB	B
from	O	ADP	O
a	O	DET	O
phage	O	NOUN	B
library	O	NOUN	I
(	O	PUNCT	O
lambda	O	NOUN	B
DASH	O	NOUN	I
II	O	NUM	I
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
YAC	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
characterised	O	VERB	B
and	O	CCONJ	O
have	O	AUX	O
been	O	AUX	O
employed	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
NDP	B-Disease	NOUN	B
)	O	PUNCT	O
patient	O	NOUN	B
who	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
lack	O	VERB	O
both	O	CCONJ	O
DXS7	O	NOUN	B
and	O	CCONJ	O
MAO	O	NOUN	B
coding	O	NOUN	O
sequences	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
retention	O	NOUN	B
of	O	ADP	O
subclones	O	NOUN	B
in	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
patient	O	NOUN	B
place	O	VERB	O
the	O	DET	O
end	O	NOUN	O
point	O	NOUN	O
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
within	O	ADP	O
30	O	NUM	O
-	O	SYM	O
130	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
YAC	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
combining	O	VERB	O
the	O	DET	O
data	O	NOUN	B
with	O	ADP	O
established	O	ADJ	O
recombination	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
all	O	DET	O
or	O	CCONJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
NDP	O	PROPN	B
lies	O	VERB	O
in	O	ADP	O
the	O	DET	O
interval	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	B
250kb	O	ADJ	O
within	O	ADP	O
the	O	DET	O
YAC	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
in	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
-	O	PUNCT	O
are	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
produce	O	VERB	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
glucose	B-Disease	NOUN	B
6	I-Disease	NUM	I
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
African	O	ADJ	B
populations	O	NOUN	I
is	O	AUX	O
due	O	ADJ	O
almost	O	ADV	O
entirely	O	ADV	O
to	O	PART	O
the	O	DET	O
enzyme	O	NOUN	B
variant	O	ADJ	O
A	O	NOUN	O
-	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
differs	O	VERB	O
from	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
G6PD	O	NOUN	B
B	O	NOUN	I
by	O	ADP	O
two	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
replacements	O	NOUN	I
,	O	PUNCT	O
68	O	NUM	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Met	O	PROPN	B
and	O	CCONJ	O
126	O	NUM	O
Asn	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asp	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
deficient	O	ADJ	B
polymorphic	O	ADJ	B
variant	O	ADJ	I
G6PD	O	NOUN	B
A	O	NOUN	O
contains	O	VERB	O
only	O	ADV	O
the	O	DET	O
mutation	O	NOUN	B
126	O	NUM	O
Asn	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asp	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequencies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
A	O	NOUN	B
-	O	PUNCT	O
genes	O	NOUN	B
in	O	ADP	O
parts	O	NOUN	B
of	O	ADP	O
Africa	O	PROPN	B
are	O	AUX	O
both	O	DET	O
about	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


2	O	X	O
.	O	PUNCT	O


The	O	DET	O
68	O	NUM	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Met	O	NOUN	B
mutation	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
a	O	DET	O
B	O	NOUN	B
background	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
could	O	AUX	O
be	O	AUX	O
because	O	SCONJ	O
the	O	DET	O
68	O	NUM	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Met	O	NOUN	B
mutation	O	NOUN	B
happened	O	VERB	O
to	O	PART	O
arise	O	VERB	O
in	O	ADP	O
an	O	DET	O
A	O	NOUN	O
gene	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
instance	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
because	O	SCONJ	O
the	O	DET	O
68	O	NUM	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Met	O	NOUN	B
mutation	O	NOUN	B
alone	O	ADV	O
is	O	AUX	O
not	O	PART	O
sufficient	O	ADJ	O
to	O	PART	O
cause	O	VERB	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
approached	O	VERB	O
this	O	DET	O
question	O	NOUN	O
by	O	ADP	O
producing	O	VERB	O
G6PD	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
A	O	NOUN	O
,	O	PUNCT	O
A	O	PROPN	B
-	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
68	O	NUM	O
Val	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Met	O	NOUN	B
in	O	ADP	O
a	O	DET	O
bacterial	O	ADJ	B
expression	O	NOUN	O
system	O	NOUN	O
and	O	CCONJ	O
analysing	O	VERB	O
their	O	PRON	O
biochemical	O	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
each	O	DET	O
single	O	ADJ	O
mutation	O	NOUN	B
we	O	PRON	O
found	O	VERB	O
a	O	DET	O
slight	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
specific	O	ADJ	O
activity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
yield	O	NOUN	B
of	O	ADP	O
enzyme	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
to	O	PART	O
G6PD	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
both	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
introduced	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
roughly	O	ADV	O
additive	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
specific	O	ADJ	O
activity	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
much	O	ADV	O
more	O	ADV	O
drastic	O	ADJ	B
effect	O	NOUN	O
on	O	ADP	O
enzyme	O	NOUN	B
yield	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
synergistic	O	ADJ	B
effect	O	NOUN	O
was	O	AUX	O
also	O	ADV	O
demonstrated	O	VERB	O
on	O	ADP	O
thermal	O	ADJ	B
stability	O	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
at	O	ADP	O
low	O	ADJ	B
NADP	O	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


Comparable	O	ADJ	O
results	O	NOUN	B
were	O	AUX	O
produced	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
replacement	O	NOUN	B
119	O	NUM	O
Gln	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Glu	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
instead	O	ADV	O
of	O	ADP	O
126	O	NUM	O
Asn	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asp	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
infer	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
coexistence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	I-Disease	ADP	O
G6PD	I-Disease	NOUN	B
A	O	NOUN	O
-	O	PUNCT	O
because	O	SCONJ	O
they	O	PRON	O
act	O	VERB	O
synergistically	O	ADV	B
in	O	ADP	O
causing	O	VERB	O
instability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
.	O	PUNCT	O


Small	O	ADJ	B
nuclear	O	ADJ	I
ribonucleoprotein	O	NOUN	I
polypeptide	O	NOUN	I
N	O	NOUN	I
(	O	PUNCT	O
SNRPN	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
expressed	O	VERB	B
gene	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
critical	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
paternally	O	ADV	B
derived	O	VERB	O
chromosomal	O	ADJ	B
deletions	O	NOUN	O
in	O	ADP	O
region	O	NOUN	B
15q11	O	PROPN	I
-	O	PUNCT	O
13	O	NUM	O
or	O	CCONJ	O
with	O	ADP	O
maternal	B-Disease	ADJ	B
disomy	I-Disease	NOUN	O
for	I-Disease	ADP	O
chromosome	I-Disease	NOUN	O
15	I-Disease	NUM	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expressed	O	VERB	B
paternal	O	ADJ	B
alleles	O	NOUN	I
of	O	ADP	O
maternally	O	ADV	B
imprinted	O	ADJ	I
genes	O	NOUN	I
must	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
mapped	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
small	O	ADJ	B
nuclear	O	ADJ	I
RNA	O	NOUN	I
associated	O	ADJ	O
polypeptide	O	NOUN	B
SmN	O	NOUN	I
(	O	PUNCT	O
SNRPN	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
15q12	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
processed	O	VERB	O
pseudogene	O	NOUN	B
SNRPNP1	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
region	O	NOUN	I
6pter	O	NOUN	I
-	O	PUNCT	O
p21	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
SNRPN	O	NOUN	B
was	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
minimal	O	ADJ	B
deletion	O	NOUN	B
interval	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
mouse	O	NOUN	B
Snrpn	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
maternally	O	ADV	B
imprinted	O	VERB	I
in	O	ADP	O
brain	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paternally	O	ADV	B
derived	O	VERB	O
SNRPN	O	NOUN	B
allele	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
infantile	O	ADJ	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
mutations	O	NOUN	I
in	O	ADP	O
a	O	DET	O
Cajun	O	PROPN	B
population	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
characterize	O	VERB	O
the	O	DET	O
mutation	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
Cajun	O	PROPN	B
population	O	NOUN	I
in	O	ADP	O
southwest	O	PROPN	B
Louisiana	O	PROPN	B
and	O	CCONJ	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
origins	O	NOUN	B
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


Eleven	O	NUM	O
of	O	ADP	O
12	O	NUM	O
infantile	O	ADJ	B
TSD	B-Disease	NOUN	B
alleles	O	NOUN	B
examined	O	VERB	B
in	O	ADP	O
six	O	NUM	O
families	O	NOUN	B
had	O	AUX	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
hexosaminidase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
Hex	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
exon	O	NOUN	I
11	O	NUM	I
insertion	O	NOUN	B
mutation	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
approximately	O	ADV	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
TSD	B-Disease	NOUN	B
heterozygotes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
allele	O	NOUN	B
was	O	AUX	O
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
transition	O	NOUN	B
in	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
intron	O	NOUN	I
9	O	NUM	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
origins	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Cajun	O	PROPN	B
population	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
TSD	B-Disease	NOUN	B
carrier	O	NOUN	O
status	O	NOUN	O
was	O	AUX	O
enzymatically	O	ADV	B
determined	O	VERB	O
for	O	ADP	O
90	O	NUM	O
members	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
extensive	O	ADJ	B
pedigrees	O	NOUN	B
were	O	AUX	O
constructed	O	VERB	O
for	O	ADP	O
all	O	DET	O
carriers	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
ancestral	O	ADJ	O
couple	O	NOUN	O
from	O	ADP	O
France	O	PROPN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
common	O	ADJ	O
to	O	PART	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exon	O	NOUN	B
11	O	NUM	I
insertion	O	NOUN	B
.	O	PUNCT	O


Pedigree	O	ADJ	B
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
in	O	ADP	O
the	O	DET	O
Cajun	O	PROPN	B
population	O	NOUN	I
since	O	SCONJ	O
its	O	PRON	O
founding	O	NOUN	B
over	O	ADP	O
2	O	NUM	O
centuries	O	NOUN	O
ago	O	ADV	O
and	O	CCONJ	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
widely	O	ADV	O
distributed	O	VERB	B
within	O	ADP	O
the	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
intron	O	NOUN	B
9	O	NUM	O
mutation	O	NOUN	B
apparently	O	ADV	O
was	O	AUX	O
introduced	O	VERB	O
within	O	ADP	O
the	O	DET	O
last	O	ADJ	O
century	O	NOUN	O
and	O	CCONJ	O
probably	O	ADV	O
is	O	AUX	O
limited	O	ADJ	O
to	O	ADP	O
a	O	DET	O
few	O	ADJ	O
Louisiana	O	PROPN	B
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
and	O	CCONJ	O
others	O	NOUN	O
have	O	AUX	O
isolated	O	VERB	B
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	O
for	O	ADP	O
X	B-Disease	NOUN	O
linked	I-Disease	VERB	O
Norrie	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ND	B-Disease	NOUN	B
)	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
deleted	O	VERB	B
or	O	CCONJ	O
disrupted	O	VERB	B
in	O	ADP	O
several	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
prerequisite	O	NOUN	O
for	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ND	B-Disease	NOUN	B
gene	O	NOUN	I
we	O	PRON	O
have	O	AUX	O
established	O	VERB	O
the	O	DET	O
exon	O	NOUN	B
-	O	PUNCT	O
intron	O	NOUN	B
structure	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
17	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
controls	O	NOUN	B
,	O	PUNCT	O
PCR	O	NOUN	B
products	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
promoter	O	NOUN	B
region	O	NOUN	I
,	O	PUNCT	O
exons	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
2	O	NUM	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
coding	O	VERB	B
part	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	O
3	O	NUM	O
were	O	AUX	O
analysed	O	VERB	B
with	O	ADP	O
the	O	DET	O
single	O	ADJ	B
strand	O	NOUN	I
conformation	O	NOUN	I
polymorphism	O	NOUN	I
(	O	PUNCT	O
SSCP	O	NOUN	O
)	O	PUNCT	O
technique	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
altered	O	ADJ	O
PCR	O	NOUN	B
fragments	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
which	O	DET	O
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
detail	O	NOUN	O
by	O	ADP	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
give	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
significant	O	ADJ	O
structural	O	ADJ	B
changes	O	NOUN	O
in	O	ADP	O
the	O	DET	O
predicted	O	VERB	B
protein	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
functionally	O	ADV	O
relevant	O	ADJ	O
base	O	NOUN	B
changes	O	NOUN	I
in	O	ADP	O
healthy	O	ADJ	B
controls	O	NOUN	I
,	O	PUNCT	O
emphasize	O	VERB	O
the	O	DET	O
causal	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
this	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
in	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
pave	O	VERB	O
the	O	DET	O
way	O	NOUN	O
for	O	ADP	O
reliable	O	ADJ	O
diagnosis	O	NOUN	B
and	O	CCONJ	O
carrier	O	NOUN	B
detection	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
by	O	ADP	O
multiple	O	ADJ	O
SSCP	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
multiplex	O	ADJ	B
PCR	O	NOUN	I
with	O	ADP	O
the	O	DET	O
single	O	ADJ	B
strand	O	NOUN	I
conformation	O	NOUN	I
polymorphism	O	NOUN	I
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
technique	O	NOUN	B
was	O	AUX	O
employed	O	VERB	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
dystrophin	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


Co	O	PROPN	B
-	O	PUNCT	O
amplification	O	NOUN	B
of	O	ADP	O
11	O	NUM	O
exons	O	NOUN	B
from	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
of	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	PROPN	B
/	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
no	O	DET	O
deletion	O	NOUN	B
or	O	CCONJ	O
duplication	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
samples	O	NOUN	B
subjected	O	VERB	O
to	O	PART	O
multiple	O	ADJ	O
SSCP	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
Duchenne	B-Disease	ADJ	B
patient	O	NOUN	B
identified	O	VERB	B
by	O	ADP	O
this	O	DET	O
approach	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
introduces	O	VERB	O
a	O	DET	O
termination	O	NOUN	B
codon	O	NOUN	B
within	O	ADP	O
exon	O	NOUN	B
8	O	NUM	O
of	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
cause	O	VERB	O
a	O	DET	O
very	O	ADV	O
premature	O	ADJ	O
translational	O	ADJ	O
termination	O	NOUN	O
accounting	O	NOUN	O
for	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
observed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
inherited	O	VERB	B
this	O	DET	O
mutation	O	NOUN	B
from	O	ADP	O
his	O	PRON	O
mother	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
the	O	DET	O
analysis	O	NOUN	B
revealed	O	VERB	O
5	O	NUM	O
polymorphisms	O	NOUN	B
useful	O	ADJ	O
for	O	ADP	O
internal	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Proliferation	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
nucleoside	O	NOUN	B
diphosphate	O	NOUN	I
kinase	O	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
level	O	NOUN	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nm23	O	NOUN	B
-	O	PUNCT	O
H1	O	NOUN	B
gene	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
for	O	ADP	O
a	O	DET	O
nucleoside	O	NOUN	B
diphosphate	O	NOUN	I
kinase	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
correlate	O	VERB	B
with	O	ADP	O
diminished	O	VERB	B
metastasis	O	NOUN	B
in	O	ADP	O
some	O	DET	O
tumors	B-Disease	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
identified	O	VERB	B
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
of	O	ADP	O
the	O	DET	O
nm23	O	NOUN	B
-	O	PUNCT	O
H1	O	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
-	O	PUNCT	O
dimensional	O	ADJ	B
electrophoretic	O	ADJ	B
gels	O	NOUN	I
and	O	CCONJ	O
have	O	AUX	O
designated	O	VERB	O
it	O	PRON	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
neuroblastoma	B-Disease	NOUN	B
,	O	PUNCT	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
myc	O	NOUN	B
oncogene	O	NOUN	I
,	O	PUNCT	O
large	O	ADJ	O
tumor	B-Disease	NOUN	B
mass	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
metastasis	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
advanced	O	ADJ	B
stage	O	NOUN	I
tumors	B-Disease	NOUN	I
compared	O	VERB	O
with	O	ADP	O
limited	O	ADJ	B
stage	O	NOUN	I
disease	O	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
variable	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
nm23	O	NOUN	B
-	O	PUNCT	O
H1	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
amounts	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
and	O	CCONJ	O
cell	O	NOUN	B
proliferation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
between	O	ADP	O
resting	O	VERB	B
and	O	CCONJ	O
mitotically	O	ADV	B
stimulated	O	VERB	O
normal	O	ADJ	O
human	O	ADJ	B
PBLs	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
leukemia	B-Disease	NOUN	B
cells	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
increased	O	VERB	B
in	O	ADP	O
normal	O	ADJ	B
lymphocytes	O	NOUN	I
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
mitotic	O	ADJ	B
stimulation	O	NOUN	I
and	O	CCONJ	O
paralleled	O	VERB	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
DNA	O	NOUN	B
synthesis	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
leukemia	B-Disease	NOUN	B
cells	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
subtypes	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
leukemia	I-Disease	NOUN	I
,	O	PUNCT	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
increased	O	VERB	B
relative	O	ADJ	O
to	O	PART	O
resting	O	VERB	B
normal	O	ADJ	I
lymphocytes	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
mitotically	O	ADV	B
stimulated	O	VERB	O
lymphocytes	O	NOUN	B
with	O	ADP	O
cyclosporin	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
inhibits	O	VERB	B
proliferation	O	NOUN	B
,	O	PUNCT	O
blocked	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
;	O	PUNCT	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
leukemia	B-Disease	NOUN	B
cell	O	NOUN	B
line	O	NOUN	I
HL	O	NOUN	B
-	O	PUNCT	O
60	O	NUM	O
with	O	ADP	O
dimethylsulfoxide	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
induces	O	VERB	O
terminal	O	ADJ	B
differentiation	O	NOUN	B
,	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
diminished	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
p19	O	NOUN	B
/	O	PUNCT	O
nm23	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
therefore	O	ADV	O
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
nm23	O	NOUN	B
-	O	PUNCT	O
H1	O	NOUN	B
expression	O	NOUN	B
is	O	AUX	O
related	O	ADJ	O
to	O	PART	O
cell	O	NOUN	B
proliferative	O	ADJ	I
activity	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
intrachromosomal	O	ADJ	B
insertion	O	NOUN	I
causing	O	VERB	O
5q22	O	NOUN	B
deletion	O	NOUN	B
and	O	CCONJ	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
in	O	ADP	O
two	O	NUM	O
generations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
FAPC	B-Disease	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
epidermoid	B-Disease	ADJ	B
cysts	I-Disease	NOUN	I
,	O	PUNCT	O
osteomata	B-Disease	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
areas	O	NOUN	B
of	O	ADP	O
congenital	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
retinal	I-Disease	ADJ	B
pigment	I-Disease	NOUN	O
epithelium	I-Disease	NOUN	O
(	O	PUNCT	O
CHRPEs	B-Disease	ADJ	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
male	O	ADJ	B
patient	O	NOUN	B
and	O	CCONJ	O
his	O	PRON	O
maternal	O	ADJ	B
aunt	O	NOUN	I
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
whom	O	PRON	O
suffered	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
degree	O	NOUN	B
of	O	ADP	O
mental	B-Disease	ADJ	B
handicap	I-Disease	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
had	O	AUX	O
an	O	DET	O
interstitial	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
5	O	NUM	I
(	O	PUNCT	O
del	O	X	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q22q23	O	INTJ	B
.	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
other	O	ADJ	O
normal	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
had	O	AUX	O
the	O	DET	O
underlying	O	ADJ	O
direct	O	ADJ	O
insertion	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	O
5	O	NUM	O
(	O	PUNCT	O
dir	O	NOUN	B
ins	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q31	O	NOUN	B
.	O	PUNCT	O
3q22q23	O	NUM	O
3q22q23	O	NOUN	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
genetic	O	ADJ	I
and	O	CCONJ	O
fluorescent	O	ADJ	B
hybridisation	O	NOUN	I
studies	O	NOUN	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
loci	O	NOUN	B
D5S37	O	NOUN	B
and	O	CCONJ	O
D5S98	O	NOUN	B
are	O	AUX	O
outside	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
whereas	O	SCONJ	O
loci	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
probes	O	NOUN	B
EF5	O	NOUN	B
.	O	PUNCT	O


44	O	NUM	O
and	O	CCONJ	O
YN5	O	NOUN	B
.	O	PUNCT	O


48	O	NUM	O
are	O	AUX	O
lost	O	VERB	B
.	O	PUNCT	O


As	O	ADP	O
expected	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
molecular	O	ADJ	B
analyses	O	NOUN	I
indicate	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
at	O	ADP	O
the	O	DET	O
MCC	O	NOUN	B
and	O	CCONJ	O
APC	B-Disease	NOUN	B
loci	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
located	O	ADJ	O
within	O	ADP	O
band	O	NOUN	O
5q22	O	NOUN	B
.	O	PUNCT	O


Familial	O	ADJ	B
direct	O	ADJ	O
insertions	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
recurrent	O	ADJ	B
microdeletion	O	NOUN	B
syndromes	O	NOUN	I
.	O	PUNCT	O


Chromosome	O	NOUN	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
rod	O	NOUN	B
photoreceptor	O	NOUN	I
cGMP	O	NOUN	B
phosphodiesterase	O	NOUN	O
beta	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
mouse	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
:	O	PUNCT	O
tight	O	ADJ	B
linkage	O	NOUN	I
to	O	ADP	O
the	O	DET	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
region	O	NOUN	I
(	O	PUNCT	O
4p16	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	O
mouse	O	NOUN	O
(	O	PUNCT	O
gene	O	NOUN	B
symbol	O	NOUN	I
,	O	PUNCT	O
rd	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
certain	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
hereditary	B-Disease	ADJ	B
retinopathies	I-Disease	NOUN	I
.	O	PUNCT	O


Recent	O	ADJ	O
findings	O	NOUN	B
of	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
rd	O	NOUN	O
mouse	O	NOUN	B
PDE	O	NOUN	B
beta	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
Pdeb	O	NOUN	B
)	O	PUNCT	O
prompted	O	VERB	O
us	O	PRON	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
chromosome	O	NOUN	B
locations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
genes	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
utilized	O	VERB	O
backcross	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
to	O	PART	O
verify	O	VERB	O
and	O	CCONJ	O
define	O	VERB	O
more	O	ADV	O
precisely	O	ADV	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Pdeb	O	NOUN	B
locus	O	NOUN	I
6	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
cM	O	NOUN	O
distal	O	ADJ	B
of	O	ADP	O
Mgsa	O	NOUN	B
on	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
5	O	NUM	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
(	O	PUNCT	O
PDEB	O	NOUN	B
)	O	PUNCT	O
maps	O	VERB	B
to	O	PART	O
4p16	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
very	O	ADV	O
close	O	ADV	O
to	O	ADP	O
the	O	DET	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
region	O	NOUN	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
comparative	O	ADJ	B
map	O	NOUN	I
for	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mouse	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	O
will	O	AUX	O
reside	O	VERB	O
on	O	ADP	O
chromosome	O	NOUN	B
5	O	NUM	I
.	O	PUNCT	O


Linkage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
Pdeb	O	NOUN	B
locus	O	NOUN	I
with	O	ADP	O
other	O	ADJ	O
homologues	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
4p16	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
region	O	NOUN	O
is	O	AUX	O
maintained	O	VERB	B
but	O	CCONJ	O
gene	O	NOUN	B
order	O	NOUN	I
is	O	AUX	O
not	O	PART	O
,	O	PUNCT	O
suggesting	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
possible	O	ADJ	O
sites	O	NOUN	B
for	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
mouse	O	NOUN	B
HD	B-Disease	NOUN	B
gene	O	NOUN	B
.	O	PUNCT	O


Coincident	O	ADJ	B
Kaposi	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
and	O	CCONJ	O
T	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
lymphoma	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
24	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
male	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
eczema	B-Disease	NOUN	B
,	O	PUNCT	O
recurrent	O	ADJ	B
mild	O	ADJ	I
infections	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
presented	O	VERB	O
with	O	ADP	O
a	O	DET	O
mediastinal	O	ADJ	B
mass	O	NOUN	I
,	O	PUNCT	O
generalized	O	VERB	B
lymphadenopathy	B-Disease	NOUN	I
,	O	PUNCT	O
splenomegaly	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
severe	O	ADJ	B
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
of	O	ADP	O
immune	O	ADJ	B
function	O	NOUN	I
including	O	VERB	O
immunoglobulin	O	NOUN	B
levels	O	NOUN	I
and	O	CCONJ	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
subsets	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
his	O	PRON	O
T	O	NOUN	B
lymphocytes	O	NOUN	I
proliferated	O	VERB	B
normally	O	ADV	O
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
phytohemagglutinin	O	NOUN	B
,	O	PUNCT	O
concanavalin	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
neuraminidase	O	NOUN	B
/	O	PUNCT	O
galactose	O	NOUN	B
oxidase	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
their	O	PRON	O
proliferative	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
anti	O	ADJ	B
-	O	PUNCT	O
CD43	O	NOUN	B
antibody	O	NOUN	I
and	O	CCONJ	O
periodate	O	NOUN	B
were	O	AUX	O
diminished	O	VERB	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
clinical	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O


An	O	DET	O
initial	O	ADJ	B
inguinal	O	ADJ	B
lymph	O	NOUN	I
node	O	NOUN	I
biopsy	O	NOUN	I
surprisingly	O	ADV	O
revealed	O	VERB	O
Kaposi	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
following	O	VERB	O
splenectomy	O	NOUN	B
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
platelet	O	NOUN	B
count	O	NOUN	I
,	O	PUNCT	O
biopsy	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mediastinal	O	ADJ	B
mass	O	NOUN	I
revealed	O	VERB	B
T	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
large	I-Disease	ADJ	O
cell	I-Disease	NOUN	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Studies	O	NOUN	B
of	O	ADP	O
biopsied	O	ADJ	B
tissue	O	NOUN	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
Epstein	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Barr	I-Disease	PROPN	B
virus	I-Disease	NOUN	I
and	O	CCONJ	O
cytomegalovirus	B-Disease	NOUN	B
were	O	AUX	O
negative	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
were	O	AUX	O
studies	O	NOUN	B
of	O	ADP	O
blood	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
virus	I-Disease	NOUN	I
(	O	PUNCT	O
HIV	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
Kaposi	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
arising	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
congenital	B-Disease	ADJ	B
immunodeficiency	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
Kaposi	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
can	O	AUX	O
arise	O	VERB	O
in	O	ADP	O
the	O	DET	O
face	O	NOUN	B
of	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
immunosuppression	O	NOUN	B
that	O	PRON	O
follows	O	VERB	O
allograft	O	NOUN	B
transplantation	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
infected	O	VERB	B
with	O	ADP	O
HIV	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
longevity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
face	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
immunosuppression	O	NOUN	B
was	O	AUX	O
the	O	DET	O
major	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
Kaposi	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
human	O	ADJ	B
gastric	B-Disease	ADJ	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
cancer	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
world	O	NOUN	B
,	O	PUNCT	O
genetic	O	ADJ	B
changes	O	NOUN	I
during	O	ADP	O
its	O	PRON	O
carcinogenesis	O	NOUN	B
are	O	AUX	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


Since	O	SCONJ	O
some	O	DET	O
gastric	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
are	O	AUX	O
considered	O	VERB	O
to	O	PART	O
originate	O	VERB	O
from	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
metaplasia	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
which	O	DET	O
causes	O	VERB	O
adenomatous	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
in	I-Disease	ADP	O
the	I-Disease	DET	O
colon	I-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
carcinogenesis	O	NOUN	B
of	O	ADP	O
gastric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
this	O	DET	O
idea	O	NOUN	O
,	O	PUNCT	O
DNAs	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
gastric	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
were	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
RNase	O	NOUN	B
protection	O	NOUN	B
analysis	O	NOUN	I
coupled	O	VERB	O
with	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
products	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
screening	O	VERB	B
nearly	O	ADV	O
one	O	NUM	O
-	O	PUNCT	O
half	O	NOUN	B
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
44	O	NUM	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
somatic	O	ADJ	B
mutations	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
three	O	NUM	O
tumors	B-Disease	NOUN	B
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
frame	O	NOUN	O
shift	O	NOUN	B
which	O	DET	O
causes	O	VERB	O
truncation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
product	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
also	O	ADV	O
plays	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
during	O	ADP	O
the	O	DET	O
carcinogenesis	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
some	O	DET	O
gastric	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
71	O	NUM	O
-	O	PUNCT	O
kilodalton	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
product	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
nonmuscle	O	NOUN	B
tissues	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
known	O	ADJ	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
products	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
muscle	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
brain	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
dystrophin	O	NOUN	B
isoforms	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
427	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
proteins	O	NOUN	I
translated	O	VERB	B
from	O	ADP	O
14	O	NUM	O
-	O	PUNCT	O
kilobase	O	NOUN	B
(	O	PUNCT	O
kb	O	NOUN	O
)	O	PUNCT	O
mRNAs	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
we	O	PRON	O
described	O	VERB	O
a	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
mRNA	O	NOUN	B
that	O	PRON	O
also	O	ADV	O
is	O	AUX	O
transcribed	O	VERB	B
from	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Cloning	O	NOUN	B
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
transcription	O	NOUN	B
and	O	CCONJ	O
translation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
mRNA	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
70	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
protein	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
product	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
contains	O	VERB	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
cysteine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
domains	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
,	O	PUNCT	O
seven	O	NUM	O
additional	O	ADJ	O
amino	O	NOUN	B
acids	O	NOUN	I
at	O	ADP	O
the	O	DET	O
N	O	NOUN	B
terminus	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
some	O	DET	O
modifications	O	NOUN	B
formed	O	VERB	O
by	O	ADP	O
alternative	O	ADJ	B
splicing	O	NOUN	B
in	O	ADP	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
lacks	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
large	O	ADJ	O
domain	O	NOUN	B
of	O	ADP	O
spectrin	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
repeats	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
actin	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
the	O	DET	O
major	O	ADJ	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
product	O	NOUN	I
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
nonmuscle	O	NOUN	B
tissues	O	NOUN	I
but	O	CCONJ	O
is	O	AUX	O
undetectable	O	ADJ	B
in	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
extracts	O	NOUN	B
.	O	PUNCT	O


Correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
colorectal	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
we	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
which	O	DET	O
causes	O	VERB	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
this	O	DET	O
information	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	B
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
22	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
)	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
colorectal	B-Disease	NOUN	B
polyps	I-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
;	O	PUNCT	O
17	O	NUM	O
were	O	AUX	O
sparse	O	ADJ	O
types	O	NOUN	O
and	O	CCONJ	O
five	O	NUM	O
were	O	AUX	O
profuse	O	NOUN	B
types	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
considered	O	VERB	O
to	O	PART	O
cause	O	VERB	O
truncation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
product	O	NOUN	I
by	O	ADP	O
frame	O	NOUN	B
-	O	PUNCT	O
shift	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
deletion	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
seven	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
correlate	O	VERB	B
with	O	ADP	O
the	O	DET	O
two	O	NUM	O
clinical	O	ADJ	B
types	O	NOUN	I
;	O	PUNCT	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
five	O	NUM	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
profuse	O	NOUN	B
polyps	B-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
codon	O	NOUN	B
1250	O	NUM	I
and	O	CCONJ	O
codon	O	NOUN	B
1464	O	NUM	I
,	O	PUNCT	O
whereas	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
17	O	NUM	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
fewer	O	ADJ	O
polyps	B-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
result	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
colorectal	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
stability	O	NOUN	B
or	O	CCONJ	O
biological	O	ADJ	B
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
truncated	O	VERB	B
APC	B-Disease	NOUN	O
protein	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
and	O	CCONJ	O
rapid	O	ADJ	O
detection	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Moroccan	O	ADJ	B
Jewish	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Infantile	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
result	O	VERB	O
in	O	ADP	O
the	O	DET	O
complete	O	ADJ	B
absence	O	NOUN	B
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
hexosaminidase	O	NOUN	B
A	O	NOUN	O
activity	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
well	O	ADV	O
known	O	VERB	O
that	O	SCONJ	O
an	O	DET	O
elevated	O	ADJ	B
frequency	O	NOUN	B
of	O	ADP	O
TSD	B-Disease	NOUN	B
mutations	O	NOUN	O
exists	O	VERB	O
among	O	ADP	O
Ashkenazi	O	PROPN	B
Jews	O	PROPN	B
.	O	PUNCT	O


More	O	ADV	O
recently	O	ADV	O
it	O	PRON	O
has	O	AUX	O
become	O	VERB	O
apparent	O	ADJ	B
that	O	SCONJ	O
elevated	O	ADJ	B
carrier	O	NOUN	O
frequencies	O	NOUN	B
for	O	ADP	O
TSD	B-Disease	NOUN	B
also	O	ADV	O
occur	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
other	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
Moroccan	O	ADJ	B
Jews	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
Sephardic	O	ADJ	B
Jews	O	PROPN	I
.	O	PUNCT	O


Elsewhere	O	ADV	O
we	O	PRON	O
reported	O	VERB	O
an	O	DET	O
in	O	X	O
-	O	PUNCT	O
frame	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
adjacent	O	ADJ	B
phenylalanine	O	NOUN	B
codons	O	NOUN	O
at	O	ADP	O
position	O	NOUN	O
304	O	NUM	O
or	O	CCONJ	O
305	O	NUM	O
(	O	PUNCT	O
delta	O	NOUN	B
F304	O	NOUN	I
/	O	SYM	O
305	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
one	O	NUM	O
HEXA	O	NOUN	B
allele	O	NOUN	B
of	O	ADP	O
a	O	DET	O
Moroccan	O	ADJ	B
Jewish	O	ADJ	B
TSD	B-Disease	NOUN	B
patient	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
three	O	NUM	O
obligate	O	ADJ	B
carriers	O	NOUN	B
from	O	ADP	O
six	O	NUM	O
unrelated	O	ADJ	O
Moroccan	O	ADJ	B
Jewish	O	ADJ	B
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
now	O	ADV	O
identified	O	VERB	O
two	O	NUM	O
additional	O	ADJ	O
mutations	O	NOUN	B
within	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
account	O	VERB	O
for	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
TSD	B-Disease	NOUN	B
alleles	O	NOUN	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
carriers	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
C	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
G	O	NOUN	B
transversion	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
Tyr180	O	NOUN	B
by	O	ADP	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	DET	O
transition	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
an	O	DET	O
Arg170	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
Gln	O	NOUN	B
substitution	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
at	O	ADP	O
a	O	DET	O
CpG	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
infant	O	NOUN	B
with	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
described	O	VERB	O
elsewhere	O	ADV	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
obligate	O	ADJ	B
carriers	O	NOUN	B
from	O	ADP	O
seven	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
four	O	NUM	O
harbor	O	VERB	O
the	O	DET	O
delta	O	NOUN	B
F304	O	NOUN	I
/	O	SYM	O
305	O	NUM	B
mutation	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
the	O	DET	O
Arg170	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Gln	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
the	O	DET	O
Tyr180	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Stop	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
have	O	AUX	O
developed	O	VERB	O
rapid	O	ADJ	O
,	O	PUNCT	O
nonradioactive	O	ADJ	B
assays	O	NOUN	I
for	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
each	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
should	O	AUX	O
be	O	AUX	O
helpful	O	ADJ	O
for	O	ADP	O
carrier	O	NOUN	B
screening	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
by	O	ADP	O
natural	O	ADJ	B
and	O	CCONJ	O
amplification	O	NOUN	B
created	O	VERB	O
restriction	O	NOUN	B
sites	O	NOUN	I
:	O	PUNCT	O
five	O	NUM	O
mutations	O	NOUN	B
account	O	VERB	O
for	O	ADP	O
most	O	ADJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
cases	O	NOUN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
a	O	DET	O
rapid	O	ADJ	B
and	O	CCONJ	O
simple	O	ADJ	O
method	O	NOUN	O
to	O	PART	O
diagnose	O	VERB	B
the	O	DET	O
molecular	O	ADJ	B
defects	O	NOUN	I
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
Chinese	O	PROPN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
method	O	NOUN	B
involves	O	VERB	O
the	O	DET	O
selective	O	ADJ	B
amplification	O	NOUN	I
of	O	ADP	O
a	O	DET	O
DNA	O	NOUN	B
fragment	O	NOUN	I
from	O	ADP	O
human	O	ADJ	B
G6PD	O	NOUN	B
gene	O	NOUN	I
with	O	ADP	O
specific	O	ADJ	O
oligonucleotide	O	NOUN	B
primers	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
digestion	O	NOUN	B
with	O	ADP	O
restriction	O	NOUN	B
enzymes	O	NOUN	I
that	O	PRON	O
recognize	O	VERB	O
artificially	O	ADV	B
created	O	VERB	O
or	O	CCONJ	O
naturally	O	ADV	O
occurring	O	VERB	O
restriction	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


Ninety	O	NUM	B
-	O	PUNCT	O
four	O	NUM	B
Chinese	O	ADJ	B
males	O	NOUN	B
with	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
were	O	AUX	O
studied	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
50	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
47	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
G	O	NOUN	B
to	O	PART	O
T	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nucleotide	O	NOUN	O
(	O	PUNCT	O
nt	O	NOUN	O
)	O	PUNCT	O
1376	O	NUM	O
,	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
1388	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
A	O	DET	O
to	O	PART	O
G	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nt	O	NOUN	O
493	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
A	O	DET	O
to	O	PART	O
G	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nt	O	NOUN	O
95	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
C	O	NOUN	O
to	O	PART	O
T	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nt	O	NOUN	O
1024	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
G	O	NOUN	B
to	O	PART	O
T	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nt	O	NOUN	O
392	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
94	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
487	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
former	O	ADJ	O
five	O	NUM	O
mutations	O	NOUN	B
account	O	VERB	O
for	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
cases	O	NOUN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


Aside	O	ADV	O
from	O	ADP	O
showing	O	VERB	O
that	O	SCONJ	O
G	O	NOUN	B
to	O	PART	O
T	O	NOUN	O
change	O	NOUN	O
at	O	ADP	O
nt	O	NOUN	O
1376	O	NUM	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutation	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
research	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
nt	O	NOUN	O
493	O	NUM	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	B
mutation	O	NOUN	B
among	O	ADP	O
Chinese	O	PROPN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	O
G6PD	O	NOUN	B
activity	O	NOUN	B
among	O	ADP	O
different	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
without	O	ADP	O
discovering	O	VERB	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


Eight	O	NUM	O
novel	O	ADJ	O
inactivating	O	ADJ	B
germ	O	NOUN	B
line	O	NOUN	I
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
identified	O	VERB	B
by	O	ADP	O
denaturing	O	VERB	B
gradient	O	NOUN	B
gel	O	NOUN	B
electrophoresis	O	NOUN	I
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
dominantly	O	ADV	O
inherited	O	VERB	B
condition	O	NOUN	B
predisposing	O	VERB	B
to	O	PART	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
responsible	O	ADJ	O
gene	O	NOUN	B
(	O	PUNCT	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
or	O	CCONJ	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
facilitated	O	VERB	O
the	O	DET	O
search	O	NOUN	B
for	O	ADP	O
germ	O	NOUN	B
line	O	NOUN	I
mutations	O	NOUN	I
in	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
authors	O	NOUN	B
have	O	AUX	O
used	O	VERB	O
the	O	DET	O
RNase	O	NOUN	B
protection	O	NOUN	B
assay	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphisms	O	NOUN	O
procedure	O	NOUN	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
mutations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
used	O	VERB	O
denaturing	O	VERB	B
gradient	O	NOUN	B
gel	O	NOUN	O
electrophoresis	O	NOUN	O
(	O	PUNCT	O
DGGE	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DGGE	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
APC	B-Disease	NOUN	B
exons	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
13	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
part	O	NOUN	O
of	O	ADP	O
15	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
33	O	NUM	O
unrelated	O	ADJ	O
Dutch	O	ADJ	B
FAP	B-Disease	NOUN	I
patients	O	NOUN	B
has	O	AUX	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
novel	O	ADJ	O
germ	O	NOUN	B
line	O	NOUN	I
mutations	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
stop	O	NOUN	B
codons	O	NOUN	I
or	O	CCONJ	O
frameshifts	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
indicate	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
an	O	DET	O
extremely	O	ADV	O
heterogeneous	O	ADJ	B
spectrum	O	NOUN	O
of	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
;	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
all	O	DET	O
the	O	DET	O
mutations	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
are	O	AUX	O
chain	O	NOUN	B
terminating	O	VERB	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
DGGE	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
rapid	O	ADJ	B
and	O	CCONJ	O
sensitive	O	ADJ	B
technique	O	NOUN	B
for	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
unusually	O	ADV	O
large	O	ADJ	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
extension	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DGGE	O	NOUN	B
analysis	O	NOUN	B
to	O	PART	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
in	O	ADP	O
a	O	DET	O
sufficient	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
clinically	O	ADV	B
well	O	ADV	O
-	O	PUNCT	O
characterized	O	VERB	B
,	O	PUNCT	O
unrelated	O	ADJ	O
patients	O	NOUN	B
will	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
establishment	O	NOUN	O
of	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
extremely	O	ADV	O
heterogeneous	O	ADJ	B
spectrum	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
spread	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
length	O	NOUN	B
of	O	ADP	O
the	O	DET	O
large	O	ADJ	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
among	O	ADP	O
the	O	DET	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
approach	O	NOUN	O
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
useful	O	ADJ	O
as	O	ADP	O
a	O	DET	O
rapid	O	ADJ	O
presymptomatic	O	ADJ	B
diagnostic	O	ADJ	B
procedure	O	NOUN	I
in	O	ADP	O
a	O	DET	O
routine	O	ADJ	O
laboratory	O	NOUN	B
.	O	PUNCT	O


Nevertheless	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
above	O	ADJ	O
DGGE	O	NOUN	B
approach	O	NOUN	B
has	O	AUX	O
incidentally	O	ADV	B
led	O	VERB	O
to	O	PART	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
common	O	ADJ	O
polymorphism	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
13	O	NUM	I
.	O	PUNCT	O


Such	O	ADJ	O
intragenic	O	ADJ	B
polymorphisms	O	NOUN	B
offer	O	VERB	O
a	O	DET	O
practical	O	ADJ	B
approach	O	NOUN	I
to	O	ADP	O
a	O	DET	O
more	O	ADV	O
rapid	O	ADJ	O
procedure	O	NOUN	B
for	O	ADP	O
presymptomatic	O	ADJ	B
diagnosis	O	NOUN	B
of	O	ADP	O
FAP	B-Disease	NOUN	B
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
informative	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Yeast	O	NOUN	B
artificial	O	ADJ	B
chromosomes	O	NOUN	I
for	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
familial	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
APC	I-Disease	NOUN	B
gene	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
yeast	O	NOUN	B
artificial	O	ADJ	B
chromosomes	O	NOUN	I
(	O	PUNCT	O
YACs	O	NOUN	B
)	O	PUNCT	O
spanning	O	VERB	O
a	O	DET	O
total	O	ADJ	O
distance	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
megabase	O	NOUN	B
pairs	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
around	O	ADP	O
the	O	DET	O
MCC	O	NOUN	B
(	O	PUNCT	O
for	O	ADP	O
mutated	O	VERB	B
in	O	ADP	O
colorectal	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
APC	B-Disease	NOUN	B
(	O	PUNCT	O
for	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
)	O	PUNCT	O
genes	O	NOUN	O
at	O	ADP	O
5q21	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
isolated	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
.	O	PUNCT	O


Starting	O	VERB	O
from	O	ADP	O
the	O	DET	O
MCC	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
strategy	O	NOUN	O
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
identify	O	VERB	O
constitutional	O	ADJ	B
submicroscopic	O	ADJ	O
deletions	O	NOUN	O
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
patients	O	NOUN	B
that	O	PRON	O
might	O	AUX	O
considerably	O	ADV	O
narrow	O	VERB	B
down	O	ADP	I
the	O	DET	O
position	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
this	O	DET	O
end	O	NOUN	O
,	O	PUNCT	O
YACs	O	NOUN	B
identified	O	VERB	B
by	O	ADP	O
the	O	DET	O
MCC	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
screened	O	VERB	B
across	O	ADP	O
a	O	DET	O
chromosome	O	NOUN	B
5	O	NUM	I
-	O	PUNCT	O
specific	O	ADJ	B
cosmid	O	NOUN	B
library	O	NOUN	O
to	O	PART	O
provide	O	VERB	O
a	O	DET	O
source	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
probes	O	NOUN	I
for	O	ADP	O
genomic	O	ADJ	B
scanning	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cosmids	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
these	O	DET	O
experiments	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
screen	O	VERB	O
a	O	DET	O
panel	O	NOUN	B
of	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
containing	O	VERB	O
chromosome	O	NOUN	O
5	O	NUM	O
segregated	O	VERB	B
from	O	ADP	O
patients	O	NOUN	B
suspected	O	VERB	B
to	O	PART	O
carry	O	VERB	O
putative	O	ADJ	O
interstitial	O	ADJ	O
deletions	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
screening	O	NOUN	B
approach	O	NOUN	I
led	O	VERB	O
to	O	PART	O
the	O	DET	O
confirmation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
small	O	ADJ	O
heterozygous	O	ADJ	B
deletion	O	NOUN	B
in	O	ADP	O
a	O	DET	O
polyposis	B-Disease	NOUN	B
patient	O	NOUN	B
that	O	PRON	O
overlaps	O	VERB	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
isolated	O	VERB	B
YACs	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
YAC	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
contain	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	O
portion	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
flanking	O	NOUN	I
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
should	O	AUX	O
therefore	O	ADV	O
prove	O	VERB	O
a	O	DET	O
valuable	O	ADJ	O
resource	O	NOUN	B
for	O	ADP	O
functional	O	ADJ	B
studies	O	NOUN	I
by	O	ADP	O
transfer	O	NOUN	O
to	O	PART	O
colorectal	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
-	O	PUNCT	O
derived	O	VERB	B
cell	O	NOUN	B
lines	O	NOUN	I
.	O	PUNCT	O


Inherited	O	VERB	B
WT1	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
Wilms	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
,	O	PUNCT	O
genital	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
nephropathy	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
carry	O	VERB	O
de	O	X	O
novo	O	X	O
constitutional	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
WT1	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
gene	O	NOUN	I
at	O	ADP	O
chromosome	O	NOUN	B
11p13	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
three	O	NUM	O
new	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
carrying	O	VERB	O
a	O	DET	O
previously	O	ADV	O
described	O	VERB	O
WT1	O	NOUN	B
exon	O	NOUN	B
9	O	NUM	I
mutation	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
with	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
WT1	O	NOUN	B
exon	O	NOUN	O
8	O	NUM	O
mutation	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
unlike	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
previous	O	ADJ	O
reports	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
our	O	PRON	O
three	O	NUM	O
patients	O	NOUN	B
inherited	O	VERB	B
the	O	DET	O
affected	O	VERB	B
allele	O	NOUN	B
from	O	ADP	O
his	O	PRON	O
phenotypically	O	ADV	B
unaffected	O	ADJ	O
father	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
WT1	O	NOUN	B
exon	O	NOUN	I
9	O	NUM	I
mutation	O	NOUN	B
affecting	O	VERB	B
394Arg	O	ADJ	O
demonstrated	O	VERB	O
in	O	ADP	O
over	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
half	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
may	O	AUX	O
exhibit	O	VERB	O
incomplete	O	ADJ	B
penetrance	O	NOUN	B
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
familial	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
are	O	AUX	O
recommended	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Submicroscopic	O	ADJ	B
deletions	O	NOUN	B
at	O	ADP	O
the	O	DET	O
WAGR	B-Disease	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
revealed	O	VERB	O
by	O	ADP	O
nonradioactive	O	ADJ	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


Fluorescence	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
biotin	O	NOUN	B
-	O	PUNCT	O
labeled	O	VERB	B
probes	O	NOUN	B
mapping	O	VERB	O
to	O	PART	O
11p13	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WAGR	B-Disease	NOUN	B
(	O	PUNCT	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
,	O	PUNCT	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
genitourinary	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
)	O	PUNCT	O
locus	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
detected	O	VERB	B
a	O	DET	O
submicroscopic	O	ADJ	B
11p13	O	NOUN	I
deletion	O	NOUN	I
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
inherited	O	VERB	B
aniridia	B-Disease	NOUN	B
who	O	PRON	O
subsequently	O	ADV	O
presented	O	VERB	O
with	O	ADP	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
horseshoe	O	ADJ	B
kidney	O	NOUN	I
,	O	PUNCT	O
only	O	ADV	O
revealed	O	VERB	B
at	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mother	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
has	O	AUX	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
also	O	ADV	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
a	O	DET	O
deletion	O	NOUN	B
including	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
candidate	O	NOUN	O
gene	O	NOUN	O
(	O	PUNCT	O
AN2	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
predisposition	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
WT1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
therefore	O	ADV	O
a	O	DET	O
rare	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
an	O	DET	O
inherited	O	VERB	B
WAGR	B-Disease	NOUN	B
deletion	O	NOUN	I
.	O	PUNCT	O


Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
has	O	AUX	O
so	O	ADV	O
far	O	ADV	O
only	O	ADV	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
sporadic	O	ADJ	B
de	O	X	B
novo	O	X	I
aniridia	B-Disease	NOUN	B
cases	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
cosmid	O	NOUN	B
probe	O	NOUN	I
for	O	ADP	O
a	O	DET	O
candidate	O	NOUN	O
aniridia	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
homologous	O	ADJ	B
to	O	PART	O
the	O	DET	O
mouse	O	NOUN	B
Pax	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
gene	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
cell	O	NOUN	B
lines	O	NOUN	I
from	O	ADP	O
aniridia	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
previously	O	ADV	O
characterized	O	VERB	B
deletions	O	NOUN	B
at	O	ADP	O
11p13	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
another	O	DET	O
cosmid	O	NOUN	B
marker	O	NOUN	I
mapping	O	NOUN	O
between	O	ADP	O
two	O	NUM	O
aniridia	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
translocation	O	NOUN	B
breakpoints	O	NOUN	O
(	O	PUNCT	O
and	O	CCONJ	O
hence	O	ADV	O
a	O	DET	O
second	O	ADJ	O
candidate	O	NOUN	O
marker	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
present	O	ADJ	O
on	O	ADP	O
both	O	DET	O
chromosomes	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
Pax	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
homologue	O	NOUN	B
as	O	ADP	O
a	O	DET	O
strong	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
the	O	DET	O
AN2	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


FISH	O	NOUN	B
with	O	ADP	O
cosmid	O	NOUN	B
probes	O	NOUN	I
has	O	AUX	O
proved	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
fast	O	ADJ	B
and	O	CCONJ	O
reliable	O	ADJ	O
technique	O	NOUN	B
for	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
deletions	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
limited	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
material	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
strong	O	ADJ	O
potential	O	NOUN	B
for	O	ADP	O
clinical	O	ADJ	B
applications	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
for	O	ADP	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
major	O	ADJ	B
histocompatibility	O	NOUN	I
complex	O	NOUN	I
MHC	O	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Family	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
a	O	DET	O
further	O	ADJ	O
case	O	NOUN	B
.	O	PUNCT	O


Close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	PROPN	B
and	O	CCONJ	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
was	O	AUX	O
first	O	ADV	O
reported	O	VERB	O
by	O	ADP	O
FU	O	PROPN	B
and	O	CCONJ	O
co	O	ADJ	B
-	O	PUNCT	O
workers	O	NOUN	B
in	O	ADP	O
1974	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
here	O	ADV	O
a	O	DET	O
pedigree	O	NOUN	B
of	O	ADP	O
a	O	DET	O
31	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
C2	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
individual	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
Hodgkins	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
markers	O	NOUN	B
were	O	AUX	O
tested	O	VERB	B
C2	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
factor	O	NOUN	B
B	O	NOUN	I
polymorphism	O	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
enzyme	O	NOUN	B
typing	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	PROPN	B
and	O	CCONJ	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
both	O	DET	O
parents	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
Bf	O	NOUN	B
(	O	PUNCT	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	PROPN	O
linked	O	VERB	O
,	O	PUNCT	O
electrophoretic	O	ADJ	B
variation	O	NOUN	I
of	O	ADP	O
B	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
HL	O	PROPN	B
-	O	PUNCT	O
A	O	NOUN	B
haplotypes	O	NOUN	B
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
are	O	AUX	O
different	O	ADJ	O
2	O	NUM	O
,	O	PUNCT	O
W18	O	NOUN	B
and	O	CCONJ	O
W24	O	NOUN	B
,	O	PUNCT	O
W18	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
share	O	VERB	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
SD2	O	NOUN	B
antigen	O	NOUN	I
W18	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
LD	O	NOUN	B
type	O	NOUN	O
7a	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Screening	O	VERB	B
for	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
patients	O	NOUN	B
:	O	PUNCT	O
61	O	NUM	O
new	O	ADJ	O
patients	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
summary	O	NOUN	O
of	O	ADP	O
150	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
screening	O	NOUN	B
for	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
in	O	ADP	O
61	O	NUM	O
new	O	ADJ	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
summary	O	NOUN	O
of	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
150	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
ribonuclease	O	NOUN	B
protection	O	NOUN	O
assay	O	NOUN	O
coupled	O	VERB	O
with	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
disclosed	O	VERB	O
mutations	O	NOUN	B
that	O	PRON	O
were	O	AUX	O
considered	O	VERB	O
to	O	PART	O
cause	O	VERB	O
significant	O	ADJ	O
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
product	O	NOUN	B
in	O	ADP	O
97	O	NUM	O
of	O	ADP	O
150	O	NUM	O
unrelated	O	ADJ	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
revealed	O	VERB	O
the	O	DET	O
following	O	VERB	O
characteristics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
the	O	DET	O
great	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
truncate	O	VERB	B
the	O	DET	O
APC	B-Disease	NOUN	B
product	O	NOUN	B
;	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
almost	O	ADV	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
located	O	ADJ	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
;	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
no	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
locations	O	NOUN	B
of	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
extracolonic	O	ADJ	B
manifestations	O	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
;	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
base	O	NOUN	B
substitutions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
from	O	ADP	O
cytosine	O	NOUN	B
to	O	PART	O
other	O	ADJ	O
nucleotides	O	NOUN	B
,	O	PUNCT	O
nearly	O	ADV	O
one	O	NUM	O
-	O	PUNCT	O
third	O	NOUN	O
of	O	ADP	O
which	O	DET	O
occurred	O	VERB	O
at	O	ADP	O
the	O	DET	O
GpG	O	NOUN	B
site	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
information	O	NOUN	B
helpful	O	ADJ	O
to	O	PART	O
an	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
will	O	AUX	O
also	O	ADV	O
contribute	O	VERB	O
to	O	PART	O
presymptomatic	O	ADJ	B
diagnosis	O	NOUN	O
of	O	ADP	O
members	O	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Somatic	O	ADJ	B
mutations	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
colorectal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
:	O	PUNCT	O
mutation	O	NOUN	B
cluster	O	NOUN	I
region	O	NOUN	I
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
somatic	O	ADJ	B
mutations	O	NOUN	O
of	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
in	O	ADP	O
63	O	NUM	O
colorectal	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
(	O	PUNCT	O
16	O	NUM	O
adenomas	B-Disease	NOUN	B
and	O	CCONJ	O
47	O	NUM	O
carcinomas	B-Disease	NOUN	B
)	O	PUNCT	O
developed	O	VERB	O
in	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
FAP	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	I
heterozygosity	O	NOUN	I
(	O	PUNCT	O
LOH	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
30	O	NUM	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
43	O	NUM	O
other	O	ADJ	O
somatic	O	ADJ	B
mutations	O	NOUN	O
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
point	O	NOUN	B
mutations	O	NOUN	I
;	O	PUNCT	O
16	O	NUM	O
nonsense	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
occurred	O	VERB	O
in	O	ADP	O
introns	O	NOUN	B
at	O	ADP	O
the	O	DET	O
splicing	O	NOUN	B
site	O	NOUN	I
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	B
tumors	B-Disease	NOUN	B
had	O	AUX	O
frameshift	O	NOUN	B
mutations	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
deletion	O	NOUN	B
or	O	CCONJ	O
insertion	O	NOUN	B
;	O	PUNCT	O
nineteen	O	NUM	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
deletions	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
to	O	PART	O
31	O	NUM	O
bp	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
were	O	AUX	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
insertion	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
tumor	B-Disease	NOUN	B
had	O	AUX	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
in	O	ADP	O
an	O	DET	O
intron	O	NOUN	B
near	O	ADP	B
the	O	DET	O
splicing	O	NOUN	B
site	O	NOUN	I
.	O	PUNCT	O


Hence	O	ADV	O
,	O	PUNCT	O
41	O	NUM	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
43	O	NUM	O
mutations	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
truncation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Over	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
somatic	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
clustered	O	VERB	B
within	O	ADP	O
a	O	DET	O
small	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
15	O	NUM	O
,	O	PUNCT	O
designated	O	VERB	O
as	O	ADP	O
MCR	O	NOUN	B
(	O	PUNCT	O
mutation	O	NOUN	B
cluster	O	NOUN	I
region	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
accounted	O	VERB	O
for	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
.	O	PUNCT	O


Combining	O	VERB	O
these	O	DET	O
data	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
LOH	O	NOUN	B
,	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
tumors	B-Disease	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
adenomas	B-Disease	NOUN	B
and	O	CCONJ	O
39	O	NUM	O
carcinomas	B-Disease	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
more	O	ADJ	O
than	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
9	O	NUM	O
adenomas	B-Disease	NOUN	B
and	O	CCONJ	O
23	O	NUM	O
carcinomas	B-Disease	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
two	O	NUM	O
mutations	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
strongly	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
somatic	O	ADJ	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
development	O	NOUN	B
of	O	ADP	O
a	O	DET	O
great	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
colorectal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Constitutional	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
characterised	O	VERB	O
by	O	ADP	O
a	O	DET	O
typical	O	ADJ	O
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
genital	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
and	O	CCONJ	O
also	O	ADV	O
predisposes	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
eventually	O	ADV	O
go	O	VERB	O
into	O	ADP	O
end	O	NOUN	B
stage	O	NOUN	I
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
candidate	O	NOUN	O
Wilms	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
WT1	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
11p13	O	NOUN	B
chromosome	O	NOUN	I
region	O	NOUN	I
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
cloned	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analysed	O	VERB	B
the	O	DET	O
DNA	O	NOUN	B
sequence	O	NOUN	I
in	O	ADP	O
constitutional	O	ADJ	B
cells	O	NOUN	I
from	O	ADP	O
eight	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
shown	O	VERB	O
heterozygous	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
,	O	PUNCT	O
all	O	DET	O
resulting	O	VERB	O
in	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
were	O	AUX	O
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
1180	O	NUM	O
resulting	O	VERB	O
in	O	ADP	O
an	O	DET	O
arg	O	NOUN	B
>	O	X	O
trp	O	NOUN	B
amino	O	NOUN	I
acid	O	NOUN	I
change	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
was	O	AUX	O
at	O	ADP	O
position	O	NOUN	O
1186	O	NUM	O
converting	O	VERB	O
an	O	DET	O
asp	O	NOUN	B
>	O	X	O
asn	O	NOUN	B
in	O	ADP	O
the	O	DET	O
predicted	O	VERB	B
resultant	O	ADJ	O
protein	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
had	O	AUX	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
,	O	PUNCT	O
converting	O	VERB	O
an	O	DET	O
arg	O	NOUN	B
>	O	PUNCT	O
his	O	PRON	O
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	B
base	O	NOUN	I
pair	O	NOUN	I
insertion	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
821	O	NUM	O
in	O	ADP	O
exon	O	NOUN	B
6	O	NUM	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
in	O	ADP	O
the	O	DET	O
last	O	ADJ	O
patient	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
find	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
despite	O	SCONJ	O
complete	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genomic	O	ADJ	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
last	O	ADJ	O
patient	O	NOUN	B
carried	O	VERB	O
a	O	DET	O
constitutional	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
11p13	O	NOUN	B
region	O	NOUN	I
and	O	CCONJ	O
no	O	DET	O
additional	O	ADJ	O
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
and	O	CCONJ	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	O
further	O	ADV	O
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
genito	O	NOUN	B
-	O	PUNCT	O
urinary	O	ADJ	B
system	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
disequilibrium	O	NOUN	I
mapping	O	NOUN	I
in	O	ADP	O
isolated	O	VERB	B
founder	O	NOUN	O
populations	O	NOUN	B
:	O	PUNCT	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
in	O	ADP	O
Finland	O	PROPN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
disequilibrium	O	NOUN	I
mapping	O	NOUN	I
in	O	ADP	O
isolated	O	VERB	B
populations	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
powerful	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
fine	O	ADJ	O
structure	O	NOUN	O
localization	O	NOUN	O
of	O	ADP	O
disease	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
Luria	O	PROPN	B
and	O	CCONJ	O
Delbrucks	O	PROPN	B
classical	O	ADJ	O
methods	O	NOUN	O
for	O	ADP	O
analysing	O	VERB	O
bacterial	O	ADJ	B
cultures	O	NOUN	I
are	O	AUX	O
adapted	O	VERB	O
to	O	PART	O
the	O	DET	O
study	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
isolated	O	VERB	O
founder	O	NOUN	O
populations	O	NOUN	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
estimate	O	VERB	B
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
the	O	DET	O
recombination	O	NOUN	B
fraction	O	NOUN	B
between	O	ADP	O
a	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
marker	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
the	O	DET	O
expected	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
allelic	O	ADJ	B
homogeneity	O	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
iii	O	X	O
)	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
marker	O	NOUN	B
loci	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
these	O	DET	O
methods	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
striking	O	ADJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
for	O	ADP	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
(	O	PUNCT	O
DTD	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Finland	O	PROPN	B
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
DTD	B-Disease	NOUN	B
gene	O	NOUN	I
should	O	AUX	O
lie	O	VERB	O
within	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


06	O	NUM	O
centimorgans	O	NOUN	B
(	O	PUNCT	O
or	O	CCONJ	O
about	O	ADV	O
60	O	NUM	O
kilobases	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
CSF1R	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Predictions	O	NOUN	B
about	O	ADP	O
allelic	O	ADJ	B
homogeneity	O	NOUN	B
in	O	ADP	O
Finland	O	PROPN	B
and	O	CCONJ	O
mutation	O	NOUN	B
rates	O	NOUN	B
in	O	ADP	O
simple	O	ADJ	O
sequence	O	NOUN	O
repeats	O	NOUN	O
are	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
independent	O	ADJ	O
observations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
refinement	O	NOUN	O
of	O	ADP	O
the	O	DET	O
localization	O	NOUN	B
on	O	ADP	O
Xp	O	NOUN	B
and	O	CCONJ	O
identification	O	NOUN	B
of	O	ADP	O
another	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
marker	O	NOUN	B
locus	O	NOUN	O
,	O	PUNCT	O
OATL1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
proximal	O	ADJ	B
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
between	O	ADP	O
the	O	DET	O
DXS14	O	NOUN	B
and	O	CCONJ	O
DXS7	O	NOUN	B
loci	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
further	O	ADJ	O
segregation	O	NOUN	B
analysis	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
a	O	DET	O
newly	O	ADV	O
identified	O	VERB	B
WAS	B-Disease	AUX	B
family	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
an	O	DET	O
additional	O	ADJ	O
marker	O	NOUN	B
probe	O	NOUN	I
,	O	PUNCT	O
HOATL1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
the	O	DET	O
WAS	B-Disease	PROPN	B
and	O	CCONJ	O
OATL1	O	NOUN	B
loci	O	NOUN	O
(	O	PUNCT	O
Z	O	NOUN	B
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
08	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
localize	O	VERB	B
the	O	DET	O
TIMP	O	NOUN	B
,	O	PUNCT	O
OATL1	O	NOUN	B
,	O	PUNCT	O
DXS255	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
WAS	B-Disease	AUX	B
loci	O	NOUN	O
distal	O	ADJ	O
to	O	PART	O
DXS146	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
OATL1	O	NOUN	B
and	O	CCONJ	O
WAS	B-Disease	AUX	B
loci	O	NOUN	B
proximal	O	ADJ	B
to	O	PART	O
TIMP	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
linkage	O	NOUN	B
data	O	NOUN	B
narrow	O	VERB	O
the	O	DET	O
boundaries	O	NOUN	B
within	O	ADP	O
which	O	DET	O
the	O	DET	O
WAS	B-Disease	NOUN	B
locus	O	NOUN	B
maps	O	VERB	O
to	O	PART	O
the	O	DET	O
chromosomal	O	ADJ	B
region	O	NOUN	I
bracketed	O	VERB	O
by	O	ADP	O
TIMP	O	NOUN	B
and	O	CCONJ	O
DXS146	O	NOUN	B
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
loci	O	NOUN	B
order	O	NOUN	O
Xpter	O	NOUN	B
-	O	PUNCT	O
DXS7	O	PROPN	B
-	O	PUNCT	O
TIMP	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
OATL1	O	NOUN	B
,	O	PUNCT	O
WAS	O	PROPN	B
,	O	PUNCT	O
DXS255	O	ADJ	B
)	O	PUNCT	O
-	O	PUNCT	O
DXS146	O	NOUN	B
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
an	O	DET	O
unstable	O	ADJ	O
fragment	O	NOUN	B
of	O	ADP	I
DNA	O	NOUN	B
specific	O	ADJ	O
to	O	PART	O
individuals	O	NOUN	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
adult	O	ADJ	B
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
-	O	SYM	O
14	O	NUM	O
per	O	ADP	O
100	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
individuals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
progressive	O	ADJ	B
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
and	O	CCONJ	O
sustained	B-Disease	ADJ	B
muscle	I-Disease	NOUN	B
contraction	I-Disease	NOUN	I
,	O	PUNCT	O
often	O	ADV	O
with	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
accompanying	O	VERB	O
symptoms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
show	O	VERB	O
extreme	O	ADJ	O
variation	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
within	O	ADP	O
and	O	CCONJ	O
between	O	ADP	O
families	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
its	O	PRON	O
clinical	O	ADJ	B
variability	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
dominant	O	ADJ	B
condition	O	NOUN	B
segregates	O	VERB	B
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
locus	O	NOUN	O
at	O	ADP	O
chromosome	O	NOUN	B
19q13	O	NOUN	I
.	O	PUNCT	O


3	O	NUM	O
in	O	ADP	O
every	O	DET	O
population	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
flanked	O	VERB	B
by	O	ADP	O
the	O	DET	O
tightly	O	ADV	O
linked	O	VERB	O
genetic	O	ADJ	B
markers	O	NOUN	I
ERCC1	O	NOUN	B
proximally	O	ADV	O
and	O	CCONJ	O
D19S51	O	NOUN	B
distally	O	ADV	I
;	O	PUNCT	O
these	O	DET	O
define	O	VERB	O
the	O	DET	O
DM	B-Disease	NOUN	B
critical	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
an	O	DET	O
expressed	O	VERB	B
sequence	O	NOUN	B
from	O	ADP	O
this	O	DET	O
region	O	NOUN	B
which	O	DET	O
detects	O	VERB	O
a	O	DET	O
DNA	O	NOUN	B
fragment	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
larger	O	ADJ	O
in	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
normal	O	ADJ	B
siblings	O	NOUN	I
or	O	CCONJ	O
unaffected	O	ADJ	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
size	O	NOUN	B
of	O	ADP	O
this	O	DET	O
fragment	O	NOUN	B
varies	O	VERB	O
between	O	ADP	O
affected	O	VERB	B
siblings	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
increases	O	VERB	B
in	O	ADP	O
size	O	NOUN	B
through	O	ADP	O
generations	O	NOUN	B
in	O	ADP	O
parallel	O	NOUN	O
with	O	ADP	O
increasing	O	VERB	B
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
unstable	O	ADJ	O
DNA	O	NOUN	B
sequence	O	NOUN	I
is	O	AUX	O
the	O	DET	O
molecular	O	ADJ	B
feature	O	NOUN	I
that	O	PRON	O
underlies	O	VERB	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


Common	O	ADJ	O
sequence	O	NOUN	O
motifs	O	NOUN	B
at	O	ADP	O
the	O	DET	O
rearrangement	O	NOUN	B
sites	O	NOUN	I
of	O	ADP	O
a	O	DET	O
constitutional	O	ADJ	B
X	O	NOUN	I
/	O	PUNCT	O
autosome	O	NOUN	B
translocation	O	NOUN	B
and	O	CCONJ	O
associated	O	VERB	O
deletion	O	NOUN	B
.	O	PUNCT	O


Reciprocal	O	ADJ	B
chromosome	O	NOUN	I
translocations	O	NOUN	I
are	O	AUX	O
common	O	ADJ	O
de	O	X	O
novo	O	X	O
rearrangements	O	NOUN	B
that	O	PRON	O
occur	O	VERB	O
randomly	O	ADV	O
throughout	O	ADP	O
the	O	DET	O
human	O	ADJ	B
genome	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
learn	O	VERB	O
about	O	ADP	O
causative	O	ADJ	B
mechanisms	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
the	O	DET	O
breakpoints	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cytologically	O	ADV	B
balanced	O	ADJ	B
constitutional	O	ADJ	B
reciprocal	O	ADJ	O
translocation	O	NOUN	B
,	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
X	O	NOUN	O
;	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
p21	O	NOUN	B
.	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
q31	O	NOUN	B
.	O	PUNCT	O
22	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
present	O	ADJ	O
in	O	ADP	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Physical	O	ADJ	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
derivative	O	ADJ	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
their	O	PRON	O
separation	O	NOUN	B
in	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
,	O	PUNCT	O
reveals	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
translocation	O	NOUN	B
disrupts	O	VERB	B
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
Xp21	O	NOUN	B
within	O	ADP	O
the	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
intron	O	NOUN	B
16	O	NUM	O
.	O	PUNCT	O


Restriction	O	NOUN	B
mapping	O	NOUN	I
and	O	CCONJ	O
sequencing	O	NOUN	B
of	O	ADP	O
clones	O	NOUN	B
that	O	PRON	O
span	O	VERB	O
both	O	CCONJ	O
translocation	O	NOUN	B
breakpoints	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
normal	O	ADJ	B
regions	O	NOUN	I
indicate	O	VERB	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
5	O	NUM	O
kb	O	NOUN	O
in	O	ADP	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
derivative	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
4	O	NUM	O
-	O	SYM	O
6	O	NUM	O
bp	O	NOUN	O
deleted	O	VERB	O
from	O	ADP	O
chromosome	O	NOUN	B
4	O	NUM	I
.	O	PUNCT	O


RFLP	O	NOUN	B
and	O	CCONJ	O
Southern	O	NOUN	B
analyses	O	NOUN	I
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
de	O	X	B
novo	O	X	I
translocation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
paternal	O	ADJ	B
origin	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
fathers	O	NOUN	B
X	O	NOUN	B
chromosome	O	NOUN	I
contains	O	VERB	O
the	O	DET	O
DNA	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
the	O	DET	O
derivative	O	ADJ	B
X	O	NOUN	I
.	O	PUNCT	O


Most	O	ADV	O
likely	O	ADV	O
,	O	PUNCT	O
deletion	O	NOUN	B
and	O	CCONJ	O
translation	O	NOUN	B
arose	O	VERB	O
simultaneously	O	ADV	O
from	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
rearrangement	O	NOUN	B
event	O	NOUN	O
that	O	PRON	O
involves	O	VERB	O
three	O	NUM	O
chromosomal	O	ADJ	B
breakpoints	O	NOUN	I
.	O	PUNCT	O


Short	O	ADJ	B
regions	O	NOUN	I
of	O	ADP	I
sequence	O	NOUN	I
homology	O	NOUN	I
were	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
the	O	DET	O
three	O	NUM	O
sites	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
sequence	O	NOUN	B
,	O	PUNCT	O
GGAAT	O	NOUN	B
,	O	PUNCT	O
found	O	VERB	O
exactly	O	ADV	O
at	O	ADP	O
the	O	DET	O
translocation	O	NOUN	B
breakpoints	O	NOUN	O
on	O	ADP	O
both	O	CCONJ	O
normal	O	ADJ	B
chromosomes	O	NOUN	I
X	O	NOUN	I
and	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
preserved	O	VERB	O
only	O	ADV	O
on	O	ADP	O
the	O	DET	O
der	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
chromosome	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
sequence	O	NOUN	B
GGAATCA	O	PROPN	B
has	O	AUX	O
been	O	AUX	O
lost	O	VERB	B
in	O	ADP	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
der	O	NOUN	O
(	O	PUNCT	O
X	O	NOUN	O
)	O	PUNCT	O
chromosome	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
it	O	PRON	O
matches	O	VERB	O
an	O	DET	O
inverted	O	ADJ	O
GAATCA	O	NOUN	B
sequence	O	NOUN	I
present	O	ADJ	O
on	O	ADP	O
the	O	DET	O
opposite	O	ADJ	O
strand	O	NOUN	B
exactly	O	ADV	O
at	O	ADP	O
the	O	DET	O
other	O	ADJ	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
deleted	O	ADJ	B
5	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
fragment	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
genetic	O	ADJ	B
etiology	O	NOUN	I
for	O	ADP	O
DiGeorge	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
consistent	O	ADJ	O
deletions	O	NOUN	B
and	O	CCONJ	O
microdeletions	O	NOUN	B
of	O	ADP	O
22q11	O	NOUN	B
.	O	PUNCT	O


DiGeorge	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
DGS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
developmental	O	ADJ	B
field	O	NOUN	I
defect	O	NOUN	I
of	O	ADP	O
the	O	DET	O
third	O	ADJ	O
and	O	CCONJ	O
fourth	O	ADJ	O
pharyngeal	O	ADJ	B
pouches	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
aplasia	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
hypoplasia	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
thymus	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
parathyroid	I-Disease	ADJ	B
glands	I-Disease	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
conotruncal	B-Disease	ADJ	B
cardiac	I-Disease	ADJ	I
malformations	I-Disease	NOUN	I
.	O	PUNCT	O


Cytogenetic	O	ADJ	B
studies	O	NOUN	I
support	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
DGS	B-Disease	NOUN	B
critical	O	ADJ	B
region	O	NOUN	I
in	O	ADP	O
band	O	NOUN	B
22q11	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
,	O	PUNCT	O
cytogenetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
molecular	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
DGS	B-Disease	NOUN	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
utilizing	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
banding	O	NOUN	B
techniques	O	NOUN	B
,	O	PUNCT	O
detected	O	VERB	B
interstitial	O	ADJ	B
deletions	O	NOUN	O
in	O	ADP	O
five	O	NUM	O
probands	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
inconclusive	O	ADJ	B
for	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
probands	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
six	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	B
karyotypes	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
molecular	O	ADJ	B
analysis	O	NOUN	I
detected	O	VERB	O
DNA	O	NOUN	B
deletions	O	NOUN	I
in	O	ADP	O
all	O	DET	O
14	O	NUM	O
probands	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
10	O	NUM	O
loci	O	NOUN	B
tested	O	VERB	B
,	O	PUNCT	O
D22S75	O	NOUN	B
and	O	CCONJ	O
D22S259	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
all	O	DET	O
14	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
third	O	ADJ	O
locus	O	NOUN	O
,	O	PUNCT	O
D22S66	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
the	O	DET	O
eight	O	NUM	O
DGS	B-Disease	PROPN	B
probands	O	NOUN	B
tested	O	VERB	B
.	O	PUNCT	O


Physical	O	ADJ	B
mapping	O	NOUN	I
using	O	VERB	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
places	O	VERB	O
D22S66	O	NOUN	B
between	O	ADP	O
D22S75	O	NOUN	B
and	O	CCONJ	O
D22S259	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
should	O	AUX	O
be	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
six	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Parent	O	PROPN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
origin	O	NOUN	B
studies	O	NOUN	B
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
five	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
probands	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
inherit	O	VERB	O
a	O	DET	O
maternal	O	ADJ	B
allele	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	PRON	O
failed	O	VERB	B
to	O	PART	O
inherit	O	VERB	O
a	O	DET	O
paternal	O	ADJ	B
allele	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
of	O	ADP	O
six	O	NUM	O
maternally	O	ADV	B
and	O	CCONJ	O
five	O	NUM	O
paternally	O	ADV	B
derived	O	VERB	O
unbalanced	O	ADJ	B
-	O	PUNCT	O
translocation	O	NOUN	B
DGS	B-Disease	NOUN	B
probands	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
parent	O	NOUN	B
of	O	ADP	O
origin	O	NOUN	B
or	O	CCONJ	O
imprinting	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
play	O	VERB	O
an	O	DET	O
important	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
DGS	B-Disease	PROPN	B
.	O	PUNCT	O


Deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
three	O	NUM	O
loci	O	NOUN	B
in	O	ADP	O
all	O	DET	O
14	O	NUM	O
DGS	B-Disease	PROPN	B
probands	O	NOUN	B
begins	O	VERB	O
to	O	PART	O
delineate	O	VERB	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
22	O	NUM	I
critical	O	ADJ	I
for	O	ADP	O
DGS	B-Disease	PROPN	B
and	O	CCONJ	O
confirms	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
submicroscopic	O	ADJ	B
deletions	O	NOUN	I
of	O	ADP	O
22q11	O	NOUN	B
are	O	AUX	O
etiologic	O	ADJ	B
in	O	ADP	O
the	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	O
allele	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
an	O	DET	O
adrenocortical	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
.	O	PUNCT	O


Endocrine	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
occasionally	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
adrenocorotical	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
FAP	B-Disease	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	I
heterozygosity	O	NOUN	I
(	O	PUNCT	O
LOH	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
region	O	NOUN	B
close	O	ADV	O
to	O	PART	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
this	O	DET	O
carcinoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
evidence	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
allele	O	NOUN	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
demonstration	O	NOUN	B
of	O	ADP	O
LOH	O	NOUN	B
at	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
locus	O	NOUN	O
in	O	ADP	O
adrenocortical	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
and	O	CCONJ	O
our	O	PRON	O
previous	O	ADJ	O
data	O	NOUN	B
on	O	ADP	O
LOH	O	NOUN	B
in	O	ADP	O
a	O	DET	O
recurring	O	VERB	O
desmoid	B-Disease	ADJ	B
tumor	I-Disease	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
heterozygous	O	ADJ	B
mutant	O	ADJ	B
/	O	SYM	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
condition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
give	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
benign	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
functional	O	ADJ	B
loss	O	NOUN	O
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
development	O	NOUN	B
of	O	ADP	O
tumors	B-Disease	NOUN	B
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
colon	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
other	O	ADJ	O
various	O	ADJ	O
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
body	O	NOUN	B
in	O	ADP	O
FAP	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Oncogenic	O	ADJ	B
point	O	NOUN	O
mutations	O	NOUN	O
in	O	ADP	O
exon	O	NOUN	B
20	O	NUM	O
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
showing	O	VERB	O
incomplete	O	ADJ	B
penetrance	O	NOUN	B
and	O	CCONJ	O
mild	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
retinoblastoma	B-Disease	NOUN	B
-	O	PUNCT	O
predisposition	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
RB1	O	NOUN	B
,	O	PUNCT	O
segregates	O	VERB	B
as	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
trait	O	NOUN	O
with	O	ADP	O
high	O	ADJ	B
(	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
penetrance	O	NOUN	B
.	O	PUNCT	O


Certain	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
show	O	VERB	O
an	O	DET	O
unusual	O	ADJ	B
low	O	ADJ	B
-	O	PUNCT	O
penetrance	O	NOUN	B
phenotype	O	NOUN	B
with	O	ADP	O
many	O	ADJ	O
individuals	O	NOUN	B
being	O	AUX	O
unaffected	O	ADJ	B
,	O	PUNCT	O
unilaterally	O	ADV	B
affected	O	VERB	B
,	O	PUNCT	O
or	O	CCONJ	O
with	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
spontaneously	O	ADV	B
regressed	O	VERB	O
tumors	B-Disease	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	O
analysis	O	NOUN	B
and	O	CCONJ	O
PCR	O	NOUN	B
sequencing	O	NOUN	I
to	O	PART	O
study	O	VERB	B
two	O	NUM	O
such	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
20	O	NUM	I
of	O	ADP	O
RB1	O	NOUN	B
in	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
in	O	ADP	O
codon	O	NOUN	B
661	O	NUM	O
converts	O	VERB	O
an	O	DET	O
arginine	O	NOUN	B
(	O	PUNCT	O
CGG	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
a	O	DET	O
tryptophan	O	NOUN	B
(	O	PUNCT	O
TGG	O	NOUN	O
)	O	PUNCT	O
codon	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
incomplete	O	ADJ	B
penetrance	O	NOUN	B
and	O	CCONJ	O
mild	O	ADJ	B
phenotypic	O	ADJ	B
expression	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
virtually	O	ADV	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
indicating	O	VERB	O
that	O	SCONJ	O
single	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
changes	O	NOUN	I
may	O	AUX	O
modify	O	VERB	O
protein	O	NOUN	B
structure	O	NOUN	I
/	O	PUNCT	O
function	O	NOUN	B
such	O	ADJ	O
that	O	DET	O
tumorigenesis	O	NOUN	B
is	O	AUX	O
not	O	PART	O
inevitable	O	ADJ	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
second	O	ADJ	O
family	O	NOUN	B
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
codon	O	NOUN	B
675	O	NUM	I
is	O	AUX	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
transversion	O	NOUN	B
that	O	PRON	O
converts	O	VERB	O
a	O	DET	O
glutamine	O	NOUN	B
(	O	PUNCT	O
GAA	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
a	O	DET	O
stop	O	NOUN	B
(	O	PUNCT	O
TAA	O	NOUN	B
)	O	PUNCT	O
codon	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
mutation	O	NOUN	B
also	O	ADV	O
occurs	O	VERB	O
near	O	ADP	O
a	O	DET	O
potential	O	ADJ	O
cryptic	O	ADJ	B
splice	O	NOUN	I
acceptor	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
raising	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
alternative	O	ADJ	B
splicing	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
less	O	ADV	O
severely	O	ADV	B
disrupted	O	VERB	O
protein	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
metachromatic	B-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
:	O	PUNCT	O
molecular	O	ADJ	B
pathology	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
siblings	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
new	O	ADJ	O
allele	O	NOUN	B
at	O	ADP	O
the	O	DET	O
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
causing	O	VERB	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
metachromatic	B-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
MLD	B-Disease	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
that	O	DET	O
allele	O	NOUN	B
arginine84	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
residue	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
highly	O	ADV	O
conserved	O	VERB	B
in	O	ADP	O
the	O	DET	O
arylsulfatase	O	NOUN	B
gene	O	NOUN	I
family	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
glutamine	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
alleles	O	NOUN	B
that	O	PRON	O
cause	O	VERB	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
MLD	B-Disease	PROPN	B
,	O	PUNCT	O
the	O	DET	O
arginine84	O	NOUN	B
to	O	PART	O
glutamine	O	NOUN	B
substitution	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
some	O	DET	O
residual	O	ADJ	B
ARSA	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
genotypes	O	NOUN	B
,	O	PUNCT	O
ARSA	O	NOUN	B
activities	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
clinical	O	ADJ	B
data	O	NOUN	I
on	O	ADP	O
4	O	NUM	O
individuals	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
allele	O	NOUN	B
of	O	ADP	O
81	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
MLD	B-Disease	NOUN	B
examined	O	VERB	B
,	O	PUNCT	O
further	O	ADV	O
validates	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
different	O	ADJ	O
degrees	O	NOUN	B
of	O	ADP	O
residual	O	ADJ	B
ARSA	O	NOUN	B
activity	O	NOUN	B
are	O	AUX	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
phenotypical	O	ADJ	B
variation	O	NOUN	B
in	O	ADP	O
MLD	B-Disease	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Trisomy	B-Disease	NOUN	B
15	I-Disease	NUM	O
with	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
15	O	NUM	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
maternal	B-Disease	ADJ	B
disomy	I-Disease	NOUN	O
.	O	PUNCT	O


Uniparental	B-Disease	NOUN	B
disomy	I-Disease	NOUN	I
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
recognized	O	VERB	O
to	O	PART	O
cause	O	VERB	O
human	O	ADJ	B
disorders	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
particularly	O	ADV	O
instructive	O	ADJ	O
case	O	NOUN	B
which	O	DET	O
raises	O	VERB	O
important	O	ADJ	O
issues	O	NOUN	B
concerning	O	VERB	O
the	O	DET	O
mechanisms	O	NOUN	B
producing	O	VERB	O
uniparental	B-Disease	ADJ	B
disomy	I-Disease	NOUN	I
and	O	CCONJ	O
whose	O	DET	O
evaluation	O	NOUN	B
provides	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
trisomy	O	NOUN	B
may	O	AUX	O
precede	O	VERB	O
uniparental	B-Disease	ADJ	B
disomy	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
fetus	O	NOUN	B
.	O	PUNCT	O


Chorionic	O	ADJ	B
villus	O	NOUN	I
sampling	O	NOUN	I
performed	O	VERB	O
for	O	ADP	O
advanced	O	ADJ	B
maternal	O	ADJ	B
age	O	NOUN	O
revealed	O	VERB	O
trisomy	B-Disease	NOUN	B
15	I-Disease	NUM	O
in	O	ADP	O
all	O	DET	O
direct	O	ADJ	O
and	O	CCONJ	O
cultured	O	VERB	B
cells	O	NOUN	I
,	O	PUNCT	O
though	O	SCONJ	O
the	O	DET	O
fetus	O	NOUN	B
appeared	O	VERB	O
normal	O	ADJ	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
amniocytes	O	NOUN	B
obtained	O	VERB	O
at	O	ADP	O
15	O	NUM	O
wk	O	NOUN	O
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
over	O	ADP	O
100	O	NUM	O
cells	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
child	O	NOUN	B
was	O	AUX	O
hypotonic	B-Disease	ADJ	B
at	O	ADP	O
birth	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
banding	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
reveal	O	VERB	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
15q11	O	NOUN	O
-	O	PUNCT	O
13	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
deletion	O	NOUN	B
which	O	DET	O
is	O	AUX	O
found	O	VERB	O
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Over	O	ADP	O
time	O	NOUN	B
,	O	PUNCT	O
typical	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
developed	O	VERB	O
.	O	PUNCT	O


Molecular	O	ADJ	B
genetic	O	ADJ	I
analysis	O	NOUN	I
using	O	VERB	O
probes	O	NOUN	B
for	O	ADP	O
chromosome	O	NOUN	O
15	O	NUM	O
revealed	O	VERB	O
maternal	O	ADJ	B
disomy	O	NOUN	O
.	O	PUNCT	O


Maternal	O	ADJ	B
nondisjunction	O	NOUN	B
with	O	ADP	O
fertilization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
disomic	O	ADJ	B
egg	O	NOUN	O
by	O	ADP	O
a	O	DET	O
normal	O	ADJ	B
sperm	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paternal	O	NOUN	B
15	O	NUM	O
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
likely	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
confined	O	VERB	O
placental	O	ADJ	B
mosaicism	O	NOUN	B
and	O	CCONJ	O
uniparental	B-Disease	ADJ	B
disomy	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
advanced	O	ADJ	B
maternal	O	ADJ	B
age	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
predisposing	O	ADJ	B
factor	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
heterogeneity	O	NOUN	I
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
amelogenesis	I-Disease	NOUN	B
imperfecta	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
AMELX	O	NOUN	B
gene	O	NOUN	B
located	O	ADJ	O
at	O	ADP	O
Xp22	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
-	O	PUNCT	O
p22	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
encodes	O	VERB	B
for	O	ADP	O
the	O	DET	O
enamel	O	NOUN	B
protein	O	NOUN	I
amelogenin	O	NOUN	O
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
dental	I-Disease	NOUN	B
abnormality	I-Disease	NOUN	I
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
amelogenesis	I-Disease	NOUN	B
imperfecta	I-Disease	NOUN	B
(	O	PUNCT	O
XAI	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
XAI	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
using	O	VERB	O
polymorphic	O	ADJ	B
DNA	O	NOUN	O
markers	O	NOUN	O
flanking	O	VERB	B
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
AMELX	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
linkage	O	NOUN	O
analysis	O	NOUN	O
,	O	PUNCT	O
linkage	O	NOUN	B
was	O	AUX	O
established	O	VERB	O
between	O	ADP	O
XAI	B-Disease	NOUN	B
and	O	CCONJ	O
several	O	ADJ	O
of	O	ADP	O
these	O	DET	O
markers	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
combined	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
6	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
for	O	ADP	O
DXS16	O	NOUN	B
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
04	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
supports	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
AMELX	O	NOUN	B
,	O	PUNCT	O
located	O	ADJ	O
close	O	ADV	O
to	O	PART	O
DXS16	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
XAI	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
process	O	NOUN	I
(	O	PUNCT	O
AIH1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
those	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
combined	O	ADJ	O
maximum	O	ADJ	O
lod	O	NOUN	O
score	O	NOUN	O
for	O	ADP	O
these	O	DET	O
two	O	NUM	O
families	O	NOUN	B
was	O	AUX	O
7	O	NUM	O
.	O	PUNCT	O


30	O	NUM	O
for	O	ADP	O
a	O	DET	O
location	O	NOUN	B
of	O	ADP	O
AIH1	O	NOUN	B
at	O	ADP	O
2	O	NUM	O
cM	O	NOUN	O
distal	O	ADJ	B
to	O	PART	O
DXS16	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
support	O	NOUN	B
interval	O	NOUN	I
around	O	ADP	O
this	O	DET	O
location	O	NOUN	B
extended	O	VERB	B
about	O	ADP	O
8	O	NUM	O
cM	O	NOUN	B
proximal	O	ADJ	B
to	O	PART	O
DXS92	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
AIH1	O	NOUN	B
location	O	NOUN	B
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
precisely	O	ADV	O
defined	O	VERB	O
by	O	ADP	O
multipoint	O	ADJ	B
mapping	O	NOUN	I
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
recombination	O	NOUN	O
events	O	NOUN	O
indicated	O	VERB	O
that	O	SCONJ	O
AIH1	O	NOUN	B
lies	O	VERB	O
in	O	ADP	O
the	O	DET	O
interval	O	NOUN	B
between	O	ADP	O
DXS143	O	NOUN	B
and	O	CCONJ	O
DXS85	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
significant	O	ADJ	O
evidence	O	NOUN	B
against	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
this	O	DET	O
region	O	NOUN	B
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
locus	O	NOUN	B
heterogeneity	O	NOUN	B
in	O	ADP	O
XAI	B-Disease	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
analysis	O	NOUN	B
with	O	ADP	O
markers	O	NOUN	B
on	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
showed	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
DXS144E	O	NOUN	B
and	O	CCONJ	O
F9	O	NOUN	B
with	O	ADP	O
no	O	DET	O
recombination	O	NOUN	O
with	O	ADP	O
either	O	DET	O
of	O	ADP	O
these	O	DET	O
markers	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
analysis	O	NOUN	I
gave	O	VERB	O
a	O	DET	O
peak	O	NOUN	O
lod	O	ADJ	O
score	O	NOUN	O
at	O	ADP	O
DXS144E	O	NOUN	B
with	O	ADP	O
a	O	DET	O
maximum	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


83	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
peak	O	NOUN	O
lod	O	ADJ	O
score	O	NOUN	O
in	O	ADP	O
multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


84	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
support	O	NOUN	B
interval	O	NOUN	I
extended	O	VERB	O
9	O	NUM	O
cM	O	NOUN	B
proximal	O	ADJ	B
to	O	PART	O
DXS144E	O	NOUN	B
and	O	CCONJ	O
14	O	NUM	O
cM	O	NOUN	O
distal	O	ADJ	O
to	O	PART	O
F9	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Multiple	O	ADJ	B
origins	O	NOUN	O
for	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
in	O	ADP	O
Europe	O	PROPN	B
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
amino	I-Disease	NOUN	B
acid	I-Disease	NOUN	I
metabolism	I-Disease	NOUN	I
prevalent	O	ADJ	O
among	O	ADP	O
Caucasians	O	PROPN	B
and	O	CCONJ	O
other	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
primarily	O	ADV	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
hepatic	I-Disease	ADJ	B
enzyme	I-Disease	NOUN	O
phenylalanine	I-Disease	NOUN	O
hydroxylase	I-Disease	NOUN	O
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


PKU	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
heterogeneous	O	ADJ	B
disorder	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
60	O	NUM	O
molecular	O	ADJ	B
lesions	O	NOUN	I
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
haplotype	O	NOUN	B
associations	O	NOUN	B
,	O	PUNCT	O
relative	O	ADJ	O
frequencies	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
distributions	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
prevalent	O	ADJ	O
PAH	O	NOUN	B
mutations	O	NOUN	B
(	O	PUNCT	O
R158Q	O	NOUN	B
,	O	PUNCT	O
R261Q	O	NOUN	B
,	O	PUNCT	O
IVS10nt546	O	ADJ	B
,	O	PUNCT	O
R408W	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
IVS12n1	O	ADV	B
)	O	PUNCT	O
were	O	AUX	O
established	O	VERB	O
in	O	ADP	O
a	O	DET	O
comprehensive	O	ADJ	B
European	O	ADJ	B
sample	O	NOUN	O
population	O	NOUN	O
and	O	CCONJ	O
subsequently	O	ADV	O
were	O	AUX	O
examined	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
roles	O	NOUN	O
of	O	ADP	O
several	O	ADJ	O
genetic	O	ADJ	B
mechanisms	O	NOUN	I
in	O	ADP	O
explaining	O	VERB	O
the	O	DET	O
present	O	ADJ	O
distribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
PKU	B-Disease	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
of	O	ADP	O
these	O	DET	O
five	O	NUM	O
mutations	O	NOUN	B
was	O	AUX	O
strongly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
more	O	ADJ	O
than	O	ADP	O
70	O	NUM	O
chromosomal	O	ADJ	B
haplotypes	O	NOUN	I
defined	O	VERB	O
by	O	ADP	O
eight	O	NUM	O
RFLPs	O	NOUN	B
in	O	ADP	O
or	O	CCONJ	O
near	O	ADP	B
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
each	O	DET	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
arose	O	VERB	O
through	O	ADP	O
a	O	DET	O
single	O	ADJ	O
founding	O	NOUN	B
event	O	NOUN	B
that	O	PRON	O
occurred	O	VERB	O
within	O	ADP	O
time	O	NOUN	B
periods	O	NOUN	I
ranging	O	VERB	O
from	O	ADP	O
several	O	ADJ	O
hundred	O	NUM	O
to	O	PART	O
several	O	ADJ	O
thousand	O	NUM	O
years	O	NOUN	B
ago	O	ADV	O
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
frequencies	O	NOUN	B
and	O	CCONJ	O
distributions	O	NOUN	B
of	O	ADP	O
these	O	DET	O
five	O	NUM	O
alleles	O	NOUN	B
throughout	O	ADP	O
Europe	O	PROPN	B
,	O	PUNCT	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
putative	O	ADJ	O
founding	O	NOUN	O
events	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
specific	O	ADJ	O
ethnic	O	ADJ	B
subgroups	O	NOUN	I
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
multiple	O	ADJ	B
,	O	PUNCT	O
geographically	O	ADV	B
and	O	CCONJ	O
ethnically	O	ADV	B
distinct	O	ADJ	O
origins	O	NOUN	B
for	O	ADP	O
PKU	B-Disease	NOUN	B
within	O	ADP	O
the	O	DET	O
European	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Complement	B-Disease	NOUN	B
factor	I-Disease	NOUN	I
2	I-Disease	NUM	I
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
serological	O	ADJ	B
family	O	NOUN	O
study	O	NOUN	O
.	O	PUNCT	O


Inherited	B-Disease	VERB	B
complement	I-Disease	NOUN	O
deficiencies	I-Disease	NOUN	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
connective	O	ADJ	B
tissue	O	NOUN	I
diseases	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
with	O	ADP	O
inherited	B-Disease	VERB	B
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
factor	I-Disease	NOUN	I
2	I-Disease	NUM	I
(	O	PUNCT	I
C2	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
which	O	DET	O
two	O	NUM	O
family	O	NOUN	B
members	O	NOUN	I
with	O	ADP	O
homozygous	O	ADJ	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
developed	O	VERB	O
cutaneous	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
and	O	CCONJ	O
sicca	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
had	O	AUX	O
heterozygous	O	ADJ	B
C2	B-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
and	O	CCONJ	O
each	O	DET	O
member	O	NOUN	B
had	O	AUX	O
the	O	DET	O
HLA	O	NOUN	B
-	O	PUNCT	O
A25	O	NOUN	B
,	O	PUNCT	O
B18	O	NOUN	B
,	O	PUNCT	O
DR2	O	NOUN	B
(	O	PUNCT	O
w15	O	NOUN	B
)	O	PUNCT	O
haplotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mother	O	NOUN	B
had	O	AUX	O
seropositive	B-Disease	ADJ	B
rheumatoid	I-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
studies	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
cryoglobulins	O	NOUN	B
,	O	PUNCT	O
antibodies	O	NOUN	B
against	O	ADP	O
endothelial	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
anticardiolipin	O	NOUN	B
antibodies	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


New	O	ADJ	O
variant	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
of	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
C	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
greater	O	ADJ	B
than	O	ADP	O
G	O	NOUN	B
transversion	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
mother	O	NOUN	B
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
sibship	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
merzbacher	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
transversion	O	NOUN	B
should	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
an	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
change	O	NOUN	I
in	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
but	O	CCONJ	O
it	O	PRON	O
does	O	AUX	O
result	O	VERB	O
in	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
a	O	DET	O
HaeIII	O	NOUN	B
restriction	O	NOUN	I
endonuclease	O	NOUN	I
cleavage	O	NOUN	I
site	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concordant	O	ADJ	B
with	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
-	O	PUNCT	O
hundred	O	NUM	B
-	O	PUNCT	O
ten	O	NUM	B
unrelated	O	ADJ	O
X	O	NOUN	B
chromosomes	O	NOUN	I
are	O	AUX	O
negative	O	ADJ	B
for	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
sequence	O	NOUN	B
defect	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
males	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
disease	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
remains	O	VERB	O
unknown	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
this	O	DET	O
rare	O	ADJ	B
mutation	O	NOUN	B
and	O	CCONJ	O
PMD	B-Disease	NOUN	B
is	O	AUX	O
intriguing	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
can	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
for	O	ADP	O
following	O	VERB	O
segregation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Uncoupling	O	NOUN	B
of	O	ADP	O
hypomyelination	B-Disease	NOUN	B
and	O	CCONJ	O
glial	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
death	I-Disease	NOUN	O
by	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
;	O	PUNCT	O
M	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
)	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
major	O	ADJ	O
polytopic	O	ADJ	B
membrane	O	NOUN	I
protein	O	NOUN	I
in	O	ADP	O
myelin	O	NOUN	B
but	O	CCONJ	O
its	O	PRON	O
cellular	O	ADJ	B
function	O	NOUN	I
remains	O	VERB	O
obscure	O	ADJ	B
.	O	PUNCT	O


Neurological	O	ADJ	B
mutant	O	ADJ	I
mice	O	NOUN	I
can	O	AUX	O
often	O	ADV	O
provide	O	VERB	O
model	O	NOUN	B
systems	O	NOUN	I
for	O	ADP	O
human	O	ADJ	B
genetic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
PLP	O	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
lethal	O	ADJ	B
,	O	PUNCT	O
identified	O	VERB	B
first	O	ADV	O
in	O	ADP	O
the	O	DET	O
jimpy	O	NOUN	B
mouse	O	NOUN	O
and	O	CCONJ	O
subsequently	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
unexplained	O	ADJ	B
phenotype	O	NOUN	B
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
includes	O	VERB	O
degeneration	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
premature	I-Disease	ADJ	B
cell	I-Disease	NOUN	I
death	I-Disease	NOUN	I
of	I-Disease	ADP	O
oligodendrocytes	I-Disease	NOUN	B
with	O	ADP	O
associated	O	VERB	O
hypomyelination	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
new	O	ADJ	O
mouse	O	NOUN	B
mutant	O	ADJ	B
rumpshaker	O	NOUN	B
is	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
acid	O	NOUN	B
substitution	O	NOUN	B
Ile	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
Thr	O	NOUN	B
at	O	ADP	O
residue	O	NOUN	O
186	O	NUM	O
in	O	ADP	O
a	O	DET	O
membrane	O	NOUN	B
-	O	PUNCT	O
embedded	O	ADJ	B
domain	O	NOUN	B
of	O	ADP	O
PLP	O	NOUN	B
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
rumpshaker	O	NOUN	B
mice	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
myelin	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
,	O	PUNCT	O
have	O	AUX	O
normal	O	ADJ	O
longevity	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
full	O	ADJ	O
complement	O	NOUN	O
of	O	ADP	O
morphologically	O	ADV	B
normal	O	ADJ	O
oligodendrocytes	O	NOUN	B
.	O	PUNCT	O


Hypomyelination	B-Disease	NOUN	B
can	O	AUX	O
thus	O	ADV	O
be	O	AUX	O
genetically	O	ADV	B
separated	O	VERB	O
from	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
oligodendrocyte	B-Disease	NOUN	B
degeneration	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
PLP	O	NOUN	B
has	O	AUX	O
a	O	DET	O
vital	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
glial	O	ADJ	B
cell	O	NOUN	I
development	O	NOUN	B
,	O	PUNCT	O
distinct	O	ADJ	O
from	O	ADP	O
its	O	PRON	O
later	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
myelin	O	NOUN	B
assembly	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
dichotomy	O	NOUN	O
of	O	ADP	O
action	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
spectrum	O	NOUN	I
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
pseudodeficiency	O	NOUN	B
allele	O	NOUN	B
common	O	ADJ	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
carriers	O	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
carrier	O	NOUN	B
screening	O	NOUN	B
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
beta	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
hexosaminidase	I-Disease	NOUN	B
A	I-Disease	NOUN	I
(	O	PUNCT	O
Hex	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
activity	O	NOUN	B
typically	O	ADV	O
results	O	VERB	O
in	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
healthy	O	ADJ	B
subjects	O	NOUN	I
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
deficient	B-Disease	ADJ	B
in	I-Disease	ADP	O
Hex	I-Disease	NOUN	B
A	I-Disease	NOUN	I
activity	O	NOUN	I
(	O	PUNCT	O
i	O	NOUN	O
.	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
pseudodeficient	O	ADJ	B
)	O	PUNCT	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
in	O	X	B
vitro	O	X	I
biochemical	O	ADJ	B
tests	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
pseudodeficient	O	ADJ	B
subject	O	NOUN	B
and	O	CCONJ	O
identified	O	VERB	B
both	O	CCONJ	O
a	O	DET	O
C739	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
substitution	O	NOUN	B
that	O	PRON	O
changes	O	VERB	B
Arg247	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Trp	O	NOUN	B
on	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
previously	O	ADV	O
identified	O	VERB	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
mutation	O	NOUN	O
on	O	ADP	O
the	O	DET	O
second	O	ADJ	O
allele	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
additional	O	ADJ	O
pseudodeficient	O	ADJ	B
subjects	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
C739	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
allele	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
32	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
/	O	SYM	O
62	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
enzyme	O	NOUN	B
-	O	PUNCT	O
defined	O	VERB	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
carriers	O	NOUN	B
but	O	CCONJ	O
for	O	ADP	O
none	O	NOUN	O
of	O	ADP	O
36	O	NUM	O
Jewish	O	ADJ	B
enzyme	O	NOUN	B
-	O	PUNCT	O
defined	O	VERB	B
carriers	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
known	O	ADJ	O
mutations	O	NOUN	B
common	O	ADJ	O
to	O	PART	O
this	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
C739	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
allele	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
a	O	DET	O
"	O	PUNCT	O
true	O	ADJ	O
"	O	PUNCT	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
allele	O	NOUN	O
,	O	PUNCT	O
causes	O	VERB	O
Hex	O	NOUN	B
A	O	NOUN	I
pseudodeficiency	O	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
large	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
carriers	O	NOUN	B
with	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
standard	O	ADJ	B
biochemical	O	ADJ	B
screening	O	NOUN	O
cannot	O	PART	O
differentiate	O	VERB	O
between	O	ADP	O
heterozygotes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
C739	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
mutations	O	NOUN	O
and	O	CCONJ	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
carriers	O	NOUN	B
,	O	PUNCT	O
DNA	O	NOUN	B
testing	O	NOUN	I
for	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
at	O	ADP	O
-	O	PUNCT	O
risk	O	NOUN	B
couples	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	B
.	O	PUNCT	O


Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
detection	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
Thr181	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Pro	O	NOUN	B
and	O	CCONJ	O
Leu223	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Pro	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
with	O	ADP	O
an	O	DET	O
apparent	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
presented	O	VERB	O
for	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
,	O	PUNCT	O
requesting	O	VERB	B
carrier	O	NOUN	B
detection	O	NOUN	O
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


RFLP	O	NOUN	B
analysis	O	NOUN	B
using	O	VERB	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
probe	O	NOUN	I
was	O	AUX	O
uninformative	O	ADJ	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
on	O	ADP	O
a	O	DET	O
chorionic	O	ADJ	B
villus	O	NOUN	I
sample	O	NOUN	I
(	O	PUNCT	O
CVS	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
using	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
variant	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
fetus	O	NOUN	B
was	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
be	O	AUX	O
unaffected	O	ADJ	B
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exon	O	NOUN	B
from	O	ADP	O
the	O	DET	O
CVS	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
predicted	O	VERB	B
-	O	PUNCT	O
carrier	O	NOUN	B
mother	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
obligate	O	ADJ	B
-	O	PUNCT	O
carrier	O	NOUN	B
grandmother	O	NOUN	B
revealed	O	VERB	B
an	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
C	O	NOUN	O
change	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
541	O	NUM	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
women	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
fetus	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
this	O	DET	O
change	O	NOUN	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
Thr	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
Pro	O	NOUN	B
change	O	NOUN	O
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
181	O	NUM	O
in	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
predicted	O	VERB	O
to	O	PART	O
be	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
transmembrane	O	ADJ	B
segment	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
was	O	AUX	O
the	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
second	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
exon	O	NOUN	B
5	O	NUM	I
variant	O	ADJ	O
band	O	NOUN	O
pattern	O	NOUN	O
on	O	ADP	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
sequencing	O	VERB	B
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
C	O	NOUN	O
change	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
668	O	NUM	I
.	O	PUNCT	O


This	O	DET	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
Leu	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
Pro	O	NOUN	B
change	O	NOUN	O
in	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
mother	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
her	O	PRON	O
two	O	NUM	O
affected	O	VERB	B
sons	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
examples	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
PLP	O	NOUN	B
that	O	PRON	O
cause	O	VERB	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
illustrate	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
SSCP	O	NOUN	B
in	O	ADP	O
genetic	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
type	I-Disease	NOUN	I
B	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
selectively	O	ADV	O
abolishes	O	VERB	O
ristocetin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
binding	O	VERB	I
to	O	PART	O
platelet	O	NOUN	B
glycoprotein	O	NOUN	I
Ib	O	NOUN	I
.	O	PUNCT	O


von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
vWF	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
multimeric	O	ADJ	B
glycoprotein	O	NOUN	I
that	O	PRON	O
mediates	O	VERB	O
the	O	DET	O
adhesion	O	NOUN	B
of	O	ADP	O
platelets	O	NOUN	B
to	O	PART	O
the	O	DET	O
subendothelium	O	NOUN	B
by	O	ADP	O
binding	O	VERB	B
to	O	PART	O
platelet	O	NOUN	B
glycoprotein	O	NOUN	I
Ib	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
human	O	ADJ	B
vWF	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
interaction	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
induced	O	VERB	B
in	O	X	B
vitro	O	X	I
by	O	ADP	O
the	O	DET	O
antibiotic	O	ADJ	B
ristocetin	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
snake	O	NOUN	B
venom	O	NOUN	I
protein	O	NOUN	I
botrocetin	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
Gly	O	NOUN	B
-	O	PUNCT	O
561	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Ser	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
within	O	ADP	O
the	O	DET	O
proposed	O	VERB	O
glycoprotein	O	NOUN	B
Ib	O	NOUN	I
binding	O	NOUN	I
domain	O	NOUN	I
of	O	ADP	O
vWF	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
with	O	ADP	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
type	I-Disease	NOUN	I
B	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
unique	O	ADJ	B
variant	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
no	O	DET	O
ristocetin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
normal	O	ADJ	O
botrocetin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
,	O	PUNCT	O
binding	O	VERB	B
to	O	PART	O
glycoprotein	O	NOUN	B
Ib	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
corresponding	O	ADJ	O
mutant	O	ADJ	B
recombinant	O	ADJ	I
protein	O	NOUN	I
,	O	PUNCT	O
rvWF	O	NOUN	B
(	O	PUNCT	O
G561S	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
formed	O	VERB	O
normal	O	ADJ	O
multimers	O	NOUN	O
and	O	CCONJ	O
exhibited	O	VERB	O
the	O	DET	O
same	O	ADJ	O
functional	O	ADJ	B
defect	O	NOUN	I
as	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
plasma	O	NOUN	B
vWF	O	NOUN	B
,	O	PUNCT	O
confirming	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
causes	O	VERB	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
type	I-Disease	NOUN	I
B	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
botrocetin	O	NOUN	B
and	O	CCONJ	O
ristocetin	O	NOUN	B
cofactor	O	NOUN	I
activities	O	NOUN	I
of	O	ADP	O
vWF	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
dissociated	O	VERB	O
by	O	ADP	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
and	O	CCONJ	O
confirm	O	VERB	B
that	O	SCONJ	O
these	O	DET	O
mediators	O	NOUN	B
promote	O	VERB	O
vWF	O	NOUN	B
binding	O	NOUN	B
to	O	PART	O
platelets	O	NOUN	B
by	O	ADP	O
different	O	ADJ	O
mechanisms	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
normal	O	ADJ	O
botrocetin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
binding	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
defective	O	ADJ	B
ristocetin	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
binding	O	NOUN	B
of	O	ADP	O
rvWF	O	NOUN	B
(	O	PUNCT	O
G561S	O	NOUN	B
)	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
primary	O	ADJ	B
defect	O	NOUN	O
in	O	ADP	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
type	I-Disease	NOUN	I
B	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
failure	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	O
allosteric	O	ADJ	B
regulation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glycoprotein	O	NOUN	B
Ib	O	NOUN	I
binding	O	NOUN	I
function	O	NOUN	I
of	O	ADP	O
vWF	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Typical	O	ADJ	B
and	O	CCONJ	O
partial	O	ADJ	B
cat	B-Disease	NOUN	B
eye	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
marker	O	NOUN	B
chromosome	O	NOUN	O
by	O	ADP	O
FISH	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
children	O	NOUN	B
are	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
typical	O	ADJ	O
cat	B-Disease	NOUN	B
eye	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
CES	B-Disease	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
more	O	ADJ	O
children	O	NOUN	B
with	O	ADP	O
partial	O	ADJ	B
CES	B-Disease	PROPN	B
because	O	SCONJ	O
of	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
coloboma	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
the	O	DET	O
supernumerary	O	ADJ	B
marker	O	NOUN	I
chromosome	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
FISH	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
genomic	O	ADJ	B
library	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
a	O	DET	O
centromeric	O	ADJ	B
and	O	CCONJ	O
particularly	O	ADV	O
a	O	DET	O
cosmid	O	NOUN	B
probe	O	NOUN	I
of	O	ADP	I
22q11	O	NOUN	I
,	O	PUNCT	O
partial	O	ADJ	B
tetrasomy	B-Disease	NOUN	O
was	O	AUX	O
shown	O	VERB	O
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


[	O	PUNCT	O
Genetic	O	ADJ	B
heterogeneity	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
mutant	O	ADJ	B
alleles	O	NOUN	I
of	O	ADP	O
G6PD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Shekii	O	PROPN	B
district	O	NOUN	I
of	O	ADP	O
Azerbaijan	O	PROPN	B
]	O	PUNCT	O


Examination	O	NOUN	B
on	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
in	O	ADP	O
349	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
Shekii	O	PROPN	B
district	O	NOUN	I
hospital	O	NOUN	I
(	O	PUNCT	O
Azerbaijan	O	PROPN	B
)	O	PUNCT	O
revealed	O	VERB	O
16	O	NUM	O
hemi	O	NOUN	B
-	O	PUNCT	O
,	O	PUNCT	O
4	O	NUM	O
homo	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
9	O	NUM	O
heterozygotic	O	ADJ	B
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
defect	O	NOUN	B
.	O	PUNCT	O


Gd	O	NOUN	B
-	O	PUNCT	O
frequency	O	NOUN	B
,	O	PUNCT	O
calculated	O	VERB	B
from	O	ADP	O
the	O	DET	O
data	O	NOUN	B
obtained	O	VERB	O
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
compared	O	VERB	B
to	O	PART	O
neighbouring	O	VERB	O
regions	O	NOUN	B
frequencies	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
-	O	SYM	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Carriers	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
are	O	AUX	O
residents	O	NOUN	B
of	O	ADP	O
11	O	NUM	O
villages	O	NOUN	B
located	O	ADJ	O
in	O	ADP	O
Alasani	O	PROPN	B
-	O	PUNCT	O
Aphtalan	O	PROPN	B
valley	O	NOUN	B
,	O	PUNCT	O
highly	O	ADV	O
endemic	O	ADJ	B
with	O	ADP	O
malaria	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
;	O	PUNCT	O
nearly	O	ADV	O
all	O	DET	O
marriages	O	NOUN	B
are	O	AUX	O
endogamic	O	ADJ	B
.	O	PUNCT	O


Physico	O	NOUN	B
-	O	PUNCT	O
chemical	O	NOUN	B
and	O	CCONJ	O
kinetic	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
mutant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
G6PD	O	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	ADP	O
WHO	O	PROPN	B
program	O	NOUN	B
,	O	PUNCT	O
led	O	VERB	O
to	O	PART	O
identification	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
variants	O	NOUN	B
of	O	ADP	O
the	O	DET	O
II	O	NUM	B
class	O	NOUN	I
(	O	PUNCT	O
Shekii	O	PROPN	B
,	O	PUNCT	O
Bideiz	O	PROPN	B
,	O	PUNCT	O
Shirin	O	PROPN	B
-	O	PUNCT	O
Bulakh	O	PROPN	B
,	O	PUNCT	O
Okhut	O	PROPN	B
I	O	NUM	I
and	O	CCONJ	O
Zakataly	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
variants	O	NOUN	B
of	O	ADP	O
the	O	DET	O
III	O	NUM	B
class	O	NOUN	I
(	O	PUNCT	O
Okhut	O	PROPN	B
II	O	NUM	I
and	O	CCONJ	O
Martinique	O	PROPN	B
-	O	PUNCT	O
like	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Resemblance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
variants	O	NOUN	B
in	O	ADP	O
electrophoretic	O	ADJ	B
mobility	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
erythrocyte	O	NOUN	B
enzyme	O	NOUN	B
activity	O	NOUN	I
permit	O	VERB	O
to	O	PART	O
suggest	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
common	O	ADJ	O
parental	O	ADJ	B
mutant	O	ADJ	O
G6PD	O	NOUN	B
allele	O	NOUN	B
distributed	O	VERB	B
in	O	ADP	O
this	O	DET	O
area	O	NOUN	B
.	O	PUNCT	O


Craniofrontonasal	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
nine	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
craniofrontonasal	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
(	O	PUNCT	O
CFND	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Seven	O	NUM	O
classical	O	ADJ	O
cases	O	NOUN	B
had	O	AUX	O
facial	O	ADJ	B
features	O	NOUN	I
suggestive	O	ADJ	O
of	O	ADP	O
frontonasal	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
and	O	CCONJ	O
coronal	B-Disease	ADJ	B
craniosynostosis	I-Disease	NOUN	I
.	O	PUNCT	O


Extracranial	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
such	O	ADJ	O
as	O	ADP	O
brittle	B-Disease	ADJ	B
nails	I-Disease	NOUN	B
with	I-Disease	ADP	O
prominent	I-Disease	ADJ	O
longitudinal	I-Disease	ADJ	B
grooves	I-Disease	NOUN	I
or	O	CCONJ	O
syndactyly	B-Disease	NOUN	B
of	I-Disease	ADP	I
fingers	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
toes	I-Disease	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
individual	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
the	O	DET	O
father	O	NOUN	B
of	O	ADP	O
classical	O	ADJ	O
cases	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
milder	O	ADJ	B
pattern	O	NOUN	B
of	O	ADP	O
abnormalities	O	NOUN	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
to	O	ADP	O
13	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
on	O	ADP	O
our	O	PRON	O
patients	O	NOUN	B
.	O	PUNCT	O


Hypotonia	B-Disease	DET	B
and	O	CCONJ	O
laxity	B-Disease	NOUN	B
of	I-Disease	ADP	O
joints	I-Disease	NOUN	B
are	O	AUX	O
common	O	ADJ	O
and	O	CCONJ	O
may	O	AUX	O
necessitate	O	VERB	O
supportive	O	ADJ	B
measures	O	NOUN	I
.	O	PUNCT	O


Mild	O	ADJ	B
developmental	B-Disease	ADJ	I
delay	I-Disease	NOUN	I
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
three	O	NUM	O
out	O	ADP	O
of	O	ADP	O
six	O	NUM	O
classical	O	ADJ	O
cases	O	NOUN	B
studied	O	VERB	O
in	O	ADP	O
detail	O	NOUN	O
.	O	PUNCT	O


Unlike	O	ADP	O
almost	O	ADV	O
all	O	DET	O
other	O	ADJ	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disorders	I-Disease	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
expression	O	NOUN	I
in	O	ADP	O
CFND	B-Disease	NOUN	B
is	O	AUX	O
generally	O	ADV	O
much	O	ADV	O
more	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
females	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
previous	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
our	O	PRON	O
severely	O	ADV	B
affected	O	VERB	B
cases	O	NOUN	B
is	O	AUX	O
a	O	DET	O
male	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
intron	O	NOUN	B
7	O	NUM	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
transition	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
second	O	ADJ	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
mutation	O	NOUN	O
in	O	ADP	O
French	O	PROPN	B
Canada	O	PROPN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
hexosaminidase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
HEXA	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
which	O	DET	O
cause	O	VERB	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
elevated	O	ADJ	B
frequency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
and	O	CCONJ	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
populations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
TSD	B-Disease	NOUN	B
allele	O	NOUN	O
in	O	ADP	O
the	O	DET	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
population	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
infantile	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
+	O	CCONJ	O
1	O	NUM	O
position	O	NOUN	O
of	O	ADP	O
intron	O	NOUN	B
7	O	NUM	O
,	O	PUNCT	O
abolishes	O	VERB	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
.	O	PUNCT	O


Cultured	O	VERB	B
human	O	ADJ	B
fibroblasts	O	NOUN	B
from	O	ADP	O
a	O	DET	O
compound	O	NOUN	B
heterozygote	O	NOUN	I
for	O	ADP	O
this	O	DET	O
transition	O	NOUN	B
(	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
mutation	O	NOUN	I
)	O	PUNCT	O
produce	O	VERB	O
no	O	DET	O
detectable	O	ADJ	B
HEXA	O	NOUN	B
mRNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
intron	O	NOUN	B
7	O	NUM	O
+	O	CCONJ	O
1	O	NUM	O
mutation	O	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
the	O	DET	O
base	O	NOUN	B
adjacent	O	ADJ	B
to	O	PART	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
TSD	B-Disease	NOUN	B
mutation	O	NOUN	O
(	O	PUNCT	O
G805A	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
mutations	O	NOUN	B
a	O	DET	O
restriction	O	NOUN	B
site	O	NOUN	I
for	O	ADP	O
the	O	DET	O
endonuclease	O	NOUN	B
EcoRII	O	NOUN	I
is	O	AUX	O
abolished	O	VERB	O
.	O	PUNCT	O


Unambiguous	O	ADJ	B
diagnosis	O	NOUN	I
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
requires	O	VERB	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
oligonucleotide	O	NOUN	B
hybridization	O	NOUN	I
to	O	PART	O
distinguish	O	VERB	O
between	O	ADP	O
these	O	DET	O
two	O	NUM	O
mutant	O	ADJ	B
alleles	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
intron	O	NOUN	B
7	O	NUM	O
+	O	CCONJ	O
1	O	NUM	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
three	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


Obligate	O	ADJ	B
heterozygotes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
7	O	NUM	O
+	O	CCONJ	O
1	O	NUM	O
mutation	O	NOUN	B
were	O	AUX	O
born	O	VERB	B
in	O	ADP	O
the	O	DET	O
Saguenay	O	PROPN	B
-	O	PUNCT	O
Lac	O	PROPN	B
-	O	PUNCT	O
St	O	PROPN	B
-	O	PUNCT	O
Jean	O	PROPN	B
region	O	NOUN	I
of	O	ADP	O
Quebec	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
recent	O	ADJ	O
ancestors	O	NOUN	B
common	O	ADJ	O
to	O	PART	O
obligate	O	ADJ	B
carriers	O	NOUN	B
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
were	O	AUX	O
from	O	ADP	O
the	O	DET	O
Charlevoix	O	PROPN	B
region	O	NOUN	O
of	O	ADP	O
the	O	DET	O
province	O	NOUN	B
of	O	ADP	O
Quebec	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
thus	O	ADV	O
has	O	AUX	O
a	O	DET	O
different	O	ADJ	O
geographic	O	ADJ	B
centre	O	NOUN	I
of	O	ADP	I
diffusion	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
probably	O	ADV	O
less	O	ADV	O
common	O	ADJ	O
than	O	ADP	O
the	O	DET	O
exon	O	NOUN	B
1	O	NUM	I
deletion	O	NOUN	B
TSD	B-Disease	NOUN	B
mutation	O	NOUN	O
in	O	ADP	O
French	O	PROPN	B
Canadians	O	PROPN	B
.	O	PUNCT	O


Neither	O	CCONJ	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
France	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
ancestral	O	ADJ	B
homeland	O	NOUN	B
of	O	ADP	O
French	O	PROPN	B
Canada	O	PROPN	I
.	O	PUNCT	O
.	O	PUNCT	O


Assignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
aspartylglucosaminidase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
AGA	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
4q33	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q35	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
decreased	O	VERB	B
activity	O	NOUN	B
in	O	ADP	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
a	O	DET	O
46	O	NUM	O
,	O	PUNCT	O
XX	O	NOUN	B
,	O	PUNCT	O
del	O	X	B
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q33	O	NOUN	O
)	O	PUNCT	O
karyotype	O	NOUN	B
.	O	PUNCT	O


Aspartylglucosaminuria	B-Disease	NOUN	B
(	O	PUNCT	O
AGU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessive	O	ADJ	B
autosomally	O	ADV	O
inherited	O	VERB	B
lysosomal	B-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
enzyme	I-Disease	NOUN	B
aspartylglucosaminidase	I-Disease	NOUN	I
(	O	PUNCT	O
AGA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
structural	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
this	O	DET	O
human	O	ADJ	B
enzyme	O	NOUN	O
(	O	PUNCT	O
AGA	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
4q21	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
determined	O	VERB	O
the	O	DET	O
AGA	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
of	O	ADP	O
a	O	DET	O
girl	O	NOUN	B
with	O	ADP	O
a	O	DET	O
46	O	NUM	O
,	O	PUNCT	O
XX	O	NOUN	B
,	O	PUNCT	O
del	O	X	B
(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q33	O	NOUN	O
)	O	PUNCT	O
karyotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
girl	O	NOUN	B
is	O	AUX	O
a	O	DET	O
hemizygote	O	NOUN	B
for	O	ADP	O
AGA	O	NOUN	B
,	O	PUNCT	O
permitting	O	VERB	O
the	O	DET	O
assignment	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
AGA	O	NOUN	B
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
4q33	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Resolution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
loci	O	NOUN	B
for	O	ADP	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	O
,	O	PUNCT	O
AN1	O	NOUN	B
and	O	CCONJ	O
AN2	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
locus	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
11p13	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
distinct	O	ADJ	O
loci	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
for	O	ADP	O
aniridia	B-Disease	NOUN	B
;	O	PUNCT	O
AN1	O	NOUN	B
for	O	ADP	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
2p	O	NOUN	I
and	O	CCONJ	O
AN2	O	NOUN	B
for	O	ADP	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
WAGR	B-Disease	NOUN	B
contiguous	I-Disease	ADJ	I
gene	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
11p13	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
kindred	O	ADJ	B
segregating	O	VERB	B
for	O	ADP	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	O
,	O	PUNCT	O
which	O	DET	O
suggested	O	VERB	O
linkage	O	NOUN	B
to	O	PART	O
acid	O	NOUN	B
phosphatase	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
ACP1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
assignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AN1	O	NOUN	B
locus	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
2p	O	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
updated	O	VERB	O
and	O	CCONJ	O
expanded	O	VERB	B
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
between	O	ADP	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
ACP1	O	NOUN	B
does	O	AUX	O
not	O	PART	O
support	O	VERB	O
the	O	DET	O
original	O	ADJ	B
linkage	O	NOUN	B
results	O	NOUN	B
,	O	PUNCT	O
excluding	O	VERB	O
linkage	O	NOUN	B
up	O	ADP	O
to	O	PART	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
with	O	ADP	O
Z	O	NOUN	B
=	O	ADJ	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O


Tests	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
other	O	ADJ	O
chromosome	O	NOUN	B
2p	O	NOUN	I
markers	O	NOUN	B
.	O	PUNCT	O


APOB	O	NOUN	B
,	O	PUNCT	O
D2S71	O	NOUN	B
,	O	PUNCT	O
D2S5	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D2S1	O	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
excluded	O	VERB	O
linkage	O	NOUN	B
to	O	PART	O
aniridia	B-Disease	NOUN	B
.	O	PUNCT	O


Markers	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
been	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
11p13	O	NOUN	I
region	O	NOUN	I
were	O	AUX	O
then	O	ADV	O
analyzed	O	VERB	B
in	O	ADP	O
this	O	DET	O
aniridia	B-Disease	NOUN	B
family	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
RFLPs	O	NOUN	B
at	O	ADP	O
the	O	DET	O
D11S323	O	ADJ	B
locus	O	NOUN	I
give	O	VERB	O
significant	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PvuII	O	NOUN	B
polymorphism	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
probe	O	NOUN	B
p5S1	O	PROPN	B
.	O	PUNCT	O


6	O	NUM	O
detects	O	VERB	O
no	O	DET	O
recombinants	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
maximum	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
Z	O	NOUN	B
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O


97	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
00	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
HaeIII	O	NOUN	B
polymorphism	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
probe	O	NOUN	B
p5BE1	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
gives	O	VERB	O
a	O	DET	O
maximum	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
Z	O	NOUN	B
=	O	ADJ	O
2	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
00	O	NUM	O
.	O	PUNCT	O


Locus	O	NOUN	B
D11S325	O	PROPN	B
gives	O	VERB	O
a	O	DET	O
lod	O	ADJ	B
score	O	NOUN	I
of	O	ADP	O
Z	O	NOUN	B
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


53	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
00	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
locus	O	NOUN	B
for	O	ADP	O
aniridia	B-Disease	NOUN	B
(	O	PUNCT	O
AN1	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
chromosome	O	NOUN	B
2p	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
misassigned	O	VERB	B
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	B
family	O	NOUN	I
is	O	AUX	O
segregating	O	VERB	B
for	O	ADP	O
an	O	DET	O
aniridia	B-Disease	NOUN	B
mutation	O	NOUN	B
linked	O	VERB	O
to	O	PART	O
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
11p13	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


Fatal	O	ADJ	B
pyoderma	B-Disease	NOUN	B
gangrenosum	I-Disease	NOUN	I
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
pyoderma	B-Disease	NOUN	B
gangrenosum	I-Disease	NOUN	I
(	O	PUNCT	O
PG	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
often	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
systemic	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
congenital	B-Disease	ADJ	B
complement	I-Disease	NOUN	I
deficiencies	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
an	O	DET	O
aggressive	O	ADJ	B
and	O	CCONJ	O
ultimately	O	ADV	O
fatal	O	ADJ	B
case	O	NOUN	B
of	O	ADP	O
PG	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
congenital	O	ADJ	B
C7	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Deficiencies	B-Disease	NOUN	B
of	I-Disease	ADP	O
C7	I-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreased	O	VERB	B
neutrophil	O	NOUN	B
chemotaxis	O	NOUN	O
,	O	PUNCT	O
phagocytosis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
opsonization	O	NOUN	B
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
immunologic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
described	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
PG	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
patients	O	NOUN	B
decreased	O	VERB	B
complement	O	NOUN	B
level	O	NOUN	I
,	O	PUNCT	O
if	O	SCONJ	O
not	O	PART	O
directly	O	ADV	O
related	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
PG	B-Disease	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	PART	O
the	O	DET	O
aggressive	O	ADJ	B
nature	O	NOUN	O
of	O	ADP	O
her	O	PRON	O
disease	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Diverse	O	ADJ	B
point	O	NOUN	O
mutations	O	NOUN	O
result	O	VERB	O
in	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
polymorphism	O	NOUN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
PHOSPHATE	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
;	I-Disease	PUNCT	O
EC	I-Disease	NOUN	B
1	I-Disease	NUM	I
.	I-Disease	PUNCT	O
1	I-Disease	NUM	O
.	I-Disease	PUNCT	O
1	I-Disease	X	O
.	I-Disease	PUNCT	O
49	I-Disease	NUM	O
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
human	O	ADJ	B
enzymopathy	B-Disease	NOUN	O
,	O	PUNCT	O
affecting	O	VERB	B
more	O	ADJ	O
than	O	ADP	O
200	O	NUM	O
million	O	NUM	O
people	O	NOUN	B
worldwide	O	ADV	O
.	O	PUNCT	O


Although	O	SCONJ	O
greater	O	ADJ	O
than	O	ADP	O
400	O	NUM	O
variants	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
criteria	O	NOUN	I
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
these	O	DET	O
G6PD	B-Disease	NOUN	B
deficiencies	I-Disease	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
encodes	O	VERB	B
human	O	ADJ	B
G6PD	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
enables	O	VERB	O
us	O	PRON	O
to	O	PART	O
examine	O	VERB	O
directly	O	ADV	O
the	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
at	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
level	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
past	O	ADJ	O
10	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
G6PD	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
21	O	NUM	O
,	O	PUNCT	O
271	O	NUM	O
newborn	O	ADJ	B
Chinese	O	ADJ	I
infants	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
,	O	PUNCT	O
400	O	NUM	O
males	O	NOUN	B
and	O	CCONJ	O
9	O	NUM	O
,	O	PUNCT	O
871	O	NUM	O
females	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
identified	O	VERB	B
314	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
males	O	NOUN	B
and	O	CCONJ	O
246	O	NUM	O
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
females	O	NOUN	B
having	O	VERB	O
low	O	ADJ	O
G6PD	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
G6PD	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
10	O	NUM	O
randomly	O	ADV	O
selected	O	VERB	O
affected	O	VERB	B
individuals	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
relatives	O	NOUN	B
was	O	AUX	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
amplified	O	VERB	B
,	O	PUNCT	O
subcloned	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
at	O	ADP	O
least	O	ADJ	O
four	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
polymorphism	O	NOUN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
(	O	PUNCT	O
487	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
an	O	DET	O
affected	O	VERB	B
Chinese	O	PROPN	B
with	O	ADP	O
a	O	DET	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
change	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
487	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
(	O	PUNCT	O
163	O	NUM	O
)	O	PUNCT	O
Gly	O	NOUN	B
to	O	PART	O
Ser	O	NOUN	B
substitution	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
(	O	PUNCT	O
493	O	NUM	O
A	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
G	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
mutation	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
any	O	DET	O
other	O	ADJ	O
ethnic	O	ADJ	B
group	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
Chinese	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
causes	O	VERB	O
an	O	DET	O
A	O	NOUN	O
to	O	PART	O
G	O	NOUN	B
change	O	NOUN	I
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
493	O	NUM	O
,	O	PUNCT	O
producing	O	VERB	O
an	O	DET	O
(	O	PUNCT	O
165	O	NUM	O
)	O	PUNCT	O
Asn	O	NOUN	B
to	O	PART	O
Asp	O	NOUN	B
substitution	O	NOUN	B
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
487	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	B
and	O	CCONJ	O
493	O	NUM	O
A	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
G	O	NOUN	B
mutations	O	NOUN	B
create	O	VERB	O
Alu	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
Ava	O	NOUN	B
II	O	NUM	I
recognition	O	NOUN	I
sites	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
which	O	DET	O
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
rapidly	O	ADV	O
detect	O	VERB	B
these	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
by	O	ADP	O
PCR	O	NOUN	B
/	O	SYM	O
restriction	O	NOUN	B
enzyme	O	NOUN	I
(	O	PUNCT	O
RE	O	NOUN	B
)	O	PUNCT	O
digestion	O	NOUN	B
method	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
third	O	ADJ	O
mutation	O	NOUN	B
(	O	PUNCT	O
1376	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
four	O	NUM	O
affected	O	VERB	B
Chinese	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
causes	O	VERB	O
a	O	DET	O
G	O	NOUN	B
to	O	PART	O
T	O	NOUN	O
change	O	NOUN	O
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
1376	O	NUM	O
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
an	O	DET	O
(	O	PUNCT	O
459	O	NUM	O
)	O	PUNCT	O
Arg	O	NOUN	B
to	O	PART	O
Leu	O	NOUN	B
substitution	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
1376	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
mutation	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
dominant	O	ADJ	B
allele	O	NOUN	B
that	O	PRON	O
causes	O	VERB	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
in	O	ADP	O
Taiwan	O	PROPN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
two	O	NUM	O
affected	O	VERB	O
Chinese	O	PROPN	B
were	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
having	O	VERB	O
the	O	DET	O
fourth	O	ADJ	O
mutation	O	NOUN	B
(	O	PUNCT	O
1388	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
causes	O	VERB	O
a	O	DET	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
change	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
1388	O	NUM	O
that	O	PRON	O
produces	O	VERB	O
an	O	DET	O
(	O	PUNCT	O
463	O	NUM	O
)	O	PUNCT	O
Arg	O	NOUN	B
to	O	PART	O
His	O	PRON	O
substitution	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
studies	O	NOUN	B
provide	O	VERB	O
the	O	DET	O
direct	O	ADJ	O
proof	O	NOUN	O
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
Chinese	O	ADJ	B
populations	O	NOUN	I
of	O	ADP	O
Taiwan	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
PCR	O	PROPN	B
/	O	SYM	O
RE	O	NOUN	B
digestion	O	NOUN	B
method	O	NOUN	I
is	O	AUX	O
suitable	O	ADJ	O
for	O	ADP	O
simultaneous	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
the	O	DET	O
487	O	NUM	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	B
and	O	CCONJ	O
493	O	NUM	O
A	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
G	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
error	O	NOUN	B
in	O	ADP	O
dystrophin	O	NOUN	B
mRNA	O	NOUN	B
processing	O	NOUN	O
in	O	ADP	O
golden	B-Disease	ADJ	B
retriever	I-Disease	NOUN	I
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
animal	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Golden	B-Disease	PROPN	B
retriever	I-Disease	NOUN	I
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
GRMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
spontaneous	O	ADJ	B
,	O	PUNCT	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	O
,	O	PUNCT	O
progressively	O	ADV	O
fatal	O	ADJ	B
disease	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
a	O	DET	O
homologue	O	NOUN	B
of	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
-	O	PUNCT	O
thirds	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
carry	O	VERB	O
detectable	O	ADJ	B
deletions	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
defect	O	NOUN	B
underlying	O	VERB	O
the	O	DET	O
remaining	O	VERB	O
one	O	NUM	O
-	O	PUNCT	O
third	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
is	O	AUX	O
undetermined	O	ADJ	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
canine	O	ADJ	B
dystrophin	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
GRMD	B-Disease	NOUN	B
dogs	O	NOUN	B
has	O	AUX	O
failed	O	VERB	B
to	O	PART	O
demonstrate	O	VERB	O
any	O	DET	O
detectable	O	ADJ	B
loss	O	NOUN	B
of	O	ADP	I
exons	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
demonstrated	O	VERB	O
a	O	DET	O
RNA	O	NOUN	B
processing	O	NOUN	I
error	O	NOUN	I
in	O	ADP	O
GRMD	B-Disease	PROPN	B
that	O	PRON	O
results	O	VERB	B
from	O	ADP	O
a	O	DET	O
single	O	ADJ	O
base	O	NOUN	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
consensus	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
6	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
seventh	O	ADJ	O
exon	O	NOUN	B
is	O	AUX	O
then	O	ADV	O
skipped	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
predicts	O	VERB	O
a	O	DET	O
termination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
reading	O	NOUN	I
frame	O	NOUN	I
within	O	ADP	O
its	O	PRON	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
example	O	NOUN	O
of	O	ADP	O
dystrophin	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Type	B-Disease	NOUN	B
I	I-Disease	NUM	I
human	I-Disease	ADJ	I
complement	I-Disease	NOUN	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
gene	O	NOUN	I
deletion	O	NOUN	O
causes	O	VERB	O
skipping	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
6	O	NUM	O
during	O	ADP	O
RNA	O	NOUN	B
splicing	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
variants	O	NOUN	B
of	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
protein	I-Disease	NOUN	I
C2	I-Disease	NOUN	I
(	O	PUNCT	O
C2D	O	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
identified	O	VERB	B
.	O	PUNCT	O


No	O	DET	B
C2	O	NOUN	I
protein	O	NOUN	I
translation	O	NOUN	B
is	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
type	O	NOUN	B
I	O	NUM	I
deficiency	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
type	O	NOUN	B
II	O	NUM	I
deficiency	O	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
block	O	NOUN	O
in	O	ADP	O
C2	O	NOUN	O
secretion	O	NOUN	B
.	O	PUNCT	O


Type	B-Disease	NOUN	B
I	I-Disease	NUM	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
was	O	AUX	O
described	O	VERB	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
C2	O	NOUN	B
null	O	ADJ	I
allele	O	NOUN	I
(	O	PUNCT	I
C2Q0	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
major	O	ADJ	O
histocompatibility	O	NOUN	B
haplotype	O	NOUN	B
/	O	PUNCT	O
complotype	O	NOUN	B
HLA	O	NOUN	B
-	O	PUNCT	O
A25	O	NOUN	B
,	O	PUNCT	O
B18	O	NOUN	B
,	O	PUNCT	O
C2Q0	O	NOUN	B
,	O	PUNCT	O
BfS	O	NOUN	B
,	O	PUNCT	O
C4A4	O	NOUN	B
,	O	PUNCT	O
C4B2	O	NOUN	B
,	O	PUNCT	O
Drw2	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
extended	O	VERB	O
haplotype	O	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
over	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
C2	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
individuals	O	NOUN	B
(	O	PUNCT	O
common	O	ADJ	O
complotype	O	NOUN	B
/	O	PUNCT	O
haplotype	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
C2	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
cDNA	O	NOUN	B
were	O	AUX	O
characterized	O	VERB	B
from	O	ADP	O
a	O	DET	O
homozygous	O	ADJ	B
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
C2	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
individual	O	NOUN	B
with	O	ADP	O
the	O	DET	O
common	O	ADJ	O
associated	O	VERB	O
haplotype	O	NOUN	B
/	O	SYM	O
complotype	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
a	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
type	O	NOUN	B
I	O	NUM	I
C2Q0	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
beginning	O	VERB	O
9	O	NUM	O
base	O	NOUN	B
pairs	O	NOUN	I
upstream	O	ADJ	I
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
end	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
that	O	PRON	O
generates	O	VERB	O
a	O	DET	O
C2	O	NOUN	O
transcript	O	NOUN	B
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
deletion	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
6	O	NUM	I
(	O	PUNCT	O
134	O	NUM	O
base	O	NOUN	B
pair	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
studies	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
kindred	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
C2Q0	O	NOUN	B
alleles	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
common	O	ADJ	O
type	O	NOUN	B
I	O	NUM	I
deficient	O	ADJ	I
complotype	O	NOUN	B
/	O	PUNCT	O
haplotype	O	NOUN	B
;	O	PUNCT	O
this	O	DET	O
deletion	O	NOUN	B
was	O	AUX	O
not	O	PART	O
present	O	ADJ	O
in	O	ADP	O
normal	O	ADJ	B
C2	O	NOUN	I
nor	O	CCONJ	O
in	O	ADP	O
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
C2	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
genes	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
1	O	X	O
)	O	PUNCT	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
human	I-Disease	ADJ	I
complement	I-Disease	NOUN	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
genomic	O	ADJ	B
deletion	O	NOUN	I
that	O	PRON	O
causes	O	VERB	O
skipping	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
6	O	NUM	O
during	O	ADP	O
RNA	O	NOUN	B
splicing	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
generation	O	NOUN	O
of	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	I
,	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
type	O	NOUN	B
I	O	NUM	I
C2Q0	O	NOUN	I
gene	O	NOUN	I
is	O	AUX	O
strongly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
HLA	O	NOUN	B
haplotype	O	NOUN	B
/	O	PUNCT	O
complotype	O	NOUN	B
A25	O	NOUN	I
,	O	PUNCT	O
B18	O	NOUN	B
,	O	PUNCT	O
C2Q0	O	NOUN	B
,	O	PUNCT	O
BfS	O	NOUN	B
,	O	PUNCT	O
C4A4	O	NOUN	B
,	O	PUNCT	O
C4B2	O	NOUN	B
,	O	PUNCT	O
Drw2	O	PROPN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
C2	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
individuals	O	NOUN	B
with	O	ADP	O
this	O	DET	O
haplotype	O	NOUN	B
/	O	SYM	O
complotype	O	NOUN	B
will	O	AUX	O
harbor	O	VERB	O
the	O	DET	O
28	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
C2	O	NOUN	I
gene	O	NOUN	I
deletion	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	X	O
)	O	PUNCT	O
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
different	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
yet	O	ADV	O
uncharacterized	O	ADJ	B
,	O	PUNCT	O
molecular	O	ADJ	B
genetic	B-Disease	ADJ	I
defect	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
polymorphism	O	NOUN	B
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
L74P	O	NOUN	B
and	O	CCONJ	O
F171S	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
polymorphism	O	NOUN	B
,	O	PUNCT	O
S135L	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
human	O	ADJ	B
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	CCONJ	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
reduced	O	VERB	B
enzymatic	O	ADJ	B
activity	O	NOUN	I
when	O	SCONJ	O
reconstructed	O	VERB	B
in	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
and	O	CCONJ	O
overexpressed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
polymorphism	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
has	O	AUX	O
near	O	ADP	O
normal	O	ADJ	O
activity	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
affect	O	VERB	O
evolutionarily	O	ADV	O
conserved	O	VERB	B
residues	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
are	O	AUX	O
functionally	O	ADV	O
important	O	ADJ	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
polymorphism	O	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
a	O	DET	O
nonconserved	O	ADJ	B
domain	O	NOUN	I
which	O	DET	O
is	O	AUX	O
presumably	O	ADV	O
not	O	PART	O
critical	O	ADJ	O
for	O	ADP	O
enzymatic	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
F171S	O	NOUN	B
mutation	O	NOUN	B
is	O	AUX	O
close	O	ADJ	O
to	O	PART	O
the	O	DET	O
putative	O	ADJ	O
active	O	ADJ	B
-	O	PUNCT	O
site	O	NOUN	B
nucleophile	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
further	O	ADV	O
support	O	VERB	O
the	O	DET	O
notion	O	NOUN	O
of	O	ADP	O
molecular	O	ADJ	B
heterogeneity	O	NOUN	I
of	O	ADP	O
galactosemia	B-Disease	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
GALT	O	NOUN	B
polymorphisms	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
tools	O	NOUN	B
in	O	ADP	O
highlighting	O	VERB	O
different	O	ADJ	O
functional	O	ADJ	B
domains	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
GALT	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	ADJ	B
relationship	O	NOUN	B
of	O	ADP	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
HLA	O	NOUN	B
and	O	CCONJ	O
glyoxalase	O	NOUN	B
I	O	NUM	I
loci	O	NOUN	I
.	O	PUNCT	O


Immunogenetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
homozygous	O	ADJ	B
C2	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
individual	O	NOUN	B
and	O	CCONJ	O
family	O	NOUN	B
members	O	NOUN	I
demonstrated	O	VERB	O
linkage	O	NOUN	B
of	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
A25	O	NOUN	B
,	O	PUNCT	O
B18	O	NOUN	B
and	O	CCONJ	O
C2o	O	NOUN	B
.	O	PUNCT	O


HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
typing	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
5	O	NUM	O
members	O	NOUN	B
typed	O	VERB	B
with	O	ADP	O
homozygous	O	ADJ	B
Dw2	O	NOUN	B
typing	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
with	O	ADP	I
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
Dw2	O	NOUN	B
typing	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
2	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
C2	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
homozygous	O	ADJ	B
C2	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
propositus	O	NOUN	B
and	O	CCONJ	O
brother	O	NOUN	B
were	O	AUX	O
HLA	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	B
and	O	CCONJ	O
B	O	NOUN	B
homozygous	O	ADJ	B
but	O	CCONJ	O
heterozygous	O	ADJ	B
at	O	ADP	O
the	O	DET	O
HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
and	O	CCONJ	O
glyoxalase	O	NOUN	B
I	O	NUM	I
loci	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
C2o	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
linked	O	VERB	O
with	O	ADP	O
two	O	NUM	O
distinct	O	ADJ	O
haplotypes	O	NOUN	B
HLA	O	NOUN	B
-	O	PUNCT	O
A25	O	NOUN	B
,	O	PUNCT	O
B18	O	NOUN	B
,	O	PUNCT	O
Dw2	O	NOUN	B
,	O	PUNCT	O
GLO1	O	NOUN	B
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
A25	O	NOUN	B
,	O	PUNCT	O
B18	O	NOUN	B
,	O	PUNCT	O
D	O	NOUN	B
unknown	O	ADJ	O
,	O	PUNCT	O
GL02	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
an	O	DET	O
ancestral	O	ADJ	B
recombinant	O	ADJ	O
event	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
occurred	O	VERB	O
between	O	ADP	O
the	O	DET	O
C2o	O	NOUN	B
locus	O	NOUN	I
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
which	O	DET	O
C2o	O	NOUN	O
segregated	O	VERB	O
with	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
B	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
would	O	AUX	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
locus	O	NOUN	B
for	O	ADP	O
the	O	DET	O
C2o	O	NOUN	B
gene	O	NOUN	I
maps	O	NOUN	O
between	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
B	O	NOUN	B
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
on	O	ADP	O
the	O	DET	O
sixth	O	ADJ	B
chromosome	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Wilms	B-Disease	NOUN	B
'	I-Disease	PART	I
tumor	I-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
abnormal	O	ADJ	B
urogenital	O	ADJ	B
development	O	NOUN	I
in	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
human	O	ADJ	B
condition	O	NOUN	B
in	O	ADP	O
which	O	DET	O
severe	O	ADJ	B
urogenital	B-Disease	ADJ	B
aberrations	I-Disease	NOUN	I
result	O	VERB	O
in	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
pseudohermaphroditism	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
(	O	PUNCT	O
nephroblastoma	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
its	O	PRON	O
possible	O	ADJ	O
role	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
the	O	DET	O
coding	O	VERB	B
exons	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Wilms	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
suppressor	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
WT1	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
ten	O	NUM	O
independent	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
domains	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
WT1	O	NOUN	B
gene	O	NOUN	I
copy	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Nine	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
found	O	VERB	O
within	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
(	O	PUNCT	O
zinc	O	NOUN	B
finger	O	NOUN	I
III	O	NUM	I
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
remaining	O	VERB	O
mutation	O	NOUN	B
is	O	AUX	O
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
(	O	PUNCT	O
zinc	O	NOUN	B
finger	O	NOUN	I
II	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
mutations	O	NOUN	B
directly	O	ADV	O
affect	O	VERB	O
DNA	O	NOUN	B
sequence	O	NOUN	I
recognition	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
analyzed	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
shown	O	VERB	O
to	O	PART	O
arise	O	VERB	O
de	O	X	O
novo	O	X	O
.	O	PUNCT	O


Wilms	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
from	O	ADP	O
three	O	NUM	O
individuals	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
juvenile	O	NOUN	B
granulosa	O	NOUN	B
cell	O	NOUN	I
tumor	B-Disease	NOUN	O
demonstrate	O	VERB	O
reduction	O	NOUN	B
to	O	PART	O
homozygosity	O	NOUN	B
for	O	ADP	O
the	O	DET	O
mutated	O	VERB	B
WT1	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
direct	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
WT1	O	NOUN	B
in	O	ADP	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
thus	O	ADV	O
urogenital	O	ADJ	B
system	O	NOUN	I
development	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
and	O	CCONJ	O
application	O	NOUN	B
in	O	ADP	O
post	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
performed	O	VERB	O
linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
markers	O	NOUN	I
DXS52	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
clotting	O	NOUN	B
factor	O	NOUN	I
VIII	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
F8C	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
several	O	ADJ	O
large	O	ADJ	O
families	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
tight	O	ADJ	O
linkage	O	NOUN	O
to	O	PART	O
DXS52	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
extended	O	VERB	B
giving	O	VERB	O
a	O	DET	O
maximal	O	ADJ	B
LOD	O	NOUN	B
score	O	NOUN	B
of	O	ADP	O
22	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
at	O	ADP	O
1	O	NUM	O
cM	O	NOUN	B
.	O	PUNCT	O


F8C	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
ALD	B-Disease	NOUN	B
with	O	ADP	O
a	O	DET	O
maximal	O	ADJ	B
LOD	O	NOUN	B
score	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
without	O	ADP	O
recombination	O	NOUN	B
.	O	PUNCT	O


Multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
with	O	ADP	O
the	O	DET	O
markers	O	NOUN	B
DXS304	O	NOUN	O
,	O	PUNCT	O
DXS52	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
F8C	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
F8C	O	NOUN	B
are	O	AUX	O
distal	O	ADJ	B
to	O	PART	O
DXS52	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
,	O	PUNCT	O
no	O	DET	O
major	O	ADJ	O
structural	O	ADJ	B
rearrangement	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Xqter	O	NOUN	B
region	O	NOUN	I
was	O	AUX	O
observed	O	VERB	B
;	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
abnormalities	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
vision	I-Disease	NOUN	B
blindness	I-Disease	NOUN	I
genes	I-Disease	NOUN	I
.	O	PUNCT	O


DNA	O	NOUN	B
analysis	O	NOUN	I
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
use	O	NOUN	O
in	O	ADP	O
determination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carrier	O	NOUN	B
status	O	NOUN	I
of	O	ADP	O
females	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
distinct	O	ADJ	O
mutations	O	NOUN	B
at	O	ADP	O
a	O	DET	O
single	O	ADJ	O
BamHI	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


Classical	B-Disease	ADJ	O
phenylketonuria	I-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
abolition	O	NOUN	B
of	O	ADP	O
an	O	DET	O
invariant	O	ADJ	O
BamHI	O	NOUN	B
site	O	NOUN	I
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
exon	O	NOUN	B
7	O	NUM	I
)	O	PUNCT	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
recognition	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
new	O	ADJ	O
point	O	NOUN	O
mutations	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
272	O	NUM	O
and	O	CCONJ	O
273	O	NUM	O
(	O	PUNCT	O
272gly	O	ADV	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
stop	O	NOUN	B
and	O	CCONJ	O
273ser	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
phe	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
north	O	NOUN	B
eastern	O	ADJ	I
France	O	PROPN	I
or	O	CCONJ	O
Belgium	O	PROPN	B
and	O	CCONJ	O
occurred	O	VERB	O
on	O	ADP	O
the	O	DET	O
background	O	NOUN	B
of	O	ADP	O
RFLP	O	NOUN	B
haplotype	O	NOUN	B
7	O	NUM	O
alleles	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
clinical	O	ADJ	B
heterogeneity	O	NOUN	O
in	O	ADP	O
PKU	B-Disease	NOUN	B
is	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
the	O	DET	O
large	O	ADJ	O
variety	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
genotypes	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
PAH	B-Disease	NOUN	B
deficiencies	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
detailed	O	ADJ	O
multipoint	O	ADJ	B
map	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
4	O	NUM	I
provides	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
heterogeneity	O	NOUN	B
and	O	CCONJ	O
position	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
recombination	O	NOUN	B
rates	O	NOUN	B
.	O	PUNCT	O


Utilizing	O	VERB	O
the	O	DET	O
CEPH	O	PROPN	B
reference	O	NOUN	B
panel	O	NOUN	I
and	O	CCONJ	O
genotypic	O	ADJ	B
data	O	NOUN	B
for	O	ADP	O
53	O	NUM	O
markers	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
constructed	O	VERB	O
a	O	DET	O
20	O	NUM	O
-	O	PUNCT	O
locus	O	NOUN	B
multipoint	O	ADJ	B
genetic	O	ADJ	I
map	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
4	O	NUM	I
.	O	PUNCT	O


New	O	ADJ	B
RFLPs	O	NOUN	I
are	O	AUX	O
reported	O	VERB	O
for	O	ADP	O
four	O	NUM	O
loci	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
map	O	NOUN	B
integrates	O	VERB	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
genetic	O	ADJ	B
map	O	NOUN	I
of	O	ADP	O
4p16	O	NOUN	B
into	O	ADP	O
a	O	DET	O
continuous	O	ADJ	B
map	O	NOUN	I
extending	O	VERB	O
to	O	PART	O
4q31	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
unlinked	O	ADJ	O
cluster	O	NOUN	O
of	O	ADP	O
three	O	NUM	O
loci	O	NOUN	B
at	O	ADP	O
4q35	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
20	O	NUM	O
linked	O	VERB	O
markers	O	NOUN	B
form	O	VERB	O
a	O	DET	O
continuous	O	ADJ	B
linkage	O	NOUN	B
group	O	NOUN	O
of	O	ADP	O
152	O	NUM	O
cM	O	NOUN	B
in	O	ADP	O
males	O	NOUN	B
and	O	CCONJ	O
202	O	NUM	O
cM	O	NOUN	B
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Likely	O	ADJ	O
genetic	O	ADJ	B
locations	O	NOUN	I
are	O	AUX	O
provided	O	VERB	O
for	O	ADP	O
25	O	NUM	O
polymorphic	O	ADJ	B
anonymous	O	ADJ	O
sequences	O	NOUN	O
and	O	CCONJ	O
28	O	NUM	O
gene	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
RFLPs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
map	O	NOUN	B
was	O	AUX	O
constructed	O	VERB	O
employing	O	VERB	O
the	O	DET	O
LINKAGE	O	NOUN	B
and	O	CCONJ	O
CRIMAP	O	NOUN	B
computational	O	ADJ	B
methodologies	O	NOUN	O
to	O	PART	O
build	O	VERB	O
the	O	DET	O
multipoint	O	ADJ	B
map	O	NOUN	I
via	O	ADP	O
a	O	DET	O
stepwise	O	ADJ	O
algorithm	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
detailed	O	ADJ	O
10	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
map	O	NOUN	I
of	O	ADP	O
the	O	DET	O
4p16	O	NOUN	B
region	O	NOUN	I
constructed	O	VERB	O
from	O	ADP	O
the	O	DET	O
CEPH	O	PROPN	B
panel	O	NOUN	B
provides	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
heterogeneity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
maps	O	NOUN	B
constructed	O	VERB	O
from	O	ADP	O
families	O	NOUN	B
segregating	O	VERB	B
for	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
additionally	O	ADV	O
provides	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
position	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
recombination	O	NOUN	B
frequencies	O	NOUN	B
in	O	ADP	O
the	O	DET	O
telomeric	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
4p	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Carrier	O	NOUN	B
detection	O	NOUN	O
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
using	O	VERB	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
anonymous	O	ADJ	B
DNA	O	NOUN	B
polymorphisms	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
cDNA	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	B
carrier	O	NOUN	B
identification	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
using	O	VERB	O
DNA	O	NOUN	B
polymorphisms	O	NOUN	I
in	O	ADP	O
2	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Pelizaeus	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
the	O	DET	O
single	O	ADJ	O
affected	O	VERB	B
male	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
traced	O	VERB	O
back	O	ADV	O
to	O	ADP	O
his	O	PRON	O
unaffected	O	ADJ	O
maternal	O	ADJ	B
grandfather	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
each	O	DET	O
family	O	NOUN	B
contains	O	VERB	O
a	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
fetus	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
cytogenetic	O	ADJ	B
analysis	O	NOUN	I
to	O	PART	O
be	O	AUX	O
a	O	DET	O
female	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
we	O	PRON	O
predict	O	VERB	O
will	O	AUX	O
be	O	AUX	O
a	O	DET	O
noncarrier	O	NOUN	B
of	O	ADP	O
PMD	B-Disease	NOUN	B
based	O	VERB	O
on	O	ADP	O
her	O	PRON	O
genotype	O	NOUN	B
with	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
intragenic	O	ADJ	B
polymorphism	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
deletion	O	NOUN	B
mutations	O	NOUN	I
and	O	CCONJ	O
three	O	NUM	O
new	O	ADJ	O
genes	O	NOUN	B
at	O	ADP	O
the	O	DET	O
familial	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


Small	O	ADJ	B
(	O	PUNCT	O
100	O	NUM	O
-	O	PUNCT	O
260	O	NUM	O
kb	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
nested	O	ADJ	B
deletions	O	NOUN	B
were	O	AUX	O
characterized	O	VERB	B
in	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
candidate	O	NOUN	O
genes	O	NOUN	B
located	O	ADJ	O
within	O	ADP	O
the	O	DET	O
deleted	O	VERB	B
region	O	NOUN	I
were	O	AUX	O
ascertained	O	VERB	O
and	O	CCONJ	O
a	O	DET	O
previous	O	ADJ	O
candidate	O	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
MCC	O	PROPN	B
,	O	PUNCT	O
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
located	O	ADJ	O
outside	O	ADP	O
the	O	DET	O
deleted	O	VERB	B
region	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
new	O	ADJ	O
genes	O	NOUN	B
contained	O	VERB	O
sequence	O	NOUN	B
identical	O	ADJ	B
to	O	PART	O
SRP19	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
the	O	DET	O
19	O	NUM	O
kd	O	NOUN	O
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ribosomal	O	ADJ	B
signal	O	NOUN	I
recognition	O	NOUN	I
particle	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	NOUN	O
,	O	PUNCT	O
provisionally	O	ADV	O
designated	O	VERB	O
DP1	O	NOUN	B
(	O	PUNCT	O
deleted	O	VERB	B
in	O	ADP	O
polyposis	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
transcribed	O	VERB	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
orientation	O	NOUN	B
as	O	ADP	O
MCC	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
other	O	ADJ	O
cDNAs	O	NOUN	B
,	O	PUNCT	O
DP2	O	NOUN	B
and	O	CCONJ	O
DP3	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
overlap	O	VERB	B
,	O	PUNCT	O
forming	O	VERB	O
a	O	DET	O
single	O	ADJ	O
gene	O	NOUN	O
,	O	PUNCT	O
DP2	O	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
,	O	PUNCT	O
that	O	PRON	O
is	O	AUX	O
transcribed	O	VERB	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
orientation	O	NOUN	B
as	O	ADP	O
SRP19	O	NOUN	B
.	O	PUNCT	O


Exclusion	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
between	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	B
fever	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
human	O	ADJ	B
serum	O	NOUN	O
amyloid	O	NOUN	O
A	O	NOUN	O
(	O	PUNCT	O
SAA	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
cluster	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	B
trait	O	NOUN	I
familial	B-Disease	ADJ	O
Mediterranean	I-Disease	ADJ	B
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
serum	O	NOUN	B
amyloid	O	NOUN	I
A	O	NOUN	I
(	O	PUNCT	O
SAA	O	NOUN	B
)	O	PUNCT	O
genes	O	NOUN	O
by	O	ADP	O
comparing	O	VERB	B
alleles	O	NOUN	B
of	O	ADP	O
a	O	DET	O
highly	O	ADV	O
polymorphic	O	ADJ	B
dinucleotide	O	NOUN	B
repeat	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
conventional	O	ADJ	O
restriction	O	NOUN	O
fragment	O	NOUN	O
length	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
RFLP	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
SAA	O	NOUN	B
gene	O	NOUN	I
cluster	O	NOUN	I
in	O	ADP	O
Israeli	O	ADJ	B
FMF	B-Disease	NOUN	B
kindreds	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
minimum	O	ADJ	O
crossover	O	NOUN	B
frequency	O	NOUN	I
of	O	ADP	O
22	O	NUM	O
%	O	NOUN	O
between	O	ADP	O
the	O	DET	O
SAA	O	NOUN	B
gene	O	NOUN	I
marker	O	NOUN	O
and	O	CCONJ	O
FMF	B-Disease	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
conventional	O	ADJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
this	O	DET	O
eliminates	O	VERB	O
a	O	DET	O
minimum	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
cM	O	NOUN	B
including	O	VERB	O
and	O	CCONJ	O
surrounding	O	VERB	B
the	O	DET	O
SAA	O	NOUN	B
gene	O	NOUN	I
cluster	O	NOUN	I
as	O	ADP	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
FMF	B-Disease	NOUN	B
mutation	O	NOUN	B
although	O	SCONJ	O
SAA	O	NOUN	B
proteins	O	NOUN	I
are	O	AUX	O
prominent	O	ADJ	O
physiologic	O	ADJ	B
markers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
acute	O	ADJ	B
attacks	O	NOUN	O
.	O	PUNCT	O


PRAD1	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
candidate	O	NOUN	O
BCL1	O	NOUN	B
oncogene	O	NOUN	I
:	O	PUNCT	O
mapping	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
in	O	ADP	O
centrocytic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Rearrangement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BCL1	O	NOUN	B
(	O	PUNCT	O
B	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
lymphoma	O	NOUN	I
1	O	NUM	I
)	O	PUNCT	O
region	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
11q13	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
highly	O	ADV	O
characteristic	O	ADJ	O
of	O	ADP	O
centrocytic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
and	O	CCONJ	O
also	O	ADV	O
is	O	AUX	O
found	O	VERB	O
infrequently	O	ADV	O
in	O	ADP	O
other	O	ADJ	O
B	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
neoplasms	I-Disease	NOUN	I
.	O	PUNCT	O


Rearrangement	O	NOUN	B
is	O	AUX	O
thought	O	VERB	O
to	O	PART	O
deregulate	O	VERB	B
a	O	DET	O
nearby	O	ADJ	O
protooncogene	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
transcribed	O	VERB	B
sequences	O	NOUN	I
in	O	ADP	O
the	O	DET	O
immediate	O	ADJ	B
vicinity	O	NOUN	O
of	O	ADP	O
BCL1	O	NOUN	B
breakpoints	O	NOUN	B
had	O	AUX	O
not	O	PART	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


PRAD1	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
designated	O	VERB	O
D11S287E	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
on	O	ADP	O
11q13	O	NOUN	B
as	O	ADP	O
a	O	DET	O
chromosomal	O	ADJ	B
breakpoint	O	NOUN	I
region	O	NOUN	I
rearranged	O	VERB	O
with	O	ADP	O
the	O	DET	O
parathyroid	O	ADJ	B
hormone	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
parathyroid	B-Disease	ADJ	B
adenomas	I-Disease	NOUN	I
;	O	PUNCT	O
this	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
putative	O	ADJ	B
oncogene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
a	O	DET	O
novel	O	ADJ	O
cyclin	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
linked	O	VERB	O
to	O	PART	O
BCL1	O	NOUN	B
and	O	CCONJ	O
implicated	O	VERB	O
also	O	ADV	O
in	O	ADP	O
subsets	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
squamous	I-Disease	ADJ	B
cell	I-Disease	NOUN	I
neoplasms	I-Disease	NOUN	I
with	O	ADP	O
11q13	O	NOUN	B
amplification	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
pulsed	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
data	O	NOUN	B
showing	O	VERB	O
BCL1	O	NOUN	B
and	O	CCONJ	O
PRAD1	O	NOUN	B
to	O	PART	O
be	O	AUX	O
no	O	DET	O
more	O	ADJ	O
than	O	ADP	O
130	O	NUM	O
kilobases	O	NOUN	B
apart	O	ADV	O
.	O	PUNCT	O


PRAD1	O	NOUN	B
mRNA	O	NOUN	B
is	O	AUX	O
abundantly	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
centrocytic	B-Disease	ADJ	B
lymphomas	I-Disease	NOUN	I
(	O	PUNCT	O
Kiel	O	NOUN	B
classification	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
13	O	NUM	O
closely	O	ADV	O
related	O	ADJ	O
but	O	CCONJ	O
noncentrocytic	B-Disease	ADJ	B
lymphomas	I-Disease	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
of	O	ADP	O
the	O	DET	O
seven	O	NUM	O
centrocytic	B-Disease	ADJ	B
lymphomas	I-Disease	NOUN	I
had	O	AUX	O
detectable	O	ADJ	B
BCL1	O	NOUN	B
DNA	O	NOUN	B
rearrangement	O	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
two	O	NUM	O
unusual	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
CLL	O	NOUN	B
with	O	ADP	O
BCL1	O	NOUN	B
rearrangement	O	NOUN	I
overexpressed	O	ADJ	B
PRAD1	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
five	O	NUM	O
CLL	O	NOUN	B
controls	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
PRAD1	O	NOUN	B
is	O	AUX	O
an	O	DET	O
excellent	O	ADJ	B
candidate	O	NOUN	O
"	O	PUNCT	O
BCL1	O	NOUN	B
oncogene	O	NOUN	I
.	O	PUNCT	O


"	O	PUNCT	O
Its	O	PRON	O
overexpression	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
key	O	ADJ	O
consequence	O	NOUN	O
of	O	ADP	O
rearrangement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BCL1	O	NOUN	B
vicinity	O	NOUN	B
in	O	ADP	O
B	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
neoplasms	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
unifying	O	ADJ	O
pathogenetic	O	ADJ	B
feature	O	NOUN	I
in	O	ADP	O
centrocytic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
new	O	ADJ	O
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
juvenile	O	ADJ	B
metachromatic	B-Disease	ADJ	I
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
MLD	B-Disease	NOUN	B
)	O	PUNCT	O
patient	O	NOUN	B
.	O	PUNCT	O


Fragments	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
juvenile	O	NOUN	B
-	O	PUNCT	O
onset	O	NOUN	B
metachromatic	B-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
MLD	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
PCR	O	NOUN	B
and	O	CCONJ	O
ligated	O	VERB	B
into	O	ADP	O
MP13	O	NOUN	B
cloning	O	NOUN	I
vectors	O	NOUN	I
.	O	PUNCT	O


Clones	O	NOUN	B
hybridizing	O	VERB	B
with	O	ADP	O
cDNA	O	NOUN	B
for	O	ADP	O
human	O	ADJ	B
ARSA	O	NOUN	B
were	O	AUX	O
selected	O	VERB	O
,	O	PUNCT	O
examined	O	VERB	O
for	O	ADP	O
appropriate	O	ADJ	B
size	O	NOUN	B
inserts	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
used	O	VERB	O
to	O	PART	O
prepare	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
stranded	O	VERB	B
phage	O	NOUN	B
DNA	O	NOUN	B
.	O	PUNCT	O


Examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	NOUN	B
and	O	CCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
intronic	O	ADJ	B
sequence	O	NOUN	I
revealed	O	VERB	O
two	O	NUM	O
putative	O	ADJ	B
disease	O	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
isoleucine	O	NOUN	B
by	O	ADP	O
serine	O	NOUN	B
.	O	PUNCT	O


Introduction	O	NOUN	O
of	O	ADP	O
this	O	DET	O
alteration	O	NOUN	B
into	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
ARSA	O	NOUN	B
cDNA	O	NOUN	B
sequence	O	NOUN	O
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
ARSA	O	NOUN	B
activity	O	NOUN	B
on	O	ADP	O
transient	O	ADJ	B
expression	O	NOUN	B
in	O	ADP	O
cultured	O	VERB	B
baby	O	NOUN	I
hamster	O	NOUN	B
kidney	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


About	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
expression	O	NOUN	B
was	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
small	O	ADJ	O
residual	O	ADJ	O
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutated	O	VERB	B
ARSA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
mutation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	DET	O
transition	O	NOUN	B
,	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
allele	O	NOUN	B
and	O	CCONJ	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
altered	O	ADJ	O
splice	O	NOUN	B
-	O	PUNCT	O
recognition	O	NOUN	B
sequence	O	NOUN	I
between	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
following	O	VERB	O
intron	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
also	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
a	O	DET	O
restriction	O	NOUN	B
site	O	NOUN	I
.	O	PUNCT	O


Apparently	O	ADV	O
normal	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
were	O	AUX	O
generated	O	VERB	O
from	O	ADP	O
this	O	DET	O
allele	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
ARSA	O	NOUN	B
activity	O	NOUN	B
or	O	CCONJ	O
immuno	O	NOUN	B
-	O	PUNCT	O
cross	O	NOUN	B
-	O	PUNCT	O
reactive	O	ADJ	B
material	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
collection	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
known	O	VERB	O
or	O	CCONJ	O
suspected	O	VERB	B
MLD	B-Disease	PROPN	B
patients	O	NOUN	B
,	O	PUNCT	O
members	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
normal	O	ADJ	B
controls	O	NOUN	I
was	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
additional	O	ADJ	O
individuals	O	NOUN	B
carrying	O	VERB	B
each	O	DET	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
among	O	ADP	O
the	O	DET	O
nearly	O	ADV	O
100	O	NUM	O
MLD	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
sample	O	NOUN	B
.	O	PUNCT	O


Gene	O	NOUN	B
segregation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
original	O	ADJ	B
patients	O	NOUN	B
family	O	NOUN	B
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
available	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
data	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
individuals	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
either	O	DET	O
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
combinations	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
MLD	B-Disease	PROPN	B
mutations	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
point	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
does	O	AUX	O
result	O	VERB	O
in	O	ADP	O
some	O	DET	O
residual	O	ADJ	B
enzyme	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
forms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
following	O	VERB	O
exon	O	NOUN	B
7	O	NUM	I
produces	O	VERB	O
late	O	ADJ	B
-	O	PUNCT	O
infantile	O	ADJ	B
MLD	B-Disease	PROPN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
other	O	ADJ	O
enzyme	O	NOUN	B
-	O	PUNCT	O
null	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
implying	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
completely	O	ADV	O
silent	O	ADJ	B
enzymatically	O	ADV	B
.	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
and	O	CCONJ	O
presumptive	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
hematopoietic	O	ADJ	B
cell	O	NOUN	I
lineages	O	NOUN	B
of	O	ADP	O
a	O	DET	O
thrombocytopenic	O	ADJ	B
carrier	O	NOUN	I
female	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
thrombocytopenic	B-Disease	ADJ	B
female	O	NOUN	B
belonging	O	VERB	O
to	O	ADP	O
a	O	DET	O
pedigree	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Restriction	O	NOUN	B
fragment	O	NOUN	O
length	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
RFLP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
with	O	ADP	O
probe	O	NOUN	B
M27	O	NOUN	I
beta	O	NOUN	I
,	O	PUNCT	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
demonstrated	O	VERB	O
that	O	SCONJ	O
she	O	PRON	O
is	O	AUX	O
a	O	DET	O
carrier	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O


Both	O	CCONJ	O
small	O	ADJ	B
-	O	PUNCT	O
sized	O	ADJ	B
and	O	CCONJ	O
normal	O	ADJ	B
-	O	PUNCT	O
sized	O	ADJ	B
platelets	O	NOUN	B
were	O	AUX	O
present	O	ADJ	O
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
unlike	O	ADP	O
the	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
WAS	B-Disease	PROPN	B
carriers	O	NOUN	B
,	O	PUNCT	O
she	O	PRON	O
does	O	AUX	O
not	O	PART	O
manifest	O	VERB	O
nonrandom	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
thrombopoietic	O	ADJ	B
cell	O	NOUN	I
lineage	O	NOUN	O
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
RFLP	O	NOUN	B
and	O	CCONJ	O
methylation	O	NOUN	B
analysis	O	NOUN	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
was	O	AUX	O
nonrandom	O	ADJ	B
in	O	ADP	O
T	O	NOUN	B
lymphocytes	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
random	O	ADJ	B
in	O	ADP	O
granulocytes	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
complete	O	ADJ	O
report	O	NOUN	B
on	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
thrombocytopenia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
female	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	AUX	B
as	O	ADP	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
atypical	O	ADJ	B
lyonization	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
also	O	ADV	O
suggests	O	VERB	O
that	O	SCONJ	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	I
occurs	O	VERB	O
at	O	ADP	O
(	O	PUNCT	O
or	O	CCONJ	O
extends	O	VERB	O
up	O	ADV	O
to	O	PART	O
)	O	PUNCT	O
a	O	DET	O
later	O	ADJ	O
stage	O	NOUN	B
than	O	ADP	O
the	O	DET	O
multipotent	O	ADJ	B
stem	O	NOUN	I
cell	O	NOUN	I
along	O	ADP	O
the	O	DET	O
hematopoietic	O	ADJ	B
differentiation	O	NOUN	I
pathway	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
a	O	DET	O
German	O	ADJ	B
family	O	NOUN	I
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
C	O	PROPN	O
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
2	O	NUM	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
obligate	O	ADJ	B
carriers	O	NOUN	B
in	O	ADP	O
a	O	DET	O
German	O	ADJ	B
family	O	NOUN	I
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
causes	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
an	O	DET	O
HphI	O	NOUN	B
site	O	NOUN	B
and	O	CCONJ	O
changes	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
155	O	NUM	O
from	O	ADP	O
threonine	O	NOUN	B
to	O	PART	O
isoleucine	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
absent	O	ADJ	B
from	O	ADP	O
108	O	NUM	O
normal	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
5	O	NUM	O
concordances	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
discrepancy	O	NOUN	B
between	O	ADP	O
these	O	DET	O
results	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
obtained	O	VERB	O
by	O	ADP	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	B
results	O	VERB	O
in	O	ADP	O
a	O	DET	O
kinetic	O	ADJ	B
variant	O	NOUN	I
of	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
a	I-Disease	DET	O
hepatic	I-Disease	ADJ	B
enzyme	I-Disease	NOUN	I
,	I-Disease	PUNCT	O
phenylalanine	I-Disease	NOUN	B
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
PAH	O	NOUN	B
activity	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
typical	O	ADJ	O
PKU	B-Disease	NOUN	B
while	O	SCONJ	O
persistence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
residual	O	ADJ	B
enzyme	O	NOUN	B
activity	O	NOUN	I
gives	O	VERB	O
rise	O	NOUN	O
to	O	ADP	O
variant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
delta	O	NOUN	O
194	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
mild	O	ADJ	B
variant	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
markedly	O	ADV	O
reduced	O	VERB	B
affinity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
for	O	ADP	O
phenylalanine	O	NOUN	B
(	O	PUNCT	O
Km	O	NOUN	B
=	O	ADJ	O
160	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
provide	O	VERB	O
functional	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
responsibility	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
deletion	O	NOUN	B
was	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
exon	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
presents	O	VERB	O
no	O	DET	O
homology	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
hydroxylases	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
exon	O	NOUN	B
3	O	NUM	I
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
specificity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
for	O	ADP	O
phenylalanine	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
since	O	SCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
98	O	NUM	O
PKU	B-Disease	NOUN	B
patients	O	NOUN	B
tested	O	VERB	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
this	O	DET	O
particular	O	ADJ	O
deletion	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
molecular	O	ADJ	B
event	O	NOUN	I
probably	O	ADV	O
occurred	O	VERB	O
recently	O	ADV	O
on	O	ADP	O
the	O	DET	O
background	O	NOUN	B
of	O	ADP	O
a	O	DET	O
haplotype	O	NOUN	B
2	O	NUM	O
gene	O	NOUN	B
in	O	ADP	O
Portugal	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KIT	O	NOUN	B
(	O	PUNCT	O
mast	O	NOUN	B
/	O	SYM	O
stem	O	NOUN	B
cell	O	NOUN	I
growth	O	NOUN	O
factor	O	NOUN	O
receptor	O	NOUN	O
)	O	PUNCT	O
protooncogene	O	NOUN	O
in	O	ADP	O
human	O	ADJ	B
piebaldism	B-Disease	NOUN	B
.	O	PUNCT	O


Piebaldism	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	B
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
cogenital	O	ADJ	B
patches	O	NOUN	B
of	O	ADP	O
skin	O	NOUN	B
and	O	CCONJ	O
hair	O	NOUN	B
from	O	ADP	O
which	O	DET	O
melanocytes	O	NOUN	B
are	O	AUX	O
completely	O	ADV	O
absent	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
similar	O	ADJ	O
disorder	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
,	O	PUNCT	O
dominant	O	ADJ	B
white	O	ADJ	O
spotting	O	NOUN	O
(	O	PUNCT	O
W	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
results	O	VERB	B
from	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
c	O	NOUN	B
-	O	PUNCT	O
Kit	O	NOUN	B
protooncogene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
and	O	CCONJ	O
receptor	O	NOUN	B
for	O	ADP	O
mast	O	NOUN	B
/	O	PUNCT	O
stem	O	NOUN	B
cell	O	NOUN	I
growth	O	NOUN	O
factor	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
KIT	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
proband	O	NOUN	B
with	O	ADP	O
classic	O	ADJ	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
piebaldism	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
Gly	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
Arg	O	NOUN	B
substitution	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
664	O	NUM	I
,	O	PUNCT	O
within	O	ADP	O
the	O	DET	O
tyrosine	O	NOUN	B
kinase	O	NOUN	I
domain	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
substitution	O	NOUN	B
was	O	AUX	O
not	O	PART	O
seen	O	VERB	O
in	O	ADP	O
any	O	DET	O
normal	O	ADJ	O
individuals	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
completely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
piebald	B-Disease	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
family	O	NOUN	B
.	O	PUNCT	O


Piebaldism	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
thus	O	ADV	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
human	O	ADJ	B
homologue	O	NOUN	B
to	O	PART	O
dominant	O	ADJ	B
white	O	ADJ	O
spotting	O	NOUN	O
(	O	PUNCT	O
W	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
Japanese	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
normotriglyceridemic	B-Disease	ADJ	B
abetalipoproteinemia	I-Disease	NOUN	I
indicates	O	VERB	O
a	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
apolipoprotein	O	NOUN	B
B	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Normotriglyceridemic	B-Disease	ADJ	B
abetalipoproteinemia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
familial	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
an	O	DET	O
isolated	O	VERB	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
apoB	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
100	I-Disease	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
reported	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
normal	O	ADJ	O
apoB	O	NOUN	B
-	O	PUNCT	O
48	O	NUM	O
but	O	CCONJ	O
no	O	DET	O
apoB	O	NOUN	B
-	O	PUNCT	O
100	O	NUM	O
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
genetic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
linkage	O	NOUN	B
of	O	ADP	O
apoB	O	NOUN	B
gene	O	NOUN	I
using	O	VERB	O
three	O	NUM	O
genetic	O	ADJ	B
markers	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
and	O	CCONJ	O
her	O	PRON	O
affected	O	ADJ	B
brother	O	NOUN	B
showed	O	VERB	O
completely	O	ADV	O
different	O	ADJ	O
apoB	O	NOUN	B
gene	O	NOUN	I
alleles	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
apoB	O	NOUN	B
gene	O	NOUN	I
itself	O	PRON	O
is	O	AUX	O
not	O	PART	O
related	O	ADJ	O
to	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
an	O	DET	O
American	O	ADJ	B
case	O	NOUN	B
had	O	AUX	O
a	O	DET	O
point	O	NOUN	O
substitution	O	NOUN	B
in	O	ADP	O
the	O	DET	O
apoB	O	NOUN	B
gene	O	NOUN	I
generating	O	VERB	O
an	O	DET	O
in	O	X	O
-	O	PUNCT	O
frame	O	NOUN	B
stop	O	VERB	O
codon	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
disorder	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
defect	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
either	O	CCONJ	O
an	O	DET	O
apoB	O	NOUN	B
gene	O	NOUN	I
or	O	CCONJ	O
other	O	ADJ	O
genes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
to	O	PART	O
between	O	ADP	O
DXS7	O	NOUN	B
and	O	CCONJ	O
DXS426	O	NOUN	B
on	O	ADP	O
Xp	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
highly	O	ADV	O
informative	O	ADJ	O
microsatellite	O	NOUN	B
marker	O	NOUN	I
,	O	PUNCT	O
DXS426	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
proximal	O	ADJ	B
to	O	PART	O
DXS7	O	NOUN	B
in	O	ADP	O
the	O	DET	O
interval	O	NOUN	B
Xp11	O	NOUN	B
.	O	PUNCT	O


4	O	NUM	O
-	O	PUNCT	O
Xp11	O	NOUN	B
4	O	NUM	I
-	O	PUNCT	O
Xp11	O	NOUN	B
.	O	PUNCT	O


23	O	NUM	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
refine	O	VERB	O
further	O	ADV	O
the	O	DET	O
localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
NDP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
from	O	ADP	O
a	O	DET	O
multiply	O	ADV	O
informative	O	ADJ	B
crossover	O	NOUN	B
localize	O	VERB	I
the	O	DET	O
NDP	B-Disease	NOUN	B
gene	O	NOUN	B
proximal	O	ADJ	I
to	O	PART	O
DXS7	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
information	O	NOUN	B
from	O	ADP	O
2	O	NUM	O
NDP	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
a	O	DET	O
deletion	O	NOUN	B
for	O	ADP	O
DXS7	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
DSX426	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
NDP	B-Disease	NOUN	B
gene	O	NOUN	B
lies	O	VERB	O
between	O	ADP	O
DXS7	O	NOUN	B
and	O	CCONJ	O
DXS426	O	NOUN	B
on	O	ADP	O
proximal	O	ADJ	B
Xp	O	NOUN	I
.	O	PUNCT	O


Aberrant	O	ADJ	B
splicing	O	NOUN	B
of	O	ADP	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
mRNA	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	B
for	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
in	O	ADP	O
parts	O	NOUN	O
of	O	ADP	O
southern	O	ADJ	B
Europe	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
within	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
that	O	PRON	O
causes	O	VERB	O
aberrant	O	ADJ	B
splicing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
and	O	CCONJ	O
that	O	DET	O
is	O	AUX	O
in	O	ADP	O
tight	O	ADJ	O
association	O	NOUN	B
with	O	ADP	O
chromosomal	O	ADJ	B
haplotypes	O	NOUN	I
6	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
36	O	NUM	O
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
these	O	DET	O
particular	O	ADJ	O
haplotypes	O	NOUN	B
in	O	ADP	O
Bulgaria	O	PROPN	B
,	O	PUNCT	O
Italy	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Turkey	O	PROPN	B
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
more	O	ADV	O
frequent	O	ADJ	B
defects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
causing	O	VERB	O
classical	O	ADJ	O
phenylketonuria	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
part	O	NOUN	O
of	O	ADP	O
Europe	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
transition	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
546	O	NUM	O
in	O	ADP	O
intron	O	NOUN	B
10	O	NUM	O
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	B
,	O	PUNCT	O
11	O	NUM	O
bp	O	NOUN	O
upstream	O	ADJ	O
from	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
10	O	NUM	O
/	O	SYM	O
exon	O	NOUN	B
11	O	NUM	I
boundary	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
activates	O	VERB	B
a	O	DET	O
cryptic	O	ADJ	B
splice	O	NOUN	I
site	O	NOUN	I
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
an	O	DET	O
in	O	X	O
-	O	PUNCT	O
frame	O	NOUN	B
insertion	O	NOUN	B
of	O	ADP	O
9	O	NUM	O
nucleotides	O	NOUN	B
between	O	ADP	O
exon	O	NOUN	B
10	O	NUM	I
and	O	CCONJ	O
exon	O	NOUN	B
11	O	NUM	I
of	O	ADP	I
the	O	DET	O
processed	O	VERB	B
mRNA	O	NOUN	B
.	O	PUNCT	O


Normal	O	ADJ	B
amounts	O	NOUN	I
of	O	ADP	O
liver	O	NOUN	B
PAH	O	NOUN	O
protein	O	NOUN	O
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
homozygous	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
catalytic	O	ADJ	B
activity	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


This	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
enzyme	O	NOUN	B
activity	O	NOUN	I
is	O	AUX	O
probably	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
conformational	O	ADJ	B
changes	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
the	O	DET	O
insertion	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
additional	O	ADJ	O
amino	O	NOUN	B
acids	O	NOUN	I
(	O	PUNCT	O
Gly	O	PROPN	B
-	O	PUNCT	O
Leu	O	NOUN	B
-	O	PUNCT	O
Gln	O	NOUN	B
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
sequences	O	NOUN	I
encoded	O	VERB	B
by	O	ADP	O
exon	O	NOUN	B
10	O	NUM	I
and	O	CCONJ	O
exon	O	NOUN	B
11	O	NUM	I
.	O	PUNCT	O
.	O	PUNCT	O


Gardner	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
with	O	ADP	O
interstitial	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
5	O	NUM	I
.	O	PUNCT	O


We	O	PRON	O
described	O	VERB	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
Gardner	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
GS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
craniofacial	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
banding	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
an	O	DET	O
interstitial	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
5	O	NUM	I
(	O	PUNCT	O
q22	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q31	O	PROPN	O
1	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q31	O	PROPN	B
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
breakpoints	O	NOUN	B
in	O	ADP	O
the	O	DET	O
present	O	ADJ	O
case	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
3	O	NUM	O
previously	O	ADV	O
reported	O	VERB	O
5q	O	NOUN	B
-	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
GS	B-Disease	PROPN	B
/	O	PUNCT	O
or	O	CCONJ	O
familial	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
FPC	B-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
in	O	ADP	O
the	O	DET	O
5q22	O	NOUN	B
region	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
result	O	NOUN	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
studies	O	NOUN	I


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
childhood	O	NOUN	B
-	O	PUNCT	O
onset	O	NOUN	B
Tourette	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
childhood	O	NOUN	B
-	O	PUNCT	O
onset	O	NOUN	B
Tourette	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
TS	B-Disease	NOUN	B
)	O	PUNCT	O
developed	O	VERB	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
believe	O	VERB	O
this	O	DET	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
childhood	O	NOUN	B
-	O	PUNCT	O
onset	O	NOUN	B
TS	B-Disease	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
onset	O	NOUN	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Discovery	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
cases	O	NOUN	B
with	O	ADP	O
both	O	DET	O
disorders	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
clues	O	NOUN	O
to	O	PART	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
both	O	DET	O
conditions	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Sequence	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
flanking	O	NOUN	I
the	O	DET	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rapid	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
causing	O	VERB	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
requires	O	VERB	O
the	O	DET	O
capacity	O	NOUN	B
to	O	PART	O
readily	O	ADV	O
screen	O	VERB	O
the	O	DET	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
most	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
mutation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
sequenced	O	VERB	B
the	O	DET	O
portions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
introns	O	NOUN	B
flanking	O	VERB	B
each	O	DET	O
of	O	ADP	O
the	O	DET	O
14	O	NUM	O
HEXA	O	NOUN	B
exons	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
specify	O	VERB	O
oligonucleotide	O	NOUN	B
primers	O	NOUN	I
for	O	ADP	O
the	O	DET	O
PCR	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
amplification	O	NOUN	B
of	O	ADP	O
each	O	DET	O
exon	O	NOUN	B
and	O	CCONJ	O
splice	O	NOUN	B
-	O	PUNCT	O
junction	O	NOUN	B
sequence	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
amplified	O	VERB	B
products	O	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
,	O	PUNCT	O
by	O	ADP	O
electrophoresis	O	NOUN	B
in	O	ADP	O
nondenaturing	O	ADJ	B
polyacrylamide	O	NOUN	I
gels	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
either	O	DET	O
heteroduplexes	O	NOUN	B
,	O	PUNCT	O
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
annealing	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
mutant	O	ADJ	B
DNA	O	NOUN	B
strands	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformational	O	ADJ	B
polymorphisms	O	NOUN	I
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
renaturation	O	NOUN	B
of	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
stranded	O	VERB	B
DNA	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
novel	O	ADJ	O
mutations	O	NOUN	B
from	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
TCTCC	O	NOUN	B
in	O	ADP	O
IVS	O	PROPN	B
-	O	PUNCT	O
9	O	NUM	B
;	O	PUNCT	O
a	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
of	O	ADP	O
TG	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
;	O	PUNCT	O
G78	O	NOUN	O
to	O	PART	O
A	O	NOUN	O
,	O	PUNCT	O
giving	O	VERB	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
1	O	NUM	I
;	O	PUNCT	O
G533	O	NOUN	O
to	O	PART	O
T	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
,	O	PUNCT	O
producing	O	VERB	O
the	O	DET	O
third	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
detected	O	VERB	B
at	O	ADP	O
this	O	DET	O
site	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
G	O	NOUN	B
to	O	PART	I
C	O	NOUN	I
at	O	ADP	I
position	O	NOUN	I
1	O	NUM	I
of	O	ADP	O
IVS	O	PROPN	B
-	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
expected	O	VERB	O
to	O	PART	O
produce	O	VERB	O
abnormal	O	ADJ	B
splicing	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
two	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
G1496	O	NOUN	B
to	O	PART	O
A	O	NOUN	O
in	O	ADP	O
exon	O	NOUN	B
13	O	NUM	I
and	O	CCONJ	O
a	O	DET	O
4	O	NUM	B
-	O	PUNCT	O
bp	O	NOUN	B
insertion	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
)	O	PUNCT	O
that	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
:	O	PUNCT	O
correlation	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
with	O	ADP	O
highly	O	ADV	O
conserved	O	VERB	O
domains	O	NOUN	O
in	O	ADP	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyl	O	ADJ	I
transferase	O	NOUN	I
.	O	PUNCT	O


Galactosemia	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
of	I-Disease	ADP	O
human	I-Disease	ADJ	B
galactose	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
enzyme	I-Disease	NOUN	B
galactose	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
1	I-Disease	NUM	B
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
uridyl	I-Disease	ADJ	I
transferase	I-Disease	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
is	O	AUX	O
at	O	ADP	O
present	O	ADJ	O
not	O	PART	O
well	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
which	O	DET	O
result	O	VERB	O
in	O	ADP	O
low	O	ADJ	B
or	O	CCONJ	O
undetectable	O	ADJ	B
enzymatic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	B
at	O	ADP	O
nucleotide	O	NOUN	B
591	O	NUM	O
a	O	DET	O
transition	O	NOUN	B
which	O	DET	O
substitutes	O	VERB	O
glutamine	O	NOUN	B
188	O	NUM	O
by	O	ADP	O
arginine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutated	O	VERB	B
glutamine	O	NOUN	B
is	O	AUX	O
not	O	PART	O
only	O	ADV	O
highly	O	ADV	O
conserved	O	VERB	O
in	O	ADP	O
evolution	O	NOUN	B
(	O	PUNCT	O
conserved	O	VERB	O
also	O	ADV	O
in	O	ADP	O
Escherichia	O	X	B
coli	O	X	I
and	O	CCONJ	O
Saccharomyces	O	X	B
cerevisiae	O	X	I
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
two	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
residues	O	NOUN	I
downstream	O	ADJ	B
from	O	ADP	O
the	O	DET	O
active	O	ADJ	B
site	O	NOUN	I
histidine	O	NOUN	B
-	O	PUNCT	O
proline	O	NOUN	B
-	O	PUNCT	O
histidine	O	NOUN	B
triad	O	NOUN	B
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
enzymatic	O	ADJ	O
activity	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
arginine	O	NOUN	B
188	O	NUM	O
mutation	O	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
galactosemia	B-Disease	NOUN	B
mutation	O	NOUN	B
characterized	O	VERB	B
to	O	PART	O
date	O	NOUN	O
.	O	PUNCT	O


It	O	PRON	O
accounts	O	VERB	O
for	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
fourth	O	NOUN	O
of	O	ADP	O
the	O	DET	O
galactosemia	B-Disease	NOUN	B
alleles	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
333	O	NUM	O
by	O	ADP	O
tryptophan	O	NOUN	B
,	O	PUNCT	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
1025	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
area	O	NOUN	B
surrounding	O	VERB	I
this	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
highly	O	ADV	O
conserved	O	VERB	B
domain	O	NOUN	I
in	O	ADP	O
the	O	DET	O
homologous	O	ADJ	B
enzymes	O	NOUN	I
from	O	ADP	O
E	O	NOUN	B
.	O	PUNCT	O
coli	O	X	B
,	O	PUNCT	O
yeast	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
humans	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
mutation	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
undetectable	O	ADJ	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
second	O	ADJ	O
mutation	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
since	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
found	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
we	O	PRON	O
sequenced	O	VERB	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
galactosemia	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
level	O	NOUN	I
,	O	PUNCT	O
heterogeneity	O	NOUN	B
which	O	DET	O
might	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
variable	O	ADJ	B
clinical	O	ADJ	B
outcome	O	NOUN	I
observed	O	VERB	O
in	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Hypoxanthine	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
guanine	I-Disease	NOUN	B
phosphoribosyltransferase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
HPRT	O	NOUN	B
mutations	O	NOUN	B
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	O
and	O	CCONJ	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
amplification	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
X	B-Disease	NOUN	B
chromosome	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
human	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
virtual	O	ADJ	B
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
hypoxanthine	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
guanine	I-Disease	NOUN	B
phosphoribosyltransferase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
HPRT	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
activity	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
partial	O	ADJ	B
deficiency	O	NOUN	I
in	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
this	O	DET	O
enzyme	O	NOUN	B
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
gouty	B-Disease	NOUN	B
arthritis	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
reduction	O	NOUN	B
or	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
enzyme	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
amplified	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
HPRT	O	NOUN	B
cDNA	O	NOUN	B
from	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
one	O	NUM	O
with	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HPRTPerth	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
with	O	ADP	O
partial	B-Disease	ADJ	B
deficiencies	I-Disease	NOUN	B
of	I-Disease	ADP	O
HPRT	I-Disease	NOUN	B
activity	I-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
designated	O	VERB	O
HPRTUrangan	O	ADJ	B
,	O	PUNCT	O
HPRTSwan	O	NOUN	B
and	O	CCONJ	O
HPRTToowong	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
only	O	ADJ	O
mutation	O	NOUN	B
identified	O	VERB	B
was	O	AUX	O
a	O	DET	O
single	O	ADJ	O
base	O	NOUN	O
substitution	O	NOUN	B
in	O	ADP	O
exons	O	NOUN	B
2	O	NUM	I
or	O	CCONJ	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
predicts	O	VERB	O
a	O	DET	O
single	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
in	O	ADP	O
the	O	DET	O
translated	O	VERB	B
protein	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
base	O	NOUN	B
change	O	NOUN	I
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
genomic	O	ADJ	B
DNA	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
interesting	O	ADJ	O
to	O	PART	O
note	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
found	O	VERB	O
for	O	ADP	O
HPRTPerth	O	NOUN	B
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
that	O	DET	O
reported	O	VERB	O
for	O	ADP	O
HPRTFlint	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
de	O	X	B
novo	O	X	I
events	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
and	O	CCONJ	O
metabolic	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
metabolic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
normotriglyceridemic	B-Disease	ADJ	B
abetalipoproteinemia	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
described	O	VERB	O
a	O	DET	O
disorder	O	NOUN	B
,	O	PUNCT	O
normotriglyceridemic	B-Disease	ADJ	B
abetalipoproteinemia	I-Disease	NOUN	I
,	O	PUNCT	O
that	O	PRON	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
virtual	O	ADJ	B
absence	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
low	O	ADJ	O
density	O	NOUN	O
lipoproteins	O	NOUN	O
and	O	CCONJ	O
complete	O	ADJ	O
absence	O	NOUN	B
of	O	ADP	O
apoB	O	NOUN	B
-	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
with	O	ADP	O
apparently	O	ADV	O
normal	O	ADJ	O
secretion	O	NOUN	B
of	O	ADP	O
triglyceride	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
lipoproteins	O	NOUN	I
containing	O	VERB	O
apoB	O	NOUN	B
-	O	PUNCT	O
48	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
plasma	O	NOUN	B
lipoproteins	O	NOUN	I
were	O	AUX	O
shown	O	VERB	O
on	O	ADP	O
polyacrylamide	O	NOUN	B
gels	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
antibody	O	NOUN	B
mapping	O	NOUN	I
to	O	PART	O
have	O	AUX	O
a	O	DET	O
new	O	ADJ	O
truncated	O	VERB	B
apoB	O	NOUN	B
variant	O	NOUN	I
,	O	PUNCT	O
apoB	O	NOUN	B
-	O	PUNCT	O
50	O	NUM	O
,	O	PUNCT	O
circulating	O	VERB	B
along	O	ADP	O
with	O	ADP	O
her	O	PRON	O
apoB	O	NOUN	B
-	O	PUNCT	O
48	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
this	O	DET	O
individual	O	NOUN	B
to	O	PART	O
be	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
single	O	ADJ	O
C	O	NOUN	O
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
T	O	NOUN	B
nucleotide	O	NOUN	I
substitution	O	NOUN	I
at	O	ADP	O
apoB	O	NOUN	B
codon	O	NOUN	I
2252	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
produces	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
stop	O	VERB	O
codon	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
example	O	NOUN	O
of	O	ADP	O
homozygous	B-Disease	ADJ	B
hypobetalipoproteinemia	I-Disease	NOUN	B
.	O	PUNCT	O


Electron	O	NOUN	B
photomicrographs	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
diameters	O	NOUN	B
of	O	ADP	O
particles	O	NOUN	B
in	O	ADP	O
the	O	DET	O
d	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
lipoprotein	O	NOUN	B
fraction	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
postprandial	O	ADJ	B
and	O	CCONJ	O
postabsorptive	O	ADJ	B
state	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
bimodally	O	ADV	O
distributed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
molar	O	ADJ	B
ratio	O	NOUN	I
of	O	ADP	O
apoE	O	NOUN	B
to	O	PART	O
apoB	O	NOUN	B
in	O	ADP	O
these	O	DET	O
particles	O	NOUN	B
is	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
1	O	NUM	O
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
normal	O	ADJ	O
VLDL	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
LDL	O	NOUN	B
interval	O	NOUN	I
contains	O	VERB	O
both	O	CCONJ	O
spherical	O	ADJ	B
and	O	CCONJ	O
cuboidal	O	ADJ	B
particles	O	NOUN	I
.	O	PUNCT	O


Autologous	O	ADJ	B
reinfusion	O	NOUN	I
of	O	ADP	O
labeled	O	VERB	B
d	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


006	O	NUM	O
g	O	NOUN	B
/	O	PUNCT	O
ml	O	NOUN	O
lipoproteins	O	NOUN	B
showed	O	VERB	O
exponential	O	ADJ	O
disappearance	O	NOUN	B
from	O	ADP	O
plasma	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
an	O	DET	O
apparent	O	ADJ	B
half	O	NOUN	B
-	O	PUNCT	O
removal	O	NOUN	B
time	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
min	O	NOUN	O
,	O	PUNCT	O
somewhat	O	ADV	O
slower	O	ADJ	O
than	O	ADP	O
for	O	ADP	O
normal	O	ADJ	B
chylomicrons	O	NOUN	I
but	O	CCONJ	O
within	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
for	O	ADP	O
VLDL	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
calculated	O	VERB	B
production	O	NOUN	B
rate	O	NOUN	B
for	O	ADP	O
apoB	O	NOUN	B
was	O	AUX	O
within	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
in	O	ADP	O
this	O	DET	O
subject	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
origin	O	NOUN	B
of	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
in	O	ADP	O
Yemenite	O	ADJ	B
Jews	O	PROPN	I
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
metabolic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
recessive	O	ADJ	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
hepatic	O	ADJ	B
enzyme	O	NOUN	O
phenylalanine	O	NOUN	O
hydroxylase	O	NOUN	O
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
PKU	B-Disease	NOUN	B
varies	O	VERB	O
widely	O	ADV	O
across	O	ADP	O
different	O	ADJ	O
geographic	O	ADJ	B
areas	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
highest	O	ADJ	B
(	O	PUNCT	O
about	O	ADV	O
1	O	NUM	O
in	O	ADP	O
5	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
live	O	ADJ	B
births	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
Ireland	O	PROPN	B
and	O	CCONJ	O
western	O	PROPN	B
Scotland	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
Yemenite	O	ADJ	B
Jews	O	PROPN	I
.	O	PUNCT	O


A	O	DET	O
limited	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
account	O	VERB	O
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
PKU	B-Disease	NOUN	B
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
European	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
single	O	ADJ	O
molecular	O	ADJ	B
defect	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
a	O	DET	O
deletion	O	NOUN	B
spanning	O	VERB	O
the	O	DET	O
third	O	ADJ	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
all	O	DET	O
the	O	DET	O
PKU	B-Disease	NOUN	B
cases	O	NOUN	B
among	O	ADP	O
the	O	DET	O
Yemenite	O	ADJ	B
Jews	O	PROPN	I
.	O	PUNCT	O


Examination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
random	O	ADJ	B
sample	O	NOUN	B
of	O	ADP	O
Yemenite	O	ADJ	B
Jews	O	PROPN	I
using	O	VERB	O
a	O	DET	O
molecular	O	ADJ	B
probe	O	NOUN	I
that	O	PRON	O
detects	O	VERB	O
the	O	DET	O
carriers	O	NOUN	B
of	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
indicated	O	VERB	O
a	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
defective	O	ADJ	B
gene	O	NOUN	O
in	O	ADP	O
this	O	DET	O
community	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
deleted	O	VERB	B
PAH	O	NOUN	B
gene	O	NOUN	O
was	O	AUX	O
traced	O	VERB	O
to	O	PART	O
25	O	NUM	O
different	O	ADJ	O
locations	O	NOUN	B
throughout	O	ADP	O
Yemen	O	PROPN	B
,	O	PUNCT	O
family	O	NOUN	B
histories	O	NOUN	I
and	O	CCONJ	O
official	O	ADJ	B
documents	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Yemenite	O	ADJ	B
Jewish	O	ADJ	B
community	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
common	O	ADJ	O
ancestor	O	NOUN	B
of	O	ADP	O
all	O	DET	O
the	O	DET	O
carriers	O	NOUN	B
of	O	ADP	O
this	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
lived	O	VERB	O
in	O	ADP	O
Sana	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
capital	O	NOUN	B
of	O	ADP	O
Yemen	O	PROPN	B
,	O	PUNCT	O
before	O	ADP	O
the	O	DET	O
eighteenth	O	ADJ	O
century	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
of	O	ADP	O
aspartylglucosaminuria	B-Disease	NOUN	B
(	O	PUNCT	O
AGU	B-Disease	NOUN	B
)	O	PUNCT	O
to	O	PART	O
marker	O	NOUN	B
loci	O	NOUN	O
on	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
4	O	NUM	I
.	O	PUNCT	O


Aspartylglucosaminuria	B-Disease	NOUN	B
(	O	PUNCT	O
AGU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
deficient	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
aspartylglucosaminidase	O	NOUN	I
(	O	PUNCT	O
AGA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
structural	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
AGA	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
4q21	O	NOUN	B
-	O	PUNCT	O
qter	O	NOUN	B
of	O	ADP	I
chromosome	O	NOUN	I
4	O	NUM	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
map	O	NOUN	B
position	O	NOUN	O
of	O	ADP	O
the	O	DET	O
AGU	O	NOUN	B
locus	O	NOUN	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
other	O	ADJ	O
marker	O	NOUN	B
loci	O	NOUN	O
on	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
4	O	NUM	I
using	O	VERB	O
linkage	O	NOUN	B
analyses	O	NOUN	I
.	O	PUNCT	O


Restriction	O	NOUN	B
fragment	O	NOUN	O
length	O	NOUN	O
polymorphism	O	NOUN	O
alleles	O	NOUN	B
for	O	ADP	O
the	O	DET	O
ADH2	O	NOUN	B
,	O	PUNCT	O
ADH3	O	NOUN	B
,	O	PUNCT	O
EGF	O	NOUN	B
,	O	PUNCT	O
FG	O	PROPN	B
alpha	O	NOUN	I
and	O	CCONJ	O
FG	O	NOUN	B
beta	O	NOUN	I
loci	O	NOUN	I
and	O	CCONJ	O
blood	O	NOUN	B
group	O	NOUN	I
antigens	O	NOUN	I
for	O	ADP	O
the	O	DET	O
MNS	O	NOUN	B
locus	O	NOUN	B
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
12	O	NUM	O
Finnish	O	ADJ	B
AGU	B-Disease	PROPN	B
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
heterozygous	O	ADJ	B
family	O	NOUN	B
members	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
reduced	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
AGA	O	NOUN	B
in	O	ADP	O
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
both	O	CCONJ	O
pairwise	O	NOUN	B
and	O	CCONJ	O
multipoint	O	ADJ	B
analyses	O	NOUN	I
.	O	PUNCT	O


Loose	O	NOUN	B
linkage	O	NOUN	I
of	O	ADP	O
the	O	DET	O
AGU	B-Disease	NOUN	B
locus	O	NOUN	O
to	O	PART	O
the	O	DET	O
FG	O	PROPN	B
and	O	CCONJ	O
MNS	O	PROPN	B
loci	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
z	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O
16	O	NUM	O
,	O	PUNCT	O
z	O	X	O
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O
39	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Multipoint	O	ADJ	B
analysis	O	NOUN	I
to	O	PART	O
the	O	DET	O
fixed	O	ADJ	B
map	O	NOUN	I
[	O	PUNCT	O
ADH	O	PROPN	B
-	O	PUNCT	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
EGF	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
35	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
FG	O	PROPN	B
-	O	PUNCT	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
-	O	PUNCT	O
MNS	O	PROPN	B
]	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AGU	O	NOUN	B
locus	O	NOUN	I
is	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O


30	O	NUM	O
recombination	O	NOUN	B
units	O	NOUN	I
distal	O	ADJ	B
to	O	PART	O
MNS	O	NOUN	B
(	O	PUNCT	O
z	O	NOUN	O
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
order	O	NOUN	O
cen	O	NOUN	B
-	O	PUNCT	O
ADH	O	NOUN	B
-	O	PUNCT	O
EGF	O	PROPN	B
-	O	PUNCT	O
FG	O	PROPN	B
-	O	PUNCT	O
MNS	O	PROPN	B
-	O	PUNCT	O
AGU	O	PROPN	B
is	O	AUX	O
35	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
than	O	ADP	O
the	O	DET	O
next	O	ADJ	O
best	O	ADJ	O
order	O	NOUN	O
cen	O	NOUN	B
-	O	PUNCT	O
ADH	O	NOUN	B
-	O	PUNCT	O
EGF	O	PROPN	B
-	O	PUNCT	O
AGU	O	PROPN	B
-	O	PUNCT	O
FG	O	PROPN	B
-	O	PUNCT	O
MNS	O	PROPN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
relationships	O	NOUN	B
of	O	ADP	O
the	O	DET	O
apolipoprotein	O	NOUN	B
C1	O	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
CYP2A	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
linkage	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
markers	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
apolipoprotein	O	NOUN	B
C1	O	NOUN	I
(	O	PUNCT	O
APOC1	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
cytochrome	O	NOUN	B
P450	O	NOUN	I
(	O	PUNCT	O
CYP2A	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
peak	O	NOUN	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
9	O	NUM	O
.	O	PUNCT	O


29	O	NUM	O
at	O	ADP	O
2	O	NUM	O
cM	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
APOC1	O	NOUN	B
-	O	PUNCT	O
DM	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
lod	O	ADJ	B
score	O	NOUN	I
of	O	ADP	O
8	O	NUM	O
.	O	PUNCT	O


55	O	NUM	O
at	O	ADP	O
4	O	NUM	O
cM	O	NOUN	O
for	O	ADP	O
CYP2A	O	NOUN	B
-	O	PUNCT	O
DM	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
two	O	NUM	O
markers	O	NOUN	B
also	O	ADV	O
show	O	VERB	O
close	O	ADJ	O
linkage	O	NOUN	B
to	O	ADP	O
each	O	DET	O
other	O	ADJ	O
(	O	PUNCT	O
theta	O	X	B
max	O	NOUN	I
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
,	O	PUNCT	O
Zmax	O	NOUN	O
=	O	ADJ	O
9	O	NUM	O
.	O	PUNCT	O
09	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


From	O	ADP	O
examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genotypes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recombinant	O	ADJ	B
individuals	O	NOUN	B
,	O	PUNCT	O
CYP2A	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
map	O	VERB	B
proximal	O	ADJ	B
to	O	PART	O
DM	O	NOUN	B
because	O	SCONJ	O
in	O	ADP	O
one	O	NUM	O
recombinant	O	ADJ	B
individual	O	ADJ	O
CYP2A	O	NOUN	B
,	O	PUNCT	O
APOC2	O	NOUN	B
and	O	CCONJ	O
CKMM	O	NOUN	B
had	O	AUX	O
all	O	DET	O
recombined	O	VERB	B
with	O	ADP	O
DM	O	NOUN	B
.	O	PUNCT	O


Evidence	O	NOUN	B
from	O	ADP	O
another	O	DET	O
CYP2A	O	NOUN	B
-	O	PUNCT	O
DM	O	NOUN	B
recombinant	O	ADJ	B
individual	O	ADJ	B
places	O	NOUN	O
CYP2A	O	NOUN	B
proximal	O	ADJ	B
to	O	PART	O
APOC2	O	NOUN	B
and	O	CCONJ	O
CKMM	O	NOUN	B
.	O	PUNCT	O


Localisation	O	NOUN	B
of	O	ADP	O
CYP2A	O	NOUN	B
on	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
also	O	ADV	O
suggests	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
proximal	O	ADJ	B
to	O	PART	O
DM	O	NOUN	B
and	O	CCONJ	O
APOC2	O	NOUN	B
/	O	SYM	O
C1	O	PROPN	B
/	O	SYM	O
E	O	NOUN	B
gene	O	NOUN	I
cluster	O	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
linkage	O	NOUN	I
map	O	NOUN	I
of	O	ADP	O
six	O	NUM	O
polymorphic	O	ADJ	B
DNA	O	NOUN	B
markers	O	NOUN	I
around	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
5	O	NUM	I
.	O	PUNCT	O


A	O	DET	O
genetic	O	ADJ	B
linkage	O	NOUN	I
map	O	NOUN	I
of	O	ADP	O
six	O	NUM	O
polymorphic	O	ADJ	B
DNA	O	NOUN	B
markers	O	NOUN	I
close	O	ADV	O
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
APC	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
chromosome	O	NOUN	B
5q	O	NOUN	I
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
hundred	O	NUM	O
fifty	O	NUM	O
-	O	PUNCT	O
five	O	NUM	O
typed	O	VERB	B
members	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
FAP	B-Disease	NOUN	B
kindred	O	NOUN	B
provided	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
90	O	NUM	O
meioses	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
number	O	NOUN	O
of	O	ADP	O
crucial	O	ADJ	O
recombination	O	NOUN	B
events	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
which	O	DET	O
are	O	AUX	O
informative	O	ADJ	B
at	O	ADP	O
three	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
loci	O	NOUN	B
,	O	PUNCT	O
allowing	O	VERB	O
confident	O	ADJ	O
ordering	O	NOUN	O
of	O	ADP	O
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
map	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
all	O	DET	O
families	O	NOUN	B
showing	O	VERB	O
linkage	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
chromosome	O	NOUN	O
5	O	NUM	O
marker	O	NOUN	B
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Recombination	O	NOUN	B
data	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
linkage	O	NOUN	O
analysis	O	NOUN	O
support	O	VERB	O
a	O	DET	O
locus	O	NOUN	B
order	O	NOUN	O
of	O	ADP	O
centromere	O	NOUN	B
-	O	PUNCT	O
pi	O	NOUN	B
227	O	NUM	O
-	O	PUNCT	O
C11P11	O	PROPN	B
-	O	PUNCT	O
ECB27	O	NOUN	B
-	O	PUNCT	O
L5	O	NOUN	B
.	O	PUNCT	O


62	O	NUM	O
-	O	PUNCT	O
APC	O	NOUN	B
-	O	PUNCT	O
EF5	O	NOUN	B
62	O	NUM	B
-	O	PUNCT	O
APC	O	NOUN	B
-	O	PUNCT	O
EF5	O	NOUN	B
.	O	PUNCT	O


44	O	NUM	O
-	O	PUNCT	O
YN5	O	NOUN	B
44	O	NUM	O
-	O	PUNCT	O
YN5	O	NOUN	B
.	O	PUNCT	O


48	O	NUM	O
-	O	PUNCT	O
telomer	O	NOUN	B
e	O	NOUN	O
,	O	PUNCT	O
although	O	SCONJ	O
EF5	O	NOUN	B
.	O	PUNCT	O


44	O	NUM	O
could	O	AUX	O
lie	O	VERB	O
in	O	ADP	O
the	O	DET	O
interval	O	NOUN	B
L5	O	NOUN	I
.	O	PUNCT	O


62	O	NUM	O
-	O	PUNCT	O
APC	O	NOUN	B
or	O	CCONJ	O
ECB27	O	NOUN	B
-	O	PUNCT	O
L5	O	NOUN	B
.	O	PUNCT	O


62	O	NUM	O
.	O	PUNCT	O


No	O	DET	O
recombinants	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
between	O	ADP	O
APC	O	NOUN	B
and	O	CCONJ	O
either	O	CCONJ	O
EF5	O	NOUN	B
.	O	PUNCT	O


44	O	NUM	O
or	O	CCONJ	O
YN5	O	NOUN	B
.	O	PUNCT	O


48	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
published	O	VERB	B
deletion	O	NOUN	B
mapping	O	NOUN	I
in	O	ADP	O
colorectal	B-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
and	O	CCONJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
FAP	B-Disease	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
YN5	O	NOUN	B
.	O	PUNCT	O


48	O	NUM	O
is	O	AUX	O
1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
cM	O	NOUN	O
from	O	ADP	O
APC	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
YN5	O	NOUN	B
.	O	PUNCT	O


48	O	NUM	O
and	O	CCONJ	O
L5	O	NOUN	B
.	O	PUNCT	O


62	O	NUM	O
delineate	O	VERB	O
a	O	DET	O
small	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	O
5	O	NUM	O
within	O	ADP	O
which	O	DET	O
the	O	DET	O
EF5	O	NOUN	B
.	O	PUNCT	O


44	O	NUM	O
locus	O	NOUN	B
lies	O	VERB	O
very	O	ADV	O
close	O	ADV	O
to	O	PART	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
not	O	PART	O
only	O	ADV	O
allow	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
flanking	O	ADJ	B
markers	O	NOUN	B
for	O	ADP	O
presymptomatic	O	ADJ	B
diagnosis	O	NOUN	B
of	O	ADP	O
FAP	B-Disease	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
provide	O	VERB	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
map	O	NOUN	I
of	O	ADP	O
the	O	DET	O
region	O	NOUN	B
for	O	ADP	O
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
itself	O	PRON	O
and	O	CCONJ	O
for	O	ADP	O
further	O	ADJ	O
assessment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	B
5	O	NUM	I
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
biology	O	NOUN	B
of	O	ADP	O
sporadic	O	ADJ	B
colorectal	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
amyloid	O	NOUN	I
A	O	NOUN	I
and	O	CCONJ	O
P	O	NOUN	O
protein	O	NOUN	B
genes	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	O
fever	I-Disease	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
amyloid	O	NOUN	I
A	O	NOUN	I
(	O	PUNCT	O
SAA	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
P	O	NOUN	O
(	O	PUNCT	O
APCS	O	NOUN	B
)	O	PUNCT	O
genes	O	NOUN	O
in	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
MEF	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
SAA	O	NOUN	B
and	O	CCONJ	O
APCS	O	NOUN	B
in	O	ADP	O
MEF	B-Disease	NOUN	B
and	O	CCONJ	O
MEF	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
amyloidosis	I-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
17	O	NUM	O
informative	O	ADJ	B
families	O	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
Armenians	O	PROPN	B
,	O	PUNCT	O
2	O	NUM	O
non	O	NOUN	B
-	O	PUNCT	O
Ashkenazi	O	PROPN	B
Jews	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
MEF	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
amyloidosis	B-Disease	NOUN	B
using	O	VERB	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
approach	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
any	O	DET	O
MEF	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
polymorphism	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
41	O	NUM	O
Armenian	O	ADJ	B
and	O	CCONJ	O
Jewish	O	ADJ	B
MEF	B-Disease	NOUN	B
patients	O	NOUN	B
tested	O	VERB	B
.	O	PUNCT	O


Our	O	PRON	O
family	O	NOUN	B
studies	O	NOUN	I
allowed	O	VERB	O
us	O	PRON	O
to	O	PART	O
rule	O	VERB	O
out	O	ADP	O
tight	O	ADJ	O
linkage	O	NOUN	O
between	O	ADP	O
SAA	O	NOUN	B
and	O	CCONJ	O
MEF	B-Disease	NOUN	B
(	O	PUNCT	O
lod	O	ADJ	B
score	O	NOUN	I
=	O	ADJ	O
-	O	SYM	O
2	O	NUM	O
.	O	PUNCT	O
16	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
less	O	ADJ	I
than	O	ADP	O
or	O	CCONJ	O
equal	O	ADJ	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O
06	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


For	O	ADP	O
APCS	O	PROPN	B
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
allele	O	NOUN	B
frequency	O	NOUN	O
in	O	ADP	O
the	O	DET	O
MEF	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
amyloidosis	I-Disease	NOUN	B
patients	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
in	O	ADP	O
18	O	NUM	O
unrelated	O	ADJ	O
MEF	B-Disease	NOUN	B
patients	O	NOUN	B
without	O	ADP	O
amyloidosis	B-Disease	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
33	O	NUM	O
healthy	O	ADJ	B
parents	O	NOUN	B
.	O	PUNCT	O


Some	O	DET	O
Mexican	O	ADJ	B
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variants	O	NOUN	B
revisited	O	VERB	O
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
fairly	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
Mexico	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
now	O	ADV	O
examined	O	VERB	O
the	O	DET	O
DNA	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
previously	O	ADV	O
reported	O	VERB	O
electrophoretically	O	ADV	B
fast	O	ADJ	B
Mexican	O	ADJ	I
G6PD	O	NOUN	B
variants	O	NOUN	B
,	O	PUNCT	O
-	O	PUNCT	O
G6PD	O	PROPN	B
Distrito	O	PROPN	B
Federal	O	PROPN	I
,	O	PUNCT	O
G6PD	O	PROPN	B
Tepic	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Castilla	O	PROPN	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
of	O	ADP	O
these	O	DET	O
variants	O	NOUN	B
,	O	PUNCT	O
believed	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
biochemical	O	ADJ	B
characterization	O	NOUN	B
and	O	CCONJ	O
population	O	NOUN	B
origin	O	NOUN	B
to	O	PART	O
be	O	AUX	O
unique	O	ADJ	B
,	O	PUNCT	O
have	O	AUX	O
the	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	O
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
202	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
G	O	NOUN	B
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
376	O	NUM	I
,	O	PUNCT	O
mutations	O	NOUN	B
that	O	SCONJ	O
we	O	PRON	O
now	O	ADV	O
recognize	O	VERB	O
to	O	PART	O
be	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
-	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
other	O	ADJ	O
Mexican	O	ADJ	B
males	O	NOUN	B
with	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
five	O	NUM	O
have	O	AUX	O
the	O	DET	O
(	O	PUNCT	O
NlaIII	O	PROPN	B
/	O	SYM	O
FokI	O	PROPN	B
/	O	PUNCT	O
PvuII	O	PROPN	B
/	O	PUNCT	O
PstI	O	NOUN	B
)	O	PUNCT	O
haplotype	O	NOUN	B
characteristic	O	ADJ	B
of	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
-	O	PUNCT	O
in	O	ADP	O
Africa	O	PROPN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
PvuII	O	NOUN	B
+	O	CCONJ	O
genotype	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
rare	O	ADJ	B
in	O	ADP	O
Europe	O	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
of	O	ADP	O
these	O	DET	O
G6PD	O	NOUN	B
A	O	NOUN	B
-	O	PUNCT	O
genes	O	NOUN	B
had	O	AUX	O
their	O	PRON	O
ancient	O	ADJ	O
origin	O	NOUN	B
in	O	ADP	O
Africa	O	PROPN	B
,	O	PUNCT	O
although	O	SCONJ	O
in	O	ADP	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
Mexican	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
202A	O	NUM	B
/	O	SYM	O
376G	O	NOUN	O
the	O	DET	O
gene	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
imported	O	VERB	B
more	O	ADV	O
recently	O	ADV	O
from	O	ADP	O
Spain	O	PROPN	B
,	O	PUNCT	O
where	O	SCONJ	O
this	O	DET	O
variant	O	NOUN	B
,	O	PUNCT	O
formerly	O	ADV	O
known	O	VERB	O
as	O	ADP	O
G6PD	O	NOUN	B
Betica	O	PROPN	B
,	O	PUNCT	O
is	O	AUX	O
also	O	ADV	O
prevalent	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


Hereditary	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
C5	I-Disease	NOUN	B
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
discoid	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
29	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
discoid	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
had	O	AUX	O
undetectable	O	ADJ	B
classic	O	ADJ	O
pathway	O	NOUN	O
complement	O	NOUN	O
activity	O	NOUN	O
.	O	PUNCT	O


Hypocomplementemia	B-Disease	NOUN	B
was	O	AUX	O
due	O	ADJ	O
to	O	PART	O
selective	O	ADJ	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
C5	I-Disease	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
her	O	PRON	O
children	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
deficient	O	ADJ	B
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
documented	O	VERB	B
case	O	NOUN	B
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
discoid	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
and	O	CCONJ	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Founder	O	NOUN	B
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
prevalent	O	ADJ	O
phenylketonuria	B-Disease	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Oriental	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
phenylalanine	O	NOUN	O
hydroxylase	O	NOUN	O
[	O	PUNCT	O
PAH	O	NOUN	B
;	O	PUNCT	O
phenylalanine	O	NOUN	B
4	O	NUM	I
-	O	PUNCT	O
monooxygenase	O	NOUN	B
;	O	PUNCT	O
L	O	NOUN	B
-	O	PUNCT	O
phenylalanine	O	NOUN	B
,	O	PUNCT	O
tetrahydrobiopterin	O	NOUN	B
oxygen	O	NOUN	I
oxidoreductase	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
hydroxylating	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
EC	O	NOUN	B
1	O	NUM	I
.	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
]	O	PUNCT	O
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Chinese	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
classic	O	ADJ	O
phenylketonuria	B-Disease	NOUN	O
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
C	O	NOUN	B
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
second	O	ADJ	O
base	O	NOUN	O
of	O	ADP	O
codon	O	NOUN	B
413	O	NUM	O
in	O	ADP	O
exon	O	NOUN	B
12	O	NUM	I
of	O	ADP	I
the	O	DET	I
gene	O	NOUN	B
results	O	VERB	O
in	O	ADP	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
Pro413	O	NOUN	B
for	O	ADP	O
Arg413	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
(	O	PUNCT	O
R413P	O	NOUN	B
)	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
negligible	O	ADJ	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
when	O	SCONJ	O
expressed	O	VERB	B
in	O	ADP	O
heterologous	O	ADJ	B
mammalian	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
a	O	DET	O
classic	O	ADJ	O
PKU	B-Disease	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Population	O	NOUN	B
genetic	O	ADJ	B
studies	O	NOUN	I
reveal	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
restriction	O	NOUN	B
fragment	O	NOUN	I
length	O	NOUN	I
polymorphism	O	NOUN	I
haplotype	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
predominant	O	ADJ	O
haplotype	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Oriental	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
accounts	O	VERB	O
for	O	ADP	O
13	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
northern	O	ADJ	B
Chinese	O	PROPN	I
and	O	CCONJ	O
27	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Japanese	O	ADJ	B
PKU	B-Disease	NOUN	B
alleles	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
rare	O	ADJ	B
in	O	ADP	O
southern	O	ADJ	B
Chinese	O	PROPN	I
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
Caucasian	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
unambiguously	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
occurred	O	VERB	O
after	O	ADP	O
racial	O	ADJ	B
divergence	O	NOUN	I
of	O	ADP	O
Orientals	O	PROPN	B
and	O	CCONJ	O
Caucasians	O	PROPN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
allele	O	NOUN	B
has	O	AUX	O
spread	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
Orient	O	PROPN	B
by	O	ADP	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


Previous	O	ADJ	O
protein	O	NOUN	B
polymorphism	O	NOUN	B
studies	O	NOUN	B
in	O	ADP	O
eastern	O	ADJ	B
Asia	O	PROPN	I
have	O	AUX	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
"	O	PUNCT	O
northern	O	ADJ	B
Mongoloids	O	NOUN	I
"	O	PUNCT	O
represented	O	VERB	O
a	O	DET	O
founding	O	VERB	B
population	O	NOUN	B
in	O	ADP	O
Asia	O	PROPN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
this	O	DET	O
hypothesis	O	NOUN	B
in	O	ADP	O
that	O	SCONJ	O
the	O	DET	O
PKU	B-Disease	NOUN	B
mutation	O	NOUN	B
might	O	AUX	O
have	O	AUX	O
occurred	O	VERB	O
in	O	ADP	O
northern	O	ADJ	B
Mongoloids	O	PROPN	I
and	O	CCONJ	O
subsequently	O	ADV	O
spread	O	VERB	B
to	O	ADP	O
the	O	DET	O
Chinese	O	ADJ	B
and	O	CCONJ	O
Japanese	O	ADJ	B
populations	O	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
defect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
(	O	PUNCT	O
GGM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
manifesting	O	VERB	O
within	O	ADP	O
the	O	DET	O
first	O	ADJ	O
weeks	O	NOUN	B
of	O	ADP	O
life	O	NOUN	B
and	O	CCONJ	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
failure	O	NOUN	B
to	O	PART	O
absorb	O	VERB	O
dietary	O	ADJ	B
glucose	O	NOUN	I
and	O	CCONJ	O
galactose	O	NOUN	B
from	O	ADP	O
the	O	DET	O
intestine	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
consequent	O	ADJ	O
severe	O	ADJ	B
diarrhoea	B-Disease	NOUN	B
and	O	CCONJ	O
dehydration	B-Disease	NOUN	B
are	O	AUX	O
usually	O	ADV	O
fatal	O	ADJ	B
unless	O	SCONJ	O
these	O	DET	O
sugars	O	NOUN	B
are	O	AUX	O
eliminated	O	VERB	O
from	O	ADP	O
the	O	DET	O
diet	O	NOUN	B
.	O	PUNCT	O


Intestinal	O	ADJ	B
biopsies	O	NOUN	I
of	O	ADP	O
GGM	B-Disease	NOUN	B
patients	O	NOUN	B
have	O	AUX	O
revealed	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
defect	O	NOUN	B
in	O	ADP	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
-	O	PUNCT	O
dependent	O	ADJ	B
absorption	O	NOUN	B
of	O	ADP	O
glucose	O	NOUN	B
in	O	ADP	O
the	O	DET	O
brush	O	NOUN	B
border	O	NOUN	I
.	O	PUNCT	O


Normal	O	ADJ	B
glucose	O	NOUN	I
absorption	O	NOUN	I
is	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
Na	O	PROPN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brush	O	NOUN	B
border	O	NOUN	I
membrane	O	NOUN	I
of	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
epithelium	O	NOUN	I
.	O	PUNCT	O


Cellular	O	ADJ	B
influx	O	NOUN	I
is	O	AUX	O
driven	O	VERB	O
by	O	ADP	O
the	O	DET	O
transmembrane	O	ADJ	B
Na	O	NOUN	I
+	O	CCONJ	O
electrochemical	O	ADJ	B
potential	O	ADJ	O
gradient	O	NOUN	B
;	O	PUNCT	O
thereafter	O	ADP	O
the	O	DET	O
sugar	O	NOUN	B
moves	O	VERB	O
to	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
across	O	ADP	O
the	O	DET	O
basolateral	O	ADJ	B
membrane	O	NOUN	I
via	O	ADP	O
the	O	DET	O
facilitated	O	ADJ	O
glucose	O	NOUN	B
carrier	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
a	O	DET	O
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
from	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
ileum	O	NOUN	B
and	O	CCONJ	O
shown	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
SGLT1	O	NOUN	B
,	O	PUNCT	O
resides	O	VERB	B
on	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
q	O	NOUN	O
arm	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
22	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
now	O	ADV	O
amplified	O	VERB	B
SGLT1	O	NOUN	B
complementary	O	ADJ	O
DNA	O	NOUN	O
and	O	CCONJ	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
affected	O	VERB	O
with	O	ADP	O
GGM	B-Disease	NOUN	B
by	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
amplified	O	VERB	B
products	O	NOUN	I
has	O	AUX	O
revealed	O	VERB	O
a	O	DET	O
single	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
SGLT1	O	NOUN	B
which	O	DET	O
cosegregates	O	VERB	B
with	O	ADP	O
the	O	DET	O
GGM	B-Disease	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
loss	O	NOUN	O
of	O	ADP	O
Na	O	NOUN	O
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
-	O	PUNCT	O
dependent	O	ADJ	B
glucose	O	NOUN	B
transport	O	NOUN	I
in	O	ADP	O
Xenopus	O	NOUN	B
oocytes	O	NOUN	B
injected	O	VERB	B
with	O	ADP	O
this	O	DET	O
complementary	O	ADJ	O
RNA	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
de	O	X	O
novo	O	X	O
unbalanced	O	ADJ	O
reciprocal	O	ADJ	B
translocation	O	NOUN	B
identified	O	VERB	B
as	O	ADP	O
paternal	O	ADJ	B
in	O	ADP	O
origin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Interstitial	O	ADJ	B
cytogenetic	O	ADJ	I
deletions	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
paternally	O	ADV	B
derived	O	VERB	I
chromosome	O	NOUN	I
15q11	O	NOUN	I
-	O	PUNCT	O
13	O	NUM	O
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
de	O	X	B
novo	O	X	I
unbalanced	O	ADJ	O
karyotype	O	NOUN	B
-	O	PUNCT	O
45	O	NUM	O
,	O	PUNCT	O
XY	O	NOUN	B
,	O	PUNCT	O
-	O	PUNCT	O
9	O	NUM	B
,	O	PUNCT	O
-	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
+	O	CCONJ	O
der	O	X	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
9	O	NUM	O
;	O	PUNCT	O
15	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q34	O	NOUN	B
;	O	PUNCT	O
q13	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
probe	O	NOUN	I
pML34	O	NOUN	B
confirmed	O	VERB	O
that	O	SCONJ	O
only	O	ADV	O
a	O	DET	O
single	O	ADJ	B
Prader	B-Disease	PROPN	I
Willi	I-Disease	PROPN	I
critical	O	ADJ	I
region	O	NOUN	I
(	O	PUNCT	O
PWCR	O	NOUN	B
15q11	O	NOUN	I
.	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
q12	O	NOUN	B
)	O	PUNCT	O
copy	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O


Hybridisation	O	NOUN	B
of	O	ADP	O
patient	O	NOUN	B
and	O	CCONJ	O
parental	O	ADJ	B
DNA	O	NOUN	O
with	O	ADP	O
the	O	DET	O
multi	O	ADJ	B
-	O	PUNCT	O
allelic	O	ADJ	B
probe	O	NOUN	I
CMW1	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
pter	O	NOUN	B
-	O	PUNCT	O
15q13	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
chromosome	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
translocation	O	NOUN	B
was	O	AUX	O
paternal	O	ADJ	B
in	O	ADP	O
origin	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
example	O	NOUN	O
of	O	ADP	O
a	O	DET	O
paternally	O	ADV	B
-	O	PUNCT	O
derived	O	VERB	B
PWCR	O	NOUN	B
allele	O	NOUN	B
loss	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
an	O	DET	O
unbalanced	O	ADJ	O
translocation	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
arisen	O	VERB	O
de	O	X	O
novo	O	X	O
.	O	PUNCT	O


Localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
to	O	PART	O
19q13	O	NOUN	B
.	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
19q13	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
its	O	PRON	O
relationship	O	NOUN	B
to	O	PART	O
twelve	O	NUM	O
polymorphic	O	ADJ	B
loci	O	NOUN	I
on	O	ADP	O
19q	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
order	O	NOUN	O
of	O	ADP	O
fourteen	O	NUM	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
localised	O	VERB	B
to	O	PART	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
19	O	NUM	O
has	O	AUX	O
been	O	AUX	O
established	O	VERB	O
by	O	ADP	O
multipoint	O	ADJ	B
mapping	O	NOUN	I
in	O	ADP	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
40	O	NUM	O
CEPH	O	PROPN	B
(	O	PUNCT	O
Centre	O	PROPN	B
dEtude	O	PROPN	O
de	O	X	O
Polymorphisme	O	PROPN	O
Humain	O	PROPN	O
,	O	PUNCT	O
Paris	O	PROPN	B
)	O	PUNCT	O
reference	O	NOUN	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
linkage	O	NOUN	B
relationship	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
to	O	PART	O
twelve	O	NUM	O
of	O	ADP	O
these	O	DET	O
markers	O	NOUN	B
as	O	ADP	O
studied	O	VERB	O
in	O	ADP	O
45	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
resulting	O	VERB	O
genetic	O	ADJ	B
map	O	NOUN	I
is	O	AUX	O
supported	O	VERB	O
by	O	ADP	O
the	O	DET	O
localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
markers	O	NOUN	I
in	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
.	O	PUNCT	O


Ten	O	NUM	O
of	O	ADP	O
the	O	DET	O
twelve	O	NUM	O
markers	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
proximal	O	ADJ	B
to	O	PART	O
the	O	DET	O
DM	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
,	O	PUNCT	O
PRKCG	O	NOUN	B
and	O	CCONJ	O
D19S22	O	NOUN	B
,	O	PUNCT	O
distal	O	ADJ	B
but	O	CCONJ	O
at	O	ADP	O
distances	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
25	O	NUM	O
cM	O	NOUN	B
and	O	CCONJ	O
15	O	NUM	O
cM	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
closest	O	ADJ	O
proximal	O	ADJ	B
markers	O	NOUN	B
are	O	AUX	O
APOC2	O	NOUN	B
(	O	PUNCT	O
apolipoprotein	O	NOUN	B
C	O	NOUN	I
-	O	PUNCT	O
II	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
CKM	O	NOUN	B
(	O	PUNCT	O
creatine	O	NOUN	B
kinase	O	NOUN	I
,	O	PUNCT	O
muscle	O	NOUN	B
)	O	PUNCT	O
approximately	O	ADV	O
3	O	NUM	O
cM	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
cM	O	NOUN	O
from	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
gene	O	NOUN	I
respectively	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
order	O	NOUN	O
APOC2	O	NOUN	B
-	O	PUNCT	O
CKM	O	PROPN	B
-	O	PUNCT	O
DM	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
distance	O	NOUN	B
between	O	ADP	O
APOC2	O	NOUN	B
,	O	PUNCT	O
CKM	O	NOUN	B
and	O	CCONJ	O
DM	B-Disease	NOUN	B
(	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
order	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
million	O	NUM	O
base	O	NOUN	O
pairs	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
known	O	ADJ	O
orientation	O	NOUN	B
should	O	AUX	O
permit	O	VERB	O
directional	O	ADJ	B
chromosome	O	NOUN	O
walking	O	NOUN	O
and	O	CCONJ	O
jumping	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
should	O	AUX	O
enable	O	VERB	O
us	O	PRON	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
new	O	ADJ	O
markers	O	NOUN	B
are	O	AUX	O
distal	O	ADJ	B
to	O	PART	O
APOC2	O	NOUN	B
/	O	PUNCT	O
CKM	O	NOUN	B
and	O	CCONJ	O
thus	O	ADV	O
potentially	O	ADV	O
flank	O	VERB	O
the	O	DET	O
DM	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Localization	O	NOUN	B
of	O	ADP	O
histidase	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	O
region	O	NOUN	O
12q22	O	NOUN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q24	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
region	O	NOUN	I
10C2	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
D1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
histidase	O	NOUN	B
(	O	PUNCT	O
histidine	O	NOUN	B
ammonia	O	NOUN	I
-	O	PUNCT	O
lyase	O	NOUN	B
;	O	PUNCT	O
HAL	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
enzyme	O	NOUN	B
deficient	O	ADJ	B
in	O	ADP	O
histidinemia	B-Disease	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
assigned	O	VERB	O
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	O
12	O	NUM	O
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
X	O	NOUN	O
mouse	O	NOUN	B
somatic	O	ADJ	B
cell	O	NOUN	I
hybrid	O	NOUN	I
DNA	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
was	O	AUX	O
sublocalized	O	VERB	B
to	O	PART	O
region	O	VERB	O
12q22	O	NOUN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q24	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
human	O	ADJ	B
histidase	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
homologous	O	ADJ	B
locus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
(	O	PUNCT	O
Hal	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
region	O	NOUN	O
10C2	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
D1	O	NOUN	B
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
a	O	DET	O
cell	O	NOUN	B
line	O	NOUN	I
from	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
1	O	NUM	O
.	O	PUNCT	O


10	O	NUM	O
Robertsonian	O	ADJ	B
translocation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
assignments	O	NOUN	B
extend	O	VERB	O
the	O	DET	O
conserved	O	VERB	O
syntenic	O	ADJ	B
region	O	NOUN	I
between	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
12	O	NUM	O
and	O	CCONJ	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
10	O	NUM	O
that	O	PRON	O
includes	O	VERB	O
the	O	DET	O
genes	O	NOUN	B
for	O	ADP	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
,	O	PUNCT	O
gamma	O	NOUN	B
interferon	O	NOUN	I
,	O	PUNCT	O
peptidase	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
citrate	O	NOUN	B
synthase	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
localization	O	NOUN	B
of	O	ADP	O
histidase	O	NOUN	B
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
10	O	NUM	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
histidase	O	NOUN	B
regulatory	O	ADJ	O
locus	O	NOUN	O
(	O	PUNCT	O
Hsd	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
histidinemia	O	NOUN	B
mutation	O	NOUN	B
(	O	PUNCT	O
his	O	INTJ	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
both	O	DET	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
on	O	ADP	O
chromosome	O	NOUN	B
10	O	NUM	I
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
histidase	O	NOUN	B
structural	O	ADJ	O
gene	O	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


Determination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
17	O	NUM	O
subjects	O	NOUN	B
.	O	PUNCT	O


Hypoxanthine	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
guanine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
purine	O	NOUN	B
salvage	O	NOUN	O
enzyme	O	NOUN	B
that	O	PRON	O
catalyzes	O	VERB	B
the	O	DET	O
conversion	O	NOUN	B
of	O	ADP	O
hypoxanthine	O	NOUN	B
to	O	PART	O
inosine	O	NOUN	B
monophosphate	O	NOUN	I
and	O	CCONJ	O
guanine	O	NOUN	B
to	O	PART	O
guanosine	O	NOUN	B
monophosphate	O	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
studies	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
HPRT	O	NOUN	B
proteins	O	NOUN	I
analyzed	O	VERB	B
at	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
level	O	NOUN	I
have	O	AUX	O
shown	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
heterogeneity	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
investigation	O	NOUN	B
further	O	ADV	O
verifies	O	VERB	O
this	O	DET	O
heterogeneity	O	NOUN	B
and	O	CCONJ	O
identifies	O	VERB	O
insertions	O	NOUN	B
,	O	PUNCT	O
deletions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
amplified	O	VERB	B
product	O	NOUN	B
of	O	ADP	O
reverse	O	ADJ	B
-	O	PUNCT	O
transcribed	O	VERB	B
HPRT	O	NOUN	B
mRNA	O	NOUN	B
enabled	O	VERB	O
the	O	DET	O
rapid	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
17	O	NUM	O
previously	O	ADV	O
uncharacterized	O	ADJ	B
cell	O	NOUN	B
lines	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
markers	O	NOUN	I
at	O	ADP	O
Xq28	O	NOUN	B
to	O	PART	I
adrenoleukodystrophy	B-Disease	NOUN	I
and	O	CCONJ	O
adrenomyeloneuropathy	B-Disease	NOUN	B
present	O	ADJ	O
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
large	O	ADJ	O
kindred	O	NOUN	B
that	O	PRON	O
contained	O	VERB	O
patients	O	NOUN	B
with	O	ADP	O
either	O	CCONJ	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
pedigree	O	NOUN	B
clearly	O	ADV	O
supported	O	VERB	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
mode	O	NOUN	B
of	O	ADP	O
inheritance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nonneonatal	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
ALD	B-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
with	O	ADP	O
DNA	O	NOUN	B
markers	O	NOUN	I
at	O	ADP	O
Xq28	O	NOUN	B
suggested	O	VERB	O
segregation	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
with	O	ADP	O
an	O	DET	O
identical	O	ADJ	B
haplotype	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
indicated	O	VERB	O
that	O	SCONJ	O
nonneonatal	O	ADJ	B
ALD	B-Disease	NOUN	I
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
are	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B
at	O	ADP	O
Xq28	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
showed	O	VERB	O
,	O	PUNCT	O
furthermore	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
phenotypic	O	ADJ	B
differences	O	NOUN	O
between	O	ADP	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
are	O	AUX	O
not	O	PART	O
necessarily	O	ADV	O
the	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
allelic	O	ADJ	B
heterogeneity	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
different	O	ADJ	O
mutations	O	NOUN	B
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
maximal	O	ADJ	B
lod	O	ADJ	O
score	O	NOUN	O
for	O	ADP	O
linkage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
gene	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
multiallelic	O	ADJ	B
anonymous	O	ADJ	O
DNA	O	NOUN	B
marker	O	NOUN	I
at	O	ADP	O
DXS52	O	NOUN	B
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
at	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
fraction	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


00	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
made	O	VERB	O
a	O	DET	O
prenatal	O	ADJ	B
or	O	CCONJ	O
presymptomatic	O	ADJ	B
diagnosis	O	NOUN	I
and	O	CCONJ	O
heterozygote	O	NOUN	B
detection	O	NOUN	B
by	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
this	O	DET	O
marker	O	NOUN	B
reliable	O	ADJ	B
.	O	PUNCT	O


Skewed	O	VERB	B
X	O	NOUN	I
inactivation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
female	O	ADJ	B
MZ	O	ADJ	B
twin	O	NOUN	B
results	O	VERB	I
in	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
female	O	ADJ	B
MZ	O	ADJ	B
twins	O	NOUN	B
presented	O	VERB	O
with	O	ADP	O
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Physical	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
creatine	O	NOUN	B
phosphokinase	O	NOUN	I
levels	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
muscle	O	NOUN	B
biopsy	O	NOUN	I
were	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
her	O	PRON	O
sex	O	NOUN	B
she	O	PRON	O
was	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
limb	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
girdle	I-Disease	NOUN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


With	O	ADP	O
cDNA	O	NOUN	B
probes	O	NOUN	O
to	O	PART	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
gene	O	NOUN	B
deletion	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
twins	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
mother	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
de	O	X	B
novo	O	X	I
mutation	O	NOUN	B
which	O	DET	O
arose	O	VERB	O
in	O	ADP	O
the	O	DET	O
mother	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
by	O	ADP	O
novel	O	ADJ	B
junction	O	NOUN	B
fragments	O	NOUN	B
generated	O	VERB	O
by	O	ADP	O
HindIII	O	NOUN	B
,	O	PUNCT	O
PstI	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
TaqI	O	NOUN	B
when	O	SCONJ	O
probed	O	VERB	B
with	O	ADP	O
cDNA8	O	NOUN	O
.	O	PUNCT	O


Additional	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
large	O	ADJ	O
gene	O	NOUN	B
deletion	O	NOUN	I
was	O	AUX	O
given	O	VERB	O
by	O	ADP	O
novel	O	ADJ	O
SfiI	O	NOUN	B
junction	O	NOUN	O
fragments	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
probes	O	NOUN	B
p20	O	NOUN	B
,	O	PUNCT	O
J	O	PROPN	B
-	O	PUNCT	O
Bir	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
J	O	PROPN	B
-	O	PUNCT	O
66	O	NUM	O
on	O	ADP	O
pulsed	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
(	O	PUNCT	O
PFGE	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Immunoblot	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
muscle	O	NOUN	B
from	O	ADP	O
the	O	DET	O
affected	O	VERB	B
twin	O	NOUN	B
showed	O	VERB	O
dystrophin	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
size	O	NOUN	I
but	O	SCONJ	O
of	O	ADP	O
reduced	O	VERB	B
amount	O	NOUN	B
.	O	PUNCT	O


Immunofluorescent	O	ADJ	B
visualization	O	NOUN	I
of	O	ADP	O
dystrophin	O	NOUN	B
revealed	O	VERB	O
foci	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
fibers	O	NOUN	B
adjacent	O	ADJ	B
to	O	PART	O
foci	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
fibers	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
affected	O	VERB	B
twin	O	NOUN	B
is	O	AUX	O
a	O	DET	O
manifesting	O	VERB	B
carrier	O	NOUN	B
of	O	ADP	O
an	O	DET	O
abnormal	O	ADJ	B
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
myopathy	B-Disease	ADJ	B
being	O	AUX	O
a	O	DET	O
direct	O	ADJ	O
result	O	NOUN	O
of	O	ADP	O
underexpression	O	NOUN	B
of	O	ADP	O
dystrophin	O	NOUN	B
.	O	PUNCT	O


Cytogenetic	O	ADJ	B
analysis	O	NOUN	I
revealed	O	VERB	O
normal	O	ADJ	B
karyotypes	O	NOUN	I
,	O	PUNCT	O
eliminating	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
translocation	O	NOUN	B
affecting	O	VERB	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
and	O	CCONJ	O
DNA	O	NOUN	B
fingerprint	O	NOUN	I
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
each	O	DET	O
twin	O	NOUN	B
has	O	AUX	O
two	O	NUM	O
different	O	ADJ	O
X	O	NOUN	B
chromosomes	O	NOUN	I
,	O	PUNCT	O
eliminating	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
uniparental	B-Disease	ADJ	B
disomy	I-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
DMD	B-Disease	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
methylation	O	NOUN	B
differences	O	NOUN	B
of	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
and	O	CCONJ	O
maternal	O	ADJ	B
X	O	NOUN	O
chromosomes	O	NOUN	O
in	O	ADP	O
these	O	DET	O
MZ	O	ADJ	B
twins	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
propose	O	VERB	O
uneven	O	ADJ	B
lyonization	O	NOUN	B
(	O	PUNCT	O
X	O	NOUN	B
chromosome	O	NOUN	I
inactivation	O	NOUN	I
)	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
disease	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
female	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
and	O	CCONJ	O
adrenomyeloneuropathy	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
partial	O	ADJ	B
adrenal	B-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
in	O	ADP	O
three	O	NUM	O
generations	O	NOUN	B
of	O	ADP	O
a	O	DET	O
kindred	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
developed	O	VERB	O
in	O	ADP	O
a	O	DET	O
kindred	O	NOUN	B
over	O	ADP	O
three	O	NUM	O
generations	O	NOUN	B
demonstrating	O	VERB	O
that	O	SCONJ	O
AMN	B-Disease	PROPN	B
is	O	AUX	O
a	O	DET	O
clinical	O	ADJ	B
variant	O	NOUN	I
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


Pituitary	O	ADJ	B
-	O	PUNCT	O
adrenal	O	ADJ	B
function	O	NOUN	I
studies	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
10	O	NUM	O
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
two	O	NUM	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
females	O	NOUN	B
identified	O	VERB	B
as	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
.	O	PUNCT	O


No	O	DET	O
pituitary	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
adrenal	I-Disease	ADJ	B
abnormality	I-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
carriers	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
basal	O	ADJ	B
morning	O	NOUN	I
plasma	O	NOUN	B
adrenocorticotropic	O	ADJ	O
hormone	O	NOUN	O
(	O	PUNCT	O
ACTH	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
were	O	AUX	O
markedly	O	ADV	O
elevated	O	ADJ	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
males	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
,	O	PUNCT	O
despite	O	SCONJ	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
they	O	PRON	O
had	O	AUX	O
no	O	DET	O
clinical	O	ADJ	B
signs	O	NOUN	I
of	O	ADP	O
adrenal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
and	O	CCONJ	O
that	O	DET	O
morning	O	NOUN	B
plasma	O	NOUN	B
cortisol	O	NOUN	O
levels	O	NOUN	O
and	O	CCONJ	O
their	O	PRON	O
response	O	NOUN	B
to	O	PART	O
maximal	O	ADJ	B
exogenous	O	ADJ	B
ACTH	O	NOUN	B
stimulation	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
normal	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
integrated	O	ADJ	O
24	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
response	O	NOUN	B
to	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
subnormal	O	ADJ	B
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
people	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
may	O	AUX	O
have	O	AUX	O
subclinical	O	ADJ	B
partial	O	ADJ	I
adrenocrotical	B-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
endocrinologic	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Regional	O	ADJ	B
localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
locus	O	NOUN	I
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	O
9q13	O	NOUN	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
assigned	O	VERB	O
the	O	DET	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
locus	O	NOUN	I
(	O	PUNCT	O
FRDA	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
chromosome	O	NOUN	B
9	O	NUM	I
;	O	PUNCT	O
the	O	DET	O
current	O	ADJ	O
maximal	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
between	O	ADP	O
FRDA	O	NOUN	B
and	O	CCONJ	O
MCT112	O	NOUN	B
(	O	PUNCT	O
D9S15	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
at	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
fraction	O	NOUN	O
of	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
physical	O	ADJ	B
assignment	O	NOUN	I
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
defined	O	VERB	O
by	O	ADP	O
MCT112	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hence	O	ADV	O
FRDA	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
determined	O	VERB	O
,	O	PUNCT	O
although	O	SCONJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
MCT112	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
chromosome	O	NOUN	B
9	O	NUM	I
markers	O	NOUN	B
inferred	O	VERB	O
a	O	DET	O
location	O	NOUN	B
close	O	ADV	O
to	O	PART	O
the	O	DET	O
centromere	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
in	O	X	B
situ	O	X	I
hybridisation	O	NOUN	I
with	O	ADP	O
MCT112	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
corresponding	O	ADJ	O
cosmid	O	NOUN	B
MJ1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
DR47	O	NOUN	B
(	O	PUNCT	O
D9S5	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
coupled	O	VERB	B
with	O	ADP	O
mapping	O	NOUN	B
studies	O	NOUN	I
on	O	ADP	O
hybrid	O	NOUN	B
cell	O	NOUN	I
panels	O	NOUN	I
,	O	PUNCT	O
to	O	PART	O
define	O	VERB	O
more	O	ADV	O
precisely	O	ADV	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
in	O	X	B
situ	O	X	I
location	O	NOUN	B
of	O	ADP	O
all	O	DET	O
three	O	NUM	O
probes	O	NOUN	B
is	O	AUX	O
9q13	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
distal	O	ADJ	B
to	O	PART	O
the	O	DET	O
variable	O	ADJ	B
heterochromatin	O	NOUN	B
region	O	NOUN	O
.	O	PUNCT	O


Physical	O	ADJ	B
assignment	O	NOUN	I
of	O	ADP	O
FRDA	O	NOUN	B
will	O	AUX	O
allow	O	VERB	O
us	O	PRON	O
to	O	PART	O
identify	O	VERB	O
hybrid	O	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
mutated	O	VERB	B
gene	O	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
levels	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
common	O	ADJ	O
cholesteryl	O	NOUN	B
-	O	PUNCT	O
ester	O	NOUN	B
transfer	O	NOUN	I
protein	O	NOUN	I
gene	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
cholesteryl	O	NOUN	B
-	O	PUNCT	O
ester	O	NOUN	B
transfer	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
CETP	O	NOUN	B
)	O	PUNCT	O
catalyzes	O	VERB	B
the	O	DET	O
transfer	O	NOUN	B
of	O	ADP	O
cholesteryl	O	NOUN	B
esters	O	NOUN	I
from	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
other	O	ADJ	O
lipoproteins	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
described	O	VERB	O
a	O	DET	O
Japanese	O	ADJ	B
family	O	NOUN	B
with	O	ADP	O
increased	O	VERB	B
HDL	O	NOUN	B
levels	O	NOUN	O
and	O	CCONJ	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
splicing	O	NOUN	B
defect	O	NOUN	O
of	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
assess	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
phenotype	O	NOUN	B
of	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
screened	O	VERB	B
11	O	NUM	O
additional	O	ADJ	O
families	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
HDL	O	NOUN	B
levels	O	NOUN	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
radioimmunoassay	O	NOUN	B
for	O	ADP	O
CETP	O	NOUN	B
and	O	CCONJ	O
DNA	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
the	O	DET	O
same	O	ADJ	O
CETP	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
families	O	NOUN	B
from	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
restriction	O	NOUN	B
-	O	PUNCT	O
fragment	O	NOUN	B
-	O	PUNCT	O
length	O	NOUN	B
polymorphisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
CETP	O	NOUN	B
allele	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
probands	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
identical	O	ADJ	B
haplotype	O	NOUN	B
.	O	PUNCT	O


Family	O	NOUN	B
members	O	NOUN	I
homozygous	O	ADJ	B
for	O	ADP	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
moderate	O	ADJ	B
hypercholesterolemia	B-Disease	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
total	O	ADJ	O
cholesterol	O	NOUN	O
level	O	NOUN	O
[	O	PUNCT	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
SD	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
83	O	NUM	O
mmol	O	NOUN	O
per	O	ADP	O
liter	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
markedly	O	ADV	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
cholesterol	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O
24	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
mmol	O	NOUN	O
per	O	ADP	O
liter	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
I	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
cholesterol	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
99	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
80	O	NUM	O
mmol	O	NOUN	O
per	O	ADP	O
liter	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
apolipoprotein	O	NOUN	B
B	O	NOUN	I
.	O	PUNCT	O


Members	O	NOUN	B
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
deficiency	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whose	O	DET	O
CETP	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
the	O	DET	O
lower	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
range	O	NOUN	I
,	O	PUNCT	O
had	O	AUX	O
moderately	O	ADV	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
cholesterol	O	NOUN	I
and	O	CCONJ	O
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
I	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
increased	O	VERB	B
ratio	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
subclass	O	NOUN	O
2	O	NUM	O
to	O	PART	O
HDL	O	NOUN	B
subclass	O	NOUN	O
3	O	NUM	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
unaffected	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
six	O	NUM	O
unrelated	O	ADJ	O
subjects	O	NOUN	B
with	O	ADP	O
elevated	O	ADJ	B
HDL	O	NOUN	O
cholesterol	O	NOUN	O
levels	O	NOUN	O
who	O	PRON	O
were	O	AUX	O
from	O	ADP	O
different	O	ADJ	O
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
.	O	PUNCT	O


CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
HDL	O	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
the	O	DET	O
population	O	NOUN	B
of	O	ADP	O
Japan	O	PROPN	B
,	O	PUNCT	O
possibly	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
that	O	SCONJ	O
we	O	PRON	O
observed	O	VERB	O
in	O	ADP	O
heterozygotes	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
CETP	O	NOUN	B
normally	O	ADV	O
plays	O	VERB	O
a	O	DET	O
part	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
levels	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
subclass	O	NOUN	O
2	O	NUM	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
premature	B-Disease	ADJ	B
atherosclerosis	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
families	O	NOUN	B
with	O	ADP	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
fact	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
lipoprotein	O	NOUN	B
profile	O	NOUN	I
of	O	ADP	O
persons	O	NOUN	B
with	O	ADP	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
potentially	O	ADV	O
antiatherogenic	O	ADJ	B
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
life	O	NOUN	B
span	O	NOUN	I
.	O	PUNCT	O


Further	O	ADV	O
mapping	O	NOUN	B
of	O	ADP	O
an	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
locus	O	NOUN	B
to	O	PART	O
the	O	DET	O
chromosome	O	NOUN	B
11q23	O	NOUN	I
region	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
mapped	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
group	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ATA	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
chromosome	O	NOUN	B
11q22	O	NOUN	I
-	O	PUNCT	O
23	O	NUM	O
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
markers	O	NOUN	I
THY1	O	NOUN	B
and	O	CCONJ	O
pYNB3	O	NOUN	B
.	O	PUNCT	O


12	O	NUM	O
(	O	PUNCT	O
D11S144	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
likely	O	ADJ	O
order	O	NOUN	O
was	O	AUX	O
cent	O	NOUN	B
-	O	PUNCT	O
AT	O	ADP	B
-	O	PUNCT	O
S144	O	NOUN	B
-	O	PUNCT	O
THY1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
paper	O	NOUN	B
describes	O	VERB	O
further	O	ADJ	O
mapping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AT	B-Disease	NOUN	B
locus	O	NOUN	I
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
10	O	NUM	O
markers	O	NOUN	B
that	O	PRON	O
span	O	VERB	O
approximately	O	ADV	O
60	O	NUM	O
cM	O	NOUN	O
in	O	ADP	O
the	O	DET	O
11q22	O	NOUN	B
-	O	PUNCT	O
23	O	NUM	O
region	O	NOUN	B
centered	O	VERB	O
around	O	ADP	O
S144	O	NOUN	B
and	O	CCONJ	O
THY1	O	NOUN	B
.	O	PUNCT	O


Location	O	NOUN	B
scores	O	NOUN	O
indicate	O	VERB	O
that	O	SCONJ	O
three	O	NUM	O
contiguous	O	ADJ	B
subsegments	O	NOUN	I
within	O	ADP	O
the	O	DET	O
[	O	PUNCT	O
S144	O	NOUN	B
-	O	PUNCT	O
THY1	O	NOUN	B
]	O	PUNCT	O
segment	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
three	O	NUM	O
contiguous	O	ADJ	O
segments	O	NOUN	B
telomeric	O	ADJ	B
to	O	PART	O
THY1	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
each	O	DET	O
unlikely	O	ADJ	O
to	O	PART	O
contain	O	VERB	O
the	O	DET	O
AT	B-Disease	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
more	O	ADV	O
centromeric	O	ADJ	B
[	O	PUNCT	O
STMY	O	PROPN	B
-	O	PUNCT	O
S144	O	NOUN	B
]	O	PUNCT	O
segment	O	NOUN	B
is	O	AUX	O
most	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
contain	O	VERB	O
the	O	DET	O
AT	B-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
recent	O	ADJ	O
refinements	O	NOUN	B
in	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
and	O	CCONJ	O
physical	O	ADJ	B
maps	O	NOUN	I
of	O	ADP	O
11q22	O	NOUN	B
-	O	PUNCT	O
23	O	NUM	O
,	O	PUNCT	O
place	O	VERB	O
the	O	DET	O
AT	B-Disease	ADP	B
locus	O	NOUN	I
at	O	ADP	O
11q23	O	NOUN	B
.	O	PUNCT	O


Recurrent	O	ADJ	B
meningitis	B-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
congenital	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
C9	I-Disease	NOUN	B
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
.	O	PUNCT	O


First	O	ADJ	O
case	O	NOUN	O
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Europe	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
first	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Europe	O	PROPN	B
that	O	PRON	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
Swiss	O	ADJ	B
family	O	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
two	O	NUM	O
members	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
one	O	NOUN	O
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
deficiency	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
with	O	ADP	O
approximately	O	ADV	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
C9	O	NOUN	B
levels	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
experienced	O	VERB	B
bacterial	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
index	O	NOUN	B
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
56	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
white	O	ADJ	O
man	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
purulent	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
23	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
presented	O	VERB	O
with	O	ADP	O
an	O	DET	O
acute	B-Disease	ADJ	B
meningococcal	I-Disease	ADJ	O
meningitis	I-Disease	NOUN	O
.	O	PUNCT	O


No	O	DET	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
cellular	I-Disease	ADJ	B
immunity	I-Disease	NOUN	I
or	O	CCONJ	O
immunoglobulin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Complement	O	NOUN	B
assays	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
complete	B-Disease	ADJ	O
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
C9	I-Disease	NOUN	B
component	I-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
individual	O	ADJ	B
component	O	NOUN	O
levels	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
hemolytic	O	ADJ	B
activity	O	NOUN	B
(	O	PUNCT	O
measured	O	VERB	B
using	O	VERB	O
the	O	DET	O
CH50	O	NOUN	B
assay	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
only	O	ADV	O
slightly	O	ADV	O
reduced	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
study	O	NOUN	I
revealed	O	VERB	O
complete	B-Disease	ADJ	O
C9	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
healthy	O	ADJ	B
brother	O	NOUN	O
and	O	CCONJ	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
C9	O	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
his	O	PRON	O
sister	O	NOUN	B
,	O	PUNCT	O
his	O	PRON	O
son	O	NOUN	O
(	O	PUNCT	O
who	O	PRON	O
also	O	ADV	O
had	O	AUX	O
experienced	O	VERB	O
an	O	DET	O
episode	O	NOUN	B
of	O	ADP	O
bacterial	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
his	O	PRON	O
niece	O	NOUN	B
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
an	O	DET	O
inherited	O	VERB	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
first	O	ADJ	O
case	O	NOUN	O
of	O	ADP	O
recurrent	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
white	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
complete	B-Disease	ADJ	B
C9	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
complement	B-Disease	NOUN	B
defect	I-Disease	NOUN	I
may	O	AUX	O
also	O	ADV	O
be	O	AUX	O
a	O	DET	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
bacterial	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
especially	I-Disease	ADV	O
neisserial	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
infections	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
98	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
DMD	B-Disease	PROPN	B
/	O	PUNCT	O
BMD	B-Disease	NOUN	B
gene	O	NOUN	B
deletions	O	NOUN	I
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
oligonucleotide	O	NOUN	B
primer	O	NOUN	I
sequences	O	NOUN	I
that	O	PRON	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
amplify	O	VERB	B
eight	O	NUM	O
exons	O	NOUN	B
plus	O	CCONJ	O
the	O	DET	O
muscle	O	NOUN	B
promoter	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
multiplex	O	ADJ	O
polymerase	O	NOUN	O
chain	O	NOUN	O
reaction	O	NOUN	O
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


When	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
an	O	DET	O
existing	O	VERB	O
primer	O	NOUN	B
set	O	NOUN	I
,	O	PUNCT	O
these	O	DET	O
two	O	NUM	O
multiplex	O	ADJ	B
reactions	O	NOUN	I
detect	O	VERB	B
about	O	ADP	O
98	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
deletions	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
Becker	I-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	PROPN	B
,	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
primers	O	NOUN	B
amplify	O	VERB	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
exons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
prone	O	ADJ	O
"	O	PUNCT	O
hot	O	ADJ	B
spot	O	NOUN	I
"	O	PUNCT	O
region	O	NOUN	O
around	O	ADP	O
exons	O	NOUN	B
44	O	NUM	O
to	O	PART	O
53	O	NUM	O
,	O	PUNCT	O
allowing	O	VERB	O
determination	O	NOUN	B
of	O	ADP	O
deletion	O	NOUN	B
endpoints	O	NOUN	B
and	O	CCONJ	O
prediction	O	NOUN	B
of	O	ADP	O
mutational	O	ADJ	B
effects	O	NOUN	I
on	O	ADP	O
the	O	DET	O
translational	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
these	O	DET	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
assays	O	NOUN	B
will	O	AUX	O
allow	O	VERB	O
deletion	O	NOUN	B
detection	O	NOUN	I
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
for	O	ADP	O
most	O	ADJ	O
DMD	B-Disease	PROPN	B
/	O	SYM	O
BMD	B-Disease	NOUN	B
patients	O	NOUN	B
in	O	ADP	O
a	O	DET	O
fraction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
required	O	VERB	O
for	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
heterogeneity	O	NOUN	I
at	O	ADP	O
the	O	DET	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
locus	O	NOUN	I
in	O	ADP	O
southern	O	ADJ	B
Italy	O	PROPN	I
:	O	PUNCT	O
a	O	DET	O
study	O	NOUN	B
on	O	ADP	O
a	O	DET	O
population	O	NOUN	B
from	O	ADP	O
the	O	DET	O
Matera	O	PROPN	B
district	O	NOUN	I
.	O	PUNCT	O


Glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
gel	O	NOUN	B
electrophoresis	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
quantitative	O	ADJ	B
assay	O	NOUN	B
in	O	ADP	O
an	O	DET	O
unselected	O	ADJ	O
sample	O	NOUN	B
of	O	ADP	O
1524	O	NUM	O
schoolboys	O	NOUN	B
from	O	ADP	O
the	O	DET	O
province	O	NOUN	B
of	O	ADP	O
Matera	O	PROPN	B
(	O	PUNCT	O
Lucania	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
southern	O	ADJ	B
Italy	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
43	O	NUM	O
subjects	O	NOUN	B
with	O	ADP	O
a	O	DET	O
G6PD	O	NOUN	B
variant	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
31	O	NUM	O
had	O	AUX	O
severe	O	ADJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
nine	O	NUM	O
had	O	AUX	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
deficiency	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
had	O	AUX	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
deficient	O	ADJ	B
electrophoretic	O	ADJ	B
variant	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
on	O	ADP	O
the	O	DET	O
Ionian	O	PROPN	B
Coast	O	PROPN	I
to	O	ADP	O
zero	O	NUM	O
on	O	ADP	O
the	O	DET	O
eastern	O	ADJ	B
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Lucanian	O	PROPN	B
Apennines	O	PROPN	I
,	O	PUNCT	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
inversely	O	ADV	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
distance	O	NOUN	B
of	O	ADP	O
each	O	DET	O
town	O	NOUN	B
examined	O	VERB	B
from	O	ADP	O
the	O	DET	O
Ionian	O	PROPN	B
Coast	O	PROPN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
geographic	O	ADJ	B
distribution	O	NOUN	I
may	O	AUX	O
reflect	O	VERB	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
part	O	NOUN	O
,	O	PUNCT	O
gene	O	NOUN	B
flow	O	NOUN	I
from	O	ADP	O
Greek	O	PROPN	B
settlers	O	NOUN	I
.	O	PUNCT	O


Biochemical	O	ADJ	B
characterization	O	NOUN	B
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
is	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
several	O	ADJ	O
examples	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
other	O	ADJ	O
known	O	ADJ	O
polymorphic	O	ADJ	B
variants	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
Cagliari	O	PROPN	I
and	O	CCONJ	O
G6PD	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
)	O	PUNCT	O
;	O	PUNCT	O
three	O	NUM	O
new	O	ADJ	O
polymorphic	O	ADJ	B
variants	O	NOUN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Metaponto	O	PROPN	B
(	O	PUNCT	O
class	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
G6PD	O	NOUN	B
Montalbano	O	PROPN	B
(	O	PUNCT	O
class	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Pisticci	O	PROPN	I
(	O	PUNCT	O
class	O	NOUN	B
IV	O	NUM	I
)	O	PUNCT	O
;	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
sporadic	O	ADJ	B
variants	O	NOUN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Tursi	O	PROPN	O
(	O	PUNCT	O
class	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Ferrandina	O	PROPN	I
(	O	PUNCT	O
class	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
the	O	DET	O
marked	O	ADJ	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
within	O	ADP	O
a	O	DET	O
relatively	O	ADV	O
narrow	O	ADJ	B
geographic	O	ADJ	O
area	O	NOUN	O
and	O	CCONJ	O
they	O	PRON	O
prove	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Italian	O	ADJ	B
peninsula	O	NOUN	I
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
GdA	O	NOUN	B
-	O	PUNCT	O
)	O	PUNCT	O
regarded	O	VERB	O
as	O	ADP	O
characteristically	O	ADV	O
African	O	ADJ	B
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
murine	I-Disease	ADJ	B
fifth	I-Disease	ADJ	B
complement	I-Disease	NOUN	I
component	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
C5	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
2	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
gene	O	NOUN	B
deletion	O	NOUN	I
in	O	ADP	O
a	O	DET	O
5	O	NUM	O
'	O	PART	O
-	O	PUNCT	O
exon	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
ascertain	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
mechanism	O	NOUN	O
that	O	PRON	O
causes	O	VERB	O
murine	O	ADJ	B
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
genomic	O	ADJ	B
and	O	CCONJ	O
cDNA	O	NOUN	B
libraries	O	NOUN	I
were	O	AUX	O
constructed	O	VERB	O
from	O	ADP	O
mouse	O	NOUN	B
liver	O	NOUN	B
DNA	O	NOUN	I
and	O	CCONJ	O
mRNA	O	NOUN	B
employing	O	VERB	O
the	O	DET	O
congenic	O	ADJ	B
strains	O	NOUN	I
B10	O	NOUN	I
.	O	PUNCT	O


D2	O	NOUN	B
/	O	SYM	O
nSnJ	O	PROPN	B
and	O	CCONJ	O
B10	O	NOUN	B
.	O	PUNCT	O


D2	O	NOUN	B
/	O	SYM	O
oSnJ	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
sufficient	O	ADJ	B
and	O	CCONJ	O
deficient	B-Disease	ADJ	B
for	I-Disease	ADP	O
C5	I-Disease	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Genomic	O	ADJ	B
fragments	O	NOUN	I
were	O	AUX	O
isolated	O	VERB	B
which	O	DET	O
correspond	O	VERB	O
to	O	PART	O
PvuII	O	NOUN	B
and	O	CCONJ	O
HindIII	O	NOUN	B
restriction	O	NOUN	I
fragment	O	NOUN	I
length	O	NOUN	I
polymorphisms	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Sequence	O	NOUN	B
analyses	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
each	O	DET	O
of	O	ADP	O
these	O	DET	O
polymorphisms	O	NOUN	B
resulted	O	VERB	O
from	O	ADP	O
single	O	ADJ	B
base	O	NOUN	I
pair	O	NOUN	I
substitutions	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
neither	O	DET	O
substitution	O	NOUN	B
would	O	AUX	O
probably	O	ADV	O
cause	O	VERB	B
or	O	CCONJ	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Sequence	O	NOUN	B
analyses	O	NOUN	I
of	O	ADP	O
C5	O	NOUN	B
sufficient	O	ADJ	B
and	O	CCONJ	O
deficient	O	ADJ	B
cDNAs	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
2	O	NUM	O
base	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
deficient	O	ADJ	B
cDNAs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
"	O	PUNCT	O
TA	O	NOUN	B
"	O	PUNCT	O
deletion	O	NOUN	B
was	O	AUX	O
located	O	ADJ	O
near	O	ADP	B
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
deletion	O	NOUN	B
shifts	O	VERB	I
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
of	O	ADP	O
the	O	DET	O
C5	O	NOUN	B
mRNA	O	NOUN	B
so	O	SCONJ	O
that	O	SCONJ	O
the	O	DET	O
termination	O	NOUN	B
codon	O	NOUN	O
UGA	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
4	O	NUM	O
base	O	NOUN	B
pairs	O	NOUN	I
downstream	O	ADJ	I
from	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


Genomic	O	ADJ	B
DNA	O	NOUN	I
was	O	AUX	O
amplified	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
corresponding	O	VERB	O
to	O	ADP	O
the	O	DET	O
area	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
2	O	NUM	B
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
C5	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
strains	O	NOUN	B
,	O	PUNCT	O
A	O	DET	B
/	O	SYM	O
HeJ	O	NOUN	B
,	O	PUNCT	O
AKR	O	PROPN	B
/	O	SYM	O
J	O	PROPN	B
,	O	PUNCT	O
DBA	O	PROPN	B
/	O	SYM	O
2J	O	NOUN	B
,	O	PUNCT	O
NZB	O	NOUN	B
/	O	PUNCT	O
B1NJ	O	NOUN	B
,	O	PUNCT	O
SWR	O	PROPN	B
/	O	SYM	O
J	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
B10	O	NOUN	B
.	O	PUNCT	O


D2	O	NOUN	B
/	O	SYM	O
oSnJ	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
four	O	NUM	O
C5	O	NOUN	B
-	O	PUNCT	O
sufficient	O	ADJ	B
strains	O	NOUN	B
,	O	PUNCT	O
Balb	O	NOUN	B
/	O	PUNCT	O
CJ	O	PROPN	B
,	O	PUNCT	O
C57Bl	O	NOUN	B
/	O	SYM	O
6J	O	NOUN	B
,	O	PUNCT	O
DBA	O	PROPN	B
/	O	SYM	O
1J	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
B10	O	NOUN	B
.	O	PUNCT	O


D2	O	NOUN	B
/	O	SYM	O
nSnJ	O	PROPN	B
,	O	PUNCT	O
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
sequencing	O	NOUN	B
data	O	NOUN	B
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
2	O	NUM	O
base	O	NOUN	O
pairs	O	NOUN	O
were	O	AUX	O
deleted	O	VERB	O
from	O	ADP	O
the	O	DET	O
C5	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
each	O	DET	O
deficient	O	ADJ	B
mouse	O	NOUN	B
tested	O	VERB	B
but	O	CCONJ	O
not	O	PART	O
from	O	ADP	O
the	O	DET	O
C5	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
any	O	DET	O
sufficient	O	ADJ	B
mouse	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
1	O	X	O
)	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
an	O	DET	O
identical	O	ADJ	B
2	O	NUM	B
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
in	O	ADP	O
an	O	DET	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C5	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
several	O	ADJ	O
different	O	ADJ	O
C5	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mouse	O	NOUN	B
strains	O	NOUN	I
;	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
mRNA	O	NOUN	B
transcribed	O	VERB	I
from	O	ADP	O
the	O	DET	O
C5D	O	NOUN	B
gene	O	NOUN	I
retains	O	VERB	O
this	O	DET	O
deletion	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
3	O	X	O
)	O	PUNCT	O
this	O	DET	O
mutation	O	NOUN	B
should	O	AUX	O
result	O	VERB	O
in	O	ADP	O
C5	B-Disease	NOUN	B
protein	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Molecular	O	ADJ	B
genetics	O	NOUN	I
of	O	ADP	O
PKU	B-Disease	NOUN	B
in	O	ADP	O
eastern	O	ADJ	B
Europe	O	PROPN	I
:	O	PUNCT	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
haplotype	O	NOUN	B
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
genetic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Several	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
RFLP	O	NOUN	B
haplotypes	O	NOUN	B
and	O	CCONJ	O
specific	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
molecular	B-Disease	ADJ	B
lesion	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	O
in	O	ADP	O
a	O	DET	O
Hungarian	O	ADJ	B
PKU	B-Disease	NOUN	B
patient	O	NOUN	B
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
PCR	O	NOUN	B
-	O	PUNCT	O
amplified	O	VERB	B
DNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
causes	O	VERB	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
Arg243	O	NOUN	B
to	O	PART	O
a	O	DET	O
termination	O	NOUN	B
codon	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
haplotype	O	NOUN	B
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
mutant	O	ADJ	B
haplotype	O	NOUN	O
4	O	NUM	O
alleles	O	NOUN	B
among	O	ADP	O
Eastern	O	ADJ	B
Europeans	O	PROPN	I
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
present	O	ADJ	O
among	O	ADP	O
Western	O	ADJ	B
Europeans	O	PROPN	I
and	O	CCONJ	O
Asians	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
rarity	O	NOUN	B
of	O	ADP	O
this	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	O
and	O	CCONJ	O
its	O	PRON	O
restricted	O	ADJ	O
geographic	O	ADJ	B
distribution	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutational	O	ADJ	B
event	O	NOUN	I
occurred	O	VERB	O
recently	O	ADV	O
on	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
haplotype	O	NOUN	B
4	O	NUM	O
background	O	NOUN	B
in	O	ADP	O
Eastern	O	PROPN	B
Europe	O	PROPN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
red	O	ADJ	B
-	O	PUNCT	O
green	O	ADJ	B
visual	O	ADJ	B
pigment	O	NOUN	O
gene	O	NOUN	O
region	O	NOUN	O
in	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
recent	O	ADJ	O
data	O	NOUN	B
established	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
specific	O	ADJ	O
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acyl	O	ADJ	I
-	O	PUNCT	O
CoA	O	NOUN	B
synthetase	O	NOUN	B
is	O	AUX	O
defective	O	ADJ	B
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
still	O	ADV	O
unidentified	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
ALD	B-Disease	NOUN	B
locus	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
Xq28	O	NOUN	B
,	O	PUNCT	O
like	O	ADP	O
the	O	DET	O
red	O	ADJ	B
and	O	CCONJ	O
green	O	ADJ	B
color	O	NOUN	I
pigment	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


Abnormal	B-Disease	ADJ	B
color	I-Disease	NOUN	O
vision	I-Disease	NOUN	O
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
12	O	NUM	O
of	O	ADP	O
27	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
milder	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
rearrangements	O	NOUN	B
of	O	ADP	O
the	O	DET	O
color	O	NOUN	B
vision	O	NOUN	I
gene	O	NOUN	I
cluster	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
eight	O	NUM	O
ALD	B-Disease	NOUN	B
kindreds	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
propose	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
single	O	ADJ	O
DNA	O	NOUN	B
rearrangement	O	NOUN	I
could	O	AUX	O
underlie	O	VERB	O
both	O	CCONJ	O
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
abnormal	B-Disease	ADJ	B
color	I-Disease	NOUN	O
vision	I-Disease	NOUN	O
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
34	O	NUM	O
French	O	ADJ	B
ALD	B-Disease	NOUN	B
patients	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
reveal	O	VERB	O
a	O	DET	O
higher	O	ADJ	B
than	O	ADP	O
expected	O	VERB	O
frequency	O	NOUN	B
of	O	ADP	O
green	O	PROPN	B
/	O	SYM	O
red	O	ADJ	B
visual	O	ADJ	I
pigment	O	NOUN	O
rearrangements	O	NOUN	O
3	O	NUM	O
to	O	PART	O
the	O	DET	O
red	O	ADJ	B
/	O	SYM	O
green	O	ADJ	B
color	O	NOUN	I
vision	O	NOUN	I
gene	O	NOUN	I
complex	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
previous	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
such	O	ADJ	O
rearrangements	O	NOUN	B
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
small	O	ADJ	B
numbers	O	NOUN	I
and	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
knowledge	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
abnormal	O	ADJ	B
"	O	PUNCT	O
color	O	NOUN	B
vision	O	NOUN	I
arrays	O	NOUN	O
on	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
twice	O	ADV	O
as	O	ADV	O
high	O	ADJ	O
as	O	ADP	O
expected	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
phenotypic	B-Disease	ADJ	B
color	I-Disease	NOUN	O
vision	I-Disease	NOUN	O
defects	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
red	O	ADJ	B
/	O	SYM	O
green	O	ADJ	B
color	O	NOUN	I
pigment	O	NOUN	I
(	O	PUNCT	O
R	O	NOUN	B
/	O	PUNCT	O
GCP	O	PROPN	B
)	O	PUNCT	O
region	O	NOUN	O
was	O	AUX	O
studied	O	VERB	O
by	O	ADP	O
pulsed	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
in	O	ADP	O
14	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
did	O	AUX	O
not	O	PART	O
find	O	VERB	O
any	O	DET	O
fragment	O	NOUN	B
size	O	NOUN	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	B
individuals	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
pigment	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
R	O	PROPN	B
/	O	SYM	O
GCP	O	NOUN	B
region	O	NOUN	O
was	O	AUX	O
also	O	ADV	O
analyzed	O	VERB	B
in	O	ADP	O
29	O	NUM	O
French	O	ADJ	B
and	O	CCONJ	O
seven	O	NUM	O
North	O	ADJ	B
American	O	ADJ	I
ALD	B-Disease	NOUN	B
patients	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
six	O	NUM	O
genomic	O	ADJ	B
DNA	O	NOUN	I
probes	O	NOUN	I
,	O	PUNCT	O
isolated	O	VERB	B
from	O	ADP	O
a	O	DET	O
cosmid	O	NOUN	B
walk	O	NOUN	I
,	O	PUNCT	O
that	O	PRON	O
flank	O	VERB	O
the	O	DET	O
color	O	NOUN	B
vision	O	NOUN	I
genes	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
deletions	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
with	O	ADP	O
probes	O	NOUN	B
that	O	PRON	O
lie	O	VERB	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
green	O	ADJ	B
pigment	O	NOUN	I
genes	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
eight	O	NUM	O
previously	O	ADV	O
reported	O	VERB	O
ALD	B-Disease	NOUN	B
individuals	O	NOUN	B
has	O	AUX	O
a	O	DET	O
long	O	ADJ	B
deletion	O	NOUN	I
5	O	NUM	I
of	O	ADP	O
the	O	DET	O
red	O	ADJ	B
pigment	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
deletion	O	NOUN	B
causing	O	VERB	O
blue	O	ADJ	B
cone	O	NOUN	I
monochromacy	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
previous	O	ADJ	O
findings	O	NOUN	B
of	O	ADP	O
a	O	DET	O
45	O	NUM	O
%	O	NOUN	O
frequency	O	NOUN	B
of	O	ADP	O
phenotypic	O	ADJ	B
color	O	NOUN	O
vision	O	NOUN	O
defects	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
AMN	B-Disease	NOUN	B
may	O	AUX	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
ALD	B-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
gene	O	NOUN	B
lies	O	VERB	O
5	O	NUM	O
to	O	PART	O
the	O	DET	O
red	O	ADJ	B
pigment	O	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
frequent	O	ADJ	B
phenotypic	O	ADJ	B
color	B-Disease	NOUN	O
vision	I-Disease	NOUN	O
anomalies	I-Disease	NOUN	O
owe	O	VERB	O
their	O	PRON	O
origin	O	NOUN	B
to	O	PART	O
deleted	O	VERB	O
DNA	O	NOUN	B
that	O	PRON	O
includes	O	VERB	O
regulatory	O	ADJ	B
genes	O	NOUN	I
for	O	ADP	O
color	O	NOUN	B
vision	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
phenotypic	O	ADJ	B
color	B-Disease	NOUN	B
vision	I-Disease	NOUN	I
anomalies	I-Disease	NOUN	O
in	O	ADP	O
AMN	B-Disease	PROPN	B
may	O	AUX	O
be	O	AUX	O
phenocopies	O	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
retinal	O	ADJ	B
or	O	CCONJ	O
neural	O	ADJ	B
involvement	O	NOUN	B
by	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
single	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
blue	O	ADJ	B
cone	O	NOUN	I
monochromacy	O	NOUN	O
may	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
a	O	DET	O
fortuitous	O	ADJ	O
coincidence	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
diseases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Paroxysmal	B-Disease	ADJ	B
nocturnal	I-Disease	ADJ	I
haemoglobinuria	I-Disease	NOUN	I
with	O	ADP	O
coexisting	O	VERB	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
ninth	I-Disease	ADJ	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
:	O	PUNCT	O
lack	O	NOUN	B
of	O	ADP	O
massive	O	ADJ	B
haemolytic	B-Disease	ADJ	B
attack	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
47	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
paroxysmal	B-Disease	ADJ	B
nocturnal	I-Disease	ADJ	I
haemoglobinuria	I-Disease	NOUN	I
(	O	PUNCT	O
PNH	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
deficiency	I-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
ninth	I-Disease	ADJ	B
complement	I-Disease	NOUN	I
component	I-Disease	NOUN	I
(	O	PUNCT	O
C9	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
complement	O	NOUN	B
-	O	PUNCT	O
sensitivity	O	NOUN	B
lysis	O	NOUN	B
tests	O	NOUN	O
,	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
her	O	PRON	O
erythrocytes	O	NOUN	B
were	O	AUX	O
markedly	O	ADV	O
complement	O	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
(	O	PUNCT	O
PNH	O	NOUN	B
-	O	PUNCT	O
III	O	NUM	B
)	O	PUNCT	O
.	O	PUNCT	O


Laser	O	NOUN	B
cytofluorimetry	O	NOUN	I
with	O	ADP	O
a	O	DET	O
monoclonal	O	ADJ	B
antibody	O	NOUN	I
against	O	ADP	O
decay	O	NOUN	B
-	O	PUNCT	O
accelerating	O	VERB	B
factor	O	NOUN	B
(	O	PUNCT	O
DAF	O	NOUN	B
)	O	PUNCT	O
revealed	O	VERB	O
that	O	SCONJ	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
her	O	PRON	O
erythrocytes	O	NOUN	B
were	O	AUX	O
DAF	O	NOUN	B
-	O	PUNCT	O
negative	O	ADJ	B
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
has	O	AUX	O
suffered	O	VERB	O
only	O	ADV	O
mild	O	ADJ	B
haemolysis	B-Disease	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
never	O	ADV	O
experienced	O	VERB	O
massive	O	ADJ	B
spontaneous	O	ADJ	B
haemolysis	B-Disease	NOUN	B
.	O	PUNCT	O


Gross	O	ADJ	B
haemoglobinuria	B-Disease	NOUN	I
and	O	CCONJ	O
jaundice	B-Disease	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
after	O	ADP	O
receiving	O	VERB	O
postoperative	O	ADJ	B
transfusion	O	NOUN	B
of	O	ADP	O
whole	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
her	O	PRON	O
serum	O	NOUN	B
,	O	PUNCT	O
C9	O	NOUN	B
was	O	AUX	O
not	O	PART	O
detectable	O	ADJ	B
either	O	CCONJ	O
by	O	ADP	O
immunological	O	ADJ	B
or	O	CCONJ	O
by	O	ADP	O
functional	O	ADJ	B
assays	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
Ham	O	NOUN	B
test	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
sugar	O	NOUN	B
water	O	NOUN	I
test	O	NOUN	I
using	O	VERB	O
normal	O	ADJ	O
human	O	ADJ	B
serum	O	NOUN	B
or	O	CCONJ	O
plasma	O	NOUN	B
yielded	O	VERB	O
marked	O	ADJ	O
haemolysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
erythrocytes	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
serum	O	NOUN	B
or	O	CCONJ	O
plasma	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
trace	O	NOUN	B
of	O	ADP	O
lysis	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Addition	O	NOUN	B
of	O	ADP	O
purified	O	VERB	B
human	O	ADJ	B
C9	O	NOUN	B
to	O	ADP	O
her	O	PRON	O
plasma	O	NOUN	B
fully	O	ADV	O
restored	O	VERB	B
haemolysis	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
C9	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
haemolytic	B-Disease	ADJ	B
attacks	I-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
PNH	B-Disease	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
characteristic	O	ADJ	O
haemolysis	B-Disease	NOUN	B
in	O	ADP	O
PNH	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
tempered	O	VERB	O
by	O	ADP	O
coexisting	O	VERB	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Duplicational	O	ADJ	B
mutation	O	NOUN	I
at	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
:	O	PUNCT	O
its	O	PRON	O
frequency	O	NOUN	B
,	O	PUNCT	O
distribution	O	NOUN	B
,	O	PUNCT	O
origin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
phenotypegenotype	O	NOUN	B
correlation	O	NOUN	B
.	O	PUNCT	O


Partial	O	ADJ	B
gene	O	NOUN	B
deletion	O	NOUN	I
is	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Partial	O	ADJ	B
gene	O	NOUN	B
duplication	O	NOUN	I
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
recognized	O	VERB	O
in	O	ADP	O
a	O	DET	O
few	O	ADJ	O
cases	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
conducted	O	VERB	O
a	O	DET	O
survey	O	NOUN	B
for	O	ADP	O
duplication	O	NOUN	B
in	O	ADP	O
72	O	NUM	O
unrelated	O	ADJ	O
nondeletion	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
analyzed	O	VERB	B
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
with	O	ADP	O
clones	O	NOUN	B
representing	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
DMD	B-Disease	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
careful	O	ADJ	O
quantitative	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
hybridization	O	NOUN	B
band	O	NOUN	I
intensity	O	NOUN	I
,	O	PUNCT	O
10	O	NUM	O
cases	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
a	O	DET	O
duplication	O	NOUN	B
of	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
14	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
nondeletion	O	ADJ	B
cases	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
/	O	SYM	O
72	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
6	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
/	O	SYM	O
181	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
these	O	DET	O
duplications	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
characterized	O	VERB	B
according	O	VERB	O
to	O	PART	O
the	O	DET	O
published	O	VERB	B
exon	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
HindIII	O	NOUN	B
fragment	O	NOUN	I
map	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
six	O	NUM	O
of	O	ADP	O
the	O	DET	O
10	O	NUM	O
duplications	O	NOUN	B
a	O	DET	O
novel	O	ADJ	O
restriction	O	NOUN	B
fragment	O	NOUN	O
that	O	PRON	O
spanned	O	VERB	O
the	O	DET	O
duplication	O	NOUN	B
junction	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
resulting	O	VERB	O
translational	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
of	O	ADP	O
mRNA	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
predicted	O	VERB	B
for	O	ADP	O
nine	O	NUM	O
duplications	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
shift	O	NOUN	B
of	O	ADP	O
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
was	O	AUX	O
predicted	O	VERB	B
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
DMD	B-Disease	NOUN	B
cases	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
intermediate	O	ADJ	O
cases	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
remained	O	VERB	O
uninterrupted	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
BMD	B-Disease	NOUN	B
cases	O	NOUN	B
.	O	PUNCT	O


RFLP	O	NOUN	B
and	O	CCONJ	O
quantitative	O	ADJ	B
Southern	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
grandpaternal	O	ADJ	B
origin	O	NOUN	I
of	O	ADP	O
duplication	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
families	O	NOUN	B
and	O	CCONJ	O
grandmaternal	O	ADJ	B
origin	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
five	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
duplication	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
originate	O	VERB	O
from	O	ADP	O
a	O	DET	O
single	O	ADJ	B
X	O	NOUN	I
chromosome	O	NOUN	I
.	O	PUNCT	O


Unequal	O	ADJ	B
sister	O	NOUN	B
-	O	PUNCT	O
chromatid	O	NOUN	B
exchange	O	NOUN	I
is	O	AUX	O
proposed	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
duplications	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Glucose	O	NOUN	B
6	O	NUM	I
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variants	O	NOUN	B
:	O	PUNCT	O
Gd	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
Alexandra	O	PROPN	B
associated	O	VERB	B
with	O	ADP	I
neonatal	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	O
and	O	CCONJ	O
Gd	O	PROPN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Camperdown	O	PROPN	B
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
lamellar	B-Disease	ADJ	B
cataracts	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
male	O	ADJ	B
subjects	O	NOUN	B
are	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
unusual	O	ADJ	O
clinical	O	ADJ	B
presentations	O	NOUN	O
and	O	CCONJ	O
with	O	ADP	O
hitherto	O	ADV	O
undescribed	O	ADJ	O
G6PD	O	NOUN	B
variants	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
,	O	PUNCT	O
of	O	ADP	O
Italian	O	ADJ	B
extraction	O	NOUN	B
,	O	PUNCT	O
suffered	O	VERB	O
from	O	ADP	O
severe	O	ADJ	B
neonatal	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	O
following	O	VERB	O
maternal	O	ADJ	B
ingestion	O	NOUN	B
of	O	ADP	O
fresh	O	ADJ	B
broad	O	ADJ	O
beans	O	NOUN	O
(	O	PUNCT	O
Vicia	O	NOUN	B
fava	O	NOUN	I
)	O	PUNCT	O
both	O	CCONJ	O
prenatally	O	ADV	B
and	O	CCONJ	O
postnatally	O	ADV	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzymatic	O	ADJ	B
defect	O	NOUN	O
was	O	AUX	O
much	O	ADV	O
more	O	ADV	O
severe	O	ADJ	B
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
period	O	NOUN	B
than	O	ADP	O
on	O	ADP	O
retesting	O	NOUN	B
in	O	ADP	O
adolescence	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
biochemical	O	ADJ	B
characterization	O	NOUN	B
showed	O	VERB	O
unique	O	ADJ	B
features	O	NOUN	B
which	O	DET	O
justify	O	VERB	O
designation	O	NOUN	O
as	O	ADP	O
a	O	DET	O
new	O	ADJ	O
variant	O	ADJ	B
Gd	O	PROPN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
Alexandra	O	PROPN	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
boy	O	NOUN	B
of	O	ADP	O
Maltese	O	ADJ	B
extraction	O	NOUN	B
who	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
bilateral	B-Disease	ADJ	B
lamellar	I-Disease	ADJ	O
cataracts	I-Disease	NOUN	O
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	O
as	O	ADP	O
G6PD	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
only	O	ADV	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
survey	O	NOUN	B
of	O	ADP	O
children	O	NOUN	B
of	O	ADP	O
Mediterranean	O	ADJ	B
origin	O	NOUN	B
with	O	ADP	O
unexplained	O	ADJ	B
cataract	B-Disease	NOUN	B
formation	O	NOUN	I
;	O	PUNCT	O
he	O	PRON	O
has	O	AUX	O
approximately	O	ADV	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
enzyme	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
another	O	DET	O
unique	O	ADJ	B
combination	O	NOUN	B
of	O	ADP	O
biochemical	O	ADJ	B
characteristics	O	NOUN	B
which	O	DET	O
has	O	AUX	O
led	O	VERB	O
to	O	ADP	O
its	O	PRON	O
designation	O	NOUN	O
as	O	ADP	O
Gd	O	PROPN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Camperdown	O	PROPN	B
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
association	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
coincidental	O	ADJ	B
,	O	PUNCT	O
it	O	PRON	O
prompts	O	VERB	O
further	O	ADJ	O
attention	O	NOUN	O
to	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
under	O	ADP	O
certain	O	ADJ	O
circumstances	O	NOUN	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
may	O	AUX	O
favor	O	VERB	O
cataract	B-Disease	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
cases	O	NOUN	B
illustrate	O	VERB	O
the	O	DET	O
value	O	NOUN	O
of	O	ADP	O
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
enzyme	O	NOUN	B
whenever	O	SCONJ	O
unexpected	O	ADJ	O
clinical	O	ADJ	B
or	O	CCONJ	O
laboratory	O	NOUN	B
results	O	NOUN	I
are	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Statistical	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
stage	O	NOUN	B
mutation	O	NOUN	B
model	O	NOUN	O
in	O	ADP	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
sporadic	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	O
haemangioblastoma	I-Disease	NOUN	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
age	O	NOUN	B
incidence	O	NOUN	O
curves	O	NOUN	O
for	O	ADP	O
unilateral	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
bilateral	I-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
led	O	VERB	O
Knudson	O	NOUN	B
to	O	PART	O
propose	O	VERB	O
that	O	SCONJ	O
hereditary	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
may	O	AUX	O
arise	O	VERB	O
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
event	O	NOUN	B
and	O	CCONJ	O
sporadic	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
by	O	ADP	O
a	O	DET	O
two	O	NUM	O
stage	O	NOUN	B
mutation	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
recently	O	ADV	O
that	O	SCONJ	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	O
cell	I-Disease	NOUN	O
carcinoma	I-Disease	NOUN	O
may	O	AUX	O
arise	O	VERB	O
from	O	ADP	O
a	O	DET	O
two	O	NUM	O
stage	O	NOUN	B
mutation	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
analysed	O	VERB	B
the	O	DET	O
age	O	NOUN	B
incidence	O	NOUN	O
curves	O	NOUN	O
for	O	ADP	O
symptomatic	O	ADJ	B
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
cerebellar	B-Disease	ADJ	B
haemangioblastoma	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
68	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
109	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	I-Disease	PUNCT	O
VHL	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
disease	I-Disease	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
compared	O	VERB	B
them	O	PRON	O
to	O	PART	O
104	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
43	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
sporadic	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	I
haemangioblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
age	O	NOUN	B
incidence	O	NOUN	B
curves	O	NOUN	I
for	O	ADP	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
cerebellar	B-Disease	ADJ	B
haemangioblastoma	I-Disease	NOUN	I
in	O	ADP	O
VHL	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
were	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
a	O	DET	O
single	O	ADJ	O
mutation	O	NOUN	B
model	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
age	O	NOUN	B
incidence	O	NOUN	O
curves	O	NOUN	O
for	O	ADP	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
cerebellar	B-Disease	ADJ	B
haemangioblastoma	I-Disease	NOUN	I
suggested	O	VERB	O
a	O	DET	O
two	O	NUM	O
stage	O	NOUN	B
mutation	O	NOUN	B
process	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
functioning	O	VERB	O
as	O	ADP	O
a	O	DET	O
recessive	O	ADJ	B
tumour	B-Disease	NOUN	I
suppressor	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Sporadic	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	B
haemangioblastoma	I-Disease	NOUN	I
and	O	CCONJ	O
some	O	DET	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
may	O	AUX	O
arise	O	VERB	O
from	O	ADP	O
somatic	O	ADJ	B
mutations	O	NOUN	B
inactivating	O	VERB	B
both	O	DET	O
alleles	O	NOUN	B
at	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Screening	O	VERB	B
for	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
among	O	ADP	O
Ashkenazi	O	PROPN	B
Jews	O	PROPN	I
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
and	O	CCONJ	O
enzyme	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
tests	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
GM2	B-Disease	NOUN	B
gangliosidosis	I-Disease	NOUN	I
,	I-Disease	PUNCT	O
type	I-Disease	NOUN	O
1	I-Disease	NUM	O
)	O	PUNCT	O
depends	O	VERB	O
on	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
this	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
the	O	DET	O
enzyme	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
test	O	NOUN	B
widely	O	ADV	O
used	O	VERB	O
in	O	ADP	O
screening	O	NOUN	B
for	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
test	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
developed	O	VERB	O
methods	O	NOUN	B
to	O	PART	O
detect	O	VERB	B
the	O	DET	O
three	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
occur	O	VERB	O
with	O	ADP	O
high	O	ADJ	O
frequency	O	NOUN	B
among	O	ADP	O
Ashkenazi	O	ADJ	B
Jews	O	PROPN	I
two	O	NUM	O
mutations	O	NOUN	B
cause	O	VERB	O
infantile	O	ADJ	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
third	O	NOUN	O
causes	O	VERB	O
the	O	DET	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
form	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


DNA	O	NOUN	B
segments	O	NOUN	I
containing	O	VERB	O
these	O	DET	O
mutation	O	NOUN	B
sites	O	NOUN	I
were	O	AUX	O
amplified	O	VERB	B
with	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
and	O	CCONJ	O
analyzed	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
62	O	NUM	O
Ashkenazi	O	ADJ	B
obligate	O	ADJ	B
carriers	O	NOUN	B
of	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
three	O	NUM	O
specific	O	ADJ	O
mutations	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
all	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
alleles	O	NOUN	O
(	O	PUNCT	O
98	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
216	O	NUM	O
Ashkenazi	O	ADJ	B
carriers	O	NOUN	B
identified	O	VERB	B
by	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
DNA	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
177	O	NUM	O
(	O	PUNCT	O
82	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
identified	O	VERB	B
mutations	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
177	O	NUM	O
,	O	PUNCT	O
79	O	NUM	O
percent	O	NOUN	O
had	O	AUX	O
the	O	DET	O
exon	O	NOUN	B
11	O	NUM	I
insertion	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
18	O	NUM	O
percent	O	NOUN	O
had	O	AUX	O
the	O	DET	O
intron	O	NOUN	B
12	O	NUM	O
splice	O	NOUN	B
-	O	PUNCT	O
junction	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
percent	O	NOUN	O
had	O	AUX	O
the	O	DET	O
less	O	ADV	O
severe	O	ADJ	B
exon	O	NOUN	B
7	O	NUM	I
mutation	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
disease	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
tests	O	NOUN	I
in	O	ADP	O
the	O	DET	O
39	O	NUM	O
subjects	O	NOUN	B
(	O	PUNCT	O
18	O	NUM	O
percent	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
were	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
carriers	O	NOUN	B
but	O	CCONJ	O
in	O	ADP	O
whom	O	PRON	O
DNA	O	NOUN	B
analysis	O	NOUN	I
did	O	AUX	O
not	O	PART	O
identify	O	VERB	O
a	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
were	O	AUX	O
probably	O	ADV	O
false	O	ADJ	O
positive	O	ADJ	O
(	O	PUNCT	O
although	O	SCONJ	O
there	O	PRON	O
remains	O	VERB	O
some	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
unidentified	O	ADJ	O
mutations	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
of	O	ADP	O
152	O	NUM	O
persons	O	NOUN	B
defined	O	VERB	O
as	O	ADP	O
noncarriers	O	NOUN	B
by	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
test	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
was	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
carrier	O	NOUN	B
by	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O
e	O	X	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
false	O	ADJ	O
negative	O	ADJ	B
enzyme	O	NOUN	B
-	O	PUNCT	O
test	O	NOUN	B
result	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
increased	O	VERB	B
specificity	O	NOUN	B
and	O	CCONJ	O
predictive	O	ADJ	B
value	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
test	O	NOUN	B
make	O	VERB	O
it	O	PRON	O
a	O	DET	O
useful	O	ADJ	O
adjunct	O	NOUN	B
to	O	PART	O
the	O	DET	O
diagnostic	O	ADJ	B
tests	O	NOUN	I
currently	O	ADV	O
used	O	VERB	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
carriers	O	NOUN	B
of	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Total	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
plasma	I-Disease	NOUN	B
cholesteryl	I-Disease	NOUN	O
ester	I-Disease	NOUN	O
transfer	I-Disease	NOUN	O
protein	I-Disease	NOUN	O
in	O	ADP	O
subjects	O	NOUN	B
homozygous	O	ADJ	B
and	O	CCONJ	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
14	O	NUM	O
splicing	O	NOUN	B
defect	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
cholesteryl	B-Disease	NOUN	B
ester	I-Disease	NOUN	I
transfer	I-Disease	NOUN	I
protein	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
CETP	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
4	O	NUM	O
unrelated	O	ADJ	O
CETP	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	O
-	O	PUNCT	O
cholesterol	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
exceeded	O	VERB	O
150	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
of	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
was	O	AUX	O
totally	O	ADV	O
deficient	O	ADJ	B
in	O	ADP	O
CETP	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
mass	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
genomic	O	ADJ	B
DNA	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
two	O	NUM	O
oligonucleotide	O	NOUN	B
primers	O	NOUN	I
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
12	O	NUM	O
and	O	CCONJ	O
14	O	NUM	O
of	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
amplified	O	VERB	B
products	O	NOUN	I
were	O	AUX	O
directly	O	ADV	O
sequenced	O	VERB	B
.	O	PUNCT	O


Two	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	NOUN	O
change	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
splice	O	NOUN	B
donor	O	NOUN	O
site	O	NOUN	O
of	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
14	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	PROPN	O
change	O	NOUN	B
would	O	AUX	O
cause	O	VERB	O
impaired	O	ADJ	B
splicing	O	NOUN	B
of	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
messenger	O	NOUN	B
RNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
two	O	NUM	O
probands	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
totally	O	ADV	O
lacked	O	VERB	O
CETP	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
lipoprotein	O	NOUN	B
patterns	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
homozygotes	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
other	O	ADJ	O
genetic	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
or	O	CCONJ	O
metabolic	O	ADJ	B
factors	O	NOUN	I
influencing	O	VERB	O
CETP	O	NOUN	B
expression	O	NOUN	B
are	O	AUX	O
implicated	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	NOUN	O
mutation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
human	O	ADJ	B
plasma	O	NOUN	B
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
could	O	AUX	O
be	O	AUX	O
compound	O	ADJ	B
heterozygotes	O	NOUN	B
who	O	PRON	O
totally	O	ADV	O
lack	O	VERB	O
plasma	O	NOUN	B
CETP	O	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
lipoprotein	O	NOUN	B
profiles	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
homozygotes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
genetics	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
Mediterranean	O	ADJ	B
variant	O	NOUN	B
and	O	CCONJ	O
description	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
G6PD	O	NOUN	B
mutant	O	NOUN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Andalus1361A	O	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
;	I-Disease	PUNCT	O
E	I-Disease	NOUN	B
.	I-Disease	PUNCT	O
C	I-Disease	NOUN	O
.	I-Disease	PUNCT	O
1	I-Disease	NUM	O
.	I-Disease	PUNCT	O
1	I-Disease	NUM	O
.	I-Disease	PUNCT	O
1	I-Disease	X	O
.	I-Disease	PUNCT	O
49	I-Disease	NUM	O
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
human	O	ADJ	B
enzymopathy	B-Disease	NOUN	I
;	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
300	O	NUM	O
different	O	ADJ	O
biochemical	O	ADJ	B
variants	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
many	O	ADJ	O
parts	O	NOUN	O
of	O	ADP	O
the	O	DET	O
world	O	NOUN	B
the	O	DET	O
Mediterranean	O	ADJ	B
type	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
prevalent	O	ADJ	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
has	O	AUX	O
come	O	VERB	O
to	O	PART	O
be	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
a	O	DET	O
generic	O	ADJ	O
term	O	NOUN	O
applied	O	VERB	O
to	O	PART	O
similar	O	ADJ	O
G6PD	O	NOUN	B
mutations	O	NOUN	B
thought	O	VERB	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
represent	O	VERB	O
a	O	DET	O
somewhat	O	ADV	O
heterogeneous	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
mutation	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
563	O	NUM	O
of	O	ADP	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
Vulliamy	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
by	O	ADP	O
De	O	PROPN	B
Vita	O	PROPN	I
et	O	X	O
al	O	X	O
.	O	PUNCT	O
in	O	ADP	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
,	O	PUNCT	O
G6PD	O	PROPN	B
Sassari	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Cagliari	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
subjects	O	NOUN	B
had	O	AUX	O
an	O	DET	O
additional	O	ADJ	O
mutation	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
nucleotide	O	NOUN	B
1311	O	NUM	I
,	O	PUNCT	O
that	O	PRON	O
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
a	O	DET	O
coding	O	VERB	B
change	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
genomic	O	ADJ	B
DNA	O	NOUN	I
of	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
four	O	NUM	O
of	O	ADP	O
Spanish	O	ADJ	B
origin	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
Jewish	O	ADJ	B
origin	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
having	O	VERB	O
enzymatically	O	ADV	B
documented	O	VERB	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
.	O	PUNCT	O


All	O	DET	O
had	O	AUX	O
both	O	CCONJ	O
the	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
563	O	NUM	I
and	O	CCONJ	O
that	O	SCONJ	O
at	O	ADP	O
nucleotide	O	NOUN	B
1311	O	NUM	I
.	O	PUNCT	O


A	O	DET	O
sixth	O	ADJ	O
sample	O	NOUN	B
,	O	PUNCT	O
resembling	O	VERB	O
G6PD	O	NOUN	B
Mediterranean	O	ADJ	B
kinetically	O	ADV	B
but	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
slightly	O	ADV	O
rapid	O	ADJ	O
electrophoretic	O	ADJ	B
mobility	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
designated	O	VERB	O
G6PD	O	NOUN	B
Andalus	O	PROPN	O
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
different	O	ADJ	O
mutation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
A	O	PROPN	O
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
1361	O	NUM	I
,	O	PUNCT	O
producing	O	VERB	O
an	O	DET	O
arginine	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
histidine	O	NOUN	B
substitution	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
G6PD	O	NOUN	B
Mediterranean	O	ADJ	B
is	O	AUX	O
,	O	PUNCT	O
after	O	ADV	O
all	O	ADV	O
,	O	PUNCT	O
relatively	O	ADV	O
homogeneous	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
normal	O	ADJ	O
male	O	NOUN	B
with	O	ADP	O
an	O	DET	O
inherited	O	VERB	B
deletion	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
exon	O	NOUN	B
within	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
two	O	NUM	O
brothers	O	NOUN	B
with	O	ADP	O
identical	O	ADJ	O
inherited	O	VERB	B
deletions	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
single	O	ADJ	O
exon	O	NOUN	B
within	O	ADP	O
the	O	DET	O
middle	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
;	O	PUNCT	O
one	O	NUM	O
brother	O	NOUN	B
has	O	AUX	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
diagnosed	O	VERB	B
at	O	ADP	O
11	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
older	O	ADJ	B
brother	O	NOUN	I
is	O	AUX	O
normal	O	ADJ	B
at	O	ADP	O
18	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
genetic	O	ADJ	B
counselling	O	NOUN	I
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
expression	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
diseased	O	ADJ	B
human	O	ADJ	B
muscle	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
probe	O	NOUN	O
for	O	ADP	O
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
study	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
muscle	O	NOUN	O
,	O	PUNCT	O
myogenic	O	ADJ	B
cell	O	NOUN	I
cultures	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
muscle	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
.	O	PUNCT	O


Expression	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
RNA	O	NOUN	B
from	O	ADP	O
normal	O	ADJ	O
fetal	O	ADJ	O
muscle	O	NOUN	O
,	O	PUNCT	O
adult	O	ADJ	B
cardiac	O	ADJ	B
and	O	CCONJ	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cultured	O	VERB	B
muscle	O	NOUN	I
after	O	ADP	O
myoblast	O	NOUN	B
fusion	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
DMD	B-Disease	NOUN	B
muscle	O	NOUN	B
,	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
this	O	DET	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
revealed	O	VERB	O
by	O	ADP	O
in	O	X	B
situ	O	X	I
RNA	O	NOUN	I
hybridization	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
regenerating	O	VERB	B
muscle	O	NOUN	B
fibers	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
and	O	CCONJ	O
phenotypic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
deletions	O	NOUN	B
within	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Eighty	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
major	O	ADJ	O
deletion	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
region	O	NOUN	B
includes	O	VERB	O
the	O	DET	O
last	O	ADJ	O
five	O	NUM	O
exons	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
cDNA5b	O	PROPN	B
-	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
all	O	DET	O
exons	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
cDNA8	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
first	O	ADJ	O
two	O	NUM	O
exons	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
cDNA9	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
80	O	NUM	O
individuals	O	NOUN	B
account	O	VERB	O
for	O	ADP	O
approximately	O	ADV	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
109	O	NUM	O
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
detected	O	VERB	B
among	O	ADP	O
181	O	NUM	O
patients	O	NOUN	B
analyzed	O	VERB	B
with	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
dystrophin	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


Endpoints	O	NOUN	B
for	O	ADP	O
many	O	ADJ	O
of	O	ADP	O
these	O	DET	O
deletions	O	NOUN	B
were	O	AUX	O
further	O	ADV	O
characterized	O	VERB	B
using	O	VERB	O
two	O	NUM	O
genomic	O	ADJ	B
probes	O	NOUN	I
,	O	PUNCT	O
p20	O	NOUN	B
(	O	PUNCT	O
DXS269	O	NOUN	B
;	O	PUNCT	O
Wapenaar	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
GMGX11	O	NOUN	B
(	O	PUNCT	O
DXS239	O	ADJ	B
;	O	PUNCT	O
present	O	ADJ	O
paper	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
findings	O	NOUN	I
are	O	AUX	O
presented	O	VERB	O
for	O	ADP	O
all	O	DET	O
80	O	NUM	O
patients	O	NOUN	B
allowing	O	VERB	O
a	O	DET	O
correlation	O	NOUN	B
of	O	ADP	O
phenotypic	O	ADJ	B
severity	O	NOUN	B
with	O	ADP	O
the	O	DET	O
genotype	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
independent	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
old	O	ADJ	O
enough	O	ADV	O
to	O	PART	O
be	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
DMD	B-Disease	PROPN	B
,	O	PUNCT	O
BMD	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
intermediate	O	ADJ	B
phenotype	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
deletions	O	NOUN	B
of	O	ADP	O
exons	O	NOUN	B
with	O	ADP	O
sequenced	O	VERB	B
intron	O	NOUN	I
/	O	SYM	O
exon	O	NOUN	B
boundaries	O	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
eight	O	NUM	O
BMD	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
intermediate	O	ADJ	B
patient	O	NOUN	B
had	O	AUX	O
gene	O	NOUN	B
deletions	O	NOUN	I
predicted	O	VERB	O
to	O	PART	O
leave	O	VERB	O
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
intact	O	ADJ	B
,	O	PUNCT	O
while	O	SCONJ	O
21	O	NUM	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
intermediate	O	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
1	O	NUM	O
BMD	B-Disease	NOUN	B
patient	O	NOUN	B
had	O	AUX	O
gene	O	NOUN	B
deletions	O	NOUN	I
predicted	O	VERB	O
to	O	PART	O
disrupt	O	VERB	B
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
with	O	ADP	O
two	O	NUM	O
exceptions	O	NOUN	O
,	O	PUNCT	O
frameshift	O	NOUN	B
deletions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
more	O	ADV	O
severe	O	ADJ	B
phenotype	O	NOUN	B
than	O	ADP	O
did	O	AUX	O
in	O	ADP	O
-	O	PUNCT	O
frame	O	NOUN	B
deletions	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
in	O	ADP	O
agreement	O	NOUN	O
with	O	ADP	O
recent	O	ADJ	O
findings	O	NOUN	B
by	O	ADP	O
Baumbach	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
and	O	CCONJ	O
Koenig	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
findings	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
Malhotra	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
'	O	PART	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Cloning	O	NOUN	B
of	O	ADP	O
breakpoints	O	NOUN	B
of	O	ADP	O
a	O	DET	O
chromosome	O	NOUN	B
translocation	O	NOUN	I
identifies	O	VERB	O
the	O	DET	O
AN2	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
translocations	O	NOUN	I
involving	O	VERB	O
11p13	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
familial	B-Disease	ADJ	B
aniridia	I-Disease	NOUN	I
in	O	ADP	O
two	O	NUM	O
kindreds	O	NOUN	B
highlighting	O	VERB	O
the	O	DET	O
chromosomal	O	ADJ	B
localization	O	NOUN	I
of	O	ADP	O
the	O	DET	O
AN2	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
locus	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
WAGR	B-Disease	NOUN	B
complex	O	NOUN	I
(	O	PUNCT	O
Wilms	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
,	O	PUNCT	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
genitourinary	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
kindred	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
translocation	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
deletion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
probes	O	NOUN	B
for	O	ADP	O
this	O	DET	O
region	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
and	O	CCONJ	O
clone	O	NOUN	B
the	O	DET	O
breakpoints	O	NOUN	B
of	O	ADP	O
the	O	DET	O
translocation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
kindred	O	NOUN	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
phage	O	NOUN	B
restriction	O	NOUN	O
maps	O	NOUN	O
exclude	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
any	O	DET	O
sizable	O	ADJ	O
deletion	O	NOUN	B
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
.	O	PUNCT	O


Sequences	O	NOUN	B
at	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	O
11	O	NUM	O
breakpoint	O	NOUN	B
are	O	AUX	O
conserved	O	VERB	O
in	O	ADP	O
multiple	O	ADJ	B
species	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
translocation	O	NOUN	B
falls	O	VERB	B
within	O	ADP	O
the	O	DET	O
AN2	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
apolipoprotein	O	NOUN	B
C2	O	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
19	O	NUM	O
reveals	O	VERB	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	O
in	O	ADP	O
a	O	DET	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
human	O	ADJ	B
apolipoprotein	O	NOUN	O
C2	O	NOUN	O
(	O	PUNCT	O
APOC2	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
situated	O	VERB	O
on	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
long	O	ADJ	O
arm	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
19	O	NUM	O
,	O	PUNCT	O
is	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
adult	O	ADJ	B
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Six	O	NUM	O
APOC2	O	NOUN	B
RFLPs	O	NOUN	I
(	O	PUNCT	O
TaqI	O	NOUN	B
,	O	PUNCT	O
BglI	O	NOUN	B
,	O	PUNCT	O
BanI	O	NOUN	B
,	O	PUNCT	O
BamHI	O	NOUN	B
,	O	PUNCT	O
NcoI	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
AvaII	O	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	O
to	O	PART	O
date	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
conducted	O	VERB	O
a	O	DET	O
comprehensive	O	ADJ	B
DM	B-Disease	NOUN	B
linkage	O	NOUN	I
study	O	NOUN	I
utilizing	O	VERB	O
all	O	DET	O
six	O	NUM	O
RFLPs	O	NOUN	B
and	O	CCONJ	O
involving	O	VERB	O
50	O	NUM	O
families	O	NOUN	B
and	O	CCONJ	O
372	O	NUM	O
individuals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
informative	O	ADJ	O
RFLPs	O	NOUN	B
are	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
descending	O	ADJ	B
order	O	NOUN	I
,	O	PUNCT	O
NcoI	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
64	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
BglI	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
AvaII	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
02	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
BanI	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
5	O	NUM	O
.	O	PUNCT	O
76	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
04	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
TaqI	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
4	O	NUM	O
.	O	PUNCT	O
29	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
06	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
BamHI	O	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O
75	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
substantial	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lod	O	NOUN	B
scores	O	NOUN	I
over	O	ADP	O
those	O	DET	O
seen	O	VERB	O
with	O	ADP	O
the	O	DET	O
individual	O	ADJ	B
RFLPs	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
when	O	SCONJ	O
the	O	DET	O
linkage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
APOC2	O	NOUN	B
haplotype	O	NOUN	B
(	O	PUNCT	O
composed	O	VERB	O
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
RFLPs	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
(	O	PUNCT	O
lod	O	NOUN	B
=	O	ADJ	O
17	O	NUM	O
.	O	PUNCT	O
87	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
observed	O	VERB	O
significant	O	ADJ	B
inter	O	ADJ	B
-	O	PUNCT	O
APOC2	O	NOUN	B
RFLP	O	NOUN	B
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
three	O	NUM	O
most	O	ADV	O
informative	O	ADJ	O
RFLPs	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
BanI	O	NOUN	B
,	O	PUNCT	O
TaqI	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
either	O	CCONJ	O
BglI	O	NOUN	B
,	O	PUNCT	O
AvaII	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
NcoI	O	NOUN	B
polymorphisms	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
demonstrate	O	VERB	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	B
between	O	ADP	O
DM	O	NOUN	B
and	O	CCONJ	O
APOC2	O	NOUN	B
in	O	ADP	O
our	O	PRON	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
population	O	NOUN	B
(	O	PUNCT	O
standardized	O	ADJ	O
disequilibrium	O	NOUN	B
constant	O	ADJ	I
phi	O	NOUN	I
=	O	ADJ	O
.	O	PUNCT	O
22	O	NUM	O
,	O	PUNCT	O
chi	O	NOUN	O
2	O	NUM	O
=	O	ADJ	O
5	O	NUM	O
.	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
df	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O
04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
between	O	ADP	O
APOC2	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


Phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	B
haplotypes	O	NOUN	I
in	O	ADP	O
Polynesians	O	NOUN	B
:	O	PUNCT	O
evolutionary	O	ADJ	B
origins	O	NOUN	I
and	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
alleles	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
severe	O	ADJ	B
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
630	O	NUM	O
haplotypes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
locus	O	NOUN	I
were	O	AUX	O
established	O	VERB	O
in	O	ADP	O
five	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
Polynesians	O	NOUN	B
comprising	O	VERB	O
Samoans	O	PROPN	B
,	O	PUNCT	O
Tongans	O	PROPN	B
,	O	PUNCT	O
Cook	O	PROPN	B
Islanders	O	PROPN	I
,	O	PUNCT	O
Maori	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Niueans	O	PROPN	B
.	O	PUNCT	O


Considerable	O	ADJ	O
genetic	O	ADJ	B
continuity	O	NOUN	I
was	O	AUX	O
demonstrated	O	VERB	O
between	O	ADP	O
these	O	DET	O
widely	O	ADV	O
dispersed	O	ADJ	B
populations	O	NOUN	B
,	O	PUNCT	O
since	O	SCONJ	O
three	O	NUM	O
common	O	ADJ	O
haplotypes	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
)	O	PUNCT	O
constituted	O	VERB	O
over	O	ADP	O
95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
alleles	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
of	O	ADP	O
individuals	O	NOUN	B
from	O	ADP	O
Southeast	O	PROPN	B
Asia	O	PROPN	I
shared	O	VERB	O
the	O	DET	O
same	O	ADJ	O
major	O	ADJ	O
haplotypes	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
,	O	PUNCT	O
with	O	ADP	O
Polynesians	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
theories	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
homogeneity	O	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
Asian	O	ADJ	B
affinities	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Polynesian	O	ADJ	B
precursor	O	NOUN	I
populations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
phenylketonuria	B-Disease	NOUN	I
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
Polynesians	O	PROPN	B
and	O	CCONJ	O
Southeast	O	PROPN	B
Asians	O	PROPN	I
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
PAH	O	NOUN	B
haplotypes	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
on	O	ADP	O
which	O	DET	O
the	O	DET	O
severe	O	ADJ	B
PKU	B-Disease	NOUN	B
mutants	O	NOUN	B
have	O	AUX	O
arisen	O	VERB	O
among	O	ADP	O
Caucasians	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Preferential	O	ADJ	O
germline	O	NOUN	B
mutation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
paternal	O	ADJ	B
allele	O	NOUN	I
in	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
event	O	NOUN	B
triggering	O	VERB	O
malignant	O	ADJ	B
proliferation	O	NOUN	I
in	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
tumours	I-Disease	NOUN	I
is	O	AUX	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
for	O	ADP	O
chromosome	O	NOUN	B
13q14	O	NOUN	I
,	O	PUNCT	O
whereby	O	SCONJ	O
the	O	DET	O
normal	O	ADJ	B
retinoblastoma	B-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
allele	O	NOUN	B
is	O	AUX	O
lost	O	VERB	B
and	O	CCONJ	O
an	O	DET	O
already	O	ADV	O
mutated	O	VERB	B
RB1	O	NOUN	B
allele	O	NOUN	B
remains	O	VERB	O
in	O	ADP	O
the	O	DET	O
tumour	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
allele	O	NOUN	B
suffers	O	VERB	O
a	O	DET	O
mutational	O	ADJ	B
event	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
deletion	O	NOUN	B
,	O	PUNCT	O
duplication	O	NOUN	B
or	O	CCONJ	O
point	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
manuscript	O	NOUN	B
in	O	ADP	O
preparation	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
either	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
line	O	NOUN	I
(	O	PUNCT	O
all	O	DET	O
bilateral	O	ADJ	B
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
somatic	O	ADJ	B
retinal	O	ADJ	I
cell	O	NOUN	I
(	O	PUNCT	O
most	O	ADV	O
unilateral	O	ADJ	B
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Most	O	ADV	O
bilateral	O	ADJ	B
patients	O	NOUN	B
have	O	AUX	O
no	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
presumed	O	VERB	O
to	O	PART	O
have	O	AUX	O
new	O	ADJ	O
germline	O	NOUN	B
mutations	O	NOUN	I
which	O	DET	O
arose	O	VERB	O
in	O	ADP	O
the	O	DET	O
egg	O	NOUN	B
,	O	PUNCT	O
sperm	O	NOUN	B
or	O	CCONJ	O
early	O	ADJ	B
embryo	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
parental	O	ADJ	B
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retained	O	VERB	B
allele	O	NOUN	B
in	O	ADP	O
nine	O	NUM	O
retinoblastoma	B-Disease	NOUN	B
tumours	I-Disease	NOUN	I
from	O	ADP	O
eight	O	NUM	O
unrelated	O	ADJ	O
non	O	ADJ	B
-	O	PUNCT	O
familial	O	ADJ	B
cases	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
RB1	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
genetic	O	ADJ	B
markers	O	NOUN	I
.	O	PUNCT	O


Six	O	NUM	O
tumours	B-Disease	NOUN	B
retained	O	VERB	O
the	O	DET	O
paternal	O	ADJ	B
allele	O	NOUN	I
and	O	CCONJ	O
three	O	NUM	O
retained	O	VERB	B
the	O	DET	O
maternal	O	ADJ	B
allele	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
three	O	NUM	O
unilateral	B-Disease	ADJ	B
tumours	I-Disease	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
retained	O	VERB	O
the	O	DET	O
paternal	O	ADJ	B
RB1	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
paternal	O	ADJ	B
RB1	O	NOUN	B
allele	O	NOUN	B
is	O	AUX	O
preferentially	O	ADV	O
retained	O	VERB	B
in	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
has	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
case	O	NOUN	B
in	O	ADP	O
osteosarcoma	B-Disease	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
tumours	B-Disease	NOUN	B
from	O	ADP	O
four	O	NUM	O
of	O	ADP	O
the	O	DET	O
five	O	NUM	O
bilateral	O	ADJ	B
patients	O	NOUN	B
retained	O	VERB	O
the	O	DET	O
paternal	O	ADJ	B
RB1	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
either	O	CCONJ	O
that	O	DET	O
new	O	ADJ	O
germline	O	NOUN	B
RB1	O	NOUN	B
mutations	O	NOUN	B
arise	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
during	O	ADP	O
spermatogenesis	O	NOUN	B
than	O	ADP	O
during	O	ADP	O
oogenesis	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
that	O	SCONJ	O
imprinting	O	NOUN	B
in	O	ADP	O
the	O	DET	O
early	O	ADJ	B
embryo	O	NOUN	B
affects	O	VERB	O
chromosomal	O	ADJ	B
susceptibility	O	NOUN	I
to	O	PART	O
mutation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Haplotype	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
Turkish	O	ADJ	B
phenylketonuria	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
estimated	O	VERB	O
the	O	DET	O
haplotype	O	NOUN	B
distribution	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
and	O	CCONJ	O
normal	O	ADJ	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
alleles	O	NOUN	B
for	O	ADP	O
17	O	NUM	O
Turkish	O	ADJ	B
phenylketonuria	B-Disease	NOUN	I
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
families	O	NOUN	B
20	O	NUM	O
normal	O	ADJ	B
and	O	CCONJ	O
27	O	NUM	O
mutated	O	VERB	B
PAH	O	NOUN	B
alleles	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
prevalent	O	ADJ	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
haplotype	O	NOUN	B
6	O	NUM	O
(	O	PUNCT	O
29	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
18	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
36	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
normal	O	ADJ	B
alleles	O	NOUN	I
were	O	AUX	O
preferentially	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
haplotype	O	NOUN	B
1	O	NUM	O
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
19	O	NUM	O
different	O	ADJ	O
haplotypes	O	NOUN	B
observed	O	VERB	B
,	O	PUNCT	O
5	O	NUM	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
described	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
haplotype	O	NOUN	B
distribution	O	NOUN	B
differed	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
Northern	O	ADJ	B
European	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
eight	O	NUM	O
polymorphic	O	ADJ	B
sites	O	NOUN	I
were	O	AUX	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
PKU	B-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
deletions	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
sequences	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
families	O	NOUN	B
analysed	O	VERB	B
.	O	PUNCT	O


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
no	O	DET	O
evidence	O	NOUN	O
for	O	ADP	O
locus	O	NOUN	B
heterogeneity	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
63	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
linkage	O	NOUN	B
between	O	ADP	O
HD	B-Disease	NOUN	B
and	O	CCONJ	O
G8	O	NOUN	B
(	O	PUNCT	O
D4S10	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
families	O	NOUN	B
included	O	VERB	O
57	O	NUM	O
Caucasian	O	ADJ	B
,	O	PUNCT	O
four	O	NUM	O
Black	O	PROPN	B
American	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
Japanese	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
combined	O	ADJ	O
maximum	O	ADJ	O
lod	O	NOUN	O
score	O	NOUN	O
was	O	AUX	O
87	O	NUM	O
.	O	PUNCT	O


69	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


04	O	NUM	O
(	O	PUNCT	O
99	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
0	O	NUM	O
.	O	PUNCT	O
018	O	NUM	O
-	O	SYM	O
0	O	NUM	O
.	O	PUNCT	O
071	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
maximum	O	ADJ	B
frequency	O	NOUN	B
of	O	ADP	O
recombination	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
in	O	ADP	O
males	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
in	O	ADP	O
females	O	NOUN	B
.	O	PUNCT	O


Fifty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
families	O	NOUN	B
gave	O	VERB	O
positive	O	ADJ	B
lod	O	NOUN	B
scores	O	NOUN	I
;	O	PUNCT	O
five	O	NUM	O
small	O	ADJ	B
families	O	NOUN	B
gave	O	VERB	O
mildly	O	ADV	B
negative	O	ADJ	B
lod	O	NOUN	B
scores	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
maximum	O	ADJ	B
likelihood	O	NOUN	B
estimate	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
linked	O	VERB	O
loci	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
with	O	ADP	O
a	O	DET	O
lower	O	ADJ	O
99	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


88	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
only	O	ADV	O
one	O	NUM	O
HD	B-Disease	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
a	O	DET	O
second	O	ADJ	O
rare	O	ADJ	B
locus	O	NOUN	B
cannot	O	PART	O
be	O	AUX	O
ruled	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


Haplotype	O	NOUN	B
and	O	CCONJ	O
multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
in	O	ADP	O
Finnish	O	ADJ	B
choroideremia	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


Multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
choroideremia	B-Disease	NOUN	B
(	O	PUNCT	O
TCD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
seven	O	NUM	O
X	O	NOUN	B
chromosomal	O	ADJ	I
restriction	O	NOUN	I
fragment	O	NOUN	I
length	O	NOUN	I
polymorphisms	O	NOUN	I
(	O	PUNCT	O
RFLPs	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
18	O	NUM	O
Finnish	O	ADJ	B
TCD	B-Disease	PROPN	B
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
place	O	NOUN	O
TCD	B-Disease	NOUN	B
distal	O	ADJ	O
to	O	PART	O
PGK	O	NOUN	B
and	O	CCONJ	O
DXS72	O	NOUN	B
,	O	PUNCT	O
very	O	ADV	O
close	O	ADV	O
to	O	ADP	O
DXYS1	O	NOUN	B
and	O	CCONJ	O
DXYS5	O	NOUN	B
(	O	PUNCT	O
Zmax	O	NOUN	O
=	O	ADJ	O
24	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
proximal	O	ADJ	B
to	O	PART	O
DXYS4	O	NOUN	B
and	O	CCONJ	O
DXYS12	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
agrees	O	VERB	O
with	O	ADP	O
the	O	DET	O
data	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
other	O	ADJ	O
linkage	O	NOUN	B
studies	O	NOUN	I
and	O	CCONJ	O
from	O	ADP	O
physical	O	ADJ	B
mapping	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
TCD	B-Disease	NOUN	B
males	O	NOUN	B
and	O	CCONJ	O
carrier	O	NOUN	B
females	O	NOUN	B
studied	O	VERB	O
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
DXYS1	O	NOUN	B
allele	O	NOUN	B
in	O	ADP	O
coupling	O	NOUN	B
with	O	ADP	O
TCD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Northeastern	O	PROPN	B
Finland	O	PROPN	I
,	O	PUNCT	O
66	O	NUM	O
/	O	SYM	O
69	O	NUM	O
chromosomes	O	NOUN	B
carrying	O	VERB	O
TCD	B-Disease	NOUN	B
had	O	AUX	O
the	O	DET	O
same	O	ADJ	O
haplotype	O	NOUN	B
at	O	ADP	O
loci	O	NOUN	B
DXS72	O	NOUN	B
,	O	PUNCT	O
DXYS1	O	NOUN	B
,	O	PUNCT	O
DXYS4	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
DXYS12	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
haplotype	O	NOUN	B
is	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
only	O	ADV	O
15	O	NUM	O
/	O	SYM	O
99	O	NUM	O
chromosomes	O	NOUN	O
not	O	PART	O
carrying	O	VERB	O
TCD	B-Disease	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
71	O	NUM	O
/	O	SYM	O
104	O	NUM	O
non	O	ADJ	B
-	O	PUNCT	O
TCD	O	NOUN	B
chromosomes	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
haplotype	O	NOUN	B
at	O	ADP	O
six	O	NUM	O
marker	O	NOUN	B
loci	O	NOUN	O
is	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
those	O	DET	O
seen	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
76	O	NUM	O
TCD	B-Disease	NOUN	B
chromosomes	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
supports	O	VERB	O
the	O	DET	O
previously	O	ADV	O
described	O	VERB	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
large	O	ADJ	O
Northern	O	ADJ	B
Finnish	O	ADJ	B
choroideremia	B-Disease	NOUN	B
pedigrees	O	NOUN	B
,	O	PUNCT	O
comprising	O	VERB	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
over	O	ADP	O
80	O	NUM	O
living	O	NOUN	B
patients	O	NOUN	B
representing	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
a	O	DET	O
fifth	O	NOUN	O
of	O	ADP	O
all	O	DET	O
TCD	B-Disease	NOUN	B
patients	O	NOUN	B
described	O	VERB	O
worldwide	O	ADV	O
,	O	PUNCT	O
carry	O	VERB	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
linkage	O	NOUN	B
and	O	CCONJ	O
haplotype	O	NOUN	B
data	O	NOUN	B
provide	O	VERB	O
improved	O	VERB	B
opportunities	O	NOUN	B
for	O	ADP	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
based	O	VERB	O
on	O	ADP	O
RFLP	O	NOUN	B
studies	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	B
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
chromosome	O	NOUN	B
11p13	O	NOUN	I
markers	O	NOUN	I
catalase	O	NOUN	I
and	O	CCONJ	O
D11S151	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Dutch	O	ADJ	B
family	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
large	O	ADJ	O
pedigree	O	NOUN	B
with	O	ADP	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
locus	O	NOUN	I
AN2	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
markers	O	NOUN	B
catalase	O	NOUN	O
(	O	PUNCT	O
CAT	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
zeta	O	NOUN	B
=	O	ADJ	O
7	O	NUM	O
.	O	PUNCT	O
27	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
D11S151	O	NOUN	B
(	O	PUNCT	O
zeta	O	NOUN	B
=	O	ADJ	O
3	O	NUM	O
.	O	PUNCT	O
86	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
10	O	NUM	O
)	O	PUNCT	O
flanking	O	VERB	B
the	O	DET	O
AN2	O	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
11p13	O	NOUN	B
.	O	PUNCT	O


Positive	O	ADJ	B
lod	O	NOUN	O
scores	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
obtained	O	VERB	O
for	O	ADP	O
the	O	DET	O
11p13	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
11p14	O	NOUN	B
markers	O	NOUN	B
D11S16	O	NOUN	B
and	O	CCONJ	O
FSHB	O	NOUN	B
with	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
group	O	NOUN	B
CAT	O	NOUN	B
/	O	PUNCT	O
AN2	O	PROPN	B
/	O	SYM	O
D11S151	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
aniridia	B-Disease	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
the	O	DET	O
AN2	O	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
11p13	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
excluded	O	VERB	O
linkage	O	NOUN	B
(	O	PUNCT	O
zeta	O	NOUN	B
less	O	ADJ	I
than	O	ADP	O
-	O	SYM	O
2	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
less	O	ADJ	I
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O
18	O	NUM	O
)	O	PUNCT	O
between	O	ADP	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
chromosome	O	NOUN	B
2p25	O	NOUN	I
marker	O	NOUN	I
D2S1	O	NOUN	I
(	O	PUNCT	O
linked	O	VERB	O
to	O	PART	O
ACP1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Recombination	O	NOUN	B
events	O	NOUN	O
that	O	PRON	O
locate	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
distal	O	ADJ	I
to	O	PART	O
APOC2	O	NOUN	B
on	O	ADP	O
19q	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
reported	O	VERB	O
a	O	DET	O
recombination	O	NOUN	B
in	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
which	O	DET	O
placed	O	VERB	O
the	O	DET	O
markers	O	NOUN	B
D19S19	O	NOUN	B
and	O	CCONJ	O
APOC2	O	NOUN	B
on	O	ADP	O
the	O	DET	O
same	O	ADJ	O
side	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


Haplotyping	O	NOUN	B
of	O	ADP	O
this	O	DET	O
family	O	NOUN	B
with	O	ADP	O
more	O	ADV	O
recently	O	ADV	O
characterized	O	VERB	B
probes	O	NOUN	B
which	O	DET	O
are	O	AUX	O
either	O	ADV	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
DM	B-Disease	NOUN	B
or	O	CCONJ	O
distal	O	ADJ	B
to	O	PART	O
the	O	DET	O
linkage	O	NOUN	B
group	O	NOUN	I
at	O	ADP	O
q13	O	NOUN	B
.	O	PUNCT	O


2	O	NUM	O
shows	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
is	O	AUX	O
distal	O	ADJ	B
to	O	PART	O
APOC2	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
other	O	ADJ	O
recombinants	O	NOUN	B
where	O	SCONJ	O
DM	B-Disease	NOUN	B
segregates	O	VERB	B
with	O	ADP	O
distal	O	ADJ	B
probes	O	NOUN	I
.	O	PUNCT	O


Additional	O	ADJ	O
marker	O	NOUN	B
to	O	PART	O
marker	O	NOUN	B
recombinations	O	NOUN	B
in	O	ADP	O
unaffected	O	ADJ	O
individuals	O	NOUN	B
are	O	AUX	O
reported	O	VERB	B
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
order	O	NOUN	O
and	O	CCONJ	O
orientation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
linkage	O	NOUN	O
group	O	NOUN	B
as	O	ADP	O
pter	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
INSR	O	NOUN	B
,	O	PUNCT	O
LDLR	O	NOUN	B
,	O	PUNCT	O
S9	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
(	O	PUNCT	O
S19	O	NOUN	B
,	O	PUNCT	O
BCL3	O	NOUN	B
,	O	PUNCT	O
APOC2	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
(	O	PUNCT	O
CKMM	O	NOUN	B
,	O	PUNCT	O
DM	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
(	O	PUNCT	O
S22	O	NOUN	B
,	O	PUNCT	O
+	O	CCONJ	O
+	O	CCONJ	O
+	O	CCONJ	O
PRKCG	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
cannot	O	ADV	O
determine	O	VERB	O
whether	O	SCONJ	O
DM	B-Disease	NOUN	B
is	O	AUX	O
proximal	O	ADJ	B
or	O	CCONJ	O
distal	O	ADJ	B
to	O	PART	O
CKMM	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
consequences	O	NOUN	B
of	O	ADP	I
this	O	DET	O
probe	O	NOUN	B
order	O	NOUN	O
for	O	ADP	O
antenatal	O	ADJ	B
diagnosis	O	NOUN	B
and	O	CCONJ	O
future	O	ADJ	O
research	O	NOUN	B
aiming	O	VERB	O
to	O	PART	O
isolate	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
which	O	DET	O
is	O	AUX	O
affected	O	VERB	B
in	O	ADP	O
DM	B-Disease	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
transcription	O	NOUN	B
.	O	PUNCT	O


Inactivation	O	NOUN	B
of	O	ADP	O
both	O	DET	O
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
during	O	ADP	O
normal	O	ADJ	O
retinal	O	ADJ	B
development	O	NOUN	B
initiates	O	VERB	B
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
retinoblastoma	B-Disease	NOUN	B
(	I-Disease	PUNCT	O
RB	I-Disease	NOUN	O
)	I-Disease	PUNCT	O
tumor	I-Disease	NOUN	O
.	O	PUNCT	O


To	O	PART	O
identify	O	VERB	O
the	O	DET	O
mutations	O	NOUN	B
which	O	DET	O
inactivate	O	VERB	B
RB1	O	NOUN	B
,	O	PUNCT	O
21	O	NUM	O
RB	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
isolated	O	VERB	B
from	O	ADP	O
19	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
with	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
or	O	CCONJ	O
an	O	DET	O
RNase	O	NOUN	B
protection	O	NOUN	B
assay	O	NOUN	O
or	O	CCONJ	O
both	O	DET	O
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
13	O	NUM	O
of	O	ADP	O
21	O	NUM	O
RB	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
;	O	PUNCT	O
in	O	ADP	O
8	O	NUM	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
precise	O	ADJ	O
errors	O	NOUN	B
in	O	ADP	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
were	O	AUX	O
characterized	O	VERB	B
.	O	PUNCT	O


Each	O	DET	O
of	O	ADP	O
four	O	NUM	O
germ	O	NOUN	B
line	O	NOUN	I
mutations	O	NOUN	I
involved	O	VERB	O
a	O	DET	O
small	O	ADJ	O
deletion	O	NOUN	B
or	O	CCONJ	O
duplication	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
three	O	NUM	O
somatic	O	ADJ	B
mutations	O	NOUN	O
were	O	AUX	O
point	O	NOUN	B
mutations	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
splice	O	NOUN	B
alterations	O	NOUN	I
and	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
an	O	DET	O
exon	O	NOUN	B
from	O	ADP	O
the	O	DET	O
mature	O	ADJ	B
RB1	O	NOUN	B
mRNA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
in	O	ADP	O
lymphoblasts	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
bilaterally	O	ADV	B
affected	O	VERB	O
patients	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
genomic	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
transcripts	O	NOUN	B
containing	O	VERB	O
the	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
obvious	O	ADJ	O
in	O	ADP	O
the	O	DET	O
RB	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
RB1	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
variations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
transcripts	O	NOUN	B
suggest	O	VERB	O
deregulation	O	NOUN	B
of	O	ADP	O
RB1	O	NOUN	B
transcription	O	NOUN	B
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
functional	O	ADJ	B
RB1	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Partial	O	ADJ	B
deletion	O	NOUN	O
8q	O	NOUN	O
without	O	ADP	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
recognisable	O	ADJ	B
syndrome	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
two	O	NUM	O
de	O	X	O
novo	O	X	O
cases	O	NOUN	B
of	O	ADP	O
del	O	X	B
(	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
pter	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
q24	O	NOUN	B
.	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
with	O	ADP	O
breakpoints	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
distal	O	ADJ	B
part	O	NOUN	O
of	O	ADP	O
band	O	NOUN	B
8q24	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
1	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
were	O	AUX	O
similar	O	ADJ	O
and	O	CCONJ	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
stigmata	O	NOUN	B
of	O	ADP	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
LGS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
three	O	NUM	O
other	O	ADJ	O
cases	O	NOUN	B
reported	O	VERB	O
with	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	O
8	O	NUM	O
at	O	ADP	O
approximately	O	ADV	O
the	O	DET	O
same	O	ADJ	O
breakpoint	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
without	O	ADP	O
LGS	B-Disease	NOUN	B
and	O	CCONJ	O
some	O	DET	O
similarities	O	NOUN	B
to	O	ADP	O
our	O	PRON	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
with	O	ADP	O
LGS	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
would	O	AUX	O
support	O	VERB	O
the	O	DET	O
observation	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
critical	O	ADJ	B
segment	O	NOUN	I
for	O	ADP	O
the	O	DET	O
assignment	O	NOUN	B
of	O	ADP	O
LGS	B-Disease	NOUN	B
is	O	AUX	O
proximal	O	ADJ	B
to	O	PART	O
or	O	CCONJ	O
involves	O	VERB	O
the	O	DET	O
proximal	O	ADJ	B
part	O	NOUN	O
of	O	ADP	O
8q24	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
review	O	NOUN	B
of	O	ADP	O
published	O	VERB	B
reports	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
LGS	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
complex	O	ADJ	B
issue	O	NOUN	B


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
is	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
muscle	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
creatine	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
CKMM	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
genetic	O	ADJ	B
linkage	O	NOUN	I
between	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
creatine	O	NOUN	B
kinase	O	NOUN	I
muscle	O	NOUN	I
type	O	NOUN	I
(	O	PUNCT	O
CKMM	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
65	O	NUM	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
families	O	NOUN	B
from	O	ADP	O
Canada	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
Netherlands	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
maximum	O	ADJ	O
lod	O	NOUN	O
score	O	NOUN	O
(	O	PUNCT	O
Zmax	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
22	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
at	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
frequency	O	NOUN	I
(	O	PUNCT	O
theta	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
was	O	AUX	O
obtained	O	VERB	O
.	O	PUNCT	O


Tight	O	ADJ	B
linkage	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
demonstrated	O	VERB	O
for	O	ADP	O
CKMM	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
apolipoprotein	O	NOUN	B
C2	O	NOUN	I
(	O	PUNCT	O
ApoC2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
establishes	O	VERB	O
CKMM	O	NOUN	B
as	O	ADP	O
a	O	DET	O
useful	O	ADJ	O
marker	O	NOUN	B
for	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I


Color	B-Disease	NOUN	B
vision	I-Disease	NOUN	I
defects	I-Disease	NOUN	B
in	O	ADP	O
adrenomyeloneuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
abnormal	B-Disease	ADJ	B
color	I-Disease	NOUN	O
vision	I-Disease	NOUN	O
and	O	CCONJ	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
27	O	NUM	O
AMN	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
31	O	NUM	O
age	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
controls	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
the	O	DET	O
Farnsworth	O	PROPN	B
-	O	PUNCT	O
Munsell	O	PROPN	B
100	O	NUM	O
Hue	O	PROPN	B
test	O	NOUN	I
.	O	PUNCT	O


Twelve	O	NUM	O
(	O	PUNCT	O
44	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
27	O	NUM	O
patients	O	NOUN	B
showed	O	VERB	O
test	O	NOUN	B
scores	O	NOUN	I
significantly	O	ADV	O
above	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
axes	O	NOUN	B
of	O	ADP	O
bipolarity	O	NOUN	B
determined	O	VERB	O
by	O	ADP	O
the	O	DET	O
testing	O	NOUN	B
differed	O	VERB	O
widely	O	ADV	O
between	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
abnormal	O	ADJ	B
scores	O	NOUN	I
,	O	PUNCT	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
different	O	ADJ	O
alterations	O	NOUN	B
in	O	ADP	O
visual	O	ADJ	B
pigment	O	NOUN	O
genes	O	NOUN	O
occur	O	VERB	O
in	O	ADP	O
different	O	ADJ	O
AMN	B-Disease	NOUN	B
kindreds	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
confirm	O	VERB	B
our	O	PRON	O
earlier	O	ADJ	O
impression	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
abnormal	B-Disease	ADJ	B
color	I-Disease	NOUN	O
vision	I-Disease	NOUN	O
is	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
these	O	DET	O
kindreds	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
supports	O	VERB	O
our	O	PRON	O
contentions	O	NOUN	B
that	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
AMN	B-Disease	PROPN	B
(	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
companion	O	NOUN	B
,	O	PUNCT	O
adrenoleukodystrophy	B-Disease	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
very	O	ADV	O
closely	O	ADV	O
linked	O	VERB	O
to	O	ADP	O
the	O	DET	O
visual	O	ADJ	B
pigment	O	NOUN	O
loci	O	NOUN	O
at	O	ADP	O
Xq28	O	NOUN	B
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
this	O	DET	O
proximity	O	NOUN	B
might	O	AUX	O
provide	O	VERB	O
the	O	DET	O
opportunity	O	NOUN	O
to	O	PART	O
observe	O	VERB	O
contiguous	B-Disease	ADJ	B
gene	I-Disease	NOUN	I
defects	I-Disease	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
female	O	NOUN	B
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patient	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
female	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
recessive	O	ADJ	B
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
hypoxanthine	B-Disease	NOUN	B
phosphoribosyltransferase	I-Disease	NOUN	I
[	I-Disease	PUNCT	O
HPRT	I-Disease	NOUN	B
]	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Cytogenetic	O	ADJ	B
and	O	CCONJ	O
carrier	O	NOUN	O
studies	O	NOUN	O
revealed	O	VERB	O
structurally	O	ADV	B
normal	O	ADJ	O
chromosomes	O	NOUN	O
for	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
her	O	PRON	O
parents	O	NOUN	B
and	O	CCONJ	O
demonstrated	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
arose	O	VERB	O
through	O	ADP	O
a	O	DET	O
de	O	X	B
novo	O	X	I
gametic	O	ADJ	B
event	O	NOUN	I
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
this	O	DET	O
patients	O	NOUN	B
DNA	O	NOUN	B
with	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
of	O	ADP	O
her	O	PRON	O
parents	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
a	O	DET	O
microdeletion	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
occurred	O	VERB	O
within	O	ADP	O
a	O	DET	O
maternal	O	ADJ	B
gamete	O	NOUN	B
and	O	CCONJ	O
involved	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
HPRT	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
partially	O	ADV	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
,	O	PUNCT	O
generated	O	VERB	O
to	O	PART	O
separate	O	VERB	O
maternal	O	ADJ	B
and	O	CCONJ	O
paternal	O	ADJ	B
X	O	NOUN	I
chromosomes	O	NOUN	I
,	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
expression	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
additional	O	ADJ	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
enzymes	O	NOUN	B
,	O	PUNCT	O
phosphoglycerate	O	NOUN	B
kinase	O	NOUN	I
and	O	CCONJ	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
expressed	O	VERB	B
only	O	ADV	O
in	O	ADP	O
cells	O	NOUN	B
that	O	PRON	O
contained	O	VERB	O
the	O	DET	O
maternal	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
functionally	O	ADV	O
inactive	O	ADJ	B
paternal	O	ADJ	B
X	O	NOUN	I
chromosome	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
comparison	O	NOUN	B
of	O	ADP	O
methylation	O	NOUN	B
patterns	O	NOUN	B
within	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HPRT	O	NOUN	B
gene	O	NOUN	I
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
gene	O	NOUN	B
regulation	O	NOUN	I
revealed	O	VERB	O
differences	O	NOUN	O
between	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
the	O	DET	O
father	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
keeping	O	VERB	O
with	O	ADP	O
an	O	DET	O
active	O	ADJ	O
HPRT	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
the	O	DET	O
father	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
inactive	O	ADJ	B
HPRT	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
these	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
nonrandom	O	ADJ	B
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cytogenetically	O	ADV	B
normal	O	ADJ	O
paternal	O	ADJ	B
X	O	NOUN	I
chromosome	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
microdeletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HPRT	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
an	O	DET	O
active	O	ADJ	B
maternal	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
were	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
HPRT	O	NOUN	B
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
neurologic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
of	I-Disease	ADP	O
myelin	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	O
with	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
nosology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
inborn	B-Disease	ADJ	B
errors	I-Disease	NOUN	I
of	I-Disease	ADP	O
myelin	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	O
has	O	AUX	O
been	O	AUX	O
stymied	O	VERB	O
by	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
molecular	O	ADJ	B
genetic	O	ADJ	I
analysis	O	NOUN	I
.	O	PUNCT	O


Historically	O	ADV	O
,	O	PUNCT	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
has	O	AUX	O
encompassed	O	VERB	O
a	O	DET	O
host	O	NOUN	B
of	O	ADP	O
neurologic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
that	O	PRON	O
present	O	VERB	O
with	O	ADP	O
a	O	DET	O
deficit	B-Disease	NOUN	B
of	I-Disease	ADP	O
myelin	I-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
membrane	O	NOUN	B
elaborated	O	VERB	O
by	O	ADP	O
glial	O	ADJ	B
cells	O	NOUN	I
that	O	PRON	O
encircles	O	VERB	B
and	O	CCONJ	O
successively	O	ADV	O
enwraps	O	ADJ	B
axons	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
here	O	ADV	O
a	O	DET	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
pedigree	O	NOUN	B
of	O	ADP	O
the	O	DET	O
classical	O	ADJ	B
type	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
inheritance	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
typical	O	ADJ	O
clinical	O	ADJ	B
progression	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
pathologic	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
myelinating	O	VERB	B
cells	O	NOUN	I
and	O	CCONJ	O
myelin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
discriminate	O	VERB	O
variants	O	NOUN	B
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
oligonucleotide	O	NOUN	B
primers	O	NOUN	I
was	O	AUX	O
constructed	O	VERB	O
to	O	PART	O
polymerase	O	NOUN	B
-	O	PUNCT	O
chain	O	NOUN	B
-	O	PUNCT	O
reaction	O	NOUN	B
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
amplify	O	VERB	O
and	O	CCONJ	O
sequence	O	NOUN	B
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
structural	O	ADJ	B
protein	O	NOUN	I
that	O	PRON	O
comprises	O	VERB	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myelin	O	NOUN	B
sheath	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
carrier	O	NOUN	B
mother	O	NOUN	B
of	O	ADP	O
this	O	DET	O
family	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
single	O	ADJ	O
base	O	NOUN	O
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
more	O	ADJ	O
than	O	ADP	O
2	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
sequenced	O	VERB	O
,	O	PUNCT	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
that	O	PRON	O
would	O	AUX	O
create	O	VERB	O
a	O	DET	O
serine	O	NOUN	B
substitution	O	NOUN	B
for	O	ADP	O
proline	O	NOUN	B
at	O	ADP	O
the	O	DET	O
carboxy	O	NOUN	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
delineate	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
define	O	VERB	O
the	O	DET	O
possible	O	ADJ	O
molecular	O	ADJ	B
pathology	O	NOUN	I
of	O	ADP	O
this	O	DET	O
dysmyelinating	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
address	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
classification	O	NOUN	I
of	O	ADP	O
inborn	B-Disease	ADJ	B
errors	I-Disease	NOUN	I
of	I-Disease	ADP	O
myelin	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	O
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
classical	O	ADJ	O
form	O	NOUN	O
(	O	PUNCT	O
type	O	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
more	O	ADV	O
severely	O	ADV	B
affected	O	VERB	B
,	O	PUNCT	O
connatal	O	ADJ	B
variant	O	NOUN	B
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
type	I-Disease	NOUN	B
II	I-Disease	NUM	I
)	I-Disease	PUNCT	O
would	O	AUX	O
be	O	AUX	O
predicted	O	VERB	B
to	O	PART	O
display	O	VERB	B
mutation	O	NOUN	B
at	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
locus	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
variants	O	NOUN	B
(	O	PUNCT	O
types	O	NOUN	B
III	O	NUM	I
-	O	PUNCT	O
VI	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
sometimes	O	ADV	O
been	O	AUX	O
categorized	O	VERB	O
as	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
represent	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
genes	O	NOUN	B
encoding	O	VERB	B
other	O	ADJ	O
structural	O	ADJ	B
myelin	O	NOUN	B
proteins	O	NOUN	I
or	O	CCONJ	O
proteins	O	NOUN	B
critical	O	ADJ	O
to	O	PART	O
myelination	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
von	B-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
platelet	O	NOUN	B
von	B-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
mRNA	O	NOUN	B
.	O	PUNCT	O


von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
vWD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
inherited	B-Disease	VERB	B
bleeding	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
result	O	VERB	O
from	O	ADP	O
either	O	CCONJ	O
a	O	DET	O
quantitative	O	ADJ	B
or	O	CCONJ	O
a	O	DET	O
qualitative	O	ADJ	B
defect	O	NOUN	O
in	O	ADP	O
the	O	DET	O
adhesive	O	ADJ	B
glycoprotein	O	NOUN	I
,	O	PUNCT	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
vWF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
vWD	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
limited	O	VERB	O
by	O	ADP	O
the	O	DET	O
large	O	ADJ	B
size	O	NOUN	I
of	O	ADP	O
the	O	DET	O
vWF	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
difficulty	O	NOUN	B
in	O	ADP	O
obtaining	O	VERB	O
the	O	DET	O
vWF	O	NOUN	B
mRNA	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
adaptation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
,	O	PUNCT	O
vWF	O	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
amplified	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
from	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
platelets	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
silent	O	ADJ	B
vWF	O	NOUN	B
allele	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
cis	O	ADJ	O
defect	O	NOUN	O
in	O	ADP	O
vWF	O	NOUN	B
mRNA	O	NOUN	B
transcription	O	NOUN	I
or	O	CCONJ	O
processing	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
type	B-Disease	NOUN	B
IIA	I-Disease	NOUN	I
vWD	I-Disease	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
different	O	ADJ	O
but	O	CCONJ	O
adjacent	O	ADJ	B
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
the	O	DET	O
locations	O	NOUN	B
of	O	ADP	O
which	O	DET	O
may	O	AUX	O
identify	O	VERB	O
an	O	DET	O
important	O	ADJ	O
vWF	O	NOUN	B
functional	O	ADJ	B
domain	O	NOUN	I
.	O	PUNCT	O


Expression	O	NOUN	B
in	O	ADP	O
heterologous	O	ADJ	B
cells	O	NOUN	I
of	O	ADP	O
recombinant	O	ADJ	B
vWF	O	NOUN	B
containing	O	VERB	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
latter	O	ADJ	O
mutations	O	NOUN	B
reproduced	O	VERB	O
the	O	DET	O
characteristic	O	ADJ	O
structural	O	ADJ	O
abnormality	O	NOUN	O
seen	O	VERB	O
in	O	ADP	O
type	B-Disease	NOUN	B
IIA	I-Disease	NOUN	I
vWD	I-Disease	NOUN	I
plasma	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
associated	O	VERB	B
with	O	ADP	I
recurrent	O	ADJ	O
meningococcal	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
an	O	DET	O
11	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
girl	O	NOUN	I
suffering	O	VERB	B
from	O	ADP	O
recurrent	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C7	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Diagnosis	O	NOUN	B
was	O	AUX	O
established	O	VERB	O
by	O	ADP	O
haemolytic	O	ADJ	B
titration	O	NOUN	B
and	O	CCONJ	O
western	O	NOUN	B
blotting	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
serum	O	NOUN	B
lacked	O	VERB	O
the	O	DET	O
85	O	NUM	O
kDa	O	NOUN	O
C7	O	NOUN	B
chain	O	NOUN	I
.	O	PUNCT	O


Haemolytic	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
was	O	AUX	O
reconstituted	O	VERB	B
with	O	ADP	O
either	O	CCONJ	O
pooled	O	VERB	B
normal	O	ADJ	O
human	O	ADJ	B
serum	O	NOUN	B
or	O	CCONJ	O
with	O	ADP	O
purified	O	VERB	B
C7	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
relatives	O	NOUN	B
(	O	PUNCT	O
parents	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
sister	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
immunochemically	O	ADV	B
and	O	CCONJ	O
functionally	O	ADV	O
determined	O	VERB	O
C7	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
heterozygous	O	ADJ	B
state	O	NOUN	I
for	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Translocation	O	NOUN	B
t	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
;	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
p13	O	NOUN	B
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
familial	O	ADJ	B
isolated	B-Disease	VERB	O
aniridia	I-Disease	NOUN	O
.	O	PUNCT	O


A	O	DET	O
father	O	NOUN	B
and	O	CCONJ	O
daughter	O	NOUN	B
with	O	ADP	O
isolated	B-Disease	VERB	B
aniridia	I-Disease	NOUN	O
were	O	AUX	O
observed	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
apparently	O	ADV	O
balanced	O	ADJ	B
,	O	PUNCT	O
reciprocal	O	ADJ	B
translocation	O	NOUN	B
involving	O	VERB	O
chromosomes	O	NOUN	B
5	O	NUM	I
and	O	CCONJ	O
11	O	NUM	O
[	O	PUNCT	O
t	O	PROPN	O
(	O	PUNCT	O
5	O	NUM	O
;	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
p13	O	NOUN	B
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	O
other	O	ADJ	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
often	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
11p13	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
3	O	NUM	O
other	O	ADJ	O
instances	O	NOUN	O
of	O	ADP	O
single	O	ADJ	B
breaks	O	NOUN	I
at	O	ADP	O
11p13	O	NOUN	B
and	O	CCONJ	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
supports	O	VERB	O
the	O	DET	O
assignment	O	NOUN	B
of	O	ADP	O
AN2	O	NOUN	B
to	O	PART	O
11p13	O	NOUN	B
.	O	PUNCT	O


Homozygous	B-Disease	ADJ	B
hypobetalipoproteinemia	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
disease	O	NOUN	B
distinct	O	ADJ	O
from	O	ADP	O
abetalipoproproteinemia	B-Disease	NOUN	B
at	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
level	O	NOUN	I
.	O	PUNCT	O


apoB	O	NOUN	B
DNA	O	NOUN	I
,	O	PUNCT	O
RNA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
protein	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
homozygous	B-Disease	ADJ	B
hypobetalipoproteinemia	I-Disease	NOUN	I
(	O	PUNCT	O
HBL	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
and	O	CCONJ	O
compared	O	VERB	B
with	O	ADP	O
normal	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
with	O	ADP	O
10	O	NUM	O
different	O	ADJ	O
cDNA	O	NOUN	B
probes	O	NOUN	O
revealed	O	VERB	O
a	O	DET	O
normal	O	ADJ	B
gene	O	NOUN	I
without	O	ADP	O
major	O	ADJ	O
insertions	O	NOUN	B
,	O	PUNCT	O
deletions	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
rearrangements	O	NOUN	B
.	O	PUNCT	O


Northern	O	NOUN	B
and	O	CCONJ	O
slot	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
of	O	ADP	O
total	O	ADJ	B
liver	O	NOUN	I
mRNA	O	NOUN	I
from	O	ADP	O
HBL	B-Disease	NOUN	B
patients	O	NOUN	B
documented	O	VERB	B
a	O	DET	O
normal	O	ADJ	B
size	O	NOUN	I
apoB	O	NOUN	B
mRNA	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
greatly	O	ADV	O
reduced	O	VERB	B
quantities	O	NOUN	B
.	O	PUNCT	O


ApoB	O	NOUN	B
protein	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
within	O	ADP	O
HBL	B-Disease	NOUN	B
hepatocytes	O	NOUN	B
utilizing	O	VERB	O
immunohistochemical	O	ADJ	B
techniques	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
markedly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
quantity	O	NOUN	B
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
control	O	NOUN	B
samples	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
apoB	O	NOUN	B
was	O	AUX	O
detectable	O	ADJ	B
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
of	O	ADP	O
HBL	B-Disease	NOUN	B
individuals	O	NOUN	B
with	O	ADP	O
an	O	DET	O
ELISA	O	NOUN	B
assay	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
are	O	AUX	O
most	O	ADV	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
portion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
apoB	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
HBL	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
an	O	DET	O
abnormal	O	ADJ	B
apoB	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
apoB	O	NOUN	B
mRNA	O	NOUN	O
instability	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
distinct	O	ADJ	O
from	O	ADP	O
those	O	DET	O
previously	O	ADV	O
noted	O	VERB	O
in	O	ADP	O
abetalipoproteinemia	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
an	O	DET	O
elevated	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
hepatic	O	ADJ	B
apoB	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
accumulation	O	NOUN	B
of	O	ADP	O
intracellular	O	ADJ	B
hepatic	O	ADJ	B
apoB	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Spontaneous	O	ADJ	B
reversion	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
mutation	O	NOUN	B
by	O	ADP	O
HPRT	O	NOUN	B
gene	O	NOUN	O
rearrangement	O	NOUN	O
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
an	O	DET	O
unusual	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
has	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
partial	O	ADJ	B
HPRT	O	NOUN	B
gene	O	NOUN	B
duplication	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
the	O	DET	O
cloning	O	NOUN	B
and	O	CCONJ	O
sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
HPRT	O	NOUN	B
cDNA	O	NOUN	B
which	O	DET	O
shows	O	VERB	O
the	O	DET	O
precise	O	ADJ	O
duplication	O	NOUN	B
of	O	ADP	O
exons	O	NOUN	B
2	O	NUM	I
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
an	O	DET	O
internal	O	ADJ	B
duplication	O	NOUN	I
of	O	ADP	O
16	O	NUM	O
-	O	SYM	O
20	O	NUM	O
kilobases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
gene	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
duplication	O	NOUN	B
was	O	AUX	O
not	O	PART	O
generated	O	VERB	O
by	O	ADP	O
a	O	DET	O
single	O	ADJ	O
unequal	O	ADJ	O
crossing	O	NOUN	B
-	O	PUNCT	O
over	O	ADP	B
event	O	NOUN	B
between	O	ADP	O
two	O	NUM	O
normal	O	ADJ	O
HPRT	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


Growth	O	NOUN	B
of	O	ADP	O
Epstein	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Barr	I-Disease	PROPN	B
virus	O	NOUN	I
-	O	PUNCT	O
transformed	O	VERB	B
lymphoblasts	O	NOUN	B
from	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
selective	O	ADJ	B
medium	O	NOUN	I
has	O	AUX	O
permitted	O	VERB	O
isolation	O	NOUN	B
of	O	ADP	O
spontaneous	O	ADJ	B
HPRT	O	NOUN	B
+	O	CCONJ	O
revertants	O	NOUN	B
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
reversion	O	NOUN	B
event	O	NOUN	B
involves	O	VERB	O
a	O	DET	O
second	O	ADJ	O
major	O	ADJ	O
HPRT	O	NOUN	B
gene	O	NOUN	B
rearrangement	O	NOUN	I
where	O	SCONJ	O
most	O	ADJ	O
or	O	CCONJ	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
duplicated	O	ADJ	B
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
gene	O	NOUN	I
is	O	AUX	O
deleted	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
original	O	ADJ	B
mutation	O	NOUN	B
therefore	O	ADV	O
has	O	AUX	O
the	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
spontaneous	O	ADJ	B
somatic	O	ADJ	B
reversion	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
relatively	O	ADV	O
mild	O	ADJ	B
symptoms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
exhibited	O	VERB	O
by	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Complex	B-Disease	ADJ	B
glycerol	I-Disease	NOUN	I
kinase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
molecular	O	ADJ	B
-	O	PUNCT	O
genetic	O	ADJ	B
,	O	PUNCT	O
cytogenetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
clinical	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
five	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
male	O	ADJ	B
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
complex	B-Disease	ADJ	B
glycerol	I-Disease	NOUN	I
kinase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
CGKD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
relatives	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
clinically	O	ADV	B
,	O	PUNCT	O
cytogenetically	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
molecular	O	ADJ	B
-	O	PUNCT	O
genetically	O	ADV	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
or	O	CCONJ	O
muscle	B-Disease	NOUN	B
weakness	I-Disease	NOUN	I
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
congenital	B-Disease	ADJ	B
adrenal	I-Disease	ADJ	I
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
glycerol	B-Disease	NOUN	B
kinase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
GTG	O	NOUN	B
-	O	PUNCT	O
banded	O	VERB	B
chromosomes	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
microdeletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Xp21	O	NOUN	B
region	O	NOUN	I
in	O	ADP	O
all	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
examined	O	VERB	B
and	O	CCONJ	O
in	O	ADP	O
all	O	DET	O
five	O	NUM	O
mothers	O	NOUN	B
.	O	PUNCT	O


Southern	O	NOUN	B
hybridizations	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
digestions	O	NOUN	B
by	O	ADP	O
restriction	O	NOUN	B
endonucleases	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
various	O	ADJ	O
cloned	O	VERB	B
DNAs	O	NOUN	B
(	O	PUNCT	O
D2	O	NOUN	B
,	O	PUNCT	O
99	O	NUM	O
-	O	SYM	O
6	O	NUM	O
,	O	PUNCT	O
B24	O	NOUN	B
,	O	PUNCT	O
C7	O	NOUN	B
,	O	PUNCT	O
L1	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
cDMD13	O	NOUN	B
-	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
J66	O	NOUN	B
-	O	PUNCT	O
HI	O	NOUN	B
,	O	PUNCT	O
P20	O	NOUN	B
,	O	PUNCT	O
J	O	PROPN	B
-	O	PUNCT	O
Bir	O	PROPN	B
,	O	PUNCT	O
ERT87	O	PROPN	B
-	O	PUNCT	O
30	O	NUM	O
,	O	PUNCT	O
ERT87	O	PROPN	B
-	O	PUNCT	O
15	O	NUM	O
,	O	PUNCT	O
ERT87	O	PROPN	B
-	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
ERT87	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
XJ	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
754	O	NUM	O
,	O	PUNCT	O
cx5	O	NUM	B
.	O	PUNCT	O
7	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
OTC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
that	O	PRON	O
are	O	AUX	O
located	O	ADJ	O
around	O	ADP	O
Xp21	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
a	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
of	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
mothers	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
deletion	O	NOUN	B
differed	O	VERB	O
in	O	ADP	O
size	O	NOUN	B
among	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
segment	O	NOUN	B
commonly	O	ADV	O
absent	O	ADJ	B
was	O	AUX	O
located	O	ADJ	O
between	O	ADP	O
the	O	DET	O
genomic	O	ADJ	B
sequences	O	NOUN	I
corresponding	O	VERB	O
to	O	PART	O
L1	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
and	O	CCONJ	O
cDMD13	O	NOUN	B
-	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
glycerol	O	NOUN	B
kinase	O	NOUN	I
(	O	PUNCT	O
GK	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
within	O	ADP	O
this	O	DET	O
segment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
manifestations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
five	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
reported	O	VERB	O
CGKD	B-Disease	NOUN	B
or	O	CCONJ	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
with	O	ADP	O
DNA	O	NOUN	B
deletion	O	NOUN	I
suggests	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
certain	O	ADJ	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
gonadotropin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
GTD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
and	O	CCONJ	O
results	O	NOUN	B
of	O	ADP	O
previous	O	ADJ	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
genes	O	NOUN	B
for	O	ADP	O
ornithine	O	NOUN	B
transcarbamylase	O	NOUN	I
(	O	PUNCT	O
OTC	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
DMD	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
GK	O	NOUN	B
and	O	CCONJ	O
putative	O	ADJ	B
genes	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
congenital	B-Disease	ADJ	B
adrenal	I-Disease	ADJ	I
hypoplasia	I-Disease	NOUN	I
(	O	PUNCT	O
AHC	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
GTD	B-Disease	NOUN	B
are	O	AUX	O
arranged	O	VERB	O
from	O	ADP	O
telomere	O	NOUN	B
to	O	PART	O
centromere	O	NOUN	B
as	O	ADP	O
pter	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
GTD	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
AHC	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
GK	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
DMD	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
OTC	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
cen	O	NOUN	B


Genetically	O	ADV	B
determined	O	VERB	O
low	O	ADJ	B
C4	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
predisposing	O	VERB	B
factor	O	NOUN	I
to	O	PART	O
autoimmune	B-Disease	ADJ	B
chronic	I-Disease	ADJ	I
active	I-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
.	O	PUNCT	O


Of	O	ADP	O
26	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
autoimmune	B-Disease	ADJ	B
chronic	I-Disease	ADJ	I
active	I-Disease	ADJ	I
hepatitis	I-Disease	NOUN	I
(	O	PUNCT	O
CAH	B-Disease	NOUN	B
)	O	PUNCT	O
starting	O	VERB	O
in	O	ADP	O
childhood	O	NOUN	B
18	O	NUM	O
(	O	PUNCT	O
69	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
low	O	ADJ	B
C4	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
(	O	PUNCT	O
19	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
low	O	ADJ	B
C3	O	NOUN	B
serum	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


Impaired	O	ADJ	B
hepatic	O	ADJ	B
synthesis	O	NOUN	I
and	O	CCONJ	O
immune	O	ADJ	B
-	O	PUNCT	O
consumption	O	NOUN	B
were	O	AUX	O
unlikely	O	ADJ	O
since	O	SCONJ	O
transferrin	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
albumin	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
persistently	O	ADV	B
low	O	ADJ	B
in	O	ADP	O
only	O	ADV	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
3	O	NUM	O
had	O	AUX	O
raised	O	VERB	O
levels	O	NOUN	B
of	O	ADP	O
activation	O	NOUN	B
fragment	O	NOUN	O
C3d	O	NOUN	B
.	O	PUNCT	O


C4d	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
families	O	NOUN	B
of	O	ADP	O
12	O	NUM	O
probands	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
C4	O	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
parents	O	NOUN	B
had	O	AUX	O
low	O	ADJ	B
C4	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
had	O	AUX	O
levels	O	NOUN	B
which	O	DET	O
were	O	AUX	O
at	O	ADP	O
the	O	DET	O
lower	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


5	O	NUM	O
of	O	ADP	O
10	O	NUM	O
siblings	O	NOUN	B
from	O	ADP	O
5	O	NUM	O
families	O	NOUN	B
had	O	AUX	O
low	O	ADJ	B
C4	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
low	O	ADJ	B
C4	O	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
CAH	B-Disease	NOUN	B
are	O	AUX	O
genetically	O	ADV	B
determined	O	VERB	O
.	O	PUNCT	O


C4	O	NOUN	B
phenotyping	O	NOUN	B
in	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
26	O	NUM	O
parents	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
90	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
81	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
had	O	AUX	O
null	O	ADJ	B
allotypes	O	NOUN	I
at	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
C4A	O	NOUN	B
or	O	CCONJ	O
C4B	O	NOUN	B
locus	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
59	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
defective	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
structural	O	ADJ	B
genes	O	NOUN	I
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
observed	O	VERB	B
C4	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
acid	O	NOUN	B
substitution	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
is	O	AUX	O
in	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
with	O	ADP	O
DNA	O	NOUN	B
haplotype	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
human	I-Disease	ADJ	B
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
,	O	PUNCT	O
phenylalanine	O	NOUN	B
4	O	NUM	O
-	O	PUNCT	O
monooxygenase	O	NOUN	B
,	O	PUNCT	O
EC	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


PKU	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
inborn	B-Disease	ADJ	B
error	I-Disease	NOUN	I
of	I-Disease	ADP	O
amino	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
acid	I-Disease	NOUN	B
metabolism	I-Disease	NOUN	I
in	O	ADP	O
caucasian	O	ADJ	B
populations	O	NOUN	B
and	O	CCONJ	O
approximately	O	ADV	O
1	O	NUM	O
in	O	ADP	O
50	O	NUM	O
individuals	O	NOUN	B
are	O	AUX	O
carriers	O	NOUN	B
of	O	ADP	O
a	O	DET	O
PKU	B-Disease	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
define	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
PKU	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
characterized	O	VERB	B
twelve	O	NUM	O
restriction	O	NOUN	B
fragment	O	NOUN	B
-	O	PUNCT	O
length	O	NOUN	B
polymorphism	O	NOUN	B
(	O	PUNCT	O
RFLP	O	NOUN	B
)	O	PUNCT	O
haplotypes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
the	O	DET	O
northern	O	ADJ	B
European	O	ADJ	B
population	O	NOUN	I
and	O	CCONJ	O
observed	O	VERB	B
that	O	SCONJ	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PKU	B-Disease	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
are	O	AUX	O
confined	O	VERB	O
to	O	PART	O
four	O	NUM	O
common	O	ADJ	O
RFLP	O	NOUN	B
haplotypes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
recently	O	ADV	O
reported	O	VERB	O
a	O	DET	O
splicing	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
RFLP	O	NOUN	B
haplotype	O	NOUN	B
3	O	NUM	O
which	O	DET	O
is	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
about	O	ADV	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
alleles	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
the	O	DET	O
molecular	B-Disease	ADJ	B
lesion	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
RFLP	O	NOUN	B
haplotype	O	NOUN	B
2	O	NUM	O
mutant	O	ADJ	B
allele	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
defect	O	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
T	O	NOUN	B
transition	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
12	O	NUM	O
resulting	O	VERB	O
in	O	ADP	O
an	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
acid	O	NOUN	B
substitution	O	NOUN	B
(	O	PUNCT	O
Arg	O	NOUN	B
to	O	PART	O
Trp	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
residue	O	NOUN	O
408	O	NUM	O
of	O	ADP	O
PAH	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	B
hybridization	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
point	O	NOUN	B
mutation	O	NOUN	I
using	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
oligonucleotide	O	NOUN	B
probe	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
in	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
with	O	ADP	O
RFLP	O	NOUN	B
haplotype	O	NOUN	B
2	O	NUM	O
alleles	O	NOUN	B
that	O	PRON	O
make	O	VERB	O
up	O	ADP	O
about	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
PAH	O	NOUN	B
genes	O	NOUN	O


Choroideremia	B-Disease	NOUN	B
:	O	PUNCT	O
close	O	ADJ	O
linkage	O	NOUN	B
to	O	ADP	O
DXYS1	O	NOUN	B
and	O	CCONJ	O
DXYS12	O	NOUN	B
demonstrated	O	VERB	O
by	O	ADP	O
segregation	O	NOUN	B
analysis	O	NOUN	O
and	O	CCONJ	O
historical	O	ADJ	B
-	O	PUNCT	O
genealogical	O	ADJ	B
evidence	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
studies	O	NOUN	I
using	O	VERB	O
restriction	O	NOUN	B
fragment	O	NOUN	I
length	O	NOUN	I
polymorphisms	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disorder	I-Disease	NOUN	B
,	O	PUNCT	O
choroideremia	B-Disease	NOUN	B
,	O	PUNCT	O
designated	O	VERB	O
TCD	B-Disease	PROPN	B
for	O	ADP	O
Progressive	B-Disease	PROPN	B
Tapeto	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Choroidal	I-Disease	ADJ	B
Dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Previously	O	ADV	O
demonstrated	O	VERB	O
close	O	ADJ	O
linkage	O	NOUN	B
with	O	ADP	O
locus	O	NOUN	B
DXYS1	O	NOUN	B
was	O	AUX	O
confirmed	O	VERB	O
(	O	PUNCT	O
lod	O	NOUN	O
11	O	NUM	O
.	O	PUNCT	O
44	O	NUM	O
at	O	ADP	O
0	O	NUM	O
recombination	O	NOUN	B
distance	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
locus	O	NOUN	B
DXYS12	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
with	O	ADP	O
TCD	B-Disease	NOUN	B
(	O	PUNCT	O
lod	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O
31	O	NUM	O
at	O	ADP	O
0	O	NUM	O
recombination	O	NOUN	B
distance	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
mainly	O	ADV	O
occurs	O	VERB	O
in	O	ADP	O
three	O	NUM	O
large	O	ADJ	O
kindreds	O	NOUN	B
in	O	ADP	O
remote	O	ADJ	B
Northern	O	PROPN	O
Finland	O	PROPN	B
.	O	PUNCT	O


While	O	SCONJ	O
formal	O	ADJ	O
genealogical	O	ADJ	B
proof	O	NOUN	O
is	O	AUX	O
lacking	O	VERB	B
,	O	PUNCT	O
all	O	DET	O
presently	O	ADV	O
living	O	VERB	B
(	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
80	O	NUM	O
affected	O	VERB	B
males	O	NOUN	B
and	O	CCONJ	O
120	O	NUM	O
carrier	O	NOUN	B
females	O	NOUN	B
)	O	PUNCT	O
probably	O	ADV	O
originate	O	VERB	O
from	O	ADP	O
a	O	DET	O
common	O	ADJ	O
founder	O	NOUN	B
couple	O	NOUN	B
born	O	VERB	I
in	O	ADP	O
1644	O	NUM	O
and	O	CCONJ	O
1646	O	NUM	O
,	O	PUNCT	O
twelve	O	NUM	O
generations	O	NOUN	B
ago	O	ADV	O
.	O	PUNCT	O


All	O	DET	O
36	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
48	O	NUM	O
carriers	O	NOUN	B
tested	O	VERB	B
from	O	ADP	O
the	O	DET	O
three	O	NUM	O
kindreds	O	NOUN	B
had	O	AUX	O
the	O	DET	O
same	O	ADJ	O
haplotype	O	NOUN	B
(	O	PUNCT	O
TCD	B-Disease	PROPN	B
/	O	SYM	O
DXYS1	O	NOUN	B
,	O	PUNCT	O
11kb	O	ADJ	B
/	O	SYM	O
DXYS12	O	NOUN	B
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
6kb	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Given	O	VERB	O
that	O	DET	O
at	O	ADP	O
least	O	ADJ	O
105	O	NUM	O
female	O	ADJ	B
meioses	O	NOUN	O
transmitting	O	VERB	O
TCD	B-Disease	NOUN	B
have	O	AUX	O
occurred	O	VERB	O
since	O	SCONJ	O
1650	O	NUM	O
in	O	ADP	O
these	O	DET	O
kindreds	O	NOUN	B
,	O	PUNCT	O
extremely	O	ADV	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
TCD	B-Disease	NOUN	B
,	O	PUNCT	O
DXYS1	O	NOUN	B
and	O	CCONJ	O
DXYS12	O	NOUN	B
is	O	AUX	O
suggested	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
above	O	ADJ	O
haplotype	O	NOUN	B
is	O	AUX	O
a	O	DET	O
very	O	ADV	O
useful	O	ADJ	O
diagnostic	O	ADJ	B
tool	O	NOUN	I
in	O	ADP	O
these	O	DET	O
TCD	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
our	O	PRON	O
historical	O	ADJ	B
-	O	PUNCT	O
genealogical	O	ADJ	B
approach	O	NOUN	O
to	O	PART	O
linkage	O	NOUN	B
analysis	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
elsewhere	O	ADV	O
in	O	ADP	O
similar	O	ADJ	O
isolated	O	VERB	B
populations	O	NOUN	O


Von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
maps	O	VERB	B
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
3	O	NUM	I
associated	O	VERB	B
with	O	ADP	I
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
VHL	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
with	O	ADP	O
inherited	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
various	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
hemangioblastomas	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
phaeochromocytomas	B-Disease	NOUN	B
,	O	PUNCT	O
pancreatic	B-Disease	ADJ	B
malignancies	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
constitute	O	VERB	O
a	O	DET	O
particularly	O	ADV	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	I
death	O	NOUN	B
in	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
,	O	PUNCT	O
occurring	O	VERB	O
as	O	ADP	O
bilateral	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
multifocal	I-Disease	ADJ	B
tumours	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
presenting	O	VERB	B
at	O	ADP	O
an	O	DET	O
earlier	O	ADJ	O
age	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
sporadic	O	ADJ	B
,	O	PUNCT	O
non	O	ADJ	B
-	O	PUNCT	O
familial	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
this	O	DET	O
tumour	B-Disease	NOUN	B
type	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
locus	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
human	O	ADJ	B
homologoue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RAF1	O	NOUN	B
oncogene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	B
3p25	O	NOUN	I
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Crossovers	O	NOUN	B
with	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
locus	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
defect	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
phenotype	O	NOUN	B
is	O	AUX	O
not	O	PART	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
RAF1	O	NOUN	B
gene	O	NOUN	I
itself	O	PRON	O
.	O	PUNCT	O


An	O	DET	O
alternative	O	ADJ	B
or	O	CCONJ	O
prior	O	ADJ	O
event	O	NOUN	B
to	O	PART	O
oncogene	O	NOUN	B
activation	O	NOUN	I
in	O	ADP	O
tumour	B-Disease	NOUN	B
formation	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
inactivation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
putative	O	ADJ	B
tumour	B-Disease	NOUN	I
suppressor	O	NOUN	I
which	O	DET	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
both	O	CCONJ	O
the	O	DET	O
inherited	B-Disease	VERB	B
and	I-Disease	CCONJ	O
sporadic	I-Disease	ADJ	B
forms	I-Disease	NOUN	O
of	I-Disease	ADP	O
the	I-Disease	DET	O
cancer	I-Disease	NOUN	B
.	O	PUNCT	O


Sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
have	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	I
regions	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
3p	O	NOUN	I
(	O	PUNCT	O
refs	O	NOUN	O
5	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
sporadic	O	ADJ	B
and	O	CCONJ	O
VHL	O	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
forms	O	NOUN	I
of	O	ADP	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
might	O	AUX	O
both	O	DET	O
result	O	VERB	O
from	O	ADP	O
alterations	O	NOUN	B
causing	O	VERB	O
loss	O	NOUN	B
of	O	ADP	I
function	O	NOUN	I
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
on	O	ADP	O
this	O	DET	O
chromosome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Tightly	O	ADV	O
linked	O	VERB	O
flanking	O	NOUN	B
markers	O	NOUN	B
for	O	ADP	O
the	O	DET	O
Lowe	B-Disease	PROPN	B
oculocerebrorenal	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
application	O	NOUN	O
to	O	PART	O
carrier	O	NOUN	B
assessment	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Lowe	B-Disease	PROPN	B
oculocerebrorenal	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
OCRL	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
congenital	O	ADJ	B
cataract	B-Disease	NOUN	I
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
defective	B-Disease	ADJ	B
renal	I-Disease	ADJ	O
tubular	I-Disease	ADJ	O
function	I-Disease	NOUN	O
.	O	PUNCT	O


A	O	DET	O
map	O	NOUN	B
assignment	O	NOUN	B
of	O	ADP	O
OCRL	B-Disease	NOUN	B
to	O	PART	O
Xq24	O	NOUN	B
-	O	PUNCT	O
q26	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
made	O	VERB	O
previously	O	ADV	O
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
DXS42	O	NOUN	B
at	O	ADP	O
Xq24	O	NOUN	B
-	O	PUNCT	O
q26	O	NOUN	B
(	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
,	O	PUNCT	O
z	O	X	O
=	O	ADJ	O
5	O	NUM	O
.	O	PUNCT	O
09	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
with	O	ADP	O
DXS10	O	NOUN	B
at	O	ADP	O
Xq26	O	NOUN	B
(	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
,	O	PUNCT	O
z	O	X	O
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
45	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
additional	O	ADJ	O
families	O	NOUN	B
were	O	AUX	O
studied	O	VERB	O
and	O	CCONJ	O
three	O	NUM	O
additional	O	ADJ	O
polymorphisms	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
at	O	ADP	O
DXS42	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
35	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
sequence	O	NOUN	O
isolated	O	VERB	B
with	O	ADP	O
the	O	DET	O
probe	O	NOUN	B
detecting	O	VERB	B
the	O	DET	O
original	O	ADJ	O
polymorphism	O	NOUN	B
at	O	ADP	O
DXS42	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
additional	O	ADJ	O
OCRL	B-Disease	NOUN	B
families	O	NOUN	B
made	O	VERB	O
informative	O	ADJ	B
for	O	ADP	O
DXS42	O	NOUN	B
,	O	PUNCT	O
theta	O	NOUN	B
remained	O	VERB	O
0	O	NUM	O
with	O	ADP	O
z	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O


63	O	NUM	O
;	O	PUNCT	O
and	O	CCONJ	O
for	O	ADP	O
DXS10	O	NOUN	B
theta	O	NOUN	I
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


03	O	NUM	O
and	O	CCONJ	O
z	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
.	O	PUNCT	O


07	O	NUM	O
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
placing	O	VERB	O
OCRL	O	NOUN	B
at	O	ADP	O
Xq25	O	NOUN	B
also	O	ADV	O
comes	O	VERB	O
from	O	ADP	O
a	O	DET	O
female	O	NOUN	B
with	O	ADP	O
Lowe	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
an	O	DET	O
X	O	NOUN	B
;	O	PUNCT	O
3	O	NUM	O
translocation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
the	O	DET	O
Xq25	O	NOUN	B
breakpoint	O	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
OCRL	O	NOUN	B
relative	O	ADJ	O
to	O	PART	O
the	O	DET	O
two	O	NUM	O
linked	O	VERB	O
markers	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
derivative	O	ADJ	B
chromosome	O	NOUN	I
was	O	AUX	O
isolated	O	VERB	B
away	O	ADV	O
from	O	ADP	O
its	O	PRON	O
normal	O	ADJ	O
counterpart	O	NOUN	O
in	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
.	O	PUNCT	O


DXS42	O	NOUN	B
was	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
derivative	O	ADJ	B
chromosome	O	NOUN	I
X	O	NOUN	I
containing	O	NOUN	O
Xpterq25	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
DXS10	O	NOUN	B
was	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
derivative	O	ADJ	B
chromosome	O	NOUN	I
3	O	NUM	I
containing	O	VERB	O
Xq25	O	NOUN	B
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
markers	O	NOUN	B
DXS10	O	NOUN	B
and	O	CCONJ	O
DXS42	O	NOUN	B
therefore	O	ADV	O
show	O	VERB	O
tight	O	ADJ	O
linkage	O	NOUN	O
with	O	ADP	O
OCRL	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
families	O	NOUN	B
and	O	CCONJ	O
flank	O	VERB	B
the	O	DET	O
Xq25	O	NOUN	B
breakpoint	O	NOUN	I
in	O	ADP	O
a	O	DET	O
female	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
an	O	DET	O
X	O	NOUN	B
;	O	PUNCT	O
3	O	NUM	O
translocation	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
flanking	O	NOUN	B
markers	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	O
OCRL	B-Disease	NOUN	B
carrier	O	NOUN	O
status	O	NOUN	O
in	O	ADP	O
women	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
compared	O	VERB	B
with	O	ADP	O
carrier	O	NOUN	B
determination	O	NOUN	B
by	O	ADP	O
ophthalmologic	O	ADJ	B
examination	O	NOUN	B
,	O	PUNCT	O
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
slit	O	NOUN	B
-	O	PUNCT	O
lamp	O	NOUN	B
exam	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
a	O	DET	O
sensitive	O	ADJ	B
and	O	CCONJ	O
specific	O	ADJ	O
method	O	NOUN	B
of	O	ADP	O
carrier	O	NOUN	B
determination	O	NOUN	B
in	O	ADP	O
many	O	ADJ	O
cases	O	NOUN	B


Identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
nucleotide	O	NOUN	O
change	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hypoxanthine	O	NOUN	B
-	O	PUNCT	O
guanine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
HPRTYale	O	NOUN	B
)	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Complete	O	ADJ	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hypoxanthine	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
guanine	I-Disease	NOUN	B
phosphoribosyltransferase	I-Disease	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
causes	O	VERB	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
characterization	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutant	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
HPRT	O	NOUN	B
,	O	PUNCT	O
HPRTYale	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
a	O	DET	O
subject	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
revealed	O	VERB	B
normal	O	ADJ	O
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
concentrations	O	NOUN	I
,	O	PUNCT	O
no	O	DET	O
residual	O	ADJ	O
catalytic	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cathodal	O	ADJ	B
migration	O	NOUN	I
upon	O	SCONJ	O
PAGE	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
HPRTYale	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
of	O	ADP	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
HPRTYale	O	NOUN	B
cDNA	O	NOUN	O
revealed	O	VERB	O
a	O	DET	O
single	O	ADJ	O
nucleotide	O	NOUN	O
substitution	O	NOUN	O
compared	O	VERB	O
with	O	ADP	O
normal	O	ADJ	O
HPRT	O	NOUN	B
cDNA	O	NOUN	B
G	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
C	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
position	O	NOUN	I
211	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
transversion	O	NOUN	B
predicts	O	VERB	O
substitution	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
for	O	ADP	O
glycine	O	NOUN	B
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
position	O	NOUN	I
71	O	NUM	O
,	O	PUNCT	O
explaining	O	VERB	O
the	O	DET	O
cathodal	O	ADJ	B
migration	O	NOUN	I
of	O	ADP	O
HPRTYale	O	NOUN	B
.	O	PUNCT	O


Chou	O	PROPN	B
-	O	PUNCT	O
Fasman	O	PROPN	B
secondary	O	ADJ	B
structure	O	NOUN	I
analysis	O	NOUN	I
predicts	O	VERB	O
a	O	DET	O
change	O	NOUN	B
in	O	ADP	O
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
turn	O	NOUN	B
formation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
region	O	NOUN	B
containing	O	VERB	O
the	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


Inclusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
bulky	O	ADJ	B
arginine	O	NOUN	B
side	O	NOUN	B
chain	O	NOUN	I
in	O	ADP	O
place	O	NOUN	O
of	O	ADP	O
glycine	O	NOUN	B
probably	O	ADV	O
disrupts	O	VERB	B
protein	O	NOUN	B
folding	O	VERB	I
as	O	ADV	O
well	O	ADV	O
.	O	PUNCT	O


Cloning	O	NOUN	B
mutant	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
cDNA	O	NOUN	B
allows	O	VERB	O
identification	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
mutations	O	NOUN	B
,	O	PUNCT	O
provides	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
mutational	O	ADJ	B
mechanisms	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
facilitates	O	VERB	O
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
proteins	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
point	O	NOUN	O
mutations	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
G6PD	O	NOUN	B
polymorphism	O	NOUN	B
in	O	ADP	O
Sardinia	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
gene	O	NOUN	B
encoding	O	NOUN	O
glucose	O	NOUN	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
highly	O	ADV	O
polymorphic	O	ADJ	B
;	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
300	O	NUM	O
G6PD	O	NOUN	B
variants	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
in	O	ADP	O
different	O	ADJ	O
geographical	O	ADJ	B
areas	O	NOUN	I
appears	O	VERB	O
to	O	PART	O
have	O	AUX	O
arisen	O	VERB	O
through	O	ADP	O
independent	O	ADJ	O
mutational	O	ADJ	B
events	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
population	O	NOUN	B
it	O	PRON	O
may	O	AUX	O
also	O	ADV	O
be	O	AUX	O
heterogeneous	O	ADJ	B
.	O	PUNCT	O


One	O	NUM	O
example	O	NOUN	O
is	O	AUX	O
the	O	DET	O
island	O	NOUN	B
of	O	ADP	O
Sardinia	O	PROPN	B
,	O	PUNCT	O
where	O	SCONJ	O
careful	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
studies	O	NOUN	I
have	O	AUX	O
identified	O	VERB	O
four	O	NUM	O
different	O	ADJ	O
G6PD	O	NOUN	B
variants	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
the	O	DET	O
four	O	NUM	O
G6PD	O	NOUN	B
variants	O	NOUN	B
from	O	ADP	O
Sardinia	O	PROPN	B
and	O	CCONJ	O
found	O	VERB	O
that	O	SCONJ	O
only	O	ADV	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
area	O	NOUN	O
one	O	NUM	O
mutation	O	NOUN	B
is	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
Seattle	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
like	I-Disease	ADJ	B
phenotype	I-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
milder	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
;	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
mutation	O	NOUN	B
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
all	O	DET	O
forms	O	NOUN	O
of	O	ADP	O
very	O	ADV	O
severe	O	ADJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Sardinia	O	PROPN	B
and	O	CCONJ	O
,	O	PUNCT	O
possibly	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Mediterranean	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Chronic	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
CNSHA	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
glucose	B-Disease	NOUN	B
6	I-Disease	NUM	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
amyloidotic	I-Disease	ADJ	I
polyneuropathy	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
variant	O	NOUN	B
(	O	PUNCT	O
G6PD	O	NOUN	B
Clinic	O	PROPN	O
)	O	PUNCT	O
with	O	ADP	O
markedly	O	ADV	O
acidic	O	ADJ	B
pH	O	NOUN	B
optimum	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
variant	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
erythrocytic	B-Disease	ADJ	B
G6PD	I-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
and	O	CCONJ	O
a	O	DET	O
unique	O	ADJ	B
pH	O	NOUN	B
optimum	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
a	O	DET	O
young	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
CNSHA	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
familial	B-Disease	ADJ	B
amyloidotic	I-Disease	ADJ	I
polyneuropathy	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Chronic	B-Disease	ADJ	B
hemolysis	I-Disease	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
infections	O	NOUN	B
,	O	PUNCT	O
oxidant	O	ADJ	B
drugs	O	NOUN	I
or	O	CCONJ	O
ingestion	O	NOUN	B
of	O	ADP	O
faba	O	NOUN	B
beans	O	NOUN	I
.	O	PUNCT	O


Residual	O	ADJ	B
enzyme	O	NOUN	B
activity	O	NOUN	I
was	O	AUX	O
about	O	ADV	O
2	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
63	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
activity	O	NOUN	O
in	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
leucocytes	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
molecular	O	ADJ	B
study	O	NOUN	I
using	O	VERB	O
standard	O	ADJ	B
methods	O	NOUN	I
showed	O	VERB	O
G6PD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
to	O	PART	O
have	O	AUX	O
normal	O	ADJ	O
electrophoretic	O	ADJ	O
mobility	O	NOUN	O
(	O	PUNCT	O
at	O	ADP	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
normal	O	ADJ	B
apparent	O	ADJ	B
affinity	O	NOUN	B
for	O	ADP	O
substrates	O	NOUN	B
(	O	PUNCT	O
Km	O	NOUN	B
,	O	PUNCT	O
G6P	O	NOUN	B
and	O	CCONJ	O
NADP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
slightly	O	ADV	O
abnormal	O	ADJ	B
utilization	O	NOUN	B
of	O	ADP	O
substrate	O	NOUN	B
analogues	O	NOUN	B
(	O	PUNCT	O
decreased	O	VERB	B
deamino	O	NOUN	B
-	O	PUNCT	O
NADP	O	NOUN	B
and	O	CCONJ	O
increased	O	VERB	B
2	O	NUM	O
-	O	PUNCT	O
deoxyglucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
utilization	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Heat	O	NOUN	B
stability	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
markedly	O	ADV	B
decreased	O	VERB	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
residual	O	ADJ	B
activity	O	NOUN	B
after	O	ADP	O
20	O	NUM	O
min	O	NOUN	O
of	O	ADP	O
incubation	O	NOUN	B
at	O	ADP	O
46	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
particular	O	ADJ	O
characteristic	O	NOUN	B
of	O	ADP	O
this	O	DET	O
enzyme	O	NOUN	B
was	O	AUX	O
a	O	DET	O
biphasic	O	ADJ	B
pH	O	NOUN	O
curve	O	NOUN	O
with	O	ADP	O
a	O	DET	O
greatly	O	ADV	O
increased	O	VERB	B
activity	O	NOUN	B
at	O	ADP	O
low	O	ADJ	B
pH	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
molecular	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
this	O	DET	O
variant	O	NOUN	B
closely	O	ADV	O
resemble	O	VERB	O
those	O	DET	O
of	O	ADP	O
G6PD	O	NOUN	B
Bangkok	O	PROPN	B
and	O	CCONJ	O
G6PD	O	NOUN	B
Duarte	O	PROPN	B
,	O	PUNCT	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
these	O	DET	O
and	O	CCONJ	O
all	O	DET	O
other	O	ADJ	O
previously	O	ADV	O
reported	O	VERB	O
variants	O	NOUN	B
by	O	ADP	O
virtue	O	NOUN	O
of	O	ADP	O
its	O	PRON	O
unusual	O	ADJ	B
pH	O	NOUN	B
curve	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
the	O	DET	O
present	O	ADJ	O
variant	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
designated	O	VERB	O
G6PD	O	NOUN	B
Clinic	O	PROPN	B
to	O	PART	O
distinguish	O	VERB	O
it	O	PRON	O
from	O	ADP	O
other	O	ADJ	O
G6PD	O	NOUN	B
variants	O	NOUN	B
previously	O	ADV	O
described	O	VERB	O


Molecular	O	ADJ	B
detection	O	NOUN	I
of	O	ADP	O
chromosomal	O	ADJ	B
translocations	O	NOUN	I
that	O	PRON	O
disrupt	O	VERB	B
the	O	DET	O
putative	O	ADJ	B
retinoblastoma	B-Disease	NOUN	I
susceptibility	O	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
candidate	O	NOUN	O
DNA	O	NOUN	B
sequence	O	NOUN	I
with	O	ADP	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
properties	O	NOUN	B
predicted	O	VERB	B
for	O	ADP	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
susceptibility	O	NOUN	I
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
(	O	PUNCT	O
S	O	NOUN	B
.	O	PUNCT	O
H	O	NOUN	O
.	O	PUNCT	O
Friend	O	NOUN	B
,	O	PUNCT	O
R	O	PROPN	B
.	O	PUNCT	O
Bernards	O	PROPN	B
,	O	PUNCT	O
S	O	PROPN	B
.	O	PUNCT	O
Rogelj	O	PROPN	O
,	O	PUNCT	O
R	O	NOUN	B
.	O	PUNCT	O
A	O	DET	O
.	O	PUNCT	O
Weinberg	O	NOUN	B
,	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O
Rapaport	O	PROPN	B
,	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O
M	O	NOUN	B
.	O	PUNCT	O
Albert	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
T	O	NOUN	B
.	O	PUNCT	O
P	O	NOUN	O
.	O	PUNCT	O
Dryja	O	NOUN	B
,	O	PUNCT	O
Nature	O	PROPN	O
[	O	PUNCT	O
London	O	PROPN	B
]	O	PUNCT	O
323	O	NUM	O
643	O	NUM	O
-	O	SYM	O
645	O	NUM	O
,	O	PUNCT	O
1986	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
large	O	ADJ	O
size	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
ca	O	AUX	O
.	O	PUNCT	O
200	O	NUM	O
kilobases	O	NOUN	B
[	O	PUNCT	O
kb	O	NOUN	O
]	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
multiple	O	ADJ	B
dispersed	O	ADJ	I
exons	O	NOUN	I
(	O	PUNCT	O
Wiggs	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
N	O	NOUN	B
.	O	PUNCT	O
Engl	O	PROPN	O
.	O	PUNCT	O
J	O	PROPN	O
.	O	PUNCT	O
Med	O	NOUN	O
.	O	PUNCT	O
318	O	NUM	O
151	O	NUM	O
-	O	SYM	O
157	O	NUM	O
,	O	PUNCT	O
1988	O	NUM	O
)	O	PUNCT	O
complicate	O	VERB	O
molecular	O	ADJ	B
screening	O	NOUN	I
strategies	O	NOUN	O
important	O	ADJ	O
in	O	ADP	O
prenatal	O	ADJ	B
and	O	CCONJ	O
presymptomatic	O	ADJ	B
diagnosis	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
carrier	O	NOUN	B
detection	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
used	O	VERB	O
field	O	NOUN	B
inversion	O	NOUN	I
gel	O	NOUN	I
electrophoresis	O	NOUN	I
(	O	PUNCT	O
FIGE	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
construct	O	VERB	O
a	O	DET	O
restriction	O	NOUN	B
map	O	NOUN	I
of	O	ADP	O
approximately	O	ADV	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
DNA	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
RB1	O	NOUN	B
locus	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
detect	O	VERB	B
the	O	DET	O
translocation	O	NOUN	B
breakpoints	O	NOUN	O
in	O	ADP	O
three	O	NUM	O
retinoblastoma	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


DNA	O	NOUN	B
probes	O	NOUN	I
from	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
5	O	NUM	O
or	O	CCONJ	O
3	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
detect	O	VERB	B
a	O	DET	O
250	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
EagI	O	NOUN	B
restriction	O	NOUN	I
fragment	O	NOUN	I
in	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
unaffected	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
probes	O	NOUN	B
identified	O	VERB	B
an	O	DET	O
additional	O	ADJ	O
hybridizing	O	NOUN	B
fragment	O	NOUN	I
in	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
from	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
permitting	O	VERB	O
the	O	DET	O
breakpoints	O	NOUN	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
to	O	PART	O
be	O	AUX	O
mapped	O	VERB	B
within	O	ADP	O
the	O	DET	O
cloned	O	VERB	B
RB1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
breakpoint	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
translocation	O	NOUN	B
cell	O	NOUN	O
line	O	NOUN	O
allowed	O	VERB	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
be	O	AUX	O
oriented	O	VERB	O
with	O	ADP	O
its	O	PRON	O
5	O	NUM	O
end	O	NOUN	O
toward	O	ADP	O
the	O	DET	O
centromere	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
also	O	ADV	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
clustering	O	NOUN	B
of	O	ADP	O
sites	O	NOUN	B
for	O	ADP	O
several	O	ADJ	O
infrequently	O	ADV	O
cleaving	O	VERB	B
restriction	O	NOUN	O
enzymes	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
HpaII	O	NOUN	B
tiny	O	ADJ	I
fragment	O	NOUN	I
island	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
detection	O	NOUN	B
and	O	CCONJ	O
mapping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
translocation	O	NOUN	B
breakpoints	O	NOUN	O
of	O	ADP	O
all	O	DET	O
three	O	NUM	O
retinoblastoma	B-Disease	NOUN	B
patients	O	NOUN	B
to	O	PART	O
within	O	ADP	O
the	O	DET	O
putative	O	ADJ	O
RB1	O	NOUN	O
gene	O	NOUN	O
substantiated	O	VERB	O
the	O	DET	O
authenticity	O	NOUN	B
of	O	ADP	O
this	O	DET	O
candidate	O	NOUN	O
sequence	O	NOUN	B
and	O	CCONJ	O
demonstrated	O	VERB	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
FIGE	O	NOUN	B
in	O	ADP	O
detecting	O	VERB	O
chromosomal	O	ADJ	B
rearrangements	O	NOUN	I
affecting	O	VERB	B
this	O	DET	O
locus	O	NOUN	B
.	O	PUNCT	O


Inherited	O	VERB	B
C3	B-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
with	O	ADP	O
recurrent	O	ADJ	B
infections	O	NOUN	I
and	O	CCONJ	O
glomerulonephritis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Laotian	O	ADJ	B
boy	O	NOUN	B
had	O	AUX	O
homozygous	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
third	I-Disease	ADJ	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
and	O	CCONJ	O
recurrent	O	ADJ	B
bacterial	B-Disease	ADJ	O
infections	I-Disease	NOUN	O
beginning	O	VERB	O
at	O	ADP	O
age	O	NOUN	B
5	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Cellular	O	ADJ	B
and	O	CCONJ	O
humoral	O	ADJ	B
immunity	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
were	O	AUX	O
polymorphonuclear	O	ADJ	B
leukocyte	O	NOUN	B
chemotaxis	O	NOUN	I
and	O	CCONJ	O
bactericidal	O	ADJ	B
activities	O	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
complement	O	NOUN	O
-	O	PUNCT	O
mediated	O	VERB	B
hemolytic	O	ADJ	B
,	O	PUNCT	O
chemotactic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
opsonic	O	ADJ	B
activities	O	NOUN	I
were	O	AUX	O
deficient	O	ADJ	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
addition	O	NOUN	O
of	O	ADP	O
purified	O	VERB	B
C3	O	NOUN	I
to	O	PART	O
patient	O	NOUN	B
serum	O	NOUN	B
restored	O	VERB	O
hemolytic	O	ADJ	B
complement	O	NOUN	O
to	O	PART	O
normal	O	ADJ	O
levels	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
plasma	O	NOUN	B
infusion	O	NOUN	B
during	O	ADP	O
each	O	DET	O
of	O	ADP	O
four	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
pneumonia	B-Disease	NOUN	B
significantly	O	ADV	O
enhanced	O	VERB	B
serum	O	NOUN	B
opsonic	O	ADJ	B
activity	O	NOUN	I
for	O	ADP	O
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
36	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
renal	O	ADJ	B
biopsy	O	NOUN	I
specimen	O	NOUN	I
revealed	O	VERB	O
mesangiopathic	B-Disease	ADJ	B
glomerulonephritis	I-Disease	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
significant	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
circulating	O	VERB	B
IgG	O	NOUN	B
immune	O	ADJ	B
complexes	O	NOUN	I
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
further	O	ADV	O
support	O	VERB	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
with	O	ADP	O
immune	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
complex	I-Disease	NOUN	B
disease	I-Disease	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
plasma	O	NOUN	B
infusion	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
adjunct	O	NOUN	B
to	O	PART	O
antibiotic	O	ADJ	B
therapy	O	NOUN	I
in	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
pyogenic	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


DNA	O	NOUN	B
restriction	O	NOUN	I
fragments	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
alpha	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
antitrypsin	O	NOUN	B
indicate	O	VERB	O
a	O	DET	O
single	O	ADJ	O
origin	O	NOUN	B
for	O	ADP	O
deficiency	O	NOUN	B
allele	O	NOUN	O
PI	O	NOUN	O
Z	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
alpha	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
protease	O	NOUN	B
inhibitor	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
alpha	O	NOUN	B
-	O	PUNCT	O
antitrypsin	O	NOUN	B
(	O	PUNCT	O
AAT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
major	O	ADJ	O
plasma	O	NOUN	B
inhibitor	O	NOUN	B
of	O	ADP	O
leukocyte	O	NOUN	B
elastase	O	NOUN	I
and	O	CCONJ	O
bacterial	O	ADJ	B
proteases	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
encoded	O	VERB	B
at	O	ADP	O
the	O	DET	O
PI	O	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	O
14	O	NUM	O
(	O	PUNCT	O
14q24	O	NOUN	O
.	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
q32	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
AAT	I-Disease	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
PI	O	NOUN	B
Z	O	NOUN	B
allele	O	NOUN	I
occurs	O	VERB	O
in	O	ADP	O
about	O	ADV	O
1	O	NUM	O
in	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
-	O	SYM	O
8	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
caucasians	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
adult	O	ADJ	I
onset	O	NOUN	O
emphysema	B-Disease	NOUN	B
and	O	CCONJ	O
liver	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
now	O	ADV	O
used	O	VERB	O
DNA	O	NOUN	B
polymorphisms	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
AAT	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PI	O	NOUN	B
Z	O	NOUN	B
allele	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
two	O	NUM	O
genomic	O	ADJ	B
probes	O	NOUN	I
extending	O	VERB	O
into	O	ADP	O
the	O	DET	O
5	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
flanking	O	NOUN	B
regions	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
eight	O	NUM	O
polymorphic	O	ADJ	B
restriction	O	NOUN	O
sites	O	NOUN	O
.	O	PUNCT	O


Extensive	O	ADJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	O
occurs	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
probed	O	VERB	B
region	O	NOUN	I
with	O	ADP	O
the	O	DET	O
PI	O	NOUN	B
Z	O	NOUN	B
allele	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
normal	O	ADJ	O
PI	O	NOUN	B
M	O	NOUN	O
alleles	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Z	O	NOUN	B
allele	O	NOUN	I
occurs	O	VERB	O
mainly	O	ADV	O
with	O	ADP	O
one	O	NUM	O
haplotype	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
a	O	DET	O
single	O	ADJ	O
,	O	PUNCT	O
relatively	O	ADV	O
recent	O	ADJ	O
,	O	PUNCT	O
origin	O	NOUN	B
in	O	ADP	O
caucasians	O	NOUN	B


Segregation	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
localised	O	ADJ	O
Xp21	O	NOUN	B
.	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
Xp21	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
DNA	O	NOUN	B
marker	O	NOUN	I
C7	O	NOUN	B
,	O	PUNCT	O
localised	O	ADJ	B
Xp21	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
-	O	PUNCT	O
Xp21	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
kindreds	O	NOUN	B
segregating	O	VERB	B
for	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
DMD	B-Disease	PROPN	B
families	O	NOUN	B
four	O	NUM	O
crossovers	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
38	O	NUM	O
informative	O	ADJ	B
meioses	O	NOUN	I
between	O	ADP	O
C7	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
(	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
z	O	X	B
max	O	NOUN	I
=	O	ADJ	O
+	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O
72	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
BMD	B-Disease	NOUN	B
families	O	NOUN	B
no	O	DET	O
recombinants	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
16	O	NUM	O
informative	O	ADJ	B
meioses	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
in	O	ADP	O
these	O	DET	O
disorders	O	NOUN	B
being	O	AUX	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
region	O	NOUN	O
of	O	ADP	O
Xp21	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
in	O	ADP	O
families	O	NOUN	B
also	O	ADV	O
segregating	O	VERB	B
for	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
marker	O	NOUN	I
754	O	NUM	O
support	O	NOUN	O
the	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
physical	O	ADJ	B
order	O	NOUN	I
of	O	ADP	O
these	O	DET	O
loci	O	NOUN	B
as	O	ADP	O
X	O	NOUN	B
centromere	O	NOUN	I
-	O	PUNCT	O
754	O	NUM	B
-	O	PUNCT	O
DMD	O	PROPN	B
-	O	PUNCT	O
BMD	O	PROPN	B
-	O	PUNCT	O
C7	O	PROPN	B
-	O	PUNCT	O
X	O	NOUN	B
telomere	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
recombination	O	NOUN	B
fraction	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
(	O	PUNCT	O
z	O	X	B
max	O	NOUN	I
=	O	ADJ	O
+	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O
58	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
DMD	O	PROPN	B
-	O	PUNCT	O
754	O	NUM	O
by	O	ADP	O
combining	O	VERB	O
our	O	PRON	O
previously	O	ADV	O
published	O	VERB	B
data	O	NOUN	I
with	O	ADP	O
the	O	DET	O
data	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
.	O	PUNCT	O


C7	O	NOUN	B
and	O	CCONJ	O
754	O	NUM	O
thus	O	ADV	O
provide	O	VERB	O
good	O	ADJ	O
bridging	O	NOUN	B
markers	O	NOUN	B
for	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
and	O	CCONJ	O
BMD	B-Disease	NOUN	B


Isolation	O	NOUN	B
of	O	ADP	O
molecular	O	ADJ	B
probes	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
chromosome	O	NOUN	O
15	O	NUM	O
instability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Flow	O	NOUN	B
cytometry	O	NOUN	I
and	O	CCONJ	O
recombinant	O	ADJ	B
DNA	O	NOUN	I
techniques	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
obtain	O	VERB	O
reagents	O	NOUN	B
for	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


HindIII	O	ADJ	B
total	O	NOUN	B
-	O	PUNCT	O
digest	O	NOUN	B
libraries	O	NOUN	B
were	O	AUX	O
prepared	O	VERB	O
in	O	ADP	O
lambda	O	NOUN	B
phage	O	NOUN	I
Charon	O	PROPN	I
21A	O	NOUN	I
from	O	ADP	O
flow	O	NOUN	B
-	O	PUNCT	O
sorted	O	VERB	B
inverted	O	ADJ	B
duplicated	O	ADJ	I
no	O	DET	B
.	O	PUNCT	O
15	O	NUM	O
human	O	ADJ	B
chromosomes	O	NOUN	O
and	O	CCONJ	O
propagated	O	VERB	O
on	O	ADP	O
recombination	O	NOUN	B
-	O	PUNCT	O
proficient	O	ADJ	B
(	O	PUNCT	O
LE392	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
recBC	O	NOUN	B
-	O	PUNCT	O
,	O	PUNCT	O
sbcB	O	PROPN	B
-	O	PUNCT	O
(	O	PUNCT	O
DB1257	O	NOUN	B
)	O	PUNCT	O
bacteria	O	NOUN	B
.	O	PUNCT	O


Twelve	O	NUM	O
distinct	O	ADJ	O
chromosome	O	NOUN	O
15	O	NUM	O
-	O	PUNCT	O
specific	O	ADJ	B
probes	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
isolated	O	VERB	B
.	O	PUNCT	O


Eight	O	NUM	O
localized	O	VERB	B
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
15q11	O	PROPN	I
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O


Four	O	NUM	O
of	O	ADP	O
these	O	DET	O
eight	O	NUM	O
sublocalized	O	VERB	B
to	O	PART	O
band	O	VERB	B
15q11	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
are	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
deleted	O	VERB	B
in	O	ADP	O
DNA	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
examined	O	VERB	O
with	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Heteroduplex	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
clones	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
grew	O	VERB	O
on	O	ADP	O
DB1257	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
on	O	ADP	O
LE392	O	NOUN	B
,	O	PUNCT	O
revealed	O	VERB	O
stem	O	NOUN	B
-	O	PUNCT	O
loop	O	NOUN	B
structures	O	NOUN	B
in	O	ADP	O
the	O	DET	O
inserts	O	NOUN	B
,	O	PUNCT	O
indicative	O	ADJ	B
of	O	ADP	O
inverted	O	ADJ	B
,	O	PUNCT	O
repeated	O	VERB	O
DNA	O	NOUN	B
elements	O	NOUN	I
.	O	PUNCT	O


Such	O	ADJ	O
DNA	O	NOUN	B
repeats	O	NOUN	I
might	O	AUX	O
account	O	VERB	O
for	O	ADP	O
some	O	DET	O
of	O	ADP	O
the	O	DET	O
cloning	O	NOUN	B
instability	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
segments	O	NOUN	I
from	O	ADP	O
proximal	O	ADJ	B
15q	O	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
and	O	CCONJ	O
physical	O	ADJ	B
instability	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
repeated	O	VERB	O
sequences	O	NOUN	B
we	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
band	O	NOUN	B
15q11	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
may	O	AUX	O
elucidate	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
the	O	DET	O
instability	O	NOUN	B
of	O	ADP	O
this	O	DET	O
chromosomal	O	ADJ	B
region	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
diseases	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
chromosomal	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
long	O	ADJ	O
arm	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
15	O	NUM	O


Analysis	O	NOUN	B
of	O	ADP	O
deletions	O	NOUN	B
in	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Becker	B-Disease	PROPN	B
and	I-Disease	CCONJ	O
Duchenne	I-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
genetic	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
for	O	ADP	O
which	O	DET	O
the	O	DET	O
biochemical	O	ADJ	B
defect	O	NOUN	O
is	O	AUX	O
as	O	ADP	O
yet	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
two	O	NUM	O
cloned	O	VERB	B
segments	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
DNA	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
which	O	DET	O
detect	O	VERB	B
structural	O	ADJ	B
alterations	O	NOUN	B
within	O	ADP	O
or	O	CCONJ	O
near	O	ADP	B
the	O	DET	O
genetic	O	ADJ	B
locus	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
of	O	ADP	O
these	O	DET	O
cloned	O	VERB	B
segments	O	NOUN	B
were	O	AUX	O
described	O	VERB	O
as	O	ADP	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
locus	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
detecting	O	VERB	B
deletions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
of	O	ADP	O
boys	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
determine	O	VERB	O
more	O	ADV	O
precisely	O	ADV	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
these	O	DET	O
deletions	O	NOUN	B
within	O	ADP	O
a	O	DET	O
large	O	ADJ	O
population	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
accuracy	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
segments	O	NOUN	B
,	O	PUNCT	O
DXS164	O	NOUN	B
(	O	PUNCT	O
pERT87	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
determining	O	VERB	O
the	O	DET	O
inheritance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
X	O	NOUN	I
chromosome	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
subclones	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
and	O	CCONJ	O
15	O	NUM	O
were	O	AUX	O
made	O	VERB	O
available	O	ADJ	O
to	O	ADP	O
many	O	ADJ	O
investigators	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
world	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
combined	O	ADJ	O
results	O	NOUN	B
of	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
research	O	NOUN	B
laboratories	O	NOUN	I
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
deletions	O	NOUN	B
at	O	ADP	O
the	O	DET	O
DXS164	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
DNA	O	NOUN	B
samples	O	NOUN	I
isolated	O	VERB	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
and	O	CCONJ	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
DXS164	O	NOUN	B
locus	O	NOUN	B
apparently	O	ADV	O
recombines	O	VERB	O
with	O	ADP	O
DMD	B-Disease	NOUN	B
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
probably	O	ADV	O
located	O	ADJ	O
between	O	ADP	O
independent	O	ADJ	B
sites	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
which	O	DET	O
yield	O	VERB	O
DMD	B-Disease	PROPN	B
.	O	PUNCT	O


The	O	DET	O
breakpoints	O	NOUN	B
of	O	ADP	O
some	O	DET	O
deletions	O	NOUN	B
are	O	AUX	O
delineated	O	VERB	O
within	O	ADP	O
the	O	DET	O
DXS164	O	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
evident	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
deletions	O	NOUN	B
at	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
are	O	AUX	O
frequent	O	ADJ	B
and	O	CCONJ	O
extremely	O	ADV	O
large	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
potential	O	ADJ	B
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
through	O	ADP	O
introduction	O	NOUN	B
of	O	ADP	O
HPRT	O	NOUN	B
mutations	O	NOUN	B
into	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
neurological	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
behavioural	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
affecting	O	VERB	B
only	O	ADV	O
males	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
an	O	DET	O
inherited	B-Disease	VERB	B
deficiency	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
purine	O	NOUN	B
salvage	O	NOUN	I
enzyme	O	NOUN	B
hypoxanthine	O	NOUN	I
-	O	PUNCT	O
guanosine	O	NOUN	B
phosphoribosyl	O	NOUN	I
transferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


How	O	SCONJ	O
the	O	DET	O
resulting	O	VERB	O
alterations	O	NOUN	B
in	O	ADP	O
purine	O	NOUN	B
metabolism	O	NOUN	I
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
severe	O	ADJ	B
symptoms	O	NOUN	B
characteristic	O	ADJ	O
of	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patients	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
not	O	PART	O
understood	O	VERB	O
.	O	PUNCT	O


No	O	DET	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
Hprt	O	NOUN	B
locus	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	I
activity	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
laboratory	O	ADJ	B
animals	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
derive	O	VERB	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
used	O	VERB	O
cultured	O	VERB	B
mouse	O	NOUN	O
embryonic	O	ADJ	O
stem	O	NOUN	O
cells	O	NOUN	O
,	O	PUNCT	O
mutagenized	O	VERB	B
by	O	ADP	O
retroviral	O	ADJ	B
insertion	O	NOUN	I
and	O	CCONJ	O
selected	O	VERB	O
for	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
HPRT	O	NOUN	B
activity	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
construct	O	VERB	O
chimaeric	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
clonal	O	ADJ	B
lines	O	NOUN	I
carrying	O	VERB	O
different	O	ADJ	O
mutant	O	ADJ	B
Hprt	O	NOUN	B
alleles	O	NOUN	I
have	O	AUX	O
given	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
germ	O	NOUN	B
cells	O	NOUN	I
in	O	ADP	O
chimaeras	O	NOUN	B
,	O	PUNCT	O
allowing	O	VERB	O
the	O	DET	O
derivation	O	NOUN	B
of	O	ADP	O
strains	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	I
having	O	VERB	O
the	O	DET	O
same	O	ADJ	O
biochemical	O	ADJ	B
defect	O	NOUN	O
as	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patients	O	NOUN	B
.	O	PUNCT	O


Male	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
the	O	DET	O
mutant	O	ADJ	B
alleles	O	NOUN	O
are	O	AUX	O
viable	O	ADJ	B
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
cells	O	NOUN	B
shows	O	VERB	O
a	O	DET	O
total	O	ADJ	O
lack	O	NOUN	O
of	O	ADP	O
HPRT	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Re	O	NOUN	B
-	O	PUNCT	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sublocalization	O	NOUN	B
of	O	ADP	O
esterase	O	NOUN	B
D	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
relation	O	NOUN	O
to	O	PART	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
locus	O	NOUN	I
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
of	O	ADP	O
a	O	DET	O
cDNA	O	NOUN	B
probe	O	NOUN	I
for	O	ADP	O
the	O	DET	O
esterase	O	NOUN	B
D	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ESD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
human	O	ADJ	B
chromosomes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
probe	O	NOUN	B
hybridized	O	VERB	B
most	O	ADV	O
strongly	O	ADV	O
to	O	PART	O
13q14	O	NOUN	B
.	O	PUNCT	O


2	O	NUM	O
and	O	CCONJ	O
13q14	O	NOUN	B
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
raises	O	VERB	O
doubts	O	NOUN	O
concerning	O	VERB	O
the	O	DET	O
most	O	ADV	O
recently	O	ADV	O
published	O	VERB	B
assignment	O	NOUN	B
of	O	ADP	O
ESD	O	NOUN	B
to	O	PART	O
13q14	O	NOUN	B
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


A	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
with	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
was	O	AUX	O
reported	O	VERB	O
to	O	PART	O
separate	O	VERB	O
the	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
ESD	O	PROPN	B
and	O	CCONJ	O
retinoblastoma	B-Disease	NOUN	B
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
loci	O	NOUN	O
,	O	PUNCT	O
placing	O	VERB	O
ESD	O	PROPN	B
proximal	O	ADJ	B
to	O	PART	O
RB1	O	NOUN	B
.	O	PUNCT	O


Quantitative	O	ADJ	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
studies	O	NOUN	B
of	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
do	O	AUX	O
not	O	PART	O
confirm	O	VERB	O
this	O	DET	O
interpretation	O	NOUN	B
.	O	PUNCT	O


Rather	O	ADV	O
,	O	PUNCT	O
they	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
ESD	O	PROPN	B
is	O	AUX	O
missing	O	VERB	O
from	O	ADP	O
the	O	DET	O
deleted	O	VERB	B
chromosome	O	NOUN	I
13	O	NUM	I
and	O	CCONJ	O
duplicated	O	VERB	B
on	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
homolog	O	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
this	O	DET	O
individual	O	NOUN	B
cannot	O	NOUN	O
be	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
orientation	O	NOUN	B
nor	O	CCONJ	O
the	O	DET	O
sublocalization	O	NOUN	B
of	O	ADP	O
ESD	O	PROPN	B
and	O	CCONJ	O
RB1	O	NOUN	B
within	O	ADP	O
the	O	DET	O
13q14	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
common	O	ADJ	O
variable	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
.	O	PUNCT	O


Homozygous	O	ADJ	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
19	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
variable	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
manifested	O	VERB	O
by	O	ADP	O
marked	O	ADJ	O
hypoimmunoglobulinemia	B-Disease	NOUN	B
and	O	CCONJ	O
impaired	O	ADJ	B
antibody	O	NOUN	O
responses	O	NOUN	O
,	O	PUNCT	O
normal	O	ADJ	B
circulating	O	VERB	I
B	O	NOUN	I
lymphocytes	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
subnormal	O	ADJ	B
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
functions	O	NOUN	I
.	O	PUNCT	O


Neither	O	CCONJ	O
antilymphocytic	O	ADJ	B
autoantibodies	O	NOUN	I
nor	O	CCONJ	O
chromosomal	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Serum	O	NOUN	B
immunoglobulin	O	NOUN	I
levels	O	NOUN	I
were	O	AUX	O
within	O	ADP	O
normal	O	ADJ	O
limits	O	NOUN	O
in	O	ADP	O
his	O	PRON	O
parents	O	NOUN	B
and	O	CCONJ	O
brother	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
lymphocytes	O	NOUN	B
were	O	AUX	O
homozygous	O	ADJ	B
at	O	ADP	O
the	O	DET	O
HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
locus	O	NOUN	B
but	O	CCONJ	O
expressed	O	VERB	B
an	O	DET	O
antigen	O	NOUN	B
different	O	ADJ	O
from	O	ADP	O
DW2	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mild	O	ADJ	B
and	O	CCONJ	O
severe	O	ADJ	B
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
deletions	O	NOUN	B
in	O	ADP	O
Xp21	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analysed	O	VERB	B
over	O	ADP	O
300	O	NUM	O
patients	O	NOUN	B
suffering	O	VERB	B
from	O	ADP	O
Duchenne	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
Becker	I-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
or	O	CCONJ	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Deletions	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
characterised	O	VERB	B
which	O	DET	O
encompass	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
pERT87	O	NOUN	B
(	O	PUNCT	O
DXS164	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
only	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
XJ1	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
(	O	PUNCT	O
DXS206	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
HIP25	O	NOUN	B
loci	O	NOUN	I
only	O	ADV	O
,	O	PUNCT	O
or	O	CCONJ	O
all	O	DET	O
three	O	NUM	O
loci	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
loci	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
lie	O	VERB	O
within	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
region	O	NOUN	B
covering	O	VERB	O
several	O	ADJ	O
hundred	O	NUM	O
kilobases	O	NOUN	B
(	O	PUNCT	O
kb	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
DNA	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
mildly	O	ADV	B
affected	O	VERB	O
BMD	B-Disease	NOUN	B
patient	O	NOUN	B
possesses	O	VERB	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
110	O	NUM	O
kb	O	NOUN	O
including	O	VERB	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
similar	O	ADJ	O
exon	O	NOUN	B
deletions	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
smaller	O	ADJ	O
deletions	O	NOUN	B
,	O	PUNCT	O
show	O	VERB	O
the	O	DET	O
more	O	ADV	O
severe	O	ADJ	B
phenotype	O	NOUN	B
typical	O	ADJ	O
of	O	ADP	O
DMD	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
from	O	ADP	O
these	O	DET	O
studies	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
phenotype	O	NOUN	B
cannot	O	PART	O
be	O	AUX	O
explained	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
discuss	O	VERB	O
this	O	DET	O
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
candidate	O	NOUN	O
gene	O	NOUN	B
sequences	O	NOUN	I
.	O	PUNCT	O


Patterns	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
deletions	O	NOUN	B
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
and	O	CCONJ	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
screened	O	VERB	B
with	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
probes	O	NOUN	O
Cf56a	O	NOUN	B
and	O	CCONJ	O
Cf23a	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
detect	O	VERB	B
exons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
exons	O	NOUN	B
were	O	AUX	O
deleted	O	VERB	O
in	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
deletions	O	NOUN	B
were	O	AUX	O
mapped	O	VERB	B
and	O	CCONJ	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
heterogeneous	O	ADJ	B
in	O	ADP	O
size	O	NOUN	B
and	O	CCONJ	O
extent	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
DMD	B-Disease	PROPN	B
.	O	PUNCT	O


Deletions	O	NOUN	B
specific	O	ADJ	O
to	O	PART	O
DMD	B-Disease	NOUN	B
and	O	CCONJ	O
to	O	PART	O
BMD	B-Disease	NOUN	B
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Half	O	NOUN	O
of	O	ADP	O
all	O	DET	O
BMD	B-Disease	NOUN	B
patients	O	NOUN	B
have	O	AUX	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
particular	O	ADJ	O
small	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
exons	O	NOUN	B
;	O	PUNCT	O
smaller	O	ADJ	O
deletions	O	NOUN	B
within	O	ADP	O
this	O	DET	O
same	O	ADJ	O
group	O	NOUN	B
produce	O	VERB	O
the	O	DET	O
more	O	ADV	O
severe	O	ADJ	B
DMD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
third	I-Disease	ADJ	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
skin	B-Disease	NOUN	B
rash	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
arthralgias	B-Disease	NOUN	B
:	O	PUNCT	O
response	O	NOUN	B
to	O	PART	O
transfusion	O	NOUN	B
of	O	ADP	O
whole	O	ADJ	B
blood	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
well	O	ADV	O
34	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
skin	B-Disease	NOUN	B
rash	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
arthralgias	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
lack	O	VERB	B
C3	O	NOUN	B
by	O	ADP	O
immunochemical	O	ADJ	B
(	O	PUNCT	O
undetectable	O	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
hemolytic	O	ADJ	B
(	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
normal	O	ADJ	B
)	O	PUNCT	O
assays	O	NOUN	O
.	O	PUNCT	O


No	O	DET	O
infectious	O	ADJ	B
agent	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


Protein	O	NOUN	B
levels	O	NOUN	I
of	O	ADP	O
Clq	O	NOUN	B
.	O	PUNCT	O


C4	O	NOUN	B
,	O	PUNCT	O
C5	O	NOUN	B
,	O	PUNCT	O
properdin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
C3b	O	NOUN	B
-	O	PUNCT	O
INA	O	NOUN	B
and	O	CCONJ	O
hemolytic	O	ADJ	B
activities	O	NOUN	B
of	O	ADP	O
complement	O	NOUN	B
components	O	NOUN	I
C1	O	NOUN	I
to	O	PART	O
C9	O	NOUN	B
except	O	SCONJ	O
C3	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	B
or	O	CCONJ	O
elevated	O	ADJ	B
;	O	PUNCT	O
total	O	ADJ	O
hemolytic	O	ADJ	B
complement	O	NOUN	O
activity	O	NOUN	O
was	O	AUX	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
was	O	AUX	O
reconstituted	O	VERB	B
by	O	ADP	O
purified	O	VERB	B
C3	O	NOUN	I
.	O	PUNCT	O


Properdin	O	NOUN	B
factor	O	NOUN	I
B	O	NOUN	I
was	O	AUX	O
702	O	NUM	O
(	O	PUNCT	O
normal	O	ADJ	O
175	O	NUM	O
to	O	PART	O
275	O	NUM	O
)	O	PUNCT	O
mug	O	NOUN	B
/	O	SYM	O
ml	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
not	O	PART	O
cleaver	O	NOUN	B
upon	O	SCONJ	O
addition	O	NOUN	O
of	O	ADP	O
zymosan	O	NOUN	B
or	O	CCONJ	O
cobra	O	NOUN	B
venom	O	NOUN	I
factor	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	O
immune	O	ADJ	B
adherence	O	NOUN	I
activity	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
was	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
ability	O	NOUN	O
to	O	PART	O
opsonize	O	VERB	B
Candida	O	NOUN	B
albicans	O	NOUN	I
for	O	ADP	O
uptake	O	NOUN	B
and	O	CCONJ	O
Escherichia	O	X	B
coli	O	X	I
for	O	ADP	O
killing	O	NOUN	B
by	O	ADP	O
neurophils	O	NOUN	B
,	O	PUNCT	O
generate	O	VERB	O
neutrophil	O	NOUN	B
chemotactic	O	ADJ	B
factors	O	NOUN	I
and	O	CCONJ	O
inhibit	O	VERB	B
the	O	DET	O
growth	O	NOUN	B
of	O	ADP	O
E	O	NOUN	B
.	O	PUNCT	O
coli	O	X	B
;	O	PUNCT	O
these	O	DET	O
activities	O	NOUN	B
were	O	AUX	O
restored	O	VERB	B
by	O	ADP	O
purified	O	VERB	B
C3	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
transfusion	O	NOUN	B
of	O	ADP	O
320	O	NUM	O
ml	O	NOUN	O
1	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
normal	O	ADJ	O
whole	O	ADJ	O
blood	O	NOUN	O
on	O	ADP	O
the	O	DET	O
fifty	O	NUM	B
-	O	PUNCT	O
second	O	ADJ	B
day	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
transitory	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C3	O	NOUN	B
level	O	NOUN	B
to	O	PART	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
with	O	ADP	O
a	O	DET	O
fall	O	NOUN	B
-	O	PUNCT	O
off	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
2	O	NUM	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
%	O	NOUN	O
per	O	ADP	O
hour	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
undetectable	O	ADJ	B
levels	O	NOUN	B
by	O	ADP	O
69	O	NUM	O
hours	O	NOUN	B
;	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
disappearance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skin	B-Disease	NOUN	B
rash	I-Disease	NOUN	I
and	O	CCONJ	O
arthralgias	B-Disease	NOUN	B
and	O	CCONJ	O
return	O	VERB	B
to	O	ADP	I
normal	O	ADJ	I
of	O	ADP	O
the	O	DET	O
previously	O	ADV	O
elevated	O	ADJ	B
temperature	O	NOUN	B
and	O	CCONJ	O
CRP	O	NOUN	B
levels	O	NOUN	I
.	O	PUNCT	O


C3	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
family	O	NOUN	B
members	O	NOUN	I
(	O	PUNCT	O
seven	O	NUM	O
of	O	ADP	O
24	O	NUM	O
half	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
lack	O	NOUN	B
of	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
C3	O	NOUN	B
activity	O	NOUN	B
,	O	PUNCT	O
normal	O	ADJ	B
C3b	O	NOUN	B
-	O	PUNCT	O
INA	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
normal	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
catabolism	O	NOUN	B
of	O	ADP	O
transfused	O	VERB	B
C3	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deficiency	O	NOUN	B
was	O	AUX	O
inherited	O	VERB	B
with	O	ADP	O
autosomal	O	ADJ	B
codominance	O	NOUN	B
and	O	CCONJ	O
involved	O	VERB	O
decreased	B-Disease	VERB	B
synthesis	I-Disease	NOUN	B
of	I-Disease	ADP	O
C3	I-Disease	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
child	O	NOUN	B
is	O	AUX	O
a	O	DET	O
unique	O	ADJ	O
individual	O	NOUN	B
with	O	ADP	O
inherited	B-Disease	VERB	B
C3	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
presenting	O	VERB	O
with	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
repeated	O	VERB	O
infections	O	NOUN	B
,	O	PUNCT	O
whose	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
skin	B-Disease	NOUN	B
rash	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
arthralgia	B-Disease	NOUN	B
were	O	AUX	O
abated	O	VERB	O
by	O	ADP	O
whole	O	ADJ	B
blood	O	NOUN	I
transfusion	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variants	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
frequency	O	NOUN	B
in	O	ADP	O
Guangdong	O	PROPN	B
,	O	PUNCT	O
China	O	PROPN	B
.	O	PUNCT	O


Erythrocyte	O	NOUN	B
glucose	O	NOUN	I
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
characterized	O	VERB	B
in	O	ADP	O
blood	O	NOUN	B
samples	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
97	O	NUM	O
randomly	O	ADV	O
selected	O	VERB	O
males	O	NOUN	B
with	O	ADP	O
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
from	O	ADP	O
various	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
Guangdong	O	PROPN	B
Province	O	PROPN	I
,	O	PUNCT	O
China	O	PROPN	B
.	O	PUNCT	O


Nine	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
(	O	PUNCT	O
Gd	O	PROPN	B
Kaiping	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Boluo	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Huiyang	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Gaomin	O	PROPN	B
,	O	PUNCT	O
Gd	O	PROPN	B
Qing	O	PROPN	I
-	O	PUNCT	O
Baijiang	O	PROPN	B
,	O	PUNCT	O
Gd	O	PROPN	B
Gaozhou	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Huazhou	O	PROPN	B
,	O	PUNCT	O
Gd	O	PROPN	B
Nanhai	O	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
Gd	O	PROPN	B
Guangzhou	O	PROPN	I
)	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
31	O	NUM	O
variants	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
this	O	DET	O
province	O	NOUN	B
,	O	PUNCT	O
Gd	O	PROPN	B
Kaiping	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Taiwan	O	PROPN	I
-	O	PUNCT	O
Hakka	O	PROPN	B
,	O	PUNCT	O
Gd	O	PROPN	B
Haad	O	PROPN	I
Yai	O	PROPN	I
,	O	PUNCT	O
Gd	O	PROPN	B
Haad	O	PROPN	I
Yai	O	PROPN	I
-	O	PUNCT	O
like	O	PROPN	B
and	O	CCONJ	O
Gd	O	PROPN	B
Huiyang	O	PROPN	I
occurred	O	VERB	O
most	O	ADV	O
frequently	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
each	O	DET	O
variant	O	NOUN	B
was	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
was	O	AUX	O
high	O	ADJ	O
in	O	ADP	O
this	O	DET	O
area	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Homozygous	O	ADJ	B
and	O	CCONJ	O
heterozygous	O	ADJ	B
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
carriers	O	NOUN	B
of	O	ADP	O
severe	B-Disease	ADJ	B
von	I-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Severe	B-Disease	ADJ	B
von	I-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
undetectable	O	ADJ	B
or	O	CCONJ	O
trace	O	NOUN	B
quantities	O	NOUN	I
of	O	ADP	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
stores	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
genomic	O	ADJ	B
DNA	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
from	O	ADP	O
six	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
using	O	VERB	O
probes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
5	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
ends	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vWF	O	NOUN	B
cDNA	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
extending	O	VERB	O
from	O	ADP	O
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
into	O	ADP	O
the	O	DET	O
central	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


Southern	O	NOUN	B
blots	O	NOUN	I
of	O	ADP	O
restriction	O	NOUN	B
endonuclease	O	NOUN	I
digests	O	NOUN	I
and	O	CCONJ	O
gene	O	NOUN	B
dosage	O	NOUN	I
analysis	O	NOUN	I
measurements	O	NOUN	B
carried	O	VERB	O
out	O	ADP	O
with	O	ADP	O
quantitative	O	ADJ	B
slot	O	NOUN	I
blots	O	NOUN	I
of	O	ADP	O
undigested	O	ADJ	B
genomic	O	ADJ	O
DNA	O	NOUN	O
separated	O	VERB	O
these	O	DET	O
patients	O	NOUN	B
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
group	O	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
complete	O	ADJ	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vWF	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
four	O	NUM	O
probands	O	NOUN	B
.	O	PUNCT	O


Gene	O	NOUN	B
dosage	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
heterozygous	O	ADJ	B
deletions	O	NOUN	B
in	O	ADP	O
both	O	DET	O
of	O	ADP	O
the	O	DET	O
asymptomatic	O	ADJ	B
parents	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
asymptomatic	O	ADJ	B
siblings	O	NOUN	B
of	O	ADP	O
this	O	DET	O
kindred	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
was	O	AUX	O
comprised	O	VERB	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
complete	O	ADJ	O
heterozygous	O	ADJ	B
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vWF	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
asymptomatic	O	ADJ	B
parent	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
different	O	ADJ	O
type	O	NOUN	O
of	O	ADP	O
genetic	B-Disease	ADJ	B
abnormality	I-Disease	NOUN	I
was	O	AUX	O
inherited	O	VERB	B
from	O	ADP	O
the	O	DET	O
other	O	ADJ	O
parent	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
patient	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
doubly	O	ADV	O
heterozygous	O	ADJ	B
for	O	ADP	O
interacting	O	VERB	B
genetic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
affecting	O	VERB	O
vWF	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
third	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
gene	O	NOUN	B
deletions	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Alloantibodies	O	NOUN	B
developed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
kindred	O	NOUN	B
with	O	ADP	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
techniques	O	NOUN	B
should	O	AUX	O
prove	O	VERB	O
useful	O	ADJ	O
in	O	ADP	O
identifying	O	VERB	O
carriers	O	NOUN	B
of	O	ADP	O
severe	B-Disease	ADJ	B
von	I-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
and	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
defining	O	VERB	O
patients	O	NOUN	B
predictably	O	ADV	O
at	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
alloantibodies	O	NOUN	B
to	O	PART	O
vWF	O	NOUN	B
.	O	PUNCT	O


Sjogren	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Larsson	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Impaired	O	ADJ	B
fatty	O	ADJ	B
alcohol	O	NOUN	I
oxidation	O	NOUN	I
in	O	ADP	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
deficient	O	ADJ	B
fatty	O	ADJ	B
alcohol	O	NOUN	I
:	O	PUNCT	O
nicotinamide	O	NOUN	B
adenine	O	NOUN	I
dinucleotide	O	NOUN	I
oxidoreductase	O	NOUN	I
activity	O	NOUN	I
.	O	PUNCT	O


Lipid	O	NOUN	B
metabolism	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
Sjogren	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Larsson	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
SLS	B-Disease	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Intact	O	ADJ	B
SLS	B-Disease	PROPN	B
fibroblasts	O	NOUN	B
incubated	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
[	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
14C	O	NOUN	B
]	O	PUNCT	O
palmitate	O	NOUN	B
accumulated	O	VERB	O
more	O	ADV	O
radioactive	O	ADJ	B
hexadecanol	O	NOUN	B
than	O	ADP	O
did	O	AUX	O
normal	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
incorporation	O	NOUN	B
of	O	ADP	O
radioactivity	O	NOUN	B
into	O	ADP	O
other	O	ADJ	O
cellular	O	ADJ	B
lipids	O	NOUN	I
was	O	AUX	O
unaltered	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
hexadecanol	O	NOUN	B
content	O	NOUN	B
of	O	ADP	O
SLS	B-Disease	NOUN	B
fibroblasts	O	NOUN	B
was	O	AUX	O
abnormally	O	ADV	O
elevated	O	ADJ	B
.	O	PUNCT	O


Hexadecanol	O	NOUN	B
accumulation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
increased	O	VERB	B
fatty	O	ADJ	B
alcohol	O	NOUN	I
synthesis	O	NOUN	I
nor	O	CCONJ	O
its	O	PRON	O
deficient	O	ADJ	B
utilization	O	NOUN	B
for	O	ADP	O
glycerol	O	NOUN	B
ether	O	ADJ	O
synthesis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
half	O	ADJ	B
-	O	PUNCT	O
life	O	NOUN	B
of	O	ADP	O
intracellular	O	ADJ	B
hexadecanol	O	NOUN	B
loaded	O	VERB	O
into	O	ADP	O
SLS	B-Disease	NOUN	B
fibroblasts	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
(	O	PUNCT	O
70	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
normal	O	ADJ	B
(	O	PUNCT	O
15	O	NUM	O
min	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
intact	O	ADJ	B
SLS	B-Disease	PROPN	B
fibroblasts	O	NOUN	B
showed	O	VERB	O
impaired	O	ADJ	B
oxidation	O	NOUN	B
of	O	ADP	O
[	O	PUNCT	O
14C	O	NOUN	O
]	O	PUNCT	O
-	O	PUNCT	O
hexadecanol	O	NOUN	B
to	O	PART	O
fatty	O	ADJ	B
acid	O	NOUN	I
.	O	PUNCT	O


Fatty	O	ADJ	B
alcohol	O	NOUN	I
NAD	O	NOUN	B
+	O	CCONJ	O
oxidoreductase	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
enzyme	O	NOUN	B
catalyzing	O	VERB	B
this	O	DET	O
reaction	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
SLS	B-Disease	NOUN	B
fibroblasts	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	O
total	O	ADJ	O
activity	O	NOUN	O
in	O	ADP	O
SLS	B-Disease	NOUN	B
fibroblasts	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
13	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
that	O	DET	O
in	O	ADP	O
normal	O	ADJ	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
palmitoyl	O	ADJ	B
CoA	O	NOUN	I
-	O	PUNCT	O
inhibitable	O	ADJ	B
activity	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


Fibroblasts	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
obligate	O	ADJ	B
SLS	B-Disease	PROPN	B
heterozygotes	O	NOUN	B
had	O	AUX	O
enzyme	O	NOUN	B
activities	O	NOUN	I
intermediate	O	VERB	O
between	O	ADP	O
that	O	DET	O
in	O	ADP	O
normal	O	ADJ	B
fibroblasts	O	NOUN	B
and	O	CCONJ	O
individuals	O	NOUN	B
with	O	ADP	O
SLS	B-Disease	PROPN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
primary	O	ADJ	B
defect	O	NOUN	O
in	O	ADP	O
SLS	B-Disease	PROPN	B
is	O	AUX	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
fatty	I-Disease	ADJ	B
alcohol	I-Disease	NOUN	I
NAD	I-Disease	NOUN	B
+	I-Disease	CCONJ	O
oxidoreductase	I-Disease	NOUN	B
.	O	PUNCT	O


SLS	B-Disease	PROPN	B
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
inherited	B-Disease	VERB	B
disorder	I-Disease	NOUN	O
in	O	ADP	O
man	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
isolated	O	VERB	B
abnormality	B-Disease	NOUN	B
in	I-Disease	ADP	O
fatty	I-Disease	ADJ	B
alcohol	I-Disease	NOUN	I
metabolism	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Germinal	O	ADJ	B
mosaicism	O	NOUN	I
in	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
a	O	DET	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
pedigree	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
molecular	O	ADJ	B
deletion	O	NOUN	I
within	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
meiotic	O	ADJ	B
segregation	O	NOUN	I
products	O	NOUN	I
of	O	ADP	O
the	O	DET	O
common	O	ADJ	O
female	O	ADJ	B
ancestor	O	NOUN	I
using	O	VERB	O
marker	O	NOUN	B
restriction	O	NOUN	O
fragment	O	NOUN	O
length	O	NOUN	O
polymorphisms	O	NOUN	O
(	O	PUNCT	O
RFLPs	O	NOUN	B
)	O	PUNCT	O
detected	O	VERB	B
by	O	ADP	O
probes	O	NOUN	B
that	O	PRON	O
lie	O	VERB	O
within	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
female	O	NOUN	B
has	O	AUX	O
transmitted	O	VERB	B
three	O	NUM	O
distinct	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
X	O	NOUN	B
chromosome	O	NOUN	I
to	O	ADP	O
her	O	PRON	O
offspring	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
postulating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
arose	O	VERB	O
as	O	ADP	O
a	O	DET	O
postzygotic	O	ADJ	B
deletion	O	NOUN	I
within	O	ADP	O
this	O	DET	O
common	O	ADJ	O
ancestor	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
consequently	O	ADV	O
germinally	O	ADV	B
mosaic	O	ADJ	I
.	O	PUNCT	O
.	O	PUNCT	O


Nebulin	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
DMD	B-Disease	NOUN	B
males	O	NOUN	B
including	O	VERB	O
one	O	NUM	O
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
large	O	ADJ	O
DNA	O	NOUN	B
deletion	O	NOUN	I
encompassing	O	VERB	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
nebulin	O	NOUN	B
in	O	ADP	O
a	O	DET	O
muscle	O	NOUN	B
specimen	O	NOUN	I
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
due	O	ADP	O
to	O	ADP	O
a	O	DET	O
large	O	ADJ	O
deletion	O	NOUN	B
precludes	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
this	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
murine	O	ADJ	B
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
muscle	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
.	O	PUNCT	O


Complementary	O	ADJ	B
DNA	O	NOUN	I
clones	O	NOUN	I
were	O	AUX	O
isolated	O	VERB	B
that	O	PRON	O
represent	O	VERB	O
the	O	DET	O
5	O	NUM	O
terminal	O	ADJ	B
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
kilobases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
murine	O	ADJ	B
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
Dmd	O	NOUN	O
)	O	PUNCT	O
messenger	O	NOUN	O
RNA	O	NOUN	O
(	O	PUNCT	O
mRNA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Mouse	O	NOUN	B
Dmd	O	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
detectable	O	ADJ	B
in	O	ADP	O
skeletal	O	ADJ	B
and	O	CCONJ	O
cardiac	O	ADJ	B
muscle	O	NOUN	I
and	O	CCONJ	O
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
approximately	O	ADV	O
90	O	NUM	O
percent	O	NOUN	O
lower	O	ADJ	O
in	O	ADP	O
brain	O	NOUN	B
.	O	PUNCT	O


Dmd	O	NOUN	B
mRNA	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
present	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
at	O	ADP	O
much	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	O
levels	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
muscle	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
strains	O	NOUN	B
of	O	ADP	O
dystrophic	B-Disease	ADJ	B
mdx	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
Dmd	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
raises	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
relation	O	NOUN	O
between	O	ADP	O
human	O	ADJ	B
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
found	O	VERB	O
in	O	ADP	O
some	O	DET	O
DMD	B-Disease	NOUN	B
males	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
also	O	ADV	O
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
mdx	O	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
allelic	O	ADJ	B
variants	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
Dmd	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
6	I-Disease	NUM	I
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
incidence	O	NOUN	B
of	O	ADP	O
hematologic	B-Disease	ADJ	B
malignancy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
evaluated	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
negative	O	ADJ	B
association	O	NOUN	B
between	O	ADP	O
glucose	B-Disease	NOUN	B
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
481	O	NUM	O
Sardinian	O	ADJ	B
males	O	NOUN	B
with	O	ADP	O
hematological	B-Disease	ADJ	B
malignancies	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
not	O	PART	O
different	O	ADJ	O
from	O	ADP	O
the	O	DET	O
incidence	O	NOUN	B
in	O	ADP	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
16	O	NUM	O
,	O	PUNCT	O
219	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
conclusion	O	NOUN	O
resulted	O	VERB	O
from	O	ADP	O
the	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GdB	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
23	O	NUM	O
heterozygous	O	ADJ	B
women	O	NOUN	B
having	O	VERB	O
a	O	DET	O
clonal	O	ADJ	B
hematologic	B-Disease	ADJ	I
disease	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
37	O	NUM	O
healthy	O	ADJ	B
heterozygotes	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
at	O	ADP	O
present	O	ADJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
evidence	O	NOUN	O
that	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
has	O	AUX	O
a	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
against	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
hematologic	B-Disease	ADJ	B
neoplasms	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Hepatoblastoma	B-Disease	NOUN	B
,	O	PUNCT	O
pigmented	B-Disease	ADJ	B
ocular	I-Disease	ADJ	B
fundus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
and	O	CCONJ	O
jaw	B-Disease	NOUN	B
lesions	I-Disease	NOUN	I
in	O	ADP	O
Gardner	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Hepatoblastoma	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
neoplasm	B-Disease	NOUN	B
of	O	ADP	O
infants	O	NOUN	B
and	O	CCONJ	O
children	O	NOUN	B
only	O	ADV	O
recently	O	ADV	O
documented	O	VERB	B
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
colon	I-Disease	NOUN	B
[	O	PUNCT	O
Kingston	O	PROPN	B
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1983	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
four	O	NUM	O
children	O	NOUN	B
with	O	ADP	O
hepatoblastoma	B-Disease	NOUN	B
from	O	ADP	O
four	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
with	O	ADP	O
Gardner	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
GS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


One	O	NUM	O
child	O	NOUN	B
,	O	PUNCT	O
now	O	ADV	O
19	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
,	O	PUNCT	O
survived	O	VERB	O
after	O	ADP	O
a	O	DET	O
resection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
hepatoblastoma	B-Disease	NOUN	B
in	O	ADP	O
infancy	O	NOUN	B
and	O	CCONJ	O
recently	O	ADV	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
GS	B-Disease	PROPN	B
.	O	PUNCT	O


He	O	PRON	O
has	O	AUX	O
an	O	DET	O
associated	O	VERB	B
odontoma	B-Disease	NOUN	B
and	O	CCONJ	O
pigmented	B-Disease	ADJ	B
ocular	I-Disease	ADJ	B
fundus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
clinical	O	ADJ	B
markers	O	NOUN	I
of	O	ADP	O
GS	B-Disease	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
individuals	O	NOUN	B
in	O	ADP	O
these	O	DET	O
four	O	NUM	O
GS	B-Disease	PROPN	B
families	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
affected	O	VERB	B
and	O	CCONJ	O
at	O	ADP	O
risk	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
osteomatous	B-Disease	ADJ	B
jaw	I-Disease	NOUN	I
lesions	I-Disease	NOUN	O
and	O	CCONJ	O
pigmented	B-Disease	ADJ	B
ocular	I-Disease	ADJ	B
fundus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
search	O	NOUN	B
for	O	ADP	O
colonic	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
should	O	AUX	O
be	O	AUX	O
made	O	VERB	O
in	O	ADP	O
families	O	NOUN	B
of	O	ADP	O
infants	O	NOUN	B
and	O	CCONJ	O
children	O	NOUN	B
with	O	ADP	O
hepatoblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
the	O	DET	O
child	O	NOUN	B
survives	O	VERB	O
,	O	PUNCT	O
he	O	PRON	O
or	O	CCONJ	O
she	O	PRON	O
should	O	AUX	O
be	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
the	O	DET	O
later	O	ADJ	O
appearance	O	NOUN	B
of	O	ADP	O
colonic	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
jaw	B-Disease	NOUN	B
lesions	I-Disease	NOUN	I
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
pigmented	B-Disease	ADJ	B
ocular	I-Disease	ADJ	B
fundus	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
in	O	ADP	O
relatives	O	NOUN	B
at	O	ADP	O
risk	O	NOUN	B
are	O	AUX	O
indications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
GS	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
an	O	DET	O
altered	O	ADJ	O
splice	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
Ashkenazi	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
encoding	O	VERB	B
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
subunit	O	NOUN	B
of	O	ADP	O
the	O	DET	O
lysosomal	O	ADJ	B
enzyme	O	NOUN	I
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
N	O	NOUN	B
-	O	PUNCT	O
acetylhexosaminidase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
relatively	O	ADV	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
carriers	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
27	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
a	O	DET	O
lethal	O	ADJ	B
,	O	PUNCT	O
infantile	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
yet	O	ADV	O
evident	O	ADJ	O
whether	O	SCONJ	O
this	O	DET	O
has	O	AUX	O
resulted	O	VERB	O
from	O	ADP	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
and	O	CCONJ	O
random	O	ADJ	B
genetic	O	ADJ	B
drift	O	NOUN	I
or	O	CCONJ	O
from	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
advantage	O	NOUN	O
of	O	ADP	O
heterozygotes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
cloned	O	VERB	B
fragment	O	NOUN	O
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
an	O	DET	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
patient	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
change	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
C	O	NOUN	O
for	O	ADP	O
G	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
nucleotide	O	NOUN	B
of	O	ADP	O
intron	O	NOUN	B
12	O	NUM	O
is	O	AUX	O
expected	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
defective	O	ADJ	B
splicing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
messenger	O	NOUN	B
RNA	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
test	O	NOUN	O
for	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
amplification	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
by	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
rection	O	NOUN	I
and	O	CCONJ	O
cleavage	O	NOUN	B
of	O	ADP	O
a	O	DET	O
DdeI	O	NOUN	B
restriction	O	NOUN	I
site	O	NOUN	I
generated	O	VERB	O
by	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
this	O	DET	O
case	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
other	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
,	O	PUNCT	O
infantile	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
are	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
mutant	O	ADJ	B
alleles	O	NOUN	O
warrants	O	VERB	O
further	O	ADJ	O
examination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
selective	O	ADJ	O
advantage	O	NOUN	O
hypothesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
glucose	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Mus	O	NOUN	B
musculus	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
mouse	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
glucose	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
has	O	AUX	O
been	O	AUX	O
recovered	O	VERB	O
in	O	ADP	O
offspring	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
ethyl	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
nitrosourea	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
male	O	NOUN	B
mice	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
activity	O	NOUN	B
alteration	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
blood	O	NOUN	B
but	O	CCONJ	O
can	O	AUX	O
also	O	ADV	O
be	O	AUX	O
observed	O	VERB	B
in	O	ADP	O
other	O	ADJ	O
tissue	O	NOUN	B
extracts	O	NOUN	I
.	O	PUNCT	O


Hemizygous	O	ADJ	B
,	O	PUNCT	O
heterozygous	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
homozygous	O	ADJ	B
mutants	O	NOUN	B
have	O	AUX	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
about	O	ADV	O
15	O	NUM	O
,	O	PUNCT	O
60	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
G6PD	O	NOUN	B
remaining	O	NOUN	O
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
as	O	ADP	O
compared	O	VERB	B
to	O	PART	O
the	O	DET	O
wild	O	ADJ	B
type	O	NOUN	I
.	O	PUNCT	O


Erythrocyte	O	NOUN	B
indices	O	NOUN	I
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
differences	O	NOUN	O
between	O	ADP	O
mutants	O	NOUN	B
and	O	CCONJ	O
wild	O	ADJ	B
types	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
does	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
electrophoretic	O	ADJ	B
migration	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
isoelectric	O	ADJ	B
point	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
thermal	O	ADJ	B
stability	O	NOUN	I
.	O	PUNCT	O


Kinetic	O	ADJ	B
properties	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
Km	O	NOUN	B
for	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
or	O	CCONJ	O
for	O	ADP	O
NADP	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
relative	O	ADJ	O
utilization	O	NOUN	B
of	O	ADP	O
substrate	O	NOUN	B
analogues	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
no	O	DET	O
differences	O	NOUN	O
between	O	ADP	O
wild	O	ADJ	B
types	O	NOUN	I
and	O	CCONJ	O
mutants	O	NOUN	B
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
utilization	O	NOUN	B
of	O	ADP	O
deamino	O	NOUN	B
-	O	PUNCT	O
NADP	O	NOUN	B
which	O	DET	O
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
mutants	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
presently	O	ADV	O
the	O	DET	O
only	O	ADJ	O
animal	O	ADJ	B
model	O	NOUN	I
for	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
G6PD	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Diverse	O	ADJ	B
point	O	NOUN	O
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
gene	O	NOUN	I
cause	O	VERB	O
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
mild	O	ADJ	B
or	O	CCONJ	O
severe	O	ADJ	B
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
;	I-Disease	PUNCT	O
EC	I-Disease	NOUN	B
1	I-Disease	NUM	I
.	I-Disease	PUNCT	O
1	I-Disease	NUM	O
.	I-Disease	PUNCT	O
1	I-Disease	X	O
.	I-Disease	PUNCT	O
49	I-Disease	NUM	O
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
genetic	B-Disease	ADJ	B
abnormality	I-Disease	NOUN	I
affecting	O	VERB	B
an	O	DET	O
estimated	O	VERB	B
400	O	NUM	O
million	O	NUM	O
people	O	NOUN	B
worldwide	O	ADV	O
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
analyses	O	NOUN	I
have	O	AUX	O
identified	O	VERB	B
many	O	ADJ	O
variants	O	NOUN	B
exhibiting	O	VERB	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
phenotypes	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
well	O	ADV	O
characterized	O	VERB	B
from	O	ADP	O
the	O	DET	O
hematological	O	ADJ	B
point	O	NOUN	O
of	O	ADP	O
view	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
until	O	ADP	O
now	O	ADV	O
,	O	PUNCT	O
their	O	PRON	O
precise	O	ADJ	O
molecular	O	ADJ	B
basis	O	NOUN	I
has	O	AUX	O
remained	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
seven	O	NUM	O
mutant	O	ADJ	B
G6PD	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
nondeficient	O	ADJ	B
polymorphic	O	ADJ	B
African	O	ADJ	B
variant	O	ADJ	O
G6PD	O	NOUN	B
A	O	NOUN	O
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
a	O	DET	O
single	O	ADJ	O
point	O	NOUN	O
mutation	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
six	O	NUM	O
mutants	O	NOUN	B
investigated	O	VERB	B
were	O	AUX	O
all	O	DET	O
associated	O	VERB	B
with	O	ADP	I
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
commonest	O	ADJ	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
favism	B-Disease	NOUN	B
among	O	ADP	O
other	O	ADJ	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
replacement	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
(	O	PUNCT	O
serine	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
phenylalanine	O	NOUN	B
)	O	PUNCT	O
it	O	PRON	O
must	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
decreased	O	VERB	B
stability	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
reduced	O	VERB	B
catalytic	O	ADJ	B
efficiency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
enzyme	O	NOUN	B
.	O	PUNCT	O


Single	O	ADJ	B
point	O	NOUN	I
mutations	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
found	O	VERB	O
in	O	ADP	O
G6PD	O	NOUN	B
Metaponto	O	PROPN	B
(	O	PUNCT	O
Southern	O	PROPN	B
Italy	O	PROPN	I
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
G6PD	O	NOUN	B
Ilesha	O	PROPN	I
(	O	PUNCT	O
Nigeria	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
asymptomatic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
G6PD	O	NOUN	B
Chatham	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
an	O	DET	O
Indian	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
neonatal	B-Disease	ADJ	B
jaundice	I-Disease	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
G6PD	O	NOUN	B
"	O	PUNCT	O
Matera	O	PROPN	B
,	O	PUNCT	O
"	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
now	O	ADV	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
same	O	ADJ	O
as	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
-	O	PUNCT	O
,	O	PUNCT	O
two	O	NUM	O
separate	O	ADJ	O
point	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
same	O	ADJ	O
as	O	ADP	O
in	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
G6PD	O	NOUN	B
Santiago	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
de	O	X	B
novo	O	X	I
mutation	O	NOUN	B
(	O	PUNCT	O
glycine	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
arginine	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
severe	O	ADJ	B
chronic	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
observed	O	VERB	B
show	O	VERB	O
a	O	DET	O
striking	O	ADJ	O
predominance	O	NOUN	O
of	O	ADP	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
T	O	NOUN	B
transitions	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
CG	O	NOUN	B
doublets	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
seven	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
diverse	O	ADJ	O
point	O	NOUN	O
mutations	O	NOUN	B
may	O	AUX	O
account	O	VERB	O
largely	O	ADV	O
for	O	ADP	O
the	O	DET	O
phenotypic	O	ADJ	B
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Tight	O	ADJ	B
linkage	O	NOUN	I
between	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
apolipoprotein	O	NOUN	B
E	O	NOUN	I
genes	O	NOUN	I
revealed	O	VERB	O
with	O	ADP	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
oligonucleotides	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
16	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
approach	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
oligonucleotides	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
employed	O	VERB	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
linkage	O	NOUN	B
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
apolipoprotein	O	NOUN	B
E	O	NOUN	I
(	O	PUNCT	O
APOE	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
and	O	CCONJ	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


Synthetic	O	ADJ	B
oligonucleotides	O	NOUN	I
,	O	PUNCT	O
designed	O	VERB	O
to	O	PART	O
discriminate	O	VERB	O
between	O	ADP	O
APOE	O	NOUN	B
alleles	O	NOUN	B
epsilon	O	NOUN	O
3	O	NUM	O
and	O	CCONJ	O
epsilon	O	NOUN	B
4	O	NUM	I
,	O	PUNCT	O
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
distinguish	O	VERB	O
heterozygous	O	ADJ	B
carriers	O	NOUN	B
in	O	ADP	O
a	O	DET	O
hybridization	O	NOUN	B
assay	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
relevant	O	ADJ	B
segment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APOE	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
enzymatically	O	ADV	B
amplified	O	VERB	I
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
method	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
DM	O	NOUN	B
and	O	CCONJ	O
APOE	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
maximum	O	ADJ	O
lod	O	NOUN	O
score	O	NOUN	O
(	O	PUNCT	O
zmax	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


47	O	NUM	O
was	O	AUX	O
obtained	O	VERB	O
at	O	ADP	O
a	O	DET	O
recombination	O	NOUN	B
frequency	O	NOUN	I
(	O	PUNCT	O
theta	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


047	O	NUM	O
(	O	PUNCT	O
male	O	NOUN	B
theta	O	NOUN	O
=	O	ADJ	O
female	O	ADJ	B
theta	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
recombination	O	NOUN	I
(	O	PUNCT	O
maximum	O	ADJ	O
lod	O	ADJ	O
score	O	NOUN	O
of	O	ADP	O
5	O	NUM	O
.	O	PUNCT	O
61	O	NUM	O
at	O	ADP	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
APOE	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
apolipoprotein	O	NOUN	B
CII	O	NOUN	I
(	O	PUNCT	O
APOC2	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
APOC2	O	NOUN	B
,	O	PUNCT	O
APOE	O	NOUN	B
is	O	AUX	O
a	O	DET	O
useful	O	ADJ	O
marker	O	NOUN	B
for	O	ADP	O
presymptomatic	O	ADJ	B
DM	B-Disease	NOUN	B
diagnosis	O	NOUN	B
.	O	PUNCT	O


Regional	O	ADJ	B
localization	O	NOUN	B
of	O	ADP	O
polymorphic	O	ADJ	B
DNA	O	NOUN	B
loci	O	NOUN	I
on	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
long	O	ADJ	O
arm	O	NOUN	O
of	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
using	O	VERB	O
deletions	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
choroideremia	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
males	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
who	O	PRON	O
suffer	O	VERB	O
from	O	ADP	O
choroideremia	B-Disease	NOUN	B
and	O	CCONJ	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
have	O	AUX	O
an	O	DET	O
interstitial	O	ADJ	B
deletion	O	NOUN	I
on	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
long	O	ADJ	O
arm	O	NOUN	O
of	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
resolution	O	NOUN	B
banding	O	NOUN	B
we	O	PRON	O
have	O	AUX	O
characterized	O	VERB	B
the	O	DET	O
deletion	O	NOUN	B
chromosomes	O	NOUN	I
as	O	ADP	O
del	O	X	O
(	O	PUNCT	O
X	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
q21	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O
33	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
del	O	X	B
(	O	PUNCT	I
X	O	NOUN	I
)	O	PUNCT	I
(	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
q21	O	NOUN	B
2	O	NUM	I
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O
31	O	NUM	O
)	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


By	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
we	O	PRON	O
have	O	AUX	O
mapped	O	VERB	B
ten	O	NUM	O
different	O	ADJ	O
polymorphic	O	ADJ	B
DNA	O	NOUN	B
loci	O	NOUN	I
relative	O	ADJ	O
to	O	PART	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
choroideremia	B-Disease	NOUN	B
locus	O	NOUN	O
TCD	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
probe	O	NOUN	B
,	O	PUNCT	O
p31	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
cover	O	VERB	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
breakpoints	O	NOUN	B
of	O	ADP	O
the	O	DET	O
smallest	O	ADJ	O
deletion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
following	O	VERB	O
order	O	NOUN	O
of	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
was	O	AUX	O
suggested	O	VERB	O
by	O	ADP	O
deletion	O	NOUN	B
mapping	O	NOUN	I
cen	O	NOUN	I
-	O	PUNCT	O
DXS106	O	NOUN	B
-	O	PUNCT	O
DXS72	O	NOUN	B
-	O	PUNCT	O
TCD	O	PROPN	B
-	O	PUNCT	O
(	O	PUNCT	O
DXYS1	O	NOUN	B
/	O	SYM	O
DXYS23	O	NOUN	B
/	O	PUNCT	O
DXYS5	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
DXYS2	O	PROPN	B
-	O	PUNCT	O
(	O	PUNCT	O
DXYS12	O	NOUN	B
/	O	SYM	O
DXS3	O	PROPN	B
)	O	PUNCT	O
-	O	PUNCT	O
(	O	PUNCT	O
DXS17	O	NOUN	B
/	O	SYM	O
DXS101	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
Xqter	O	NOUN	B
.	O	PUNCT	O


Retroviral	O	ADJ	B
-	O	PUNCT	O
mediated	O	VERB	B
gene	O	NOUN	B
transfer	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
into	O	ADP	O
NIH	O	NOUN	B
3T3	O	NOUN	I
and	O	CCONJ	O
hepatoma	B-Disease	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
hepatic	I-Disease	ADJ	B
enzyme	I-Disease	NOUN	O
phenylalanine	I-Disease	NOUN	O
hydroxylase	I-Disease	NOUN	O
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
human	O	ADJ	B
PAH	O	NOUN	B
cDNA	O	NOUN	B
sequence	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
inserted	O	VERB	B
into	O	ADP	O
pzip	O	NOUN	B
-	O	PUNCT	O
neoSV	O	PROPN	B
(	O	PUNCT	O
X	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
retroviral	O	ADJ	B
vector	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
bacterial	O	ADJ	B
neo	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
recombinant	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
transfected	O	VERB	B
into	O	ADP	O
psi	O	NOUN	B
2	O	NUM	I
cells	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
provide	O	VERB	O
synthesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retroviral	O	ADJ	B
capsid	O	NOUN	O
.	O	PUNCT	O


Recombinant	O	ADJ	B
virus	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
culture	O	NOUN	B
medium	O	NOUN	I
of	O	ADP	O
the	O	DET	O
transfected	O	VERB	B
psi	O	NOUN	O
2	O	NUM	O
cells	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
transmitting	O	VERB	B
the	O	DET	O
human	O	ADJ	B
PAH	O	NOUN	B
gene	O	NOUN	O
into	O	ADP	O
mouse	O	NOUN	B
NIH	O	NOUN	B
3T3	O	NOUN	I
cells	O	NOUN	I
by	O	ADP	O
infection	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
stable	O	ADJ	B
incorporation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recombinant	O	ADJ	B
provirus	O	NOUN	I
.	O	PUNCT	O


Infected	O	ADJ	B
cells	O	NOUN	O
express	O	VERB	O
PAH	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
immunoreactive	O	ADJ	B
PAH	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
exhibit	O	VERB	O
pterin	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recombinant	O	ADJ	B
virus	O	NOUN	I
is	O	AUX	O
also	O	ADV	O
capable	O	ADJ	O
of	O	ADP	O
infecting	O	VERB	B
a	O	DET	O
mouse	O	NOUN	B
hepatoma	B-Disease	NOUN	B
cell	O	NOUN	B
line	O	NOUN	I
that	O	PRON	O
does	O	AUX	O
not	O	PART	O
normally	O	ADV	O
synthesize	O	VERB	B
PAH	O	NOUN	B
.	O	PUNCT	O


PAH	O	NOUN	B
activity	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
extracts	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
entire	O	ADJ	O
hydroxylation	O	NOUN	B
system	O	NOUN	I
is	O	AUX	O
reconstituted	O	VERB	B
in	O	ADP	O
the	O	DET	O
hepatoma	B-Disease	NOUN	B
cells	O	NOUN	I
infected	O	VERB	B
with	O	ADP	O
the	O	DET	O
recombinant	O	ADJ	B
viruses	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
recombinant	O	ADJ	B
viruses	O	NOUN	I
containing	O	VERB	O
human	O	ADJ	B
PAH	O	NOUN	B
cDNA	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
means	O	NOUN	O
for	O	ADP	O
introducing	O	VERB	O
functional	O	ADJ	B
PAH	O	NOUN	B
into	O	ADP	O
mammalian	O	ADJ	B
cells	O	NOUN	O
of	O	ADP	O
hepatic	O	ADJ	B
origin	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
potentially	O	ADV	O
be	O	AUX	O
introduced	O	VERB	O
into	O	ADP	O
whole	O	ADJ	O
animals	O	NOUN	B
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
somatic	O	ADJ	B
gene	O	NOUN	I
therapy	O	NOUN	I
for	O	ADP	O
PKU	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Estimation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
male	O	NOUN	B
to	O	PART	O
female	O	ADJ	B
ratio	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
rates	O	NOUN	B
from	O	ADP	O
the	O	DET	O
segregation	O	NOUN	B
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
chromosomal	O	ADJ	B
DNA	O	NOUN	O
haplotypes	O	NOUN	O
in	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	O
procedure	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
male	O	NOUN	B
to	O	PART	O
female	O	ADJ	B
mutation	O	NOUN	B
rates	O	NOUN	O
for	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


X	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
restriction	O	NOUN	B
fragment	O	NOUN	O
length	O	NOUN	O
polymorphisms	O	NOUN	B
are	O	AUX	O
used	O	VERB	O
to	O	PART	O
establish	O	VERB	O
DNA	O	NOUN	B
haplotypes	O	NOUN	I
in	O	ADP	O
three	O	NUM	O
-	O	PUNCT	O
generation	O	NOUN	B
DMD	B-Disease	PROPN	B
families	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
inherited	O	VERB	B
their	O	PRON	O
maternal	O	ADJ	B
grandfathers	O	NOUN	O
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
rates	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
calculated	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
classical	O	ADJ	O
methods	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
proposed	O	VERB	O
procedure	O	NOUN	B
is	O	AUX	O
not	O	PART	O
restricted	O	ADJ	O
to	O	PART	O
sporadic	O	ADJ	B
or	O	CCONJ	O
familiar	O	ADJ	O
cases	O	NOUN	B
nor	O	CCONJ	O
is	O	AUX	O
any	O	DET	O
information	O	NOUN	B
on	O	ADP	O
the	O	DET	O
carrier	O	NOUN	B
status	O	NOUN	I
of	O	ADP	O
female	O	ADJ	B
relatives	O	NOUN	I
required	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Deletions	O	NOUN	B
of	O	ADP	O
a	O	DET	O
DNA	O	NOUN	B
sequence	O	NOUN	I
in	O	ADP	O
retinoblastomas	B-Disease	NOUN	B
and	O	CCONJ	O
mesenchymal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
:	O	PUNCT	O
organization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sequence	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
encoded	O	VERB	B
protein	O	NOUN	I
.	O	PUNCT	O


Retinoblastoma	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
childhood	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
that	O	PRON	O
can	O	AUX	O
arise	O	VERB	O
because	O	SCONJ	O
of	O	ADP	O
mutant	O	ADJ	B
alleles	O	NOUN	O
acquired	O	VERB	O
as	O	ADP	O
somatic	O	ADJ	B
or	O	CCONJ	O
germinal	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
carried	O	VERB	O
in	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
line	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
creating	O	VERB	O
these	O	DET	O
alleles	O	NOUN	B
act	O	VERB	O
by	O	ADP	O
inactivating	O	VERB	B
copies	O	NOUN	B
of	O	ADP	O
a	O	DET	O
recessive	O	ADJ	B
oncogene	O	NOUN	I
located	O	ADJ	O
within	O	ADP	O
band	O	NOUN	B
q14	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
13	O	NUM	I
and	O	CCONJ	O
termed	O	VERB	O
the	O	DET	O
RB1	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
reported	O	VERB	O
isolation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cDNA	O	NOUN	B
fragment	O	NOUN	O
that	O	PRON	O
recognizes	O	VERB	O
chromosomal	O	ADJ	B
sequences	O	NOUN	I
possessing	O	VERB	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
attributes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
gene	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
RB1	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
segment	O	NOUN	B
is	O	AUX	O
additionally	O	ADV	O
the	O	DET	O
target	O	NOUN	B
of	O	ADP	O
somatic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
mesenchymal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
having	O	VERB	O
no	O	DET	O
apparent	O	ADJ	O
predisposition	O	NOUN	B
to	O	PART	O
retinoblastoma	B-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	O
previous	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
tumors	B-Disease	NOUN	B
provide	O	VERB	O
additional	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
cloned	O	VERB	B
sequences	O	NOUN	B
are	O	AUX	O
representative	O	ADJ	O
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	B
target	O	NOUN	B
of	O	ADP	O
inactivation	O	NOUN	B
during	O	ADP	O
tumorigenesis	O	NOUN	B
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
this	O	DET	O
cDNA	O	NOUN	B
provides	O	VERB	O
little	O	ADJ	O
insight	O	NOUN	O
into	O	ADP	O
its	O	PRON	O
normal	O	ADJ	O
functional	O	ADJ	O
role	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
with	O	ADP	O
growth	O	NOUN	B
hormone	O	NOUN	I
inhibitors	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
controlled	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
therapeutic	O	ADJ	B
trial	O	NOUN	I
with	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
mazindol	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
growth	O	NOUN	B
hormone	O	NOUN	I
inhibitor	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
a	O	DET	O
pair	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
monozygotic	O	ADJ	B
twins	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
rationale	O	NOUN	O
for	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
based	O	VERB	O
on	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
(	O	PUNCT	O
reported	O	VERB	O
previously	O	ADV	O
)	O	PUNCT	O
affected	O	VERB	B
simultaneously	O	ADV	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
and	O	CCONJ	O
growth	B-Disease	NOUN	B
hormone	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
GH	I-Disease	NOUN	O
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
,	O	PUNCT	O
who	O	PRON	O
is	O	AUX	O
showing	O	VERB	O
a	O	DET	O
benign	O	ADJ	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
dystrophic	B-Disease	ADJ	B
process	I-Disease	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
still	O	ADV	O
walking	O	VERB	B
at	O	ADP	O
18	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
twins	O	NOUN	B
received	O	VERB	O
2	O	NUM	O
mg	O	NOUN	O
of	O	ADP	O
mazindol	O	NOUN	B
daily	O	ADV	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
received	O	VERB	O
a	O	DET	O
placebo	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
assessment	O	NOUN	B
,	O	PUNCT	O
repeated	O	VERB	O
every	O	DET	O
2	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
included	O	VERB	O
weight	O	NOUN	B
and	O	CCONJ	O
height	O	NOUN	B
measurements	O	NOUN	I
,	O	PUNCT	O
functional	O	ADJ	B
and	O	CCONJ	O
motor	O	NOUN	B
ability	O	NOUN	I
tests	O	NOUN	I
,	O	PUNCT	O
ergometry	O	NOUN	B
and	O	CCONJ	O
determinations	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
enzymes	O	NOUN	I
and	O	CCONJ	O
GH	O	NOUN	B
levels	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
trial	O	NOUN	B
the	O	DET	O
code	O	NOUN	B
was	O	AUX	O
broken	O	VERB	O
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
seen	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
twin	O	NOUN	B
under	O	ADP	O
placebo	O	ADJ	B
treatment	O	NOUN	B
was	O	AUX	O
strikingly	O	ADV	O
worse	O	ADJ	O
than	O	ADP	O
his	O	PRON	O
brother	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
whose	O	DET	O
condition	O	NOUN	B
was	O	AUX	O
practically	O	ADV	O
arrested	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
strongly	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
GH	O	NOUN	B
inhibitor	O	NOUN	I
is	O	AUX	O
beneficial	O	ADJ	O
for	O	ADP	O
DMD	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
and	O	CCONJ	O
localization	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
locus	O	NOUN	B
by	O	ADP	O
ribonuclease	O	NOUN	B
A	O	NOUN	I
cleavage	O	NOUN	B
.	O	PUNCT	O


Many	O	ADJ	O
mutations	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
human	O	ADJ	B
disease	O	NOUN	I
are	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
single	O	ADJ	O
DNA	O	NOUN	B
base	O	NOUN	I
pair	O	NOUN	I
changes	O	NOUN	B
that	O	PRON	O
cannot	O	VERB	O
be	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
Southern	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
has	O	AUX	O
prompted	O	VERB	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
alternative	O	ADJ	B
assays	O	NOUN	I
for	O	ADP	O
point	O	NOUN	O
mutation	O	NOUN	B
detection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recently	O	ADV	O
described	O	VERB	O
ribonuclease	O	NOUN	B
A	O	NOUN	I
cleavage	O	NOUN	B
procedure	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
polyuridylic	O	ADJ	B
acid	O	NOUN	I
-	O	PUNCT	O
paper	O	NOUN	B
affinity	O	NOUN	B
chromatography	O	NOUN	I
step	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
the	O	DET	O
mutational	O	ADJ	B
lesions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
hypoxanthine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
)	O	PUNCT	O
messenger	O	NOUN	B
RNAs	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Distinctive	O	ADJ	B
ribonuclease	O	NOUN	I
A	O	NOUN	I
cleavage	O	NOUN	B
patterns	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
messenger	O	NOUN	B
RNA	O	NOUN	I
from	O	ADP	O
5	O	NUM	O
of	O	ADP	O
14	O	NUM	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
chosen	O	VERB	O
because	O	SCONJ	O
no	O	DET	O
HPRT	O	NOUN	B
Southern	O	PROPN	B
or	O	CCONJ	O
Northern	O	NOUN	B
blotting	O	NOUN	I
pattern	O	NOUN	O
changes	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
now	O	ADV	O
allows	O	VERB	O
HPRT	O	NOUN	B
mutation	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
50	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
of	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
polyuridylic	O	ADJ	B
acid	O	NOUN	I
-	O	PUNCT	O
paper	O	NOUN	B
affinity	O	NOUN	B
procedure	O	NOUN	I
provides	O	VERB	O
a	O	DET	O
general	O	ADJ	B
method	O	NOUN	I
for	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
abundance	O	NOUN	O
messenger	O	NOUN	O
RNAs	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
hereditary	B-Disease	ADJ	B
non	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
spherocytic	I-Disease	ADJ	B
hemolytic	I-Disease	ADJ	B
anemia	I-Disease	NOUN	I
:	O	PUNCT	O
G6PD	O	NOUN	B
Wayne	O	PROPN	I
and	O	CCONJ	O
G6PD	O	NOUN	B
Huron	O	PROPN	B
.	O	PUNCT	O


Two	O	NUM	O
new	O	ADJ	O
deficient	O	ADJ	B
variants	O	NOUN	B
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
causing	O	VERB	O
hereditary	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
HNSHA	B-Disease	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Both	O	DET	O
of	O	ADP	O
these	O	DET	O
are	O	AUX	O
unique	O	ADJ	B
and	O	CCONJ	O
they	O	PRON	O
have	O	AUX	O
been	O	AUX	O
named	O	VERB	O
G6PD	O	NOUN	B
Wayne	O	PROPN	I
and	O	CCONJ	O
G6PD	O	NOUN	B
Huron	O	PROPN	B
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
G6PD	O	NOUN	B
Wayne	O	PROPN	I
underwent	O	VERB	O
splenectomy	O	NOUN	B
and	O	CCONJ	O
no	O	DET	O
objective	O	ADJ	O
improvement	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
G6PD	O	NOUN	B
Huron	O	PROPN	I
were	O	AUX	O
under	O	ADP	O
medical	O	ADJ	B
observation	O	NOUN	I
for	O	ADP	O
a	O	DET	O
considerable	O	ADJ	O
period	O	NOUN	O
of	O	ADP	O
time	O	NOUN	B
without	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
being	O	AUX	O
entertained	O	VERB	O
because	O	SCONJ	O
the	O	DET	O
family	O	NOUN	B
was	O	AUX	O
of	O	ADP	O
Northern	O	ADJ	B
European	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
sporadic	O	ADJ	B
variants	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
causing	O	VERB	O
HNSHA	B-Disease	NOUN	B
show	O	VERB	O
no	O	DET	O
special	O	ADJ	O
racial	O	ADJ	B
predilection	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
should	O	AUX	O
always	O	ADV	O
be	O	AUX	O
considered	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Sialophorin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
surface	O	NOUN	B
sialoglycoprotein	O	NOUN	B
defective	O	ADJ	B
in	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
T	O	NOUN	B
lymphocyte	O	NOUN	I
proliferation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mAb	O	NOUN	B
L10	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
distribution	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
sialophorin	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
heavily	O	ADV	O
glycosylated	O	VERB	B
surface	O	NOUN	O
molecule	O	NOUN	O
that	O	PRON	O
is	O	AUX	O
deficient	O	ADJ	B
/	O	PUNCT	O
defective	O	ADJ	B
in	O	ADP	O
lymphocytes	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
immunodeficiency	I-Disease	NOUN	B
Wiskott	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Dual	O	ADJ	B
-	O	PUNCT	O
parameter	O	NOUN	B
FACS	O	NOUN	B
analysis	O	NOUN	O
indicated	O	VERB	O
that	O	SCONJ	O
sialophorin	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
on	O	ADP	O
CD4	O	NOUN	B
+	O	CCONJ	O
and	O	CCONJ	O
CD8	O	NOUN	B
+	O	CCONJ	I
lymphocytes	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
a	O	DET	O
subpopulation	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
B	O	NOUN	I
lymphocytes	O	NOUN	I
,	O	PUNCT	O
on	O	ADP	O
all	O	DET	O
thymocytes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
a	O	DET	O
subpopulation	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
marrow	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


Functional	O	ADJ	B
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
L10	O	NOUN	B
mAb	O	NOUN	B
stimulates	O	VERB	B
the	O	DET	O
proliferation	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
T	O	NOUN	I
lymphocytes	O	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
stimulation	O	NOUN	B
of	O	ADP	O
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
thymidine	O	NOUN	B
incorporation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
time	O	NOUN	B
course	O	NOUN	I
and	O	CCONJ	O
magnitude	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
[	O	PUNCT	O
3H	O	NOUN	B
]	O	PUNCT	O
thymidine	O	NOUN	B
incorporation	O	NOUN	B
by	O	ADP	O
T	O	NOUN	B
lymphocytes	O	NOUN	I
in	O	ADP	O
response	O	NOUN	O
to	O	PART	O
L10	O	NOUN	B
mAb	O	NOUN	B
paralleled	O	VERB	O
that	O	SCONJ	O
induced	O	VERB	B
by	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
CD3	O	NOUN	B
mAb	O	NOUN	B
.	O	PUNCT	O


Effective	O	ADJ	B
stimulation	O	NOUN	B
was	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
monocytes	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
Fc	O	NOUN	B
portion	O	NOUN	I
of	O	ADP	O
L10	O	NOUN	B
mAb	O	NOUN	B
.	O	PUNCT	O


Stimulation	O	NOUN	B
of	O	ADP	O
lymphocytes	O	NOUN	B
by	O	ADP	O
L10	O	NOUN	B
,	O	PUNCT	O
like	O	ADP	O
stimulation	O	NOUN	B
by	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
CD3	O	NOUN	B
mAb	O	NOUN	B
,	O	PUNCT	O
involves	O	VERB	O
increased	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
4F2	O	NOUN	B
,	O	PUNCT	O
HLA	O	NOUN	B
-	O	PUNCT	O
DR	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
IL	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
R	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
sialophorin	O	NOUN	B
functions	O	NOUN	B
in	O	ADP	O
T	O	NOUN	B
cell	O	NOUN	I
activation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Hypopigmentation	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Cutaneous	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
ocular	I-Disease	ADJ	B
pigmentation	I-Disease	NOUN	O
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
29	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Criteria	O	NOUN	B
for	O	ADP	O
hypopigmentation	B-Disease	NOUN	B
included	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
type	O	NOUN	B
I	O	NUM	I
or	O	CCONJ	O
II	O	NUM	B
skin	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
lightest	O	ADJ	B
skin	O	NOUN	B
type	O	NOUN	I
in	O	ADP	O
the	O	DET	O
family	O	NOUN	B
by	O	ADP	O
history	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
iris	O	ADJ	B
translucency	O	NOUN	I
on	O	ADP	O
globe	O	NOUN	B
transillumination	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
these	O	DET	O
criteria	O	NOUN	B
,	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
individuals	O	NOUN	B
were	O	AUX	O
hypopigmented	B-Disease	VERB	B
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
hypopigmentation	B-Disease	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
a	O	DET	O
small	O	ADJ	B
interstitial	O	ADJ	I
deletion	O	NOUN	I
on	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
long	O	ADJ	O
arm	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
15	O	NUM	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
deletion	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
found	O	VERB	O
in	O	ADP	O
individuals	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
meet	O	VERB	O
the	O	DET	O
full	O	ADJ	O
criteria	O	NOUN	B
for	O	ADP	O
hypopigmentation	B-Disease	NOUN	B
.	O	PUNCT	O


Hairbulb	O	NOUN	B
tyrosinase	O	NOUN	I
activity	O	NOUN	B
and	O	CCONJ	O
glutathione	O	NOUN	B
content	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
urine	O	NOUN	B
cysteinyldopa	O	ADJ	B
excretion	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
low	O	ADJ	B
in	O	ADP	O
PWS	B-Disease	NOUN	B
individuals	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
hypopigmentation	B-Disease	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
separate	O	VERB	O
these	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
hypopigmentation	B-Disease	NOUN	B
is	O	AUX	O
found	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
PWS	B-Disease	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
hypopigmentation	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
15	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
the	O	DET	O
hypopigmentation	B-Disease	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


Phenotype	O	NOUN	B
heterogeneity	O	NOUN	B
among	O	ADP	O
hemizygotes	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
biochemically	O	ADV	I
screened	O	VERB	I
for	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
two	O	NUM	O
clinically	O	ADV	B
,	O	PUNCT	O
neurologically	O	ADV	B
normal	O	ADJ	O
relatives	O	NOUN	O
of	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
they	O	PRON	O
were	O	AUX	O
found	O	VERB	O
repeatedly	O	ADV	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
biochemical	O	ADJ	B
defect	O	NOUN	B
of	O	ADP	O
an	O	DET	O
ALD	B-Disease	NOUN	B
hemizygote	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
assay	O	NOUN	B
consisted	O	VERB	O
in	O	ADP	O
the	O	DET	O
determination	O	NOUN	B
of	O	ADP	O
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
in	O	ADP	O
lyophilized	O	ADJ	B
and	O	CCONJ	O
reconstituted	O	VERB	B
plasma	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
neurologic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
leukodystrophy	B-Disease	NOUN	B
or	O	CCONJ	O
myeloneuropathy	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
these	O	DET	O
hemizygotes	O	NOUN	B
,	O	PUNCT	O
adrenocortical	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
provoking	O	VERB	O
compensatory	O	ADJ	B
high	O	ADJ	O
ACTH	O	NOUN	B
release	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
both	O	DET	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
taken	O	VERB	O
into	O	ADP	O
consideration	O	NOUN	O
when	O	SCONJ	O
counseling	O	NOUN	B
families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
clinically	O	ADV	B
expressed	O	VERB	B
ALD	B-Disease	NOUN	B
are	O	AUX	O
represented	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
generations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mapping	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cDNA	O	NOUN	B
from	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Duchenne	I-Disease	NOUN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
to	O	PART	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
discovery	O	NOUN	B
of	O	ADP	O
sequences	O	NOUN	B
at	O	ADP	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
humans	O	NOUN	B
has	O	AUX	O
opened	O	VERB	O
up	O	ADP	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
detailed	O	ADJ	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
genes	O	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
related	O	ADJ	O
mammalian	O	ADJ	B
species	O	NOUN	B
.	O	PUNCT	O


Until	O	ADP	O
relatively	O	ADV	O
recently	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
obvious	O	ADJ	O
mouse	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
this	O	DET	O
genetic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
therapeutic	O	ADJ	B
strategies	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
-	O	PUNCT	O
linked	O	VERB	B
mutant	O	ADJ	B
showing	O	VERB	O
muscular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
mdx	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
provided	O	VERB	O
a	O	DET	O
candidate	O	NOUN	O
mouse	O	NOUN	B
genetic	O	ADJ	B
homologue	O	NOUN	I
to	O	PART	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
;	O	PUNCT	O
the	O	DET	O
relatively	O	ADV	O
mild	O	ADJ	B
pathological	O	ADJ	B
features	O	NOUN	O
of	O	ADP	O
mdx	O	NOUN	B
suggest	O	VERB	O
it	O	PRON	O
may	O	AUX	O
have	O	AUX	O
more	O	ADJ	O
in	O	ADP	O
common	O	ADJ	O
with	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
type	O	NOUN	I
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
human	O	ADJ	B
locus	O	NOUN	O
,	O	PUNCT	O
however	O	ADV	O
.	O	PUNCT	O


But	O	CCONJ	O
the	O	DET	O
close	O	ADJ	O
genetic	O	ADJ	B
linkage	O	NOUN	I
of	O	ADP	O
mdx	O	NOUN	B
to	O	PART	O
G6PD	O	NOUN	B
and	O	CCONJ	O
Hprt	O	NOUN	B
on	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
coupled	O	VERB	B
with	O	ADP	O
its	O	PRON	O
comparatively	O	ADV	O
mild	O	ADJ	O
pathology	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mdx	O	NOUN	B
mutation	O	NOUN	B
may	O	AUX	O
instead	O	ADV	O
correspond	O	VERB	O
to	O	ADP	O
Emery	B-Disease	PROPN	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
which	O	DET	O
itself	O	PRON	O
is	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
DNA	O	NOUN	B
markers	O	NOUN	I
at	O	ADP	O
Xq28	O	NOUN	B
-	O	PUNCT	O
qter	O	NOUN	B
in	O	ADP	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
on	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
an	O	DET	O
interspecific	O	ADJ	B
mouse	O	NOUN	O
domesticus	O	X	O
/	O	SYM	O
spretus	O	NOUN	B
cross	O	NOUN	O
,	O	PUNCT	O
segregating	O	VERB	B
for	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
markers	O	NOUN	B
on	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
positioned	O	VERB	O
on	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
sequences	O	NOUN	O
homologous	O	ADJ	O
to	O	PART	O
a	O	DET	O
DMD	B-Disease	NOUN	B
cDNA	O	NOUN	B
clone	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
sequences	O	NOUN	B
map	O	VERB	I
provocatively	O	ADV	O
close	O	ADV	O
to	O	PART	O
the	O	DET	O
mdx	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
unexpectedly	O	ADV	O
distant	O	ADJ	B
from	O	ADP	O
sparse	O	ADJ	O
fur	O	NOUN	O
,	O	PUNCT	O
spf	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
OTC	O	PROPN	B
(	O	PUNCT	O
ornithine	O	NOUN	B
transcarbamylase	O	NOUN	I
)	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	ADP	O
DMD	B-Disease	PROPN	B
on	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
region	O	NOUN	B
homologous	O	ADJ	B
to	O	PART	O
the	O	DET	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
on	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


Recent	O	ADJ	O
progress	O	NOUN	B
has	O	AUX	O
resulted	O	VERB	O
in	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
Duchenne	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
the	I-Disease	DET	O
milder	I-Disease	ADJ	B
Becker	I-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophies	I-Disease	NOUN	I
being	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
has	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
itself	O	PRON	O
extends	O	VERB	O
over	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
to	O	PART	O
2	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
kilobases	O	NOUN	B
(	O	PUNCT	O
kb	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
how	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
affect	O	VERB	O
muscle	O	NOUN	B
development	O	NOUN	I
and	O	CCONJ	O
integrity	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
would	O	AUX	O
be	O	AUX	O
of	O	ADP	O
interest	O	NOUN	O
to	O	PART	O
have	O	AUX	O
available	O	ADJ	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mouse	O	NOUN	B
mdx	O	NOUN	B
mutation	O	NOUN	B
affects	O	VERB	O
muscle	O	NOUN	B
and	O	CCONJ	O
confers	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
dystrophic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
clear	O	ADJ	O
whether	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
equivalent	O	ADJ	O
to	O	ADP	O
Duchenne	B-Disease	PROPN	B
/	I-Disease	PUNCT	O
Becker	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
two	O	NUM	O
sequences	O	NOUN	B
from	O	ADP	O
the	O	DET	O
human	O	ADJ	B
Duchenne	B-Disease	NOUN	I
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
that	O	PRON	O
cross	O	NOUN	B
-	O	PUNCT	O
hybridize	O	NOUN	B
to	O	PART	O
mouse	O	NOUN	B
X	O	NOUN	O
-	O	PUNCT	O
linked	O	VERB	B
sequences	O	NOUN	B
to	O	PART	O
localize	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
homologous	O	ADJ	I
to	O	PART	O
DMD	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
sequences	O	NOUN	B
map	O	VERB	I
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
centimorgan	O	NOUN	B
lying	O	VERB	O
between	O	ADP	O
the	O	DET	O
Tabby	O	NOUN	B
(	O	PUNCT	O
Ta	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
St14	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
DxPas8	O	NOUN	B
)	O	PUNCT	O
loci	O	NOUN	O
,	O	PUNCT	O
close	O	ADV	O
to	O	PART	O
the	O	DET	O
phosphorylase	O	NOUN	B
b	O	NOUN	I
kinase	O	NOUN	I
locus	O	NOUN	I
(	O	PUNCT	O
Phk	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
analogy	O	NOUN	B
with	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
region	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
around	O	ADP	O
the	O	DET	O
G6pd	O	NOUN	B
and	O	CCONJ	O
St14	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
loci	O	NOUN	B
may	O	AUX	O
contain	O	VERB	O
two	O	NUM	O
genes	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
distinct	O	ADJ	O
human	O	ADJ	B
myopathies	B-Disease	NOUN	B
Emery	B-Disease	PROPN	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
which	O	DET	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
St14	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
man	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
DMD	B-Disease	NOUN	B
homologue	O	NOUN	B
described	O	VERB	O
here	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


GT	O	NOUN	B
to	O	PART	O
AT	O	ADP	B
transition	O	NOUN	B
at	O	ADP	O
a	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
causes	O	VERB	O
skipping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
preceding	O	VERB	O
exon	O	NOUN	B
in	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


Classical	B-Disease	ADJ	B
Phenylketonuria	I-Disease	NOUN	I
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
human	I-Disease	ADJ	B
genetic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
isolated	O	VERB	B
several	O	ADJ	O
mutant	O	ADJ	B
PAH	O	NOUN	B
cDNA	O	NOUN	B
clones	O	NOUN	I
from	O	ADP	O
a	O	DET	O
PKU	B-Disease	NOUN	B
carrier	O	NOUN	B
individual	O	NOUN	B
and	O	CCONJ	O
showed	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
contained	O	VERB	O
an	O	DET	O
internal	O	ADJ	B
116	O	NUM	I
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
,	O	PUNCT	O
corresponding	O	VERB	O
precisely	O	ADV	O
to	O	PART	O
exon	O	NOUN	B
12	O	NUM	O
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
chromosomal	O	ADJ	B
PAH	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
causes	O	VERB	O
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
truncated	O	VERB	B
protein	O	NOUN	I
lacking	O	VERB	O
the	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
52	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
.	O	PUNCT	O


Gene	O	NOUN	B
transfer	O	NOUN	I
and	O	CCONJ	O
expression	O	NOUN	B
studies	O	NOUN	I
using	O	VERB	O
the	O	DET	O
mutant	O	ADJ	B
PAH	O	NOUN	B
cDNA	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deletion	O	NOUN	B
abolishes	O	VERB	O
PAH	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
protein	O	NOUN	B
instability	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mutant	O	ADJ	B
chromosomal	O	ADJ	O
PAH	O	NOUN	O
gene	O	NOUN	O
was	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
this	O	DET	O
individual	O	NOUN	B
and	O	CCONJ	O
shown	O	VERB	O
to	O	PART	O
contain	O	VERB	O
a	O	DET	O
GT	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
greater	O	ADJ	B
than	O	ADP	O
AT	O	ADP	B
substitution	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
the	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
liver	O	NOUN	B
is	O	AUX	O
the	O	DET	O
skipping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
preceding	O	VERB	O
exon	O	NOUN	B
during	O	ADP	O
RNA	O	NOUN	B
splicing	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Conservation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
transcript	O	NOUN	I
from	O	ADP	O
human	O	ADJ	B
fetal	O	ADJ	O
skeletal	O	ADJ	O
muscle	O	NOUN	O
and	O	CCONJ	O
mouse	O	NOUN	B
adult	O	ADJ	I
heart	O	NOUN	B
was	O	AUX	O
sequenced	O	VERB	B
,	O	PUNCT	O
representing	O	VERB	O
approximately	O	ADV	O
25	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	NOUN	O
,	O	PUNCT	O
14	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
DMD	B-Disease	NOUN	B
transcript	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nucleic	O	ADJ	B
acid	O	NOUN	I
and	O	CCONJ	O
predicted	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
sequences	O	NOUN	I
from	O	ADP	O
the	O	DET	O
two	O	NUM	O
species	O	NOUN	B
are	O	AUX	O
nearly	O	ADV	O
90	O	NUM	O
percent	O	NOUN	O
homologous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
predicted	O	VERB	B
from	O	ADP	O
this	O	DET	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protein	O	NOUN	B
product	O	NOUN	I
might	O	AUX	O
serve	O	VERB	O
a	O	DET	O
structural	O	ADJ	B
role	O	NOUN	O
in	O	ADP	O
muscle	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
abundance	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
distribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
messenger	O	NOUN	B
RNA	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
DMD	B-Disease	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
not	O	PART	O
nebulin	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Familial	O	ADJ	B
Prader	B-Disease	PROPN	I
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
with	O	ADP	O
apparently	O	ADV	O
normal	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
4	O	NUM	O
sibs	O	NOUN	B
(	O	PUNCT	O
2F	O	NOUN	B
,	O	PUNCT	O
2M	O	NOUN	B
)	O	PUNCT	O
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Diagnosis	O	NOUN	B
was	O	AUX	O
made	O	VERB	O
clinically	O	ADV	B
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
history	O	NOUN	B
,	O	PUNCT	O
behavior	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
physical	O	ADJ	B
findings	O	NOUN	I
in	O	ADP	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
sibs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
child	O	NOUN	B
had	O	AUX	O
died	O	VERB	B
at	O	ADP	O
age	O	NOUN	B
10	O	NUM	O
months	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
findings	O	NOUN	I
typical	O	ADJ	O
of	O	ADP	O
first	O	ADJ	O
phase	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
studies	O	NOUN	I
on	O	ADP	O
the	O	DET	O
parents	O	NOUN	B
and	O	CCONJ	O
surviving	O	VERB	B
sibs	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
implications	O	NOUN	O
of	O	ADP	O
this	O	DET	O
unusual	O	ADJ	O
familial	O	ADJ	B
occurrence	O	NOUN	B
for	O	ADP	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
PWS	B-Disease	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Nebulin	O	NOUN	B
and	O	CCONJ	O
titin	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
appears	O	VERB	O
normal	O	ADJ	O
.	O	PUNCT	O


Monoclonal	O	ADJ	B
antibodies	O	NOUN	I
which	O	DET	O
recognize	O	VERB	O
different	O	ADJ	O
epitopes	O	NOUN	B
on	O	ADP	O
either	O	CCONJ	O
titin	O	NOUN	B
or	O	CCONJ	O
nebulin	O	NOUN	B
show	O	VERB	O
normal	O	ADJ	B
staining	O	NOUN	I
patterns	O	NOUN	O
on	O	ADP	O
frozen	O	ADJ	B
sections	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
muscle	O	NOUN	B
biopsies	O	NOUN	I
of	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Gel	O	NOUN	B
electrophoresis	O	NOUN	I
and	O	CCONJ	O
immunoblotting	O	NOUN	B
performed	O	VERB	O
on	O	ADP	O
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
muscle	O	NOUN	B
biopsies	O	NOUN	I
show	O	VERB	O
the	O	DET	O
normal	O	ADJ	B
pattern	O	NOUN	I
of	O	ADP	O
titin	O	NOUN	B
and	O	CCONJ	O
nebulin	O	NOUN	B
polypeptides	O	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
donor	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
biopsies	O	NOUN	B
has	O	AUX	O
a	O	DET	O
large	O	ADJ	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
,	O	PUNCT	O
our	O	PRON	O
results	O	NOUN	B
argue	O	VERB	O
against	O	ADP	O
the	O	DET	O
recent	O	ADJ	O
proposal	O	NOUN	B
that	O	SCONJ	O
nebulin	O	NOUN	B
is	O	AUX	O
the	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
DMD	B-Disease	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Heterozygous	B-Disease	ADJ	B
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
angioedema	B-Disease	NOUN	B
,	O	PUNCT	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
,	O	PUNCT	O
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
angioedema	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
heterozygous	O	ADJ	B
complement	B-Disease	NOUN	O
factor	I-Disease	NOUN	O
2	I-Disease	NUM	O
(	I-Disease	PUNCT	O
C2	I-Disease	NOUN	O
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
significance	O	NOUN	B
of	O	ADP	O
this	O	DET	O
association	O	NOUN	B
is	O	AUX	O
controversial	O	ADJ	O
,	O	PUNCT	O
though	O	SCONJ	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
with	O	ADP	O
certain	O	ADJ	O
histocompatibility	O	NOUN	B
antigens	O	NOUN	I
suggests	O	VERB	O
possible	O	ADJ	O
linkage	O	NOUN	B
to	O	PART	O
immune	O	ADJ	B
response	O	NOUN	I
genes	O	NOUN	I
.	O	PUNCT	O


To	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
this	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
heterozygous	O	ADJ	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	O
this	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
autoimmune	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
discuss	O	VERB	O
the	O	DET	O
aetiological	O	ADJ	B
implications	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
an	O	DET	O
inherited	O	VERB	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
third	I-Disease	ADJ	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
in	O	ADP	O
Brittany	O	ADJ	B
spaniel	O	NOUN	I
dogs	O	NOUN	I
.	O	PUNCT	O


Genetically	O	ADV	B
determined	O	VERB	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Brittany	O	ADJ	B
spaniel	O	NOUN	I
dogs	O	NOUN	I
shares	O	VERB	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
biochemical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
characteristics	O	NOUN	I
with	O	ADP	O
the	O	DET	O
human	O	ADJ	B
disorder	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
null	O	ADJ	B
gene	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
allelic	O	ADJ	B
to	O	PART	O
the	O	DET	O
structural	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
C3	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
major	O	ADJ	O
histocompatibility	O	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
used	O	VERB	O
allotype	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
canine	O	ADJ	B
C3	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
these	O	DET	O
dogs	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
a	O	DET	O
null	O	ADJ	B
gene	O	NOUN	I
allelic	O	ADJ	I
to	O	PART	O
the	O	DET	O
structural	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
C3	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
preliminary	O	ADJ	B
pedigree	O	NOUN	B
analysis	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
canine	O	ADJ	B
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
apparently	O	ADV	O
not	O	PART	O
closely	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
major	O	ADJ	O
histocompatibility	O	NOUN	B
complex	O	NOUN	I
of	O	ADP	O
the	O	DET	O
dog	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Brittany	O	NOUN	B
spaniel	O	NOUN	I
dogs	O	NOUN	O
not	O	PART	O
only	O	ADV	O
shares	O	NOUN	O
biochemical	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
features	O	NOUN	I
with	O	ADP	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
shares	O	VERB	O
some	O	DET	O
genetic	O	ADJ	B
characteristics	O	NOUN	I
with	O	ADP	O
the	O	DET	O
human	O	ADJ	B
disorder	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Gene	O	NOUN	B
transfer	O	NOUN	I
and	O	CCONJ	O
expression	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
phenylalanine	O	NOUN	O
hydroxylase	O	NOUN	O
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
enzyme	I-Disease	NOUN	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
complementary	O	ADJ	O
DNA	O	NOUN	O
clone	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
PAH	O	NOUN	B
was	O	AUX	O
inserted	O	VERB	O
into	O	ADP	O
a	O	DET	O
eukaryotic	O	ADJ	B
expression	O	NOUN	I
vector	O	NOUN	I
and	O	CCONJ	O
transferred	O	VERB	B
into	O	ADP	O
mouse	O	NOUN	B
NIH3T3	O	NOUN	B
cells	O	NOUN	I
which	O	DET	O
do	O	AUX	O
not	O	PART	O
normally	O	ADV	O
express	O	VERB	O
PAH	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
transformed	O	VERB	O
mouse	O	NOUN	B
cells	O	NOUN	I
expressed	O	VERB	B
PAH	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
,	O	PUNCT	O
immunoreactive	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
human	O	ADJ	B
liver	O	NOUN	O
products	O	NOUN	O
,	O	PUNCT	O
demonstrating	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
single	O	ADJ	O
gene	O	NOUN	B
contains	O	VERB	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
necessary	O	ADJ	O
genetic	O	ADJ	B
information	O	NOUN	I
to	O	PART	O
code	O	VERB	B
for	O	ADP	O
functional	O	ADJ	B
PAH	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
PAH	O	NOUN	B
probe	O	NOUN	O
in	O	ADP	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
and	O	CCONJ	O
detection	O	NOUN	B
of	O	ADP	O
carriers	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
provide	O	VERB	O
new	O	ADJ	O
opportunities	O	NOUN	B
for	O	ADP	O
the	O	DET	O
biochemical	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
mutant	O	ADJ	B
enzymes	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
investigation	O	NOUN	B
of	O	ADP	O
alternative	O	ADJ	B
genetic	O	ADJ	B
therapies	O	NOUN	I
for	O	ADP	O
PKU	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Regional	O	ADJ	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
phenylketonuria	B-Disease	NOUN	B
locus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
genome	O	NOUN	B
.	O	PUNCT	O


Phenylketonuria	B-Disease	NOUN	B
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
of	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
metabolism	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
hepatic	I-Disease	ADJ	B
enzyme	I-Disease	NOUN	O
phenylalanine	I-Disease	NOUN	O
hydroxylase	I-Disease	NOUN	O
(	O	PUNCT	O
PAH	O	NOUN	B
;	O	PUNCT	O
phenylalanine	O	NOUN	B
4	O	NUM	I
-	O	PUNCT	O
monooxygenase	O	NOUN	B
,	O	PUNCT	O
EC	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
cDNA	O	NOUN	B
clone	O	NOUN	O
for	O	ADP	O
human	O	ADJ	B
PAH	O	NOUN	B
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
assign	O	VERB	O
the	O	DET	O
corresponding	O	ADJ	O
gene	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	O
12	O	NUM	O
.	O	PUNCT	O


To	O	PART	O
define	O	VERB	O
the	O	DET	O
regional	O	ADJ	B
map	O	NOUN	I
position	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
12	O	NUM	I
,	O	PUNCT	O
DNA	O	NOUN	B
was	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
human	O	ADJ	B
-	O	PUNCT	O
hamster	O	NOUN	B
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
with	O	ADP	O
various	O	ADJ	O
deletions	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
12	O	NUM	O
and	O	CCONJ	O
was	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
using	O	VERB	O
the	O	DET	O
human	O	ADJ	B
cDNA	O	NOUN	B
PAH	O	NOUN	B
clone	O	NOUN	B
as	O	ADP	O
a	O	DET	O
hybridization	O	NOUN	B
probe	O	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
detailed	O	ADJ	O
biochemical	O	ADJ	B
and	O	CCONJ	O
cytogenetic	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hybrid	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
region	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
12	O	NUM	O
containing	O	VERB	O
the	O	DET	O
human	O	ADJ	B
PAH	O	NOUN	B
gene	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
12q14	O	NOUN	O
.	O	PUNCT	O


3	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
qter	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PAH	O	NOUN	B
map	O	NOUN	B
position	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
12	O	NUM	I
was	O	AUX	O
further	O	ADV	O
localized	O	VERB	B
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
of	O	ADP	O
125I	O	NOUN	B
-	O	PUNCT	O
labeled	O	VERB	B
human	O	ADJ	B
PAH	O	NOUN	B
cDNA	O	NOUN	B
to	O	PART	O
chromosomes	O	NOUN	B
prepared	O	VERB	O
from	O	ADP	O
a	O	DET	O
human	O	ADJ	B
lymphoblastoid	O	ADJ	O
cell	O	NOUN	O
line	O	NOUN	O
.	O	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
these	O	DET	O
experiments	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
region	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
12	O	NUM	O
containing	O	VERB	O
the	O	DET	O
PAH	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
PKU	B-Disease	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
man	O	NOUN	B
is	O	AUX	O
12q22	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
-	O	PUNCT	O
12q24	O	NOUN	O
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
not	O	PART	O
only	O	ADV	O
provide	O	VERB	O
a	O	DET	O
regionalized	O	ADJ	B
map	O	NOUN	I
position	O	NOUN	O
for	O	ADP	O
a	O	DET	O
major	O	ADJ	O
human	O	ADJ	B
disease	O	NOUN	O
locus	O	NOUN	O
but	O	CCONJ	O
also	O	ADV	O
can	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
reference	O	NOUN	O
point	O	NOUN	O
for	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
other	O	ADJ	O
DNA	O	NOUN	B
markers	O	NOUN	I
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
12	O	NUM	O


Heterogeneity	O	NOUN	B
of	O	ADP	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
von	I-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
:	O	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
with	O	ADP	O
an	O	DET	O
abnormal	O	ADJ	B
von	B-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
.	O	PUNCT	O


Type	B-Disease	NOUN	B
I	I-Disease	NUM	I
von	I-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
vWD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
equally	O	ADV	O
low	O	ADJ	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
antigen	O	NOUN	I
(	O	PUNCT	O
vWF	O	NOUN	B
Ag	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
ristocetin	O	NOUN	B
cofactor	O	NOUN	I
(	O	PUNCT	O
RiCof	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
all	O	DET	O
vWF	O	NOUN	B
multimers	O	NOUN	B
in	O	ADP	O
sodium	O	NOUN	B
dodecyl	O	NOUN	I
sulfate	O	NOUN	I
(	O	PUNCT	I
SDS	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
agarose	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
17	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
13	O	NUM	O
kindreds	O	NOUN	B
)	O	PUNCT	O
diagnosed	O	VERB	B
with	O	ADP	O
these	O	DET	O
criteria	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
the	O	DET	O
platelet	O	NOUN	B
contents	O	NOUN	B
of	O	ADP	O
vWF	O	NOUN	B
Ag	O	NOUN	B
and	O	CCONJ	O
RiCof	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
changes	O	NOUN	B
of	O	ADP	O
these	O	DET	O
in	O	ADP	O
plasma	O	NOUN	B
after	O	ADP	O
DDAVP	O	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Platelet	O	NOUN	B
vWF	O	NOUN	I
Ag	O	NOUN	B
and	O	CCONJ	O
RiCof	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
four	O	NUM	O
kindreds	O	NOUN	B
(	O	PUNCT	O
called	O	VERB	O
"	O	PUNCT	O
platelet	O	NOUN	B
normal	O	ADJ	I
"	O	PUNCT	O
subgroup	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
following	O	VERB	O
1	O	NUM	O
-	O	PUNCT	O
deamino	O	NOUN	B
-	O	PUNCT	O
8	O	NUM	B
-	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
arginine	O	NOUN	B
vasopressin	O	NOUN	B
;	O	PUNCT	O
plasma	O	NOUN	B
vWF	O	NOUN	B
Ag	O	NOUN	B
,	O	PUNCT	O
RiCof	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
bleeding	O	ADJ	B
time	O	NOUN	I
(	O	PUNCT	O
BT	O	NOUN	B
)	O	PUNCT	O
became	O	VERB	O
normal	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
six	O	NUM	O
kindreds	O	NOUN	B
,	O	PUNCT	O
platelet	O	NOUN	B
vWF	O	NOUN	I
Ag	O	NOUN	B
and	O	CCONJ	O
RiCof	O	NOUN	B
were	O	AUX	O
equally	O	ADV	O
low	O	ADJ	B
(	O	PUNCT	O
platelet	O	NOUN	B
low	O	ADJ	I
)	O	PUNCT	O
;	O	PUNCT	O
after	O	ADP	O
DDAVP	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
vWF	O	NOUN	B
Ag	O	NOUN	B
and	O	CCONJ	O
RiCof	O	NOUN	B
remained	O	VERB	O
low	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
BT	O	NOUN	B
was	O	AUX	O
prolonged	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
three	O	NUM	O
additional	O	ADJ	O
kindreds	O	NOUN	B
,	O	PUNCT	O
platelets	O	NOUN	B
contained	O	VERB	O
normal	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
vWF	O	NOUN	B
Ag	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
RiCof	O	NOUN	B
was	O	AUX	O
very	O	ADV	O
low	O	ADJ	O
(	O	PUNCT	O
platelet	O	NOUN	B
discordant	O	ADJ	I
)	O	PUNCT	O
;	O	PUNCT	O
even	O	ADV	O
though	O	SCONJ	O
a	O	DET	O
complete	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
multimers	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
platelets	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
relatively	O	ADV	O
small	O	ADJ	O
amount	O	NOUN	B
of	O	ADP	O
large	O	ADJ	O
multimers	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
DDAVP	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
vWF	O	NOUN	B
Ag	O	NOUN	B
became	O	VERB	O
normal	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
RiCof	O	NOUN	B
remained	O	VERB	O
low	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
BT	O	PROPN	B
was	O	AUX	O
very	O	ADV	O
prolonged	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
can	O	AUX	O
be	O	AUX	O
an	O	DET	O
abnormal	O	ADJ	B
vWF	O	NOUN	B
(	O	PUNCT	O
RiCof	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
vWF	O	NOUN	B
Ag	O	NOUN	B
)	O	PUNCT	O
even	O	ADV	O
in	O	ADP	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
vWD	I-Disease	NOUN	I
,	O	PUNCT	O
coexisting	O	VERB	B
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
vWF	O	NOUN	B
multimers	O	NOUN	B
(	O	PUNCT	O
platelet	O	NOUN	B
discordant	O	ADJ	I
)	O	PUNCT	O
;	O	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
abnormal	O	ADJ	B
vWF	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
shown	O	VERB	O
more	O	ADV	O
clearly	O	ADV	O
in	O	ADP	O
platelets	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
plasma	O	NOUN	B
or	O	CCONJ	O
else	O	ADV	O
in	O	ADP	O
plasma	O	NOUN	B
after	O	ADP	O
DDAVP	O	NOUN	B
infusion	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
DDAVP	O	NOUN	B
normalizes	O	VERB	B
the	O	DET	O
BT	O	PROPN	B
only	O	ADV	O
in	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
platelet	O	NOUN	O
levels	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
vWF	O	NOUN	B
Ag	O	NOUN	B
and	O	CCONJ	O
RiCof	O	NOUN	B
(	O	PUNCT	O
platelet	O	NOUN	B
normal	O	ADJ	I
)	O	PUNCT	O
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
van	B-Disease	X	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
brought	O	VERB	O
together	O	ADV	O
information	O	NOUN	B
on	O	ADP	O
864	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
in	O	ADP	O
164	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
including	O	VERB	O
three	O	NUM	O
new	O	ADJ	O
pedigrees	O	NOUN	B
)	O	PUNCT	O
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
137	O	NUM	O
year	O	NOUN	B
period	O	NOUN	B
since	O	SCONJ	O
1845	O	NUM	O
when	O	SCONJ	O
Demarquay	O	PROPN	B
first	O	ADV	O
described	O	VERB	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
what	O	PRON	O
was	O	AUX	O
later	O	ADV	O
called	O	VERB	O
van	B-Disease	X	B
der	I-Disease	NOUN	I
Woude	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
VWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
oral	B-Disease	ADJ	B
cleft	I-Disease	NOUN	I
,	O	PUNCT	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
(	O	PUNCT	I
CP	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
cleft	B-Disease	NOUN	B
lip	I-Disease	NOUN	I
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
CP	B-Disease	NOUN	B
(	O	PUNCT	O
CLP	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
segregate	O	VERB	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
together	O	ADV	O
with	O	ADP	O
lower	O	ADJ	O
lip	B-Disease	NOUN	O
pits	I-Disease	NOUN	O
or	O	CCONJ	O
fistulae	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
mode	O	NOUN	O
with	O	ADP	O
high	O	ADJ	O
penetrance	O	NOUN	B
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
K	O	PROPN	B
=	O	ADJ	O
.	O	PUNCT	O


89	O	NUM	O
and	O	CCONJ	O
.	O	PUNCT	O


99	O	NUM	O
by	O	ADP	O
different	O	ADJ	O
methods	O	NOUN	B
.	O	PUNCT	O


Cleft	O	NOUN	B
types	O	NOUN	I
(	O	PUNCT	O
CLP	B-Disease	NOUN	B
and	O	CCONJ	O
CP	B-Disease	NOUN	B
)	O	PUNCT	O
occur	O	VERB	O
in	O	ADP	O
VWS	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
proportions	O	NOUN	B
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
general	O	ADJ	O
non	O	NOUN	B
-	O	PUNCT	O
VWS	O	NOUN	B
population	O	NOUN	B
,	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
about	O	ADV	O
twice	O	ADV	O
as	O	ADV	O
many	O	ADJ	O
cleft	O	NOUN	B
-	O	PUNCT	O
bearing	O	VERB	B
individuals	O	NOUN	B
have	O	AUX	O
CLP	B-Disease	NOUN	B
as	O	ADP	O
have	O	AUX	O
CP	B-Disease	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
do	O	AUX	O
not	O	PART	O
find	O	VERB	O
the	O	DET	O
usually	O	ADV	O
observed	O	VERB	O
excess	O	NOUN	B
of	O	ADP	O
females	O	NOUN	B
with	O	ADP	O
CP	B-Disease	NOUN	B
and	O	CCONJ	O
excess	O	NOUN	B
of	O	ADP	O
males	O	NOUN	B
with	O	ADP	O
CLP	B-Disease	NOUN	B
;	O	PUNCT	O
in	O	ADP	O
VWS	B-Disease	NOUN	B
the	O	DET	O
sex	O	NOUN	B
ratios	O	NOUN	I
are	O	AUX	O
more	O	ADV	O
nearly	O	ADV	O
equal	O	ADJ	O
.	O	PUNCT	O


Lip	B-Disease	NOUN	B
pits	I-Disease	NOUN	I
also	O	ADV	O
are	O	AUX	O
equally	O	ADV	O
distributed	O	VERB	B
between	O	ADP	O
the	O	DET	O
sexes	O	NOUN	B
.	O	PUNCT	O


Affected	O	ADJ	B
males	O	NOUN	B
and	O	CCONJ	O
females	O	NOUN	B
are	O	AUX	O
equally	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
transmit	O	VERB	B
VWS	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
an	O	DET	O
excess	O	NOUN	B
of	O	ADP	O
less	O	ADV	O
severely	O	ADV	B
affected	O	VERB	B
individuals	O	NOUN	B
among	O	ADP	O
transmitters	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
deficiency	O	NOUN	B
of	O	ADP	O
more	O	ADV	O
severely	O	ADV	B
affected	O	VERB	B
,	O	PUNCT	O
brought	O	VERB	O
about	O	ADP	O
by	O	ADP	O
a	O	DET	O
proband	O	NOUN	B
bias	O	NOUN	B
and	O	CCONJ	O
differential	O	ADJ	B
fecundity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
VWS	B-Disease	NOUN	B
is	O	AUX	O
significantly	O	ADV	O
modified	O	VERB	B
by	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
background	O	NOUN	I
More	O	ADV	O
extreme	O	ADJ	O
phenotypes	O	NOUN	B
in	O	ADP	O
parents	O	NOUN	B
tend	O	VERB	O
to	O	PART	O
produce	O	VERB	O
more	O	ADV	O
extreme	O	ADJ	O
expression	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
children	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
a	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	B
carrier	O	NOUN	I
the	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
transmitting	O	VERB	O
a	O	DET	O
cleft	O	NOUN	B
is	O	AUX	O
26	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
that	O	DET	O
of	O	ADP	O
transmitting	O	VERB	B
lower	O	ADJ	O
lip	B-Disease	NOUN	O
pits	I-Disease	NOUN	O
is	O	AUX	O
23	O	NUM	O
.	O	PUNCT	O


55	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Three	O	NUM	O
pedigrees	O	NOUN	B
of	O	ADP	O
lip	B-Disease	NOUN	B
pits	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
show	O	VERB	O
no	O	DET	B
clefts	O	NOUN	I
among	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
.	O	PUNCT	O


Control	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
VWS	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
target	O	NOUN	B
tissues	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
independent	O	ADJ	B
and	O	CCONJ	O
separately	O	ADV	O
designated	O	VERB	O
.	O	PUNCT	O


Mutation	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VWS	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
calculated	O	VERB	O
to	O	PART	O
be	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
X	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
C7	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Diagnosis	O	NOUN	B
and	O	CCONJ	O
HLA	O	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
a	O	DET	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
of	O	ADP	O
a	O	DET	O
44	O	NUM	O
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
of	O	ADP	O
French	O	PROPN	B
-	O	PUNCT	O
Canadian	O	ADJ	B
descent	O	NOUN	B
having	O	VERB	O
a	O	DET	O
B	O	NOUN	B
-	O	PUNCT	O
27	O	NUM	O
positive	O	ADJ	B
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
was	O	AUX	O
deficient	B-Disease	ADJ	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C7	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
hemolytic	O	ADJ	B
and	O	CCONJ	O
immunochemical	O	ADJ	B
methods	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
inhibitor	O	NOUN	I
against	O	ADP	O
C7	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
levels	O	NOUN	B
of	O	ADP	O
all	O	DET	O
other	O	ADJ	O
complement	O	NOUN	B
components	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


No	O	DET	O
deficiency	O	NOUN	O
in	O	ADP	O
the	O	DET	O
opsonic	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
basic	O	ADJ	O
coagulation	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	B
.	O	PUNCT	O


On	O	ADP	O
investigation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
family	O	NOUN	B
,	O	PUNCT	O
two	O	NUM	O
sisters	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
same	O	ADJ	O
deficiency	O	NOUN	B
but	O	CCONJ	O
were	O	AUX	O
otherwise	O	ADV	O
in	O	ADP	O
good	O	ADJ	O
health	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
seven	O	NUM	O
other	O	ADJ	O
siblings	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
paternal	O	ADJ	B
aunt	O	NOUN	I
had	O	AUX	O
a	O	DET	O
normal	O	ADJ	O
C7	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
third	O	ADJ	O
generation	O	NOUN	B
,	O	PUNCT	O
six	O	NUM	O
children	O	NOUN	B
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
homozygous	O	ADJ	B
sisters	O	NOUN	B
and	O	CCONJ	O
five	O	NUM	O
children	O	NOUN	B
of	O	ADP	O
heterozygotes	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
testing	O	NOUN	B
.	O	PUNCT	O


Studies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HLA	O	NOUN	B
antigens	O	NOUN	I
in	O	ADP	O
all	O	DET	O
the	O	DET	O
22	O	NUM	O
subjects	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
three	O	NUM	O
spouses	O	NOUN	B
indicated	O	VERB	O
no	O	DET	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
the	O	DET	O
CM	B-Disease	NOUN	B
deficienty	I-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
HLA	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
simultaneous	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
hereditary	O	ADJ	B
complement	B-Disease	NOUN	I
deficiencies	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
C2	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
was	O	AUX	O
discovered	O	VERB	O
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
of	O	ADP	O
this	O	DET	O
remarkable	O	ADJ	O
kindred	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
defect	B-Disease	NOUN	I
in	I-Disease	ADP	O
secretion	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
C5	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
genetic	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
fifth	I-Disease	ADJ	O
(	I-Disease	PUNCT	O
C5	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
component	I-Disease	NOUN	B
of	I-Disease	ADP	O
complement1	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
3	I-Disease	NUM	O
,	O	PUNCT	O
a	O	DET	O
serum	O	NOUN	B
glycoprotein	O	NOUN	I
of	O	ADP	O
molecular	O	ADJ	O
weight	O	NOUN	O
(	O	PUNCT	O
MW	O	NOUN	B
)	O	PUNCT	O
220	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
4	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
39	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
inbred	O	ADJ	B
strains	O	NOUN	I
of	O	ADP	O
mice3	O	NOUN	B
.	O	PUNCT	O


Sera	O	NOUN	B
of	O	ADP	O
deficient	O	ADJ	B
mice	O	NOUN	B
lack	O	VERB	O
detectable	O	ADJ	B
C5	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
protein2	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
deficient	O	ADJ	B
mice	O	NOUN	B
produce	O	VERB	O
antibody	O	NOUN	B
to	O	PART	O
mouse	O	NOUN	B
C5	O	NOUN	B
when	O	SCONJ	O
injected	O	VERB	B
with	O	ADP	O
sera	O	NOUN	B
from	O	ADP	O
C5	O	NOUN	B
sufficient	O	ADJ	O
(	O	PUNCT	O
normal	O	ADJ	B
)	O	PUNCT	O
strains	O	NOUN	B
.	O	PUNCT	O


Levy	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O


5	O	NUM	O
showed	O	VERB	O
that	O	SCONJ	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
between	O	ADP	O
C5	O	NOUN	B
deficient	O	ADJ	I
(	O	PUNCT	O
B10	O	NOUN	B
.	O	PUNCT	O
D2	O	NOUN	B
/	O	PUNCT	O
old	O	ADJ	B
line	O	NOUN	I
)	O	PUNCT	O
macrophages	O	NOUN	B
and	O	CCONJ	O
either	O	CCONJ	O
C5	O	NOUN	B
sufficient	O	ADJ	O
(	O	PUNCT	O
B10	O	NOUN	B
.	O	PUNCT	O
D2	O	NOUN	B
/	O	SYM	O
new	O	ADJ	B
line	O	NOUN	I
)	O	PUNCT	O
mouse	O	NOUN	B
kidney	O	NOUN	I
or	O	CCONJ	O
chicken	O	NOUN	B
erythroblasts	O	NOUN	B
secreted	O	VERB	B
haemolytically	O	ADV	B
active	O	ADJ	B
mouse	O	NOUN	B
C5	O	NOUN	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Several	O	ADJ	O
possible	O	ADJ	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
to	O	PART	O
account	O	VERB	O
for	O	ADP	O
the	O	DET	O
findings	O	NOUN	B
were	O	AUX	O
considered	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
insufficient	O	ADJ	O
direct	O	ADJ	O
data	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
to	O	PART	O
choose	O	VERB	O
among	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


We	O	PRON	O
recently	O	ADV	O
reported	O	VERB	O
that	O	SCONJ	O
mouse	O	NOUN	B
(	O	PUNCT	O
CD	O	NOUN	B
.	O	PUNCT	O
1	O	NUM	O
strain	O	NOUN	B
)	O	PUNCT	O
peritoneal	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
culture	O	NOUN	B
synthesise	O	VERB	B
and	O	CCONJ	O
secrete	O	VERB	B
a	O	DET	O
single	O	ADJ	O
chain	O	NOUN	O
precursor	O	NOUN	O
,	O	PUNCT	O
pro	O	ADJ	B
-	O	PUNCT	O
C5	O	NOUN	B
(	O	PUNCT	O
MW	O	NOUN	B
approximately	O	ADV	O
210	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	B
-	O	PUNCT	O
chain	O	NOUN	B
(	O	PUNCT	O
alpha	O	NOUN	B
chain	O	NOUN	I
,	O	PUNCT	O
125	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
and	O	CCONJ	O
beta	O	NOUN	B
chain	O	NOUN	I
83	O	NUM	I
,	O	PUNCT	O
000	O	NUM	O
MW	O	NOUN	B
)	O	PUNCT	O
C5	O	NOUN	B
protein6	O	NOUN	I
.	O	PUNCT	O


Radiolabelled	O	VERB	B
precursor	O	NOUN	O
C5	O	NOUN	O
was	O	AUX	O
contained	O	VERB	O
within	O	ADP	O
the	O	DET	O
cells	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
secreted	O	VERB	B
into	O	ADP	O
the	O	DET	O
tissue	O	NOUN	B
culture	O	NOUN	I
media	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
similar	O	ADJ	O
methods	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
now	O	ADV	O
find	O	VERB	O
that	O	SCONJ	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
five	O	NUM	O
different	O	ADJ	O
mouse	O	NOUN	B
strains	O	NOUN	I
(	O	PUNCT	O
AKR	O	NOUN	B
,	O	PUNCT	O
SWR	O	NOUN	B
,	O	PUNCT	O
DBA	O	PROPN	B
/	O	SYM	O
2J8	O	PROPN	B
A	O	PROPN	B
/	O	SYM	O
HeJ	O	NOUN	B
and	O	CCONJ	O
B10	O	NOUN	B
.	O	PUNCT	O
D2	O	NOUN	B
/	O	PUNCT	O
old	O	ADJ	B
line	O	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
failure	O	NOUN	B
in	O	ADP	O
secretion	O	NOUN	B
of	O	ADP	O
C5	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
not	O	PART	O
to	O	PART	O
a	O	DET	O
failure	O	NOUN	B
in	O	ADP	O
biosynthesis	O	NOUN	B
of	O	ADP	O
pro	O	ADJ	B
-	O	PUNCT	O
C5	O	NOUN	B


Recurrent	O	ADJ	B
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
with	O	ADP	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
sixth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
:	O	PUNCT	O
an	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
underlying	O	VERB	O
immunologic	O	ADJ	B
mechanisms	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
51	O	NUM	O
/	O	SYM	O
2	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
black	O	ADJ	B
girl	O	NOUN	I
with	O	ADP	O
recurrent	O	ADJ	O
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
and	O	CCONJ	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
sixth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C6	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
explore	O	VERB	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
recurrent	O	ADJ	B
neisserial	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
in	O	ADP	O
C6	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
detailed	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
her	O	PRON	O
immune	O	ADJ	B
competence	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


Her	O	PRON	O
serum	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	O
chemotactic	O	ADJ	O
,	O	PUNCT	O
opsonic	O	ADJ	B
,	O	PUNCT	O
alternative	O	ADJ	B
complement	O	NOUN	O
pathway	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
specific	O	ADJ	O
antibody	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
lacked	O	VERB	O
complement	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
bacteriolytic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
her	O	PRON	O
C6	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
serum	O	NOUN	B
was	O	AUX	O
indistinguishable	O	ADJ	B
from	O	ADP	O
normal	O	ADJ	O
serum	O	NOUN	B
in	O	ADP	O
a	O	DET	O
complement	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
assay	O	NOUN	B
of	O	ADP	O
phagocyte	O	NOUN	B
bactericidal	O	ADJ	O
activity	O	NOUN	O
.	O	PUNCT	O


Absent	O	ADJ	B
bacteriolysis	O	NOUN	B
remains	O	VERB	O
the	O	DET	O
only	O	ADV	O
consistent	O	ADJ	O
defect	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
recurrent	O	ADJ	O
neisserial	B-Disease	ADJ	B
infections	I-Disease	NOUN	I
and	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
late	O	ADV	B
-	O	PUNCT	O
acting	O	VERB	B
complement	O	NOUN	B
components	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
fifth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
in	O	ADP	O
human	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
,	O	PUNCT	O
genetic	O	ADJ	B
and	O	CCONJ	O
immunologic	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
kindred	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
discovery	O	NOUN	B
of	O	ADP	O
a	O	DET	O
large	O	ADJ	O
kindred	O	NOUN	B
with	O	ADP	O
a	O	DET	O
heritable	O	ADJ	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
fifth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C5	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
permitted	O	VERB	O
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
clinical	O	ADJ	B
,	O	PUNCT	O
genetic	O	ADJ	B
and	O	CCONJ	O
immunologic	O	ADJ	B
data	O	NOUN	B
concerning	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
C5	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
has	O	AUX	O
had	O	AUX	O
nine	O	NUM	O
episodes	O	NOUN	B
of	O	ADP	O
disseminated	O	ADJ	B
gonococcal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
hemolytic	O	ADJ	B
C5	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


No	O	DET	B
C5	O	NOUN	B
protein	O	NOUN	I
was	O	AUX	O
detectable	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
low	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
C5	O	NOUN	B
activity	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
using	O	VERB	O
a	O	DET	O
sensitive	O	ADJ	B
bactericidal	O	ADJ	B
assay	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
probands	O	NOUN	B
twin	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
another	O	DET	O
sister	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
extremely	O	ADV	O
low	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
hemolytic	O	ADJ	B
C5	O	NOUN	I
(	O	PUNCT	O
approximately	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
normal	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
both	O	CCONJ	O
these	O	DET	O
subjects	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
healthy	O	ADJ	B
.	O	PUNCT	O


Hemolytic	O	ADJ	B
complement	O	NOUN	I
and	O	CCONJ	O
bacteriolytic	O	ADJ	B
activity	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
restored	O	VERB	B
by	O	ADP	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
purified	O	VERB	B
C5	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
chemotactic	O	ADJ	B
activity	O	NOUN	I
for	O	ADP	O
polymorphonuclear	O	ADJ	B
leukocytes	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
generated	O	VERB	O
in	O	ADP	O
the	O	DET	O
C5	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
serums	O	NOUN	B
upon	O	SCONJ	O
activation	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
classic	O	ADJ	B
or	O	CCONJ	O
alternative	O	ADJ	B
pathways	O	NOUN	I
,	O	PUNCT	O
again	O	ADV	O
demonstrating	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
C5	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
subjects	O	NOUN	B
for	O	ADP	O
the	O	DET	O
production	O	NOUN	B
of	O	ADP	O
chemotactic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
chemotactic	O	ADJ	B
responsiveness	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
polymorphonuclear	O	ADJ	B
leukocytes	O	NOUN	B
and	O	CCONJ	O
monocytes	O	NOUN	B
to	O	PART	O
preformed	O	ADJ	B
chemotactic	O	ADJ	B
factors	O	NOUN	I
was	O	AUX	O
not	O	PART	O
depressed	O	ADJ	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
of	O	ADP	O
32	O	NUM	O
other	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
from	O	ADP	O
three	O	NUM	O
generations	O	NOUN	B
had	O	AUX	O
depressed	O	VERB	B
whole	O	ADJ	I
hemolytic	O	ADJ	I
complement	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
19	O	NUM	O
of	O	ADP	O
30	O	NUM	O
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
levels	O	NOUN	B
of	O	ADP	O
hemolytic	O	ADJ	B
C5	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
13	O	NUM	O
to	O	PART	O
64	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


No	O	DET	O
linkage	O	NOUN	O
for	O	ADP	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
A	O	NOUN	B
or	O	CCONJ	O
B	O	NOUN	B
loci	O	NOUN	I
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
histocompatibility	O	NOUN	O
complex	O	NOUN	O
could	O	AUX	O
be	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
an	O	DET	O
autosomal	O	ADJ	B
codominant	O	ADJ	I
mode	O	NOUN	O
of	O	ADP	O
inheritance	O	NOUN	B
of	O	ADP	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
C5	I-Disease	NOUN	B
is	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
good	O	ADJ	O
health	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
repeated	O	VERB	O
disseminated	O	ADJ	B
gonococcal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I


Incidence	O	NOUN	B
and	O	CCONJ	O
characteristics	O	NOUN	B
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variants	O	NOUN	B
in	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
3000	O	NUM	O
men	O	NOUN	B
living	O	VERB	B
in	O	ADP	O
Yamaguchi	O	PROPN	O
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
using	O	VERB	O
Beutlers	O	PROPN	B
spot	O	VERB	I
test	O	NOUN	I
and	O	CCONJ	O
three	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
starch	O	NOUN	B
gel	O	NOUN	I
electrophoresis	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
electrophoresis	O	NOUN	B
used	O	VERB	O
a	O	DET	O
phosphate	O	NOUN	B
buffer	O	NOUN	I
system	O	NOUN	I
at	O	ADP	O
pH	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
TRIS	O	NOUN	B
-	O	PUNCT	O
EDTA	O	NOUN	B
-	O	PUNCT	O
borate	O	NOUN	B
buffer	O	NOUN	I
system	O	NOUN	O
at	O	ADP	O
pH	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
TRIS	O	NOUN	B
-	O	PUNCT	O
hydrochloride	O	NOUN	B
buffer	O	NOUN	I
system	O	NOUN	I
at	O	ADP	O
pH	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O
.	O	PUNCT	O


Fifteen	O	NUM	O
G6PD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
variants	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
at	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
classified	O	VERB	B
into	O	ADP	O
four	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
new	O	ADJ	O
variants	O	NOUN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Konan	O	PROPN	I
,	O	PUNCT	O
Kamiube	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Kiwa	O	PROPN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
three	O	NUM	O
variants	O	NOUN	B
had	O	AUX	O
a	O	DET	O
mild	O	ADJ	B
to	O	PART	O
moderate	O	ADJ	B
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
any	O	DET	O
clinical	O	ADJ	B
signs	O	NOUN	I
.	O	PUNCT	O


G6PD	O	NOUN	B
Konan	O	PROPN	I
had	O	AUX	O
fast	O	ADJ	O
electrophoretic	O	ADJ	O
mobility	O	NOUN	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
normal	O	ADJ	O
levels	O	NOUN	O
,	O	PUNCT	O
G6PD	O	NOUN	B
Kiwa	O	PROPN	B
had	O	AUX	O
slightly	O	ADV	O
elevated	O	ADJ	B
electrophoretic	O	ADJ	B
mobility	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Kamiube	O	PROPN	I
had	O	AUX	O
normal	O	ADJ	O
electrophoretic	O	ADJ	B
mobility	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
three	O	NUM	O
variants	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
Km	O	NOUN	B
G6P	O	NOUN	B
,	O	PUNCT	O
Km	O	NOUN	B
NADP	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Ki	O	NOUN	B
NADPH	O	NOUN	I
,	O	PUNCT	O
normal	O	ADJ	O
utilizations	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
2	O	NUM	B
-	O	PUNCT	O
deoxy	O	NOUN	B
-	O	PUNCT	O
G6P	O	NOUN	B
and	O	CCONJ	O
deamino	O	NOUN	B
-	O	PUNCT	O
NAPD	O	NOUN	B
,	O	PUNCT	O
normal	O	ADJ	B
heat	O	NOUN	I
stability	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
normal	O	ADJ	O
pH	O	NOUN	B
curve	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
variant	O	NOUN	B
was	O	AUX	O
G6PD	O	NOUN	B
Ube	O	PROPN	O
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
had	O	AUX	O
previously	O	ADV	O
found	O	VERB	O
in	O	ADP	O
Yamaguchi	O	PROPN	O
(	O	PUNCT	O
Nakashima	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1977	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


One	O	NUM	O
boy	O	NOUN	B
with	O	ADP	O
G6PD	O	NOUN	B
Ube	O	PROPN	O
was	O	AUX	O
Korean	O	ADJ	B


Utilization	O	NOUN	B
of	O	ADP	O
purines	O	NOUN	B
by	O	ADP	O
an	O	DET	O
HPRT	O	NOUN	B
variant	O	NOUN	B
in	O	ADP	O
an	O	DET	O
intelligent	O	ADJ	B
,	O	PUNCT	O
nonmutilative	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
features	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
H	O	NOUN	B
.	O	PUNCT	O


Chr	O	NOUN	B
.	O	PUNCT	O


B	O	NOUN	B
.	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
among	O	ADP	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
with	O	ADP	O
hyperuricemia	B-Disease	NOUN	B
and	O	CCONJ	O
central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
symptoms	I-Disease	NOUN	B
.	O	PUNCT	O


He	O	PRON	O
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
variant	O	NOUN	B
of	O	ADP	O
hypoxanthine	O	NOUN	B
guanine	O	NOUN	I
phosphoribosyl	O	NOUN	I
transferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
;	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
distinct	O	ADJ	O
from	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
present	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
chroeoathetosis	B-Disease	NOUN	B
,	O	PUNCT	O
spasticity	B-Disease	NOUN	B
,	O	PUNCT	O
dysarthric	B-Disease	ADJ	B
speech	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
hyperuricemia	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
his	O	PRON	O
intelligence	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	B
and	O	CCONJ	O
he	O	PRON	O
had	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
self	O	NOUN	B
-	O	PUNCT	O
mutilation	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
HPRT	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lysates	O	NOUN	B
of	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
cultured	O	VERB	B
fibroblasts	O	NOUN	B
when	O	SCONJ	O
analyzed	O	VERB	B
in	O	ADP	O
the	O	DET	O
usual	O	ADJ	O
manner	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
newly	O	ADV	O
developed	O	VERB	O
method	O	NOUN	B
for	O	ADP	O
the	O	DET	O
study	O	NOUN	B
of	O	ADP	O
purine	O	NOUN	B
metabolism	O	NOUN	I
in	O	ADP	O
intact	O	ADJ	B
cultured	O	VERB	B
cells	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
metabolize	O	VERB	B
some	O	DET	O
9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
8	O	NUM	O
-	O	PUNCT	O
14C	O	NOUN	B
-	O	PUNCT	O
hypoxanthine	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
isotope	O	NOUN	B
utilized	O	VERB	O
was	O	AUX	O
converted	O	VERB	O
to	O	PART	O
adenine	O	NOUN	B
and	O	CCONJ	O
guanine	O	NOUN	B
nucleotides	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
cells	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
were	O	AUX	O
virtually	O	ADV	O
completely	O	ADV	O
unable	O	ADJ	O
to	O	PART	O
convert	O	VERB	O
hypoxanthine	O	NOUN	B
to	O	PART	O
nucleotides	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
fibroblasts	O	NOUN	B
were	O	AUX	O
even	O	ADV	O
more	O	ADV	O
efficient	O	ADJ	B
in	O	ADP	O
the	O	DET	O
metabolism	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
-	O	PUNCT	O
14C	O	NOUN	B
-	O	PUNCT	O
guanine	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
utilized	O	VERB	O
to	O	PART	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
27	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
over	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
which	O	DET	O
was	O	AUX	O
converted	O	VERB	O
to	O	PART	O
guanine	O	NOUN	B
and	O	CCONJ	O
adenine	O	NOUN	B
nucleotides	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
growth	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cultured	O	VERB	B
fibroblasts	O	NOUN	B
of	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
intermediate	O	ADJ	B
in	O	ADP	O
media	O	NOUN	B
containing	O	VERB	O
hypoxanthine	O	NOUN	B
aminopterin	O	NOUN	B
thymidine	O	NOUN	I
(	O	PUNCT	O
HAT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
growth	O	NOUN	B
of	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
cells	O	NOUN	I
was	O	AUX	O
inhibited	O	VERB	B
and	O	CCONJ	O
normal	O	ADJ	B
cells	O	NOUN	I
grew	O	VERB	O
normally	O	ADV	O
.	O	PUNCT	O


Similarly	O	ADV	O
in	O	ADP	O
8	O	NUM	O
-	O	PUNCT	O
azaguanine	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
thioguanine	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
8	O	NUM	O
-	O	PUNCT	O
azahypoxanthine	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
growth	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
cells	O	NOUN	I
was	O	AUX	O
intermediate	O	ADJ	B
between	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
disorders	O	NOUN	B
in	O	ADP	O
purine	O	NOUN	B
metabolism	O	NOUN	I
involving	O	VERB	O
the	O	DET	O
HPRT	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
document	O	VERB	B
that	O	SCONJ	O
this	O	DET	O
famous	O	ADJ	O
patient	O	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I


Localisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Becker	B-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
on	O	ADP	O
the	O	DET	O
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
by	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
cloned	O	VERB	B
DNA	O	NOUN	B
sequences	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
linkage	O	NOUN	B
study	O	NOUN	I
in	O	ADP	O
30	O	NUM	O
Becker	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
BMD	B-Disease	NOUN	B
)	O	PUNCT	O
kindreds	O	NOUN	B
using	O	VERB	O
three	O	NUM	O
cloned	O	VERB	B
DNA	O	NOUN	B
sequences	O	NOUN	I
from	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
which	O	DET	O
demonstrate	O	VERB	O
restriction	O	NOUN	B
fragment	O	NOUN	I
length	O	NOUN	I
polymorphisms	O	NOUN	I
(	O	PUNCT	O
RFLPs	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
BMD	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
located	O	ADJ	O
on	O	ADP	O
the	O	DET	O
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
p21	O	NOUN	B
region	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
genes	O	NOUN	B
for	O	ADP	O
Becker	B-Disease	PROPN	B
and	I-Disease	CCONJ	O
Duchenne	I-Disease	NOUN	B
dystrophies	I-Disease	NOUN	I
must	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
,	O	PUNCT	O
if	O	SCONJ	O
not	O	PART	O
allelic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
any	O	DET	O
future	O	ADJ	O
DNA	O	NOUN	B
probes	O	NOUN	I
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
of	O	ADP	O
practical	O	ADJ	O
use	O	NOUN	O
in	O	ADP	O
one	O	NUM	O
disorder	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
equally	O	ADV	O
applicable	O	ADJ	O
to	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
linkage	O	NOUN	B
analysis	O	NOUN	I
also	O	ADV	O
provides	O	VERB	O
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
recombination	O	NOUN	B
along	O	ADP	O
the	O	DET	O
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
across	O	ADP	O
the	O	DET	O
centromeric	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
new	O	ADJ	O
mutation	O	NOUN	B
at	O	ADP	O
the	O	DET	O
hprt	O	NOUN	B
locus	O	NOUN	I
in	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
patients	O	NOUN	B
.	O	PUNCT	O


Hypoxanthine	O	NOUN	B
-	O	PUNCT	O
guanine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
(	O	PUNCT	O
HPRT	O	NOUN	B
;	O	PUNCT	O
EC2	O	NOUN	B
.	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
functions	O	VERB	B
in	O	ADP	O
the	O	DET	O
metabolic	O	ADJ	B
salvage	O	NOUN	I
of	O	ADP	O
purines	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
encoded	O	VERB	B
by	O	ADP	O
an	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
gene	O	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


Partial	O	ADJ	B
HPRT	B-Disease	NOUN	B
deficiencies	I-Disease	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
gouty	B-Disease	NOUN	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
absence	O	NOUN	B
of	O	ADP	O
activity	O	NOUN	B
results	O	NOUN	O
in	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
L	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
N	I-Disease	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


L	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
N	I-Disease	NOUN	B
patients	O	NOUN	B
fail	O	VERB	B
to	O	PART	O
reproduce	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
heterozygous	O	ADJ	B
state	O	NOUN	O
appears	O	VERB	O
to	O	PART	O
confer	O	VERB	O
no	O	DET	O
selective	O	ADJ	O
advantage	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
Haldanes	O	ADJ	B
principle	O	NOUN	I
predicts	O	VERB	O
that	O	SCONJ	O
new	O	ADJ	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
hprt	O	NOUN	B
locus	O	NOUN	I
must	O	AUX	O
occur	O	VERB	O
frequently	O	ADV	O
in	O	ADP	O
order	O	NOUN	O
for	O	ADP	O
L	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
N	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
to	O	PART	O
be	O	AUX	O
maintained	O	VERB	B
in	O	ADP	O
the	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
constant	O	ADJ	B
introduction	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
mutations	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
expected	O	VERB	O
to	O	PART	O
result	O	VERB	O
in	O	ADP	O
a	O	DET	O
heterogeneous	O	ADJ	B
collection	O	NOUN	B
of	O	ADP	O
genetic	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
,	O	PUNCT	O
some	O	DET	O
of	O	ADP	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
novel	O	ADJ	B
.	O	PUNCT	O


As	O	ADP	O
we	O	PRON	O
report	O	VERB	O
here	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hprt	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
seven	O	NUM	O
L	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
N	I-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
selected	O	VERB	O
from	O	ADP	O
an	O	DET	O
initial	O	ADJ	B
survey	O	NOUN	B
of	O	ADP	O
28	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
characterized	O	VERB	B
and	O	CCONJ	O
all	O	DET	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
distinctly	O	ADV	O
different	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
predicted	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
unusual	O	ADJ	B
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
four	O	NUM	O
generations	O	NOUN	B
of	O	ADP	O
family	O	NOUN	B
members	O	NOUN	I
.	O	PUNCT	O


Further	O	ADJ	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
hprt	O	NOUN	B
locus	O	NOUN	I
should	O	AUX	O
aid	O	VERB	O
in	O	ADP	O
resolving	O	VERB	O
the	O	DET	O
issue	O	NOUN	B
of	O	ADP	O
an	O	DET	O
apparent	O	ADJ	B
difference	O	NOUN	O
in	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
hprt	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
males	O	NOUN	B
and	O	CCONJ	O
females	O	NOUN	B


Allelic	O	ADJ	B
exclusion	O	NOUN	B
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
in	O	ADP	O
platelets	O	NOUN	B
and	O	CCONJ	O
T	O	NOUN	B
lymphocytes	O	NOUN	I
from	O	ADP	O
a	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
carrier	O	NOUN	O
.	O	PUNCT	O


An	O	DET	O
obligate	O	ADJ	B
carrier	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
was	O	AUX	O
also	O	ADV	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
A	O	NOUN	B
and	O	CCONJ	O
B	O	NOUN	B
types	O	NOUN	I
of	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


With	O	ADP	O
her	O	PRON	O
it	O	PRON	O
became	O	VERB	O
possible	O	ADJ	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
allelic	O	ADJ	B
exclusion	O	NOUN	B
occurs	O	VERB	O
in	O	ADP	O
particular	O	ADJ	O
cell	O	NOUN	B
-	O	PUNCT	O
types	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WAS	B-Disease	PROPN	B
carrier	O	NOUN	B
.	O	PUNCT	O


If	O	SCONJ	O
so	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
remaining	O	VERB	O
cells	O	NOUN	B
of	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
cell	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
would	O	AUX	O
express	O	VERB	O
only	O	ADV	O
the	O	DET	O
normal	O	ADJ	B
X	O	NOUN	I
chromosome	O	NOUN	I
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
isoenzyme	O	NOUN	B
would	O	AUX	O
be	O	AUX	O
demonstrable	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
carrier	O	NOUN	B
had	O	AUX	O
only	O	ADV	O
the	O	DET	O
B	O	NOUN	B
isoenzyme	O	NOUN	I
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
in	O	ADP	O
platelets	O	NOUN	B
and	O	CCONJ	O
thymus	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
T	O	NOUN	B
lymphocytes	O	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
both	O	DET	O
isoenzymes	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
neutrophils	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
selection	O	NOUN	B
against	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	I
occurs	O	VERB	O
in	O	ADP	O
platelets	O	NOUN	B
and	O	CCONJ	O
thymus	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
T	O	NOUN	B
lymphocytes	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
defects	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
WAS	B-Disease	NOUN	B
expressed	O	VERB	B
in	O	ADP	O
these	O	DET	O
cell	O	NOUN	B
-	O	PUNCT	O
types	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
genesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Complement	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
nephritis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
report	O	NOUN	B
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
which	O	DET	O
three	O	NUM	O
children	O	NOUN	B
had	O	AUX	O
homozygous	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
C3	I-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
which	O	DET	O
both	O	DET	O
parents	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
other	O	ADJ	O
children	O	NOUN	B
were	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
C3	O	NOUN	B
null	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
child	O	NOUN	B
with	O	ADP	O
heterozygous	O	ADJ	B
C3	B-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
membranoproliferative	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
;	O	PUNCT	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
microscopical	O	ADJ	B
haematuria	B-Disease	NOUN	I
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
homozygous	O	ADJ	B
C3	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
children	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
children	O	NOUN	B
with	O	ADP	O
homozygous	O	ADJ	B
or	O	CCONJ	O
heterozygous	O	ADJ	B
C3	B-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
were	O	AUX	O
,	O	PUNCT	O
to	O	PART	O
a	O	DET	O
varying	O	VERB	O
degree	O	NOUN	B
,	O	PUNCT	O
susceptible	O	ADJ	B
to	O	PART	O
infection	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
only	O	ADJ	O
child	O	NOUN	B
of	O	ADP	O
the	O	DET	O
family	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
complement	O	NOUN	O
had	O	AUX	O
no	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
infection	O	NOUN	B
and	O	CCONJ	O
no	O	DET	B
renal	B-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
family	O	NOUN	B
study	O	NOUN	I
provides	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
proposal	O	NOUN	B
that	O	SCONJ	O
C3	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
predisposes	O	VERB	O
to	O	PART	O
nephritis	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Heterogeneity	O	NOUN	B
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Algeria	O	PROPN	B
.	O	PUNCT	O


Study	O	NOUN	B
in	O	ADP	O
Northern	O	PROPN	B
Algeria	O	PROPN	I
with	O	ADP	O
description	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
male	O	NOUN	B
population	O	NOUN	B
living	O	VERB	B
in	O	ADP	O
the	O	DET	O
urban	O	ADJ	B
area	O	NOUN	I
of	O	ADP	O
Algiers	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
deficient	O	ADJ	B
subjects	O	NOUN	B
originated	O	VERB	O
from	O	ADP	O
multiple	O	ADJ	B
geographic	O	ADJ	B
regions	O	NOUN	I
of	O	ADP	O
Northern	O	PROPN	B
Algeria	O	PROPN	I
,	O	PUNCT	O
with	O	ADP	O
prevalence	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
of	O	ADP	O
Berber	O	PROPN	B
-	O	PUNCT	O
Kabyle	O	PROPN	B
origin	O	NOUN	B
.	O	PUNCT	O


Red	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
G6PD	O	NOUN	B
was	O	AUX	O
partially	O	ADV	O
purified	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
in	O	ADP	O
deficient	O	ADJ	B
males	O	NOUN	B
from	O	ADP	O
17	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
different	O	ADJ	O
variants	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Among	O	ADP	O
them	O	PRON	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
Gd	O	PROPN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Kabyle	O	PROPN	B
variant	O	NOUN	I
,	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
nine	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
five	O	NUM	O
variants	O	NOUN	B
were	O	AUX	O
new	O	ADJ	O
Gd	O	PROPN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Laghouat	O	PROPN	B
(	O	PUNCT	O
four	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
Gd	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Blida	O	PROPN	B
(	O	PUNCT	O
one	O	NUM	O
case	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
Gd	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Thenia	O	PROPN	B
(	O	PUNCT	O
one	O	NUM	O
case	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
Gd	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Titteri	O	PROPN	B
(	O	PUNCT	O
one	O	NUM	O
case	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Gd	O	PROPN	B
(	O	PUNCT	O
-	O	PUNCT	O
)	O	PUNCT	O
Alger	O	PROPN	B
(	O	PUNCT	O
two	O	NUM	O
brothers	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Strikingly	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
common	O	ADJ	O
Mediterranean	O	ADJ	B
variant	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
.	O	PUNCT	O


G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
is	O	AUX	O
heterogeneous	O	ADJ	B
in	O	ADP	O
northern	O	ADJ	B
Algeria	O	PROPN	I
where	O	SCONJ	O
autochtonous	O	ADJ	B
variants	O	NOUN	B
seem	O	VERB	O
to	O	PART	O
prevail	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
Kabyle	O	PROPN	B
variant	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
common	O	ADJ	O
in	O	ADP	O
this	O	DET	O
country	O	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
inhibits	O	VERB	B
in	O	X	B
vitro	O	X	I
growth	O	NOUN	B
of	O	ADP	O
Plasmodium	O	NOUN	B
falciparum	O	NOUN	I
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
;	I-Disease	PUNCT	O
EC	I-Disease	NOUN	B
1	I-Disease	NUM	I
.	I-Disease	PUNCT	O
1	I-Disease	NUM	O
.	I-Disease	PUNCT	O
1	I-Disease	X	O
.	I-Disease	PUNCT	O
49	I-Disease	NUM	O
)	I-Disease	PUNCT	O
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
from	O	ADP	O
male	O	NOUN	B
hemizygotes	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
heterozygotes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
island	O	NOUN	B
of	O	ADP	O
Sardinia	O	PROPN	B
were	O	AUX	O
studied	O	VERB	O
for	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
support	O	VERB	O
growth	O	NOUN	B
in	O	X	B
vitro	O	X	I
of	O	ADP	O
the	O	DET	O
malaria	B-Disease	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
organism	O	NOUN	B
Plasmodium	O	NOUN	B
falciparum	O	NOUN	I
.	O	PUNCT	O


Parasite	O	ADJ	B
growth	O	NOUN	B
was	O	AUX	O
approximately	O	ADV	O
one	O	NUM	O
-	O	PUNCT	O
third	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
in	O	ADP	O
both	O	CCONJ	O
hemi	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
heterozygotes	O	NOUN	B
for	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Sardinians	O	PROPN	B
with	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
0	O	NUM	I
-	O	PUNCT	O
thalassemia	O	NOUN	B
trait	O	NOUN	B
,	O	PUNCT	O
parasite	O	ADJ	B
growth	O	NOUN	B
was	O	AUX	O
normal	O	ADJ	O
except	O	SCONJ	O
when	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
occurred	O	VERB	O
together	O	ADV	O
with	O	ADP	O
the	O	DET	O
thalassemia	B-Disease	NOUN	B
trait	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
may	O	AUX	O
confer	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
advantage	O	NOUN	O
in	O	ADP	O
a	O	DET	O
malarious	B-Disease	ADJ	B
area	O	NOUN	I
;	O	PUNCT	O
the	O	DET	O
female	O	ADJ	B
heterozygote	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
at	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
advantage	O	NOUN	O
because	O	SCONJ	O
resistance	O	NOUN	B
to	O	ADP	O
malaria	B-Disease	NOUN	B
equals	O	VERB	O
that	O	DET	O
of	O	ADP	O
male	O	ADJ	B
hemizygotes	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
fatal	B-Disease	ADJ	B
hemolysis	I-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
less	O	ADJ	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
more	O	ADV	O
female	O	ADJ	B
heterozygotes	O	NOUN	B
must	O	AUX	O
be	O	AUX	O
studied	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
protective	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
beta	O	NOUN	B
0	O	NUM	I
-	O	PUNCT	O
thalassemia	O	NOUN	B
trait	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
demonstrated	O	VERB	O
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
in	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
.	O	PUNCT	O


An	O	DET	O
allogeneic	O	ADJ	B
bone	O	NOUN	I
marrow	O	NOUN	I
transplant	O	NOUN	I
(	O	PUNCT	O
BMT	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
HLA	O	NOUN	B
identical	O	ADJ	O
sibling	O	NOUN	B
donor	O	NOUN	O
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
a	O	DET	O
13	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
rapidly	O	ADV	O
progressive	O	ADJ	O
adrenoleukodystrophy	B-Disease	NOUN	O
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Engraftment	O	NOUN	B
and	O	CCONJ	O
complete	O	ADJ	B
hematologic	O	ADJ	B
recovery	O	NOUN	B
occurred	O	VERB	O
within	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
neurologic	B-Disease	ADJ	B
deterioration	I-Disease	NOUN	B
continued	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
died	O	VERB	B
of	O	ADP	O
an	O	DET	O
adenovirus	B-Disease	NOUN	B
infection	I-Disease	NOUN	I
141	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
BMT	O	NOUN	B
.	O	PUNCT	O


ALD	B-Disease	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
abnormally	O	ADV	O
high	O	ADJ	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
(	O	PUNCT	O
VLCFA	O	NOUN	B
)	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
impaired	O	ADJ	B
capacity	O	NOUN	B
to	O	PART	O
degrade	O	VERB	O
them	O	PRON	O
.	O	PUNCT	O


Ten	O	NUM	B
days	O	NOUN	I
after	O	ADP	O
BMT	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
white	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
VLCFA	O	NOUN	B
levels	O	NOUN	B
and	O	CCONJ	O
enzyme	O	NOUN	B
activity	O	NOUN	I
became	O	VERB	O
normal	O	ADJ	B
;	O	PUNCT	O
after	O	ADP	O
3	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
progressive	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
VLCFA	O	NOUN	B
to	O	PART	O
levels	O	NOUN	B
only	O	ADV	O
slightly	O	ADV	O
above	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


[	O	PUNCT	O
Gd	O	PROPN	B
-	O	PUNCT	O
allele	O	NOUN	B
distribution	O	NOUN	B
patterns	O	NOUN	I
in	O	ADP	O
Azerbaijan	O	PROPN	B
.	O	PUNCT	O
III	O	NUM	O
.	O	PUNCT	O
The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
]	O	PUNCT	O


In	O	ADP	O
28	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
living	O	VERB	B
in	O	ADP	O
3	O	NUM	O
settlements	O	NOUN	B
of	O	ADP	O
Shekii	O	PROPN	B
district	O	NOUN	I
of	O	ADP	O
Azerbaijan	O	PROPN	B
11	O	NUM	O
G6PD	O	NOUN	B
variants	O	NOUN	B
of	O	ADP	O
II	O	NUM	O
and	O	CCONJ	O
III	O	NUM	B
classes	O	NOUN	I
differing	O	VERB	O
by	O	ADP	O
kinetic	O	ADJ	B
properties	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
according	O	VERB	O
WHO	O	PRON	B
program	O	NOUN	B
.	O	PUNCT	O


9	O	NUM	O
of	O	ADP	O
them	O	PRON	O
are	O	AUX	O
characterized	O	VERB	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
electrophoretic	O	ADJ	B
mobility	O	NOUN	I
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
spectra	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
subpopulations	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
mixed	O	ADJ	O
group	O	NOUN	B
permits	O	VERB	O
to	O	PART	O
make	O	VERB	O
a	O	DET	O
conclusion	O	NOUN	O
about	O	ADP	O
existence	O	NOUN	O
of	O	ADP	O
common	O	ADJ	O
and	O	CCONJ	O
rare	O	ADJ	O
G6PD	O	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
examined	O	VERB	O
population	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
distribute	O	VERB	B
by	O	ADP	O
gene	O	NOUN	B
drift	O	NOUN	I
supported	O	VERB	O
by	O	ADP	O
natural	O	ADJ	B
selection	O	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
7	O	NUM	O
samples	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
increased	O	VERB	B
activity	O	NOUN	B
two	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
of	O	ADP	O
IV	O	NUM	B
class	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
Nukha	O	PROPN	B
and	O	CCONJ	O
Bash	O	PROPN	B
-	O	PUNCT	O
Kungut	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
:	O	PUNCT	O
survey	O	NOUN	B
of	O	ADP	O
303	O	NUM	O
cases	O	NOUN	B
:	O	PUNCT	O
biochemistry	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
therapy	O	NOUN	B
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
genetically	O	ADV	B
determined	O	VERB	O
disorder	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
progressive	B-Disease	ADJ	B
central	I-Disease	ADJ	B
demyelination	I-Disease	NOUN	I
and	O	CCONJ	O
adrenal	B-Disease	ADJ	B
cortical	I-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
affected	O	VERB	B
persons	O	NOUN	B
show	O	VERB	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
saturated	O	ADJ	B
unbranched	O	ADJ	O
very	O	ADV	O
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
,	O	PUNCT	O
particularly	O	ADV	O
hexacosanoate	O	NOUN	B
(	O	PUNCT	O
C26	O	NOUN	O
0	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
impaired	O	ADJ	B
capacity	O	NOUN	B
to	O	PART	O
degrade	O	VERB	O
these	O	DET	O
acids	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
degradation	O	NOUN	B
normally	O	ADV	O
takes	O	VERB	O
place	O	NOUN	O
in	O	ADP	O
a	O	DET	O
subcellular	O	ADJ	B
organelle	O	NOUN	O
called	O	VERB	O
the	O	DET	O
peroxisome	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
ALD	B-Disease	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
Zellwegers	B-Disease	PROPN	B
cerebrohepatorenal	I-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
now	O	ADV	O
considered	O	VERB	O
to	O	PART	O
belong	O	VERB	O
to	O	ADP	O
the	O	DET	O
newly	O	ADV	O
formed	O	VERB	O
category	O	NOUN	O
of	O	ADP	O
peroxisomal	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Biochemical	O	ADJ	B
assays	O	NOUN	I
permit	O	VERB	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
identification	O	NOUN	B
of	O	ADP	O
most	O	ADJ	O
heterozygotes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
303	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
in	O	ADP	O
217	O	NUM	O
kindreds	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
patients	O	NOUN	B
show	O	VERB	O
a	O	DET	O
wide	O	ADJ	O
phenotypic	O	ADJ	B
variation	O	NOUN	O
.	O	PUNCT	O


Sixty	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
had	O	AUX	O
childhood	O	NOUN	B
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
adrenomyeloneuropathy	B-Disease	ADJ	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
mapped	O	VERB	O
to	O	PART	O
Xq28	O	NOUN	B
.	O	PUNCT	O


Neonatal	B-Disease	ADJ	B
ALD	I-Disease	PROPN	B
,	O	PUNCT	O
a	O	DET	O
distinct	O	ADJ	O
entity	O	NOUN	B
with	O	ADP	O
autosomal	O	ADJ	B
recessive	O	ADJ	I
inheritance	O	NOUN	I
and	O	CCONJ	O
points	O	NOUN	O
of	O	ADP	O
resemblance	O	NOUN	O
to	O	ADP	O
Zellwegers	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
accounted	O	VERB	O
for	O	ADP	O
7	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
excess	O	ADJ	O
C26	O	NOUN	B
0	O	NUM	O
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
is	O	AUX	O
partially	O	ADV	O
of	O	ADP	O
dietary	O	ADJ	B
origin	O	NOUN	I
,	O	PUNCT	O
dietary	O	ADJ	B
C26	O	NOUN	O
0	O	NUM	O
restriction	O	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
clear	O	ADJ	O
benefit	O	NOUN	B
.	O	PUNCT	O


Bone	O	NOUN	B
marrow	O	NOUN	I
transplant	O	NOUN	I
lowered	O	VERB	B
the	O	DET	O
plasma	O	NOUN	B
C26	O	NOUN	O
0	O	NUM	O
level	O	NOUN	B
but	O	CCONJ	O
failed	O	VERB	O
to	O	PART	O
arrest	O	VERB	B
neurological	O	ADJ	B
progression	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
polymorphism	O	NOUN	I
of	O	ADP	O
G6PD	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Bulgarian	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Considerable	O	ADJ	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
in	O	ADP	O
G6PD	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
Bulgarian	O	ADJ	B
population	O	NOUN	I
-	O	PUNCT	O
14	O	NUM	O
G6PD	O	NOUN	B
variants	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
117	O	NUM	O
hemizygous	O	ADJ	B
carriers	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
G6PD	O	NOUN	B
Mediterranean	O	ADJ	B
type	O	NOUN	O
was	O	AUX	O
a	O	DET	O
polymorphic	O	ADJ	B
variant	O	NOUN	I
and	O	CCONJ	O
G6PD	O	NOUN	B
Corinth	O	PROPN	B
occurred	O	VERB	O
with	O	ADP	O
high	O	ADJ	O
frequency	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
-	O	PUNCT	O
G6PD	O	NOUN	B
Rudosem	O	PROPN	B
and	O	CCONJ	O
G6PD	O	NOUN	B
Nedelino	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
selected	O	VERB	O
group	O	NOUN	B
of	O	ADP	O
78	O	NUM	O
subjects	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
,	O	PUNCT	O
four	O	NUM	O
variants	O	NOUN	B
were	O	AUX	O
established	O	VERB	O
G6PD	O	NOUN	B
Mediterranian	O	PROPN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Corinth	O	PROPN	B
,	O	PUNCT	O
G6PD	O	PROPN	B
Seattle	O	PROPN	B
and	O	CCONJ	O
G6PD	O	NOUN	B
Ohut	O	PROPN	B
II	O	NUM	I
.	O	PUNCT	O
.	O	PUNCT	O


Clinical	O	ADJ	B
use	O	NOUN	I
of	O	ADP	I
DNA	O	NOUN	B
markers	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Seventy	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
known	O	VERB	O
to	O	ADP	O
the	O	DET	O
Institute	O	PROPN	B
of	O	ADP	I
Child	O	PROPN	I
Health	O	PROPN	I
fall	O	NOUN	O
into	O	ADP	O
three	O	NUM	O
categories	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
potential	O	ADJ	B
linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
DNA	O	NOUN	I
markers	O	NOUN	O
RC8	O	NOUN	B
and	O	CCONJ	O
L1	O	NOUN	B
.	O	PUNCT	O


28	O	NUM	O
that	O	PRON	O
bridge	O	VERB	B
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
there	O	PRON	O
is	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
obligatory	O	ADJ	B
female	O	ADJ	B
heterozygote	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
prediction	O	NOUN	B
and	O	CCONJ	O
exclusion	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
transmission	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
accuracy	O	NOUN	B
being	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
closeness	O	NOUN	B
of	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
marker	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
to	O	PART	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
;	O	PUNCT	O
an	O	DET	O
illustrative	O	ADJ	O
case	O	NOUN	B
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
single	O	ADJ	O
affected	O	VERB	B
boy	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
also	O	ADV	O
has	O	AUX	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
healthy	O	ADJ	B
brothers	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
26	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Given	O	VERB	O
an	O	DET	O
informative	O	ADJ	O
restriction	O	NOUN	O
fragment	O	NOUN	O
length	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
RFLP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
probability	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
boy	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
reassessed	O	VERB	B
;	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
also	O	ADV	O
possible	O	ADJ	O
to	O	PART	O
exclude	O	VERB	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sister	O	NOUN	B
.	O	PUNCT	O


Families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
single	O	ADJ	O
affected	O	VERB	B
boy	O	NOUN	B
with	O	ADP	O
no	O	DET	B
brother	O	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
30	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
exclusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sister	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
possible	O	ADJ	O
.	O	PUNCT	O


Only	O	ADV	O
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
was	O	AUX	O
there	O	PRON	O
no	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
useful	O	ADJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
linkage	O	NOUN	B
analysis	O	NOUN	I
required	O	VERB	O
is	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
check	O	VERB	O
DMD	B-Disease	PROPN	B
families	O	NOUN	B
for	O	ADP	O
informative	O	ADJ	B
RFLPs	O	NOUN	B
is	O	AUX	O
stressed	O	VERB	B
.	O	PUNCT	O


Family	O	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
Bechterew	B-Disease	NOUN	B
'	I-Disease	PART	I
s	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
)	O	PUNCT	O
III	O	NUM	O
.	O	PUNCT	O


Genetics	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
segregation	O	NOUN	B
analyses	O	NOUN	B
in	O	ADP	O
75	O	NUM	O
families	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
proband	O	NOUN	B
had	O	AUX	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
278	O	NUM	O
adult	O	NOUN	B
,	O	PUNCT	O
living	O	VERB	O
first	O	ADJ	O
degree	O	NOUN	O
relatives	O	NOUN	O
,	O	PUNCT	O
approximately	O	ADV	O
85	O	NUM	O
%	O	NOUN	O
cooperated	O	VERB	B
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
radiographical	O	ADJ	B
examinations	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
and	O	CCONJ	O
HLA	O	NOUN	B
typing	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
were	O	AUX	O
in	O	ADP	O
agreement	O	NOUN	O
with	O	ADP	O
our	O	PRON	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
is	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
syndrome	O	NOUN	B
where	O	SCONJ	O
different	O	ADJ	O
genetic	O	ADJ	B
factors	O	NOUN	I
interact	O	VERB	B
.	O	PUNCT	O


Such	O	ADJ	O
known	O	ADJ	O
factors	O	NOUN	B
are	O	AUX	O
HLA	O	NOUN	B
B27	O	NOUN	I
associated	O	ADJ	O
disease	O	NOUN	B
susceptibility	O	NOUN	I
,	O	PUNCT	O
susceptibility	O	NOUN	B
to	O	PART	O
psoriatic	B-Disease	ADJ	B
arthropathy	I-Disease	ADJ	I
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	ADP	O
entero	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
arthropathy	I-Disease	NOUN	B
.	O	PUNCT	O


Radiographical	O	ADJ	B
sacro	B-Disease	NOUN	O
-	I-Disease	PUNCT	O
iliitis	I-Disease	NOUN	B
was	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
HLA	O	NOUN	B
B27	O	NOUN	I
positive	O	ADJ	O
relatives	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
more	O	ADV	O
frequently	O	ADV	O
found	O	VERB	O
in	O	ADP	O
relatives	O	NOUN	B
to	O	ADP	O
probands	O	NOUN	B
with	O	ADP	O
psoriasis	B-Disease	NOUN	B
than	O	ADP	O
in	O	ADP	O
relatives	O	NOUN	B
to	O	ADP	O
probands	O	NOUN	B
without	O	ADP	O
psoriasis	B-Disease	NOUN	B
.	O	PUNCT	O


Environmental	O	ADJ	B
factors	O	NOUN	I
(	O	PUNCT	O
intestinal	O	ADJ	B
bacteria	O	NOUN	I
)	O	PUNCT	O
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
trigger	O	VERB	B
the	O	DET	O
disease	O	NOUN	B
at	O	ADP	O
least	O	ADJ	O
in	O	ADP	O
some	O	DET	O
persons	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
we	O	PRON	O
have	O	AUX	O
postulated	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
or	O	CCONJ	O
most	O	ADJ	O
of	O	ADP	O
them	O	PRON	O
have	O	AUX	O
the	O	DET	O
predisposition	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
disease	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
syndrome	O	NOUN	B
has	O	AUX	O
a	O	DET	O
multifactorial	O	ADJ	B
etiology	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
phenotypic	O	ADJ	B
expressions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
different	O	ADJ	O
genetic	O	ADJ	B
predispositions	O	NOUN	I
involved	O	VERB	O
,	O	PUNCT	O
include	O	VERB	O
sacro	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
iliitis	I-Disease	NOUN	B
,	O	PUNCT	O
psoriasis	B-Disease	NOUN	B
,	O	PUNCT	O
acute	B-Disease	ADJ	B
anterior	I-Disease	ADJ	I
uveitis	I-Disease	NOUN	I
,	O	PUNCT	O
peripheral	O	ADJ	B
arthropathy	B-Disease	ADJ	I
and	O	CCONJ	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
the	O	DET	O
descriptive	O	ADJ	O
name	O	NOUN	O
HEREDITARY	B-Disease	PROPN	O
MULTIFOCAL	I-Disease	PROPN	O
RELAPSING	I-Disease	NOUN	O
INFLAMMATION	I-Disease	NOUN	O
(	O	PUNCT	O
HEMRI	B-Disease	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O


Ankylosing	B-Disease	ADJ	B
spondylitis	I-Disease	NOUN	I
,	O	PUNCT	O
psoriatic	B-Disease	ADJ	B
arthropathy	I-Disease	ADJ	I
and	O	CCONJ	O
entero	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
arthropathy	I-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
clinical	O	ADJ	B
sub	O	NOUN	I
-	O	PUNCT	O
types	O	NOUN	B
of	O	ADP	O
the	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Prader	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
chromosome	O	NOUN	O
15	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
discussion	O	NOUN	O
of	O	ADP	O
20	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
chromosome	B-Disease	NOUN	O
15	I-Disease	NUM	O
anomaly	I-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
12	O	NUM	O
of	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
17	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
clinically	O	ADV	B
suspected	O	VERB	B
of	O	ADP	O
having	O	VERB	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
eight	O	NUM	O
cases	O	NOUN	B
with	O	ADP	O
15q11	O	NOUN	B
-	O	PUNCT	O
12	O	NUM	O
deletion	O	NOUN	B
were	O	AUX	O
very	O	ADV	O
similar	O	ADJ	O
to	O	ADP	O
those	O	DET	O
originally	O	ADV	O
described	O	VERB	O
in	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
other	O	ADJ	O
hand	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
group	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
karyotype	O	NOUN	B
patients	O	NOUN	B
is	O	AUX	O
heterogeneous	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
features	O	NOUN	B
do	O	AUX	O
not	O	PART	O
strictly	O	ADV	O
correspond	O	VERB	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
definition	O	NOUN	I
of	O	ADP	O
PWS	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
PWS	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
deletion	O	NOUN	B
of	O	ADP	O
15q11	O	NOUN	O
-	O	PUNCT	O
12	O	NUM	O
can	O	AUX	O
neither	O	DET	O
explain	O	VERB	O
the	O	DET	O
apparently	O	ADV	O
balanced	O	ADJ	O
translocations	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
15	O	NUM	O
nor	O	CCONJ	O
account	O	VERB	O
for	O	ADP	O
the	O	DET	O
small	O	ADJ	B
supernumerary	O	ADJ	I
metacentric	O	ADJ	I
chromosomes	O	NOUN	I
corresponding	O	VERB	O
to	O	PART	O
an	O	DET	O
isochromosome	O	NOUN	B
15	O	NUM	O
for	O	ADP	O
band	O	NOUN	B
15q11	O	NOUN	I
observed	O	VERB	B
in	O	ADP	O
some	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
North	O	ADJ	B
American	O	ADJ	I
Jewish	O	ADJ	B
populations	O	NOUN	I
:	O	PUNCT	O
geographic	O	ADJ	B
variations	O	NOUN	I
and	O	CCONJ	O
origin	O	NOUN	B
.	O	PUNCT	O


From	O	ADP	O
data	O	NOUN	B
collected	O	VERB	O
in	O	ADP	O
a	O	DET	O
North	O	ADJ	B
American	O	PROPN	I
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
heterozygote	O	NOUN	B
screening	O	NOUN	I
program	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
TSD	B-Disease	NOUN	B
carrier	O	NOUN	O
frequency	O	NOUN	B
among	O	ADP	O
46	O	NUM	O
,	O	PUNCT	O
304	O	NUM	O
Jewish	O	ADJ	B
individuals	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
.	O	PUNCT	O


0324	O	NUM	O
(	O	PUNCT	O
1	O	NUM	O
in	O	ADP	O
31	O	NUM	O
individuals	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
frequency	O	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
earlier	O	ADJ	O
estimates	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
TSD	B-Disease	NOUN	B
incidence	O	NOUN	B
data	O	NOUN	B
.	O	PUNCT	O


TSD	B-Disease	NOUN	B
carrier	O	NOUN	O
frequencies	O	NOUN	B
were	O	AUX	O
then	O	ADV	O
examined	O	VERB	O
by	O	ADP	O
single	O	ADJ	O
country	O	NOUN	B
and	O	CCONJ	O
single	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
origin	O	NOUN	B
in	O	ADP	O
28	O	NUM	O
,	O	PUNCT	O
029	O	NUM	O
Jews	O	PROPN	B
within	O	ADP	O
this	O	DET	O
sample	O	NOUN	B
for	O	ADP	O
whom	O	PRON	O
such	O	ADJ	O
data	O	NOUN	B
were	O	AUX	O
available	O	ADJ	O
for	O	ADP	O
analysis	O	NOUN	B
.	O	PUNCT	O


Jews	O	PROPN	B
with	O	ADP	O
Polish	O	PROPN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
Russian	O	ADJ	B
ancestry	O	NOUN	B
constituted	O	VERB	O
88	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
this	O	DET	O
sample	O	NOUN	B
and	O	CCONJ	O
had	O	AUX	O
a	O	DET	O
TSD	B-Disease	NOUN	B
carrier	O	NOUN	O
frequency	O	NOUN	B
of	O	ADP	O
.	O	PUNCT	O


0327	O	NUM	O
.	O	PUNCT	O


No	O	DET	O
TSD	B-Disease	NOUN	B
carriers	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
among	O	ADP	O
the	O	DET	O
166	O	NUM	O
Jews	O	PROPN	B
of	O	ADP	O
Near	O	PROPN	B
Eastern	O	ADJ	I
origins	O	NOUN	I
.	O	PUNCT	O


Relative	O	ADJ	O
to	O	ADP	O
Jews	O	PROPN	B
of	O	ADP	O
Polish	O	ADJ	B
and	O	CCONJ	O
Russian	O	ADJ	B
origins	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
twofold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
TSD	B-Disease	NOUN	B
carrier	O	NOUN	O
frequency	O	NOUN	B
in	O	ADP	O
Jews	O	PROPN	B
of	O	ADP	O
Austrian	O	ADJ	B
,	O	PUNCT	O
Hungarian	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
Czechoslovakian	O	ADJ	B
origins	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.	O	PUNCT	O
005	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
TSD	B-Disease	NOUN	B
gene	O	NOUN	I
proliferated	O	VERB	B
among	O	ADP	O
the	O	DET	O
antecedents	O	NOUN	B
of	O	ADP	O
modern	O	ADJ	O
Ashkenazi	O	PROPN	B
Jewry	O	PROPN	B
after	O	ADP	O
the	O	DET	O
Second	O	PROPN	O
Diaspora	O	PROPN	B
(	O	PUNCT	O
70	O	NUM	O
A	O	NOUN	O
.	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O
)	O	PUNCT	O
and	O	CCONJ	O
before	O	ADP	O
their	O	PRON	O
major	O	ADJ	O
migrations	O	NOUN	B
to	O	ADP	O
regions	O	NOUN	B
of	O	ADP	O
Poland	O	PROPN	B
and	O	CCONJ	O
Russia	O	PROPN	B
(	O	PUNCT	O
before	O	ADP	O
1100	O	NUM	O
A	O	NOUN	O
.	O	PUNCT	O
D	O	NOUN	B
.	O	PUNCT	O
)	O	PUNCT	O
.	O	PUNCT	O


Human	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
sixth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
and	O	CCONJ	O
no	O	DET	O
haemostasis	B-Disease	NOUN	B
abnormality	I-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
complete	O	ADJ	O
C6	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
31	O	NUM	O
year	O	NOUN	B
old	O	ADJ	B
white	O	ADJ	I
male	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
seen	O	VERB	O
on	O	ADP	O
the	O	DET	O
occasion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
isolated	O	VERB	B
episode	O	NOUN	B
of	O	ADP	O
meningococcal	B-Disease	ADJ	B
meningitis	I-Disease	NOUN	I
.	O	PUNCT	O


Serum	O	NOUN	B
complement	O	NOUN	I
hemolytic	O	ADJ	I
and	O	CCONJ	O
bactericidal	O	ADJ	B
activities	O	NOUN	I
were	O	AUX	O
lacking	O	VERB	B
and	O	CCONJ	O
could	O	AUX	O
be	O	AUX	O
restored	O	VERB	B
to	O	PART	O
normal	O	ADJ	O
by	O	ADP	O
addition	O	NOUN	O
of	O	ADP	O
appropriate	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
purified	O	VERB	B
C6	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
hemostatic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
meningococcemia	I-Disease	NOUN	I
presenting	O	VERB	O
as	O	ADP	O
vasculitis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
healthy	O	ADJ	B
40	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
fever	B-Disease	NOUN	B
,	O	PUNCT	O
arthritis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cutaneous	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
chronic	B-Disease	ADJ	B
meningococcemia	I-Disease	NOUN	I
.	O	PUNCT	O


Evaluation	O	NOUN	B
of	O	ADP	O
his	O	PRON	O
complement	O	NOUN	O
system	O	NOUN	O
showed	O	VERB	O
an	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
and	O	CCONJ	O
antigenic	O	ADJ	B
C7	O	NOUN	I
,	O	PUNCT	O
compatible	O	ADJ	O
with	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
.	O	PUNCT	O


Study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
family	O	NOUN	B
spanning	O	VERB	O
four	O	NUM	O
generations	O	NOUN	B
showed	O	VERB	O
heterozygous	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
C7	I-Disease	NOUN	B
in	O	ADP	O
five	O	NUM	O
members	O	NOUN	B
.	O	PUNCT	O


Chronic	B-Disease	ADJ	B
neisserial	I-Disease	ADJ	O
infection	I-Disease	NOUN	O
can	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
must	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
other	O	ADJ	O
causes	O	NOUN	O
of	O	ADP	O
cutaneous	B-Disease	ADJ	B
vasculitis	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
discoid	I-Disease	ADJ	I
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
heterozygote	O	NOUN	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
siblings	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
discoid	I-Disease	ADJ	I
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
and	O	CCONJ	O
several	O	ADJ	O
family	O	NOUN	B
members	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
with	O	ADP	O
heterozygous	O	ADJ	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
association	O	NOUN	B
with	O	ADP	I
histocompatibility	O	NOUN	B
markers	O	NOUN	I
HLA	O	NOUN	B
-	O	PUNCT	O
B18	O	NOUN	B
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
Dw2	O	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
slow	O	ADJ	B
allotype	O	NOUN	I
of	O	ADP	I
factor	O	NOUN	I
B	O	NOUN	I
was	O	AUX	O
present	O	ADJ	O
.	O	PUNCT	O


Linkage	O	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
suggested	O	VERB	O
a	O	DET	O
close	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
the	O	DET	O
C2	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
gene	O	NOUN	I
and	O	CCONJ	O
genes	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
B18	O	NOUN	B
,	O	PUNCT	O
Dw2	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
BfS	O	NOUN	B
antigens	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
HLA	O	PROPN	B
-	O	PUNCT	O
ACB	O	PROPN	B
/	O	SYM	O
DBf	O	NOUN	B
recombinant	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
showing	O	VERB	O
closer	O	ADJ	O
linkage	O	NOUN	B
between	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
D	O	NOUN	B
and	O	CCONJ	O
Bf	O	NOUN	B
than	O	ADP	O
between	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
B	O	NOUN	B
and	O	CCONJ	O
Bf	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Severe	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
glucose	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
associated	O	VERB	B
with	O	ADP	I
chronic	O	ADJ	B
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
granulocyte	B-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	ADP	O
infections	O	NOUN	B
:	O	PUNCT	O
description	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
molecular	O	ADJ	B
variant	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
Barcelona	O	PROPN	O
)	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
,	O	PUNCT	O
kinetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	O	ADJ	B
studies	O	NOUN	I
were	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
on	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
leukocytes	O	NOUN	B
in	O	ADP	O
a	O	DET	O
Spanish	O	ADJ	B
male	O	NOUN	B
with	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
congenital	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
(	O	PUNCT	O
CNSHA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
infections	O	NOUN	B
.	O	PUNCT	O


G6PD	O	NOUN	B
activity	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	O
in	O	ADP	O
patients	O	NOUN	B
red	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
about	O	ADV	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
in	O	ADP	O
leukocytes	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
studies	O	NOUN	I
using	O	VERB	O
standard	O	ADJ	B
methods	O	NOUN	I
(	O	PUNCT	O
WHO	O	PRON	B
,	O	PUNCT	O
1967	O	NUM	O
)	O	PUNCT	O
showed	O	VERB	O
G6PD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
to	O	PART	O
have	O	AUX	O
a	O	DET	O
slightly	O	ADV	O
fast	O	ADJ	O
electrophoretic	O	ADJ	O
mobility	O	NOUN	O
at	O	ADP	O
pH	O	NOUN	B
8	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
with	O	ADP	O
otherwise	O	ADV	O
normal	O	ADJ	O
properties	O	NOUN	O
(	O	PUNCT	O
heat	O	NOUN	B
stability	O	NOUN	I
at	O	ADP	O
46	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	I
,	O	PUNCT	O
apparent	O	ADJ	B
affinity	O	NOUN	B
for	O	ADP	O
substrates	O	NOUN	B
,	O	PUNCT	O
optimum	O	NOUN	B
pH	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
utilization	O	NOUN	B
of	O	ADP	O
substrate	O	NOUN	B
analogues	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Other	O	ADJ	O
tests	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
patients	O	NOUN	B
granulocytes	O	NOUN	B
to	O	PART	O
engulf	O	VERB	B
latex	O	NOUN	I
particles	O	NOUN	B
normally	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
to	O	PART	O
have	O	AUX	O
impaired	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
nitroblue	O	ADJ	B
tetrazolium	O	NOUN	I
and	O	CCONJ	O
ferricytochrome	O	NOUN	B
-	O	PUNCT	O
c	O	PROPN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
reduced	O	VERB	B
iodination	O	NOUN	B
.	O	PUNCT	O


Chemotaxis	O	NOUN	B
and	O	CCONJ	O
random	O	ADJ	B
migration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
granulocytes	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
as	O	ADP	O
were	O	AUX	O
myeloperoxidase	O	NOUN	B
,	O	PUNCT	O
leukocyte	O	NOUN	B
alkaline	O	NOUN	I
phosphatase	O	NOUN	I
(	O	PUNCT	O
LAP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
ultrastructural	O	ADJ	B
features	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
G6PD	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
differed	O	VERB	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
all	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
variants	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
CNSHA	B-Disease	NOUN	B
,	O	PUNCT	O
so	O	SCONJ	O
the	O	DET	O
present	O	ADJ	O
variant	O	NOUN	B
was	O	AUX	O
provisionally	O	ADV	O
called	O	VERB	O
G6PD	O	NOUN	B
Barcelona	O	PROPN	B
to	O	PART	O
distinguish	O	VERB	O
it	O	PRON	O
from	O	ADP	O
other	O	ADJ	O
G6PD	O	NOUN	B
variants	O	NOUN	B
previously	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


Possible	O	ADJ	O
mechanisms	O	NOUN	B
for	O	ADP	O
the	O	DET	O
severe	O	ADJ	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
G6PD	I-Disease	NOUN	B
in	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
granulocytes	O	NOUN	B
was	O	AUX	O
investigated	O	VERB	B
by	O	ADP	O
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
immunologic	O	ADJ	B
specific	O	ADJ	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
enzyme	O	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	O
.	O	PUNCT	O


The	O	DET	O
description	O	NOUN	B
of	O	ADP	O
13	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
362	O	NUM	O
males	O	NOUN	B
from	O	ADP	O
various	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	O
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
red	O	ADJ	B
cell	O	NOUN	I
glucose	O	NOUN	O
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	O
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
six	O	NUM	B
G6PD	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
individuals	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
purified	O	VERB	B
from	O	ADP	O
these	O	DET	O
subjects	O	NOUN	B
has	O	AUX	O
revealed	O	VERB	B
13	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
and	O	CCONJ	O
several	O	ADJ	O
copies	O	NOUN	B
of	O	ADP	O
previously	O	ADV	O
described	O	VERB	O
forms	O	NOUN	O
of	O	ADP	O
G6PD	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
illustrates	O	VERB	O
the	O	DET	O
extreme	O	ADJ	O
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
among	O	ADP	O
the	O	DET	O
people	O	NOUN	B
of	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	O
.	O	PUNCT	O
.	O	PUNCT	O


Heterogeneity	O	NOUN	B
of	O	ADP	O
"	O	PUNCT	O
Mediterranean	O	ADJ	B
type	O	NOUN	O
"	O	PUNCT	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
Spain	O	PROPN	B
and	O	CCONJ	O
description	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
favism	B-Disease	NOUN	B
.	O	PUNCT	O


Glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
EC	O	NOUN	B
1	O	NUM	I
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


1	O	X	O
.	O	PUNCT	O


49	O	NUM	O
from	O	ADP	O
thirty	O	NUM	O
-	O	PUNCT	O
six	O	NUM	O
unrelated	O	ADJ	O
Spanish	O	ADJ	B
males	O	NOUN	B
was	O	AUX	O
partially	O	ADV	O
purified	O	VERB	B
from	O	ADP	O
blood	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
variants	O	NOUN	B
were	O	AUX	O
characterized	O	VERB	O
biochemically	O	ADV	B
and	O	CCONJ	O
electrophoretically	O	ADV	B
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
methods	O	NOUN	B
recommended	O	VERB	B
by	O	ADP	O
the	O	DET	O
world	O	NOUN	B
Health	O	PROPN	I
Organization	O	PROPN	I
.	O	PUNCT	O


Subjects	O	NOUN	B
were	O	AUX	O
from	O	ADP	O
multiple	O	ADJ	B
geographic	O	ADJ	B
regions	O	NOUN	I
within	O	ADP	O
Spain	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
suffered	O	VERB	O
from	O	ADP	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
either	O	CCONJ	O
acute	O	ADJ	B
(	O	PUNCT	O
34	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
chronic	O	ADJ	B
nonspherocytic	O	ADJ	I
(	O	PUNCT	O
2	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Almost	O	ADV	O
all	O	DET	O
the	O	DET	O
variants	O	NOUN	B
studied	O	VERB	O
presented	O	VERB	O
residual	O	ADJ	B
erythrocyte	O	NOUN	B
G6PD	O	NOUN	B
activity	O	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
five	O	NUM	O
different	O	ADJ	O
mutants	O	NOUN	B
were	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
deficient	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
variants	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
to	O	ADP	O
others	O	NOUN	O
previously	O	ADV	O
described	O	VERB	O
G6PD	O	NOUN	B
Mediterranean	O	PROPN	B
(	O	PUNCT	O
11	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
G6PD	O	PROPN	B
Athens	O	PROPN	B
-	O	PUNCT	O
like	O	PROPN	B
(	O	PUNCT	O
3	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Union	O	PROPN	I
(	O	PUNCT	O
2	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
variants	O	NOUN	B
were	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
the	O	DET	O
numerous	O	ADJ	B
variants	O	NOUN	B
already	O	ADV	O
reported	O	VERB	B
and	O	CCONJ	O
have	O	AUX	O
been	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
new	O	ADJ	O
mutants	O	NOUN	B
.	O	PUNCT	O


Provisionally	O	ADV	B
they	O	PRON	O
are	O	AUX	O
called	O	VERB	O
G6PD	O	NOUN	B
Betica	O	PROPN	B
(	O	PUNCT	O
19	O	NUM	O
cases	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Menorca	O	PROPN	I
(	O	PUNCT	O
1	O	NUM	O
case	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
constitutes	O	VERB	O
the	O	DET	O
first	O	ADJ	O
attempt	O	NOUN	O
to	O	PART	O
characterize	O	VERB	B
the	O	DET	O
deficient	B-Disease	ADJ	B
G6PD	I-Disease	NOUN	B
variants	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
Spain	O	PROPN	B
and	O	CCONJ	O
supplies	O	VERB	B
new	O	ADJ	O
data	O	NOUN	B
on	O	ADP	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
molecular	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
deficient	O	ADJ	B
variants	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
important	O	ADJ	O
findings	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
summarized	O	VERB	O
as	O	ADP	O
follows	O	VERB	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
The	O	DET	O
Spanish	O	ADJ	B
population	O	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
an	O	DET	O
important	O	ADJ	O
heterogeneity	O	NOUN	B
in	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
Although	O	SCONJ	O
G6PD	O	NOUN	B
Mediterranean	O	ADJ	B
is	O	AUX	O
very	O	ADV	O
frequent	O	ADJ	B
,	O	PUNCT	O
it	O	PRON	O
presents	O	VERB	O
a	O	DET	O
relatively	O	ADV	O
high	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
polymorphism	O	NOUN	B
.	O	PUNCT	O


(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
Favism	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
associated	O	VERB	B
with	O	ADP	I
all	O	DET	O
kinds	O	NOUN	O
of	O	ADP	O
variants	O	NOUN	B
described	O	VERB	O
here	O	ADV	O
.	O	PUNCT	O


(	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
G6PD	O	NOUN	B
Betica	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
variant	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
subjects	O	NOUN	B
of	O	ADP	O
Southern	O	ADJ	B
Spanish	O	ADJ	B
origin	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
associated	O	VERB	B
with	O	ADP	I
favism	B-Disease	NOUN	B
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
except	O	SCONJ	O
one	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variant	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
Nagano	O	PROPN	O
)	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
congenital	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
variant	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
chronic	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
was	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Japanese	O	ADJ	B
male	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
noticed	O	VERB	O
to	O	PART	O
have	O	AUX	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	I
soon	O	ADV	O
after	O	ADP	O
birth	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
was	O	AUX	O
made	O	VERB	O
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


He	O	PRON	O
had	O	AUX	O
episodes	O	NOUN	B
of	O	ADP	O
hemolytic	B-Disease	ADJ	B
crisis	I-Disease	NOUN	I
several	O	ADJ	O
times	O	NOUN	O
after	O	ADP	O
upper	B-Disease	ADJ	B
respiratory	I-Disease	ADJ	I
infection	I-Disease	NOUN	I
.	O	PUNCT	O


G6PD	O	NOUN	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
5	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
enzymatic	O	ADJ	B
characteristics	O	NOUN	B
were	O	AUX	O
examined	O	VERB	O
when	O	SCONJ	O
he	O	PRON	O
was	O	AUX	O
5	O	NUM	O
years	O	NOUN	B
old	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
his	O	PRON	O
G6PD	O	NOUN	B
showed	O	VERB	O
faster	O	ADV	B
-	O	PUNCT	O
than	O	ADP	O
-	O	PUNCT	O
normal	O	ADJ	B
electrophoretic	O	ADJ	B
mobility	O	NOUN	I
,	O	PUNCT	O
low	O	ADJ	O
Km	O	NOUN	B
G6P	O	NOUN	B
,	O	PUNCT	O
high	O	ADJ	O
Km	O	NOUN	B
NADP	O	NOUN	B
,	O	PUNCT	O
low	O	ADJ	B
Ki	O	NOUN	B
NADPH	O	NOUN	I
,	O	PUNCT	O
normal	O	ADJ	O
utilization	O	NOUN	B
of	O	ADP	O
substrate	O	NOUN	B
analogues	O	NOUN	B
,	O	PUNCT	O
heat	O	NOUN	B
instability	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
normal	O	ADJ	O
pH	O	NOUN	B
optimum	O	NOUN	O
curve	O	NOUN	O
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
was	O	AUX	O
considered	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
new	O	ADJ	O
variant	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
designated	O	VERB	O
G6PD	O	NOUN	B
Nagano	O	PROPN	B
.	O	PUNCT	O


Infection	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hemolysis	B-Disease	NOUN	B
and	O	CCONJ	O
chronic	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
seem	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
markedly	O	ADV	O
impaired	O	ADJ	B
enzyme	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
thermal	O	ADJ	B
instability	O	NOUN	I
.	O	PUNCT	O


Heterozygous	O	ADJ	B
C2	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
and	O	CCONJ	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
.	O	PUNCT	O


Complement	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
states	O	NOUN	I
in	O	ADP	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
(	O	PUNCT	O
MG	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
19	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
typical	O	ADJ	O
MG	B-Disease	NOUN	B
and	O	CCONJ	O
heterozygous	O	ADJ	B
C2	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
HLA	O	NOUN	B
typing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
and	O	CCONJ	O
her	O	PRON	O
immediate	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
:	O	PUNCT	O
increased	O	VERB	B
plasma	O	NOUN	B
content	O	NOUN	B
of	O	ADP	O
saturated	O	VERB	B
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
.	O	PUNCT	O


With	O	ADP	O
a	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
we	O	PRON	O
measured	O	VERB	B
the	O	DET	O
saturated	O	ADJ	B
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
in	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
of	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
hemizygotes	O	NOUN	B
,	O	PUNCT	O
ALD	B-Disease	NOUN	B
heterozygotes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
controls	O	NOUN	B
.	O	PUNCT	O


ALD	B-Disease	NOUN	B
hemizygotes	O	NOUN	B
showed	O	VERB	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
hexacosanoate	O	NOUN	B
(	O	PUNCT	O
C26	O	NOUN	B
fatty	O	ADJ	I
acid	O	NOUN	I
)	O	PUNCT	O
which	O	DET	O
represented	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O


081	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


0066	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
SEM	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
total	O	ADJ	B
fatty	O	ADJ	I
acids	O	NOUN	I
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


015	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


0032	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
.	O	PUNCT	O


C25	O	NOUN	B
,	O	PUNCT	O
C24	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
C23	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
were	O	AUX	O
also	O	ADV	O
increased	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
C22	O	NOUN	B
and	O	CCONJ	O
C20	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


C26	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
most	O	ADJ	O
ALD	B-Disease	NOUN	B
heterozygotes	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
level	O	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


057	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


0063	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
total	O	ADJ	B
fatty	O	ADJ	I
acids	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
technique	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
diagnosis	O	NOUN	B
and	O	CCONJ	O
carrier	O	NOUN	B
identification	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
high	O	ADJ	B
density	O	NOUN	I
lipoproteins	O	NOUN	I
in	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
plasma	O	NOUN	B
lipoprotein	O	NOUN	B
profiles	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
density	O	NOUN	I
lipoproteins	O	NOUN	I
(	O	PUNCT	O
HDL	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
characterized	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
genetic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Abnormalities	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
HDL	I-Disease	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
their	O	PRON	O
increased	O	VERB	B
atherogenesis	O	NOUN	B
and	O	CCONJ	O
excessive	O	ADJ	B
deposits	O	NOUN	B
of	O	ADP	O
tissue	O	NOUN	B
sterols	O	NOUN	I
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
low	O	ADJ	B
or	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
normal	O	ADJ	B
concentrations	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
cholesterol	O	NOUN	I
(	O	PUNCT	O
165	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
density	O	NOUN	I
lipoproteins	O	NOUN	I
(	O	PUNCT	O
LDL	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
concentration	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CTX	B-Disease	NOUN	B
plasmas	O	NOUN	B
was	O	AUX	O
14	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
about	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
third	O	NOUN	O
the	O	DET	O
normal	O	ADJ	B
value	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
reflects	O	VERB	O
a	O	DET	O
low	O	ADJ	B
concentration	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
abnormal	O	ADJ	B
lipid	O	NOUN	B
composition	O	NOUN	I
of	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
HDL	O	NOUN	I
.	O	PUNCT	O


Relative	O	ADJ	O
to	O	PART	O
normal	O	ADJ	B
HDL	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
cholesteryl	O	NOUN	B
esters	O	NOUN	I
are	O	AUX	O
low	O	ADJ	B
,	O	PUNCT	O
free	O	ADJ	B
cholesterol	O	NOUN	I
and	O	CCONJ	O
phospholipids	O	NOUN	B
essentially	O	ADV	O
normal	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
triglycerides	O	NOUN	B
increased	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
apoprotein	O	NOUN	O
(	O	PUNCT	O
apo	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
total	O	ADJ	O
cholesterol	O	NOUN	O
in	O	ADP	O
the	O	DET	O
HDL	O	NOUN	B
of	O	ADP	O
CTX	B-Disease	NOUN	B
was	O	AUX	O
two	O	NUM	O
to	O	PART	O
three	O	NUM	O
times	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
CTX	B-Disease	NOUN	B
HDL	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
apoAI	O	NOUN	B
to	O	PART	O
apoAII	O	NOUN	B
was	O	AUX	O
high	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
apoC	O	NOUN	B
low	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
normally	O	ADV	O
minor	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
apoAI	O	NOUN	B
increased	O	VERB	B
relative	O	ADJ	O
to	O	PART	O
other	O	ADJ	O
forms	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
HDL	O	NOUN	B
in	O	ADP	O
electron	O	NOUN	B
micrographs	O	NOUN	I
appeared	O	VERB	O
normal	O	ADJ	O
morphologically	O	ADV	B
and	O	CCONJ	O
in	O	ADP	O
particle	O	NOUN	B
size	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
abnormalities	O	NOUN	B
in	O	ADP	O
lipoprotein	O	NOUN	B
distribution	O	NOUN	I
profile	O	NOUN	I
and	O	CCONJ	O
composition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
HDL	O	NOUN	O
result	O	VERB	O
from	O	ADP	O
metabolic	O	ADJ	B
defects	O	NOUN	O
that	O	PRON	O
are	O	AUX	O
not	O	PART	O
understood	O	VERB	O
but	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
in	O	ADP	O
bile	O	NOUN	B
acid	O	NOUN	I
synthesis	O	NOUN	O
in	O	ADP	O
CTX	B-Disease	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
consequence	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
probable	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
normal	O	ADJ	B
functions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
HDL	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
including	O	VERB	O
modulation	O	NOUN	B
of	O	ADP	O
LDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
uptake	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
removal	O	NOUN	B
of	O	ADP	O
excess	O	ADJ	B
cholesterol	O	NOUN	B
from	O	ADP	O
peripheral	O	ADJ	B
tissues	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
perturbed	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Genetics	O	NOUN	B
of	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	O
trait	O	NOUN	O
with	O	ADP	O
high	O	ADJ	O
gene	O	NOUN	B
frequency	O	NOUN	I
in	O	ADP	O
Sephardim	O	PROPN	B
of	O	ADP	O
Moroccan	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
described	O	VERB	O
6	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
3	O	NUM	O
families	O	NOUN	B
)	O	PUNCT	O
affected	O	VERB	B
with	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
are	O	AUX	O
Sephardic	O	ADJ	B
Jews	O	PROPN	I
of	O	ADP	O
Moroccan	O	ADJ	B
extraction	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
CTX	B-Disease	NOUN	B
patients	O	NOUN	B
diagnosed	O	VERB	B
in	O	ADP	O
the	O	DET	O
world	O	NOUN	B
(	O	PUNCT	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
50	O	NUM	O
including	O	VERB	O
our	O	PRON	O
6	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
we	O	PRON	O
are	O	AUX	O
probably	O	ADV	O
dealing	O	VERB	B
with	O	ADP	O
an	O	DET	O
ethnic	O	ADJ	B
subgroup	O	NOUN	I
with	O	ADP	O
a	O	DET	O
high	O	ADJ	O
CTX	O	NOUN	B
gene	O	NOUN	B
frequency	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
have	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
1	O	NUM	O
/	O	SYM	O
108	O	NUM	O
.	O	PUNCT	O


Since	O	SCONJ	O
there	O	PRON	O
are	O	AUX	O
differences	O	NOUN	O
in	O	ADP	O
expression	O	NOUN	B
in	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
recommend	O	VERB	O
cholestanol	O	NOUN	B
study	O	NOUN	B
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
undiagnosed	O	ADJ	B
cataract	B-Disease	NOUN	B
or	O	CCONJ	O
tendinous	B-Disease	ADJ	B
xanthomas	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
or	O	CCONJ	O
early	O	ADJ	B
adolescence	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
diagnosis	O	NOUN	B
in	O	ADP	O
CTX	B-Disease	NOUN	B
is	O	AUX	O
important	O	ADJ	O
not	O	PART	O
only	O	ADV	O
for	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
veiw	O	NOUN	B
of	O	ADP	O
possible	O	ADJ	O
treatment	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


New	O	ADJ	O
genetic	O	ADJ	B
variants	O	NOUN	I
of	O	ADP	O
glucose	O	NOUN	B
6	O	NUM	I
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Italy	O	PROPN	B
.	O	PUNCT	O


Six	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
erythrocyte	O	NOUN	B
G6PD	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
characterized	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
of	O	ADP	O
them	O	PRON	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
Italian	O	ADJ	B
males	O	NOUN	B
and	O	CCONJ	O
all	O	DET	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
two	O	NUM	O
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
haemolysis	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
and	O	CCONJ	O
other	O	ADJ	O
variants	O	NOUN	B
reported	O	VERB	O
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
must	O	AUX	O
thus	O	ADV	O
far	O	ADV	O
be	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
sporadic	O	ADJ	B
,	O	PUNCT	O
are	O	AUX	O
found	O	VERB	O
to	O	PART	O
map	O	VERB	B
in	O	ADP	O
parts	O	NOUN	B
of	O	ADP	O
Italy	O	PROPN	B
where	O	SCONJ	O
common	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
are	O	AUX	O
also	O	ADV	O
prevalent	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


Variants	O	NOUN	B
of	O	ADP	O
erythrocyte	O	NOUN	B
glucose	O	NOUN	O
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Bulgarian	O	ADJ	B
populations	O	NOUN	B
.	O	PUNCT	O


Ten	O	NUM	O
variants	O	NOUN	B
of	O	ADP	O
erythrocyte	O	NOUN	B
glucose	O	NOUN	O
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
22	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
from	O	ADP	O
three	O	NUM	O
districts	O	NOUN	B
of	O	ADP	O
Bulgaria	O	PROPN	B
.	O	PUNCT	O


Corinth	O	PROPN	B
-	O	PUNCT	O
like	O	PROPN	B
and	O	CCONJ	O
Fayoum	O	PROPN	B
-	O	PUNCT	O
like	O	ADJ	B
variants	O	NOUN	B
were	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
;	O	PUNCT	O
Mediterranean	O	PROPN	B
,	O	PUNCT	O
Ohut	O	PROPN	B
II	O	PROPN	I
,	O	PUNCT	O
Kilgore	O	PROPN	B
,	O	PUNCT	O
Boston	O	PROPN	B
,	O	PUNCT	O
Poznan	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Panay	O	PROPN	B
variants	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
new	O	ADJ	O
variants	O	NOUN	B
,	O	PUNCT	O
Petrich	O	PROPN	B
and	O	CCONJ	O
Gotze	O	PROPN	B
Delchev	O	PROPN	I
,	O	PUNCT	O
were	O	AUX	O
each	O	DET	O
found	O	VERB	O
in	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
two	O	NUM	O
carriers	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
correlation	O	NOUN	B
was	O	AUX	O
revealed	O	VERB	O
between	O	ADP	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
polymorphism	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Nephropathy	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Nephropathy	B-Disease	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
five	O	NUM	O
of	O	ADP	O
32	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
who	O	PRON	O
were	O	AUX	O
participating	O	VERB	O
in	O	ADP	O
a	O	DET	O
study	O	NOUN	B
of	O	ADP	O
transfer	O	NOUN	B
factor	O	NOUN	I
(	O	PUNCT	O
TF	O	NOUN	O
)	O	PUNCT	O
therapy	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
nephropathy	B-Disease	NOUN	B
was	O	AUX	O
present	O	ADJ	O
before	O	ADP	B
TF	O	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
appear	O	VERB	O
changed	O	VERB	O
by	O	ADP	O
TF	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
subsequently	O	ADV	O
developed	O	VERB	O
progressive	O	ADJ	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
requiring	O	VERB	O
dialysis	O	NOUN	B
beginning	O	VERB	O
5	O	NUM	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
TF	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
decreased	O	VERB	B
renal	O	ADJ	B
function	O	NOUN	I
appeared	O	VERB	O
very	O	ADV	O
soon	O	ADV	O
after	O	ADP	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
TF	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
showed	O	VERB	O
gradually	O	ADV	O
decreasing	O	VERB	B
renal	O	ADJ	B
function	O	NOUN	I
beginning	O	VERB	O
after	O	ADP	O
two	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
TF	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
additional	O	ADJ	O
patient	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
who	O	PRON	O
died	O	VERB	B
with	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
without	O	ADP	O
having	O	VERB	O
received	O	VERB	O
TF	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
occurs	O	VERB	O
in	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
more	O	ADV	O
frequently	O	ADV	O
than	O	ADP	O
generally	O	ADV	O
recognized	O	VERB	O
and	O	CCONJ	O
that	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
TF	O	NOUN	B
may	O	AUX	O
precipitate	O	VERB	B
or	O	CCONJ	O
accelerate	O	VERB	O
the	O	DET	O
renal	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
this	O	DET	O
syndrome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
cellular	O	ADJ	B
impairments	O	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
implication	O	NOUN	B
for	O	ADP	O
carrier	O	NOUN	B
detection	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
two	O	NUM	O
male	O	NOUN	B
siblings	O	NOUN	B
were	O	AUX	O
affected	O	VERB	B
with	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
studied	O	VERB	O
using	O	VERB	O
G	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
PD	O	NOUN	B
isoenzymes	O	NOUN	B
as	O	ADP	O
an	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
marker	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
cellular	O	ADJ	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


Isolated	O	ADJ	B
peripheral	O	ADJ	B
blood	O	NOUN	I
cell	O	NOUN	I
types	O	NOUN	O
from	O	ADP	O
the	O	DET	O
doubly	O	ADV	O
heterozygous	O	ADJ	B
mother	O	NOUN	B
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
males	O	NOUN	B
seemingly	O	ADV	O
failed	O	VERB	O
to	O	PART	O
express	O	VERB	B
the	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	B
-	O	PUNCT	O
PD	O	NOUN	B
allele	O	NOUN	B
in	O	ADP	O
cis	O	ADJ	B
position	O	NOUN	I
with	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
allele	O	NOUN	B
while	O	SCONJ	O
her	O	PRON	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	B
expressed	O	VERB	B
both	O	CCONJ	O
G	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	B
-	O	PUNCT	O
PD	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
histogram	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
platelet	O	NOUN	B
size	O	NOUN	I
revealed	O	VERB	B
a	O	DET	O
single	O	ADJ	O
population	O	NOUN	B
of	O	ADP	O
abnormally	O	ADV	B
small	O	ADJ	O
platelets	O	NOUN	B
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
propositus	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
heterozygous	O	ADJ	B
mother	O	NOUN	B
had	O	AUX	O
no	O	DET	O
appreciable	O	ADJ	O
small	O	ADJ	O
platelet	O	NOUN	B
subpopulation	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
culture	O	NOUN	B
of	O	ADP	O
hemopoietic	O	ADJ	B
progenitor	O	NOUN	I
cells	O	NOUN	I
of	O	ADP	O
the	O	DET	O
heterozygous	O	ADJ	B
mother	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
progenitor	O	NOUN	B
cells	O	NOUN	I
did	O	AUX	O
not	O	PART	O
express	O	VERB	O
the	O	DET	O
WAS	B-Disease	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
cells	O	NOUN	B
expressing	O	VERB	B
the	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	B
-	O	PUNCT	O
PD	O	NOUN	B
type	O	NOUN	O
linked	O	VERB	O
with	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
allele	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
progenitors	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
among	O	ADP	O
more	O	ADV	O
primitive	O	ADJ	B
progenitors	O	NOUN	B
(	O	PUNCT	O
those	O	DET	O
giving	O	VERB	O
rise	O	NOUN	O
to	O	ADP	O
later	O	ADV	O
appearing	O	VERB	O
colonies	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
selection	O	NOUN	B
against	O	ADP	O
cells	O	NOUN	B
expressing	O	VERB	B
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
defect	I-Disease	NOUN	B
takes	O	VERB	O
place	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hemopoietic	O	ADJ	B
system	O	NOUN	I
of	O	ADP	O
the	O	DET	O
heterozygous	O	ADJ	B
female	O	NOUN	B
and	O	CCONJ	O
offers	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
means	O	NOUN	O
of	O	ADP	O
carrier	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
some	O	DET	O
women	O	NOUN	B
.	O	PUNCT	O


Linkage	O	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
revealed	O	VERB	B
one	O	NUM	O
example	O	NOUN	O
of	O	ADP	O
probable	O	ADJ	B
recombination	O	NOUN	B
between	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
for	O	ADP	O
WAS	B-Disease	PROPN	B
and	O	CCONJ	O
G	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	B
-	O	PUNCT	O
PD	O	NOUN	B
among	O	ADP	O
three	O	NUM	O
informative	O	ADJ	O
subjects	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
two	O	NUM	O
loci	O	NOUN	B
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
closely	O	ADV	O
linked	O	VERB	O
on	O	ADP	O
the	O	DET	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
CT	O	NOUN	B
pattern	O	NOUN	B
in	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
CT	O	NOUN	B
pattern	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
pattern	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
the	O	DET	O
authors	O	NOUN	B
call	O	VERB	O
Type	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
posterior	O	ADJ	B
periventricular	O	ADJ	I
areas	O	NOUN	I
of	O	ADP	O
decreased	O	VERB	B
attenuation	O	NOUN	B
around	O	ADP	O
the	O	DET	O
trigone	O	NOUN	B
on	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
contrast	O	NOUN	B
scans	O	NOUN	I
after	O	ADP	O
contrast	O	NOUN	O
infusion	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
striking	O	ADJ	O
enhancement	O	NOUN	B
of	O	ADP	O
various	O	ADJ	O
white	O	ADJ	B
-	O	PUNCT	O
matter	O	NOUN	B
structures	O	NOUN	B
(	O	PUNCT	O
tracts	O	NOUN	B
or	O	CCONJ	O
fiber	O	NOUN	B
systems	O	NOUN	O
)	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
internal	O	ADJ	B
capsules	O	NOUN	I
,	O	PUNCT	O
corpus	O	NOUN	B
callosum	O	NOUN	I
,	O	PUNCT	O
corona	O	NOUN	B
radiata	O	NOUN	I
,	O	PUNCT	O
forceps	O	VERB	B
major	O	ADJ	I
,	O	PUNCT	O
and	O	CCONJ	O
cerebral	O	ADJ	B
peduncles	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
numerous	O	ADJ	O
previous	O	ADJ	O
descriptions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CT	O	NOUN	B
pattern	O	NOUN	B
in	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


Type	B-Disease	NOUN	B
II	I-Disease	NUM	I
ALD	I-Disease	PROPN	I
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
been	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
any	O	DET	O
other	O	ADJ	O
leukoencephalopathy	B-Disease	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
probably	O	ADV	O
specific	O	ADJ	O
for	O	ADP	O
a	O	DET	O
phenotypic	O	ADJ	B
variant	O	NOUN	O
or	O	CCONJ	O
an	O	DET	O
evolving	O	ADJ	B
stage	O	NOUN	O
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Further	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
heterogeneity	O	NOUN	B
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	O
.	O	PUNCT	O


Four	O	NUM	O
new	O	ADJ	O
G6PD	O	NOUN	B
variants	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
characterized	O	VERB	B
in	O	ADP	O
individuals	O	NOUN	B
from	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
Markham	O	PROPN	B
variant	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
newly	O	ADV	O
characterized	O	VERB	O
Salata	O	PROPN	B
variant	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
widely	O	ADV	O
distributed	O	VERB	B
in	O	ADP	O
Papua	O	PROPN	B
New	O	PROPN	O
Guinea	O	PROPN	O
.	O	PUNCT	O


Th	O	NOUN	B
data	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
together	O	ADV	O
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
previously	O	ADV	O
published	O	VERB	B
studies	O	NOUN	I
demonstrate	O	VERB	O
a	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
that	O	PRON	O
is	O	AUX	O
much	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
other	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
world	O	NOUN	B
where	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
common	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


Increased	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
cataracts	B-Disease	NOUN	B
in	O	ADP	O
male	O	ADJ	B
subjects	O	NOUN	O
deficient	B-Disease	ADJ	B
in	I-Disease	ADP	O
glucose	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
RBCs	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
significantly	O	ADV	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
210	O	NUM	O
male	O	ADJ	B
cataractous	B-Disease	ADJ	B
patients	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
672	O	NUM	O
control	O	ADJ	B
subjects	O	NOUN	I
of	O	ADP	O
Sardinian	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deficiency	O	NOUN	B
was	O	AUX	O
increasingly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
presenile	O	NOUN	B
cataracts	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
group	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
cortical	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
total	I-Disease	ADJ	O
cataracts	I-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
increased	O	VERB	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
decrease	O	NOUN	B
of	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lens	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
accompanies	O	VERB	O
its	O	PRON	O
deficiency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
erythrocyte	O	NOUN	B
,	O	PUNCT	O
might	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
cataracto	O	NOUN	B
-	O	PUNCT	O
genesis	O	NOUN	B
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
should	O	AUX	O
be	O	AUX	O
added	O	VERB	O
to	O	ADP	O
other	O	ADJ	O
conditions	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
the	O	DET	O
galactosemic	B-Disease	ADJ	B
states	O	NOUN	I
and	O	CCONJ	O
riboflavin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
where	O	SCONJ	O
cataracts	B-Disease	NOUN	B
represent	O	VERB	O
a	O	DET	O
sensitive	O	ADJ	B
indicator	O	NOUN	B
of	O	ADP	O
metabolic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
RBC	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
mitochondrial	O	ADJ	B
very	B-Disease	ADV	O
-	I-Disease	PUNCT	O
long	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
chain	I-Disease	NOUN	B
acyl	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
CoA	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
causing	O	VERB	O
cardiomyopathy	B-Disease	NOUN	B
and	O	CCONJ	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


beta	O	NOUN	B
-	O	PUNCT	O
Oxidation	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
provides	O	VERB	O
the	O	DET	O
major	O	ADJ	O
source	O	NOUN	B
of	O	ADP	O
energy	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heart	O	NOUN	B
.	O	PUNCT	O


Defects	O	NOUN	B
in	O	ADP	O
enzymes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
pathway	O	NOUN	O
cause	O	VERB	O
sudden	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
unexplained	I-Disease	ADJ	B
death	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
,	O	PUNCT	O
acute	O	ADJ	B
hepatic	B-Disease	ADJ	I
encephalopathy	I-Disease	NOUN	I
or	O	CCONJ	O
liver	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
,	O	PUNCT	O
skeletal	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	I
[	O	PUNCT	O
VLCAD	O	NOUN	B
;	O	PUNCT	O
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
-	O	PUNCT	O
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
(	O	PUNCT	O
acceptor	O	NOUN	B
)	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
oxidoreductase	O	NOUN	B
,	O	PUNCT	O
EC	O	NOUN	B
1	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
3	O	NUM	O
.	O	PUNCT	O
99	O	NUM	O
99	O	NUM	O
.	O	PUNCT	O
13	O	NUM	O
]	O	PUNCT	O
catalyzes	O	VERB	B
the	O	DET	O
first	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
the	O	DET	O
human	O	ADJ	B
VLCAD	O	NOUN	B
cDNA	O	NOUN	B
and	O	CCONJ	O
gene	O	NOUN	B
and	O	CCONJ	O
determined	O	VERB	O
the	O	DET	O
complete	O	ADJ	B
nucleotide	O	NOUN	B
sequences	O	NOUN	I
.	O	PUNCT	O


Polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
amplification	O	NOUN	I
of	O	ADP	O
VLCAD	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
genomic	O	ADJ	B
exons	O	NOUN	I
defined	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
defects	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
unexplained	O	ADJ	B
cardiac	B-Disease	ADJ	B
arrest	I-Disease	NOUN	I
and	O	CCONJ	O
cardiomyopathy	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
homozygous	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
consensus	O	NOUN	B
dinucleotide	O	NOUN	I
of	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
(	O	PUNCT	O
g	O	NOUN	O
+	O	CCONJ	O
1	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
a	O	X	O
)	O	PUNCT	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
universal	O	ADJ	O
skipping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
prior	O	ADJ	O
exon	O	NOUN	O
(	O	PUNCT	O
exon	O	NOUN	O
11	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
was	O	AUX	O
a	O	DET	O
compound	O	NOUN	B
heterozygote	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
C1837	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
,	O	PUNCT	O
changing	O	VERB	B
the	O	DET	O
arginine	O	NOUN	B
at	O	ADP	O
residue	O	NOUN	B
613	O	NUM	O
to	O	PART	O
tryptophan	O	NOUN	B
on	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
single	O	ADJ	B
base	O	NOUN	I
deletion	O	NOUN	O
at	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
-	O	PUNCT	O
exon	O	NOUN	B
6	O	NUM	O
boundary	O	NOUN	B
as	O	ADP	O
the	O	DET	O
second	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
initial	O	ADJ	O
delineation	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
VLCAD	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
reduces	O	VERB	O
myocardial	O	ADJ	B
fatty	O	ADJ	I
acid	O	NOUN	I
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
and	O	CCONJ	O
energy	O	NOUN	B
production	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
cardiomyopathy	B-Disease	NOUN	B
and	O	CCONJ	O
sudden	B-Disease	ADJ	B
death	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
.	O	PUNCT	O


Aberrant	O	ADJ	B
subcellular	O	ADJ	B
localization	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	B
product	O	NOUN	I
was	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
220	O	NUM	O
-	O	PUNCT	O
kilodalton	O	ADJ	B
nuclear	O	ADJ	B
phosphoprotein	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
cells	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
breast	O	NOUN	B
ductal	O	ADJ	I
epithelial	O	ADJ	I
cells	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
18	O	NUM	O
of	O	ADP	O
20	O	NUM	O
tumor	B-Disease	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
tissues	O	NOUN	B
other	O	ADJ	O
than	O	ADP	O
breast	O	NOUN	B
and	O	CCONJ	O
ovary	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
16	O	NUM	O
of	O	ADP	O
17	O	NUM	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
lines	O	NOUN	O
and	O	CCONJ	O
17	O	NUM	O
of	O	ADP	O
17	O	NUM	O
samples	O	NOUN	B
of	O	ADP	O
cells	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
malignant	O	ADJ	B
effusions	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
BRCA1	O	NOUN	B
localized	O	VERB	B
mainly	O	ADV	O
in	O	ADP	O
cytoplasm	O	NOUN	B
.	O	PUNCT	O


Absence	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
aberrant	O	ADJ	B
subcellular	O	ADJ	B
location	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
observed	O	VERB	O
to	O	PART	O
a	O	DET	O
variable	O	ADJ	B
extent	O	NOUN	O
in	O	ADP	O
histological	O	ADJ	B
sections	O	NOUN	I
of	O	ADP	O
many	O	ADJ	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
biopsies	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
BRCA1	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
many	O	ADJ	O
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
sporadic	O	ADJ	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
familial	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


Mapping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
8	O	NUM	I
.	O	PUNCT	O


ATP7B	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
altered	O	VERB	O
in	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
WD	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
,	O	PUNCT	O
lies	O	VERB	O
in	O	ADP	O
a	O	DET	O
block	O	NOUN	B
of	O	ADP	O
homology	O	NOUN	B
shared	O	VERB	O
between	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
13q14	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
central	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
14	O	NUM	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
mapped	O	VERB	B
the	O	DET	O
murine	O	ADJ	B
homologue	O	NOUN	B
of	O	ADP	O
ATP7B	O	NOUN	B
(	O	PUNCT	O
Atp7b	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
8	O	NUM	O
by	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrid	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
80	O	NUM	O
interspecific	O	ADJ	B
backcross	O	NOUN	O
offspring	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
position	O	VERB	B
Atp7b	O	NOUN	B
close	O	ADV	O
to	O	PART	O
D8Mit3	O	NOUN	B
and	O	CCONJ	O
another	O	DET	O
ATPase	O	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
Atp4b	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
8	O	NUM	I
.	O	PUNCT	O


ATP4B	O	ADJ	B
lies	O	NOUN	O
in	O	ADP	O
13q34	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
separated	O	VERB	O
from	O	ADP	O
ATP7B	O	NOUN	B
by	O	ADP	O
several	O	ADJ	O
loci	O	NOUN	B
whose	O	DET	O
mouse	O	NOUN	B
homologues	O	NOUN	I
map	O	NOUN	O
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
14	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
assignment	O	NOUN	B
of	O	ADP	O
Atp7b	O	NOUN	B
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
8	O	NUM	O
identifies	O	VERB	O
a	O	DET	O
previously	O	ADV	O
unrecognized	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
homology	O	NOUN	B
between	O	ADP	O
this	O	DET	O
chromosome	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
chromosome	O	NOUN	O
13	O	NUM	O
.	O	PUNCT	O


This	O	DET	O
assignment	O	NOUN	B
suggests	O	VERB	O
a	O	DET	O
possible	O	ADJ	O
location	O	NOUN	B
for	O	ADP	O
the	O	DET	O
toxic	O	ADJ	B
milk	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
a	O	DET	O
homologue	O	NOUN	B
of	O	ADP	O
WD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
provide	O	VERB	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
discovered	O	VERB	O
in	O	ADP	O
1994	O	NUM	O
,	O	PUNCT	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
80	O	NUM	O
-	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
lifetime	O	NOUN	B
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analysed	O	VERB	B
60	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
for	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
two	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
32	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
53	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
14	O	NUM	O
are	O	AUX	O
previously	O	ADV	O
unreported	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	O
to	I-Disease	PART	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
incidence	O	NOUN	B
within	O	ADP	O
each	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
transition	O	NOUN	B
in	O	ADP	O
risk	O	NOUN	B
such	O	ADJ	O
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
third	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
lower	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Haplotype	O	NOUN	B
analysis	O	NOUN	B
supports	O	VERB	O
previous	O	ADJ	O
data	O	NOUN	B
which	O	DET	O
suggest	O	VERB	O
some	O	DET	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
carriers	O	NOUN	B
have	O	AUX	O
common	O	ADJ	O
ancestors	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
two	O	NUM	O
examples	O	NOUN	B
where	O	SCONJ	O
recurrent	O	ADJ	B
mutations	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
arisen	O	VERB	O
independently	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


Hereditary	O	ADJ	B
deficiency	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
and	O	CCONJ	O
recurrent	O	ADJ	O
meningococcal	B-Disease	ADJ	O
infection	I-Disease	NOUN	O
:	O	PUNCT	O
investigations	O	NOUN	B
of	O	ADP	O
an	O	DET	O
Irish	O	ADJ	B
family	O	NOUN	B
using	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
haemolytic	O	ADJ	B
screening	O	NOUN	O
assay	O	NOUN	O
for	O	ADP	O
complement	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
C7	O	NOUN	B
M	O	PROPN	I
/	O	SYM	O
N	O	NOUN	B
allotyping	O	NOUN	I
.	O	PUNCT	O


Terminal	B-Disease	ADJ	B
complement	I-Disease	NOUN	O
component	I-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
predisposes	O	VERB	O
to	O	PART	O
meningococcal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
inherited	O	VERB	B
in	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
co	O	ADP	B
-	O	PUNCT	O
dominant	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


An	O	DET	O
Irish	O	ADJ	B
family	O	NOUN	O
is	O	AUX	O
described	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
2	O	NUM	O
of	O	ADP	O
3	O	NUM	O
brothers	O	NOUN	B
had	O	AUX	O
recurrent	O	ADJ	B
meningococcal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	O
screening	O	NOUN	B
assay	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
for	O	ADP	O
terminal	B-Disease	ADJ	B
complement	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
2	O	NUM	O
affected	O	VERB	B
brothers	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
completely	B-Disease	ADV	O
deficient	I-Disease	ADJ	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
seventh	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C7	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Enzyme	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
immunosorbent	O	ADJ	I
assay	O	NOUN	I
for	O	ADP	O
C7	O	NOUN	B
revealed	O	VERB	B
lower	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
brother	O	NOUN	B
and	O	CCONJ	O
parents	O	NOUN	B
.	O	PUNCT	O


C7	O	NOUN	B
M	O	PROPN	I
/	O	SYM	O
N	O	NOUN	B
protein	O	NOUN	I
polymorphism	O	NOUN	B
allotyping	O	NOUN	B
,	O	PUNCT	O
used	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
segregation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
genes	O	NOUN	I
,	O	PUNCT	O
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
apparently	O	ADV	O
complement	O	NOUN	B
sufficient	O	ADJ	I
brother	O	NOUN	I
was	O	AUX	O
heterozygous	O	ADJ	B
C7	B-Disease	NOUN	B
deficient	I-Disease	ADJ	I
and	O	CCONJ	O
a	O	DET	O
carrier	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
deficiency	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


Complement	O	NOUN	B
screening	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
any	O	DET	O
individual	O	ADJ	O
suffering	O	NOUN	B
recurrent	O	ADJ	B
meningococcal	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
or	O	CCONJ	O
infection	O	NOUN	B
with	O	ADP	O
an	O	DET	O
uncommon	O	ADJ	O
meningococcal	B-Disease	ADJ	B
serogroup	O	NOUN	I
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
complement	B-Disease	NOUN	B
deficient	I-Disease	ADJ	I
patients	O	NOUN	B
allows	O	VERB	O
the	O	DET	O
implementation	O	NOUN	B
of	O	ADP	O
strategies	O	NOUN	O
to	O	PART	O
prevent	O	VERB	B
recurrent	O	ADJ	B
infection	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
subtotal	B-Disease	ADJ	B
complement	I-Disease	NOUN	I
C6	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminally	O	ADV	B
truncated	O	VERB	B
but	O	CCONJ	O
functionally	O	ADV	O
active	O	ADJ	O
C6	O	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
with	O	ADP	O
subtotal	B-Disease	ADJ	B
complement	I-Disease	NOUN	I
C6	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
possess	O	VERB	O
a	O	DET	O
C6	O	NOUN	B
molecule	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
14	O	NUM	O
%	O	NOUN	O
shorter	O	ADJ	B
than	O	ADP	O
normal	O	ADJ	B
C6	O	NOUN	B
and	O	CCONJ	O
present	O	ADJ	O
in	O	ADP	O
low	O	ADJ	B
but	O	CCONJ	O
detectable	O	ADJ	B
concentrations	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
mean	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
dysmorphic	O	ADJ	B
C6	O	NOUN	O
is	O	AUX	O
bactericidally	O	ADV	B
active	O	ADJ	B
and	O	CCONJ	O
lacks	O	VERB	B
an	O	DET	O
epitope	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
most	O	ADJ	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
part	O	NOUN	O
of	O	ADP	O
C6	O	NOUN	B
using	O	VERB	O
C6	O	NOUN	B
cDNA	O	NOUN	I
fragments	O	NOUN	B
expressed	O	VERB	B
as	O	ADP	O
fusion	O	NOUN	B
proteins	O	NOUN	I
in	O	ADP	O
the	O	DET	O
pUEX	O	NOUN	B
expression	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
thus	O	ADV	O
predicted	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
abnormal	O	ADJ	B
C6	O	NOUN	B
molecule	O	NOUN	I
might	O	AUX	O
be	O	AUX	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminally	O	ADV	B
truncated	O	VERB	B
and	O	CCONJ	O
sought	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
an	O	DET	O
area	O	NOUN	B
approximately	O	ADV	O
14	O	NUM	O
%	O	NOUN	O
from	O	ADP	O
the	O	DET	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
sequencing	O	VERB	B
PCR	O	NOUN	I
-	O	PUNCT	O
amplified	O	VERB	B
products	O	NOUN	B
from	O	ADP	O
this	O	DET	O
region	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
three	O	NUM	O
individuals	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
mutation	O	NOUN	B
that	O	PRON	O
might	O	AUX	O
plausibly	O	ADV	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
defect	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
three	O	NUM	O
have	O	AUX	O
an	O	DET	O
abnormal	O	ADJ	B
5	O	NUM	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
15	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
would	O	AUX	O
probably	O	ADV	O
prevent	O	VERB	B
splicing	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
in	O	X	O
-	O	PUNCT	O
frame	O	NOUN	B
stop	O	NOUN	O
codon	O	NOUN	B
is	O	AUX	O
found	O	VERB	O
17	O	NUM	O
codons	O	NOUN	B
downstream	O	ADJ	B
from	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
boundary	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
would	O	AUX	O
lead	O	VERB	O
to	O	PART	O
a	O	DET	O
truncated	O	VERB	O
polypeptide	O	NOUN	O
13	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
smaller	O	ADJ	O
than	O	ADP	O
normal	O	ADJ	B
C6	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	B
was	O	AUX	O
unexpected	O	ADJ	O
,	O	PUNCT	O
as	O	ADP	O
earlier	O	ADJ	O
studies	O	NOUN	B
mapped	O	VERB	B
the	O	DET	O
C5b	O	NOUN	B
binding	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
putative	O	ADJ	O
enzymatic	O	ADJ	O
region	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
this	O	DET	O
part	O	NOUN	O
of	O	ADP	O
C6	O	NOUN	B
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
three	O	NUM	O
subjects	O	NOUN	B
were	O	AUX	O
probably	O	ADV	O
heterozygous	O	ADJ	B
for	O	ADP	O
both	O	CCONJ	O
subtotal	B-Disease	ADJ	B
C6	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
complete	I-Disease	ADJ	B
C6	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
:	O	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
dominant	O	ADJ	B
-	O	PUNCT	O
negative	O	ADJ	B
RNA	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
trinucleotide	O	NOUN	B
expansion	O	NOUN	B
mutation	O	NOUN	B
causing	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
is	O	AUX	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
by	O	ADP	O
which	O	DET	O
the	O	DET	O
expanded	O	ADJ	O
repeat	O	NOUN	O
causes	O	VERB	O
the	O	DET	O
clinically	O	ADV	B
variable	O	ADJ	I
and	O	CCONJ	O
multisystemic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
not	O	PART	O
understood	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
particularly	O	ADV	O
difficult	O	ADJ	O
to	O	PART	O
rationalize	O	VERB	O
the	O	DET	O
dominant	O	ADJ	B
inheritance	O	NOUN	B
with	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
expansion	O	NOUN	B
mutation	O	NOUN	B
lies	O	VERB	O
outside	O	ADV	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
encoding	O	VERB	B
gene	O	NOUN	B
elements	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
should	O	AUX	O
not	O	PART	O
be	O	AUX	O
translated	O	VERB	B
into	O	ADP	O
protein	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
use	O	VERB	O
muscle	O	NOUN	B
biopsies	O	NOUN	I
from	O	ADP	O
classical	O	ADJ	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
patients	O	NOUN	B
to	O	PART	O
study	O	VERB	B
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
transcripts	O	NOUN	B
from	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
expanded	O	VERB	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
genes	O	NOUN	I
in	O	ADP	O
patient	O	NOUN	B
muscle	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
results	O	NOUN	B
to	O	PART	O
normal	O	ADJ	B
and	O	CCONJ	O
myopathic	B-Disease	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
relatively	O	ADV	O
small	O	ADJ	O
decreases	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
RNA	O	NOUN	I
in	O	ADP	O
the	O	DET	O
total	O	ADJ	O
RNA	O	NOUN	B
pool	O	NOUN	O
from	O	ADP	O
muscle	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
reductions	O	NOUN	B
were	O	AUX	O
not	O	PART	O
disease	O	NOUN	B
specific	O	ADJ	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
poly	O	NOUN	B
(	O	PUNCT	I
A	O	NOUN	I
)	O	PUNCT	I
+	O	CCONJ	O
RNA	O	NOUN	B
showed	O	VERB	O
dramatic	O	ADJ	O
decreases	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
mutant	O	ADJ	B
and	O	CCONJ	O
normal	O	ADJ	B
DM	B-Disease	NOUN	I
kinase	O	NOUN	I
RNAs	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
these	O	DET	O
changes	O	NOUN	B
were	O	AUX	O
disease	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
novel	O	ADJ	O
molecular	O	ADJ	B
pathogenetic	O	ADJ	I
mechanism	O	NOUN	I
for	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
both	O	CCONJ	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
expanded	O	VERB	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
genes	O	NOUN	I
are	O	AUX	O
transcribed	O	VERB	B
in	O	ADP	O
patient	O	NOUN	B
muscle	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
abnormal	O	ADJ	B
expansion	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
RNA	O	NOUN	B
has	O	AUX	O
a	O	DET	O
dominant	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
RNA	O	NOUN	B
metabolism	O	NOUN	I
by	O	ADP	O
preventing	O	VERB	B
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
poly	O	NOUN	B
(	O	PUNCT	I
A	O	NOUN	I
)	O	PUNCT	I
+	O	CCONJ	O
RNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
the	O	DET	O
expansion	O	NOUN	B
mutation	O	NOUN	B
to	O	PART	O
alter	O	VERB	O
accumulation	O	NOUN	B
of	O	ADP	O
poly	O	NOUN	B
(	O	PUNCT	I
A	O	NOUN	I
)	O	PUNCT	I
+	O	CCONJ	O
RNA	O	NOUN	B
in	O	ADP	O
trans	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
first	O	ADJ	O
example	O	NOUN	O
of	O	ADP	O
a	O	DET	O
dominant	O	ADJ	B
-	O	PUNCT	O
negative	O	ADJ	B
mutation	O	NOUN	B
manifested	O	VERB	O
at	O	ADP	O
the	O	DET	O
RNA	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
strong	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
BRCA1	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
strong	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
the	O	DET	O
17q	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
BRCA1	O	NOUN	B
gene	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
influences	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
positional	O	ADJ	B
cloning	O	NOUN	I
methods	O	NOUN	I
.	O	PUNCT	O


Probable	O	ADJ	B
predisposing	O	VERB	B
mutations	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
five	O	NUM	O
of	O	ADP	O
eight	O	NUM	O
kindreds	O	NOUN	B
presumed	O	VERB	O
to	O	PART	O
segregate	O	VERB	O
BRCA1	O	NOUN	B
susceptibility	O	NOUN	B
alleles	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
include	O	VERB	O
an	O	DET	O
11	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
insertion	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
substitution	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
inferred	O	VERB	O
regulatory	O	ADJ	B
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
numerous	O	ADJ	B
tissues	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
breast	O	NOUN	B
and	O	CCONJ	O
ovary	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
encodes	O	VERB	B
a	O	DET	O
predicted	O	VERB	O
protein	O	NOUN	B
of	O	ADP	O
1863	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
protein	O	NOUN	B
contains	O	VERB	O
a	O	DET	O
zinc	O	NOUN	B
finger	O	NOUN	I
domain	O	NOUN	I
in	O	ADP	O
its	O	PRON	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
otherwise	O	ADV	O
unrelated	O	ADJ	O
to	O	PART	O
previously	O	ADV	O
described	O	VERB	O
proteins	O	NOUN	B
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
should	O	AUX	O
facilitate	O	VERB	O
early	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
in	O	ADP	O
some	O	DET	O
individuals	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
better	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
biology	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
galactosemia	B-Disease	NOUN	B
(	O	PUNCT	O
type	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
Japanese	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
characterized	O	VERB	B
two	O	NUM	O
novel	O	ADJ	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
GALT	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
identified	O	VERB	B
N314D	O	NOUN	B
and	O	CCONJ	O
R333W	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
found	O	VERB	O
in	O	ADP	O
Caucasians	O	PROPN	B
.	O	PUNCT	O


One	O	NUM	O
novel	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
an	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	DET	O
transition	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
8	O	NUM	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
by	O	ADP	O
histidine	O	NOUN	B
at	O	ADP	O
the	O	DET	O
codon	O	NOUN	B
231	O	NUM	I
(	O	PUNCT	O
R231H	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


GALT	O	NOUN	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
R231H	O	ADJ	B
mutant	O	ADJ	I
construct	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
to	O	PART	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
controls	O	NOUN	I
in	O	ADP	O
a	O	DET	O
COS	O	NOUN	B
cell	O	NOUN	O
expression	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
was	O	AUX	O
a	O	DET	O
splicing	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
G	O	NOUN	B
transition	O	NOUN	B
at	O	ADP	O
the	O	DET	O
38th	O	ADJ	O
nucleotide	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
(	O	PUNCT	O
318A	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
38	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GALT	O	NOUN	B
cDNA	O	NOUN	B
by	O	ADP	O
activating	O	VERB	B
a	O	DET	O
cryptic	O	ADJ	B
splice	O	NOUN	I
acceptor	O	NOUN	I
site	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
seven	O	NUM	O
Japanese	O	ADJ	B
families	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
alleles	O	NOUN	B
for	O	ADP	O
classic	O	ADJ	O
form	O	NOUN	O
and	O	CCONJ	O
one	O	NUM	O
allele	O	NOUN	B
for	O	ADP	O
Duarte	O	PROPN	B
variant	O	NOUN	I
)	O	PUNCT	O
with	O	ADP	O
GALT	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
R231H	O	NOUN	B
and	O	CCONJ	O
318A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
only	O	ADV	O
on	O	ADP	O
both	O	DET	O
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
N314D	O	NOUN	B
and	O	CCONJ	O
R333W	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
on	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
each	O	DET	O
.	O	PUNCT	O


The	O	DET	O
Q188R	O	NOUN	B
was	O	AUX	O
prevalent	O	ADJ	O
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
N314D	O	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
Duarte	O	PROPN	B
variant	O	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
persons	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


We	O	PRON	O
speculate	O	VERB	O
that	O	SCONJ	O
classic	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
mutations	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
differ	O	VERB	O
between	O	ADP	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
limited	O	ADJ	O
data	O	NOUN	B
set	O	VERB	I
on	O	ADP	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
Japanese	O	PROPN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
N314D	O	NOUN	B
GALT	O	NOUN	B
mutation	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
Duarte	O	PROPN	B
variant	O	NOUN	B
arose	O	VERB	O
before	O	ADP	O
Asian	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
people	O	NOUN	B
diverged	O	VERB	B
and	O	CCONJ	O
that	O	SCONJ	O
classic	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
mutations	O	NOUN	B
arose	O	VERB	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
accumulated	O	VERB	O
after	O	ADP	O
the	O	DET	O
divergence	O	NOUN	B
of	O	ADP	O
Asian	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
populations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
novel	O	ADJ	O
aniridia	B-Disease	NOUN	B
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
PAX6	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Aniridia	B-Disease	NOUN	B
(	O	PUNCT	O
iris	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
congenital	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
eye	I-Disease	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
aniridia	B-Disease	NOUN	I
(	O	PUNCT	O
PAX6	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
many	O	ADJ	O
patients	O	NOUN	B
from	O	ADP	O
various	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
study	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
PAX6	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
sporadic	O	ADJ	B
and	O	CCONJ	O
five	O	NUM	O
familial	O	ADJ	B
cases	O	NOUN	O
with	O	ADP	O
aniridia	B-Disease	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
four	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
identified	O	VERB	B
,	O	PUNCT	O
one	O	NUM	O
was	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
a	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
mutation	O	NOUN	B
(	O	PUNCT	O
C	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
at	O	ADP	O
codon	O	NOUN	B
240	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
were	O	AUX	O
novel	O	ADJ	O
two	O	NUM	O
in	O	ADP	O
the	O	DET	O
glycine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
region	O	NOUN	I
and	O	CCONJ	O
one	O	NUM	O
in	O	ADP	O
the	O	DET	O
proline	O	NOUN	B
/	O	SYM	O
serine	O	NOUN	B
/	O	PUNCT	O
threonine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
(	O	PUNCT	O
PST	O	NOUN	B
)	O	PUNCT	O
region	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
PAX6	O	NOUN	B
mutation	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
PST	O	NOUN	B
region	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
cataracts	B-Disease	NOUN	B
in	O	ADP	O
an	O	DET	O
aniridia	B-Disease	NOUN	B
family	O	NOUN	I
.	O	PUNCT	O


Another	O	DET	O
splice	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
PST	O	NOUN	B
domain	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
an	O	DET	O
aniridia	B-Disease	NOUN	B
patient	O	NOUN	B
with	O	ADP	O
anosmia	B-Disease	NOUN	B
(	O	PUNCT	O
inability	O	NOUN	O
to	O	PART	O
smell	O	VERB	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
six	O	NUM	O
new	O	ADJ	O
aniridia	B-Disease	NOUN	B
cases	O	NOUN	B
reported	O	VERB	O
here	O	ADV	O
have	O	AUX	O
mutations	O	NOUN	B
predicted	O	VERB	O
to	O	PART	O
generate	O	VERB	O
incomplete	O	ADJ	B
PAX6	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
the	O	DET	O
theory	O	NOUN	B
that	O	SCONJ	O
human	O	ADJ	B
aniridia	B-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
haploinsufficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
PAX6	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
carrier	O	NOUN	B
frequency	O	NOUN	O
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
185delAG	O	NOUN	O
mutation	O	NOUN	B
is	O	AUX	O
approximately	O	ADV	O
1	O	NUM	O
percent	O	NOUN	O
in	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
major	O	ADJ	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
cloned	O	VERB	B
,	O	PUNCT	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
unique	O	ADJ	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
germline	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
pedigrees	O	NOUN	B
,	O	PUNCT	O
female	O	ADJ	B
carriers	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
an	O	DET	O
80	O	NUM	O
-	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
lifetime	O	NOUN	B
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
%	O	NOUN	O
risk	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
stats	O	NOUN	I
of	O	ADP	O
individuals	O	NOUN	B
unselected	O	ADJ	O
for	O	ADP	O
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
determined	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
known	O	VERB	O
whether	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
such	O	ADJ	O
individuals	O	NOUN	B
confer	O	VERB	O
the	O	DET	O
same	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
as	O	ADP	O
in	O	ADP	O
individuals	O	NOUN	B
from	O	ADP	O
the	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
families	O	NOUN	B
studied	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


Following	O	VERB	O
the	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
a	O	DET	O
185delAG	O	ADJ	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
several	O	ADJ	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
breast	O	NOUN	I
/	O	PUNCT	O
ovarian	O	ADJ	B
families	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
858	O	NUM	O
Ashkenazim	O	PROPN	B
seeking	O	VERB	O
genetic	O	ADJ	B
testing	O	NOUN	I
for	O	ADP	O
conditions	O	NOUN	B
unrelated	O	ADJ	O
to	O	PART	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
815	O	NUM	O
reference	O	NOUN	O
individuals	O	NOUN	B
not	O	PART	O
selected	O	VERB	O
for	O	ADP	O
ethnic	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
observed	O	VERB	O
the	O	DET	O
185delAG	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
Ashkenazim	O	PROPN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
limit	O	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
reference	O	NOUN	B
samples	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	O
suggest	O	VERB	O
that	O	SCONJ	O
one	O	NUM	O
in	O	ADP	O
a	O	DET	O
hundred	O	NUM	O
women	O	NOUN	B
of	O	ADP	O
Ashkenazi	O	ADJ	B
descent	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
at	O	ADP	O
especially	O	ADV	O
high	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Identification	O	NOUN	B
and	O	CCONJ	O
localization	O	NOUN	B
of	O	ADP	O
huntingtin	O	NOUN	B
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
lymphoblastoid	O	ADJ	O
cell	O	NOUN	O
lines	O	NOUN	O
with	O	ADP	O
anti	O	ADJ	B
-	O	PUNCT	O
fusion	O	NOUN	B
protein	O	NOUN	I
antibodies	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
phenotype	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
trinucleotide	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
IT15	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
encode	O	VERB	B
a	O	DET	O
348	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
protein	O	NOUN	I
named	O	VERB	O
huntington	O	PROPN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
polyclonal	O	ADJ	B
and	O	CCONJ	O
monoclonal	O	ADJ	B
anti	O	ADJ	I
-	O	PUNCT	O
fusion	O	NOUN	B
protein	O	NOUN	I
antibodies	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
native	O	ADJ	B
huntingtin	O	NOUN	B
in	O	ADP	O
rat	O	NOUN	B
,	O	PUNCT	O
monkey	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
human	O	ADJ	B
.	O	PUNCT	O


Western	O	NOUN	B
blots	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
protein	O	NOUN	B
with	O	ADP	O
the	O	DET	O
expected	O	ADJ	O
molecular	O	ADJ	B
weight	O	NOUN	I
which	O	DET	O
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
soluble	O	ADJ	B
fraction	O	NOUN	B
of	O	ADP	O
rat	O	NOUN	B
and	O	CCONJ	O
monkey	O	NOUN	B
brain	O	NOUN	B
tissues	O	NOUN	I
and	O	CCONJ	O
lymphoblastoid	O	ADJ	B
cells	O	NOUN	I
from	O	ADP	O
control	O	NOUN	B
cases	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
lymphoblastoid	O	ADJ	B
cell	O	NOUN	I
lines	O	NOUN	I
from	O	ADP	O
juvenile	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
heterozygote	O	NOUN	B
HD	B-Disease	NOUN	B
cases	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
normal	O	ADJ	B
and	O	CCONJ	O
mutant	O	ADJ	B
huntingtin	O	NOUN	B
are	O	AUX	O
expressed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
increasing	O	VERB	B
repeat	O	NOUN	O
expansion	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O


Immunocytochemistry	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
huntingtin	O	NOUN	B
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
neurons	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
levels	O	NOUN	B
evident	O	ADJ	O
in	O	ADP	O
larger	O	ADJ	O
neurons	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
human	O	ADJ	B
striatum	O	NOUN	B
,	O	PUNCT	O
huntingtin	O	NOUN	B
is	O	AUX	O
enriched	O	VERB	O
in	O	ADP	O
a	O	DET	O
patch	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
distribution	O	NOUN	B
,	O	PUNCT	O
potentially	O	ADV	O
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
first	O	ADJ	O
areas	O	NOUN	O
affected	O	VERB	B
in	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Subcellular	O	ADJ	B
localization	O	NOUN	O
of	O	ADP	O
huntingtin	O	NOUN	B
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
cytosolic	O	ADJ	B
protein	O	NOUN	I
primarily	O	ADV	O
found	O	VERB	O
in	O	ADP	O
somatodendritic	O	ADJ	B
regions	O	NOUN	I
.	O	PUNCT	O


Huntingtin	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
particularly	O	ADV	O
associate	O	VERB	B
with	O	ADP	I
microtubules	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
some	O	DET	O
is	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
synaptic	O	ADJ	B
vesicles	O	NOUN	I
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
localization	O	NOUN	B
of	O	ADP	O
huntingtin	O	NOUN	B
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
microtubules	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
speculate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
impairs	O	VERB	B
the	O	DET	O
cytoskeletal	O	ADJ	B
anchoring	O	NOUN	I
or	O	CCONJ	O
transport	O	NOUN	B
of	O	ADP	O
mitochondria	O	NOUN	B
,	O	PUNCT	O
vesicles	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
other	O	ADJ	O
organelles	O	NOUN	B
or	O	CCONJ	O
molecules	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Marked	O	ADJ	O
phenotypic	O	ADJ	B
heterogeneity	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
sequence	O	NOUN	I
at	O	ADP	O
the	O	DET	O
spinocerebellar	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
3	I-Disease	NUM	I
/	I-Disease	SYM	O
Machado	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
spinocerebellar	B-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
3	I-Disease	NUM	I
locus	O	NOUN	I
(	O	PUNCT	O
SCA3	B-Disease	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
autosomal	I-Disease	ADJ	I
dominant	I-Disease	ADJ	O
cerebellar	I-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
ADCA	B-Disease	NOUN	B
type	I-Disease	NOUN	O
I	I-Disease	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
clinically	O	ADV	B
and	O	CCONJ	O
genetically	O	ADV	B
heterogeneous	O	ADJ	O
group	O	NOUN	O
of	O	ADP	O
neurodegenerative	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
14q32	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
1	O	NUM	O
.	O	PUNCT	O


ADCA	B-Disease	NOUN	B
type	I-Disease	NOUN	B
I	I-Disease	NUM	I
patients	O	NOUN	B
from	O	ADP	O
families	O	NOUN	B
segregating	O	VERB	O
SCA3	B-Disease	NOUN	B
share	O	VERB	O
clinical	O	ADJ	B
features	O	NOUN	I
in	O	ADP	O
common	O	ADJ	O
with	O	ADP	O
those	O	DET	O
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
of	O	ADP	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
region	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
here	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
segregating	O	VERB	O
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
three	O	NUM	O
French	O	ADJ	B
ADCA	B-Disease	NOUN	O
type	I-Disease	NOUN	O
I	I-Disease	NUM	O
kindreds	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
French	O	ADJ	B
family	O	NOUN	O
with	O	ADP	O
neuropathological	O	ADJ	B
findings	O	NOUN	I
suggesting	O	VERB	O
the	O	DET	O
ataxochoreic	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
dentatorubropallidoluysian	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
carries	O	VERB	O
an	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
repeat	O	NOUN	I
sequence	O	NOUN	I
located	O	ADJ	O
at	O	ADP	O
the	O	DET	O
same	O	ADJ	O
locus	O	NOUN	B
as	O	ADP	O
that	O	DET	O
for	O	ADP	O
MJD	B-Disease	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
shows	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
negative	O	ADJ	B
correlation	O	NOUN	B
between	O	ADP	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
repeat	O	NOUN	I
and	O	CCONJ	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
clinical	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


Instability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
triplet	O	NOUN	B
repeat	O	NOUN	I
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
sex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
parent	O	NOUN	B
transmitting	O	VERB	B
the	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


Evidence	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
for	O	ADP	O
somatic	O	ADJ	B
and	O	CCONJ	O
gonadal	O	NOUN	B
mosaicism	O	NOUN	B
for	O	ADP	O
alleles	O	NOUN	B
carrying	O	VERB	O
expanded	O	VERB	O
trinucleotide	O	NOUN	B
repeats	O	NOUN	I
.	O	PUNCT	O


Overexpression	O	NOUN	B
of	O	ADP	O
DM20	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
brothers	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
sex	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
dysmyelinating	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
that	O	PRON	O
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myelin	O	NOUN	B
proteolipid	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Only	O	ADV	O
25	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
studied	O	VERB	O
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
have	O	AUX	O
exonic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
underlying	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
encodes	O	VERB	B
two	O	NUM	O
major	O	ADJ	O
alternatively	O	ADV	O
spliced	O	VERB	B
transcripts	O	NOUN	B
called	O	VERB	O
PLP	O	NOUN	B
and	O	CCONJ	O
DM20	O	NOUN	B
.	O	PUNCT	O


PLP	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
is	O	AUX	O
specifically	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
tissue	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
DM20	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
is	O	AUX	O
found	O	VERB	O
in	O	ADP	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
cardiac	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
tissues	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
cultured	O	VERB	B
skin	O	NOUN	O
fibroblasts	O	NOUN	O
from	O	ADP	O
2	O	NUM	O
brothers	O	NOUN	B
with	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
who	O	PRON	O
exhibited	O	VERB	O
no	O	DET	O
detectable	O	ADJ	B
exonic	O	ADJ	B
mutation	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PLP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Examination	O	NOUN	B
of	O	ADP	O
RNA	O	NOUN	B
from	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
DM20	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
is	O	AUX	O
elevated	O	VERB	B
sixfold	O	ADV	B
relative	O	ADJ	O
to	O	PART	O
male	O	NOUN	B
control	O	NOUN	O
skin	O	NOUN	O
fibroblasts	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
unrelated	O	ADJ	O
female	O	ADJ	B
carrier	O	NOUN	O
,	O	PUNCT	O
also	O	ADV	O
with	O	ADP	O
no	O	DET	O
detectable	O	ADJ	B
exonic	O	ADJ	B
mutation	O	NOUN	I
,	O	PUNCT	O
showed	O	VERB	O
a	O	DET	O
threefold	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
DM20	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
in	O	ADP	O
cultured	O	VERB	B
skin	O	NOUN	I
fibroblasts	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
some	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
overexpression	O	NOUN	B
of	O	ADP	O
PLP	O	NOUN	B
gene	O	NOUN	O
transcripts	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
of	O	ADP	O
DM20	O	NOUN	B
messenger	O	NOUN	O
RNA	O	NOUN	O
in	O	ADP	O
females	O	NOUN	B
,	O	PUNCT	O
relative	O	ADJ	O
to	O	PART	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
identify	O	VERB	O
a	O	DET	O
female	O	ADJ	B
carrier	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
congenital	I-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
are	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	AUX	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
small	O	ADJ	B
platelets	O	NOUN	I
,	O	PUNCT	O
eczema	B-Disease	NOUN	B
,	O	PUNCT	O
recurrent	O	ADJ	B
infections	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
immunodeficiency	B-Disease	NOUN	B
.	O	PUNCT	O


Besides	O	SCONJ	O
the	O	DET	O
classic	O	ADJ	O
WAS	B-Disease	AUX	B
phenotype	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
congenital	B-Disease	ADJ	B
X	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
(	O	PUNCT	O
XLT	B-Disease	NOUN	B
)	O	PUNCT	O
who	O	PRON	O
have	O	AUX	O
small	O	ADJ	B
platelets	O	NOUN	B
but	O	CCONJ	O
only	O	ADV	O
transient	O	ADJ	B
eczema	B-Disease	NOUN	I
,	O	PUNCT	O
if	O	SCONJ	O
any	O	DET	O
,	O	PUNCT	O
and	O	CCONJ	O
minimal	O	ADJ	B
immune	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
WAS	B-Disease	AUX	B
has	O	AUX	O
been	O	AUX	O
sequenced	O	VERB	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
correlate	O	VERB	B
the	O	DET	O
WAS	B-Disease	NOUN	B
phenotypes	O	NOUN	B
with	O	ADP	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
fingerprinting	O	ADJ	B
screening	O	NOUN	I
technique	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
determined	O	VERB	O
the	O	DET	O
approximate	O	ADJ	B
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
13	O	NUM	O
unrelated	O	ADJ	B
WAS	B-Disease	AUX	B
patients	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
to	O	PART	O
severe	O	ADJ	B
clinical	O	ADJ	B
symptoms	O	NOUN	I
.	O	PUNCT	O


Direct	O	ADJ	B
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
cDNA	O	NOUN	B
and	O	CCONJ	O
genomic	O	ADJ	B
DNA	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
patient	O	NOUN	B
-	O	PUNCT	O
derived	O	VERB	B
cell	O	NOUN	B
lines	O	NOUN	I
showed	O	VERB	O
12	O	NUM	O
unique	O	ADJ	B
mutations	O	NOUN	B
distributed	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
insertions	O	NOUN	B
,	O	PUNCT	O
deletions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
,	O	PUNCT	O
termination	O	NOUN	B
,	O	PUNCT	O
exon	O	NOUN	B
skipping	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
splicing	O	NOUN	B
defects	O	NOUN	O
.	O	PUNCT	O


Of	O	ADP	O
4	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
XLT	B-Disease	NOUN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
3	O	NUM	O
had	O	AUX	O
missense	O	NOUN	B
mutations	O	NOUN	I
affecting	O	VERB	O
exon	O	NOUN	B
2	O	NUM	I
and	O	CCONJ	O
1	O	NUM	O
had	O	AUX	O
a	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
affecting	O	VERB	O
exon	O	NOUN	B
9	O	NUM	I
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
classic	O	ADJ	O
WAS	B-Disease	AUX	B
had	O	AUX	O
more	O	ADV	O
complex	O	ADJ	B
mutations	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
termination	O	NOUN	B
codons	O	NOUN	I
,	O	PUNCT	O
frameshift	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
early	O	ADJ	B
termination	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
provide	O	VERB	O
direct	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
XLT	B-Disease	NOUN	B
and	O	CCONJ	O
WAS	B-Disease	AUX	B
are	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
severe	O	ADJ	B
clinical	O	ADJ	B
phenotypes	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
complex	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Myotonia	B-Disease	NOUN	B
levior	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
chloride	B-Disease	NOUN	B
channel	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
group	O	NOUN	B
of	O	ADP	O
dominant	B-Disease	ADJ	B
non	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
dystrophic	I-Disease	ADJ	B
myotonias	I-Disease	NOUN	B
,	O	PUNCT	O
comprising	O	VERB	O
disorders	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
clinically	O	ADV	B
similar	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
myogenic	O	ADJ	B
muscle	O	NOUN	I
stiffness	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
genetically	O	ADV	B
inhomogeneous	O	ADJ	B
.	O	PUNCT	O


Dominant	B-Disease	ADJ	B
myotonia	I-Disease	NOUN	I
congenita	I-Disease	NOUN	I
(	O	PUNCT	O
Thomsens	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
linked	O	VERB	O
to	O	PART	O
CLCN1	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
major	O	ADJ	O
muscle	O	NOUN	B
chloride	O	NOUN	I
channel	O	NOUN	I
,	O	PUNCT	O
localized	O	VERB	B
on	O	ADP	O
chromosome	O	NOUN	B
7q35	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
dominant	B-Disease	ADJ	B
myotonias	I-Disease	NOUN	B
sensitive	O	ADJ	B
to	O	PART	O
potassium	O	NOUN	B
are	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
point	O	NOUN	O
mutations	O	NOUN	B
in	O	ADP	O
SCN4A	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
17q	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
the	O	DET	O
alpha	O	NOUN	B
subunit	O	NOUN	I
of	O	ADP	O
the	O	DET	O
adult	O	ADJ	B
skeletal	O	ADJ	B
muscle	O	NOUN	I
sodium	O	NOUN	B
channel	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
linkage	O	NOUN	O
or	O	CCONJ	O
molecular	O	ADJ	B
genetic	O	ADJ	I
data	O	NOUN	I
are	O	AUX	O
as	O	ADP	O
yet	O	ADV	O
available	O	ADJ	O
on	O	ADP	O
myotonia	B-Disease	NOUN	B
levior	I-Disease	ADJ	B
characterized	O	VERB	B
by	O	ADP	O
milder	O	ADJ	B
symptoms	O	NOUN	B
and	O	CCONJ	O
later	O	ADV	O
onset	O	NOUN	O
of	O	ADP	O
myotonia	B-Disease	NOUN	B
than	O	ADP	O
in	O	ADP	O
Thomsens	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
muscle	B-Disease	NOUN	B
hypertrophy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
CLCN1	O	NOUN	B
Gln	O	PROPN	B
-	O	PUNCT	O
552	O	NUM	B
-	O	PUNCT	O
Arg	O	NOUN	B
substitution	O	NOUN	B
for	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
dominant	O	ADJ	B
inheritance	O	NOUN	B
previously	O	ADV	O
diagnosed	O	VERB	B
to	O	PART	O
have	O	AUX	O
myotonia	B-Disease	NOUN	B
levior	I-Disease	ADJ	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
disorder	O	NOUN	B
appears	O	VERB	O
as	O	ADP	O
a	O	DET	O
variant	O	NOUN	B
of	O	ADP	O
Thomsens	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
mutations	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
low	O	ADJ	O
clinical	O	ADJ	B
expressivity	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
Ile	O	NOUN	B
-	O	PUNCT	O
290	O	NUM	O
-	O	PUNCT	O
Met	O	NOUN	B
CLCN1	O	NOUN	B
mutation	O	NOUN	B
for	O	ADP	O
a	O	DET	O
typical	O	ADJ	O
Thomsen	O	PROPN	B
pedigree	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
another	O	DET	O
family	O	NOUN	B
previously	O	ADV	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
Thomsens	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
unexpectedly	O	ADV	O
found	O	VERB	O
a	O	DET	O
CLCN1	O	NOUN	B
14	O	NUM	I
bp	O	NOUN	I
deletion	O	NOUN	B
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
recessive	B-Disease	ADJ	B
myotonia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
rare	O	ADJ	B
Trp	O	NOUN	B
-	O	PUNCT	O
118	O	NUM	B
-	O	PUNCT	O
Gly	O	NOUN	B
polymorphism	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Southern	O	NOUN	B
analysis	O	NOUN	I
reveals	O	VERB	O
a	O	DET	O
large	O	ADJ	O
deletion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
hypoxanthine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
locus	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Whole	O	ADJ	B
genomic	O	ADJ	I
hprt	O	NOUN	I
clones	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
in	O	ADP	O
Southern	O	NOUN	B
analysis	O	NOUN	O
to	O	PART	O
screen	O	VERB	B
the	O	DET	O
integrity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hprt	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
that	O	PRON	O
includes	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
HPRT	B-Disease	NOUN	B
enzyme	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
causal	O	ADJ	O
to	O	ADP	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
5	O	NUM	O
kb	O	NOUN	O
DNA	O	NOUN	B
sequence	O	NOUN	I
deletion	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
its	O	PRON	O
endpoints	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
third	O	ADJ	O
introns	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
probes	O	NOUN	B
identified	O	VERB	B
the	O	DET	O
carrier	O	NOUN	B
status	O	NOUN	I
of	O	ADP	O
female	O	ADJ	B
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
aided	O	VERB	O
by	O	ADP	O
an	O	DET	O
RFLP	O	NOUN	B
carried	O	VERB	O
by	O	ADP	O
the	O	DET	O
mothers	O	NOUN	B
normal	O	ADJ	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Characterisation	O	NOUN	B
of	O	ADP	O
molecular	O	ADJ	B
defects	O	NOUN	I
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
amelogenesis	I-Disease	NOUN	B
imperfecta	I-Disease	NOUN	B
(	O	PUNCT	O
AIH1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Amelogenins	O	NOUN	B
are	O	AUX	O
an	O	DET	O
heterogenous	O	ADJ	B
family	O	NOUN	O
of	O	ADP	O
proteins	O	NOUN	B
produced	O	VERB	O
by	O	ADP	O
ameloblasts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enamel	O	NOUN	B
organ	O	NOUN	I
during	O	ADP	O
tooth	O	NOUN	B
development	O	NOUN	I
.	O	PUNCT	O


Disturbances	O	NOUN	B
of	O	ADP	O
enamel	O	NOUN	B
formation	O	NOUN	O
occur	O	VERB	O
in	O	ADP	O
amelogenesis	B-Disease	NOUN	B
imperfecta	I-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
clinically	O	ADV	B
heterogenous	O	ADJ	O
group	O	NOUN	O
of	O	ADP	O
inherited	B-Disease	VERB	B
disorders	I-Disease	NOUN	I
characterised	O	VERB	O
by	O	ADP	O
defective	O	ADJ	B
enamel	O	NOUN	B
biomineralisation	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
amelogenin	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
AMGX	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
short	O	NOUN	O
of	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
(	O	PUNCT	O
Xp22	O	NOUN	B
.	O	PUNCT	O
1	O	X	O
-	O	PUNCT	O
p22	O	NOUN	B
.	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
pathology	O	NOUN	I
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
amelogenesis	I-Disease	NOUN	B
imperfecta	I-Disease	NOUN	B
(	O	PUNCT	O
AIH1	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
three	O	NUM	O
families	O	NOUN	B
exhibiting	O	VERB	O
AIH1	B-Disease	NOUN	B
and	O	CCONJ	O
screened	O	VERB	B
the	O	DET	O
AMGX	O	NOUN	B
gene	O	NOUN	I
for	O	ADP	O
mutations	O	NOUN	B
using	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformational	O	ADJ	B
polymorphism	O	NOUN	O
analysis	O	NOUN	O
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	O
a	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
T	O	NOUN	B
substitution	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
T	O	NOUN	B
substitution	O	NOUN	B
and	O	CCONJ	O
single	O	ADJ	B
cytosine	O	NOUN	I
deletion	O	NOUN	O
in	O	ADP	O
exon	O	NOUN	B
6	O	NUM	I
,	O	PUNCT	O
confirming	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
extensive	O	ADJ	B
allelic	O	ADJ	B
heterogeneity	O	NOUN	B
in	O	ADP	O
this	O	DET	O
condition	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
family	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mutations	O	NOUN	B
will	O	AUX	O
enable	O	VERB	O
early	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
and	O	CCONJ	O
correlation	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
phenotype	O	NOUN	B
with	O	ADP	O
genotype	O	NOUN	B
will	O	AUX	O
facilitate	O	VERB	O
an	O	DET	O
objective	O	ADJ	O
system	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
classification	O	NOUN	I
.	O	PUNCT	O


Frequency	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	O
15	O	NUM	O
missense	O	NOUN	O
mutation	O	NOUN	O
(	O	PUNCT	O
442D	O	NOUN	O
:	O	PUNCT	O
G	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
hyperalphalipoproteinemic	B-Disease	ADJ	B
Japanese	O	ADJ	B
subjects	O	NOUN	B
.	O	PUNCT	O


Cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
CETP	O	NOUN	B
)	O	PUNCT	O
transfers	O	NOUN	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
from	O	ADP	O
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
apo	O	NOUN	B
B	O	NOUN	I
-	O	PUNCT	O
containing	O	VERB	B
lipoproteins	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
hyperalphalipoproteinemia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
is	O	AUX	O
fairly	O	ADV	O
common	O	ADJ	O
in	O	ADP	O
Japan	O	PROPN	B
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
the	O	DET	O
splicing	O	NOUN	B
defect	O	NOUN	O
of	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
14	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
allelic	O	ADJ	B
frequency	O	NOUN	O
of	O	ADP	O
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


0049	O	NUM	O
in	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
reported	O	VERB	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
15	O	NUM	O
of	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
442D	O	NOUN	O
G	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
showing	O	VERB	O
a	O	DET	O
dominant	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
activity	O	NOUN	B
and	O	CCONJ	O
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
level	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
determined	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
Japanese	O	ADJ	B
hyperalphalipoproteinemic	B-Disease	ADJ	B
(	O	PUNCT	O
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
subjects	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
rapid	O	ADJ	B
and	O	CCONJ	O
easy	O	ADJ	O
screening	O	NOUN	B
method	O	NOUN	I
for	O	ADP	O
this	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
using	O	VERB	O
a	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
mediated	O	VERB	B
site	O	NOUN	B
-	O	PUNCT	O
directed	O	VERB	B
mutagenesis	O	NOUN	B
.	O	PUNCT	O


Among	O	ADP	O
117	O	NUM	O
Japanese	O	ADJ	B
hyperalphalipoproteinemic	B-Disease	ADJ	B
subjects	O	NOUN	O
(	O	PUNCT	O
HDL	O	NOUN	B
-	O	PUNCT	O
cholesterol	O	NOUN	B
;	O	PUNCT	O
116	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
16	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
mean	O	VERB	B
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
S	O	PROPN	B
.	O	PUNCT	O
D	O	NOUN	O
.	O	PUNCT	O
)	O	PUNCT	O
without	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
14	O	NUM	O
splice	O	NOUN	B
defect	O	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
homozygotes	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
34	O	NUM	O
heterozygotes	O	NOUN	B
(	O	PUNCT	O
29	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
the	O	DET	O
442D	O	NOUN	O
G	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
relative	O	ADJ	O
allelic	O	ADJ	B
frequency	O	NOUN	O
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
calculated	O	VERB	O
to	O	PART	O
be	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


17	O	NUM	O
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
homozygotes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
442D	O	NOUN	O
G	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
the	O	DET	O
patient	O	NOUN	B
previously	O	ADV	O
described	O	VERB	O
by	O	ADP	O
us	O	PRON	O
as	O	ADP	O
having	O	VERB	O
hyperalphalipoproteinemia	B-Disease	NOUN	B
with	O	ADP	O
corneal	B-Disease	NOUN	B
opacity	I-Disease	NOUN	I
and	O	CCONJ	O
coronary	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
subject	O	ADJ	B
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
who	O	PRON	O
also	O	ADV	O
demonstrated	O	VERB	O
atherosclerotic	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
homozygous	O	ADJ	B
subjects	O	NOUN	B
,	O	PUNCT	O
CETP	O	NOUN	B
activity	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
37	O	NUM	O
%	O	NOUN	O
to	O	PART	O
62	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
value	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
results	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
transient	O	ADJ	B
expression	O	NOUN	B
experiment	O	NOUN	I
previously	O	ADV	O
reported	O	VERB	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
specific	O	ADJ	O
activity	O	NOUN	B
of	O	ADP	O
CETP	O	NOUN	B
was	O	AUX	O
not	O	PART	O
as	O	ADV	O
low	O	ADJ	O
as	O	ADP	O
expected	O	VERB	O
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Mucopolysaccharidosis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
IVA	I-Disease	NOUN	B
:	O	PUNCT	O
common	O	ADJ	O
double	O	ADJ	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
acetylgalactosamine	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
sulfatase	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
GALNS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Mucopolysaccharidosis	B-Disease	NOUN	B
IVA	I-Disease	NOUN	I
(	O	PUNCT	O
MPS	B-Disease	PROPN	B
IVA	I-Disease	PROPN	I
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
in	I-Disease	ADP	O
N	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
acetylgalactosamine	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	B
-	I-Disease	PUNCT	O
sulfatase	I-Disease	NOUN	B
(	O	PUNCT	O
GALNS	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
two	O	NUM	O
separate	O	ADJ	O
deletions	O	NOUN	B
of	O	ADP	O
nearly	O	ADV	O
8	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
kb	O	NOUN	O
in	O	ADP	O
the	O	DET	O
GALNS	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
some	O	DET	O
exons	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
Alu	O	NOUN	B
repetitive	O	ADJ	I
elements	O	NOUN	I
near	O	ADP	O
the	O	DET	O
breakpoints	O	NOUN	B
of	O	ADP	O
the	O	DET	O
8	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
deletion	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
deletion	O	NOUN	B
resulted	O	VERB	O
from	O	ADP	O
an	O	DET	O
Alu	O	NOUN	B
-	O	PUNCT	O
Alu	O	NOUN	B
recombination	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
deletion	O	NOUN	B
involved	O	VERB	O
illegitimate	O	ADJ	B
recombinational	O	ADJ	O
events	O	NOUN	O
between	O	ADP	O
incomplete	O	ADJ	B
short	O	ADJ	B
direct	O	ADJ	I
repeats	O	NOUN	I
of	O	ADP	O
8	O	NUM	O
bp	O	NOUN	O
at	O	ADP	O
deletion	O	NOUN	B
breakpoints	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
rearrangement	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
a	O	DET	O
heteroallelic	O	ADJ	B
state	O	NOUN	I
in	O	ADP	O
four	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
documentation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
common	O	ADJ	O
double	O	ADJ	B
deletion	O	NOUN	I
a	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
not	O	PART	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
cluster	O	NOUN	I
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
10	O	NUM	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
1	O	NUM	O
family	O	NOUN	B
with	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Genetic	O	ADJ	B
epidemiological	O	ADJ	B
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
approximately	O	ADV	B
one	O	NUM	O
half	O	NOUN	O
of	O	ADP	O
early	O	ADJ	B
onset	O	NOUN	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
and	O	CCONJ	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
cloning	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
allows	O	VERB	O
for	O	ADP	O
the	O	DET	O
direct	O	ADJ	O
detection	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
feasibility	O	NOUN	B
of	O	ADP	O
presymptomatic	O	ADJ	B
screening	O	NOUN	B
for	O	ADP	O
cancer	B-Disease	NOUN	B
susceptibility	O	NOUN	I
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
one	O	NUM	O
affected	O	VERB	B
individual	O	NOUN	B
from	O	ADP	O
each	O	DET	O
of	O	ADP	O
24	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
three	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
SSCP	O	NOUN	B
assays	O	NOUN	I
.	O	PUNCT	O


Variant	O	ADJ	B
SSCP	O	NOUN	B
bands	O	NOUN	I
were	O	AUX	O
subcloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O


Allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
oligonucleotide	O	NOUN	B
hybridization	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
verify	O	VERB	O
sequence	O	NOUN	B
changes	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
screen	O	VERB	B
DNA	O	NOUN	B
from	O	ADP	O
control	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
frameshift	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
10	O	NUM	O
different	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
male	O	NOUN	B
proband	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
prostate	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
intra	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
abdominal	I-Disease	ADJ	B
carcinomatosis	I-Disease	NOUN	I
1	O	NUM	I
year	O	NOUN	B
after	O	ADP	O
prophylactic	O	ADJ	B
oophorectomy	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
a	O	DET	O
single	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
that	O	PRON	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
can	O	AUX	O
occur	O	VERB	O
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	O
of	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
array	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
development	O	NOUN	B
of	O	ADP	O
a	O	DET	O
screening	O	NOUN	B
test	O	NOUN	I
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
technically	O	ADV	O
challenging	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
,	O	PUNCT	O
not	O	PART	O
previously	O	ADV	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
also	O	ADV	O
illustrates	O	VERB	O
the	O	DET	O
potential	O	ADJ	B
difficulties	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
counseling	O	NOUN	I
for	O	ADP	O
individuals	O	NOUN	B
known	O	VERB	O
to	O	PART	O
carry	O	VERB	O
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Natural	O	ADJ	B
selection	O	NOUN	I
of	O	ADP	O
hemi	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
heterozygotes	O	NOUN	B
for	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
Africa	O	PROPN	B
by	O	ADP	O
resistance	O	NOUN	B
to	O	ADP	O
severe	O	ADJ	B
malaria	B-Disease	NOUN	B
.	O	PUNCT	O


Glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
enzymopathy	B-Disease	NOUN	B
of	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
affects	O	VERB	O
over	O	ADP	O
400	O	NUM	O
million	O	NUM	O
people	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
geographical	O	ADJ	B
correlation	O	NOUN	I
of	O	ADP	O
its	O	PRON	O
distribution	O	NOUN	B
with	O	ADP	O
the	O	DET	O
historical	O	ADJ	B
endemicity	O	NOUN	B
of	O	ADP	O
malaria	B-Disease	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
disorder	O	NOUN	B
has	O	AUX	O
risen	O	VERB	O
in	O	ADP	O
frequency	O	NOUN	B
through	O	ADP	O
natural	O	ADJ	B
selection	O	NOUN	I
by	O	ADP	O
malaria	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
attempts	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
that	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
protective	O	ADJ	O
in	O	ADP	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
studies	O	NOUN	O
of	O	ADP	O
malaria	B-Disease	NOUN	B
have	O	AUX	O
yielded	O	VERB	O
conflicting	O	ADJ	O
results	O	NOUN	B
.	O	PUNCT	O


Hence	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
this	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disorder	I-Disease	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
unclear	O	ADJ	O
whether	O	SCONJ	O
both	O	CCONJ	O
male	O	ADJ	B
hemizygotes	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
heterozygotes	O	NOUN	B
are	O	AUX	O
protected	O	VERB	O
or	O	CCONJ	O
,	O	PUNCT	O
as	O	ADP	O
frequently	O	ADV	O
suggested	O	VERB	O
,	O	PUNCT	O
only	O	ADV	O
females	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
how	O	SCONJ	O
much	O	ADJ	O
protection	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
afforded	O	VERB	O
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
two	O	NUM	O
large	O	ADJ	O
case	O	NOUN	B
-	O	PUNCT	O
control	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
over	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
African	O	ADJ	B
children	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
common	O	ADJ	O
African	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
G6PD	B-Disease	NOUN	B
A	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
46	O	NUM	O
-	O	SYM	O
58	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
risk	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
malaria	B-Disease	NOUN	B
for	O	ADP	O
both	O	CCONJ	O
female	O	ADJ	B
heterozygotes	O	NOUN	B
and	O	CCONJ	O
male	O	ADJ	B
hemizygotes	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
mathematical	O	ADJ	B
model	O	NOUN	I
incorporating	O	VERB	O
the	O	DET	O
measured	O	VERB	B
selective	O	ADJ	O
advantage	O	NOUN	O
against	O	ADP	O
malaria	B-Disease	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
counterbalancing	O	VERB	O
selective	O	ADJ	O
disadvantage	O	NOUN	B
,	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
this	O	DET	O
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
retarded	O	VERB	B
its	O	PRON	O
rise	O	NOUN	O
in	O	ADP	O
frequency	O	NOUN	B
in	O	ADP	O
malaria	B-Disease	NOUN	B
-	O	PUNCT	O
endemic	O	ADJ	B
regions	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
is	O	AUX	O
now	O	ADV	O
regarded	O	VERB	O
as	O	ADP	O
a	O	DET	O
generally	O	ADV	O
benign	O	ADJ	B
disorder	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
earlier	O	ADV	O
environmental	O	ADJ	B
conditions	O	NOUN	I
it	O	PRON	O
could	O	AUX	O
have	O	AUX	O
been	O	AUX	O
significantly	O	ADV	O
disadvantageous	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
PAX3	O	NOUN	B
/	O	PUNCT	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
a	O	DET	O
transcriptional	O	ADJ	B
activator	O	NOUN	I
.	O	PUNCT	O


Chimeric	O	ADJ	B
transcription	O	NOUN	I
factors	O	NOUN	I
,	O	PUNCT	O
created	O	VERB	O
by	O	ADP	O
gene	O	NOUN	B
fusions	O	NOUN	I
as	O	ADP	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
chromosomal	O	ADJ	B
translocations	O	NOUN	I
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
pathologically	O	ADV	B
disparate	O	ADJ	O
solid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PAX3	O	NOUN	B
/	O	SYM	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
formed	O	VERB	O
by	O	ADP	O
a	O	DET	O
t	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
13	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q35	O	NOUN	B
;	O	PUNCT	O
q14	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
,	O	PUNCT	O
encodes	O	VERB	B
a	O	DET	O
hybrid	O	NOUN	B
protein	O	NOUN	I
that	O	PRON	O
contains	O	VERB	O
both	O	CCONJ	O
PAX3	O	NOUN	B
DNA	O	NOUN	B
binding	O	NOUN	I
domains	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
paired	O	ADJ	O
box	O	NOUN	O
and	O	CCONJ	O
homeodomain	O	NOUN	B
,	O	PUNCT	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
bisected	O	VERB	B
DNA	O	NOUN	B
binding	O	NOUN	I
domain	O	NOUN	I
of	O	ADP	O
FKHR	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
forkhead	O	NOUN	B
family	O	NOUN	I
of	O	ADP	O
transcription	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
PAX3	O	NOUN	B
and	O	CCONJ	O
PAX3	O	NOUN	B
/	O	SYM	O
FKHR	O	NOUN	B
display	O	VERB	B
similar	O	ADJ	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
identical	O	ADJ	O
transactivation	O	NOUN	B
activities	O	NOUN	I
when	O	SCONJ	O
tested	O	VERB	B
with	O	ADP	O
model	O	NOUN	B
Pax	O	NOUN	B
recognition	O	NOUN	I
sequences	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
functional	O	ADJ	I
role	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
ascribed	O	VERB	O
solely	O	ADV	O
to	O	ADP	O
the	O	DET	O
residual	O	ADJ	B
FKHR	O	NOUN	B
binding	O	NOUN	O
domain	O	NOUN	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
fusion	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
FKHR	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
contribute	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
carboxyl	O	ADJ	B
terminal	O	ADJ	O
activation	O	NOUN	B
domain	O	NOUN	I
replacing	O	VERB	O
the	O	DET	O
one	O	NOUN	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
unrearranged	O	ADJ	B
PAX3	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
native	O	ADJ	B
PAX3	O	NOUN	B
/	O	SYM	O
FKHR	O	NOUN	B
protein	O	NOUN	O
present	O	ADJ	O
in	O	ADP	O
tumor	B-Disease	NOUN	B
cells	O	NOUN	I
with	O	ADP	O
this	O	DET	O
translocation	O	NOUN	B
has	O	AUX	O
transcriptional	O	ADJ	B
characteristics	O	NOUN	I
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
in	O	X	B
vitro	O	X	I
expressed	O	VERB	B
protein	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
the	O	DET	O
PAX3	O	NOUN	B
/	O	SYM	O
FKHR	O	NOUN	B
hybrid	O	NOUN	O
protein	O	NOUN	O
to	O	PART	O
bind	O	VERB	B
DNA	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sequence	O	NOUN	B
specific	O	ADJ	O
manner	O	NOUN	O
and	O	CCONJ	O
to	O	PART	O
transactivate	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
artificial	O	ADJ	B
reporter	O	NOUN	I
genes	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
its	O	PRON	O
aberrant	O	ADJ	B
expression	O	NOUN	B
could	O	AUX	O
subvert	O	VERB	B
the	O	DET	O
transcriptional	O	ADJ	B
programs	O	NOUN	I
that	O	PRON	O
normally	O	ADV	O
control	O	VERB	B
the	O	DET	O
growth	O	NOUN	B
,	O	PUNCT	O
differentiation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
survival	O	NOUN	B
of	O	ADP	O
primitive	O	ADJ	B
myogenic	O	ADJ	B
precursors	O	NOUN	I
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
p16INK4a	O	NOUN	B
-	O	PUNCT	O
insensitive	O	ADJ	B
CDK4	O	NOUN	B
mutant	O	NOUN	B
targeted	O	VERB	B
by	O	ADP	O
cytolytic	O	ADJ	B
T	O	NOUN	I
lymphocytes	O	NOUN	I
in	O	ADP	O
a	O	DET	O
human	O	ADJ	B
melanoma	B-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
mutated	O	VERB	B
cyclin	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
kinase	O	NOUN	O
4	O	NUM	O
(	O	PUNCT	O
CDK4	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
antigen	O	NOUN	B
recognized	O	VERB	O
by	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
A2	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
-	O	PUNCT	O
restricted	O	ADJ	B
autologous	O	ADJ	B
cytolytic	O	ADJ	B
T	O	NOUN	I
lymphocytes	O	NOUN	I
(	O	PUNCT	O
CTLs	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
human	O	ADJ	B
melanoma	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutated	O	VERB	B
CDK4	O	NOUN	B
allele	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
autologous	O	ADJ	B
cultured	O	VERB	O
melanoma	B-Disease	NOUN	O
cells	O	NOUN	O
and	O	CCONJ	O
metastasis	O	NOUN	B
tissue	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
lymphocytes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
arginine	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
cysteine	O	NOUN	B
exchange	O	NOUN	O
at	O	ADP	O
residue	O	NOUN	O
24	O	NUM	O
,	O	PUNCT	O
was	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
CDK4	O	NOUN	B
peptide	O	NOUN	B
recognized	O	VERB	O
by	O	ADP	O
CTLs	O	NOUN	B
and	O	CCONJ	O
prevented	O	VERB	B
binding	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CDK4	O	NOUN	B
inhibitor	O	NOUN	B
p16INK4a	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
of	O	ADP	O
p21	O	NOUN	B
or	O	CCONJ	O
of	O	ADP	O
p27KIP1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
one	O	NUM	O
additional	O	ADJ	O
melanoma	B-Disease	NOUN	B
among	O	ADP	O
28	O	NUM	O
melanomas	B-Disease	NOUN	B
analyzed	O	VERB	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
mutation	O	NOUN	B
of	O	ADP	O
CDK4	O	NOUN	B
can	O	AUX	O
create	O	VERB	O
a	O	DET	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
antigen	O	NOUN	B
and	O	CCONJ	O
can	O	AUX	O
disrupt	O	VERB	B
the	O	DET	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
regulation	O	NOUN	I
exerted	O	VERB	O
by	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
p16INK4a	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Rapid	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
by	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
truncation	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


More	O	ADJ	O
than	O	ADP	O
75	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
reported	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
gene	O	NOUN	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
result	O	VERB	O
in	O	ADP	O
truncated	O	VERB	B
proteins	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
the	O	DET	O
protein	O	NOUN	B
truncation	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
PTT	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	O
61	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
45	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
we	O	PRON	O
found	O	VERB	O
six	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
two	O	NUM	O
single	O	ADJ	B
nucleotide	O	NOUN	I
insertions	O	NOUN	I
,	O	PUNCT	O
three	O	NUM	O
small	O	ADJ	O
deletions	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
5	O	NUM	O
bp	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
identified	O	VERB	B
two	O	NUM	O
unrelated	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
amplify	O	VERB	B
the	O	DET	O
remaining	O	VERB	O
coding	O	VERB	B
region	O	NOUN	I
by	O	ADP	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
using	O	VERB	O
lymphocyte	O	NOUN	B
RNA	O	NOUN	I
.	O	PUNCT	O


Combined	O	VERB	B
with	O	ADP	O
PTT	O	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
aberrantly	O	ADV	B
spliced	O	VERB	O
products	O	NOUN	O
affecting	O	VERB	O
exons	O	NOUN	B
5	O	NUM	I
and	O	CCONJ	O
6	O	NUM	O
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
families	O	NOUN	B
examined	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
truncation	O	NOUN	I
test	O	NOUN	I
promises	O	NOUN	O
to	O	PART	O
become	O	VERB	O
a	O	DET	O
valuable	O	ADJ	O
technique	O	NOUN	B
in	O	ADP	O
detecting	O	VERB	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Cloning	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
coenzyme	O	NOUN	B
A	O	NOUN	I
dehydrogenase	O	NOUN	I
and	O	CCONJ	O
molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
deficiency	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
overlapping	O	VERB	O
cDNA	O	NOUN	B
clones	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
991	O	NUM	O
bp	O	NOUN	O
and	O	CCONJ	O
736	O	NUM	O
bp	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
encoding	O	VERB	B
the	O	DET	O
precursor	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
mitochondrial	O	ADJ	B
very	O	ADV	O
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
coenzyme	O	NOUN	B
A	O	NOUN	I
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
VLCAD	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
cDNA	O	NOUN	B
inserts	O	NOUN	I
of	O	ADP	O
these	O	DET	O
clones	O	NOUN	B
together	O	ADV	O
encompass	O	VERB	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
,	O	PUNCT	O
177	O	NUM	O
bases	O	NOUN	B
,	O	PUNCT	O
encoding	O	VERB	B
the	O	DET	O
entire	O	ADJ	O
protein	O	NOUN	B
of	O	ADP	O
655	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
40	O	NUM	O
-	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
leader	O	NOUN	I
peptide	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
615	O	NUM	O
-	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
mature	O	ADJ	B
polypeptide	O	NOUN	B
.	O	PUNCT	O


PCR	O	NOUN	B
-	O	PUNCT	O
amplified	O	VERB	B
VLCAD	O	NOUN	B
cDNAs	O	NOUN	B
were	O	AUX	O
sequenced	O	VERB	B
in	O	ADP	O
cultured	O	VERB	B
fibroblasts	O	NOUN	I
from	O	ADP	O
two	O	NUM	O
VLCAD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
105	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
encompassing	O	NOUN	O
bases	O	NOUN	B
1078	O	NUM	O
-	O	SYM	O
1182	O	NUM	O
in	O	ADP	O
VLCAD	O	NOUN	B
cDNA	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
occur	O	VERB	O
due	O	ADJ	O
to	O	PART	O
exon	O	NOUN	B
skipping	O	NOUN	I
during	O	ADP	O
processing	O	NOUN	B
of	O	ADP	O
VLCAD	O	NOUN	B
pre	O	NOUN	B
-	O	PUNCT	O
mRNA	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
demonstration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Quantitative	O	ADJ	B
cDNA	O	NOUN	O
expression	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
VLCAD	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
vaccinia	O	NOUN	B
viral	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
normal	I-Disease	ADJ	O
VLCAD	I-Disease	NOUN	B
protein	I-Disease	NOUN	I
causes	O	VERB	O
impaired	O	ADJ	B
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	ADJ	I
acid	O	NOUN	I
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
fibroblasts	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patient	O	NOUN	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
raising	O	VERB	O
VLCAD	O	NOUN	B
activity	O	NOUN	B
to	O	PART	O
approximately	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
control	O	ADJ	O
fibroblast	O	NOUN	B
activity	O	NOUN	I
raised	O	VERB	O
palmitic	O	ADJ	B
acid	O	NOUN	I
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
flux	O	NOUN	B
to	O	ADP	O
the	O	DET	O
level	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
control	O	ADJ	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
may	O	AUX	O
offer	O	VERB	O
important	O	ADJ	O
information	O	NOUN	B
for	O	ADP	O
the	O	DET	O
rational	O	ADJ	O
design	O	NOUN	B
of	O	ADP	O
future	O	ADJ	O
somatic	O	ADJ	B
gene	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Brain	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
molecular	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Abnormal	O	ADJ	B
amplification	O	NOUN	O
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
19	O	NUM	I
is	O	AUX	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	O
of	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
severity	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
performed	O	VERB	O
extensive	O	ADJ	O
cognitive	O	ADJ	B
testing	O	NOUN	I
,	O	PUNCT	O
cerebral	O	ADJ	B
magnetic	O	ADJ	I
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
MRI	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
in	O	ADP	O
28	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
defect	O	NOUN	I
and	O	CCONJ	O
brain	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Performance	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
cognitive	O	ADJ	B
tests	O	NOUN	I
was	O	AUX	O
pathological	O	ADJ	B
in	O	ADP	O
10	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Fourteen	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
subcortical	O	ADJ	B
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
on	O	ADP	O
MRI	O	NOUN	B
,	O	PUNCT	O
14	O	NUM	O
had	O	AUX	O
cerebral	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
correlation	O	NOUN	B
with	O	ADP	O
cognitive	O	ADJ	B
test	O	NOUN	I
deficits	O	NOUN	I
when	O	SCONJ	O
exceeding	O	VERB	O
a	O	DET	O
length	O	NOUN	B
of	O	ADP	O
over	O	ADP	O
1000	O	NUM	O
trinucleotides	O	NOUN	B
.	O	PUNCT	O


MRI	O	NOUN	B
lesions	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
impaired	O	ADJ	B
psychometric	O	ADJ	B
performance	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
MRI	O	NOUN	B
and	O	CCONJ	O
molecular	O	ADJ	B
findings	O	NOUN	I
were	O	AUX	O
only	O	ADV	O
weakly	O	ADV	O
related	O	VERB	O
.	O	PUNCT	O


Disease	O	NOUN	B
duration	O	NOUN	I
influenced	O	VERB	B
the	O	DET	O
appearance	O	NOUN	B
and	O	CCONJ	O
amount	O	NOUN	B
of	O	ADP	O
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
on	O	ADP	O
MRI	O	NOUN	B
.	O	PUNCT	O


Quantification	O	NOUN	B
of	O	ADP	O
CTG	O	NOUN	B
repeat	O	NOUN	I
size	O	NOUN	I
may	O	AUX	O
allow	O	VERB	O
an	O	DET	O
early	O	ADJ	O
estimate	O	NOUN	B
on	O	ADP	O
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
involvement	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
;	O	PUNCT	O
cognitive	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
white	B-Disease	ADJ	B
matter	I-Disease	NOUN	I
lesions	I-Disease	NOUN	B
and	O	CCONJ	O
cerebral	B-Disease	ADJ	B
atrophy	I-Disease	NOUN	I
later	O	ADV	O
on	O	ADV	O
in	O	ADP	O
the	O	DET	O
course	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
clinical	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
peroxisomal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
encoding	O	VERB	B
a	O	DET	O
peroxisomal	O	ADJ	B
membrane	O	NOUN	I
transporter	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
entire	O	ADJ	O
protein	O	NOUN	B
-	O	PUNCT	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
by	O	ADP	O
reverse	O	NOUN	B
-	O	PUNCT	O
transcription	O	NOUN	B
PCR	O	NOUN	I
,	O	PUNCT	O
SSCP	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
different	O	ADJ	O
clinical	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
and	O	CCONJ	O
in	O	ADP	O
their	O	PRON	O
female	O	ADJ	B
relatives	O	NOUN	I
;	O	PUNCT	O
these	O	DET	O
clinical	O	ADJ	B
expressions	O	NOUN	I
were	O	AUX	O
cerebral	O	ADJ	B
childhood	O	NOUN	I
ALD	B-Disease	NOUN	B
,	O	PUNCT	O
adrenomyeloneuropathy	B-Disease	ADJ	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
"	O	PUNCT	O
Addison	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
only	I-Disease	ADV	O
"	O	PUNCT	O
(	O	PUNCT	O
ADO	B-Disease	NOUN	B
)	O	PUNCT	O
phenotype	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
three	O	NUM	O
patients	O	NOUN	B
exhibiting	O	VERB	O
the	O	DET	O
classical	O	ADJ	O
picture	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
childhood	O	NOUN	B
ALD	B-Disease	NOUN	B
we	O	PRON	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	NOUN	B
gene	O	NOUN	B
a	O	DET	O
38	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
that	O	PRON	O
causes	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ATP	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
phenotype	O	NOUN	B
of	O	ADP	O
AMN	B-Disease	PROPN	B
,	O	PUNCT	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
codon	O	NOUN	B
212	O	NUM	O
,	O	PUNCT	O
along	O	ADP	O
with	O	ADP	O
a	O	DET	O
second	O	ADJ	O
site	O	NOUN	B
mutation	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
178	O	NUM	O
,	O	PUNCT	O
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
the	O	DET	O
ADO	B-Disease	NOUN	B
phenotype	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
further	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
position	O	NOUN	O
in	O	ADP	O
the	O	DET	O
ALDP	O	PROPN	B
/	O	PUNCT	O
PMP70	O	NOUN	B
comparison	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
disruptive	O	ADJ	B
nature	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
mutations	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
frameshift	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
biochemically	O	ADV	B
proved	O	VERB	O
childhood	O	NOUN	B
ALD	B-Disease	NOUN	B
and	O	CCONJ	O
AMN	B-Disease	PROPN	B
further	O	ADV	O
strongly	O	ADV	O
supports	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
alterations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
play	O	VERB	O
a	O	DET	O
crucial	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
current	O	ADJ	O
biochemical	O	ADJ	B
techniques	O	NOUN	O
for	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
carrier	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
families	O	NOUN	B
lack	O	VERB	B
sufficient	O	ADJ	O
reliability	O	NOUN	O
,	O	PUNCT	O
our	O	PRON	O
procedure	O	NOUN	B
described	O	VERB	O
for	O	ADP	O
systematic	O	ADJ	B
mutation	O	NOUN	I
scanning	O	NOUN	I
is	O	AUX	O
also	O	ADV	O
capable	O	ADJ	O
of	O	ADP	O
improving	O	VERB	B
genetic	O	ADJ	B
counseling	O	NOUN	I
and	O	CCONJ	O
prenatal	O	ADJ	B
diagnosis	O	NOUN	I


Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
patient	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
patient	O	NOUN	B
identified	O	VERB	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
Duchenne	B-Disease	NOUN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
family	O	NOUN	B
of	O	ADP	O
the	O	DET	O
propositus	O	NOUN	B
had	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
history	O	NOUN	B
of	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
was	O	AUX	O
an	O	DET	O
intrafamilial	O	ADJ	B
pathological	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
responsible	O	ADJ	O
CTG	O	NOUN	B
repeat	O	NOUN	O
between	O	ADP	O
the	O	DET	O
mildly	O	ADV	B
affected	O	VERB	B
mother	O	NOUN	B
(	O	PUNCT	O
160	O	NUM	O
repeats	O	NOUN	B
;	O	PUNCT	O
normal	O	ADJ	O
27	O	NUM	O
repeats	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
her	O	PRON	O
more	O	ADV	O
severely	O	ADV	B
affected	O	VERB	B
son	O	NOUN	O
(	O	PUNCT	O
650	O	NUM	O
repeats	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
his	O	PRON	O
sister	O	NOUN	B
(	O	PUNCT	O
650	O	NUM	O
repeats	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
propositus	O	NOUN	B
was	O	AUX	O
an	O	DET	O
isolated	O	VERB	B
case	O	NOUN	B
of	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
with	O	ADP	I
marked	O	ADJ	O
dystrophin	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
muscle	O	NOUN	B
biopsy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
still	O	ADV	O
ambulatory	O	ADJ	B
post	O	NOUN	O
age	O	NOUN	B
16	O	NUM	O
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
could	O	AUX	O
interfere	O	VERB	O
to	O	PART	O
some	O	DET	O
extent	O	NOUN	O
with	O	ADP	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
Duchenne	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
other	O	ADJ	O
interpretations	O	NOUN	B
are	O	AUX	O
possible	O	ADJ	O
.	O	PUNCT	O


Twelve	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
dystrophin	O	NOUN	B
revertant	O	ADJ	O
fibers	O	NOUN	O
as	O	ADP	O
observed	O	VERB	O
by	O	ADP	O
immunohistochemistry	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
ameliorate	O	VERB	B
typical	O	ADJ	O
DMD	B-Disease	NOUN	B
clinical	O	ADJ	B
severity	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
may	O	AUX	O
present	O	VERB	O
a	O	DET	O
somatic	O	ADJ	B
mosaic	O	ADJ	I
.	O	PUNCT	O


The	O	DET	O
pathophysiological	O	ADJ	B
interactions	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
unlinked	O	ADJ	B
disorders	O	NOUN	I
are	O	AUX	O
discussed	O	VERB	O
at	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
histopathological	O	ADJ	B
levels	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
as	O	ADP	O
an	O	DET	O
indicator	O	NOUN	B
of	O	ADP	O
eligibility	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
DNA	O	NOUN	B
testing	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
searched	O	VERB	O
for	O	ADP	O
criteria	O	NOUN	B
that	O	PRON	O
could	O	AUX	O
indicate	O	VERB	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	O
prior	O	ADJ	O
probability	O	NOUN	B
of	O	ADP	O
being	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
locus	O	NOUN	I
BRCA1	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
17	O	NUM	I
.	O	PUNCT	O


To	O	ADP	O
this	O	DET	O
end	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
a	O	DET	O
linkage	O	NOUN	B
study	O	NOUN	I
with	O	ADP	O
59	O	NUM	O
consecutively	O	ADV	O
collected	O	VERB	O
Dutch	O	ADJ	O
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
families	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
16	O	NUM	O
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
an	O	DET	O
intake	O	NOUN	B
cut	O	NOUN	B
-	O	PUNCT	O
off	O	NOUN	B
of	O	ADP	O
at	O	ADV	O
least	O	ADJ	O
three	O	NUM	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
at	O	ADP	O
any	O	DET	O
age	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
only	O	ADV	O
among	O	ADP	O
the	O	DET	O
13	O	NUM	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
mean	O	ADJ	O
age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
45	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
unexpectedly	O	ADV	O
low	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
were	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
linked	O	VERB	O
to	O	PART	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
could	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Dutch	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
expected	O	VERB	O
logistical	O	ADJ	B
problems	O	NOUN	I
in	O	ADP	O
clinical	O	ADJ	B
management	O	NOUN	I
now	O	ADV	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
we	O	PRON	O
propose	O	VERB	O
an	O	DET	O
interim	O	ADJ	B
period	O	NOUN	B
in	O	ADP	O
which	O	DET	O
only	O	ADV	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
strong	O	ADJ	O
positive	O	ADJ	B
family	O	NOUN	B
history	O	NOUN	I
for	O	ADP	O
early	O	ADJ	B
onset	O	NOUN	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
will	O	AUX	O
be	O	AUX	O
offered	O	VERB	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
testing	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
26	O	NUM	O
Canadian	O	ADJ	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
breast	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
26	O	NUM	O
Canadian	O	ADJ	B
families	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
markers	O	NOUN	B
flanking	O	VERB	B
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
17q12	O	NOUN	I
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
15	O	NUM	O
families	O	NOUN	B
that	O	PRON	O
contain	O	VERB	O
cases	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
94	O	NUM	O
%	O	NOUN	O
were	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
linked	O	VERB	O
to	O	PART	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
overall	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
in	O	ADP	O
the	O	DET	O
group	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
without	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
genetic	O	ADJ	B
recombinant	O	NOUN	I
in	O	ADP	O
a	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
family	O	NOUN	B
indicates	O	VERB	O
a	O	DET	O
placement	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
telomeric	O	NOUN	B
to	O	PART	O
D17S776	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
helps	O	VERB	O
to	O	PART	O
define	O	VERB	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
assignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cancer	B-Disease	NOUN	B
susceptibility	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Other	O	ADJ	O
cancers	B-Disease	NOUN	B
of	O	ADP	O
interest	O	NOUN	O
that	O	PRON	O
appeared	O	VERB	O
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
families	O	NOUN	B
included	O	VERB	O
primary	B-Disease	ADJ	B
peritoneal	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
fallopian	I-Disease	ADJ	B
tube	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
malignant	B-Disease	ADJ	B
melanoma	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Structural	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
'	O	PART	O
region	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
genes	O	NOUN	O
reveals	O	VERB	O
conservation	O	NOUN	B
of	O	ADP	O
putative	O	ADJ	O
promoter	O	NOUN	B
region	O	NOUN	I
and	O	CCONJ	O
di	O	PROPN	B
-	O	PUNCT	O
and	O	CCONJ	O
trinucleotide	O	NOUN	B
polymorphisms	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
previously	O	ADV	O
cloned	O	VERB	B
and	O	CCONJ	O
characterized	O	VERB	B
the	O	DET	O
murine	O	ADJ	B
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
and	O	CCONJ	O
shown	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
maps	O	VERB	B
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
5	O	NUM	I
within	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
conserved	O	VERB	B
synteny	O	NOUN	I
with	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
4p16	O	NOUN	I
.	O	PUNCT	O


3	O	NUM	O
3	O	NUM	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
present	O	VERB	O
a	O	DET	O
detailed	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sequence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
putative	O	ADJ	O
promoter	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
organization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
genomic	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
murine	O	NOUN	B
(	O	PUNCT	O
Hdh	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
human	O	ADJ	B
HD	B-Disease	NOUN	B
genes	O	NOUN	O
encompassing	O	VERB	O
the	O	DET	O
first	O	ADJ	O
five	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B
these	O	DET	O
two	O	NUM	O
genes	O	NOUN	B
share	O	VERB	O
identical	O	ADJ	O
exon	O	NOUN	B
boundaries	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
have	O	AUX	O
different	O	ADJ	B
-	O	PUNCT	O
size	O	NOUN	B
introns	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
dinucleotide	O	NOUN	B
(	O	PUNCT	O
CT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
trinucleotide	O	NOUN	B
intronic	O	ADJ	I
polymorphism	O	NOUN	I
in	O	ADP	O
Hdh	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
intronic	O	ADJ	B
CA	O	NOUN	I
polymorphism	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
940	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
sequence	O	NOUN	B
5	O	NUM	O
to	O	PART	O
the	O	DET	O
putative	O	ADJ	B
translation	O	NOUN	I
start	O	NOUN	O
site	O	NOUN	B
reveals	O	VERB	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	B
region	O	NOUN	I
(	O	PUNCT	O
78	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
nucleotide	O	NOUN	B
identity	O	NOUN	B
)	O	PUNCT	O
between	O	ADP	O
Hdh	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
nucleotide	O	NOUN	B
-	O	PUNCT	O
56	O	NUM	O
to	O	PART	O
-	O	PUNCT	O
206	O	NUM	O
(	O	PUNCT	O
of	O	ADP	O
Hdh	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Neither	O	CCONJ	O
Hdh	O	NOUN	B
nor	O	CCONJ	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
typical	O	ADJ	O
TATA	O	NOUN	B
or	O	CCONJ	O
CCAAT	O	NOUN	B
elements	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
both	O	DET	O
show	O	VERB	O
one	O	NUM	O
putative	O	ADJ	O
AP2	O	NOUN	B
binding	O	NOUN	I
site	O	NOUN	I
and	O	CCONJ	O
numerous	O	ADJ	O
potential	O	ADJ	B
Sp1	O	NOUN	B
binding	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
sequence	O	NOUN	O
identity	O	NOUN	B
between	O	ADP	O
Hdh	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
for	O	ADP	O
approximately	O	ADV	B
200	O	NUM	O
bp	O	NOUN	O
5	O	NUM	O
to	O	PART	O
the	O	DET	O
putative	O	ADJ	B
translation	O	NOUN	I
start	O	NOUN	I
site	O	NOUN	I
indicates	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
sequences	O	NOUN	B
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
regulating	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I


The	O	DET	O
protein	O	NOUN	B
deficient	O	ADJ	B
in	O	ADP	O
Lowe	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
phosphatidylinositol	O	NOUN	B
-	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
bisphosphate	O	NOUN	B
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
.	O	PUNCT	O


Lowe	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
also	O	ADV	O
known	O	VERB	O
as	O	ADP	O
oculocerebrorenal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
-	O	PUNCT	O
encoded	O	VERB	B
OCRL	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
OCRL	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
51	O	NUM	O
%	O	NOUN	O
identical	O	ADJ	B
to	O	PART	O
inositol	O	NOUN	B
polyphosphate	O	NOUN	I
5	O	NUM	I
-	O	PUNCT	O
phosphatase	O	NOUN	B
II	O	NUM	I
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
from	O	ADP	O
human	O	ADJ	B
platelets	O	NOUN	B
over	O	ADP	O
a	O	DET	O
span	O	NOUN	O
of	O	ADP	O
744	O	NUM	O
aa	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
OCRL	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
enzyme	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
engineered	O	VERB	B
a	O	DET	O
construct	O	NOUN	O
of	O	ADP	O
the	O	DET	O
OCRL	O	NOUN	B
cDNA	O	NOUN	B
that	O	PRON	O
encodes	O	VERB	B
amino	O	NOUN	B
acids	O	NOUN	I
homologous	O	ADJ	I
to	O	PART	O
the	O	DET	O
platelet	O	NOUN	B
5	O	NUM	I
-	O	PUNCT	O
phosphatase	O	NOUN	B
for	O	ADP	O
expression	O	NOUN	B
in	O	ADP	O
baculovirus	O	NOUN	B
-	O	PUNCT	O
infected	O	ADJ	B
Sf9	O	NOUN	B
insect	O	NOUN	O
cells	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
cDNA	O	NOUN	B
encodes	O	VERB	O
aa	O	NOUN	O
264	O	NUM	O
-	O	SYM	O
968	O	NUM	O
of	O	ADP	O
the	O	DET	O
OCRL	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recombinant	O	ADJ	B
protein	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
catalyze	O	VERB	B
the	O	DET	O
reactions	O	NOUN	B
also	O	ADV	O
carried	O	VERB	O
out	O	ADP	O
by	O	ADP	O
platelet	O	NOUN	B
5	O	NUM	I
-	O	PUNCT	O
phosphatase	O	NOUN	B
II	O	NUM	I
.	O	PUNCT	O


Thus	O	ADV	O
OCRL	O	NOUN	B
converts	O	VERB	O
inositol	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
trisphosphate	O	NOUN	B
to	O	PART	O
inositol	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
bisphosphate	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
converts	O	VERB	O
inositol	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
tetrakisphosphate	O	NOUN	B
to	O	PART	O
inositol	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
trisphosphate	O	NOUN	B
.	O	PUNCT	O


Most	O	ADV	O
important	O	ADJ	O
,	O	PUNCT	O
the	O	DET	O
enzyme	O	NOUN	B
converts	O	VERB	O
phosphatidylinositol	O	NOUN	O
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
bisphosphate	O	NOUN	B
to	O	PART	O
phosphatidylinositol	O	NOUN	B
4	O	NUM	I
-	O	PUNCT	O
phosphate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relative	O	ADJ	O
ability	O	NOUN	O
of	O	ADP	O
OCRL	O	NOUN	B
to	O	PART	O
catalyze	O	VERB	B
the	O	DET	O
three	O	NUM	O
reactions	O	NOUN	B
is	O	AUX	O
different	O	ADJ	O
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
II	O	NUM	I
and	O	CCONJ	O
from	O	ADP	O
that	O	DET	O
of	O	ADP	O
another	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
isoenzyme	O	NOUN	B
from	O	ADP	O
platelets	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
I	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recombinant	O	ADJ	B
OCRL	O	NOUN	O
protein	O	NOUN	O
hydrolyzes	O	VERB	O
the	O	DET	O
phospholipid	O	ADJ	B
substrate	O	NOUN	I
10	O	NUM	O
-	O	PUNCT	O
to	O	ADP	O
30	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
better	O	ADJ	O
than	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
II	O	NUM	I
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
I	O	PRON	I
does	O	AUX	O
not	O	PART	O
cleave	O	VERB	B
the	O	DET	O
lipid	O	NOUN	B
at	O	ADV	O
all	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
OCRL	O	NOUN	B
functions	O	VERB	B
as	O	ADP	O
a	O	DET	O
phosphatidylinositol	O	NOUN	B
4	O	NUM	I
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
bisphosphate	O	NOUN	B
5	O	NUM	O
-	O	PUNCT	O
phosphatase	O	NOUN	B
in	O	ADP	O
OCRL	O	NOUN	B
-	O	PUNCT	O
expressing	O	VERB	B
Sf9	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
OCRL	O	NOUN	B
is	O	AUX	O
mainly	O	ADV	O
a	O	DET	O
lipid	O	NOUN	B
phosphatase	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
control	O	VERB	O
cellular	O	ADJ	B
levels	O	NOUN	I
of	O	ADP	O
a	O	DET	O
critical	O	ADJ	B
metabolite	O	NOUN	I
,	O	PUNCT	O
phosphatidylinositol	O	NOUN	B
4	O	NUM	I
,	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
bisphosphate	O	NOUN	B
.	O	PUNCT	O


Deficiency	O	NOUN	B
of	O	ADP	O
this	O	DET	O
enzyme	O	NOUN	B
apparently	O	ADV	O
causes	O	VERB	O
the	O	DET	O
protean	O	ADJ	B
manifestations	O	NOUN	I
of	O	ADP	O
Lowe	B-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


New	O	ADJ	O
founder	O	NOUN	B
haplotypes	O	NOUN	B
at	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
in	O	ADP	O
southern	O	ADJ	B
Africa	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
association	O	NOUN	B
between	O	ADP	O
normal	O	ADJ	B
alleles	O	NOUN	B
at	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
and	O	CCONJ	O
two	O	NUM	O
nearby	O	ADJ	O
polymorphisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
myotonin	O	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
Alu	O	NOUN	B
insertion	O	NOUN	I
/	O	PUNCT	O
deletion	O	NOUN	B
polymorphism	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
DMK	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
G	O	NOUN	B
/	O	PUNCT	O
T	O	NOUN	B
)	O	PUNCT	O
intron	O	NOUN	O
9	O	NUM	O
/	O	SYM	O
HinfI	O	NOUN	B
polymorphism	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
analyzed	O	VERB	B
in	O	ADP	O
South	O	ADJ	B
African	O	ADJ	I
Negroids	O	PROPN	I
,	O	PUNCT	O
a	O	DET	O
population	O	NOUN	B
in	O	ADP	O
which	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


South	O	ADJ	B
African	O	ADJ	I
Negroids	O	PROPN	I
have	O	AUX	O
a	O	DET	O
CTG	O	NOUN	B
allelic	O	ADJ	B
distribution	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
that	O	DET	O
in	O	ADP	O
Caucasoids	O	PROPN	B
and	O	CCONJ	O
Japanese	O	ADJ	B
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
lengths	O	NOUN	B
of	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
19	O	NUM	O
are	O	AUX	O
very	O	ADV	O
rare	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
striking	O	ADJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
between	O	ADP	O
specific	O	ADJ	O
alleles	O	NOUN	B
at	O	ADP	O
the	O	DET	O
Alu	O	NOUN	B
polymorphism	O	NOUN	I
(	O	PUNCT	O
Alu	O	NOUN	B
(	O	PUNCT	O
ins	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
Alu	O	NOUN	B
(	O	PUNCT	I
del	O	X	I
)	O	PUNCT	I
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
HinfI	O	NOUN	B
polymorphism	O	NOUN	B
(	O	PUNCT	O
HinfI	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
and	O	CCONJ	O
HinfI	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
polymorphism	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
Caucasoid	O	PROPN	B
(	O	PUNCT	O
Europeans	O	PROPN	B
and	O	CCONJ	O
Canadians	O	PROPN	B
)	O	PUNCT	O
populations	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
South	O	ADJ	B
African	O	ADJ	I
Negroid	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Numerous	O	ADJ	O
haplotypes	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
previously	O	ADV	O
described	O	VERB	O
in	O	ADP	O
Europeans	O	PROPN	B
,	O	PUNCT	O
were	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
found	O	VERB	O
.	O	PUNCT	O


It	O	PRON	O
thus	O	ADV	O
seems	O	VERB	O
likely	O	ADJ	O
that	O	SCONJ	O
only	O	ADV	O
a	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
these	O	DET	O
"	O	PUNCT	O
African	O	ADJ	B
"	O	PUNCT	O
chromosomes	O	NOUN	O
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
progenitors	O	NOUN	B
of	O	ADP	O
all	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
African	O	ADJ	B
peoples	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
provide	O	VERB	O
support	O	NOUN	O
for	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
out	O	ADP	O
of	O	ADP	O
Africa	O	PROPN	B
"	O	PUNCT	O
model	O	NOUN	B
for	O	ADP	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
modern	O	ADJ	O
humans	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
rare	O	ADJ	B
ancestral	O	ADJ	B
DM	B-Disease	NOUN	B
mutation	O	NOUN	I
event	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
occurred	O	VERB	O
after	O	ADP	O
the	O	DET	O
migration	O	NOUN	B
from	O	ADP	O
Africa	O	PROPN	B
,	O	PUNCT	O
hence	O	ADV	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
in	O	ADP	O
sub	O	ADV	B
-	O	PUNCT	O
Saharan	O	PROPN	B
Negroid	O	ADJ	B
peoples	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Discordant	O	ADJ	B
clinical	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
relatives	O	NOUN	I
showing	O	VERB	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
>	O	X	O
700	O	NUM	O
repeats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
family	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
in	O	ADP	O
which	O	DET	O
discordant	O	ADJ	B
DM	B-Disease	NOUN	B
phenotypes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
children	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
sisters	O	NOUN	B
with	O	ADP	O
similar	O	ADJ	O
CTG	O	NOUN	B
expansion	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
family	O	NOUN	B
,	O	PUNCT	O
congenital	O	ADJ	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
early	O	ADV	O
severe	O	ADJ	B
childhood	O	NOUN	B
and	O	CCONJ	O
later	O	ADV	O
childhood	O	NOUN	B
onset	O	NOUN	O
DM	B-Disease	NOUN	B
coexist	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
strengthens	O	VERB	O
the	O	DET	O
limited	O	ADJ	O
ability	O	NOUN	O
of	O	ADP	O
lymphocytes	O	NOUN	B
CTG	O	NOUN	O
repeat	O	NOUN	O
number	O	NOUN	O
analysis	O	NOUN	O
in	O	ADP	O
predicting	O	VERB	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Purification	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
coenzyme	O	NOUN	B
A	O	NOUN	I
dehydrogenase	O	NOUN	I
and	O	CCONJ	O
characterization	O	NOUN	B
of	O	ADP	O
its	O	PRON	O
deficiency	O	NOUN	B
in	O	ADP	O
seven	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Mitochondrial	O	ADJ	B
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
coenzyme	O	NOUN	B
A	O	NOUN	I
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
VLCAD	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
purified	O	VERB	O
from	O	ADP	O
human	O	ADJ	B
liver	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
masses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
native	O	ADJ	B
enzyme	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
subunit	O	NOUN	B
were	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
154	O	NUM	O
and	O	CCONJ	O
70	O	NUM	O
kD	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
enzyme	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
catalyze	O	VERB	B
the	O	DET	O
major	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
mitochondrial	O	ADJ	B
palmitoylcoenzyme	O	NOUN	O
A	O	DET	O
dehydrogenation	O	NOUN	B
in	O	ADP	O
liver	O	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
,	O	PUNCT	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
skin	O	NOUN	B
fibroblasts	O	NOUN	I
(	O	PUNCT	O
89	O	NUM	O
-	O	SYM	O
97	O	NUM	O
,	O	PUNCT	O
86	O	NUM	O
-	O	SYM	O
99	O	NUM	O
,	O	PUNCT	O
96	O	NUM	O
-	O	SYM	O
99	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
78	O	NUM	O
-	O	SYM	O
87	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Skin	O	NOUN	B
fibroblasts	O	NOUN	B
from	O	ADP	O
26	O	NUM	O
patients	O	NOUN	B
suspected	O	VERB	B
of	O	ADP	O
having	O	VERB	O
a	O	DET	O
disorder	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
VLCAD	O	NOUN	B
protein	O	NOUN	I
using	O	VERB	O
immunoblotting	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
7	O	NUM	O
of	O	ADP	O
them	O	PRON	O
contained	O	VERB	O
undetectable	O	ADJ	B
or	O	CCONJ	O
trace	O	NOUN	B
levels	O	NOUN	I
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
seven	O	NUM	O
deficient	O	ADJ	B
fibroblast	O	NOUN	B
lines	O	NOUN	I
were	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
measuring	O	VERB	B
acyl	O	ADJ	B
-	O	PUNCT	O
coenzyme	O	NOUN	B
A	O	NOUN	I
dehydrogenation	O	NOUN	O
activities	O	NOUN	O
,	O	PUNCT	O
overall	O	ADJ	B
palmitic	O	ADJ	B
acid	O	NOUN	I
oxidation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
VLCAD	O	NOUN	B
protein	O	NOUN	I
synthesis	O	NOUN	O
using	O	VERB	O
pulse	O	NOUN	B
-	O	PUNCT	O
chase	O	NOUN	B
,	O	PUNCT	O
further	O	ADV	O
confirming	O	VERB	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggested	O	VERB	O
the	O	DET	O
heterogenous	O	ADJ	B
nature	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
causing	O	VERB	O
the	O	DET	O
deficiency	O	NOUN	B
in	O	ADP	O
the	O	DET	O
seven	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Clinically	O	ADV	B
,	O	PUNCT	O
all	O	DET	O
patients	O	NOUN	B
with	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
exhibited	O	VERB	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


At	O	ADP	O
least	O	ADJ	O
four	O	NUM	O
of	O	ADP	O
them	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
hypertrophic	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
frequency	O	NOUN	B
(	O	PUNCT	O
>	O	NOUN	O
57	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
much	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
disorders	O	NOUN	B
of	O	ADP	O
mitochondrial	O	ADJ	B
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	ADJ	I
acid	O	NOUN	I
oxidation	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
be	O	AUX	O
accompanied	O	VERB	O
by	O	ADP	O
cardiac	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
infants	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
fifth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


II	O	NUM	O
.	O	PUNCT	O


Biological	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
C5	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
human	O	ADJ	B
serum	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
known	O	ADJ	O
human	O	ADJ	B
kindred	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
fifth	I-Disease	ADJ	O
component	I-Disease	NOUN	O
of	I-Disease	ADP	O
complement	I-Disease	NOUN	O
(	O	PUNCT	O
C5	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
documented	O	VERB	B
in	O	ADP	O
the	O	DET	O
accompanying	O	VERB	O
report	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
examines	O	VERB	O
several	O	ADJ	O
biological	O	ADJ	B
properties	O	NOUN	B
of	O	ADP	O
C5	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
(	O	PUNCT	O
C5D	B-Disease	NOUN	B
)	O	PUNCT	O
human	O	ADJ	B
serum	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
sera	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
two	O	NUM	O
C5D	B-Disease	NOUN	B
homozygotes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
has	O	AUX	O
inactive	O	ADJ	B
systemic	B-Disease	ADJ	B
lupus	I-Disease	NOUN	I
erythematosus	I-Disease	NOUN	I
is	O	AUX	O
completely	O	ADV	O
lacking	O	VERB	B
C5	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
her	O	PRON	O
healthy	O	ADJ	B
half	O	NOUN	B
-	O	PUNCT	O
sister	O	NOUN	B
has	O	AUX	O
1	O	NUM	O
-	O	SYM	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
levels	O	NOUN	O
.	O	PUNCT	O


Both	O	DET	O
sera	O	NOUN	B
were	O	AUX	O
severely	O	ADV	O
impaired	O	ADJ	B
in	O	ADP	O
their	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
generate	O	VERB	O
chemotactic	O	ADJ	B
activity	O	NOUN	I
for	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
neutrophils	O	NOUN	B
upon	O	SCONJ	O
incubation	O	NOUN	B
with	O	ADP	O
aggregated	O	ADJ	B
human	O	ADJ	B
gamma	O	NOUN	B
-	O	PUNCT	O
globulin	O	NOUN	B
or	O	CCONJ	O
Escherichia	O	X	B
coli	O	X	I
endotoxin	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
function	O	NOUN	B
was	O	AUX	O
fully	O	ADV	O
restored	O	VERB	B
in	O	ADP	O
the	O	DET	O
siblings	O	NOUN	B
serum	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
substantially	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
serum	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
addition	O	NOUN	O
of	O	ADP	O
highly	O	ADV	O
purified	O	VERB	B
human	O	ADJ	B
C5	O	NOUN	B
to	O	PART	O
normal	O	ADJ	O
serum	O	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


Sera	O	NOUN	B
from	O	ADP	O
eight	O	NUM	O
family	O	NOUN	B
members	O	NOUN	I
who	O	PRON	O
were	O	AUX	O
apparently	O	ADV	O
heterozygous	O	ADJ	B
for	O	ADP	O
C5	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
gave	O	VERB	O
normal	O	ADJ	O
chemotactic	O	ADJ	B
scores	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
C5D	B-Disease	NOUN	B
serum	O	NOUN	B
to	O	PART	O
opsonize	O	VERB	B
Saccharomyces	O	X	B
cerevisiae	O	X	I
(	O	PUNCT	O
bakers	O	NOUN	B
yeast	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
Candida	O	NOUN	B
albicans	O	NOUN	I
for	O	ADP	O
ingestion	O	NOUN	B
by	O	ADP	O
normal	O	ADJ	O
neutrophils	O	NOUN	B
was	O	AUX	O
completely	O	ADV	O
normal	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
C5D	B-Disease	NOUN	B
serum	O	NOUN	B
was	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
promoting	O	VERB	B
normal	O	ADJ	O
phagocytosis	O	NOUN	B
and	O	CCONJ	O
intracellular	O	ADJ	B
killing	O	NOUN	B
of	O	ADP	O
Staphylococcus	O	X	B
aureus	O	X	I
.	O	PUNCT	O


The	O	DET	O
probands	O	NOUN	B
serum	O	NOUN	B
was	O	AUX	O
incapable	O	ADJ	O
of	O	ADP	O
mediating	O	VERB	O
lysis	O	NOUN	B
of	O	ADP	O
erythrocytes	O	NOUN	B
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
paroxysmal	B-Disease	ADJ	B
nocturnal	I-Disease	ADJ	I
hemoglobinuria	I-Disease	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
sucrose	O	NOUN	B
hemolysia	O	NOUN	I
and	O	CCONJ	O
acid	O	NOUN	B
hemolysis	O	NOUN	I
tests	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
lacked	O	VERB	O
bactericidal	O	ADJ	B
activity	O	NOUN	I
against	O	ADP	O
sensitized	O	VERB	B
or	O	CCONJ	O
unsensitized	O	ADJ	B
Salmonella	O	X	B
typhi	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
siblings	O	NOUN	B
serum	O	NOUN	B
,	O	PUNCT	O
containing	O	VERB	O
only	O	ADV	O
1	O	NUM	O
-	O	SYM	O
2	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
C5	O	NOUN	B
,	O	PUNCT	O
effectively	O	ADV	O
lysed	O	VERB	B
S	O	NOUN	B
.	O	PUNCT	O
typhi	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
at	O	ADP	O
eightfold	O	ADV	O
lower	O	ADJ	O
serum	O	NOUN	B
dilutions	O	NOUN	I
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
normals	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
underscore	O	VERB	O
the	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
C5	O	NOUN	B
in	O	ADP	O
the	O	DET	O
generation	O	NOUN	B
of	O	ADP	O
chemotactic	O	ADJ	B
activity	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
cytolytic	O	ADJ	B
reactions	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
opposed	O	VERB	O
to	O	ADP	O
a	O	DET	O
nonobligatory	O	ADJ	B
or	O	CCONJ	O
minimal	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
opsonization	O	NOUN	B
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
for	O	ADP	O
the	O	DET	O
organisms	O	NOUN	B
under	O	ADP	O
study	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Human	O	ADJ	B
peroxisomal	O	ADJ	B
targeting	O	VERB	B
signal	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
receptor	O	NOUN	O
restores	O	VERB	B
peroxisomal	O	ADJ	B
protein	O	NOUN	I
import	O	NOUN	O
in	O	ADP	O
cells	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
fatal	O	ADJ	B
peroxisomal	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
peroxisomal	O	ADJ	B
targeting	O	NOUN	O
signals	O	NOUN	B
,	O	PUNCT	O
PTS1	O	NOUN	B
and	O	CCONJ	O
PTS2	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
import	O	NOUN	B
of	O	ADP	O
proteins	O	NOUN	B
into	O	ADP	O
the	O	DET	O
peroxisome	O	NOUN	B
matrix	O	NOUN	I
.	O	PUNCT	O


Human	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
fatal	O	ADJ	B
generalized	O	ADJ	B
peroxisomal	B-Disease	ADJ	I
deficiency	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
fall	O	VERB	B
into	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
nine	O	NUM	O
genetic	O	ADJ	B
complementation	O	NOUN	I
groups	O	NOUN	B
.	O	PUNCT	O


Cells	O	NOUN	B
from	O	ADP	O
many	O	ADJ	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
the	O	DET	O
import	O	NOUN	B
of	O	ADP	O
PTS1	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
proteins	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
causes	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
import	O	NOUN	B
defect	O	NOUN	I
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
are	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
the	O	DET	O
human	O	ADJ	B
cDNA	O	NOUN	O
homologue	O	NOUN	O
(	O	PUNCT	O
PTS1R	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
Pichia	O	PROPN	B
pastoris	O	X	I
PAS8	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
PTS1	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
McCollum	O	PROPN	B
,	O	PUNCT	O
D	O	PROPN	B
.	O	PUNCT	O
,	O	PUNCT	O
E	O	PROPN	B
.	O	PUNCT	O
Monosov	O	PROPN	O
,	O	PUNCT	O
and	O	CCONJ	O
S	O	PROPN	B
.	O	PUNCT	O
Subramani	O	PROPN	O
.	O	PUNCT	O
1993	O	NUM	O
.	O	PUNCT	O
J	O	NOUN	O
.	O	PUNCT	O
Cell	O	NOUN	B
Biol	O	NOUN	I
.	O	PUNCT	O
121	O	NUM	O
761	O	NUM	O
-	O	SYM	O
774	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
PTS1R	O	NOUN	B
mRNA	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
all	O	DET	O
human	O	ADJ	B
tissues	O	NOUN	B
examined	O	VERB	B
.	O	PUNCT	O


Antibodies	O	NOUN	B
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
PTS1R	O	NOUN	B
recognize	O	VERB	O
this	O	DET	O
protein	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
,	O	PUNCT	O
monkey	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hamster	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
localized	O	VERB	B
mainly	O	ADV	O
in	O	ADP	O
the	O	DET	O
cytosol	O	NOUN	B
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
peroxisomes	O	NOUN	B
.	O	PUNCT	O


Part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
peroxisomal	O	ADJ	B
PTS1R	O	NOUN	I
protein	O	NOUN	I
is	O	AUX	O
tightly	O	ADV	O
bound	O	VERB	O
to	O	PART	O
the	O	DET	O
peroxisomal	O	ADJ	B
membrane	O	NOUN	I
.	O	PUNCT	O


Antibodies	O	NOUN	B
to	O	PART	O
PTS1R	O	NOUN	B
inhibit	O	VERB	B
peroxisomal	O	ADJ	B
protein	O	NOUN	I
-	O	PUNCT	O
import	O	NOUN	B
of	O	ADP	O
PTS1	O	PROPN	B
-	O	PUNCT	O
containing	O	VERB	B
proteins	O	NOUN	B
in	O	ADP	O
a	O	DET	O
permeabilized	O	ADJ	B
CHO	O	NOUN	B
cell	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
-	O	PUNCT	O
translated	O	VERB	B
PTS1R	O	NOUN	B
protein	O	NOUN	O
specifically	O	ADV	O
binds	O	VERB	B
a	O	DET	O
serine	O	NOUN	B
-	O	PUNCT	O
lysine	O	NOUN	B
-	O	PUNCT	O
leucine	O	NOUN	B
-	O	PUNCT	O
peptide	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
PAS8	O	NOUN	B
-	O	PUNCT	O
PTS1R	O	NOUN	B
fusion	O	NOUN	B
protein	O	NOUN	I
complements	O	VERB	O
the	O	DET	O
P	O	NOUN	O
.	O	PUNCT	O
pastoris	O	NOUN	B
pas8	O	NOUN	O
mutant	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
PTS1R	O	NOUN	B
cDNA	O	NOUN	B
also	O	ADV	O
complements	O	VERB	O
the	O	DET	O
PTS1	B-Disease	NOUN	B
protein	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
import	I-Disease	NOUN	B
defect	I-Disease	NOUN	I
in	O	ADP	O
skin	O	NOUN	B
fibroblasts	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
belonging	O	VERB	O
to	O	PART	O
complementation	O	NOUN	B
group	O	NOUN	I
two	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
neonatal	B-Disease	ADJ	B
adrenoleukodystrophy	I-Disease	NOUN	B
or	O	CCONJ	O
Zellweger	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PTS1R	O	NOUN	B
gene	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
a	O	DET	O
chromosomal	O	ADJ	B
location	O	NOUN	B
where	O	SCONJ	O
no	O	DET	O
other	O	ADJ	O
peroxisomal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
genes	O	NOUN	B
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
map	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
represent	O	VERB	O
the	O	DET	O
only	O	ADJ	O
case	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
protein	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
import	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
human	O	ADJ	B
peroxisomal	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
is	O	AUX	O
understood	O	VERB	O
.	O	PUNCT	O


Spectrum	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
study	O	NOUN	B
of	O	ADP	O
232	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
non	I-Disease	ADJ	B
hereditary	I-Disease	ADJ	I
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
confer	O	VERB	O
hereditary	O	ADJ	B
predisposition	O	NOUN	B
to	O	PART	O
retinoblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
performed	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
survey	O	NOUN	I
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
232	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
non	I-Disease	ADJ	B
hereditary	I-Disease	ADJ	I
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
systematically	O	ADV	B
explored	O	VERB	O
all	O	DET	O
27	O	NUM	O
exons	O	NOUN	B
and	O	CCONJ	O
flanking	O	ADJ	O
sequences	O	NOUN	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
promotor	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
types	O	NOUN	O
of	O	ADP	O
point	O	NOUN	B
mutations	O	NOUN	I
are	O	AUX	O
represented	O	VERB	O
and	O	CCONJ	O
are	O	AUX	O
found	O	VERB	O
unequally	O	ADV	O
distributed	O	VERB	B
along	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	B
sequence	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
population	O	NOUN	B
we	O	PRON	O
studied	O	VERB	O
,	O	PUNCT	O
exons	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
18	O	NUM	O
and	O	CCONJ	O
19	O	NUM	O
are	O	AUX	O
preferentially	O	ADV	O
altered	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
range	O	NOUN	O
of	O	ADP	O
frequency	O	NOUN	B
of	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
is	O	AUX	O
about	O	ADV	O
20	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
mechanisms	O	NOUN	B
of	O	ADP	O
inactivation	O	NOUN	B
of	O	ADP	O
RB1	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
presented	O	VERB	O
here	O	ADV	O
should	O	AUX	O
help	O	VERB	O
to	O	PART	O
improve	O	VERB	B
the	O	DET	O
clinical	O	ADJ	B
management	O	NOUN	I
of	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
and	O	CCONJ	O
to	O	PART	O
understand	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
tumorigenesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Aniridia	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cytogenetic	O	ADJ	B
rearrangements	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
position	O	NOUN	B
effect	O	NOUN	I
may	O	AUX	O
cause	O	VERB	O
the	O	DET	O
mutant	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Current	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
aniridia	B-Disease	NOUN	B
(	O	PUNCT	O
absence	B-Disease	NOUN	B
of	I-Disease	ADP	O
iris	I-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
loss	O	NOUN	B
of	O	ADP	I
function	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
copy	O	NOUN	B
of	O	ADP	I
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
11p13	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
the	O	DET	O
further	O	ADJ	O
characterisation	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
aniridia	B-Disease	NOUN	B
pedigrees	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
disease	O	NOUN	B
segregates	O	VERB	B
with	O	ADP	O
chromosomal	O	ADJ	B
rearrangements	O	NOUN	I
which	O	DET	O
involve	O	VERB	O
11p13	O	NOUN	B
but	O	CCONJ	O
do	O	AUX	O
not	O	PART	O
disrupt	O	VERB	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
three	O	NUM	O
human	O	ADJ	B
YAC	O	NOUN	B
clones	O	NOUN	I
which	O	DET	O
encompass	O	VERB	O
the	O	DET	O
PAX6	O	NOUN	B
locus	O	NOUN	B
and	O	CCONJ	O
we	O	PRON	O
have	O	AUX	O
used	O	VERB	O
these	O	DET	O
to	O	PART	O
show	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
the	O	DET	O
chromosomal	O	ADJ	B
breakpoint	O	NOUN	I
is	O	AUX	O
at	O	ADP	O
least	O	ADJ	O
85	O	NUM	O
kb	O	NOUN	O
distal	O	ADJ	B
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
PAX6	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
open	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
of	O	ADP	O
PAX6	O	NOUN	B
is	O	AUX	O
apparently	O	ADV	O
free	O	ADJ	B
of	O	ADP	O
mutations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
the	O	DET	O
rearranged	O	ADJ	B
chromosome	O	NOUN	I
11	O	NUM	I
is	O	AUX	O
in	O	ADP	O
an	O	DET	O
inappropriate	O	ADJ	O
chromatin	O	NOUN	B
environment	O	NOUN	I
for	O	ADP	O
normal	O	ADJ	O
expression	O	NOUN	B
and	O	CCONJ	O
therefore	O	ADV	O
that	O	SCONJ	O
a	O	DET	O
position	O	NOUN	B
effect	O	NOUN	I
is	O	AUX	O
the	O	DET	O
underlying	O	ADJ	O
mechanism	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Somatic	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
sporadic	B-Disease	ADJ	B
ovarian	I-Disease	ADJ	B
tumours	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
17q21	O	NOUN	I
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
syndrome	I-Disease	NOUN	O
of	O	ADP	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
but	O	CCONJ	O
no	O	DET	O
somatic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
tumours	B-Disease	NOUN	B
have	O	AUX	O
yet	O	ADV	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
the	O	DET	O
potential	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
sporadic	O	ADJ	B
carcinogenesis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
analysed	O	VERB	B
the	O	DET	O
genomic	O	ADJ	B
DNA	O	NOUN	I
of	O	ADP	O
tumour	B-Disease	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
fractions	O	NOUN	B
of	O	ADP	O
47	O	NUM	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
using	O	VERB	O
the	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	O
technique	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
describe	O	VERB	O
somatic	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
tumours	B-Disease	NOUN	B
which	O	DET	O
also	O	ADV	O
had	O	AUX	O
loss	O	NOUN	B
of	O	ADP	I
heterozygosity	O	NOUN	I
(	O	PUNCT	O
LOH	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
a	O	DET	O
BRCA1	O	NOUN	B
intragenic	O	ADJ	B
marker	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
support	O	VERB	O
a	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
mechanism	O	NOUN	O
for	O	ADP	O
BRCA1	O	NOUN	B
;	O	PUNCT	O
somatic	O	ADJ	B
mutations	O	NOUN	I
and	O	CCONJ	O
LOH	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
inactivation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
small	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Decreased	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
accelerates	O	VERB	B
growth	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
often	O	ADV	O
present	O	ADJ	O
during	O	ADP	O
sporadic	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
progression	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
characterized	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
gene	O	NOUN	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
hereditary	I-Disease	ADJ	B
(	I-Disease	PUNCT	O
sporadic	I-Disease	ADJ	B
)	I-Disease	PUNCT	O
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
analyzed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
antisense	O	ADJ	B
inhibition	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
on	O	ADP	O
the	O	DET	O
proliferative	O	ADJ	B
rate	O	NOUN	B
of	O	ADP	O
mammary	O	ADJ	B
epithelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	I
are	O	AUX	O
markedly	O	ADV	O
decreased	O	VERB	B
during	O	ADP	O
the	O	DET	O
transition	O	NOUN	B
from	O	ADP	O
carcinoma	B-Disease	NOUN	B
in	I-Disease	X	B
situ	I-Disease	X	I
to	O	PART	O
invasive	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Experimental	O	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
expression	O	NOUN	B
with	O	ADP	O
antisense	O	ADJ	B
oligonucleotides	O	NOUN	I
produced	O	VERB	O
accelerated	O	VERB	B
growth	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
malignant	O	ADJ	B
mammary	O	ADJ	I
cells	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
mammary	O	ADJ	B
epithelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
may	O	AUX	O
normally	O	ADV	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
negative	O	ADJ	B
regulator	O	NOUN	B
of	O	ADP	O
mammary	O	ADJ	B
epithelial	O	ADJ	B
cell	O	NOUN	I
growth	O	NOUN	O
whose	O	DET	O
function	O	NOUN	B
is	O	AUX	O
compromised	O	VERB	O
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
either	O	CCONJ	O
by	O	ADP	O
direct	O	ADJ	O
mutation	O	NOUN	B
or	O	CCONJ	O
alterations	O	NOUN	B
in	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Additional	O	ADJ	O
case	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
monozygotic	O	ADJ	B
twins	O	NOUN	I
discordant	O	ADJ	B
for	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
opposite	O	ADJ	O
X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
pair	O	NOUN	B
of	O	ADP	O
female	O	ADJ	B
monozygotic	O	ADJ	O
(	O	PUNCT	O
MZ	O	ADJ	B
)	O	PUNCT	O
twins	O	NOUN	B
,	O	PUNCT	O
heterozygous	O	ADJ	B
carriers	O	NOUN	B
for	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
discordant	O	ADJ	B
for	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
manifestations	O	NOUN	O
of	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
molecular	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
methylation	O	NOUN	B
pattern	O	NOUN	B
of	O	ADP	O
X	O	NOUN	B
chromosomes	O	NOUN	I
to	O	PART	O
search	O	VERB	O
for	O	ADP	O
opposite	O	ADJ	O
X	O	NOUN	B
inactivation	O	NOUN	B
as	O	ADP	O
an	O	DET	O
explanation	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
clinical	O	ADJ	B
discordance	O	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
in	O	ADP	O
lymphocytes	O	NOUN	B
and	O	CCONJ	O
skin	O	NOUN	B
fibroblast	O	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
suggest	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
mirror	O	NOUN	B
inactivation	O	NOUN	B
with	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
X	O	NOUN	I
chromosome	O	NOUN	I
preferentially	O	ADV	O
active	O	ADJ	B
in	O	ADP	O
the	O	DET	O
unaffected	O	ADJ	O
twin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
maternal	O	ADJ	B
deleted	O	VERB	I
X	O	NOUN	I
chromosome	O	NOUN	I
preferentially	O	ADV	O
active	O	ADJ	B
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
twin	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
review	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
MZ	O	ADJ	B
female	O	ADJ	B
twins	O	NOUN	B
discordant	O	ADJ	B
for	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
diseases	I-Disease	NOUN	B
are	O	AUX	O
not	O	PART	O
uncommon	O	ADJ	O
.	O	PUNCT	O


Twinning	O	NOUN	B
and	O	CCONJ	O
X	O	NOUN	B
inactivation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
interrelated	O	ADJ	B
and	O	CCONJ	O
could	O	AUX	O
explain	O	VERB	O
the	O	DET	O
female	O	ADJ	B
twins	O	NOUN	O
discordant	O	ADJ	B
for	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
traits	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
in	O	ADP	O
6	O	NUM	O
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
5	O	NUM	O
different	O	ADJ	O
phenotypes	O	NOUN	B
.	O	PUNCT	O


Fragments	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
cDNA	O	NOUN	B
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
adolescent	B-Disease	ADJ	B
ALD	I-Disease	NOUN	B
were	O	AUX	O
amplified	O	VERB	B
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
and	O	CCONJ	O
subcloned	O	VERB	B
.	O	PUNCT	O


Bidirectional	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	O
ALD	B-Disease	NOUN	O
gene	O	NOUN	B
disclosed	O	VERB	O
a	O	DET	O
cytosine	O	NOUN	B
to	O	PART	O
guanine	O	NOUN	B
transversion	O	NOUN	I
at	O	ADP	O
nucleotide	O	NOUN	B
1451	O	NUM	I
in	O	ADP	O
exon	O	NOUN	B
five	O	NUM	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
substitution	O	NOUN	B
of	O	ADP	O
proline	O	NOUN	B
484	O	NUM	O
by	O	ADP	O
arginine	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
nine	O	NUM	O
siblings	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
comprising	O	VERB	O
two	O	NUM	O
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
adrenomyeloneuropathy	B-Disease	ADJ	B
,	O	PUNCT	O
one	O	NUM	O
Addison	B-Disease	NOUN	B
only	I-Disease	ADV	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
symptomatic	O	ADJ	B
mother	O	NOUN	B
(	O	PUNCT	O
all	O	DET	O
accumulating	O	VERB	O
very	O	ADV	O
long	O	ADJ	B
chain	O	NOUN	I
fatty	O	ADJ	I
acids	O	NOUN	I
)	O	PUNCT	O
carried	O	VERB	O
this	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
unaffected	O	ADJ	O
persons	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
five	O	NUM	O
unrelated	O	ADJ	O
ALD	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
twenty	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
generated	O	VERB	O
the	O	DET	O
disease	O	NOUN	B
per	O	X	O
se	O	X	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
metabolic	O	ADJ	B
defect	O	NOUN	O
;	O	PUNCT	O
the	O	DET	O
different	O	ADJ	O
phenotypes	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
must	O	AUX	O
have	O	AUX	O
originated	O	VERB	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
additional	O	ADJ	O
pathogenetic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Novel	O	ADJ	B
mutation	O	NOUN	B
at	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
codon	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
Japanese	O	ADJ	B
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
a	O	DET	O
new	O	ADJ	O
mutation	O	NOUN	B
of	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ND	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
Japanese	O	ADJ	B
males	O	NOUN	B
from	O	ADP	O
unrelated	O	ADJ	O
families	O	NOUN	B
;	O	PUNCT	O
they	O	PRON	O
showed	O	VERB	O
typical	O	ADJ	O
ocular	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
ND	B-Disease	NOUN	B
but	O	CCONJ	O
no	O	DET	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
or	O	CCONJ	O
hearing	B-Disease	VERB	B
impairment	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
both	O	DET	O
patients	O	NOUN	B
at	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
codon	O	NOUN	B
of	O	ADP	I
exon	O	NOUN	I
2	O	NUM	I
of	O	ADP	O
the	O	DET	O
ND	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
ATG	O	NOUN	B
to	O	PART	O
GTG	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
otherwise	O	ADV	O
normal	O	ADJ	O
nucleotide	O	NOUN	O
sequences	O	NOUN	O
.	O	PUNCT	O


Their	O	PRON	O
mothers	O	NOUN	B
had	O	AUX	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
mutant	O	ADJ	B
types	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
expected	O	VERB	O
for	O	ADP	O
heterozygotes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
codon	O	NOUN	B
would	O	AUX	O
cause	O	VERB	O
the	O	DET	O
failure	O	NOUN	B
of	O	ADP	O
ND	B-Disease	NOUN	B
gene	O	NOUN	B
expression	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
defect	O	NOUN	B
in	O	ADP	O
translation	O	NOUN	B
thereby	O	ADV	O
truncating	O	VERB	B
the	O	DET	O
amino	O	NOUN	B
terminus	O	NOUN	I
of	O	ADP	O
ND	B-Disease	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
view	O	NOUN	O
of	O	ADP	O
the	O	DET	O
rarity	O	NOUN	B
and	O	CCONJ	O
marked	O	ADJ	O
heterogeneity	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ND	B-Disease	NOUN	B
gene	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
apparently	O	ADV	O
unrelated	O	ADJ	O
Japanese	O	ADJ	B
families	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
lived	O	VERB	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
area	O	NOUN	B
for	O	ADP	O
over	O	ADP	O
two	O	NUM	O
centuries	O	NOUN	O
presumably	O	ADV	O
share	O	VERB	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Anticipation	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
elimination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
gene	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
follow	O	NOUN	B
up	O	ADP	I
study	O	NOUN	I
of	O	ADP	O
one	O	NUM	O
extended	O	VERB	B
family	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
re	O	ADV	O
-	O	PUNCT	O
examined	O	VERB	B
an	O	DET	O
extended	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
family	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
described	O	VERB	O
in	O	ADP	O
1955	O	NUM	O
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
long	O	ADJ	B
term	O	NOUN	I
effects	O	NOUN	B
of	O	ADP	O
anticipation	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
particular	O	ADJ	O
the	O	DET	O
implications	O	NOUN	O
for	O	ADP	O
families	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
follow	O	VERB	B
up	O	ADP	I
study	O	NOUN	I
provides	O	VERB	O
data	O	NOUN	B
on	O	ADP	O
35	O	NUM	O
gene	O	NOUN	B
carriers	O	NOUN	I
and	O	CCONJ	O
46	O	NUM	O
asymptomatic	O	ADJ	B
at	O	ADP	O
risk	O	NOUN	B
family	O	NOUN	I
members	O	NOUN	I
in	O	ADP	O
five	O	NUM	O
generations	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
anticipation	O	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
the	O	DET	O
cascade	O	NOUN	O
of	O	ADP	O
mild	O	ADJ	B
,	O	PUNCT	O
adult	O	ADJ	B
,	O	PUNCT	O
childhood	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
congenital	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
subsequent	O	ADJ	O
generations	O	NOUN	B
,	O	PUNCT	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
relentless	O	ADJ	O
process	O	NOUN	B
,	O	PUNCT	O
occurring	O	VERB	O
in	O	ADP	O
all	O	DET	O
affected	O	VERB	B
branches	O	NOUN	B
of	O	ADP	O
the	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cascade	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
proceed	O	VERB	O
asynchronously	O	ADV	B
in	O	ADP	O
the	O	DET	O
different	O	ADJ	O
branches	O	NOUN	B
,	O	PUNCT	O
mainly	O	ADV	O
because	O	SCONJ	O
of	O	ADP	O
an	O	DET	O
unequal	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
generations	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
transition	O	NOUN	B
from	O	ADP	O
the	O	DET	O
mild	O	ADJ	B
to	O	PART	O
the	O	DET	O
adult	O	ADJ	B
type	O	NOUN	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
transmission	O	NOUN	B
through	O	ADP	O
a	O	DET	O
male	O	ADJ	B
parent	O	NOUN	B
.	O	PUNCT	O


Stable	O	ADJ	B
transmission	O	NOUN	I
of	O	ADP	O
the	O	DET	O
asymptomatic	O	ADJ	B
/	O	SYM	O
mild	O	ADJ	B
phenotype	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
female	O	ADJ	B
transmission	O	NOUN	B
bias	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
further	O	ADV	O
examined	O	VERB	O
the	O	DET	O
extent	O	NOUN	B
and	O	CCONJ	O
causes	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
this	O	DET	O
pedigree	O	NOUN	B
.	O	PUNCT	O


Gene	O	NOUN	B
loss	O	NOUN	I
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
complete	O	ADJ	B
,	O	PUNCT	O
owing	O	VERB	O
to	O	ADP	O
infertility	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
male	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
adult	O	ADJ	B
onset	O	NOUN	O
disease	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
mentally	B-Disease	ADV	B
retarded	I-Disease	VERB	B
patients	O	NOUN	B
did	O	AUX	O
not	O	PART	O
procreate	O	VERB	B
.	O	PUNCT	O


Out	O	ADP	O
of	O	ADP	O
the	O	DET	O
46	O	NUM	O
at	O	ADP	O
risk	O	NOUN	B
subjects	O	NOUN	I
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
youngest	O	ADJ	O
generations	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
full	O	ADJ	O
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
only	O	ADV	O
subject	O	NOUN	B
who	O	PRON	O
may	O	AUX	O
transmit	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
to	O	ADP	O
the	O	DET	O
sixth	O	ADJ	O
generation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
protomutation	O	NOUN	B
carriers	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
fourth	O	ADJ	O
and	O	CCONJ	O
fifth	O	ADJ	O
generations	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
it	O	PRON	O
is	O	AUX	O
highly	O	ADV	O
probable	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
gene	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
eliminated	O	VERB	O
from	O	ADP	O
this	O	DET	O
pedigree	O	NOUN	B
within	O	ADP	O
one	O	NUM	O
generation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	B
population	O	NOUN	B
frequency	O	NOUN	O
of	O	ADP	O
DM	B-Disease	NOUN	B
can	O	AUX	O
at	O	ADP	O
present	O	ADJ	O
not	O	PART	O
be	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
asymptomatic	O	ADJ	B
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
younger	O	ADJ	B
generations	O	NOUN	I
of	O	ADP	O
known	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
probably	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
events	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ancestral	O	ADJ	B
generations	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
spinal	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	I
ataxia	I-Disease	NOUN	I
3	O	NUM	I
(	O	PUNCT	O
SCA3	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
approximately	O	ADV	O
3	O	NUM	O
cM	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
14q24	O	NOUN	I
.	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
q32	O	NOUN	B
.	O	PUNCT	O
2	O	X	O
.	O	PUNCT	O


SCA3	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
spinal	B-Disease	ADJ	B
cerebellar	I-Disease	ADJ	I
ataxia	I-Disease	NOUN	I
3	O	NUM	I
,	O	PUNCT	O
was	O	AUX	O
recently	O	ADV	O
mapped	O	VERB	B
to	O	PART	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
interval	O	NOUN	B
between	O	ADP	O
D14S67	O	NOUN	B
and	O	CCONJ	O
D14S81	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
14q	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
of	O	ADP	O
French	O	ADJ	B
ancestry	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SCA3	O	NOUN	B
candidate	O	NOUN	B
region	O	NOUN	I
has	O	AUX	O
now	O	ADV	O
been	O	AUX	O
refined	O	VERB	O
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
four	O	NUM	O
new	O	ADJ	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
(	O	PUNCT	O
D14S256	O	NOUN	B
,	O	PUNCT	O
D14S291	O	NOUN	B
,	O	PUNCT	O
D14S280	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
AFM343vf1	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
two	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
19	O	NUM	O
additional	O	ADJ	O
individuals	O	NOUN	B
were	O	AUX	O
genotyped	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
third	O	ADJ	O
French	O	ADJ	B
family	O	NOUN	O
.	O	PUNCT	O


Combined	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
point	O	NOUN	B
linkage	O	NOUN	I
analyses	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
new	O	ADJ	O
markers	O	NOUN	B
,	O	PUNCT	O
D14S280	O	NOUN	B
and	O	CCONJ	O
AFM343vf1	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
SCA3	O	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
maximal	O	ADJ	B
lod	O	NOUN	O
scores	O	NOUN	O
,	O	PUNCT	O
at	O	ADP	O
recombination	O	NOUN	B
fraction	O	NOUN	I
,	O	PUNCT	O
(	O	PUNCT	O
theta	O	NOUN	B
)	O	PUNCT	O
=	O	ADJ	O
.	O	PUNCT	O


00	O	NUM	O
,	O	PUNCT	O
of	O	ADP	O
7	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
and	O	CCONJ	O
13	O	NUM	O
.	O	PUNCT	O


70	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Combined	O	ADJ	B
multipoint	O	ADJ	O
and	O	CCONJ	O
recombinant	O	ADJ	B
haplotype	O	NOUN	O
analyses	O	NOUN	O
localize	O	VERB	B
the	O	DET	O
SCA3	O	NOUN	B
locus	O	NOUN	B
to	O	PART	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
interval	O	NOUN	B
flanked	O	VERB	I
by	O	ADP	O
D14S291	O	NOUN	B
and	O	CCONJ	O
D14S81	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
allele	O	NOUN	B
for	O	ADP	O
D14S280	O	NOUN	B
segregates	O	VERB	B
with	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
kindreds	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
allele	O	NOUN	B
is	O	AUX	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
French	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
is	O	AUX	O
not	O	PART	O
clearly	O	ADV	O
established	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
SCA3	O	NOUN	B
locus	O	NOUN	B
remains	O	VERB	O
within	O	ADP	O
the	O	DET	O
29	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
region	O	NOUN	B
on	O	ADP	O
14q24	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
-	O	PUNCT	O
q32	O	NOUN	B
.	O	PUNCT	O


2	O	NUM	O
containing	O	VERB	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
the	O	DET	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
clinically	O	ADV	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
phenotype	O	NOUN	B
determined	O	VERB	O
by	O	ADP	O
SCA3	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
cannot	O	VERB	O
yet	O	ADV	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
diseases	O	NOUN	B
result	O	VERB	O
from	O	ADP	O
alterations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
heterogeneity	O	NOUN	I
in	O	ADP	O
145	O	NUM	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


Breast	B-Disease	PROPN	B
Cancer	I-Disease	PROPN	I
Linkage	O	PROPN	I
Consortium	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovary	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
family	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
dominant	O	ADJ	B
predisposition	O	NOUN	B
to	O	PART	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovaries	I-Disease	NOUN	B
which	O	DET	O
has	O	AUX	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
region	O	NOUN	I
17q12	O	NOUN	I
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
,	O	PUNCT	O
of	O	ADP	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovary	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
show	O	VERB	O
linkage	O	NOUN	B
to	O	PART	O
this	O	DET	O
susceptibility	O	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
designated	O	VERB	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
a	O	DET	O
linkage	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
145	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
families	O	NOUN	B
contain	O	VERB	O
either	O	CCONJ	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
three	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
(	O	PUNCT	O
before	O	ADP	O
age	O	NOUN	B
60	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
or	O	CCONJ	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
families	O	NOUN	B
contained	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
an	O	DET	O
estimated	O	VERB	O
76	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
145	O	NUM	O
families	O	NOUN	B
are	O	AUX	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
BRCA1	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
13	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
linked	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
estimated	O	VERB	O
that	O	SCONJ	O
92	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
76	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
no	O	DET	O
male	B-Disease	NOUN	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
and	O	CCONJ	O
with	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
are	O	AUX	O
linked	O	VERB	O
to	O	PART	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
family	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
genetically	O	ADV	B
heterogeneous	O	ADJ	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
large	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
with	O	ADP	O
two	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
essential	B-Disease	ADJ	B
fructosuria	I-Disease	NOUN	B
:	O	PUNCT	O
molecular	O	ADJ	B
cloning	O	NOUN	I
and	O	CCONJ	O
mutational	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
ketohexokinase	O	NOUN	O
(	O	PUNCT	O
fructokinase	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Essential	B-Disease	ADJ	B
fructosuria	I-Disease	NOUN	I
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
oldest	O	ADJ	O
known	O	VERB	O
inborn	B-Disease	ADJ	B
errors	I-Disease	NOUN	I
of	I-Disease	ADP	O
metabolism	I-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
a	O	DET	O
benign	O	ADJ	B
condition	O	NOUN	I
which	O	DET	O
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
result	O	VERB	O
from	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
fructokinase	I-Disease	NOUN	I
(	O	PUNCT	O
ketohexokinase	O	NOUN	B
,	O	PUNCT	O
KHK	O	NOUN	B
,	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
enzyme	O	NOUN	B
catalyses	O	VERB	B
the	O	DET	O
first	O	ADJ	O
step	O	NOUN	O
of	O	ADP	O
metabolism	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
fructose	O	NOUN	I
,	O	PUNCT	O
conversion	O	NOUN	B
of	O	ADP	O
fructose	O	NOUN	B
to	O	PART	O
fructose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
early	O	ADJ	B
recognition	O	NOUN	I
of	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
primary	O	ADJ	B
structure	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
KHK	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
essential	B-Disease	ADJ	B
fructosuria	I-Disease	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
previously	O	ADV	O
defined	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
isolation	O	NOUN	B
and	O	CCONJ	O
sequencing	O	NOUN	B
of	O	ADP	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
cDNA	O	NOUN	B
clones	O	NOUN	I
encoding	O	VERB	O
human	O	ADJ	B
ketohexokinase	O	NOUN	B
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


Alternative	O	ADJ	B
mRNA	O	NOUN	B
species	O	NOUN	I
and	O	CCONJ	O
alternative	O	ADJ	B
KHK	O	NOUN	B
isozymes	O	NOUN	O
are	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
alternative	O	ADJ	B
polyadenylation	O	NOUN	B
and	O	CCONJ	O
splicing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KHK	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
KHK	O	NOUN	B
proteins	O	NOUN	I
show	O	VERB	O
a	O	DET	O
high	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
sequence	O	NOUN	B
conservation	O	NOUN	B
relative	O	ADJ	O
to	O	PART	O
rat	O	NOUN	B
KHK	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
KHK	O	NOUN	B
structural	O	ADJ	O
gene	O	NOUN	O
is	O	AUX	O
the	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
essential	B-Disease	ADJ	B
fructosuria	I-Disease	NOUN	B
was	O	AUX	O
also	O	ADV	O
obtained	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
characterized	O	VERB	B
family	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
three	O	NUM	O
of	O	ADP	O
eight	O	NUM	O
siblings	O	NOUN	B
have	O	AUX	O
fructosuria	B-Disease	NOUN	B
,	O	PUNCT	O
all	O	DET	O
affected	O	VERB	O
individuals	O	NOUN	B
are	O	AUX	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
for	O	ADP	O
two	O	NUM	O
mutations	O	NOUN	B
Gly40Arg	O	ADJ	B
and	O	CCONJ	O
Ala43Thr	O	PROPN	B
.	O	PUNCT	O


Both	O	DET	O
mutations	O	NOUN	B
result	O	VERB	O
from	O	ADP	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transitions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
each	O	DET	O
alters	O	VERB	O
the	O	DET	O
same	O	ADJ	O
conserved	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
KHK	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Neither	O	CCONJ	O
mutation	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
52	O	NUM	O
unrelated	O	ADJ	O
control	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
additional	O	ADJ	O
conservative	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
change	O	NOUN	I
(	O	PUNCT	O
Val49IIe	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
present	O	ADJ	O
on	O	ADP	O
the	O	DET	O
KHK	O	NOUN	B
allele	O	NOUN	B
bearing	O	VERB	O
Ala43Thr	O	ADJ	B


Homozygous	O	ADJ	B
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
crossover	O	NOUN	B
(	O	PUNCT	O
fusion	O	NOUN	B
gene	O	NOUN	I
)	O	PUNCT	O
mutation	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
a	O	DET	O
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
Gaucher	I-Disease	NOUN	I
disease	I-Disease	NOUN	O
fetus	O	NOUN	B
:	O	PUNCT	O
is	O	AUX	O
this	O	DET	O
analogous	O	ADJ	O
to	O	PART	O
the	O	DET	O
Gaucher	O	PROPN	B
knock	O	NOUN	B
-	O	PUNCT	O
out	O	ADP	B
mouse	O	NOUN	B
model	O	NOUN	I
?	O	PUNCT	O


Gaucher	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
GD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	O	VERB	B
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
beta	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
glucocerebrosidase	I-Disease	NOUN	B
(	O	PUNCT	O
EC	O	NOUN	B
3	O	NUM	I
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
45	O	NUM	O
,	O	PUNCT	O
gene	O	NOUN	B
symbol	O	NOUN	I
GBA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
type	B-Disease	NOUN	B
I	I-Disease	NUM	I
GD	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
CNS	O	NOUN	B
is	O	AUX	O
not	O	PART	O
involved	O	VERB	O
(	O	PUNCT	O
nonneuronopathic	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
GD	I-Disease	NOUN	I
(	O	PUNCT	O
acute	O	ADJ	B
neuronopathic	O	ADJ	I
)	O	PUNCT	O
CNS	O	NOUN	B
involvement	O	NOUN	B
is	O	AUX	O
early	O	ADJ	B
and	O	CCONJ	O
rapidly	O	ADV	O
progressive	O	ADJ	B
,	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
type	B-Disease	NOUN	B
III	I-Disease	NUM	I
GD	I-Disease	NOUN	I
(	O	PUNCT	O
subacute	O	ADJ	B
neuronopathic	O	ADJ	I
)	O	PUNCT	O
CNS	O	NOUN	B
involvement	O	NOUN	B
occurs	O	VERB	O
later	O	ADV	O
and	O	CCONJ	O
is	O	AUX	O
slowly	O	ADV	O
progressive	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
T6433C	O	NOUN	B
(	O	PUNCT	O
L444P	O	NOUN	B
)	O	PUNCT	O
substitution	O	NOUN	B
is	O	AUX	O
prevalent	O	ADJ	O
in	O	ADP	O
type	B-Disease	NOUN	B
GD	I-Disease	NOUN	I
II	I-Disease	NUM	I
.	O	PUNCT	O


It	O	PRON	O
may	O	AUX	O
occur	O	VERB	O
alone	O	ADV	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
base	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
mutation	O	NOUN	B
but	O	CCONJ	O
often	O	ADV	O
is	O	AUX	O
found	O	VERB	O
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
complex	O	ADJ	B
allele	O	NOUN	B
containing	O	VERB	O
additional	O	ADJ	O
GBA	O	NOUN	B
nucleotide	O	NOUN	B
substitutions	O	NOUN	I
,	O	PUNCT	O
G6468C	O	NOUN	B
(	O	PUNCT	O
A456P	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
G6482C	O	NOUN	B
(	O	PUNCT	O
V460V	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
without	O	ADP	O
(	O	PUNCT	O
recNciI	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
with	O	ADP	O
(	O	PUNCT	O
recTL	O	NOUN	B
)	O	PUNCT	O
G5957C	O	NOUN	B
(	O	PUNCT	O
D409H	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
complex	O	NOUN	B
allele	O	NOUN	B
is	O	AUX	O
presumed	O	VERB	O
to	O	PART	O
have	O	AUX	O
formed	O	VERB	O
by	O	ADP	O
recombination	O	NOUN	B
(	O	PUNCT	O
crossover	O	NOUN	B
,	O	PUNCT	O
fusion	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
gene	O	NOUN	I
with	O	ADP	O
the	O	DET	O
pseudogene	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
contains	O	VERB	O
the	O	DET	O
mutated	O	VERB	B
sequences	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
complex	O	ADJ	B
alleles	O	NOUN	B
have	O	AUX	O
never	O	ADV	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
coexist	O	VERB	O
in	O	ADP	O
any	O	DET	O
individual	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
devised	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
PCR	O	NOUN	B
method	O	NOUN	I
for	O	ADP	O
the	O	DET	O
specific	O	ADJ	O
amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
fusion	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
procedure	O	NOUN	B
we	O	PRON	O
demonstrated	O	VERB	O
the	O	DET	O
fusion	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
homozygous	O	ADJ	B
form	O	NOUN	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
Macedonian	O	PROPN	B
/	O	SYM	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
GD	B-Disease	NOUN	O
type	I-Disease	NOUN	O
II	I-Disease	NUM	O
fetus	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
parents	O	NOUN	B
were	O	AUX	O
carriers	O	NOUN	B
of	O	ADP	O
the	O	DET	O
recombination	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
sequence	O	NOUN	O
analysis	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
previous	O	ADJ	O
conceptus	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
was	O	AUX	O
stillborn	B-Disease	ADJ	B
at	O	ADP	O
36	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
features	O	NOUN	B
of	O	ADP	O
severe	O	ADJ	B
type	B-Disease	NOUN	B
II	I-Disease	NUM	I
GD	I-Disease	NOUN	I
.	O	PUNCT	O


Neonates	O	NOUN	B
showing	O	VERB	O
a	O	DET	O
severe	O	ADJ	B
clinical	O	ADJ	B
phenotype	O	NOUN	B
,	O	PUNCT	O
analogous	O	ADJ	O
to	O	PART	O
the	O	DET	O
early	O	ADJ	B
neonatal	O	ADJ	B
lethal	O	ADJ	B
disease	O	NOUN	I
occurring	O	VERB	O
in	O	ADP	O
mice	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
targeted	O	VERB	B
disruption	O	NOUN	B
of	O	ADP	O
GBA	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
elsewhere	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
specific	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
these	O	DET	O
cases	O	NOUN	B
have	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
characterized	O	VERB	B
.	O	PUNCT	O


(	O	PUNCT	O
ABSTRACT	O	NOUN	B
TRUNCATED	O	VERB	I
AT	O	ADP	I
250	O	NUM	I
WORDS	O	NOUN	I
)	O	PUNCT	O


Late	O	ADJ	B
infantile	O	ADJ	I
metachromatic	B-Disease	ADJ	I
leukodystrophy	I-Disease	NOUN	I
in	O	ADP	O
Israel	O	PROPN	B
.	O	PUNCT	O


Metachromatic	B-Disease	PROPN	B
Leukodystrophy	I-Disease	PROPN	I
(	O	PUNCT	O
MLD	B-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
neurodegenerative	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
in	O	ADP	O
which	O	DET	O
the	O	DET	O
lysosomal	O	ADJ	B
enzyme	O	NOUN	I
,	O	PUNCT	O
Aryl	O	ADJ	B
sulfatase	O	NOUN	I
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
deficient	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
inherited	O	VERB	B
as	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	B
trait	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
frequency	O	NOUN	B
is	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
be	O	AUX	O
1	O	NUM	O
/	O	SYM	O
40	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
live	O	ADJ	B
births	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
of	O	ADP	O
ARSA	O	PROPN	B
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
up	O	ADV	O
to	O	ADP	O
now	O	ADV	O
eight	O	NUM	O
mutations	O	NOUN	B
causing	O	VERB	O
MLD	B-Disease	PROPN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Another	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
PD	O	NOUN	B
,	O	PUNCT	O
leads	O	VERB	O
to	O	PART	O
the	O	DET	O
deficiency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
in	O	X	B
vitro	O	X	I
(	O	PUNCT	O
pseudodeficiency	O	NOUN	B
)	O	PUNCT	O
without	O	ADP	O
any	O	DET	O
known	O	ADJ	O
clinical	O	ADJ	B
effect	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PD	O	NOUN	B
mutation	O	NOUN	B
is	O	AUX	O
frequent	O	ADJ	B
in	O	ADP	O
all	O	DET	O
populations	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Israel	O	PROPN	B
,	O	PUNCT	O
late	O	ADJ	O
infantile	O	ADJ	O
MLD	B-Disease	PROPN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
very	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
a	O	DET	O
small	O	ADJ	O
Jewish	O	ADJ	B
isolate	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
Habbanite	O	ADJ	B
Jews	O	PROPN	I
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
75	O	NUM	O
live	O	ADJ	B
births	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
analysis	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
Habbanite	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
occurred	O	VERB	O
on	O	ADP	O
an	O	DET	O
allele	O	NOUN	B
with	O	ADP	I
the	O	DET	O
PD	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
ARSA	O	NOUN	B
activity	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	O
C	O	NOUN	O
>	O	X	O
T	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
change	O	NOUN	O
of	O	ADP	O
proline	O	NOUN	B
to	O	PART	O
leucine	O	NOUN	B
.	O	PUNCT	O


MLD	B-Disease	PROPN	B
is	O	AUX	O
also	O	ADV	O
frequent	O	ADJ	B
among	O	ADP	O
Moslem	O	PROPN	B
Arabs	O	PROPN	B
in	O	ADP	O
Jerusalem	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
transition	O	NOUN	B
G	O	NOUN	I
>	O	X	O
A	O	NOUN	O
destroying	O	VERB	B
the	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
late	O	ADJ	B
infantile	O	ADJ	I
MLD	B-Disease	PROPN	B
from	O	ADP	O
different	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Christian	O	ADJ	B
Arabs	O	PROPN	I
in	O	ADP	O
Israel	O	PROPN	B
also	O	ADV	O
have	O	AUX	O
a	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
live	O	ADJ	B
births	O	NOUN	I
)	O	PUNCT	O
;	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
unknown	O	ADJ	O
.	O	PUNCT	O


Knowledge	O	NOUN	B
of	O	ADP	O
the	O	DET	O
different	O	ADJ	O
mutations	O	NOUN	B
causing	O	VERB	O
MLD	B-Disease	PROPN	B
in	O	ADP	O
these	O	DET	O
defined	O	VERB	O
populations	O	NOUN	B
will	O	AUX	O
allow	O	VERB	O
a	O	DET	O
carrier	O	NOUN	B
screening	O	NOUN	O
program	O	NOUN	O
to	O	PART	O
be	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
and	O	CCONJ	O
prevent	O	VERB	B
the	O	DET	O
birth	O	NOUN	B
of	O	ADP	O
additional	O	ADJ	O
affected	O	VERB	B
children	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
single	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
(	O	PUNCT	O
G103D	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
triple	O	ADJ	I
helix	O	NOUN	I
produces	O	VERB	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
moderately	O	ADV	O
severe	O	ADJ	B
chondrodysplasia	B-Disease	NOUN	B
phenotype	O	NOUN	B
that	O	PRON	O
results	O	VERB	O
from	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
,	O	PUNCT	O
COL2A1	O	NOUN	B
.	O	PUNCT	O


Characteristics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disorder	O	NOUN	B
include	O	VERB	O
a	O	DET	O
short	B-Disease	ADJ	B
trunk	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
extremities	I-Disease	NOUN	B
,	O	PUNCT	O
mid	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
face	I-Disease	NOUN	B
hypoplasia	I-Disease	NOUN	B
,	O	PUNCT	O
cleft	B-Disease	ADJ	B
palate	I-Disease	NOUN	I
,	O	PUNCT	O
myopia	B-Disease	NOUN	B
,	O	PUNCT	O
retinal	B-Disease	ADJ	B
detachment	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
deletions	O	NOUN	B
of	O	ADP	O
all	O	DET	O
or	O	CCONJ	O
part	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	B
12	O	NUM	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
within	O	ADP	O
this	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
may	O	AUX	O
primarily	O	ADV	O
result	O	VERB	O
in	O	ADP	O
the	O	DET	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
phenotype	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
SSCP	O	NOUN	B
to	O	PART	O
analyze	O	VERB	B
an	O	DET	O
amplified	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
fragment	O	NOUN	I
containing	O	VERB	O
exon	O	NOUN	B
12	O	NUM	O
from	O	ADP	O
seven	O	NUM	O
individuals	O	NOUN	B
with	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


An	O	DET	O
abnormality	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
.	O	PUNCT	O


DNA	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
G	O	NOUN	B
to	O	PART	O
A	O	DET	O
transition	O	NOUN	B
that	O	PRON	O
implied	O	VERB	O
substitution	O	NOUN	B
of	O	ADP	O
glycine103	O	NOUN	B
of	O	ADP	I
the	O	DET	O
triple	O	ADJ	B
helical	O	ADJ	I
domain	O	NOUN	I
by	O	ADP	O
aspartate	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
DNA	O	NOUN	B
from	O	ADP	O
either	O	DET	O
of	O	ADP	O
the	O	DET	O
clinically	O	ADV	B
unaffected	O	ADJ	O
parents	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
.	O	PUNCT	O


Protein	O	NOUN	B
microsequencing	O	NOUN	I
demonstrated	O	VERB	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
abnormal	O	ADJ	B
allele	O	NOUN	B
in	O	ADP	O
cartilage	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
which	O	DET	O
result	O	VERB	O
in	O	ADP	O
single	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
can	O	AUX	O
produce	O	VERB	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
and	O	CCONJ	O
further	O	ADV	O
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
alteration	O	NOUN	B
of	O	ADP	O
a	O	DET	O
domain	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
includes	O	VERB	O
the	O	DET	O
region	O	NOUN	B
encoded	O	VERB	B
by	O	ADP	O
exon	O	NOUN	B
12	O	NUM	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
type	O	NOUN	B
II	O	NUM	I
collagen	O	NOUN	I
protein	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


CAG	O	NOUN	B
expansions	O	NOUN	O
in	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	B
for	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
at	O	ADP	O
chromosome	O	NOUN	B
14q32	O	NOUN	I
.	O	PUNCT	O
1	O	X	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	B
containing	O	VERB	O
CAG	O	NOUN	B
repeats	O	NOUN	I
and	O	CCONJ	O
mapped	O	VERB	B
it	O	PRON	O
to	O	PART	O
chromosome	O	NOUN	B
14q32	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
genetic	O	ADJ	B
locus	O	NOUN	I
for	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
normal	O	ADJ	O
individuals	O	NOUN	B
the	O	DET	O
gene	O	NOUN	B
contains	O	VERB	O
between	O	ADP	O
13	O	NUM	O
and	O	CCONJ	O
36	O	NUM	O
CAG	O	NOUN	B
repeats	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
clinically	O	ADV	B
diagnosed	O	VERB	I
patients	O	NOUN	B
and	O	CCONJ	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
pathological	O	ADJ	B
diagnosis	O	NOUN	O
of	O	ADP	O
MJD	B-Disease	NOUN	B
show	O	VERB	O
expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	B
-	O	PUNCT	O
number	O	NOUN	B
(	O	PUNCT	O
from	O	ADP	O
68	O	NUM	O
-	O	SYM	O
79	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Southern	O	NOUN	B
blot	O	NOUN	I
analyses	O	NOUN	I
and	O	CCONJ	O
genomic	O	ADJ	B
cloning	O	NOUN	I
demonstrates	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
of	O	ADP	O
related	O	ADJ	O
genes	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
raise	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
similar	O	ADJ	O
abnormalities	O	NOUN	B
in	O	ADP	O
related	O	ADJ	O
genes	O	NOUN	B
may	O	AUX	O
give	O	VERB	O
rise	O	NOUN	O
to	O	ADP	O
diseases	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
MJD	B-Disease	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
analysed	O	VERB	B
50	O	NUM	O
probands	O	NOUN	B
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
for	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
candidate	O	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
using	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
on	O	ADP	O
PCR	O	NOUN	B
-	O	PUNCT	O
amplified	O	VERB	B
genomic	O	ADJ	B
DNA	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
eight	O	NUM	O
putative	O	ADJ	B
disease	O	NOUN	I
-	O	PUNCT	O
causing	O	VERB	B
alterations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
are	O	AUX	O
frameshifts	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
are	O	AUX	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
two	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
which	O	DET	O
changes	O	VERB	B
the	O	DET	O
final	O	ADJ	O
cysteine	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
zinc	O	NOUN	B
finger	O	NOUN	I
motif	O	NOUN	B
to	O	PART	O
glycine	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
model	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
support	O	VERB	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
this	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
is	O	AUX	O
in	O	ADP	O
fact	O	NOUN	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
heterogeneity	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
,	O	PUNCT	O
coupled	O	VERB	B
with	O	ADP	O
the	O	DET	O
large	O	ADJ	B
size	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
clinical	O	ADJ	B
application	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
testing	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
technically	O	ADV	O
challenging	O	ADJ	O
.	O	PUNCT	O
.	O	PUNCT	O


Confirmation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
ten	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
provide	O	VERB	O
genetic	O	ADJ	B
evidence	O	NOUN	I
supporting	O	VERB	O
the	O	DET	O
identity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
through	O	ADP	O
the	O	DET	O
characterization	O	NOUN	B
of	O	ADP	O
germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
63	O	NUM	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
in	O	ADP	O
ten	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
cancer	B-Disease	NOUN	B
linked	O	VERB	O
to	O	PART	O
chromosome	O	NOUN	B
17q21	O	NOUN	I
.	O	PUNCT	O


Nine	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
screening	O	VERB	B
BRCA1	O	NOUN	B
DNA	O	NOUN	B
and	O	CCONJ	O
RNA	O	NOUN	B
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Seven	O	NUM	O
mutations	O	NOUN	B
lead	O	VERB	O
to	O	PART	O
protein	O	NOUN	B
truncations	O	NOUN	I
at	O	ADP	O
sites	O	NOUN	B
throughout	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
which	O	DET	O
occurred	O	VERB	O
independently	O	ADV	O
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
)	O	PUNCT	O
leads	O	VERB	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	O
a	O	DET	O
cysteine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
zinc	O	NOUN	B
binding	O	NOUN	I
domain	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
intronic	O	ADJ	B
single	O	ADJ	I
basepair	O	NOUN	I
substitution	O	NOUN	I
destroys	O	VERB	O
an	O	DET	O
acceptor	O	NOUN	B
site	O	NOUN	I
and	O	CCONJ	O
activates	O	VERB	B
a	O	DET	O
cryptic	O	ADJ	B
splice	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
59	O	NUM	O
basepair	O	NOUN	B
insertion	O	NOUN	I
and	O	CCONJ	O
chain	O	NOUN	B
termination	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
four	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
had	O	AUX	O
chain	O	NOUN	B
termination	O	NOUN	I
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
half	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


High	O	ADJ	B
resolution	O	NOUN	I
genetic	O	ADJ	B
analysis	O	NOUN	I
suggests	O	VERB	O
one	O	NUM	O
ancestral	O	ADJ	O
predisposing	O	VERB	B
haplotype	O	NOUN	B
for	O	ADP	O
the	O	DET	O
origin	O	NOUN	B
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
an	O	DET	O
amplification	O	NOUN	B
of	O	ADP	O
an	O	DET	O
unstable	O	ADJ	B
trinucleotide	O	NOUN	B
(	O	PUNCT	I
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
in	O	ADP	O
over	O	ADP	O
99	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
global	O	ADJ	B
DM	B-Disease	NOUN	I
population	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
in	O	ADP	O
complete	O	ADJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
with	O	ADP	O
an	O	DET	O
Alu	O	NOUN	B
element	O	NOUN	I
polymorphism	O	NOUN	B
within	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
DM	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
consequence	O	NOUN	B
of	O	ADP	I
one	O	NUM	O
or	O	CCONJ	O
few	O	ADJ	O
ancestral	O	ADJ	B
mutations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
recent	O	ADJ	O
analysis	O	NOUN	B
utilizing	O	VERB	O
this	O	DET	O
polymorphism	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
flanking	O	ADJ	B
dinucleotide	O	NOUN	B
marker	O	NOUN	I
,	O	PUNCT	O
suggested	O	VERB	O
that	O	SCONJ	O
similar	O	ADJ	O
to	O	PART	O
Fragile	B-Disease	VERB	B
X	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
DM	B-Disease	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	O
(	O	PUNCT	O
Imbert	O	PROPN	O
et	O	X	O
al	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
1993	O	NUM	O
Nature	O	NOUN	B
Genet	O	PROPN	I
.	O	PUNCT	O
4	O	NUM	O
,	O	PUNCT	O
72	O	NUM	O
-	O	SYM	O
76	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
low	O	ADJ	B
reproductive	O	ADJ	O
fitness	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
congenital	O	ADJ	B
DM	B-Disease	NOUN	I
(	O	PUNCT	O
the	O	DET	O
endpoint	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
anticipation	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
)	O	PUNCT	O
suggests	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
rate	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
a	O	DET	O
high	O	ADJ	O
resolution	O	NOUN	B
genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
using	O	VERB	O
PCR	O	NOUN	B
based	O	ADJ	O
assays	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
polymorphisms	O	NOUN	B
,	O	PUNCT	O
spanning	O	VERB	O
a	O	DET	O
physical	O	ADJ	B
distance	O	NOUN	I
of	O	ADP	O
30	O	NUM	O
kb	O	NOUN	O
,	O	PUNCT	O
within	O	ADP	O
and	O	CCONJ	O
immediately	O	ADV	O
flanking	O	VERB	B
the	O	DET	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
persistent	O	ADJ	B
complete	O	ADJ	O
allelic	O	ADJ	B
association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	O
with	O	ADP	O
all	O	DET	O
these	O	DET	O
polymorphisms	O	NOUN	B
provides	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
to	O	PART	O
previous	O	ADJ	O
observations	O	NOUN	B
and	O	CCONJ	O
suggests	O	VERB	O
more	O	ADV	O
strongly	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	O
occurred	O	VERB	O
on	O	ADP	O
the	O	DET	O
background	O	NOUN	B
of	O	ADP	O
a	O	DET	O
particular	O	ADJ	O
haplotype	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
became	O	VERB	O
inherently	O	ADV	O
unstable	O	ADJ	B
and	O	CCONJ	O
therefore	O	ADV	O
predisposed	O	VERB	O
to	O	PART	O
amplification	O	NOUN	B
.	O	PUNCT	O


Genetic	O	ADJ	B
instability	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
ovarian	B-Disease	ADJ	O
cancer	I-Disease	NOUN	O
cell	O	NOUN	B
lines	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
the	O	DET	O
stability	O	NOUN	B
of	O	ADP	O
microsatellites	O	NOUN	B
in	O	ADP	O
cell	O	NOUN	B
lines	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
human	O	ADJ	B
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
and	O	CCONJ	O
found	O	VERB	O
that	O	SCONJ	O
5	O	NUM	O
out	O	ADP	O
of	O	ADP	O
10	O	NUM	O
of	O	ADP	O
the	O	DET	O
ovarian	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
cell	O	NOUN	O
lines	O	NOUN	O
are	O	AUX	O
genetically	O	ADV	B
unstable	O	ADJ	B
at	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
analyzed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
clones	O	NOUN	B
and	O	CCONJ	O
subclones	O	NOUN	B
derived	O	VERB	O
serially	O	ADV	O
from	O	ADP	O
one	O	NUM	O
of	O	ADP	O
these	O	DET	O
cell	O	NOUN	B
lines	O	NOUN	I
(	O	PUNCT	O
2774	O	NUM	O
;	O	PUNCT	O
serous	B-Disease	ADJ	B
cystadenocarcinoma	I-Disease	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
very	O	ADV	O
high	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
microsatellites	O	NOUN	B
distributed	O	VERB	B
in	O	ADP	O
many	O	ADJ	O
different	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
change	O	VERB	O
their	O	PRON	O
size	O	NOUN	B
in	O	ADP	O
a	O	DET	O
mercurial	O	ADJ	B
fashion	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
genomic	O	ADJ	B
instability	O	NOUN	I
in	O	ADP	O
ovarian	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
dynamic	O	ADJ	B
and	O	CCONJ	O
ongoing	O	ADJ	O
process	O	NOUN	B
whose	O	DET	O
high	O	ADJ	B
frequency	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
been	O	AUX	O
previously	O	ADV	O
underestimated	O	VERB	O
by	O	ADP	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
allelotyping	O	NOUN	B
of	O	ADP	O
bulk	O	ADJ	O
tumor	B-Disease	NOUN	B
tissue	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
the	O	DET	O
source	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
instability	O	NOUN	I
in	O	ADP	O
one	O	NUM	O
ovarian	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
point	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
R524P	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
mismatch	O	NOUN	B
-	O	PUNCT	O
repair	O	NOUN	B
gene	O	NOUN	I
MSH2	O	NOUN	O
(	O	PUNCT	O
Salmonella	O	X	B
MutS	O	NOUN	B
homologue	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
hereditary	B-Disease	ADJ	B
nonpolyposis	I-Disease	NOUN	I
colorectal	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Patient	O	NOUN	B
2774	O	NUM	O
was	O	AUX	O
a	O	DET	O
38	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
heterozygote	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
her	O	PRON	O
normal	O	ADJ	B
tissue	O	NOUN	I
carried	O	VERB	O
both	O	CCONJ	O
mutant	O	ADJ	B
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
MSH2	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


However	O	SCONJ	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
was	O	AUX	O
lost	O	VERB	B
at	O	ADP	O
some	O	DET	O
point	O	NOUN	O
early	O	ADV	O
during	O	ADP	O
tumorigenesis	O	NOUN	B
so	O	SCONJ	O
that	O	SCONJ	O
DNA	O	NOUN	B
isolated	O	VERB	B
either	O	CCONJ	O
from	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
ovarian	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
or	O	CCONJ	O
from	O	ADP	O
the	O	DET	O
2774	O	NUM	O
cell	O	NOUN	B
line	O	NOUN	I
carries	O	VERB	O
only	O	ADV	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	O
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
MSH2	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
genetic	O	ADJ	B
instability	O	NOUN	I
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
and	O	CCONJ	O
cell	O	NOUN	B
line	O	NOUN	I
DNA	O	NOUN	I
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
mismatch	O	NOUN	B
-	O	PUNCT	O
repair	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
MSH2	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
progression	O	NOUN	B
in	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
breast	B-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
data	O	NOUN	B
from	O	ADP	O
familial	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
gene	O	NOUN	B
that	O	PRON	O
confers	O	VERB	O
susceptibility	O	NOUN	B
to	O	PART	O
ovarian	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
early	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
onset	I-Disease	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
encodes	O	VERB	B
a	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
region	O	NOUN	B
is	O	AUX	O
also	O	ADV	O
subject	O	ADJ	O
to	O	PART	O
allelic	O	ADJ	B
loss	O	NOUN	O
in	O	ADP	O
sporadic	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
indication	O	NOUN	B
that	O	SCONJ	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
may	O	AUX	O
occur	O	VERB	O
somatically	O	ADV	B
in	O	ADP	O
these	O	DET	O
tumors	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
coding	O	NOUN	B
region	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
breast	B-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
tumors	I-Disease	NOUN	I
that	O	PRON	O
show	O	VERB	O
allele	O	NOUN	B
loss	O	NOUN	I
at	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
3	O	NUM	O
of	O	ADP	O
32	O	NUM	O
breast	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
of	O	ADP	O
12	O	NUM	O
ovarian	B-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
;	O	PUNCT	O
all	O	DET	O
four	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
germline	O	NOUN	B
alterations	O	NOUN	I
and	O	CCONJ	O
occurred	O	VERB	O
in	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
cancers	B-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
mutation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
critical	O	ADJ	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
that	O	PRON	O
arise	O	VERB	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutant	O	ADJ	B
germline	O	NOUN	B
allele	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


PAX6	O	NOUN	B
gene	O	NOUN	B
dosage	O	NOUN	I
effect	O	NOUN	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
congenital	B-Disease	ADJ	B
cataracts	I-Disease	NOUN	I
,	O	PUNCT	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
anophthalmia	B-Disease	NOUN	B
and	O	CCONJ	O
central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
defects	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
eye	O	NOUN	O
malformation	O	NOUN	O
aniridia	B-Disease	NOUN	O
results	O	VERB	B
from	O	ADP	O
haploinsufficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
PAX6	I-Disease	NOUN	B
,	O	PUNCT	O
a	O	DET	O
paired	O	ADJ	O
box	O	NOUN	O
DNA	O	NOUN	O
-	O	PUNCT	O
binding	O	VERB	B
protein	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
this	O	DET	O
dosage	O	NOUN	B
effect	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
characterized	O	VERB	B
two	O	NUM	O
PAX6	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
segregating	O	NOUN	I
aniridia	B-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
milder	O	ADJ	B
syndrome	O	NOUN	I
consisting	O	VERB	O
of	O	ADP	O
congenital	B-Disease	ADJ	B
cataracts	I-Disease	NOUN	I
and	O	CCONJ	O
late	O	ADJ	O
onset	O	NOUN	O
corneal	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
,	O	PUNCT	O
at	O	ADP	O
codons	O	NOUN	B
103	O	NUM	O
and	O	CCONJ	O
353	O	NUM	O
,	O	PUNCT	O
truncate	O	ADJ	B
PAX6	O	NOUN	B
within	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
paired	O	ADJ	B
and	O	CCONJ	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
PST	O	NOUN	B
domains	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
PST	O	NOUN	B
domain	O	NOUN	B
activates	O	VERB	B
transcription	O	NOUN	B
autonomously	O	ADV	I
and	O	CCONJ	O
the	O	DET	O
mutant	O	ADJ	B
form	O	NOUN	O
has	O	AUX	O
partial	O	ADJ	B
activity	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
compound	O	NOUN	B
heterozygote	O	NOUN	B
had	O	AUX	O
severe	O	ADJ	B
craniofacial	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
defects	I-Disease	NOUN	B
and	O	CCONJ	O
no	B-Disease	DET	O
eyes	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
malformations	O	NOUN	B
is	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
in	O	ADP	O
homozygous	O	ADJ	B
Sey	O	ADJ	B
mice	O	NOUN	B
and	O	CCONJ	O
suggests	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
for	O	ADP	O
PAX6	O	NOUN	B
in	O	ADP	O
controlling	O	VERB	B
the	O	DET	O
migration	O	NOUN	B
and	O	CCONJ	O
differentiation	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
neuronal	O	ADJ	B
progenitor	O	NOUN	I
cells	O	NOUN	I
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
physical	O	ADJ	B
map	O	NOUN	I
and	O	CCONJ	O
candidate	O	NOUN	O
genes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
region	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
17q12	O	NOUN	I
-	O	PUNCT	O
21	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
constructed	O	VERB	O
a	O	DET	O
physical	O	ADJ	B
map	O	NOUN	I
of	O	ADP	O
a	O	DET	O
4	O	NUM	O
cM	O	NOUN	O
region	O	NOUN	O
on	O	ADP	O
chromosome	O	NOUN	B
17q12	O	NOUN	I
-	O	PUNCT	O
21	O	NUM	O
that	O	PRON	O
contains	O	VERB	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
gene	O	NOUN	B
BRCA1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
map	O	NOUN	B
comprises	O	VERB	O
a	O	DET	O
contig	O	NOUN	B
of	O	ADP	O
137	O	NUM	O
overlapping	O	VERB	O
yeast	O	NOUN	B
artificial	O	ADJ	B
chromosomes	O	NOUN	I
and	O	CCONJ	O
P1	O	NOUN	B
clones	O	NOUN	I
,	O	PUNCT	O
onto	O	ADP	O
which	O	DET	O
we	O	PRON	O
have	O	AUX	O
placed	O	VERB	O
112	O	NUM	O
PCR	O	NOUN	B
markers	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
localized	O	VERB	B
more	O	ADJ	O
than	O	ADP	O
20	O	NUM	O
genes	O	NOUN	B
on	O	ADP	O
this	O	DET	O
map	O	NOUN	B
,	O	PUNCT	O
ten	O	NUM	O
of	O	ADP	O
which	O	DET	O
had	O	AUX	O
not	O	PART	O
been	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
the	O	DET	O
region	O	NOUN	B
previously	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
have	O	AUX	O
isolated	O	VERB	B
30	O	NUM	O
cDNA	O	NOUN	B
clones	O	NOUN	I
representing	O	VERB	O
partial	O	ADJ	O
sequences	O	NOUN	O
of	O	ADP	O
as	O	ADV	O
yet	O	ADV	O
unidentified	O	ADJ	O
genes	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
genes	O	NOUN	B
that	O	PRON	O
lie	O	VERB	O
within	O	ADP	O
a	O	DET	O
narrow	O	ADJ	B
region	O	NOUN	I
defined	O	VERB	O
by	O	ADP	O
meiotic	O	ADJ	B
breakpoints	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
patients	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
sequenced	O	VERB	B
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
without	O	ADP	O
revealing	O	VERB	O
any	O	DET	O
deleterious	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
new	O	ADJ	O
reagents	O	NOUN	B
should	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
LEC	O	NOUN	B
rat	O	NOUN	B
has	O	AUX	O
a	O	DET	O
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
copper	O	NOUN	B
transporting	O	NOUN	O
ATPase	O	NOUN	B
gene	O	NOUN	I
homologous	O	ADJ	O
to	O	PART	O
the	O	DET	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Long	O	PROPN	B
-	O	PUNCT	O
Evans	O	PROPN	B
Cinnamon	O	PROPN	I
(	O	PUNCT	O
LEC	O	NOUN	B
)	O	PUNCT	O
rat	O	NOUN	B
shows	O	VERB	O
similarity	O	NOUN	B
to	O	PART	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
many	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
biochemical	O	ADJ	B
features	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
cloned	O	VERB	B
cDNAs	O	NOUN	B
for	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
gene	O	NOUN	O
(	O	PUNCT	O
Atp7b	O	NOUN	B
)	O	PUNCT	O
homologous	O	ADJ	O
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
Wilson	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ATP7B	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
have	O	AUX	O
used	O	VERB	O
them	O	PRON	O
to	O	PART	O
identify	O	VERB	O
a	O	DET	O
partial	O	ADJ	B
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Atp7b	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
LEC	O	NOUN	B
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
removes	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
900	O	NUM	O
bp	O	NOUN	O
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
at	O	ADP	O
the	O	DET	O
3	O	NUM	O
end	O	NOUN	O
,	O	PUNCT	O
includes	O	VERB	O
the	O	DET	O
crucial	O	ADJ	O
ATP	O	NOUN	B
binding	O	NOUN	B
domain	O	NOUN	I
and	O	CCONJ	O
extends	O	VERB	O
downstream	O	ADV	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
convincing	O	ADJ	O
evidence	O	NOUN	B
for	O	ADP	O
defining	O	VERB	O
the	O	DET	O
LEC	O	NOUN	B
rat	O	NOUN	B
as	O	ADP	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
model	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
studying	O	VERB	O
liver	O	NOUN	B
pathophysiology	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
developing	O	VERB	O
therapy	O	NOUN	B
for	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
studying	O	VERB	O
the	O	DET	O
pathway	O	NOUN	B
of	O	ADP	O
copper	O	NOUN	B
transport	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
possible	O	ADJ	O
interaction	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
heavy	O	ADJ	B
metals	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genomic	O	ADJ	B
organization	O	NOUN	I
of	O	ADP	O
the	O	DET	O
adrenoleukodystrophy	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
peroxisomal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	O
neurodegenerative	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
very	I-Disease	ADV	O
long	I-Disease	ADJ	O
chain	I-Disease	NOUN	O
fatty	I-Disease	ADJ	O
acids	I-Disease	NOUN	O
beta	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
oxidation	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
recently	O	ADV	O
identified	O	VERB	B
by	O	ADP	O
positional	O	ADJ	B
cloning	O	VERB	I
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
ALD	B-Disease	NOUN	B
,	O	PUNCT	O
located	O	ADJ	O
in	O	ADP	O
Xq28	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
encodes	O	VERB	B
a	O	DET	O
new	O	ADJ	O
member	O	NOUN	O
of	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
ABC	O	PROPN	B
"	O	PUNCT	O
superfamily	O	NOUN	B
of	O	ADP	O
membrane	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
transporters	O	NOUN	B
that	O	PRON	O
shows	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
significant	O	ADJ	B
homology	O	NOUN	B
to	O	PART	O
the	O	DET	O
70	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
peroxisomal	O	ADJ	B
membrane	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
PMP70	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
a	O	DET	O
detailed	O	ADJ	O
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
extends	O	VERB	O
over	O	ADP	O
21	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
consists	O	VERB	O
of	O	ADP	O
10	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
facilitate	O	VERB	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
ALD	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
intronic	O	ADJ	B
sequences	O	NOUN	I
flanking	O	VERB	I
the	O	DET	O
exons	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
sequence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
and	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
immediate	O	ADJ	B
5	O	NUM	O
promoter	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


Sequences	O	NOUN	B
present	O	ADJ	O
in	O	ADP	O
distal	O	ADJ	B
exons	O	NOUN	I
cross	O	NOUN	B
-	O	PUNCT	O
hybridize	O	VERB	B
strongly	O	ADV	O
to	O	PART	O
additional	O	ADJ	O
sequences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
genome	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
positioned	O	ADJ	O
on	O	ADP	O
a	O	DET	O
pulsed	O	ADJ	B
-	O	PUNCT	O
field	O	NOUN	B
map	O	NOUN	I
between	O	ADP	O
DXS15	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
L1CAM	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
about	O	ADV	O
650	O	NUM	O
kb	O	NOUN	O
upstream	O	ADJ	O
from	O	ADP	O
the	O	DET	O
color	O	NOUN	B
pigment	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequent	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
color	O	NOUN	B
vision	O	NOUN	I
anomalies	O	NOUN	I
observed	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
the	O	DET	O
adult	O	ADJ	B
onset	O	NOUN	B
form	O	NOUN	I
of	O	ADP	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
thus	O	ADV	O
does	O	AUX	O
not	O	PART	O
represent	O	VERB	O
a	O	DET	O
contiguous	B-Disease	ADJ	B
gene	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
but	O	CCONJ	O
a	O	DET	O
secondary	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
murine	O	ADJ	B
homologues	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
Hdh	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
alpha	O	NOUN	B
-	O	PUNCT	O
adducin	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
Add1	O	NOUN	B
)	O	PUNCT	O
map	O	NOUN	O
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
5	O	NUM	I
within	O	ADP	O
a	O	DET	O
region	O	NOUN	B
of	O	ADP	O
conserved	O	VERB	B
synteny	O	NOUN	I
with	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
4p16	O	NOUN	I
.	O	PUNCT	O
3	O	X	O
.	O	PUNCT	O


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
neurodegenerative	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	O
(	O	PUNCT	O
IT15	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
reported	O	VERB	O
the	O	DET	O
cloning	O	NOUN	B
of	O	ADP	O
Hdh	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
murine	O	ADJ	B
homologue	O	NOUN	B
of	O	ADP	O
IT15	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
using	O	VERB	O
an	O	DET	O
interspecific	O	ADJ	B
backcross	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
mapped	O	VERB	O
both	O	CCONJ	O
Hdh	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mouse	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
adducin	O	NOUN	B
(	O	PUNCT	O
Add1	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
membrane	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cytoskeletal	O	ADJ	B
protein	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
of	O	ADP	O
these	O	DET	O
genes	O	NOUN	B
map	O	NOUN	I
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
position	O	NOUN	O
on	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
5	O	NUM	I
in	O	ADP	O
a	O	DET	O
region	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
ancestral	O	ADJ	B
chromosomal	O	ADJ	B
rearrangements	O	NOUN	I
and	O	CCONJ	O
show	O	VERB	O
no	O	DET	O
recombination	O	NOUN	B
with	O	ADP	O
D5H4S43	O	PROPN	B
,	O	PUNCT	O
D5H4S115	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
D5H4S62	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
murine	O	ADJ	B
homologues	O	NOUN	B
of	O	ADP	O
D4S43	O	NOUN	B
,	O	PUNCT	O
D4S115	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D4S62	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Further	O	ADV	O
mapping	O	VERB	B
studies	O	NOUN	I
of	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
mice	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
mammalian	O	ADJ	B
species	O	NOUN	B
should	O	AUX	O
reveal	O	VERB	O
the	O	DET	O
nature	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rearrangements	O	NOUN	B
affecting	O	VERB	B
this	O	DET	O
chromosomal	O	ADJ	B
segment	O	NOUN	I
during	O	ADP	O
mammalian	O	ADJ	B
evolution	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
cholesteryl	B-Disease	NOUN	I
ester	I-Disease	NOUN	I
transfer	I-Disease	NOUN	I
protein	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
two	O	NUM	O
prevalent	O	ADJ	O
mutations	O	NOUN	B
as	O	ADP	O
a	O	DET	O
major	O	ADJ	O
determinant	O	NOUN	O
of	O	ADP	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	I
cholesterol	O	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
determinants	O	NOUN	I
of	O	ADP	O
HDL	O	NOUN	B
cholesterol	O	NOUN	I
(	O	PUNCT	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
)	O	PUNCT	O
levels	O	NOUN	B
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
are	O	AUX	O
poorly	O	ADV	O
understood	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
previously	O	ADV	O
described	O	VERB	O
plasma	O	NOUN	B
cholesteryl	B-Disease	NOUN	B
ester	I-Disease	NOUN	I
transfer	I-Disease	NOUN	I
protein	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
CETP	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
intron	O	NOUN	B
14	O	NUM	O
G	O	NOUN	O
(	O	PUNCT	O
+	O	CCONJ	O
1	O	X	O
)	O	PUNCT	O
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
A	O	NOUN	O
mutation	O	NOUN	B
(	O	PUNCT	O
Int14	O	NOUN	B
A	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
several	O	ADJ	O
families	O	NOUN	B
with	O	ADP	O
very	O	ADV	O
high	O	ADJ	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
Japan	O	PROPN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
with	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
100	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
130	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
screened	O	VERB	B
by	O	ADP	O
PCR	O	NOUN	B
single	O	ADJ	I
strand	O	NOUN	I
conformational	O	ADJ	O
polymorphism	O	NOUN	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
other	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	O
by	O	ADP	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
or	O	CCONJ	O
primer	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
restriction	O	NOUN	B
map	O	NOUN	I
modification	O	NOUN	B
of	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
a	O	DET	O
novel	O	ADJ	O
intron	O	NOUN	B
14	O	NUM	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
mutation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
T	O	NOUN	B
insertion	O	NOUN	I
at	O	ADP	O
position	O	NOUN	O
+	O	CCONJ	O
3	O	NUM	O
from	O	ADP	O
the	O	DET	O
exon14	O	NOUN	B
/	O	SYM	O
intron14	O	NOUN	B
boundary	O	NOUN	O
(	O	PUNCT	O
Int14	O	NOUN	B
T	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
Asp442	O	NOUN	B
to	O	PART	O
Gly	O	NOUN	B
)	O	PUNCT	O
within	O	ADP	O
exon	O	NOUN	B
15	O	NUM	I
(	O	PUNCT	O
D442G	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Int14	O	NOUN	B
T	O	NOUN	I
mutation	O	NOUN	I
was	O	AUX	O
only	O	ADV	O
found	O	VERB	O
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
D442G	O	NOUN	B
and	O	CCONJ	O
Int14	O	NOUN	B
A	O	NOUN	O
mutations	O	NOUN	B
were	O	AUX	O
highly	O	ADV	O
prevalent	O	ADJ	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
with	O	ADP	O
combined	O	ADJ	O
allele	O	NOUN	B
frequencies	O	NOUN	B
of	O	ADP	O
9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
12	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
21	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
43	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
60	O	NUM	O
-	O	SYM	O
79	O	NUM	O
,	O	PUNCT	O
80	O	NUM	O
-	O	SYM	O
99	O	NUM	O
,	O	PUNCT	O
100	O	NUM	O
-	O	SYM	O
119	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
>	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
120	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
prevalences	O	NOUN	B
of	O	ADP	O
the	O	DET	O
D442G	O	NOUN	B
and	O	CCONJ	O
Int14	O	NOUN	B
A	O	NOUN	O
mutations	O	NOUN	B
were	O	AUX	O
extremely	O	ADV	O
high	O	ADJ	O
in	O	ADP	O
a	O	DET	O
general	O	ADJ	O
sample	O	NOUN	O
of	O	ADP	O
Japanese	O	ADJ	B
men	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
236	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
heterozygote	O	NOUN	B
frequencies	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


These	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	O
variance	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
phenotype	O	NOUN	B
in	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
compound	O	NOUN	I
heterozygote	O	NOUN	I
(	O	PUNCT	O
Int14	O	NOUN	B
T	O	NOUN	I
and	O	CCONJ	O
Int14	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
was	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
Int14	O	NOUN	B
A	O	NOUN	O
homozygotes	O	NOUN	B
(	O	PUNCT	O
no	O	DET	O
detectable	O	ADJ	B
CETP	O	NOUN	B
and	O	CCONJ	O
markedly	O	ADV	O
increased	O	VERB	B
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Int14	O	NOUN	B
T	O	NOUN	I
produces	O	VERB	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
D442G	O	NOUN	B
homozygotes	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
86	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
26	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
Int14	O	NOUN	B
A	O	NOUN	O
homozygotes	O	NOUN	B
(	O	PUNCT	O
158	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
35	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
reflecting	O	VERB	O
residual	O	ADJ	B
CETP	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
47	O	NUM	O
D442G	O	NOUN	O
heterozygotes	O	NOUN	B
,	O	PUNCT	O
mean	O	VERB	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
levels	O	NOUN	B
were	O	AUX	O
91	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
23	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
level	O	NOUN	B
in	O	ADP	O
D442G	O	NOUN	B
homozygotes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
mean	O	VERB	B
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
Int14	O	NOUN	B
A	O	NOUN	O
heterozygotes	O	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
15	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
D442G	O	NOUN	B
mutation	O	NOUN	B
acts	O	VERB	O
differently	O	ADV	O
to	O	PART	O
the	O	DET	O
null	O	ADJ	B
mutations	O	NOUN	I
with	O	ADP	O
weaker	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
HDL	O	NOUN	B
in	O	ADP	O
the	O	DET	O
homozygous	O	ADJ	B
state	O	NOUN	O
and	O	CCONJ	O
stronger	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heterozygotes	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
dominant	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
a	O	DET	O
partially	O	ADV	O
defective	O	ADJ	B
allele	O	NOUN	B
.	O	PUNCT	O


CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
,	O	PUNCT	O
reflecting	O	VERB	O
two	O	NUM	O
prevalent	O	ADJ	O
mutations	O	NOUN	B
(	O	PUNCT	O
D442G	O	NOUN	B
and	O	CCONJ	O
Int14	O	NOUN	B
A	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
example	O	NOUN	O
of	O	ADP	O
a	O	DET	O
genetic	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
state	O	NOUN	I
which	O	DET	O
is	O	AUX	O
sufficiently	O	ADV	O
common	O	ADJ	O
to	O	PART	O
explain	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
fraction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
variation	O	NOUN	B
in	O	ADP	O
HDL	O	NOUN	B
-	O	PUNCT	O
C	O	NOUN	B
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
:	O	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
chenodeoxycholic	O	ADJ	B
acid	O	NOUN	I
,	O	PUNCT	O
pravastatin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
combined	O	ADJ	O
use	O	NOUN	O
.	O	PUNCT	O


Treatments	O	NOUN	B
by	O	ADP	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
chenodeoxycholic	O	ADJ	B
acid	O	NOUN	I
(	O	PUNCT	O
CDCA	O	NOUN	B
)	O	PUNCT	O
alone	O	ADV	O
,	O	PUNCT	O
3	O	NUM	O
-	O	PUNCT	O
hydroxy	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
-	O	PUNCT	O
methylglutaryl	O	NOUN	B
(	O	PUNCT	O
HMG	O	NOUN	O
)	O	PUNCT	O
CoA	O	NOUN	O
reductase	O	NOUN	O
inhibitor	O	NOUN	O
(	O	PUNCT	O
pravastatin	O	NOUN	B
)	O	PUNCT	O
alone	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
combination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
were	O	AUX	O
attempted	O	VERB	O
for	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
cerebrotendinous	B-Disease	ADJ	B
xanthomatosis	I-Disease	NOUN	I
(	O	PUNCT	O
CTX	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


CDCA	O	NOUN	B
treatment	O	NOUN	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
300	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
reduced	O	VERB	B
serum	O	NOUN	B
cholestanol	O	NOUN	B
(	O	PUNCT	O
67	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
lathosterol	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
campesterol	O	NOUN	B
(	O	PUNCT	O
61	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
sitosterol	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
sera	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
changed	O	VERB	O
to	O	PART	O
be	O	AUX	O
"	O	PUNCT	O
atherogenic	O	ADJ	B
"	O	PUNCT	O
;	O	PUNCT	O
total	O	ADJ	B
cholesterol	O	NOUN	I
,	O	PUNCT	O
triglyceride	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
(	O	PUNCT	O
LDL	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
cholesterol	O	NOUN	B
were	O	AUX	O
increased	O	VERB	B
,	O	PUNCT	O
while	O	SCONJ	O
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
cholesterol	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
.	O	PUNCT	O


Contrarily	O	ADV	O
,	O	PUNCT	O
pravastatin	O	NOUN	B
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
improved	O	VERB	B
the	O	DET	O
sera	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
to	O	PART	O
be	O	AUX	O
markedly	O	ADV	B
"	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
atherogenic	O	ADJ	B
"	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
reductions	O	NOUN	B
of	O	ADP	O
cholestanol	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
lathosterol	O	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
campesterol	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
sitosterol	O	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
inadequate	O	ADJ	B
.	O	PUNCT	O


Combined	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
CDCA	O	NOUN	B
and	O	CCONJ	O
pravastatin	O	NOUN	B
showed	O	VERB	O
good	O	ADJ	O
overlapping	O	NOUN	O
of	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
each	O	DET	O
drug	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
sera	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
apparently	O	ADV	O
more	O	ADJ	O
"	O	PUNCT	O
anti	O	ADJ	B
-	O	PUNCT	O
atherogenic	O	ADJ	B
"	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
after	O	ADP	O
CDCA	O	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Serum	O	NOUN	B
cholestanol	O	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
still	O	ADV	O
2	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
times	O	NOUN	O
higher	O	ADJ	B
than	O	ADP	O
in	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
serum	O	NOUN	B
lathosterol	O	NOUN	I
level	O	NOUN	I
was	O	AUX	O
within	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
enhancement	O	NOUN	B
of	O	ADP	O
overall	O	ADJ	B
cholesterol	O	NOUN	B
synthesis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
was	O	AUX	O
sufficiently	O	ADV	O
suppressed	O	VERB	B
.	O	PUNCT	O


Plant	O	NOUN	B
sterol	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
within	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
CDCA	O	NOUN	B
and	O	CCONJ	O
pravastatin	O	NOUN	B
was	O	AUX	O
a	O	DET	O
good	O	ADJ	O
treatment	O	NOUN	B
for	O	ADP	O
CTX	B-Disease	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
improvement	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
lipoprotein	O	NOUN	I
metabolism	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
suppression	O	NOUN	B
of	O	ADP	O
cholesterol	O	NOUN	B
synthesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
reductions	O	NOUN	B
of	O	ADP	O
cholestanol	O	NOUN	B
and	O	CCONJ	O
plant	O	NOUN	B
sterol	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
of	O	ADP	O
7	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
was	O	AUX	O
arrested	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
dramatic	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
clinical	O	ADJ	B
manifestations	O	NOUN	I
,	O	PUNCT	O
xanthoma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
electrophysiological	O	ADJ	B
findings	O	NOUN	I
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
found	O	VERB	O
after	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B


Mutation	O	NOUN	B
spectrum	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
Danish	O	ADJ	B
and	O	CCONJ	O
Swedish	O	ADJ	B
choroideremia	B-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
recent	O	ADJ	O
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
complete	O	ADJ	B
open	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
of	O	ADP	O
the	O	DET	O
choroideremia	B-Disease	NOUN	B
(	O	PUNCT	O
CHM	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
and	O	CCONJ	O
the	O	DET	O
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
exon	O	NOUN	B
-	O	PUNCT	O
intron	O	NOUN	B
boundaries	O	NOUN	B
has	O	AUX	O
paved	O	VERB	O
the	O	DET	O
way	O	NOUN	O
to	O	PART	O
mutation	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
classical	O	ADJ	O
choroideremia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
performed	O	VERB	O
mutation	O	NOUN	B
screening	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
from	O	ADP	O
15	O	NUM	O
Danish	O	ADJ	B
and	O	CCONJ	O
Swedish	O	ADJ	B
families	O	NOUN	B
by	O	ADP	O
using	O	VERB	O
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
single	O	ADJ	I
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	B
(	O	PUNCT	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
technique	O	NOUN	O
.	O	PUNCT	O


Causative	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
12	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
substantial	O	ADJ	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
this	O	DET	O
approach	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
deletions	O	NOUN	B
of	O	ADP	O
different	O	ADJ	O
sizes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
deletion	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
only	O	ADV	O
one	O	NUM	O
exon	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
in	O	ADP	O
another	O	DET	O
the	O	DET	O
deletion	O	NOUN	B
comprised	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Mapping	O	NOUN	B
of	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
endpoints	O	NOUN	B
in	O	ADP	O
these	O	DET	O
four	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
another	O	DET	O
11	O	NUM	O
male	O	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
sizeable	O	ADJ	B
deletions	O	NOUN	I
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
construct	O	VERB	O
a	O	DET	O
very	O	ADV	O
detailed	O	ADJ	O
map	O	NOUN	B
of	O	ADP	O
intervals	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
of	O	ADP	O
Xq21	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
11	O	NUM	O
Danish	O	ADJ	B
and	O	CCONJ	O
Swedish	O	ADJ	B
families	O	NOUN	B
at	O	ADP	O
least	O	ADJ	O
8	O	NUM	O
causative	O	ADJ	B
mutations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
by	O	ADP	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
all	O	DET	O
CHM	B-Disease	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
detected	O	VERB	B
thus	O	ADV	O
far	O	ADV	O
in	O	ADP	O
choroideremia	B-Disease	NOUN	B
patients	O	NOUN	B
give	O	VERB	O
rise	O	NOUN	O
to	O	ADP	O
the	O	DET	O
introduction	O	NOUN	B
of	O	ADP	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Predominance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adrenomyeloneuropathy	B-Disease	ADJ	B
phenotype	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
in	O	ADP	O
The	O	DET	O
Netherlands	O	PROPN	B
:	O	PUNCT	O
a	O	DET	O
survey	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
kindreds	O	NOUN	B
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
disorder	I-Disease	NOUN	B
of	O	ADP	O
peroxisomal	O	ADJ	B
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
accumulation	O	NOUN	B
of	O	ADP	O
saturated	O	VERB	B
very	O	ADV	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
central	O	ADJ	B
and	O	CCONJ	O
peripheral	O	ADJ	B
demyelination	B-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
impaired	B-Disease	ADJ	B
function	I-Disease	NOUN	I
of	I-Disease	ADP	O
adrenal	I-Disease	ADJ	B
cortex	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
testes	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
is	O	AUX	O
highly	O	ADV	O
variable	O	ADJ	B
,	O	PUNCT	O
childhood	B-Disease	ADJ	B
cerebral	I-Disease	ADJ	I
ALD	I-Disease	NOUN	I
(	O	PUNCT	O
CCALD	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
being	O	AUX	O
the	O	DET	O
main	O	ADJ	O
variants	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
explored	O	VERB	O
the	O	DET	O
30	O	NUM	O
Dutch	O	ADJ	B
kindreds	O	NOUN	B
well	O	ADV	O
known	O	VERB	O
to	O	ADP	O
the	O	DET	O
Dutch	O	ADJ	B
X	B-Disease	PROPN	I
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
Study	O	PROPN	O
Group	O	PROPN	B
and	O	CCONJ	O
phenotyped	O	VERB	B
77	O	NUM	O
male	O	NOUN	B
patients	O	NOUN	B
35	O	NUM	O
(	O	PUNCT	O
46	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
AMN	B-Disease	PROPN	B
and	O	CCONJ	O
24	O	NUM	O
(	O	PUNCT	O
31	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
CCALD	B-Disease	NOUN	B
or	O	CCONJ	O
adolescent	B-Disease	ADJ	B
cerebral	I-Disease	ADJ	B
ALD	I-Disease	NOUN	I
(	O	PUNCT	O
AdolCALD	B-Disease	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
percentages	O	NOUN	B
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
previous	O	ADJ	O
reports	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
25	O	NUM	O
to	O	PART	O
28	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
developed	O	VERB	O
AMN	B-Disease	PROPN	B
and	O	CCONJ	O
53	O	NUM	O
to	O	PART	O
57	O	NUM	O
%	O	NOUN	O
CCALD	B-Disease	NOUN	B
or	O	CCONJ	O
AdolCALD	B-Disease	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
-	O	PUNCT	O
-	O	PUNCT	O
at	O	ADV	O
least	O	ADJ	O
in	O	ADP	O
the	O	DET	O
Netherlands	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
AMN	B-Disease	PROPN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
phenotype	O	NOUN	B
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ALD	I-Disease	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
gene	O	NOUN	I
encodes	O	VERB	B
an	O	DET	O
80	O	NUM	O
kDa	O	NOUN	O
membrane	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
antibody	O	NOUN	B
against	O	ADP	O
the	O	DET	O
synthetic	O	ADJ	B
C	O	NOUN	I
-	O	PUNCT	O
terminal	O	ADJ	B
peptides	O	NOUN	B
deduced	O	VERB	O
from	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
produced	O	VERB	O
to	O	PART	O
characterize	O	VERB	B
the	O	DET	O
product	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
antibody	O	NOUN	B
reacted	O	VERB	B
with	O	ADP	O
the	O	DET	O
80	O	NUM	O
kDa	O	NOUN	O
band	O	NOUN	O
protein	O	NOUN	O
in	O	ADP	O
control	O	NOUN	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
no	O	DET	O
bands	O	NOUN	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
fibroblasts	O	NOUN	B
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
(	O	PUNCT	O
#	O	NOUN	O
163	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
mRNA	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	O
was	O	AUX	O
undetectable	O	ADJ	B
based	O	VERB	O
on	O	ADP	O
Northern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
293T	O	NOUN	B
cells	O	NOUN	I
transfected	O	VERB	B
with	O	ADP	O
the	O	DET	O
full	O	ADJ	B
-	O	PUNCT	O
coding	O	VERB	B
cDNA	O	NOUN	B
inserted	O	VERB	B
in	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
vector	O	NOUN	I
produced	O	VERB	O
a	O	DET	O
new	O	ADJ	O
80	O	NUM	O
kDa	O	NOUN	O
protein	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
detected	O	VERB	B
by	O	ADP	O
Western	O	NOUN	B
blot	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
immunocytological	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
staining	O	NOUN	B
was	O	AUX	O
in	O	ADP	O
a	O	DET	O
punctate	O	ADJ	B
pattern	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
fibroblasts	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
punctate	O	ADJ	O
staining	O	NOUN	O
in	O	ADP	O
the	O	DET	O
#	O	NOUN	O
163	O	NUM	O
cells	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
thus	O	ADV	O
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	O
encodes	O	VERB	B
an	O	DET	O
80	O	NUM	O
kDa	O	NOUN	O
membrane	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
McLeod	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
that	O	PRON	O
encodes	O	VERB	B
a	O	DET	O
novel	O	ADJ	B
membrane	O	NOUN	B
transport	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


McLeod	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
multisystem	I-Disease	NOUN	B
disorder	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
abnormalities	O	NOUN	B
in	O	ADP	O
the	O	DET	O
neuromuscular	O	ADJ	B
and	O	CCONJ	O
hematopoietic	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
assembled	O	VERB	O
a	O	DET	O
cosmid	O	NOUN	B
contig	O	NOUN	B
of	O	ADP	O
360	O	NUM	O
kb	O	NOUN	O
that	O	PRON	O
encompasses	O	VERB	O
the	O	DET	O
McLeod	B-Disease	NOUN	B
gene	O	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
50	O	NUM	O
kb	O	NOUN	O
deletion	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
screening	O	VERB	B
DNA	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
radiolabeled	O	VERB	B
whole	O	ADJ	O
cosmids	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
transcription	O	NOUN	B
units	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
within	O	ADP	O
this	O	DET	O
deletion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mRNA	O	NOUN	B
expression	O	NOUN	O
pattern	O	NOUN	O
of	O	ADP	O
one	O	NUM	O
of	O	ADP	O
them	O	PRON	O
,	O	PUNCT	O
designated	O	VERB	O
as	O	ADP	O
XK	O	NOUN	B
,	O	PUNCT	O
correlates	O	VERB	O
closely	O	ADV	O
to	O	ADP	O
the	O	DET	O
McLeod	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


XK	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
protein	O	NOUN	B
with	O	ADP	O
structural	O	ADJ	B
characteristics	O	NOUN	I
of	O	ADP	O
prokaryotic	O	ADJ	B
and	O	CCONJ	O
eukaryotic	O	ADJ	B
membrane	O	NOUN	I
transport	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O


Nucleotide	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
XK	O	NOUN	B
from	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
McLeod	B-Disease	ADJ	B
patients	O	NOUN	B
has	O	AUX	O
identified	O	VERB	O
point	O	NOUN	O
mutations	O	NOUN	O
at	O	ADP	O
conserved	O	VERB	O
splice	O	NOUN	O
donor	O	NOUN	O
and	O	CCONJ	O
acceptor	O	NOUN	B
sites	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
provide	O	VERB	O
direct	O	ADJ	O
evidence	O	NOUN	B
that	O	SCONJ	O
XK	O	NOUN	B
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
McLeod	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
spastic	I-Disease	ADJ	B
paraplegia	I-Disease	NOUN	I
and	O	CCONJ	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
are	O	AUX	O
allelic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
forms	O	NOUN	O
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
spastic	I-Disease	ADJ	B
paraplegia	I-Disease	NOUN	I
(	O	PUNCT	O
SPG	B-Disease	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
defined	O	VERB	O
.	O	PUNCT	O


One	O	NUM	O
locus	O	NOUN	B
(	O	PUNCT	O
SPG	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
maps	O	NOUN	B
to	O	PART	O
Xq28	O	NOUN	B
while	O	SCONJ	O
two	O	NUM	O
clinically	O	ADV	B
distinct	O	ADJ	O
forms	O	NOUN	O
map	O	VERB	B
to	O	PART	O
Xq22	O	NOUN	B
(	O	PUNCT	O
SPG2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
rare	O	ADJ	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
dysmyelinating	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
Xq21	O	NOUN	B
-	O	PUNCT	O
q22	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
two	O	NUM	O
myelin	O	NOUN	B
proteins	O	NOUN	I
,	O	PUNCT	O
PLP	O	NOUN	B
and	O	CCONJ	O
DM20	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
narrowing	O	VERB	B
the	O	DET	O
genetic	O	ADJ	B
interval	O	NOUN	I
containing	O	VERB	O
SPG2	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
pedigree	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
PLP	O	NOUN	B
was	O	AUX	O
the	O	DET	O
closest	O	ADJ	O
marker	O	NOUN	B
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
implicating	O	VERB	O
PLP	O	NOUN	B
as	O	ADP	O
a	O	DET	O
possible	O	ADJ	O
candidate	O	NOUN	O
gene	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
point	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
His139Tyr	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
exon	O	NOUN	B
3B	O	NOUN	I
of	O	ADP	O
an	O	DET	O
affected	O	VERB	B
male	O	NOUN	B
produces	O	VERB	O
a	O	DET	O
mutant	O	ADJ	B
PLP	O	NOUN	B
but	O	CCONJ	O
a	O	DET	O
normal	O	ADJ	O
DM20	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
segregates	O	VERB	B
with	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
(	O	PUNCT	O
Zmax	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
.	O	PUNCT	O
63	O	NUM	O
,	O	PUNCT	O
theta	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
appears	O	VERB	O
,	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
that	O	SCONJ	O
SPG2	O	NOUN	B
and	O	CCONJ	O
PMD	B-Disease	NOUN	B
are	O	AUX	O
allelic	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I


Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
mutations	O	NOUN	B
among	O	ADP	O
Jewish	O	ADJ	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
leukodystrophy	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
aspartoacylase	I-Disease	NOUN	B
(	O	PUNCT	O
ASPA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Sixty	O	PROPN	B
-	O	PUNCT	O
four	O	NUM	B
probands	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ASPA	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
point	O	NOUN	O
mutations	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
693C	O	NUM	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	PROPN	O
,	O	PUNCT	O
854A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
914C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
693C	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	B
and	O	CCONJ	O
914C	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
base	O	NOUN	B
changes	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
nonsense	O	ADJ	B
tyr231	O	PROPN	I
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
ter	O	NOUN	B
and	O	CCONJ	O
missense	O	ADJ	B
ala305	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
glu	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
lead	O	VERB	O
to	O	PART	O
complete	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
ASPA	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
in	O	X	B
vitro	O	X	I
expression	O	NOUN	B
studies	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
854A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	B
transversion	O	NOUN	I
converted	O	VERB	O
glu	O	NOUN	B
to	O	PART	O
ala	O	NOUN	B
in	O	ADP	O
codon	O	NOUN	B
285	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
glu285	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
ala	O	NOUN	B
mutant	O	ADJ	I
ASPA	O	PROPN	B
has	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
expressed	O	VERB	B
by	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
enzyme	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
fourth	O	ADJ	O
mutation	O	NOUN	B
,	O	PUNCT	O
433	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
2	O	NUM	O
(	O	PUNCT	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
transition	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
at	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
acceptor	O	NOUN	B
site	O	NOUN	I
in	O	ADP	O
intron	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
would	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
skipping	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
,	O	PUNCT	O
accompanied	O	VERB	O
by	O	ADP	O
a	O	DET	O
frameshift	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
thus	O	ADV	O
would	O	AUX	O
produce	O	VERB	O
aberrant	O	ADJ	B
ASPA	O	PROPN	B
.	O	PUNCT	O


Of	O	ADP	O
the	O	DET	O
128	O	NUM	O
unrelated	O	ADJ	O
Canavan	B-Disease	NOUN	B
chromosomes	O	NOUN	I
analyzed	O	VERB	B
,	O	PUNCT	O
88	O	NUM	O
were	O	AUX	O
from	O	ADP	O
probands	O	NOUN	B
of	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
descent	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
glu285	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
ala	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
predominant	O	ADJ	B
(	O	PUNCT	O
82	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
the	O	DET	O
tyr231	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
ter	O	X	B
(	O	PUNCT	O
14	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
433	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
2	O	NUM	O
(	O	PUNCT	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
mutations	O	NOUN	B
account	O	VERB	O
for	O	ADP	O
98	O	NUM	O
.	O	PUNCT	O


8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
Canavan	B-Disease	NOUN	B
chromosomes	O	NOUN	I
of	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ala305	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
glu	O	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
exclusively	O	ADV	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
probands	O	NOUN	B
of	O	ADP	O
European	O	ADJ	B
descent	O	NOUN	I
and	O	CCONJ	O
constituted	O	VERB	O
60	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
40	O	NUM	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


Predominant	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
certain	O	ADJ	O
mutations	O	NOUN	B
among	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
would	O	AUX	O
suggest	O	VERB	O
a	O	DET	O
founding	O	NOUN	B
-	O	PUNCT	O
father	O	NOUN	B
effect	O	NOUN	B
in	O	ADP	O
propagation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I


Intelligence	O	NOUN	B
quotient	O	NOUN	I
profile	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
intergenerational	O	ADJ	B
deficit	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
correlation	O	NOUN	B
with	O	ADP	O
CTG	O	NOUN	B
amplification	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
abbreviated	O	ADJ	O
Wechsler	O	PROPN	O
Adult	O	PROPN	O
Intelligence	O	PROPN	O
Scale	O	PROPN	O
Revised	O	PROPN	O
(	O	PUNCT	O
WAIS	O	PROPN	B
-	O	PUNCT	O
R	O	PROPN	B
)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
verbal	O	ADJ	B
and	O	CCONJ	O
arithmetical	O	ADJ	B
cognitive	O	ADJ	I
performance	O	NOUN	B
in	O	ADP	O
55	O	NUM	O
subjects	O	NOUN	B
with	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
covering	O	VERB	O
all	O	DET	O
grades	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
severity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
31	O	NUM	O
controls	O	NOUN	B
at	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
risk	O	NOUN	B
of	O	ADP	O
inheriting	O	VERB	B
DM	B-Disease	NOUN	I
.	O	PUNCT	O


Scaled	O	VERB	B
scores	O	NOUN	I
from	O	ADP	O
the	O	DET	O
assessment	O	NOUN	B
were	O	AUX	O
converted	O	VERB	O
into	O	ADP	O
an	O	DET	O
intelligence	O	NOUN	B
quotient	O	NOUN	I
(	O	PUNCT	O
IQ	O	NOUN	B
)	O	PUNCT	O
estimation	O	NOUN	B
on	O	ADP	O
each	O	DET	O
person	O	NOUN	B
.	O	PUNCT	O


Significant	O	ADJ	B
IQ	O	NOUN	B
differences	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
(	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
all	O	DET	O
55	O	NUM	O
DM	B-Disease	NOUN	B
subjects	O	NOUN	B
(	O	PUNCT	O
mean	O	VERB	O
90	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
16	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
31	O	NUM	O
controls	O	NOUN	B
(	O	PUNCT	O
102	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
9	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
sex	O	NOUN	O
differences	O	NOUN	O
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
;	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
15	O	NUM	O
affected	O	VERB	B
parents	O	NOUN	B
(	O	PUNCT	O
99	O	NUM	O
.	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
12	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
affected	O	VERB	B
children	O	NOUN	B
(	O	PUNCT	O
88	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
17	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
where	O	SCONJ	O
significance	O	NOUN	B
was	O	AUX	O
dependent	O	ADJ	O
on	O	ADP	O
parental	O	ADJ	B
sex	O	NOUN	B
being	O	NOUN	O
female	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
15	O	NUM	O
pairs	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
sibs	O	NOUN	B
(	O	PUNCT	O
89	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
13	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
normal	O	ADJ	B
sibs	O	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
SD	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


IQ	O	NOUN	B
steadily	O	ADV	O
declined	O	VERB	O
as	O	ADP	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
signs	O	NOUN	B
and	O	CCONJ	O
symptoms	O	NOUN	B
decreased	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
CTG	O	NOUN	B
expansion	O	NOUN	B
size	O	NOUN	B
increased	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
correlation	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
linear	O	ADJ	B
with	O	ADP	I
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
correlation	O	NOUN	B
of	O	ADP	O
IQ	O	NOUN	B
difference	O	NOUN	O
and	O	CCONJ	O
CTG	O	NOUN	B
expansion	O	NOUN	B
difference	O	NOUN	O
in	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
parent	O	NOUN	B
-	O	PUNCT	O
child	O	NOUN	B
pairs	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
sib	O	NOUN	B
-	O	PUNCT	O
affected	O	VERB	B
sib	O	NOUN	B
pairs	O	NOUN	I
was	O	AUX	O
poor	O	ADJ	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
CTG	O	NOUN	B
expansion	O	NOUN	B
is	O	AUX	O
not	O	PART	O
a	O	DET	O
reliable	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
IQ	O	NOUN	B
either	O	CCONJ	O
in	O	ADP	O
individual	O	ADJ	B
persons	O	NOUN	B
or	O	CCONJ	O
families	O	NOUN	B
.	O	PUNCT	O


Further	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
cognitive	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
DM	B-Disease	NOUN	B
is	O	AUX	O
required	O	VERB	O
to	O	PART	O
clarify	O	VERB	O
specific	O	ADJ	O
deficits	O	NOUN	B
characteristic	O	ADJ	B
of	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
group	O	NOUN	I


Adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
and	O	CCONJ	O
a	O	DET	O
cytogenetic	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	O
5	O	NUM	O
resulting	O	VERB	O
from	O	ADP	O
a	O	DET	O
maternal	O	ADJ	B
intrachromosomal	O	ADJ	B
insertion	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
present	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	NOUN	B
findings	O	NOUN	I
in	O	ADP	O
an	O	DET	O
institutionalised	O	ADJ	B
adult	O	ADJ	I
patient	O	NOUN	B
originally	O	ADV	O
referred	O	VERB	O
for	O	ADP	O
autism	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
predicted	O	VERB	B
when	O	SCONJ	O
an	O	DET	O
interstitial	O	ADJ	B
deletion	O	NOUN	I
of	O	ADP	O
the	O	DET	O
long	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
chromosome	O	NOUN	I
5	O	NUM	I
,	O	PUNCT	O
del	O	X	B
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q15q22	O	NOUN	O
.	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
her	O	PRON	O
lymphocytes	O	NOUN	B
and	O	CCONJ	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
MCC	O	NOUN	B
and	O	CCONJ	O
APC	B-Disease	NOUN	B
genes	O	NOUN	I
confirmed	O	VERB	O
by	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
and	O	CCONJ	O
carcinoma	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
rectum	I-Disease	NOUN	B
were	O	AUX	O
subsequently	O	ADV	O
diagnosed	O	VERB	B
in	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


She	O	PRON	O
was	O	AUX	O
profoundly	O	ADV	O
mentally	B-Disease	ADV	B
retarded	I-Disease	VERB	B
,	O	PUNCT	O
autistic	B-Disease	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
minor	O	ADJ	O
dysmorphic	B-Disease	ADJ	B
features	I-Disease	NOUN	I
consistent	O	ADJ	B
with	O	ADP	I
those	O	DET	O
of	O	ADP	O
previous	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
similar	O	ADJ	O
deletions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
deletion	O	NOUN	B
arose	O	VERB	O
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
recombination	O	NOUN	B
within	O	ADP	O
the	O	DET	O
small	O	ADJ	O
insertion	O	NOUN	B
loop	O	NOUN	O
formed	O	VERB	O
at	O	ADP	O
meiosis	O	NOUN	B
by	O	ADP	O
the	O	DET	O
direct	O	ADJ	O
insertion	O	NOUN	B
(	O	PUNCT	O
dir	O	NOUN	O
ins	O	NOUN	O
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q22	O	NOUN	B
.	O	PUNCT	O
3q14	O	NOUN	O
.	O	PUNCT	O
2q15	O	NOUN	B
)	O	PUNCT	O
)	O	PUNCT	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
mother	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
family	O	NOUN	B
further	O	ADV	O
confirms	O	VERB	O
the	O	DET	O
cytogenetic	O	ADJ	B
mapping	O	NOUN	I
of	O	ADP	O
both	O	CCONJ	O
MCC	O	NOUN	B
and	O	CCONJ	O
APC	B-Disease	NOUN	B
genes	O	NOUN	I
to	O	PART	O
5q22	O	NOUN	B
and	O	CCONJ	O
comparison	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
recent	O	ADJ	O
cases	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
genes	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
closely	O	ADV	O
linked	O	VERB	O
markers	O	NOUN	B
lie	O	VERB	O
within	O	ADP	O
the	O	DET	O
5q22	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
subband	O	NOUN	O


Familial	B-Disease	ADJ	B
male	I-Disease	NOUN	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
BRCA1	O	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
17q	O	NOUN	I
.	O	PUNCT	O


Breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
men	O	NOUN	B
is	O	AUX	O
about	O	ADV	O
a	O	DET	O
hundredfold	O	ADV	B
less	O	ADV	O
common	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
women	O	NOUN	B
and	O	CCONJ	O
this	O	DET	O
has	O	AUX	O
hindered	O	VERB	O
research	O	NOUN	B
into	O	ADP	O
its	O	PRON	O
genetic	O	ADJ	B
basis	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
22	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
locus	O	NOUN	O
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
chromosome	O	NOUN	B
17q	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
strong	O	ADJ	O
evidence	O	NOUN	B
against	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
BRCA1	O	NOUN	B
(	O	PUNCT	O
lod	O	ADJ	B
score	O	NOUN	I
-	O	SYM	O
16	O	NUM	O
.	O	PUNCT	O
63	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
best	O	ADJ	O
estimate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
linked	O	VERB	O
families	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0	O	NUM	O
-	O	SYM	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
gene	O	NOUN	B
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
other	O	ADJ	O
than	O	ADP	O
BRCA1	O	NOUN	B
which	O	DET	O
predisposes	O	VERB	O
to	O	PART	O
early	O	ADV	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
women	O	NOUN	B
and	O	CCONJ	O
which	O	DET	O
confers	O	VERB	O
a	O	DET	O
higher	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
additional	O	ADJ	O
pedigrees	O	NOUN	B
that	O	PRON	O
include	O	VERB	O
cases	O	NOUN	B
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
may	O	AUX	O
therefore	O	ADV	O
facilitate	O	VERB	O
the	O	DET	O
mapping	O	NOUN	B
and	O	CCONJ	O
isolation	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
EWS	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
involved	O	VERB	O
in	O	ADP	O
Ewing	B-Disease	NOUN	B
family	I-Disease	NOUN	I
of	I-Disease	ADP	I
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
malignant	B-Disease	ADJ	B
melanoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
soft	I-Disease	ADJ	B
parts	I-Disease	NOUN	I
and	O	CCONJ	O
desmoplastic	B-Disease	ADJ	B
small	I-Disease	ADJ	I
round	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
codes	O	VERB	B
for	O	ADP	O
an	O	DET	O
RNA	O	NOUN	B
binding	O	NOUN	I
protein	O	NOUN	I
with	O	ADP	O
novel	O	ADJ	O
regulatory	O	ADJ	B
domains	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
EWS	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
band	O	VERB	B
q12	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
22	O	NUM	O
,	O	PUNCT	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
variety	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
solid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
including	O	VERB	O
Ewing	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
,	O	PUNCT	O
related	O	ADJ	O
primitive	O	ADJ	O
neuroectodermal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
malignant	B-Disease	ADJ	B
melanoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
soft	I-Disease	ADJ	B
parts	I-Disease	NOUN	I
and	O	CCONJ	O
desmoplastic	B-Disease	ADJ	B
small	I-Disease	ADJ	I
round	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
EWS	O	PROPN	B
is	O	AUX	O
fused	O	VERB	O
to	O	PART	O
genes	O	NOUN	B
encoding	O	VERB	O
transcriptional	O	ADJ	B
activators	O	NOUN	I
/	O	PUNCT	O
repressors	O	NOUN	B
,	O	PUNCT	O
like	O	ADP	O
Fli	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
or	O	CCONJ	O
erg	O	NOUN	B
or	O	CCONJ	O
ATF	O	NOUN	B
1	O	NUM	I
or	O	CCONJ	O
wt1	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
better	O	ADV	O
understand	O	VERB	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
EWS	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
cloned	O	VERB	B
the	O	DET	O
EWS	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
this	O	DET	O
cDNA	O	NOUN	B
revealed	O	VERB	O
differential	O	ADJ	B
splicing	O	NOUN	I
involving	O	VERB	O
two	O	NUM	O
exons	O	NOUN	B
encoding	O	VERB	B
72	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
alternatively	O	ADV	O
spliced	O	VERB	B
transcripts	O	NOUN	B
,	O	PUNCT	O
EWS	O	NOUN	B
and	O	CCONJ	O
EWS	O	PROPN	B
-	O	PUNCT	O
b	O	PROPN	B
,	O	PUNCT	O
are	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
cells	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
EWS	O	NOUN	B
proteins	O	NOUN	O
contain	O	VERB	O
putative	O	ADJ	O
conserved	O	VERB	O
RNA	O	NOUN	B
binding	O	NOUN	I
motifs	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
the	O	DET	O
RNA	O	NOUN	B
binding	O	NOUN	O
properties	O	NOUN	B
of	O	ADP	O
the	O	DET	O
EWS	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
EWS	O	PROPN	B
-	O	PUNCT	O
b	O	NOUN	O
protein	O	NOUN	B
binds	O	VERB	B
to	O	PART	O
RNA	O	NOUN	B
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
,	O	PUNCT	O
specifically	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
poly	O	VERB	B
G	O	NOUN	I
and	O	CCONJ	O
poly	O	ADJ	B
U	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
RNA	O	NOUN	B
binding	O	NOUN	I
activity	O	NOUN	I
was	O	AUX	O
localized	O	ADJ	B
to	O	PART	O
the	O	DET	O
carboxy	O	NOUN	B
terminal	O	ADJ	I
86	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
constitute	O	VERB	O
RGG	O	NOUN	B
box	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
amino	O	NOUN	B
terminal	O	ADJ	I
domain	O	NOUN	I
of	O	ADP	O
EWS	O	NOUN	B
(	O	PUNCT	O
NTD	O	PROPN	B
-	O	PUNCT	O
EWS	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
chromosome	O	NOUN	B
translocation	O	NOUN	I
may	O	AUX	O
regulate	O	VERB	B
the	O	DET	O
specificity	O	NOUN	B
of	O	ADP	O
RNA	O	NOUN	B
binding	O	NOUN	I
activity	O	NOUN	I
of	O	ADP	O
EWS	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
EWS	O	PROPN	B
-	O	PUNCT	O
erg	O	NOUN	B
chimeric	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
found	O	VERB	O
in	O	ADP	O
Ewings	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
functions	O	VERB	B
as	O	ADP	O
a	O	DET	O
transcriptional	O	ADJ	B
activator	O	NOUN	I
.	O	PUNCT	O


Mutational	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
EWS	O	NOUN	B
-	O	PUNCT	O
erg	O	NOUN	B
chimeric	O	ADJ	B
protein	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
NTD	O	PROPN	B
-	O	PUNCT	O
EWS	O	PROPN	B
functions	O	VERB	B
as	O	ADP	O
a	O	DET	O
regulatory	O	ADJ	B
domain	O	NOUN	I
for	O	ADP	O
the	O	DET	O
transcriptional	O	ADJ	B
activation	O	NOUN	O
properties	O	NOUN	B
of	O	ADP	O
EWS	O	NOUN	B
-	O	PUNCT	O
erg	O	NOUN	B
chimeric	O	ADJ	B
protein	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
:	O	PUNCT	O
genomic	O	ADJ	B
organization	O	NOUN	I
and	O	CCONJ	O
localization	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
ASPA	O	NOUN	B
to	O	PART	O
17p13	O	NOUN	B
-	O	PUNCT	O
ter	O	NOUN	B
and	O	CCONJ	O
conservation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ASPA	O	NOUN	B
gene	O	NOUN	I
during	O	ADP	O
evolution	O	NOUN	B
.	O	PUNCT	O


Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
spongy	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
brain	I-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
leukodystrophy	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
aspartoacylase	I-Disease	NOUN	B
(	O	PUNCT	O
ASPA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
identified	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
ASPA	O	NOUN	O
coding	O	NOUN	O
sequence	O	NOUN	O
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
ASPA	O	NOUN	O
gene	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
found	O	VERB	O
to	O	PART	O
span	O	VERB	O
29	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
.	O	PUNCT	O


Human	O	ADJ	B
aspartoacylase	O	NOUN	I
is	O	AUX	O
coded	O	VERB	O
by	O	ADP	O
six	O	NUM	O
exons	O	NOUN	B
intervened	O	VERB	B
by	O	ADP	O
five	O	NUM	O
introns	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
exons	O	NOUN	B
vary	O	VERB	O
from	O	ADP	O
94	O	NUM	O
(	O	PUNCT	O
exon	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
to	O	PART	O
514	O	NUM	O
(	O	PUNCT	O
exon	O	NOUN	B
VI	O	NOUN	I
)	O	PUNCT	O
bases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
exon	O	NOUN	B
/	O	SYM	O
intron	O	NOUN	B
splice	O	NOUN	B
junction	O	NOUN	I
sites	O	NOUN	O
follow	O	VERB	O
the	O	DET	O
gt	O	ADJ	B
/	O	SYM	O
ag	O	NOUN	B
consensus	O	NOUN	B
sequence	O	NOUN	I
rule	O	NOUN	O
.	O	PUNCT	O


Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
human	O	ADJ	B
/	O	SYM	O
mouse	O	NOUN	B
somatic	O	ADJ	B
cell	O	NOUN	I
hybrid	O	NOUN	I
cell	O	NOUN	I
lines	O	NOUN	I
localized	O	VERB	B
ASPA	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
17	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
ASPA	O	NOUN	B
locus	O	NOUN	O
was	O	AUX	O
further	O	ADV	O
mapped	O	VERB	B
in	O	ADP	O
the	O	DET	O
17p13	O	NOUN	B
-	O	PUNCT	O
ter	O	NOUN	B
region	O	NOUN	I
by	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
bovine	O	ADJ	B
aspa	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
cloned	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
its	O	PRON	O
exon	O	NOUN	B
/	O	SYM	O
intron	O	NOUN	B
organization	O	NOUN	O
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
500	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
sequence	O	NOUN	I
upstream	O	ADJ	O
of	O	ADP	O
the	O	DET	O
initiator	O	NOUN	B
ATG	O	NOUN	O
codon	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
bovine	O	ADJ	B
gene	O	NOUN	I
are	O	AUX	O
77	O	NUM	O
%	O	NOUN	O
identical	O	ADJ	B
.	O	PUNCT	O


Human	O	ADJ	B
ASPA	O	PROPN	O
coding	O	NOUN	O
sequences	O	NOUN	O
cross	O	VERB	B
-	O	PUNCT	O
hybridize	O	NOUN	B
with	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
yeast	O	NOUN	B
,	O	PUNCT	O
chicken	O	NOUN	B
,	O	PUNCT	O
rabbit	O	NOUN	B
,	O	PUNCT	O
cow	O	NOUN	B
,	O	PUNCT	O
dog	O	NOUN	B
,	O	PUNCT	O
mouse	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
monkey	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
specificity	O	NOUN	B
of	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
species	O	NOUN	B
hybridization	O	NOUN	B
of	O	ADP	O
coding	O	VERB	B
sequences	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
aspartoacylase	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
conserved	O	VERB	O
during	O	ADP	O
evolution	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
should	O	AUX	O
now	O	ADV	O
be	O	AUX	O
possible	O	ADJ	O
to	O	PART	O
identify	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
noncoding	O	ADJ	B
genomic	O	ADJ	I
sequences	O	NOUN	I
that	O	PRON	O
lead	O	VERB	O
to	O	PART	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
study	O	VERB	B
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
ASPA	O	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
:	O	PUNCT	O
size	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
sex	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
dynamics	O	NOUN	B
of	O	ADP	O
CTG	O	NOUN	B
meiotic	O	ADJ	B
instability	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
somatic	O	ADJ	B
mosaicism	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
progressive	O	ADJ	B
neuromuscular	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
which	O	DET	O
results	O	VERB	O
from	O	ADP	O
elongations	O	NOUN	B
of	O	ADP	O
an	O	DET	O
unstable	O	ADJ	B
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
,	O	PUNCT	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
correlation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
between	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
number	O	NOUN	O
of	O	ADP	O
this	O	DET	O
sequence	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
status	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
cannot	O	VERB	O
be	O	AUX	O
unambiguously	O	ADV	O
ascertained	O	VERB	O
solely	O	ADV	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
CTG	O	NOUN	B
repeats	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
exclusive	O	ADJ	O
maternal	O	ADJ	B
inheritance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
congenital	O	ADJ	B
form	O	NOUN	I
remains	O	VERB	O
unexplained	O	ADJ	B
.	O	PUNCT	O


Our	O	PRON	O
observation	O	NOUN	B
of	O	ADP	O
differently	O	ADV	O
sized	O	ADJ	O
repeats	O	NOUN	B
in	O	ADP	O
various	O	ADJ	O
DM	B-Disease	NOUN	B
tissues	O	NOUN	B
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
individual	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
why	O	SCONJ	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
lymphocytes	O	NOUN	B
does	O	AUX	O
not	O	PART	O
necessarily	O	ADV	O
correlate	O	VERB	B
with	O	ADP	O
the	O	DET	O
severity	O	NOUN	B
and	O	CCONJ	O
nature	O	NOUN	B
of	O	ADP	O
symptoms	O	NOUN	B
.	O	PUNCT	O


Through	O	ADP	O
a	O	DET	O
molecular	O	ADJ	B
and	O	CCONJ	O
genetic	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
142	O	NUM	O
families	O	NOUN	B
including	O	VERB	O
418	O	NUM	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
investigated	O	VERB	B
the	O	DET	O
dynamics	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	O
meiotic	O	ADJ	B
instability	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
positive	O	ADJ	B
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
intergenerational	O	ADJ	B
enlargement	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
similarly	O	ADV	O
through	O	ADP	O
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
meioses	O	NOUN	I
for	O	ADP	O
<	O	X	O
or	O	CCONJ	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
CTG	O	NOUN	I
sequences	O	NOUN	I
.	O	PUNCT	O


Beyond	O	NOUN	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
kb	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
intergenerational	O	ADJ	B
variation	O	NOUN	I
was	O	AUX	O
more	O	ADV	O
important	O	ADJ	O
through	O	ADP	O
female	O	ADJ	B
meioses	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
a	O	DET	O
tendency	O	NOUN	O
to	O	PART	O
compression	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
almost	O	ADV	O
exclusively	O	ADV	O
in	O	ADP	O
male	O	NOUN	B
meioses	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
>	O	NOUN	O
or	O	CCONJ	O
=	O	ADJ	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
fragments	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
implies	O	VERB	O
a	O	DET	O
size	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
sex	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
meiotic	O	ADJ	B
instability	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
segregation	O	NOUN	B
analysis	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
maternal	O	ADJ	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
familial	O	ADJ	B
predisposition	O	NOUN	I
for	O	ADP	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
congenital	O	ADJ	B
form	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
analysis	O	NOUN	B
reveals	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
excess	O	NOUN	B
of	O	ADP	O
transmitting	O	VERB	B
grandfathers	O	NOUN	B
partially	O	ADV	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
increased	O	VERB	B
fertility	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
males	O	NOUN	B


Illegitimate	O	ADJ	B
transcription	O	NOUN	I
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
lymphocytes	O	NOUN	B
for	O	ADP	O
identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


Taking	O	VERB	O
advantage	O	NOUN	O
of	O	ADP	O
the	O	DET	O
illegitimate	O	NOUN	B
transcription	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenylalanine	O	NOUN	B
hydroxylase	O	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
been	O	AUX	O
able	O	ADJ	O
to	O	PART	O
analyse	O	VERB	O
the	O	DET	O
PAH	O	NOUN	B
cDNA	O	NOUN	B
sequence	O	NOUN	O
of	O	ADP	O
hyperphenylalaninemic	B-Disease	ADJ	B
children	O	NOUN	B
in	O	ADP	O
circulating	O	VERB	B
lymphocytes	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
approach	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
also	O	ADV	O
identified	O	VERB	O
3	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
cDNA	O	NOUN	B
from	O	ADP	O
liver	O	NOUN	B
and	O	CCONJ	O
lymphocytes	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
mutation	O	NOUN	B
,	O	PUNCT	O
detected	O	VERB	B
by	O	ADP	O
the	O	DET	O
abnormal	O	ADJ	B
pattern	O	NOUN	O
of	O	ADP	O
migration	O	NOUN	B
of	O	ADP	O
an	O	DET	O
amplified	O	VERB	B
fragment	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
C	O	NOUN	O
to	O	PART	O
T	O	NOUN	B
transition	O	NOUN	I
in	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
acceptor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
10	O	NUM	O
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
skipping	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
with	O	ADP	I
the	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
of	O	ADP	O
RNA	O	NOUN	B
translation	O	NOUN	I
downstream	O	ADJ	I
from	O	ADP	O
exon	O	NOUN	B
12	O	NUM	I
(	O	PUNCT	O
-	O	PUNCT	O
3	O	NUM	O
IVS10	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
exons	O	NOUN	B
10	O	NUM	O
and	O	CCONJ	O
11	O	NUM	O
(	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
L333F	O	NOUN	B
and	O	CCONJ	O
E390G	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
circulating	O	VERB	B
lymphocytes	O	NOUN	B
give	O	VERB	O
easy	O	ADJ	O
access	O	NOUN	O
to	O	ADP	O
PAH	O	NOUN	B
gene	O	NOUN	B
transcripts	O	NOUN	I
whose	O	DET	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
that	O	DET	O
reported	O	VERB	O
in	O	ADP	O
liver	O	NOUN	B
and	O	CCONJ	O
therefore	O	ADV	O
represent	O	VERB	O
a	O	DET	O
useful	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
molecular	O	ADJ	B
genetic	O	ADJ	I
studies	O	NOUN	I
in	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


High	O	ADJ	O
residual	O	ADJ	B
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
infantile	I-Disease	ADJ	B
metachromatic	I-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
patient	O	NOUN	B
suffering	O	VERB	O
from	O	ADP	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
infantile	I-Disease	ADJ	B
metachromatic	I-Disease	ADJ	I
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
MLD	B-Disease	PROPN	B
)	O	PUNCT	O
who	O	PRON	O
has	O	AUX	O
a	O	DET	O
residual	O	ADJ	B
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
of	O	ADP	O
about	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


Fibroblasts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
show	O	VERB	O
significant	O	ADJ	B
sulfatide	O	NOUN	B
degradation	O	NOUN	O
activity	O	NOUN	O
exceeding	O	VERB	O
that	O	DET	O
of	O	ADP	O
adult	B-Disease	ADJ	B
MLD	I-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ARSA	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
this	O	DET	O
patient	O	NOUN	B
revealed	O	VERB	O
heterozygosity	O	NOUN	B
for	O	ADP	O
two	O	NUM	O
new	O	ADJ	O
mutant	O	ADJ	B
alleles	O	NOUN	O
in	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
,	O	PUNCT	O
deletion	O	NOUN	B
of	O	ADP	O
C	O	NOUN	O
447	O	NUM	O
in	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
leads	O	VERB	O
to	O	PART	O
a	O	DET	O
frameshift	O	NOUN	B
and	O	CCONJ	O
to	O	PART	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	I
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
position	O	NOUN	I
105	O	NUM	O
;	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
allele	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	DET	O
transition	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
causes	O	VERB	O
a	O	DET	O
Gly309	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Ser	O	NOUN	B
substitution	O	NOUN	B
.	O	PUNCT	O


Transient	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
Ser309	O	NOUN	B
-	O	PUNCT	O
ARSA	O	PROPN	B
resulted	O	VERB	O
in	O	ADP	O
only	O	ADV	O
13	O	NUM	O
%	O	NOUN	O
enzyme	O	NOUN	B
activity	O	NOUN	I
of	O	ADP	O
that	O	DET	O
observed	O	VERB	B
in	O	ADP	O
cells	O	NOUN	B
expressing	O	VERB	B
normal	O	ADJ	O
ARSA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutant	O	ADJ	B
ARSA	O	NOUN	B
is	O	AUX	O
correctly	O	ADV	O
targeted	O	VERB	B
to	O	PART	O
the	O	DET	O
lysosomes	O	NOUN	B
but	O	CCONJ	O
is	O	AUX	O
unstable	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
previous	O	ADJ	O
results	O	NOUN	B
showing	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
infantile	I-Disease	ADJ	B
type	I-Disease	NOUN	O
of	I-Disease	ADP	O
MLD	I-Disease	PROPN	B
is	O	AUX	O
always	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
complete	O	ADJ	O
absence	O	NOUN	B
of	O	ADP	O
ARSA	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
ARSA	O	NOUN	O
protein	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
particular	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
oligodendrocytes	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
enzyme	O	NOUN	B
is	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
others	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
arylsulfatase	O	NOUN	B
A	O	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
)	O	PUNCT	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
T274M	O	NOUN	B
)	O	PUNCT	O
causing	O	VERB	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
infantile	I-Disease	ADJ	B
metachromatic	I-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Metachromatic	B-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
MLD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
lysosomal	I-Disease	ADJ	B
storage	I-Disease	NOUN	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
arylsulfatase	I-Disease	NOUN	B
A	I-Disease	NOUN	I
(	O	PUNCT	O
ARSA	O	NOUN	B
;	O	PUNCT	O
EC	O	PROPN	B
3	O	NUM	I
.	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
8	O	NUM	O
ARSA	O	NOUN	B
exons	O	NOUN	B
and	O	CCONJ	O
adjacent	O	ADJ	B
intron	O	NOUN	B
boundaries	O	NOUN	O
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
late	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
infantile	I-Disease	ADJ	B
metachromatic	I-Disease	ADJ	B
leukodystrophy	I-Disease	NOUN	I
were	O	AUX	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
amplified	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
discrete	O	ADJ	B
reactions	O	NOUN	I
.	O	PUNCT	O


Amplified	O	VERB	B
ARSA	O	NOUN	B
exons	O	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
sequence	O	NOUN	B
alterations	O	NOUN	B
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
IV	O	NUM	I
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
threonine	O	NOUN	B
residue	O	NOUN	B
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
274	O	NUM	I
with	O	ADP	O
a	O	DET	O
methionine	O	NOUN	B
(	O	PUNCT	O
T274M	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
further	O	ADV	O
29	O	NUM	O
MLD	B-Disease	PROPN	B
patients	O	NOUN	B
revealed	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
additional	O	ADJ	O
homozygotes	O	NOUN	B
for	O	ADP	O
T274M	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
6	O	NUM	O
T274M	O	NOUN	B
homozygotes	O	NOUN	I
(	O	PUNCT	O
representing	O	VERB	O
four	O	NUM	O
families	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
of	O	ADP	O
Lebanese	O	ADJ	B
descent	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
were	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
consanguineous	O	ADJ	B
marriages	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
altered	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
is	O	AUX	O
rigidly	O	ADV	O
conserved	O	VERB	O
among	O	ADP	O
10	O	NUM	O
sulfatases	O	NOUN	B
from	O	ADP	O
Escherichia	O	X	B
coli	O	X	I
to	O	ADP	O
humans	O	NOUN	B
;	O	PUNCT	O
therefore	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
most	O	ADV	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
resultant	O	ADJ	O
mutant	O	ADJ	B
protein	O	NOUN	I
will	O	AUX	O
have	O	AUX	O
little	O	ADJ	O
or	O	CCONJ	O
no	O	DET	O
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
very	O	ADV	O
low	O	ADJ	O
ARSA	O	NOUN	B
activity	O	NOUN	B
measured	O	VERB	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
and	O	CCONJ	O
their	O	PRON	O
uniformly	O	ADV	O
severe	O	ADJ	B
clinical	O	ADJ	B
presentation	O	NOUN	I


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	O	ADJ	B
aniridia	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
14	O	NUM	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
analysed	O	VERB	B
exon	O	NOUN	B
-	O	PUNCT	O
by	O	ADP	B
-	O	PUNCT	O
exon	O	NOUN	B
using	O	VERB	O
SSCP	O	NOUN	B
in	O	ADP	O
6	O	NUM	O
aniridia	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
each	O	DET	O
family	O	NOUN	B
band	O	NOUN	I
shifts	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
on	O	ADP	O
the	O	DET	O
SSCP	O	NOUN	B
gels	O	NOUN	B
for	O	ADP	O
only	O	ADV	O
one	O	NUM	O
exon	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	O
PCR	O	NOUN	B
-	O	PUNCT	O
sequencing	O	NOUN	B
revealed	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
mutations	O	NOUN	B
involved	O	VERB	O
C	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transitions	O	NOUN	I
in	O	ADP	O
CGAarg	O	NOUN	B
codons	O	NOUN	O
in	O	ADP	O
exons	O	NOUN	B
9	O	NUM	I
and	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


Another	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
converted	O	VERB	O
a	O	DET	O
CAG	O	NOUN	B
-	O	PUNCT	O
glutamine	O	NOUN	B
to	O	PART	O
a	O	DET	O
TAG	O	NOUN	B
-	O	PUNCT	O
stop	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
.	O	PUNCT	O


Small	O	ADJ	B
insertions	O	NOUN	I
created	O	VERB	O
frameshifts	O	NOUN	B
which	O	DET	O
produced	O	VERB	O
downstream	O	ADJ	B
stop	O	NOUN	I
codons	O	NOUN	O
in	O	ADP	O
another	O	DET	O
two	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
an	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
mutation	O	NOUN	I
disrupted	O	VERB	B
the	O	DET	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
family	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
complete	O	ADJ	O
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
predicted	O	VERB	B
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
affected	O	VERB	B
members	O	NOUN	B
of	O	ADP	O
the	O	DET	O
families	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
affected	O	VERB	B
individuals	O	NOUN	B
carried	O	VERB	O
the	O	DET	O
same	O	ADJ	O
family	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mutation	O	NOUN	B
.	O	PUNCT	O


One	O	NUM	O
polymorphism	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
.	O	PUNCT	O


This	O	DET	O
data	O	NOUN	B
strongly	O	ADV	O
supports	O	VERB	O
the	O	DET	O
candidature	O	NOUN	B
of	O	ADP	O
PAX6	O	NOUN	B
as	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
hereditary	O	ADJ	B
aniridia	B-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
five	O	NUM	O
unrelated	O	ADJ	O
subjects	O	NOUN	B
with	O	ADP	O
hereditary	O	ADJ	B
protein	B-Disease	NOUN	I
S	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
type	I-Disease	NOUN	I
I	I-Disease	NUM	I
.	O	PUNCT	O


A	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
eight	O	NUM	O
unrelated	O	ADJ	O
subjects	O	NOUN	B
with	O	ADP	O
inherited	O	VERB	B
type	B-Disease	NOUN	O
I	I-Disease	NUM	O
protein	I-Disease	NOUN	O
S	I-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
was	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PROS1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
five	O	NUM	O
subjects	O	NOUN	B
an	O	DET	O
abnormality	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
but	O	CCONJ	O
mutations	O	NOUN	B
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
three	O	NUM	O
subjects	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
subjects	O	NOUN	B
shared	O	VERB	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
position	O	NOUN	B
+	O	CCONJ	O
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
consensus	O	NOUN	B
sequence	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
10	O	NUM	O
.	O	PUNCT	O


Also	O	ADV	O
in	O	ADP	O
two	O	NUM	O
subjects	O	NOUN	B
an	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transversion	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
stopcodon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PROS1	O	NOUN	B
gene	O	NOUN	I
;	O	PUNCT	O
this	O	DET	O
transversion	O	NOUN	B
predicts	O	VERB	O
a	O	DET	O
protein	O	NOUN	B
S	O	NOUN	I
molecule	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
extended	O	VERB	O
by	O	ADP	O
14	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
fifth	O	ADJ	O
subject	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
possess	O	VERB	O
two	O	NUM	O
sequence	O	NOUN	B
abnormalities	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
allele	O	NOUN	B
carried	O	VERB	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	DET	O
transition	O	NOUN	B
near	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
splice	O	NOUN	O
junction	O	NOUN	O
of	O	ADP	O
intron	O	NOUN	B
2	O	NUM	O
,	O	PUNCT	O
but	O	CCONJ	O
this	O	DET	O
abnormality	O	NOUN	B
is	O	AUX	O
probably	O	ADV	O
neutral	O	ADJ	B
,	O	PUNCT	O
since	O	SCONJ	O
it	O	PRON	O
was	O	AUX	O
inherited	O	VERB	B
from	O	ADP	O
the	O	DET	O
parent	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
protein	O	NOUN	B
S	O	NOUN	I
antigen	O	NOUN	I
levels	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
allele	O	NOUN	B
a	O	DET	O
single	O	ADJ	O
T	O	NOUN	O
insertion	O	NOUN	O
in	O	ADP	O
codon	O	NOUN	B
-	O	PUNCT	O
25	O	NUM	O
was	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
platelet	O	NOUN	B
RNA	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
only	O	ADV	O
the	O	DET	O
mRNA	O	NOUN	B
with	O	ADP	O
the	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
stopcodon	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
amounts	O	NOUN	O
comparable	O	ADJ	O
to	O	PART	O
wildtype	O	ADJ	B
RNA	O	NOUN	I
.	O	PUNCT	O


mRNA	O	NOUN	B
from	O	ADP	O
the	O	DET	O
alleles	O	NOUN	B
with	O	ADP	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
mutations	O	NOUN	B
was	O	AUX	O
either	O	CCONJ	O
undetectable	O	ADJ	B
or	O	CCONJ	O
present	O	ADJ	O
in	O	ADP	O
greatly	O	ADV	O
reduced	O	VERB	B
amounts	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
latter	O	ADJ	O
indicates	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
mRNA	O	NOUN	B
based	O	VERB	O
approach	O	NOUN	O
is	O	AUX	O
not	O	PART	O
feasible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
protein	B-Disease	NOUN	B
S	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
type	I-Disease	NOUN	I
I	I-Disease	NUM	I
.	O	PUNCT	O
.	O	PUNCT	O


Characteristics	O	NOUN	B
of	O	ADP	O
intergenerational	O	ADJ	B
contractions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
generally	O	ADV	O
increases	O	VERB	B
in	O	ADP	O
successive	O	ADJ	O
generations	O	NOUN	B
with	O	ADP	O
clinical	O	ADJ	B
evidence	O	NOUN	I
of	O	ADP	O
anticipation	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
cases	O	NOUN	B
with	O	ADP	O
an	O	DET	O
intergenerational	O	ADJ	B
contraction	O	NOUN	I
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	O
1	O	NUM	O
,	O	PUNCT	O
489	O	NUM	O
DM	B-Disease	NOUN	B
parent	O	NOUN	B
-	O	PUNCT	O
offspring	O	NOUN	B
pairs	O	NOUN	B
,	O	PUNCT	O
of	O	ADP	O
which	O	DET	O
95	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
showed	O	VERB	O
such	O	ADJ	O
contractions	O	NOUN	B
in	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	I
(	O	PUNCT	O
PBL	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
56	O	NUM	O
of	O	ADP	O
the	O	DET	O
95	O	NUM	O
pairs	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
data	O	NOUN	I
allowed	O	VERB	O
an	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
their	O	PRON	O
anticipation	O	NOUN	B
status	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
surprising	O	ADJ	O
that	O	SCONJ	O
anticipation	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
27	O	NUM	O
(	O	PUNCT	O
48	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
these	O	DET	O
56	O	NUM	O
pairs	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
none	O	NOUN	O
clearly	O	ADV	O
showed	O	VERB	O
a	O	DET	O
later	O	ADJ	O
onset	O	NOUN	O
of	O	ADP	O
DM	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
symptomatic	O	ADJ	B
offspring	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
contraction	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
76	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
753	O	NUM	O
paternal	O	ADJ	B
transmissions	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
19	O	NUM	O
(	O	PUNCT	O
3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
736	O	NUM	O
maternal	O	ADJ	B
transmissions	O	NOUN	B
.	O	PUNCT	O


Anticipation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
maternal	O	ADJ	B
(	O	PUNCT	O
85	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
paternal	O	ADJ	B
(	O	PUNCT	O
37	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
transmissions	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
parental	O	ADJ	B
repeat	O	NOUN	O
size	O	NOUN	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
intergenerational	O	ADJ	B
contraction	O	NOUN	I
(	O	PUNCT	O
r2	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
50	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
<	O	X	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
slope	O	NOUN	O
of	O	ADP	O
linear	O	ADJ	B
regression	O	NOUN	I
was	O	AUX	O
steeper	O	ADJ	O
in	O	ADP	O
paternal	O	ADJ	B
(	O	PUNCT	O
-	O	PUNCT	O
.	O	PUNCT	O
62	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
maternal	O	ADJ	B
(	O	PUNCT	O
-	O	PUNCT	O
.	O	PUNCT	O
30	O	NUM	O
)	O	PUNCT	O
transmissions	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
<	O	X	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Sixteen	O	NUM	O
DM	B-Disease	NOUN	B
parents	O	NOUN	B
had	O	AUX	O
multiple	O	ADJ	B
DM	B-Disease	NOUN	B
offspring	O	NOUN	B
with	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
contractions	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
frequency	O	NOUN	B
was	O	AUX	O
higher	O	ADJ	O
than	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
expected	O	VERB	O
from	O	ADP	O
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
contractions	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
sib	O	NOUN	I
population	O	NOUN	I
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O
54	O	NUM	O
DM	B-Disease	NOUN	B
offspring	O	NOUN	B
per	O	ADP	O
DM	B-Disease	NOUN	B
parent	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
968	O	NUM	O
DM	B-Disease	NOUN	B
parents	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
intergenerational	O	ADJ	B
contractions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	O
in	O	ADP	O
leukocyte	O	NOUN	B
DNA	O	NOUN	I
frequently	O	ADV	O
accompanies	O	VERB	O
apparent	O	ADJ	B
anticipation	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
DM	B-Disease	NOUN	B
is	O	AUX	O
maternally	O	ADV	B
transmitted	O	VERB	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
the	O	DET	O
paternal	O	ADJ	B
origin	O	NOUN	I
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
contraction	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sibling	O	NOUN	B
increase	O	VERB	B
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
contraction	O	NOUN	I


Gonosomal	O	ADJ	B
mosaicism	O	NOUN	I
in	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
patients	O	NOUN	B
:	O	PUNCT	O
involvement	O	NOUN	B
of	O	ADP	O
mitotic	O	ADJ	B
events	O	NOUN	I
in	O	ADP	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
variation	O	NOUN	B
and	O	CCONJ	O
selection	O	NOUN	B
against	O	ADP	O
extreme	O	ADJ	O
expansion	O	NOUN	B
in	O	ADP	O
sperm	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
abnormal	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
polymorphic	O	ADJ	B
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
,	O	PUNCT	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
determined	O	VERB	O
the	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
lengths	O	NOUN	B
in	O	ADP	O
a	O	DET	O
broad	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
tissue	O	NOUN	B
DNAs	O	NOUN	I
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
mild	O	ADJ	B
,	O	PUNCT	O
classical	O	ADJ	O
,	O	PUNCT	O
or	O	CCONJ	O
congenital	O	ADJ	B
manifestation	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


Differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
length	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
somatic	O	ADJ	B
tissues	O	NOUN	I
from	O	ADP	O
single	O	ADJ	O
DM	B-Disease	NOUN	B
individuals	O	NOUN	B
and	O	CCONJ	O
twins	O	NOUN	B
.	O	PUNCT	O


Repeats	O	NOUN	B
appeared	O	VERB	O
to	O	PART	O
expand	O	VERB	O
to	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
extent	O	NOUN	O
in	O	ADP	O
tissues	O	NOUN	B
originating	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
embryonal	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
most	O	ADJ	O
male	O	ADJ	B
patients	O	NOUN	B
carrying	O	VERB	O
intermediate	O	ADJ	B
-	O	PUNCT	O
or	O	CCONJ	O
small	O	ADJ	B
-	O	PUNCT	O
sized	O	ADJ	B
expansions	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
repeat	O	NOUN	O
lengths	O	NOUN	B
covered	O	VERB	O
a	O	DET	O
markedly	O	ADV	O
wider	O	ADJ	O
range	O	NOUN	O
in	O	ADP	O
sperm	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
male	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
allele	O	NOUN	B
expansions	O	NOUN	I
in	O	ADP	O
blood	O	NOUN	B
(	O	PUNCT	O
>	O	NOUN	O
700	O	NUM	O
CTGs	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
similar	O	ADJ	O
or	O	CCONJ	O
smaller	O	ADJ	O
repeats	O	NOUN	B
in	O	ADP	O
sperm	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
detectable	O	ADJ	B
.	O	PUNCT	O


Sperm	O	NOUN	B
alleles	O	NOUN	B
with	O	ADP	O
>	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
CTGs	O	NOUN	B
were	O	AUX	O
not	O	PART	O
seen	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
considered	O	VERB	O
gonosomal	O	ADJ	B
mosaics	O	NOUN	I
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
combined	O	ADJ	O
somatic	O	ADJ	B
and	O	CCONJ	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
tissue	O	NOUN	B
mosaics	O	NOUN	B
.	O	PUNCT	O


Most	O	ADV	O
remarkably	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
observed	O	VERB	O
multiple	O	ADJ	B
cases	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
length	O	NOUN	B
distributions	O	NOUN	B
of	O	ADP	O
intermediate	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
small	O	ADJ	B
-	O	PUNCT	O
sized	O	ADJ	B
alleles	O	NOUN	B
in	O	ADP	O
fathers	O	NOUN	B
sperm	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
different	O	ADJ	O
from	O	ADP	O
that	O	DET	O
in	O	ADP	O
their	O	PRON	O
offsprings	O	NOUN	B
blood	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
combined	O	ADJ	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
intergenerational	O	ADJ	B
length	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
unstable	O	ADJ	B
CTG	O	NOUN	B
repeat	O	NOUN	I
are	O	AUX	O
most	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
occur	O	VERB	O
during	O	ADP	O
early	O	ADJ	B
embryonic	O	ADJ	B
mitotic	O	ADJ	I
divisions	O	NOUN	I
in	O	ADP	O
both	O	CCONJ	O
somatic	O	ADJ	B
and	O	CCONJ	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
tissue	O	NOUN	B
formation	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
the	O	DET	O
initial	O	ADJ	O
CTG	O	NOUN	B
length	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
cell	O	NOUN	B
divisions	O	NOUN	I
involved	O	VERB	O
in	O	ADP	O
tissue	O	NOUN	B
formation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
perhaps	O	ADV	O
a	O	DET	O
specific	O	ADJ	O
selection	O	NOUN	B
process	O	NOUN	I
in	O	ADP	O
spermatogenesis	O	NOUN	B
may	O	AUX	O
influence	O	VERB	B
the	O	DET	O
dynamics	O	NOUN	B
of	O	ADP	O
this	O	DET	O
process	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
model	O	NOUN	B
explaining	O	VERB	O
mitotic	O	ADJ	B
instability	O	NOUN	I
and	O	CCONJ	O
sex	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
segregation	O	NOUN	B
phenomena	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
manifestation	O	NOUN	B
is	O	AUX	O
discussed	O	VERB	O


Regionally	O	ADV	B
clustered	O	ADJ	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
and	O	CCONJ	O
occur	O	VERB	O
at	O	ADP	O
a	O	DET	O
high	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
new	O	ADJ	O
mutation	O	NOUN	B
cases	O	NOUN	B
of	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
APC	O	NOUN	B
at	O	ADP	O
5q21	O	NOUN	B
-	O	PUNCT	O
22	O	NUM	O
results	O	NOUN	B
in	O	ADP	O
the	O	DET	O
dominantly	O	ADV	O
inherited	O	VERB	B
syndrome	O	NOUN	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Somatic	O	ADJ	B
mutation	O	NOUN	O
in	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
is	O	AUX	O
an	O	DET	O
early	O	ADJ	B
event	O	NOUN	O
in	O	ADP	O
colorectal	O	ADJ	B
tumourigenesis	O	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
are	O	AUX	O
concentrated	O	VERB	O
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
half	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	B
15	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
single	O	ADJ	O
strand	O	NOUN	B
conformational	O	ADJ	O
polymorphism	O	NOUN	O
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
heteroduplex	O	NOUN	B
analysis	O	NOUN	I
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
variants	O	NOUN	B
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
45	O	NUM	O
affected	O	VERB	B
but	O	CCONJ	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


Eighteen	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
the	O	DET	I
disease	O	NOUN	I
;	O	PUNCT	O
of	O	ADP	O
these	O	DET	O
11	O	NUM	O
were	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
having	O	VERB	O
a	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
an	O	DET	O
early	O	ADJ	B
age	O	NOUN	B
at	O	ADP	O
presentation	O	NOUN	B
or	O	CCONJ	O
cancer	B-Disease	NOUN	B
development	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
compared	O	VERB	B
with	O	ADP	O
6	O	NUM	O
of	O	ADP	O
27	O	NUM	O
familial	O	ADJ	B
cases	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
5	O	NUM	O
bp	O	NOUN	O
deletion	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
1309	O	NUM	O
reported	O	VERB	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
10	O	NUM	O
-	O	SYM	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
unselected	O	ADJ	O
APC	B-Disease	NOUN	B
patients	O	NOUN	B
worldwide	O	ADV	O
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
5	O	NUM	O
of	O	ADP	O
the	O	DET	O
18	O	NUM	O
new	O	ADJ	O
mutation	O	NOUN	B
cases	O	NOUN	B
and	O	CCONJ	O
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
27	O	NUM	O
familial	O	ADJ	B
cases	O	NOUN	B
all	O	DET	O
nine	O	NUM	O
were	O	AUX	O
classed	O	VERB	O
as	O	ADP	O
severe	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
further	O	ADJ	O
3	O	NUM	O
new	O	ADJ	O
mutations	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
familial	O	ADJ	B
mutation	O	NOUN	I
were	O	AUX	O
located	O	ADJ	O
downstream	O	ADJ	B
from	O	ADP	O
codon	O	NOUN	B
1309	O	NUM	I
,	O	PUNCT	O
these	O	DET	O
individuals	O	NOUN	B
similarly	O	ADV	O
being	O	AUX	O
classed	O	VERB	O
as	O	ADP	O
phenotypically	O	ADV	B
severe	O	ADJ	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
all	O	DET	O
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
detected	O	VERB	B
in	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
with	O	ADP	O
an	O	DET	O
average	O	ADJ	B
phenotype	O	NOUN	B
were	O	AUX	O
located	O	ADJ	O
prior	O	ADJ	O
to	O	PART	O
codon	O	NOUN	B
1309	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
frequent	O	ADJ	B
association	O	NOUN	B
of	O	ADP	O
a	O	DET	O
severe	O	ADJ	B
phenotype	O	NOUN	B
with	O	ADP	O
fresh	O	ADJ	B
mutation	O	NOUN	B
may	O	AUX	O
explain	O	VERB	O
the	O	DET	O
apparent	O	ADJ	B
conflict	O	NOUN	B
of	O	ADP	O
a	O	DET	O
high	O	ADJ	O
mutation	O	NOUN	B
rate	O	NOUN	O
(	O	PUNCT	O
20	O	NUM	O
-	O	SYM	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
condition	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
on	O	ADP	O
average	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
lethal	O	ADJ	B
at	O	ADP	O
a	O	DET	O
post	O	NOUN	B
-	O	PUNCT	O
reproductive	O	ADJ	B
age	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
locus	O	NOUN	B
are	O	AUX	O
found	O	VERB	O
in	O	ADP	O
heterogeneous	O	ADJ	B
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
malformations	I-Disease	NOUN	O
including	O	VERB	O
Peters	B-Disease	PROPN	B
'	I-Disease	PART	I
anomaly	I-Disease	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
or	O	CCONJ	O
deletion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
underlies	O	VERB	O
many	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
aniridia	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
lines	O	NOUN	B
of	O	ADP	O
evidence	O	NOUN	B
now	O	ADV	O
converge	O	VERB	O
to	O	PART	O
implicate	O	VERB	O
PAX6	O	NOUN	B
more	O	ADV	O
widely	O	ADV	O
in	O	ADP	O
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
malformations	I-Disease	NOUN	O
including	O	VERB	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
child	O	NOUN	B
with	O	ADP	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
is	O	AUX	O
deleted	O	VERB	O
for	O	ADP	O
one	O	NUM	O
copy	O	NOUN	B
of	O	ADP	O
PAX6	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
affected	O	VERB	B
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
dominantly	O	ADV	O
inherited	O	VERB	B
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
malformations	I-Disease	NOUN	O
,	O	PUNCT	O
including	O	VERB	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
are	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
an	O	DET	O
R26G	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
PAX6	O	NOUN	B
paired	O	ADJ	O
box	O	NOUN	B
.	O	PUNCT	O


Third	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
Sey	O	PROPN	B
/	O	PUNCT	O
+	O	CCONJ	O
Smalleye	O	ADJ	B
mice	O	NOUN	I
,	O	PUNCT	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
murine	O	ADJ	B
Pax	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
have	O	AUX	O
an	O	DET	O
ocular	O	ADJ	B
phenotype	O	NOUN	B
resembling	O	VERB	O
Peters	B-Disease	PROPN	B
anomaly	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
propose	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
anterior	B-Disease	ADJ	B
segment	I-Disease	NOUN	O
anomalies	I-Disease	NOUN	O
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
PAX6	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
without	O	ADP	O
CAG	O	NOUN	B
expansion	O	NOUN	B
:	O	PUNCT	O
phenocopies	O	NOUN	B
or	O	CCONJ	O
errors	O	NOUN	B
in	O	ADP	O
assignment	O	NOUN	B
?	O	PUNCT	O


Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
repeat	O	NOUN	I
within	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
gene	O	NOUN	B
on	O	ADP	O
4p16	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
IT15	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
30	O	NUM	O
of	O	ADP	O
1	O	NUM	O
,	O	PUNCT	O
022	O	NUM	O
affected	O	VERB	B
persons	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
cohort	O	NOUN	B
)	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
an	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
in	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
range	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
reasons	O	NOUN	B
for	O	ADP	O
not	O	PART	O
observing	O	VERB	O
expansion	O	NOUN	B
in	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
are	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
determining	O	VERB	O
the	O	DET	O
sensitivity	O	NOUN	B
of	O	ADP	O
using	O	VERB	O
repeat	O	NOUN	O
length	O	NOUN	O
both	O	CCONJ	O
for	O	ADP	O
diagnosis	O	NOUN	B
of	O	ADP	O
affected	O	VERB	B
patients	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
predictive	O	ADJ	B
testing	O	NOUN	I
programs	O	NOUN	O
and	O	CCONJ	O
may	O	AUX	O
have	O	AUX	O
biological	O	ADJ	B
relevance	O	NOUN	B
for	O	ADP	O
the	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
mechanism	O	NOUN	O
underlying	O	VERB	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
majority	O	NOUN	O
(	O	PUNCT	O
18	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
individuals	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	O
sized	O	ADJ	O
alleles	O	NOUN	B
represent	O	VERB	O
misdiagnosis	O	NOUN	B
,	O	PUNCT	O
sample	O	NOUN	B
mix	O	NOUN	O
-	O	PUNCT	O
up	O	ADP	B
,	O	PUNCT	O
or	O	CCONJ	O
clerical	O	ADJ	B
error	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
12	O	NUM	O
patients	O	NOUN	B
represent	O	VERB	O
possible	O	ADJ	O
phenocopies	O	NOUN	B
for	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
four	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
family	O	NOUN	B
studies	O	NOUN	I
of	O	ADP	O
these	O	DET	O
phenocopies	O	NOUN	B
excluded	O	VERB	O
4p16	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
as	O	ADP	O
the	O	DET	O
region	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
phenotype	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
other	O	ADJ	O
than	O	ADP	O
CAG	O	NOUN	B
expansion	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
excluded	O	VERB	O
for	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
eight	O	NUM	O
cases	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
as	O	ADV	O
many	O	ADJ	O
as	O	ADP	O
seven	O	NUM	O
of	O	ADP	O
these	O	DET	O
persons	O	NOUN	B
,	O	PUNCT	O
retrospective	O	ADJ	B
review	O	NOUN	I
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
clinical	O	ADJ	B
features	O	NOUN	I
identified	O	VERB	O
characteristics	O	NOUN	B
not	O	PART	O
typical	O	ADJ	O
for	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
on	O	ADP	O
rare	O	ADJ	B
occasions	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
other	O	ADJ	O
,	O	PUNCT	O
as	O	ADP	O
-	O	PUNCT	O
yet	O	ADV	O
-	O	PUNCT	O
undefined	O	ADJ	B
genes	O	NOUN	B
can	O	AUX	O
present	O	VERB	O
with	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
phenotype	O	NOUN	B
very	O	ADV	O
similar	O	ADJ	O
to	O	PART	O
that	O	DET	O
of	O	ADP	O
HD	B-Disease	NOUN	B


Frequent	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
877	O	NUM	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
androgen	O	NOUN	B
receptor	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
advanced	B-Disease	ADJ	B
prostate	I-Disease	NOUN	O
cancers	I-Disease	NOUN	O
.	O	PUNCT	O


Prostatic	O	ADJ	B
tissue	O	NOUN	I
specimens	O	NOUN	O
derived	O	VERB	O
from	O	ADP	O
transurethral	O	ADJ	B
resections	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
metastatic	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
genetic	O	ADJ	B
alterations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
hormone	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
of	O	ADP	O
the	O	DET	O
androgen	O	NOUN	B
receptor	O	NOUN	I
(	O	PUNCT	O
AR	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
-	O	PUNCT	O
derived	O	VERB	B
DNAs	O	NOUN	B
of	O	ADP	O
6	O	NUM	O
of	O	ADP	O
24	O	NUM	O
specimens	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
codon	O	NOUN	B
877	O	NUM	I
mutation	O	NOUN	B
(	O	PUNCT	O
ACT	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
GCT	O	NOUN	B
,	O	PUNCT	O
Thr	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Ala	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
hormone	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
of	O	ADP	O
the	O	DET	O
AR	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
same	O	ADJ	O
AR	O	NOUN	B
mutation	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
in	O	ADP	O
a	O	DET	O
metastatic	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
cell	O	NOUN	B
line	O	NOUN	I
,	O	PUNCT	O
LNCaP	O	NOUN	B
,	O	PUNCT	O
where	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
confers	O	VERB	O
upon	O	SCONJ	O
the	O	DET	O
AR	O	NOUN	B
an	O	DET	O
altered	O	ADJ	O
ligand	O	NOUN	B
-	O	PUNCT	O
binding	O	NOUN	B
specificity	O	NOUN	B
which	O	DET	O
is	O	AUX	O
stimulated	O	VERB	B
by	O	ADP	O
estrogens	O	NOUN	B
,	O	PUNCT	O
progestagens	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
antiandrogens	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
that	O	SCONJ	O
analogous	O	ADJ	O
to	O	PART	O
an	O	DET	O
activated	O	VERB	B
/	O	SYM	O
altered	O	VERB	B
growth	O	NOUN	O
factor	O	NOUN	O
receptor	O	NOUN	O
oncogene	O	NOUN	O
,	O	PUNCT	O
codon	O	NOUN	B
877	O	NUM	O
mutant	O	ADJ	B
AR	O	NOUN	B
with	O	ADP	O
altered	O	ADJ	O
ligand	O	NOUN	B
binding	O	NOUN	O
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
selective	O	ADJ	O
growth	O	NOUN	B
advantage	O	NOUN	O
in	O	ADP	O
the	O	DET	O
genesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
advanced	B-Disease	ADJ	B
prostate	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Although	O	SCONJ	O
estrogens	O	NOUN	B
are	O	AUX	O
used	O	VERB	O
infrequently	O	ADV	O
,	O	PUNCT	O
antiandrogens	O	NOUN	B
are	O	AUX	O
used	O	VERB	O
increasingly	O	ADV	O
in	O	ADP	O
hormonal	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	B-Disease	ADJ	B
prostate	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
stimulatory	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
these	O	DET	O
therapeutic	O	ADJ	B
agents	O	NOUN	I
on	O	ADP	O
the	O	DET	O
codon	O	NOUN	B
877	O	NUM	O
mutant	O	ADJ	B
AR	O	NOUN	B
further	O	ADV	O
suggests	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
frequently	O	ADV	O
observed	O	VERB	O
AR	O	NOUN	B
mutation	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
treatment	O	NOUN	B
refractory	O	ADJ	I
disease	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
for	O	ADP	O
alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
AKU	B-Disease	NOUN	B
)	O	PUNCT	O
maps	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	B
3q	O	NOUN	I
.	O	PUNCT	O


Alkaptonuria	B-Disease	NOUN	B
(	O	PUNCT	O
AKU	B-Disease	PROPN	B
;	O	PUNCT	O
McKusick	O	PROPN	O
no	O	INTJ	O
.	O	PUNCT	O
203500	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
homogentisic	O	ADJ	B
acid	O	NOUN	I
oxidase	O	NOUN	I
activity	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
excrete	O	VERB	B
large	O	ADJ	O
amounts	O	NOUN	O
of	O	ADP	O
homogentisic	O	ADJ	B
acid	O	NOUN	I
in	O	ADP	O
their	O	PRON	O
urine	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
black	O	ADJ	B
ochronotic	O	ADJ	I
pigment	O	NOUN	B
is	O	AUX	O
deposited	O	VERB	O
in	O	ADP	O
their	O	PRON	O
cartilage	O	NOUN	B
and	O	CCONJ	O
collagenous	O	ADJ	B
tissues	O	NOUN	I
.	O	PUNCT	O


Ochronosis	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
predominant	O	ADJ	O
clinical	O	ADJ	B
complication	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
ochronotic	B-Disease	ADJ	B
arthropathy	I-Disease	ADJ	I
,	O	PUNCT	O
dark	O	ADJ	B
urine	O	NOUN	B
,	O	PUNCT	O
pigment	O	NOUN	B
changes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
skin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
alkaptonuria	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
has	O	AUX	O
mapped	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	O
16	O	NUM	O
.	O	PUNCT	O


Considering	O	VERB	O
conserved	O	VERB	B
synteny	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
map	O	VERB	B
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
to	O	PART	O
chromosome	O	NOUN	B
3q	O	NOUN	I
in	O	ADP	O
six	O	NUM	O
alkaptonuria	B-Disease	NOUN	B
pedigrees	O	NOUN	B
of	O	ADP	O
Slovak	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
gene	O	NOUN	O
SGLT1	O	NOUN	B
.	O	PUNCT	O


Intestinal	O	ADJ	B
uptake	O	NOUN	B
of	O	ADP	O
dietary	O	ADJ	B
glucose	O	NOUN	I
and	O	CCONJ	O
galactose	O	NOUN	B
is	O	AUX	O
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
SGLT1	O	NOUN	B
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
of	O	ADP	O
the	O	DET	O
brush	O	NOUN	B
border	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
SGLT1	O	NOUN	B
missense	O	NOUN	B
mutation	O	NOUN	I
underlies	O	VERB	O
hereditary	B-Disease	ADJ	B
glucose	I-Disease	NOUN	I
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
potentially	O	ADV	O
fatal	O	ADJ	B
diarrhea	B-Disease	NOUN	B
;	O	PUNCT	O
conversely	O	ADV	O
,	O	PUNCT	O
oral	O	ADJ	B
rehydration	O	NOUN	I
therapy	O	NOUN	I
exploits	O	VERB	O
normal	O	ADJ	B
transport	O	NOUN	I
to	O	PART	O
alleviate	O	VERB	B
life	O	NOUN	B
-	O	PUNCT	O
threatening	O	VERB	B
diarrhea	B-Disease	NOUN	B
of	O	ADP	O
infectious	O	ADJ	B
origin	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
mapped	O	VERB	B
the	O	DET	O
entire	O	ADJ	O
human	O	ADJ	B
SGLT1	O	NOUN	B
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
gene	O	NOUN	I
from	O	ADP	O
cosmid	O	NOUN	B
and	O	CCONJ	O
lambda	O	NOUN	B
phage	O	NOUN	I
clones	O	NOUN	I
representing	O	VERB	O
a	O	DET	O
genomic	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
112	O	NUM	O
kilobases	O	NOUN	B
.	O	PUNCT	O


Transcription	O	NOUN	B
initiation	O	NOUN	B
occurred	O	VERB	O
from	O	ADP	O
a	O	DET	O
site	O	NOUN	B
27	O	NUM	O
base	O	NOUN	O
pairs	O	NOUN	O
3	O	NUM	O
of	O	ADP	O
a	O	DET	O
TATAA	O	NOUN	B
sequence	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
exon	O	NOUN	B
-	O	PUNCT	O
flanking	O	VERB	B
regions	O	NOUN	I
were	O	AUX	O
sequenced	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
entire	O	ADJ	O
112	O	NUM	O
-	O	PUNCT	O
kilobase	O	NOUN	B
region	O	NOUN	B
mapped	O	VERB	B
with	O	ADP	O
four	O	NUM	O
restriction	O	NOUN	B
enzymes	O	NOUN	B
.	O	PUNCT	O


SGLT1	O	NOUN	B
is	O	AUX	O
comprised	O	VERB	O
of	O	ADP	O
15	O	NUM	O
exons	O	NOUN	B
(	O	PUNCT	O
spanning	O	VERB	O
72	O	NUM	O
kilobases	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
a	O	DET	O
possible	O	ADJ	O
evolutionary	O	ADJ	B
origin	O	NOUN	I
from	O	ADP	O
a	O	DET	O
six	O	NUM	B
-	O	PUNCT	O
membrane	O	NOUN	B
-	O	PUNCT	O
span	O	NOUN	B
ancestral	O	ADJ	B
precursor	O	NOUN	I
via	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
duplication	O	NOUN	I
event	O	NOUN	B
is	O	AUX	O
suggested	O	VERB	O
from	O	ADP	O
comparison	O	NOUN	B
of	O	ADP	O
exons	O	NOUN	B
against	O	ADP	O
protein	O	NOUN	B
secondary	O	ADJ	O
structure	O	NOUN	O
and	O	CCONJ	O
from	O	ADP	O
sequence	O	NOUN	B
considerations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
1	O	NUM	I
causing	O	VERB	O
glucose	B-Disease	NOUN	B
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
is	O	AUX	O
also	O	ADV	O
described	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
-	O	PUNCT	O
dependent	O	ADJ	B
cotransporter	O	NOUN	B
gene	O	NOUN	B
structure	O	NOUN	I
reported	O	VERB	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
facilitate	O	VERB	O
the	O	DET	O
search	O	NOUN	B
for	O	ADP	O
new	O	ADJ	O
glucose	B-Disease	NOUN	B
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
-	O	PUNCT	O
related	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
important	O	ADJ	O
gene	O	NOUN	B
and	O	CCONJ	O
provide	O	VERB	O
a	O	DET	O
basis	O	NOUN	O
for	O	ADP	O
future	O	ADJ	O
evolutionary	O	ADJ	B
comparisons	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
Na	O	NOUN	B
(	O	PUNCT	O
+	O	CCONJ	O
)	O	PUNCT	O
-	O	PUNCT	O
dependent	O	ADJ	B
cotransporters	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Four	O	NUM	O
novel	O	ADJ	B
PEPD	O	NOUN	B
alleles	O	NOUN	B
causing	O	VERB	O
prolidase	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
PEPD	O	NOUN	B
locus	O	NOUN	B
cause	O	VERB	O
prolidase	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
McKusick	O	NOUN	B
170100	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
rare	O	ADJ	B
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
iminodipeptiduria	B-Disease	NOUN	B
,	O	PUNCT	O
skin	B-Disease	NOUN	B
ulcers	I-Disease	NOUN	I
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
recurrent	O	ADJ	B
infections	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
PEPD	O	NOUN	B
mutations	O	NOUN	B
from	O	ADP	O
five	O	NUM	O
severely	O	ADV	B
affected	O	VERB	B
individuals	O	NOUN	B
were	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
reverse	O	NOUN	B
-	O	PUNCT	O
transcribed	O	VERB	B
,	O	PUNCT	O
PCR	O	NOUN	B
-	O	PUNCT	O
amplified	O	VERB	B
(	O	PUNCT	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
cDNA	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
on	O	ADP	O
four	O	NUM	O
overlapping	O	VERB	O
cDNA	O	NOUN	B
fragments	O	NOUN	B
covering	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PEPD	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
detected	O	VERB	B
abnormal	O	ADJ	B
SSCP	O	NOUN	B
bands	O	NOUN	I
for	O	ADP	O
the	O	DET	O
fragment	O	NOUN	B
spanning	O	VERB	O
all	O	DET	O
or	O	CCONJ	O
part	O	NOUN	O
of	O	ADP	O
exons	O	NOUN	B
13	O	NUM	O
-	O	SYM	O
15	O	NUM	O
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
probands	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
cDNAs	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	PROPN	O
,	O	PUNCT	O
1342	O	NUM	O
substitution	O	NOUN	B
(	O	PUNCT	O
G448R	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
(	O	PUNCT	O
delta	O	NOUN	O
E452	O	NOUN	O
or	O	CCONJ	O
delta	O	NOUN	O
E453	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
another	O	DET	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
two	O	NUM	O
probands	O	NOUN	B
the	O	DET	O
amplified	O	VERB	B
products	O	NOUN	I
were	O	AUX	O
of	O	ADP	O
reduced	O	VERB	B
size	O	NOUN	I
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
these	O	DET	O
mutant	O	ADJ	B
cDNAs	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
.	O	PUNCT	O


Intronic	O	ADJ	B
sequences	O	NOUN	I
flanking	O	NOUN	I
exons	O	NOUN	I
5	O	NUM	I
and	O	CCONJ	O
7	O	NUM	O
were	O	AUX	O
identified	O	VERB	B
using	O	VERB	O
inverse	O	ADJ	B
PCR	O	NOUN	O
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


Conventional	O	ADJ	B
PCR	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
then	O	ADV	O
established	O	VERB	O
the	O	DET	O
intron	O	NOUN	B
-	O	PUNCT	O
exon	O	NOUN	B
borders	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
genomic	O	ADJ	B
DNA	O	NOUN	I
revealing	O	VERB	O
two	O	NUM	O
splice	O	NOUN	B
acceptor	O	NOUN	I
mutations	O	NOUN	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	B
substitution	O	NOUN	B
at	O	ADP	O
position	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
intron	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
an	O	DET	O
A	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
substitution	O	NOUN	B
at	O	ADP	O
position	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
of	O	ADP	O
intron	O	NOUN	B
6	O	NUM	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
severe	O	ADJ	B
form	O	NOUN	O
of	O	ADP	O
prolidase	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
multiple	O	ADJ	B
PEPD	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	O
we	O	PRON	O
attempt	O	VERB	O
to	O	PART	O
begin	O	VERB	O
the	O	DET	O
process	O	NOUN	B
of	O	ADP	O
describing	O	VERB	O
these	O	DET	O
alleles	O	NOUN	B
and	O	CCONJ	O
cataloging	O	VERB	B
their	O	PRON	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Recombinations	O	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
homozygous	O	ADJ	B
by	O	ADP	O
descent	O	NOUN	B
localize	O	VERB	I
the	O	DET	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
locus	O	NOUN	I
in	O	ADP	O
a	O	DET	O
cloned	O	VERB	B
450	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
locus	O	NOUN	B
for	O	ADP	O
Friedreich	B-Disease	NOUN	B
ataxia	I-Disease	NOUN	I
(	O	PUNCT	O
FRDA	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
severe	O	ADJ	O
neurodegenerative	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
tightly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
markers	O	NOUN	B
D9S5	O	NOUN	B
and	O	CCONJ	O
D9S15	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
rare	O	ADJ	B
recombination	O	NOUN	O
events	O	NOUN	O
has	O	AUX	O
suggested	O	VERB	O
the	O	DET	O
order	O	NOUN	O
cen	O	NOUN	B
-	O	PUNCT	O
FRDA	O	NOUN	B
-	O	PUNCT	O
D9S5	O	NOUN	B
-	O	PUNCT	O
D9S15	O	NOUN	B
-	O	PUNCT	O
qter	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
the	O	DET	O
construction	O	NOUN	B
of	O	ADP	O
a	O	DET	O
YAC	O	NOUN	B
contig	O	NOUN	B
extending	O	VERB	O
800	O	NUM	O
kb	O	NOUN	O
centromeric	O	ADJ	O
to	O	PART	O
D9S5	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
five	O	NUM	O
new	O	ADJ	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
from	O	ADP	O
this	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
map	O	VERB	B
these	O	DET	O
markers	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
FRDA	B-Disease	NOUN	B
locus	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
within	O	ADP	O
a	O	DET	O
1	O	NUM	O
-	O	PUNCT	O
cM	O	NOUN	B
confidence	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
sought	O	VERB	O
to	O	PART	O
increase	O	VERB	B
the	O	DET	O
genetic	O	ADJ	B
information	O	NOUN	I
of	O	ADP	O
available	O	ADJ	O
FRDA	B-Disease	NOUN	B
families	O	NOUN	B
by	O	ADP	O
considering	O	VERB	O
homozygosity	O	NOUN	B
by	O	ADP	O
descent	O	NOUN	B
and	O	CCONJ	O
association	O	NOUN	B
with	O	ADP	O
founder	O	NOUN	B
haplotypes	O	NOUN	B
in	O	ADP	O
isolated	O	VERB	B
populations	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
allowed	O	VERB	O
us	O	PRON	O
to	O	PART	O
identify	O	VERB	O
one	O	NUM	O
phase	O	NOUN	B
-	O	PUNCT	O
known	O	VERB	B
recombination	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
probable	O	ADJ	O
historic	O	ADJ	B
recombination	O	NOUN	I
on	O	ADP	O
haplotypes	O	NOUN	B
from	O	ADP	O
Reunion	O	PROPN	B
Island	O	PROPN	I
patients	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
place	O	NOUN	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
five	O	NUM	O
markers	O	NOUN	B
proximal	O	ADJ	B
to	O	PART	O
FRDA	B-Disease	NOUN	B
.	O	PUNCT	O


This	O	DET	O
represents	O	VERB	O
the	O	DET	O
first	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
close	O	ADJ	O
FRDA	B-Disease	NOUN	B
flanking	O	NOUN	B
markers	O	NOUN	B
on	O	ADP	O
the	O	DET	O
centromeric	O	ADJ	B
side	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
other	O	ADJ	O
markers	O	NOUN	B
allowed	O	VERB	O
us	O	PRON	O
to	O	PART	O
narrow	O	VERB	O
the	O	DET	O
breakpoint	O	NOUN	B
of	O	ADP	O
a	O	DET	O
previously	O	ADV	O
identified	O	VERB	O
distal	O	ADJ	B
recombination	O	NOUN	O
that	O	PRON	O
is	O	AUX	O
>	O	DET	O
180	O	NUM	O
kb	O	NOUN	O
from	O	ADP	O
D9S5	O	NOUN	B
(	O	PUNCT	O
26P	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
results	O	NOUN	B
place	O	VERB	O
the	O	DET	O
FRDA	B-Disease	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
a	O	DET	O
450	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
interval	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
small	O	ADJ	O
enough	O	ADV	O
for	O	ADP	O
direct	O	ADJ	O
search	O	NOUN	O
of	O	ADP	O
candidate	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
detailed	O	ADJ	O
rare	O	ADJ	B
cutter	O	NOUN	B
restriction	O	NOUN	I
map	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
cosmid	O	NOUN	B
contig	O	NOUN	B
covering	O	VERB	O
this	O	DET	O
interval	O	NOUN	B
were	O	AUX	O
constructed	O	VERB	O
and	O	CCONJ	O
should	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
search	O	NOUN	B
of	O	ADP	O
genes	O	NOUN	B
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Investigation	O	NOUN	B
of	O	ADP	O
thermoregulatory	O	ADJ	B
characteristics	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
survey	O	NOUN	B
instrument	O	NOUN	O
is	O	AUX	O
used	O	VERB	O
to	O	PART	O
assess	O	VERB	B
temperature	O	NOUN	B
regulation	O	NOUN	B
characteristics	O	NOUN	B
in	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
compared	O	VERB	B
to	O	PART	O
3	O	NUM	O
control	O	NOUN	B
groups	O	NOUN	I
sibs	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
SIB	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
neurodevelopmentally	B-Disease	ADV	B
handicapped	I-Disease	VERB	I
children	O	NOUN	B
(	O	PUNCT	O
ND	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
and	O	CCONJ	O
gender	O	NOUN	B
matched	O	VERB	O
well	O	ADV	O
children	O	NOUN	O
(	O	PUNCT	O
WC	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Significant	O	ADJ	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
PWS	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
SIB	O	NOUN	B
controls	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
WC	O	NOUN	B
controls	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
febrile	O	ADJ	B
convulsions	O	NOUN	I
,	O	PUNCT	O
fever	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
symptoms	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
temperature	O	NOUN	B
less	O	ADJ	O
than	O	ADP	O
94	O	NUM	O
degrees	O	NOUN	B
F	O	PROPN	I
.	O	PUNCT	O


No	O	DET	B
differences	O	NOUN	I
were	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
any	O	DET	O
variable	O	NOUN	B
between	O	ADP	O
the	O	DET	O
PWS	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
ND	O	NOUN	B
controls	O	VERB	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
abnormalities	O	NOUN	B
are	O	AUX	O
not	O	PART	O
unique	O	ADJ	O
to	O	PART	O
PWS	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
can	O	AUX	O
occur	O	VERB	O
in	O	ADP	O
any	O	DET	O
neurodevelopmentally	B-Disease	ADV	B
handicapped	I-Disease	VERB	I
individual	O	NOUN	B
,	O	PUNCT	O
further	O	ADV	O
suggesting	O	VERB	O
these	O	DET	O
do	O	AUX	O
not	O	PART	O
necessarily	O	ADV	O
reflect	O	VERB	O
syndrome	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
hypothalamic	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Phenotypic	O	ADJ	B
variation	O	NOUN	I
including	O	VERB	O
retinitis	B-Disease	NOUN	B
pigmentosa	I-Disease	NOUN	I
,	O	PUNCT	O
pattern	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
fundus	B-Disease	NOUN	B
flavimaculatus	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
family	O	NOUN	B
with	O	ADP	O
a	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
153	O	NUM	I
or	O	CCONJ	O
154	O	NUM	O
of	O	ADP	O
the	O	DET	O
peripherin	O	NOUN	B
/	O	SYM	O
RDS	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
AND	O	CCONJ	O
OBJECTIVES	O	NOUN	O
Mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
peripherin	O	NOUN	B
/	O	SYM	O
RDS	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
retinitis	I-Disease	NOUN	B
pigmentosa	I-Disease	NOUN	I
,	O	PUNCT	O
pattern	O	NOUN	B
macular	B-Disease	NOUN	I
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
retinitis	B-Disease	NOUN	B
punctata	I-Disease	X	B
albescens	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
herein	O	ADV	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
three	O	NUM	O
separate	O	ADJ	B
phenotypes	O	NOUN	B
within	O	ADP	O
a	O	DET	O
single	O	ADJ	O
family	O	NOUN	B
with	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
3	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
153	O	NUM	I
or	O	CCONJ	O
154	O	NUM	O
of	O	ADP	O
the	O	DET	O
peripherin	O	NOUN	B
/	O	SYM	O
RDS	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


DESIGN	O	NOUN	O
Case	O	NOUN	B
reports	O	VERB	I
with	O	ADP	O
clinical	O	ADJ	B
features	O	NOUN	I
,	O	PUNCT	O
fluorescein	O	NOUN	B
angiography	O	NOUN	I
,	O	PUNCT	O
kinetic	O	ADJ	B
perimetry	O	NOUN	I
,	O	PUNCT	O
electrophysiological	O	ADJ	B
studies	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
molecular	O	ADJ	B
genetics	O	NOUN	I
.	O	PUNCT	O


SETTING	O	VERB	O
University	O	PROPN	B
medical	O	ADJ	I
centers	O	NOUN	I
.	O	PUNCT	O


PATIENTS	O	VERB	B
A	O	DET	O
75	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
two	O	NUM	O
daughters	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
44	O	NUM	O
and	O	CCONJ	O
50	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
her	O	PRON	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
son	O	NOUN	I
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
peripherin	O	NOUN	B
/	O	SYM	O
RDS	O	NOUN	B
mutations	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	B
phenotypes	O	NOUN	B
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
mother	O	NOUN	B
presented	O	VERB	O
at	O	ADP	O
age	O	NOUN	B
63	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
a	O	DET	O
profoundly	O	ADV	O
abnormal	O	ADJ	B
electroretinogram	O	NOUN	B
(	O	PUNCT	O
ERG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
adult	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
retinitis	B-Disease	NOUN	I
pigmentosa	I-Disease	NOUN	I
that	O	PRON	O
progressed	O	VERB	O
dramatically	O	ADV	O
over	O	ADP	O
12	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
marked	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
visual	O	ADJ	O
field	O	NOUN	O
.	O	PUNCT	O


One	O	NUM	O
daughter	O	NOUN	B
developed	O	VERB	O
pattern	B-Disease	NOUN	B
macular	I-Disease	NOUN	I
dystrophy	I-Disease	NOUN	I
at	O	ADP	O
age	O	NOUN	B
31	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
age	O	NOUN	B
44	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
ERG	O	NOUN	B
was	O	AUX	O
moderately	O	ADV	O
abnormal	O	ADJ	B
but	O	CCONJ	O
her	O	PRON	O
clinical	O	ADJ	B
disease	O	NOUN	I
was	O	AUX	O
limited	O	ADJ	O
to	O	ADP	O
the	O	DET	O
macula	O	NOUN	B
.	O	PUNCT	O


Another	O	DET	O
daughter	O	NOUN	B
presented	O	VERB	O
at	O	ADP	O
age	O	NOUN	B
42	O	NUM	O
years	O	NOUN	B
with	O	ADP	O
macular	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
and	O	CCONJ	O
over	O	ADP	O
10	O	NUM	O
years	O	NOUN	B
developed	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
picture	O	NOUN	I
of	O	ADP	O
fundus	B-Disease	NOUN	B
flavimaculatus	I-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
peripheral	O	ADJ	B
visual	O	ADJ	B
field	O	NOUN	I
was	O	AUX	O
preserved	O	VERB	O
but	O	CCONJ	O
her	O	PRON	O
ERG	O	NOUN	B
was	O	AUX	O
moderately	O	ADV	O
abnormal	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
son	O	NOUN	O
had	O	AUX	O
onset	O	NOUN	O
of	O	ADP	O
macular	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
at	O	ADP	O
age	O	NOUN	B
44	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Pericentral	B-Disease	ADJ	B
scotomas	I-Disease	NOUN	I
were	O	AUX	O
present	O	ADJ	O
and	O	CCONJ	O
the	O	DET	O
ERG	O	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
abnormal	O	ADJ	B
.	O	PUNCT	O


Fluorescein	O	NOUN	B
angiography	O	NOUN	I
revealed	O	VERB	O
punctate	O	ADJ	B
pigment	O	NOUN	B
epithelial	O	ADJ	B
transmission	O	NOUN	I
defects	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
A	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
153	O	NUM	I
or	O	CCONJ	O
154	O	NUM	O
of	O	ADP	O
the	O	DET	O
peripherin	O	NOUN	B
/	O	SYM	O
RDS	O	NOUN	B
gene	O	NOUN	I
can	O	AUX	O
produce	O	VERB	O
clinically	O	ADV	B
disparate	O	ADJ	O
phenotypes	O	NOUN	B
even	O	ADV	O
within	O	ADP	O
the	O	DET	O
same	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Assignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
gene	O	NOUN	O
SGLT1	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
22q13	O	NOUN	I
.	O	PUNCT	O
1	O	X	O
.	O	PUNCT	O


The	O	DET	O
Na	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	O
glucose	O	NOUN	B
cotransporter	O	NOUN	I
gene	O	NOUN	I
SGLT1	O	NOUN	B
encodes	O	VERB	O
the	O	DET	O
primary	O	ADJ	B
carrier	O	NOUN	I
protein	O	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
uptake	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dietary	O	ADJ	B
sugars	O	NOUN	I
glucose	O	NOUN	I
and	O	CCONJ	O
galactose	O	NOUN	B
from	O	ADP	O
the	O	DET	O
intestinal	O	ADJ	B
lumen	O	NOUN	O
.	O	PUNCT	O


SGLT1	O	NOUN	B
transport	O	NOUN	B
activity	O	NOUN	I
is	O	AUX	O
currently	O	ADV	O
exploited	O	VERB	O
in	O	ADP	O
oral	O	ADJ	B
rehydration	O	NOUN	I
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
75	O	NUM	O
-	O	PUNCT	O
kDa	O	NOUN	B
glycoprotein	O	NOUN	I
is	O	AUX	O
localized	O	ADJ	B
in	O	ADP	O
the	O	DET	O
brush	O	NOUN	B
border	O	NOUN	I
of	O	ADP	I
the	O	DET	I
intestinal	O	ADJ	B
epithelium	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
comprise	O	VERB	O
12	O	NUM	O
membrane	O	NOUN	B
spans	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
glucose	I-Disease	NOUN	O
/	I-Disease	SYM	O
galactose	I-Disease	NOUN	B
malabsorption	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
underlying	O	ADJ	O
cause	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
SGLT1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Asp28	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asn	O	NOUN	B
change	O	NOUN	O
was	O	AUX	O
demonstrated	O	VERB	O
in	O	X	B
vitro	O	X	I
to	O	PART	O
eliminate	O	VERB	O
SGLT1	O	NOUN	B
transport	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
SGLT1	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
previously	O	ADV	O
shown	O	VERB	O
to	O	PART	O
reside	O	VERB	O
on	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
q	O	NOUN	O
arm	O	NOUN	O
of	O	ADP	O
chromosome	O	NOUN	O
22	O	NUM	O
(	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
qter	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
a	O	DET	O
cosmid	O	NOUN	B
probe	O	NOUN	I
for	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
refines	O	VERB	O
the	O	DET	O
localization	O	NOUN	B
to	O	PART	O
22q13	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
provide	O	VERB	O
an	O	DET	O
example	O	NOUN	O
of	O	ADP	O
the	O	DET	O
utility	O	NOUN	O
of	O	ADP	O
the	O	DET	O
SGLT1	O	NOUN	B
probe	O	NOUN	I
as	O	ADP	O
a	O	DET	O
diagnostic	O	ADJ	B
for	O	ADP	O
genetic	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
translocations	O	NOUN	B
of	O	ADP	I
chromosome	O	NOUN	I
22	O	NUM	I
.	O	PUNCT	O


Restriction	O	NOUN	B
of	O	ADP	O
ocular	O	ADJ	B
fundus	O	NOUN	I
lesions	O	NOUN	B
to	O	PART	O
a	O	DET	O
specific	O	ADJ	O
subgroup	O	NOUN	B
of	O	ADP	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
alteration	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
APC	B-Disease	NOUN	B
,	O	PUNCT	O
causes	O	VERB	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
condition	O	NOUN	B
causing	O	VERB	O
predisposition	O	NOUN	B
to	O	PART	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
syndrome	O	NOUN	B
inconsistently	O	ADV	O
associates	O	VERB	O
characteristic	O	ADJ	O
patches	O	NOUN	B
of	O	ADP	O
congenital	B-Disease	ADJ	B
hypertrophy	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
retinal	I-Disease	ADJ	B
pigment	I-Disease	NOUN	O
epithelium	I-Disease	NOUN	O
(	O	PUNCT	O
CHRPE	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Ocular	O	ADJ	B
examination	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
patients	O	NOUN	B
expressing	O	VERB	B
CHRPE	B-Disease	NOUN	B
tend	O	VERB	O
to	O	PART	O
cluster	O	VERB	B
within	O	ADP	O
specific	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
exact	O	ADJ	O
APC	B-Disease	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
42	O	NUM	O
unrelated	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
these	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
truncated	O	VERB	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
CHRPE	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
along	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
.	O	PUNCT	O


CHRPE	B-Disease	NOUN	B
lesions	O	NOUN	B
are	O	AUX	O
almost	O	ADV	O
always	O	ADV	O
absent	O	ADJ	B
if	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
occurs	O	VERB	O
before	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
,	O	PUNCT	O
but	O	CCONJ	O
are	O	AUX	O
systematically	O	ADV	B
present	O	ADJ	O
if	O	SCONJ	O
it	O	PRON	O
occurs	O	VERB	O
after	O	ADP	O
this	O	DET	O
exon	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
range	O	NOUN	O
of	O	ADP	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
observed	O	VERB	O
among	O	ADP	O
affected	O	VERB	B
patients	O	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
part	O	NOUN	O
from	O	ADP	O
different	O	ADJ	O
allelic	O	ADJ	B
manifestations	O	NOUN	B
of	O	ADP	O
APC	B-Disease	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
dystrophin	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
on	O	ADP	O
the	O	DET	O
ERG	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
.	O	PUNCT	O


PURPOSE	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
earlier	O	ADJ	O
findings	O	NOUN	B
of	O	ADP	O
a	O	DET	O
negative	O	ADJ	B
electroretinogram	O	NOUN	B
(	O	PUNCT	O
ERG	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
boy	O	NOUN	B
with	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
led	O	VERB	O
them	O	PRON	O
to	O	PART	O
investigate	O	VERB	B
dystrophin	O	NOUN	B
gene	O	NOUN	I
deletions	O	NOUN	B
and	O	CCONJ	O
ERGs	O	NOUN	B
in	O	ADP	O
five	O	NUM	O
boys	O	NOUN	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
wanted	O	VERB	O
to	O	PART	O
determined	O	VERB	O
whether	O	SCONJ	O
there	O	PRON	O
were	O	AUX	O
similar	O	ADJ	O
ERG	O	NOUN	B
findings	O	NOUN	B
in	O	ADP	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
DMD	B-Disease	PROPN	B
,	O	PUNCT	O
the	O	DET	O
mdx	O	NOUN	B
mouse	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
.	O	PUNCT	O


Ganzfeld	O	ADJ	B
ERGs	O	NOUN	I
were	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
five	O	NUM	O
boys	O	NOUN	B
with	O	ADP	O
DMD	B-Disease	NOUN	B
after	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
ophthalmic	O	ADJ	B
examination	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
.	O	PUNCT	O


ERGs	O	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
in	O	ADP	O
anesthetized	O	ADJ	B
mdx	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
modified	O	VERB	O
Grass	O	NOUN	B
photostimulator	O	NOUN	I
(	O	PUNCT	O
Grass	O	PROPN	B
Instrument	O	PROPN	I
Company	O	PROPN	I
,	O	PUNCT	O
Quincy	O	PROPN	B
,	O	PUNCT	O
MA	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
.	O	PUNCT	O


Ophthalmic	O	ADJ	B
examinations	O	NOUN	I
in	O	ADP	O
all	O	DET	O
five	O	NUM	O
boys	O	NOUN	B
had	O	AUX	O
normal	O	ADJ	O
findings	O	NOUN	B
,	O	PUNCT	O
yet	O	CCONJ	O
an	O	DET	O
abnormal	O	ADJ	B
negative	O	ADJ	B
ERG	O	NOUN	B
was	O	AUX	O
recorded	O	VERB	O
for	O	ADP	O
each	O	DET	O
subject	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
subjects	O	NOUN	B
gene	O	NOUN	B
deletions	O	NOUN	I
were	O	AUX	O
variable	O	ADJ	B
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
large	O	ADJ	O
deletions	O	NOUN	B
to	O	PART	O
no	O	DET	O
detectable	O	ADJ	B
deletions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ERGs	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mdx	O	NOUN	B
mice	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
from	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
believe	O	VERB	O
the	O	DET	O
unique	O	ADJ	B
ERG	O	NOUN	B
recorded	O	VERB	O
for	O	ADP	O
the	O	DET	O
human	O	ADJ	B
subjects	O	NOUN	B
is	O	AUX	O
a	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
DMD	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
defects	O	NOUN	B
at	O	ADP	O
the	O	DET	O
dystrophin	O	NOUN	B
gene	O	NOUN	I
locus	O	NOUN	I
and	O	CCONJ	O
represents	O	VERB	O
a	O	DET	O
new	O	ADJ	O
clinical	O	ADJ	B
entity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ERG	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mdx	O	NOUN	B
mouse	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
spared	O	VERB	O
for	O	ADP	O
several	O	ADJ	O
reasons	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
milder	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	I
the	O	DET	O
mouse	O	NOUN	B
gene	O	NOUN	B
defect	O	NOUN	I
,	O	PUNCT	O
differences	O	NOUN	O
in	O	ADP	O
muscle	O	NOUN	B
and	O	CCONJ	O
retinal	O	ADJ	B
gene	O	NOUN	O
product	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
species	O	NOUN	B
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
biochemical	O	ADJ	B
role	O	NOUN	O
of	O	ADP	O
dystrophin	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ERG	O	NOUN	B
shows	O	VERB	O
promise	O	NOUN	O
of	O	ADP	O
becoming	O	VERB	O
a	O	DET	O
noninvasive	O	ADJ	B
diagnostic	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
DMD	B-Disease	PROPN	B
and	O	CCONJ	O
its	O	PRON	O
milder	O	ADJ	O
allelic	O	ADJ	B
forms	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


Association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
tumor	I-Disease	NOUN	B
suppressor	O	NOUN	I
protein	O	NOUN	I
with	O	ADP	O
catenins	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
initiate	O	VERB	B
sporadic	O	ADJ	B
and	O	CCONJ	O
inherited	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
colorectal	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
these	O	DET	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
well	O	ADV	O
characterized	O	VERB	B
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
APC	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
.	O	PUNCT	O


Two	O	NUM	O
cellular	O	ADJ	B
proteins	O	NOUN	I
that	O	PRON	O
associate	O	VERB	B
with	O	ADP	I
APC	B-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
peptide	O	NOUN	B
mapping	O	NOUN	I
as	O	ADP	O
the	O	DET	O
E	O	PROPN	B
-	O	PUNCT	O
cadherin	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
proteins	O	NOUN	B
alpha	O	NOUN	I
-	O	PUNCT	O
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
catenin	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
27	O	NUM	O
-	O	PUNCT	O
residue	O	NOUN	B
fragment	O	NOUN	B
of	O	ADP	O
APC	O	NOUN	B
containing	O	VERB	O
a	O	DET	O
15	O	NUM	O
-	O	PUNCT	O
amino	O	NOUN	B
acid	O	NOUN	I
repeat	O	NOUN	I
was	O	AUX	O
sufficient	O	ADJ	O
for	O	ADP	O
the	O	DET	O
interaction	O	NOUN	B
with	O	ADP	O
the	O	DET	O
catenins	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
an	O	DET	O
important	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
tumor	B-Disease	NOUN	B
initiation	O	NOUN	B
and	O	CCONJ	O
cell	O	NOUN	B
adhesion	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Difference	O	NOUN	O
in	O	ADP	O
methylation	O	NOUN	B
patterns	O	NOUN	B
within	O	ADP	O
the	O	DET	O
D15S9	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	B
15q11	O	NOUN	I
-	O	PUNCT	O
13	O	NUM	O
in	O	ADP	O
first	O	ADJ	O
cousins	O	NOUN	B
with	O	ADP	O
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Abnormalities	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
region	O	NOUN	I
15q11	O	NOUN	I
-	O	PUNCT	O
13	O	NUM	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
Angelman	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
AS	B-Disease	ADJ	B
)	O	PUNCT	O
and	O	CCONJ	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Differences	O	NOUN	B
between	O	ADP	O
the	O	DET	O
methylation	O	NOUN	B
patterns	O	NOUN	B
of	O	ADP	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	B
15q11	O	NOUN	I
-	O	PUNCT	O
13	O	NUM	O
which	O	DET	O
hybridizes	O	VERB	B
to	O	PART	O
the	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
DNA	O	NOUN	B
,	O	PUNCT	O
DN34	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
normal	O	ADJ	O
individuals	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
AS	B-Disease	ADJ	B
and	O	CCONJ	O
PWS	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
on	O	ADP	O
a	O	DET	O
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
first	O	ADJ	O
cousins	O	NOUN	B
are	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
AS	B-Disease	ADJ	B
and	O	CCONJ	O
PWS	B-Disease	PROPN	B
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
familial	O	ADJ	B
paracentric	O	ADJ	O
inversion	O	NOUN	O
of	O	ADP	O
15q11	O	NOUN	O
-	O	PUNCT	O
q13	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
studies	O	NOUN	B
on	O	ADP	O
this	O	DET	O
family	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
differences	O	NOUN	B
in	O	ADP	O
the	O	DET	O
methylation	O	NOUN	B
patterns	O	NOUN	B
in	O	ADP	O
the	O	DET	O
2	O	NUM	O
conditions	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
phenomenon	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
imprinting	O	NOUN	I
,	O	PUNCT	O
whereby	O	SCONJ	O
genetic	O	ADJ	B
information	O	NOUN	I
is	O	AUX	O
expressed	O	VERB	B
differently	O	ADV	O
dependent	O	ADJ	O
on	O	ADP	O
the	O	DET	O
parent	O	NOUN	B
of	O	ADP	O
origin	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Haplotype	O	ADJ	B
studies	O	NOUN	B
in	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
51	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
DNA	O	NOUN	B
haplotypes	O	NOUN	I
of	O	ADP	O
dinucleotide	O	NOUN	B
repeat	O	NOUN	I
polymorphisms	O	NOUN	I
(	O	PUNCT	O
CA	O	NOUN	B
repeats	O	NOUN	I
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
13q14	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
region	O	NOUN	O
,	O	PUNCT	O
to	O	PART	O
examine	O	VERB	O
these	O	DET	O
markers	O	NOUN	B
for	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
the	O	DET	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
WND	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
a	O	DET	O
marker	O	NOUN	B
(	O	PUNCT	O
D13S133	O	NOUN	B
)	O	PUNCT	O
described	O	VERB	O
elsewhere	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
three	O	NUM	O
new	O	ADJ	O
highly	O	ADV	O
polymorphic	O	ADJ	B
markers	O	NOUN	O
(	O	PUNCT	O
D13S314	O	NOUN	B
,	O	PUNCT	O
D13S315	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D13S316	O	NOUN	B
)	O	PUNCT	O
close	O	NOUN	O
to	O	PART	O
the	O	DET	O
WND	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
marker	O	NOUN	B
alleles	O	NOUN	B
at	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
studied	O	VERB	B
and	O	CCONJ	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
D13S314	O	NOUN	B
,	O	PUNCT	O
D13S133	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D13S316	O	NOUN	B
each	O	DET	O
show	O	VERB	O
nonrandom	O	ADJ	B
distribution	O	NOUN	B
on	O	ADP	O
chromosomes	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
WND	B-Disease	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
haplotypes	O	NOUN	B
of	O	ADP	O
these	O	DET	O
three	O	NUM	O
markers	O	NOUN	B
and	O	CCONJ	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
are	O	AUX	O
highly	O	ADV	O
significant	O	ADJ	O
differences	O	NOUN	O
between	O	ADP	O
WND	B-Disease	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	O
haplotypes	O	NOUN	B
in	O	ADP	O
northern	O	ADJ	B
European	O	ADJ	B
families	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
have	O	AUX	O
important	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
mutation	O	NOUN	B
detection	O	NOUN	B
and	O	CCONJ	O
molecular	O	ADJ	B
diagnosis	O	NOUN	I
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
Wilson	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
region	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
breast	O	NOUN	B
/	O	PUNCT	O
ovarian	O	ADJ	B
family	O	NOUN	I
:	O	PUNCT	O
refinement	O	NOUN	O
of	O	ADP	O
the	O	DET	O
minimal	O	ADJ	B
region	O	NOUN	I
containing	O	VERB	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
a	O	DET	O
single	O	ADJ	O
multi	O	ADJ	B
-	O	PUNCT	O
affected	O	VERB	B
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
pedigree	O	NOUN	B
(	O	PUNCT	O
BOV3	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
have	O	AUX	O
shown	O	VERB	O
consistent	O	ADJ	O
inheritance	O	NOUN	B
of	O	ADP	O
markers	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
17q	O	NOUN	I
with	O	ADP	I
the	O	DET	O
disease	O	NOUN	B
confirming	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
family	O	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
17q	O	NOUN	B
haplotypes	O	NOUN	I
shows	O	VERB	O
a	O	DET	O
recombination	O	NOUN	B
event	O	NOUN	B
in	O	ADP	O
a	O	DET	O
bilateral	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
case	O	NOUN	B
which	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
lies	O	VERB	O
distal	O	ADJ	B
to	O	ADP	O
D17S857	O	PROPN	B
;	O	PUNCT	O
D17S857	O	PROPN	B
is	O	AUX	O
thus	O	ADV	O
the	O	DET	O
new	O	ADJ	O
proximal	O	ADJ	B
boundary	O	NOUN	B
for	O	ADP	O
the	O	DET	O
region	O	NOUN	B
containing	O	VERB	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Combining	O	VERB	O
this	O	DET	O
information	O	NOUN	B
with	O	ADP	O
previously	O	ADV	O
published	O	VERB	B
mapping	O	NOUN	O
information	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
is	O	AUX	O
contained	O	VERB	O
in	O	ADP	O
a	O	DET	O
region	O	NOUN	B
estimated	O	VERB	B
at	O	ADP	O
1	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
Mb	O	NOUN	O
in	O	ADP	O
length	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
seven	O	NUM	O
breast	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
/	O	SYM	O
blood	O	NOUN	B
pairs	O	NOUN	O
examined	O	VERB	O
from	O	ADP	O
this	O	DET	O
family	O	NOUN	B
show	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
tumours	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
allel	O	NOUN	B
retained	O	VERB	O
in	O	ADP	O
each	O	DET	O
tumour	B-Disease	NOUN	B
was	O	AUX	O
from	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
-	O	PUNCT	O
bearing	O	VERB	B
chromosome	O	NOUN	I
implicating	O	VERB	O
BRCA1	O	NOUN	B
as	O	ADP	O
a	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
sequenced	O	VERB	B
the	O	DET	O
17	O	NUM	O
beta	O	NOUN	B
-	O	PUNCT	O
oestradiol	O	NOUN	B
dehydrogenase	O	NOUN	I
genes	O	NOUN	I
(	O	PUNCT	O
EDH17B1	O	NOUN	B
and	O	CCONJ	O
EDH17B2	O	NOUN	B
)	O	PUNCT	O
which	O	DET	O
have	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
as	O	ADP	O
candidate	O	NOUN	O
genes	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
members	O	NOUN	B
of	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
germline	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
kinase	O	NOUN	I
is	O	AUX	O
a	O	DET	O
component	O	NOUN	B
of	O	ADP	O
neuromuscular	O	ADJ	B
junctions	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
manifestation	O	NOUN	B
of	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
correlated	O	VERB	B
to	O	PART	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
expansion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
unstable	O	ADJ	B
[	O	PUNCT	O
CTG	O	NOUN	B
]	O	PUNCT	O
n	O	NOUN	O
DNA	O	NOUN	B
motif	O	NOUN	I
.	O	PUNCT	O


Recent	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
trinucleotide	O	NOUN	B
motif	O	NOUN	I
forms	O	VERB	I
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
last	O	ADJ	O
,	O	PUNCT	O
3	O	NUM	O
untranslated	O	ADJ	B
exon	O	NOUN	I
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
which	O	DET	O
potentially	O	ADV	O
encodes	O	VERB	B
multiple	O	ADJ	O
protein	O	NOUN	O
isoforms	O	NOUN	O
of	O	ADP	O
a	O	DET	O
serine	O	NOUN	B
/	O	SYM	O
threonine	O	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
kinase	O	NOUN	I
,	O	PUNCT	O
DM	O	NOUN	B
-	O	PUNCT	O
PK	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
here	O	ADV	O
on	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
antisera	O	NOUN	B
against	O	ADP	O
synthetic	O	ADJ	B
DM	O	NOUN	I
-	O	PUNCT	O
PK	O	NOUN	B
peptide	O	NOUN	B
antigens	O	NOUN	I
and	O	CCONJ	O
their	O	PRON	O
use	O	NOUN	O
in	O	ADP	O
biochemical	O	ADJ	B
and	O	CCONJ	O
histochemical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


Immunoreactive	O	ADJ	B
DM	O	NOUN	B
-	O	PUNCT	O
kinase	O	NOUN	B
protein	O	NOUN	I
of	O	ADP	O
53	O	NUM	O
kD	O	NOUN	B
is	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
low	O	ADJ	B
levels	O	NOUN	B
in	O	ADP	O
skeletal	O	ADJ	B
and	O	CCONJ	O
cardiac	O	ADJ	B
muscle	O	NOUN	I
extracts	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
staining	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
DM	O	NOUN	B
-	O	PUNCT	O
PK	O	PROPN	B
is	O	AUX	O
localised	O	VERB	O
prominently	O	ADV	O
at	O	ADP	O
sites	O	NOUN	B
of	O	ADP	O
neuromuscular	O	ADJ	B
and	O	CCONJ	O
myotendinous	O	ADJ	B
junctions	O	NOUN	I
(	O	PUNCT	O
NMJs	O	NOUN	B
and	O	CCONJ	O
MTJs	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
human	O	ADJ	B
and	O	CCONJ	O
rodent	O	ADJ	B
skeletal	O	ADJ	B
muscles	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
very	O	ADV	O
low	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
immunoreactive	O	ADJ	B
DM	O	NOUN	B
-	O	PUNCT	O
PK	O	NOUN	B
protein	O	NOUN	B
are	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
the	O	DET	O
sarcoplasm	O	NOUN	B
of	O	ADP	O
predominantly	O	ADV	O
type	O	NOUN	B
I	O	NUM	I
fibres	O	NOUN	I
in	O	ADP	O
various	O	ADJ	O
muscles	O	NOUN	B
.	O	PUNCT	O


Strikingly	O	ADV	B
,	O	PUNCT	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
can	O	AUX	O
also	O	ADV	O
be	O	AUX	O
demonstrated	O	VERB	O
for	O	ADP	O
NMJs	O	NOUN	B
of	O	ADP	O
muscular	O	ADJ	B
tissues	O	NOUN	I
of	O	ADP	O
adult	O	ADJ	B
and	O	CCONJ	O
congenital	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
gross	O	ADJ	B
changes	O	NOUN	I
in	O	ADP	O
structural	O	ADJ	B
organisation	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
provide	O	VERB	O
a	O	DET	O
basis	O	NOUN	O
for	O	ADP	O
further	O	ADJ	O
characterisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
kinase	O	NOUN	B
in	O	ADP	O
protein	O	NOUN	B
assembly	O	NOUN	I
processes	O	NOUN	I
or	O	CCONJ	O
signal	O	NOUN	B
mediation	O	NOUN	I
at	O	ADP	O
synaptic	O	ADJ	B
sites	O	NOUN	I
and	O	CCONJ	O
ultimately	O	ADV	O
for	O	ADP	O
the	O	DET	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
complex	O	ADJ	B
pathophysiology	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Markedly	O	ADV	O
accelerated	O	VERB	B
catabolism	O	NOUN	B
of	O	ADP	O
apolipoprotein	O	NOUN	B
A	O	NOUN	I
-	O	PUNCT	O
II	O	PROPN	B
(	O	PUNCT	O
ApoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
high	O	ADJ	B
density	O	NOUN	I
lipoproteins	O	NOUN	I
containing	O	VERB	O
ApoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
in	O	ADP	O
classic	O	ADJ	O
lecithin	O	NOUN	B
:	O	PUNCT	O
cholesterol	B-Disease	NOUN	B
acyltransferase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
fish	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Classic	B-Disease	PROPN	B
(	I-Disease	PUNCT	O
complete	I-Disease	ADJ	O
)	I-Disease	PUNCT	O
lecithin	I-Disease	NOUN	B
cholesterol	I-Disease	NOUN	I
acyltransferase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
LCAT	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
and	O	CCONJ	O
Fish	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
partial	B-Disease	ADJ	B
LCAT	I-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
)	O	PUNCT	O
are	O	AUX	O
genetic	O	ADJ	B
syndromes	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
markedly	O	ADV	O
decreased	O	VERB	B
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	O
)	O	PUNCT	O
cholesterol	O	NOUN	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
atherosclerotic	B-Disease	ADJ	B
cardiovascular	I-Disease	ADJ	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
metabolism	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HDL	O	NOUN	B
apolipoproteins	O	NOUN	I
(	O	PUNCT	I
apo	O	NOUN	B
)	O	PUNCT	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
and	O	CCONJ	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
in	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
five	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
LCAT	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
one	O	NUM	O
with	O	ADP	O
classic	B-Disease	ADJ	O
LCAT	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
four	O	NUM	O
with	O	ADP	O
Fish	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
were	O	AUX	O
decreased	O	VERB	B
to	O	PART	O
a	O	DET	O
proportionately	O	ADV	O
greater	O	ADJ	O
extent	O	NOUN	B
(	O	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
)	O	PUNCT	O
than	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
particles	O	NOUN	I
containing	O	VERB	O
both	O	CCONJ	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
and	O	CCONJ	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
(	O	PUNCT	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
A	O	PROPN	B
-	O	PUNCT	O
II	O	PROPN	B
)	O	PUNCT	O
were	O	AUX	O
much	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
)	O	PUNCT	O
than	O	ADP	O
those	O	DET	O
of	O	ADP	O
particles	O	NOUN	B
containing	O	VERB	O
only	O	ADV	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
(	O	PUNCT	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
)	O	PUNCT	O
(	O	PUNCT	O
51	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
metabolic	O	ADJ	B
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
low	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	NUM	B
and	O	CCONJ	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
A	O	PROPN	B
-	O	PUNCT	O
II	O	PROPN	B
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
all	O	DET	O
five	O	NUM	O
patients	O	NOUN	B
using	O	VERB	O
both	O	CCONJ	O
exogenous	O	ADJ	B
radiotracer	O	NOUN	O
and	O	CCONJ	O
endogenous	O	ADJ	B
stable	O	ADJ	B
isotope	O	NOUN	I
labeling	O	NOUN	I
techniques	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mean	O	ADJ	O
plasma	O	NOUN	B
residence	O	NOUN	B
time	O	NOUN	I
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B
was	O	AUX	O
decreased	O	VERB	B
at	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
d	O	NOUN	O
(	O	PUNCT	O
controls	O	NOUN	B
4	O	NUM	O
.	O	PUNCT	O
74	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
65	O	NUM	O
days	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
residence	O	NOUN	B
time	O	NOUN	I
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
was	O	AUX	O
even	O	ADV	O
shorter	O	ADJ	B
at	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


66	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


24	O	NUM	O
d	O	NOUN	O
(	O	PUNCT	O
controls	O	NOUN	B
5	O	NUM	O
.	O	PUNCT	O
25	O	NUM	O
+	O	CCONJ	O
/	O	SYM	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
61	O	NUM	O
d	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
catabolism	O	NOUN	B
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
in	O	ADP	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
A	O	PROPN	B
-	O	PUNCT	O
II	O	PROPN	B
was	O	AUX	O
substantially	O	ADV	O
faster	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
in	O	ADP	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
genetic	O	ADJ	B
syndromes	O	NOUN	I
of	O	ADP	O
either	O	CCONJ	O
complete	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
partial	I-Disease	ADJ	B
LCAT	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
result	O	VERB	O
in	O	ADP	O
low	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
through	O	ADP	O
preferential	O	ADJ	O
hypercatabolism	O	NOUN	B
of	O	ADP	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	NUM	B
and	O	CCONJ	O
HDL	O	NOUN	B
particles	O	NOUN	I
containing	O	VERB	O
apoA	O	NOUN	B
-	O	PUNCT	O
II	O	PROPN	B
.	O	PUNCT	O


Because	O	SCONJ	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B
has	O	AUX	O
been	O	AUX	O
proposed	O	VERB	O
to	O	PART	O
be	O	AUX	O
more	O	ADV	O
protective	O	ADJ	O
than	O	ADP	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
A	O	PROPN	B
-	O	PUNCT	O
II	O	PROPN	B
against	O	ADP	O
atherosclerosis	B-Disease	NOUN	B
,	O	PUNCT	O
this	O	DET	O
selective	O	ADJ	O
effect	O	NOUN	O
on	O	ADP	O
the	O	DET	O
metabolism	O	NOUN	B
of	O	ADP	O
LpA	O	NOUN	B
-	O	PUNCT	O
I	O	NOUN	B
A	O	PROPN	B
-	O	PUNCT	O
II	O	PROPN	B
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
explanation	O	NOUN	B
why	O	SCONJ	O
patients	O	NOUN	B
with	O	ADP	O
classic	B-Disease	ADJ	O
LCAT	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
and	O	CCONJ	O
Fish	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
are	O	AUX	O
not	O	PART	O
at	O	ADP	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
premature	O	ADJ	B
atherosclerosis	B-Disease	NOUN	I
despite	O	SCONJ	O
markedly	O	ADV	O
decreased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
HDL	O	NOUN	B
cholesterol	O	NOUN	I
and	O	CCONJ	O
apoA	O	NOUN	B
-	O	PUNCT	O
I	O	PRON	B


X	B-Disease	NOUN	B
linked	I-Disease	VERB	O
recessive	I-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
Saudi	O	ADJ	B
Arab	O	ADJ	B
boy	O	NOUN	B
presented	O	VERB	O
in	O	ADP	O
early	O	ADJ	B
childhood	O	NOUN	I
with	O	ADP	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
morphologically	O	ADV	B
large	O	ADJ	O
and	O	CCONJ	O
normal	O	ADJ	O
sized	O	ADJ	O
platelets	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
mean	O	ADJ	O
platelet	O	NOUN	O
volume	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
hypermegakaryocytic	O	ADJ	B
bone	O	NOUN	I
marrow	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
laboratory	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
any	O	DET	O
significant	O	ADJ	O
immunological	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Similar	O	ADJ	O
findings	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
other	O	ADJ	O
brothers	O	NOUN	B
suggested	O	VERB	O
strongly	O	ADV	O
that	O	SCONJ	O
they	O	PRON	O
were	O	AUX	O
all	O	DET	O
suffering	O	VERB	B
from	O	ADP	O
an	O	DET	O
X	B-Disease	NOUN	B
linked	I-Disease	VERB	O
recessive	I-Disease	ADJ	B
thrombocytopenic	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Results	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
with	O	ADP	O
the	O	DET	O
probe	O	NOUN	B
M27	O	NOUN	I
beta	O	NOUN	I
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
X	O	NOUN	B
linkage	O	NOUN	I
and	O	CCONJ	O
indicate	O	VERB	O
also	O	ADV	O
that	O	SCONJ	O
the	O	DET	O
locus	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relevant	O	ADJ	B
gene	O	NOUN	B
lies	O	VERB	O
close	O	ADV	O
to	O	PART	O
or	O	CCONJ	O
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
the	O	DET	O
locus	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
various	O	ADJ	O
features	O	NOUN	B
which	O	DET	O
include	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
large	O	ADJ	B
and	O	CCONJ	O
normal	O	ADJ	O
sized	O	ADJ	O
platelets	O	NOUN	B
(	O	PUNCT	O
rather	O	ADV	O
than	O	ADP	O
small	O	ADJ	B
platelets	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
freedom	O	NOUN	B
from	O	ADP	O
significant	O	ADJ	B
immune	B-Disease	ADJ	B
deficiencies	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
likely	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
X	B-Disease	NOUN	B
linked	I-Disease	VERB	O
recessive	I-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
is	O	AUX	O
an	O	DET	O
isolated	O	VERB	B
entity	O	NOUN	B
quite	O	ADV	O
distinct	O	ADJ	O
from	O	ADP	O
the	O	DET	O
classical	O	ADJ	O
WAS	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
modified	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
gene	O	NOUN	I
producing	O	VERB	O
a	O	DET	O
mild	O	ADJ	O
phenotypic	O	ADJ	B
variant	O	NOUN	O
cannot	O	PART	O
be	O	AUX	O
excluded	O	VERB	O
entirely	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


Macular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
mutations	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
172	O	NUM	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	O
slow	O	ADJ	O
gene	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
Recently	O	ADV	O
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
retinal	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	O
slow	O	NOUN	O
(	O	PUNCT	O
rds	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
which	O	DET	O
codes	O	VERB	B
for	O	ADP	O
peripherin	O	NOUN	B
-	O	PUNCT	O
rds	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
retinitis	I-Disease	NOUN	B
pigmentosa	I-Disease	NOUN	I
.	O	PUNCT	O


Because	O	SCONJ	O
this	O	DET	O
gene	O	NOUN	B
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
both	O	DET	O
rods	O	NOUN	B
and	O	CCONJ	O
cones	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rds	O	NOUN	B
gene	O	NOUN	I
might	O	AUX	O
be	O	AUX	O
expected	O	VERB	O
to	O	PART	O
cause	O	VERB	O
degeneration	O	NOUN	B
affecting	O	VERB	B
either	O	CCONJ	O
the	O	DET	O
scotopic	O	ADJ	B
or	O	CCONJ	O
photopic	O	ADJ	B
systems	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
172	O	NUM	I
of	O	ADP	O
the	O	DET	O
rds	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
three	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
autosomal	O	ADJ	B
dominantly	O	ADV	O
inherited	O	VERB	B
,	O	PUNCT	O
progressive	O	ADJ	B
macular	B-Disease	NOUN	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Affected	O	ADJ	B
individuals	O	NOUN	B
underwent	O	VERB	O
ophthalmic	O	ADJ	B
examination	O	NOUN	I
,	O	PUNCT	O
scotopic	O	ADJ	B
perimetry	O	NOUN	I
,	O	PUNCT	O
dark	O	ADJ	B
adaptometry	O	NOUN	I
,	O	PUNCT	O
measurement	O	NOUN	B
of	O	ADP	O
color	O	NOUN	B
-	O	PUNCT	O
contrast	O	NOUN	B
sensitivity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
electroretinography	O	NOUN	B
to	O	PART	O
characterize	O	VERB	O
the	O	DET	O
photoreceptor	O	NOUN	B
dysfunction	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
all	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
affected	O	VERB	B
member	O	NOUN	O
,	O	PUNCT	O
symptoms	O	NOUN	B
of	O	ADP	O
progressive	O	ADJ	B
central	O	ADJ	B
visual	B-Disease	ADJ	I
loss	I-Disease	NOUN	I
developed	O	VERB	O
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
or	O	CCONJ	O
fourth	O	ADJ	O
decade	O	NOUN	O
of	O	ADP	O
life	O	NOUN	B
accompanied	O	VERB	O
by	O	ADP	O
central	B-Disease	ADJ	B
scotoma	I-Disease	NOUN	I
and	O	CCONJ	O
well	O	ADV	B
-	O	PUNCT	O
demarcated	O	VERB	B
atrophy	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
retinal	I-Disease	ADJ	B
pigment	I-Disease	NOUN	B
epithelium	I-Disease	NOUN	I
and	O	CCONJ	O
choriocapillaris	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
macula	I-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
general	O	ADJ	O
,	O	PUNCT	O
cone	O	NOUN	B
and	O	CCONJ	O
rod	O	NOUN	B
thresholds	O	NOUN	I
were	O	AUX	O
elevated	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
color	O	NOUN	B
-	O	PUNCT	O
contrast	O	NOUN	B
sensitivity	O	NOUN	B
was	O	AUX	O
absent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
visual	O	ADJ	I
field	O	NOUN	I
.	O	PUNCT	O


Peripherally	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
scotopic	O	ADJ	B
sensitivities	O	NOUN	I
were	O	AUX	O
normal	O	ADJ	B
,	O	PUNCT	O
as	O	ADP	O
was	O	AUX	O
the	O	DET	O
recovery	O	NOUN	B
from	O	ADP	O
bleach	O	NOUN	B
.	O	PUNCT	O


Cone	O	NOUN	B
electroretinograms	O	NOUN	I
were	O	AUX	O
diminished	O	VERB	B
in	O	ADP	O
amplitude	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
delayed	O	VERB	B
in	O	ADP	O
all	O	DET	O
affected	O	VERB	B
adults	O	NOUN	B
except	O	SCONJ	O
one	O	NUM	O
.	O	PUNCT	O


Rod	O	NOUN	B
electroretinograms	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	B
or	O	CCONJ	O
near	O	ADP	B
normal	O	ADJ	B
in	O	ADP	O
amplitude	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
had	O	AUX	O
normal	O	ADJ	O
implicit	O	NOUN	B
times	O	NOUN	O
.	O	PUNCT	O


Affected	O	ADJ	B
asymptomatic	O	ADJ	B
children	O	NOUN	B
had	O	AUX	O
macular	O	ADJ	B
changes	O	NOUN	B
,	O	PUNCT	O
abnormal	O	ADJ	B
color	O	NOUN	B
-	O	PUNCT	O
contrast	O	NOUN	B
sensitivity	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
pattern	O	NOUN	B
and	O	CCONJ	O
cone	O	NOUN	B
electroretinograms	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rds	O	NOUN	B
gene	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
macular	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
evidence	O	NOUN	B
of	O	ADP	O
primary	O	ADJ	B
cone	B-Disease	NOUN	I
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
preservation	O	NOUN	B
of	O	ADP	O
peripheral	O	ADJ	B
rod	O	NOUN	I
function	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Anonymous	O	ADJ	B
marker	O	NOUN	I
loci	O	NOUN	O
within	O	ADP	O
400	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	O
generate	O	NOUN	O
haplotypes	O	NOUN	B
in	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
with	O	ADP	O
the	O	DET	O
hemochromatosis	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
HFE	O	NOUN	B
)	O	PUNCT	O


The	O	DET	O
hemochromatosis	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
HFE	O	NOUN	B
)	O	PUNCT	O
maps	O	NOUN	B
to	O	PART	O
6p21	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
and	O	CCONJ	O
is	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
1	O	NUM	O
cM	O	NOUN	O
from	O	ADP	O
the	O	DET	O
HLA	O	NOUN	B
class	O	NOUN	I
I	O	NUM	I
genes	O	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
precise	O	ADJ	O
physical	O	ADJ	B
location	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
has	O	AUX	O
remained	O	VERB	O
elusive	O	ADJ	O
and	O	CCONJ	O
controversial	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
unambiguous	O	ADJ	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
crossover	O	NOUN	B
event	O	NOUN	I
within	O	ADP	O
hemochromatosis	B-Disease	NOUN	B
families	O	NOUN	B
is	O	AUX	O
very	O	ADV	O
difficult	O	ADJ	O
;	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
particularly	O	ADV	O
hampered	O	VERB	O
by	O	ADP	O
the	O	DET	O
variability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
by	O	ADP	O
the	O	DET	O
sex	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
age	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
penetrance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
these	O	DET	O
practical	O	ADJ	O
considerations	O	NOUN	B
,	O	PUNCT	O
traditional	O	ADJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
could	O	AUX	O
prove	O	VERB	O
of	O	ADP	O
limited	O	ADJ	B
value	O	NOUN	I
in	O	ADP	O
further	O	ADV	O
refining	O	VERB	B
the	O	DET	O
extrapolated	O	VERB	O
physical	O	ADJ	B
position	O	NOUN	I
of	O	ADP	O
HFE	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
embarked	O	VERB	O
upon	O	SCONJ	O
a	O	DET	O
linkage	O	NOUN	B
-	O	PUNCT	O
disequilibrium	O	NOUN	B
analysis	O	NOUN	O
of	O	ADP	O
HFE	O	NOUN	B
and	O	CCONJ	O
normal	O	ADJ	B
chromosomes	O	NOUN	I
from	O	ADP	O
the	O	DET	O
Brittany	O	NOUN	B
population	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
report	O	NOUN	B
,	O	PUNCT	O
66	O	NUM	O
hemochromatosis	B-Disease	NOUN	B
families	O	NOUN	B
yielding	O	VERB	O
151	O	NUM	O
hemochromatosis	B-Disease	NOUN	B
chromosomes	O	NOUN	I
and	O	CCONJ	O
182	O	NUM	O
normal	O	ADJ	B
chromosomes	O	NOUN	I
were	O	AUX	O
RFLP	O	NOUN	B
-	O	PUNCT	O
typed	O	VERB	B
with	O	ADP	O
a	O	DET	O
battery	O	NOUN	B
of	O	ADP	I
probes	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
two	O	NUM	O
newly	O	ADV	O
derived	O	VERB	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
from	O	ADP	O
the	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
F	O	PROPN	B
loci	O	NOUN	B
located	O	ADJ	O
150	O	NUM	O
and	O	CCONJ	O
250	O	NUM	O
kb	O	NOUN	O
telomeric	O	ADJ	O
to	O	PART	O
HLA	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
peak	O	NOUN	O
of	O	ADP	O
existing	O	VERB	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	B
focused	O	VERB	O
within	O	ADP	O
the	O	DET	O
i82	O	PROPN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
interval	O	NOUN	B
(	O	PUNCT	O
approximately	O	ADV	O
250	O	NUM	O
kb	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
zone	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
is	O	AUX	O
flanked	O	VERB	B
by	O	ADP	O
the	O	DET	O
i97	O	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
positioned	O	VERB	O
30	O	NUM	O
kb	O	NOUN	O
proximal	O	ADJ	B
to	O	ADP	O
i82	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
HLA	O	NOUN	B
-	O	PUNCT	O
F	O	PROPN	B
gene	O	NOUN	B
,	O	PUNCT	O
found	O	VERB	O
250	O	NUM	O
kb	O	NOUN	O
distal	O	ADJ	B
to	O	PART	O
HLA	O	NOUN	B
-	O	PUNCT	O
A	O	PROPN	B
,	O	PUNCT	O
markers	O	NOUN	B
of	O	ADP	O
which	O	DET	O
display	O	VERB	O
no	O	DET	O
significant	O	ADJ	O
association	O	NOUN	B
with	O	ADP	O
HFE	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
HFE	O	NOUN	B
resides	O	VERB	B
within	O	ADP	O
the	O	DET	O
400	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
expanse	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
between	O	ADP	O
i97	O	NOUN	B
and	O	CCONJ	O
HLA	O	NOUN	B
-	O	PUNCT	O
F	O	PROPN	B
.	O	PUNCT	O


Alternatively	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
very	O	ADV	O
tight	O	ADJ	O
association	O	NOUN	B
of	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
A3	O	NOUN	B
and	O	CCONJ	O
allele	O	NOUN	B
1	O	NUM	I
of	O	ADP	O
the	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
locus	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
comprised	O	VERB	O
by	O	ADP	O
the	O	DET	O
major	O	ADJ	O
ancestral	O	ADJ	B
or	O	CCONJ	O
founder	O	NOUN	B
HFE	O	NOUN	B
haplotype	O	NOUN	B
in	O	ADP	O
Brittany	O	NOUN	B
,	O	PUNCT	O
supports	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
disease	O	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
reside	O	VERB	O
immediately	O	ADV	O
telomeric	O	ADJ	B
to	O	PART	O
the	O	DET	O
6	O	NUM	O
.	O	PUNCT	O


7	O	NUM	O
locus	O	NOUN	B
within	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
-	O	PUNCT	O
disequilibrium	O	NOUN	B
zone	O	NOUN	O
.	O	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
hemochromatosis	B-Disease	NOUN	B
haplotypes	O	NOUN	B
possessing	O	VERB	O
HLA	O	NOUN	B
-	O	PUNCT	O
A11	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
low	O	ADJ	B
-	O	PUNCT	O
frequency	O	NOUN	B
HLA	O	NOUN	B
-	O	PUNCT	O
F	O	NOUN	B
polymorphism	O	NOUN	B
(	O	PUNCT	O
allele	O	NOUN	B
2	O	NUM	I
)	O	PUNCT	O
are	O	AUX	O
supportive	O	ADJ	B
of	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
founder	O	NOUN	B
chromosome	O	NOUN	O
containing	O	VERB	O
a	O	DET	O
second	O	NOUN	O
,	O	PUNCT	O
independently	O	ADV	O
arising	O	VERB	O
mutant	O	ADJ	B
allele	O	NOUN	O
.	O	PUNCT	O


Overall	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
establishment	O	NOUN	O
of	O	ADP	O
a	O	DET	O
likely	O	ADJ	O
"	O	PUNCT	O
hemochromatosis	B-Disease	NOUN	B
critical	O	ADJ	B
region	O	NOUN	I
"	O	PUNCT	O
centromeric	O	ADJ	B
boundary	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
linkage	O	NOUN	B
-	O	PUNCT	O
disequilibrium	O	NOUN	B
zone	O	NOUN	B
both	O	CCONJ	O
significantly	O	ADV	O
contribute	O	VERB	O
to	O	PART	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
required	O	VERB	O
to	O	PART	O
be	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
novel	O	ADJ	B
coding	O	NOUN	B
sequences	O	NOUN	I
constituting	O	VERB	O
the	O	DET	O
HFE	B-Disease	NOUN	B
defect	I-Disease	NOUN	B


Genomic	O	ADJ	B
structure	O	NOUN	I
of	O	ADP	O
the	O	DET	O
EWS	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
relationship	O	NOUN	B
to	O	PART	O
EWSR1	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
site	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
chromosome	O	NOUN	O
translocation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
EWS	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
based	O	VERB	O
on	O	ADP	O
its	O	PRON	O
location	O	NOUN	B
at	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
22	O	NUM	I
breakpoint	O	NOUN	I
of	O	ADP	O
the	O	DET	O
t	O	NOUN	O
(	O	PUNCT	O
11	O	NUM	O
;	O	PUNCT	O
22	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q24	O	NOUN	B
;	O	PUNCT	O
q12	O	NOUN	O
)	O	PUNCT	O
translocation	O	NOUN	B
that	O	PRON	O
characterizes	O	VERB	O
Ewing	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
and	O	CCONJ	O
related	O	ADJ	O
neuroectodermal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
EWS	O	NOUN	B
gene	O	NOUN	O
spans	O	VERB	O
about	O	ADV	O
40	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
DNA	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
encoded	O	VERB	B
by	O	ADP	O
17	O	NUM	O
exons	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
exons	O	NOUN	B
is	O	AUX	O
identical	O	ADJ	B
to	O	PART	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
previously	O	ADV	O
described	O	VERB	O
cDNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
7	O	NUM	O
exons	O	NOUN	B
encode	O	VERB	B
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	B
of	O	ADP	O
EWS	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
consists	O	VERB	O
of	O	ADP	O
a	O	DET	O
repeated	O	VERB	O
degenerated	O	ADJ	O
polypeptide	O	NOUN	B
of	O	ADP	O
7	O	NUM	O
to	O	PART	O
12	O	NUM	O
residues	O	NOUN	B
rich	O	ADJ	O
in	O	ADP	O
tyrosine	O	NOUN	B
,	O	PUNCT	O
serine	O	NOUN	B
,	O	PUNCT	O
threonine	O	NOUN	B
,	O	PUNCT	O
glycine	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
glutamine	O	NOUN	B
.	O	PUNCT	O


Exons	O	NOUN	B
11	O	NUM	O
,	O	PUNCT	O
12	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
13	O	NUM	O
encode	O	VERB	B
the	O	DET	O
putative	O	ADJ	O
RNA	O	NOUN	B
binding	O	NOUN	I
domain	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
three	O	NUM	O
glycine	O	NOUN	B
-	O	PUNCT	O
and	O	CCONJ	O
arginine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
motifs	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
are	O	AUX	O
mainly	O	ADV	O
encoded	O	VERB	B
by	O	ADP	O
exons	O	NOUN	B
8	O	NUM	O
-	O	SYM	O
9	O	NUM	B
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
16	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
DNA	O	NOUN	B
sequence	O	NOUN	I
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
has	O	AUX	O
features	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CpG	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
island	O	NOUN	I
and	O	CCONJ	O
lacks	O	VERB	B
canonical	O	ADJ	O
promoter	O	NOUN	O
elements	O	NOUN	O
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
TATA	O	NOUN	B
and	O	CCONJ	O
CCAAT	O	NOUN	B
consensus	O	NOUN	O
sequences	O	NOUN	O
.	O	PUNCT	O


Positions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
22	O	NUM	I
breakpoints	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
for	O	ADP	O
19	O	NUM	O
Ewing	B-Disease	NOUN	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


They	O	PRON	O
were	O	AUX	O
localized	O	ADJ	B
in	O	ADP	O
introns	O	NOUN	B
7	O	NUM	O
or	O	CCONJ	O
8	O	NUM	O
in	O	ADP	O
18	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
intron	O	NOUN	B
10	O	NUM	O
in	O	ADP	O
1	O	NUM	O
case	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Norrie	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
gene	O	NOUN	I
:	O	PUNCT	O
characterization	O	NOUN	B
of	O	ADP	O
deletions	O	NOUN	B
and	O	CCONJ	O
possible	O	ADJ	O
function	O	NOUN	B
.	O	PUNCT	O


Positional	O	ADJ	B
cloning	O	NOUN	I
experiments	O	NOUN	B
have	O	AUX	O
resulted	O	VERB	O
recently	O	ADV	O
in	O	ADP	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
pseudoglioma	B-Disease	NOUN	B
;	O	PUNCT	O
NDP	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
severe	O	ADJ	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
neurodevelopmental	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
isolation	O	NOUN	B
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
genomic	O	ADJ	B
DNA	O	NOUN	I
clones	O	NOUN	I
encompassing	O	VERB	O
the	O	DET	O
NDP	B-Disease	NOUN	B
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
spans	O	VERB	O
28	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
consists	O	VERB	O
of	O	ADP	O
3	O	NUM	O
exons	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
first	O	ADJ	O
of	O	ADP	O
which	O	DET	O
is	O	AUX	O
entirely	O	ADV	O
contained	O	VERB	O
within	O	ADP	O
the	O	DET	O
5	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


Detailed	O	ADJ	O
analysis	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
deletions	O	NOUN	I
in	O	ADP	O
Norrie	B-Disease	NOUN	B
patients	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
they	O	PRON	O
are	O	AUX	O
heterogeneous	O	ADJ	B
,	O	PUNCT	O
both	O	CCONJ	O
in	O	ADP	O
size	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
position	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
PCR	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
NDP	B-Disease	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
not	O	PART	O
confined	O	VERB	O
to	O	ADP	O
the	O	DET	O
eye	O	NOUN	B
or	O	CCONJ	O
to	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
extensive	O	ADJ	B
DNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
sequence	O	NOUN	I
comparison	O	NOUN	B
between	O	ADP	O
the	O	DET	O
human	O	ADJ	B
NDP	B-Disease	NOUN	B
gene	O	NOUN	O
and	O	CCONJ	O
related	O	ADJ	O
genes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
database	O	NOUN	B
revealed	O	VERB	O
homology	O	NOUN	B
with	O	ADP	O
cysteine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
protein	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domains	O	NOUN	O
of	O	ADP	O
immediate	O	ADJ	B
-	O	PUNCT	O
-	O	PUNCT	O
early	O	ADJ	B
genes	O	NOUN	B
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
cell	O	NOUN	B
proliferation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
NDP	O	NOUN	B
is	O	AUX	O
a	O	DET	O
molecule	O	NOUN	B
related	O	ADJ	O
in	O	ADP	O
function	O	NOUN	B
to	O	PART	O
these	O	DET	O
genes	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
a	O	DET	O
pathway	O	NOUN	B
that	O	PRON	O
regulates	O	VERB	B
neural	O	ADJ	B
cell	O	NOUN	I
differentiation	O	NOUN	I
and	O	CCONJ	O
proliferation	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
normal	O	ADJ	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
allele	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
gene	O	NOUN	B
,	O	PUNCT	O
influences	O	VERB	B
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
influenced	O	VERB	B
by	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
HD	B-Disease	NOUN	B
allele	O	NOUN	B
by	O	ADP	O
comparing	O	VERB	O
transmission	O	NOUN	B
patterns	O	NOUN	O
of	O	ADP	O
genetically	O	ADV	B
linked	O	VERB	O
markers	O	NOUN	B
at	O	ADP	O
the	O	DET	O
D4S10	O	NOUN	B
locus	O	NOUN	I
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
parent	O	NOUN	I
against	O	ADP	O
age	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
in	O	ADP	O
the	O	DET	O
affected	O	VERB	B
offspring	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
information	O	NOUN	B
from	O	ADP	O
21	O	NUM	O
sibships	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
kindreds	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
tendency	O	NOUN	O
for	O	ADP	O
sibs	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
similar	O	ADJ	O
onset	O	NOUN	O
ages	O	NOUN	B
to	O	PART	O
share	O	VERB	O
the	O	DET	O
same	O	ADJ	O
D4S10	O	NOUN	B
allele	O	NOUN	I
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
parent	O	NOUN	I
.	O	PUNCT	O


Affected	O	ADJ	B
sibs	O	NOUN	I
who	O	PRON	O
inherited	O	VERB	B
different	O	ADJ	O
D4S10	O	NOUN	B
alleles	O	NOUN	I
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
parent	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
have	O	AUX	O
more	O	ADV	O
variable	O	ADJ	B
ages	O	NOUN	B
at	O	ADP	O
onset	O	NOUN	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
is	O	AUX	O
modulated	O	VERB	B
by	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
HD	B-Disease	NOUN	B
allele	O	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
locus	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Further	O	ADJ	O
investigation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
intron	O	NOUN	I
9	O	NUM	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
mutation	O	NOUN	B
frequently	O	ADV	O
found	O	VERB	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	PROPN	B
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
from	O	ADP	O
the	O	DET	O
British	O	ADJ	B
Isles	O	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
previous	O	ADJ	O
study	O	NOUN	B
we	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
Tay	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Sachs	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
TSD	B-Disease	NOUN	B
)	O	PUNCT	O
causing	O	VERB	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
9	O	NUM	O
donor	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
the	O	DET	O
HEXA	O	NOUN	B
gene	O	NOUN	I
occurs	O	VERB	O
at	O	ADP	O
high	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
patients	O	NOUN	B
and	O	CCONJ	O
carriers	O	NOUN	B
from	O	ADP	O
the	O	DET	O
British	O	ADJ	B
Isles	O	PROPN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
subjects	O	NOUN	B
of	O	ADP	O
Irish	O	PROPN	B
,	O	PUNCT	O
Scottish	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
Welsh	O	NOUN	B
origin	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
English	O	ADJ	B
origin	O	NOUN	I
(	O	PUNCT	O
63	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
31	O	NUM	O
%	O	NOUN	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
now	O	ADV	O
tested	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
blind	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
26	O	NUM	O
American	O	ADJ	B
TSD	B-Disease	NOUN	B
carriers	O	NOUN	B
and	O	CCONJ	O
28	O	NUM	O
non	O	ADJ	B
-	O	PUNCT	O
carriers	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
British	O	ADJ	B
ancestry	O	NOUN	B
for	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
9	O	NUM	O
splice	O	NOUN	B
site	O	NOUN	I
mutation	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
of	O	ADP	O
the	O	DET	O
carriers	O	NOUN	B
and	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
for	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
six	O	NUM	O
had	O	AUX	O
Irish	O	ADJ	B
ancestry	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
nine	O	NUM	O
of	O	ADP	O
the	O	DET	O
20	O	NUM	O
other	O	ADJ	O
(	O	PUNCT	O
intron	O	NOUN	B
9	O	NUM	O
mutation	O	NOUN	B
negative	O	ADJ	I
)	O	PUNCT	O
TSD	B-Disease	NOUN	B
carriers	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	O
confirm	O	VERB	O
the	O	DET	O
previously	O	ADV	O
found	O	VERB	O
high	O	ADJ	O
frequency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
9	O	NUM	O
mutation	O	NOUN	B
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
TSD	B-Disease	NOUN	B
families	O	NOUN	B
of	O	ADP	O
British	O	ADJ	B
Isles	O	PROPN	B
,	O	PUNCT	O
particularly	O	ADV	O
Irish	O	ADJ	B
,	O	PUNCT	O
origin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
reinforce	O	VERB	O
the	O	DET	O
need	O	NOUN	O
to	O	PART	O
screen	O	VERB	B
such	O	ADJ	O
families	O	NOUN	B
for	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
.	O	PUNCT	O


Molecular	O	ADJ	B
mechanisms	O	NOUN	I
of	O	ADP	O
oncogenic	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
tumors	B-Disease	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
bilateral	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
unilateral	I-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
12	O	NUM	O
human	O	ADJ	B
retinoblastoma	B-Disease	NOUN	I
tumors	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
analyzed	O	VERB	B
exon	O	NOUN	B
-	O	PUNCT	O
by	O	ADP	B
-	O	PUNCT	O
exon	O	NOUN	B
with	O	ADP	O
the	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	O
technique	O	NOUN	O
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
all	O	DET	O
tumors	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
-	O	PUNCT	O
third	O	NOUN	O
of	O	ADP	O
the	O	DET	O
tumors	B-Disease	NOUN	B
had	O	AUX	O
independent	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
both	O	DET	O
alleles	O	NOUN	B
neither	O	DET	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
germ	O	NOUN	B
line	O	NOUN	I
,	O	PUNCT	O
confirming	O	VERB	O
their	O	PRON	O
true	O	ADJ	O
sporadic	O	ADJ	B
nature	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
two	O	NUM	O
-	O	PUNCT	O
thirds	O	NOUN	B
of	O	ADP	O
the	O	DET	O
tumors	B-Disease	NOUN	B
only	O	ADV	O
one	O	NUM	O
mutation	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
loss	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
heterozygosity	O	NOUN	B
theory	O	NOUN	B
of	O	ADP	O
tumorigenesis	O	NOUN	B
.	O	PUNCT	O


Point	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transitions	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
abnormality	O	NOUN	B
and	O	CCONJ	O
usually	O	ADV	O
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
conversion	O	NOUN	B
of	O	ADP	O
an	O	DET	O
arginine	O	NOUN	B
codon	O	NOUN	B
to	O	PART	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
.	O	PUNCT	O


Small	O	ADJ	B
deletions	O	NOUN	B
were	O	AUX	O
the	O	DET	O
second	O	ADV	O
most	O	ADV	O
common	O	ADJ	O
abnormality	O	NOUN	B
and	O	CCONJ	O
most	O	ADV	O
often	O	ADV	O
created	O	VERB	O
a	O	DET	O
downstream	O	ADJ	B
stop	O	NOUN	O
codon	O	NOUN	B
as	O	ADP	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
a	O	DET	O
reading	O	NOUN	B
frameshift	O	NOUN	I
.	O	PUNCT	O


Deletions	O	NOUN	B
and	O	CCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
also	O	ADV	O
affected	O	VERB	O
splice	O	NOUN	B
junctions	O	NOUN	I
.	O	PUNCT	O


Direct	O	ADJ	B
repeats	O	NOUN	I
were	O	AUX	O
present	O	ADJ	O
at	O	ADP	O
the	O	DET	O
breakpoint	O	NOUN	B
junctions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
deletions	O	NOUN	B
,	O	PUNCT	O
supporting	O	VERB	O
a	O	DET	O
slipped	O	ADJ	B
-	O	PUNCT	O
mispairing	O	VERB	B
mechanism	O	NOUN	B
.	O	PUNCT	O


Point	O	NOUN	B
mutations	O	NOUN	I
generally	O	ADV	O
produced	O	VERB	O
DNA	O	NOUN	B
sequences	O	NOUN	I
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
perfect	O	ADJ	O
homology	O	NOUN	B
with	O	ADP	O
endogenous	O	ADJ	B
sequences	O	NOUN	B
which	O	DET	O
lay	O	VERB	O
within	O	ADP	O
14	O	NUM	O
bp	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


PAX6	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
aniridia	B-Disease	NOUN	B
.	O	PUNCT	O


Aniridia	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
congenital	B-Disease	ADJ	B
malformation	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
eye	I-Disease	NOUN	B
,	O	PUNCT	O
chiefly	O	ADV	O
characterised	O	VERB	B
by	O	ADP	O
iris	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
can	O	AUX	O
cause	O	VERB	O
blindness	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
PAX6	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
isolated	O	VERB	B
as	O	ADP	O
a	O	DET	O
candidate	O	NOUN	O
aniridia	B-Disease	NOUN	B
gene	O	NOUN	I
by	O	ADP	O
positional	O	ADJ	B
cloning	O	NOUN	I
from	O	ADP	O
the	O	DET	O
smallest	O	ADJ	O
region	O	NOUN	O
of	O	ADP	O
overlap	O	NOUN	B
of	O	ADP	O
aniridia	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
deletions	O	NOUN	B
.	O	PUNCT	O


Subsequently	O	ADV	O
PAX6	O	NOUN	B
intragenic	O	ADJ	B
mutations	O	NOUN	I
were	O	AUX	O
demonstrated	O	VERB	O
in	O	ADP	O
Smalleye	O	PROPN	B
,	O	PUNCT	O
a	O	DET	O
mouse	O	NOUN	B
mutant	O	NOUN	I
which	O	DET	O
is	O	AUX	O
an	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
six	O	NUM	O
human	O	ADJ	B
aniridia	B-Disease	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
paper	O	NOUN	O
we	O	PRON	O
describe	O	VERB	O
four	O	NUM	O
additional	O	ADJ	O
PAX6	O	NOUN	B
point	O	NOUN	O
mutations	O	NOUN	O
in	O	ADP	O
aniridia	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
sporadic	O	ADJ	B
and	O	CCONJ	O
familial	O	ADJ	B
.	O	PUNCT	O


These	O	DET	O
mutations	O	NOUN	B
highlight	O	VERB	O
regions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
which	O	DET	O
are	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	O
PAX6	O	NOUN	B
function	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
frequency	O	NOUN	B
at	O	ADP	O
which	O	DET	O
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
PAX6	O	NOUN	B
mutations	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
lesions	O	NOUN	B
in	O	ADP	O
PAX6	O	NOUN	B
will	O	AUX	O
account	O	VERB	O
for	O	ADP	O
most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
aniridia	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
arginine	O	NOUN	B
vasopressin	O	NOUN	I
defect	O	NOUN	I
by	O	ADP	O
dideoxy	O	ADJ	B
fingerprinting	O	NOUN	I
.	O	PUNCT	O


Autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	B
neurohypophyseal	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
familial	O	ADJ	B
form	O	NOUN	I
of	O	ADP	O
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
disorder	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
variable	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
arginine	O	NOUN	B
vasopressin	O	NOUN	I
(	O	PUNCT	I
AVP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I
of	O	ADP	O
varying	O	VERB	O
severity	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
responds	O	VERB	O
to	O	PART	O
exogenous	O	ADJ	B
AVP	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
neurohypophyseal	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	I
insipidus	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
AVP	O	NOUN	B
genes	O	NOUN	B
of	O	ADP	O
members	O	NOUN	B
of	O	ADP	O
a	O	DET	O
large	O	ADJ	O
kindred	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
method	O	NOUN	B
,	O	PUNCT	O
called	O	VERB	O
dideoxy	O	ADJ	B
fingerprinting	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
detect	O	VERB	B
an	O	DET	O
AVP	O	NOUN	B
mutation	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
novel	O	ADJ	O
defect	O	NOUN	B
found	O	VERB	O
changes	O	NOUN	B
the	O	DET	O
last	O	ADJ	O
codon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
AVP	O	NOUN	B
signal	O	NOUN	B
peptide	O	NOUN	I
from	O	ADP	O
alanine	O	NOUN	B
to	O	PART	O
threonine	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
should	O	AUX	O
perturb	O	VERB	B
cleavage	O	NOUN	B
of	O	ADP	O
mature	O	ADJ	B
AVP	O	NOUN	B
from	O	ADP	O
its	O	PRON	O
precursor	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
inhibit	O	VERB	B
its	O	PRON	O
secretion	O	NOUN	B
or	O	CCONJ	O
action	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Germinal	O	ADJ	B
mosaicism	O	NOUN	I
in	O	ADP	O
a	O	DET	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
family	O	NOUN	I
:	O	PUNCT	O
implications	O	NOUN	O
for	O	ADP	O
genetic	O	ADJ	B
counselling	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
describe	O	VERB	O
a	O	DET	O
three	O	NUM	B
-	O	PUNCT	O
generation	O	NOUN	B
family	O	NOUN	B
in	O	ADP	O
which	O	DET	O
two	O	NUM	O
siblings	O	NOUN	B
were	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
Duchenne	B-Disease	ADJ	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
muscle	O	NOUN	B
dystrophin	O	NOUN	I
and	O	CCONJ	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
locus	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
carrying	O	VERB	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
transmitted	O	VERB	B
from	O	ADP	O
the	O	DET	O
healthy	O	ADJ	B
maternal	O	ADJ	B
grandfather	O	NOUN	I
to	O	ADP	O
his	O	PRON	O
three	O	NUM	O
daughters	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
probands	O	NOUN	B
mother	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
grandfather	O	NOUN	B
was	O	AUX	O
a	O	DET	O
germinal	O	ADJ	B
mosaic	O	ADJ	I
for	O	ADP	O
the	O	DET	O
DMD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
definition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
carrier	O	NOUN	B
status	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
possible	O	ADJ	O
carriers	O	NOUN	B
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
give	O	VERB	O
accurate	O	ADJ	B
genetic	O	ADJ	B
counselling	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
prevent	O	VERB	B
the	O	DET	O
birth	O	NOUN	B
of	O	ADP	O
an	O	DET	O
affected	O	VERB	B
boy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
demonstrate	O	VERB	O
the	O	DET	O
usefulness	O	NOUN	B
of	O	ADP	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
and	O	CCONJ	O
immunohistochemical	O	ADJ	B
muscle	O	NOUN	I
dystrophin	O	NOUN	B
studies	O	NOUN	I
to	O	PART	O
detect	O	VERB	B
hidden	O	VERB	B
germinal	O	ADJ	I
mosaicism	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
improve	O	VERB	B
genetic	O	ADJ	B
counselling	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
mapping	O	NOUN	I
of	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	O
to	O	PART	O
a	O	DET	O
small	O	ADJ	B
interval	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
17q12	O	NOUN	I
-	O	PUNCT	O
21	O	NUM	O
:	O	PUNCT	O
exclusion	O	NOUN	B
of	O	ADP	O
candidate	O	NOUN	O
genes	O	NOUN	O
EDH17B2	O	NOUN	B
and	O	CCONJ	O
RARA	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
susceptibility	O	NOUN	B
gene	O	NOUN	I
for	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
assigned	O	VERB	O
by	O	ADP	O
linkage	O	NOUN	B
analysis	O	NOUN	I
to	O	PART	O
chromosome	O	NOUN	B
17q21	O	NOUN	I
.	O	PUNCT	O


Candidate	O	NOUN	B
genes	O	NOUN	I
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B
include	O	VERB	O
EDH17B2	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
encodes	O	VERB	B
estradiol	O	NOUN	B
17	O	NUM	O
beta	O	NOUN	B
-	O	PUNCT	O
hydroxysteroid	O	NOUN	B
dehydrogenase	O	NOUN	I
II	O	NUM	I
(	O	PUNCT	O
17	O	NUM	O
beta	O	NOUN	B
-	O	PUNCT	O
HSD	O	PROPN	B
II	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
RARA	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
retinoic	O	ADJ	B
acid	O	NOUN	I
receptor	O	NOUN	I
alpha	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
typed	O	VERB	B
22	O	NUM	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
breast	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
with	O	ADP	O
eight	O	NUM	O
polymorphisms	O	NOUN	B
from	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
17q12	O	NOUN	I
-	O	PUNCT	I
21	O	NUM	I
region	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
two	O	NUM	O
in	O	ADP	O
the	O	DET	O
EDH17B2	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
recombination	O	NOUN	I
with	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
trait	O	NOUN	B
excludes	O	VERB	O
RARA	O	NOUN	B
from	O	ADP	O
further	O	ADJ	O
consideration	O	NOUN	O
as	O	ADP	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
EDH17B2	O	NOUN	B
map	O	NOUN	O
to	O	PART	O
a	O	DET	O
6	O	NUM	O
cM	O	NOUN	B
interval	O	NOUN	I
(	O	PUNCT	O
between	O	ADP	O
THRA1	O	NOUN	B
and	O	CCONJ	O
D17S579	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
recombination	O	NOUN	O
was	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
genes	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
direct	O	ADJ	O
sequencing	O	NOUN	O
of	O	ADP	O
overlapping	O	VERB	O
PCR	O	NOUN	B
products	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
entire	O	ADJ	O
EDH17B2	O	NOUN	B
gene	O	NOUN	O
in	O	ADP	O
four	O	NUM	O
unrelated	O	ADJ	O
affected	O	VERB	B
women	O	NOUN	B
did	O	AUX	O
not	O	PART	O
uncover	O	VERB	O
any	O	DET	O
sequence	O	NOUN	B
variation	O	NOUN	B
,	O	PUNCT	O
other	O	ADJ	O
than	O	ADP	O
previously	O	ADV	O
described	O	VERB	O
polymorphisms	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
EDH17B2	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
therefore	O	ADV	O
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	O
.	O	PUNCT	O


Single	O	ADJ	O
meiotic	O	ADJ	B
crossovers	O	NOUN	O
in	O	ADP	O
affected	O	VERB	O
women	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
is	O	AUX	O
flanked	O	VERB	B
by	O	ADP	O
the	O	DET	O
loci	O	NOUN	B
RARA	O	NOUN	B
and	O	CCONJ	O
D17S78	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
gene	O	NOUN	I
with	O	ADP	O
possible	O	ADJ	O
dominant	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
high	O	ADJ	O
density	O	NOUN	O
lipoproteins	O	NOUN	O
.	O	PUNCT	O


Plasma	O	NOUN	B
HDL	O	NOUN	B
are	O	AUX	O
a	O	DET	O
negative	O	ADJ	B
risk	O	NOUN	O
factor	O	NOUN	O
for	O	ADP	O
atherosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


Cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
CETP	O	NOUN	B
;	O	PUNCT	O
476	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
)	O	PUNCT	O
transfers	O	NOUN	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
from	O	ADP	O
HDL	O	NOUN	B
to	O	PART	O
other	O	ADJ	O
lipoproteins	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
with	O	ADP	O
homozygous	O	ADJ	B
CETP	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
splicing	O	NOUN	I
defect	O	NOUN	I
have	O	AUX	O
markedly	O	ADV	O
elevated	O	ADJ	B
HDL	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
heterozygotes	O	NOUN	B
have	O	AUX	O
only	O	ADV	O
mild	O	ADJ	B
increases	O	NOUN	B
in	O	ADP	O
HDL	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
two	O	NUM	O
probands	O	NOUN	B
with	O	ADP	O
a	O	DET	O
CETP	O	NOUN	B
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
442	O	NUM	O
D	O	NOUN	B
G	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
heterozygous	O	ADJ	B
,	O	PUNCT	O
they	O	PRON	O
have	O	AUX	O
threefold	O	ADV	O
increases	O	NOUN	B
in	O	ADP	O
HDL	O	NOUN	B
concentration	O	NOUN	B
and	O	CCONJ	O
markedly	O	ADV	O
decreased	O	VERB	B
plasma	O	NOUN	B
CETP	O	NOUN	B
mass	O	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
dominant	O	ADJ	B
effects	O	NOUN	B
on	O	ADP	O
CETP	O	NOUN	B
and	O	CCONJ	O
HDL	O	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


Cellular	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
mutant	O	ADJ	B
cDNA	O	NOUN	B
results	O	NOUN	O
in	O	ADP	O
secretion	O	NOUN	B
of	O	ADP	O
only	O	ADV	O
30	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
wild	O	ADJ	B
type	O	NOUN	I
CETP	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
coexpression	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
type	O	NOUN	I
and	O	CCONJ	O
mutant	O	ADJ	B
cDNAs	O	NOUN	I
leads	O	VERB	O
to	O	PART	O
inhibition	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
type	O	NOUN	I
secretion	O	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
dominant	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CETP	O	NOUN	B
missense	O	NOUN	B
mutation	O	NOUN	I
during	O	ADP	O
cellular	O	ADJ	B
expression	O	NOUN	I
probably	O	ADV	O
explains	O	VERB	O
why	O	SCONJ	O
the	O	DET	O
probands	O	NOUN	B
have	O	AUX	O
markedly	O	ADV	O
increased	O	VERB	B
HDL	O	NOUN	B
in	O	ADP	O
the	O	DET	O
heterozygous	O	ADJ	B
state	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
active	O	ADJ	B
molecular	O	ADJ	B
species	O	NOUN	I
of	O	ADP	O
CETP	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
multimeric	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
colchicine	O	NOUN	B
era	O	NOUN	B
:	O	PUNCT	O
the	O	DET	O
fate	O	NOUN	O
of	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
demonstrate	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prophylactic	O	ADJ	B
colchicine	O	NOUN	I
treatment	O	NOUN	B
on	O	ADP	O
the	O	DET	O
natural	O	ADJ	B
history	O	NOUN	I
of	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
family	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
with	O	ADP	O
6	O	NUM	O
out	O	ADP	O
of	O	ADP	O
9	O	NUM	O
siblings	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
FMF	B-Disease	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
represents	O	VERB	O
a	O	DET	O
different	O	ADJ	O
stage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
amyloidotic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
of	O	ADP	O
FMF	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
continuous	O	ADJ	B
colchicine	O	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
its	O	PRON	O
course	O	NOUN	B
.	O	PUNCT	O


Considered	O	VERB	B
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
members	O	NOUN	B
of	O	ADP	O
this	O	DET	O
family	O	NOUN	B
present	O	VERB	O
an	O	DET	O
almost	O	ADV	O
complete	O	ADJ	O
clinical	O	ADJ	B
,	O	PUNCT	O
genetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
behavioral	O	ADJ	B
picture	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
submicroscopic	O	ADJ	B
Norrie	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
deletion	O	NOUN	B
interval	O	NOUN	I
with	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
DNA	O	NOUN	B
probe	O	NOUN	I
isolated	O	VERB	B
by	O	ADP	O
differential	O	ADJ	O
Alu	O	NOUN	B
PCR	O	NOUN	I
fingerprint	O	NOUN	O
cloning	O	NOUN	O
.	O	PUNCT	O


Differential	O	ADJ	B
Alu	O	NOUN	B
PCR	O	NOUN	I
fingerprint	O	NOUN	O
cloning	O	NOUN	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
isolate	O	VERB	B
a	O	DET	O
DNA	O	NOUN	B
probe	O	NOUN	I
from	O	ADP	O
the	O	DET	O
Xp11	O	NOUN	B
.	O	PUNCT	O


4	O	NUM	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
p11	O	NOUN	B
.	O	PUNCT	O


21	O	NUM	O
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
X	O	NOUN	O
chromosome	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
novel	O	ADJ	O
sequence	O	NOUN	B
,	O	PUNCT	O
cpXr318	O	NOUN	B
(	O	PUNCT	O
DXS742	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
detects	O	VERB	O
a	O	DET	O
new	O	ADJ	O
submicroscopic	O	ADJ	B
deletion	O	NOUN	I
interval	O	NOUN	I
at	O	ADP	O
the	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
locus	O	NOUN	I
(	O	PUNCT	O
NDP	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Combining	O	VERB	O
our	O	PRON	O
data	O	NOUN	B
with	O	ADP	O
the	O	DET	O
consensus	O	NOUN	B
genetic	O	ADJ	I
map	O	NOUN	I
of	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
short	O	ADJ	B
arm	O	NOUN	I
of	O	ADP	I
the	O	DET	I
X	O	NOUN	I
chromosome	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
propose	O	VERB	O
the	O	DET	O
physical	O	ADJ	B
order	O	NOUN	O
Xcen	O	NOUN	B
-	O	PUNCT	O
DXS14	O	NOUN	B
-	O	PUNCT	O
DXS255	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
DXS426	O	NOUN	B
,	O	PUNCT	O
TIMP	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
(	O	PUNCT	O
DXS742	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
[	O	PUNCT	O
MAOB	O	PROPN	B
-	O	PUNCT	O
MAOA	O	PROPN	B
-	O	PUNCT	O
DXS7	O	NOUN	B
]	O	PUNCT	O
,	O	PUNCT	O
NDP	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
DXS77	O	NOUN	B
-	O	PUNCT	O
DXS228	O	PROPN	B
)	O	PUNCT	O
-	O	PUNCT	O
DXS209	O	NOUN	B
-	O	PUNCT	O
DXS148	O	NOUN	B
-	O	PUNCT	O
DXS196	O	NOUN	B
-	O	PUNCT	O
+	O	CCONJ	O
+	O	CCONJ	O
+	O	CCONJ	O
Xpter	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cpXr318	O	NOUN	B
probe	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
subclone	O	NOUN	B
from	O	ADP	O
a	O	DET	O
cosmid	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
DXS7	O	NOUN	B
locus	O	NOUN	I
were	O	AUX	O
converted	O	VERB	O
into	O	ADP	O
sequence	O	NOUN	B
-	O	PUNCT	O
tagged	O	VERB	B
sites	O	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
DXS742	O	NOUN	B
,	O	PUNCT	O
DSX7	O	NOUN	B
,	O	PUNCT	O
DXS77	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
MAOA	O	NOUN	B
were	O	AUX	O
integrated	O	VERB	O
into	O	ADP	O
a	O	DET	O
physical	O	ADJ	B
map	O	NOUN	I
spanning	O	VERB	O
the	O	DET	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
locus	O	NOUN	I


Putative	O	ADJ	B
X	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
gene	O	NOUN	I
shares	O	VERB	O
unexpected	O	ADJ	O
homology	O	NOUN	B
with	O	ADP	O
ABC	O	NOUN	B
transporters	O	NOUN	I
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
disease	I-Disease	NOUN	B
affecting	O	VERB	B
1	O	NUM	O
/	O	SYM	O
20	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
males	O	NOUN	B
either	O	CCONJ	O
as	O	ADP	O
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
in	O	ADP	O
childhood	O	NOUN	B
or	O	CCONJ	O
as	O	ADP	O
adrenomyeloneuropathy	B-Disease	ADJ	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
adults	O	NOUN	B
.	O	PUNCT	O


Childhood	O	NOUN	B
ALD	B-Disease	PROPN	B
is	O	AUX	O
the	O	DET	O
more	O	ADV	O
severe	O	ADJ	B
form	O	NOUN	O
,	O	PUNCT	O
with	O	ADP	O
onset	O	NOUN	O
of	O	ADP	O
neurological	O	ADJ	B
symptoms	O	NOUN	I
between	O	ADP	O
5	O	NUM	O
-	O	SYM	O
12	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


Central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
demyelination	I-Disease	NOUN	B
progresses	O	VERB	O
rapidly	O	ADV	B
and	O	CCONJ	O
death	O	NOUN	B
occurs	O	VERB	O
within	O	ADP	O
a	O	DET	O
few	O	ADJ	O
years	O	NOUN	B
.	O	PUNCT	O


AMN	B-Disease	PROPN	B
is	O	AUX	O
a	O	DET	O
milder	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
with	O	ADP	O
onset	O	NOUN	O
at	O	ADP	O
15	O	NUM	O
-	O	SYM	O
30	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
more	O	ADV	O
progressive	O	ADJ	B
course	O	NOUN	B
.	O	PUNCT	O


Adrenal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
(	O	PUNCT	O
Addisons	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
may	O	AUX	O
remain	O	VERB	O
the	O	DET	O
only	O	ADJ	O
clinical	O	ADJ	B
manifestation	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
principal	O	ADJ	B
biochemical	O	ADJ	B
abnormality	O	NOUN	O
of	O	ADP	O
ALD	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
fatty	O	NOUN	I
acids	O	NOUN	I
(	O	PUNCT	O
VLCFA	O	NOUN	B
)	O	PUNCT	O
because	O	SCONJ	O
of	O	ADP	O
impaired	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
in	O	ADP	O
peroxisomes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
normal	O	ADJ	B
oxidation	O	NOUN	I
of	O	ADP	O
VLCFA	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
fibroblasts	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
gene	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
the	O	DET	O
VLCFA	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
synthetase	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
a	O	DET	O
candidate	O	NOUN	O
gene	O	NOUN	B
for	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
use	O	VERB	O
positional	O	ADJ	B
cloning	O	NOUN	I
to	O	PART	O
identify	O	VERB	O
a	O	DET	O
gene	O	NOUN	B
partially	O	ADV	I
deleted	O	VERB	I
in	O	ADP	O
6	O	NUM	O
of	O	ADP	O
85	O	NUM	O
independent	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
ALD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
familial	O	ADJ	B
cases	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
deletions	O	NOUN	B
segregated	O	VERB	O
with	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
identical	O	ADJ	B
deletion	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
two	O	NUM	O
brothers	O	NOUN	B
presenting	O	VERB	B
with	O	ADP	O
different	O	ADJ	O
clinical	O	ADJ	B
ALD	B-Disease	NOUN	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


Candidate	O	NOUN	B
exons	O	NOUN	O
were	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
computer	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
genomic	O	ADJ	B
sequences	O	NOUN	I
and	O	CCONJ	O
used	O	VERB	O
to	O	PART	O
isolate	O	VERB	B
complementary	O	ADJ	O
DNAs	O	NOUN	B
by	O	ADP	O
exon	O	NOUN	B
connection	O	NOUN	I
and	O	CCONJ	O
screening	O	NOUN	B
of	O	ADP	O
cDNA	O	NOUN	B
libraries	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
deduced	O	VERB	O
protein	O	NOUN	O
sequence	O	NOUN	O
shows	O	VERB	O
significant	O	ADJ	O
sequence	O	NOUN	B
identity	O	NOUN	B
to	O	PART	O
a	O	DET	O
peroxisomal	O	ADJ	B
membrane	O	NOUN	I
protein	O	NOUN	I
of	O	ADP	O
M	O	NOUN	O
(	O	PUNCT	O
r	O	NOUN	O
)	O	PUNCT	O
70K	O	NOUN	O
that	O	PRON	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
peroxisome	O	NOUN	B
biogenesis	O	NOUN	I
and	O	CCONJ	O
belongs	O	VERB	O
to	O	PART	O
the	O	DET	O
ATP	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
cassette	O	NOUN	I
superfamily	O	NOUN	O
of	O	ADP	O
transporters	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Targeted	O	VERB	B
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
apolipoprotein	O	NOUN	B
B	O	NOUN	I
gene	O	NOUN	I
results	O	VERB	O
in	O	ADP	O
hypobetalipoproteinemia	B-Disease	NOUN	B
and	O	CCONJ	O
developmental	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
hypobetalipoproteinemia	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
codominant	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
dramatic	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
apolipoprotein	O	NOUN	B
(	O	PUNCT	I
apo	O	NOUN	O
)	O	PUNCT	O
B	O	NOUN	O
,	O	PUNCT	O
cholesterol	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
migrating	O	VERB	B
lipoproteins	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
benefit	O	NOUN	B
of	O	ADP	O
hypobetalipoproteinemia	B-Disease	NOUN	B
is	O	AUX	O
that	O	SCONJ	O
mildly	O	ADV	B
affected	O	VERB	B
individuals	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
protected	O	VERB	O
from	O	ADP	O
coronary	B-Disease	ADJ	B
vascular	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
gene	O	NOUN	B
targeting	O	VERB	B
to	O	PART	O
generate	O	VERB	O
mice	O	NOUN	B
with	O	ADP	O
a	O	DET	O
modified	O	ADJ	O
Apob	O	NOUN	B
allele	O	NOUN	I
.	O	PUNCT	O


Mice	O	NOUN	B
containing	O	VERB	O
this	O	DET	O
allele	O	NOUN	B
display	O	VERB	B
all	O	DET	O
of	O	ADP	O
the	O	DET	O
hallmarks	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
hypobetalipoproteinemia	B-Disease	NOUN	B
they	O	PRON	O
produce	O	VERB	O
a	O	DET	O
truncated	O	VERB	B
apoB	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
apoB70	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
have	O	AUX	O
markedly	O	ADV	O
decreased	O	VERB	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
apoB	O	NOUN	B
,	O	PUNCT	O
beta	O	NOUN	B
-	O	PUNCT	O
lipoproteins	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
total	O	ADJ	B
cholesterol	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
mice	O	NOUN	B
manifest	O	VERB	B
several	O	ADJ	O
characteristics	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
occasionally	O	ADV	O
observed	O	VERB	O
in	O	ADP	O
human	O	ADJ	B
hypobetalipoproteinemia	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
reduced	O	VERB	B
plasma	O	NOUN	B
triglyceride	O	NOUN	O
concentrations	O	NOUN	B
,	O	PUNCT	O
fasting	O	VERB	B
chylomicronemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
reduced	O	VERB	B
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	I
cholesterol	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
unexpected	O	ADJ	O
finding	O	NOUN	B
is	O	AUX	O
that	O	SCONJ	O
the	O	DET	O
modified	O	ADJ	B
Apob	O	NOUN	B
allele	O	NOUN	I
is	O	AUX	O
strongly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
exencephalus	B-Disease	NOUN	B
and	O	CCONJ	O
hydrocephalus	B-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
mice	O	NOUN	B
should	O	AUX	O
help	O	VERB	O
increase	O	VERB	B
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
hypobetalipoproteinemia	B-Disease	NOUN	B
,	O	PUNCT	O
atherogenesis	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
etiology	O	NOUN	B
of	O	ADP	O
exencephalus	B-Disease	NOUN	B
and	O	CCONJ	O
hydrocephalus	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
novel	O	ADJ	O
disease	O	NOUN	O
with	O	ADP	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
mitochondrial	I-Disease	ADJ	B
very	I-Disease	ADV	B
-	I-Disease	PUNCT	O
long	I-Disease	ADJ	B
-	I-Disease	PUNCT	O
chain	I-Disease	NOUN	B
acyl	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
CoA	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	B
.	O	PUNCT	O


Palmitoyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
skin	O	NOUN	B
fibroblasts	O	NOUN	I
from	O	ADP	O
seven	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
unidentified	O	ADJ	O
defects	O	NOUN	B
of	O	ADP	O
fatty	O	ADJ	B
acid	O	NOUN	I
oxidation	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
and	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
antibodies	O	NOUN	B
against	O	ADP	O
medium	O	NOUN	B
-	O	PUNCT	O
chain	O	NOUN	B
,	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenases	O	NOUN	B
(	O	PUNCT	O
VLCAD	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
4	O	NUM	O
-	O	SYM	O
5	O	NUM	O
month	O	NOUN	B
old	O	ADJ	O
boys	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
disease	O	NOUN	B
,	O	PUNCT	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
judged	O	VERB	O
from	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
low	O	ADJ	O
palmitoyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
immunoreactivity	O	NOUN	B
toward	O	ADP	O
antibody	O	NOUN	B
raised	O	VERB	B
to	O	PART	O
purified	O	VERB	B
VLCAD	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
Chinese	O	ADJ	B
descent	O	NOUN	I
and	O	CCONJ	O
identification	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
base	O	NOUN	B
substitutions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
G6PD	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
underlying	O	ADJ	O
DNA	O	NOUN	B
changes	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
Asians	O	PROPN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
extensively	O	ADV	O
investigated	O	VERB	B
.	O	PUNCT	O


To	O	PART	O
fill	O	VERB	O
this	O	DET	O
gap	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
sequenced	O	VERB	B
the	O	DET	O
G6PD	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
43	O	NUM	O
G6PD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
Chinese	O	PROPN	B
whose	O	DET	O
G6PD	O	NOUN	B
was	O	AUX	O
well	O	ADV	O
characterized	O	VERB	O
biochemically	O	ADV	B
.	O	PUNCT	O


DNA	O	NOUN	B
samples	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
of	O	ADP	O
these	O	DET	O
individuals	O	NOUN	B
for	O	ADP	O
sequencing	O	NOUN	B
using	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
sequencing	O	NOUN	O
procedure	O	NOUN	O
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
43	O	NUM	O
samples	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
identified	O	VERB	B
five	O	NUM	O
different	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
nucleotide	O	NOUN	B
substitutions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
gene	O	NOUN	I
at	O	ADP	O
cDNA	O	NOUN	B
1388	O	NUM	O
from	O	ADP	O
G	O	NOUN	B
to	O	PART	O
A	O	NOUN	O
(	O	PUNCT	O
Arg	O	NOUN	B
to	O	ADP	O
His	O	PRON	O
)	O	PUNCT	O
;	O	PUNCT	O
at	O	ADP	O
cDNA	O	NOUN	B
1376	O	NUM	O
from	O	ADP	O
G	O	NOUN	B
to	O	PART	I
T	O	NOUN	I
(	O	PUNCT	O
Arg	O	NOUN	B
to	O	PART	O
Leu	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
at	O	ADP	O
cDNA	O	NOUN	B
1024	O	NUM	O
from	O	ADP	O
C	O	NOUN	O
to	O	PART	O
T	O	NOUN	B
(	O	PUNCT	O
Leu	O	NOUN	B
to	O	PART	O
Phe	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
at	O	ADP	O
cDNA	O	NOUN	B
392	O	NUM	O
from	O	ADP	O
G	O	NOUN	B
to	O	PART	I
T	O	NOUN	I
(	O	PUNCT	O
Gly	O	NOUN	B
to	O	PART	O
Val	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
at	O	ADP	O
cDNA	O	NOUN	B
95	O	NUM	O
from	O	ADP	O
A	O	NOUN	O
to	O	PART	O
G	O	NOUN	B
(	O	PUNCT	O
His	O	PRON	O
to	O	PART	O
Arg	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
five	O	NUM	O
nucleotide	O	NOUN	B
substitutions	O	NOUN	I
account	O	VERB	O
for	O	ADP	O
over	O	ADP	O
83	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
our	O	PRON	O
43	O	NUM	O
G6PD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
samples	O	NOUN	B
and	O	CCONJ	O
these	O	DET	O
substitutions	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Asians	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
substitutions	O	NOUN	B
found	O	VERB	O
at	O	ADP	O
cDNA	O	NOUN	B
392	O	NUM	O
and	O	CCONJ	O
cDNA	O	NOUN	B
1024	O	NUM	O
are	O	AUX	O
new	O	ADJ	O
findings	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
substitutions	O	NOUN	B
at	O	ADP	O
cDNA	O	NOUN	B
1376	O	NUM	O
and	O	CCONJ	O
1388	O	NUM	O
account	O	NOUN	O
for	O	ADP	O
over	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
43	O	NUM	O
samples	O	NOUN	B
examined	O	VERB	O
indicating	O	VERB	O
a	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
alleles	O	NOUN	B
among	O	ADP	O
G6PD	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
Chinese	O	PROPN	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
add	O	VERB	O
support	O	NOUN	O
to	O	ADP	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
diverse	O	ADJ	B
point	O	NOUN	B
mutations	O	NOUN	I
may	O	AUX	O
account	O	VERB	O
largely	O	ADV	O
for	O	ADP	O
much	O	ADJ	O
of	O	ADP	O
the	O	DET	O
phenotypic	O	ADJ	B
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
Danish	O	ADJ	B
choroideremia	B-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
choroideremia	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CHM	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
from	O	ADP	O
12	O	NUM	O
Danish	O	ADJ	B
families	O	NOUN	I
in	O	ADP	O
which	O	DET	O
CHM	B-Disease	PROPN	B
is	O	AUX	O
segregating	O	VERB	B
.	O	PUNCT	O


Employing	O	VERB	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
single	O	ADJ	B
strand	O	NOUN	I
conformation	O	NOUN	I
polymorphism	O	NOUN	I
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
direct	O	ADJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
,	O	PUNCT	O
different	O	ADJ	O
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
6	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
mutations	O	NOUN	B
will	O	AUX	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
correct	O	ADJ	B
translation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mRNA	O	NOUN	B
predicting	O	VERB	B
a	O	DET	O
truncated	O	VERB	B
protein	O	NOUN	I
or	O	CCONJ	O
no	O	DET	O
gene	O	NOUN	B
product	O	NOUN	I
at	O	ADP	O
all	O	ADV	O
.	O	PUNCT	O
.	O	PUNCT	O


Structure	O	NOUN	B
and	O	CCONJ	O
genomic	O	ADJ	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
an	O	DET	O
unstable	O	ADJ	B
CTG	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
for	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
with	O	ADP	O
putative	O	ADJ	O
serine	O	NOUN	B
-	O	PUNCT	O
threonine	O	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
activity	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	O
we	O	PRON	O
present	O	VERB	O
the	O	DET	O
genomic	O	ADJ	B
sequences	O	NOUN	I
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
and	O	CCONJ	O
murine	O	ADJ	B
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
these	O	DET	O
sequences	O	NOUN	B
with	O	ADP	O
each	O	DET	O
other	O	ADJ	O
and	O	CCONJ	O
with	O	ADP	O
known	O	ADJ	O
cDNA	O	NOUN	B
sequences	O	NOUN	I
from	O	ADP	O
both	O	DET	O
species	O	NOUN	B
,	O	PUNCT	O
led	O	VERB	O
us	O	PRON	O
to	O	PART	O
predict	O	VERB	O
a	O	DET	O
translation	O	NOUN	B
initiation	O	NOUN	B
codon	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
determine	O	VERB	O
the	O	DET	O
organization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
polymorphisms	O	NOUN	B
within	O	ADP	O
the	O	DET	O
human	O	ADJ	B
DM	B-Disease	NOUN	O
kinase	O	NOUN	O
gene	O	NOUN	O
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
PCR	O	NOUN	B
assays	O	NOUN	I
to	O	PART	O
detect	O	VERB	B
two	O	NUM	O
of	O	ADP	O
these	O	DET	O
are	O	AUX	O
described	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
complete	O	ADJ	B
sequence	O	NOUN	B
and	O	CCONJ	O
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
kinase	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
polymorphisms	O	NOUN	B
within	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
represent	O	VERB	O
an	O	DET	O
important	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
a	O	DET	O
further	O	ADJ	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
genetics	O	NOUN	B
of	O	ADP	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
molecular	O	ADJ	B
biology	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Autosomal	O	ADJ	B
recessive	O	ADJ	B
transmission	O	NOUN	I
of	O	ADP	O
hemophilia	B-Disease	NOUN	B
A	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
a	O	DET	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
differential	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
genetic	B-Disease	ADJ	B
bleeding	I-Disease	NOUN	I
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
hemophilia	B-Disease	NOUN	B
A	I-Disease	NOUN	I
and	O	CCONJ	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
occasionally	O	ADV	O
confounded	O	VERB	O
by	O	ADP	O
the	O	DET	O
close	O	ADJ	O
molecular	O	ADJ	B
relationship	O	NOUN	B
of	O	ADP	O
coagulation	O	NOUN	B
factor	O	NOUN	I
VIII	O	NOUN	I
and	O	CCONJ	O
von	B-Disease	NOUN	O
Willebrand	I-Disease	NOUN	O
factor	O	NOUN	O
(	O	PUNCT	O
vWF	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
describes	O	VERB	O
the	O	DET	O
autosomal	O	ADJ	B
inheritance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
hemophilia	B-Disease	NOUN	B
A	I-Disease	NOUN	O
phenotype	O	NOUN	B
due	O	ADP	O
to	O	PART	O
a	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
vWF	O	NOUN	B
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
defective	O	ADJ	B
factor	O	NOUN	O
VIII	O	NOUN	O
binding	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
proband	O	NOUN	B
was	O	AUX	O
a	O	DET	O
female	O	ADJ	B
patient	O	NOUN	B
with	O	ADP	O
low	O	ADJ	B
levels	O	NOUN	O
of	O	ADP	O
factor	O	NOUN	B
VIII	O	NOUN	I
activity	O	NOUN	I
.	O	PUNCT	O


Polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
amplification	O	NOUN	O
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
were	O	AUX	O
employed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
exons	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
putative	O	ADJ	B
factor	O	NOUN	I
VIII	O	NOUN	I
binding	O	NOUN	I
domain	O	NOUN	I
of	O	ADP	O
vWF	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
single	O	ADJ	O
point	O	NOUN	O
mutation	O	NOUN	O
causing	O	VERB	O
a	O	DET	O
Thr	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Met	O	NOUN	B
substitution	O	NOUN	B
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
position	O	NOUN	I
28	O	NUM	O
in	O	ADP	O
the	O	DET	O
mature	O	ADJ	B
vWF	O	NOUN	B
subunit	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
phenotypic	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
determined	O	VERB	O
to	O	PART	O
be	O	AUX	O
recessive	O	ADJ	B
because	O	SCONJ	O
heterozygous	O	ADJ	B
family	O	NOUN	B
members	O	NOUN	I
were	O	AUX	O
clinically	O	ADV	B
unaffected	O	ADJ	O
.	O	PUNCT	O


Recombinant	O	ADJ	B
vWF	O	NOUN	B
containing	O	VERB	O
the	O	DET	O
observed	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	I
was	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
COS	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
cells	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutant	O	ADJ	B
vWF	O	NOUN	B
was	O	AUX	O
processed	O	VERB	B
and	O	CCONJ	O
secreted	O	VERB	B
normally	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
was	O	AUX	O
functionally	O	ADV	O
equivalent	O	ADJ	O
to	O	PART	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
vWF	O	NOUN	B
in	O	ADP	O
its	O	PRON	O
ability	O	NOUN	O
to	O	PART	O
bind	O	VERB	B
to	O	PART	O
platelets	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mutant	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
bind	O	VERB	B
factor	O	NOUN	O
VIII	O	NOUN	O
,	O	PUNCT	O
demonstrating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
functionally	O	ADV	O
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
observed	O	VERB	O
hemophilia	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
family	O	NOUN	B
we	O	PRON	O
describe	O	VERB	O
demonstrates	O	VERB	O
the	O	DET	O
recessive	O	ADJ	B
inheritance	O	NOUN	B
of	O	ADP	O
a	O	DET	O
recently	O	ADV	O
recognized	O	VERB	O
class	O	NOUN	O
of	O	ADP	O
genetic	O	ADJ	B
bleeding	O	NOUN	I
disorders	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
call	O	VERB	O
"	O	PUNCT	O
autosomal	O	ADJ	B
hemophilia	B-Disease	NOUN	O
.	O	PUNCT	O


"	O	PUNCT	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
vWF	O	NOUN	B
mutation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
an	O	DET	O
under	O	ADP	O
recognized	O	VERB	O
cause	O	NOUN	B
of	O	ADP	O
hemophilia	B-Disease	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
where	O	SCONJ	O
the	O	DET	O
inheritance	O	NOUN	B
pattern	O	NOUN	B
is	O	AUX	O
not	O	PART	O
consistent	O	ADJ	B
with	O	ADP	I
X	O	NOUN	B
-	O	PUNCT	O
linked	O	VERB	B
transmission	O	NOUN	B
.	O	PUNCT	O


Somatic	O	ADJ	B
von	B-Disease	NOUN	I
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
mutation	O	NOUN	B
in	O	ADP	O
clear	O	ADJ	O
cell	O	NOUN	B
papillary	B-Disease	ADJ	I
cystadenoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
epididymis	I-Disease	NOUN	B
.	O	PUNCT	O


Papillary	B-Disease	ADJ	B
cystadenoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
epididymis	I-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
uncommon	O	ADJ	O
benign	O	ADJ	B
lesion	O	NOUN	B
that	O	PRON	O
may	O	AUX	O
occur	O	VERB	O
sporadically	O	ADV	B
or	O	CCONJ	O
as	O	ADP	O
a	O	DET	O
manifestation	O	NOUN	B
of	O	ADP	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	I-Disease	PUNCT	O
VHL	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
disease	I-Disease	NOUN	O
.	O	PUNCT	O


Neither	O	CCONJ	O
immunohistochemical	O	ADJ	B
studies	O	NOUN	I
nor	O	CCONJ	O
molecular	O	ADJ	B
genetic	O	ADJ	I
analyses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
for	O	ADP	O
this	O	DET	O
lesion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
describe	O	VERB	O
two	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
clear	O	ADJ	B
cell	O	NOUN	I
papillary	B-Disease	ADJ	I
cystadenoma	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
epididymis	I-Disease	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
initially	O	ADV	O
confused	O	VERB	O
with	O	ADP	O
metastatic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


Both	O	DET	O
lesions	O	NOUN	B
showed	O	VERB	O
positive	O	ADJ	B
immunohistochemical	O	ADJ	B
staining	O	NOUN	I
for	O	ADP	O
low	O	ADJ	B
and	O	CCONJ	O
intermediate	O	ADJ	B
molecular	O	ADJ	O
weight	O	NOUN	O
keratins	O	NOUN	O
(	O	PUNCT	O
Cam	O	NOUN	O
5	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
and	O	CCONJ	O
AE1	O	NOUN	B
/	O	SYM	O
AE3	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
EMA	O	NOUN	B
,	O	PUNCT	O
vimentin	O	NOUN	B
,	O	PUNCT	O
alpha	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
antitrypsin	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
alpha	O	NOUN	B
1	O	NUM	I
-	O	PUNCT	O
antichymotrypsin	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
was	O	AUX	O
negative	O	ADJ	B
for	O	ADP	O
CEA	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
clear	O	ADJ	O
cell	O	NOUN	B
papillary	B-Disease	ADJ	I
cystadenoma	I-Disease	NOUN	I
is	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
histologically	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
because	O	SCONJ	O
both	O	DET	O
occur	O	VERB	O
as	O	ADP	O
components	O	NOUN	B
of	O	ADP	O
the	O	DET	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
complex	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
authors	O	NOUN	B
analyzed	O	VERB	B
both	O	DET	O
cases	O	NOUN	B
for	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
somatic	O	ADJ	B
VHL	B-Disease	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
tumors	B-Disease	NOUN	B
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
followed	O	VERB	O
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


Direct	O	ADJ	B
sequencing	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
cytosine	O	NOUN	B
to	O	PART	O
thymine	O	NOUN	B
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
694	O	NUM	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
replacement	O	NOUN	B
of	O	ADP	O
an	O	DET	O
arginine	O	NOUN	B
with	O	ADP	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
after	O	ADP	O
the	O	DET	O
sixth	O	ADJ	O
amino	O	NOUN	B
acid	O	NOUN	I
of	O	ADP	O
exon	O	NOUN	O
3	O	NUM	O
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
believed	O	VERB	O
to	O	PART	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
mutations	O	NOUN	I
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
initiation	O	NOUN	B
of	O	ADP	O
tumorigenesis	O	NOUN	B
in	O	ADP	O
sporadic	O	ADJ	B
cystadenomas	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
epididymis	I-Disease	NOUN	B
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	I
reveals	O	VERB	O
allelic	O	ADJ	B
heterogeneity	O	NOUN	B
at	O	ADP	O
the	O	DET	O
WAS	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
encoding	O	VERB	B
the	O	DET	O
recently	O	ADV	O
isolated	O	VERB	B
WASP	O	NOUN	B
protein	O	NOUN	I
has	O	AUX	O
now	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
the	O	DET	O
genetic	B-Disease	ADJ	B
defect	I-Disease	NOUN	I
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Wiskott	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
primary	O	ADJ	B
immunodeficiency	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
extensive	O	ADJ	O
phenotypic	O	ADJ	B
variability	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
range	O	NOUN	O
of	O	ADP	O
WASP	O	NOUN	B
mutations	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
WAS	B-Disease	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
analysis	O	NOUN	B
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
WASP	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
19	O	NUM	O
unrelated	O	ADJ	O
boys	O	NOUN	B
with	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
classical	O	ADJ	O
or	O	CCONJ	O
attenuated	O	VERB	B
WAS	B-Disease	PROPN	B
or	O	CCONJ	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	I
.	O	PUNCT	O


All	O	DET	O
19	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
WASP	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
each	O	DET	O
of	O	ADP	O
which	O	DET	O
localized	O	VERB	B
to	O	PART	O
the	O	DET	O
initial	O	ADJ	B
three	O	NUM	O
or	O	CCONJ	O
terminal	O	ADJ	B
three	O	NUM	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
which	O	DET	O
were	O	AUX	O
unique	O	ADJ	B
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
which	O	DET	O
results	O	VERB	O
in	O	ADP	O
substitution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
arginine	O	NOUN	B
at	O	ADP	O
WAS	B-Disease	AUX	B
codon	O	NOUN	B
86	O	NUM	O
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
three	O	NUM	O
boys	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
WAS	B-Disease	AUX	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
one	O	NUM	O
boy	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
thrombocytopenia	B-Disease	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
three	O	NUM	O
mutations	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
patients	O	NOUN	B
leave	O	VERB	O
the	O	DET	O
reading	O	NOUN	B
frame	O	NOUN	I
intact	O	ADJ	B
,	O	PUNCT	O
about	O	ADP	O
one	O	NUM	O
-	O	PUNCT	O
half	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
alterations	O	NOUN	I
detected	O	VERB	B
in	O	ADP	O
both	O	CCONJ	O
severe	O	ADJ	B
and	O	CCONJ	O
attenuated	O	VERB	B
WAS	B-Disease	AUX	B
patients	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
frameshifted	O	ADJ	B
transcript	O	NOUN	I
and	O	CCONJ	O
premature	O	ADJ	B
translation	O	NOUN	I
termination	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
therefore	O	ADV	O
confirm	O	VERB	B
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	NOUN	B
with	O	ADP	O
WASP	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
identify	O	VERB	O
WASP	O	NOUN	B
mutation	O	NOUN	B
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
for	O	ADP	O
isolated	O	VERB	B
congenital	B-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
in	O	ADP	O
males	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
defects	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
and	O	CCONJ	O
other	O	ADJ	O
mild	O	ADJ	B
presentations	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	AUX	B
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
distinct	O	ADJ	O
from	O	ADP	O
those	O	DET	O
resulting	O	VERB	O
in	O	ADP	O
severe	O	ADJ	B
WAS	B-Disease	AUX	B
,	O	PUNCT	O
these	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
gene	O	NOUN	B
mutation	O	NOUN	I
provides	O	VERB	O
a	O	DET	O
valuable	O	ADJ	O
tool	O	NOUN	O
for	O	ADP	O
distinguishing	O	VERB	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	AUX	B
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
males	O	NOUN	B
with	O	ADP	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	I
who	O	PRON	O
represent	O	VERB	O
mild	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O
.	O	PUNCT	O


WASP	O	NOUN	B
gene	O	NOUN	I
mutations	O	NOUN	O
in	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
cloned	O	VERB	B
from	O	ADP	O
Xp11	O	NOUN	B
.	O	PUNCT	O


23	O	NUM	O
and	O	CCONJ	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
a	O	DET	O
screening	O	NOUN	B
protocol	O	NOUN	I
for	O	ADP	O
identifying	O	VERB	O
WASP	O	NOUN	B
gene	O	NOUN	I
alterations	O	NOUN	B
in	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
have	O	AUX	O
identified	O	VERB	B
a	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
novel	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
12	O	NUM	O
additional	O	ADJ	O
unrelated	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
missense	O	NOUN	B
,	O	PUNCT	O
nonsense	O	ADJ	B
and	O	CCONJ	O
frameshift	O	NOUN	B
mutations	O	NOUN	I
involve	O	VERB	O
eight	O	NUM	O
of	O	ADP	O
the	O	DET	O
12	O	NUM	O
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
mutations	O	NOUN	B
creating	O	VERB	O
premature	O	ADJ	B
termination	O	NOUN	I
codons	O	NOUN	I
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
lack	O	NOUN	O
of	O	ADP	O
detectable	O	ADJ	B
mRNA	O	NOUN	B
on	O	ADP	O
Northern	O	NOUN	B
blots	O	NOUN	I
.	O	PUNCT	O


Four	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
,	O	PUNCT	O
Leu27Phe	O	NOUN	B
,	O	PUNCT	O
Thr48Ile	O	NOUN	B
,	O	PUNCT	O
Val75Met	O	NOUN	B
and	O	CCONJ	O
Arg477Lys	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
congenital	B-Disease	ADJ	B
thrombocytopenia	I-Disease	NOUN	I
and	O	CCONJ	O
no	O	DET	O
clinically	O	ADV	O
evident	O	ADJ	O
immune	O	ADJ	B
defect	O	NOUN	I
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
the	O	DET	O
site	O	NOUN	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O


A	O	DET	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
line	O	NOUN	I
from	O	ADP	O
a	O	DET	O
WAS	B-Disease	NOUN	B
patient	O	NOUN	B
contained	O	VERB	O
two	O	NUM	O
independent	O	ADJ	O
DNA	O	NOUN	B
alterations	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
constitutional	O	ADJ	B
frameshift	O	NOUN	O
mutation	O	NOUN	O
,	O	PUNCT	O
also	O	ADV	O
present	O	ADJ	O
in	O	ADP	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	B
from	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compensatory	O	ADJ	B
splice	O	NOUN	B
site	O	NOUN	I
mutation	O	NOUN	B
unique	O	ADJ	B
to	O	PART	O
the	O	DET	O
cell	O	NOUN	B
line	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
distribution	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
provides	O	VERB	O
valuable	O	ADJ	O
information	O	NOUN	B
on	O	ADP	O
amino	O	NOUN	B
acids	O	NOUN	I
which	O	DET	O
are	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	B
protein	O	NOUN	I
function	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
sites	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
two	O	NUM	O
exons	O	NOUN	B
are	O	AUX	O
hot	O	ADJ	B
-	O	PUNCT	O
spots	O	NOUN	B
for	O	ADP	O
mutation	O	NOUN	B
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
inter	O	ADJ	B
-	O	PUNCT	O
generational	O	ADJ	B
instability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
conserved	O	VERB	O
haplotypes	O	NOUN	B
at	O	ADP	O
flanking	O	NOUN	B
markers	O	NOUN	B
amongst	O	ADP	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
CAG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
array	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
'	O	PART	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
haplotype	O	NOUN	B
at	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
cohort	O	NOUN	B
of	O	ADP	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
provide	O	VERB	O
five	O	NUM	O
novel	O	ADJ	O
observations	O	NOUN	B
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
MJD	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
expansion	O	NOUN	B
fo	O	ADP	O
the	O	DET	O
array	O	NOUN	B
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
14	O	NUM	O
-	O	SYM	O
37	O	NUM	O
repeats	O	NOUN	B
to	O	PART	O
68	O	NUM	O
-	O	SYM	O
84	O	NUM	O
repeats	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
subjects	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
expansions	O	NOUN	B
intermediate	O	NOUN	B
in	O	ADP	O
size	O	NOUN	B
between	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
MJD	B-Disease	NOUN	B
affected	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
MJD	B-Disease	NOUN	B
displays	O	VERB	O
inter	O	ADJ	B
-	O	PUNCT	O
generational	O	ADJ	B
instability	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
male	O	NOUN	B
meioses	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
instability	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
clinical	O	ADJ	B
phenomenon	O	NOUN	I
of	O	ADP	O
anticipation	O	NOUN	B
.	O	PUNCT	O


Third	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
is	O	AUX	O
not	O	PART	O
only	O	ADV	O
inversely	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
onset	O	NOUN	B
of	O	ADP	O
MJD	B-Disease	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
738	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
[	O	PUNCT	O
e	O	PUNCT	O
.	O	PUNCT	O
g	O	NOUN	O
.	O	PUNCT	O
pseudoexophthalmos	O	NOUN	B
and	O	CCONJ	O
pyramidal	O	ADJ	B
signs	O	NOUN	O
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
repeats	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
respectively	O	ADV	O
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


Fourth	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
phenotype	O	NOUN	B
is	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
severe	O	ADJ	B
and	O	CCONJ	O
had	O	AUX	O
an	O	DET	O
early	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
(	O	PUNCT	O
16	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
subject	O	ADJ	B
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
contrasts	O	VERB	O
with	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
expanded	O	ADJ	O
allele	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
could	O	AUX	O
exert	O	VERB	O
its	O	PRON	O
effect	O	NOUN	B
either	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
dominant	O	ADJ	B
negative	O	ADJ	B
effect	O	NOUN	O
(	O	PUNCT	O
putatively	O	ADV	O
excluded	O	VERB	O
in	O	ADP	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
gain	O	NOUN	B
of	O	ADP	O
function	O	NOUN	B
effect	O	NOUN	I
as	O	ADP	O
proposed	O	VERB	O
for	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
affected	O	VERB	O
with	O	ADP	O
MJD	B-Disease	NOUN	B
share	O	NOUN	O
haplotypes	O	NOUN	B
at	O	ADP	O
several	O	ADJ	O
markers	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
uncommon	O	ADJ	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
which	O	DET	O
suggests	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
either	O	CCONJ	O
of	O	ADP	O
common	O	ADJ	O
founders	O	NOUN	B
in	O	ADP	O
these	O	DET	O
populations	O	NOUN	B
or	O	CCONJ	O
of	O	ADP	O
chromosomes	O	NOUN	B
susceptible	O	ADJ	B
to	O	PART	O
pathologic	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
inter	O	ADJ	B
-	O	PUNCT	O
generational	O	ADJ	B
instability	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
conserved	O	VERB	O
haplotypes	O	NOUN	B
at	O	ADP	O
flanking	O	NOUN	B
markers	O	NOUN	B
amongst	O	ADP	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
CAG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
array	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
'	O	PART	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
haplotype	O	NOUN	B
at	O	ADP	O
a	O	DET	O
series	O	NOUN	O
of	O	ADP	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
cohort	O	NOUN	B
of	O	ADP	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
affected	O	VERB	B
with	O	ADP	O
Machado	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Joseph	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
MJD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
provide	O	VERB	O
five	O	NUM	O
novel	O	ADJ	O
observations	O	NOUN	B
.	O	PUNCT	O


First	O	ADV	O
,	O	PUNCT	O
MJD	B-Disease	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
expansion	O	NOUN	B
fo	O	ADP	O
the	O	DET	O
array	O	NOUN	B
from	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
14	O	NUM	O
-	O	SYM	O
37	O	NUM	O
repeats	O	NOUN	B
to	O	PART	O
68	O	NUM	O
-	O	SYM	O
84	O	NUM	O
repeats	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
subjects	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
with	O	ADP	O
expansions	O	NOUN	B
intermediate	O	NOUN	B
in	O	ADP	O
size	O	NOUN	B
between	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
MJD	B-Disease	NOUN	B
affected	O	VERB	B
groups	O	NOUN	B
.	O	PUNCT	O


Second	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
MJD	B-Disease	NOUN	B
displays	O	VERB	O
inter	O	ADJ	B
-	O	PUNCT	O
generational	O	ADJ	B
instability	O	NOUN	B
,	O	PUNCT	O
particularly	O	ADV	O
in	O	ADP	O
male	O	NOUN	B
meioses	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
instability	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
clinical	O	ADJ	B
phenomenon	O	NOUN	I
of	O	ADP	O
anticipation	O	NOUN	B
.	O	PUNCT	O


Third	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
is	O	AUX	O
not	O	PART	O
only	O	ADV	O
inversely	O	ADV	B
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
age	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
onset	O	NOUN	B
of	O	ADP	O
MJD	B-Disease	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
-	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
738	O	NUM	O
,	O	PUNCT	O
p	O	X	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
[	O	PUNCT	O
e	O	PUNCT	O
.	O	PUNCT	O
g	O	NOUN	O
.	O	PUNCT	O
pseudoexophthalmos	O	NOUN	B
and	O	CCONJ	O
pyramidal	O	ADJ	B
signs	O	NOUN	O
were	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
subjects	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
repeats	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
05	O	NUM	O
respectively	O	ADV	O
)	O	PUNCT	O
]	O	PUNCT	O
.	O	PUNCT	O


Fourth	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
phenotype	O	NOUN	B
is	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
severe	O	ADJ	B
and	O	CCONJ	O
had	O	AUX	O
an	O	DET	O
early	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
(	O	PUNCT	O
16	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
subject	O	ADJ	B
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
contrasts	O	VERB	O
with	O	ADP	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
expanded	O	ADJ	O
allele	O	NOUN	B
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
could	O	AUX	O
exert	O	VERB	O
its	O	PRON	O
effect	O	NOUN	B
either	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
dominant	O	ADJ	B
negative	O	ADJ	B
effect	O	NOUN	O
(	O	PUNCT	O
putatively	O	ADV	O
excluded	O	VERB	O
in	O	ADP	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
gain	O	NOUN	B
of	O	ADP	O
function	O	NOUN	B
effect	O	NOUN	I
as	O	ADP	O
proposed	O	VERB	O
for	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
subjects	O	NOUN	B
affected	O	VERB	O
with	O	ADP	O
MJD	B-Disease	NOUN	B
share	O	NOUN	O
haplotypes	O	NOUN	B
at	O	ADP	O
several	O	ADJ	O
markers	O	NOUN	B
surrounding	O	VERB	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
uncommon	O	ADJ	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	O
Japanese	O	ADJ	B
and	O	CCONJ	O
Caucasian	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
which	O	DET	O
suggests	O	VERB	O
the	O	DET	O
existence	O	NOUN	O
either	O	CCONJ	O
of	O	ADP	O
common	O	ADJ	O
founders	O	NOUN	B
in	O	ADP	O
these	O	DET	O
populations	O	NOUN	B
or	O	CCONJ	O
of	O	ADP	O
chromosomes	O	NOUN	B
susceptible	O	ADJ	B
to	O	PART	O
pathologic	O	ADJ	B
expansion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MJD1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
4	O	NUM	O
-	O	PUNCT	O
megabase	O	NOUN	B
YAC	O	NOUN	B
contig	O	NOUN	B
that	O	PRON	O
spans	O	VERB	O
the	O	DET	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
region	O	NOUN	O
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
8q24	O	NOUN	I
.	O	PUNCT	O
1	O	X	O
:	O	PUNCT	O
use	O	NOUN	O
in	O	ADP	O
refining	O	VERB	B
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
trichorhinophalangeal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
multiple	O	ADJ	B
exostoses	O	ADJ	I
genes	O	NOUN	I
(	O	PUNCT	O
TRPS1	O	NOUN	B
and	O	CCONJ	O
EXT1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
constructed	O	VERB	O
a	O	DET	O
physical	O	ADJ	B
map	O	NOUN	I
covering	O	VERB	O
over	O	ADP	O
4	O	NUM	O
Mb	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
8q24	O	NOUN	O
.	O	PUNCT	O


1	O	NUM	O
and	O	CCONJ	O
used	O	VERB	O
this	O	DET	O
map	O	NOUN	B
to	O	PART	O
refine	O	VERB	O
the	O	DET	O
locations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genes	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
map	O	NOUN	B
is	O	AUX	O
composed	O	VERB	O
of	O	ADP	O
overlapping	O	VERB	O
YAC	O	NOUN	B
clones	O	NOUN	O
that	O	PRON	O
were	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
ordered	O	VERB	B
in	O	ADP	O
relation	O	NOUN	O
to	O	PART	O
sequence	O	NOUN	B
tagged	O	ADJ	B
sites	O	NOUN	I
mapped	O	VERB	B
to	O	ADP	O
the	O	DET	O
Langer	O	PROPN	B
-	O	PUNCT	O
Giedion	O	NOUN	B
chromosomal	O	ADJ	B
region	O	NOUN	I
on	O	ADP	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
minimal	O	ADJ	B
region	O	NOUN	O
of	O	ADP	O
overlap	O	NOUN	B
of	O	ADP	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
deletions	O	NOUN	B
,	O	PUNCT	O
previously	O	ADV	O
identified	O	VERB	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
15	O	NUM	O
patients	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
placed	O	VERB	O
on	O	ADP	O
the	O	DET	O
map	O	NOUN	B
by	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
patients	O	NOUN	B
whose	O	DET	O
deletions	O	NOUN	B
define	O	VERB	O
the	O	DET	O
endpoints	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
chromosome	O	NOUN	B
8	O	NUM	I
breakpoint	O	NOUN	O
of	O	ADP	O
a	O	DET	O
balanced	O	ADJ	B
t	O	NOUN	O
(	O	PUNCT	O
8	O	NUM	O
;	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q24	O	NOUN	B
.	O	PUNCT	O
11	O	NUM	O
;	O	PUNCT	O
q33	O	NOUN	B
.	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
translocation	O	NOUN	B
from	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
trichorhinophalangeal	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
TRPS	B-Disease	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
located	O	ADJ	O
just	O	ADV	O
within	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
minimal	O	ADJ	B
deletion	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
8q24	O	NOUN	B
.	O	PUNCT	O


11	O	NUM	O
-	O	PUNCT	O
q24	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
multiple	O	ADJ	B
exostoses	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
overlap	O	VERB	B
the	O	DET	O
distal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
LGS	B-Disease	NOUN	B
deletion	O	NOUN	B
region	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
EXT1	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
distal	O	ADJ	B
to	O	PART	O
the	O	DET	O
TRPS1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
supporting	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
Langer	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Giedion	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	O
functional	O	ADJ	B
copies	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
TRPS1	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
EXT1	O	NOUN	B
genes	O	NOUN	I


BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
sample	O	NOUN	B
of	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
.	O	PUNCT	O


Inherited	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
high	O	ADJ	B
risk	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
some	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
DNA	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
women	O	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
spectrum	O	NOUN	B
and	O	CCONJ	O
frequency	O	NOUN	B
of	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
80	O	NUM	O
women	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
diagnosed	O	VERB	B
before	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
35	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
who	O	PRON	O
were	O	AUX	O
not	O	PART	O
selected	O	VERB	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
family	O	NOUN	B
history	O	NOUN	I
.	O	PUNCT	O


Genomic	O	ADJ	B
DNA	O	NOUN	I
was	O	AUX	O
studied	O	VERB	O
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
by	O	ADP	O
analysis	O	NOUN	B
involving	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphisms	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
assays	O	NOUN	B
.	O	PUNCT	O


Alterations	O	NOUN	B
were	O	AUX	O
defined	O	VERB	O
by	O	ADP	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
.	O	PUNCT	O


Germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
6	O	NUM	O
of	O	ADP	O
the	O	DET	O
80	O	NUM	O
women	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
additional	O	ADJ	O
rare	O	ADJ	O
sequence	O	NOUN	B
variants	O	NOUN	B
of	O	ADP	O
unknown	O	ADJ	O
functional	O	ADJ	B
importance	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
identified	O	VERB	B
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
rare	O	ADJ	B
sequence	O	NOUN	B
variants	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
among	O	ADP	O
the	O	DET	O
39	O	NUM	O
women	O	NOUN	B
who	O	PRON	O
reported	O	VERB	O
no	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
and	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
rare	O	ADJ	B
variants	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
a	O	DET	O
reference	O	NOUN	B
population	O	NOUN	I
of	O	ADP	O
73	O	NUM	O
unrelated	O	ADJ	O
subjects	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
.	O	PUNCT	O


Alterations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
approximately	O	ADV	O
10	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
this	O	DET	O
cohort	O	NOUN	B
of	O	ADP	O
young	O	ADJ	B
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
harboring	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
limited	O	VERB	O
to	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
family	O	NOUN	B
histories	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
represent	O	VERB	O
a	O	DET	O
minimal	O	ADJ	B
estimate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Comprehensive	O	ADJ	B
methods	O	NOUN	O
of	O	ADP	O
identifying	O	VERB	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
understanding	O	VERB	O
their	O	PRON	O
importance	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
needed	O	VERB	O
before	O	ADP	O
testing	O	NOUN	B
of	O	ADP	O
women	O	NOUN	B
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
undertaken	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Novel	O	ADJ	B
inherited	O	VERB	B
mutations	O	NOUN	B
and	O	CCONJ	O
variable	O	ADJ	B
expressivity	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
alleles	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
founder	O	NOUN	B
mutation	O	NOUN	B
185delAG	O	NOUN	I
in	O	ADP	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
families	O	NOUN	B
.	O	PUNCT	O


Thirty	O	NUM	B
-	O	PUNCT	O
seven	O	NUM	B
families	O	NOUN	B
with	O	ADP	O
four	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
or	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Twelve	O	NUM	O
different	O	ADJ	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
novel	O	ADJ	B
and	O	CCONJ	O
eight	O	NUM	O
previously	O	ADV	O
observed	O	VERB	B
,	O	PUNCT	O
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
16	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
families	O	NOUN	B
of	O	ADP	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
descent	O	NOUN	I
carried	O	VERB	O
the	O	DET	O
185delAG	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
shared	O	VERB	O
the	O	DET	O
same	O	ADJ	O
haplotype	O	NOUN	B
at	O	ADP	O
eight	O	NUM	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
spanning	O	VERB	O
approximately	O	ADV	O
850	O	NUM	O
kb	O	NOUN	O
at	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Expressivity	O	NOUN	B
of	O	ADP	O
185delAG	O	NOUN	B
in	O	ADP	O
these	O	DET	O
families	O	NOUN	B
varied	O	VERB	O
,	O	PUNCT	O
from	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
without	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Mutation	O	NOUN	B
4184delTCAA	O	NOUN	O
occurred	O	VERB	O
independently	O	ADV	O
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
,	O	PUNCT	O
penetrance	O	NOUN	B
was	O	AUX	O
complete	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
females	O	NOUN	B
developing	O	VERB	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
or	O	CCONJ	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
male	O	NOUN	B
carrier	O	NOUN	B
developing	O	VERB	O
prostatic	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
penetrance	O	NOUN	B
was	O	AUX	O
incomplete	O	ADJ	B
and	O	CCONJ	O
only	O	ADV	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
occurred	O	VERB	B
,	O	PUNCT	O
diagnosed	O	VERB	B
at	O	ADP	O
ages	O	NOUN	B
38	O	NUM	O
-	O	SYM	O
81	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
novel	O	ADJ	O
nonsense	O	NOUN	B
mutations	O	NOUN	I
led	O	VERB	O
to	O	PART	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
BRCA1	O	NOUN	B
transcript	O	NOUN	B
in	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
10	O	NUM	O
and	O	CCONJ	O
6	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
665	O	NUM	O
-	O	PUNCT	O
nt	O	NOUN	B
segment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
UTR	O	NOUN	B
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
genomic	O	ADJ	B
sequence	O	NOUN	I
including	O	VERB	O
the	O	DET	O
putative	O	ADJ	O
promoter	O	NOUN	B
region	O	NOUN	I
were	O	AUX	O
invariant	O	ADJ	O
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
analysis	O	NOUN	O
in	O	ADP	O
13	O	NUM	O
families	O	NOUN	B
without	O	ADP	O
coding	O	VERB	B
-	O	PUNCT	O
sequence	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Overall	O	ADV	O
in	O	ADP	O
our	O	PRON	O
series	O	NOUN	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
26	O	NUM	O
families	O	NOUN	B
16	O	NUM	O
with	O	ADP	O
positive	O	ADJ	B
BRCA1	O	NOUN	B
lod	O	NOUN	B
scores	O	NOUN	I
,	O	PUNCT	O
7	O	NUM	O
with	O	ADP	O
negative	O	ADJ	B
lod	O	NOUN	O
scores	O	NOUN	O
(	O	PUNCT	O
reflecting	O	VERB	O
multiple	O	ADJ	O
sporadic	O	ADJ	B
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
not	O	PART	O
tested	O	VERB	O
for	O	ADP	O
linkage	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
other	O	ADJ	O
families	O	NOUN	B
have	O	AUX	O
positive	O	ADJ	B
lod	O	NOUN	B
scores	O	NOUN	I
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
BRCA2	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
13	O	NUM	O
families	O	NOUN	B
without	O	ADP	O
detected	O	VERB	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
negative	O	ADJ	B
lod	O	NOUN	B
scores	O	NOUN	I
for	O	ADP	O
both	O	CCONJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
new	O	ADJ	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
variant	O	NOUN	O
,	O	PUNCT	O
G6PD	O	NOUN	B
Orissa	O	PROPN	I
(	O	PUNCT	O
44	O	NUM	O
Ala	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Gly	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
major	O	ADJ	O
polymorphic	O	ADJ	B
variant	O	NOUN	O
in	O	ADP	O
tribal	O	ADJ	B
populations	O	NOUN	I
in	O	ADP	O
India	O	PROPN	B
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
glucose	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	O	PUNCT	O
G6PD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
usually	O	ADV	O
found	O	VERB	O
at	O	ADP	O
high	O	ADJ	O
frequencies	O	NOUN	B
in	O	ADP	O
areas	O	NOUN	O
of	O	ADP	O
the	O	DET	O
world	O	NOUN	B
where	O	SCONJ	O
malaria	B-Disease	NOUN	B
has	O	AUX	O
been	O	AUX	O
endemic	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
genetic	O	ADJ	B
basis	O	NOUN	O
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
have	O	AUX	O
been	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
Africa	O	PROPN	B
,	O	PUNCT	O
around	O	ADP	O
the	O	DET	O
Mediterranean	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
Far	O	PROPN	B
East	O	PROPN	I
,	O	PUNCT	O
but	O	CCONJ	O
little	O	ADJ	O
such	O	ADJ	O
information	O	NOUN	B
is	O	AUX	O
available	O	ADJ	O
about	O	ADP	O
the	O	DET	O
situation	O	NOUN	B
in	O	ADP	O
India	O	PROPN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
heterogeneity	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
several	O	ADJ	O
different	O	ADJ	O
Indian	O	ADJ	B
populations	O	NOUN	B
by	O	ADP	O
screening	O	VERB	B
for	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	B
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
deficient	O	ADJ	B
alleles	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
varies	O	VERB	O
between	O	ADP	O
3	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
15	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
different	O	ADJ	O
tribal	O	ADJ	B
and	O	CCONJ	O
urban	O	ADJ	B
groups	O	NOUN	I
.	O	PUNCT	O


Remarkably	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
previously	O	ADV	O
unreported	O	ADJ	O
deficient	O	ADJ	B
variant	O	NOUN	B
,	O	PUNCT	O
G6PD	O	NOUN	B
Orissa	O	PROPN	I
(	O	PUNCT	O
44	O	NUM	O
Ala	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Gly	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
in	O	ADP	O
tribal	O	ADJ	B
Indian	O	ADJ	I
populations	O	NOUN	I
but	O	CCONJ	O
is	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
urban	O	ADJ	B
populations	O	NOUN	B
,	O	PUNCT	O
where	O	SCONJ	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	O
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
the	O	DET	O
G6PD	O	NOUN	B
Mediterranean	O	ADJ	B
(	O	PUNCT	O
188	O	NUM	O
Ser	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Phe	O	NOUN	B
)	O	PUNCT	O
variant	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
KmNADP	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
Orissa	O	PROPN	B
is	O	AUX	O
fivefold	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
enzyme	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
the	O	DET	O
alanine	O	NOUN	B
residue	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
glycine	O	NOUN	B
is	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
a	O	DET	O
putative	O	ADJ	O
coenzyme	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
site	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
of	O	ADP	O
bipolar	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
to	O	PART	O
chromosome	O	NOUN	O
18	O	NUM	O
with	O	ADP	O
a	O	DET	O
parent	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
origin	O	NOUN	B
effect	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
susceptibility	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
18	O	NUM	I
and	O	CCONJ	O
a	O	DET	O
parent	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
origin	O	NOUN	B
effect	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
suggested	O	VERB	O
for	O	ADP	O
bipolar	B-Disease	ADJ	B
affective	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
BPAD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
28	O	NUM	O
nuclear	O	ADJ	B
families	O	NOUN	I
selected	O	VERB	O
for	O	ADP	O
apparent	O	ADJ	B
unilineal	O	ADJ	B
transmission	O	NOUN	I
of	O	ADP	O
the	O	DET	O
BPAD	B-Disease	NOUN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
using	O	VERB	O
31	O	NUM	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
spanning	O	VERB	O
chromosome	O	NOUN	B
18	O	NUM	I
.	O	PUNCT	O


Evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
was	O	AUX	O
tested	O	VERB	B
with	O	ADP	O
affected	O	VERB	B
-	O	PUNCT	O
sib	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
and	O	CCONJ	O
LOD	O	NOUN	B
score	O	NOUN	O
methods	O	NOUN	O
under	O	ADP	O
two	O	NUM	O
definitions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
affected	O	VERB	B
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
affected	O	VERB	B
-	O	PUNCT	O
sibpair	O	NOUN	B
analyses	O	NOUN	O
indicated	O	VERB	O
excess	O	ADJ	B
allele	O	NOUN	B
sharing	O	NOUN	O
for	O	ADP	O
markers	O	NOUN	B
on	O	ADP	O
18p	O	NOUN	B
within	O	ADP	O
the	O	DET	O
region	O	NOUN	B
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
greatest	O	ADJ	O
sharing	O	NOUN	B
was	O	AUX	O
at	O	ADP	O
D18S37	O	NOUN	O
64	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
bipolar	O	ADJ	B
and	O	CCONJ	O
recurrent	O	ADJ	O
unipolar	O	ADJ	O
(	O	PUNCT	O
RUP	O	NOUN	B
)	O	PUNCT	O
sib	O	NOUN	B
pairs	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
0006	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
excess	O	ADJ	B
sharing	O	NOUN	O
of	O	ADP	O
the	O	DET	O
paternally	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
maternally	O	ADV	B
,	O	PUNCT	O
transmitted	O	VERB	B
alleles	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
three	O	NUM	O
markers	O	NOUN	B
on	O	ADP	O
18q	O	NOUN	B
at	O	ADP	O
D18S41	O	NOUN	B
,	O	PUNCT	O
51	O	NUM	O
bipolar	O	NOUN	B
and	O	CCONJ	O
RUP	O	NOUN	B
sib	O	NOUN	O
pairs	O	NOUN	O
were	O	AUX	O
concordant	O	ADJ	B
for	O	ADP	O
paternally	O	ADV	B
transmitted	O	VERB	I
alleles	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
pairs	O	NOUN	B
were	O	AUX	O
discordant	O	ADJ	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
evidence	O	NOUN	B
for	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
loci	O	NOUN	B
on	O	ADP	O
both	O	CCONJ	O
18p	O	NOUN	B
and	O	CCONJ	O
18q	O	NOUN	B
was	O	AUX	O
strongest	O	ADJ	O
in	O	ADP	O
the	O	DET	O
11	O	NUM	O
paternal	O	ADJ	B
pedigrees	O	NOUN	I
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
those	O	DET	O
in	O	ADP	O
which	O	DET	O
the	O	DET	O
father	O	NOUN	B
or	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
fathers	O	NOUN	B
sibs	O	NOUN	B
is	O	AUX	O
affected	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
these	O	DET	O
pedigrees	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
greatest	O	ADJ	O
allele	O	NOUN	B
sharing	O	NOUN	B
(	O	PUNCT	O
81	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
00002	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
highest	O	ADJ	B
LOD	O	NOUN	B
score	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
.	O	PUNCT	O
51	O	NUM	O
;	O	PUNCT	O
phi	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
0	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
D18S41	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
provide	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
for	O	ADP	O
linkage	O	NOUN	B
of	O	ADP	O
BPAD	B-Disease	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
18	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
first	O	ADJ	O
molecular	O	ADJ	B
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
parent	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
origin	O	NOUN	B
effect	O	NOUN	B
operating	O	VERB	O
in	O	ADP	O
this	O	DET	O
disorder	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
loci	O	NOUN	B
involved	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
precise	O	ADJ	O
location	O	NOUN	B
,	O	PUNCT	O
require	O	VERB	O
further	O	ADJ	O
study	O	NOUN	B


A	O	DET	O
prevalent	O	ADJ	O
mutation	O	NOUN	B
for	O	ADP	O
galactosemia	B-Disease	NOUN	B
among	O	ADP	O
black	O	ADJ	B
Americans	O	PROPN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
define	O	VERB	O
the	O	DET	O
mutation	O	NOUN	B
causing	O	VERB	O
galactosemia	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
black	O	ADJ	B
American	O	ADJ	I
origin	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
no	O	DET	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
in	O	ADP	O
erythrocytes	O	NOUN	B
but	O	CCONJ	O
good	O	ADJ	O
clinical	O	ADJ	B
outcome	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
discovered	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
at	O	ADP	O
base	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
1158	O	NUM	O
of	O	ADP	O
the	O	DET	O
GALT	O	NOUN	B
gene	O	NOUN	I
that	O	PRON	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
serine	O	NOUN	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
leucine	O	NOUN	B
substitution	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
135	O	NUM	I
(	O	PUNCT	O
S135L	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
developed	O	VERB	O
a	O	DET	O
method	O	NOUN	B
with	O	ADP	O
which	O	DET	O
to	O	PART	O
screen	O	VERB	B
populations	O	NOUN	B
for	O	ADP	O
its	O	PRON	O
prevalence	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
compared	O	VERB	B
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
among	O	ADP	O
erythrocytes	O	NOUN	B
,	O	PUNCT	O
leukocytes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
transformed	O	VERB	B
lymphoblasts	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
total	O	ADJ	B
body	O	NOUN	I
oxidation	O	NOUN	I
of	O	ADP	O
D	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
13C	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
galactose	O	NOUN	B
to	O	ADP	O
13CO2	O	NOUN	B
among	O	ADP	O
three	O	NUM	O
genotypes	O	NOUN	B
for	O	ADP	O
GALT	O	NOUN	B
(	O	PUNCT	O
S135L	O	NOUN	B
/	O	SYM	O
S135L	O	NOUN	B
,	O	PUNCT	O
Q188R	O	NOUN	B
/	O	SYM	O
Q188R	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Normal	O	ADJ	B
/	O	SYM	O
Normal	O	ADJ	B
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	VERB	B
We	O	PRON	O
found	O	VERB	O
a	O	DET	O
48	O	NUM	O
%	O	NOUN	O
prevalence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
S135L	O	NOUN	B
mutation	O	NOUN	I
among	O	ADP	O
17	O	NUM	O
black	O	ADJ	B
American	O	ADJ	I
patients	O	NOUN	B
with	O	ADP	O
classic	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
1	O	NUM	O
%	O	NOUN	O
prevalence	O	NOUN	B
in	O	ADP	O
a	O	DET	O
population	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
black	O	ADJ	B
Americans	O	PROPN	I
without	O	ADP	O
galactosemia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
S135L	O	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
84	O	NUM	O
white	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
G	O	NOUN	B
/	O	PUNCT	O
G	O	NOUN	B
galactosemia	B-Disease	NOUN	I
nor	O	CCONJ	O
in	O	ADP	O
87	O	NUM	O
white	O	ADJ	B
control	O	ADJ	I
subjects	O	NOUN	I
without	O	ADP	O
galactosemia	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
normal	O	ADJ	O
whole	O	ADJ	B
body	O	NOUN	I
oxidation	O	NOUN	I
of	O	ADP	O
D	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
13C	O	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
galactose	O	NOUN	B
by	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
S135L	O	NOUN	B
and	O	CCONJ	O
various	O	ADJ	O
degrees	O	NOUN	B
of	O	ADP	O
enzyme	O	NOUN	B
impairment	O	NOUN	O
among	O	ADP	O
different	O	ADJ	O
tissues	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
S135L	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
GALT	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
a	O	DET	O
prevalent	O	ADJ	O
cause	O	NOUN	B
of	O	ADP	O
galactosemia	B-Disease	NOUN	B
among	O	ADP	O
black	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
GALT	O	NOUN	B
activity	O	NOUN	B
varies	O	VERB	O
in	O	ADP	O
different	O	ADJ	O
tissues	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
S135L	O	NOUN	B
,	O	PUNCT	O
they	O	PRON	O
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
better	O	ADV	O
clinical	O	ADJ	B
outcome	O	NOUN	I
than	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
Q188R	O	NOUN	B
when	O	SCONJ	O
both	O	DET	O
are	O	AUX	O
treated	O	VERB	B
from	O	ADP	O
infancy	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
20	O	NUM	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
20	O	NUM	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
which	O	DET	O
show	O	VERB	O
positive	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	O
17q12	O	NOUN	O
for	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
mutations	O	NOUN	B
cosegregating	O	VERB	I
with	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
16	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
1	O	NUM	O
family	O	NOUN	B
with	O	ADP	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Nine	O	NUM	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
generate	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
stop	O	NOUN	I
codon	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
truncated	O	VERB	B
BRCA1	O	NOUN	O
protein	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
88	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
expected	O	ADJ	O
normal	O	ADJ	O
length	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
mutations	O	NOUN	B
altered	O	VERB	O
the	O	DET	O
RING	O	NOUN	B
finger	O	NOUN	I
domain	O	NOUN	I
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
led	O	VERB	O
to	O	PART	O
the	O	DET	O
identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
12	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cDNA	O	NOUN	B
analysis	O	NOUN	I
revealed	O	VERB	O
an	O	DET	O
abnormal	O	ADJ	B
or	O	CCONJ	O
missing	O	ADJ	O
BRCA1	O	NOUN	B
transcript	O	NOUN	B
in	O	ADP	O
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
8	O	NUM	O
remaining	O	VERB	O
families	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
eight	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduced	O	VERB	B
quantity	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
transcript	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
detect	O	VERB	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
4	O	NUM	O
of	O	ADP	O
the	O	DET	O
20	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
1	O	NUM	O
of	O	ADP	O
these	O	DET	O
was	O	AUX	O
clearly	O	ADV	O
linked	O	VERB	O
to	O	PART	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
expected	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
clear	O	ADJ	O
examples	O	NOUN	B
of	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
will	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Brca1	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
results	O	VERB	B
in	O	ADP	O
early	O	ADJ	O
embryonic	B-Disease	ADJ	B
lethality	I-Disease	NOUN	O
characterized	O	VERB	B
by	O	ADP	O
neuroepithelial	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
shown	O	VERB	O
to	O	PART	O
encode	O	VERB	B
a	O	DET	O
zinc	O	NOUN	B
-	O	PUNCT	O
finger	O	NOUN	B
protein	O	NOUN	B
of	O	ADP	O
unknown	O	ADJ	O
function	O	NOUN	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
account	O	NOUN	O
for	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
some	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
familial	O	ADJ	B
sporadic	O	ADJ	B
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
BRCA1	O	NOUN	B
in	O	ADP	O
tumours	B-Disease	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
carrying	O	VERB	O
one	O	NUM	O
nonfunctional	O	ADJ	B
BRCA1	O	NOUN	B
allele	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
encodes	O	VERB	B
a	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
inhibit	O	VERB	B
the	O	DET	O
proliferation	O	NOUN	B
of	O	ADP	O
mammary	O	ADJ	B
epithelial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	O
tissue	O	NOUN	B
growth	O	NOUN	I
and	O	CCONJ	O
differentiation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
generate	O	VERB	O
a	O	DET	O
potential	O	ADJ	B
model	O	NOUN	B
for	O	ADP	O
the	O	DET	O
cancer	B-Disease	NOUN	B
susceptibility	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
loss	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
function	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
created	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
line	O	NOUN	I
carrying	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
one	O	NUM	O
Brca1	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
mice	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
allele	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
Brca1	O	NOUN	B
is	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
these	O	DET	O
mice	O	NOUN	B
died	O	VERB	B
in	O	ADP	O
utero	O	NOUN	B
between	O	ADP	O
10	O	NUM	O
and	O	CCONJ	O
13	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
gestation	O	NOUN	B
(	O	PUNCT	O
E10	O	NOUN	B
-	O	PUNCT	O
E13	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Abnormalities	O	NOUN	B
in	O	ADP	O
Brca1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
embryos	O	NOUN	B
were	O	AUX	O
most	O	ADV	O
evident	O	ADJ	O
in	O	ADP	O
the	O	DET	O
neural	O	ADJ	B
tube	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
embryos	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
varying	O	VERB	O
degrees	O	NOUN	B
of	O	ADP	O
spina	B-Disease	ADJ	B
bifida	I-Disease	NOUN	I
and	O	CCONJ	O
anencephaly	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
neuroepithelium	O	NOUN	B
in	O	ADP	O
Brca1	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
embryos	O	NOUN	B
appeared	O	VERB	O
disorganized	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
rapid	O	ADJ	O
proliferation	O	NOUN	B
and	O	CCONJ	O
excessive	O	ADJ	B
cell	O	NOUN	B
death	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ALD	O	PROPN	B
-	O	PUNCT	O
gene	O	NOUN	B
of	O	ADP	O
20	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
/	O	SYM	O
adrenomyeloneuropathy	B-Disease	ADJ	B
.	O	PUNCT	O


Adrenoleukodystrophy	B-Disease	NOUN	B
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	O
inherited	I-Disease	VERB	B
metabolic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
inborn	B-Disease	ADJ	B
peroxisomal	I-Disease	ADJ	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


It	O	PRON	O
leads	O	VERB	O
to	O	PART	O
demyelination	B-Disease	NOUN	B
in	I-Disease	ADP	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
peripheral	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
.	O	PUNCT	O


Defective	O	ADJ	B
beta	O	NOUN	B
-	O	PUNCT	O
oxidation	O	NOUN	B
of	O	ADP	O
saturated	O	VERB	B
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
(	O	PUNCT	O
VLCFAs	O	NOUN	B
;	O	PUNCT	O
C22	O	NOUN	O
0	O	NUM	O
-	O	PUNCT	O
C26	O	NOUN	B
0	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
peroxisomes	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
lead	O	VERB	O
to	O	PART	O
an	O	DET	O
accumulation	O	NOUN	B
of	O	ADP	O
VLCFAs	O	NOUN	B
in	O	ADP	O
leukoid	O	NOUN	B
areas	O	NOUN	I
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
peripheral	O	ADJ	B
nerves	O	NOUN	I
,	O	PUNCT	O
adrenal	O	ADJ	B
gland	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
blood	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
recently	O	ADV	O
identified	O	VERB	B
and	O	CCONJ	O
encodes	O	VERB	B
a	O	DET	O
745	O	NUM	B
-	O	PUNCT	O
amino	O	NOUN	B
-	O	PUNCT	O
acid	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
screened	O	VERB	B
patients	O	NOUN	B
with	O	ADP	O
adrenoleukodystrophy	B-Disease	NOUN	B
/	O	SYM	O
adrenomyeloneuropathy	B-Disease	ADJ	B
(	O	PUNCT	O
ALD	B-Disease	PROPN	B
/	O	SYM	O
AMN	B-Disease	PROPN	B
)	O	PUNCT	O
from	O	ADP	O
20	O	NUM	O
kindreds	O	NOUN	B
for	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NUM	O
missense	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
,	O	PUNCT	O
five	O	NUM	O
deletions	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
insertion	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
direct	O	ADJ	O
sequencing	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
reverse	O	ADJ	B
transcribed	O	VERB	I
fragments	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ALD	B-Disease	PROPN	B
-	O	PUNCT	O
gene	O	NOUN	B
mRNA	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
mutations	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
de	O	X	O
novo	O	X	O
.	O	PUNCT	O


All	O	DET	O
mutations	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
confirmed	O	VERB	O
in	O	ADP	O
carriers	O	NOUN	B
by	O	ADP	O
sequencing	O	VERB	B
genomic	O	ADJ	I
DNA	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenotype	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
ALD	B-Disease	NOUN	B
gene	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
healthy	O	ADJ	B
persons	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
murine	O	ADJ	B
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
Brca1	O	NOUN	B
maps	O	NOUN	B
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
11D	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
recently	O	ADV	O
cloned	O	VERB	B
human	O	ADJ	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
17q21	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
isolated	O	VERB	B
murine	O	ADJ	B
genomic	O	ADJ	B
clones	O	NOUN	I
containing	O	VERB	O
Brca1	O	NOUN	B
as	O	ADP	O
a	O	DET	O
first	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
generating	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
the	O	DET	O
loss	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
function	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
mouse	O	NOUN	B
genomic	O	ADJ	B
library	O	NOUN	I
was	O	AUX	O
screened	O	VERB	B
using	O	VERB	O
probes	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
exon	O	NOUN	B
11	O	NUM	I
of	O	ADP	I
the	O	DET	O
human	O	ADJ	B
BRCA1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
overlapping	O	VERB	O
mouse	O	NOUN	B
clones	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
that	O	PRON	O
hybridized	O	VERB	B
to	O	PART	O
human	O	ADJ	B
BRCA1	O	NOUN	B
exons	O	NOUN	B
9	O	NUM	O
-	O	SYM	O
12	O	NUM	O
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
the	O	DET	O
region	O	NOUN	B
of	O	ADP	O
these	O	DET	O
clones	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
part	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
exon	O	NOUN	O
11	O	NUM	O
revealed	O	VERB	B
72	O	NUM	O
%	O	NOUN	O
nucleic	O	ADJ	B
acid	O	NOUN	I
identity	O	NOUN	B
but	O	CCONJ	O
only	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
amino	O	NOUN	B
acid	O	NOUN	I
identity	O	NOUN	B
with	O	ADP	O
the	O	DET	O
human	O	ADJ	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
longest	O	ADJ	O
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
Brca1	O	NOUN	B
genomic	O	ADJ	B
clones	O	NOUN	I
maps	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	B
11D	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
two	O	NUM	O
-	O	PUNCT	O
color	O	NOUN	B
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
synteny	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
17	O	NUM	I
was	O	AUX	O
confirmed	O	VERB	O
by	O	ADP	O
cohybridization	O	NOUN	B
with	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
probe	O	NOUN	I
for	O	ADP	O
the	O	DET	O
NF1	O	NOUN	B
-	O	PUNCT	O
gene	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
comparative	O	ADJ	B
study	O	NOUN	I
confirms	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
relative	O	ADJ	O
location	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
conserved	O	VERB	O
between	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
humans	O	NOUN	B
.	O	PUNCT	O


Atelosteogenesis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
II	I-Disease	NUM	I
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
sulfate	O	NOUN	B
-	O	PUNCT	O
transporter	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
DTDST	O	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
evidence	O	NOUN	B
for	O	ADP	O
a	O	DET	O
phenotypic	O	ADJ	B
series	O	NOUN	O
involving	O	VERB	O
three	O	NUM	O
chondrodysplasias	B-Disease	NOUN	B
.	O	PUNCT	O


Atelosteogenesis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
II	I-Disease	NUM	I
(	O	PUNCT	O
AO	B-Disease	PROPN	B
II	I-Disease	NUM	I
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
neonatally	O	ADV	B
lethal	O	ADJ	I
chondrodysplasia	B-Disease	NOUN	I
whose	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
histological	O	ADJ	B
characteristics	O	NOUN	B
resemble	O	VERB	O
those	O	DET	O
of	O	ADP	O
another	O	DET	O
chondrodysplasia	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
much	O	ADV	O
less	O	ADV	O
severe	O	ADJ	B
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
(	O	PUNCT	O
DTD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
similarity	O	NOUN	B
suggests	O	VERB	O
a	O	DET	O
shared	O	VERB	O
pathogenesis	O	NOUN	B
involving	O	VERB	O
lesions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
biochemical	O	ADJ	B
pathway	O	NOUN	I
and	O	CCONJ	O
perhaps	O	ADV	O
the	O	DET	O
same	O	ADJ	O
gene	O	NOUN	B
.	O	PUNCT	O


DTD	B-Disease	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
recently	O	ADV	O
identified	O	VERB	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
sulfate	O	NOUN	B
-	O	PUNCT	O
transporter	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
DTDST	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
AOII	B-Disease	NOUN	B
patients	O	NOUN	B
also	O	ADV	O
have	O	AUX	O
DTDST	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
lead	O	VERB	O
to	O	PART	O
defective	O	ADJ	B
uptake	O	NOUN	B
of	O	ADP	O
inorganic	O	ADJ	B
sulfate	O	NOUN	I
and	O	CCONJ	O
insufficient	O	ADJ	B
sulfation	O	NOUN	B
of	O	ADP	O
macromolecules	O	NOUN	B
by	O	ADP	O
patient	O	NOUN	B
mesenchymal	O	ADJ	B
cells	O	NOUN	I
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Together	O	ADV	O
with	O	ADP	O
our	O	PRON	O
recent	O	ADJ	O
observation	O	NOUN	B
that	O	SCONJ	O
a	O	DET	O
third	O	ADJ	O
even	O	ADV	O
more	O	ADV	O
severe	O	ADJ	B
chondrodysplasia	B-Disease	NOUN	B
,	O	PUNCT	O
achondrogenesis	O	ADJ	B
type	O	NOUN	I
IB	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
also	O	ADV	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
DTDST	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
a	O	DET	O
phenotypic	O	ADJ	B
series	O	NOUN	O
of	O	ADP	O
three	O	NUM	O
chondrodysplasias	B-Disease	NOUN	B
of	O	ADP	O
increasing	O	VERB	B
severity	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
lesions	O	NOUN	B
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
sulfate	O	NOUN	B
-	O	PUNCT	O
transporter	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
severity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phenotype	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
predicted	O	VERB	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
on	O	ADP	O
the	O	DET	O
residual	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DTDST	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Haplotype	O	NOUN	B
and	O	CCONJ	O
phenotype	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
six	O	NUM	O
recurrent	O	ADJ	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
61	O	NUM	O
families	O	NOUN	B
:	O	PUNCT	O
results	O	NOUN	B
of	O	ADP	O
an	O	DET	O
international	O	ADJ	B
study	O	NOUN	I
.	O	PUNCT	O


Several	O	ADJ	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
now	O	ADV	O
been	O	AUX	O
found	O	VERB	O
to	O	PART	O
occur	O	VERB	O
in	O	ADP	O
geographically	O	ADV	B
diverse	O	ADJ	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
mutation	O	NOUN	B
origin	O	NOUN	B
and	O	CCONJ	O
mutation	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
phenotypes	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
constructed	O	VERB	O
a	O	DET	O
haplotype	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
polymorphic	O	ADJ	B
markers	O	NOUN	B
within	O	ADP	O
or	O	CCONJ	O
immediately	O	ADV	O
flanking	O	VERB	B
the	O	DET	O
BRCA1	O	NOUN	B
locus	O	NOUN	B
in	O	ADP	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
61	O	NUM	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
selected	O	VERB	O
for	O	ADP	O
having	O	VERB	O
one	O	NUM	O
of	O	ADP	O
six	O	NUM	O
recurrent	O	ADJ	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Tests	O	NOUN	B
of	O	ADP	O
both	O	DET	O
mutations	O	NOUN	B
and	O	CCONJ	O
family	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
differences	O	NOUN	B
in	O	ADP	O
age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
were	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
.	O	PUNCT	O


A	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
six	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
proportions	O	NOUN	B
of	O	ADP	O
cases	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
suggestive	O	ADJ	O
of	O	ADP	O
an	O	DET	O
effect	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
069	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
57	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
women	O	NOUN	B
presumed	O	VERB	O
affected	O	VERB	B
because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
1294	O	NUM	O
del	O	X	O
40	O	NUM	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
having	O	VERB	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
14	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
affected	O	VERB	B
women	O	NOUN	B
with	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
site	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
intron	O	NOUN	B
5	O	NUM	O
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
studied	O	VERB	O
here	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
individual	O	ADJ	B
mutations	O	NOUN	B
are	O	AUX	O
estimated	O	VERB	O
to	O	PART	O
have	O	AUX	O
arisen	O	VERB	O
9	O	NUM	O
-	O	PUNCT	O
170	O	NUM	O
generations	O	NOUN	B
ago	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
general	O	ADJ	O
,	O	PUNCT	O
a	O	DET	O
high	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
haplotype	O	NOUN	B
conservation	O	NOUN	B
across	O	ADP	O
the	O	DET	O
region	O	NOUN	B
was	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
haplotype	O	NOUN	B
differences	O	VERB	B
most	O	ADV	O
often	O	ADV	O
due	O	ADP	O
to	O	PART	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
short	O	ADJ	B
-	O	PUNCT	O
tandem	O	ADJ	B
-	O	PUNCT	O
repeat	O	NOUN	B
markers	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
some	O	DET	O
likely	O	ADJ	O
instances	O	NOUN	O
of	O	ADP	O
recombination	O	NOUN	B
also	O	ADV	O
were	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


For	O	ADP	O
several	O	ADJ	O
of	O	ADP	O
the	O	DET	O
instances	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
evidence	O	NOUN	B
for	O	ADP	O
multiple	O	ADJ	B
,	O	PUNCT	O
independent	O	ADJ	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
mutational	O	ADJ	B
events	O	NOUN	I
.	O	PUNCT	O


Isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
homologue	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
genetic	O	ADJ	B
mapping	O	NOUN	I
to	O	PART	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
11	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	B
is	O	AUX	O
in	O	ADP	O
large	O	ADJ	O
part	O	NOUN	O
responsible	O	ADJ	O
for	O	ADP	O
hereditary	B-Disease	ADJ	B
human	I-Disease	ADJ	B
breast	I-Disease	NOUN	O
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
murine	O	ADJ	B
Brca1	O	NOUN	B
homologue	O	NOUN	B
cDNA	O	NOUN	B
clones	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
identified	O	VERB	O
genomic	O	ADJ	B
P1	O	NOUN	I
clones	O	NOUN	O
that	O	PRON	O
contain	O	VERB	O
most	O	ADJ	O
,	O	PUNCT	O
if	O	SCONJ	O
not	O	PART	O
all	O	DET	O
,	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
Brca1	O	NOUN	B
locus	O	NOUN	O
.	O	PUNCT	O


DNA	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
coding	O	NOUN	O
regions	O	NOUN	O
are	O	AUX	O
75	O	NUM	O
%	O	NOUN	O
identical	O	ADJ	B
at	O	ADP	O
the	O	DET	O
nucleotide	O	NOUN	B
level	O	NOUN	O
while	O	SCONJ	O
the	O	DET	O
predicted	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
identity	O	NOUN	B
is	O	AUX	O
only	O	ADV	O
58	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
DNA	O	NOUN	B
sequence	O	NOUN	I
variant	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Brca1	O	NOUN	B
locus	O	NOUN	O
was	O	AUX	O
identified	O	VERB	B
and	O	CCONJ	O
used	O	VERB	O
to	O	PART	O
map	O	VERB	B
this	O	DET	O
gene	O	NOUN	B
on	O	ADP	O
a	O	DET	O
(	O	PUNCT	O
Mus	O	NOUN	B
m	O	NOUN	I
.	O	PUNCT	O
musculus	O	ADJ	B
Czech	O	PROPN	B
II	O	NUM	I
x	O	NOUN	O
C57BL	O	NOUN	B
/	O	SYM	O
KsJ	O	NOUN	B
)	O	PUNCT	O
F1	O	NOUN	B
x	O	NOUN	O
C57BL	O	NOUN	B
/	O	PUNCT	O
KsJ	O	NOUN	B
intersubspecific	O	ADJ	O
backcross	O	NOUN	O
to	O	PART	O
distal	O	ADJ	B
mouse	O	NOUN	O
chromosome	O	NOUN	O
11	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
mapping	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
to	O	PART	O
a	O	DET	O
region	O	NOUN	B
highly	O	ADV	O
syntenic	O	ADJ	B
with	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
17	O	NUM	I
,	O	PUNCT	O
coupled	O	VERB	B
with	O	ADP	O
Southern	O	NOUN	B
and	O	CCONJ	O
Northern	O	NOUN	B
analyses	O	NOUN	I
,	O	PUNCT	O
confirms	O	VERB	O
that	O	SCONJ	O
we	O	PRON	O
isolated	O	VERB	B
the	O	DET	O
murine	O	ADJ	B
Brca1	O	NOUN	B
homologue	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
a	O	DET	O
related	O	ADJ	O
RING	O	NOUN	B
finger	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
Brca1	O	NOUN	B
homologue	O	NOUN	B
will	O	AUX	O
facilitate	O	VERB	O
the	O	DET	O
creation	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
models	O	NOUN	I
for	O	ADP	O
germline	O	NOUN	B
BRCA1	B-Disease	NOUN	B
defects	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Emerin	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
membrane	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
STA	O	NOUN	B
gene	O	NOUN	I
at	O	ADP	O
the	O	DET	O
Xq28	O	NOUN	B
locus	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
Emery	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EDMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
gene	O	NOUN	B
encodes	O	VERB	O
a	O	DET	O
hitherto	O	ADV	O
unknown	O	ADJ	O
protein	O	NOUN	B
named	O	VERB	O
emerin	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
subcellular	O	ADJ	B
localization	O	NOUN	B
of	O	ADP	O
emerin	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
raised	O	VERB	O
two	O	NUM	O
antisera	O	NOUN	B
against	O	ADP	O
synthetic	O	ADJ	B
peptide	O	NOUN	I
fragments	O	NOUN	O
predicted	O	VERB	O
from	O	ADP	O
emerin	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
both	O	DET	O
antisera	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
positive	O	ADJ	B
nuclear	O	ADJ	B
membrane	O	NOUN	I
staining	O	NOUN	I
in	O	ADP	O
skeletal	O	ADJ	B
,	O	PUNCT	O
cardiac	O	ADJ	B
and	O	CCONJ	O
smooth	O	ADJ	B
muscles	O	NOUN	I
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
controls	O	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
neuromuscular	B-Disease	ADJ	B
diseases	I-Disease	NOUN	I
other	O	ADJ	O
than	O	ADP	O
EDMD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
deficiency	O	NOUN	B
in	O	ADP	O
immunofluorescent	O	ADJ	B
staining	O	NOUN	I
of	O	ADP	O
skeletal	O	ADJ	B
and	O	CCONJ	O
cardiac	O	ADJ	B
muscle	O	NOUN	I
from	O	ADP	O
EDMD	B-Disease	NOUN	B
patients	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
34	O	NUM	O
kD	O	NOUN	O
protein	O	NOUN	O
is	O	AUX	O
immunoreactive	O	ADJ	B
with	O	ADP	O
the	O	DET	O
antisera	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
equivalent	O	ADJ	O
to	O	PART	O
that	O	DET	O
predicted	O	VERB	B
for	O	ADP	O
emerin	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
findings	O	NOUN	B
suggest	O	VERB	O
the	O	DET	O
specific	O	ADJ	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
emerin	I-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
membrane	O	NOUN	I
of	O	ADP	O
muscle	O	NOUN	B
cells	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
EDMD	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Growth	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
and	O	CCONJ	O
tumour	B-Disease	NOUN	B
inhibition	O	NOUN	I
by	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Inherited	O	VERB	B
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
predispose	O	VERB	O
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
sporadic	O	ADJ	B
breast	B-Disease	NOUN	O
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
elusive	O	ADJ	O
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
retroviral	O	ADJ	B
transfer	O	NOUN	I
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
BRCA1	O	NOUN	B
gene	O	NOUN	O
inhibits	O	VERB	B
growth	O	NOUN	B
in	O	X	B
vitro	O	X	I
of	O	ADP	O
all	O	DET	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cell	O	NOUN	B
lines	O	NOUN	I
tested	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
colon	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
lung	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cells	O	NOUN	O
or	O	CCONJ	O
fibroblasts	O	NOUN	B
.	O	PUNCT	O


Mutant	O	ADJ	B
BRCA1	O	NOUN	B
has	O	AUX	O
no	O	DET	O
effect	O	NOUN	O
on	O	ADP	O
growth	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cells	O	NOUN	I
;	O	PUNCT	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cell	O	NOUN	B
growth	O	NOUN	I
is	O	AUX	O
not	O	PART	O
affected	O	VERB	O
by	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
5	O	NUM	O
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
3	O	NUM	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


Development	O	NOUN	B
of	O	ADP	O
MCF	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
7	I-Disease	NUM	B
tumours	I-Disease	NOUN	B
in	O	ADP	O
nude	O	ADJ	B
mice	O	NOUN	I
is	O	AUX	O
inhibited	O	VERB	B
when	O	SCONJ	O
MCF	O	NOUN	B
-	O	PUNCT	O
7	O	NUM	B
cells	O	NOUN	B
are	O	AUX	O
transfected	O	VERB	B
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
mutant	O	ADJ	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Most	O	ADV	O
importantly	O	ADV	O
,	O	PUNCT	O
among	O	ADP	O
mice	O	NOUN	B
with	O	ADP	O
established	O	ADJ	O
MCF	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
7	I-Disease	NUM	B
tumours	I-Disease	NOUN	B
,	O	PUNCT	O
peritoneal	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
retroviral	O	ADJ	B
vector	O	NOUN	I
expressing	O	VERB	B
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
BRCA1	O	NOUN	B
significantly	O	ADV	O
inhibits	O	VERB	B
tumour	B-Disease	NOUN	B
growth	O	NOUN	I
and	O	CCONJ	O
increased	O	VERB	B
survival	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


